<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<html>
 <body>
  <pmc-articleset>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Gen Virol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Gen. Virol
      </journal-id>
      <journal-id journal-id-type="hwp">
       jgv
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       jgv
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Journal of General Virology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0022-1317
      </issn>
      <issn pub-type="epub">
       1465-2099
      </issn>
      <publisher>
       <publisher-name>
        Microbiology Society
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       28840816
      </article-id>
      <article-id pub-id-type="pmc">
       7079692
      </article-id>
      <article-id pub-id-type="publisher-id">
       000898
      </article-id>
      <article-id pub-id-type="doi">
       10.1099/jgv.0.000898
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research Article
        </subject>
        <subj-group subj-group-type="heading">
         <subject>
          Animal
         </subject>
         <subj-group subj-group-type="heading">
          <subject>
           Positive-strand RNA Viruses
          </subject>
         </subj-group>
        </subj-group>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        A persistently infecting coronavirus in hibernating
        <italic>
         Myotis lucifugus,
        </italic>
        the North American little brown bat
       </article-title>
       <alt-title alt-title-type="recto-page-foot">
        <ext-link ext-link-type="uri" xlink:href="http://jgv.microbiologyresearch.org">
         http://jgv.microbiologyresearch.org
        </ext-link>
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Subudhi
         </surname>
         <given-names>
          Sonu
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rapin
         </surname>
         <given-names>
          Noreen
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bollinger
         </surname>
         <given-names>
          Trent K.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hill
         </surname>
         <given-names>
          Janet E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Donaldson
         </surname>
         <given-names>
          Michael E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Davy
         </surname>
         <given-names>
          Christina M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Warnecke
         </surname>
         <given-names>
          Lisa
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         <sup>
          4
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Turner
         </surname>
         <given-names>
          James M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         <sup>
          4
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kyle
         </surname>
         <given-names>
          Christopher J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Willis
         </surname>
         <given-names>
          Craig K. R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         <sup>
          4
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Misra
         </surname>
         <given-names>
          Vikram
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="corresp" rid="cor1">
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         <sup>
          1
         </sup>
         ​
        </label>
        <institution>
         Department of Veterinary Microbiology, University of Saskatchewan
        </institution>
        ,
        <addr-line>
         Saskatoon, Saskatchewan
        </addr-line>
        ,
        <country>
         Canada
        </country>
       </aff>
       <aff id="aff2">
        <label>
         <sup>
          2
         </sup>
         ​
        </label>
        <institution>
         Department of Pathology, University of Saskatchewan
        </institution>
        ,
        <addr-line>
         Saskatoon, Saskatchewan
        </addr-line>
        ,
        <country>
         Canada
        </country>
       </aff>
       <aff id="aff3">
        <label>
         <sup>
          3
         </sup>
         ​
        </label>
        <institution>
         Trent University
        </institution>
        ,
        <addr-line>
         Peterborough, Ontario
        </addr-line>
        ,
        <country>
         Canada
        </country>
       </aff>
       <aff id="aff4">
        <label>
         <sup>
          4
         </sup>
         ​
        </label>
        <institution>
         Department of Biology, University of Winnipeg
        </institution>
        ,
        <addr-line>
         Winnipeg, Manitoba
        </addr-line>
        ,
        <country>
         Canada
        </country>
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        <bold>
         *Correspondence:
        </bold>
        Vikram Misra,
        <email xlink:href="vikram.misra@usask.ca">
         vikram.misra@usask.ca
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        9
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        25
       </day>
       <month>
        8
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        25
       </day>
       <month>
        8
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>
       98
      </volume>
      <issue>
       9
      </issue>
      <fpage>
       2297
      </fpage>
      <lpage>
       2309
      </lpage>
      <history>
       <date date-type="received">
        <day>
         30
        </day>
        <month>
         5
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="accepted">
        <day>
         19
        </day>
        <month>
         7
        </month>
        <year>
         2017
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2017 The Authors
       </copyright-statement>
       <copyright-year>
        2017
       </copyright-year>
      </permissions>
      <self-uri content-type="pdf" xlink:href="jgv-98-2297.pdf">
      </self-uri>
      <abstract>
       <p>
        Bats are important reservoir hosts for emerging viruses, including coronaviruses that cause diseases in people. Although there have been several studies on the pathogenesis of coronaviruses in humans and surrogate animals, there is little information on the interactions of these viruses with their natural bat hosts. We detected a coronavirus in the intestines of 53/174 hibernating little brown bats (
        <italic>
         Myotis lucifugus
        </italic>
        ), as well as in the lungs of some of these individuals. Interestingly, the presence of the virus was not accompanied by overt inflammation. Viral RNA amplified from little brown bats in this study appeared to be from two distinct clades. The sequences in clade 1 were very similar to the archived sequence derived from little brown bats and the sequences from clade 2 were more closely related to the archived sequence from big brown bats. This suggests that two closely related coronaviruses may circulate in little brown bats. Sequence variation among coronavirus detected from individual bats suggested that infection occurred prior to hibernation, and that the virus persisted for up to 4 months of hibernation in the laboratory. Based on the sequence of its genome, the coronavirus was placed in the
        <italic>
         Alphacoronavirus
        </italic>
        genus, along with some human coronaviruses, bat viruses and the porcine epidemic diarrhoea virus. The detection and identification of an apparently persistent coronavirus in a local bat species creates opportunities to understand the dynamics of coronavirus circulation in bat populations.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        bats
       </kwd>
       <kwd>
        <italic>
         Myotis lucifugus
        </italic>
       </kwd>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        persistent infection
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         Natural Sciences and Engineering Research Council of Canada
        </funding-source>
       </award-group>
       <award-group>
        <funding-source>
         Natural Sciences and Engineering Research Council of Canada
        </funding-source>
       </award-group>
      </funding-group>
     </article-meta>
    </front>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Virus Res
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Virus Res
      </journal-id>
      <journal-title-group>
       <journal-title>
        Virus Research
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0168-1702
      </issn>
      <issn pub-type="epub">
       1872-7492
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25281913
      </article-id>
      <article-id pub-id-type="pmc">
       7114389
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0168-1702(14)00398-0
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.virusres.2014.09.011
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Human coronaviruses: Viral and cellular factors involved in neuroinvasiveness and neuropathogenesis
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="aut0005">
        <name>
         <surname>
          Desforges
         </surname>
         <given-names>
          Marc
         </given-names>
        </name>
        <email>
         marc.desforges@iaf.inrs.ca
        </email>
        <xref ref-type="corresp" rid="cor0005">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0010">
        <name>
         <surname>
          Le Coupanec
         </surname>
         <given-names>
          Alain
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="aut0015">
        <name>
         <surname>
          Stodola
         </surname>
         <given-names>
          Jenny K.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="aut0020">
        <name>
         <surname>
          Meessen-Pinard
         </surname>
         <given-names>
          Mathieu
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="aut0025">
        <name>
         <surname>
          Talbot
         </surname>
         <given-names>
          Pierre J.
         </given-names>
        </name>
        <email>
         pierre.talbot@iaf.inrs.ca
        </email>
        <xref ref-type="corresp" rid="cor0010">
         ⁎⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0005">
       Laboratory of Neuroimmunovirology, INRS-Institut Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, 531 boulevard des Prairies, Laval, Québec, Canada H7V 1B7
      </aff>
      <author-notes>
       <corresp id="cor0005">
        <label>
         ⁎
        </label>
        Corresponding author. Tel.: +450 687 5010x4342; fax: +450 686 5501.
        <email>
         marc.desforges@iaf.inrs.ca
        </email>
       </corresp>
       <corresp id="cor0010">
        <label>
         ⁎⁎
        </label>
        Corresponding author. Tel.: +450 687 5010x4300; fax: +450 686 5501.
        <email>
         pierre.talbot@iaf.inrs.ca
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        2
       </day>
       <month>
        10
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <day>
        19
       </day>
       <month>
        12
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        2
       </day>
       <month>
        10
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <volume>
       194
      </volume>
      <fpage>
       145
      </fpage>
      <lpage>
       158
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2014 Elsevier B.V. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2014
       </copyright-year>
       <copyright-holder>
        Elsevier B.V.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="author-highlights" id="abs0005">
       <title>
        Highlights
       </title>
       <p>
        <list id="lis0005" list-type="simple">
         <list-item id="lsti0005">
          <label>
           •
          </label>
          <p id="par0005">
           Human coronavirus (HCoV) are naturally neuroinvasive in both mice and humans.
          </p>
         </list-item>
         <list-item id="lsti0010">
          <label>
           •
          </label>
          <p id="par0010">
           Both transneuronal and hematogenous route may allow virus invasion of the CNS.
          </p>
         </list-item>
         <list-item id="lsti0015">
          <label>
           •
          </label>
          <p id="par0015">
           Infection of neurons leads to excitotoxicity, neurodegeneration and cell-death.
          </p>
         </list-item>
         <list-item id="lsti0020">
          <label>
           •
          </label>
          <p id="par0020">
           HCoV are potentially associated with human neurological disorders.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <abstract id="abs0010">
       <p>
        Among the various respiratory viruses infecting human beings, coronaviruses are important pathogens, which usually infect the upper respiratory tract, where they are mainly associated with common colds. However, in more vulnerable populations, such as newborns, infants, the elderly and immune-compromised individuals, these opportunistic pathogens can also affect the lower respiratory tract, leading to pneumonia, exacerbations of asthma, and various types of respiratory distress syndrome. The respiratory involvement of human coronaviruses has been clearly established since the 1960s. Nevertheless, for almost three decades now, data reported in the scientific literature has also demonstrated that, like it was described for other human viruses, coronaviruses have neuroinvasive capacities since they can spread from the respiratory tract to the central nervous system (CNS). Once there, infection of CNS cells (neurotropism) could lead to human health problems, such as encephalitis and long-term neurological diseases. Neuroinvasive coronaviruses could damage the CNS as a result of misdirected host immune responses that could be associated with autoimmunity in susceptible individuals (virus-induced neuroimmunopathology) and/or viral replication, which directly induces damage to CNS cells (virus-induced neuropathology). Given all these properties, it has been suggested that these opportunistic human respiratory pathogens could be associated with the triggering or the exacerbation of neurologic diseases for which the etiology remains poorly understood. Herein, we present host and viral factors that participate in the regulation of the possible pathogenic processes associated with CNS infection by human coronaviruses and we try to decipher the intricate interplay between virus and host target cells in order to characterize their role in the virus life cycle as well as in the capacity of the cell to respond to viral invasion.
       </p>
      </abstract>
      <kwd-group id="kwd0005">
       <title>
        Keywords
       </title>
       <kwd>
        Human coronavirus
       </kwd>
       <kwd>
        Respiratory viral infection
       </kwd>
       <kwd>
        Neuroinvasion
       </kwd>
       <kwd>
        CNS infection
       </kwd>
       <kwd>
        Neurological diseases
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="par0025">
      Viral infections of the respiratory tract represent a major problem for human and animal health around the world. These respiratory infections induce the most common illnesses (
      <xref ref-type="bibr" rid="bib0880">
       Vareille et al., 2011
      </xref>
      ) and are a leading cause of morbidity and mortality in humans worldwide, especially children, the elderly and immune-compromised individuals (
      <xref ref-type="bibr" rid="bib0155">
       Cesario, 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0425">
       Ison and Hayden, 2002
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0455">
       Jartti et al., 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0785">
       Sloots et al., 2008
      </xref>
      ). The idea that viruses can cause respiratory tract infections has been demonstrated since the early 1930s (
      <xref ref-type="bibr" rid="bib0455">
       Jartti et al., 2012
      </xref>
      ). Nevertheless, with the help of modern diagnostic tools, a significant number of new respiratory viruses have been discovered since the beginning of the 21st century and it is estimated that there are about 200 antigenically distinct viruses able to cause infection of the respiratory tract, especially in infants and children (
      <xref ref-type="bibr" rid="bib0110">
       Brouard et al., 2007
      </xref>
      ). In fact, it is now believed that viruses cause 95% of respiratory diseases in children and infants and about 30–40% in the elderly (
      <xref ref-type="bibr" rid="bib0455">
       Jartti et al., 2012
      </xref>
      ). Among the various respiratory viruses, coronaviruses are important pathogens of humans and animals. Most of the coronaviruses that infect human beings usually reach the upper respiratory tract, where they are mainly associated with symptoms of common colds. However, being opportunistic pathogens, they can also affect the lower respiratory tract in more vulnerable populations, such as newborns, infants, the elderly and immune-compromised individuals, where they can lead to pneumonia, exacerbations of asthma, respiratory distress syndrome or even severe acute respiratory syndrome (SARS) or Middle-East respiratory syndrome (MERS) (
      <xref ref-type="bibr" rid="bib0720">
       Raj et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0860">
       Vabret et al., 2009
      </xref>
      ).
     </p>
     <p id="par0030">
      Even though the airway epithelial cells of the respiratory tract represent a first line of defense against pathogens, they can become a target for infection by several different respiratory viruses, as a way for them to penetrate the human host. Several infections of epithelial cells, including those that involve coronaviruses, are self-limited and the infection remains local as the virus will be cleared by the immune system in the respiratory tract, with minimal clinical consequences. However, in some circumstances, opportunistic viral pathogens like the human coronaviruses can avoid the immune response and cause more severe respiratory diseases (
      <xref ref-type="bibr" rid="bib0880">
       Vareille et al., 2011
      </xref>
      ) or even spread to other tissues, including the central nervous system (CNS), where they could induce other types of pathologies (
      <xref ref-type="bibr" rid="bib0605">
       McGavern and Kang, 2011
      </xref>
      ). Human coronaviruses are molecularly related in structure and mode of replication with neuroinvasive animal coronaviruses (
      <xref ref-type="bibr" rid="bib0095">
       Brian and Baric, 2005
      </xref>
      ) such as PHEV (porcine hemagglutinating encephalitis virus) (
      <xref ref-type="bibr" rid="bib0360">
       Greig et al., 1962
      </xref>
      ), FCoV (feline coronavirus) (
      <xref ref-type="bibr" rid="bib0295">
       Foley et al., 2003
      </xref>
      ), and MHV (mouse hepatitis virus) (
      <xref ref-type="bibr" rid="bib0535">
       Lampert et al., 1973
      </xref>
      ), which have all been shown to invade the CNS and induce different types of neuropathologies. The MHV, represents the best described case of coronaviruses involved in neurological diseases and several excellent reviews have highlighted the importance of both viral and host factors in the process (
      <xref ref-type="bibr" rid="bib0050">
       Bender and Weiss, 2010
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0190">
       Cowley and Weiss, 2010
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0405">
       Hosking and Lane, 2010
      </xref>
      ). MHV can also persist in the mouse CNS and induce a chronic demyelinating disease, which is partially immune-mediated, similar to what is observed in multiple sclerosis (MS) in humans (
      <xref ref-type="bibr" rid="bib0405">
       Hosking and Lane, 2010
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0895">
       Weiss and Leibowitz, 2011
      </xref>
      ). Therefore, the close structural and biological relatedness of human coronaviruses to the neurotropic animal coronaviruses has led to speculation about possible involvement of human coronaviruses in neurological diseases. Because they are themselves also naturally neuroinvasive in humans and mice, a possible association between the presence of ubiquitous human coronaviruses in the establishment or the exarcerbation of neurological human pathologies has over the years been suggested.
     </p>
     <p id="par0035">
      Up until now, no clear specific association has ever been made with any known human neuropathology. However, even though the mechanism by which they reach the human CNS is still to be decrypted, at least three of the six coronaviruses that infect humans were shown to be neuroinvasive and neurotropic in humans: HCoV-229E and HCoV-OC43 (
      <xref ref-type="bibr" rid="bib0010">
       Arbour et al., 1999a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0020">
       Arbour et al., 1999b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0015">
       Arbour et al., 2000
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0075">
       Bonavia et al., 1997
      </xref>
      ), as well as SARS-CoV (
      <xref ref-type="bibr" rid="bib0365">
       Gu et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0940">
       Xu et al., 2005
      </xref>
      ).
     </p>
     <p id="par0040">
      Even though this association between coronavirus infection of the CNS and human diseases remains circumstantial and even to a certain degree controversial, the current review aims at presenting interesting and important data that clearly illustrates the natural neuroinvasive potential of these human pathogens and underlines that further research is warranted in order to better characterize the real impact of coronavirus infection of the human CNS on human health.
     </p>
    </sec>
    <sec id="sec0010">
     <label>
      2
     </label>
     <title>
      Coronaviruses: an overview
     </title>
     <p id="par0045">
      Coronaviruses display a characteristic crown-shaped appearance, are widespread in nature and can infect several different species (
      <xref ref-type="bibr" rid="bib0860">
       Vabret et al., 2009
      </xref>
      ), in which they cause mainly respiratory and enteric pathologies, with neurotropic and neuroinvasive properties in various hosts including humans, cats, pigs, rodents and fowl (
      <xref ref-type="bibr" rid="bib0115">
       Buchmeier and Lane, 1999
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0150">
       Cavanagh, 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0820">
       Talbot et al., 2011
      </xref>
      ). They form a group of enveloped viruses that have the largest genome among RNA viruses. This non-segmented 30 kb positive-single-stranded polyadenylated RNA possesses 4 or 5 genes encoding structural proteins (S, E, M, N; HE for several members of the Betacoronavirus genus) and several genes encoding non-structural proteins, mostly comprised in ORF1a and 1b, which encode two polyproteins (pp1a and pp1ab) that are cleaved by two viral proteases to yield 15 to 16 non-structural proteins (nsp), including the RNA-dependent RNA polymerase (RdRp), helicase and exonuclease, which all play a role in viral replication (
      <xref ref-type="bibr" rid="bib0350">
       Gorbalenya et al., 2006
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0530">
       Lai and Cavanagh, 1997
      </xref>
      ).
     </p>
     <sec id="sec0015">
      <label>
       2.1
      </label>
      <title>
       Viral molecular determinants of pathogenesis
      </title>
      <p id="par0050">
       The spike protein (S) is a large type 1 transmembrane glycosylated protein responsible for recognition of the cellular receptor used by the virus to infect a susceptible cell (
       <xref ref-type="bibr" rid="bib0145">
        Cavanagh, 1995
       </xref>
       ). During infection of susceptible hosts, the S protein represents an important factor of virulence as it appears to be associated with most of the cytotoxic effects that lead to degeneration of infected cells following infection by different coronaviruses (
       <xref ref-type="bibr" rid="bib0100">
        Brison et al., 2011
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0105">
        Brison et al., 2014
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0280">
        Favreau et al., 2009
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0285">
        Favreau et al., 2012
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0420">
        Iacono et al., 2006
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0440">
        Jacomy et al., 2010
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0710">
        Phillips et al., 1999
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0715">
        Phillips et al., 2002
       </xref>
       ).
      </p>
      <p id="par0055">
       The envelope (E) protein is a small structural protein anchored in the viral envelope and which has a role in the morphogenesis, trafficking within the infected cells and budding of the virion, and which appears responsible for the curvature of the viral envelope (
       <xref ref-type="bibr" rid="bib0565">
        Liu et al., 2007
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0755">
        Ruch and Machamer, 2012
       </xref>
       ). Similarly to the S protein, but in a different manner, it also represents a virulence factor: during infection of host cells, it appears to be associated with the induction of the cell stress response and apoptosis (
       <xref ref-type="bibr" rid="bib0225">
        DeDiego et al., 2011
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0690">
        Nieto-Torres et al., 2014
       </xref>
       ), and it may be associated with disruption of the lung epithelium after a SARS-CoV infection (
       <xref ref-type="bibr" rid="bib0835">
        Teoh et al., 2010
       </xref>
       ) and participate to the SARS-CoV-associated immunopathology in the respiratory tract (
       <xref ref-type="bibr" rid="bib0460">
        Jimenez-Guardeno et al., 2014
       </xref>
       ).
      </p>
      <p id="par0060">
       The membrane (M) protein interacts with all the other structural proteins of the virus and therefore helps to shape and maintain the structure of the virion (
       <xref ref-type="bibr" rid="bib0400">
        Hogue and Machamer, 2008
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0675">
        Neuman et al., 2011
       </xref>
       ). During infection of cells, this protein can participate in the virus-induced inhibition of the type 1 interferon response by the infected cells (
       <xref ref-type="bibr" rid="bib0780">
        Siu et al., 2009
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0945">
        Yang et al., 2013
       </xref>
       ) and therefore influence the outcome of infection and cell fate after infection.
      </p>
      <p id="par0065">
       The nucleocapsid (N) protein associates with the viral genome and plays an essential role in encapsidating it in a helical nucleocapsid within the viral particle (
       <xref ref-type="bibr" rid="bib0400">
        Hogue and Machamer, 2008
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0580">
        Macneughton and Davies, 1978
       </xref>
       ). It also is an RNA chaperone that facilitates template switching during replication of the genome and transcription of the sgRNA (
       <xref ref-type="bibr" rid="bib0995">
        Zuniga et al., 2010
       </xref>
       ,
       <xref ref-type="bibr" rid="bib1000">
        Zuniga et al., 2007
       </xref>
       ). The N protein of SARS-CoV was shown to partially localize to the nucleolus (
       <xref ref-type="bibr" rid="bib0960">
        You et al., 2005
       </xref>
       ), and to deregulate the host cell cycle (
       <xref ref-type="bibr" rid="bib0555">
        Li et al., 2005a
       </xref>
       ). Moreover, like the M protein, the N protein of different coronaviruses can participate in the inhibition of type 1 interferon response by the infected cell and in the induction of apoptosis (
       <xref ref-type="bibr" rid="bib0250">
        Ding et al., 2014
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0510">
        Kopecky-Bromberg et al., 2007
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0810">
        Surjit and Lal, 2008
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0950">
        Ye et al., 2007
       </xref>
       ).
      </p>
      <p id="par0070">
       The hemagglutinin-esterase (HE) is only present in species of the betacoronavirus genus. Like the S protein, it is a type 1 transmembrane protein which forms homodimers (
       <xref ref-type="bibr" rid="bib0400">
        Hogue and Machamer, 2008
       </xref>
       ) and which may interact with different types of acetylated sialic acid (
       <xref ref-type="bibr" rid="bib0210">
        de Groot, 2006
       </xref>
       ). It may be important early during infection or during the release of viral particles from the infected cells at the end of the replication cycle of the betacoronaviruses (
       <xref ref-type="bibr" rid="bib0750">
        Rottier, 1990
       </xref>
       ). Moreover, its acetyl-esterase activity strongly enhances the production of infectious virions, which can disseminate in murine mixed primary CNS cultures (
       <xref ref-type="bibr" rid="bib0230">
        Desforges et al., 2013a
       </xref>
       ). Coronaviruses also possess non-structural (ns) or accessory proteins that appear to mainly play a role in pathogenesis and in the virus-host interactions (
       <xref ref-type="bibr" rid="bib0655">
        Narayanan et al., 2008
       </xref>
       ) as well as in virulence and tropism associated with the capacity to replicate in different cell types and organs (
       <xref ref-type="bibr" rid="bib0200">
        Cruz et al., 2011
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0220">
        Dedeurwaerder et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0505">
        Koetzner et al., 2010
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0975">
        Zhao et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0980">
        Zhao et al., 2012
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0985">
        Zhao et al., 2011
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec0020">
      <label>
       2.2
      </label>
      <title>
       Human coronaviruses: recognized respiratory pathogens
      </title>
      <p id="par0075">
       Human coronaviruses (HCoV) were first isolated in the mid-60s from patients with upper respiratory tract disease (
       <xref ref-type="bibr" rid="bib0650">
        Myint, 1995
       </xref>
       ). In 1965, Tyrrell and Bynoe isolated the first HCoV (B814 strain) that was able to cause a common cold in human volunteers after intranasal inoculation (
       <xref ref-type="bibr" rid="bib0855">
        Tyrrell and Bynoe, 1965
       </xref>
       ). Shortly thereafter,
       <xref ref-type="bibr" rid="bib0385">
        Hamre and Procknow (1966)
       </xref>
       isolated the prototype HCoV-229E strain, and McIntosh and collaborators (1967) were able to identify various viruses, which comprise the now recognized prototype HCoV-OC43 strain (
       <xref ref-type="bibr" rid="bib0385">
        Hamre and Procknow, 1966
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0610">
        McIntosh et al., 1967
       </xref>
       ).
      </p>
      <p id="par0080">
       Up until the Severe Acute Respiratory Syndrome (SARS) appeared in China during the fall of 2002 and was associated with SARS-CoV (
       <xref ref-type="bibr" rid="bib0260">
        Drosten et al., 2003
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0300">
        Fouchier et al., 2003
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0515">
        Ksiazek et al., 2003
       </xref>
       ), serological studies only distinguished between two groups of HCoV, namely HCoV-229E (previous group 1, now classified in the Alphacoronavirus genus) and HCoV-OC43 (previous group 2, now classified in the Betacoronavirus genus). Since the SARS outbreak of 2002, research on coronaviruses have entered a new era, which led to the identification of several new coronaviruses, including three that infect humans. Namely, they are HCoV-NL63 (
       <xref ref-type="bibr" rid="bib0875">
        van der Hoek et al., 2004
       </xref>
       ) in the genus Alphacoronavirus, HCoV-HKU1, which is part of the Betacoronavirus genus (
       <xref ref-type="bibr" rid="bib0925">
        Woo et al., 2005
       </xref>
       ) and more recently, MERS-CoV, a newly identified Betacoronavirus (
       <xref ref-type="bibr" rid="bib0965">
        Zaki et al., 2012
       </xref>
       ).
      </p>
      <p id="par0085">
       The HCoV-229E, -OC43, -NL63 and -HKU1 strains all present a worldwide distribution and genetic variability, as they exist in different genotypes (
       <xref ref-type="bibr" rid="bib0255">
        Dominguez et al., 2012
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0325">
        Gerna et al., 2006
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0550">
        Lau et al., 2011
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0865">
        Vabret et al., 2006
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0885">
        Vijgen et al., 2005
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0930">
        Woo et al., 2006
       </xref>
       ). These four strains are endemic in humans and infections mainly occurs in winter and early spring (
       <xref ref-type="bibr" rid="bib0125">
        Cabeca et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0320">
        Gaunt et al., 2010
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0540">
        Larson et al., 1980
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0650">
        Myint, 1995
       </xref>
       ), in different parts of the world (
       <xref ref-type="bibr" rid="bib0175">
        Chiu et al., 2005
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0570">
        Mackay et al., 2012
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0840">
        Theamboonlers et al., 2007
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0860">
        Vabret et al., 2009
       </xref>
       ). Most of the times, they infect the upper respiratory tract, where they are mainly associated with rhinitis, laryngitis or otitis but, as opportunistic pathogens, in more vulnerable populations such as newborns, infants, the elderly and immune-compromised individuals, they can also reach the lower respiratory tract, where they could instead be associated with bronchitis, bronchiolitis, pneumonia, exacerbations of asthma, respiratory distress syndrome (
       <xref ref-type="bibr" rid="bib0825">
        Talbot et al., 2008
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0860">
        Vabret et al., 2009
       </xref>
       ).
      </p>
      <p id="par0090">
       The 2002–2003 SARS pandemic was caused by a coronavirus variant that appears to have emerged from a bat reservoir (
       <xref ref-type="bibr" rid="bib0560">
        Li et al., 2005b
       </xref>
       ) to infect palm civets, sold live in open markets, the intermediary reservoir, and then to humans (
       <xref ref-type="bibr" rid="bib0370">
        Guan et al., 2003
       </xref>
       ). During this pandemic, a total of 8096 probable cases were reported and almost 10% (774 cases in more than 30 countries) of these resulted in death (
       <xref ref-type="bibr" rid="bib0090">
        Braden et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0165">
        Cherry, 2004
       </xref>
       ). After an incubation period, the typical clinical portrait was described by a flu-like syndrome, followed by a respiratory syndrome first associated mainly with cough and dyspnea before the “real” severe acute respiratory syndrome (SARS) took over in about 20% of the patients (
       <xref ref-type="bibr" rid="bib0860">
        Vabret et al., 2009
       </xref>
       ). Furthermore, a typical pathological portrait of the respiratory tract showed edema, hemorrhage and congestion of the lungs, as well as pleural effusion in the thoracic cavity associated with infiltration of immune cells (
       <xref ref-type="bibr" rid="bib0870">
        van den Brand et al., 2014
       </xref>
       ). Multiple organ failure was also observed in several SARS-CoV-infected patients (
       <xref ref-type="bibr" rid="bib0365">
        Gu et al., 2005
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0860">
        Vabret et al., 2009
       </xref>
       ).
      </p>
      <p id="par0095">
       Recently, in the fall of 2012, ten years after the SARS episode, a SARS-like disease affected individuals that traveled from the Arabian Peninsula to the United Kingdom. Using molecular sequencing, it was rapidly shown that this new respiratory coronavirus was genetically different than SARS-CoV and it is now recognized that the new epidemic is caused by a new coronavirus from the genus Betacoronavirus (
       <xref ref-type="bibr" rid="bib0965">
        Zaki et al., 2012
       </xref>
       ), that was first named HCoV-EMC (for Human Coronavirus – Erasmus Medical Center), human betacoronavirus 2c and NcoV or nCoV (for novel Coronavirus), and that is now known under the official name MERS-CoV: Middle-East Respiratory Syndrome Coronavirus (
       <xref ref-type="bibr" rid="bib0180">
        Coleman and Frieman, 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0215">
        de Groot et al., 2013
       </xref>
       ), which is the etiologic agent of a severe lower respiratory tract infection that resembles SARS and which can be associated with gastrointestinal symptoms and possible renal failure (
       <xref ref-type="bibr" rid="bib0720">
        Raj et al., 2014
       </xref>
       ). Like other coronaviruses that infect humans, MERS-CoV most likely originated from bats before infecting an intermediary reservoir (probably the dromedary camel in that case), and thus represents a zoonotic transmission to humans. However, human to human transmission has now been demonstrated in several cases (
       <xref ref-type="bibr" rid="bib0035">
        Assiri et al., 2013b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0380">
        Haagmans et al., 2014
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0720">
        Raj et al., 2014
       </xref>
       ). As of September 18th, 2014, the Public Health Agency of Canada revealed that the World Health Organization (WHO) has reported that the MERS-CoV has spread to at least twenty-one different countries, where 841 laboratory-confirmed cases of individuals (including 402 between April 11 and June 9, 2014 in Saudi Arabia alone) have been identified as infected by the MERS-CoV, with 298 being fatal (
       <xref ref-type="bibr" rid="bib0135">
        Public Health Agency of Canada, 2014
       </xref>
       ). As do the four circulating strains of HCoV (
       <xref ref-type="bibr" rid="bib0125">
        Cabeca et al., 2013
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0860">
        Vabret et al., 2009
       </xref>
       ), both SARS-CoV and MERS-CoV usually induce more (
       <xref ref-type="bibr" rid="bib0030">
        Assiri et al., 2013a
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0415">
        Hui et al., 2014
       </xref>
       ) severe illnesses in vulnerable populations such as the elderly, infants, immune-compromised individuals or patients with comorbidities (
       <xref ref-type="bibr" rid="bib0705">
        Peiris et al., 2004
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0860">
        Vabret et al., 2009
       </xref>
       ).
      </p>
      <p id="par0100">
       Over the years, the four circulating HCoV have been associated with pathologies outside the respiratory tract, such as myocardites and meningitis (
       <xref ref-type="bibr" rid="bib0740">
        Riski and Hovi, 1980
       </xref>
       ) and severe diarrhea (
       <xref ref-type="bibr" rid="bib0330">
        Gerna et al., 1985
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0725">
        Resta et al., 1985
       </xref>
       ), as seen with animal coronaviruses. Recent investigations on the HCoV as enteric pathogens demonstrated that all the HCoV can be found in stool samples of children with acute gastroenteritis but could not conclude on their “true association” with disease etiology (
       <xref ref-type="bibr" rid="bib0270">
        Esper et al., 2010
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0745">
        Risku et al., 2010
       </xref>
       ). As previously mentioned, different reports have also presented a possible link between the presence of HCoV within the human central nervous system (CNS) and some neurological disorders (
       <xref ref-type="bibr" rid="bib0015">
        Arbour et al., 2000
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0195">
        Cristallo et al., 1997
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0290">
        Fazzini et al., 1992
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0805">
        Stewart et al., 1992
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0955">
        Yeh et al., 2004
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec id="sec0025">
     <label>
      3
     </label>
     <title>
      Neuroinvasive and neurotropic viruses
     </title>
     <p id="par0105">
      Several viruses have the ability to invade the CNS, where they can infect the resident cells, including the neurons. In fact, as stated by Big and colleagues (
      <xref ref-type="bibr" rid="bib0070">
       Big et al., 2009
      </xref>
      ), even though the incidence of viral infections of the CNS is not well defined, they are not uncommon occurences in clinical practice and an increasing number of positive viral identifications are now made with the help of modern molecular diagnostics. Using different routes of entry, several different viruses have been shown to be able to penetrate the CNS (neuroinvasion), where they can infect neurons and glial cells (neurotropism) and possibly induce or participate in the induction of neurological diseases (neurovirulence) (
      <xref ref-type="bibr" rid="bib0345">
       Giraudon and Bernard, 2010
      </xref>
      ). In humans, a long list of viruses, for which the primary site of infection in human is not the CNS, possess these “neuroproperties” and neuroviral infection often leads to acute encephalitis, which can be fatal depending on virus tropism (
      <xref ref-type="bibr" rid="bib0910">
       Whitley and Gnann, 2002
      </xref>
      ). For example, rabies virus (
      <xref ref-type="bibr" rid="bib0390">
       Hankins and Rosekrans, 2004
      </xref>
      ), herpes simplex virus (HSV) (
      <xref ref-type="bibr" rid="bib0040">
       Aurelian, 2005
      </xref>
      ), arthropod-borne flaviviruses such as West Nile virus (WNV) or Japanese encephalitis virus (JEV) (
      <xref ref-type="bibr" rid="bib0575">
       Mackenzie et al., 2004
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0665">
       Neal, 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0775">
       Sips et al., 2012
      </xref>
      ) and enteroviruses such as poliovirus (PV) and coxsakievirus (CV) (
      <xref ref-type="bibr" rid="bib0640">
       Mueller et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0735">
       Rhoades et al., 2011
      </xref>
      ), affect millions of individuals worldwide each year and can induce encephalitis, meningitis and paralysis in humans. Chronic human neurological diseases and/or sequelae may also be linked to viral infection. In acquired immunodeficiency syndrome (AIDS) dementia and related disorders, human immunodeficiency virus (HIV) induces neurodegeneration (
      <xref ref-type="bibr" rid="bib0595">
       Mattson et al., 2005
      </xref>
      ), which can result in motor dysfunctions and possibly cognitive impairments (
      <xref ref-type="bibr" rid="bib0660">
       Nath and Berger, 2004
      </xref>
      ). Progressive multifocal leukoencephalopathy (PML) is a human demyelinating disease (
      <xref ref-type="bibr" rid="bib0355">
       Gordon et al., 2000
      </xref>
      ) where prolonged immunosuppression leads to reactivation of latent polyoma JC virus (JCV) (
      <xref ref-type="bibr" rid="bib0900">
       Weissert, 2011
      </xref>
      ). Human T-lymphotropic virus (HTLV-1) causes progressive tropical spastic paraperesis/HTLV-1-associated myelopathy (PTSP/HAM) in 1–2% of infected individuals (
      <xref ref-type="bibr" rid="bib0480">
       Kaplan et al., 1990
      </xref>
      ) and HSV-1 and human herpes virus 6 (HHV-6) were proposed to cause or exacerbate Alzheimer's disease (AD) (
      <xref ref-type="bibr" rid="bib0430">
       Itzhaki et al., 2004
      </xref>
      ).
     </p>
     <p id="par0110">
      Respiratory viral agents also have the capacity to invade the human CNS where they will infect resident cells and potentially be neurovirulent in inducing a neuropathology. Several of these recognized respiratory pathogens can gain access to the CNS, where they can eventually cause health problems in humans.
     </p>
     <sec id="sec0030">
      <label>
       3.1
      </label>
      <title>
       Respiratory viruses with neuroinvasive and neurotropic properties: associated neuropathologies
      </title>
      <p id="par0115">
       Respiratory syncytial virus (RSV), the most common pathogen to cause lower respiratory tract infection in infants worldwide (
       <xref ref-type="bibr" rid="bib0800">
        Stensballe et al., 2003
       </xref>
       ), is one such neuroinvasive respiratory agent that has been detected in the cerebrospinal fluid (CSF) of patients (
       <xref ref-type="bibr" rid="bib0485">
        Kawashima et al., 2009
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0990">
        Zlateva and Van Ranst, 2004
       </xref>
       ) and that was associated with convulsions (
       <xref ref-type="bibr" rid="bib0635">
        Morichi et al., 2011
       </xref>
       ), febrile seizures, and encephalitis (
       <xref ref-type="bibr" rid="bib0625">
        Millichap and Wainwright, 2009
       </xref>
       ). Furthermore, it was recently shown that RSV can spread from the airways to the CNS in mice after intranasal inoculation, and that it induces behavioral and cognitive impairments (
       <xref ref-type="bibr" rid="bib0275">
        Espinoza et al., 2013
       </xref>
       ).
      </p>
      <p id="par0120">
       Measles virus (MV), is another common virus that causes a disease of the respiratory airways associated with fever, cough and congestion. However, MV infection also induces other symptoms including a characteristic rash and Koplik's spots (
       <xref ref-type="bibr" rid="bib0695">
        O’Donnell and Rall, 2010
       </xref>
       ) in the oral mucosa. A second type of rare but significant sequelae is long-term CNS disease (
       <xref ref-type="bibr" rid="bib0695">
        O’Donnell and Rall, 2010
       </xref>
       ). Post-infectious encephalomyelitis (PIE) or acute disseminated encephalomyelitis (ADEM) occurs in 1 of 1000 measles cases in children and adolescents. Measles inclusion body encephalitis (MIBE) is a second CNS complication that can arise after a MV infection in immune-compromised patients. Finally, subacute sclerosing panencephalitis (SSPE) is a third form of CNS disease associated with MV infection. It is a slow progressive neurological disease that appears 6–10 years after infection in about 4 to 11 cases per 100,000 cases of measles (for review see (
       <xref ref-type="bibr" rid="bib0915">
        Wilson et al., 2013
       </xref>
       )).
      </p>
      <p id="par0125">
       Hendra virus (HeV) and Nipah virus (NiV) represent important emerging viruses discovered in the 1990s (
       <xref ref-type="bibr" rid="bib0265">
        Escaffre et al., 2013
       </xref>
       ) and cause acute and severe respiratory disease in humans, including necrotizing alveolitis with hemorrhage, pulmonary edema and pneumonia (
       <xref ref-type="bibr" rid="bib0265">
        Escaffre et al., 2013
       </xref>
       ). Neurological signs of pathology include confusion, motor deficits, seizures, febrile encephalitic syndrome, and reduced level of consciousness. Moreover, neuropsychiatric sequelae have been reported but it is not known whether post-infectious encephalo-myelitis occurs following infection (
       <xref ref-type="bibr" rid="bib0920">
        Wong, 2010
       </xref>
       ). The use of animal models showed that the main route of entry into the CNS is the olfactory nerve (
       <xref ref-type="bibr" rid="bib0645">
        Munster et al., 2012
       </xref>
       ).
      </p>
      <p id="par0130">
       Influenza virus comes in three types: A, B, and C. Types A and B are most prevalent and cause the flu syndrome, characterized by chills, fever, headache, sore throat and muscle pains (
       <xref ref-type="bibr" rid="bib0970">
        Zeng et al., 2013
       </xref>
       ), and are responsible for seasonal epidemics that affect 3–5 million humans, of which 250,000–500,000 cases are lethal each year (
       <xref ref-type="bibr" rid="bib0520">
        Kuiken et al., 2012
       </xref>
       ). Most infections of influenza virus A are localized to the upper respiratory tract but some more severe cases may result in pneumonia (
       <xref ref-type="bibr" rid="bib0685">
        Nicholson et al., 2003
       </xref>
       ) and even complications involving the CNS (
       <xref ref-type="bibr" rid="bib0450">
        Jang et al., 2009
       </xref>
       ). Several studies have shown that influenza A can be associated with encephalitis, Reye's syndrome, febrile seizure, acute necrotizing encephalopathy, and possibly acute disseminated encephalomyelitis (ADEM) in humans (
       <xref ref-type="bibr" rid="bib0620">
        Millichap and Millichap, 2006
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0700">
        Ozkale et al., 2012
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0845">
        Toovey, 2008
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0890">
        Wang et al., 2010
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0970">
        Zeng et al., 2013
       </xref>
       ). Making use of murine models, it has also been shown that influenza A virus could reach the CNS through the olfactory nerve route and alter hippocampal morphology or expression of synaptic regulatory genes while impairing cognition and emotional behavior (
       <xref ref-type="bibr" rid="bib0060">
        Beraki et al., 2005
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0465">
        Jurgens et al., 2012
       </xref>
       ). Influenza A virus was also described as a factor which may increase the risk of Parkinson's disease (PD) (
       <xref ref-type="bibr" rid="bib0450">
        Jang et al., 2009
       </xref>
       ).
      </p>
      <p id="par0135">
       As previously mentioned, among these different respiratory viruses that can reach the CNS where they could be associated with neurological symptoms in humans and animals, are the coronaviruses.
      </p>
     </sec>
     <sec id="sec0035">
      <label>
       3.2
      </label>
      <title>
       Human coronaviruses in the CNS
      </title>
      <p id="par0140">
       Coronaviruses that infect humans are not well characterized concerning their capacity to invade and infect the CNS. However, the detection of coronaviral RNA in human brain samples clearly demonstrates that these respiratory pathogens are naturally neuroinvasive in humans and suggests that they establish a persistent infection in human CNS (
       <xref ref-type="bibr" rid="bib0015">
        Arbour et al., 2000
       </xref>
       ). Furthermore, we have shown that these viruses are able to establish a persistent infection in human cells representative of the CNS (
       <xref ref-type="bibr" rid="bib0010">
        Arbour et al., 1999a
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0020">
        Arbour et al., 1999b
       </xref>
       ) and that HCoV-OC43 RNA could be detected for at least a year in the CNS of infected mice that survived the acute encephalitis. A significant portion of these surviving mice exhibited abnormal reflexes shown by limb clasping, presented clinical signs of decreased activity in an open field test, and had a smaller hippocampus associated with a loss of hippocampal neurons, particularly in the CA1 and CA3 layers (
       <xref ref-type="bibr" rid="bib0435">
        Jacomy et al., 2006
       </xref>
       ), similar to what is seen after neuroinvasion of the CNS by the influenza A virus (
       <xref ref-type="bibr" rid="bib0465">
        Jurgens et al., 2012
       </xref>
       ). Therefore, an apparently innocuous human respiratory pathogen may persist in the human CNS and it would therefore be possible that such a persistent infection may become a factor or co-factor of neuropathogenesis associated with long-term neurological sequelae in genetically or otherwise predisposed individuals.
      </p>
      <sec id="sec0040">
       <label>
        3.2.1
       </label>
       <title>
        Possible mechanisms of coronaviruses neuroinvasiveness
       </title>
       <p id="par0145">
        Viruses may enter the CNS through two distinct routes: hematogenous dissemination or neuronal retrograde dissemination. Hematogenous spread involves the presence of a given virus in the bloodstream and retrograde viral spread toward the CNS happens when a given virus infects neurons in the periphery and uses the transport machinery within those cells in order to gain access to the CNS (
        <xref ref-type="bibr" rid="bib0065">
         Berth et al., 2009
        </xref>
        ).
       </p>
       <p id="par0150">
        In order to be neuroinvasive, human coronaviruses may use both CNS entry routes from the periphery. The hematogenous route involves the presence of a given virus in the blood where it can either remain free for a period of time before it infects endothelial cells of the blood–brain barrier (BBB), or infect leukocytes that will become a viral reservoir for dissemination toward the CNS. Both situations do occur during human immunodeficiency virus (HIV) infection of the CNS, as infected leukocytes migrate through the blood–brain barrier (BBB) (
        <xref ref-type="bibr" rid="bib0495">
         Kim et al., 2003
        </xref>
        ), with direct infection of endothelial cells of the BBB having also been reported (
        <xref ref-type="bibr" rid="bib0025">
         Argyris et al., 2007
        </xref>
        ). Human cytomegalovirus (HCMV) (
        <xref ref-type="bibr" rid="bib0055">
         Bentz et al., 2006
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0160">
         Chan et al., 2012
        </xref>
        ), enteroviruses including poliovirus (
        <xref ref-type="bibr" rid="bib0735">
         Rhoades et al., 2011
        </xref>
        ) and flaviviruses (
        <xref ref-type="bibr" rid="bib0665">
         Neal, 2014
        </xref>
        ) have also been shown to infect different types of leukocytes and to use them as a reservoir for hematogenous dissemination toward the CNS.
       </p>
       <p id="par0155">
        In the human airways, it is still unclear what type of damage may be induced by HCoV in epithelial cells of the respiratory tract after infection. One report indicated that experimental intranasal inoculation of HCoV-229E to human volunteers led to disruption of the nasal epithelium, leading to damage of the ciliated cells and to a significant decrease in the number of cells and to a lowered frequency of cilium beating (
        <xref ref-type="bibr" rid="bib0170">
         Chilvers et al., 2001
        </xref>
        ). On the other hand, using primary cultures of cells from the human respiratory tract, Dijkman and collaborators were able to further characterize the interaction between HCoV and epithelial cells and detected no cytopathic effect. Even though they showed that after infection all four circulating HCoV strains were budding and released preferentially on the apical side of the cells, a low but significant amount of virus was also found to be released from the basolateral side (
        <xref ref-type="bibr" rid="bib0245">
         Dijkman et al., 2013
        </xref>
        ). This suggests that, even though HCoV infection are, most of the time, self-restricted to the airway lumen since they do not induce important disruption of the epithelium, they may, under certain circumstances, pass through the epithelium barrier and gain access to the bloodstream or lymph, where they can infect leukocytes and consequently disseminate toward other tissues, including the CNS (
        <xref ref-type="fig" rid="fig0005">
         Fig. 1
        </xref>
        A; adapted from
        <xref ref-type="bibr" rid="bib0240">
         Desforges et al., 2007
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0825">
         Talbot et al., 2008
        </xref>
        ) as it has been suggested for other important human respiratory viruses; namely measles virus (
        <xref ref-type="bibr" rid="bib0915">
         Wilson et al., 2013
        </xref>
        ), Nipah virus (
        <xref ref-type="bibr" rid="bib0585">
         Mathieu et al., 2011
        </xref>
        ) and influenza B virus (
        <xref ref-type="bibr" rid="bib0935">
         Xu et al., 1998
        </xref>
        ).
        <fig id="fig0005">
         <label>
          Fig. 1
         </label>
         <caption>
          <p>
           Potential route of infection used by HCoV for neuroinvasion into the human central nervous system (CNS) and possible mechanisms of neurovirulence. (A) Following infection of human airways, human coronaviruses may, in some conditions, pass through the epithelium, gain access to the bloodstream and infect monocytes, which are activated by the infection. Among other factors, MMP9, which increases BBB permeability and TNF-alpha, which leads to up-regulation of ICAM-1 expression on endothelial cells, facilitates the passage of infected and activated monocytes into the CNS. Once in the CNS, these cells produce proinflammatory cytokines (such as TNF-alpha) that can damage the oligodendrocytes and/or the neurons. Infiltrated infected monocyte-derived macrophages (or microglia) may produce chemokines (CCL-5, CXCL10, CXCL11), which will induce chemoattraction of activated T cells and/or other monocytes. After sensing the infection, astrocytes may also produce other chemokines (CCL2, CCL5 and CXCL12) that will also participate in the recruitment of more infected leukocytes. Human coronaviruses may therefore initiate an aberrant neuroinflammatory loop which will mediate an immune-mediated neuropathology (adapted from
           <xref ref-type="bibr" rid="bib0825">
            Talbot et al., 2008
           </xref>
           ). (B) Following intranasal infection in human, coronaviruses may infect the olfactory receptor neurons (ORN) and pass through the neuroepithelium of the olfactory mucosa to reach the mitral cells and the olfactory nerve (ON) and gain access to the olfactory bulb (OB) and eventually to the hippocampus and other regions of the brain.
          </p>
         </caption>
         <graphic xlink:href="gr1">
         </graphic>
        </fig>
       </p>
       <p id="par0160">
        Infection of human monocytes/macrophages by HCoV-229E and HCoV-OC43 was reported (
        <xref ref-type="bibr" rid="bib0185">
         Collins, 2002
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0240">
         Desforges et al., 2007
        </xref>
        ) and infection by HCoV-229E of human (
        <xref ref-type="bibr" rid="bib0615">
         Mesel-Lemoine et al., 2012
        </xref>
        ) and murine dendritic cells expressing the human aminopeptidase N (
        <xref ref-type="bibr" rid="bib0905">
         Wentworth et al., 2005
        </xref>
        ) suggests that HCoV may on one hand manipulate the immune system and on the other hand use dendritic cells to disseminate to other tissues, including the CNS, where they could be associated with other type of pathologies.
       </p>
       <p id="par0165">
        Human primary monocytes are activated following HCoV-229E infection (
        <xref ref-type="bibr" rid="bib0240">
         Desforges et al., 2007
        </xref>
        ). Since they eventually become macrophages as they invade tissues, this activation suggests that HCoV-229E-infected monocytes would serve to facilitate their passage toward other tissues including the CNS, especially in immune-compromised individuals, as this was observed for murine cytomegalovirus (MCMV) (
        <xref ref-type="bibr" rid="bib0730">
         Reuter et al., 2004
        </xref>
        ). The fact that HCoV-229E could only infect partially immune-compromised transgenic mice (
        <xref ref-type="bibr" rid="bib0545">
         Lassnig et al., 2005
        </xref>
        ) suggests that, being an opportunistic pathogen, HCoV-229E could take advantage of an immune-suppressed environment and disseminate to the CNS within susceptible individuals. The establishment of a persistent infection in a human leukocytic cell line (
        <xref ref-type="bibr" rid="bib0240">
         Desforges et al., 2007
        </xref>
        ) is also consistent with the possibility that monocytes/macrophages serve as a reservoir and vector for this neuroinvasive HCoV (
        <xref ref-type="bibr" rid="bib0015">
         Arbour et al., 2000
        </xref>
        ). The SARS-CoV was also shown to infect monocytes-macrophages (
        <xref ref-type="bibr" rid="bib0365">
         Gu et al., 2005
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0680">
         Nicholls et al., 2006
        </xref>
        ) and dendritic cells, where it modulates innate immunity (
        <xref ref-type="bibr" rid="bib0790">
         Spiegel et al., 2006
        </xref>
        ). These cells could also serve as a reservoir for virus to reach and maintain itself in the CNS. Our results indicate that HCoV are able to infect human endothelial cells of the BBB in culture (unpublished data). It has also been speculated that SARS-CoV could do the same after viremia (
        <xref ref-type="bibr" rid="bib0375">
         Guo et al., 2008
        </xref>
        ). Therefore, neuroinvasive coronaviruses that infect humans could use the hematogenous route to penetrate into the CNS.
       </p>
       <p id="par0170">
        The second form of any viral spread toward the CNS is through neuronal dissemination, where a given virus infects neurons in periphery and uses the machinery of active transport within those cells in order to gain access to the CNS (
        <xref ref-type="bibr" rid="bib0065">
         Berth et al., 2009
        </xref>
        ). After an intranasal infection, both HCoV-OC43 (
        <xref ref-type="bibr" rid="bib0445">
         Jacomy and Talbot, 2003
        </xref>
        ) and SARS-CoV (
        <xref ref-type="bibr" rid="bib0600">
         McCray et al., 2007
        </xref>
        ) were shown to infect the respiratory tract in mice and to be neuroinvasive as HCoV-OC43 (
        <xref ref-type="bibr" rid="bib0120">
         Butler et al., 2006
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0795">
         St-Jean et al., 2004
        </xref>
        ) and SARS-CoV (
        <xref ref-type="bibr" rid="bib0670">
         Netland et al., 2008
        </xref>
        ) were detected in the CNS of susceptible mice. Interestingly, the neurotropic MHV strains of the murine coronavirus (MuCoV) also reach the CNS through the olfactory nerve (
        <xref ref-type="bibr" rid="bib0045">
         Barnett and Perlman, 1993
        </xref>
        ). Furthermore, as shown here in
        <xref ref-type="fig" rid="fig0010">
         Fig. 2
        </xref>
        , once in the brain, HCoV-OC43 is able to disseminate from the olfactory bulb to other regions of the brain, including the cortex and the hippocampus, from which it appears to spread by a trans-neuronal route before it eventually reaches the brainstem and spinal cord (
        <xref ref-type="bibr" rid="bib0235">
         Desforges et al., 2013b
        </xref>
        ). These results suggest that coronaviruses may also invade the human CNS from the external environment through the neuroepithelium of the olfactory nerve and olfactory bulb before infecting the resident cells of the brain, and potentially the spinal cord (
        <xref ref-type="fig" rid="fig0005">
         Fig. 1
        </xref>
        B), as reviewed by Mori and colleagues for some neuroinvasive human viruses such as influenza virus, Herpes simplex virus (HSV), and borna disease virus (BDV) (
        <xref ref-type="bibr" rid="bib0630">
         Mori et al., 2005
        </xref>
        ).
        <fig id="fig0010">
         <label>
          Fig. 2
         </label>
         <caption>
          <p>
           Human coronavirus transneuronal route of neuroinvasion through the olfactory nerve and spread into the CNS in susceptible mice. Following intranasal infection or 14 day-old susceptible mice, HCoV-OC43 infects first the olfactory bulb (left panel) and then disseminate to other regions of the brain, including the hippocampus (right panel). In both regions of the brain, neurons are the main target of infection.
          </p>
         </caption>
         <graphic xlink:href="gr2">
         </graphic>
        </fig>
       </p>
       <p id="par0175">
        Like several human viruses listed previously in the present review, coronaviruses that infect human beings are naturally neuroinvasive and neurotropic and potentially neurovirulent as a result of misdirected host immune responses (virus-induced neuroimmunopathology) and/or viral replication, which directly induces damage to CNS cells (virus-induced neuropathology).
       </p>
      </sec>
      <sec id="sec0045">
       <label>
        3.2.2
       </label>
       <title>
        Mechanisms of HCoV-induced neurodegeneration: possible associated neuropathologies
       </title>
       <p id="par0180">
        Even though no direct association has ever been made with the onset of human neurological diseases, the presence of HCoV-229E and HCoV-OC43 was detected in various neurological diseases in humans, including Parkinson's disease (PD) and multiple sclerosis (MS) (
        <xref ref-type="bibr" rid="bib0015">
         Arbour et al., 2000
        </xref>
        ), as well as ADEM (
        <xref ref-type="bibr" rid="bib0955">
         Yeh et al., 2004
        </xref>
        ).
       </p>
       <p id="par0185">
        Multiple sclerosis truly represents a human neurological disease where an infectious agent or agents may play a triggering role, with viruses the most likely culprit in genetically predisposed individuals (
        <xref ref-type="bibr" rid="bib0525">
         Kurtzke, 1993
        </xref>
        ). There is a presumption that several neurotropic viruses could be involved in MS pathogenesis but that they may do so through similar direct and/or indirect mechanisms (
        <xref ref-type="bibr" rid="bib0205">
         Cusick et al., 2013
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0335">
         Gilden, 2005
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0475">
         Kakalacheva et al., 2011
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0815">
         Talbot et al., 2001
        </xref>
        ). However, research has not yet led to a direct link to any specific virus or other microbes with MS. Association of coronaviruses with MS was suggested in numerous reports that are reviewed elsewhere (
        <xref ref-type="bibr" rid="bib0235">
         Desforges et al., 2013b
        </xref>
        ). One of these reports demonstrated a significant association of colds with MS exacerbations and a significant association of HCoV-229E infection in MS patients (
        <xref ref-type="bibr" rid="bib0410">
         Hovanec and Flanagan, 1983
        </xref>
        ) and another report on the association of viral infections and MS (
        <xref ref-type="bibr" rid="bib0770">
         Sibley et al., 1985
        </xref>
        ) commented that seasonal HCoV infection patterns do fit the observed occurrence of MS exacerbations.
       </p>
       <p id="par0190">
        We were previously able to confirm that HCoV-OC43 and HCoV-229E are naturally neuroinvasive in humans. Indeed, viruses were detected in some control brains and in some brains coming from patients different neurological diseases, including Alzheimer's and Parkinson's disease, there was a significantly higher prevalence of HCoV-OC43 in brains of MS patients (
        <xref ref-type="bibr" rid="bib0015">
         Arbour et al., 2000
        </xref>
        ) and viral RNA was found more often in female brain samples (
        <xref ref-type="fig" rid="fig0015">
         Fig. 3
        </xref>
        A). Even though this observation is only circumstantial, it is interesting to note that MS is more prevalent in women than in men (
        <xref ref-type="bibr" rid="bib0085">
         Bove and Chitnis, 2013
        </xref>
        ). Moreover, this data, in association with the observation that autoreactive T cells were able to recognize both viral and myelin antigens in MS patients but not in controls during infection by HCoV-OC43 and HCoV-229E (
        <xref ref-type="bibr" rid="bib0080">
         Boucher et al., 2007
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0830">
         Talbot et al., 1996
        </xref>
        ), suggest that the immune response may participate in the induction or exacerbation of neuropathologies such as MS in genetically or otherwise susceptible individuals (
        <xref ref-type="fig" rid="fig0015">
         Fig. 3
        </xref>
        B). Furthermore, even though the use of the immunosuppressive drug cyclosporin A in HCoV-OC43-infected mice resulted in a faster onset of encephalitis, suggesting a role for T cells in viral clearance and survival with no related immunopathology (
        <xref ref-type="bibr" rid="bib0435">
         Jacomy et al., 2006
        </xref>
        ), it was shown that in recombination activation gene (RAG) knock-out mice, HCoV-OC43-induced encephalitis could be partially mediated by the T-cell response to infection (
        <xref ref-type="bibr" rid="bib0120">
         Butler et al., 2006
        </xref>
        ). The participation of different types of T cells has been shown to play a significant role in the demyelinating neurological disease induced by the murine CoV, in particular for strain MHV-JHM (
        <xref ref-type="bibr" rid="bib0590">
         Matthews et al., 2002
        </xref>
        ). Furthermore, used as an experimental model of chronic viral infection associated with demyelination in the mouse CNS, this murine coronavirus has recently been shown to reflect partial oxidative tissue injury found in MS lesion in humans (
        <xref ref-type="bibr" rid="bib0760">
         Schuh et al., 2014
        </xref>
        ), underlining the possibility that long term infection of the CNS by coronaviruses may induce MS-like lesions. This may also apply for persistence of HCoV RNA in the human CNS (
        <xref ref-type="bibr" rid="bib0015">
         Arbour et al., 2000
        </xref>
        ), which in some conditions, could be associated with onset or exacerbation of neuropathologies, including MS.
        <fig id="fig0015">
         <label>
          Fig. 3
         </label>
         <caption>
          <p>
           Detection of coronaviral RNA in human CNS and of HCoV-myelin antigens cross-reactive T cells in MS patients. (A) Double-blind analysis of ninety human brain autopsy samples revealed the presence of HCoV-229E and HCoV-OC43 RNA in normal controls, patients with other neurological disorders (OND) and patients with multiple sclerosis (MS). The proportion of brain samples from MS patients containing HCoV-OC43 RNA was significantly greater than OND and normal controls. RNA from both HCoV was found more often in Female brains compared to male. (B) More monospecific T-cell clones were isolated from MS patients compared to normal controls and cross-reactive T-cell clones were isolated only from MS patients.
          </p>
         </caption>
         <graphic xlink:href="gr3">
         </graphic>
         <attrib>
          Adapted from Arbour et al, 2000 and
          <xref ref-type="bibr" rid="bib0080">
           Boucher et al., 2007
          </xref>
          .
         </attrib>
        </fig>
       </p>
       <p id="par0195">
        Making use of another mouse model, we showed that HCoV-OC43 induced immune cell infiltration and cytokine production within the mouse CNS. This immune response was significantly increased after infection by virus variants which harbor mutations in the surface viral glycoprotein (S), consequent of viral persistent infection of human neural cells (
        <xref ref-type="bibr" rid="bib0440">
         Jacomy et al., 2010
        </xref>
        ), and which induce glutamate excitotoxicity (
        <xref ref-type="bibr" rid="bib0100">
         Brison et al., 2011
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0105">
         Brison et al., 2014
        </xref>
        ). The increased cytokine production following infection by the S-mutant viruses may induce direct damage to neurons (
        <xref ref-type="bibr" rid="bib0005">
         Amor et al., 2010
        </xref>
        ) and/or disturb glutamate homeostasis by down-regulating the glutamate transporter GLT-1 on astrocytes that should recapture the excess of glutamate, which may generate glutamate excitotoxicity (
        <xref ref-type="bibr" rid="bib0140">
         Carmen et al., 2009
        </xref>
        ) and thereby contribute to neuronal degeneration (
        <xref ref-type="fig" rid="fig0020">
         Fig. 4
        </xref>
        ;
        <xref ref-type="bibr" rid="bib0100">
         Brison et al., 2011
        </xref>
        ), which can be associated with hind-limb paralysis and possible demyelination (
        <xref ref-type="bibr" rid="bib0100">
         Brison et al., 2011
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0440">
         Jacomy et al., 2010
        </xref>
        ). The outcome of the observed degeneration of neurons may eventually be death of these essential cells.
        <fig id="fig0020">
         <label>
          Fig. 4
         </label>
         <caption>
          <p>
           HCoV infection induces increased production of proinflammatory cytokines and neuronal degeneration as a consequence of glutamate excitotoxicity. In physiological conditions, glutamate is mainly synthesized by neurons and released in the synaptic cleft as the primary excitatory neurotransmitter of the CNS that activates the ligand-dependant receptor AMPAr (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionoc acid receptor), which allows the entry of sodium ions and the passage of the nerve impulse in the post-synaptic neuron, leading to activation of the NMDA receptor (N-methyl-D-aspartate receptor) that allows the entry of calcium ions. During infection of neurons by HCoV-OC43, microglial cells detect the presence of virus and produce pro-inflammatory cytokines (TNF-alpha, IL-1 beta and IL-6) that down-regulate the astrocytic receptor GLT-1 (glutamate transporter 1) and prevent the efficient recapture of glutamate. This situation disturbs the regulation of glutamate homeostasis and the excess of this neurotransmitter in the synaptic cleft leads to excitotoxicity associated with a massive entry of calcium which eventually leads to degeneration of and death of neuronal cells.
          </p>
         </caption>
         <graphic xlink:href="gr4">
         </graphic>
        </fig>
       </p>
       <p id="par0200">
        As previously mentioned, infection of neurons by itself may also participate in the process of cell death by directly generating a cytotoxic insult related to viral replication and/or to the induction of different cell death pathways.
       </p>
       <p id="par0205">
        When present in the murine CNS, HCoV-OC43 infects neurons in different regions of the brain (
        <xref ref-type="fig" rid="fig0010">
         Fig. 2
        </xref>
        ), before reaching the spinal cord. Infection of these essential cells induces their degeneration as observed by aberrant state of neurofilament phosphorylation (
        <xref ref-type="bibr" rid="bib0100">
         Brison et al., 2011
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0105">
         Brison et al., 2014
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0440">
         Jacomy et al., 2010
        </xref>
        ), a situation that often leads to cell death and that could be directly induced by viral replication. Furthermore, using two model cell lines representing differentiated human neurons, we were able to demonstrate that programmed cell death (PCD) was induced after HCoV-OC43 infection (
        <xref ref-type="bibr" rid="bib0280">
         Favreau et al., 2009
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0285">
         Favreau et al., 2012
        </xref>
        ) and that the inhibition of viral replication was also in direct correlation with increased cell survival, suggesting that infection and production of progeny infectious viruses directly participate in the process of degeneration and eventual death of neurons. Our results indicate that the underlying mechanisms appear to involve different cellular factors and pathways, including caspase-independent apoptosis, parthanatos and necroptosis, three forms of programmed cell death (PCD) reviewed elsewhere by the Nomenclature Committee on Cell Death (NCCD) (
        <xref ref-type="bibr" rid="bib0315">
         Galluzzi et al., 2012
        </xref>
        ). These cell death pathways can act separately but may also interact in response to a stimulus (including a viral infection), as they share some of the cellular factors involved in the overall process that leads to cell death and that often converges toward mitochondria (
        <xref ref-type="bibr" rid="bib0315">
         Galluzzi et al., 2012
        </xref>
        ).
        <xref ref-type="fig" rid="fig0025">
         Fig. 5
        </xref>
        is a tentative representation of the various pathways and cellular factors associated with PCD that may be activated and/or inhibited during HCoV-OC43 infection of neurons. It is based on our data (
        <xref ref-type="bibr" rid="bib0100">
         Brison et al., 2011
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0280">
         Favreau et al., 2009
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0285">
         Favreau et al., 2012
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0440">
         Jacomy et al., 2010
        </xref>
        ) and on the scientific literature that describes some molecular pathways (parthanatos, necroptosis and apoptosis) and cellular factors, including calcium overload, endoplasmic reticulum stress, excitotoxicity, poly(ADP-ribose) polymerase (PARP) and calpain involved in mitochondrial dysfunction and eventual neurodegeneration and neuronal cell death (
        <xref ref-type="bibr" rid="bib0130">
         Cali et al., 2011
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0315">
         Galluzzi et al., 2012
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0470">
         Kaiser et al., 2013
        </xref>
        ).
        <fig id="fig0025">
         <label>
          Fig. 5
         </label>
         <caption>
          <p>
           Pathways of neuronal degeneration and programmed cell death (PCD) activated or potentially inhibited after HCoV-OC43 infection of neuronal cells. Hallmarks of apoptosis, including the relocalization of the activated pro-apoptotic protein BAX (Bcl-2 associated protein X) from the cytosol to the mitochondrial membrane, cytochrome C release from mitochondria toward the cytosol, DNA fragmentation and activation of caspases-3 and -9, are observed during infection of human neurons. However, even though virus induces Bax relocalization, it may inhibit classical apoptosis by blocking Bax pro-apoptotic function at the mitochondria and/or downstream of caspase activation, suggesting a caspase-independent type of apoptosis. Relocalization of the mitochondrial protein AIF (apoptosis-inducing factor) toward the nucleus (truncated tAIF) is observed after infection and participates in DNA fragmentation. AIF is known to be activated during caspase-independent apoptosis. However, AIF is also involved in Parthanatos, another form of PCD potentially associated with neurodegeneration. As they are synthesized by the poly(ADP-ribose) polymerase (PARP) during a neuronal stress, including during HCoV-OC43 infection, polymers of ADP-ribose (PAR) may relocalize toward mitochondria and participate in the activation and relocalization of AIF toward the cytosol before it reaches the nucleus. Cyclophilin D (CypD) inhibition decreases AIF release from mitochondria and abrogates cell death induced by infection. AIF release from mitochondria may be induced through its truncation (tAIF) by activated calpain, which is usually activated by a rise in the mitochondrial calcium concentration. This increase in calcium concentration may be linked with either an important entry from the extracellular milieu (for instance during glutamate excitotoxicity) or with a release of calcium from the ER following induction of ER stress. However HCoV-OC43 may inhibit the ER stress-related pathway in infected neurons. Infection induces RIP1 gene expression and the knock-down of the receptor interacting protein kinase-1 (RIP-1), significantly increases cell survival, suggesting that necroptosis, a third form of PCD which involves RIP-1 and RIP-3 downstream of the death receptor family, may play a role in HCoV-OC43-induced neuronal death. Solid arrows indicate experimental data and dashed arrows represent possible pathways based on the literature (see text for details).
          </p>
         </caption>
         <graphic xlink:href="gr5">
         </graphic>
        </fig>
       </p>
       <p id="par0210">
        Virus-cell interactions are always important in the regulation of cell response to infection. For HCoV-OC43, we clearly showed that the viral S glycoprotein is an important factor of neurovirulence and neurodegeneration of infected cells (
        <xref ref-type="bibr" rid="bib0100">
         Brison et al., 2011
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0280">
         Favreau et al., 2009
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0440">
         Jacomy et al., 2010
        </xref>
        ). This was similarly shown for the strains MHV-A59 and MHV–JHM of the MuCoV species, the murine counterpart of HCoV-OC43. Indeed, several reports and reviews have, over the years, shown that the S protein of this neuroinvasive and neurotropic murine coronavirus is a major factor associated with neurovirulence during encephalitis and the eventual demyelinating disease in susceptible mice (
        <xref ref-type="bibr" rid="bib0050">
         Bender and Weiss, 2010
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0405">
         Hosking and Lane, 2010
        </xref>
        ). We have also demonstrated that the HE protein is an important factor for the production of infectious HCoV-OC43, suggesting an attenuation of the eventual spread into the CNS of viruses made deficient in fully active HE protein (
        <xref ref-type="bibr" rid="bib0230">
         Desforges et al., 2013a
        </xref>
        ). Therefore, as the infection of neuronal cells and production of infectious virus apparently directly participate in the induction of neuronal death, the HE protein of HCoV-OC43 could play a role in neurovirulence of HCoV-OC43, like it does for MHV (
        <xref ref-type="bibr" rid="bib0490">
         Kazi et al., 2005
        </xref>
        ). In recent years, several coronavirus accessory proteins, including the TGEV protein 7 and the MHV ns2 protein have been extensively studied and are now considered as important viral factors of virulence implicated in pathogenesis as they are able to counteract host-cell response associated with the activation of RNAse L and the type 1 interferon response (
        <xref ref-type="bibr" rid="bib0200">
         Cruz et al., 2011
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0975">
         Zhao et al., 2013
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0980">
         Zhao et al., 2012
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0985">
         Zhao et al., 2011
        </xref>
        ). Our more recent work on the on-going characterization of HCoV interactions with the cells from the CNS has led us to determine that two of these accessory proteins (ns2 and ns5), produced during infection of susceptible cells by HCoV-OC43, play a significant role in virulence and pathogenesis in the mouse CNS (
        <xref ref-type="fig" rid="fig0030">
         Fig. 6
        </xref>
        ) partially by modulating virus production (data not shown).
        <fig id="fig0030">
         <label>
          Fig. 6
         </label>
         <caption>
          <p>
           Importance of HCoV-OC43 non-structural accessory proteins as neurovirulence factors in infected mice depends of the mouse strain. Groups of 20 mice (A) of three different strains were infected by the intracerebral route with reference wild-type HCoV-OC43 (ATCC) or with a mutant deleted for the ns2 accessory protein (ns2-KO) and (B) with reference wild-type HCoV-OC43 (ATCC) or with a mutant deleted for the ns5 accessory protein (ns5-KO). Infection with ten times (ns5-KO-10×) or even a hundred times (ns5-KO-100×) more ns5 mutant virus led to a reduced neurovirulence compared to wild type virus (ATCC). Survival was evaluated daily over a period of 21 days. Results are representative of two independent experiments.
          </p>
         </caption>
         <graphic xlink:href="gr6">
         </graphic>
        </fig>
       </p>
       <p id="par0215">
        As mentioned above, SARS-CoV is also neuroinvasive and neurotropic in humans (
        <xref ref-type="bibr" rid="bib0365">
         Gu et al., 2005
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0940">
         Xu et al., 2005
        </xref>
        ) and it could therefore be associated with the development of a neurological symptoms as infected neurons were shown to be necrotic in human brain of deceased patients (
        <xref ref-type="bibr" rid="bib0365">
         Gu et al., 2005
        </xref>
        ). Furthermore, the involvement of SARS-CoV in CNS infections was underscored by the findings that made use of transgenic mouse models expressing the human angiotensin-converting enzyme-2 (the cellular receptor used by SARS-CoV to infect susceptible cells). Indeed, using these mice, it was shown that SARS-CoV could invade the CNS after an intranasal infection primarily through the olfactory bulb (
        <xref ref-type="bibr" rid="bib0670">
         Netland et al., 2008
        </xref>
        ) or even after an intra-peritoneal infection (
        <xref ref-type="bibr" rid="bib0850">
         Tseng et al., 2007
        </xref>
        ), with concomitant neuronal loss (
        <xref ref-type="bibr" rid="bib0670">
         Netland et al., 2008
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0850">
         Tseng et al., 2007
        </xref>
        ); a phenomenon that can eventually lead to neurological problems. To our knowledge, there exist no reports on the detection of HCoV-HKU1, HCoV-NL63 and MERS-CoV in the human CNS. On the other hand, neurological symptoms have been described in association with both HCoV-HKU1 and HCoV-NL63 (
        <xref ref-type="bibr" rid="bib0765">
         Severance et al., 2011
        </xref>
        ) and a recent report, which evaluated MERS-CoV cell tropism, suggest that, among several cell lines representative of different tissues and organs, this virus seems to be able to infect the neuron-committed human cell line NT2 (
        <xref ref-type="bibr" rid="bib0310">
         Fuk-Woo Chan et al., 2013
        </xref>
        ).
       </p>
       <p id="par0220">
        Based on several pieces of evidence presented herein, we hypothesize that neuroinvasive coronaviruses could participate in the damage of the human CNS as a result of misdirected host immune responses (virus-induced neuroimmunopathology) and/or viral replication, which directly induces damage to CNS cells (virus-induced neuropathology). In acute encephalitis, viral replication occurs in the brain tissue itself, possibly causing destructive lesions of the nervous tissue (
        <xref ref-type="bibr" rid="bib0820">
         Talbot et al., 2011
        </xref>
        ). As previously mentioned, chronic human neurological diseases may also be linked to viral infection. However, in several cases of these chronic diseases, it is very hard to ascertain a role for any given virus, in part due to the difficulty of establishing the time at which these viruses become involved. Also, the four Koch's postulates dictate whether a particular infectious agent causes a specific disease (
        <xref ref-type="bibr" rid="bib0500">
         Koch, 1942
        </xref>
        ). However, several viral infections, especially slow viral infections related to diseases that are rare manifestations of an infection, represent situations where Koch's postulates need to be modified (
        <xref ref-type="bibr" rid="bib0305">
         Fredericks and Relman, 1996
        </xref>
        ,
        <xref ref-type="bibr" rid="bib0395">
         Hill, 1965
        </xref>
        ). A series of new criteria, adapted from Sir Austin Bradford Hill's for causation (
        <xref ref-type="bibr" rid="bib0395">
         Hill, 1965
        </xref>
        ), was elaborated by Giovannoni and collaborators (
        <xref ref-type="bibr" rid="bib0340">
         Giovannoni et al., 2006
        </xref>
        ) and should replace Koch's postulates when one wants to evaluate the relevance of any given virus in relation to, for example, MS etiology (
        <xref ref-type="bibr" rid="bib0340">
         Giovannoni et al., 2006
        </xref>
        ) or any other long-term human neurological diseases potentially related to a viral infection as well, including infection by human coronaviruses.
       </p>
      </sec>
     </sec>
    </sec>
    <sec id="sec0050">
     <label>
      4
     </label>
     <title>
      Conclusions
     </title>
     <p id="par0225">
      Respiratory human coronaviruses are naturally neuroinvasive and neurotropic, with potential neuropathological consequences in genetically or otherwise susceptible individuals, with or without additional environmental insults. Even though their use of the hematogenous or transneuronal route to gain access to the CNS in human beings remains to be elucidated, their presence in the human CNS is now a recognized fact. Furthermore, knowledge of mechanisms and consequences of coronavirus interactions with the nervous system is essential to better understand potentially pathological consequences and design intervention strategies that are appropriate to encephalitis or exacerbations of other types of neurological diseases for which a given virus is involved. In that regard, the Hill's criteria adapted by Giovannoni and collaborators may represent a highly relevant tool to evaluate the relevance of human coronaviruses as a factor which will influence the development and/or exacerbation of a long-term human neurological disease potentially related to a viral infection. Therefore, collecting new epidemiological data on a larger scale is certainly warranted to establish a more solid and direct link between coronaviruses and human neurological diseases. We have already gathered important and interesting data and identified some viral and cellular factors involved in HCoV/CNS cells interactions. However, further basic research that help decipher complex underlying mechanisms involved in virus-host-cell interactions is warranted and will be instrumental to our understanding of how coronaviruses that infect human beings, given the proper susceptibility conditions and proper virus evolution and infection conditions, may induce neuronal degeneration and could participate in the induction or exacerbation of human neuropathologies.
     </p>
    </sec>
    <back>
     <ref-list id="bibl0005">
      <title>
       References
      </title>
      <ref id="bib0005">
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amor
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Puentes
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           van der Valk
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inflammation in neurodegenerative diseases
        </article-title>
        <source>
         Immunology
        </source>
        <volume>
         129
        </volume>
        <issue>
         2
        </issue>
        <year>
         2010
        </year>
        <fpage>
         154
        </fpage>
        <lpage>
         169
        </lpage>
        <pub-id pub-id-type="pmid">
         20561356
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arbour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Cote
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Lachance
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tardieu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cashman
          </surname>
          <given-names>
           N.R.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute and persistent infection of human neural cell lines by human coronavirus OC43
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         73
        </volume>
        <issue>
         4
        </issue>
        <year>
         1999
        </year>
        <fpage>
         3338
        </fpage>
        <lpage>
         3350
        </lpage>
        <pub-id pub-id-type="pmid">
         10074188
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arbour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Newcombe
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neuroinvasion by human respiratory coronaviruses
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         74
        </volume>
        <issue>
         19
        </issue>
        <year>
         2000
        </year>
        <fpage>
         8913
        </fpage>
        <lpage>
         8921
        </lpage>
        <pub-id pub-id-type="pmid">
         10982334
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arbour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ekande
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Cote
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Lachance
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chagnon
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Tardieu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cashman
          </surname>
          <given-names>
           N.R.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         73
        </volume>
        <issue>
         4
        </issue>
        <year>
         1999
        </year>
        <fpage>
         3326
        </fpage>
        <lpage>
         3337
        </lpage>
        <pub-id pub-id-type="pmid">
         10074187
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <element-citation id="sbref0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Argyris
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
         <name>
          <surname>
           Acheampong
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Mukhtar
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The interferon-induced expression of APOBEC3G in human blood–brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         367
        </volume>
        <issue>
         2
        </issue>
        <year>
         2007
        </year>
        <fpage>
         440
        </fpage>
        <lpage>
         451
        </lpage>
        <pub-id pub-id-type="pmid">
         17631933
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabiah
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hajjar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Barrak
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Flemban
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Nassir
          </surname>
          <given-names>
           W.N.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hakeem
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           H.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.I.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         13
        </volume>
        <issue>
         9
        </issue>
        <year>
         2013
        </year>
        <fpage>
         752
        </fpage>
        <lpage>
         761
        </lpage>
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0035">
       <element-citation id="sbref0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Price
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Al Rabeeah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cummings
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alabdullatif
          </surname>
          <given-names>
           Z.N.
          </given-names>
         </name>
         <name>
          <surname>
           Assad
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Almulhim
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alhakeem
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kellam
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.I.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hospital outbreak of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         369
        </volume>
        <issue>
         5
        </issue>
        <year>
         2013
        </year>
        <fpage>
         407
        </fpage>
        <lpage>
         416
        </lpage>
        <pub-id pub-id-type="pmid">
         23782161
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <element-citation id="sbref0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aurelian
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         HSV-induced apoptosis in herpes encephalitis
        </article-title>
        <source>
         Curr. Top. Microbiol. Immunol.
        </source>
        <volume>
         289
        </volume>
        <year>
         2005
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         111
        </lpage>
        <pub-id pub-id-type="pmid">
         15791952
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0045">
       <element-citation id="sbref0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnett
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The olfactory nerve and not the trigeminal nerve is the major site of CNS entry for mouse hepatitis virus, strain JHM
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         194
        </volume>
        <issue>
         1
        </issue>
        <year>
         1993
        </year>
        <fpage>
         185
        </fpage>
        <lpage>
         191
        </lpage>
        <pub-id pub-id-type="pmid">
         8386871
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <element-citation id="sbref0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bender
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenesis of murine coronavirus in the central nervous system
        </article-title>
        <source>
         J. Neuroimmune Pharmacol.: Off. J. Soc. Neuroimmune Pharmacol.
        </source>
        <volume>
         5
        </volume>
        <issue>
         3
        </issue>
        <year>
         2010
        </year>
        <fpage>
         336
        </fpage>
        <lpage>
         354
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <element-citation id="sbref0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bentz
          </surname>
          <given-names>
           G.L.
          </given-names>
         </name>
         <name>
          <surname>
           Jarquin-Pardo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Sinzger
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Yurochko
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human cytomegalovirus (HCMV) infection of endothelial cells promotes naive monocyte extravasation and transfer of productive virus to enhance hematogenous dissemination of HCMV
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         80
        </volume>
        <issue>
         23
        </issue>
        <year>
         2006
        </year>
        <fpage>
         11539
        </fpage>
        <lpage>
         11555
        </lpage>
        <pub-id pub-id-type="pmid">
         16987970
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <element-citation id="sbref0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beraki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Aronsson
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Karlsson
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ogren
          </surname>
          <given-names>
           S.O.
          </given-names>
         </name>
         <name>
          <surname>
           Kristensson
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influenza A virus infection causes alterations in expression of synaptic regulatory genes combined with changes in cognitive and emotional behaviors in mice
        </article-title>
        <source>
         Mol. Psychiatry
        </source>
        <volume>
         10
        </volume>
        <issue>
         3
        </issue>
        <year>
         2005
        </year>
        <fpage>
         299
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         15241434
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <element-citation id="sbref0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Berth
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Leopold
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Morfini
          </surname>
          <given-names>
           G.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Virus-induced neuronal dysfunction and degeneration
        </article-title>
        <source>
         Front. Biosci.
        </source>
        <volume>
         14
        </volume>
        <year>
         2009
        </year>
        <fpage>
         5239
        </fpage>
        <lpage>
         5259
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <element-citation id="sbref0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Big
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Reineck
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Aronoff
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral infections of the central nervous system: a case-based review
        </article-title>
        <source>
         Clin. Med. Res.
        </source>
        <volume>
         7
        </volume>
        <issue>
         4
        </issue>
        <year>
         2009
        </year>
        <fpage>
         142
        </fpage>
        <lpage>
         146
        </lpage>
        <pub-id pub-id-type="pmid">
         19889944
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0075">
       <element-citation id="sbref0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bonavia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Arbour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Yong
          </surname>
          <given-names>
           V.W.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection of primary cultures of human neural cells by human coronaviruses 229E and OC43
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         71
        </volume>
        <issue>
         1
        </issue>
        <year>
         1997
        </year>
        <fpage>
         800
        </fpage>
        <lpage>
         806
        </lpage>
        <pub-id pub-id-type="pmid">
         8985420
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0080">
       <element-citation id="sbref0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boucher
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Duquette
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Long-term human coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients
        </article-title>
        <source>
         Clin. Immunol.
        </source>
        <volume>
         123
        </volume>
        <issue>
         3
        </issue>
        <year>
         2007
        </year>
        <fpage>
         258
        </fpage>
        <lpage>
         267
        </lpage>
        <pub-id pub-id-type="pmid">
         17448727
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0085">
       <element-citation id="sbref0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bove
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Chitnis
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sexual disparities in the incidence and course of MS
        </article-title>
        <source>
         Clin. Immunol.
        </source>
        <volume>
         149
        </volume>
        <issue>
         2
        </issue>
        <year>
         2013
        </year>
        <fpage>
         201
        </fpage>
        <lpage>
         210
        </lpage>
        <pub-id pub-id-type="pmid">
         23608496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0090">
       <element-citation id="sbref0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Braden
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Dowell
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Jernigan
          </surname>
          <given-names>
           D.B.
          </given-names>
         </name>
         <name>
          <surname>
           Hughes
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Progress in global surveillance and response capacity 10 years after severe acute respiratory syndrome
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <issue>
         6
        </issue>
        <year>
         2013
        </year>
        <fpage>
         864
        </fpage>
        <lpage>
         869
        </lpage>
        <pub-id pub-id-type="pmid">
         23731871
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0095">
       <element-citation id="sbref0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brian
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus genome structure and replication
        </article-title>
        <source>
         Curr. Top. Microbiol. Immunol.
        </source>
        <volume>
         287
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         15609507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0100">
       <element-citation id="sbref0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brison
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <issue>
         23
        </issue>
        <year>
         2011
        </year>
        <fpage>
         12464
        </fpage>
        <lpage>
         12473
        </lpage>
        <pub-id pub-id-type="pmid">
         21957311
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0105">
       <element-citation id="sbref0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brison
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         88
        </volume>
        <issue>
         3
        </issue>
        <year>
         2014
        </year>
        <fpage>
         1548
        </fpage>
        <lpage>
         1563
        </lpage>
        <pub-id pub-id-type="pmid">
         24227863
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0110">
       <element-citation id="sbref0110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brouard
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Nimal-Cuvillon
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bach
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bessiere
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Arion
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Freymuth
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology of acute upper and lower respiratory tract infections in children
        </article-title>
        <source>
         Rev. Prat.
        </source>
        <volume>
         57
        </volume>
        <issue>
         16
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1759
        </fpage>
        <lpage>
         1766
        </lpage>
        <pub-id pub-id-type="pmid">
         18092718
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0115">
       <element-citation id="sbref0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Buchmeier
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lane
          </surname>
          <given-names>
           T.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral-induced neurodegenerative disease
        </article-title>
        <source>
         Curr. Opin. Microbiol.
        </source>
        <volume>
         2
        </volume>
        <issue>
         4
        </issue>
        <year>
         1999
        </year>
        <fpage>
         398
        </fpage>
        <lpage>
         402
        </lpage>
        <pub-id pub-id-type="pmid">
         10458992
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0120">
       <element-citation id="sbref0120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Butler
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Pewe
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Trandem
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Murine encephalitis caused by HCoV-OC43, a human coronavirus with broad species specificity, is partly immune-mediated
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         347
        </volume>
        <issue>
         2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         410
        </fpage>
        <lpage>
         421
        </lpage>
        <pub-id pub-id-type="pmid">
         16413043
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0125">
       <element-citation id="sbref0125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cabeca
          </surname>
          <given-names>
           T.K.
          </given-names>
         </name>
         <name>
          <surname>
           Granato
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Bellei
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical features of human coronavirus infections among different subsets of patients
        </article-title>
        <source>
         Influenza Other Respir. Viruses
        </source>
        <volume>
         7
        </volume>
        <issue>
         6
        </issue>
        <year>
         2013
        </year>
        <fpage>
         1040
        </fpage>
        <lpage>
         1047
        </lpage>
        <pub-id pub-id-type="pmid">
         23462106
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0130">
       <element-citation id="sbref0130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cali
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ottolini
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Brini
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease
        </article-title>
        <source>
         Biofactors
        </source>
        <volume>
         37
        </volume>
        <issue>
         3
        </issue>
        <year>
         2011
        </year>
        <fpage>
         228
        </fpage>
        <lpage>
         240
        </lpage>
        <pub-id pub-id-type="pmid">
         21674642
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0140">
       <element-citation id="sbref0140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carmen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Rothstein
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Kerr
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tumor necrosis factor-alpha modulates glutamate transport in the CNS and is a critical determinant of outcome from viral encephalomyelitis
        </article-title>
        <source>
         Brain Res.
        </source>
        <volume>
         1263
        </volume>
        <year>
         2009
        </year>
        <fpage>
         143
        </fpage>
        <lpage>
         154
        </lpage>
        <pub-id pub-id-type="pmid">
         19368827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0145">
       <element-citation id="sbref0145" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The coronavirus surface glycoprotein
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Siddell
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
        </person-group>
        <source>
         The Coronaviridae
        </source>
        <year>
         1995
        </year>
        <publisher-name>
         Plenum Press
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
        <fpage>
         73
        </fpage>
        <lpage>
         113
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0150">
       <element-citation id="sbref0150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses in poultry and other birds
        </article-title>
        <source>
         Avian Pathol.
        </source>
        <volume>
         34
        </volume>
        <issue>
         6
        </issue>
        <year>
         2005
        </year>
        <fpage>
         439
        </fpage>
        <lpage>
         448
        </lpage>
        <pub-id pub-id-type="pmid">
         16537157
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0155">
       <element-citation id="sbref0155" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cesario
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viruses associated with pneumonia in adults
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         55
        </volume>
        <issue>
         1
        </issue>
        <year>
         2012
        </year>
        <fpage>
         107
        </fpage>
        <lpage>
         113
        </lpage>
        <pub-id pub-id-type="pmid">
         22423119
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0160">
       <element-citation id="sbref0160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Nogalski
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Stevenson
          </surname>
          <given-names>
           E.V.
          </given-names>
         </name>
         <name>
          <surname>
           Yurochko
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human cytomegalovirus induction of a unique signalsome during viral entry into monocytes mediates distinct functional changes: a strategy for viral dissemination
        </article-title>
        <source>
         J. Leukoc. Biol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2012
        </year>
        <fpage>
         743
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="pmid">
         22715139
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0165">
       <element-citation id="sbref0165" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cherry
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The chronology of the 2002–2003 SARS mini pandemic
        </article-title>
        <source>
         Paediatr. Respir. Rev.
        </source>
        <volume>
         5
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         262
        </fpage>
        <lpage>
         269
        </lpage>
        <pub-id pub-id-type="pmid">
         15531249
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0170">
       <element-citation id="sbref0170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chilvers
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           McKean
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rutman
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Myint
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
         <name>
          <surname>
           Silverman
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           O’Callaghan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effects of coronavirus on human nasal ciliated respiratory epithelium
        </article-title>
        <source>
         Eur. Respir. J.
        </source>
        <volume>
         18
        </volume>
        <issue>
         6
        </issue>
        <year>
         2001
        </year>
        <fpage>
         965
        </fpage>
        <lpage>
         970
        </lpage>
        <pub-id pub-id-type="pmid">
         11829103
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0175">
       <element-citation id="sbref0175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kwan
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         40
        </volume>
        <issue>
         12
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1721
        </fpage>
        <lpage>
         1729
        </lpage>
        <pub-id pub-id-type="pmid">
         15909257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0180">
       <element-citation id="sbref0180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emergence of the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         9
        </volume>
        <issue>
         9
        </issue>
        <year>
         2013
        </year>
        <fpage>
         e1003595
        </fpage>
        <pub-id pub-id-type="pmid">
         24039577
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0185">
       <element-citation id="sbref0185" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro detection of apoptosis in monocytes/macrophages infected with human coronavirus
        </article-title>
        <source>
         Clin. Diagn. Lab. Immunol.
        </source>
        <volume>
         9
        </volume>
        <issue>
         6
        </issue>
        <year>
         2002
        </year>
        <fpage>
         1392
        </fpage>
        <lpage>
         1395
        </lpage>
        <pub-id pub-id-type="pmid">
         12414783
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0190">
       <element-citation id="sbref0190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowley
          </surname>
          <given-names>
           T.J.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Murine coronavirus neuropathogenesis: determinants of virulence
        </article-title>
        <source>
         J. Neurovirol.
        </source>
        <volume>
         16
        </volume>
        <issue>
         6
        </issue>
        <year>
         2010
        </year>
        <fpage>
         427
        </fpage>
        <lpage>
         434
        </lpage>
        <pub-id pub-id-type="pmid">
         21073281
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0195">
       <element-citation id="sbref0195" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cristallo
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gambaro
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Biamonti
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ferrante
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Battaglia
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cereda
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients
        </article-title>
        <source>
         N. Microbiol.
        </source>
        <volume>
         20
        </volume>
        <issue>
         2
        </issue>
        <year>
         1997
        </year>
        <fpage>
         105
        </fpage>
        <lpage>
         114
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0200">
       <element-citation id="sbref0200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cruz
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Becares
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Alberca
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Plana
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zuniga
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus gene 7 counteracts host defenses and modulates virus virulence
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         7
        </volume>
        <issue>
         6
        </issue>
        <year>
         2011
        </year>
        <fpage>
         e1002090
        </fpage>
        <pub-id pub-id-type="pmid">
         21695242
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0205">
       <element-citation id="sbref0205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cusick
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Libbey
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Fujinami
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multiple sclerosis: autoimmunity and viruses
        </article-title>
        <source>
         Curr. Opin. Rheumatol.
        </source>
        <volume>
         25
        </volume>
        <issue>
         4
        </issue>
        <year>
         2013
        </year>
        <fpage>
         496
        </fpage>
        <lpage>
         501
        </lpage>
        <pub-id pub-id-type="pmid">
         23656710
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0210">
       <element-citation id="sbref0210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure, function and evolution of the hemagglutinin-esterase proteins of corona- and toroviruses
        </article-title>
        <source>
         Glycoconj. J.
        </source>
        <volume>
         23
        </volume>
        <issue>
         1-2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         59
        </fpage>
        <lpage>
         72
        </lpage>
        <pub-id pub-id-type="pmid">
         16575523
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0215">
       <element-citation id="sbref0215" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Stephens
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Zambon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV); announcement of the Coronavirus Study Group
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         7790
        </fpage>
        <lpage>
         7792
        </lpage>
        <pub-id pub-id-type="pmid">
         23678167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0220">
       <element-citation id="sbref0220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dedeurwaerder
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Desmarets
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Olyslaegers
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Vermeulen
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dewerchin
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Nauwynck
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of accessory proteins in the replication of feline infectious peritonitis virus in peripheral blood monocytes
        </article-title>
        <source>
         Vet. Microbiol.
        </source>
        <volume>
         162
        </volume>
        <issue>
         2-4
        </issue>
        <year>
         2013
        </year>
        <fpage>
         447
        </fpage>
        <lpage>
         455
        </lpage>
        <pub-id pub-id-type="pmid">
         23182908
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0225">
       <element-citation id="sbref0225" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Jimenez-Guardeno
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Oliveros
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         7
        </volume>
        <issue>
         10
        </issue>
        <year>
         2011
        </year>
        <fpage>
         e1002315
        </fpage>
        <pub-id pub-id-type="pmid">
         22028656
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0230">
       <element-citation id="sbref0230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Desjardins
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <issue>
         6
        </issue>
        <year>
         2013
        </year>
        <fpage>
         3097
        </fpage>
        <lpage>
         3107
        </lpage>
        <pub-id pub-id-type="pmid">
         23283955
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0235">
       <element-citation id="sbref0235" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Favreau
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Brison
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Desjardins
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Meessen-Pinard
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Human coronaviruses. Respiratory pathogens revisited as infectious neuroinvasive, neurtropic, and neurovirulent agents
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Ruzek
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <source>
         Neuroviral Infections. RNA Viruses and Retroviruses
        </source>
        <year>
         2013
        </year>
        <publisher-name>
         CRC Press/Taylor and Francis
        </publisher-name>
        <publisher-loc>
         Boca Raton
        </publisher-loc>
        <fpage>
         93
        </fpage>
        <lpage>
         121
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0240">
       <element-citation id="sbref0240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Miletti
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Gagnon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activation of human monocytes after infection by human coronavirus 229E
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         130
        </volume>
        <issue>
         1-2
        </issue>
        <year>
         2007
        </year>
        <fpage>
         228
        </fpage>
        <lpage>
         240
        </lpage>
        <pub-id pub-id-type="pmid">
         17669539
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0245">
       <element-citation id="sbref0245" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Jebbink
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Koekkoek
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Deijs
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Jonsdottir
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Molenkamp
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ieven
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Goossens
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Thiel
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <issue>
         11
        </issue>
        <year>
         2013
        </year>
        <fpage>
         6081
        </fpage>
        <lpage>
         6090
        </lpage>
        <pub-id pub-id-type="pmid">
         23427150
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0250">
       <element-citation id="sbref0250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jing
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine epidemic diarrhea virus (PEDV) nucleocapsid protein antagonizes IFN-beta production by sequestering the interaction between IRF3 and TBK1
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="bib0255">
       <element-citation id="sbref0255" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dominguez
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Wentworth
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Halpin
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Robinson
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Town
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic analysis of 16 Colorado human NL63 coronaviruses identifies a new genotype, high sequence diversity in the N-terminal domain of the spike gene and evidence of recombination
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <volume>
         93
        </volume>
        <issue>
         Pt 11
        </issue>
        <year>
         2012
        </year>
        <fpage>
         2387
        </fpage>
        <lpage>
         2398
        </lpage>
        <pub-id pub-id-type="pmid">
         22837419
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0260">
       <element-citation id="sbref0260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gunther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           van der Werf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Brodt
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rabenau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Panning
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Berger
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Burguiere
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Eickmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Escriou
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Grywna
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kramme
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Manuguerra
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rickerts
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Sturmer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Vieth
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Klenk
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Schmitz
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <issue>
         20
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1967
        </fpage>
        <lpage>
         1976
        </lpage>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0265">
       <element-citation id="sbref0265" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Escaffre
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Borisevich
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Rockx
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenesis of Hendra and Nipah virus infection in humans
        </article-title>
        <source>
         J. Infect. Dev. Ctries.
        </source>
        <volume>
         7
        </volume>
        <issue>
         4
        </issue>
        <year>
         2013
        </year>
        <fpage>
         308
        </fpage>
        <lpage>
         311
        </lpage>
        <pub-id pub-id-type="pmid">
         23592639
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0270">
       <element-citation id="sbref0270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Esper
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronaviruses are uncommon in patients with gastrointestinal illness
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <volume>
         48
        </volume>
        <issue>
         2
        </issue>
        <year>
         2010
        </year>
        <fpage>
         131
        </fpage>
        <lpage>
         133
        </lpage>
        <pub-id pub-id-type="pmid">
         20362494
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0275">
       <element-citation id="sbref0275" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Espinoza
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bohmwald
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Cespedes
          </surname>
          <given-names>
           P.F.
          </given-names>
         </name>
         <name>
          <surname>
           Gomez
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Riquelme
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cortes
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Valenzuela
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Sandoval
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Pancetti
          </surname>
          <given-names>
           F.C.
          </given-names>
         </name>
         <name>
          <surname>
           Bueno
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Riedel
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kalergis
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impaired learning resulting from Respiratory Syncytial Virus infection
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A.
        </source>
        <volume>
         110
        </volume>
        <issue>
         22
        </issue>
        <year>
         2013
        </year>
        <fpage>
         9112
        </fpage>
        <lpage>
         9117
        </lpage>
        <pub-id pub-id-type="pmid">
         23650398
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0280">
       <element-citation id="sbref0280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Favreau
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           St-Jean
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human coronavirus OC43 variant harboring persistence-associated mutations in the S glycoprotein differentially induces the unfolded protein response in human neurons as compared to wild-type virus
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         395
        </volume>
        <issue>
         2
        </issue>
        <year>
         2009
        </year>
        <fpage>
         255
        </fpage>
        <lpage>
         267
        </lpage>
        <pub-id pub-id-type="pmid">
         19846189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0285">
       <element-citation id="sbref0285" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Favreau
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Meessen-Pinard
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus-induced neuronal programmed cell death is cyclophilin d dependent and potentially caspase dispensable
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         86
        </volume>
        <issue>
         1
        </issue>
        <year>
         2012
        </year>
        <fpage>
         81
        </fpage>
        <lpage>
         93
        </lpage>
        <pub-id pub-id-type="pmid">
         22013052
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0290">
       <element-citation id="sbref0290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fazzini
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Fleming
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Fahn
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease
        </article-title>
        <source>
         Move. Disord.: Off. J. Move. Disord. Soc.
        </source>
        <volume>
         7
        </volume>
        <issue>
         2
        </issue>
        <year>
         1992
        </year>
        <fpage>
         153
        </fpage>
        <lpage>
         158
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0295">
       <element-citation id="sbref0295" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Foley
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Rand
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Leutenegger
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inflammation and changes in cytokine levels in neurological feline infectious peritonitis
        </article-title>
        <source>
         J. Feline Med. Surg.
        </source>
        <volume>
         5
        </volume>
        <issue>
         6
        </issue>
        <year>
         2003
        </year>
        <fpage>
         313
        </fpage>
        <lpage>
         322
        </lpage>
        <pub-id pub-id-type="pmid">
         14623200
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0300">
       <element-citation id="sbref0300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Schutten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           van Doornum
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           van den Hoogen
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Stohr
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aetiology: Koch's postulates fulfilled for SARS virus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         423
        </volume>
        <issue>
         6937
        </issue>
        <year>
         2003
        </year>
        <fpage>
         240
        </fpage>
        <pub-id pub-id-type="pmid">
         12748632
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0305">
       <element-citation id="sbref0305" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fredericks
          </surname>
          <given-names>
           D.N.
          </given-names>
         </name>
         <name>
          <surname>
           Relman
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates
        </article-title>
        <source>
         Clin. Microbiol. Rev.
        </source>
        <volume>
         9
        </volume>
        <issue>
         1
        </issue>
        <year>
         1996
        </year>
        <fpage>
         18
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         8665474
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0310">
       <element-citation id="sbref0310" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fuk-Woo Chan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           G.K.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         207
        </volume>
        <issue>
         11
        </issue>
        <year>
         2013
        </year>
        <fpage>
         1743
        </fpage>
        <lpage>
         1752
        </lpage>
        <pub-id pub-id-type="pmid">
         23532101
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0315">
       <element-citation id="sbref0315" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Galluzzi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Vitale
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Abrams
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Alnemri
          </surname>
          <given-names>
           E.S.
          </given-names>
         </name>
         <name>
          <surname>
           Baehrecke
          </surname>
          <given-names>
           E.H.
          </given-names>
         </name>
         <name>
          <surname>
           Blagosklonny
          </surname>
          <given-names>
           M.V.
          </given-names>
         </name>
         <name>
          <surname>
           Dawson
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Dawson
          </surname>
          <given-names>
           V.L.
          </given-names>
         </name>
         <name>
          <surname>
           El-Deiry
          </surname>
          <given-names>
           W.S.
          </given-names>
         </name>
         <name>
          <surname>
           Fulda
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gottlieb
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hengartner
          </surname>
          <given-names>
           M.O.
          </given-names>
         </name>
         <name>
          <surname>
           Kepp
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Knight
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lipton
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Madeo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Malorni
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Mehlen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Nunez
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Peter
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Piacentini
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rubinsztein
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Simon
          </surname>
          <given-names>
           H.U.
          </given-names>
         </name>
         <name>
          <surname>
           Vandenabeele
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           White
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhivotovsky
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Melino
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Kroemer
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012
        </article-title>
        <source>
         Cell Death Differ.
        </source>
        <volume>
         19
        </volume>
        <issue>
         1
        </issue>
        <year>
         2012
        </year>
        <fpage>
         107
        </fpage>
        <lpage>
         120
        </lpage>
        <pub-id pub-id-type="pmid">
         21760595
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0320">
       <element-citation id="sbref0320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gaunt
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hardie
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Claas
          </surname>
          <given-names>
           E.C.
          </given-names>
         </name>
         <name>
          <surname>
           Simmonds
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Templeton
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         48
        </volume>
        <issue>
         8
        </issue>
        <year>
         2010
        </year>
        <fpage>
         2940
        </fpage>
        <lpage>
         2947
        </lpage>
        <pub-id pub-id-type="pmid">
         20554810
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0325">
       <element-citation id="sbref0325" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gerna
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Campanini
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Rovida
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Percivalle
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Sarasini
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Marchi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baldanti
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         78
        </volume>
        <issue>
         7
        </issue>
        <year>
         2006
        </year>
        <fpage>
         938
        </fpage>
        <lpage>
         949
        </lpage>
        <pub-id pub-id-type="pmid">
         16721849
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0330">
       <element-citation id="sbref0330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gerna
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Passarani
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Battaglia
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rondanelli
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human enteric coronaviruses: antigenic relatedness to human coronavirus OC43 and possible etiologic role in viral gastroenteritis
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         151
        </volume>
        <issue>
         5
        </issue>
        <year>
         1985
        </year>
        <fpage>
         796
        </fpage>
        <lpage>
         803
        </lpage>
        <pub-id pub-id-type="pmid">
         2985710
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0335">
       <element-citation id="sbref0335" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gilden
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious causes of multiple sclerosis
        </article-title>
        <source>
         Lancet Neurol.
        </source>
        <volume>
         4
        </volume>
        <issue>
         3
        </issue>
        <year>
         2005
        </year>
        <fpage>
         195
        </fpage>
        <lpage>
         202
        </lpage>
        <pub-id pub-id-type="pmid">
         15721830
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0340">
       <element-citation id="sbref0340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giovannoni
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Cutter
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
         <name>
          <surname>
           Lunemann
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Munz
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sriram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Steiner
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Hammerschlag
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Gaydos
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious causes of multiple sclerosis
        </article-title>
        <source>
         Lancet Neurol.
        </source>
        <volume>
         5
        </volume>
        <issue>
         10
        </issue>
        <year>
         2006
        </year>
        <fpage>
         887
        </fpage>
        <lpage>
         894
        </lpage>
        <pub-id pub-id-type="pmid">
         16987736
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0345">
       <element-citation id="sbref0345" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giraudon
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Bernard
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inflammation in neuroviral diseases
        </article-title>
        <source>
         J. Neural Transm.
        </source>
        <volume>
         117
        </volume>
        <issue>
         8
        </issue>
        <year>
         2010
        </year>
        <fpage>
         899
        </fpage>
        <lpage>
         906
        </lpage>
        <pub-id pub-id-type="pmid">
         20390431
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0350">
       <element-citation id="sbref0350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nidovirales: evolving the largest RNA virus genome
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         117
        </volume>
        <issue>
         1
        </issue>
        <year>
         2006
        </year>
        <fpage>
         17
        </fpage>
        <lpage>
         37
        </lpage>
        <pub-id pub-id-type="pmid">
         16503362
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0355">
       <element-citation id="sbref0355" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gordon
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gallia
          </surname>
          <given-names>
           G.L.
          </given-names>
         </name>
         <name>
          <surname>
           Del Valle
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Amini
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Khalili
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human polyomavirus JCV and expression of myelin genes
        </article-title>
        <source>
         J. Neurovirol.
        </source>
        <volume>
         6
        </volume>
        <issue>
         Suppl 2
        </issue>
        <year>
         2000
        </year>
        <fpage>
         S92L 97
        </fpage>
        <pub-id pub-id-type="pmid">
         10871794
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0360">
       <element-citation id="sbref0360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greig
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Corner
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Bannister
          </surname>
          <given-names>
           G.L.
          </given-names>
         </name>
         <name>
          <surname>
           Meads
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
         <name>
          <surname>
           Julian
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A hemagglutinating virus producing encephalomyelitis in baby pigs
        </article-title>
        <source>
         Can. J. Comp. Med. Vet. Sci.
        </source>
        <volume>
         26
        </volume>
        <issue>
         3
        </issue>
        <year>
         1962
        </year>
        <fpage>
         49
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         17649356
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0365">
       <element-citation id="sbref0365" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Shao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pei
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Leong
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multiple organ infection and the pathogenesis of SARS
        </article-title>
        <source>
         J. Exp. Med.
        </source>
        <volume>
         202
        </volume>
        <issue>
         3
        </issue>
        <year>
         2005
        </year>
        <fpage>
         415
        </fpage>
        <lpage>
         424
        </lpage>
        <pub-id pub-id-type="pmid">
         16043521
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0370">
       <element-citation id="sbref0370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           Z.X.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Butt
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Shortridge
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
        </article-title>
        <source>
         Science
        </source>
        <volume>
         302
        </volume>
        <issue>
         5643
        </issue>
        <year>
         2003
        </year>
        <fpage>
         276
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0375">
       <element-citation id="sbref0375" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Korteweg
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           McNutt
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenetic mechanisms of severe acute respiratory syndrome
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         133
        </volume>
        <issue>
         1
        </issue>
        <year>
         2008
        </year>
        <fpage>
         4
        </fpage>
        <lpage>
         12
        </lpage>
        <pub-id pub-id-type="pmid">
         17825937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0380">
       <element-citation id="sbref0380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jonges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Diab
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ghobashy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alhajri
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Thani
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Marri
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Romaihi
          </surname>
          <given-names>
           H.E.
          </given-names>
         </name>
         <name>
          <surname>
           Al Khal
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           AlHajri
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         14
        </volume>
        <issue>
         2
        </issue>
        <year>
         2014
        </year>
        <fpage>
         140
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0385">
       <element-citation id="sbref0385" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamre
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Procknow
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new virus isolated from the human respiratory tract
        </article-title>
        <issue-title>
         Proceedings of the Society for Experimental Biology and Medicine
        </issue-title>
        <source>
         Soc. Exp. Biol. Med.
        </source>
        <volume>
         121
        </volume>
        <issue>
         1
        </issue>
        <year>
         1966
        </year>
        <fpage>
         190
        </fpage>
        <lpage>
         193
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0390">
       <element-citation id="sbref0390" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hankins
          </surname>
          <given-names>
           D.G.
          </given-names>
         </name>
         <name>
          <surname>
           Rosekrans
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overview, prevention, and treatment of rabies
        </article-title>
        <issue-title>
         Mayo Clinic Proceedings
        </issue-title>
        <source>
         Mayo Clinic
        </source>
        <volume>
         79
        </volume>
        <issue>
         5
        </issue>
        <year>
         2004
        </year>
        <fpage>
         671
        </fpage>
        <lpage>
         676
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0395">
       <element-citation id="sbref0395" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The environment and disease: association or causation?
        </article-title>
        <source>
         Proc. R. Soc. Med.
        </source>
        <volume>
         58
        </volume>
        <year>
         1965
        </year>
        <fpage>
         295
        </fpage>
        <lpage>
         300
        </lpage>
        <pub-id pub-id-type="pmid">
         14283879
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0400">
       <element-citation id="sbref0400" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hogue
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
         <name>
          <surname>
           Machamer
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronavirus structural proteins and virus assembly
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <source>
         Nidoviruses
        </source>
        <year>
         2008
        </year>
        <publisher-name>
         ASM Press
        </publisher-name>
        <publisher-loc>
         Washington
        </publisher-loc>
        <fpage>
         179
        </fpage>
        <lpage>
         200
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0405">
       <element-citation id="sbref0405" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hosking
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Lane
          </surname>
          <given-names>
           T.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The pathogenesis of murine coronavirus infection of the central nervous system
        </article-title>
        <source>
         Crit. Rev. Immunol.
        </source>
        <volume>
         30
        </volume>
        <issue>
         2
        </issue>
        <year>
         2010
        </year>
        <fpage>
         119
        </fpage>
        <lpage>
         130
        </lpage>
        <pub-id pub-id-type="pmid">
         20370625
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0410">
       <element-citation id="sbref0410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hovanec
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Flanagan
          </surname>
          <given-names>
           T.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of antibodies to human coronaviruses 229E and OC43 in the sera of multiple sclerosis patients and normal subjects
        </article-title>
        <source>
         Infect. Immun.
        </source>
        <volume>
         41
        </volume>
        <issue>
         1
        </issue>
        <year>
         1983
        </year>
        <fpage>
         426
        </fpage>
        <lpage>
         429
        </lpage>
        <pub-id pub-id-type="pmid">
         6345398
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0415">
       <element-citation id="sbref0415" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome vs. the Middle East respiratory syndrome
        </article-title>
        <source>
         Curr. Opin. Pulm. Med.
        </source>
        <volume>
         20
        </volume>
        <issue>
         3
        </issue>
        <year>
         2014
        </year>
        <fpage>
         233
        </fpage>
        <lpage>
         241
        </lpage>
        <pub-id pub-id-type="pmid">
         24626235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0420">
       <element-citation id="sbref0420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Iacono
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
         <name>
          <surname>
           Kazi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Both spike and background genes contribute to murine coronavirus neurovirulence
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         80
        </volume>
        <issue>
         14
        </issue>
        <year>
         2006
        </year>
        <fpage>
         6834
        </fpage>
        <lpage>
         6843
        </lpage>
        <pub-id pub-id-type="pmid">
         16809289
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0425">
       <element-citation id="sbref0425" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ison
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           F.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral infections in immunocompromised patients: what's new with respiratory viruses?
        </article-title>
        <source>
         Curr Opin Infect Dis
        </source>
        <volume>
         15
        </volume>
        <issue>
         4
        </issue>
        <year>
         2002
        </year>
        <fpage>
         355
        </fpage>
        <lpage>
         367
        </lpage>
        <pub-id pub-id-type="pmid">
         12130931
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0430">
       <element-citation id="sbref0430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Itzhaki
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Wozniak
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Appelt
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Balin
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infiltration of the brain by pathogens causes Alzheimer's disease
        </article-title>
        <source>
         Neurobiol. Aging
        </source>
        <volume>
         25
        </volume>
        <issue>
         5
        </issue>
        <year>
         2004
        </year>
        <fpage>
         619
        </fpage>
        <lpage>
         627
        </lpage>
        <pub-id pub-id-type="pmid">
         15172740
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0435">
       <element-citation id="sbref0435" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Fragoso
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Almazan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Mushynski
          </surname>
          <given-names>
           W.E.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         349
        </volume>
        <issue>
         2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         335
        </fpage>
        <lpage>
         346
        </lpage>
        <pub-id pub-id-type="pmid">
         16527322
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0440">
       <element-citation id="sbref0440" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           St-Jean
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Brison
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Marceau
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mutations in the spike glycoprotein of human coronavirus OC43 modulate disease in BALB/c mice from encephalitis to flaccid paralysis and demyelination
        </article-title>
        <source>
         J. Neurovirol.
        </source>
        <volume>
         16
        </volume>
        <issue>
         4
        </issue>
        <year>
         2010
        </year>
        <fpage>
         279
        </fpage>
        <lpage>
         293
        </lpage>
        <pub-id pub-id-type="pmid">
         20642316
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0445">
       <element-citation id="sbref0445" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vacuolating encephalitis in mice infected by human coronavirus OC43
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         315
        </volume>
        <issue>
         1
        </issue>
        <year>
         2003
        </year>
        <fpage>
         20
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         14592756
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0450">
       <element-citation id="sbref0450" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Boltz
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Webster
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Smeyne
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral parkinsonism
        </article-title>
        <source>
         Biochim. Biophys. Acta
        </source>
        <volume>
         1792
        </volume>
        <issue>
         7
        </issue>
        <year>
         2009
        </year>
        <fpage>
         714
        </fpage>
        <lpage>
         721
        </lpage>
        <pub-id pub-id-type="pmid">
         18760350
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0455">
       <element-citation id="sbref0455" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jartti
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Jartti
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ruuskanen
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Soderlund-Venermo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         New respiratory viral infections
        </article-title>
        <source>
         Curr. Opin. Pulm. Med.
        </source>
        <volume>
         18
        </volume>
        <issue>
         3
        </issue>
        <year>
         2012
        </year>
        <fpage>
         271
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         22366993
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0460">
       <element-citation id="sbref0460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jimenez-Guardeno
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Delgado
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Castano-Rodriguez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         10
        </volume>
        <issue>
         8
        </issue>
        <year>
         2014
        </year>
        <fpage>
         e1004320
        </fpage>
        <pub-id pub-id-type="pmid">
         25122212
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0465">
       <element-citation id="sbref0465" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jurgens
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Amancherla
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influenza infection induces neuroinflammation, alters hippocampal neuron morphology, and impairs cognition in adult mice
        </article-title>
        <source>
         J. Neurosci.
        </source>
        <volume>
         32
        </volume>
        <issue>
         12
        </issue>
        <year>
         2012
        </year>
        <fpage>
         3958
        </fpage>
        <lpage>
         3968
        </lpage>
        <pub-id pub-id-type="pmid">
         22442063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0470">
       <element-citation id="sbref0470" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kaiser
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Upton
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Mocarski
          </surname>
          <given-names>
           E.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral modulation of programmed necrosis
        </article-title>
        <source>
         Curr Opin Virol
        </source>
        <volume>
         3
        </volume>
        <year>
         2013
        </year>
        <fpage>
         296
        </fpage>
        <lpage>
         306
        </lpage>
        <pub-id pub-id-type="pmid">
         23773332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0475">
       <element-citation id="sbref0475" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kakalacheva
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Munz
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lunemann
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral triggers of multiple sclerosis
        </article-title>
        <source>
         Biochim. Biophys. Acta
        </source>
        <volume>
         1812
        </volume>
        <issue>
         2
        </issue>
        <year>
         2011
        </year>
        <fpage>
         132
        </fpage>
        <lpage>
         140
        </lpage>
        <pub-id pub-id-type="pmid">
         20600868
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0480">
       <element-citation id="sbref0480" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kaplan
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Osame
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kubota
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Igata
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Nishitani
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Maeda
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Khabbaz
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Janssen
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I
        </article-title>
        <source>
         J. Acquir. Immune Defic. Syndr.
        </source>
        <volume>
         3
        </volume>
        <issue>
         11
        </issue>
        <year>
         1990
        </year>
        <fpage>
         1096
        </fpage>
        <lpage>
         1101
        </lpage>
        <pub-id pub-id-type="pmid">
         2213510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0485">
       <element-citation id="sbref0485" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kawashima
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ioi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ushio
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yamanaka
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Matsumoto
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Nakayama
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cerebrospinal fluid analysis in children with seizures from respiratory syncytial virus infection
        </article-title>
        <source>
         Scand. J. Infect. Dis.
        </source>
        <volume>
         41
        </volume>
        <issue>
         3
        </issue>
        <year>
         2009
        </year>
        <fpage>
         228
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="pmid">
         19117245
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0490">
       <element-citation id="sbref0490" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kazi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lissenberg
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression of hemagglutinin esterase protein from recombinant mouse hepatitis virus enhances neurovirulence
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         79
        </volume>
        <issue>
         24
        </issue>
        <year>
         2005
        </year>
        <fpage>
         15064
        </fpage>
        <lpage>
         15073
        </lpage>
        <pub-id pub-id-type="pmid">
         16306577
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0495">
       <element-citation id="sbref0495" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Corey
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Monocyte/macrophage traffic in HIV and SIV encephalitis
        </article-title>
        <source>
         J. Leukoc. Biol.
        </source>
        <volume>
         74
        </volume>
        <issue>
         5
        </issue>
        <year>
         2003
        </year>
        <fpage>
         650
        </fpage>
        <lpage>
         656
        </lpage>
        <pub-id pub-id-type="pmid">
         12960230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0500">
       <element-citation id="sbref0500" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koch
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The Aetiology of Tuberculosis
        </chapter-title>
        <comment>
         (translation of Die Aetiologie der Tuberculose (1882))
        </comment>
        <year>
         1942
        </year>
        <publisher-name>
         Dover Publications
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib0505">
       <element-citation id="sbref0505" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koetzner
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kuo
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Goebel
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dean
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
         <name>
          <surname>
           Parker
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Accessory protein 5a is a major antagonist of the antiviral action of interferon against murine coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         84
        </volume>
        <issue>
         16
        </issue>
        <year>
         2010
        </year>
        <fpage>
         8262
        </fpage>
        <lpage>
         8274
        </lpage>
        <pub-id pub-id-type="pmid">
         20519394
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0510">
       <element-citation id="sbref0510" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kopecky-Bromberg
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Martinez-Sobrido
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Palese
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <issue>
         2
        </issue>
        <year>
         2007
        </year>
        <fpage>
         548
        </fpage>
        <lpage>
         557
        </lpage>
        <pub-id pub-id-type="pmid">
         17108024
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0515">
       <element-citation id="sbref0515" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Peret
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Emery
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Urbani
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Comer
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Dowell
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Humphrey
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Shieh
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Guarner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Paddock
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Fields
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           DeRisi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hughes
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           LeDuc
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Bellini
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <issue>
         20
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0520">
       <element-citation id="sbref0520" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Riteau
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rimmelzwaan
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenesis of influenza virus infections: the good, the bad and the ugly
        </article-title>
        <source>
         Curr Opin Virol
        </source>
        <volume>
         2
        </volume>
        <issue>
         3
        </issue>
        <year>
         2012
        </year>
        <fpage>
         276
        </fpage>
        <lpage>
         286
        </lpage>
        <pub-id pub-id-type="pmid">
         22709515
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0525">
       <element-citation id="sbref0525" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kurtzke
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiologic evidence for multiple sclerosis as an infection
        </article-title>
        <source>
         Clin. Microbiol. Rev.
        </source>
        <volume>
         6
        </volume>
        <issue>
         4
        </issue>
        <year>
         1993
        </year>
        <fpage>
         382
        </fpage>
        <lpage>
         427
        </lpage>
        <pub-id pub-id-type="pmid">
         8269393
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0530">
       <element-citation id="sbref0530" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The molecular biology of coronaviruses
        </article-title>
        <source>
         Adv. Virus Res.
        </source>
        <volume>
         48
        </volume>
        <year>
         1997
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         100
        </lpage>
        <pub-id pub-id-type="pmid">
         9233431
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0535">
       <element-citation id="sbref0535" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lampert
          </surname>
          <given-names>
           P.W.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Kniazeff
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanism of demyelination in JHM virus encephalomyelitis. Electron microscopic studies
        </article-title>
        <source>
         Acta Neuropathol. (Berl.)
        </source>
        <volume>
         24
        </volume>
        <issue>
         1
        </issue>
        <year>
         1973
        </year>
        <fpage>
         76
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         4349379
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0540">
       <element-citation id="sbref0540" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           H.E.
          </given-names>
         </name>
         <name>
          <surname>
           Reed
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Tyrrell
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of rhinoviruses and coronaviruses from 38 colds in adults
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         5
        </volume>
        <issue>
         3
        </issue>
        <year>
         1980
        </year>
        <fpage>
         221
        </fpage>
        <lpage>
         229
        </lpage>
        <pub-id pub-id-type="pmid">
         6262450
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0545">
       <element-citation id="sbref0545" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lassnig
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sanchez
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Egerbacher
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Walter
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Majer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kolbe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Pallares
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of a transgenic mouse model susceptible to human coronavirus 229E
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A.
        </source>
        <volume>
         102
        </volume>
        <issue>
         23
        </issue>
        <year>
         2005
        </year>
        <fpage>
         8275
        </fpage>
        <lpage>
         8280
        </lpage>
        <pub-id pub-id-type="pmid">
         15919828
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0550">
       <element-citation id="sbref0550" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           So
          </surname>
          <given-names>
           L.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular epidemiology of human coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <issue>
         21
        </issue>
        <year>
         2011
        </year>
        <fpage>
         11325
        </fpage>
        <lpage>
         11337
        </lpage>
        <pub-id pub-id-type="pmid">
         21849456
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0555">
       <element-citation id="sbref0555" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sumoylation of the nucleocapsid protein of severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         FEBS Lett.
        </source>
        <volume>
         579
        </volume>
        <issue>
         11
        </issue>
        <year>
         2005
        </year>
        <fpage>
         2387
        </fpage>
        <lpage>
         2396
        </lpage>
        <pub-id pub-id-type="pmid">
         15848177
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0560">
       <element-citation id="sbref0560" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           McEachern
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Field
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Eaton
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <volume>
         310
        </volume>
        <issue>
         5748
        </issue>
        <year>
         2005
        </year>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0565">
       <element-citation id="sbref0565" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.X.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus envelope protein: a small membrane protein with multiple functions
        </article-title>
        <source>
         Cell. Mol. Life Sci.: CMLS
        </source>
        <volume>
         64
        </volume>
        <issue>
         16
        </issue>
        <year>
         2007
        </year>
        <fpage>
         2043
        </fpage>
        <lpage>
         2048
        </lpage>
        <pub-id pub-id-type="pmid">
         17530462
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0570">
       <element-citation id="sbref0570" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackay
          </surname>
          <given-names>
           I.M.
          </given-names>
         </name>
         <name>
          <surname>
           Arden
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
         <name>
          <surname>
           Speicher
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           O’Neil
          </surname>
          <given-names>
           N.T.
          </given-names>
         </name>
         <name>
          <surname>
           McErlean
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Greer
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Nissen
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Sloots
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Co-circulation of four human coronaviruses (HCoVs) in Queensland children with acute respiratory tract illnesses in 2004
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         4
        </volume>
        <issue>
         4
        </issue>
        <year>
         2012
        </year>
        <fpage>
         637
        </fpage>
        <lpage>
         653
        </lpage>
        <pub-id pub-id-type="pmid">
         22590689
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0575">
       <element-citation id="sbref0575" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Gubler
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Petersen
          </surname>
          <given-names>
           L.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses
        </article-title>
        <source>
         Nat. Med.
        </source>
        <volume>
         10
        </volume>
        <issue>
         12 Suppl
        </issue>
        <year>
         2004
        </year>
        <fpage>
         S98
        </fpage>
        <lpage>
         S109
        </lpage>
        <pub-id pub-id-type="pmid">
         15577938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0580">
       <element-citation id="sbref0580" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Macneughton
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ribonucleoprotein-like structures from coronavirus particles
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <volume>
         39
        </volume>
        <issue>
         3
        </issue>
        <year>
         1978
        </year>
        <fpage>
         545
        </fpage>
        <lpage>
         549
        </lpage>
        <pub-id pub-id-type="pmid">
         207820
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0585">
       <element-citation id="sbref0585" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mathieu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pohl
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Szecsi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Trajkovic-Bodennec
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Devergnas
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Raoul
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cosset
          </surname>
          <given-names>
           F.L.
          </given-names>
         </name>
         <name>
          <surname>
           Gerlier
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wild
          </surname>
          <given-names>
           T.F.
          </given-names>
         </name>
         <name>
          <surname>
           Horvat
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nipah virus uses leukocytes for efficient dissemination within a host
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <issue>
         15
        </issue>
        <year>
         2011
        </year>
        <fpage>
         7863
        </fpage>
        <lpage>
         7871
        </lpage>
        <pub-id pub-id-type="pmid">
         21593145
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0590">
       <element-citation id="sbref0590" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Paterson
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Murine hepatitis virus--a model for virus-induced CNS demyelination
        </article-title>
        <source>
         J. Neurovirol.
        </source>
        <volume>
         8
        </volume>
        <issue>
         2
        </issue>
        <year>
         2002
        </year>
        <fpage>
         76
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         11935460
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0595">
       <element-citation id="sbref0595" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mattson
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Haughey
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Nath
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cell death in HIV dementia
        </article-title>
        <source>
         Cell Death Differ.
        </source>
        <volume>
         12
        </volume>
        <issue>
         Suppl. 1
        </issue>
        <year>
         2005
        </year>
        <fpage>
         893
        </fpage>
        <lpage>
         904
        </lpage>
        <pub-id pub-id-type="pmid">
         15761472
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0600">
       <element-citation id="sbref0600" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P.B.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Pewe
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hickey
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Manzel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           H.P.
          </given-names>
         </name>
         <name>
          <surname>
           Halabi
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sigmund
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Kirby
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Look
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <issue>
         2
        </issue>
        <year>
         2007
        </year>
        <fpage>
         813
        </fpage>
        <lpage>
         821
        </lpage>
        <pub-id pub-id-type="pmid">
         17079315
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0605">
       <element-citation id="sbref0605" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McGavern
          </surname>
          <given-names>
           D.B.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Illuminating viral infections in the nervous system
        </article-title>
        <source>
         Nat. Rev. Immunol.
        </source>
        <volume>
         11
        </volume>
        <issue>
         5
        </issue>
        <year>
         2011
        </year>
        <fpage>
         318
        </fpage>
        <lpage>
         329
        </lpage>
        <pub-id pub-id-type="pmid">
         21508982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0610">
       <element-citation id="sbref0610" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McIntosh
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Chanock
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Growth in suckling-mouse brain of IBV-like viruses from patients with upper respiratory tract disease
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A.
        </source>
        <volume>
         58
        </volume>
        <issue>
         6
        </issue>
        <year>
         1967
        </year>
        <fpage>
         2268
        </fpage>
        <lpage>
         2273
        </lpage>
        <pub-id pub-id-type="pmid">
         4298953
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0615">
       <element-citation id="sbref0615" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mesel-Lemoine
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Millet
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Vidalain
          </surname>
          <given-names>
           P.O.
          </given-names>
         </name>
         <name>
          <surname>
           Law
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lorin
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Escriou
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Albert
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Nal
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Tangy
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human coronavirus responsible for the common cold massively kills dendritic cells but not monocytes
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         86
        </volume>
        <issue>
         14
        </issue>
        <year>
         2012
        </year>
        <fpage>
         7577
        </fpage>
        <lpage>
         7587
        </lpage>
        <pub-id pub-id-type="pmid">
         22553325
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0620">
       <element-citation id="sbref0620" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Millichap
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Millichap
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of viral infections in the etiology of febrile seizures
        </article-title>
        <source>
         Pediatr. Neurol.
        </source>
        <volume>
         35
        </volume>
        <issue>
         3
        </issue>
        <year>
         2006
        </year>
        <fpage>
         165
        </fpage>
        <lpage>
         172
        </lpage>
        <pub-id pub-id-type="pmid">
         16939854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0625">
       <element-citation id="sbref0625" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Millichap
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wainwright
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neurological complications of respiratory syncytial virus infection: case series and review of literature
        </article-title>
        <source>
         J. Child Neurol.
        </source>
        <volume>
         24
        </volume>
        <issue>
         12
        </issue>
        <year>
         2009
        </year>
        <fpage>
         1499
        </fpage>
        <lpage>
         1503
        </lpage>
        <pub-id pub-id-type="pmid">
         19264736
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0630">
       <element-citation id="sbref0630" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mori
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Nishiyama
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yokochi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kimura
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Olfactory transmission of neurotropic viruses
        </article-title>
        <source>
         J. Neurovirol.
        </source>
        <volume>
         11
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         129
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="pmid">
         16036791
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0635">
       <element-citation id="sbref0635" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morichi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kawashima
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ioi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yamanaka
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Kashiwagi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hoshika
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Nakayama
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Classification of acute encephalopathy in respiratory syncytial virus infection
        </article-title>
        <source>
         J. Infect. Chemother.
        </source>
        <volume>
         17
        </volume>
        <issue>
         6
        </issue>
        <year>
         2011
        </year>
        <fpage>
         776
        </fpage>
        <lpage>
         781
        </lpage>
        <pub-id pub-id-type="pmid">
         21647570
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0640">
       <element-citation id="sbref0640" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mueller
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wimmer
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Cello
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         111
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         175
        </fpage>
        <lpage>
         193
        </lpage>
        <pub-id pub-id-type="pmid">
         15885840
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0645">
       <element-citation id="sbref0645" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Prescott
          </surname>
          <given-names>
           J.B.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Long
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenke
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <volume>
         2
        </volume>
        <year>
         2012
        </year>
        <fpage>
         736
        </fpage>
        <pub-id pub-id-type="pmid">
         23071900
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0650">
       <element-citation id="sbref0650" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Myint
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Human coronavirus infections
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Siddell
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
        </person-group>
        <source>
         The Coronaviridae
        </source>
        <year>
         1995
        </year>
        <publisher-name>
         Plenum Press
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
        <fpage>
         389
        </fpage>
        <lpage>
         401
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0655">
       <element-citation id="sbref0655" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronavirus accessory proteins
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <source>
         Nidoviruses
        </source>
        <year>
         2008
        </year>
        <publisher-name>
         ASM Press
        </publisher-name>
        <publisher-loc>
         Washington, DC
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib0660">
       <element-citation id="sbref0660" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nath
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Berger
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         HIV dementia
        </article-title>
        <source>
         Curr. Treat. Options Neurol.
        </source>
        <volume>
         6
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         139
        </fpage>
        <lpage>
         151
        </lpage>
        <pub-id pub-id-type="pmid">
         14759346
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0665">
       <element-citation id="sbref0665" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Neal
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Flaviviruses are neurotropic, but how do they invade the CNS?
        </article-title>
        <source>
         J. Infect.
        </source>
        <volume>
         69
        </volume>
        <issue>
         3
        </issue>
        <year>
         2014
        </year>
        <fpage>
         203
        </fpage>
        <lpage>
         215
        </lpage>
        <pub-id pub-id-type="pmid">
         24880028
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0670">
       <element-citation id="sbref0670" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Cassell
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         82
        </volume>
        <issue>
         15
        </issue>
        <year>
         2008
        </year>
        <fpage>
         7264
        </fpage>
        <lpage>
         7275
        </lpage>
        <pub-id pub-id-type="pmid">
         18495771
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0675">
       <element-citation id="sbref0675" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Neuman
          </surname>
          <given-names>
           B.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kiss
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Kunding
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Bhella
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Baksh
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Connelly
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Droese
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Klaus
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sawicki
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Siddell
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Stamou
          </surname>
          <given-names>
           D.G.
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           I.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Buchmeier
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A structural analysis of M protein in coronavirus assembly and morphology
        </article-title>
        <source>
         J. Struct. Biol.
        </source>
        <volume>
         174
        </volume>
        <issue>
         1
        </issue>
        <year>
         2011
        </year>
        <fpage>
         11
        </fpage>
        <lpage>
         22
        </lpage>
        <pub-id pub-id-type="pmid">
         21130884
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0680">
       <element-citation id="sbref0680" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Butany
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Beh
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Poutanen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS
        </article-title>
        <source>
         PLoS Med.
        </source>
        <volume>
         3
        </volume>
        <issue>
         2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         e27
        </fpage>
        <pub-id pub-id-type="pmid">
         16379499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0685">
       <element-citation id="sbref0685" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nicholson
          </surname>
          <given-names>
           K.G.
          </given-names>
         </name>
         <name>
          <surname>
           Wood
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Zambon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influenza
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         362
        </volume>
        <issue>
         9397
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1733
        </fpage>
        <lpage>
         1745
        </lpage>
        <pub-id pub-id-type="pmid">
         14643124
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0690">
       <element-citation id="sbref0690" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Verdia-Baguena
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Jimenez-Guardeno
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Delgado
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Castano-Rodriguez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Alcaraz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Aguilella
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         10
        </volume>
        <issue>
         5
        </issue>
        <year>
         2014
        </year>
        <fpage>
         e1004077
        </fpage>
        <pub-id pub-id-type="pmid">
         24788150
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0695">
       <element-citation id="sbref0695" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O’Donnell
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rall
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Blue moon neurovirology: the merits of studying rare CNS diseases of viral origin
        </article-title>
        <source>
         J. Neuroimmune Pharmacol.
        </source>
        <volume>
         5
        </volume>
        <issue>
         3
        </issue>
        <year>
         2010
        </year>
        <fpage>
         443
        </fpage>
        <lpage>
         455
        </lpage>
        <pub-id pub-id-type="pmid">
         20419352
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0700">
       <element-citation id="sbref0700" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ozkale
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Erol
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Ozkale
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Demir
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Alehan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute disseminated encephalomyelitis associated with influenza A H1N1 infection
        </article-title>
        <source>
         Pediatr. Neurol.
        </source>
        <volume>
         47
        </volume>
        <issue>
         1
        </issue>
        <year>
         2012
        </year>
        <fpage>
         62
        </fpage>
        <lpage>
         64
        </lpage>
        <pub-id pub-id-type="pmid">
         22704021
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0705">
       <element-citation id="sbref0705" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome
        </article-title>
        <source>
         Nat. Med.
        </source>
        <volume>
         10
        </volume>
        <issue>
         12 Suppl
        </issue>
        <year>
         2004
        </year>
        <fpage>
         S88
        </fpage>
        <lpage>
         S97
        </lpage>
        <pub-id pub-id-type="pmid">
         15577937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0710">
       <element-citation id="sbref0710" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Phillips
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chua
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lavi
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenesis of chimeric MHV4/MHV-A59 recombinant viruses: the murine coronavirus spike protein is a major determinant of neurovirulence
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         73
        </volume>
        <issue>
         9
        </issue>
        <year>
         1999
        </year>
        <fpage>
         7752
        </fpage>
        <lpage>
         7760
        </lpage>
        <pub-id pub-id-type="pmid">
         10438865
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0715">
       <element-citation id="sbref0715" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Phillips
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chua
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Rall
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Murine coronavirus spike glycoprotein mediates degree of viral spread, inflammation, and virus-induced immunopathology in the central nervous system
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         301
        </volume>
        <issue>
         1
        </issue>
        <year>
         2002
        </year>
        <fpage>
         109
        </fpage>
        <lpage>
         120
        </lpage>
        <pub-id pub-id-type="pmid">
         12359451
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0135">
       <element-citation id="sbref0135" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Public Health Agency of Canada
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Public Health Notice: Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
        </chapter-title>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="bib0720">
       <element-citation id="sbref0720" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS: emergence of a novel human coronavirus
        </article-title>
        <source>
         Curr Opin Virol
        </source>
        <volume>
         5
        </volume>
        <year>
         2014
        </year>
        <fpage>
         58
        </fpage>
        <lpage>
         62
        </lpage>
        <pub-id pub-id-type="pmid">
         24584035
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0725">
       <element-citation id="sbref0725" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Resta
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Luby
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenfeld
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Siegel
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and propagation of a human enteric coronavirus
        </article-title>
        <source>
         Science
        </source>
        <volume>
         229
        </volume>
        <issue>
         4717
        </issue>
        <year>
         1985
        </year>
        <fpage>
         978
        </fpage>
        <lpage>
         981
        </lpage>
        <pub-id pub-id-type="pmid">
         2992091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0730">
       <element-citation id="sbref0730" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reuter
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Gomez
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Van Den Pol
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Systemic immune deficiency necessary for cytomegalovirus invasion of the mature brain
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         78
        </volume>
        <issue>
         3
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1473
        </fpage>
        <lpage>
         1487
        </lpage>
        <pub-id pub-id-type="pmid">
         14722303
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0735">
       <element-citation id="sbref0735" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rhoades
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Tabor-Godwin
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tsueng
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Feuer
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enterovirus infections of the central nervous system
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         411
        </volume>
        <issue>
         2
        </issue>
        <year>
         2011
        </year>
        <fpage>
         288
        </fpage>
        <lpage>
         305
        </lpage>
        <pub-id pub-id-type="pmid">
         21251690
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0740">
       <element-citation id="sbref0740" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riski
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hovi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus infections of man associated with diseases other than the common cold
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         6
        </volume>
        <issue>
         3
        </issue>
        <year>
         1980
        </year>
        <fpage>
         259
        </fpage>
        <lpage>
         265
        </lpage>
        <pub-id pub-id-type="pmid">
         6262459
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0745">
       <element-citation id="sbref0745" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Risku
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lappalainen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rasanen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Vesikari
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of human coronaviruses in children with acute gastroenteritis
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <volume>
         48
        </volume>
        <issue>
         1
        </issue>
        <year>
         2010
        </year>
        <fpage>
         27
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         20233673
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0750">
       <element-citation id="sbref0750" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Background paper. Coronavirus M and HE: two peculiar glycoproteins
        </article-title>
        <source>
         Adv. Exp. Med. Biol.
        </source>
        <volume>
         276
        </volume>
        <year>
         1990
        </year>
        <fpage>
         91
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="pmid">
         2103107
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0755">
       <element-citation id="sbref0755" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ruch
          </surname>
          <given-names>
           T.R.
          </given-names>
         </name>
         <name>
          <surname>
           Machamer
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The coronavirus E protein: assembly and beyond
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         4
        </volume>
        <issue>
         3
        </issue>
        <year>
         2012
        </year>
        <fpage>
         363
        </fpage>
        <lpage>
         382
        </lpage>
        <pub-id pub-id-type="pmid">
         22590676
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0760">
       <element-citation id="sbref0760" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schuh
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wimmer
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Hametner
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Haider
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Van Dam
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Liblau
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Probert
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Binder
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bauer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bradl
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Mahad
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lassmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models
        </article-title>
        <source>
         Acta Neuropathol.
        </source>
        <volume>
         128
        </volume>
        <issue>
         2
        </issue>
        <year>
         2014
        </year>
        <fpage>
         247
        </fpage>
        <lpage>
         266
        </lpage>
        <pub-id pub-id-type="pmid">
         24622774
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0765">
       <element-citation id="sbref0765" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Severance
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
         <name>
          <surname>
           Dickerson
          </surname>
          <given-names>
           F.B.
          </given-names>
         </name>
         <name>
          <surname>
           Viscidi
          </surname>
          <given-names>
           R.P.
          </given-names>
         </name>
         <name>
          <surname>
           Bossis
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Stallings
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Origoni
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Sullens
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yolken
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms
        </article-title>
        <source>
         Schizophr. Bull.
        </source>
        <volume>
         37
        </volume>
        <issue>
         1
        </issue>
        <year>
         2011
        </year>
        <fpage>
         101
        </fpage>
        <lpage>
         107
        </lpage>
        <pub-id pub-id-type="pmid">
         19491313
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0770">
       <element-citation id="sbref0770" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sibley
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bamford
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Clark
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical viral infections and multiple sclerosis
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         1
        </volume>
        <issue>
         8441
        </issue>
        <year>
         1985
        </year>
        <fpage>
         1313
        </fpage>
        <lpage>
         1315
        </lpage>
        <pub-id pub-id-type="pmid">
         2860501
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0775">
       <element-citation id="sbref0775" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sips
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wilschut
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Smit
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neuroinvasive flavivirus infections
        </article-title>
        <source>
         Rev. Med. Virol.
        </source>
        <volume>
         22
        </volume>
        <issue>
         2
        </issue>
        <year>
         2012
        </year>
        <fpage>
         69
        </fpage>
        <lpage>
         87
        </lpage>
        <pub-id pub-id-type="pmid">
         22086854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0780">
       <element-citation id="sbref0780" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus nucleocapsid protein does not modulate transcription of the human FGL2 gene
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <volume>
         90
        </volume>
        <issue>
         Pt 9
        </issue>
        <year>
         2009
        </year>
        <fpage>
         2107
        </fpage>
        <lpage>
         2113
        </lpage>
        <pub-id pub-id-type="pmid">
         19423547
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0785">
       <element-citation id="sbref0785" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sloots
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Whiley
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lambert
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
         <name>
          <surname>
           Nissen
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging respiratory agents: new viruses for old diseases?
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <volume>
         42
        </volume>
        <issue>
         3
        </issue>
        <year>
         2008
        </year>
        <fpage>
         233
        </fpage>
        <lpage>
         243
        </lpage>
        <pub-id pub-id-type="pmid">
         18406664
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0790">
       <element-citation id="sbref0790" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spiegel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Schneider
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Weidmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hufert
          </surname>
          <given-names>
           F.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <volume>
         87
        </volume>
        <issue>
         Pt 7
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1953
        </fpage>
        <lpage>
         1960
        </lpage>
        <pub-id pub-id-type="pmid">
         16760397
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0795">
       <element-citation id="sbref0795" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           St-Jean
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Freymuth
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human respiratory coronavirus OC43: genetic stability and neuroinvasion
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         78
        </volume>
        <issue>
         16
        </issue>
        <year>
         2004
        </year>
        <fpage>
         8824
        </fpage>
        <lpage>
         8834
        </lpage>
        <pub-id pub-id-type="pmid">
         15280490
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0800">
       <element-citation id="sbref0800" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stensballe
          </surname>
          <given-names>
           L.G.
          </given-names>
         </name>
         <name>
          <surname>
           Devasundaram
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Simoes
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus
        </article-title>
        <source>
         Pediatr. Infect. Dis. J.
        </source>
        <volume>
         22
        </volume>
        <issue>
         2 Suppl
        </issue>
        <year>
         2003
        </year>
        <fpage>
         S21
        </fpage>
        <lpage>
         S32
        </lpage>
        <pub-id pub-id-type="pmid">
         12671449
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0805">
       <element-citation id="sbref0805" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stewart
          </surname>
          <given-names>
           J.N.
          </given-names>
         </name>
         <name>
          <surname>
           Mounir
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus gene expression in the brains of multiple sclerosis patients
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         191
        </volume>
        <issue>
         1
        </issue>
        <year>
         1992
        </year>
        <fpage>
         502
        </fpage>
        <lpage>
         505
        </lpage>
        <pub-id pub-id-type="pmid">
         1413524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0810">
       <element-citation id="sbref0810" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Surjit
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lal
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS-CoV nucleocapsid protein: a protein with multifarious activities
        </article-title>
        <source>
         Infect. Genet. Evol.
        </source>
        <volume>
         8
        </volume>
        <issue>
         4
        </issue>
        <year>
         2008
        </year>
        <fpage>
         397
        </fpage>
        <lpage>
         405
        </lpage>
        <pub-id pub-id-type="pmid">
         17881296
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0815">
       <element-citation id="sbref0815" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Arnold
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Antel
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Virus-induced autoimmune reactions in the CNS
        </article-title>
        <source>
         Curr. Top. Microbiol. Immunol.
        </source>
        <volume>
         253
        </volume>
        <year>
         2001
        </year>
        <fpage>
         247
        </fpage>
        <lpage>
         271
        </lpage>
        <pub-id pub-id-type="pmid">
         11417138
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0820">
       <element-citation id="sbref0820" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Brison
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviruses as encephalitis-inducing infectious agents
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Tkachev
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <source>
         Non-flavirus Encephalitis
        </source>
        <year>
         2011
        </year>
        <publisher-name>
         In-Tech
        </publisher-name>
        <fpage>
         185
        </fpage>
        <lpage>
         202
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0825">
       <element-citation id="sbref0825" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Pathogenesis of human coronaviruses other than severe acute respiratory syndrome coronavirus
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <source>
         Nidoviruses
        </source>
        <year>
         2008
        </year>
        <publisher-name>
         ASM Press
        </publisher-name>
        <publisher-loc>
         Washington, DC
        </publisher-loc>
        <fpage>
         313
        </fpage>
        <lpage>
         324
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0830">
       <element-citation id="sbref0830" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Paquette
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ciurli
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Antel
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Ouellet
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Myelin basic protein and human coronavirus 229E cross-reactive T cells in multiple sclerosis
        </article-title>
        <source>
         Ann. Neurol.
        </source>
        <volume>
         39
        </volume>
        <issue>
         2
        </issue>
        <year>
         1996
        </year>
        <fpage>
         233
        </fpage>
        <lpage>
         240
        </lpage>
        <pub-id pub-id-type="pmid">
         8967755
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0835">
       <element-citation id="sbref0835" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Teoh
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           W.L.
          </given-names>
         </name>
         <name>
          <surname>
           Schluter
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Bruzzone
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Margolis
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Nal
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis
        </article-title>
        <source>
         Mol. Biol. Cell
        </source>
        <volume>
         21
        </volume>
        <issue>
         22
        </issue>
        <year>
         2010
        </year>
        <fpage>
         3838
        </fpage>
        <lpage>
         3852
        </lpage>
        <pub-id pub-id-type="pmid">
         20861307
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0840">
       <element-citation id="sbref0840" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Theamboonlers
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Samransamruajkit
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Thongme
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Amonsin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chongsrisawat
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Poovorawan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus infection among children with acute lower respiratory tract infection in Thailand
        </article-title>
        <source>
         Intervirology
        </source>
        <volume>
         50
        </volume>
        <issue>
         2
        </issue>
        <year>
         2007
        </year>
        <fpage>
         71
        </fpage>
        <lpage>
         77
        </lpage>
        <pub-id pub-id-type="pmid">
         17139182
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0845">
       <element-citation id="sbref0845" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Toovey
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influenza-associated central nervous system dysfunction: a literature review
        </article-title>
        <source>
         Travel. Med. Infect. Dis.
        </source>
        <volume>
         6
        </volume>
        <issue>
         3
        </issue>
        <year>
         2008
        </year>
        <fpage>
         114
        </fpage>
        <lpage>
         124
        </lpage>
        <pub-id pub-id-type="pmid">
         18486065
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0850">
       <element-citation id="sbref0850" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Newman
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Watts
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Packard
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <issue>
         3
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1162
        </fpage>
        <lpage>
         1173
        </lpage>
        <pub-id pub-id-type="pmid">
         17108019
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0855">
       <element-citation id="sbref0855" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tyrrell
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bynoe
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cultivation of a novel type of common-cold virus in organ cultures
        </article-title>
        <source>
         Br. Med. J.
        </source>
        <volume>
         1
        </volume>
        <issue>
         5448
        </issue>
        <year>
         1965
        </year>
        <fpage>
         1467
        </fpage>
        <lpage>
         1470
        </lpage>
        <pub-id pub-id-type="pmid">
         14288084
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0860">
       <element-citation id="sbref0860" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Dina
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Brison
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Brouard
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Freymuth
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronaviruses
        </article-title>
        <source>
         Pathol.-Biol.
        </source>
        <volume>
         57
        </volume>
        <issue>
         2
        </issue>
        <year>
         2009
        </year>
        <fpage>
         149
        </fpage>
        <lpage>
         160
        </lpage>
        <pub-id pub-id-type="pmid">
         18456429
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0865">
       <element-citation id="sbref0865" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Dina
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Mourez
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Gouarin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Petitjean
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           van der Werf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Freymuth
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inter- and intra-variant genetic heterogeneity of human coronavirus OC43 strains in France
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <volume>
         87
        </volume>
        <issue>
         Pt 11
        </issue>
        <year>
         2006
        </year>
        <fpage>
         3349
        </fpage>
        <lpage>
         3353
        </lpage>
        <pub-id pub-id-type="pmid">
         17030869
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0870">
       <element-citation id="sbref0870" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           van Riel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models
        </article-title>
        <source>
         J. Comp. Pathol.
        </source>
        <volume>
         151
        </volume>
        <issue>
         1
        </issue>
        <year>
         2014
        </year>
        <fpage>
         83
        </fpage>
        <lpage>
         112
        </lpage>
        <pub-id pub-id-type="pmid">
         24581932
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0875">
       <element-citation id="sbref0875" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Jebbink
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Vermeulen-Oost
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wolthers
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wertheim-van Dillen
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kaandorp
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Spaargaren
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a new human coronavirus
        </article-title>
        <source>
         Nat. Med.
        </source>
        <volume>
         10
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         368
        </fpage>
        <lpage>
         373
        </lpage>
        <pub-id pub-id-type="pmid">
         15034574
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0880">
       <element-citation id="sbref0880" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vareille
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kieninger
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Regamey
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The airway epithelium: soldier in the fight against respiratory viruses
        </article-title>
        <source>
         Clin. Microbiol. Rev.
        </source>
        <volume>
         24
        </volume>
        <issue>
         1
        </issue>
        <year>
         2011
        </year>
        <fpage>
         210
        </fpage>
        <lpage>
         229
        </lpage>
        <pub-id pub-id-type="pmid">
         21233513
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0885">
       <element-citation id="sbref0885" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Lemey
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Moes
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Vandamme
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Van Ranst
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Circulation of genetically distinct contemporary human coronavirus OC43 strains
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         337
        </volume>
        <issue>
         1
        </issue>
        <year>
         2005
        </year>
        <fpage>
         85
        </fpage>
        <lpage>
         92
        </lpage>
        <pub-id pub-id-type="pmid">
         15914223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0890">
       <element-citation id="sbref0890" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute encephalopathy and encephalitis caused by influenza virus infection
        </article-title>
        <source>
         Curr. Opin. Neurol.
        </source>
        <volume>
         23
        </volume>
        <issue>
         3
        </issue>
        <year>
         2010
        </year>
        <fpage>
         305
        </fpage>
        <lpage>
         311
        </lpage>
        <pub-id pub-id-type="pmid">
         20455276
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0895">
       <element-citation id="sbref0895" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Leibowitz
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronavirus pathogenesis
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Maramorosch
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Shatkin
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
        </person-group>
        <series>
         Advances in Virus Research
        </series>
        <volume>
         vol. 81
        </volume>
        <year>
         2011
        </year>
        <publisher-name>
         Elsevier
        </publisher-name>
        <publisher-loc>
         Boston
        </publisher-loc>
        <fpage>
         85
        </fpage>
        <lpage>
         164
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0900">
       <element-citation id="sbref0900" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weissert
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Progressive multifocal leukoencephalopathy
        </article-title>
        <source>
         J. Neuroimmunol.
        </source>
        <volume>
         231
        </volume>
        <issue>
         1-2
        </issue>
        <year>
         2011
        </year>
        <fpage>
         73
        </fpage>
        <lpage>
         77
        </lpage>
        <pub-id pub-id-type="pmid">
         20937530
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0905">
       <element-citation id="sbref0905" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wentworth
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Tresnan
          </surname>
          <given-names>
           D.B.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           B.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lerman
          </surname>
          <given-names>
           I.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bullis
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Hemmila
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Levis
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Shapiro
          </surname>
          <given-names>
           L.H.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cells of human aminopeptidase N (CD13) transgenic mice are infected by human coronavirus-229E in vitro, but not in vivo
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         335
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         185
        </fpage>
        <lpage>
         197
        </lpage>
        <pub-id pub-id-type="pmid">
         15840518
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0910">
       <element-citation id="sbref0910" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Whitley
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gnann
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral encephalitis: familiar infections and emerging pathogens
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         359
        </volume>
        <issue>
         9305
        </issue>
        <year>
         2002
        </year>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="pmid">
         11853816
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0915">
       <element-citation id="sbref0915" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Ludlow
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Duprex
          </surname>
          <given-names>
           W.P.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Human paramyxoviruses and infections of the central nervous system
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           S.K.R.D.
          </given-names>
         </name>
        </person-group>
        <source>
         Neuroviral Infections. RNA Viruses and Retroviruses
        </source>
        <year>
         2013
        </year>
        <publisher-name>
         CRC Press/Taylor and Francis
        </publisher-name>
        <publisher-loc>
         Boca Raton
        </publisher-loc>
        <fpage>
         341
        </fpage>
        <lpage>
         372
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0920">
       <element-citation id="sbref0920" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging epidemic viral encephalitides with a special focus on henipaviruses
        </article-title>
        <source>
         Acta Neuropathol.
        </source>
        <volume>
         120
        </volume>
        <issue>
         3
        </issue>
        <year>
         2010
        </year>
        <fpage>
         317
        </fpage>
        <lpage>
         325
        </lpage>
        <pub-id pub-id-type="pmid">
         20652579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0925">
       <element-citation id="sbref0925" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Luk
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         79
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         884
        </fpage>
        <lpage>
         895
        </lpage>
        <pub-id pub-id-type="pmid">
         15613317
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0930">
       <element-citation id="sbref0930" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative analysis of 22 coronavirus HKU1 genomes reveals a novel genotype and evidence of natural recombination in coronavirus HKU1
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         80
        </volume>
        <issue>
         14
        </issue>
        <year>
         2006
        </year>
        <fpage>
         7136
        </fpage>
        <lpage>
         7145
        </lpage>
        <pub-id pub-id-type="pmid">
         16809319
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0935">
       <element-citation id="sbref0935" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yasui
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Tsuruoka
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kuroda
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Hayashi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ishizaki
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Hosaka
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of type B influenza virus from the blood of children
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         27
        </volume>
        <issue>
         3
        </issue>
        <year>
         1998
        </year>
        <fpage>
         654
        </fpage>
        <lpage>
         655
        </lpage>
        <pub-id pub-id-type="pmid">
         9770177
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0940">
       <element-citation id="sbref0940" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis
        </article-title>
        <source>
         Clin. Infect. Dis.: Off. Pub. Infect. Dis. Soc. Am.
        </source>
        <volume>
         41
        </volume>
        <issue>
         8
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1089
        </fpage>
        <lpage>
         1096
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0945">
       <element-citation id="sbref0945" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists
        </article-title>
        <source>
         Protein Cell
        </source>
        <volume>
         4
        </volume>
        <issue>
         12
        </issue>
        <year>
         2013
        </year>
        <fpage>
         951
        </fpage>
        <lpage>
         961
        </lpage>
        <pub-id pub-id-type="pmid">
         24318862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0950">
       <element-citation id="sbref0950" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hauns
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Langland
          </surname>
          <given-names>
           J.O.
          </given-names>
         </name>
         <name>
          <surname>
           Jacobs
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Hogue
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <issue>
         6
        </issue>
        <year>
         2007
        </year>
        <fpage>
         2554
        </fpage>
        <lpage>
         2563
        </lpage>
        <pub-id pub-id-type="pmid">
         17182678
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0955">
       <element-citation id="sbref0955" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeh
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Duffner
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Faden
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis
        </article-title>
        <source>
         Pediatrics
        </source>
        <volume>
         113
        </volume>
        <issue>
         1 Pt 1
        </issue>
        <year>
         2004
        </year>
        <fpage>
         e73
        </fpage>
        <lpage>
         e76
        </lpage>
        <pub-id pub-id-type="pmid">
         14702500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0960">
       <element-citation id="sbref0960" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           You
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Dove
          </surname>
          <given-names>
           B.K.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Howell
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Heinen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zambon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hiscox
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Subcellular localization of the severe acute respiratory syndrome coronavirus nucleocapsid protein
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <volume>
         86
        </volume>
        <issue>
         Pt 12
        </issue>
        <year>
         2005
        </year>
        <fpage>
         3303
        </fpage>
        <lpage>
         3310
        </lpage>
        <pub-id pub-id-type="pmid">
         16298975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0965">
       <element-citation id="sbref0965" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         367
        </volume>
        <issue>
         19
        </issue>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0970">
       <element-citation id="sbref0970" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Kang-Sheng
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Influenza virus and CNS infections
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           S.K.R.D.
          </given-names>
         </name>
        </person-group>
        <source>
         Neuroviral Infections. RNA Viruses and Retroviruses
        </source>
        <year>
         2013
        </year>
        <publisher-name>
         CRC Press/Taylor and Francis
        </publisher-name>
        <publisher-loc>
         Boca Raton
        </publisher-loc>
        <fpage>
         325
        </fpage>
        <lpage>
         339
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0975">
       <element-citation id="sbref0975" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Birdwell
          </surname>
          <given-names>
           L.D.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Phillips
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Grinspan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Silverman
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cell-type-specific activation of the oligoadenylate synthetase-RNase L pathway by a murine coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <issue>
         15
        </issue>
        <year>
         2013
        </year>
        <fpage>
         8408
        </fpage>
        <lpage>
         8418
        </lpage>
        <pub-id pub-id-type="pmid">
         23698313
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0980">
       <element-citation id="sbref0980" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jha
          </surname>
          <given-names>
           B.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Silverman
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <volume>
         11
        </volume>
        <issue>
         6
        </issue>
        <year>
         2012
        </year>
        <fpage>
         607
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="pmid">
         22704621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0985">
       <element-citation id="sbref0985" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Van Rooijen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cell-type-specific type I interferon antagonism influences organ tropism of murine coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <issue>
         19
        </issue>
        <year>
         2011
        </year>
        <fpage>
         10058
        </fpage>
        <lpage>
         10068
        </lpage>
        <pub-id pub-id-type="pmid">
         21752905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0990">
       <element-citation id="sbref0990" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zlateva
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
         <name>
          <surname>
           Van Ranst
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of subgroup B respiratory syncytial virus in the cerebrospinal fluid of a patient with respiratory syncytial virus pneumonia
        </article-title>
        <source>
         Pediatr. Infect. Dis. J.
        </source>
        <volume>
         23
        </volume>
        <issue>
         11
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1065
        </fpage>
        <lpage>
         1066
        </lpage>
        <pub-id pub-id-type="pmid">
         15545869
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0995">
       <element-citation id="sbref0995" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zuniga
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Cruz
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Mateos-Gomez
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Palacio
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus nucleocapsid protein facilitates template switching and is required for efficient transcription
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         84
        </volume>
        <issue>
         4
        </issue>
        <year>
         2010
        </year>
        <fpage>
         2169
        </fpage>
        <lpage>
         2175
        </lpage>
        <pub-id pub-id-type="pmid">
         19955314
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib1000">
       <element-citation id="sbref1000" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zuniga
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Moreno
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sabella
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Plana-Duran
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus nucleocapsid protein is an RNA chaperone
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         357
        </volume>
        <issue>
         2
        </issue>
        <year>
         2007
        </year>
        <fpage>
         215
        </fpage>
        <lpage>
         227
        </lpage>
        <pub-id pub-id-type="pmid">
         16979208
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0005">
      <title>
       Acknowledgments
      </title>
      <p>
       We thank Nathalie Arbour, Annie Boucher, Julien St-Jean, Hélène Jacomy and Élodie Brison for previous work adapted in this manuscript. This work was supported by Discovery grant 42619-2009 from the
       <funding-source id="gs1">
        National Sciences and Engineering Research Council of Canada
       </funding-source>
       and by Operating Grant No. MT-9203 from the
       <funding-source id="gs2">
        Institute of Infection and Immunity
       </funding-source>
       (III) of the
       <funding-source id="gs3">
        Canadian Institutes of Health Research
       </funding-source>
       (CIHR) to Pierre J. Talbot, who is the holder of the Tier-1 (Senior) Canada Research Chair in Neuroimmunovirology award. Mathieu Meessen-Pinard gratefully acknowledges studentship support from the Fonds de Recherche Québec – Santé, Alain Le Coupanec and Jenny K. Stodola both gratefully acknowledge studentship support from Fondation Universitaire Armand-Frappier INRS.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Clin Microbiol Rev
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Clin. Microbiol. Rev
      </journal-id>
      <journal-id journal-id-type="hwp">
       cmr
      </journal-id>
      <journal-id journal-id-type="pmc">
       cmr
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       CMR
      </journal-id>
      <journal-title-group>
       <journal-title>
        Clinical Microbiology Reviews
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0893-8512
      </issn>
      <issn pub-type="epub">
       1098-6618
      </issn>
      <publisher>
       <publisher-name>
        American Society for Microbiology
       </publisher-name>
       <publisher-loc>
        1752 N St., N.W., Washington, DC
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25810418
      </article-id>
      <article-id pub-id-type="pmc">
       4402954
      </article-id>
      <article-id pub-id-type="publisher-id">
       00102-14
      </article-id>
      <article-id pub-id-type="doi">
       10.1128/CMR.00102-14
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Reviews
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease
       </article-title>
       <alt-title alt-title-type="running-head">
        Middle East Respiratory Syndrome Coronavirus
       </alt-title>
       <alt-title alt-title-type="short-authors">
        Chan et al.
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Jasper F. W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e53">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lau
         </surname>
         <given-names>
          Susanna K. P.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e76">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          To
         </surname>
         <given-names>
          Kelvin K. W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e105">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cheng
         </surname>
         <given-names>
          Vincent C. C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e131">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Woo
         </surname>
         <given-names>
          Patrick C. Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e151">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          Kwok-Yung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e171">
         *
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         a
        </label>
        State Key Laboratory of Emerging Infectious Diseases and Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, China
       </aff>
       <aff id="aff2">
        <label>
         b
        </label>
        Carol Yu Centre for Infection, Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, China
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address correspondence to Kwok-Yung Yuen,
        <email>
         kyyuen@hku.hk
        </email>
        .
       </corresp>
       <fn fn-type="other">
        <p>
         <bold>
          Citation
         </bold>
         Chan JFW, Lau SKP, To KKW, Cheng VCC, Woo PCY, Yuen K-Y. 25 March 2015. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev doi:
         <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/CMR.00102-14">
          10.1128/CMR.00102-14
         </ext-link>
         .
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        25
       </day>
       <month>
        3
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        4
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       28
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       465
      </fpage>
      <lpage>
       522
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2015, American Society for Microbiology. All Rights Reserved.
       </copyright-statement>
       <copyright-year>
        2015
       </copyright-year>
       <copyright-holder>
        American Society for Microbiology
       </copyright-holder>
      </permissions>
      <self-uri content-type="pdf" xlink:href="zcm002152507465.pdf">
      </self-uri>
      <abstract>
       <title>
        SUMMARY
       </title>
       <p>
        The source of the severe acute respiratory syndrome (SARS) epidemic was traced to wildlife market civets and ultimately to bats. Subsequent hunting for novel coronaviruses (CoVs) led to the discovery of two additional human and over 40 animal CoVs, including the prototype lineage C betacoronaviruses,
        <named-content content-type="genus-species">
         Tylonycteris
        </named-content>
        bat CoV HKU4 and
        <named-content content-type="genus-species">
         Pipistrellus
        </named-content>
        bat CoV HKU5; these are phylogenetically closely related to the Middle East respiratory syndrome (MERS) CoV, which has affected more than 1,000 patients with over 35% fatality since its emergence in 2012. All primary cases of MERS are epidemiologically linked to the Middle East. Some of these patients had contacted camels which shed virus and/or had positive serology. Most secondary cases are related to health care-associated clusters. The disease is especially severe in elderly men with comorbidities. Clinical severity may be related to MERS-CoV's ability to infect a broad range of cells with DPP4 expression, evade the host innate immune response, and induce cytokine dysregulation. Reverse transcription-PCR on respiratory and/or extrapulmonary specimens rapidly establishes diagnosis. Supportive treatment with extracorporeal membrane oxygenation and dialysis is often required in patients with organ failure. Antivirals with potent
        <italic>
         in vitro
        </italic>
        activities include neutralizing monoclonal antibodies, antiviral peptides, interferons, mycophenolic acid, and lopinavir. They should be evaluated in suitable animal models before clinical trials. Developing an effective camel MERS-CoV vaccine and implementing appropriate infection control measures may control the continuing epidemic.
       </p>
      </abstract>
      <counts>
       <fig-count count="10">
       </fig-count>
       <table-count count="12">
       </table-count>
       <equation-count count="0">
       </equation-count>
       <ref-count count="345">
       </ref-count>
       <page-count count="58">
       </page-count>
       <word-count count="46818">
       </word-count>
      </counts>
     </article-meta>
    </front>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Virol Methods
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Virol. Methods
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Virological Methods
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0166-0934
      </issn>
      <issn pub-type="epub">
       1879-0984
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       15488617
      </article-id>
      <article-id pub-id-type="pmc">
       7112817
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0166-0934(04)00216-2
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.jviromet.2004.07.008
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Comprehensive detection and identification of human coronaviruses, including the SARS-associated coronavirus, with a single RT-PCR assay
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Adachi
         </surname>
         <given-names>
          D.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Johnson
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Draker
         </surname>
         <given-names>
          R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ayers
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mazzulli
         </surname>
         <given-names>
          T.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Talbot
         </surname>
         <given-names>
          P.J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tellier
         </surname>
         <given-names>
          R.
         </given-names>
        </name>
        <email>
         raymond.tellier@sickkids.ca
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Division of Microbiology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ont., Canada M5G 1X8
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Metabolism Research Program, The Hospital for Sick Children, 555 University Avenue, Toronto, Ont., Canada M5G 1X8
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Department of Microbiology, Mt Sinai Hospital Toronto, Ont., Canada
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       INRS- Institut Armand Frappier, Laval, Qué., Canada
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Corresponding author. Tel.: +1 416 813 6592; fax: +1 416 813 6257.
        <email>
         raymond.tellier@sickkids.ca
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        11
       </day>
       <month>
        9
       </month>
       <year>
        2004
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <day>
        1
       </day>
       <month>
        12
       </month>
       <year>
        2004
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        11
       </day>
       <month>
        9
       </month>
       <year>
        2004
       </year>
      </pub-date>
      <volume>
       122
      </volume>
      <issue>
       1
      </issue>
      <fpage>
       29
      </fpage>
      <lpage>
       36
      </lpage>
      <history>
       <date date-type="received">
        <day>
         11
        </day>
        <month>
         6
        </month>
        <year>
         2004
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         17
        </day>
        <month>
         7
        </month>
        <year>
         2004
        </year>
       </date>
       <date date-type="accepted">
        <day>
         28
        </day>
        <month>
         7
        </month>
        <year>
         2004
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2004 Elsevier B.V. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2004
       </copyright-year>
       <copyright-holder>
        Elsevier B.V.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        The SARS-associated human coronavirus (SARS-HCoV) is a newly described, emerging virus conclusively established as the etiologic agent of the severe acute respiratory syndrome (SARS). This study presents a single-tube RT-PCR assay that can detect with high analytical sensitivity the SARS-HCoV, as well as several other coronaviruses including other known human respiratory coronaviruses (HCoV-OC43 and HCoV-229E). Species identification is provided by sequencing the amplicon, although a rapid screening test by restriction enzyme analysis has proved to be very useful for the analysis of samples obtained during the SARS outbreak in Toronto, Canada.
       </p>
      </abstract>
      <kwd-group>
       <title>
        Keywords
       </title>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        Human coronaviruses
       </kwd>
       <kwd>
        RT-PCR assay
       </kwd>
       <kwd>
        SARS
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec>
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p>
      Severe acute respiratory syndrome (SARS) is a newly described, emerging infectious disease presenting with high fever and atypical pneumonia. The disease first appeared in the Guangdong province of China and quickly spread to other countries; outbreaks were reported in mainland China, Vietnam, Singapore, Hong Kong, Taiwan and Canada (
      <xref ref-type="bibr" rid="bib2">
       Drazen, 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       Lee et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib15">
       Poutanen et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib22">
       Tsang et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib25">
       Vu et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib27">
       WHO, 2003a
      </xref>
      ). A new, previously unknown coronavirus was first isolated from patients with SARS at the University of Hong-Kong (
      <xref ref-type="bibr" rid="bib13">
       Peiris et al., 2003a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib27">
       WHO, 2003a
      </xref>
      ); this was quickly followed by reports from several other laboratories of the demonstration of a new coronavirus in samples from patients with SARS (
      <xref ref-type="bibr" rid="bib1">
       Drosten et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib8">
       Ksiazek et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib15">
       Poutanen et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib27">
       WHO, 2003a
      </xref>
      ). The complete genomic sequence of the virus has been determined (
      <xref ref-type="bibr" rid="bib11">
       Marra et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib16">
       Rota et al., 2003
      </xref>
      ) and confirmed the classification of the SARS-associated agent as a new coronavirus, distinct from the previously known groups of coronavirus (
      <xref ref-type="bibr" rid="bib11">
       Marra et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib16">
       Rota et al., 2003
      </xref>
      ) but with some relationship with group 2 (
      <xref ref-type="bibr" rid="bib19">
       Snijder et al., 2003
      </xref>
      ). Experimental infection of cynomolgous monkeys permitted the fulfillment of Koch's postulates for this pathogen and firmly established the SARS-associated human coronavirus (SARS-HCoV) as the etiologic agent of SARS (
      <xref ref-type="bibr" rid="bib3">
       Fouchier et al., 2003
      </xref>
      ).
     </p>
     <p>
      This study presents a RT-PCR protocol that allows for the detection of the SARS-HCoV in clinical samples. This single-tube RT-PCR is based on consensus primers targeting conserved regions of coronavirus genome sequences and allows for the detection and species identification of several coronaviruses including SARS-HCoV, with high analytical sensitivity. This assay is expected to be helpful in fulfilling the World Health Organization laboratory case definition of SARS, which recommends the use of two different PCR assays (
      <xref ref-type="bibr" rid="bib28">
       WHO, 2003b
      </xref>
      ). In addition, even if the SARS-HCoV does not reappear in the human population, this assay will still be useful, since it provides a diagnostic test for the respiratory coronaviruses HCoV-229E and HCoV-OC43.
     </p>
    </sec>
    <sec id="sec1">
     <label>
      2
     </label>
     <title>
      Material and methods
     </title>
     <sec>
      <label>
       2.1
      </label>
      <title>
       SARS coronavirus RNA
      </title>
      <p>
       RNA was extracted with TRIzol reagent (Life Technologies), as per manufacturer's recommendations, from a lung biopsy from a patient with SARS. The RNA pellet was resuspended in 30 μl of 10 mM of dithiotreitol with 5% (v/v) of RNasin (20–40 U/μl, Promega), serially diluted, aliquoted and frozen at −80 °C. Quantification of the RNA serial dilution was achieved by measuring the amount of SARS-HCoV RNA in the aliquots with the RealArt HPA coronavirus RT-PCR (Artus GmbH, Hamburg, Germany).
      </p>
     </sec>
     <sec>
      <label>
       2.2
      </label>
      <title>
       RNA from human coronaviruses OC43 and 229E
      </title>
      <p>
       Human coronaviruses OC43 and 229E strains were initially obtained from ATCC and passaged in cell culture as described (
       <xref ref-type="bibr" rid="bib18">
        Sizun et al., 1998
       </xref>
       ). Stocks of viruses were titrated as described (
       <xref ref-type="bibr" rid="bib18">
        Sizun et al., 1998
       </xref>
       ). RNA was extracted from the titrated stocks using TRIzol (Life Technologies) as per the manufacturer's recommendations and serially diluted.
      </p>
     </sec>
     <sec>
      <label>
       2.3
      </label>
      <title>
       RNA from infectious bronchitis virus
      </title>
      <p>
       Tissue culture-adapted infectious bronchitis virus (IBV) stocks, strain Massachussets 41 and strain Baudette, were obtained from Dr. E. Nagy, Ontario Veterinary College, University of Guelph, Ontario. RNA was extracted and serially diluted as for HCoV-OC43 and HCoV-229E.
      </p>
     </sec>
     <sec>
      <label>
       2.4
      </label>
      <title>
       Clinical samples
      </title>
      <p>
       During the SARS outbreak in Toronto (2003), several samples from patients with probable or suspected SARS were referred to our laboratory for SARS-HCoV detection by RT-PCR. Of these, 44 were assayed using the new primers described here, including 7 lung biopsies, 2 bronchoalveolar lavages, 7 nasopharyngeal swabs, 3 throat swabs, 2 pleural fluid samples, 2 endotracheal aspirates, 4 blood samples, 11 stool samples and 6 urine samples. RNA was extracted from lung tissue using the RNeasy kit (Qiagen) as per the manufacturer's recommendations. For all other samples, RNA was extracted using the guanidium thiocyanate buffer (GTC) extraction methods, as described (
       <xref ref-type="bibr" rid="bib7">
        Johnson et al., 2000
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <label>
       2.5
      </label>
      <title>
       Primers
      </title>
      <p>
       Primers were designed to target segments of the pol 1b coding region conserved among several species of coronavirus (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       ). We used the sense primer CORO1 (5′-TGA TGG GTT GGG ACT ATC CTA AAT GTG A-3′) and the antisense primer CORO2 (5′-GTA GTT GCA TCA CCG GAA GTT GTG CCA CC-3′), homologous to the segments [15211, 15238] and [15402, 15430] of the sequence of the Tor2 strain of SARS-HCoV (GenBank Accession number
       <ext-link ext-link-type="gen" xlink:href="AY274119">
        AY274119
       </ext-link>
       ), respectively.
       <fig id="fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Alignment calculated from the nucleotide sequence of segments homologous to the segment [15211, 15430] of SARS-HCoV strain TOR2 (GenBank Accession number
          <ext-link ext-link-type="gen" xlink:href="AY274119">
           AY274119
          </ext-link>
          ) from 12 other species of coronaviruses. HCoV-NL63 (
          <ext-link ext-link-type="gen" xlink:href="AY567487">
           AY567487
          </ext-link>
          ): human coronavirus NL63. HCoV-229E (
          <ext-link ext-link-type="gen" xlink:href="NV_002645">
           NV_002645
          </ext-link>
          ): human respiratory coronavirus 229E. PEDV (
          <ext-link ext-link-type="gen" xlink:href="NC_003436">
           NC_003436
          </ext-link>
          ): porcine epidemic diarrhea virus. FIPV (
          <ext-link ext-link-type="gen" xlink:href="AF124987">
           AF124987
          </ext-link>
          ): feline infectious peritonitis virus. CCoV (
          <ext-link ext-link-type="gen" xlink:href="AF124986">
           AF124986
          </ext-link>
          ): canine coronavirus. TGEV (
          <ext-link ext-link-type="gen" xlink:href="AJ271965">
           AJ271965
          </ext-link>
          ): porcine transmissible gastroenteritis virus. SDAV (
          <ext-link ext-link-type="gen" xlink:href="AF124990">
           AF124990
          </ext-link>
          ): sialodacryoadenitis virus. MHV (
          <ext-link ext-link-type="gen" xlink:href="NC_001846">
           NC_001846
          </ext-link>
          ): murine hepatitis virus. BCoV (
          <ext-link ext-link-type="gen" xlink:href="NC_003045">
           NC_003045
          </ext-link>
          ): bovine coronavirus. HCoV-OC43 (
          <ext-link ext-link-type="gen" xlink:href="AF124989">
           AF124989
          </ext-link>
          ): human respiratory coronavirus OC43. IBV (
          <ext-link ext-link-type="gen" xlink:href="NC_001451">
           NC_001451
          </ext-link>
          ): avian infectious bronchitis virus. TCoV (
          <ext-link ext-link-type="gen" xlink:href="AF124991">
           AF124991
          </ext-link>
          ): turkey coronavirus. Also aligned with the coronaviruses sequences are the sequences of the sense primer (CORO1) and the complement of the antisense primer (CORO2rc). Dots denote homology with the consensus sequence on top. The sequence alignment was calculated using ClustalX for Windows version 1.81 (
          <xref ref-type="bibr" rid="bib21">
           Thompson et al., 1997
          </xref>
          ) and edited with Genedoc version 2.3 for Windows (Nicholas K.B., 1997).
         </p>
        </caption>
        <graphic xlink:href="gr1">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       2.6
      </label>
      <title>
       RT-PCR
      </title>
      <p>
       This was done using the Qiagen one-step RT-PCR kit. Each reaction was performed in a 0.6 ml tube (Diamed PRE 050) in a total volume of 50 μl overlaid with 50 μl of mineral oil. Each reaction mix contains 10 μl of 5× Qiagen buffer, 2 μl of dNTP mix (each dNTP at 10 mM concentration), 3 μl of each primer (10 μM stock), 20 μl of molecular grade double distilled water (ddH
       <sub>
        2
       </sub>
       O) and 2 μl of the one-step enzyme mix (Qiagen). The master mix was then aliquoted in tubes, to which 10 μl of template RNA was added. The PCR thermal cycling was done on a Stratagene Robocycler 40, with an initial incubation at 50 °C for 30 min, followed by an incubation at 95 °C for 15 min, and 40 cycles consisting of denaturation at 94 °C for 1 min, annealing at 56 °C for 1 min, and elongation at 72 °C for 1 min. Extensive precautions against PCR contamination, as previously described (
       <xref ref-type="bibr" rid="bib7">
        Johnson et al., 2000
       </xref>
       ), were strictly observed. Positive and negative controls, as well as extraction controls and controls for PCR inhibition, were set up essentially as described (Johnson et al, 2000).
      </p>
     </sec>
     <sec>
      <label>
       2.7
      </label>
      <title>
       Electrophoresis analysis of the amplicons
      </title>
      <p>
       A 10 μl volume of each reaction was submitted to electrophoresis on 2% agarose or 4% NuSieve 3:1 (Biowhittaker Molecular Applications, Rockland, USA) gels containing ethidium bromide. The gels were visualized on a UV transilluminator and photographed.
      </p>
     </sec>
     <sec>
      <label>
       2.8
      </label>
      <title>
       Restriction enzyme analysis
      </title>
      <p>
       Each reaction mixture in which the expected 220 bp amplicon was detected was digested with the restriction enzyme
       <italic>
        Alu
       </italic>
       I, which cuts within the sequence AGCT. The digestion reaction consisted of 10 μl of the RT-PCR mixture, 1.5 μl of the 10× enzyme buffer, 1 μl of
       <italic>
        Alu
       </italic>
       I (10 U/μl, New England Biolabs) and 2.5 μl of ddH
       <sub>
        2
       </sub>
       O for a total of 15 μl. The reaction was incubated at 37 °C for 1 h and analyzed by agarose gel electrophoresis.
      </p>
     </sec>
     <sec>
      <label>
       2.9
      </label>
      <title>
       Sequencing
      </title>
      <p>
       Amplicons were submitted to automated sequencing, for both strands, using the PCR primers as sequencing primers. Sequencing was performed by the DNA Sequencing Facility, Centre for Applied Genomics, Hospital for Sick Children.
      </p>
     </sec>
     <sec>
      <label>
       2.10
      </label>
      <title>
       Sequences analysis
      </title>
      <p>
       Sequence editing and analysis were done using the programs Generunner for Windows version 3.05 (Hasting software). Sequence alignments were calculated using ClustalX for Windows version 1.81 (
       <xref ref-type="bibr" rid="bib21">
        Thompson et al., 1997
       </xref>
       ), with the default parameters for gap opening and gap extension. Phylogenetic trees were inferred using Treecon for Windows version 1.3.b (
       <xref ref-type="bibr" rid="bib23">
        Van de Peer and De Wachter, 1994
       </xref>
       ), using a distance method; in brief, the distance was calculated without correction; the tree topology was inferred with the neighbor joining method and the trees re-rooted at the internode. Bootstrap analyses were done with 1000 replicates.
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      3
     </label>
     <title>
      Results
     </title>
     <sec>
      <label>
       3.1
      </label>
      <title>
       Sequence alignments and primer design
      </title>
      <p>
       Initially, an amino acid sequence alignment of the pol 1b open-reading frame (ORF) was used to identify well-conserved regions across 12 species of coronaviruses comprising the SARS-HCoV and members of the three previously described groups of coronaviruses. The corresponding nucleotides alignment was then used to design PCR primers targeting these well-conserved regions.
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       illustrates the alignment of the 220 nt segments of these 12 coronavirus sequences homologous to the segment [15211, 15430] of the Tor2 strain of SARS-HCoV, as well as the corresponding sequence of the newly described human coronavirus HCoV-NL63 (
       <xref ref-type="bibr" rid="bib4">
        Fouchier et al., 2004
       </xref>
       ,
       <xref ref-type="bibr" rid="bib24">
        Van der Hoek et al., 2004
       </xref>
       ), along with the sequence of the primers.
      </p>
      <p>
       <xref ref-type="fig" rid="fig2">
        Fig. 2
       </xref>
       illustrates the phylogenetic trees of the nucleotide sequences (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       A) and amino acid sequences (
       <xref ref-type="fig" rid="fig2">
        Fig. 2
       </xref>
       B) in that segment, demonstrating that there are enough sequence diversity in the region bracketed by the primers to allow for unambiguous species identification.
       <fig id="fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          (A) Phylogenetic tree calculated from the nucleotide sequence of segments homologous to the segment [15211, 15430] of SARS-HCoV strain TOR2 from the 13 species of coronaviruses in
          <xref ref-type="fig" rid="fig1">
           Fig. 1
          </xref>
          . 1.The boostrap values are displayed (as percentages) above the node. (B) Phylogenetic tree calculated from the amino acid sequences corresponding to the nucleotide sequences in (A). The boostrap values are displayed (as percentages) above the node. The phylogenetic trees were drawn using the program Treecon for Windows version 1.3.b (
          <xref ref-type="bibr" rid="bib23">
           Van de Peer and De Wachter, 1994
          </xref>
          ).
         </p>
        </caption>
        <graphic xlink:href="gr2">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       3.2
      </label>
      <title>
       Detection of coronavirus RNA
      </title>
      <p>
       Using as templates the RNA of SARS-HCoV, HCoV-229E and HCoV-OC43, as well as RNA from two strains of IBV, we could readily and reproducibly obtain the expected 220 bp amplicon.
      </p>
     </sec>
     <sec>
      <label>
       3.3
      </label>
      <title>
       Sensitivity and specificity
      </title>
      <p>
       Aliquots of a 10-fold serial RNA dilution prepared from a lung biopsy sample of a patient with SARS (see Section
       <xref ref-type="sec" rid="sec1">
        2
       </xref>
       ) were used to compare our assay with the RealArt HPA coronavirus RT-PCR (Artus GmbH). The results are displayed in
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       and show that our assay has essentially the same sensitivity as that of the RealArt HPA coronavirus RT-PCR assay; it is estimated that the analytical sensitivity is between 1 and 10 genome copies.
       <table-wrap id="tbl1" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Comparison between our RT-PCR assay and the RealArt HPA coronavirus RT-PCR (Artus GmbH)
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th align="left">
            Dilution
           </th>
           <th align="left">
            RT-PCR with CORO1 and CORO2
           </th>
           <th align="left">
            RealArt HPA coronavirus RT-PCR (genome copies)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            10
            <sup>
             −3
            </sup>
           </td>
           <td align="left">
            +
           </td>
           <td align="right">
            33000
           </td>
          </tr>
          <tr>
           <td align="left">
            10
            <sup>
             −4
            </sup>
           </td>
           <td align="left">
            +
           </td>
           <td align="right">
            2480
           </td>
          </tr>
          <tr>
           <td align="left">
            10
            <sup>
             −5
            </sup>
           </td>
           <td align="left">
            +
           </td>
           <td align="right">
            89
           </td>
          </tr>
          <tr>
           <td align="left">
            10
            <sup>
             −6
            </sup>
           </td>
           <td align="left">
            +
           </td>
           <td align="right">
            19
           </td>
          </tr>
          <tr>
           <td align="left">
            10
            <sup>
             −7
            </sup>
           </td>
           <td align="left">
            +
           </td>
           <td align="right">
            3
           </td>
          </tr>
          <tr>
           <td align="left">
            10
            <sup>
             −8
            </sup>
           </td>
           <td align="left">
            −
           </td>
           <td align="right">
            –
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           Column two shows the result (scored as positive or negative) obtained with our assay using 10 μl of the indicated RNA dilution (see Section
           <xref ref-type="sec" rid="sec1">
            2
           </xref>
           ). For each dilution the assay was done on two different aliquots and the results were in agreement. Column three shows the average (on two experiments) of the measured number of genome copies in 5 μl of the RNA dilution with RealArt HPA coronavirus RT-PCR.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p>
       For HCoV-OC43, viral RNA could be detected from as little as 6 × 10
       <sup>
        −2
       </sup>
       TCID
       <sub>
        50
       </sub>
       (tissue culture infective dose 50); for HCoV-229E, viral RNA could be detected from as little as 6 × 10
       <sup>
        −3
       </sup>
       TCID
       <sub>
        50
       </sub>
       . For all coronaviruses tested in this study the species was verified by sequencing; in all cases the sequence internal to the primers were identical to the expected sequences. Based on the expected sequences of the amplicons a rapid screening test for species identification for the human coronaviruses was designed using the
       <italic>
        Alu
       </italic>
       I restriction enzyme. As illustrated on
       <xref ref-type="fig" rid="fig3">
        Fig. 3
       </xref>
       , the SARS-HCoV amplicon is cut into 126-bp and 94-bp fragments, the HCoV-229E amplicon into 101-bp, 86-bp and 33-bp fragments, and the HCoV-OC43 amplicon is not cut by
       <italic>
        Alu
       </italic>
       I; based on the reference sequence, the amplicon of IBV would not contain a
       <italic>
        Alu
       </italic>
       I site. Nucleic acids from human tissue, or from other respiratory viruses whose presence was detected in various samples (including influenza A, respiratory syncytial virus, parainfluenza 3 and adenoviruses), did not generate amplicons of 220 bp.
       <fig id="fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          <italic>
           Alu
          </italic>
          I digestion of amplicons from SARS-HCoV, HCoV-229E and HCoV-OC43. Lanes 1, 3 and 5 (MW): molecular weight markers (Amplisize ladder 50–2000 bp, Bio-Rad Laboratories, Mississauga, Canada); Lane 2: SARS-HCoV (predicted fragments: 126 bp, 94 bp); Lane 4: HCoV-229E (predicted fragments: 101 bp, 86 bp, 33 bp); Lane 6: HCoV-OC43 (predicted fragment: 220 bp).
         </p>
        </caption>
        <graphic xlink:href="gr3">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec>
      <label>
       3.4
      </label>
      <title>
       Clinical samples
      </title>
      <p>
       From the clinical samples listed above, the presence of the SARS-HCoV RNA was demonstrated in one lung biopsy, two bronchoalveolar lavages, two nasopharyngeal swabs, two urine samples and one throat swab.
      </p>
     </sec>
    </sec>
    <sec>
     <label>
      4
     </label>
     <title>
      Discussion
     </title>
     <p>
      This study presents a single-tube RT-PCR assay designed to detect several species of coronaviruses, including the SARS coronaviruses, by using consensus primers designed from an alignment of the sequences of a region in the pol 1b ORF of 12 species of coronaviruses. A previous version of these primers, based on an alignment of four species of coronaviruses and of the Berne torovirus, was used to demonstrate the presence of a new coronavirus in patients with SARS in Canada (
      <xref ref-type="bibr" rid="bib9">
       Kumar et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib15">
       Poutanen et al., 2003
      </xref>
      ) at a time when the complete sequence of the SARS coronavirus was still unknown. The use of the revised primers and the optimization of the RT-PCR has led to an improvement in analytical sensitivity of three orders of magnitude compared to the previous assay. Its sensitivity has proven sufficient for the detection of the SARS-HCoV in several clinical samples.
     </p>
     <p>
      The assay was designed to be broadly reactive with the genome of many coronavirus species; it is demonstrated here that it can detect coronaviruses from all four known groups of coronaviruses, including the HCoV-229E and HCoV-OC43, which are well-recognized human pathogens (
      <xref ref-type="bibr" rid="bib6">
       Holmes, 2001
      </xref>
      ). Although not all the known coronavirus species were tested, it is expected that the primer pair can amplify with high analytical sensitivity the targeted genome segment from the 12 species used in the design of the primers, with the possible exception of the porcine epidemic diarrhea virus (PEDV) whose sequence has a mismatch at the third nt from the 3′ end of the primer CORO1 (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ). The current assay can detect with high sensitivity three coronaviruses known to infect humans, and sequencing of the amplicons would unambiguously identify the species (
      <xref ref-type="fig" rid="fig2">
       Fig. 2
      </xref>
      ). Although there has not been yet an opportunity to test this assay on isolates of the newly described HCoV-NL63 (
      <xref ref-type="bibr" rid="bib24">
       Van der Hoek et al., 2004
      </xref>
      ), it is predicted, based on the sequence alignment in
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      , that our RT-PCR assay would also detect HCoV-NL63, and sequencing of the amplicon followed by phylogenetic analysis (
      <xref ref-type="fig" rid="fig2">
       Fig. 2
      </xref>
      ) would readily confirm the identity of the virus. Based on the published sequence of HCoV-NL63, digestion of the amplicon by
      <italic>
       Alu
      </italic>
      I would yield a distinct pattern consisting of bands of 187 bp and 33 bp. Since the sequences targeted by the primers CORO1 and CORO2 are conserved across several coronavirus species (and this is particularly clear at the amino acid level), this suggests strong selective pressure on that part of the genome. In turn, this suggests that the assay would still be able to detect mutant or variant strains of SARS-HCoV, as mutations would likely not occur in the regions targeted by the primers. To date, the various isolates of SARS-HCoV have all displayed a great genetic homogeneity (
      <xref ref-type="bibr" rid="bib17">
       Ruan et al., 2003
      </xref>
      ), which argues for the emergence of SARS-HCoV in the human population only very recently. However, should the virus emerge again and be allowed to propagate, its genetic diversity may well increase (although the genomes of many known coronaviruses appear relatively stable). Of note, a BLAST search in the GenBank database using the 220-nt segment of SARS-HCoV (
      <xref ref-type="fig" rid="fig1">
       Fig. 1
      </xref>
      ) showed a 100% homology with 105 sequences of SARS-HCoV deposited to date, including representative of all clusters (
      <xref ref-type="bibr" rid="bib5">
       Guan et al., 2004
      </xref>
      ), and an homology greater than 99% (219/220) with two other sequences of SARS-HCoV. As well, the recent SARS outbreak suggests that other coronaviruses may emerge as new human pathogens. Again, assuming that the conservation of the sequences targeted by the primers stems from strong evolutionary constraints, the RT-PCR assay described here would very likely detect such an emerging coronavirus.
     </p>
     <p>
      In this study a simple restriction enzyme analysis as a screening test was shown to be very helpful in identifying the SARS-HCoV. Indeed, in all the samples that tested positive for SARS-HCoV in our laboratory during the Toronto outbreak, the expected restriction pattern was demonstrated (and based on sequences deposited in GenBank this pattern would have been demonstrated in all isolates of SARS-HCoV sequenced to date). However, because RNA virus genomes are much more variable than DNA virus genomes, one should not rely completely on such an analysis and the failure to obtain the expected digestion fragments (or if the amplicon is not cut, as is the case for HCoV-OC43) should prompt the determination of the sequence of the amplicon. As an illustrative case in point, whereas the amplicon from the IBV strain Baudette is not cleaved by
      <italic>
       Alu
      </italic>
      I, the amplicon from strain Massachussetts 41 is in fact cleaved by
      <italic>
       Alu
      </italic>
      I, as verified by both sequencing and digestion of the amplicon (data not shown). After sequencing the amplicon, a comparison of the sequence to that of several coronaviruses in a phylogenetic analysis, as in
      <xref ref-type="fig" rid="fig2">
       Fig. 2
      </xref>
      , should permit a definitive identification. Indeed, should a new coronavirus emerge, it appears likely that it could be detected and identified as a new virus by using our RT-PCR assay followed by sequencing and phylogenetic analysis.
     </p>
     <p>
      Since the end of the global SARS outbreak in 2003, a total of three laboratory confirmed sporadic cases of SARS in Guangdong have occurred (
      <xref ref-type="bibr" rid="bib29">
       WHO, 2004
      </xref>
      ), which however did not spread further, as well as three laboratory acquired incidents (
      <xref ref-type="bibr" rid="bib12">
       Normile, 2004
      </xref>
      ). While surveillance for SARS is still recommended (
      <xref ref-type="bibr" rid="bib28">
       WHO, 2003b
      </xref>
      ) there is great concern about the negative impact of a false positive laboratory test, and the World Health Organization has recommended protocols for the laboratory diagnosis of SARS in the post outbreak period (
      <xref ref-type="bibr" rid="bib28">
       WHO, 2003b
      </xref>
      ), which includes the use of two different RT-PCR assays. The assay described here provides an alternative test that can be helpful in that regard. Furthermore, because our assay detects several coronaviruses, it is quite feasible to use RNA from a coronavirus other than SARS-HCoV as a positive control. In fact, our laboratory now uses as positive control RNA transcribed from the cloned amplicon of the IBV; IBV has never been implicated in human infections. The use of IBV as a positive control removes a potential source of PCR contamination by SARS-HCoV genetic material in the laboratory.
     </p>
     <p>
      In this study, the presence of the SARS-HCoV was demonstrated in a variety of clinical samples, which illustrates the usefulness of the assay. The number of positive samples reported here is too small to draw firm conclusions but taking into account the distinction between probable and suspected cases of SARS, as well as previous observations made earlier in our laboratory during the outbreak, it appears that the SARS-HCoV is more likely to be demonstrated in lower respiratory tract samples, such as broncho-alveolar lavages or lung biopsies rather than in a nasopharyngeal swab; this parallels the findings of other reports (
      <xref ref-type="bibr" rid="bib14">
       Peiris et al., 2003b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib20">
       Tang et al., 2004
      </xref>
      ) and it has been suggested that the SARS-HCoV appears at a high titer in the nasopharynx relatively late in the disease (
      <xref ref-type="bibr" rid="bib14">
       Peiris et al., 2003b
      </xref>
      ). Thus, the negative RT-PCR results on such samples do not reflect a poor analytical sensitivity of the assay but rather the biology of the virus. A systematic study of various samples obtained throughout the course of the disease in several patients will be required to determine the best testing algorithm. Certainly in the control of the outbreak in Toronto, carefully established epidemiological links between patients fitting the case definition seemed the most effective method, but laboratory confirmation of some cases in the chain also proved to be very helpful (
      <xref ref-type="bibr" rid="bib26">
       Wallington et al., 2003
      </xref>
      ).
     </p>
     <p>
      In summary, a single-tube RT-PCR assay for the detection of human coronaviruses, including the SARS-HCoV, has been developed. It is expected to remain effective with possible SARS-HCoV mutants and to be of value should other new coronaviruses emerge as human pathogens.
     </p>
    </sec>
    <back>
     <ref-list>
      <title>
       References
      </title>
      <ref id="bib1">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Günther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           van der Werf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Brodt
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rabenau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Panning
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Berger
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Burguière
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Eickmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Escriou
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Grywna
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kramme
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Manuguerra
          </surname>
          <given-names>
           J.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rickerts
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Stürmer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Vieth
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Klenk
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Schmitz
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1967
        </fpage>
        <lpage>
         1976
        </lpage>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drazen
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Case cluster of the severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         e6
        </fpage>
        <lpage>
         e7
        </lpage>
        <pub-id pub-id-type="pmid">
         12671060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Schutten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           van Doornum
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           van den Hoogen
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Stöhr
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.M.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Koch's postulates fulfilled for SARS virus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         423
        </volume>
        <year>
         2003
        </year>
        <fpage>
         240
        </fpage>
        <pub-id pub-id-type="pmid">
         12748632
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hartwig
          </surname>
          <given-names>
           N.G.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Niemeyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           De Jong
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Simon
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.M.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A previously undescribed coronavirus associated with respiratory disease in humans
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U.S.A.
        </source>
        <volume>
         101
        </volume>
        <year>
         2004
        </year>
        <fpage>
         6212
        </fpage>
        <lpage>
         6216
        </lpage>
        <pub-id pub-id-type="pmid">
         15073334
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           F.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.W.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           M.N.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Chow
          </surname>
          <given-names>
           K.Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hon
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           V.Y.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           F.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         363
        </volume>
        <year>
         2004
        </year>
        <fpage>
         99
        </fpage>
        <lpage>
         104
        </lpage>
        <pub-id pub-id-type="pmid">
         14726162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviruses
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Knipe
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Howley
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
        </person-group>
        <source>
         Fields Virology
        </source>
        <edition>
         fourth ed
        </edition>
        <year>
         2001
        </year>
        <publisher-name>
         Lippincott Williams &amp; Williams
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         1197
        </fpage>
        <lpage>
         1204
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib7">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tellier
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comprehensive PCR-based assay for detection and species identification of human herpesviruses
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         38
        </volume>
        <year>
         2000
        </year>
        <fpage>
         3274
        </fpage>
        <lpage>
         3279
        </lpage>
        <pub-id pub-id-type="pmid">
         10970370
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Peret
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Emery
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Urbani
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Comer
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Dowell
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.-E.
          </given-names>
         </name>
         <name>
          <surname>
           Humphrey
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Shieh
          </surname>
          <given-names>
           W.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Guarner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Paddock
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Fields
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           DeRisi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hughes
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           LeDuc
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Bellini
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <collab>
          SARS Working Group
         </collab>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tellier
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Draker
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Levy
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Humar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening
        </article-title>
        <source>
         Am. J. Transplant.
        </source>
        <volume>
         3
        </volume>
        <year>
         2003
        </year>
        <fpage>
         977
        </fpage>
        <lpage>
         981
        </lpage>
        <pub-id pub-id-type="pmid">
         12859532
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Cameron
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Joynt
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ahuja
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yung
          </surname>
          <given-names>
           M.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Lui
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Szeto
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A major outbreak of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1986
        </fpage>
        <lpage>
         1994
        </lpage>
        <pub-id pub-id-type="pmid">
         12682352
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marra
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Astell
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Holt
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brooks-Wilson
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Butterfield
          </surname>
          <given-names>
           Y.S.N.
          </given-names>
         </name>
         <name>
          <surname>
           Khattra
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Asano
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Barber
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cloutier
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Coughlin
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Freeman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Girn
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Griffith
          </surname>
          <given-names>
           O.L.
          </given-names>
         </name>
         <name>
          <surname>
           Leach
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Mayo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           McDonald
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Montgomery
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
         <name>
          <surname>
           Pandoh
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Petrescu
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           A.G.
          </given-names>
         </name>
         <name>
          <surname>
           Schein
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Siddiqui
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Smailus
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Stott
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
         <name>
          <surname>
           Plummer
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Andonov
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Artsob
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Bastien
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bernard
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Booth
          </surname>
          <given-names>
           T.F.
          </given-names>
         </name>
         <name>
          <surname>
           Bowness
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Drebot
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Fernando
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Flick
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Garbutt
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gray
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Grolla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Meyers
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kabani
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Normand
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Stroher
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Tipples
          </surname>
          <given-names>
           G.A.
          </given-names>
         </name>
         <name>
          <surname>
           Tyler
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Vogrig
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Brunham
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Krajden
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Skowronski
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Upton
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Roper
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The genome sequence of the SARS-associated coronavirus
        </article-title>
        <source>
         Science
        </source>
        <volume>
         300
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1399
        </fpage>
        <lpage>
         1404
        </lpage>
        <pub-id pub-id-type="pmid">
         12730501
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Normile
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mounting lab accidents raise SARS fears
        </article-title>
        <source>
         Science
        </source>
        <volume>
         304
        </volume>
        <year>
         2004
        </year>
        <fpage>
         659
        </fpage>
        <lpage>
         661
        </lpage>
        <pub-id pub-id-type="pmid">
         15118129
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yam
          </surname>
          <given-names>
           L.Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yee
          </surname>
          <given-names>
           W.K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           D.N.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yung
          </surname>
          <given-names>
           R.W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           T.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <collab>
          SARS study group
         </collab>
        </person-group>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1319
        </fpage>
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           I.F.N.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Law
          </surname>
          <given-names>
           K.I.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           B.S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Hon
          </surname>
          <given-names>
           T.Y.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           J.S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           W.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           R.W.M.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <collab>
          HKU/UCH SARS Study Group
         </collab>
        </person-group>
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus associated SARS pneumonia: a prospective study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1767
        </fpage>
        <lpage>
         1772
        </lpage>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poutanen
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Henry
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Finkelstein
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Tellier
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Draker
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Adachi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ayers
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Skowronski
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Salit
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Simor
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Slutsky
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Doyle
          </surname>
          <given-names>
           P.W.
          </given-names>
         </name>
         <name>
          <surname>
           Krajden
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Brunham
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <collab>
          National Microbiology Laboratory, Canada, Canadian Severe Acute Respiratory Syndrome Study Team
         </collab>
        </person-group>
        <article-title>
         Identification of severe acute respiratory syndrome in Canada
        </article-title>
        <source>
         N. Engl. J. Med
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1995
        </fpage>
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="pmid">
         12671061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Oberste
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Monroe
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Nix
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Campagnoli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Icenogle
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Peñaranda
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bankamp
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Maher
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lowe
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Frace
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           DeRisi
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.D.
          </given-names>
         </name>
         <name>
          <surname>
           Peret
          </surname>
          <given-names>
           T.C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Burns
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Sanchez
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Liffick
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Holloway
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Limor
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           McCaustland
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Olsen-Rasmussen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Günther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pallansch
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bellini
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of a novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         Science
        </source>
        <volume>
         300
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1394
        </fpage>
        <lpage>
         1398
        </lpage>
        <pub-id pub-id-type="pmid">
         12730500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ruan
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Vega
          </surname>
          <given-names>
           V.B.
          </given-names>
         </name>
         <name>
          <surname>
           Thoreau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Se Thoe
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chia
          </surname>
          <given-names>
           J.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Oon
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Leo
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           L.F.P.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           E.C.
          </given-names>
         </name>
         <name>
          <surname>
           Stanton
          </surname>
          <given-names>
           L.W.
          </given-names>
         </name>
         <name>
          <surname>
           Long
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           E.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infections
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1779
        </fpage>
        <lpage>
         1785
        </lpage>
        <pub-id pub-id-type="pmid">
         12781537
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Arbour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of immunofluorescence with monoclonal antibodies and RT-PCR for the detection of human coronaviruses 229E and OC43 in cell culture
        </article-title>
        <source>
         J. Virol. Methods
        </source>
        <volume>
         72
        </volume>
        <year>
         1998
        </year>
        <fpage>
         145
        </fpage>
        <lpage>
         152
        </lpage>
        <pub-id pub-id-type="pmid">
         9694322
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bredenbeek
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dobbe
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Thiel
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rozanov
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Spaan
          </surname>
          <given-names>
           W.J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage
        </article-title>
        <source>
         J. Mol. Biol.
        </source>
        <volume>
         331
        </volume>
        <year>
         2003
        </year>
        <fpage>
         991
        </fpage>
        <lpage>
         1004
        </lpage>
        <pub-id pub-id-type="pmid">
         12927536
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Louie
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Smieja
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Simor
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Jamieson
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Fearon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Poutanen
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Mazzulli
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tellier
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Mahony
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Loeb
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Petrich
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chernesky
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Phillips
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bastien
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Dick
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Grolla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fernando
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Booth
          </surname>
          <given-names>
           T.F.
          </given-names>
         </name>
         <name>
          <surname>
           Henry
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Rachlis
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Matukas
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           D.B.
          </given-names>
         </name>
         <name>
          <surname>
           Lovinsky
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Walmsley
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gold
          </surname>
          <given-names>
           W.L.
          </given-names>
         </name>
         <name>
          <surname>
           Krajden
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <collab>
          The Ontario Laboratory Working Group for the Rapid Diagnosis of Emerging Infections
         </collab>
        </person-group>
        <article-title>
         Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience
        </article-title>
        <source>
         Can. Med. Assoc. J.
        </source>
        <volume>
         170
        </volume>
        <year>
         2004
        </year>
        <fpage>
         47
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         14707219
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thompson
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Gibson
          </surname>
          <given-names>
           T.J.
          </given-names>
         </name>
         <name>
          <surname>
           Plewniak
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jeanmougin
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Higgins
          </surname>
          <given-names>
           D.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The ClustalX Windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools
        </article-title>
        <source>
         Nucl. Acids Res.
        </source>
        <volume>
         24
        </volume>
        <year>
         1997
        </year>
        <fpage>
         4876
        </fpage>
        <lpage>
         4882
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib22">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           G.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yee
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chan-Yeung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Seto
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yam
          </surname>
          <given-names>
           L.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Ip
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           K.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A cluster of cases of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1977
        </fpage>
        <lpage>
         1985
        </lpage>
        <pub-id pub-id-type="pmid">
         12671062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Van de Peer
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           De Wachter
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         TREECON for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment
        </article-title>
        <source>
         Comput. Appl. Biosci.
        </source>
        <volume>
         10
        </volume>
        <year>
         1994
        </year>
        <fpage>
         569
        </fpage>
        <lpage>
         570
        </lpage>
        <pub-id pub-id-type="pmid">
         7828077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Jebbink
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Vermeulen-Oost
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           R.J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wolthers
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wertheim-van Dillen
          </surname>
          <given-names>
           P.M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kaandorp
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Spaargaren
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a new human coronavirus
        </article-title>
        <source>
         Nat. Med.
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         368
        </fpage>
        <lpage>
         373
        </lpage>
        <pub-id pub-id-type="pmid">
         15034574
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vu
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Cabau
          </surname>
          <given-names>
           J.-F.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           N.T.
          </given-names>
         </name>
         <name>
          <surname>
           Lenoir
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS in Northern Vietnam
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         2035
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib26">
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wallington
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Berger
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Henry
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Shahin
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Yaffe
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Mederski
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Berall
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Christian
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ofner
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hansen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gravel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           King
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <collab>
          SARS Investigation Team
         </collab>
        </person-group>
        <article-title>
         Update: severe acute respiratory syndrome–Toronto, Canada
        </article-title>
        <source>
         Comm. Dis.
        </source>
        <volume>
         29
        </volume>
        <year>
         2003
        </year>
        <fpage>
         113
        </fpage>
        <lpage>
         116
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib27">
       <mixed-citation publication-type="other">
        World Health Organization Multicentre Collaborative Network for Severe Acute Respiratory Syndrome (SARS) Diagnosis, 2003. A multicentre collaboration to investigate the cause of severe acute respiratory syndrome. Lancet 361, 1730-1733.
       </mixed-citation>
      </ref>
      <ref id="bib28">
       <mixed-citation publication-type="other">
        World Health Organization, 2003 Alert, verification and public health management of SARS in the post outbreak period.
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/postoutbreak/en/">
         http://www.who.int/csr/sars/postoutbreak/en/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib29">
       <mixed-citation publication-type="other">
        World Health Organization. 2004. New case of laboratory confirmed SARS in Guangdong, China (update 5).
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/2004_01_31/en/">
         http://www.who.int/csr/don/2004_01_31/en/
        </ext-link>
       </mixed-citation>
      </ref>
     </ref-list>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       This work was supported by the Canadian Institutes for Health Research and by the Department of Paediatric Laboratory Medicine, Hospital for Sick Children, Toronto.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="chapter-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="publisher-id">
       978-1-4939-2438-7
      </journal-id>
      <journal-id journal-id-type="doi">
       10.1007/978-1-4939-2438-7
      </journal-id>
      <journal-id journal-id-type="nlm-ta">
       Coronaviruses
      </journal-id>
      <journal-title-group>
       <journal-title>
        Coronaviruses
       </journal-title>
       <journal-subtitle>
        Methods and Protocols
       </journal-subtitle>
      </journal-title-group>
      <isbn publication-format="print">
       978-1-4939-2437-0
      </isbn>
      <isbn publication-format="electronic">
       978-1-4939-2438-7
      </isbn>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25720466
      </article-id>
      <article-id pub-id-type="pmc">
       4369385
      </article-id>
      <article-id pub-id-type="publisher-id">
       1
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/978-1-4939-2438-7_1
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Coronaviruses: An Overview of Their Replication and Pathogenesis
       </article-title>
      </title-group>
      <contrib-group content-type="book editors">
       <contrib contrib-type="editor">
        <name>
         <surname>
          Maier
         </surname>
         <given-names>
          Helena Jane
         </given-names>
        </name>
        <address>
         <email>
          helena.maier@pirbright.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Bickerton
         </surname>
         <given-names>
          Erica
         </given-names>
        </name>
        <address>
         <email>
          erica.bickerton@pirbright.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Britton
         </surname>
         <given-names>
          Paul
         </given-names>
        </name>
        <address>
         <email>
          paul.britton@pirbright.ac.uk
         </email>
        </address>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.63622.33
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000403887540
         </institution-id>
         <institution>
          The Pirbright Institute,
         </institution>
        </institution-wrap>
        Compton, United Kingdom
       </aff>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.63622.33
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000403887540
         </institution-id>
         <institution>
          The Pirbright Institute,
         </institution>
        </institution-wrap>
        Compton, United Kingdom
       </aff>
       <aff id="Aff4">
        <label>
         4
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.63622.33
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000403887540
         </institution-id>
         <institution>
          The Pirbright Institute,
         </institution>
        </institution-wrap>
        Compton, United Kingdom
       </aff>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Fehr
         </surname>
         <given-names>
          Anthony R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff5">
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Perlman
         </surname>
         <given-names>
          Stanley
         </given-names>
        </name>
        <degrees>
         M.D., Ph.D.
        </degrees>
        <address>
         <email>
          stanley-perlman@uiowa.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff5">
        </xref>
       </contrib>
       <aff id="Aff5">
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.214572.7
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000419368294
         </institution-id>
         <institution>
          Department of Microbiology,
         </institution>
         <institution>
          University of Iowa Carver College of Medicine,
         </institution>
        </institution-wrap>
        Iowa City, IA 52242 USA
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        12
       </day>
       <month>
        2
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       1282
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       23
      </lpage>
      <permissions>
       <copyright-statement>
        © Springer Science+Business Media New York 2015
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p id="Par1">
        Coronaviruses (CoVs), enveloped positive-sense RNA viruses, are characterized by club-like spikes that project from their surface, an unusually large RNA genome, and a unique replication strategy. Coronaviruses cause a variety of diseases in mammals and birds ranging from enteritis in cows and pigs and upper respiratory disease in chickens to potentially lethal human respiratory infections. Here we provide a brief introduction to coronaviruses discussing their replication and pathogenicity, and current prevention and treatment strategies. We also discuss the outbreaks of the highly pathogenic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the recently identified Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).
       </p>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Key words
       </title>
       <kwd>
        Nidovirales
       </kwd>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        Positive-sense RNA viruses
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer Science+Business Media New York 2015
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Classification
     </title>
     <p id="Par2">
      Coronaviruses (CoVs) are the largest group of viruses belonging to the
      <italic>
       Nidovirales
      </italic>
      order, which includes
      <italic>
       Coronaviridae
      </italic>
      ,
      <italic>
       Arteriviridae
      </italic>
      ,
      <italic>
       Mesoniviridae
      </italic>
      , and
      <italic>
       Roniviridae
      </italic>
      families. The
      <italic>
       Coronavirinae
      </italic>
      comprise one of two subfamilies in the
      <italic>
       Coronaviridae
      </italic>
      family, with the other being the
      <italic>
       Torovirinae
      </italic>
      . The
      <italic>
       Coronavirinae
      </italic>
      are further subdivided into four genera, the alpha, beta, gamma, and delta coronaviruses. The viruses were initially sorted into these genera based on serology but are now divided by phylogenetic clustering.
     </p>
     <p id="Par3">
      All viruses in the
      <italic>
       Nidovirales
      </italic>
      order are enveloped, non-segmented positive-sense RNA viruses. They all contain very large genomes for RNA viruses, with some viruses having the largest identified RNA genomes, containing up to 33.5 kilobase (kb) genomes. Other common features within the
      <italic>
       Nidovirales
      </italic>
      order include: (1) a highly conserved genomic organization, with a large replicase gene preceding structural and accessory genes; (2) expression of many non-structural genes by ribosomal frameshifting; (3) several unique or unusual enzymatic activities encoded within the large replicase–transcriptase polyprotein; and (4) expression of downstream genes by synthesis of 3′ nested sub-genomic mRNAs. In fact, the
      <italic>
       Nidovirales
      </italic>
      order name is derived from these nested 3′ mRNAs as
      <italic>
       nido
      </italic>
      is Latin for “nest.” The major differences within the Nidovirus families are in the number, type, and sizes of the structural proteins. These differences cause significant alterations in the structure and morphology of the nucleocapsids and virions.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Genomic Organization
     </title>
     <p id="Par4">
      Coronaviruses contain a non-segmented, positive-sense RNA genome of ~30 kb. The genome contains a 5′ cap structure along with a 3′ poly (A) tail, allowing it to act as an mRNA for translation of the replicase polyproteins. The replicase gene encoding the non-structural proteins (nsps) occupies two-thirds of the genome, about 20 kb, as opposed to the structural and accessory proteins, which make up only about 10 kb of the viral genome. The 5′ end of the genome contains a leader sequence and untranslated region (UTR) that contains multiple stem loop structures required for RNA replication and transcription. Additionally, at the beginning of each structural or accessory gene are transcriptional regulatory sequences (TRSs) that are required for expression of each of these genes (
      <italic>
       see
      </italic>
      Subheading
      <xref ref-type="sec" rid="Sec7">
       4.3
      </xref>
      on RNA replication). The 3′ UTR also contains RNA structures required for replication and synthesis of viral RNA. The organization of the coronavirus genome is 5′-leader-UTR-replicase-S (Spike)-E (Envelope)-M (Membrane)-N (Nucleocapsid)-3′ UTR-poly (A) tail with accessory genes interspersed within the structural genes at the 3′ end of the genome (Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ). The accessory proteins are almost exclusively nonessential for replication in tissue culture; however, some have been shown to have important roles in viral pathogenesis [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ].
      <fig id="Fig1">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Genomic organization of representative α, β, and γ CoVs. An illustration of the MHV genome is depicted at the
         <italic>
          top
         </italic>
         . The expanded regions below show the structural and accessory proteins in the 3′ regions of the HCoV-229E, MHV, SARS-CoV, MERS-CoV and IBV. Size of the genome and individual genes are approximated using the legend at the
         <italic>
          top
         </italic>
         of the diagram but are not drawn to scale.
         <italic>
          HCoV-229E
         </italic>
         human coronavirus 229E,
         <italic>
          MHV
         </italic>
         mouse hepatitis virus,
         <italic>
          SARS-CoV
         </italic>
         severe acute respiratory syndrome coronavirus,
         <italic>
          MERS-CoV
         </italic>
         Middle East respiratory syndrome coronavirus,
         <italic>
          IBV
         </italic>
         infectious bronchitis virus
        </p>
       </caption>
       <graphic id="MO1" xlink:href="317916_1_En_1_Fig1_HTML">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec id="Sec3">
     <title>
      Virion Structure
     </title>
     <p id="Par5">
      Coronavirus virions are spherical with diameters of approximately 125 nm as depicted in recent studies by cryo-electron tomography and cryo-electron microscopy [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ]. The most prominent feature of coronaviruses is the club-shaped spike projections emanating from the surface of the virion. These spikes are a defining feature of the virion and give them the appearance of a solar corona, prompting the name, coronaviruses. Within the envelope of the virion is the nucleocapsid. Coronaviruses have helically symmetrical nucleocapsids, which is uncommon among positive-sense RNA viruses, but far more common for negative-sense RNA viruses.
     </p>
     <p id="Par6">
      Coronavirus particles contain four main structural proteins. These are the spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins, all of which are encoded within the 3′ end of the viral genome. The S protein (~150 kDa), utilizes an N-terminal signal sequence to gain access to the ER, and is heavily N-linked glycosylated. Homotrimers of the virus encoded S protein make up the distinctive spike structure on the surface of the virus [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ]. The trimeric S glycoprotein is a class I fusion protein [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ] and mediates attachment to the host receptor [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. In most, coronaviruses, S is cleaved by a host cell furin-like protease into two separate polypeptides noted S1 and S2 [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ]. S1 makes up the large receptor-binding domain of the S protein, while S2 forms the stalk of the spike molecule [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ].
     </p>
     <p id="Par7">
      The M protein is the most abundant structural protein in the virion. It is a small (~25–30 kDa) protein with three transmembrane domains [
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ] and is thought to give the virion its shape. It has a small N-terminal glycosylated ectodomain and a much larger C-terminal endodomain that extends 6–8 nm into the viral particle [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ]. Despite being co-translationally inserted in the ER membrane, most M proteins do not contain a signal sequence. Recent studies suggest the M protein exists as a dimer in the virion, and may adopt two different conformations, allowing it to promote membrane curvature as well as to bind to the nucleocapsid [
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      ].
     </p>
     <p id="Par8">
      The E protein (~8–12 kDa) is found in small quantities within the virion. The coronavirus E proteins are highly divergent but have a common architecture [
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
      ]. The membrane topology of E protein is not completely resolved but most data suggest that it is a transmembrane protein. The E protein has an N-terminal ectodomain and a C-terminal endodomain and has ion channel activity. As opposed to other structural proteins, recombinant viruses lacking the E protein are not always lethal, although this is virus type dependent [
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      ]. The E protein facilitates assembly and release of the virus (
      <italic>
       see
      </italic>
      Subheading
      <xref ref-type="sec" rid="Sec8">
       4.4
      </xref>
      ), but also has other functions. For instance, the ion channel activity in SARS-CoV E protein is not required for viral replication but is required for pathogenesis [
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ].
     </p>
     <p id="Par9">
      The N protein constitutes the only protein present in the nucleocapsid. It is composed of two separate domains, an N-terminal domain (NTD) and a C-terminal domain (CTD), both capable of binding RNA in vitro, but each domain uses different mechanisms to bind RNA. It has been suggested that optimal RNA binding requires contributions from both domains [
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
      ]. N protein is also heavily phosphorylated [
      <xref ref-type="bibr" rid="CR19">
       19
      </xref>
      ], and phosphorylation has been suggested to trigger a structural change enhancing the affinity for viral versus nonviral RNA. N protein binds the viral genome in a beads-on-a-string type conformation. Two specific RNA substrates have been identified for N protein; the TRSs [
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ] and the genomic packaging signal [
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ]. The genomic packaging signal has been found to bind specifically to the second, or C-terminal RNA binding domain [
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
      ]. N protein also binds nsp3 [
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      ], a key component of the replicase complex, and the M protein [
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ]. These protein interactions likely help tether the viral genome to the replicase–transcriptase complex (RTC), and subsequently package the encapsidated genome into viral particles.
     </p>
     <p id="Par10">
      A fifth structural protein, the hemagglutinin-esterase (HE), is present in a subset of β-coronaviruses. The protein acts as a hemagglutinin, binds sialic acids on surface glycoproteins, and contains acetyl-esterase activity [
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ]. These activities are thought to enhance S protein-mediated cell entry and virus spread through the mucosa [
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
      ]. Interestingly, HE enhances murine hepatitis virus (MHV) neurovirulence [
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      ]; however, it is selected against in tissue culture for unknown reasons [
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      ].
     </p>
    </sec>
    <sec id="Sec4">
     <title>
      Coronavirus Life Cycle
     </title>
     <sec id="Sec5">
      <title>
       Attachment and Entry
      </title>
      <p id="Par11">
       The initial attachment of the virion to the host cell is initiated by interactions between the S protein and its receptor. The sites of receptor binding domains (RBD) within the S1 region of a coronavirus S protein vary depending on the virus, with some having the RBD at the N-terminus of S1 (MHV), while others (SARS-CoV) have the RBD at the C-terminus of S1 [
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
       ]. The S-protein–receptor interaction is the primary determinant for a coronavirus to infect a host species and also governs the tissue tropism of the virus. Many coronaviruses utilize peptidases as their cellular receptor. It is unclear why peptidases are used, as entry occurs even in the absence of the enzymatic domain of these proteins. Many α-coronaviruses utilize aminopeptidase N (APN) as their receptor, SARS-CoV and HCoV-NL63 use angiotensin-converting enzyme 2 (ACE2) as their receptor, MHV enters through CEACAM1, and the recently identified MERS-CoV binds to dipeptidyl-peptidase 4 (DPP4) to gain entry into human cells (
       <italic>
        see
       </italic>
       Table
       <xref ref-type="table" rid="Tab1">
        1
       </xref>
       for a list of known CoV receptors).
       <table-wrap id="Tab1">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Coronavirus receptors
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Virus
           </th>
           <th>
            Receptor
           </th>
           <th>
            References
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td colspan="3">
            Alphacoronaviruses
           </td>
          </tr>
          <tr>
           <td>
            HCoV-229E
           </td>
           <td>
            APN
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR115">
             115
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            HCoV-NL63
           </td>
           <td>
            ACE2
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR116">
             116
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            TGEV
           </td>
           <td>
            APN
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR117">
             117
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            PEDV
           </td>
           <td>
            APN
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR118">
             118
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            FIPV
           </td>
           <td>
            APN
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR119">
             119
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            CCoV
           </td>
           <td>
            APN
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR120">
             120
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td colspan="3">
            Betacoronaviruses
           </td>
          </tr>
          <tr>
           <td>
            MHV
           </td>
           <td>
            mCEACAM
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR121">
             121
            </xref>
            ,
            <xref ref-type="bibr" rid="CR122">
             122
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            BCoV
           </td>
           <td>
            <italic>
             N
            </italic>
            -acetyl-9-
            <italic>
             O
            </italic>
            -acetylneuraminic acid
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR123">
             123
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            SARS-CoV
           </td>
           <td>
            ACE2
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR124">
             124
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            MERS-CoV
           </td>
           <td>
            DPP4
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR100">
             100
            </xref>
            ]
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          <italic>
           APN
          </italic>
          aminopeptidase N,
          <italic>
           ACE2
          </italic>
          angiotensin-converting enzyme 2,
          <italic>
           mCEACAM
          </italic>
          murine carcinoembryonic antigen-related adhesion molecule 1,
          <italic>
           DPP4
          </italic>
          dipeptidyl peptidase 4,
          <italic>
           HCoV
          </italic>
          human coronavirus,
          <italic>
           TGEV
          </italic>
          transmissible gastroenteritis virus,
          <italic>
           PEDV
          </italic>
          porcine epidemic diarrhea virus,
          <italic>
           FIPV
          </italic>
          feline infectious peritonitis virus,
          <italic>
           CCoV
          </italic>
          canine coronavirus,
          <italic>
           MHV
          </italic>
          murine hepatitis virus,
          <italic>
           BCoV
          </italic>
          bovine coronavirus,
          <italic>
           SARS-CoV
          </italic>
          severe acute respiratory syndrome coronavirus,
          <italic>
           MERS-CoV
          </italic>
          Middle East respiratory syndrome coronavirus
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p id="Par12">
       Following receptor binding, the virus must next gain access to the host cell cytosol. This is generally accomplished by acid-dependent proteolytic cleavage of S protein by a cathepsin, TMPRRS2 or another protease, followed by fusion of the viral and cellular membranes. S protein cleavage occurs at two sites within the S2 portion of the protein, with the first cleavage important for separating the RBD and fusion domains of the S protein [
       <xref ref-type="bibr" rid="CR31">
        31
       </xref>
       ] and the second for exposing the fusion peptide (cleavage at S2′). Fusion generally occurs within acidified endosomes, but some coronaviruses, such as MHV, can fuse at the plasma membrane. Cleavage at S2′ exposes a fusion peptide that inserts into the membrane, which is followed by joining of two heptad repeats in S2 forming an antiparallel six-helix bundle [
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
       ]. The formation of this bundle allows for the mixing of viral and cellular membranes, resulting in fusion and ultimately release of the viral genome into the cytoplasm.
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       Replicase Protein Expression
      </title>
      <p id="Par13">
       The next step in the coronavirus lifecycle is the translation of the replicase gene from the virion genomic RNA. The replicase gene encodes two large ORFs, rep1a and rep1b, which express two co-terminal polyproteins, pp1a and pp1ab (Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       ). In order to express both polyproteins, the virus utilizes a slippery sequence (5′-UUUAAAC-3′) and an RNA pseudoknot that cause ribosomal frameshifting from the rep1a reading frame into the rep1b ORF. In most cases, the ribosome unwinds the pseudoknot structure, and continues translation until it encounters the rep1a stop codon. Occasionally the pseudoknot blocks the ribosome from continuing elongation, causing it to pause on the slippery sequence, changing the reading frame by moving back one nucleotide, a -1 frameshift, before the ribosome is able to melt the pseudoknot structure and extend translation into rep1b, resulting in the translation of pp1ab [
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
       ]. In vitro studies predict the incidence of ribosomal frameshifting to be as high as 25 %, but this has not been determined in the context of virus infection. It is unknown exactly why these viruses utilize frameshifting to control protein expression, but it is hypothesized to either control the precise ratio of rep1b and rep1a proteins or delay the production of rep1b products until the products of rep1a have created a suitable environment for RNA replication [
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
       ].
      </p>
      <p id="Par14">
       Polyproteins pp1a and pp1ab contain the nsps 1–11 and 1–16, respectively. In pp1ab, nsp11 from pp1a becomes nsp12 following extension of pp1a into pp1b. However, γ-coronaviruses do not contain a comparable nsp1. These polyproteins are subsequently cleaved into the individual nsps [
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
       ]. Coronaviruses encode either two or three proteases that cleave the replicase polyproteins. They are the papain-like proteases (PLpro), encoded within nsp3, and a serine type protease, the main protease, or Mpro, encoded by nsp5. Most coronaviruses encode two PLpros within nsp3, except the γ-coronaviruses, SARS-CoV and MERS-CoV, which only express one PLpro [
       <xref ref-type="bibr" rid="CR36">
        36
       </xref>
       ]. The PLpros cleave the nsp1/2, nsp2/3, and nsp3/4 boundaries, while the Mpro is responsible for the remaining 11 cleavage events.
      </p>
      <p id="Par15">
       Next, many of the nsps assemble into the replicase–transcriptase complex (RTC) to create an environment suitable for RNA synthesis, and ultimately are responsible for RNA replication and transcription of the sub-genomic RNAs. The nsps also contain other enzyme domains and functions, including those important for RNA replication, for example nsp12 encodes the RNA-dependent RNA polymerase (RdRp) domain; nsp13 encodes the RNA helicase domain and RNA 5′-triphosphatase activity; nsp14 encodes the exoribonuclease (ExoN) involved in replication fidelity and N7-methyltransferase activity; and nsp16 encodes 2′-O-methyltransferase activity. In addition to the replication functions other activities, such as blocking innate immune responses (nsp1; nsp16-2′-O-methyl transferase; nsp3-deubiquitinase) have been identified for some of the nsps, while others have largely unknown functions (nsp3-ADP-ribose-1″-phosphatase; nsp15-endoribo-nuclease (NendoU)). For a list of non-structural proteins and their proposed functions,
       <italic>
        see
       </italic>
       Table
       <xref ref-type="table" rid="Tab2">
        2
       </xref>
       . Interestingly, ribonucleases nsp15-NendoU and nsp14-ExoN activities are unique to the
       <italic>
        Nidovirales
       </italic>
       order and are considered genetic markers for these viruses [
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ].
       <table-wrap id="Tab2">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Functions of coronavirus non-structural proteins (nsps)
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Protein
           </th>
           <th>
            Function
           </th>
           <th>
            References
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            nsp1
           </td>
           <td>
            Promotes cellular mRNA degradation and blocks host cell translation, results in blocking innate immune response
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR125">
             125
            </xref>
            –
            <xref ref-type="bibr" rid="CR128">
             128
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp2
           </td>
           <td>
            No known function, binds to prohibitin proteins
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR129">
             129
            </xref>
            ,
            <xref ref-type="bibr" rid="CR130">
             130
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp3
           </td>
           <td>
            <p>
             Large, multi-domain transmembrane protein, activities include:
            </p>
            <p>
             • Ubl1 and Ac domains, interact with N protein
            </p>
            <p>
             • ADRP activity, promotes cytokine expression
            </p>
            <p>
             • PLPro/Deubiquitinase domain, cleaves viral polyprotein and blocks host innate immune response
            </p>
            <p>
             • Ubl2, NAB, G2M, SUD, Y domains, unknown functions
            </p>
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR131">
             131
            </xref>
            –
            <xref ref-type="bibr" rid="CR138">
             138
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp4
           </td>
           <td>
            Potential transmembrane scaffold protein, important for proper structure of DMVs
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR139">
             139
            </xref>
            ,
            <xref ref-type="bibr" rid="CR140">
             140
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp5
           </td>
           <td>
            Mpro, cleaves viral polyprotein
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR141">
             141
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp6
           </td>
           <td>
            Potential transmembrane scaffold protein
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR142">
             142
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp7
           </td>
           <td>
            Forms hexadecameric complex with nsp8, may act as processivity clamp for RNA polymerase
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR143">
             143
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp8
           </td>
           <td>
            Forms hexadecameric complex with nsp7, may act as processivity clamp for RNA polymerase; may act as primase
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR143">
             143
            </xref>
            ,
            <xref ref-type="bibr" rid="CR144">
             144
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp9
           </td>
           <td>
            RNA binding protein
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR145">
             145
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp10
           </td>
           <td>
            Cofactor for nsp16 and nsp14, forms heterodimer with both and stimulates ExoN and 2-O-MT activity
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR146">
             146
            </xref>
            ,
            <xref ref-type="bibr" rid="CR147">
             147
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp12
           </td>
           <td>
            RdRp
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR148">
             148
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp13
           </td>
           <td>
            RNA helicase, 5′ triphosphatase
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR149">
             149
            </xref>
            ,
            <xref ref-type="bibr" rid="CR150">
             150
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp14
           </td>
           <td>
            N7 MTase and 3′-5′ exoribonuclease, ExoN; N7 MTase adds 5′ cap to viral RNAs, ExoN activity is important for proofreading of viral genome
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR151">
             151
            </xref>
            –
            <xref ref-type="bibr" rid="CR154">
             154
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp15
           </td>
           <td>
            Viral endoribonuclease, NendoU
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR155">
             155
            </xref>
            ,
            <xref ref-type="bibr" rid="CR156">
             156
            </xref>
            ]
           </td>
          </tr>
          <tr>
           <td>
            nsp16
           </td>
           <td>
            2′-O-MT; shields viral RNA from MDA5 recognition
           </td>
           <td>
            [
            <xref ref-type="bibr" rid="CR157">
             157
            </xref>
            ,
            <xref ref-type="bibr" rid="CR158">
             158
            </xref>
            ]
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          <italic>
           Ubl
          </italic>
          ubiquitin-like,
          <italic>
           Ac
          </italic>
          acidic,
          <italic>
           ADRP
          </italic>
          ADP-ribose-1′-phosphatase,
          <italic>
           PLPro
          </italic>
          papain-like protease,
          <italic>
           NAB
          </italic>
          nucleic acid binding,
          <italic>
           SUD
          </italic>
          SARS-unique domain,
          <italic>
           DMVs
          </italic>
          double-membrane vesicles,
          <italic>
           Mpro
          </italic>
          main protease,
          <italic>
           RdRp
          </italic>
          RNA-dependent RNA polymerase,
          <italic>
           MTase
          </italic>
          methyltransferase,
          <italic>
           Exo N
          </italic>
          viral exoribonuclease,
          <italic>
           Nendo U
          </italic>
          viral endoribonuclease,
          <italic>
           2′-O-MT
          </italic>
          2′-O-methyltransferase,
          <italic>
           MDA5
          </italic>
          melanoma differentiation associated protein 5
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       Replication and Transcription
      </title>
      <p id="Par16">
       Viral RNA synthesis follows the translation and assembly of the viral replicase complexes. Viral RNA synthesis produces both genomic and sub-genomic RNAs. Sub-genomic RNAs serve as mRNAs for the structural and accessory genes which reside downstream of the replicase polyproteins. All positive-sense sub-genomic RNAs are 3′ co-terminal with the full-length viral genome and thus form a set of nested RNAs, a distinctive property of the order
       <italic>
        Nidovirales
       </italic>
       . Both genomic and sub-genomic RNAs are produced through negative-strand intermediates. These negative-strand intermediates are only about 1 % as abundant as their positive-sense counterparts and contain both poly-uridylate and anti-leader sequences [
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ].
      </p>
      <p id="Par17">
       Many cis-acting sequences are important for the replication of viral RNAs. Within the 5′ UTR of the genome are seven stem-loop structures that may extend into the replicase 1a gene [
       <xref ref-type="bibr" rid="CR39">
        39
       </xref>
       –
       <xref ref-type="bibr" rid="CR42">
        42
       </xref>
       ]. The 3′ UTR contains a bulged stem-loop, a pseudoknot, and a hypervariable region [
       <xref ref-type="bibr" rid="CR43">
        43
       </xref>
       –
       <xref ref-type="bibr" rid="CR46">
        46
       </xref>
       ]. Interestingly, the stem-loop and the pseudoknot at the 3′ end overlap, and thus cannot form simultaneously [
       <xref ref-type="bibr" rid="CR44">
        44
       </xref>
       ,
       <xref ref-type="bibr" rid="CR47">
        47
       </xref>
       ]. Therefore, these different structures are proposed to regulate alternate stages of RNA synthesis, although exactly which stages are regulated and their precise mechanism of action are still unknown.
      </p>
      <p id="Par18">
       Perhaps the most novel aspect of coronavirus replication is how the leader and body TRS segments fuse during production of sub-genomic RNAs. This was originally thought to occur during positive-strand synthesis, but now it is largely believed to occur during the discontinuous extension of negative-strand RNA [
       <xref ref-type="bibr" rid="CR48">
        48
       </xref>
       ]. The current model proposes that the RdRp pauses at any one of the body TRS sequences (TRS-B); following this pause the RdRp either continues elongation to the next TRS or it switches to amplifying the leader sequence at the 5′ end of the genome guided by complementarity of the TRS-B to the leader TRS (TRS-L). Many pieces of evidence currently support this model, including the presence of anti-leader sequence at the 3′ end of the negative-strand sub-genomic RNAs [
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ]. However, many questions remain to fully define the model. For instance, how does the RdRp bypass all of the TRS-B sequences to produce full-length negative-strand genomic RNA? Also, how are the TRS-B sequences directed to the TRS-L and how much complementarity is necessary [
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
       ]? Answers to these questions and others will be necessary to gain a full perspective of how RNA replication occurs in coronaviruses.
      </p>
      <p id="Par19">
       Finally, coronaviruses are also known for their ability to recombine using both homologous and nonhomologous recombination [
       <xref ref-type="bibr" rid="CR50">
        50
       </xref>
       ,
       <xref ref-type="bibr" rid="CR51">
        51
       </xref>
       ]. The ability of these viruses to recombine is tied to the strand switching ability of the RdRp. Recombination likely plays a prominent role in viral evolution and is the basis for targeted RNA recombination, a reverse genetics tool used to engineer viral recombinants at the 3′ end of the genome.
      </p>
     </sec>
     <sec id="Sec8">
      <title>
       Assembly and Release
      </title>
      <p id="Par20">
       Following replication and sub-genomic RNA synthesis, the viral structural proteins, S, E, and M are translated and inserted into the endoplasmic reticulum (ER). These proteins move along the secretory pathway into the endoplasmic reticulum–Golgi intermediate compartment (ERGIC) [
       <xref ref-type="bibr" rid="CR52">
        52
       </xref>
       ,
       <xref ref-type="bibr" rid="CR53">
        53
       </xref>
       ]. There, viral genomes encapsidated by N protein bud into membranes of the ERGIC containing viral structural proteins, forming mature virions [
       <xref ref-type="bibr" rid="CR54">
        54
       </xref>
       ].
      </p>
      <p id="Par21">
       The M protein directs most protein–protein interactions required for assembly of coronaviruses. However, M protein is not sufficient for virion formation, as virus-like particles (VLPs) cannot be formed by M protein expression alone. When M protein is expressed along with E protein VLPs are formed, suggesting these two proteins function together to produce coronavirus envelopes [
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
       ]. N protein enhances VLP formation, suggesting that fusion of encapsidated genomes into the ERGIC enhances viral envelopment [
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
       ]. The S protein is incorporated into virions at this step, but is not required for assembly. The ability of the S protein to traffic to the ERGIC and interact with the M protein is critical for its incorporation into virions.
      </p>
      <p id="Par22">
       While the M protein is relatively abundant, the E protein is only present in small quantities in the virion. Thus, it is likely that M protein interactions provide the impetus for envelope maturation. It is unknown how E protein assists M protein in assembly of the virion, and several possibilities have been suggested. Some work has indicated a role for the E protein in inducing membrane curvature [
       <xref ref-type="bibr" rid="CR57">
        57
       </xref>
       –
       <xref ref-type="bibr" rid="CR59">
        59
       </xref>
       ], although others have suggested that E protein prevents the aggregation of M protein [
       <xref ref-type="bibr" rid="CR60">
        60
       </xref>
       ]. The E protein may also have a separate role in promoting viral release by altering the host secretory pathway [
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
       ].
      </p>
      <p id="Par23">
       The M protein also binds to the nucleocapsid, and this interaction promotes the completion of virion assembly. These interactions have been mapped to the C-terminus of the endodomain of M with CTD of the N-protein [
       <xref ref-type="bibr" rid="CR62">
        62
       </xref>
       ]. However, it is unclear exactly how the nucleocapsid complexed with virion RNA traffics to the ERGIC to interact with M protein and become incorporated into the viral envelope. Another outstanding question is how the N protein selectively packages only positive-sense full-length genomes among the many different RNA species produced during infection. A packaging signal for MHV has been identified in the nsp15 coding sequence, but mutation of this signal does not appear to affect virus production, and a mechanism for how this packaging signal works has not been determined [
       <xref ref-type="bibr" rid="CR22">
        22
       </xref>
       ]. Furthermore, most coronaviruses do not contain similar sequences at this locus, indicating that packaging may be virus specific.
      </p>
      <p id="Par24">
       Following assembly, virions are transported to the cell surface in vesicles and released by exocytosis. It is not known if the virions use the traditional pathway for transport of large cargo from the Golgi or if the virus has diverted a separate, unique pathway for its own exit. In several coronaviruses, S protein that does not get assembled into virions transits to the cell surface where it mediates cell–cell fusion between infected cells and adjacent, uninfected cells. This leads to the formation of giant, multinucleated cells, which allows the virus to spread within an infected organism without being detected or neutralized by virus-specific antibodies.
      </p>
     </sec>
    </sec>
    <sec id="Sec9">
     <title>
      Pathogenesis
     </title>
     <sec id="Sec10">
      <title>
       Animal Coronaviruses
      </title>
      <p id="Par25">
       Coronaviruses cause a large variety of diseases in animals, and their ability to cause severe disease in livestock and companion animals such as pigs, cows, chickens, dogs, and cats led to significant research on these viruses in the last half of the twentieth century. For instance, Transmissible Gastroenteritis Virus (TGEV) and Porcine Epidemic Diarrhea Virus (PEDV) cause severe gastroenteritis in young piglets, leading to significant morbidity, mortality, and ultimately economic losses. PEDV recently emerged in North America for the first time, causing significant losses of young piglets. Porcine hemagglutinating encephalomyelitis virus (PHEV) mostly leads to enteric infection but has the ability to infect the nervous system, causing encephalitis, vomiting, and wasting in pigs. Feline enteric coronavirus (FCoV) causes a mild or asymptomatic infection in domestic cats, but during persistent infection, mutation transforms the virus into a highly virulent strain of FCoV, Feline Infectious Peritonitis Virus (FIPV), that leads to development of a lethal disease called feline infectious peritonitis (FIP). FIP has wet and dry forms, with similarities to the human disease, sarcoidosis. FIPV is macrophage tropic and it is believed that it causes aberrant cytokine and/or chemokine expression and lymphocyte depletion, resulting in lethal disease [
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
       ]. However, additional research is needed to confirm this hypothesis. Bovine CoV, Rat CoV, and Infectious Bronchitis Virus (IBV) cause mild to severe respiratory tract infections in cattle, rats, and chickens, respectively. Bovine CoV causes significant losses in the cattle industry and also has spread to infect a variety of ruminants, including elk, deer, and camels. In addition to severe respiratory disease, the virus causes diarrhea (“winter dysentery” and “shipping fever”), all leading to weight loss, dehydration, decreased milk production, and depression [
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
       ]. Some strains of IBV, a γ-coronavirus, also affect the urogenital tract of chickens causing renal disease. Infection of the reproductive tract with IBV significantly diminishes egg production, causing substantial losses in the egg-production industry each year [
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
       ]. More recently, a novel coronavirus named SW1 has been identified in a deceased Beluga whale [
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
       ]. Large numbers of virus particles were identified in the liver of the deceased whale with respiratory disease and acute liver failure. Although, electron microscopic images were not sufficient to identify the virus as a coronavirus, sequencing of the liver tissue clearly identified the virus as a coronavirus. It was subsequently determined to be a γ-coronavirus based on phylogenetic analysis but it has not yet been verified experimentally that this virus is actually a causative agent of disease in whales. In addition, there has been intense interest in identifying novel bat CoVs, since these are the likely ancestors for SARS-CoV and MERS-CoV, and hundreds of novel bat coronaviruses have been identified over the past decade [
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
       ]. Finally, another novel family of nidoviruses,
       <italic>
        Mesoniviridae
       </italic>
       , has been recently identified as the first nidoviruses to exclusively infect insect hosts [
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
       ,
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
       ]. These viruses are highly divergent from other nidoviruses but are most closely related to the roniviruses. In size, they are ~20 kb, falling in between large and small nidoviruses. Interestingly, these viruses do not encode for an endoribonuclease, which is present in all other nidoviruses. These attributes suggest these viruses are the prototype of a new nidovirus family and may be a missing link in the transition from small to large nidoviruses.
      </p>
      <p id="Par26">
       The most heavily studied animal coronavirus is murine hepatitis virus (MHV), which causes a variety of outcomes in mice, including respiratory, enteric, hepatic, and neurologic infections. These infections often serve as highly useful models of disease. For instance, MHV-1 causes severe respiratory disease in susceptible A/J and C3H/HeJ mice, A59 and MHV-3 induce severe hepatitis, while JHMV causes severe encephalitis. Interestingly, MHV-3 induces cellular injury through the activation of the coagulation cascade [
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
       ]. Most notably, A59 and attenuated versions of JHMV cause a chronic demyelinating disease that bears similarities to multiple sclerosis (MS), making MHV infection one of the best models for this debilitating human disease. Early studies suggested that demyelination was dependent on viral replication in oligodendrocytes in the brain and spinal cord [
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
       ]; however, more recent reports clearly demonstrate that the disease is immune-mediated. Irradiated mice or immunodeficient (lacking T and B cells) mice do not develop demyelination, but addition of virus-specific T cells restores the development of demyelination [
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="CR72">
        72
       </xref>
       ]. Additionally, demyelination is accompanied by a large influx of macrophages and microglia that can phagocytose infected myelin [
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
       ], although it is unknown what the signals are that direct immune cells to destroy myelin. Finally, MHV can be studied under BSL2 laboratory conditions, unlike SARS-CoV or MERS-CoV, which require a BSL3 laboratory, and provides a large number of suitable animal models. These factors make MHV an ideal model for studying the basics of viral replication in tissue culture cells as well as for studying the pathogenesis and immune response to coronaviruses.
      </p>
     </sec>
     <sec id="Sec11">
      <title>
       Human Coronaviruses
      </title>
      <p id="Par27">
       Prior to the SARS-CoV outbreak, coronaviruses were only thought to cause mild, self-limiting respiratory infections in humans. Two of these human coronaviruses are α-coronaviruses, HCoV-229E and HCoV-NL63, while the other two are β-coronaviruses, HCoV-OC43 and HCoV-HKU1. HCoV-229E and HCoV-OC43 were isolated nearly 50 years ago [
       <xref ref-type="bibr" rid="CR74">
        74
       </xref>
       –
       <xref ref-type="bibr" rid="CR76">
        76
       </xref>
       ], while HCoV-NL63 and HCoV-HKU1 have only recently been identified following the SARS-CoV outbreak [
       <xref ref-type="bibr" rid="CR77">
        77
       </xref>
       ,
       <xref ref-type="bibr" rid="CR78">
        78
       </xref>
       ]. These viruses are endemic in the human populations, causing 15–30 % of respiratory tract infections each year. They cause more severe disease in neonates, the elderly, and in individuals with underlying illnesses, with a greater incidence of lower respiratory tract infection in these populations. HCoV-NL63 is also associated with acute laryngotracheitis (croup) [
       <xref ref-type="bibr" rid="CR79">
        79
       </xref>
       ]. One interesting aspect of these viruses is their differences in tolerance to genetic variability. HCoV-229E isolates from around the world have only minimal sequence divergence [
       <xref ref-type="bibr" rid="CR80">
        80
       </xref>
       ], while HCoV-OC43 isolates from the same location but isolated in different years show significant genetic variability [
       <xref ref-type="bibr" rid="CR81">
        81
       </xref>
       ]. This likely explains the inability of HCoV-229E to cross the species barrier to infect mice while HCoV-OC43 and the closely related bovine coronavirus, BCoV, are capable of infecting mice and several ruminant species. Based on the ability of MHV to cause demyelinating disease, it has been suggested that human CoVs may be involved in the development of multiple sclerosis (MS). However, no evidence to date suggests that human CoVs play a significant role in MS.
      </p>
      <p id="Par28">
       SARS-CoV, a group 2b β-coronavirus, was identified as the causative agent of the Severe Acute Respiratory Syndrome (SARS) outbreak that occurred in 2002–2003 in the Guangdong Province of China. It is the most severe human disease caused by any coronavirus. During the 2002–2003 outbreak approximately 8,098 cases occurred with 774 deaths, resulting in a mortality rate of 9 %. This rate was much higher in elderly individuals, with mortality rates approaching 50 % in individuals over 60 years of age. Furthermore, the outbreak resulted in the loss of nearly $40 billion dollars in economic activity, as the virus nearly shut down many activities in Southeast Asia and Toronto, Canada for several months. The outbreak began in a hotel in Hong Kong and ultimately spread to more than two dozen countries. During the epidemic, closely related viruses were isolated from several exotic animals including Himalayan palm civets and raccoon dogs [
       <xref ref-type="bibr" rid="CR82">
        82
       </xref>
       ]. However, it is widely accepted that SARS-CoV originated in bats as a large number of Chinese horseshoe bats contain sequences of SARS-related CoVs and contain serologic evidence for a prior infection with a related CoV [
       <xref ref-type="bibr" rid="CR83">
        83
       </xref>
       ,
       <xref ref-type="bibr" rid="CR84">
        84
       </xref>
       ]. In fact, two novel bat SARS-related CoVs have been recently identified that are more similar to SARS-CoV than any other virus identified to date [
       <xref ref-type="bibr" rid="CR85">
        85
       </xref>
       ]. They were also found to use the same receptor as the human virus, angiotensin converting enzyme 2 (ACE2), providing further evidence that SARS-CoV originated in bats. Although some human individuals within wet animal markets had serologic evidence of SARS-CoV infection prior to the outbreak, these individuals had no apparent symptoms [
       <xref ref-type="bibr" rid="CR82">
        82
       </xref>
       ]. Thus, it is likely that a closely related virus circulated in the wet animal markets for several years before a series of factors facilitated its spread into the larger population.
      </p>
      <p id="Par29">
       Transmission of SARS-CoV was relatively inefficient, as it only spread through direct contact with infected individuals after the onset of illness. Thus, the outbreak was largely contained within households and healthcare settings [
       <xref ref-type="bibr" rid="CR86">
        86
       </xref>
       ], except in a few cases of superspreading events where one individual was able to infect multiple contacts due to an enhanced development of high viral burdens or ability to aerosolize virus. As a result of the relatively inefficient transmission of SARS-CoV, the outbreak was controllable through the use of quarantining. Only a small number of SARS cases occurred after the outbreak was controlled in June 2003.
      </p>
      <p id="Par30">
       SARS-CoV primarily infects epithelial cells within the lung. The virus is capable of entering macrophages and dendritic cells but only leads to an abortive infection [
       <xref ref-type="bibr" rid="CR87">
        87
       </xref>
       ,
       <xref ref-type="bibr" rid="CR88">
        88
       </xref>
       ]. Despite this, infection of these cell types may be important in inducing pro-inflammatory cytokines that may contribute to disease [
       <xref ref-type="bibr" rid="CR89">
        89
       </xref>
       ]. In fact, many cytokines and chemokines are produced by these cell types and are elevated in the serum of SARS-CoV infected patients [
       <xref ref-type="bibr" rid="CR90">
        90
       </xref>
       ]. The exact mechanism of lung injury and cause of severe disease in humans remains undetermined. Viral titers seem to diminish when severe disease develops in both humans and in several animal models of the disease. Furthermore, animals infected with rodent-adapted SARS-CoV strains show similar clinical features to the human disease, including an age-dependent increase in disease severity [
       <xref ref-type="bibr" rid="CR91">
        91
       </xref>
       ]. These animals also show increased levels of proinflammatory cytokines and reduced T-cell responses, suggesting a possible immunopathological mechanism of disease [
       <xref ref-type="bibr" rid="CR92">
        92
       </xref>
       ,
       <xref ref-type="bibr" rid="CR93">
        93
       </xref>
       ].
      </p>
      <p id="Par31">
       While the SARS-CoV epidemic was controlled in 2003 and the virus has not since returned, a novel human CoV emerged in the Middle East in 2012. This virus, named Middle East Respiratory Syndrome-CoV (MERS-CoV), was found to be the causative agent in a series of highly pathogenic respiratory tract infections in Saudi Arabia and other countries in the Middle East [
       <xref ref-type="bibr" rid="CR94">
        94
       </xref>
       ]. Based on the high mortality rate of ~50 % in the early stages of the outbreak, it was feared the virus would lead to a very serious outbreak. However, the outbreak did not accelerate in 2013, although sporadic cases continued throughout the rest of the year. In April 2014, a spike of over 200 cases and almost 40 deaths occurred, prompting fears that the virus had mutated and was more capable of human-to-human transmission. More likely, the increased number of cases resulted from improved detection and reporting methods combined with a seasonal increase in birthing camels. As of August 27th, 2014 there have been a total of 855 cases of MERS-CoV, with 333 deaths and a case fatality rate of nearly 40 %, according to the European Center for Disease Prevention and Control.
      </p>
      <p id="Par32">
       MERS-CoV is a group 2c β-coronavirus highly related to two previously identified bat coronaviruses, HKU4 and HKU5 [
       <xref ref-type="bibr" rid="CR95">
        95
       </xref>
       ]. It is believed that the virus originated from bats, but likely had an intermediate host as humans rarely come in contact with bat secreta. Serological studies have identified MERS-CoV antibodies in dromedary camels in the Middle East [
       <xref ref-type="bibr" rid="CR96">
        96
       </xref>
       ], and cell lines from camels have been found to be permissive for MERS-CoV replication [
       <xref ref-type="bibr" rid="CR97">
        97
       </xref>
       ] providing evidence that dromedary camels may be the natural host. More convincing evidence for this comes from recent studies identifying nearly identical MERS-CoVs in both camels and human cases in nearby proximities in Saudi Arabia [
       <xref ref-type="bibr" rid="CR98">
        98
       </xref>
       ,
       <xref ref-type="bibr" rid="CR99">
        99
       </xref>
       ]. In one of these studies the human case had direct contact with an infected camel and the virus isolated from this patient was identical to the virus isolated from the camel [
       <xref ref-type="bibr" rid="CR99">
        99
       </xref>
       ]. At the present time it remains to be determined how many MERS-CoV cases can be attributed to an intermediate host as opposed to human-to-human transmission. It has also been postulated that human-to-camel spread contributed to the outbreak.
      </p>
      <p id="Par33">
       MERS-CoV utilizes Dipeptidyl peptidase 4 (DPP4) as its receptor [
       <xref ref-type="bibr" rid="CR100">
        100
       </xref>
       ]. The virus is only able to use the receptor from certain species such as bats, humans, camels, rabbits, and horses to establish infection. Unfortunately for researchers, the virus is unable to infect mouse cells due to differences in the structure of DPP4, making it difficult to evaluate potential vaccines or antivirals. Recently, a small animal model for MERS-CoV has been developed using an Adenoviral vector to introduce the human DPP4 gene into mouse lungs [
       <xref ref-type="bibr" rid="CR101">
        101
       </xref>
       ]. This unique system makes it possible to test therapeutic interventions and novel vaccines for MERS-CoV in any animal sensitive to adenoviral transductions.
      </p>
     </sec>
    </sec>
    <sec id="Sec12">
     <title>
      Diagnosis, Treatment, and Prevention
     </title>
     <p id="Par34">
      In most cases of self-limited infection, diagnosis of coronaviruses is unnecessary, as the disease will naturally run its course. However, it may be important in certain clinical and veterinary settings or in epidemiological studies to identify an etiological agent. Diagnosis is also important in locations where a severe CoV outbreak is occurring, such as, at present, in the Middle East, where MERS-CoV continues to circulate. The identification of cases will guide the development of public health measures to control outbreaks. It is also important to diagnose cases of severe veterinary CoV-induced disease, such as PEDV and IBV, to control these pathogens and protect food supplies. RT-PCR has become the method of choice for diagnosis of human CoV, as multiplex real-time RT-PCR assays have been developed, are able to detect all four respiratory HCoVs and could be further adapted to novel CoVs [
      <xref ref-type="bibr" rid="CR102">
       102
      </xref>
      ,
      <xref ref-type="bibr" rid="CR103">
       103
      </xref>
      ]. Serologic assays are important in cases where RNA is difficult to isolate or is no longer present, and for epidemiological studies.
     </p>
     <p id="Par35">
      To date, there are no antiviral therapeutics that specifically target human coronaviruses, so treatments are only supportive. In vitro, interferons (IFNs) are only partially effective against coronaviruses [
      <xref ref-type="bibr" rid="CR104">
       104
      </xref>
      ]. IFNs in combination with ribavirin may have increased activity in vitro when compared to IFNs alone against some coronaviruses; however, the effectiveness of this combination in vivo requires further evaluation [
      <xref ref-type="bibr" rid="CR105">
       105
      </xref>
      ]. The SARS and MERS outbreaks have stimulated research on these viruses and this research has identified a large number of suitable antiviral targets, such as viral proteases, polymerases, and entry proteins. Significant work remains, however, to develop drugs that target these processes and are able to inhibit viral replication.
     </p>
     <p id="Par36">
      Only limited options are available to prevent coronavirus infections. Vaccines have only been approved for IBV, TGEV, and Canine CoV, but these vaccines are not always used because they are either not very effective, or in some cases have been reported to be involved in the selection of novel pathogenic CoVs via recombination of circulating strains. Vaccines for veterinary pathogens, such as PEDV, may be useful in such cases where spread of the virus to a new location could lead to severe losses of veterinary animals. In the case of SARS-CoV, several potential vaccines have been developed but none are yet approved for use. These vaccines include recombinant attenuated viruses, live virus vectors, or individual viral proteins expressed from DNA plasmids. Therapeutic SARS-CoV neutralizing antibodies have been generated and could be retrieved and used again in the event of another SARS-CoV outbreak. Such antibodies would be most useful for protecting healthcare workers. In general, it is thought that live attenuated vaccines would be the most efficacious in targeting coronaviruses. This was illustrated in the case of TGEV, where an attenuated variant, PRCV, appeared in Europe in the 1980s. This variant only caused mild disease and completely protected swine from TGEV. Thus, this attenuated virus has naturally prevented the reoccurrence of severe TGEV in Europe and the U.S. over the past 30 years [
      <xref ref-type="bibr" rid="CR106">
       106
      </xref>
      ]. Despite this success, vaccine development for coronaviruses faces many challenges [
      <xref ref-type="bibr" rid="CR107">
       107
      </xref>
      ]. First, for mucosal infections, natural infection does not prevent subsequent infection, and so vaccines must either induce better immunity than the original virus or must at least lessen the disease incurred during a secondary infection. Second, the propensity of the viruses to recombine may pose a problem by rendering the vaccine useless and potentially increasing the evolution and diversity of the virus in the wild [
      <xref ref-type="bibr" rid="CR108">
       108
      </xref>
      ]. Finally, it has been shown in FIPV that vaccination with S protein leads to enhanced disease [
      <xref ref-type="bibr" rid="CR109">
       109
      </xref>
      ]. Despite this, several strategies are being developed for vaccine development to reduce the likelihood of recombination, for instance by making large deletions in the nsp1 [
      <xref ref-type="bibr" rid="CR110">
       110
      </xref>
      ] or E proteins [
      <xref ref-type="bibr" rid="CR111">
       111
      </xref>
      ], rearranging the 3′ end of the genome [
      <xref ref-type="bibr" rid="CR112">
       112
      </xref>
      ], modifying the TRS sequences [
      <xref ref-type="bibr" rid="CR113">
       113
      </xref>
      ], or using mutant viruses with abnormally high mutation rates that significantly attenuate the virus [
      <xref ref-type="bibr" rid="CR114">
       114
      </xref>
      ].
     </p>
     <p id="Par37">
      Owing to the lack of effective therapeutics or vaccines, the best measures to control human coronaviruses remain a strong public health surveillance system coupled with rapid diagnostic testing and quarantine when necessary. For international outbreaks, cooperation of governmental entities, public health authorities, and health care providers is critical. During veterinary outbreaks that are readily transmitted, such as PEDV, more drastic measures such as destruction of entire herds of pigs may be necessary to prevent transmission of these deadly viruses.
     </p>
    </sec>
    <sec id="Sec13">
     <title>
      Conclusion
     </title>
     <p id="Par38">
      Over the past 50 years the emergence of many different coronaviruses that cause a wide variety of human and veterinary diseases has occurred. It is likely that these viruses will continue to emerge and to evolve and cause both human and veterinary outbreaks owing to their ability to recombine, mutate, and infect multiple species and cell types.
     </p>
     <p id="Par39">
      Future research on coronaviruses will continue to investigate many aspects of viral replication and pathogenesis. First, understanding the propensity of these viruses to jump between species, to establish infection in a new host, and to identify significant reservoirs of coronaviruses will dramatically aid in our ability to predict when and where potential epidemics may occur. As bats seem to be a significant reservoir for these viruses, it will be interesting to determine how they seem to avoid clinically evident disease and become persistently infected. Second, many of the non-structural and accessory proteins encoded by these viruses remain uncharacterized with no known function, and it will be important to identify mechanisms of action for these proteins as well as defining their role in viral replication and pathogenesis. These studies should lead to a large increase in the number of suitable therapeutic targets to combat infections. Furthermore, many of the unique enzymes encoded by coronaviruses, such as ADP-ribose-1″-phosphatase, are also present in higher eukaryotes, making their study relevant to understanding general aspects of molecular biology and biochemistry. Third, gaining a complete picture of the intricacies of the RTC will provide a framework for understanding the unique RNA replication process used by these viruses. Finally, defining the mechanism of how coronaviruses cause disease and understanding the host immunopathological response will significantly improve our ability to design vaccines and reduce disease burden.
     </p>
    </sec>
    <back>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Jha
          </surname>
          <given-names>
           BK
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <year>
         2012
        </year>
        <volume>
         11
        </volume>
        <fpage>
         607
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="pmid">
         22704621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barcena
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Oostergetel
          </surname>
          <given-names>
           GT
          </given-names>
         </name>
         <name>
          <surname>
           Bartelink
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cryo-electron tomography of mouse hepatitis virus: insights into the structure of the coronavirion
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2009
        </year>
        <volume>
         106
        </volume>
        <fpage>
         582
        </fpage>
        <lpage>
         587
        </lpage>
        <pub-id pub-id-type="pmid">
         19124777
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Neuman
          </surname>
          <given-names>
           BW
          </given-names>
         </name>
         <name>
          <surname>
           Adair
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         <name>
          <surname>
           Yoshioka
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2006
        </year>
        <volume>
         80
        </volume>
        <fpage>
         7918
        </fpage>
        <lpage>
         7928
        </lpage>
        <pub-id pub-id-type="pmid">
         16873249
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beniac
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Andonov
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Grudeski
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Architecture of the SARS coronavirus prefusion spike
        </article-title>
        <source>
         Nat Struct Mol Biol
        </source>
        <year>
         2006
        </year>
        <volume>
         13
        </volume>
        <fpage>
         751
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="pmid">
         16845391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delmas
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Laude
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assembly of coronavirus spike protein into trimers and its role in epitope expression
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1990
        </year>
        <volume>
         64
        </volume>
        <fpage>
         5367
        </fpage>
        <lpage>
         5375
        </lpage>
        <pub-id pub-id-type="pmid">
         2170676
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           van der Zee
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           de Haan
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2003
        </year>
        <volume>
         77
        </volume>
        <fpage>
         8801
        </fpage>
        <lpage>
         8811
        </lpage>
        <pub-id pub-id-type="pmid">
         12885899
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Knobler
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Powell
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell–cell fusion
        </article-title>
        <source>
         Virology
        </source>
        <year>
         1982
        </year>
        <volume>
         119
        </volume>
        <fpage>
         358
        </fpage>
        <lpage>
         371
        </lpage>
        <pub-id pub-id-type="pmid">
         6281979
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abraham
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kienzle
          </surname>
          <given-names>
           TE
          </given-names>
         </name>
         <name>
          <surname>
           Lapps
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Deduced sequence of the bovine coronavirus spike protein and identification of the internal proteolytic cleavage site
        </article-title>
        <source>
         Virology
        </source>
        <year>
         1990
        </year>
        <volume>
         176
        </volume>
        <fpage>
         296
        </fpage>
        <lpage>
         301
        </lpage>
        <pub-id pub-id-type="pmid">
         2184576
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luytjes
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Sturman
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <name>
          <surname>
           Bredenbeek
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site
        </article-title>
        <source>
         Virology
        </source>
        <year>
         1987
        </year>
        <volume>
         161
        </volume>
        <fpage>
         479
        </fpage>
        <lpage>
         487
        </lpage>
        <pub-id pub-id-type="pmid">
         2825419
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Luytjes
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Horzinek
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence for a coiled-coil structure in the spike proteins of coronaviruses
        </article-title>
        <source>
         J Mol Biol
        </source>
        <year>
         1987
        </year>
        <volume>
         196
        </volume>
        <fpage>
         963
        </fpage>
        <lpage>
         966
        </lpage>
        <pub-id pub-id-type="pmid">
         3681988
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Armstrong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Niemann
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Smeekens
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Sequence and topology of a model intracellular membrane protein, E1 glycoprotein, from a coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <year>
         1984
        </year>
        <volume>
         308
        </volume>
        <fpage>
         751
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="pmid">
         6325918
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nal
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Kien
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         86
        </volume>
        <fpage>
         1423
        </fpage>
        <lpage>
         1434
        </lpage>
        <pub-id pub-id-type="pmid">
         15831954
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Neuman
          </surname>
          <given-names>
           BW
          </given-names>
         </name>
         <name>
          <surname>
           Kiss
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Kunding
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A structural analysis of M protein in coronavirus assembly and morphology
        </article-title>
        <source>
         J Struct Biol
        </source>
        <year>
         2011
        </year>
        <volume>
         174
        </volume>
        <fpage>
         11
        </fpage>
        <lpage>
         22
        </lpage>
        <pub-id pub-id-type="pmid">
         21130884
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Godet
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           L’Haridon
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Vautherot
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         TGEV corona virus ORF4 encodes a membrane protein that is incorporated into virions
        </article-title>
        <source>
         Virology
        </source>
        <year>
         1992
        </year>
        <volume>
         188
        </volume>
        <fpage>
         666
        </fpage>
        <lpage>
         675
        </lpage>
        <pub-id pub-id-type="pmid">
         1316677
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Almazan
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         1701
        </fpage>
        <lpage>
         1713
        </lpage>
        <pub-id pub-id-type="pmid">
         17108030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Dediego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Verdia-Baguena
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <year>
         2014
        </year>
        <volume>
         10
        </volume>
        <fpage>
         e1004077
        </fpage>
        <pub-id pub-id-type="pmid">
         24788150
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
         <name>
          <surname>
           Sue
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Modular organization of SARS coronavirus nucleocapsid protein
        </article-title>
        <source>
         J Biomed Sci
        </source>
        <year>
         2006
        </year>
        <volume>
         13
        </volume>
        <fpage>
         59
        </fpage>
        <lpage>
         72
        </lpage>
        <pub-id pub-id-type="pmid">
         16228284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hurst
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Koetzner
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <fpage>
         7221
        </fpage>
        <lpage>
         7234
        </lpage>
        <pub-id pub-id-type="pmid">
         19420077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stohlman
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Phosphoproteins of murine hepatitis viruses
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1979
        </year>
        <volume>
         32
        </volume>
        <fpage>
         672
        </fpage>
        <lpage>
         675
        </lpage>
        <pub-id pub-id-type="pmid">
         228084
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stohlman
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           GN
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Specific interaction between coronavirus leader RNA and nucleocapsid protein
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1988
        </year>
        <volume>
         62
        </volume>
        <fpage>
         4288
        </fpage>
        <lpage>
         4295
        </lpage>
        <pub-id pub-id-type="pmid">
         2845141
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Molenkamp
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Spaan
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a specific interaction between the coronavirus mouse hepatitis virus A59 nucleocapsid protein and packaging signal
        </article-title>
        <source>
         Virology
        </source>
        <year>
         1997
        </year>
        <volume>
         239
        </volume>
        <fpage>
         78
        </fpage>
        <lpage>
         86
        </lpage>
        <pub-id pub-id-type="pmid">
         9426448
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuo
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Functional analysis of the murine coronavirus genomic RNA packaging signal
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         5182
        </fpage>
        <lpage>
         5192
        </lpage>
        <pub-id pub-id-type="pmid">
         23449786
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hurst
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Koetzner
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of a critical interaction between the coronavirus nucleocapsid protein and nonstructural protein 3 of the viral replicase-transcriptase complex
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         9159
        </fpage>
        <lpage>
         9172
        </lpage>
        <pub-id pub-id-type="pmid">
         23760243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sturman
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
         <name>
          <surname>
           Behnke
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of coronavirus envelope glycoproteins and interaction with the viral nucleocapsid
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1980
        </year>
        <volume>
         33
        </volume>
        <fpage>
         449
        </fpage>
        <lpage>
         462
        </lpage>
        <pub-id pub-id-type="pmid">
         6245243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klausegger
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Strobl
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Regl
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1999
        </year>
        <volume>
         73
        </volume>
        <fpage>
         3737
        </fpage>
        <lpage>
         3743
        </lpage>
        <pub-id pub-id-type="pmid">
         10196267
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cornelissen
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Wierda
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           van der Meer
          </surname>
          <given-names>
           FJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hemagglutinin-esterase, a novel structural protein of torovirus
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1997
        </year>
        <volume>
         71
        </volume>
        <fpage>
         5277
        </fpage>
        <lpage>
         5286
        </lpage>
        <pub-id pub-id-type="pmid">
         9188596
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kazi
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lissenberg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Expression of hemagglutinin esterase protein from recombinant mouse hepatitis virus enhances neurovirulence
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         15064
        </fpage>
        <lpage>
         15073
        </lpage>
        <pub-id pub-id-type="pmid">
         16306577
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lissenberg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Vrolijk
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           van Vliet
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in vitro
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         15054
        </fpage>
        <lpage>
         15063
        </lpage>
        <pub-id pub-id-type="pmid">
         16306576
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kubo
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           YK
          </given-names>
         </name>
         <name>
          <surname>
           Taguchi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1994
        </year>
        <volume>
         68
        </volume>
        <fpage>
         5403
        </fpage>
        <lpage>
         5410
        </lpage>
        <pub-id pub-id-type="pmid">
         7520090
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           LK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2004
        </year>
        <volume>
         363
        </volume>
        <fpage>
         1699
        </fpage>
        <lpage>
         1700
        </lpage>
        <pub-id pub-id-type="pmid">
         15158632
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belouzard
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2009
        </year>
        <volume>
         106
        </volume>
        <fpage>
         5871
        </fpage>
        <lpage>
         5876
        </lpage>
        <pub-id pub-id-type="pmid">
         19321428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baranov
          </surname>
          <given-names>
           PV
          </given-names>
         </name>
         <name>
          <surname>
           Henderson
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Programmed ribosomal frameshifting in decoding the SARS-CoV genome
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2005
        </year>
        <volume>
         332
        </volume>
        <fpage>
         498
        </fpage>
        <lpage>
         510
        </lpage>
        <pub-id pub-id-type="pmid">
         15680415
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brierley
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Digard
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Inglis
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of an efficient coronavirus ribosomal frameshifting signal: requirement for an RNA pseudoknot
        </article-title>
        <source>
         Cell
        </source>
        <year>
         1989
        </year>
        <volume>
         57
        </volume>
        <fpage>
         537
        </fpage>
        <lpage>
         547
        </lpage>
        <pub-id pub-id-type="pmid">
         2720781
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Araki
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Gangappa
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Dillehay
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation
        </article-title>
        <source>
         J Exp Med
        </source>
        <year>
         2010
        </year>
        <volume>
         207
        </volume>
        <fpage>
         2355
        </fpage>
        <lpage>
         2367
        </lpage>
        <pub-id pub-id-type="pmid">
         20921283
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Virus-encoded proteinases and proteolytic processing in the Nidovirales
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2000
        </year>
        <volume>
         81
        </volume>
        <fpage>
         853
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="pmid">
         10725411
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mielech
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Mesecar
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2014
        </year>
        <pub-id pub-id-type="pmid">
         24512893
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Bredenbeek
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name>
          <surname>
           Dobbe
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage
        </article-title>
        <source>
         J Mol Biol
        </source>
        <year>
         2003
        </year>
        <volume>
         331
        </volume>
        <fpage>
         991
        </fpage>
        <lpage>
         1004
        </lpage>
        <pub-id pub-id-type="pmid">
         12927536
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sethna
          </surname>
          <given-names>
           PB
          </given-names>
         </name>
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Brian
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Minus-strand copies of replicating coronavirus mRNAs contain antileaders
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1991
        </year>
        <volume>
         65
        </volume>
        <fpage>
         320
        </fpage>
        <lpage>
         325
        </lpage>
        <pub-id pub-id-type="pmid">
         1985203
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           CG
          </given-names>
         </name>
         <name>
          <surname>
           Nixon
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Senanayake
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An RNA stem-loop within the bovine coronavirus nsp1 coding region is a cis-acting element in defective interfering RNA replication
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         7716
        </fpage>
        <lpage>
         7724
        </lpage>
        <pub-id pub-id-type="pmid">
         17475638
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
         <name>
          <surname>
           Brian
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
        </person-group>
        <article-title>
         An optimal cis-replication stem-loop IV in the 5′ untranslated region of the mouse coronavirus genome extends 16 nucleotides into open reading frame 1
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         5593
        </fpage>
        <lpage>
         5605
        </lpage>
        <pub-id pub-id-type="pmid">
         21430057
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Keane
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mouse hepatitis virus stem-loop 2 adopts a uYNMG(U)a-like tetraloop structure that is highly functionally tolerant of base substitutions
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <fpage>
         12084
        </fpage>
        <lpage>
         12093
        </lpage>
        <pub-id pub-id-type="pmid">
         19759148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bouma
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           GD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Stem-loop III in the 5′ untranslated region is a cis-acting element in bovine coronavirus defective interfering RNA replication
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2003
        </year>
        <volume>
         77
        </volume>
        <fpage>
         6720
        </fpage>
        <lpage>
         6730
        </lpage>
        <pub-id pub-id-type="pmid">
         12767992
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Leibowitz
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Secondary structural elements within the 3′ untranslated region of mouse hepatitis virus strain JHM genomic RNA
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2001
        </year>
        <volume>
         75
        </volume>
        <fpage>
         12105
        </fpage>
        <lpage>
         12113
        </lpage>
        <pub-id pub-id-type="pmid">
         11711601
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goebel
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           TB
          </given-names>
         </name>
         <name>
          <surname>
           Bennett
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A hypervariable region within the 3′ cis-acting element of the murine coronavirus genome is nonessential for RNA synthesis but affects pathogenesis
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         1274
        </fpage>
        <lpage>
         1287
        </lpage>
        <pub-id pub-id-type="pmid">
         17093194
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           GD
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           RY
          </given-names>
         </name>
         <name>
          <surname>
           Brian
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
        </person-group>
        <article-title>
         A phylogenetically conserved hairpin-type 3′ untranslated region pseudoknot functions in coronavirus RNA replication
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1999
        </year>
        <volume>
         73
        </volume>
        <fpage>
         8349
        </fpage>
        <lpage>
         8355
        </lpage>
        <pub-id pub-id-type="pmid">
         10482585
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsue
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <article-title>
         A bulged stem-loop structure in the 3′ untranslated region of the genome of the coronavirus mouse hepatitis virus is essential for replication
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1997
        </year>
        <volume>
         71
        </volume>
        <fpage>
         7567
        </fpage>
        <lpage>
         7578
        </lpage>
        <pub-id pub-id-type="pmid">
         9311837
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsue
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Hartshorne
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of an essential RNA secondary structure in the 3′ untranslated region of the murine coronavirus genome
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2000
        </year>
        <volume>
         74
        </volume>
        <fpage>
         6911
        </fpage>
        <lpage>
         6921
        </lpage>
        <pub-id pub-id-type="pmid">
         10888630
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sawicki
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
         <name>
          <surname>
           Sawicki
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Siddell
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
        </person-group>
        <article-title>
         A contemporary view of coronavirus transcription
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         20
        </fpage>
        <lpage>
         29
        </lpage>
        <pub-id pub-id-type="pmid">
         16928755
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bentley
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Keep
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Armesto
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a noncanonically transcribed subgenomic mRNA of infectious bronchitis virus and other gammacoronaviruses
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         2128
        </fpage>
        <lpage>
         2136
        </lpage>
        <pub-id pub-id-type="pmid">
         23221558
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keck
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Soe
          </surname>
          <given-names>
           LH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         RNA recombination of coronavirus
        </article-title>
        <source>
         Adv Exp Med Biol
        </source>
        <year>
         1987
        </year>
        <volume>
         218
        </volume>
        <fpage>
         99
        </fpage>
        <lpage>
         107
        </lpage>
        <pub-id pub-id-type="pmid">
         2829575
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recombination between nonsegmented RNA genomes of murine coronaviruses
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1985
        </year>
        <volume>
         56
        </volume>
        <fpage>
         449
        </fpage>
        <lpage>
         456
        </lpage>
        <pub-id pub-id-type="pmid">
         2997467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Krijnse-Locker
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ericsson
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           PJM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step
        </article-title>
        <source>
         J Cell Biol
        </source>
        <year>
         1994
        </year>
        <volume>
         124
        </volume>
        <fpage>
         55
        </fpage>
        <lpage>
         70
        </lpage>
        <pub-id pub-id-type="pmid">
         8294506
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tooze
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Tooze
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Warren
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Replication of coronavirus MHV-A59 in sac-cells: determination of the first site of budding of progeny virions
        </article-title>
        <source>
         Eur J Cell Biol
        </source>
        <year>
         1984
        </year>
        <volume>
         33
        </volume>
        <fpage>
         281
        </fpage>
        <lpage>
         293
        </lpage>
        <pub-id pub-id-type="pmid">
         6325194
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Haan
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular interactions in the assembly of coronaviruses
        </article-title>
        <source>
         Adv Virus Res
        </source>
        <year>
         2005
        </year>
        <volume>
         64
        </volume>
        <fpage>
         165
        </fpage>
        <lpage>
         230
        </lpage>
        <pub-id pub-id-type="pmid">
         16139595
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bos
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Luytjes
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           van der Meulen
          </surname>
          <given-names>
           HV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus
        </article-title>
        <source>
         Virology
        </source>
        <year>
         1996
        </year>
        <volume>
         218
        </volume>
        <fpage>
         52
        </fpage>
        <lpage>
         60
        </lpage>
        <pub-id pub-id-type="pmid">
         8615041
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           YL
          </given-names>
         </name>
         <name>
          <surname>
           Teoh
          </surname>
          <given-names>
           KT
          </given-names>
         </name>
         <name>
          <surname>
           Lo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         11318
        </fpage>
        <lpage>
         11330
        </lpage>
        <pub-id pub-id-type="pmid">
         18753196
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raamsman
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Locker
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           de Hooge
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Characterization of the coronavirus mouse hepatitis virus strain A59 small membrane protein E
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2000
        </year>
        <volume>
         74
        </volume>
        <fpage>
         2333
        </fpage>
        <lpage>
         2342
        </lpage>
        <pub-id pub-id-type="pmid">
         10666264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corse
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Machamer
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious bronchitis virus E protein is targeted to the Golgi complex and directs release of virus-like particles
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2000
        </year>
        <volume>
         74
        </volume>
        <fpage>
         4319
        </fpage>
        <lpage>
         4326
        </lpage>
        <pub-id pub-id-type="pmid">
         10756047
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Stegen
          </surname>
          <given-names>
           CF
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Analysis of constructed E gene mutants of mouse hepatitis virus confirms a pivotal role for E protein in coronavirus assembly
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1998
        </year>
        <volume>
         72
        </volume>
        <fpage>
         7885
        </fpage>
        <lpage>
         7894
        </lpage>
        <pub-id pub-id-type="pmid">
         9733825
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boscarino
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Logan
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
         <name>
          <surname>
           Lacny
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Envelope protein palmitoylations are crucial for murine coronavirus assembly
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         2989
        </fpage>
        <lpage>
         2999
        </lpage>
        <pub-id pub-id-type="pmid">
         18184706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Hogue
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of the coronavirus E viroporin protein transmembrane domain in virus assembly
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         3597
        </fpage>
        <lpage>
         3607
        </lpage>
        <pub-id pub-id-type="pmid">
         17229680
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hurst
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Kuo
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Koetzner
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A major determinant for membrane protein interaction localizes to the carboxy-terminal domain of the mouse coronavirus nucleocapsid protein
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         13285
        </fpage>
        <lpage>
         13297
        </lpage>
        <pub-id pub-id-type="pmid">
         16227251
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses post-SARS: update on replication and pathogenesis
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        <year>
         2009
        </year>
        <volume>
         7
        </volume>
        <fpage>
         439
        </fpage>
        <lpage>
         450
        </lpage>
        <pub-id pub-id-type="pmid">
         19430490
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mihindukulasuriya
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           St
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a novel coronavirus from a beluga whale by using a panviral microarray
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         5084
        </fpage>
        <lpage>
         5088
        </lpage>
        <pub-id pub-id-type="pmid">
         18353961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR65">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of diverse alphacoronaviruses and genomic characterization of a novel severe acute respiratory syndrome-like coronavirus from bats in china
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         7070
        </fpage>
        <lpage>
         7082
        </lpage>
        <pub-id pub-id-type="pmid">
         24719429
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR66">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nga
          </surname>
          <given-names>
           PT
          </given-names>
         </name>
         <name>
          <surname>
           Parquet Mdel
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Lauber
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of the first insect nidovirus, a missing evolutionary link in the emergence of the largest RNA virus genomes
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <year>
         2011
        </year>
        <volume>
         7
        </volume>
        <fpage>
         e1002215
        </fpage>
        <pub-id pub-id-type="pmid">
         21931546
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR67">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lauber
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Junglen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mesoniviridae: a proposed new family in the order Nidovirales formed by a single species of mosquito-borne viruses
        </article-title>
        <source>
         Arch Virol
        </source>
        <year>
         2012
        </year>
        <volume>
         157
        </volume>
        <fpage>
         1623
        </fpage>
        <lpage>
         1628
        </lpage>
        <pub-id pub-id-type="pmid">
         22527862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR68">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Levy
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis
        </article-title>
        <source>
         Am J Pathol
        </source>
        <year>
         2000
        </year>
        <volume>
         156
        </volume>
        <fpage>
         1217
        </fpage>
        <lpage>
         1225
        </lpage>
        <pub-id pub-id-type="pmid">
         10751347
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR69">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lampert
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Kniazeff
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanism of demyelination in JHM virus encephalomyelitis
        </article-title>
        <source>
         Acta Neuropathol
        </source>
        <year>
         1973
        </year>
        <volume>
         24
        </volume>
        <fpage>
         76
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         4349379
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR70">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiner
          </surname>
          <given-names>
           LP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenesis of demyelination induced by a mouse hepatitis virus (JHM virus)
        </article-title>
        <source>
         Arch Neurol
        </source>
        <year>
         1973
        </year>
        <volume>
         28
        </volume>
        <fpage>
         298
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="pmid">
         4348723
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR71">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
         <name>
          <surname>
           Dandekar
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Pewe
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination
        </article-title>
        <source>
         J Immunol
        </source>
        <year>
         2000
        </year>
        <volume>
         165
        </volume>
        <fpage>
         2278
        </fpage>
        <lpage>
         2286
        </lpage>
        <pub-id pub-id-type="pmid">
         10925317
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR72">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Stohlman
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Fleming
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
        </person-group>
        <article-title>
         Demyelination induced by murine hepatitis virus JHM strain (MHV-4) is immunologically mediated
        </article-title>
        <source>
         J Neuroimmunol
        </source>
        <year>
         1990
        </year>
        <volume>
         30
        </volume>
        <fpage>
         31
        </fpage>
        <lpage>
         41
        </lpage>
        <pub-id pub-id-type="pmid">
         2172304
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR73">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Macrophage infiltration, but not apoptosis, is correlated with immune-mediated demyelination following murine infection with a neurotropic coronavirus
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1999
        </year>
        <volume>
         73
        </volume>
        <fpage>
         8771
        </fpage>
        <lpage>
         8780
        </lpage>
        <pub-id pub-id-type="pmid">
         10482631
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR74">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McIntosh
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <name>
          <surname>
           Chanock
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Growth in suckling-mouse brain of “IBV-like” viruses from patients with upper respiratory tract disease
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         1967
        </year>
        <volume>
         58
        </volume>
        <fpage>
         2268
        </fpage>
        <lpage>
         2273
        </lpage>
        <pub-id pub-id-type="pmid">
         4298953
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR75">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bradburne
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <name>
          <surname>
           Bynoe
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Tyrell
          </surname>
          <given-names>
           DAJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of a “new” human respiratory virus in volunteers
        </article-title>
        <source>
         Br Med J
        </source>
        <year>
         1967
        </year>
        <volume>
         3
        </volume>
        <fpage>
         767
        </fpage>
        <lpage>
         769
        </lpage>
        <pub-id pub-id-type="pmid">
         6043624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR76">
       <label>
        76.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamre
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Procknow
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new virus isolated from the human respiratory tract
        </article-title>
        <source>
         Proc Soc Exp Biol Med
        </source>
        <year>
         1966
        </year>
        <volume>
         121
        </volume>
        <fpage>
         190
        </fpage>
        <lpage>
         193
        </lpage>
        <pub-id pub-id-type="pmid">
         4285768
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR77">
       <label>
        77.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         884
        </fpage>
        <lpage>
         895
        </lpage>
        <pub-id pub-id-type="pmid">
         15613317
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR78">
       <label>
        78.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Jebbink
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a new human coronavirus
        </article-title>
        <source>
         Nat Med
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         368
        </fpage>
        <lpage>
         373
        </lpage>
        <pub-id pub-id-type="pmid">
         15034574
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR79">
       <label>
        79.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Sure
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Ihorst
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Croup is associated with the novel coronavirus NL63
        </article-title>
        <source>
         PLoS Med
        </source>
        <year>
         2005
        </year>
        <volume>
         2
        </volume>
        <fpage>
         e240
        </fpage>
        <pub-id pub-id-type="pmid">
         16104827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR80">
       <label>
        80.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chibo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Birch
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of human coronavirus 229E spike and nucleoprotein genes demonstrates genetic drift between chronologically distinct strains
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2006
        </year>
        <volume>
         87
        </volume>
        <fpage>
         1203
        </fpage>
        <lpage>
         1208
        </lpage>
        <pub-id pub-id-type="pmid">
         16603522
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR81">
       <label>
        81.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lemey
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Circulation of genetically distinct contemporary human coronavirus OC43 strains
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2005
        </year>
        <volume>
         337
        </volume>
        <fpage>
         85
        </fpage>
        <lpage>
         92
        </lpage>
        <pub-id pub-id-type="pmid">
         15914223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR82">
       <label>
        82.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           YQ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
        </article-title>
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        <volume>
         302
        </volume>
        <fpage>
         276
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR83">
       <label>
        83.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2005
        </year>
        <volume>
         102
        </volume>
        <fpage>
         14040
        </fpage>
        <lpage>
         14045
        </lpage>
        <pub-id pub-id-type="pmid">
         16169905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR84">
       <label>
        84.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <year>
         2005
        </year>
        <volume>
         310
        </volume>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR85">
       <label>
        85.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           XY
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           XL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         503
        </volume>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR86">
       <label>
        86.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           KY
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The severe acute respiratory syndrome
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2003
        </year>
        <volume>
         349
        </volume>
        <fpage>
         2431
        </fpage>
        <lpage>
         2441
        </lpage>
        <pub-id pub-id-type="pmid">
         14681510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR87">
       <label>
        87.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         1767
        </fpage>
        <lpage>
         1772
        </lpage>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR88">
       <label>
        88.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spiegel
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Schneider
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2006
        </year>
        <volume>
         87
        </volume>
        <fpage>
         1953
        </fpage>
        <lpage>
         1960
        </lpage>
        <pub-id pub-id-type="pmid">
         16760397
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR89">
       <label>
        89.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Law
          </surname>
          <given-names>
           HK
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           HY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Chemokine upregulation in SARS coronavirus infected human monocyte derived dendritic cells
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2005
        </year>
        <volume>
         106
        </volume>
        <fpage>
         2366
        </fpage>
        <lpage>
         2376
        </lpage>
        <pub-id pub-id-type="pmid">
         15860669
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR90">
       <label>
        90.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           YL
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JSM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenesis of severe acute respiratory syndrome
        </article-title>
        <source>
         Curr Opin Immunol
        </source>
        <year>
         2005
        </year>
        <volume>
         17
        </volume>
        <fpage>
         404
        </fpage>
        <lpage>
         410
        </lpage>
        <pub-id pub-id-type="pmid">
         15950449
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR91">
       <label>
        91.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Paddock
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         5833
        </fpage>
        <lpage>
         5838
        </lpage>
        <pub-id pub-id-type="pmid">
         15827197
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR92">
       <label>
        92.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2010
        </year>
        <volume>
         84
        </volume>
        <fpage>
         9318
        </fpage>
        <lpage>
         9325
        </lpage>
        <pub-id pub-id-type="pmid">
         20610717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR93">
       <label>
        93.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Legge
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice
        </article-title>
        <source>
         J Clin Invest
        </source>
        <year>
         2011
        </year>
        <volume>
         121
        </volume>
        <fpage>
         4921
        </fpage>
        <lpage>
         4930
        </lpage>
        <pub-id pub-id-type="pmid">
         22105170
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR94">
       <label>
        94.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR95">
       <label>
        95.
       </label>
       <mixed-citation publication-type="other">
        van Boheemen S, de Graaf M, Lauber C et al (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3. doi:10.1128/mBio.00473-12
       </mixed-citation>
      </ref>
      <ref id="CR96">
       <label>
        96.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         552
        </fpage>
        <lpage>
         559
        </lpage>
        <pub-id pub-id-type="pmid">
         24655412
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR97">
       <label>
        97.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replicative capacity of MERS coronavirus in livestock cell lines
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         276
        </fpage>
        <lpage>
         279
        </lpage>
        <pub-id pub-id-type="pmid">
         24457147
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR98">
       <label>
        98.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1012
        </fpage>
        <lpage>
         1015
        </lpage>
        <pub-id pub-id-type="pmid">
         24857749
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR99">
       <label>
        99.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <name>
          <surname>
           El-Kafrawy
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Farraj
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="CR100">
       <label>
        100.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         495
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR101">
       <label>
        101.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rapid generation of a mouse model for Middle East respiratory syndrome
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2014
        </year>
        <volume>
         111
        </volume>
        <fpage>
         4970
        </fpage>
        <lpage>
         4975
        </lpage>
        <pub-id pub-id-type="pmid">
         24599590
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR102">
       <label>
        102.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Emery
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           DD
          </given-names>
         </name>
         <name>
          <surname>
           Bowen
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         311
        </fpage>
        <lpage>
         316
        </lpage>
        <pub-id pub-id-type="pmid">
         15030703
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR103">
       <label>
        103.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gaunt
          </surname>
          <given-names>
           ER
          </given-names>
         </name>
         <name>
          <surname>
           Hardie
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Claas
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <year>
         2010
        </year>
        <volume>
         48
        </volume>
        <fpage>
         2940
        </fpage>
        <lpage>
         2947
        </lpage>
        <pub-id pub-id-type="pmid">
         20554810
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR104">
       <label>
        104.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Bauer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment of SARS with human interferons
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         362
        </volume>
        <fpage>
         293
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="pmid">
         12892961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR105">
       <label>
        105.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stockman
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Bellamy
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Garner
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: systematic review of treatment effects
        </article-title>
        <source>
         PLoS Med
        </source>
        <year>
         2006
        </year>
        <volume>
         3
        </volume>
        <fpage>
         e343
        </fpage>
        <pub-id pub-id-type="pmid">
         16968120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR106">
       <label>
        106.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Laude
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Van Reeth
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Pensaert
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine respiratory coronavirus: molecular features and virus-host interactions
        </article-title>
        <source>
         Vet Res
        </source>
        <year>
         1993
        </year>
        <volume>
         24
        </volume>
        <fpage>
         125
        </fpage>
        <lpage>
         150
        </lpage>
        <pub-id pub-id-type="pmid">
         8393722
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR107">
       <label>
        107.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Animal coronavirus vaccines: lessons for SARS
        </article-title>
        <source>
         Dev Biol (Basel)
        </source>
        <year>
         2004
        </year>
        <volume>
         119
        </volume>
        <fpage>
         129
        </fpage>
        <lpage>
         140
        </lpage>
        <pub-id pub-id-type="pmid">
         15742624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR108">
       <label>
        108.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Junker
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Collisson
          </surname>
          <given-names>
           EW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence of natural recombination within the S1 gene of infectious bronchitis virus
        </article-title>
        <source>
         Virology
        </source>
        <year>
         1993
        </year>
        <volume>
         192
        </volume>
        <fpage>
         710
        </fpage>
        <lpage>
         716
        </lpage>
        <pub-id pub-id-type="pmid">
         8380672
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR109">
       <label>
        109.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vennema
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Harbour
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1990
        </year>
        <volume>
         64
        </volume>
        <fpage>
         1407
        </fpage>
        <lpage>
         1409
        </lpage>
        <pub-id pub-id-type="pmid">
         2154621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR110">
       <label>
        110.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zust
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Cervantes-Barragan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Kuri
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <year>
         2007
        </year>
        <volume>
         3
        </volume>
        <fpage>
         e109
        </fpage>
        <pub-id pub-id-type="pmid">
         17696607
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR111">
       <label>
        111.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2010
        </year>
        <volume>
         399
        </volume>
        <fpage>
         120
        </fpage>
        <lpage>
         128
        </lpage>
        <pub-id pub-id-type="pmid">
         20110095
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR112">
       <label>
        112.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Haan
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Volders
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Koetzner
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronaviruses maintain viability despite dramatic rearrangements of the strictly conserved genome organization
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2002
        </year>
        <volume>
         76
        </volume>
        <fpage>
         12491
        </fpage>
        <lpage>
         12502
        </lpage>
        <pub-id pub-id-type="pmid">
         12438575
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR113">
       <label>
        113.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Lindesmith
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2006
        </year>
        <volume>
         103
        </volume>
        <fpage>
         12546
        </fpage>
        <lpage>
         12551
        </lpage>
        <pub-id pub-id-type="pmid">
         16891412
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR114">
       <label>
        114.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           LD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease
        </article-title>
        <source>
         Nat Med
        </source>
        <year>
         2012
        </year>
        <volume>
         18
        </volume>
        <fpage>
         1820
        </fpage>
        <lpage>
         1826
        </lpage>
        <pub-id pub-id-type="pmid">
         23142821
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR115">
       <label>
        115.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeager
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         <name>
          <surname>
           Ashmun
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human aminopeptidase N is a receptor for human coronavirus 229E
        </article-title>
        <source>
         Nature
        </source>
        <year>
         1992
        </year>
        <volume>
         357
        </volume>
        <fpage>
         420
        </fpage>
        <lpage>
         422
        </lpage>
        <pub-id pub-id-type="pmid">
         1350662
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR116">
       <label>
        116.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2005
        </year>
        <volume>
         102
        </volume>
        <fpage>
         7988
        </fpage>
        <lpage>
         7993
        </lpage>
        <pub-id pub-id-type="pmid">
         15897467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR117">
       <label>
        117.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delmas
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Gelfi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           L’Haridon
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV
        </article-title>
        <source>
         Nature
        </source>
        <year>
         1992
        </year>
        <volume>
         357
        </volume>
        <fpage>
         417
        </fpage>
        <lpage>
         420
        </lpage>
        <pub-id pub-id-type="pmid">
         1350661
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR118">
       <label>
        118.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           BX
          </given-names>
         </name>
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine aminopeptidase N is a functional receptor for the PEDV coronavirus
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         365
        </volume>
        <fpage>
         166
        </fpage>
        <lpage>
         172
        </lpage>
        <pub-id pub-id-type="pmid">
         17467767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR119">
       <label>
        119.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tresnan
          </surname>
          <given-names>
           DB
          </given-names>
         </name>
         <name>
          <surname>
           Levis
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup I
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1996
        </year>
        <volume>
         70
        </volume>
        <fpage>
         8669
        </fpage>
        <lpage>
         8674
        </lpage>
        <pub-id pub-id-type="pmid">
         8970993
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR120">
       <label>
        120.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benbacer
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Kut
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Besnardeau
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interspecies aminopeptidase-N chimeras reveal species-specific receptor recognition by canine coronavirus, feline infectious peritonitis virus, and transmissible gastroenteritis virus
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1997
        </year>
        <volume>
         71
        </volume>
        <fpage>
         734
        </fpage>
        <lpage>
         737
        </lpage>
        <pub-id pub-id-type="pmid">
         8985407
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR121">
       <label>
        121.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nedellec
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Dveksler
          </surname>
          <given-names>
           GS
          </given-names>
         </name>
         <name>
          <surname>
           Daniels
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Bgp2, a new member of the carcinoembryonic antigen-related gene family, encodes an alternative receptor for mouse hepatitis viruses
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1994
        </year>
        <volume>
         68
        </volume>
        <fpage>
         4525
        </fpage>
        <lpage>
         4537
        </lpage>
        <pub-id pub-id-type="pmid">
         8207827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR122">
       <label>
        122.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           GS
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         1991
        </year>
        <volume>
         88
        </volume>
        <fpage>
         5533
        </fpage>
        <lpage>
         5536
        </lpage>
        <pub-id pub-id-type="pmid">
         1648219
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR123">
       <label>
        123.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schultze
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Herrler
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bovine coronavirus uses N-acetyl-9-O-acetylneuraminic acid as a receptor determinant to initiate the infection of cultured cells
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         1992
        </year>
        <volume>
         73
        </volume>
        <issue>
         Pt 4
        </issue>
        <fpage>
         901
        </fpage>
        <lpage>
         906
        </lpage>
        <pub-id pub-id-type="pmid">
         1321878
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR124">
       <label>
        124.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         426
        </volume>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR125">
       <label>
        125.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Lokugamage
          </surname>
          <given-names>
           KG
          </given-names>
         </name>
         <name>
          <surname>
           Rozovics
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Alphacoronavirus transmissible gastroenteritis virus nsp1 protein suppresses protein translation in mammalian cells and in cell-free HeLa cell extracts but not in rabbit reticulocyte lysate
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         638
        </fpage>
        <lpage>
         643
        </lpage>
        <pub-id pub-id-type="pmid">
         21047955
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR126">
       <label>
        126.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kamitani
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein
        </article-title>
        <source>
         Nat Struct Mol Biol
        </source>
        <year>
         2009
        </year>
        <volume>
         16
        </volume>
        <fpage>
         1134
        </fpage>
        <lpage>
         1140
        </lpage>
        <pub-id pub-id-type="pmid">
         19838190
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR127">
       <label>
        127.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kamitani
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2006
        </year>
        <volume>
         103
        </volume>
        <fpage>
         12885
        </fpage>
        <lpage>
         12890
        </lpage>
        <pub-id pub-id-type="pmid">
         16912115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR128">
       <label>
        128.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Kamitani
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a specific translational shutoff of host mRNA
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <fpage>
         11128
        </fpage>
        <lpage>
         11137
        </lpage>
        <pub-id pub-id-type="pmid">
         22855488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR129">
       <label>
        129.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name>
          <surname>
           Brockway
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         13399
        </fpage>
        <lpage>
         13411
        </lpage>
        <pub-id pub-id-type="pmid">
         16227261
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR130">
       <label>
        130.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cornillez-Ty
          </surname>
          <given-names>
           CT
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Yates
          </surname>
          <given-names>
           JR
          </given-names>
          <suffix>
           3rd
          </suffix>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein complex involved in mitochondrial biogenesis and intracellular signaling
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <fpage>
         10314
        </fpage>
        <lpage>
         10318
        </lpage>
        <pub-id pub-id-type="pmid">
         19640993
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR131">
       <label>
        131.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chatterjee
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Serrano
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nuclear magnetic resonance structure shows that the severe acute respiratory syndrome coronavirus-unique domain contains a macrodomain fold
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <fpage>
         1823
        </fpage>
        <lpage>
         1836
        </lpage>
        <pub-id pub-id-type="pmid">
         19052085
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR132">
       <label>
        132.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Egloff
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name>
          <surname>
           Malet
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Putics
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Structural and functional basis for ADP-ribose and poly(ADP-ribose) binding by viral macro domains
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2006
        </year>
        <volume>
         80
        </volume>
        <fpage>
         8493
        </fpage>
        <lpage>
         8502
        </lpage>
        <pub-id pub-id-type="pmid">
         16912299
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR133">
       <label>
        133.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eriksson
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Cervantes-Barragan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Ludewig
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mouse hepatitis virus liver pathology is dependent on ADP-ribose-1″-phosphatase, a viral function conserved in the alpha-like supergroup
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         12325
        </fpage>
        <lpage>
         12334
        </lpage>
        <pub-id pub-id-type="pmid">
         18922871
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR134">
       <label>
        134.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ratia
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <fpage>
         6689
        </fpage>
        <lpage>
         6705
        </lpage>
        <pub-id pub-id-type="pmid">
         19369340
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR135">
       <label>
        135.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Neuman
          </surname>
          <given-names>
           BW
          </given-names>
         </name>
         <name>
          <surname>
           Joseph
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Saikatendu
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         5279
        </fpage>
        <lpage>
         5294
        </lpage>
        <pub-id pub-id-type="pmid">
         18367524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR136">
       <label>
        136.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Serrano
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Almeida
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nuclear magnetic resonance structure of the N-terminal domain of nonstructural protein 3 from the severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         12049
        </fpage>
        <lpage>
         12060
        </lpage>
        <pub-id pub-id-type="pmid">
         17728234
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR137">
       <label>
        137.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Serrano
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Chatterjee
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nuclear magnetic resonance structure of the nucleic acid-binding domain of severe acute respiratory syndrome coronavirus nonstructural protein 3
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <fpage>
         12998
        </fpage>
        <lpage>
         13008
        </lpage>
        <pub-id pub-id-type="pmid">
         19828617
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR138">
       <label>
        138.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Thiel
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        <article-title>
         The autocatalytic release of a putative RNA virus transcription factor from its polyprotein precursor involves two paralogous papain-like proteases that cleave the same peptide bond
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2001
        </year>
        <volume>
         276
        </volume>
        <fpage>
         33220
        </fpage>
        <lpage>
         33232
        </lpage>
        <pub-id pub-id-type="pmid">
         11431476
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR139">
       <label>
        139.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Clementz
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Kanjanahaluethai
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           O’Brien
          </surname>
          <given-names>
           TE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mutation in murine coronavirus replication protein nsp4 alters assembly of double membrane vesicles
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2008
        </year>
        <volume>
         375
        </volume>
        <fpage>
         118
        </fpage>
        <lpage>
         129
        </lpage>
        <pub-id pub-id-type="pmid">
         18295294
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR140">
       <label>
        140.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gadlage
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Sparks
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Beachboard
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Murine hepatitis virus nonstructural protein 4 regulates virus-induced membrane modifications and replication complex function
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2010
        </year>
        <volume>
         84
        </volume>
        <fpage>
         280
        </fpage>
        <lpage>
         290
        </lpage>
        <pub-id pub-id-type="pmid">
         19846526
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR141">
       <label>
        141.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Denison
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification and characterization of a serine-like proteinase of the murine coronavirus MHV-A59
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         1995
        </year>
        <volume>
         69
        </volume>
        <fpage>
         3554
        </fpage>
        <lpage>
         3559
        </lpage>
        <pub-id pub-id-type="pmid">
         7745703
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR142">
       <label>
        142.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oostra
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hagemeijer
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           van Gent
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Topology and membrane anchoring of the coronavirus replication complex: not all hydrophobic domains of nsp3 and nsp6 are membrane spanning
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         12392
        </fpage>
        <lpage>
         12405
        </lpage>
        <pub-id pub-id-type="pmid">
         18842706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR143">
       <label>
        143.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhai
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer
        </article-title>
        <source>
         Nat Struct Mol Biol
        </source>
        <year>
         2005
        </year>
        <volume>
         12
        </volume>
        <fpage>
         980
        </fpage>
        <lpage>
         986
        </lpage>
        <pub-id pub-id-type="pmid">
         16228002
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR144">
       <label>
        144.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imbert
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Guillemot
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Bourhis
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus
        </article-title>
        <source>
         EMBO J
        </source>
        <year>
         2006
        </year>
        <volume>
         25
        </volume>
        <fpage>
         4933
        </fpage>
        <lpage>
         4942
        </lpage>
        <pub-id pub-id-type="pmid">
         17024178
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR145">
       <label>
        145.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Egloff
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name>
          <surname>
           Ferron
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Campanacci
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         3792
        </fpage>
        <lpage>
         3796
        </lpage>
        <pub-id pub-id-type="pmid">
         15007178
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR146">
       <label>
        146.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bouvet
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Debarnot
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Imbert
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         In vitro reconstitution of SARS-coronavirus mRNA cap methylation
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <year>
         2010
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e1000863
        </fpage>
        <pub-id pub-id-type="pmid">
         20421945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR147">
       <label>
        147.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Decroly
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Debarnot
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ferron
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2′-O-methyltransferase nsp10/nsp16 complex
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <year>
         2011
        </year>
        <volume>
         7
        </volume>
        <fpage>
         e1002059
        </fpage>
        <pub-id pub-id-type="pmid">
         21637813
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR148">
       <label>
        148.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design
        </article-title>
        <source>
         Nucleic Acids Res
        </source>
        <year>
         2003
        </year>
        <volume>
         31
        </volume>
        <fpage>
         7117
        </fpage>
        <lpage>
         7130
        </lpage>
        <pub-id pub-id-type="pmid">
         14654687
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR149">
       <label>
        149.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ivanov
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Thiel
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Dobbe
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         5619
        </fpage>
        <lpage>
         5632
        </lpage>
        <pub-id pub-id-type="pmid">
         15140959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR150">
       <label>
        150.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ivanov
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus 229E nonstructural protein 13: characterization of duplex-unwinding, nucleoside triphosphatase, and RNA 5′-triphosphatase activities
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         7833
        </fpage>
        <lpage>
         7838
        </lpage>
        <pub-id pub-id-type="pmid">
         15220459
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR151">
       <label>
        151.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           LD
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Halpin
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <year>
         2010
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e1000896
        </fpage>
        <pub-id pub-id-type="pmid">
         20463816
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR152">
       <label>
        152.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           LD
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Sperry
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         12135
        </fpage>
        <lpage>
         12144
        </lpage>
        <pub-id pub-id-type="pmid">
         17804504
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR153">
       <label>
        153.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Minskaia
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Hertzig
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of an RNA virus 3′-&gt;5′ exoribonuclease that is critically involved in coronavirus RNA synthesis
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2006
        </year>
        <volume>
         103
        </volume>
        <fpage>
         5108
        </fpage>
        <lpage>
         5113
        </lpage>
        <pub-id pub-id-type="pmid">
         16549795
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR154">
       <label>
        154.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2009
        </year>
        <volume>
         106
        </volume>
        <fpage>
         3484
        </fpage>
        <lpage>
         3489
        </lpage>
        <pub-id pub-id-type="pmid">
         19208801
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR155">
       <label>
        155.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bhardwaj
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Holzenburg
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         RNA recognition and cleavage by the SARS coronavirus endoribonuclease
        </article-title>
        <source>
         J Mol Biol
        </source>
        <year>
         2006
        </year>
        <volume>
         361
        </volume>
        <fpage>
         243
        </fpage>
        <lpage>
         256
        </lpage>
        <pub-id pub-id-type="pmid">
         16828802
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR156">
       <label>
        156.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ivanov
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Hertzig
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Rozanov
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Major genetic marker of nidoviruses encodes a replicative endoribonuclease
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         12694
        </fpage>
        <lpage>
         12699
        </lpage>
        <pub-id pub-id-type="pmid">
         15304651
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR157">
       <label>
        157.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Decroly
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Imbert
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Coutard
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2′O)-methyltransferase activity
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         8071
        </fpage>
        <lpage>
         8084
        </lpage>
        <pub-id pub-id-type="pmid">
         18417574
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR158">
       <label>
        158.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zust
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Cervantes-Barragan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Habjan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5
        </article-title>
        <source>
         Nat Immunol
        </source>
        <year>
         2011
        </year>
        <volume>
         12
        </volume>
        <fpage>
         137
        </fpage>
        <lpage>
         143
        </lpage>
        <pub-id pub-id-type="pmid">
         21217758
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Ecancermedicalscience
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Ecancermedicalscience
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       ecancermedicalscience
      </journal-id>
      <journal-title-group>
       <journal-title>
        ecancermedicalscience
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1754-6605
      </issn>
      <publisher>
       <publisher-name>
        Cancer Intelligence
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32256705
      </article-id>
      <article-id pub-id-type="pmc">
       7105343
      </article-id>
      <article-id pub-id-type="doi">
       10.3332/ecancer.2020.1022
      </article-id>
      <article-id pub-id-type="publisher-id">
       can-14-1022
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Russell
         </surname>
         <given-names>
          Beth
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Moss
         </surname>
         <given-names>
          Charlotte
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          George
         </surname>
         <given-names>
          Gincy
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Santaolalla
         </surname>
         <given-names>
          Aida
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cope
         </surname>
         <given-names>
          Andrew
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Papa
         </surname>
         <given-names>
          Sophie
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
        <xref ref-type="aff" rid="aff6">
         **
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Van Hemelrijck
         </surname>
         <given-names>
          Mieke
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff6">
         **
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         1
        </label>
        Translational Oncology and Urology Research, King’s College London, London, UK
       </aff>
       <aff id="aff2">
        <label>
         2
        </label>
        Guy’s and St. Thomas NHS Foundation Trust, London, UK
       </aff>
       <aff id="aff3">
        <label>
         3
        </label>
        Centre for Rheumatic Diseases, King’s College London, London, UK
       </aff>
       <aff id="aff4">
        <label>
         4
        </label>
        School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK
       </aff>
       <aff id="aff5">
        <label>
         *
        </label>
        All authors contributed equally.
       </aff>
       <aff id="aff6">
        <label>
         **
        </label>
        Both senior authors contributed equally.
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="c1-can-14-1022">
        <bold>
         Correspondence to:
        </bold>
        Mieke Van Hemelrijck
        <email>
         mieke.vanhemelrijck@kcl.ac.uk
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="collection">
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        27
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       14
      </volume>
      <elocation-id>
       1022
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         20
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © the authors; licensee
        <italic>
         e
        </italic>
        cancermedicalscience.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
        <license-p>
         <!--CREATIVE COMMONS-->
         This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">
          http://creativecommons.org/licenses/by/3.0
         </ext-link>
         ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <sec>
        <title>
         Background
        </title>
        <p>
         Cancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.
        </p>
       </sec>
       <sec sec-type="methods">
        <title>
         Methods
        </title>
        <p>
         Using Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 blockade, mycophenolate, tacrolimus, anti-CD20 and CTLA4-Ig.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         89 studies were included. Cytotoxic chemotherapy has been shown to be a specific inhibitor for severe acute respiratory syndrome coronavirus in in vitro studies, but no specific studies exist as of yet for COVID-19. No conclusive evidence for or against the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of COVID-19 patients is available, nor is there evidence indicating that TNFα blockade is harmful to patients in the context of COVID-19. COVID-19 has been observed to induce a pro-inflammatory cytokine generation and secretion of cytokines, such as IL-6, but there is no evidence of the beneficial impact of IL-6 inhibitors on the modulation of COVID-19. Although there are potential targets in the JAK-STAT pathway that can be manipulated in treatment for coronaviruses and it is evident that IL-1 is elevated in patients with a coronavirus, there is currently no evidence for a role of these drugs in treatment of COVID-19.
        </p>
       </sec>
       <sec>
        <title>
         Conclusion
        </title>
        <p>
         The COVID-19 pandemic has led to challenging decision-making about treatment of critically unwell patients. Low-dose prednisolone and tacrolimus may have beneficial impacts on COVID-19. The mycophenolate mofetil picture is less clear, with conflicting data from pre-clinical studies. There is no definitive evidence that specific cytotoxic drugs, low-dose methotrexate for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFα agents are contraindicated. There is clear evidence that IL-6 peak levels are associated with severity of pulmonary complications.
        </p>
       </sec>
      </abstract>
      <kwd-group>
       <kwd>
        immune modulation
       </kwd>
       <kwd>
        immune suppression
       </kwd>
       <kwd>
        cancer
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        adverse events
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec>
     <title>
      Introduction
     </title>
     <p>
      Since the outbreak of severe acute respiratory syndrome (SARS)-CoV-2 or COVID-19 coronavirus started in China in December 2019, there is increasing evidence that those with existing comorbidities, older age or a compromised immune system are at higher risk of developing severe and even fatal respiratory diseases [
      <xref ref-type="bibr" rid="ref1">
       1
      </xref>
      ]. Cancer and transplant patients are also considered to be in this risk group [
      <xref ref-type="bibr" rid="ref2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="ref3">
       3
      </xref>
      ], especially as they may be treated with immune-suppressive or immune-stimulating drugs.
     </p>
     <p>
      The current review focuses on the effects of immune-suppressive or immune-stimulating drugs on the host immunity against COVID-19. Here, we report a short introduction to each drug, followed by a summary of the results from the identified studies for each relative drug.
     </p>
     <p>
      We hypothesise that the drugs selected will likely be categorised into one of two groups: 1) those that may be harmful for patients and put them at risk of increased morbidity/mortality associated with COVID-19 infection and 2) those that may be used to treat the immunopathology associated with severe persistent viral infection. The clinical impact of this review is, thus, twofold. It aims to identify which drugs clinicians should be thinking about taking patients off to protect them from increased harm from COVID-19 and also which drugs could be potentially beneficial in the fight against the disease.
     </p>
     <p>
      This review covers the information available today. As the COVID-19 pandemic progresses, there is an opportunity and responsibility to collect prospective data using established randomised controlled trial involving drugs of interest and cohort-based translational studies.
      <list list-type="order">
       <list-item>
        <p>
         All cytotoxic chemotherapy
        </p>
       </list-item>
       <list-item>
        <p>
         Low-dose steroids and non-steroidal anti-inflammatory drugs (NSAIDs)
        </p>
       </list-item>
       <list-item>
        <p>
         Any tumour necrosis factor (TNF) blocker
        </p>
       </list-item>
       <list-item>
        <p>
         interlukin-6 (IL-6) blockade
        </p>
       </list-item>
       <list-item>
        <p>
         Janus kinase (JAK) inhibitors
        </p>
       </list-item>
       <list-item>
        <p>
         IL-1 blockade
        </p>
       </list-item>
       <list-item>
        <p>
         Mycophenolate
        </p>
       </list-item>
       <list-item>
        <p>
         Tacrolimus
        </p>
       </list-item>
       <list-item>
        <p>
         Anti-CD20
        </p>
       </list-item>
       <list-item>
        <p>
         CTLA4-Ig
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec sec-type="methods">
     <title>
      Methods
     </title>
     <p>
      A search was conducted using Ovid MEDLINE and a total of 89 studies were included in this review for 10 different types of immune-suppressing or immune-stimulating drug groups.
      <xref ref-type="table" rid="table1">
       Table 1
      </xref>
      shows the search terms and the number of studies included in the review.
     </p>
    </sec>
    <sec>
     <title>
      Results
     </title>
     <sec>
      <title>
       All cytotoxic chemotherapy
      </title>
      <p>
       Cytotoxic chemotherapy inhibits cell division through multiple mechanisms. It may have therapeutic activity as compounds against corona viral strains. Moreover, cancer patients who have undergone chemotherapy may be at increased risk of developing symptoms of SARS.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        The search yielded 24 results, of which 18 were included (
        <xref ref-type="table" rid="Stable1">
         Supplementary Table 1
        </xref>
        ). Below are key case-reports of interest to highlight:
        <list list-type="bullet">
         <list-item>
          <p>
           Coronavirus was one of the most common viral pathogens identified in paediatric cancer patients undergoing chemotherapy, second to human rhinovirus [
           <xref ref-type="bibr" rid="ref4">
            4
           </xref>
           ]. Viral co-detection was frequent in patients with cancer and acute respiratory infections.
          </p>
         </list-item>
         <list-item>
          <p>
           A brain biopsy was HCoV-OC43-positive by metagenomic next-generation sequencing in the case of a 1-year-old child with pre-B acute lymphoblastic leukaemia [
           <xref ref-type="bibr" rid="ref5">
            5
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           A case of a young woman with stage IIIA breast cancer from 1999 reported that diagnosis of coronavirus following treatment for cancer using a high-dose chemotherapy regimen and autologous bone marrow and stem cell transplantation. The electron microscopy revealed coronavirus pneumonia [
           <xref ref-type="bibr" rid="ref6">
            6
           </xref>
           ]. Coronavirus should be potentially considered in the differential diagnoses of respiratory failure in patients who have undergone high-dose chemotherapy and autologous bone marrow transplantation.
          </p>
         </list-item>
        </list>
       </p>
       <p>
        In addition, some further observations have been made in relation to specific treatments:
        <list list-type="bullet">
         <list-item>
          <p>
           Although HIV protease inhibitors such as lopinavir has been suggested as a low-micromolar inhibitor of MERS-CoV, the different mechanistic classes that HIV and coronavirus fall under meant that there was low affinity for coronavirus strains compared to HIV [
           <xref ref-type="bibr" rid="ref7">
            7
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           The following compounds have been shown to be active
           <italic>
            in vitro
           </italic>
           against the SARS-CoV virus: TNFα-converting enzyme inhibitor (TAPI-2); IFN-α (B/D, mDEF201 by adenovirus 5 vector, CR3014 humanized monoclonal antibody (a neutralising antibody specific for SARS-CoV), recombinant IFN-α2b and type I IFN-β); Interferon inducers (Ampligen and polyinosinic–polycytidylic); therapeutic antibodies (2978/10, equine anti-SARS-CoV F[ab’] and monoclonal antibody 201); attachment inhibitors (Urtica Dioica lectin and griffithsin); host immune system [
           <xref ref-type="bibr" rid="ref8">
            8
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           6-mercaptopurine (6MP) and 6-thioguanine (6TG) have been used in cancer chemotherapy for treatment of acute lymphoblastic or myeloblastic leukaemia and were found to be specific inhibitors for the SARS coronavirus [
           <xref ref-type="bibr" rid="ref9">
            9
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           Carbohydrate-binding agents (CBA) may be able to block enveloped viruses other than HIV in their entry process and coronaviruses and influenza viruses are other examples of enveloped viruses that may be highly susceptible to the antiviral action of CBAs [
           <xref ref-type="bibr" rid="ref10">
            10
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           The genome of SARS-CoV encodes five major proteins: the spike protein (S), the envelope protein (E), the membrane glycoprotein (M), and the nucleocapsid protein (N). M and E may help host cells to induce the production of protective IFN-α to fight against the virus. Bananin 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol acts as zinc (Zn
           <sup>
            2+
           </sup>
           ) chelator and is therefore of interest to target and inhibit immunodeficiency virus type 1 (HIV-1) zinc finger HIV-1 RNA-binding nucleocapsid protein p7 (NCp7). Bananin is converted to bananin 5’-monophosphate (BNP) which together with B6RA (vitamin A-vitamin B6 conjugate) and could inhibit infectious virion encapsidation. Targets of BNP and B6RA has shown to be present also in SARS-associated coronavirus making them possible therapeutic candidates [
           <xref ref-type="bibr" rid="ref11">
            11
           </xref>
           ].
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Coronavirus strains were one of the most common viral pathogens identified in paediatric cancer patients undergoing chemotherapy. Patients with pre-B acute lymphoblastic leukaemia and breast cancer who have undergone chemotherapy have reported cases of coronavirus infection. Cytotoxic therapies used in cancer chemotherapy such as 6MP and 6TG have shown to be specific inhibitors for SARS coronavirus in
        <italic>
         in vitro
        </italic>
        studies. However, further
        <italic>
         in vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        studies are required to confirm this, especially in COVID-19. Currently, there is no scientific evidence of the interaction between methotrexate and COVID-19.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Low-dose steroids and NSAIDs
      </title>
      <p>
       Since the outbreak of the novel COVID-19 infection, various contradictory information has been circulated regarding the potentially negative effect of treating patients with NSAIDs, non-NSAIDs and corticosteroids. NSAIDs work through inhibition of the cyclooxygenase enzymes (COX-1/COX-2), which are involved in the synthesis of key biological mediators. These mediators in turn control inflammation. Corticosteroids are involved in a number of key physiological processes including the immune response and inflammation and low-dose steroids are often prescribed to cancer patients with suppressed immune systems to prevent the development of related auto-immune diseases.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 58 studies were identified from the search terms, of which 13 were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable2">
         Supplementary Table 2
        </xref>
        ). Our search did not identify any strong evidence for or against the use of ibuprofen for treatment of COVID-19 specifically. One study did however link SARS-CoV to the downregulation of angiotensin converting enzyme-2 (ACE2) which is upregulated by ibuprofen [
        <xref ref-type="bibr" rid="ref12">
         12
        </xref>
        ]. The authors of this study were investigating the link between the severity of COVID-19 symptoms in patients with asthma and hypertension.
       </p>
       <p>
        The only other study to investigate a non-steroidal anti-inflammatory drug was one which looked at indomethacin [
        <xref ref-type="bibr" rid="ref13">
         13
        </xref>
        ]. This study suggested that indomethacin exhibited potent antiviral activity against canine coronavirus (dramatically inhibiting virus replication and protecting the host cell from virus-induced damage). This activity was also observed against human SARS-CoV at a concentration dose of 1 mg/kg.
       </p>
       <p>
        In general, there appeared to be a few positive results for the use of corticosteroids in viral infections such as SARS-CoV [
        <xref ref-type="bibr" rid="ref14">
         14
        </xref>
        -
        <xref ref-type="bibr" rid="ref19">
         19
        </xref>
        ]. Corticosteroids were widely used during the SARS-CoV outbreak due to their known ability to modulate a variety of involved cytokines (including IL-1, IL-6, IL-8, IL-12 and TNFα) [
        <xref ref-type="bibr" rid="ref14">
         14
        </xref>
        ,
        <xref ref-type="bibr" rid="ref16">
         16
        </xref>
        ]. Various studies in humans noted that corticosteroids appeared effective in reducing immunopathological damage but concerns centred around the promotion of viral rebound and association with adverse events (including acute respiratory distress syndrome) [
        <xref ref-type="bibr" rid="ref14">
         14
        </xref>
        ]. One laboratory study which treated porcine respiratory coronavirus infected pigs with dexamethasone suggested that one or two doses of the corticosteroid in the acute phase of infection may effectively alleviate early pro-inflammatory response, but prolonged administration may play a role in enhancing viral replication [
        <xref ref-type="bibr" rid="ref18">
         18
        </xref>
        ]. A separate Chinese study, which separated SARS-CoV patients into 4 treatment groups, identified early high-dose steroids in combination with a quinolone as producing the best patient outcomes [
        <xref ref-type="bibr" rid="ref19">
         19
        </xref>
        ]. Nevertheless, one review stated that the WHO does not currently recommend corticosteroids in other viral diseases such as Dengue as the ‘glucocorticoid-mediated stimulation of the hypothalamic-pituitaryadrenal axis can also drive lymphocytopenia, or it may promote exaggerated pro-inflammatory responses that eventually cause a worsening of the pathogenic condition’ [
        <xref ref-type="bibr" rid="ref20">
         20
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        The current literature does not give conclusive evidence for or against the use of NSAIDs in the treatment of COVID-19 patients, though there appears to be some evidence that corticosteroids may be beneficial in the treatment of SARS-CoV. However, it is important to note this is not specific to COVID-19.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       TNFa blocker
      </title>
      <p>
       TNF family of receptors and cytokines is very large and are often the targets for drugs. One example are TNFa inhibitors, which act by supressing the physiologic response to TNFa. TNFa is a pro-inflammatory cytokine involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma. Inhibitors of TNFa may be used in their treatment.
      </p>
      <p>
       Inhibition of TNFa can be achieved with a monoclonal antibody, such as infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia) and golimumab (Simponi), or with the receptor fusion protein etanercept (Enbrel).
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of three studies were identified, of which two were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable3">
         Supplementary Table 3
        </xref>
        ). The first study was a research letter that suggested that TNFa has been implicated in the severe immune-based pulmonary injury caused by SARS coronavirus, suggesting that TNFa inhibitors could be a potential treatment for the acute respiratory disease syndrome caused by coronavirus [
        <xref ref-type="bibr" rid="ref21">
         21
        </xref>
        ]
       </p>
       <p>
        The second study utilised 22 piglets to assess the efficacy of an anti-TNFa)therapy for endotoxin respiratory diseases and observed that TNFa blockade was not associated with decrease in disease severity [
        <xref ref-type="bibr" rid="ref22">
         22
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Currently, there is no evidence indicating that TNFa blockade is harmful to patients in the context of COVID-19.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       IL-6 blockade
      </title>
      <p>
       IL-6, promptly and transiently produced in response to infections and tissue injuries, contributes to host defence through the stimulation of acute phase responses, hematopoiesis, and immune reactions. Although its expression is strictly controlled by transcriptional and posttranscriptional mechanisms, dysregulated continual synthesis of IL-6 plays a pathological effect on chronic inflammation and autoimmunity [
       <xref ref-type="bibr" rid="ref23">
        23
       </xref>
       ]. For this reason, tocilizumab, a humanized anti-IL-6 receptor antibody was developed. Other approved anti IL-6 drugs are siltuximab (Sylvant) and sarilumab. Several agents are in clinical trials:olokizumab (CDP6038), elsilimomab, BMS945429(ALD518), sirukumab (CNTO 136), CPSI-2364, ALX-0061, clazakizumab, olokizumab, sarilumab, sirukumab, ARGX-109, FE301 and FM101
       <sup>
        .
       </sup>
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 108 studies were identified from the second search strategy, 23 were suitable for inclusion (
        <xref ref-type="table" rid="Stable4">
         Supplementary Table 4
        </xref>
        ). The first search strategy found no hits.
       </p>
      </sec>
      <sec>
       <title>
        IL6 an actor in the pathogenetic mechanisms of the coronavirus infection
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          COVID-19 induces a pro-inflammatory generation and secretion of cytokines including IL-1b and IL-6 via the toll like receptors (TLR) that causes the production of active mature IL-1b which is a mediator of lung inflammation, fever and fibrosis. Anti-inflammatory cytokines, such as IL1-Ra, IL-37 or IL-38 could potentially provide relief in both systemic inflammation and fever occurring after infection [
          <xref ref-type="bibr" rid="ref24">
           24
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Cytokine profiles in patients diagnosed with SARS showed marked elevation of T-helper lymphocyte type 1 (Th1) cytokine interferon-gamma (IFN-γ), inflammatory cytokines IL-1β, IL-6 and IL-12 for at least two weeks after disease onset. Children however presented a much milder cytokine and chemokine storm [
          <xref ref-type="bibr" rid="ref16">
           16
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The high levels of IL-6 in the acute stage associated with lung lesions found in SARS patients are activated by the viral nucleocapsid SARS-CoV N protein [
          <xref ref-type="bibr" rid="ref25">
           25
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Over induction of inflammatory cytokine and dysregulation of cytokine signalling has been observed in patients with SARS in comparison with other respiratory viruses including respiratory syncytial virus (RSV), influenza A virus (FluAV), and human parainfluenza virus type 2 (hPIV2). SARS-CoV and RSV induced high levels of IL-6 and RANTES compared with FluAV and hPIV2 [
          <xref ref-type="bibr" rid="ref26">
           26
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The N-protein of SARS-CoV induces pulmonary inflammatory reaction and acute lung injury, which were related to the increase and imbalance of pro-inflammatory and anti-inflammatory cytokines. Glucocorticoids could effectively alleviate the pulmonary inflammatory reaction induced by N-protein of SARS-CoV [
          <xref ref-type="bibr" rid="ref15">
           15
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          SARS-CoV does not productively infect human macrophages (Mphi) or dentritic cells (DCs), however it modulates a massive release of IL-6 and IL-12 and compromises the endocytic capacity (e.g., antigen capture capture) of Mphi was significantly compromised [
          <xref ref-type="bibr" rid="ref27">
           27
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Changes in plasma T helper (Th) cell cytokines, inflammatory cytokines and chemokines in 20 patients diagnosed with SARS were assessed. The elevation of Th1 cytokine IFN-γ, inflammatory cytokines IL-1, IL-6 and IL-12 and chemokines IL-8, MCP-1 and IP-10 confirmed the activation of Th1 cell-mediated immunity and hyper-innate inflammatory response in SARS through the accumulation of monocytes/macrophages and neutrophils [
          <xref ref-type="bibr" rid="ref17">
           17
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        IL-6 as a potential marker of disease severity in coronavirus infected patients
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          IL-6 blood measurements seem useful to diagnose severe COVID-19 cases. The findings suggest that IL-6 and D-Dimer level can be used to estimate the severity of COVID-19. The optimum critical point of IL-6 in the group was 24.3 pg/ml, which was the upper limit of no severe pneumonia [
          <xref ref-type="bibr" rid="ref28">
           28
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The increased expression of IL-2R and IL-6 in serum is expected to predict the severity of the 2019-nCoV pneumonia and the prognosis of patients [
          <xref ref-type="bibr" rid="ref29">
           29
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The serum levels of IL-6 and CXCL-10 were significantly elevated in MERS-CoV patients who developed severe diseases [
          <xref ref-type="bibr" rid="ref30">
           30
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          A new lethal animal model was characterised for SARS-CoV. Strain v2163 had nine mutations that increased levels of IL-1alpha and IL-6 in mice. The high IL-6 expression was correlated with mortality [
          <xref ref-type="bibr" rid="ref31">
           31
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          SARS vaccination was tested in a murine SARS model. A high level of IL-6 and on days 2 and 3 after SARS-CoV infection was closely linked to the virus replication and disease severity [
          <xref ref-type="bibr" rid="ref32">
           32
          </xref>
          ]
         </p>
        </list-item>
        <list-item>
         <p>
          Interleukin-6 (IL-6) and IL-8 are key SARS-CoV-induced epithelial cytokines capable of inhibiting the T-cell-priming ability of dendritic cells, a cellular element of the host innate defenses against respiratory infections, leading to an exacerbated inflammatory cascades and severe tissue damage in SARS patients [
          <xref ref-type="bibr" rid="ref33">
           33
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          In patients with a diagnosis of SARS-associated coronavirus infection, there were no significant differences in peak levels of IL-6, IL-8 and TNF
          <bold>
           α
          </bold>
          between patients with and without acute respiratory distress syndrome. However , CRP and TNFα were associated with worse outcomes and might be used as prognostic markers of SARS [
          <xref ref-type="bibr" rid="ref34">
           34
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          IFN-gamma, IL-18, TGF-beta, IL-6, IP-10, MCP-1, MIG were highly elevated in the acute phase sera of Taiwan SARS patients, being IL-18, IP-10, MIG, and MCP-1 were significantly higher in the death group than in the survival group. It suggests that an interferon-gamma-related cytokine storm was induced post SARS coronavirus infection [
          <xref ref-type="bibr" rid="ref35">
           35
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Eight patients with SARS [
          <xref ref-type="bibr" rid="ref36">
           36
          </xref>
          ] were treated with ribavirin, which was not effective in reducing the SARS coronavirus load in three of eight. Elevated levels of interleukin (IL)-6 and IL-8 subsequent to the peak viral load were found in eight and six cases [
          <xref ref-type="bibr" rid="ref37">
           37
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          A cytokine profiling was performed for 110 serum from healthy donors, patients with SARS, patients with severe SARS, and patients with SARS in convalescence. IL6 concentrations were significantly elevated in severe SARS patients, but the IL-6 concentrations were similar in convalescent patients and control subjects which suggested that IL6 is associated with SARS severity [
          <xref ref-type="bibr" rid="ref38">
           38
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The authors of this study set out to study the inflammatory cytokine profile in children with SARS. They found that the plasma concentrations’ key proinflammatory cytokines, including IL-6, were not substantially increased in any of the patients throughout the course of illness. From this, the authors stated that the cytokine results cast doubt on the liberal use of corticosteroids in paediatric SARS patients [
          <xref ref-type="bibr" rid="ref39">
           39
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        Potential targets for therapeutic intervention related to IL6 regulation during infection
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          ADAM-17 regulates IL-6 class switching as a mediator between pro- and anti-inflammatory responses to viral antigenic stimuli in Ebola, SARS-CoV and dengue infections in humans. Therefore, ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery for infections, such as SARS-CoV [
          <xref ref-type="bibr" rid="ref20">
           20
          </xref>
          ]
         </p>
        </list-item>
        <list-item>
         <p>
          SARS-CoV ssRNA is a new therapeutic target given its capacity to cause acute lung injury in mice with a high mortality rate
          <italic>
           in vivo
          </italic>
          experiment suggesting that SARS-CoV specific GU-rich ssRNA plays a very important role in the cytokine storm associated with a dysregulation of the innate immunity [
          <xref ref-type="bibr" rid="ref40">
           40
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          DUSP1 and p38 MAPK are potential therapeutic targets for coronavirus infectious bronchitis virus, given their capability to reduce the production of an excessive amount of IL-6 and IL-8 in the infected cells [
          <xref ref-type="bibr" rid="ref41">
           41
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        Potential therapeutic agents that inhibit the infection-induced production of IL6
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          Pretreatment of primary cultures of human nasal and tracheal epithelial cells with glycopyrronium or formoterol decreased viral RNA levels and/or titers, the expression of the HCoV-229E and the infection-induced production of cytokines, including IL-6, IL-8 and IFN-beta. Treatment of the cells with the CD13 inhibitor 2’2’-dipyridyl decreased viral titers. Pretreatment of the cells with a combination of three drugs (glycopyrronium, formoterol and budesonide) exerted additive inhibitory effects on viral titers and cytokine production [
          <xref ref-type="bibr" rid="ref42">
           42
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        It has been suggested that the pathogenesis of SARS-CoV is mediated by disproportional immune responses and the ability of the virus to circumvent innate immunity. The COVID-19 infection has also been observed to induce pro-inflammatory cytokine generation and secretion of cytokines, such as IL-6, which dysregulates the local inflammatory responses that have been suggested as partially responsible for the devastating acute respiratory distress syndrome.
       </p>
       <p>
        Moreover, it has been observed that COVID-19 induces high levels of IL-6 for at least 2 weeks after disease onset. Children presented lower levels of cytokine production. IL-6 has been suggested as a potential prognostic marker of COVID-19 disease severity. Different molecules related with the IL6 pathway have been suggested as potential therapeutic targets such as ADAM-17, SARS-CoV ssRNA, DUSP1 and p38 MAPK.
       </p>
       <p>
        Currently, there is no scientific evidence of the beneficial impact of IL-6 inhibitors in the modulation of the COVID-19 infection. Further understanding of the role of IL-6 reduction will be forthcoming as the pandemic progresses and further clinical data becomes available.
        <italic>
         In vitro
        </italic>
        treatment with glycopyrronium, formoterol and budesonide exerted additive inhibitory effects on viral titers and cytokine production human nasal and tracheal epithelial cells.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       JAK inhibitors
      </title>
      <p>
       JAK inhibitors work by inhibiting the activity of one or more of the JAK family of enzymes, including, JAK1, JAK2, JAK3 and TYK3. JAKs interact with signal transducer and activator of transcription proteins (STATs) and the JAK-STAT pathway is central to cellular response to exogenous signals in the immune system. The JAK family of enzymes are responsible for signal transduction and JAK inhibitors play a major role in inhibiting and blocking cytokine release that can contribute to growth of malignant cells in cancer. JAK inhibitors are used in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis [
       <xref ref-type="bibr" rid="ref43">
        43
       </xref>
       ].
      </p>
      <p>
       This review focuses on how the JAK-STAT pathway can be manipulated to reduce viral entry and inflammation in patients with coronavirus. The main targets that the review highlighted were baricitinib (JAK inhibitor), IRE1α (an endoplasmic reticulum stress sensor, leading to an increased expression of negative regulators of JAK-STAT SOCS1 and SOCS3) and combination therapies using tylophorine-based compounds with JAK2 inhibitors.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        Fifteen studies were yielded from the search of which 4 were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable5">
         Supplementary Table 5
        </xref>
        ).
       </p>
      </sec>
      <sec>
       <title>
        Baricitinib
       </title>
       <p>
        Baricitinib (Olumiant) is a JAK inhibitor that was approved by the European Medicines Agency in February 2017 for the treatment of moderate-to-severe active rheumatoid arthritis in adults with an inadequate response to one or more disease-modifying anti-rheumatic drugs [
        <xref ref-type="bibr" rid="ref44">
         44
        </xref>
        ]. One study suggested the use of Baricitinib to reduce the viral entry and inflammation caused by 2019-nCoV. Most viruses enter cells through receptor-mediated endocytosis. ACE2, a cell-surface protein expressed on cells in the kidney, blood vessels, heart, and alveola type 2 (AT2) cells in the pulmonary epithelia, may be the receptor that 2019-nCoV uses to infect lung cells. The authors of Richardson
        <italic>
         et al
        </italic>
        [
        <xref ref-type="bibr" rid="ref45">
         45
        </xref>
        ] suggest that by inhibiting adaptor associated protein kinase 1 (AAK1) receptor that promotes endocytosis involved in ACE2, Baricitinib may reduce both the viral entry and the inflammation in 2019-nCoV patients.
       </p>
      </sec>
      <sec>
       <title>
        IRE1α
       </title>
       <p>
        Inositol-requiring transmembrane kinase/endoribonuclease 1α (IRE1α) is an endoplasmic reticulum stress sensor that leads to increased expression of negative regulators of JAK-STAT, suppressor of cytokine signalling (SOCS)-1 and SOCS-3 [
        <xref ref-type="bibr" rid="ref46">
         46
        </xref>
        ]. Therefore, IRE1α may be a novel target against coronavirus infection requiring further exploration.
       </p>
      </sec>
      <sec>
       <title>
        Tylophorine-based compounds
       </title>
       <p>
        Tylophorine-based compounds are isolated from plants and exert potent anti-coronaviral activities against SARS-CoV and MERS-CoV [
        <xref ref-type="bibr" rid="ref47">
         47
        </xref>
        ]. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation is a common pro-inflammatory response of host cells to viral infection. Following
        <italic>
         in vitro
        </italic>
        analysis, Yang
        <italic>
         et al
        </italic>
        [
        <xref ref-type="bibr" rid="ref48">
         48
        </xref>
        ] suggests the use of a combination therapy for SARS-CoV or MERS-CoV, wherein a tylophorine compound known to target transmissible gastroenteritis virus and a JAK2 inhibitor synergise to block the alternative dominant NF-κB activation mediated by JAK2. Therefore, the combination treatment for the inhibition of coronavirus per se, e.g. viral genome replication, and blocking cellular NF-κB activation by coronaviruses, is a promising approach for the development of anti-coronavirals.
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Current studies suggest that although there are potential targets in the JAK-STAT pathway that can be manipulated in the treatment for coronaviruses, they are all in early stages and require further
        <italic>
         in vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        studies to confirm their therapeutic effects.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       IL-1 blockade
      </title>
      <p>
       IL-1 is a pro-inflammatory cytokine and an important mediator of local and systemic inflammation. Excessive IL-1 release during viral infections can cause lung and tissue inflammation, fever and fibrosis. IL-1 suppression has found to be effective in many inflammatory diseases including rheumatoid arthritis [
       <xref ref-type="bibr" rid="ref24">
        24
       </xref>
       ].
      </p>
      <p>
       It is well established that an over-expression of interleukin-1 is a hallmark of SARS-CoV infection, probably through activation of transcription factor nuclear factor, activator protein 1 and activating factor 2. In COVID-19 specifically, the virus is thought to bind to TLRs which activate the formation of pro-IL-1 and activation of the inflammasome [
       <xref ref-type="bibr" rid="ref24">
        24
       </xref>
       ]. This inflammasome activation is important for the regulation of cells of both the innate and adaptive immune system paving the way for specific immune responses. As part of the inflammasome activation, IL1-b is subsequently produced which mediates the inflammation of the lungs, fever and fibrosis thus causing respiratory complications in the infected host.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 37 studies were identified from the search of which 9 were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable6">
         Supplementary Table 6
        </xref>
        ). Many of the studies were
        <italic>
         in vitro
        </italic>
        studies and repeatedly demonstrated increased IL-1 levels in patients infected with a coronavirus. One study investigated the levels of various inflammatory cytokines in 29, COVID-19 patients in China and compared the levels between general, severe and critically ill groups [
        <xref ref-type="bibr" rid="ref49">
         49
        </xref>
        ]. The authors reported no significant differences in IL-1b levels between the three groups of patients. Another study involving 20 consecutive SARS patients admitted to a Hong Kong hospital identified significantly elevated levels of IL-1β within the first 12, 7 and 5 days following onset of infection [
        <xref ref-type="bibr" rid="ref17">
         17
        </xref>
        ]. Those patients with more severe disease were treated with pulsed methylprednisolone and IL-1β levels returned to normal after 7 days. The seven patients with less severe disease did not receive any dosage of corticosteroids and their cytokine levels returned to normal range levels over the same 7-day time period.
       </p>
       <p>
        A further Chinese study also identified reduced levels of IL-1β following administration of corticosteroids- suggesting inhibition of pro-inflammatory cytokines such as IL-1 may be a beneficial treatment strategy for treatment of SARS [
        <xref ref-type="bibr" rid="ref50">
         50
        </xref>
        ]. A third study, which measured serum cytokine levels in four patient groups including controls, patients with SARS, patients with severe SARS and convalescent SARS patients suggested that longer term treatment (over a period of 7-10 days) with low-dose steroids can alter serum cytokine levels, including IL-1α [
        <xref ref-type="bibr" rid="ref38">
         38
        </xref>
        ].
       </p>
       <p>
        One rat model showed promising results for an IL-1 receptor antagonist which reduced the chemokine expression in infected animals [
        <xref ref-type="bibr" rid="ref51">
         51
        </xref>
        ]. However, this result cannot be generalised for humans. Unfortunately, one study, in which the authors state the ‘demonstrate for the first time that inflammation by coronavirus may be inhibited by anti-inflammatory cytokines belonging to the IL-1 family’, was only available as an abstract [
        <xref ref-type="bibr" rid="ref52">
         52
        </xref>
        ]. Therefore, further evidence or information to back this claim up is not available.
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Overall, this review demonstrated that although it is evident that IL-1 is elevated in patients infected with a coronavirus, there is not at present evidence for an established role for IL-1 blockers in the treatment of COVID-19 in humans. The literature did, however, suggest a potential role for low-dose corticosteroids to reduce levels of pro-inflammatory markers, such as IL-1, which are elevated as part of the immune response and may have a role in the severe lung damage associated with human coronaviruses.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Mycophenolate
      </title>
      <p>
       Mycophenolate mofetil (which is a derivative of mycophenolic acid (MPA)) is an immune suppressant, antineoplastic and antiviral mediation. According to the British National Formulary, mycophenolate mofetil is used for the prophylaxis of acute rejection in renal transplantation and is usually used in combination with a corticosteroid and ciclosporin.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        Almost all of the studies investigated MPA as a potential therapy for MERS-CoV due to its anti-viral properties. Six of the 13 selected studies were
        <italic>
         in vitro
        </italic>
        studies, two were
        <italic>
         in vivo,
        </italic>
        one was a clinical example and four were reviews (therefore there was some overlapping of results) (
        <xref ref-type="table" rid="Stable7">
         Supplementary Table 7
        </xref>
        ).
       </p>
      </sec>
      <sec>
       <title>
        In-vitro studies
       </title>
       <p>
        In general, the
        <italic>
         in vitro
        </italic>
        studies looked positive with MPA targeting the papain like proteases of both MERS-CoV and SARS-CoV [
        <xref ref-type="bibr" rid="ref53">
         53
        </xref>
        ,
        <xref ref-type="bibr" rid="ref54">
         54
        </xref>
        ]. The studies found that MPA showed strong inhibition of the virus with a very low IC50 [
        <xref ref-type="bibr" rid="ref55">
         55
        </xref>
        -
        <xref ref-type="bibr" rid="ref57">
         57
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        In vivo study
       </title>
       <p>
        MPA can been used in combination with interferon-beta (IFN-b). One study, which applied this regime in marmosets exhibiting a severe disease resembling human MERS, reported high viral loads with more severe or even fatal disease [
        <xref ref-type="bibr" rid="ref28">
         28
        </xref>
        ]. The authors of this study state that MPA is likely to cause more harm than benefit to MERS patients.
       </p>
      </sec>
      <sec>
       <title>
        Clinical studies
       </title>
       <p>
        According to the review by Mo and Fisher [
        <xref ref-type="bibr" rid="ref58">
         58
        </xref>
        ], MPA monotherapy had not been tested in a clinical setting for the treatment of MERS-CoV. Al Ghamdi
        <italic>
         et al
        </italic>
        [
        <xref ref-type="bibr" rid="ref59">
         59
        </xref>
        ], presented an example where eight patients were treated with MPA for MERS-CoV, seven in combination with IFN-β. All eight of these patients survived, however the review by Mo and Fisher stated that this group of patients had lower Acute Physiology and Chronic Health Evaluation II scores compared with others in the cohort who received a variety of antiviral agents including ribavirin and IFN-a, steroids and antibiotics. Therefore, the results must be interpreted with caution.
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Whilst the
        <italic>
         in vitro
        </italic>
        studies showed promising results for MPA against MERS, the
        <italic>
         in vivo
        </italic>
        studies suggest that its use is likely to cause more harm than benefit and hence is not likely to be useful against coronavirus infections. The clinical studies are too small to confirm or deny any beneficial use for MERS-CoV patients.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Tacrolimus
      </title>
      <p>
       Tacroliumus, also known as fujimycin, envarsus or FK506, is an immunosuppressive drug which is mainly administered after allogeneic organ transplant to lower risk of organ rejection. It’s mechanism of action focusses on inhibition of calcineurin which is involved in the production of IL-2. IL-2 is a cytokine which promotes the development and proliferation of T cells which form a vital component of the human adaptive immune response.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 18 studies were identified from the search terms, of which three were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable8">
         Supplementary Table 8
        </xref>
        ).
       </p>
       <p>
        Overall, the literature appeared to suggest a potential role for tacrolimus in the treatment of human coronaviruses. In a case study of two renal transplant recipients who tested positive for MERS CoV, a patient who was being treated with an immunosuppressive regimen of tacrolimus underwent full recovery whilst the other patient (who was not on this treatment regimen) succumbed to the infection [
        <xref ref-type="bibr" rid="ref60">
         60
        </xref>
        ]. The patient who eventually made a full recovery was also treated with antibacterial therapy and a reduced dose of mycophenolate mofetil and it is therefore not possible to conclude that patient recovery due to tacrolimus.
       </p>
       <p>
        The two other included studies were both laboratory studies involving cell line culture. The first investigated pathways of coronavirus viral replication as potential antiviral therapeutic targets [
        <xref ref-type="bibr" rid="ref61">
         61
        </xref>
        ]. Genome-wide SARS-CoV yeast-two-hybrid interaction screen with human cDNA libraries identified FK506-binding proteins as interaction partners of SARS-CoV non-structural protein 1. Subsequently, the authors investigated whether tacrolimus inhibits viral replication of human coronaviruses. VeroFM cells infected with SARS-CoV and other human coronaviruses were treated with FK506. Results showed that FK506 effectively inhibited viral replication of SARS-CoV, HCoV-NL63 and HCoV-229E at non-toxic, low-micromolar concentrations with a reduction in viral titers to undetectable levels. The second study further confirmed this inhibition using novel non-immunosuppressive derivatives of FK506 in the context of HCoV-NL63 at low-micromolar, non-cytotoxic concentrations in cell culture [
        <xref ref-type="bibr" rid="ref62">
         62
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Overall the small amount of literature available suggests a potential role of FK506 (tacrolimus) as a potent antiviral in the treatment of human coronaviruses. It is important to note, however, that COVID-19 is a novel disease and may have different aetiology and mechanistic action compared to existing strains and to date, this immunosuppressive drug and its derivatives has not been tested in humans. Further study is warranted, both in the clinical setting and laboratory.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Anti-CD20
      </title>
      <p>
       No studies were identified for inclusion.
      </p>
     </sec>
     <sec>
      <title>
       CTLA-4 Ig
      </title>
      <p>
       No studies were identified for inclusion.
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Overall conclusion
     </title>
     <p>
      The rapidly progressing SARS-CoV-2 pandemic has led to challenging decision-making about the treatment of critically unwell patients with the novel viral infection. In parallel, doctors across multiple specialties are making clinical decisions about the appropriate continuation of treatments for patients with chronic illnesses requiring immune-suppressive medication. This systematic review looks to provide guidance from the current available literature.
     </p>
     <p>
      As the COVID-19 pandemic progresses, collective effort to capture data from prospective trials is required. Sponsors of randomized controlled trials recruiting patients randomized to receive immune modulatory drugs that may be affected by COVID-19 should collect data about the disease outcomes and consider interim analysis of potential advantages and disadvantages associated with using one of these medications.
     </p>
     <p>
      Low-dose prednisolone and tacrolimus therapy may have beneficial impacts on the course of SARS-CoV-2. This observation requires further validation. The mycophenolate mofetil picture is less clear, with conflicting data from pre-clinical studies. There is no definitive evidence that specific cytotoxic drugs, low-dose methotrexate for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFa biological agents are contraindicated. There is evidence that IL-6 peak levels are associated with severity of pulmonary complications. Ongoing studies of blockade of the IL-6 pathway are rational and will hopefully inform practice as the pandemic progresses.
     </p>
    </sec>
    <sec>
     <title>
      Funding declaration
     </title>
     <p>
      We would like to thank our various funders: Guy’s and St Thomas’ Charity, Cancer Research UK (C45074/A26553), and the CRUK King’s Health Partner Centre.
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Conflicts of interest
     </title>
     <p>
      The authors have no conflicts of interest to declare.
     </p>
    </sec>
    <back>
     <sec>
      <title>
       Supplementary tables of summarised literature
      </title>
      <table-wrap id="Stable1" position="anchor">
       <label>
        Supplementary Table 1.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19 and cytotoxic chemotherapy.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS1">
            1
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of the 2019 novel coronavirus disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhu
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           COVID-19 complicates the clinical scenario of pulmonary infiltrates in cancer patients. Active treatment against the infection and patient surveillance should be initiated if infectious disease is considered.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS2">
            2
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chemotherapy strategy for colorectal cancer under the outbreak of novel coronavirus pneumonia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Li
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Recommendations based on stage of cancer:
           <list list-type="bullet">
            <list-item>
             <p>
              Recurrent metastatic colorectal cancer: low-intensity maintenance therapy
             </p>
            </list-item>
            <list-item>
             <p>
              Patients with tumour changes or higher malignancy still need to receive combined chemotherapy.
             </p>
            </list-item>
            <list-item>
             <p>
              After radical surgery, given the relatively limited benefits of adjuvant chemotherapy, the intensity and duration of treatment can be reduced.
             </p>
            </list-item>
            <list-item>
             <p>
              In the face of patients with febrile tumour chemotherapy, it is necessary to analyse the cause of the fever of the patient.
             </p>
            </list-item>
            <list-item>
             <p>
              Stable disease and good general condition: elect to delay the time of imaging evaluation.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS3">
            3
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Nilsson
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sweden
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A one-year-old child with pre-B acute lymphoblastic leukaemia (ALL) developed fatal encephalitis associated with human coronavirus OC43 (HCoV-OC43). During chemotherapy the child had a persistent HCoV-OC43 respiratory infection and later developed progressive encephalitis. Cerebrospinal fluid was negative for pathogens including HCoV-OC43, but a brain biopsy was HCoV-OC43-positive.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS4">
            4
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Barnard and Kumaki
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2011
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Anti-SARS-CoV therapies recently published from 2007 to 2010 reviewed in this paper and the following compounds have been shown to be active in vitro against the virus:
           <break>
           </break>
           TNF-α-converting enzyme inhibitor (TAPI-2); IFN-α (B/D, mDEF201 by adenovirus 5 vector, CR3014 humanised monoclonal antibody, recombinant IFN-α2b and type I IFN-β); Interferon inducers (Ampligen and polyinosinic–polycytidylic);
           <break>
           </break>
           therapeutic antibodies (2978/10, equine anti-SARS-CoV F[ab’] and monoclonal antibody 201); attachment inhibitors (Urtica Dioica lectin and griffithsin); host immune system.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS5">
            5
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A 3-Year Retrospective Study of the Epidemiology of Acute Respiratory Viral Infections in Pediatric Patients With Cancer Undergoing Chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Aydin Köker et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Turkey
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Nasopharyngeal aspirates were analysed in patients younger than 21 years with acute respiratory infections.
             </p>
            </list-item>
            <list-item>
             <p>
              Coinfection with 2 viruses was present in 20.5% (45/219) of the episodes.
             </p>
            </list-item>
            <list-item>
             <p>
              Most frequent coinfections of respiratory viruses: 6 cases of HRV+hBoV, 5 of HRV, +AdRV, 4 of PI3+CoV 43, 3 of HRV+CoV 43, 3 of HRV, +IF A/H1N1, 3 of HRV+RSV A/B, and 2 of HRV+EV
             </p>
            </list-item>
            <list-item>
             <p>
              Detected more often in the months of January (16%) and October (15%) than in the other months
             </p>
            </list-item>
            <list-item>
             <p>
              Conclusion: no increase in mortality of cancer patients but cause for significant delays to chemotherapy, which might have an indirect impact on patient survival rates.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS6">
            6
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Frequent Respiratory Viral Infections in Children with Febrile Neutropenia - A Prospective Follow-Up Study
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Söderman
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sweden
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Nasopharyngeal aspirates were collected during 87 episodes of febrile neutropenia in children age 0-18 years
             </p>
            </list-item>
            <list-item>
             <p>
              No symptoms were apparent in four episodes involving RV and one episode involving HCoV
             </p>
            </list-item>
            <list-item>
             <p>
              Persistent HCoV with a median follow-up time of 31 days
             </p>
            </list-item>
            <list-item>
             <p>
              High viral loads were correlated to more symptoms
             </p>
            </list-item>
            <list-item>
             <p>
              Respiratory viruses play an etiologic role in febrile neutropenia in children receiving treatment for a malignancy.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS7">
            7
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Pillaiyar
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The paper focuses on on the status of various efficacious anti-SARS-CoV 3CLpro chemotherapies discovered during the last 12 years (2003−2015) from all sources, including laboratory synthetic methods, natural products, and virtual screening.
             </p>
            </list-item>
            <list-item>
             <p>
              Conclusion: No coronavirus protease inhibitor has yet successfully completed a preclinical development program
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS8">
            8
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant. [Review]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hijano
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Switzerland
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2018
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Clinical manifestations vary significantly depending on the type of virus and the type and degree of immunosuppression.
             </p>
            </list-item>
            <list-item>
             <p>
              Risk factors associated with prolonged viral shedding can include viral load, use of steroids, and myeloablative conditioning.
             </p>
            </list-item>
            <list-item>
             <p>
              Mortality associated with coronavirus in HCT recipients was inconclusive. While some studies [
              <xref ref-type="bibr" rid="refS9">
               9
              </xref>
              ] reported no associations, other studies [
              <xref ref-type="bibr" rid="refS10">
               10
              </xref>
              ] reported similar mortality rates in HCT recipients to those observed with other viruses such as RSV, influenza virus, and PIV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS11">
            11
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ghosh et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              SARS-CoV proteases are attractive targets for the development of antiviral drugs to reduce viral replication and pathogenicity.
             </p>
            </list-item>
            <list-item>
             <p>
              Glycyrrhizin showed inhibitory activity for SARS-CoV replication but it has high cytotoxicity.
             </p>
            </list-item>
            <list-item>
             <p>
              HIV protease inhibitor nelfinavir, antihelminthic drug niclosamide and antimalarial agent chloroquine have also showed strong inhibitory activity against SARS-CoV replication.
             </p>
            </list-item>
            <list-item>
             <p>
              A human lgG1 form of 80R was found to bind the S1 domain of the SARS-CoV S protein (with a higher affinity comparable to that of ACE2 suggesting that the 80R human monoclonal antibody is a useful viral entry inhibitor for SARS treatment.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS12">
            12
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           LaFemina, RL.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Lopinavir is an HIV protease inhibitor.
             </p>
            </list-item>
            <list-item>
             <p>
              Lopinavir has been suggested as a low-micromolar inhibitor of MERS-CoV.
             </p>
            </list-item>
            <list-item>
             <p>
              However, proteases of HIV and coronaviruses fall into different mechanistic classes of proteases.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS13">
            13
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Acute respiratory viral infections in paediatric cancer patients undergoing chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Benites
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Brazil
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Paediatric patients with cancer and acute respiratory infection [
              <xref ref-type="bibr" rid="refS14">
               14
              </xref>
              ] and/or fever.
             </p>
            </list-item>
            <list-item>
             <p>
              Coronavirus was identified in 6.8% in the 50 samples of respiratory cases.
             </p>
            </list-item>
            <list-item>
             <p>
              Human rhinovirus (HRV) was the most common viral pathogen, followed by coronavirus, respiratory syncytial virus (RSV), and metapneumovirus, demonstrating the importance of these pathogens in the studied population.
             </p>
            </list-item>
            <list-item>
             <p>
              The prevalence of respiratory viruses was relevant in the infectious episode, with no increase in morbidity and mortality. Viral co-detection was frequent in patients with cancer and ARIs.
             </p>
            </list-item>
            <list-item>
             <p>
              The link of whether severe acute infection was directly related to the type of cancer or viral pathogen was not identified in the study.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS15">
            15
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              6-mercaptopurine (6MP) and 6-thioguanine (6TG) have been used in cancer chemotherapy for treatment of acute lymphoblastic or myeloblastic leukaemia and were found to be specific inhibitors for the SARS coronavirus.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS14">
            14
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Balzarini, J.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Belgium
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Carbohydrate-binding agents (CBA) may be able to block enveloped viruses other than HIV in their entry process and coronaviruses and influenza viruses are other examples of enveloped viruses that may be highly susceptible to the antiviral action of CBAs.
             </p>
            </list-item>
            <list-item>
             <p>
              In HIV, glycan deletions in gp120 delays the spread of virus.
             </p>
            </list-item>
            <list-item>
             <p>
              CBA administration may bring the viral infection under control before glycan deletions occur and the immune system can get involved in the further clearance of the virus.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS16">
            16
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Molecular biology investigation of respiratory viruses as a factor of infectious complications in hemoblastosis and myelodepression
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chebotkevich et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Russia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Only abstract available, article in Russian and not accessible.
           <list list-type="bullet">
            <list-item>
             <p>
              Communicable respiratory viruses were investigated in 51 patients as a causative factor of infectious complication in hemoblastosis and myelodepression
             </p>
            </list-item>
            <list-item>
             <p>
              Coronaviruses detected in 13.7%
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS17">
            17
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome [
           <xref ref-type="bibr" rid="refS18">
            18
           </xref>
           ]. [Review]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Kesel AJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           United Arab Emirates
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              25 test materials including interferon-inducer
             </p>
            </list-item>
            <list-item>
             <p>
              Bananin (BN) was an effective inhibitor of SARS-CoV in cell culture.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS19">
            19
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Huali
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The M and E are play a role in coronaviral particle assembling. Targeting these agents may lead to immune responses by inducing the production of protective IFN-α.
             </p>
            </list-item>
            <list-item>
             <p>
              N, M, and E genes may be used as the targets to prevent SARS-CoV infection.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS20">
            20
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A system of protein target sequences for anti-RNA-viral chemotherapy by a vitamin B6-derived zinc-chelating trioxa-adamantane-triol.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Keseal AJ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Bananin acts as zinc (Zn2+) chelator
             </p>
            </list-item>
            <list-item>
             <p>
              Targets and inhibits zinc finger of HIV-1 RNA-binding nucleocapsid protein p7 (NCp7).
             </p>
            </list-item>
            <list-item>
             <p>
              Bananin is converted to bananin 5’-monophosphate (BNP) which together with B6RA (vitamin A-vitamin B6 conjugate) and could inhibit infectious virion encapsidation.
             </p>
            </list-item>
            <list-item>
             <p>
              Targets of BNP and B6RA have shown to be present also in SARS-associated coronavirus making them possible therapeutic candidates.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS21">
            21
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Coronavirus Pneumonia
           <break>
           </break>
           Following Autologous Bone
           <break>
           </break>
           Marrow Transplantation for
           <break>
           </break>
           Breast Cancer
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Folz and Elkordy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1999
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Case report: coronavirus in woman with stage III breast cancer following treatment with hig-dose chemotherapy and autologous bone marrow and stem cell transplant.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable2" position="anchor">
       <label>
        Supplementary Table 2.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and low-dose steroids.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS22">
            22
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Fu, Cheng and Wu
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           This review suggests that:
           <list list-type="bullet">
            <list-item>
             <p>
              SARS-CoV S protein can downregulate ACE2
             </p>
            </list-item>
            <list-item>
             <p>
              Loss of pulmonary ACE2 function has been suggested to be associated with acute lung injury; the reduction in ACE2 function can cause dysfunction of the renin-angiotensin system [
              <xref ref-type="bibr" rid="refS23">
               23
              </xref>
              ] and enhance inflammation and vascular permeability.
             </p>
            </list-item>
            <list-item>
             <p>
              ACE2-associated lung injury has been suggested in SARS- CoV infection
             </p>
            </list-item>
            <list-item>
             <p>
              From reading this article the following article was then discovered…
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS24">
            24
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Fang, Karakiulakis and Roth
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Greece
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The expression of ACE2 is substantially increased in patients with type 1 or type 2 diabetes, who are treated with ACE inhibitors and angiotensin II type-I receptor blockers (ARBs). Hypertension is also treated with ACE inhibitors and ARBs, which results in an upregulation of ACE2
           <break>
           </break>
           ACE2 can be increased by thiazolidinediones and ibuprofen. These data suggest that ACE2 expression is increased in diabetes and treatment with ACE inhibitors and ARBs increases ACE2 expression. Consequently, the increased expression of ACE2 would facilitate infection with COVID-19.
           <break>
           </break>
           The authors therefore hypothesise that diabetes and hypertension treatment with ACE2-stimulating drugs increases the risk of developing severe and fatal COVID-19.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS25">
            25
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Drug treatment options for the 2019-new coronavirus (2019- nCoV)
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lu
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           No evidence given for or against using ibuprofen only that ‘anti-inflammatory drugs (such as hormones and other molecules)’ are potential therapeutic options for 2019-nCoV.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS26">
            26
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome: clinical and laboratory manifestations.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lam, Chan, Wong
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Corticosteroid treatment reduced interleukin 8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and IFN-γ-inducible protein-10 (IP-10) concentrations from 5 - 8 days after treatment in SARS patients. These were all inflammatory markers which were remarkably increased in SARS patients. NB. This study is not specifically looking at SARS-CoV2 only at SARS-CoV.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS27">
            27
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Decoding the enigma of antiviral crisis: Does one target molecule regulate all?
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mahmud-Al-Rafat
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Bangladesh, Germany, Canada, UK and Australia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           This review article aimed to look at multiple diseases caused by various viruses including Dengue, Ebola and SARS-CoV. They stated that ribavirin (an antiviral) is the most frequently used drug to combat SARS-CoV, and is administered together with corticosteroids.
           <break>
           </break>
           Although immunosuppressive corticosteroid drugs are commonly used in an attempt to reduce fatality rates, the results of clinical trials are not sufficiently satisfactory to approve as an effective class of therapeutic
           <break>
           </break>
           Glucocorticoid-mediated stimulation of the hypothalamic-pituitaryadrenal axis can also drive lymphocytopenia, or it may promote exaggerated pro-inflammatory responses that eventually cause a worsening of the pathogenic condition. (Please note this is not specific for SARS-CoV-19 and is referring to the 3 viral diseases mentioned).
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS28">
            28
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The management of coronavirus infections with particular reference to SARS.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong SS, Yuen KY
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2008
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HCoV-OC43 and HCoV-229E initial principal pathogens discovered in 1960’s; acute respiratory diseases of less severity and mortality than SARS-CoV which promoted rapid search for effective antiviral treatments.
           <break>
           </break>
           Immunomodulatory agents (primarily corticosteroids) widely used during SARS to avoid excessive tissue damage by cytokine dysregulation but benefit of use not conclusively demonstrated.
           <break>
           </break>
           Multiple studies demonstrated increased plasma viral load with use of corticosteroids (RCT measured plasma viral load at regular intervals in non-intubated cases found higher concentrations of SARS-CoV RNA in week 2/3 of illness compared to patients who received placebo).
           <break>
           </break>
           9.9% of patients in Hong Kong cohort study also suffered opportunitistic infections such as aspergillosis and late sequelae (including avascular osteonecrosis) with corticosteroid use.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS29">
            29
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang X, Alekseev K, Jung K, Vlasova A, Hadya N, Saif LJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2008
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Laboratory study which treated porcine respiratory coronavirus infected pigs with corticosteroid dexamethasone as a model for SARS.
           <break>
           </break>
           Goal to define whether corticosteroid treatment altered immunity and lung inflammatory response at cytokine level and how changes correlated with pig lung lesions.
           <break>
           </break>
           Confirmed infection model applicable and resembled SARS.
           <break>
           </break>
           Treatment with dexamethasone suppressed early local IL-6 levels but increased later on in disease. Suggests may decrease inflammation at early infection stage but not later.
           <break>
           </break>
           Results also suggest that dexamethasone induced reduction of IL-6 might play a role in delayed onset of lung lesions but increases of IL-6 at later infection stage may contribute to severity of lung lesions (mimicking delayed onset of disease severity as seen in SARS patients treated with corticosteroids).
           <break>
           </break>
           <bold>
            Overall findings suggest that 1 or 2 doses of dexamethasone in acute phase of infection may effectively alleviate early pro-inflammatory response, but prolonged DEX administration may play role in enhancing viral replication.
           </bold>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS30">
            30
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Indomethacin has a potent antiviral activity against SARS coronavirus.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Amici C,
           <break>
           </break>
           Di Caro A, Ciucci A, Chiappa L, Castilletti C, Martella V, Decaro N, Buonavoglia C, Capobianchi MR, Santoro MG
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Italy
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Utilised observation that cyclopentenone cyclooxygenase (COX) metabolites are active against several RNA viruses to investigate effect of COX inhibitor indomethacin on coronavirus replication.
           <break>
           </break>
           Indomethacin is common NSAID.
           <break>
           </break>
           Report describes how indomethacin was unexpectedly found to possess potent antiviral activity against canine coronavirus (dramatically inhibit virus replication and protect the host cell from virus-induced damage).
           <break>
           </break>
           Activity also observed in vivo and against human SARS-CoV.
           <break>
           </break>
           Oral administration of concentration 1mg/kg found to be effective.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS31">
            31
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hao D, He LX, Qu JM, Pan J, Hu BJ, Zhang J, Li ZZ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China (full article only available in Chinese but informative abstract)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Studied pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on inflammatory reaction.
           <break>
           </break>
           Mice treated with dexamethasone.
           <break>
           </break>
           N-protein of SARS-CoV shown to have pathogenicity inducing pulmonary inflammatory reaction and acute lung injury which were related to the increase and imbalance of pro-inflammatory and anti-inflammatory cytokines.
           <break>
           </break>
           Glucocorticoids (dexamethasone) demonstrated effectively alleviate pulmonary inflammatory reaction.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS32">
            32
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chihrin S, Loutfy MR
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Canada
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Anti-inflammatory agents heavily utilised during SARS outbreak as it was believed that the development and worsening of the pulmonary disease had inflammatory aetiology and pathogenesis.
           <break>
           </break>
           Immunopathological analysis of 20 SARS patients demonstrated increased Th1 cytokine interferon y and inflammatory cytokines IL-1, IL-6 and IL-12 for &gt; 2 weeks following onset of symptoms.
           <break>
           </break>
           Also observed decrease in viral activity and IgG seroconversion during 2nd week of illness despite general progression of respiratory disease- suggesting respiratory damage is secondary to immune-mediated inflammatory response.
           <break>
           </break>
           Corticosteroids used during SARS outbreak for their ability to module variety of involved cytokines.
           <break>
           </break>
           Numerous papers published outcomes of patients administered corticosteroids (mostly IV hydrocortisone or methylprednisolone) in either early low-dose or pulsed-dose strategies. Most concluded corticosteroids appeared to be effective in reducing immunopathological damage (resulting in improved and rapid resolution of symptoms).
           <break>
           </break>
           Opposition to corticosteroid use centred around use of corticosteroid use in treatment of acute respiratory distress syndrome- concern that corticosteroid treatment may weaken immune response and promote viral rebound. Reports also add evidence to theory.
           <break>
           </break>
           Further opposition includes association with adverse events such as hyperglycaemia, hypokalaemia, hypertension, gastrointestinal haemorrhage and avascular necrosis (AVN).
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS33">
            33
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cinatl J Jr, Michaelis M, Morgenstern B, Doerr HW
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany (needs to be purchased)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Investigated influence of SARS-CoV infection on CXCL8 and CXCL10 in human intestinal epithelial cells.
           <break>
           </break>
           High concentrations of hydrocortisone prevented DNA binding activity of AP-1 and NF-kappabeta and inhibited upregulation of CXCL8 and CXCL10 but did not reduce chemokine expression to basal.
           <break>
           </break>
           Results suggest corticosteroid may be of limited benefit in suppression of chemokine production by SARS-CoV infected cells.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS34">
            34
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Overproduction of TNF-alpha, IL-1, IL-6 and IL-10 hallmark of viral infection.
           <break>
           </break>
           Investigated inflammatory profiles of patients infected with SARS in Hong Kong hospital.
           <break>
           </break>
           Use of corticosteroids significantly reduced IL-8, MCP-1 and IP-10 concentrations from 5-8 days after treatment.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS35">
            35
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Description and clinical treatment of an early outbreak of severe acute respiratory syndrome [
           <xref ref-type="bibr" rid="refS18">
            18
           </xref>
           ] in Guangzhou, PR China.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, Xiong J, Hawkey PM
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Patients treated in different methods. 2 groups of 4 received steroids (in form of methyl prednisolone).
           <break>
           </break>
           Early use of high-dose steroids appeared to help recovery from SARS.
           <break>
           </break>
           Early use of high-dose steroids in combination with a quinolone plus azithromycin gave the best outcome with improvement of clinical signs and symptoms, decreased incidence of ARDs and mechanical ventilation as well as mortality.
           <break>
           </break>
           Hypothesised that steroids may help by reducing the damaging effect of the local inflammatory response.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable3" position="anchor">
       <label>
        Supplementary Table 3.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/other coronavirus strains and TNF blockers.
         <italic>
          (continued)
         </italic>
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS36">
            36
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Tobinick E.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Clinical and experimental evidence implicate TNF as a possible mediator of the severe immune-based pulmonary injury which can follow infection with H5N1 influenza and SARS coronavirus.
             </p>
            </list-item>
            <list-item>
             <p>
              In humans, anti-TNF therapy utilising etanercept has been reported to be beneficial for treatment of the non-infectious idiopathic pneumonia syndrome which can follow stem-cell transplantation, a pulmonary syndrome that resembles SARS pneumonia in some respect.
             </p>
            </list-item>
            <list-item>
             <p>
              If the SARS coronavirus does indeed lead to massive release of TNF-αf rom alveolar macrophages, then early inhibition of TNF-α might be able to prevent TNF-αmediated immune activation and therefore reduce pulmonary injury in these patients.
             </p>
            </list-item>
            <list-item>
             <p>
              Compared with the use of corticosteroids, the use of biologic TNF inhibitors, including etanercept, has the potential to be a more specific and more effective method of ameliorating the severe alveolar damage which can occur following infection with these agents.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS37">
            37
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Anti-TNF alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Atanasova K; Van Gucht S; Van Reeth K.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Netherlands
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2010
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           22 piglets were assessed to to elucidate the role of TNF-α in the development of virus-endotoxin-induced respiratory disease.
           <break>
           </break>
           The study demonstrates that after intratracheal administration etanercept is able to successfully block TNF-α activity in vivo in the lungs of PRCV-LPS inoculated pigs during the first 4–8 HPI.
           <break>
           </break>
           TNF-α reduction, however, was not associated with decrease in disease severity, bronchoalveolar neutrophil infiltration, or altered virus replication and induction of IL-1, IL-6, IL-12/IL-23 or IFN-α in the lungs.
           <break>
           </break>
           There was no obvious difference in macroscopic lung lesions and histopathological findings in the lungs. This data confirms the generally accepted belief that TNF-α, though very important, is not the sole culprit in development of respiratory disease and pathology, and possibly other, yet unidentified, components and mechanisms of the immune system are involved.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable4" position="anchor">
       <label>
        Supplementary Table 4.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and IL-6.
         <italic>
          (continued)
         </italic>
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS38">
            38
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Gao Y; Li T; Han M; Li X; Wu D; Xu Y; Zhu Y; Liu Y; Wang X; Wang L.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They investigated forty‐three adult patients with COVID‐19. The patients were classified into mild group (28 patients) and severe group (15 patients).
             </p>
            </list-item>
            <list-item>
             <p>
              Comparison of the haematological parameters between the mild and severe groups showed significant differences in IL‐6, D‐Dimer, GLU, TT, FIB and CRP (
              <italic>
               p
              </italic>
              &lt;0.05).
             </p>
            </list-item>
            <list-item>
             <p>
              Infection-related biomarkers appeared to differ between the two groups (IL-6).However, the proportion of IL-6 above normal was [36.10(23.00,59.20) pg/mL]in the severe group, which was significantly higher than that in the mild group [10.60(5.13,24.18) pg/mL].
             </p>
            </list-item>
            <list-item>
             <p>
              The AUC of IL-6 which was used to predict the severity of COVID-19 was 0.795 (P&lt;0.0001), which could better predict whetherrCOVID-19 was complicated by severe pneumonia. The optimum critical point of IL-6 in the group was 24.3 pg/ml, which was the upper limit of no severe pneumonia.
             </p>
            </list-item>
            <list-item>
             <p>
              IL‐6 and D‐Dimer were closely related to the occurrence of severe COVID‐19 in the adult patients, and their combined detection had the highest specificity and sensitivity for early prediction of the severity of COVID‐19 patients.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS39">
            39
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Conti, P; Ronconi, G; Caraffa, A; Gallenga, C; Ross, R; Frydas, I; Kritas, S.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Italy
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              When COVID-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1b and IL-6.
             </p>
            </list-item>
            <list-item>
             <p>
              The binding of COVID-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1b which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1b which is a mediator of lung inflammation, fever and fibrosis.
             </p>
            </list-item>
            <list-item>
             <p>
              Proinflammatory cytokines levels are correlated with COVID-19 replication and disease.
             </p>
            </list-item>
            <list-item>
             <p>
              Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS40">
            40
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Yamaya M; Nishimura H; Deng X; Sugawara M; Watanabe O; Nomura K; Shimotai Y; Momma H; Ichinose M; Kawase T.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Netherlands
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Primary human nasal (HNE) and tracheal (HTE) epithelial cell cultures were infected with HCoV-229E coronavirus.
             </p>
            </list-item>
            <list-item>
             <p>
              Pretreatment of HNE and HTE cells with glycopyrronium or formoterol decreased viral RNA levels and/or titers, the expression of the HCoV-229E receptor CD13, the number and fluorescence intensity of acidic endosomes where HCoV-229E RNA enters the cytoplasm, and the infection-induced production of cytokines, including IL-6, IL-8, and IFN-beta.
             </p>
            </list-item>
            <list-item>
             <p>
              IL-6 and IL-8 are related to airway inflammation in COPD and bronchial asthma exacerbation induced by viral infection. The decreased production of IL-6 and IL-8 in cells pretreated with glycopyrronium, formoterol, and budesonide, as well as the increased inhibitory effects of GFB observed in the present study, may be associated with the inhibitory effects of these drugs on COPD and bronchial asthma exacerbation.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS41">
            41
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of clinical features of 29 patients with 2019 novel
           <bold>
            coronavirus
           </bold>
           pneumonia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen, L; Liu, H G; Liu, W; Liu, J; Liu, K; Shang, J; Deng, Y; Wei, S.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              29 patients with 2019-ncov admitted to the isolation ward of Tongji hospital ( mild (15 cases), severe (9 cases) and critical (5 cases).
             </p>
            </list-item>
            <list-item>
             <p>
              The expression levels of inflammatory cytokines and other markers in the serum of each group were detected.
             </p>
            </list-item>
            <list-item>
             <p>
              There were statistically significant differences in the expression levels of interleukin-2 receptor (IL-2R) and IL-6
              <bold>
               in the serum of the three groups (
              </bold>
              <italic>
               p
              </italic>
              &lt; 0.05), among which the critical group was higher than the severe group and the severe group was higher than the mild group.
             </p>
            </list-item>
            <list-item>
             <p>
              However, there were no statistically significant differences in serum levels of tumor necrosis factor-alpha (TNF-alpha), IL-1, IL-8, IL-10, hs-CRP, lymphocyte count and LDH among the three groups (P&gt;0.05).
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS26">
            26
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome: clinical and laboratory manifestations.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lam, Christopher W K; Chan, Michael H M; Wong, Chun K.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Australia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They have investigated daily changes in plasma inflammatory cytokines and chemokines in 20 adult SARS patients [19 men and 1 woman, mean (SD) age 33 (12) years, range 21–58] for 19 consecutive days upon hospital admission (from ≤ 2 days after disease onset).
             </p>
            </list-item>
            <list-item>
             <p>
              The cytokine profile showed marked elevation of T-helper lymphocyte type 1 (Th1) cytokine IFN-γ, inflammatory cytokines IL-1β, IL-6 and IL-12 for at least two weeks after disease onset, but there was no significant increase in inflammatory cytokine TNF-α, anti-inflammatory cytokine IL-10, Th1 cytokine IL-2, and T-helper lymphocyte type 2 (Th2) cytokine IL-4.
             </p>
            </list-item>
            <list-item>
             <p>
              We have also performed serial studies of plasma cytokine and chemokine profiles of 8 children with SARS (5 boys and 3 girls, age 0.3 – 6.2 years) and found that these patients had a much milder cytokine and chemokine storm, rendering the use of corticosteroids more controversial if not unjustified.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS42">
            42
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection.
           <break>
           </break>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Kim ES; Choe PG; Park WB; Oh HS; Kim EJ; Nam EY; Na SH; Kim M; Song KH; Bang JH; Park SW; Kim HB; Kim NJ; Oh MD.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Korea (South)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              17 patients with laboratory-confirmed MERS-CoV during the 2015 outbreak in Korea were studied.
             </p>
            </list-item>
            <list-item>
             <p>
              The severe group had higher neutrophil counts during week 1 than the mild group (4,500 versus 2,200/muL, P = 0.026). In the second week of illness, the severe group had higher serum levels of IL-6 (54 versus 4 pg/ml,
              <italic>
               p
              </italic>
              = 0.006) and CXCL-10 (2,642 versus 382 pg/ml,
              <italic>
               p
              </italic>
              &lt; 0.001).
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS27">
            27
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Decoding the enigma of antiviral crisis: Does one target molecule regulate all?. [Review]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mahmud-Al-Rafat A; Majumder A; Taufiqur Rahman KM; Mahedi Hasan AM; Didarul Islam KM; Taylor-Robinson AW; Billah MM
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              IL-6 Interleukin acts as a mediator between pro- and anti-inflammatory reactivity by initiating trans- and classical-signalling, which might relate to the cytokine storm that is triggered by excessive pro-inflammatory responses to Ebola, SARS-CoV and dengue infections in humans.
             </p>
            </list-item>
            <list-item>
             <p>
              Future antivirals should thus aim to target the mechanism that regulates switching between IL-6 trans- and classical-signaling
             </p>
            </list-item>
            <list-item>
             <p>
              The tumour necrosis factor-α converting enzyme ADAM-17 could be the master molecule involved in regulating IL-6 class switching and through this in controlling pro- and anti-inflammatory responses to viral antigenic stimuli.
             </p>
            </list-item>
            <list-item>
             <p>
              ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery that would regulate host reactivity to infection and thereby limit or prevent fatal outcomes.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS43">
            43
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Li Y; Chen M; Cao H; Zhu Y; Zheng J; Zhou H.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           France
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2013
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They identified a set of SARS-CoV specific GU-rich ssRNA fragments with a high-density distribution in the genome.
             </p>
            </list-item>
            <list-item>
             <p>
              In vitro experiments, the result showed the representative SARS-CoV ssRNAs had powerful immunostimulatory activities to induce considerable level of pro-inflammatory cytokine TNF-a, IL-6 and IL-12 release via the TLR7 and TLR8, almost 2-fold higher than the strong stimulatory ssRNA40 that was found previously from other virus.
             </p>
            </list-item>
            <list-item>
             <p>
              Moreover, SARS-CoV ssRNA was able to cause acute lung injury in mice with a high mortality rate in vivo experiment. It suggests that SARS-CoV specific GU-rich ssRNA plays a very important role in the cytokine storm associated with a dysregulation of the innate immunity and could open a new therapeutic strategy.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS44">
            44
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Liao Y; Wang X; Huang M; Tam JP; Liu DX
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2011
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Characterised cellular mechanisms exploited by coronavirus infectious bronchitis virus (IBV) to regulate the induction of two pro-inflammatory cytokines, interleukin (IL)-6 and IL-8, at the transcriptional level.
             </p>
            </list-item>
            <list-item>
             <p>
              IBV modulates the infection by inducing the expression of dual-specificity phosphatase 1 (DUSP1), a negative regulator of the p38 MAPK, in order to limit the production of an excessive amount of IL-6 and IL-8 in the infected cells.
             </p>
            </list-item>
            <list-item>
             <p>
              DUSP1 and p38 MAPK are possible therapeutic targets for IBV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS45">
            45
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Day CW; Baric R; Cai SX; Frieman M; Kumaki Y; Morrey JD; Smee DF; Barnard DL.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              A new strain of SARS-CoV (strain v2163) was characterised and it was highly lethal in 5- to 6-week-old BALB/c mice. It had nine mutations affecting 10 amino acid residues.
             </p>
            </list-item>
            <list-item>
             <p>
              Strain v2163 increased IL-1alpha, IL-6, MIP-1alpha, MCP-1, and RANTES in mice, and high IL-6 expression correlated with mortality.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS46">
            46
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutralising antibody against severe acute respiratory syndrome -coronavirus spike is highly effective for the protection of mice in the murine SARS model.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Australia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The efficacy of three SARS vaccine candidates was tested in a murine SARS model utilising low-virulence Pp and SARS-CoV coinfection.
             </p>
            </list-item>
            <list-item>
             <p>
              Vaccinated mice were protected from severe respiratory disease.
             </p>
            </list-item>
            <list-item>
             <p>
              A high level of IL-6 and on days 2 and 3 after SARS-CoV infection was closely linked to the virus replication and disease severity, suggesting the importance of these cytokines in the lung pathogenicity of SARS-CoV infection.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS47">
            47
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome (18) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Yoshikawa T; Hill T; Li K; Peters CJ; Tseng CT.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              In highly polarised human lung epithelial Calu-3 cells modelled the cellular bases of the host antiviral innate immunity within the lungs.
             </p>
            </list-item>
            <list-item>
             <p>
              Role of IL-6 as a key SARS-CoV-induced epithelial cytokine capable of inhibiting the T-cell-priming ability of Denditric cells leading to an exacerbated inflammatory cascades and severe tissue damage in SARS patients.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS48">
            48
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang X; Wu K; Wang D; Yue X; Song D; Zhu Y; Wu J.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              High levels of IL6 High levels of interleukin-6 (IL-6) in the acute stage associated with lung lesions were found in SARS patients.
             </p>
            </list-item>
            <list-item>
             <p>
              The viral nucleocapsid SARS-CoV N protein
              <bold>
               activate
              </bold>
              IL-6 expression in the lung cells.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS49">
            49
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Okabayashi T; Kariwa H; Yokota S; Iki S; Indoh T; Yokosawa N; Takashima I; Tsutsumi H; Fujii N.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They compared the cytokine profile in Caco2 cells after infection of SARS coronavirus (SARS-CoV) with other respiratory viruses including respiratory syncytial virus (RSV), influenza A virus (FluAV), and human parainfluenza virus type 2 (hPIV2).
             </p>
            </list-item>
            <list-item>
             <p>
              Interferon (IFN) system (production and response) was not suppressed by SARS-CoV infection
             </p>
            </list-item>
            <list-item>
             <p>
              SARS-CoV and RSV induced high levels of IL-6 and RANTES compared with FluAV and hPIV2.
             </p>
            </list-item>
            <list-item>
             <p>
              Induction level of suppressor of cytokine signaling-3 (SOCS3) by SARS-CoV was significantly lower than that by RSV in spite of the significant production of IL-6.
             </p>
            </list-item>
            <list-item>
             <p>
              Collectively, overinduction of inflammatory cytokine and dysregulation of cytokine signaling may contribute to the immunopathology associated with “severe” inflammation in SARS.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS31">
            31
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hao D; He LX; Qu JM; Pan J; Hu BJ; Zhang J; Li ZZ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The pulmonary inflammatory reaction in rat models were induced by intratracheal instillation of N-protein of SARS-CoV and glucocorticoids were administrated to one of the groups.
             </p>
            </list-item>
            <list-item>
             <p>
              The N-protein of SARS-CoV presented pathogenicity and could induce pulmonary inflammatory reaction and acute lung injury, which were related to the increase and imbalance of pro-inflammatory and anti-inflammatory cytokines. Glucocorticoids could effectively alleviate the pulmonary inflammatory reaction induced by N-protein of SARS-CoV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS50">
            50
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sheng WH; Chiang BL; Chang SC; Ho HN; Wang JT; Chen YC; Hsiao CH; Hseuh PR; Chie WC; Yang PC.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Singapore
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Fourteen hospitalised patients with a diagnosis of SARS-associated coronavirus infection.
             </p>
            </list-item>
            <list-item>
             <p>
              There were no significant differences in peak levels of IL-6, IL-8 and TNF-alpha between patients with and without acute respiratory distress syndrome.
             </p>
            </list-item>
            <list-item>
             <p>
              CRP and TNF-alpha are associated with worse outcomes and might be used as prognostic markers of SARS.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS51">
            51
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Tseng CT; Perrone LA; Zhu H; Makino S; Peters CJ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              SARS-CoV does not productively infect human macrophages or Dentritic cells, it appears to exert differential effects on Mphi and DC maturation and functions, which might contribute to SARS pathogenesis.
             </p>
            </list-item>
            <list-item>
             <p>
              It modulates a massive release of IL-6 and IL-12. However, the endocytic capacity (e.g., Ag capture) of Mphi was significantly compromised upon exposure to infectious SARS-CoV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS52">
            52
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           An interferon-gamma-related cytokine storm in SARS patients.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Huang KJ; Su IJ; Theron M; Wu YC; Lai SK; Liu CC; Lei HY.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Fourteen cytokines or chemokines were analysed on 88 RT-PCR-confirmed severe acute respiratory syndrome [
              <xref ref-type="bibr" rid="refS18">
               18
              </xref>
              ] patients.
             </p>
            </list-item>
            <list-item>
             <p>
              IFN-gamma, IL-18, TGF-beta, IL-6, IP-10, MCP-1, MIG, and IL-8, but not of TNF-alpha, IL-2, IL-4, IL-10, IL-13, or TNFRI, were highly elevated in the acute phase sera of Taiwan SARS patients.
             </p>
            </list-item>
            <list-item>
             <p>
              IL-18, IP-10, MIG, and MCP-1 were significantly higher in the death group than in the survival group
             </p>
            </list-item>
            <list-item>
             <p>
              An interferon-gamma-related cytokine storm was induced post SARS coronavirus infection, and this cytokine storm might be involved in the immunopathological damage in SARS patients.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS53">
            53
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wang WK; Chen SY; Liu IJ; Kao CL; Chen HL; Chiang BL; Wang JT; Sheng WH; Hsueh PR; Yang CF; Yang PC; Chang SC;
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              8 patients with acute respiratory syndrome [
              <xref ref-type="bibr" rid="refS18">
               18
              </xref>
              ], were included to study the link between viral load, ribavirin, proinflammatory cytokines, and clinical progression.
             </p>
            </list-item>
            <list-item>
             <p>
              ribavirin was not effective in reducing the SARS coronavirus load in 3 of 8 probable cases studied
             </p>
            </list-item>
            <list-item>
             <p>
              elevated levels of interleukin (IL)-6 and IL-8 subsequent to the peak viral load were found in 8 and 6 cases, respectively.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS54">
            54
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of serum cytokines in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang Y; Li J; Zhan Y; Wu L; Yu X; Zhang W; Ye L; Xu S; Sun R; Wang Y; Lou J.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Serum from 110 individuals (healthy donors, patients with SARS, patients with severe SARS, and patients with SARS in convalescence) was collected and cytokine profile was studied.
             </p>
            </list-item>
            <list-item>
             <p>
              The IL-6 concentration was increased in SARS patients and was significantly elevated in severe SARS patients, but the IL-6 concentrations were similar in convalescent patients and control subjects, suggesting that there was a positive relationship between the serum IL-6 concentration and
             </p>
            </list-item>
            <list-item>
             <p>
              SARS severity.
             </p>
            </list-item>
            <list-item>
             <p>
              The concentrations of IL-8 and TGF-beta were decreased in SARS patients and significantly reduced in severe SARS patients, but they were comparable in convalescent SARS patients and control subjects, suggesting that there was a negative relationship between the IL-8 and TGF-beta concentrations and SARS severity.
             </p>
            </list-item>
            <list-item>
             <p>
              The concentrations of IL-1 and TNF-alpha were not significantly different in different groups.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS34">
            34
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong CK; Lam CW; Wu AK; Ip WK; Lee NL; Chan IH; Lit LC; Hui DS; Chan MH; Chung SS; Sung JJ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Changes in plasma T helper (Th) cell cytokines, inflammatory cytokines and chemokines in 20 patients diagnosed with SARS were assessed.
             </p>
            </list-item>
            <list-item>
             <p>
              Th1 cytokine interferon (IFN)-gamma, inflammatory cytokines interleukin (IL)-1, IL-6 and IL-12 was elevated for at least 2 weeks after disease onset, but there was no significant elevation of inflammatory cytokine tumour necrosis factor (TNF)-alpha, anti-inflammatory cytokine IL-10, Th1 cytokine IL-2 and Th2 cytokine IL-4.
             </p>
            </list-item>
            <list-item>
             <p>
              The chemokine profile demonstrated significant elevation of neutrophil chemokine IL-8, monocyte chemoattractant protein-1 (MCP-1), and Th1 chemokine IFN-gamma-inducible protein-10 (IP-10).
             </p>
            </list-item>
            <list-item>
             <p>
              Corticosteroid reduced significantly IL-8, MCP-1 and IP-10 concentrations from 5 to 8 days after treatment (all p &lt; 0.001).
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS55">
            55
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wang and Pang
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              (Abstract only)
             </p>
            </list-item>
            <list-item>
             <p>
              This study observed changed in various serum IL levels in patients with SARS. The authors stated that the mean concentration of serum IL-6 in SARS patients did not differ from the control group in 3-7-day group and 8-14-day group, but became significantly higher in over 14-day group as compared to the control group, 3-7-day group and 8-14-day group (
              <italic>
               p
              </italic>
              &lt; 0.01). The results of the study led the authors to conclude that the immune state of SARS was abnormal. However, as only the abstract was available it is hard to draw upon any more conclusions from this study in relation in IL-6 specifically.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS56">
            56
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Inflammatory Cytokine Profile in Children With Severe Acute Respiratory Syndrome
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ng
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The authors of this study set out to study the inflammatory cytokine profile in children with SARS. They found that the plasma concentrations key proinflammatory cytokines, including IL-6 were not substantially increased in any of the patients throughout the course of illness. From this the authors stated that the cytokine results cast doubt on the liberal use of corticosteroids in paediatric SARS patients, as the host immunologic response did not seem to be as severe as initially anticipated.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable5" position="anchor">
       <label>
        Supplementary Table 5.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and JAK inhibitors
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS57">
            57
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Richardson
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              ACE2 is a cell-surface protein on lung cells in corona viral infected patients
             </p>
            </list-item>
            <list-item>
             <p>
              AAK1 receptor promoted endocytosis involved in ACE2
             </p>
            </list-item>
            <list-item>
             <p>
              The study suggests the use of Baricitinib to inhibit AAK1 in patients with 2019-nCoV acute respiratory disease, to reduce both the viral entry and the inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia [
              <xref ref-type="bibr" rid="refS58">
               58
              </xref>
              ].
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS59">
            59
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The Coronavirus Transmissible Gastroenteritis Virus Evades the Type I Interferon Response through IRE1α-Mediated Manipulation of the MicroRNA miR-30a-5p/SOCS1/3 Axis
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ma
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2018
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              JAK-signal transducer and activator of transcription (STAT), the suppressor of cytokine signaling protein 1 (SOCS1), and SOCS3.
             </p>
            </list-item>
            <list-item>
             <p>
              IFN-I are major antiviral molecules, and coronaviruses have evolved diverse strategies to counter the IFN-I response during infection.
             </p>
            </list-item>
            <list-item>
             <p>
              This study uses endoplasmic reticulum stress and IFN-I production after infection with transmissible gastroenteritis virus (TGEV) to understand how coronavirus-elicited ER stress is actively involved in viral replication and manipulates the host IFN-I response.
             </p>
            </list-item>
            <list-item>
             <p>
              Increased SOCS1 or SOCS3 expression impaired the IFN-I antiviral response, promoting TGEV replication.
             </p>
            </list-item>
            <list-item>
             <p>
              IRE1α is an endoplasmic reticulum stress sensor, which led to the increased expression of negative regulators of JAK-STAT SOCS1 and SOCS3.
             </p>
            </list-item>
            <list-item>
             <p>
              Therefore, IRE1α may be a novel target against coronavirus infection.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS60">
            60
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-kappaB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Yang
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Tylophorine-based compounds exert broad spectral, potent inhibition of coronaviruses.
             </p>
            </list-item>
            <list-item>
             <p>
              NF-
              <bold>
               κB
              </bold>
              activation is a common pro-inflammatory response of host cells to viral infection.
             </p>
            </list-item>
            <list-item>
             <p>
              The combination treatment, wherein a tylophorine compound targets TGEV and a JAK2 inhibitor blocks the alternative dominant NF-
              <bold>
               κB
              </bold>
              activation mediated by JAK2, is more effective and comprehensive than either one alone and constitutes a feasible approach for the treatment of SARS-CoV or MERS-CoV
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS61">
            61
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of nsp1 and Rational Design of an Attenuated Strain
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wathelet
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Expression of non-structural protein 1 (nsp1) significantly inhibited the activation of SARS-Cov signaling pathways.
             </p>
            </list-item>
            <list-item>
             <p>
              However, the study results show that SARS-CoV nsp1 does not inhibit JAK phosphorylation.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable6" position="anchor">
       <label>
        Supplementary Table 6.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and IL-1 blockade.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS62">
            62
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The levels of several inflammatory markers were
           <break>
           </break>
           measured in 29 COVID-19 patients and were compared between general, severe and critically ill groups. The authors reported no significant differences in IL-1b levels between the three groups of patients.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS63">
            63
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Miura
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The authors used two rat coronaviruses on alveolar epithelial cells taken from 6-8 weeks old rats. Infection with the viruses caused the increase in expressed of both IL-1a and IL-1b. The authors concluded that the virus-induced chemokine expression was subsequently reduced by the IL-1 receptor antagonist, suggesting that IL-1 produced by infected cells induces uninfected cells to express chemokines.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS64">
            64
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zalinger, Elliott and Weiss
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The authors used several infectious agents including murine coronavirus to assess the role of the inflammasome and its related cytokines on pathogenesis and host defence during viral infection. The authors concluded that mice lacking IL-1 signalling experienced elevated viral replication but similar survival compared to wild-type controls.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS65">
            65
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe Acute Respiratory
           <break>
           </break>
           Syndrome Coronavirus Viroporin 3a Activates the NLRP3
           <break>
           </break>
           Inflammasome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Japan and Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The authors provide evidence that SARS-CoV 3a protein activates the NLRP3 inflammasome in lipopolysaccharide-primed macrophages and that the ion channel activity of the 3a protein was essential for 3a-mediated IL-1β secretion. The macrophages obtained in this study were from 6-week-old female mice.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS66">
            66
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Kritas
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Greece, Italy and USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Abstract Only)
           <break>
           </break>
           Infection with coronavirus activates mast cells which in turn causes the generation of pro-inflammatory IL-1 family members. The authors state that they demonstrate for the first time that inflammation by coronavirus may be inhibited by anti-inflammatory cytokines belonging to the IL-1 family. However, as this is only an abstract there is no further information to support this statement.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS67">
            67
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           SARS Immunity and Vaccination.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhu M
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           SARS-CoV binds to host cells via a specific SARS receptor, angiotensin converting enzyme 2 (ACE-2).
           <break>
           </break>
           Following entry into the cell, the virus uncoats, nucleic acid is released and transcription occurs for production of viral proteins. During this course, the host immune system is activated (B and T-cells).
           <break>
           </break>
           Specifically, CD4+ T helper cells recognise antigenic peptides produced by antigen presenting cells and produce cytokines that promote cell mediated and/or humoral immunity.
           <break>
           </break>
           Similarly to avian flu, SARS infection induced similar pro-inflammatory cytokine pattern and might contribute to the severe nature of the virus.
           <break>
           </break>
           Clinical evidence of SARS treatment by corticosteroids where levels of IL-1beta reduced after administration- thus inhibition of inflammatory cytokines such as IL-1 may be beneficial strategy for treatment of SARS.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS54">
            54
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of serum cytokines in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, Ye L, Xu S, Sun R, Wang Y, Lou J
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Following the discovery of SARS-CoV, no specific or efficient clinical treatments were available since pathogenesis was not well understood.
           <break>
           </break>
           Acute lung injury associated with SARS can be attributed to complex and multifactorial pathophysiological process involving cytokines. Demonstrated that IL-1 play key role in pathogenesis of acute lung injury. WHO inferred that severe immune response kills SARS patients and that some cytokines may play important role in the process.
           <break>
           </break>
           IL-1 cytokine promotes inflammation by inducing cell injury.
           <break>
           </break>
           Study measured levels of IL-1 in 4 patient groups: controls, patients with SARS, patients with severe SARS and convalescent SARS patients.
           <break>
           </break>
           Study showed that levels of IL-1alpha did not differ between 3 SARS groups or controls.
           <break>
           </break>
           Suggests that host immune response to novel coronavirus may be different from the immune reaction to other pathogens.
           <break>
           </break>
           Overall results suggest that acute lung injury associated with SARS may not be induced by circulating cytokines. HOWEVER some patients had accepted corticosteroids and therefore results consistent with reports that only long term treatment (7-10 days) with a steroid can alter serum cytokine levels.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS34">
            34
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Known that over-expression of IL-1beta hallmark of SARS infection probably through activation of transcription factor nuclear factor, activator protein AP1 and activating factor 2. Therefore lung damage associated with SARS postulated to occur through cytokine and chemokine dysregulation.
           <break>
           </break>
           Study involved measurement of cytokines and chemokines including IL-1beta in 20 consecutive patients admitted to Hong Kong hospital.
           <break>
           </break>
           IL-1beta was significantly elevated above normal range within first 12, 7 and 5 days after disease onset.
           <break>
           </break>
           Those patients with more severe disease treated with pulsed methylprednisolone. IL-1beta levels higher in this patient group particularly 3-10 days after onset but returned to normal levels 1 week after disease onset in both sets of patients.
           <break>
           </break>
           IL-1beta can act as early response cytokine to viral infection. IL-1 elevation in SARS can induce hyperinnate inflammatory response leading to recruitment and accumulation of alveolar macrophages and PMN.
           <break>
           </break>
           Higher disease severity associated with more elevated plasma IL-1beta and addition of pulsed steroid controlled rapidly deteriorating clinical condition and attenuated otherwise exaggerated immunological response.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable7" position="anchor">
       <label>
        Supplementary Table 7.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and Mycophenolate.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS68">
            68
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Interferon-β and mycophenolic acid are potent inhibitors of middle east respiratory syndrome coronavirus in cell-based assays
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hart
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (
           <italic>
            In vitro
           </italic>
           only)
           <break>
           </break>
           MPA showed strong inhibition, with an IC50 of 2.87 mM. This drug may provide an alternative to ribavirin for treatment of MERS-CoV. In conclusion, IFN-b, MPA or a combination of the two may be beneficial in the treatment of MERS-CoV or as a post-exposure intervention in high-risk patients with known exposures to MERS-CoV.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS69">
            69
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lin
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2018
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vitro)
           <break>
           </break>
           Note. (PLpros)= Papain-like proteases MERS-CoV and SARS-CoV – act as a potential anti-viral target for drugs
           <break>
           </break>
           Multiple inhibition assays also support a kinetic mechanism by which disulfiram together with 6TG and/or MPA can synergistically inhibit MERS-CoV PLpro, but not, due to its competitive mode of inhibition, SARS-CoV PLpro.
           <break>
           </break>
           Synergistic inhibition of MERS-CoV PLpro by disulfiram and 6-thioguanine or
           <bold>
            mycophenolic acid
           </bold>
           implies the potential for combination treatments using these three clinically available drugs.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS70">
            70
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cheng et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vitro)
           <break>
           </break>
           At the time of the study, there were no potent inhibitors that target MERS-CoV PLpro. The authors report that the immunosuppressive drug mycophenolic acid, was able to inhibit MERS-CoV PLpro.
           <break>
           </break>
           MPA is a non-competitive inhibitor of MERS-CoV PLpro.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS71">
            71
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chan
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong/China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2013
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (
           <italic>
            In vitro
           </italic>
           )
           <break>
           </break>
           The authors assessed the anti-MERS-CoV activities of several compounds. Only mycophenolic acid exhibited low EC50 and high selectivity index.
           <break>
           </break>
           They found that a combination of mycophenolic acid and IFN-b1b lowered the EC50 of each drug by 1-3 times.
           <break>
           </break>
           Mycophenolic acid exhibits a number of attributes that support its practical use in MERS-CoV infection. It is commonly available in two forms, the prodrug mycophenolate mofetil and the salt mycophenolate sodium, and could be given orally.
           <break>
           </break>
           Interferon-b1b with mycophenolic acid should be considered in treatment trials of MERS.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS72">
            72
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Shen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <italic>
            (In vitro)
           </italic>
           <break>
           </break>
           The authors sought to identify potent broad-spectrum inhibitors of corona viruses. They concluded that they had identified seven compounds (lycorine, emetine, monensin sodium,
           <bold>
            mycophenolate mofetil, mycophenolic acid
           </bold>
           , phenazopyridine, and pyrvinium pamoate) as broad-spectrum inhibitors according to their strong inhibition of replication by four CoVs in vitro at low-micromolar concentrations. They all inhibited the replication of all CoVs with EC50 values of 5μm.
           <break>
           </break>
           Mycophenolate mofetil and mycophenolic acid, showed a similar antiviral effect on the four CoVs suggesting that the two drugs might harbour similar core structures and antiviral mechanisms.
           <break>
           </break>
           In vivo antiviral activity is unknown from this study.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS73">
            73
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cinatl
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vitro but using clinical samples - Abstract only)
           <break>
           </break>
           The authors assessed the antiviral activities of ribavirin, 6-azauridine, pyrazofurin,
           <bold>
            mycophenolic acid
           </bold>
           , and glycyrrhizin against two clinical isolates of coronavirus (FFM-1 and FFM-2) from patients with SARS admitted to the clinical centre of Frankfurt University, Germany.
           <break>
           </break>
           Mycophenolic acid did not affect replication of the SARS-associated coronaviruses.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS74">
            74
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Al Ghamdi et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Clinical example)
           <break>
           </break>
           Eight patients (15.7%) received mycophenolate mofetil, seven of these patients received it in combination with interferon beta. All patients who received mycophenolate mofetil survived. The authors concluded that whilst treatment with beta interferon and mycophenolate mofetil predicted survival (in univariate analysis only), the greatest predictor of survival was the severity of illness on presentation.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS75">
            75
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERSCoV infection in a nonhuman primate model of common marmoset
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chan
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong/China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vivo)
           <break>
           </break>
           The authors assessed 3 repurposed drugs with potent in vitro anti-MERS-CoV activity (mycophenolate mofetil, lopinavir/ritonavir, and interferon-β1b) in common marmosets with severe disease resembling MERS in humans.
           <break>
           </break>
           all MMF-treated animals developed severe and/or fatal disease with higher mean viral loads.
           <break>
           </break>
           The authors concluded that MMF alone may worsen MERS and should not be used.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS76">
            76
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Barnard
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           In vivo study in BALB/c mice (a replication model for SARS infections)
           <break>
           </break>
           In mycophenolic acid-treated mice, the lung virus titers (aka viral load) increased with increasing dosage, although these increases in lung virus titers were not quite significantly different from the lung virus titers in placebo-treated, infected mice.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS77">
            77
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A review of treatment modalities for Middle East Respiratory Syndrome
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mo and Fisher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Singapore
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           Mycophenolic acid also inhibits purine nucleotide synthesis in lymphocytes. This makes it a popular immunosuppressant in solid-organ transplants and autoimmune diseases such as systemic lupus erythematosus.
           <break>
           </break>
           The use of mycophenolic acid monotherapy has not been reported in MERS. IFN-b and mycophenolic acid combination therapy was described in a retrospective observational study in Saudi Arabia involving 51 patients; all of the 8 patients who received IFN-b and mycophenolic acid survived.
           <break>
           </break>
           Corticosteroids, ribavirin monotherapy and mycophenolic acid are likely to cause more harm than benefit.
           <break>
           </break>
           There are no clinical data on the efficacy of mycophenolic acid in SARS or MERS. However, it led to severe and/or fatal disease with higher mean viral loads in an animal model.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS78">
            78
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Al-Tawfiq and Memish
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           MPA mechanism of action - Direct and indirect antiviral activity by modulation of IFN response
           <break>
           </break>
           The use of mycophenolate in the common marmoset animal model resulted in higher mortality than untreated animals: Mortality rate was 67% (untreated and MMF treated) at 36 h post inoculation versus 0%–33% (lopinavir/ ritonavir-treated and interferon-β1b- treated
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS79">
            79
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Middle East Respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chan et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong/China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           The combination of mycophenolic acid and interferon beta 1b shows synergistic activity against MERS-CoV in Vero cells. The desirable pharmacokinetics of mycophenolic acid compared to ribavirin warrants further evaluation, although the potential inhibitory effect on the immune system and therefore neutralising antibody production should be fully assessed in animal models before use in humans.
           <break>
           </break>
           A fatal case of MERS was reported in a renal transplant recipient who was receiving antirejection therapy consisting of prednisone, mycophenolate mofetil, and cyclosporine, but the dosage, serum drug level of mycophenolate mofetil, and resulting lymphocyte count were not reported
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS80">
            80
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Rabaan
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           Reiteration of the promising results of MPA in an in vitro setting, however, the marmoset animal model resulted in fatal disease and high viral loads. The authors therefore state that MPA should be used with caution for treatment of MERS-CoV.
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          The EC50 is the concentration of a drug that gives half-maximal response. The IC50 is the concentration of an inhibitor where the response (or binding) is reduced by half. These terms are referred to a few times within the summary table.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="Stable8" position="anchor">
       <label>
        Supplementary Table 8.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and Tacrolimus.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS81">
            81
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Carbajo-Lozoya
           <italic>
            et al
           </italic>
           .
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany/Switzerland
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2012
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Coronaviruses represent the group of RNA viruses with the largest RNA genome to date therefore the development of resistant mutants to targeted drugs remains a concern.
           <break>
           </break>
           Viral replication represents potential antiviral targets.
           <break>
           </break>
           Study performed genome-wide SARS-CoV yeast-two-hybrid interaction screen with human cDNA libraries identifying FK506-binding proteins as interaction partners of SARS-CoV non-structural protein 1 (Nsp1).
           <break>
           </break>
           FK506-binding proteins bind the immunosuppressive drug FK506 (tacrolimus).
           <break>
           </break>
           Since Nsp1 interacts with FK506-binding proteins, investigated whether FK506 inhibits replication of human coronaviruses.
           <break>
           </break>
           VeroFM cells infected with SARS-CoV and other human coronaviruses and treated with FK506.
           <break>
           </break>
           Study found that FK506 inhibits the replication of SARS-CoV, HCoV-NL63 and HCoV-229E at non-toxic, low-micromolar concentrations with reduction in viral titers to undetectable levels.
           <break>
           </break>
           All human coronaviruses sensitive to FK506 indicating the involvement of FK506-binding proteins in viral replication.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS82">
            82
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           MERS CoV infection in two renal transplant recipients: Case report
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Al Ghamdi et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Pneumonia caused by MERS-CoV associated with severe morbidity and mortality in immunocompromised patients.
           <break>
           </break>
           Data on clinical picture in solid organ transplant recipients and effect of anti-rejection immunosuppressive regimens unclear.
           <break>
           </break>
           30-year old patient with renal transplant on immunosuppressive regimen of tacrolimus.
           <break>
           </break>
           Tested positive for MERS CoV through nasopharyngeal swab.
           <break>
           </break>
           Received antibacterial therapy and mycophenolate mofetil dose reduced and underwent full recovery.
           <break>
           </break>
           Difficult to pinpoint why made full recovery compared to other case study (not on tacrolimus) who died.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS83">
            83
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Human coronavirus NL63 replication is cyclophilin
           <break>
           </break>
           A-dependent and inhibited by non-immunosuppressive
           <break>
           </break>
           cyclosporine A-derivatives
           <break>
           </break>
           including Alisporivir
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Carbajo-Lozoya
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Previous study shown that FK506 inhibit coronavirus replication.
           <break>
           </break>
           This study further shows that novel non-immunosuppressive derivatives of CsA and FK506 strongly inhibit the growth of human coronavirus HCoV-NL63 at low-micromolar, non-cytotoxic concentrations in cell culture.
           <break>
           </break>
           HCoV-NL63 and HCoV-HKU1 discovered in 2004 and 2005 causing more severe lower respiratory tract
           <break>
           </break>
           infections in younger children.
           <break>
           </break>
           PPIase-independent activities of CsA and FK506 exerted by gain-of-function, result from binary complexes formed by binding of the drugs to FKBPs. Based on inhibition of the protein phosphatase activity of calcineurin, these complexes block the cellular calcineurin/NFAT pathway
           <break>
           </break>
           thereby interfering with T-cell activation and IL-2 production.
           <break>
           </break>
           FK506 analogues (altered by side chain modification)
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
     <ref-list>
      <title>
       References
      </title>
      <ref id="ref1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref2">
       <label>
        2.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of COVID-19 for patients with cancer
        </article-title>
        <source>
         Lancet Oncol
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S1470-2045(20)30149-2
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref3">
       <label>
        3.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Risk of COVID-19 for cancer patients
        </article-title>
        <source>
         Lancet Oncol
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S1470-2045(20)30150-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         32142622
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benites
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Cabrini
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy
        </article-title>
        <source>
         J Pediatr (Rio J)
        </source>
        <year>
         2014
        </year>
        <volume>
         90
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         370
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jped.2014.01.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         24703819
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref5">
       <label>
        5.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nilsson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Edner
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Albert
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child
        </article-title>
        <source>
         Infect Dis (Lond)
        </source>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         4
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Folz
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Elkordy
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer
        </article-title>
        <source>
         Chest
        </source>
        <year>
         1999
        </year>
        <volume>
         115
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         901
        </fpage>
        <lpage>
         905
        </lpage>
        <pub-id pub-id-type="doi">
         10.1378/chest.115.3.901
        </pub-id>
        <pub-id pub-id-type="pmid">
         10084516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           LaFemina
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alternative screening approaches for discovery of middle east respiratory syndrome coronavirus inhibitors
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4251
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.03406-14
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4135998</pub-id>-->
        <pub-id pub-id-type="pmid">
         24867994
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Kumaki
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
        </article-title>
        <source>
         Future Virol
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         615
        </fpage>
        <lpage>
         631
        </lpage>
        <pub-id pub-id-type="doi">
         10.2217/fvl.11.33
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3136164</pub-id>-->
        <pub-id pub-id-type="pmid">
         21765859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2009
        </year>
        <volume>
         19
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         151
        </fpage>
        <lpage>
         156
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020901900402
        </pub-id>
        <pub-id pub-id-type="pmid">
         19374142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balzarini
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2007
        </year>
        <volume>
         18
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020701800101
        </pub-id>
        <pub-id pub-id-type="pmid">
         17354647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kesel
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A system of protein target sequences for anti-RNA-viral chemotherapy by a vitamin B6-derived zinc-chelating trioxa-adamantane-triol
        </article-title>
        <source>
         Bioorg Med Chem
        </source>
        <year>
         2003
        </year>
        <volume>
         11
        </volume>
        <issue>
         21
        </issue>
        <fpage>
         4599
        </fpage>
        <lpage>
         4613
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0968-0896(03)00500-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         14527557
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref12">
       <label>
        12.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Karakiulakis
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S2213-2600(20)30116-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         32171062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amici
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Di Caro
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ciucci
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Indomethacin has a potent antiviral activity against SARS coronavirus
        </article-title>
        <source>
         Antivir therapy
        </source>
        <year>
         2006
        </year>
        <volume>
         11
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         1021
        </fpage>
        <lpage>
         1030
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chihrin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Loutfy
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome
        </article-title>
        <source>
         Expert Rev Anti Infect Ther
        </source>
        <year>
         2005
        </year>
        <volume>
         3
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         251
        </fpage>
        <lpage>
         262
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/14787210.3.2.251
        </pub-id>
        <pub-id pub-id-type="pmid">
         15918782
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L-X
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J-M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it]
        </article-title>
        <source>
         Zhonghua nei ke za zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         44
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         890
        </fpage>
        <lpage>
         893
        </lpage>
        <pub-id pub-id-type="pmid">
         16409721
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           MHM
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: clinical and laboratory manifestations
        </article-title>
        <source>
         Clin Biochem Rev
        </source>
        <year>
         2004
        </year>
        <volume>
         25
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         121
        </fpage>
        <lpage>
         132
        </lpage>
        <pub-id pub-id-type="pmid">
         18458712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           AKL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Exp Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         136
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         95
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1365-2249.2004.02415.x
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">1808997</pub-id>-->
        <pub-id pub-id-type="pmid">
         15030519
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Alekseev
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         4420
        </fpage>
        <lpage>
         4428
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02190-07
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2293053</pub-id>-->
        <pub-id pub-id-type="pmid">
         18287230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <issue>
         Pt 8
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         720
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.05320-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         12867568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahmud-Al-Rafat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Taufiqur Rahman
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Decoding the enigma of antiviral crisis: does one target molecule regulate all? Cytokine
        </article-title>
        <source>
         Cytokine
        </source>
        <year>
         2019
        </year>
        <volume>
         115
        </volume>
        <fpage>
         13
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cyto.2018.12.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         30616034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tobinick
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection
        </article-title>
        <source>
         Curr Med Res Opin
        </source>
        <year>
         2004
        </year>
        <volume>
         20
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         39
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="doi">
         10.1185/030079903125002757
        </pub-id>
        <pub-id pub-id-type="pmid">
         14741070
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Atanasova
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Van Gucht
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Van Reeth
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-TNF-alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs
        </article-title>
        <source>
         Vet Immunol Immunopathol
        </source>
        <year>
         2010
        </year>
        <volume>
         137
        </volume>
        <issue>
         1–2
        </issue>
        <fpage>
         12
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vetimm.2010.04.003
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2922464</pub-id>-->
        <pub-id pub-id-type="pmid">
         20466438
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Narazaki
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kishimoto
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         IL-6 in inflammation, immunity, and disease
        </article-title>
        <source>
         Cold Spring Harb Perspect Biol
        </source>
        <year>
         2014
        </year>
        <volume>
         6
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         a016295
        </fpage>
        <pub-id pub-id-type="doi">
         10.1101/cshperspect.a016295
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4176007</pub-id>-->
        <pub-id pub-id-type="pmid">
         25190079
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Conti
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies
        </article-title>
        <source>
         J Biol Regul Homeost Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         2
        </issue>
        <comment>
         pii:1
        </comment>
        <pub-id pub-id-type="pmid">
         32171193
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         365
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         324
        </fpage>
        <lpage>
         335
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.04.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         17490702
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okabayashi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Kariwa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Yokota
          </surname>
          <given-names>
           S-I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2006
        </year>
        <volume>
         78
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         417
        </fpage>
        <lpage>
         424
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20556
        </pub-id>
        <pub-id pub-id-type="pmid">
         16482545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C-TK
          </given-names>
         </name>
         <name>
          <surname>
           Perrone
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection
        </article-title>
        <source>
         J Immunol
        </source>
        <year>
         2005
        </year>
        <volume>
         174
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         7977
        </fpage>
        <lpage>
         7985
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.174.12.7977
        </pub-id>
        <pub-id pub-id-type="pmid">
         15944304
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv392
        </pub-id>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         203
        </fpage>
        <lpage>
         208
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J Korean Medi Sci
        </source>
        <year>
         2016
        </year>
        <volume>
         31
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1717
        </fpage>
        <lpage>
         1725
        </lpage>
        <pub-id pub-id-type="doi">
         10.3346/jkms.2016.31.11.1717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Bailey
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2006
        </year>
        <volume>
         71
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         53
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2006.03.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         16621037
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ishii
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hasegawa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Nagata
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model
        </article-title>
        <source>
         Microbiol Immunol
        </source>
        <volume>
         53
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         75
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         19291090
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yoshikawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         3039
        </fpage>
        <lpage>
         3048
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01792-08
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2655569</pub-id>-->
        <pub-id pub-id-type="pmid">
         19004938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheng
          </surname>
          <given-names>
           W-H
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           B-L
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           S-C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         J Formosan Med Assoc = Taiwan yi zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         104
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         723
        </lpage>
        <pub-id pub-id-type="pmid">
         16385373
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           K-J
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           I-J
          </given-names>
         </name>
         <name>
          <surname>
           Theron
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An interferon-gamma-related cytokine storm in SARS patients
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         75
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         185
        </fpage>
        <lpage>
         194
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20255
        </pub-id>
        <pub-id pub-id-type="pmid">
         15602737
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           B-S
          </given-names>
         </name>
         <name>
          <surname>
           National Research Project for Sars
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         26
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         586
        </fpage>
        <lpage>
         589
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W-K
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S-Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         39
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1071
        </fpage>
        <lpage>
         1075
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/423808
        </pub-id>
        <pub-id pub-id-type="pmid">
         15472864
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Analysis of serum cytokines in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Infect Immun
        </source>
        <year>
         2004
        </year>
        <volume>
         72
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4410
        </fpage>
        <lpage>
         4415
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/IAI.72.8.4410-4415.2004
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">470699</pub-id>-->
        <pub-id pub-id-type="pmid">
         15271897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inflammatory cytokine profile in children with severe acute respiratory syndrome
        </article-title>
        <source>
         Pediatrics
        </source>
        <year>
         2004
        </year>
        <volume>
         113
        </volume>
        <fpage>
         e7
        </fpage>
        <lpage>
         e14
        </lpage>
        <pub-id pub-id-type="doi">
         10.1542/peds.113.1.e7
        </pub-id>
        <pub-id pub-id-type="pmid">
         14702488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response
        </article-title>
        <source>
         Microb Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         15
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         88
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.micinf.2012.10.008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2011
        </year>
        <volume>
         420
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         106
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2011.09.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         21959016
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref42">
       <label>
        42.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamaya
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Nishimura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells
        </article-title>
        <source>
         Respir Investig
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/j.resinv.2019.12.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         32094077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kontzias
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Kotlyar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Laurence
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
        </article-title>
        <source>
         Curr Opin Pharmacol
        </source>
        <year>
         2012
        </year>
        <volume>
         12
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         464
        </fpage>
        <lpage>
         470
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.coph.2012.06.008
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3419278</pub-id>-->
        <pub-id pub-id-type="pmid">
         22819198
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref44">
       <label>
        44.
       </label>
       <element-citation publication-type="webpage">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agency
          </surname>
          <given-names>
           EM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Olumiant (baricitinib)
        </article-title>
        <year>
         2019
        </year>
        <comment>
         [
         <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant">
          https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant
         </ext-link>
         ]
        </comment>
       </element-citation>
      </ref>
      <ref id="ref45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Griffin
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Tucker
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         e30
        </fpage>
        <lpage>
         e1
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30304-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The coronavirus transmissible gastroenteritis virus evades the type I interferon response through IRE1alpha-mediated manipulation of the microRNA miR-30a-5p/SOCS1/3 axis
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <issue>
         22
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00728-18
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           YZ
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         Antivir Res
        </source>
        <year>
         2010
        </year>
        <volume>
         88
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         160
        </fpage>
        <lpage>
         168
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2010.08.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         20727913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           C-W
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           Y-Z
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           H-Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Targeting coronaviral replication and cellular JAK2 mediated dominant NF-κB activation for comprehensive and ultimate inhibition of coronaviral activity
        </article-title>
        <source>
         Sci Rep
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         4105
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41598-017-04203-9
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5481340</pub-id>-->
        <pub-id pub-id-type="pmid">
         28642467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E005
        </fpage>
       </element-citation>
      </ref>
      <ref id="ref50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS immunity and vaccination
        </article-title>
        <source>
         Cell Mol Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         1
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         193
        </fpage>
        <lpage>
         198
        </lpage>
        <pub-id pub-id-type="pmid">
         16219167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miura
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         369
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         288
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.07.030
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2170429</pub-id>-->
        <pub-id pub-id-type="pmid">
         17804032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kritas
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy
        </article-title>
        <source>
         J Biol Regul Homeost Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         1
        </issue>
       </element-citation>
      </ref>
      <ref id="ref53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Moses
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2018
        </year>
        <volume>
         150
        </volume>
        <fpage>
         155
        </fpage>
        <lpage>
         163
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2017.12.015
        </pub-id>
        <pub-id pub-id-type="pmid">
         29289665
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           WY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2015
        </year>
        <volume>
         115
        </volume>
        <fpage>
         9
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2014.12.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         25542975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           RY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         606
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2013.09.029
        </pub-id>
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2019
        </year>
        <volume>
         93
        </volume>
        <issue>
         12
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00023-19
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <issue>
         Pt 3
        </issue>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.061911-0
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3929173</pub-id>-->
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Fisher
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of treatment modalities for Middle East Respiratory Syndrome
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <year>
         2016
        </year>
        <volume>
         71
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         3340
        </fpage>
        <lpage>
         3350
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/jac/dkw338
        </pub-id>
        <pub-id pub-id-type="pmid">
         27585965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Ghamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Ghandoora
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <year>
         2016
        </year>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         174
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12879-016-1492-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4839124</pub-id>-->
        <pub-id pub-id-type="pmid">
         27097824
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AlGhamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mushtaq
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Awn
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS CoV infection in two renal transplant recipients: case report
        </article-title>
        <source>
         Am J Transplant
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         1101
        </fpage>
        <lpage>
         1104
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/ajt.13085
        </pub-id>
        <pub-id pub-id-type="pmid">
         25716741
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2012
        </year>
        <volume>
         165
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         112
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2012.02.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         22349148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ma-Lauer
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Malesevic
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2014
        </year>
        <volume>
         184
        </volume>
        <fpage>
         44
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2014.02.010
        </pub-id>
        <pub-id pub-id-type="pmid">
         24566223
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ref-list>
      <title>
       References
      </title>
      <ref id="refS1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           XH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [The differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of the 2019 novel coronavirus disease]
        </article-title>
        <source>
         Zhonghua Zhong Liu Za Zhi
        </source>
        <year>
         2020
        </year>
        <volume>
         42
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E008
        </fpage>
        <pub-id pub-id-type="pmid">
         32133833
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           YH
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Chemotherapy strategy for colorectal cancer under the outbreak of novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua Wei Chang Wai Ke Za Zhi
        </source>
        <year>
         2020
        </year>
        <volume>
         23
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E004
        </fpage>
        <pub-id pub-id-type="pmid">
         32100980
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS3">
       <label>
        3.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nilsson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Edner
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Albert
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child
        </article-title>
        <source>
         Infect Dis (Lond)
        </source>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         4
        </lpage>
       </element-citation>
      </ref>
      <ref id="refS4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Kumaki
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
        </article-title>
        <source>
         Future Virol
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         615
        </fpage>
        <lpage>
         631
        </lpage>
        <pub-id pub-id-type="doi">
         10.2217/fvl.11.33
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3136164</pub-id>-->
        <pub-id pub-id-type="pmid">
         21765859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aydin Köker
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Demirag
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Tahta
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A 3-year retrospective study of the epidemiology of acute respiratory viral infections in pediatric patients with cancer undergoing chemotherapy
        </article-title>
        <source>
         J Pediatr Hematol Oncol
        </source>
        <year>
         2019
        </year>
        <volume>
         41
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         e242
        </fpage>
        <lpage>
         e246
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/MPH.0000000000001418
        </pub-id>
        <pub-id pub-id-type="pmid">
         30688827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soderman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Rhedin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Tolfvenstam
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Frequent respiratory viral infections in children with febrile neutropenia—a prospective follow-up study
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2016
        </year>
        <volume>
         11
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         e0157398
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0157398
        </pub-id>
        <pub-id pub-id-type="pmid">
         27309354
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pillaiyar
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Manickam
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Namasivayam
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy
        </article-title>
        <source>
         J Med Chem
        </source>
        <year>
         2016
        </year>
        <volume>
         59
        </volume>
        <issue>
         14
        </issue>
        <fpage>
         6595
        </fpage>
        <lpage>
         6628
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/acs.jmedchem.5b01461
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">7075650</pub-id>-->
        <pub-id pub-id-type="pmid">
         26878082
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hijano
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Maron
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           RT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Respiratory viral infections in patients with cancer or undergoing hematopoietic cell transplant
        </article-title>
        <source>
         Front Microbiol
        </source>
        <year>
         2018
        </year>
        <volume>
         9
        </volume>
        <fpage>
         3097
        </fpage>
        <pub-id pub-id-type="doi">
         10.3389/fmicb.2018.03097
        </pub-id>
        <pub-id pub-id-type="pmid">
         30619176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Milano
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Guthrie
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2010
        </year>
        <volume>
         115
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         2088
        </fpage>
        <lpage>
         2094
        </lpage>
        <pub-id pub-id-type="doi">
         10.1182/blood-2009-09-244152
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2837322</pub-id>-->
        <pub-id pub-id-type="pmid">
         20042728
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ogimi
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Waghmare
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Kuypers
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical significance of human coronavirus in bronchoalveolar lavage samples from hematopoietic cell transplant recipients and patients with hematologic malignancies
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2017
        </year>
        <volume>
         64
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1532
        </fpage>
        <lpage>
         1539
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/cix160
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5434339</pub-id>-->
        <pub-id pub-id-type="pmid">
         28329354
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ghosh
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name>
          <surname>
           Xi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Progress in anti-SARS coronavirus chemistry, biology and chemotherapy
        </article-title>
        <source>
         Annu Rep Med Chem
        </source>
        <year>
         2007
        </year>
        <volume>
         41
        </volume>
        <fpage>
         183
        </fpage>
        <lpage>
         196
        </lpage>
        <!--<pub-id pub-id-type="pmcid">2718771</pub-id>-->
        <pub-id pub-id-type="pmid">
         19649165
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           LaFemina
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alternative screening approaches for discovery of middle east respiratory syndrome coronavirus inhibitors
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4251
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.03406-14
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4135998</pub-id>-->
        <pub-id pub-id-type="pmid">
         24867994
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benites
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Cabrini
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy
        </article-title>
        <source>
         J Pediatr (Rio J)
        </source>
        <year>
         2014
        </year>
        <volume>
         90
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         370
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jped.2014.01.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         24703819
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balzarini
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2007
        </year>
        <volume>
         18
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020701800101
        </pub-id>
        <pub-id pub-id-type="pmid">
         17354647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2009
        </year>
        <volume>
         19
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         151
        </fpage>
        <lpage>
         156
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020901900402
        </pub-id>
        <pub-id pub-id-type="pmid">
         19374142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chebotkevich
          </surname>
          <given-names>
           VN
          </given-names>
         </name>
         <name>
          <surname>
           Bessmel'tsev
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Volkov
          </surname>
          <given-names>
           AV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Molecular biology investigation of respiratory viruses as a factor of infectious complications in hemoblastosis and myelodepression]
        </article-title>
        <source>
         Vopr Onkol
        </source>
        <year>
         2006
        </year>
        <volume>
         52
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         421
        </fpage>
        <lpage>
         426
        </lpage>
        <pub-id pub-id-type="pmid">
         17024815
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kesel
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         Curr Med Chem
        </source>
        <year>
         2005
        </year>
        <volume>
         12
        </volume>
        <issue>
         18
        </issue>
        <fpage>
         2095
        </fpage>
        <lpage>
         2162
        </lpage>
        <pub-id pub-id-type="doi">
         10.2174/0929867054637644
        </pub-id>
        <pub-id pub-id-type="pmid">
         16101496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           B-S
          </given-names>
         </name>
         <name>
          <surname>
           National Research Project for Sars
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         26
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         586
        </fpage>
        <lpage>
         589
        </lpage>
       </element-citation>
      </ref>
      <ref id="refS19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <year>
         2005
        </year>
        <volume>
         328
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         979
        </fpage>
        <lpage>
         986
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2005.01.048
        </pub-id>
        <pub-id pub-id-type="pmid">
         15707974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kesel
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A system of protein target sequences for anti-RNA-viral chemotherapy by a vitamin B6-derived zinc-chelating trioxa-adamantane-triol
        </article-title>
        <source>
         Bioorg Med Chem
        </source>
        <year>
         2003
        </year>
        <volume>
         11
        </volume>
        <issue>
         21
        </issue>
        <fpage>
         4599
        </fpage>
        <lpage>
         4613
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0968-0896(03)00500-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         14527557
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Folz
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Elkordy
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer
        </article-title>
        <source>
         Chest
        </source>
        <year>
         1999
        </year>
        <volume>
         115
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         901
        </fpage>
        <lpage>
         905
        </lpage>
        <pub-id pub-id-type="doi">
         10.1378/chest.115.3.901
        </pub-id>
        <pub-id pub-id-type="pmid">
         10084516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS22">
       <label>
        22.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools
        </article-title>
        <source>
         Virol Sin
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1007/s12250-020-00207-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">7035235</pub-id>-->
        <pub-id pub-id-type="pmid">
         32125642
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Acland
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
         <name>
          <surname>
           Gunson
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name>
          <surname>
           Gillette
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ulcerative duodenitis in foals
        </article-title>
        <source>
         Vet Pathol
        </source>
        <year>
         1983
        </year>
        <volume>
         20
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         653
        </fpage>
        <lpage>
         661
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/030098588302000601
        </pub-id>
        <pub-id pub-id-type="pmid">
         6649336
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS24">
       <label>
        24.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Karakiulakis
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S2213-2600(20)30116-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         32171062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS25">
       <label>
        25.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug treatment options for the 2019-new coronavirus (2019-nCoV)
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.5582/bst.2020.01020
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           MHM
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: clinical and laboratory manifestations
        </article-title>
        <source>
         Clin Biochem Rev
        </source>
        <year>
         2004
        </year>
        <volume>
         25
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         121
        </fpage>
        <lpage>
         132
        </lpage>
        <pub-id pub-id-type="pmid">
         18458712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahmud-Al-Rafat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Taufiqur Rahman
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Decoding the enigma of antiviral crisis: does one target molecule regulate all? Cytokine
        </article-title>
        <source>
         Cytokine
        </source>
        <year>
         2019
        </year>
        <volume>
         115
        </volume>
        <fpage>
         13
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cyto.2018.12.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         30616034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           SSY
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K-Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         The management of coronavirus infections with particular reference to SARS
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <year>
         2008
        </year>
        <volume>
         62
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         437
        </fpage>
        <lpage>
         441
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/jac/dkn243
        </pub-id>
        <pub-id pub-id-type="pmid">
         18565970
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Alekseev
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         4420
        </fpage>
        <lpage>
         4428
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02190-07
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2293053</pub-id>-->
        <pub-id pub-id-type="pmid">
         18287230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amici
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Di Caro
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ciucci
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Indomethacin has a potent antiviral activity against SARS coronavirus
        </article-title>
        <source>
         Antivir Ther
        </source>
        <year>
         2006
        </year>
        <volume>
         11
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         1021
        </fpage>
        <lpage>
         1030
        </lpage>
        <pub-id pub-id-type="pmid">
         17302372
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L-X
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J-M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it]
        </article-title>
        <source>
         Zhonghua nei ke za zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         44
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         890
        </fpage>
        <lpage>
         893
        </lpage>
        <pub-id pub-id-type="pmid">
         16409721
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chihrin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Loutfy
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome
        </article-title>
        <source>
         Expert Rev Anti-infect Ther
        </source>
        <year>
         2005
        </year>
        <volume>
         3
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         251
        </fpage>
        <lpage>
         262
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/14787210.3.2.251
        </pub-id>
        <pub-id pub-id-type="pmid">
         15918782
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Michaelis
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells
        </article-title>
        <source>
         Int J Mol Med
        </source>
        <year>
         2005
        </year>
        <volume>
         15
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         323
        </fpage>
        <lpage>
         327
        </lpage>
        <pub-id pub-id-type="pmid">
         15647850
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           AKL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Exp Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         136
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         95
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1365-2249.2004.02415.x
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">1808997</pub-id>-->
        <pub-id pub-id-type="pmid">
         15030519
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <issue>
         Pt 8
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         720
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.05320-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         12867568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tobinick
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection
        </article-title>
        <source>
         Curr Med Res Opin
        </source>
        <year>
         2004
        </year>
        <volume>
         20
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         39
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="doi">
         10.1185/030079903125002757
        </pub-id>
        <pub-id pub-id-type="pmid">
         14741070
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Atanasova
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Van Gucht
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Van Reeth
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-TNF-alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs
        </article-title>
        <source>
         Vet Immunol Immunopathol
        </source>
        <year>
         2010
        </year>
        <volume>
         137
        </volume>
        <issue>
         1–2
        </issue>
        <fpage>
         12
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vetimm.2010.04.003
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2922464</pub-id>-->
        <pub-id pub-id-type="pmid">
         20466438
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS38">
       <label>
        38.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25770
        </pub-id>
        <pub-id pub-id-type="pmid">
         32181911
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Conti
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies
        </article-title>
        <source>
         J Biol Regul Homeost Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         pii:1
        </fpage>
       </element-citation>
      </ref>
      <ref id="refS40">
       <label>
        40.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamaya
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Nishimura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells
        </article-title>
        <source>
         Respir Investig
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/j.resinv.2019.12.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         32094077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E005
        </fpage>
       </element-citation>
      </ref>
      <ref id="refS42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J Korean Medi Sci
        </source>
        <year>
         2016
        </year>
        <volume>
         31
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1717
        </fpage>
        <lpage>
         1725
        </lpage>
        <pub-id pub-id-type="doi">
         10.3346/jkms.2016.31.11.1717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response
        </article-title>
        <source>
         Microb Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         15
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         88
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.micinf.2012.10.008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2011
        </year>
        <volume>
         420
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         106
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2011.09.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         21959016
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           SX
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2009
        </year>
        <volume>
         395
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         210
        </fpage>
        <lpage>
         222
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2009.09.023
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2787736</pub-id>-->
        <pub-id pub-id-type="pmid">
         19853271
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ishii
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hasegawa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Nagata
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model
        </article-title>
        <source>
         Microbiol Immunol
        </source>
        <volume>
         53
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         75
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         19291090
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yoshikawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         3039
        </fpage>
        <lpage>
         3048
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01792-08
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2655569</pub-id>-->
        <pub-id pub-id-type="pmid">
         19004938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         365
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         324
        </fpage>
        <lpage>
         335
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.04.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         17490702
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okabayashi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Kariwa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Yokota
          </surname>
          <given-names>
           S-I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2006
        </year>
        <volume>
         78
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         417
        </fpage>
        <lpage>
         424
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20556
        </pub-id>
        <pub-id pub-id-type="pmid">
         16482545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheng
          </surname>
          <given-names>
           W-H
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           B-L
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           S-C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         J Formosan Med Assoc = Taiwan yi zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         104
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         723
        </lpage>
        <pub-id pub-id-type="pmid">
         16385373
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C-TK
          </given-names>
         </name>
         <name>
          <surname>
           Perrone
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection
        </article-title>
        <source>
         J Immunol
        </source>
        <year>
         2005
        </year>
        <volume>
         174
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         7977
        </fpage>
        <lpage>
         7985
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.174.12.7977
        </pub-id>
        <pub-id pub-id-type="pmid">
         15944304
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           K-J
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           I-J
          </given-names>
         </name>
         <name>
          <surname>
           Theron
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An interferon-gamma-related cytokine storm in SARS patients
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         75
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         185
        </fpage>
        <lpage>
         194
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20255
        </pub-id>
        <pub-id pub-id-type="pmid">
         15602737
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W-K
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S-Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         39
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1071
        </fpage>
        <lpage>
         1075
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/423808
        </pub-id>
        <pub-id pub-id-type="pmid">
         15472864
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Analysis of serum cytokines in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Infect Immun
        </source>
        <year>
         2004
        </year>
        <volume>
         72
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4410
        </fpage>
        <lpage>
         4415
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/IAI.72.8.4410-4415.2004
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">470699</pub-id>-->
        <pub-id pub-id-type="pmid">
         15271897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome
        </article-title>
        <source>
         Chin J Tuberc Respir Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         26
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         586
        </fpage>
        <lpage>
         589
        </lpage>
       </element-citation>
      </ref>
      <ref id="refS56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inflammatory cytokine profile in children with severe acute respiratory syndrome
        </article-title>
        <source>
         Pediatrics
        </source>
        <year>
         2004
        </year>
        <volume>
         113
        </volume>
        <fpage>
         e7
        </fpage>
        <lpage>
         e14
        </lpage>
        <pub-id pub-id-type="doi">
         10.1542/peds.113.1.e7
        </pub-id>
        <pub-id pub-id-type="pmid">
         14702488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Griffin
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Tucker
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         e30
        </fpage>
        <lpage>
         e1
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30304-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The coronavirus transmissible gastroenteritis virus evades the type I interferon response through IRE1alpha-mediated manipulation of the microRNA miR-30a-5p/SOCS1/3 axis
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <issue>
         22
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00728-18
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           C-W
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           Y-Z
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           H-Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Targeting coronaviral replication and cellular JAK2 mediated dominant NF-κB activation for comprehensive and ultimate inhibition of coronaviral activity
        </article-title>
        <source>
         Sci Rep
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         4105
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41598-017-04203-9
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5481340</pub-id>-->
        <pub-id pub-id-type="pmid">
         28642467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wathelet
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Orr
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <issue>
         21
        </issue>
        <fpage>
         11620
        </fpage>
        <lpage>
         11633
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00702-07
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2168762</pub-id>-->
        <pub-id pub-id-type="pmid">
         17715225
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E005
        </fpage>
       </element-citation>
      </ref>
      <ref id="refS63">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miura
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         369
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         288
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.07.030
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2170429</pub-id>-->
        <pub-id pub-id-type="pmid">
         17804032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS64">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zalinger
          </surname>
          <given-names>
           ZB
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus
        </article-title>
        <source>
         J Neurovirol
        </source>
        <year>
         2017
        </year>
        <volume>
         23
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         845
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s13365-017-0574-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5726909</pub-id>-->
        <pub-id pub-id-type="pmid">
         28895072
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS65">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           IY
          </given-names>
         </name>
         <name>
          <surname>
           Moriyama
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           M-F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus viroporin 3a activates the nlrp3 inflammasome
        </article-title>
        <source>
         Front Microbiol
        </source>
        <year>
         2019
        </year>
        <volume>
         10
        </volume>
        <fpage>
         50
        </fpage>
        <pub-id pub-id-type="doi">
         10.3389/fmicb.2019.00050
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">6361828</pub-id>-->
        <pub-id pub-id-type="pmid">
         30761102
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS66">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kritas
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy
        </article-title>
        <source>
         J Biol Regul Homeostat Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         1
        </issue>
       </element-citation>
      </ref>
      <ref id="refS67">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS immunity and vaccination
        </article-title>
        <source>
         Cell Mol Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         1
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         193
        </fpage>
        <lpage>
         198
        </lpage>
        <pub-id pub-id-type="pmid">
         16219167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS68">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <issue>
         Pt 3
        </issue>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.061911-0
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3929173</pub-id>-->
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS69">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Moses
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2018
        </year>
        <volume>
         150
        </volume>
        <fpage>
         155
        </fpage>
        <lpage>
         163
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2017.12.015
        </pub-id>
        <pub-id pub-id-type="pmid">
         29289665
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS70">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           WY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2015
        </year>
        <volume>
         115
        </volume>
        <fpage>
         9
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2014.12.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         25542975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS71">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           RY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         606
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2013.09.029
        </pub-id>
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS72">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2019
        </year>
        <volume>
         93
        </volume>
        <issue>
         12
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00023-19
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS73">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Bauer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <issue>
         9374
        </issue>
        <fpage>
         2045
        </fpage>
        <lpage>
         2046
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13615-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         12814717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS74">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Ghamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Ghandoora
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <year>
         2016
        </year>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         174
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12879-016-1492-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4839124</pub-id>-->
        <pub-id pub-id-type="pmid">
         27097824
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS75">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv392
        </pub-id>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS76">
       <label>
        76.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Bailey
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2006
        </year>
        <volume>
         71
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         53
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2006.03.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         16621037
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS77">
       <label>
        77.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Fisher
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of treatment modalities for Middle East Respiratory Syndrome
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <year>
         2016
        </year>
        <volume>
         71
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         3340
        </fpage>
        <lpage>
         3350
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/jac/dkw338
        </pub-id>
        <pub-id pub-id-type="pmid">
         27585965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS78">
       <label>
        78.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
        </article-title>
        <source>
         Expert Rev Anti Infect Ther
        </source>
        <year>
         2017
        </year>
        <volume>
         15
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         269
        </fpage>
        <lpage>
         275
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/14787210.2017.1271712
        </pub-id>
        <pub-id pub-id-type="pmid">
         27937060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS79">
       <label>
        79.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <year>
         2015
        </year>
        <volume>
         28
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         465
        </fpage>
        <lpage>
         522
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CMR.00102-14
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4402954</pub-id>-->
        <pub-id pub-id-type="pmid">
         25810418
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS80">
       <label>
        80.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabaan
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Alahmed
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Bazzi
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2017
        </year>
        <volume>
         66
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         1261
        </fpage>
        <lpage>
         1274
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.000565
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">7079582</pub-id>-->
        <pub-id pub-id-type="pmid">
         28855003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS81">
       <label>
        81.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2012
        </year>
        <volume>
         165
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         112
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2012.02.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         22349148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS82">
       <label>
        82.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AlGhamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mushtaq
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Awn
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS CoV infection in two renal transplant recipients: case report
        </article-title>
        <source>
         Am J Transplant
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         1101
        </fpage>
        <lpage>
         1104
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/ajt.13085
        </pub-id>
        <pub-id pub-id-type="pmid">
         25716741
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS83">
       <label>
        83.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ma-Lauer
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Malesevic
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir
        </article-title>
        <source>
         Virus Res
        </source>
        <volume>
         184
        </volume>
        <fpage>
         44
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="pmid">
         24566223
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <table-wrap id="table1" position="float">
      <label>
       Table 1.
      </label>
      <caption>
       <title>
        Search terms and the number of studies included for each investigated drug group.
       </title>
      </caption>
      <table frame="border" rules="all">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="1" valign="middle">
          Drug group
         </th>
         <th align="center" colspan="1" rowspan="1" valign="middle">
          Search terms
         </th>
         <th align="center" colspan="1" rowspan="1" valign="middle">
          Number of studies included
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          All cytotoxic
          <break>
          </break>
          chemotherapy
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or Middle East Respiratory Syndrome Coronavirus (MERS-CoV) or SARS-CoV AND
          <break>
          </break>
          chemotherapy)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          24/30
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Low-dose steroids/NSAIDs
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (anti-inflammatory or ibuprofen or isobutylphenylpropionic acid or cortisone or non-steroidal anti-inflammatory)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          13/58
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Any TNF blocker
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (TNF blocker or Anti-TNF therapy or TNFα inhibitor or infliximab or etanercept or Certolizumab or Golimumab or adalimumab))
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2/3
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          IL-6 blockade
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Two different search strategies were explored due to the number of agents that block the IL-6:
          <break>
          </break>
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (Anti-IL-6 therapy or anti-interleukin-6 receptor antibody or anti-interlukin-6 therapy or interlukin 6 blockage or interlukin-6 blockage or IL 6 blockage or IL-6 blockage or tocilizumab or siltuximab or Sylvant or sarilumab or olokizumab or CDP6038 or elsilimomab or BMS-945429 or ALD518 or sirukumab or CNTO 136 or CPSI-2364 or ALX-0061 or clazakizumab or olokizumab or sarilumab or sirukumab or ARGX-109 or FE301 or FM101))
          <break>
          </break>
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) and (IL-6 or interlukin 6 or Anti-IL-6 therapy or IL-6 blockage or tocilizumab or siltuximab))
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
          <break>
          </break>
          23/108
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          JAK inhibitors
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) and (JAK or JAK1 or JAK2 or TYK3 or tofacitinib or baricitinib or filgotinib or peficitinib or ABT494 or decernotinib))
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          4/15
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          IL-1 blockade
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (Interleukin-1 or IL-1 or IL-1RA or canakinumab or anti-IL-1 or IL-1 antagonists or IL-1 blockers or rilonacept or IL-1 trap or ACZ885 or anakinra)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          9/37
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Mycophenylate
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (mycophenolate mofetil OR mycophenolate OR myfortic)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          13/29
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Tacrolimus
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (envarsus or tacni or tacrolimus or prograf or FK506)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          3/18
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Anti-CD20
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (anti-cd20 monoclonal antibodies or anti-cd20 or rituximab or truxima or zevalin or ruxience or rituxan or arzerra or gazyva)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          CTLA4-Ig
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (CTLA-4 Ig or CTLA4 or CTLA-4 or Ipilimumab or yervoy)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Virology
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Virology
      </journal-id>
      <journal-title-group>
       <journal-title>
        Virology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0042-6822
      </issn>
      <issn pub-type="epub">
       1096-0341
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Inc.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       29287230
      </article-id>
      <article-id pub-id-type="pmc">
       7118982
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0042-6822(17)30436-1
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.virol.2017.12.023
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The OC43 human coronavirus envelope protein is critical for infectious virus production and propagation in neuronal cells and is a determinant of neurovirulence and CNS pathology
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Stodola
         </surname>
         <given-names>
          Jenny K.
         </given-names>
        </name>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0010">
        <name>
         <surname>
          Dubois
         </surname>
         <given-names>
          Guillaume
         </given-names>
        </name>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0015">
        <name>
         <surname>
          Le Coupanec
         </surname>
         <given-names>
          Alain
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au0020">
        <name>
         <surname>
          Desforges
         </surname>
         <given-names>
          Marc
         </given-names>
        </name>
        <email>
         marc.desforges@iaf.inrs.ca
        </email>
        <xref ref-type="corresp" rid="cor1">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0025">
        <name>
         <surname>
          Talbot
         </surname>
         <given-names>
          Pierre J.
         </given-names>
        </name>
        <email>
         pierre.talbot@iaf.inrs.ca
        </email>
        <xref ref-type="corresp" rid="cor1">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0005">
       Laboratory of Neuroimmunovirology, INRS-Institut Armand‐ Frappier, Laval, Québec, Canada
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ⁎
        </label>
        Correspondence to: 531, Boulevard des Prairies, Laval, Québec, Canada H7V 1B7.
        <email>
         marc.desforges@iaf.inrs.ca
        </email>
        <email>
         pierre.talbot@iaf.inrs.ca
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         1
        </label>
        <p id="ntp0005">
         Contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        26
       </day>
       <month>
        12
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        2
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        26
       </day>
       <month>
        12
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <volume>
       515
      </volume>
      <fpage>
       134
      </fpage>
      <lpage>
       149
      </lpage>
      <history>
       <date date-type="received">
        <day>
         15
        </day>
        <month>
         11
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         8
        </day>
        <month>
         12
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="accepted">
        <day>
         20
        </day>
        <month>
         12
        </month>
        <year>
         2017
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2017 Elsevier Inc.
       </copyright-statement>
       <copyright-year>
        2017
       </copyright-year>
       <copyright-holder>
        Elsevier Inc.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ab0010">
       <p>
        The OC43 strain of human coronavirus (HCoV-OC43) is an ubiquitous respiratory tract pathogen possessing neurotropic capacities. Coronavirus structural envelope (E) protein possesses specific motifs involved in protein-protein interaction or in homo-oligomeric ion channel formation, which are known to play various roles including in virion morphology/assembly and in cell response to infection and/or virulence. Making use of recombinant viruses either devoid of the E protein or harboring mutations either in putative transmembrane domain or PDZ-binding motif, we demonstrated that a fully functional HCoV-OC43 E protein is first needed for optimal production of recombinant infectious viruses. Furthermore, HCoV-OC43 infection of human epithelial and neuronal cell lines, of mixed murine primary cultures from the central nervous system and of mouse central nervous system showed that the E protein is critical for efficient and optimal virus replication and propagation, and thereby for neurovirulence.
       </p>
      </abstract>
      <abstract abstract-type="author-highlights" id="ab0015">
       <title>
        Highlights
       </title>
       <p>
        <list id="li0005" list-type="simple">
         <list-item id="u0005">
          <label>
           •
          </label>
          <p id="p0005">
           Coronavirus structural envelope (E) protein specific motifs involved in protein-protein interaction or in homo-oligomeric ion channel formation are needed for optimal production of recombinant infectious virus.
          </p>
         </list-item>
         <list-item id="u0010">
          <label>
           •
          </label>
          <p id="p0010">
           Fully functional E protein of HCoV-OC43 is crucial for viral propagation in the CNS and neurovirulence.
          </p>
         </list-item>
         <list-item id="u0015">
          <label>
           •
          </label>
          <p id="p0015">
           Fully functional E protein of HCoV-OC43 is crucial for efficient viral propagation in the central nervous system and thereby for neurovirulence.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <kwd-group id="keys0005">
       <title>
        Keywords
       </title>
       <kwd>
        HCoV-OC43
       </kwd>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        E protein
       </kwd>
       <kwd>
        Transmembrane domain
       </kwd>
       <kwd>
        PDZ binding motif
       </kwd>
       <kwd>
        Virus production
       </kwd>
       <kwd>
        Pathogenesis
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="s0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0020">
      Coronaviruses are widespread RNA viruses of the Nidovirales order, Coronaviridae family, most often associated with human and veterinary respiratory infections (
      <xref ref-type="bibr" rid="bib21">
       de Groot et al., 2012
      </xref>
      ). Of the six human-infecting coronavirus strains, four (HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43) are currently co-circulating and elicit respiratory illnesses (
      <xref ref-type="bibr" rid="bib53">
       Vabret et al., 2009
      </xref>
      ). Coronaviruses also represent a significant public health concern due to the recent zoonotically emerged, highly pathogenic species, SARS corovonavirus (SARS-CoV) (
      <xref ref-type="bibr" rid="bib15">
       Drosten et al., 2003
      </xref>
      ,
      <xref ref-type="bibr" rid="bib29">
       Ksiazek et al., 2003
      </xref>
      ) in 2002–2003 and, since 2012, Middle-East respiratory syndrome coronavirus (MERS-CoV) (
      <xref ref-type="bibr" rid="bib66">
       Zaki et al., 2012
      </xref>
      ), localized to the Arabian Peninsula, but with sporadic travel-related outbreaks worldwide. In addition to their respiratory tropism, human coronaviruses have been detected concurrently with severe and acute neurological symptoms (
      <xref ref-type="bibr" rid="bib3">
       Arabi et al., 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bib36">
       Morfopoulou et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib64">
       Yeh et al., 2004
      </xref>
      ) and shown to naturally infect the central nervous system (CNS) (
      <xref ref-type="bibr" rid="bib4">
       Arbour et al., 2000
      </xref>
      ,
      <xref ref-type="bibr" rid="bib22">
       Gu et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib61">
       Xu et al., 2005
      </xref>
      ) with neurons demonstrated as the main target of infection in HCoV-OC43 (
      <xref ref-type="bibr" rid="bib5">
       Bonavia et al., 1997
      </xref>
      ,
      <xref ref-type="bibr" rid="bib16">
       Favreau et al., 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="bib25">
       Jacomy et al., 2006
      </xref>
      ,
      <xref ref-type="bibr" rid="bib24">
       Jacomy and Talbot, 2003
      </xref>
      ) and SARS-CoV (
      <xref ref-type="bibr" rid="bib22">
       Gu et al., 2005
      </xref>
      ,
      <xref ref-type="bibr" rid="bib61">
       Xu et al., 2005
      </xref>
      ).
     </p>
     <p id="p0025">
      Coronaviruses represent the largest known enveloped RNA (single-stranded positive sense) viruses with a genome of approximately 30 kb (
      <xref ref-type="bibr" rid="bib21">
       de Groot et al., 2012
      </xref>
      ). The viral envelope is composed of four or five proteins, the spike (S), membrane (M), envelope (E) and hemagglutinin-esterase protein (HE), the latter in some β coronaviruses genus, such as HCoV-OC43. Coronavirus E proteins are 74–109 amino acids in length, 84 amino acids for HCoV-OC43, and share only a small amount of sequence identity between coronavirus species. However, its secondary structure, composed of a short N-terminal domain followed by a single hydrophobic transmembrane domain (TMD) and hydrophilic cytoplasmic tail, remains overall conserved and is suggested to be more important than sequence for function (
      <xref ref-type="bibr" rid="bib32">
       Kuo et al., 2007
      </xref>
      ,
      <xref ref-type="bibr" rid="bib51">
       Torres et al., 2005
      </xref>
      ). The importance of the presence of the E protein in the viral envelope is emphasized by the fact that there are only about twenty E molecules incorporated within the virion structure (
      <xref ref-type="bibr" rid="bib20">
       Godet et al., 1992
      </xref>
      ,
      <xref ref-type="bibr" rid="bib35">
       Liu and Inglis, 1991
      </xref>
      ,
      <xref ref-type="bibr" rid="bib65">
       Yu et al., 1994
      </xref>
      ) and deletion of the protein can either completely prevent the production of detectable infectious virions (
      <xref ref-type="bibr" rid="bib1">
       Almazán et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib9">
       Curtis et al., 2002
      </xref>
      ,
      <xref ref-type="bibr" rid="bib41">
       Ortego et al., 2007
      </xref>
      ,
      <xref ref-type="bibr" rid="bib40">
       Ortego et al., 2002
      </xref>
      ) or significantly reduce infectious virus titers (
      <xref ref-type="bibr" rid="bib11">
       DeDiego et al., 2008
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       DeDiego et al., 2007
      </xref>
      ,
      <xref ref-type="bibr" rid="bib32">
       Kuo et al., 2007
      </xref>
      ,
      <xref ref-type="bibr" rid="bib30">
       Kuo and Masters, 2003
      </xref>
      ).
     </p>
     <p id="p0030">
      The majority of the coronavirus E protein in the infected cell is localized within the secretory pathway between the membranes of the endoplasmic reticulum (ER), Golgi and intermediate compartment between them (ERGIC) (
      <xref ref-type="bibr" rid="bib8">
       Cohen et al., 2011
      </xref>
      ,
      <xref ref-type="bibr" rid="bib37">
       Nieto-Torres et al., 2011
      </xref>
      ,
      <xref ref-type="bibr" rid="bib54">
       Venkatagopalan et al., 2015
      </xref>
      ). It is in this intracellular region that additional functions mediated by various domains of the coronavirus E proteins are proposed to occur. Homo-pentameric oligomerization of the E protein TMD in membranes to form ion channels, called viroporins, has been predicted for several coronaviruses (
      <xref ref-type="bibr" rid="bib51">
       Torres et al., 2005
      </xref>
      ) and extensively studied for species such as SARS-CoV (
      <xref ref-type="bibr" rid="bib38">
       Nieto-Torres et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib42">
       Pervushin et al., 2009
      </xref>
      ) or avian infectious bronchitis virus (IBV) (
      <xref ref-type="bibr" rid="bib46">
       Ruch and Machamer, 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="bib58">
       Westerbeck and Machamer, 2015
      </xref>
      ). Another domain found at the extreme C-terminal end of the E protein, a PDZ-domain binding motif (PBM), has also been predicted for several coronavirus species (
      <xref ref-type="bibr" rid="bib27">
       Jimenez-Guardeño et al., 2014
      </xref>
      ). This protein-protein interaction motif capable of interrupting normal cellular functions, has been demonstrated in other viruses to play important roles in replication, dissemination in the host and pathogenesis (
      <xref ref-type="bibr" rid="bib26">
       Javier and Rice, 2011
      </xref>
      ). The multiple properties of coronavirus E proteins have not yet been fully investigated or explained, and can at times differ between coronavirus species. The multifunctionality of the E protein could be explained by the presence of two distinct pools (monomeric versus homo-oligomeric states) present in the infected cell (
      <xref ref-type="bibr" rid="bib58">
       Westerbeck and Machamer, 2015
      </xref>
      ). Furthermore, the different motifs found within the protein (
      <xref ref-type="bibr" rid="bib28">
       Jimenez-Guardeño et al., 2015
      </xref>
      ) could mediate different specific functions. The coronavirus E protein was also recently recognized as an important virulence factor for the SARS-CoV (
      <xref ref-type="bibr" rid="bib27">
       Jimenez-Guardeño et al., 2014
      </xref>
      ), where deletion of the whole or part of the protein led to an attenuated pathology in mouse lungs (
      <xref ref-type="bibr" rid="bib11">
       DeDiego et al., 2008
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       DeDiego et al., 2007
      </xref>
      ), attenuation which was later linked to the E protein TMD and PBM (
      <xref ref-type="bibr" rid="bib27">
       Jimenez-Guardeño et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib38">
       Nieto-Torres et al., 2014
      </xref>
      ).
     </p>
     <p id="p0035">
      HCoV-OC43 represents a circulating strain of human coronavirus causing respiratory illness, which is naturally capable of invading the CNS where neurons are preferentially targeted for infection. In this study, we demonstrate that the fully functional HCoV-OC43 E protein (harboring specific TMD and PBM) is critical in infectious virus production and dissemination in epithelial and neuronal cell cultures and in the murine CNS and that it is a determinant of neurovirulence, a first demonstration for this coronavirus species.
     </p>
    </sec>
    <sec id="s0010">
     <label>
      2
     </label>
     <title>
      Results
     </title>
     <sec id="s0015">
      <label>
       2.1
      </label>
      <title>
       Deletion of HCoV-OC43 E protein abrogates infectious virion production, introduces a strong selection pressure for reversion in progeny production
      </title>
      <p id="p0040">
       In order to evaluate the importance of the HCoV-OC43 E protein in infectious virion production, a stop codon was introduced at the beginning of the E gene of our cDNA infectious clone, pBAC-OC43
       <sup>
        FL
       </sup>
       (
       <xref ref-type="bibr" rid="bib48">
        St-Jean et al., 2006
       </xref>
       ), preventing corresponding full-length E protein production in the resultant recombinant virus (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       A). Transfection of BHK-21 cells with the pBAC-OC43FL led to the detection of reference HCoV-OC43 recombinant infectious virus (rOC/ATCC) whereas transfection with the pBAC-OC43-E-Stop mutant did not lead to any detectable infectious virus (rOC/E-Stop) (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       B).
       <fig id="f0005">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          The HCoV-OC43 E protein is critical for infectious particle production. (A) Representation of the full-length HCoV-OC43 genome found within the pBAC-OC43
          <sub>
           FL
          </sub>
          infectious clone (top) with a schematic representation of the HCoV-OC43 E gene to be modified at various amino acid positions indicated at their relative positions within the protein (bottom). TM, transmembrane; PBM, PDZ-binding motif. (B) Evaluation of infectious virus production corresponding to pBAC-E-Stop transfection of BHK-21 cells compared to pBAC-OC43FL. (C) Insertion of wild-type E gene into pcDNA3.1(+) expression vector, pcDNA(OC-E), yielded corresponding HCoV-OC43 E protein expression compared to empty vector. (D) Visualization of transfection efficiency on BHK-21 cells of various conditions by immunofluorescence detection of HCoV-OC43 S protein (green), nucleus staining with DAPI (blue). Subpanels: (a) mock, (b) pBAC-OC43FL (rOC/ATCC), (c) pBAC-E-Stop (rOC/E-Stop + 2 μg pcDNA(OC-E)), (d) pBAC-E-Stop (rOC/E-Stop + 2 μg pcDNA(empty)). (E) Transient co-transfection of pBAC-E-Stop and 1or 2 μg pcDNA(OC-E) in BHK-21 cells rescued detectable infectious virus in a dose-dependent manner. (* P&lt;0.05) (F) Evaluation of infectious recombinant virus production after transient co-transfection of pBAC-E-Stop and pcDNA(OC-E) in BHK-21 cells (BHK 0). The supernatants (P0) were amplified three times by inoculation of HRT-18 cells (HRT 1–3). Infectious viral titer differences observed between experiments, revealed, by sequencing (G), the appearance of reversions at the position in the E gene where a stop codon was introduced are indicated by bold and underline. LOD, limit of detection. ┼ (cross) indicates appearance of reversion(s) in the HCoV-OC43 E gene in viral stocks as detected by sequencing.
         </p>
        </caption>
        <alt-text id="at0005">
         Fig. 1
        </alt-text>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0045">
       To confirm that the inability to detect infectious viral particles was due to the lack of E protein expression, we wished to verify whether viral production could be rescued with wild-type E protein. Transfection of a plasmid containing the reference HCoV-OC43 E gene, pcDNA(OC-E), in BHK-21 cells clearly showed via Western blot assay (WB) that the E protein was produced compared to an empty plasmid condition (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       C). Subsequently, a transient co-transfection was conducted in the same cells with pBAC-E-Stop and pcDNA(OC-E) and, by making use of a monoclonal antibody against the S protein of HCoV-OC43, we confirmed that the co-transfection did not affect transfection efficiency, and that the viral S protein was produced at equivalent levels in cells transfected with pBAC-OC43
       <sup>
        FL
       </sup>
       alone or pBAC-E-Stop with pcDNA(OC-E) or empty plasmid (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       D). Following the co-transfection, infectious particles production was rescued to detectable levels in a dose-dependent manner (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       E). Viral RNA was harvested and cDNA sequenced to confirm that the infectious particles detected after transfection corresponded to rOC/ATCC and rOC/E-Stop mutant (data not shown).
      </p>
      <p id="p0050">
       As we were able to rescue infectious particles production through transient complementation, we wondered whether this resultant virus, still lacking the E gene, could be amplified further in subsequent passages. To this end, we amplified the viral stocks of all transfected plasmids three times without trans-complementation on HRT-18 epithelial cells, each time normalizing to the lowest detectable viral titer to infect cells at an identical MOI for all recombinant viruses (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       F). Throughout the amplification process we were consistently unable to detect infectious viral particles issuing from viral stocks of rOC/E-Stop. Amplifications of initially complemented viral stocks of rOC/E-Stop led to detectable titers which decreased over the course of each subsequent amplification compared to rOC/ATCC. Sequencing of viral RNA confirmed that the E gene in the viral rOC/E-Stop stocks contained the introduced stop codon at each amplification step (data not shown). These results demonstrate that production of progeny infectious HCoV-OC43 virions is still possible in the absence E protein, however the efficiency of the process is dramatically diminished.
      </p>
      <p id="p0055">
       Interestingly, when conducting independent experiments following the same experimental approach, the titers of initially complemented rOC/E-Stop sometimes increased substantially after two or three amplifications, approaching reference virus titer levels after three rounds of amplification on HRT-18 cells (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       F). Sequence analysis of the E gene of the corresponding viral stocks revealed that a reversion of sequence appeared at the position where the stop codon had been initially introduced; representing reversion to wild-type or new amino acids (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       G). Taken together, these data demonstrate that the HCoV-OC43 E protein is critical for efficient infectious virion production in epithelial cells.
      </p>
     </sec>
     <sec id="s0020">
      <label>
       2.2
      </label>
      <title>
       Neuronal cells are susceptible to infection with HCoV-OC43 lacking E protein but progeny virus production is severely inhibited
      </title>
      <p id="p0060">
       HCoV-OC43 is neuroinvasive (
       <xref ref-type="bibr" rid="bib4">
        Arbour et al., 2000
       </xref>
       ) and neurotropic, with the neuron being the main target of infection in the CNS (
       <xref ref-type="bibr" rid="bib25">
        Jacomy et al., 2006
       </xref>
       ,
       <xref ref-type="bibr" rid="bib24">
        Jacomy and Talbot, 2003
       </xref>
       ). Therefore, we sought to investigate whether the absence of the E protein would modify these neurotropic capacities by infecting a susceptible differentiated human neuronal cell line (LA-N-5) or mixed primary cultures of murine CNS cells. Initially complemented rOC/E-Stop, previously recovered from transfection on BHK-21 cells (P0), was used for infection and infectious viral titers determined over a period of 72 h post-infection (hpi). This revealed an important decrease of infectious virus production for human cells (
       <xref ref-type="fig" rid="f0010">
        Fig. 2
       </xref>
       A), which was exacerbated in primary murine cells, where virus titers were under the limit of detection (
       <xref ref-type="fig" rid="f0010">
        Fig. 2
       </xref>
       B). However, in these primary cultures, low levels of infected cells were visualized by immunofluorescence (IFA) where we detect the viral S protein, suggesting that infection was possible even for the complemented rOC/E-Stop virus but that production of new infectious progeny and eventual propagation were severely inhibited compared to wild type virus (
       <xref ref-type="fig" rid="f0010">
        Fig. 2
       </xref>
       C).
       <fig id="f0010">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          HCoV-OC43 lacking E protein can infect neuronal cells but replication is severely impaired. LA-N-5 (A) and mixed primary mouse CNS cells (B) were infected with supernatant coming from BHK21 supernatant (P0) and containing virus lacking E protein, rOC/E-Stop + pcDNA(empty), or initially complemented virus, rOC/E-Stop + pcDNA(OC-E). Cell-free and cell-associated virus infectious titers were determined over 72 h post-infection. Representative of three different experiments. Statistical significance was tested at 72hpi (*** P &lt; 0.001). (C) IFA on infected mixed primary murine CNS cells over 48 h. Green represents the microtubule associated protein 2 (MAP2) staining in neurons; red represents viral S protein.
         </p>
        </caption>
        <alt-text id="at0010">
         Fig. 2
        </alt-text>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="s0025">
      <label>
       2.3
      </label>
      <title>
       HCoV-OC43 E protein putative transmembrane domain integrity is important for efficient infectious virion production and efficient infection of neuronal cells
      </title>
      <p id="p0065">
       The transmembrane domain (TMD) of some coronavirus E protein is known to homo-oligomerize in membranes and appears to modulate infectious virus production (
       <xref ref-type="bibr" rid="bib38">
        Nieto-Torres et al., 2014
       </xref>
       ). In order to determine the effect of HCoV-OC43 E protein TMD on virus production in cell culture, pBAC-OC43FL was modified at a key amino acid position previously identified in other coronaviruses to be critical for the stability of this specific domain (
       <xref ref-type="bibr" rid="bib38">
        Nieto-Torres et al., 2014
       </xref>
       ,
       <xref ref-type="bibr" rid="bib46">
        Ruch and Machamer, 2012
       </xref>
       ) and compared against wild-type virus during infection of cells. The large, polar glutamine at position 17 of the HCoV-OC43 E protein putative TMD was modified into a smaller, non-polar alanine (pBAC-E-TM-Q17A) in order to diminish any possible ion channel selectivity conveyed by this amino acid (
       <xref ref-type="bibr" rid="bib42">
        Pervushin et al., 2009
       </xref>
       ) at the opening of the putative ion channel.
      </p>
      <p id="p0070">
       Transfection of transmembrane mutant in BHK-21 cells yielded detectable virus titers of rOC/E-TM
       <sub>
        Q17A
       </sub>
       , which was further amplified on HRT-18 cells (P1) to significantly lower titers compared to reference virus (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       A). Infection of human LA-N-5 cells and mixed primary cultures of mouse CNS cells showed a similar virus production kinetic with an initial delay over the first 24hpi in the cell-free fraction (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       B and C, left panels). However, in the cell-associated fractions, the amount of recovered infectious virus particles was almost identical to those of the reference virus (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       B and C, right panels), suggesting a possible defect in virus release. In order to ascertain this potential defect, human LA-N-5 cells were infected with either rOC/ATCC or rOC/E-TM
       <sub>
        Q17A
       </sub>
       , and both infectious titer and viral RNA copies (associated to total viral particles) in the cell-free fraction were quantified at 16 h post-infection (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       D). Only the infectious titer was quantified in the cell-associated fraction as (with our system of q-RT-PCR), we are not able to differentiate between viral genomic and subgenomic RNA and between viral RNA that would be inserted in virion or free in the infected cell. Similar levels of viral infectious particles were measured in the cell-associated fractions for both viruses at 16hpi indicating that the cells have been infected with the same efficiency and that the viral replication early steps are not affected by the alteration of the TMD. However infectious viral titer in the supernatant (cell-free fraction) of cells infected with rOC/E-TM
       <sub>
        Q17A
       </sub>
       was significantly reduced compared to cells infected with rOC/ATCC, although both viruses produced similar amount of total viral particles. These findings are supported by immunofluorescence assay showing a delay in propagation of rOC/E-TM
       <sub>
        Q17A
       </sub>
       over 72 hpi compared to reference virus (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       E, Figure S1A and B).
       <fig id="f0015">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          The putative HCoV-OC43 transmembrane domain plays an important role in infectious virion production, release, replication and propagation in neuronal cells. (A) Production of infectious virus after transfection of E protein transmembrane mutant in BHK-21 cells (BHK 0) and amplification on HRT-18 cells (HRT 1). (B) LA-N-5 human neuronal cells and (C) mixed primary mouse CNS cells were infected with rOC/E-TM
          <sub>
           Q17A
          </sub>
          . Cell-free and cell-associated virus fractions were recovered and tittered over 72 h. The results show a representative experiment. Statistical significance was tested at 72hpi (** P &lt; 0.01; *** P &lt; 0.001). (D) Infectious virus production was evaluated in the cell-associated or cell-free fraction, and total viral RNA (representative of total viral particles production) was quantified by RT-qPCR in the cell-free fraction of rOC/ATCC or rOC/E-TM
          <sub>
           Q17A
          </sub>
          infected cells following 16 h of incubation with 200 nM chloroquine to prevent re-infection. (E) The percentage of LA-N-5 cells infected by the transmembrane mutant (representative of viral propagation) was quantified by immunofluorescence and cell profiler software and compared to the reference virus over 72 h post-infection. LOD, limit of detection.
         </p>
        </caption>
        <alt-text id="at0015">
         Fig. 3
        </alt-text>
        <graphic xlink:href="gr3_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="s0030">
      <label>
       2.4
      </label>
      <title>
       HCoV-OC43 E protein putative C-terminal protein-protein interaction motif is critical for efficient infectious virion production and dissemination
      </title>
      <p id="p0075">
       Bioinformatics analysis and modeling suggest that several coronavirus species possess a PDZ-domain binding motif (PBM) at the extreme C-terminus of their E protein that could interact with cellular and viral proteins (
       <xref ref-type="bibr" rid="bib27">
        Jimenez-Guardeño et al., 2014
       </xref>
       ). We sought to investigate whether the putative four-amino acid E protein PBM of HCoV-OC43 modulates production of infectious particles and infection of susceptible cells. To this end, we modified our cDNA infectious clone to change the two key amino acids of the putative PBM motif, at the −0 and −2 positions from the C-terminal end respectively, into inert alanines, and thereby abrogated putative motif recognition by potential interaction partner(s). Single amino acid mutants (pBAC-OC-E-PBM-D82A and pBAC-OC-E-PBM-V84 A) or double mutant (pBAC-OC-E-PBM-D82A-V84A) (
       <xref ref-type="fig" rid="f0005">
        Fig. 1
       </xref>
       A), were transfected in BHK-21 cells and amplified on HRT-18 cells at the same multiplicity of infection and compared to reference virus (
       <xref ref-type="fig" rid="f0020">
        Fig. 4
       </xref>
       A). Amplification on HRT-18 cells demonstrated that viral titers of the double mutant were significantly decreased compared to other viruses.
       <fig id="f0020">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          A functional PDZ-domain binding motif at the C-terminal end of the HCoV-OC43 E protein is critical for efficient virus production and spread in neuronal cells. (A) Production of infectious virus after transfection of various E protein mutants with fully or partially abrogated predicted PBM after transfection in BHK-21 cells (BHK 0) and amplification on HRT-18 cells (HRT 1). The results show a representative experiment. Cell-free and cell-associated infectious virus production were determined at indicated timepoints after infection at an MOI of 0.05 on (B) LA-N-5 cells and (C) mixed primary cultures of mouse CNS cells. The results show a representative experiment. Statistical significance was tested at 72hpi (** P &lt; 0.01; *** P &lt; 0.001). (D) The percentage of LA-N-5 cells infected by the transmembrane mutant (representative of viral propagation) was quantified by immunofluorescence and cell profiler software and compared to the reference virus over 72 h post-infection. LOD, limit of detection.
         </p>
        </caption>
        <alt-text id="at0020">
         Fig. 4
        </alt-text>
        <graphic xlink:href="gr4_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0080">
       To investigate whether the ability to infect susceptible cells, replicate and disseminate is affected by the putative C-terminal PBM in the context of the CNS, LA-N-5 or mixed primary cultures of murine CNS cells were infected with single or double mutant PBM viruses and viral titers and propagation were analyzed. In LA-N-5 cells, after 18 hpi, the titers of rOC/E-PBM
       <sub>
        D82A-V84A
       </sub>
       were significantly decreased in the cell-free and cell-associated virus fraction compared to single PBM mutants or reference viruses and total infectious virus titers of the double mutant was severely altered over 72 h (
       <xref ref-type="fig" rid="f0020">
        Fig. 4
       </xref>
       B). This trend was exacerbated in primary mixed murine CNS cultures, which showed no detection of infectious rOC/E-PBM
       <sub>
        D82A-V84A
       </sub>
       compared to single mutant PBM and reference viruses (
       <xref ref-type="fig" rid="f0020">
        Fig. 4
       </xref>
       C). As no differences were observed between both single PBM mutant (rOC/E-PBM
       <sub>
        D82A
       </sub>
       and rOC/E-PBM
       <sub>
        V84A
       </sub>
       ) and reference virus, we continued the characterization of the potential PBM only with the double mutant virus (rOC/E-PBM
       <sub>
        D82A-V84A
       </sub>
       ). Immunofluorescence analysis indicated that cells could be infected by all viruses but we detected a significant difference in propagation for both LA-N-5 cells (
       <xref ref-type="fig" rid="f0020">
        Fig. 4
       </xref>
       D, Figure S2A) and primary mixed murine CNS cultures (Figure S2B), showing a significantly reduced propagation for the double PBM mutant rOC/E-PBM
       <sub>
        D82A-V84A
       </sub>
       .
      </p>
     </sec>
     <sec id="s0035">
      <label>
       2.5
      </label>
      <title>
       Deletion of HCoV-OC43 E protein or alteration of its putative TMD and PBM alter its relative infectivity
      </title>
      <p id="p0085">
       Given that the coronavirus E protein is known to play an important role in infectious virion formation and maturation (
       <xref ref-type="bibr" rid="bib21">
        de Groot et al., 2012
       </xref>
       ), we then looked if its deletion or the alteration of its putative functional domains could also alter the total virion production. Using a RT-qPCR approach, the quantity of total viral particles in stocks of rOC/ATCC, rOC/E
       <sub>
        stop
       </sub>
       , rOC/E-TM
       <sub>
        Q17A
       </sub>
       or rOC/E-PBM
       <sub>
        D82A-V84A
       </sub>
       were evaluated and compared to the infectious titer of the corresponding viruses (
       <xref ref-type="fig" rid="f0025">
        Fig. 5
       </xref>
       A). Whereas the reference virus possesses a ratio of infectious virion to total viral particles of approximately 1:100, the rOC/E
       <sub>
        stop
       </sub>
       mutant has a ratio of 1:56 000 correlating with the default in infectious virion production previously observed. Surprisingly, the quantity of total viral particles (evaluated as total RNA copy number by RT-qPCR) was close to the reference virus. The same defect was observed for rOC/E-TM
       <sub>
        Q17A
       </sub>
       but to a lesser extent with a ratio of 1:1065, but it was absent for the rOC/E-PBM
       <sub>
        D82A-V84A
       </sub>
       mutant. Indeed, even though this latter mutant produces less virions compared to the reference virus, a very high proportion of them are infectious, as the ratio of infectious over total particles is about 1:2 (
       <xref ref-type="fig" rid="f0025">
        Fig. 5
       </xref>
       A). These observations of modified ratio were confirmed by immunofluorescence comparing the percentage of infected cells when the quantity of virus used for the infection of LA-N-5 cells was normalized either to the number of infectious virions or to the number of total viral particles (
       <xref ref-type="fig" rid="f0025">
        Fig. 5
       </xref>
       B). All these findings demonstrate that the HCoV-OC43 E protein is critical for efficient replication in epithelial and neuronal cells, and that its functional domains play important and potentially distinct roles during the production of new infectious virions.
       <fig id="f0025">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          <bold>
           HCoV-OC43 E protein and its putative TMD and PBM modulate relative virus infectivity.
          </bold>
          (A) Infectivity assay between viruses: quantification of viral RNA in viral stocks (absolute quantity in RNA copy representative of total viral particles) and of the number of infectious particles in viral stocks. Ratio of infectious to total viral particles are indicated over each virus. (B) The percentage of LA-N-5 cells infected by the different viruses was quantified by immunofluorescence and cell profiler software at 16hpi in the presence of 200 µM Chloroquine (reinfection inhibitor). Infection were performed with amount of viruses normalized either on the quantity of viral RNA (total particles) or on the number of infectious viral particles. (** P &lt; 0.01; *** P &lt; 0.001).
         </p>
        </caption>
        <alt-text id="at0025">
         Fig. 5
        </alt-text>
        <graphic xlink:href="gr5_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="s0040">
      <label>
       2.6
      </label>
      <title>
       Fully competent HCoV-OC43 E protein is not essential for neuroinvasion but is a determinant factor of neurovirulence
      </title>
      <p id="p0090">
       As HCoV-OC43 is naturally neuroinvasive and neurovirulent in mice (
       <xref ref-type="bibr" rid="bib6">
        Brison et al., 2011
       </xref>
       ,
       <xref ref-type="bibr" rid="bib14">
        Desforges et al., 2014
       </xref>
       ,
       <xref ref-type="bibr" rid="bib34">
        Le Coupanec et al., 2015
       </xref>
       ) and that the E protein is important for efficient propagation in neuronal cells (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       ,
       <xref ref-type="fig" rid="f0020">
        Fig. 4
       </xref>
       ), we wished to investigate the importance of the two functional domains of E in the process of neuroinvasion. Seven-day-old C57Bl/6 mice were infected and RT-qPCR performed at 5 days post-infection on complete brain revealed that mutant viruses were still neuroinvasive compared to the reference virus, however the copy number of viral RNA was significantly lower for both mutants (
       <xref ref-type="fig" rid="f0030">
        Fig. 6
       </xref>
       A). This indicates that the TMD and PBM are not essential for HCoV-OC43 neuroinvasion. Moreover, it is interesting to note that the 4 mice (3 infected with the reference virus, and one with the TMD mutant) with a high number of viral RNA copy (&gt;10
       <sup>
        13
       </sup>
       ) were the only ones to show signs of illness at 5 dpi.
       <fig id="f0030">
        <label>
         Fig. 6
        </label>
        <caption>
         <p>
          A fully functional HCoV-OC43 E protein is associated with optimal neuroinvasion and increases neurovirulence. (A) 7-day-old C57Bl/6 mice received 10
          <sup>
           3
          </sup>
          TCID
          <sub>
           50
          </sub>
          /20 µL of rOC/ATCC, rOC/E-TM
          <sub>
           Q17A
          </sub>
          or rOC/E-PBM
          <sub>
           D82A-V84A
          </sub>
          by the IN route. Neuroinvasion was detected and quantified by RT-qPCR on brain RNA at 5 days post-infection, each point represents a single mouse. (B) Twenty-two-day-old C57Bl/6 mice received 10
          <sup>
           2.5
          </sup>
          TCID
          <sub>
           50
          </sub>
          /10 µL of rOC/ATCC, rOC/E-TM
          <sub>
           Q17A
          </sub>
          or rOC/E-PBM
          <sub>
           D82A-V84A
          </sub>
          by the IC route and were observed for survival over 21 days following the injection. (C) Infected mice were weighted every 2 days for a period of 21 days following infection. The weight gain is shown as percentage of d0 set at 100%. (D) Evaluation of the clinical scores (percentage of mice at each level of the scale) of mice infected by rOC/ATCC, rOC/E-TM
          <sub>
           Q17A
          </sub>
          or rOC/E-PBM
          <sub>
           D82A-V84A
          </sub>
          based on neurological symptoms described in clinical score scale between level 0 and 4 over a period of 21 days (see Materials and methods). Representative of three different experiments. (* P &lt; 0.05; ** P &lt; 0.01; *** P &lt; 0.001).
         </p>
        </caption>
        <alt-text id="at0030">
         Fig. 6
        </alt-text>
        <graphic xlink:href="gr6_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0095">
       To investigate the role of the E protein in the induction of HCoV-OC43-induced neurological pathology, 22-day-old C57Bl/6 mice were intracerebrally infected with either rOC/ATCC, rOC/E-TM
       <sub>
        Q17A
       </sub>
       or rOC/E-PBM
       <sub>
        D82A-V84A
       </sub>
       , and the development of illness was monitored for 21 days after infection. During this period, only mice infected with the reference virus died, all other mice survived the infection (
       <xref ref-type="fig" rid="f0030">
        Fig. 6
       </xref>
       B). Moreover, mice infected with rOC/E-PBM
       <sub>
        D82A-V84A
       </sub>
       did not show any significant differences of weight gain compared to sham infected mice (
       <xref ref-type="fig" rid="f0030">
        Fig. 6
       </xref>
       C), nor did they show any sign of neurological disease compared to mice infected with the reference virus (
       <xref ref-type="fig" rid="f0030">
        Fig. 6
       </xref>
       D). However, mice infected with rOC/E-TM
       <sub>
        Q17A
       </sub>
       showed an intermediate weight gain profile between mice infected with the reference virus and the sham infected mice (
       <xref ref-type="fig" rid="f0030">
        Fig. 6
       </xref>
       C), suggesting that these mice were developing a disease, which was confirmed by the neurological symptoms developed by several mice, although to a lesser extent than mice infected with the reference virus (
       <xref ref-type="fig" rid="f0030">
        Fig. 6
       </xref>
       D). Mice infected with rOC/E
       <sub>
        stop
       </sub>
       did not show any signs of illness whether in terms of weight gain, or neurological symptoms (Figure S3A-C).
      </p>
     </sec>
     <sec id="s0045">
      <label>
       2.7
      </label>
      <title>
       HCoV-OC43 E protein and its TMD and PBM are essential for efficient replication in the murine CNS
      </title>
      <p id="p0100">
       As HCoV-OC43 E protein and its functional domains modulate viral replication and propagation in human and murine neuronal cultures (
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       ,
       <xref ref-type="fig" rid="f0020">
        Fig. 4
       </xref>
       ), we examined if the differences in neurovirulence observed (
       <xref ref-type="fig" rid="f0030">
        Fig. 6
       </xref>
       ) were also to be associated with defective infectious virus productions and propagation in the CNS. Infection of 22-day-old C57Bl/6 mice with reference and E protein mutants revealed that the infectious titer in the brain (
       <xref ref-type="fig" rid="f0035">
        Fig. 7
       </xref>
       A) and the spinal cord (
       <xref ref-type="fig" rid="f0035">
        Fig. 7
       </xref>
       B) was significantly reduced for the TMD mutant. This altered replication in the brain correlates with an extremely weak production in the spinal cord, where infectious virions were detected in only one mouse at 5 dpi. Production of infectious particles was under the limit of detection in mice infected with the PBM mutant, correlating with the total absence of neurovirulence (
       <xref ref-type="fig" rid="f0030">
        Fig. 6
       </xref>
       ). However, the PBM mutant RNA was detected in the brain at 5 and 9 dpi, although at a lower level than the reference virus or the TMD mutant (
       <xref ref-type="fig" rid="f0035">
        Fig. 7
       </xref>
       C), indicating that this virus was capable of replicating at a low level in the brain. Similar observations were obtained following mouse infection with rOC/E
       <sub>
        stop
       </sub>
       (
       <xref ref-type="sec" rid="s0145">
        Fig. S3D
       </xref>
       ). Viral RNA of each mutant was extracted at 5 and 9 dpi and sequenced for the E and M gene. No reversion in the targeted genes were observed (data not shown), indicating that the inserted mutations are stable during replication in the murine brain for at least 9 days. It is interesting to note than when infected with a higher viral dose (10
       <sup>
        2.5
       </sup>
       TCID
       <sub>
        50
       </sub>
       /10 µL vs 10
       <sup>
        1.5
       </sup>
       TCID
       <sub>
        50
       </sub>
       /10 µL), infectious virions of the PBM mutant could be detected in low amount in the brain of mice (Figure S4A). Our system only allows to detect infectious titer over 10
       <sup>
        2.5
       </sup>
       . Thus, the apparent (but very low) increase of infectious virus production observed at 10–11 days post-infection may be explained by the fact that the PBM mutant replicates at very low level between 3 and 11 days pi and that, by doing this, this mutant could be able to avoid detection by the immune system and delay its clearance from the CNS. Viral RNA was also detected in both the brain and spinal cord (Figure S4B and C). Sequencing of the E and M genes again revealed the absence of reversion, again suggesting that the absence of detectable infectious virion production previously observed (
       <xref ref-type="fig" rid="f0035">
        Fig. 7
       </xref>
       ) was probably due to the low infectious dose. Taken together, these data demonstrate that a fully competent E protein (with both functional TMD and PBM) is essential for HCoV-OC43 neurovirulence in association with efficient replication in the CNS, correlating with the early observations in neuronal cells (
       <xref ref-type="fig" rid="f0010">
        Fig. 2
       </xref>
       ,
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       ,
       <xref ref-type="fig" rid="f0020">
        Fig. 4
       </xref>
       ).
       <fig id="f0035">
        <label>
         Fig. 7
        </label>
        <caption>
         <p>
          The E protein TM and PBM domain are essential for optimal replication in the murine brain and spinal cord. Infectious viral particles were quantified in (A) the brains and (B) the spinal cord of 22-day-old C57Bl/6 mice infected by the IC route with 10
          <sup>
           1.5
          </sup>
          TCID
          <sub>
           50
          </sub>
          /10 µL rOC/ATCC, rOC/E-TM-Q17A or rOC/E-PBM-82–84 over a period of 15 days. (C) Viral RNA was detected and quantified by RT-qPCR in the brain of infected mice at 5 and 9 days post-infection. LOD, limit of detection. Representative of three different experiments.
         </p>
        </caption>
        <alt-text id="at0035">
         Fig. 7
        </alt-text>
        <graphic xlink:href="gr7_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="s0050">
      <label>
       2.8
      </label>
      <title>
       The putative TMD decreases HCoV-OC43 propagation in the murine brain
      </title>
      <p id="p0105">
       When infection was performed at a 10
       <sup>
        1.5
       </sup>
       TCID
       <sub>
        50
       </sub>
       /10 µL dose, only the E protein TMD mutant produced detectable virions in the brain (infectious virus is under the limit of detection for PBM mutant). However, this production was significantly lowered compared to reference virus. Therefore, based on data obtained in neuronal cultures (
       <xref ref-type="fig" rid="f0010">
        Fig. 2
       </xref>
       ,
       <xref ref-type="fig" rid="f0015">
        Fig. 3
       </xref>
       ,
       <xref ref-type="fig" rid="f0020">
        Fig. 4
       </xref>
       ), we investigated if the TMD mutation also induced a defect in propagation within the brain. Brains of mice infected intracerebrally with rOC/ATCC or rOC/E-TM
       <sub>
        Q17A
       </sub>
       were harvested at 3 and 7 dpi, and viral spreading was observed by immunofluorescence. Whereas the reference virus had already infected the hippocampus at 3 days post-infection (with positive cells around the lateral ventricle and in the hypothalamus), and then continued to spread until the rest of the brain was infected at 7 dpi (
       <xref ref-type="fig" rid="f0040">
        Fig. 8
       </xref>
       left panels), the rOC/E-TM
       <sub>
        Q17A
       </sub>
       presented an important delay in spreading as only a few number of infected cells were visible at 3 dpi except for a small focus of infection around the hippocampus and the lateral ventricle. Spreading then occurred to the same brain regions compared to reference virus but to a much lower extent (
       <xref ref-type="fig" rid="f0040">
        Fig. 8
       </xref>
       right panels). This suggests that although the TMD mutant seems to follow the same spreading path in the murine brain, its spreading is greatly delayed and underlines the fact that HCoV-OC43 E protein TMD is important for efficient propagation in the murine brain.
       <fig id="f0040">
        <label>
         Fig. 8
        </label>
        <caption>
         <p>
          HCoV-OC43 E protein putative TM domain is required for efficient spreading in mouse CNS. Viral spreading in mice brain was examined by immunofluorescence at 3 and 7 days post-infection. The virus was detected using an antibody against the HCoV-OC43 S protein (green) and nuclei were detected using DAPI (blue). Small white arrows point to isolated infected cells. Brain regions: 1, Olfactory Bulb; 2, Lateral Ventricle; 3, Hippocampus; 4, Brainstem; 5, Hypothalamus.
         </p>
        </caption>
        <alt-text id="at0040">
         Fig. 8
        </alt-text>
        <graphic xlink:href="gr8_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="s0055">
     <label>
      3
     </label>
     <title>
      Discussion
     </title>
     <p id="p0110">
      In this study, by modifying a full-length cDNA infectious clone of the human HCoV-OC43 virus, we demonstrate that E protein is critical for the production of infectious virions, as transient complementation with wild type E protein rescued infectious viral production and a strong selection pressure to revert to a functional E protein was observed. Moreover, mutations of specific domains revealed that a fully functional protein participate in the efficient viral spreading, associated with neuropathogenesis.
     </p>
     <p id="p0115">
      Deletion of the E protein leads to varying degrees of defects for coronaviruses. Indeed, whereas murine hepatitis virus (MHV) and SARS-CoV are attenuated, showing a reduced ability to produce infectious virus without E protein, in a cell-type specific manner (
      <xref ref-type="bibr" rid="bib11">
       DeDiego et al., 2008
      </xref>
      ,
      <xref ref-type="bibr" rid="bib10">
       DeDiego et al., 2007
      </xref>
      ,
      <xref ref-type="bibr" rid="bib28">
       Jimenez-Guardeño et al., 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bib30">
       Kuo and Masters, 2003
      </xref>
      ), transmissible gastroenteritis virus (TGEV) (
      <xref ref-type="bibr" rid="bib40">
       Ortego et al., 2002
      </xref>
      ) and MERS-CoV (
      <xref ref-type="bibr" rid="bib1">
       Almazán et al., 2013
      </xref>
      ) are replication competent, but completely propagation defective, with no detectable infectious virus production when the E protein is deleted. Similarly, we were able to rescue infectious rOC/E
      <sub>
       stop
      </sub>
      production by providing wild-type E protein in trans, as the recovery of initially complemented rOC/E
      <sub>
       stop
      </sub>
      through complementation, and amplification on epithelial cells yielded detectable infectious virus (
      <xref ref-type="fig" rid="f0005">
       Fig. 1
      </xref>
      ). As suggested for MERS-CoV (
      <xref ref-type="bibr" rid="bib1">
       Almazán et al., 2013
      </xref>
      ), the apparent low titer detected after the first passage on HRT-18 cells (especially at P1), could be due to a transfer of detached cells transfected with the initially complemented pBAC-OC43-E-Stop. Furthermore, the production of infectious particles (for initially complemented mutant lacking the E protein) was low and decreased with subsequent amplification attempts. On the other hand, these results also suggest that production of infectious virions without E protein is possible but with severely affected efficiency, underlining the requirement of a fully functional E protein. Coronavirus E protein has been suggested to allow correct virion formation in part by inhibiting M protein aggregation (
      <xref ref-type="bibr" rid="bib32">
       Kuo et al., 2007
      </xref>
      ), or by inducing scission events at the ERGIC (
      <xref ref-type="bibr" rid="bib18">
       Fischer et al., 1998
      </xref>
      ). Our data indicate that while reducing dramatically the quantity of infectious viral particles formed, the complete abrogation of HCoV-OC43 E protein did not significantly alter the quantity of total viral particles produced compared to the reference virus (
      <xref ref-type="fig" rid="f0025">
       Fig. 5
      </xref>
      ), suggesting that the protein is important for efficient virion maturation that lead to good infectivity.
     </p>
     <p id="p0120">
      This concept is emphasized by the appearance of recombinant HCoV-OC43 E protein revertants at a very low passage number (P2 or P3) on HRT-18 cells. Indeed, the appearance of revertants with different E sequences after only a few rounds of amplification on HRT-18 cells indicates that low level of viral particles must have been produced earlier during the process as we already observed previously for HE-deleted recombinant HCoV-OC43 (
      <xref ref-type="bibr" rid="bib13">
       Desforges et al., 2013
      </xref>
      ). We observed strong selective pressure at the position where we introduced a stop codon where nucleotide changes led to reversion to reference E sequence or to another amino acid residue (tryptophan or leucine). It was previously described that SARS-CoV (
      <xref ref-type="bibr" rid="bib28">
       Jimenez-Guardeño et al., 2015
      </xref>
      ) and MHV (
      <xref ref-type="bibr" rid="bib31">
       Kuo and Masters, 2010
      </xref>
      ) E protein deletion mutants underwent compensatory mutations after a few passages in culture to utilize a partially duplicated version of the adjacent M protein to recover partial virus production. A second type of reversion was observed for SARS-CoV E protein deletion mutant after an intranasal infection of susceptible mice as the small transmembrane ion channel forming 8a was modified to incorporate a potential PBM associated with increased infectious virus production compared to E protein deletion mutant (
      <xref ref-type="bibr" rid="bib28">
       Jimenez-Guardeño et al., 2015
      </xref>
      ). Our results support the hypothesis that there is selective pressure to specifically restore the E protein functionality itself without partial duplication of the M gene (data not shown), however, it is important to note that we only introduced a stop codon at the beginning of the E gene instead of deleting part or all of the gene, as it was done for SARS-CoV and MHV (
      <xref ref-type="bibr" rid="bib28">
       Jimenez-Guardeño et al., 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bib31">
       Kuo and Masters, 2010
      </xref>
      ). A recombinant HCoV-OC43 in which the E gene would have been deleted could have used the same reversion process in other viral gene.
     </p>
     <p id="p0125">
      Production of infectious virus was reduced after infection of neuronal cell cultures with initially complemented rOC/E
      <sub>
       stop
      </sub>
      compared to reference virus. Immunofluorescence assay for viral proteins confirmed these latter results showing no defect in entry for the initially complemented rOC/E
      <sub>
       stop
      </sub>
      virus compared to reference virus at 16 hpi, while observations at 48 h indicated an important defect of viral propagation (
      <xref ref-type="fig" rid="f0010">
       Fig. 2
      </xref>
      ). A decrease in virus spread was also reported for MHV (
      <xref ref-type="bibr" rid="bib32">
       Kuo et al., 2007
      </xref>
      ,
      <xref ref-type="bibr" rid="bib30">
       Kuo and Masters, 2003
      </xref>
      ) and SARS-CoV (
      <xref ref-type="bibr" rid="bib10">
       DeDiego et al., 2007
      </xref>
      ) ΔE mutants which formed smaller and less numerous plaques.
     </p>
     <p id="p0130">
      The coronavirus E protein is now considered as a virulence factor (reviewed extensively in (
      <xref ref-type="bibr" rid="bib12">
       DeDiego et al., 2014
      </xref>
      )) and there have been extensive efforts to characterize the different domains of this relatively small transmembrane protein and the possibility that it acts as a viroporin, with ion channel activity. The TMD of several coronavirus E proteins (including HCoV-OC43) was predicted (
      <xref ref-type="bibr" rid="bib51">
       Torres et al., 2005
      </xref>
      ) and shown to form ion channels permeable to small cations in artificial membranes for species such as IBV, MHV, HCoV-229E (
      <xref ref-type="bibr" rid="bib60">
       Wilson et al., 2006
      </xref>
      ), MERS-CoV (
      <xref ref-type="bibr" rid="bib49">
       Surya et al., 2015
      </xref>
      ) and SARS-CoV (
      <xref ref-type="bibr" rid="bib59">
       Wilson et al., 2004
      </xref>
      ). Furthermore, it was demonstrated that the IBV E protein can exist in a penta-oligomeric state (
      <xref ref-type="bibr" rid="bib58">
       Westerbeck and Machamer, 2015
      </xref>
      ), and that for MERS-CoV (
      <xref ref-type="bibr" rid="bib49">
       Surya et al., 2015
      </xref>
      ) and SARS-CoV (
      <xref ref-type="bibr" rid="bib42">
       Pervushin et al., 2009
      </xref>
      ,
      <xref ref-type="bibr" rid="bib52">
       Torres et al., 2006
      </xref>
      ,
      <xref ref-type="bibr" rid="bib56">
       Verdiá-Báguena et al., 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib55">
       Verdiá-Báguena et al., 2012
      </xref>
      ), it forms pentameric channels in lipid membranes. Chemical inhibition of ion channel activity (
      <xref ref-type="bibr" rid="bib60">
       Wilson et al., 2006
      </xref>
      ), destruction of the integrity of (
      <xref ref-type="bibr" rid="bib2">
       Almazán et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib44">
       Regla-Nava et al., 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bib63">
       Ye and Hogue, 2007
      </xref>
      ) or replacement of the TMD with those of other viral species (
      <xref ref-type="bibr" rid="bib45">
       Ruch and Machamer, 2011
      </xref>
      ) all led to reduced viral titers for other coronaviruses species. The E protein of coronaviruses is largely localized within the secretory pathway (
      <xref ref-type="bibr" rid="bib8">
       Cohen et al., 2011
      </xref>
      ,
      <xref ref-type="bibr" rid="bib37">
       Nieto-Torres et al., 2011
      </xref>
      ,
      <xref ref-type="bibr" rid="bib54">
       Venkatagopalan et al., 2015
      </xref>
      ) where it has recently been described for IBV to exist in two different pools; one of monomeric E proteins that disrupt the secretory pathway and a second pool in an oligomeric state, likely serving to facilitate the assembly of progeny virions (
      <xref ref-type="bibr" rid="bib58">
       Westerbeck and Machamer, 2015
      </xref>
      ). The transient delay in infectious virus release observed for the TMD mutant compared to the reference virus (
      <xref ref-type="fig" rid="f0015">
       Fig. 3
      </xref>
      ) suggests a defect in virus release that could be the result of damaged infectious particles as it was observed for IBV, for which a TMD mutant of the E protein induces a similar defect associated with increased quantity of non-infectious viral particles released possessing a cleaved S protein near the virion surface (
      <xref ref-type="bibr" rid="bib45">
       Ruch and Machamer, 2011
      </xref>
      ). Considering the higher proportion of non-infectious virions released by cells infected with the TMD mutant compared to cells infected with the reference virus (
      <xref ref-type="fig" rid="f0015">
       Figs. 3
      </xref>
      D and
      <xref ref-type="fig" rid="f0025">
       5
      </xref>
      A), a similar process consisting in an alteration of infectious virions in the secretory pathway may also be involved here, suggesting an important role for TMD within the cellular secretory pathway. Furthermore, mutation at homologous position T16 of IBV did not have an effect on VLP formation but rather was required for secretory pathway disruption (
      <xref ref-type="bibr" rid="bib46">
       Ruch and Machamer, 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="bib58">
       Westerbeck and Machamer, 2015
      </xref>
      ). These results suggest that mutation Q17A (homologous to IBV T16A) in the HCoV-OC43 E protein putative TMD plays a role in modulating infectious virus release from infected cells.
     </p>
     <p id="p0135">
      A four-amino acid C-terminal PBM protein-protein interaction motif has been predicted for HCoV-OC43 (
      <xref ref-type="bibr" rid="bib27">
       Jimenez-Guardeño et al., 2014
      </xref>
      ). Through the replacement of the key amino acids of this motif by alanines, we demonstrated its importance in infectious virion production in the epithelial and neuronal cells tested (
      <xref ref-type="fig" rid="f0020">
       Fig. 4
      </xref>
      ). Defective propagation without an effect on the ability to infect cells was observed with the recombinant virus with an abrogated putative PBM. Deletion of the PBM in SARS-CoV E protein led to slight decreases in viral titers in some cell types (
      <xref ref-type="bibr" rid="bib27">
       Jimenez-Guardeño et al., 2014
      </xref>
      ) while in others viral titers remained unaffected (
      <xref ref-type="bibr" rid="bib44">
       Regla-Nava et al., 2015
      </xref>
      ). Our data on HCoV-OC43 reveal significant infectious virus production defects in an epithelial cell line which was further accentuated in neurons, but only after infection by the double mutant rOC/E-PBM
      <sub>
       D82A-V84A
      </sub>
      , suggesting that HCoV-OC43 replication in cultured cells can tolerate a slight flexibility in the putative PBM sequence. Among coronavirus E proteins, only the SARS-CoV E protein has been shown to per se possess such a functional motif, which interacts with PALS1 to disturb secretory pathway membranes to alter tight junction formation (
      <xref ref-type="bibr" rid="bib50">
       Teoh et al., 2010
      </xref>
      ) and syntenin to play a role in the exacerbated inflammatory response typical of infection via p38 MAPK activation (
      <xref ref-type="bibr" rid="bib27">
       Jimenez-Guardeño et al., 2014
      </xref>
      ). For SARS-CoV E protein, the PBM is suggested to be important in two independent functions: virus stability and virulence/pathogenesis rather than virus production (
      <xref ref-type="bibr" rid="bib28">
       Jimenez-Guardeño et al., 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bib27">
       Jimenez-Guardeño et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib44">
       Regla-Nava et al., 2015
      </xref>
      ). Given that the functions of PBM is dependent on their sequence and surrounding sequence context (
      <xref ref-type="bibr" rid="bib62">
       Ye and Zhang, 2013
      </xref>
      ), further study of the HCoV-OC43 E protein neuronal interactome is warranted and could provide new insights on the precise function of the protein in infected cells. Prevention of a functional interaction between HCoV-OC43 E protein PBM and its PDZ domain-containing ligand could conceivably function in the same vein as seen in case of neurotropic encephalitic rabies virus, for which differences in disease phenotype, rapid versus attenuated spread of virus infection, was attributed to differences in PBM sequences on the C-terminal of the rabies envelope glycoprotein G leading to different cellular interaction partners to mediate either neuronal cell survival or death (
      <xref ref-type="bibr" rid="bib43">
       Préhaud et al., 2010
      </xref>
      ). Surprisingly, the PBM mutant forms less total viral particles but almost all of them are infectious. As protein-protein interaction motifs, viral PBM are involved in a variety of processes, including viral particle assembly and maturation (
      <xref ref-type="bibr" rid="bib26">
       Javier and Rice, 2011
      </xref>
      ). Abrogation of the E PBM, could prevent critical cellular and/or viral interaction necessary for the rapid and efficient formation and maturation of viral particles, making propagation highly inefficient.
     </p>
     <p id="p0140">
      The SARS-CoV E protein is critical for neuroinvasiveness in susceptible mice (
      <xref ref-type="bibr" rid="bib11">
       DeDiego et al., 2008
      </xref>
      ). HCoV-OC43 E protein seems to differ from its SARS-CoV homolog as viral RNA is present in the brain of all mice intranasally infected with either the reference virus, the TMD mutant or the PBM mutant (
      <xref ref-type="fig" rid="f0030">
       Fig. 6
      </xref>
      -A), indicating that the fully functional protein is not essential for neuroinvasion. On the other hand, the amount of viral RNA was significantly lower in the brain of E mutant-infected mice. Although we cannot rule out that these data represent a difference in replication and propagation once the virus is already in the brain, optimal HCoV-OC43 neuroinvasion may necessitate a fully functional E protein. The SARS-CoV E protein was recently described as an important virulence factor during infection of the lungs, being in part responsible for the immune response exacerbation (
      <xref ref-type="bibr" rid="bib27">
       Jimenez-Guardeño et al., 2014
      </xref>
      ), the lung epithelium destruction (
      <xref ref-type="bibr" rid="bib50">
       Teoh et al., 2010
      </xref>
      ), and edema accumulation in the lungs (
      <xref ref-type="bibr" rid="bib38">
       Nieto-Torres et al., 2014
      </xref>
      ). We demonstrate here that HCoV-OC43 E protein deletion as well as abrogation of the putative PBM prevented neurological symptoms following CNS infection, correlating with replication and propagation observations in epithelial and neuronal cells (
      <xref ref-type="fig" rid="f0030">
       Fig. 6
      </xref>
      ). Disappearance of respiratory tract disease was observed for SARS-CoV in which E PBM was abrogated, preventing interaction of the viral protein with the PDZ-containing protein syntenin (
      <xref ref-type="bibr" rid="bib27">
       Jimenez-Guardeño et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib44">
       Regla-Nava et al., 2015
      </xref>
      ). The absence of neurological symptoms following infection by either rOC/E
      <sub>
       stop
      </sub>
      or rOC/E-PBM
      <sub>
       D82A-V84A
      </sub>
      could potentially be linked to glutamate excitotoxicity that we have previously observed in mice (
      <xref ref-type="bibr" rid="bib6">
       Brison et al., 2011
      </xref>
      ), possibly by interfering with PDZ-domain containing proteins found in neuronal cells (
      <xref ref-type="bibr" rid="bib17">
       Feng and Zhang, 2009
      </xref>
      ). We also demonstrate that HCoV-OC43 putative TMD plays a role in the neuropathogenesis following the CNS infection, albeit to a lesser extent than its PBM. Indeed, infected mice showed some neurological symptoms, even if their severity and frequency were lower than for the reference virus. This attenuated phenotype was also associated with reduced viral particles production and propagation in the CNS. Homologous mutation at the position 15 of SARS-CoV E protein also led to an attenuated pathology, although infectious viral particle production was not significantly affected compared to wild-type virus (
      <xref ref-type="bibr" rid="bib38">
       Nieto-Torres et al., 2014
      </xref>
      ). Taken together, these results demonstrate that HCoV-OC43 E protein is a virulence factor, with TMD and PBM being important determinants in that matter.
     </p>
     <p id="p0145">
      In summary, the current study demonstrates the critical importance of a fully functional HCoV-OC43 E protein in infectious virus production and efficient spread in both epithelial and neuronal cells. Modifications to key amino acids in putative functionally important domains modulated infectious virion production and delayed virus spread in human and murine neuronal cells and within mouse CNS. This points towards the presence of a true TMD, which has a role in the secretory pathway, as seen for other coronaviruses and that the HCoV-OC43 E protein putative C-terminal PBM plays a significant role in infectious virion production as well as efficient virus spread. In addition, this study establishes a clear link between both putative functional domains of HCoV-OC43 E protein and CNS pathogenesis. Functional viroporins and viral PBM are associated with viral pathogenesis for a growing number of viruses and their studies to better understand virus-host interaction represent an emerging field (
      <xref ref-type="bibr" rid="bib26">
       Javier and Rice, 2011
      </xref>
      ,
      <xref ref-type="bibr" rid="bib39">
       Nieva et al., 2012
      </xref>
      ,
      <xref ref-type="bibr" rid="bib47">
       Scott and Griffin, 2015
      </xref>
      ). Considering that the HCoV-OC43 E protein seems to possess both functions and that they seem to be important for the induction of disease, future studies regarding their functionality and underlying mechanisms resulting in HCoV-OC43 neuropathogenesis previously described (
      <xref ref-type="bibr" rid="bib6">
       Brison et al., 2011
      </xref>
      ,
      <xref ref-type="bibr" rid="bib25">
       Jacomy et al., 2006
      </xref>
      ,
      <xref ref-type="bibr" rid="bib34">
       Le Coupanec et al., 2015
      </xref>
      ) are warranted and necessary as they will help to identify virus-host interfaces which could represent therapeutic target.
     </p>
    </sec>
    <sec id="s0060">
     <label>
      4
     </label>
     <title>
      Materials and methods
     </title>
     <sec id="s0065">
      <label>
       4.1
      </label>
      <title>
       Ethics statement
      </title>
      <p id="p0150">
       All animal experiments were approved by the Institutional Animal Care and Use Ethics Committee (IACUC) of the Institut National de la Recherche Scientifique (INRS) and conform to the Canadian Council on Animal Care (CCAC). Animal care and used protocols numbers 1304-02 and 1604-02 were issued by the IACUC of INRS for the animal experiments described herein.
      </p>
     </sec>
     <sec id="s0070">
      <label>
       4.2
      </label>
      <title>
       Cell lines and mixed primary murine CNS cells
      </title>
      <p id="p0155">
       The BHK-21 cell line (ATCC-CCL10) was cultured in minimal essential medium alpha (MEM-α; Life Technologies) supplemented with 10% (vol/vol) fetal bovine serum (FBS; PAA GE Healthcare) and used for transfection. The HRT-18 cell line (a gift from the late David Brian, University of Tennessee) was cultured in the same medium and used for virus infections/amplifications. The LA-N-5 cell line (a kind gift of Stephan Ladisch, George Washington University School of Medicine) was cultured in RPMI medium supplemented with 15% (vol/vol) fetal bovine serum (FBS), 10 mM HEPES, 1 mM sodium pyruvate, and 100 μM non-essential amino acids (Gibco - Invitrogen). The LA-N-5 cells were differentiated into human neurons as previously described (
       <xref ref-type="bibr" rid="bib23">
        Hill and Robertson, 1998
       </xref>
       ). Briefly, cells were seeded in 24-well plates pre-coated with 0.1% gelatin (1.25 × 10
       <sup>
        3
       </sup>
       cells/well) in RPMI medium supplemented with 10% (vol/vol) FBS, 10 mM HEPES, 1 mM sodium pyruvate, and 100 μM non-essential amino acids. The next day and every 2 days for 6 days, the medium was replaced with the same medium supplemented with 10% (vol/vol) FBS and 10 μM all-trans retinoic acid (Sigma-Aldrich).
      </p>
      <p id="p0160">
       Mixed primary cultures of mouse CNS cells were prepared as previously described (
       <xref ref-type="bibr" rid="bib34">
        Le Coupanec et al., 2015
       </xref>
       ). Briefly, embryos at 15 days of gestation were removed from pregnant anesthetized CD1 mice and their cortex and hippocampus were harvested and placed in Hanks balanced salt solution (HBSS) medium, without Ca
       <sup>
        2+
       </sup>
       and Mg
       <sup>
        2+
       </sup>
       , supplemented with 1 mM sodium pyruvate and 10 mM HEPES buffer. Tissues were gently pipetted up and down with a Pasteur pipette to dissociate the cells. After a decantation step of 3 min at room temperature, supernatants were transferred into a 50-ml tube with 36 ml of Neurobasal Medium (Invitrogen) supplemented with 0.5 mM GlutaMAX-I (Life Technologies), 10 mM HEPES buffer, B27 supplement (Life Technologies), gentamycin and 10% (vol/vol) of horse serum (Life Technologies). Cells were then seeded at 1 × 10
       <sup>
        5
       </sup>
       cells/cm
       <sup>
        2
       </sup>
       and grown on 50 µM poly-
       <sc>
        d
       </sc>
       -lysine-treated 12-well plates containing glass coverslips (for immunofluorescence) or not (for evaluation of infectious virus production) in the same medium, which was replaced by fresh Neurobasal Medium without horse medium the next day. The medium was changed every 2 days after and the cultures were ready for infection after 7 days in culture.
      </p>
     </sec>
     <sec id="s0075">
      <label>
       4.3
      </label>
      <title>
       Site-directed mutagenesis
      </title>
      <p id="p0165">
       Using our full-length, cDNA infectious clone pBAC-OC43
       <sup>
        FL
       </sup>
       (
       <xref ref-type="bibr" rid="bib48">
        St-Jean et al., 2006
       </xref>
       ) the recombinant HCoV-OC43 virus (rOC/ATCC) was generated. In parallel, a series of recombinant mutant viruses were produced by site-directed mutagenesis using the QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene) and a variety of primers (
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       , Section A) to introduce nucleotide substitutions in the E gene. These substitutions in the cDNA clone introduced were: nucleotide mutations at positions 24 and 25, corresponding to a change of amino acid position 9 into a stop codon (pBAC-OC43-E-Stop, plasmid; rOC/E
       <sub>
        stop
       </sub>
       , recombinant virus) or mutations at nucleotide positions 49 and 50 corresponding to amino acid 17 (pBAC-OC43-E-TM-Q17A; rOC/E-TM
       <sub>
        Q17A
       </sub>
       ), nucleotide position 245 and 246; amino acid 82 (pBAC-OC43-E-PBM-D82A; rOC/E-PBM
       <sub>
        D82A
       </sub>
       ) or nucleotide position 251; amino acid 84 (pBAC-OC43-E-PBM-V84A; rOC/E-PBM
       <sub>
        V84A
       </sub>
       ). A double mutant cDNA clone pBAC-OC43-E-PBM-D82A-V84A (rOC/E-PBM
       <sub>
        D82A-V84A
       </sub>
       ) was also produced using the pBAC-OC43-E-PBM-D82A as a DNA template for a second-round of mutagenesis reaction with OC-E-PBM-D82A-V84A primer to introduce a second mutation at nucleotide position 251; amino acid 84. Prior to transfection of BHK-21 cells, all samples were sequenced to make sure that only the introduced mutations were present and that no other mutations appeared.
       <table-wrap id="t0005" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Primers used to introduce nucleotide substitutions in the E gene of pBAC-OC43
          <sup>
           FL
          </sup>
          (
          <xref ref-type="bibr" rid="bib48">
           St-Jean et al., 2006
          </xref>
          ) for recombinant HCoV-OC43 virus production with amino acid modifications within the E protein (Section A). Primers used to verify sequences of the full HCoV-OC43 E and M gene of recombinant viruses (Section B). Bold and underlined sections represent newly introduced nucleotide substitutions. Underlined section in mutant E-PBM 82–84 represents previously introduced nucleotide substitutions.
         </p>
        </caption>
        <alt-text id="at0045">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th colspan="3">
            <bold>
             A – Primers for site-directed mutagenesis
            </bold>
            <hr/>
           </th>
          </tr>
          <tr>
           <th>
            <bold>
             Recombinant Virus
            </bold>
           </th>
           <th>
            <bold>
             Primer Name
            </bold>
           </th>
           <th>
            <bold>
             Primer Sequence
            </bold>
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            rOC/E
            <sub>
             stop
            </sub>
           </td>
           <td>
            OC-E-stop
           </td>
           <td>
            5’-CT GAT GCT TAT CTT
            <bold>
             <underline>
              TG
             </underline>
            </bold>
            A GAC ACT GTG TGG-3’
           </td>
          </tr>
          <tr>
           <td>
            rOC/E-TM
            <sub>
             Q17A
            </sub>
           </td>
           <td>
            OC-E-TM-Q17A
           </td>
           <td>
            5’-GTG TGG TAT GTG GGG
            <bold>
             <underline>
              GC
             </underline>
            </bold>
            A ATA ATT TTT ATA GTT GCC-3’
           </td>
          </tr>
          <tr>
           <td>
            rOC/E-PBM
            <sub>
             D82A
            </sub>
           </td>
           <td>
            OC-E-PBM-D82A
           </td>
           <td>
            5’-CA GTC CTT GAT GTG G
            <bold>
             <underline>
              CC
             </underline>
            </bold>
            GAC GTT TAG GTA ATC-3’
           </td>
          </tr>
          <tr>
           <td>
            rOC/E-PBM
            <sub>
             V84A
            </sub>
           </td>
           <td>
            OC-E-PBM-V84A
           </td>
           <td>
            3’-GT TTG GAT TAC CTA A
            <bold>
             <underline>
              G
             </underline>
            </bold>
            C GTC ATC CAC ATC AAG-5’
           </td>
          </tr>
          <tr>
           <td>
            rOC/E-PBM
            <sub>
             D82A-V84A
            </sub>
           </td>
           <td>
            OC-E-PBM-D82V-V84A
           </td>
           <td>
            5’-CTT GAT GTG G
            <underline>
             CC
            </underline>
            GAC G
            <bold>
             <underline>
              C
             </underline>
            </bold>
            T TAG GTA ATC CAA AC-3’
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <bold>
             B – Primer for sequence verification
            </bold>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            <bold>
             Primer Name
            </bold>
           </td>
           <td>
            <bold>
             Primer Sequence
            </bold>
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
          <tr>
           <td rowspan="10">
           </td>
           <td>
            OC-ns5-116-E-For
           </td>
           <td>
            5’-GTA GAG TTC CTA GTC ATG CTT G-3’
           </td>
          </tr>
          <tr>
           <td>
            OC-E-222-For
           </td>
           <td>
            5’-GAT GTA AAA CCA CCA GTC CT-3’
           </td>
          </tr>
          <tr>
           <td>
            OC-M-127-E-Rev
           </td>
           <td>
            5’-ACA TAC TGC GAC TTG TAT AGC C-3’
           </td>
          </tr>
          <tr>
           <td>
            OC-M-172-For
           </td>
           <td>
            5’-ATT TTG TGG CTT ATG TGG CCC-3’
           </td>
          </tr>
          <tr>
           <td>
            OC-M-241-E-Rev
           </td>
           <td>
            5’-CTA TAG AAA GGC CAA GAT ACA C-3’
           </td>
          </tr>
          <tr>
           <td>
            OC-M-439-For
           </td>
           <td>
            5’-GTC ACA ATA ATA CGC GGC CA-3’
           </td>
          </tr>
          <tr>
           <td>
            OC-M-514-Rev
           </td>
           <td>
            5’-CCT TAG CAA CAG TCA TAT AAG C-3’
           </td>
          </tr>
          <tr>
           <td>
            OC-N-60-Rev
           </td>
           <td>
            5‘-CAT TAC CAG AAC GAT TTC C-3’
           </td>
          </tr>
          <tr>
           <td>
            GAPDH-For
           </td>
           <td>
            5’-CGG AGT CAA CGG ATT TGG TCG TAT-3’
           </td>
          </tr>
          <tr>
           <td>
            GAPDH-Rev
           </td>
           <td>
            5’-AGC CTT CTC CAT GGT GGT GAA GAC-3’
           </td>
          </tr>
          <tr>
           <td colspan="3">
            <hr/>
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="s0080">
      <label>
       4.4
      </label>
      <title>
       Plasmid for transient co-transfection rescue
      </title>
      <p id="p0170">
       In order to insert the HCoV-OC43 E gene into the pcDNA3.1(+) expression vector (pcDNA; Invitrogen) and allow for E protein expression upon transient co-transfection with pBAC-OC43 infectious clones in BHK-21 cells, restriction enzymes
       <italic>
        Nhe
       </italic>
       I and
       <italic>
        Bam
       </italic>
       HI were added to the 5’ (primer: 5’-
       <underline>
        GCTAGC
       </underline>
       ATG TTT ATG GCT GAT GCT TA-3’) and 3’ (primer: 5’-
       <underline>
        GGATCC
       </underline>
       CTA AAC GTC ATC CAC AT-5’) ends of the E gene respectively. The E gene with added restriction enzyme sites was PCR-amplified from cDNA originating from a HCoV-OC43 reference strain (ATCC) infection on HRT-18 cells using Accuprime
       <italic>
        Pfx
       </italic>
       Supermix (Life Technologies) with 1 cycle at 95 °C for 5 min, followed by 35 cycles at 94 °C for 15 s, 48 °C for 30 s and 68 °C for 1 min and 1 cycle at 68 °C for 4 min and then introduced into the pcDNA plasmid.
      </p>
     </sec>
     <sec id="s0085">
      <label>
       4.5
      </label>
      <title>
       Recombinant virus production, transient co-transfection and virus amplification
      </title>
      <p id="p0175">
       The BHK-21 cells were cultured in MEM-α supplemented with 10% (vol/vol) FBS and used for transfection of pBAC-OC43 cDNA infectious clones with Lipofectamine 3000 Reagent (Life Technologies) according to the manufacturer's instructions. Briefly, for production of recombinant viruses, BHK-21 cells were seeded in 6-well cell culture plates at 6×10
       <sup>
        5
       </sup>
       cells/well. The next day, when cells were 70–90% confluent, the medium was replaced and cells were transfected with 7.5 µL Lipofectamine 3000 Transfection Reagent, 10 µL P3000 Reagent, 5 μg of pBAC-OC43
       <sup>
        FL
       </sup>
       or other modified pBAC DNA, and 2 μg of pcDNA(OC-E) or empty pcDNA plasmid per well. For semi-quantitative determination of transfection efficiency by immunofluorescence assay (IFA), BHK-21 cells were seeded at 5 × 10
       <sup>
        4
       </sup>
       cells/well onto glass coverslips in 24-well plates and transfected with 1.5 µL Lipofectamine 3000 Transfection Reagent, 6 µL P3000 Reagent, 1.5 μg of pBAC-OC43
       <sup>
        FL
       </sup>
       or other modified pBAC DNA, and 500 ng of pcDNA(OC-E) or empty pcDNA plasmid per well. The plates were incubated at 37 °C for 8 h and then medium replaced with MEM-α supplemented with 10% (vol/vol) FBS and 0.01% (vol/vol) gentamycin and incubated for 3 days.
      </p>
      <p id="p0180">
       The cells from 6-well culture plates were harvested either to recover total RNA or total protein while the supernatant (P0) was recovered by aspiration after centrifugation at 500 ×
       <italic>
        g
       </italic>
       for 7 min and then clarified at 1000 ×
       <italic>
        g
       </italic>
       for 10 min. The supernatant (P0) served to inoculate HRT-18 cells in order to amplify the viral stocks. The supernatant from this first-round amplification (P1) served for a second round of viral amplification on HRT-18 cells from which supernatant was recovered (P2) and in some cases, was repeated again for a third round of amplification (P3). The production of infectious viral particles corresponding to the different pBAC-OC43 cDNA clones was titrated by an immunoperoxidase assay (IPA) prior to each amplification step in order that titers could be normalized to the lowest detectable titer and replication rates be compared.
      </p>
     </sec>
     <sec id="s0090">
      <label>
       4.6
      </label>
      <title>
       Infection of human cell lines and of primary mouse CNS cultures
      </title>
      <p id="p0185">
       The HRT-18 and LA-N-5 cells as well as mixed primary cultures of mouse CNS cells were infected at a MOI equivalent to the lowest detectable titer of the series of recombinant virus stock used during each experiment or mock-infected and then incubated at 33 °C (HRT-18) or 37 °C (LA-N-5 cell line and primary CNS cultures), for 2 h (for virus adsorption), and incubated at 33 °C with fresh MEM-α supplemented with 1% (vol/vol) FBS (for HRT-18 cells), at 37 °C with fresh RPMI medium supplemented with 2.5% (vol/vol) FBS (for LA-N-5 cells) or at 37 °C with fresh Neurobasal Medium with B27-GlutaMAX-I (for primary murine CNS cell cultures) for different periods of time before fixing cells for immunofluorescence detection or harvesting the cell-associated and/or cell-free medium fractions for infectious virus titer determination by IPA. For relative infectivity and release assay, LA-N-5 cells were infected at a MOI equivalent to the lowest titer of the compared recombinant viruses and incubated at 37 °C for 16 h with fresh RPMI medium supplemented with 2.5% (vol/vol) FBS and 200 nM chloroquine (N
       <sup>
        4
       </sup>
       -(7-Chloro-4-quinolinyl)-N
       <sup>
        1
       </sup>
       ,N
       <sup>
        1
       </sup>
       -dimethyl-1,4-pentanediamine diphosphate salt, Sigma, CAS number 50–63-5) in order to prevent re-infection.
      </p>
     </sec>
     <sec id="s0095">
      <label>
       4.7
      </label>
      <title>
       Mice, survival curves, body weight variations and evaluation of clinical scores
      </title>
      <p id="p0190">
       Infection of 22-day-old female or 7-day-old male and female C57Bl/6 mice (Charles River) were performed as previously described (
       <xref ref-type="bibr" rid="bib34">
        Le Coupanec et al., 2015
       </xref>
       ). Briefly, mice were inoculated respectively by the IC route with 10
       <sup>
        1.5
       </sup>
       or the intranasal route with 10
       <sup>
        3
       </sup>
       of 50% tissue culture infective doses (TCID
       <sub>
        50
       </sub>
       ) recombinant virus. Groups of 10 mice infected by each recombinant virus were observed on a daily basis over a period of 21 dpi, and survival and weight variations were evaluated. Clinical scores were evaluated using a scale with 5 distinctive levels 0–4); where 0 was equivalent to the asymptomatic mouse; 1 for mice with early hunched backs; 2 for mice presenting slight social isolation, weight loss, and abnormal gait; 3 for mice presenting total social isolation, ruffled fur, hunched backs, weight loss and almost no movement; and number 4 was attributed to mice that were in moribund state or dead.
      </p>
     </sec>
     <sec id="s0100">
      <label>
       4.8
      </label>
      <title>
       Titration of infectious virus using an immunoperoxidase assay (IPA)
      </title>
      <p id="p0195">
       The IPA was performed on HRT-18 cells, as previously described (
       <xref ref-type="bibr" rid="bib33">
        Lambert et al., 2008
       </xref>
       ). Briefly, the primary antibody used was mAb 4.3E4 (hybridoma supernatant; ½ dilution) directed against the S protein of HCoV-OC43. The secondary antibody was horseradish peroxidase-conjugated goat anti-mouse immunoglobulin (KPL; 1/500). Immune complexes were detected by incubation with 0.025% (w/v) 3,3’-diaminobenzidine tetrahydrochloride (Bio-Rad) and 0.01% (vol/vol) hydrogen peroxide in PBS and infectious virus titers were calculated by the Karber method, as previously described (
       <xref ref-type="bibr" rid="bib33">
        Lambert et al., 2008
       </xref>
       ).
      </p>
     </sec>
     <sec id="s0105">
      <label>
       4.9
      </label>
      <title>
       Immunofluorescence for semi-quantification of transfection efficiency or virus propagation
      </title>
      <p id="p0200">
       BHK-21 and LAN-5 cells as well as mixed primary cultures of mouse CNS were fixed onto glass coverslips with 4% (wt/vol) paraformaldahyde for 30 min at room temperature and permeabilized for 5 min with 100% methanol at −20 °C. For LA-N-5 and BHK-21 cells, to detect HCoV-OC43 spike (S) protein, one-hour incubations of primary 4.3.E.4 (hybridoma supernatant; ½ dilution;) followed by secondary antibody AlexaFluor 488 donkey anti-mouse IgG (H + L) (1/1000; Life Technologies-Molecular probes) were conducted with three PBS washes between steps. For primary mouse CNS cultures, after blocking with a PBS-BSA 2% (wt/vol) solution for one hour at room temperature, primary antibody polyclonal rabbit anti-S protein (dilution 1/1000) and mouse monoclonal antibody against the neuron-specific MAP2 protein (1/1000; BD Pharmagen, catalog no. 556320) were diluted in PBS + 0.1% Triton X-100 and incubated on cells for one hour at room temperature followed by three PBS washes. Cells were then incubated one hour at room temperature with anti-rabbit Alexa Fluor 568- and anti-mouse Alexa Fluor 488-conjugated secondary antibodies (1/1000; Life Technologies-Molecular probes) in PBS. For all cell types, nucleus detection was accomplished by a 5-min incubation with 4',6-diamidino-2-phenylindole (DAPI; 1 μg/ml; Life Technologies). Triplicate samples were mounted on glass slides with Immuno-Mount medium (Fisher Scientific). Immunofluorescent staining was observed under a Nikon Eclipse E800 microscope with a QImaging Retiga-EXi Fast 1394 digital camera using Procapture system software. Percentage of infected cells was quantified from immunofluorescence pictures with the CellProfiler software (
       <xref ref-type="bibr" rid="bib7">
        Carpenter et al., 2006
       </xref>
       ).
      </p>
      <p id="p0205">
       For immunofluorescence on brain section, perfusion with 4% (wt/vol) paraformaldehyde (PFA) was performed on infected C57Bl/6 mice for each virus, at 3 and 7 dpi. Murine brains were carefully harvested and conserved in 30% (wt/vol) sucrose at 4 °C for 72 h. Prior to section, harvested brains were embedded in Tissue-Tek OCT compound (Sakura Finetek, WWR) at −20 °C. Sagittal brain sections were prepared at a thickness of 60 µm with a microtome cryostat HM 525; Microm. Serial sections were collected and Prior to staining, sections were incubated with a solution of two droplets of H
       <sub>
        2
       </sub>
       O
       <sub>
        2
       </sub>
       in PBS for 10 min at RT and washed with PBS. Sections were then permeabilized with a solution of 0,1% Triton in PBS for 2 h at RT, and blocked with a solution of PBS containing 1 droplet of horse normal serum according to the manufacturer's protocol (ABC kit Vectastain, Vector Laboratories) for 1 h at RT. For detection of viral antigens, sections were incubated overnight at 4 °C in a 1/500 dilution of polyclonal rabbit anti-S protein of bovine coronavirus (BCoV). After three washes with PBS, sections were incubated in the dark for 1 h at room temperature with the secondary fluorescent antibodies Alexa Fluor 488 anti-mouse (1/500; Life Technologies). After three PBS washes, sections were incubated for 5 min at room temperature with 4’,6-diamidino-2 phenylindole (DAPI; 1 μg/ml; Life Technologies), washed once with PBS and water and then mounted with Immuno-Mount mounting medium (Fisher Scientific). Immunofluorescent staining was observed under a Zeiss LSM780 confocal microscope.
      </p>
     </sec>
     <sec id="s0110">
      <label>
       4.10
      </label>
      <title>
       RNA extraction, cDNA synthesis and gene amplification
      </title>
      <p id="p0210">
       After transfection of BHK-21 cells or infection of HRT-18 cells, cells were scraped from wells or plates, centrifuged at 500 ×
       <italic>
        g
       </italic>
       for 7 min at 4 °C, medium was removed and cell pellet resuspended with 1.5 ml ice-cold PBS and centrifuged at 1000 ×
       <italic>
        g
       </italic>
       for 10 min at 4 °C. PBS was aspirated and the dry pellet stored at −80 °C until use. Total RNA was extracted using the RNeasy Mini Kit (QIAGEN) with QIAshredder spin columns (QIAGEN) to lyse cells according to manufacturer's instructions. RNA quality was verified using the Agilent 2100 Bioanalyzer using the Agilent RNA 6000 Nano Assay protocol according to manufacturer's instructions and concentration measured using a ND1000 spectrophotometer (Nanodrop). To produce cDNA, 5 μg of total extracted RNA was reverse transcribed using the SuperScript III First-Strand Synthesis Supermix Kit using oligo(dT) primer (Invitrogen) according to manufacturer's instructions.
      </p>
      <p id="p0215">
       PCR was conducted using Accuprime
       <italic>
        Pfx
       </italic>
       Supermix (Life Technologies) with one cycle at 95 °C for 1 min, followed by 40 cycles at 95 °C for 35 s, 50 °C for 45 s and 68 °C for 2 min, followed by one cycle at 68 °C for 7 min using several sets of primers to amplify the E gene (forward primer, OC-ns5-116-E-For, OC-E-222-For, OC-M-172-For or OC-M-439-For; reverse primers, OC-M127-E-Rev, OC-M-514-Rev, OC-M241-E-Rev or OC-N-60-Rev) and GAPDH gene as control (forward primer, GAPDH-For; reverse primer, GADPH-Rev). A complete list and description of all primers is presented in
       <xref ref-type="table" rid="t0005">
        Table 1
       </xref>
       , section B.
      </p>
     </sec>
     <sec id="s0115">
      <label>
       4.11
      </label>
      <title>
       RNA extraction for infectivity assay and quantification of viral RNA in mouse tissue
      </title>
      <p id="p0220">
       Real time RT-PCR for the absolute quantification of viral RNA in viral stocks and during infection of murine CNS, was modified from Vijgen and collaborators (
       <xref ref-type="bibr" rid="bib57">
        Vijgen et al., 2005
       </xref>
       ) using the Taqman technology and the use of cRNA standards for the generation of a standard curve and to evaluate the copy number of viral RNA in samples with the MEGAshortscript kit (Ambion/Life Technologies) (
       <xref ref-type="bibr" rid="bib19">
        Fronhoffs et al., 2002
       </xref>
       ,
       <xref ref-type="bibr" rid="bib57">
        Vijgen et al., 2005
       </xref>
       ). Briefly, total RNA was extracted with the Qiazol reagent (Qiagen) for HRT-18 cell culture supernatant and mouse tissue to evaluate the amount of viral RNA in virus stock and in mouse tissue respectively. cRNA standards were constructed exactly as described elsewhere made as previously described (
       <xref ref-type="bibr" rid="bib57">
        Vijgen et al., 2005
       </xref>
       ). RNA concentrations were evaluated in all samples and quantified using a ND1000 spectrophotometer (Nanodrop). Real-time quantitative RT-PCR was performed with the TaqMan-RNA-to-CT 1-Step kit (Applied Biosystems/Life Technologies) in a 20 µL reaction mixture with 10 µL of 2× TaqMan RT-PCR Mix (containing ROX as a passive reference dye), 900 nM of forward and reverse primers, and 200 nM of FAM BHQ1-TP probe. Four µL of RNA for supernatant samples and cRNA standards (serial dilutions), were used for the reaction. Amplification and detection were performed in a StepOnePlus Realtime PCR system apparatus and analysis were performed with the StepOne software version 2.3 (Applied Biosystems).
      </p>
     </sec>
     <sec id="s0120">
      <label>
       4.12
      </label>
      <title>
       Protein extraction and Western blot analysis
      </title>
      <p id="p0225">
       To confirm E protein production after transfection of pcDNA(OC-E) in BHK-21 cells, proteins from whole cell lysates were extracted. Harvested cells were pipetted up and down into RIPA buffer (150 mM NaCl, 50 mM Tris, pH 7.4, 1% (v/v) NP-40, 0.25% (wt/vol) sodium deoxycholate, 1 mM EDTA) supplemented with protease cocktail inhibitor (Sigma). Lysates were incubated on ice for 20 min and centrifuged at 17,000 ×
       <italic>
        g
       </italic>
       for 10 min at 4 °C. Supernatants were harvested, aliquoted and stored at −80 °C until further analyzed.
      </p>
      <p id="p0230">
       Protein concentrations were determined using a bicinchoninic acid (BCA) protein assay kit (Novagen) according to the manufacturer's instructions. Ten μg of protein was loaded on a Tris-Glycine 4–15% gradient gel, transferred to PVDF membrane with a semi-dry trans-blot apparatus (Bio-Rad). Membranes were blocked overnight at 4 °C with TBS buffer containing 1% (vol/vol) Tween (TBS-T) and 5% (wt/vol) non-fat milk. The following day all steps were conducted at room temperature, with, or solutions diluted in, TBS-T and milk. A primary rabbit polyclonal antibody was used to detect either the HCoV-OC43 E protein (1/5000) or GAPDH (1/10 000) for 1 h, followed by three 10 min washes. Anti-rabbit IgG horseradish peroxidase linked whole antibody (from donkey) (GE Healthcare) was the secondary antibody used, followed by three 10 min washes. Detection was performed using 1/1 solution of Clarity Western ECL Substrate (Bio-Rad) for one minute followed by membrane exposure on CL-X-Posure Film (Thermo Scientific).
      </p>
     </sec>
     <sec id="s0125">
      <label>
       4.13
      </label>
      <title>
       Statistical tests
      </title>
      <p id="p0235">
       For cell experiments (percentage of infection), statistical analysis were conducted by one-way analysis of variance (ANOVA), followed by Tukey's post hoc test, or a
       <italic>
        t
       </italic>
       -test. For mice experiments, results were compared using two non-parametric statistical tests: Kruskal-Wallis and Mann-Whitney. Statistical significance was defined as p &lt; 0.05 and is indicated with * (Student's
       <italic>
        t
       </italic>
       -test p value &lt; 0.05), ** (Student's
       <italic>
        t
       </italic>
       -test p value &lt; 0.01) or *** (Student's
       <italic>
        t
       </italic>
       -test p value &lt; 0.001).
      </p>
     </sec>
    </sec>
    <back>
     <ref-list id="bibliog0005">
      <title>
       References
      </title>
      <ref id="bib1">
       <element-citation id="sbref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Almazán
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Dediego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Zuñiga
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Nieto-torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Marquez-jurado
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Andrés
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A vaccine candidate east respiratory syndrome coronavirus as a vaccine candidate
        </article-title>
        <source>
         MBio
        </source>
        <volume>
         4
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib2">
       <element-citation id="sbref2" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Almazán
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Zuñiga
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Marquez-Jurado
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Morales
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Becares
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus reverse genetic systems: infectious clones and replicons
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         189
        </volume>
        <year>
         2014
        </year>
        <fpage>
         262
        </fpage>
        <lpage>
         270
        </lpage>
        <pub-id pub-id-type="pmid">
         24930446
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <element-citation id="sbref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Harthi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hussein
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bouchama
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Johani
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hajeer
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Saeed
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Wahbi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Saedy
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           AlDabbagh
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Okaili
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Sadat
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)
        </article-title>
        <source>
         Infection
        </source>
        <volume>
         43
        </volume>
        <year>
         2015
        </year>
        <fpage>
         495
        </fpage>
        <lpage>
         501
        </lpage>
        <pub-id pub-id-type="pmid">
         25600929
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <element-citation id="sbref4" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arbour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Newcombe
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neuroinvasion by human respiratory coronaviruses
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         74
        </volume>
        <year>
         2000
        </year>
        <fpage>
         8913
        </fpage>
        <lpage>
         8921
        </lpage>
        <pub-id pub-id-type="pmid">
         10982334
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib5">
       <element-citation id="sbref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bonavia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Arbour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Yong
          </surname>
          <given-names>
           V.W.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection of primary cultures of human neural cells by human coronaviruses 229E and OC43
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         71
        </volume>
        <year>
         1997
        </year>
        <fpage>
         800
        </fpage>
        <lpage>
         806
        </lpage>
        <pub-id pub-id-type="pmid">
         8985420
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <element-citation id="sbref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brison
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <year>
         2011
        </year>
        <fpage>
         12464
        </fpage>
        <lpage>
         12473
        </lpage>
        <pub-id pub-id-type="pmid">
         21957311
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <element-citation id="sbref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carpenter
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           T.R.
          </given-names>
         </name>
         <name>
          <surname>
           Lamprecht
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Clarke
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           I.H.
          </given-names>
         </name>
         <name>
          <surname>
           Friman
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Guertin
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lindquist
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Moffat
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Golland
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Sabatini
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         CellProfiler: image analysis software for identifying and quantifying cell phenotypes
        </article-title>
        <source>
         Genome Biol.
        </source>
        <volume>
         7
        </volume>
        <year>
         2006
        </year>
        <fpage>
         R100
        </fpage>
        <pub-id pub-id-type="pmid">
         17076895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <element-citation id="sbref8" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           L.D.
          </given-names>
         </name>
         <name>
          <surname>
           Machamer
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a Golgi complex-targeting signal in the cytoplasmic tail of the severe acute respiratory syndrome coronavirus envelope protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <year>
         2011
        </year>
        <fpage>
         5794
        </fpage>
        <lpage>
         5803
        </lpage>
        <pub-id pub-id-type="pmid">
         21450821
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib9">
       <element-citation id="sbref9" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Curtis
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Heterologous gene expression from transmissible gastroenteritis virus replicon particles
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         76
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1422
        </fpage>
        <lpage>
         1434
        </lpage>
        <pub-id pub-id-type="pmid">
         11773416
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib10">
       <element-citation id="sbref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Almazan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rejas
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Shieh
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1701
        </fpage>
        <lpage>
         1713
        </lpage>
        <pub-id pub-id-type="pmid">
         17108030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib11">
       <element-citation id="sbref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Pewe
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rejas
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         376
        </volume>
        <year>
         2008
        </year>
        <fpage>
         379
        </fpage>
        <lpage>
         389
        </lpage>
        <pub-id pub-id-type="pmid">
         18452964
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <element-citation id="sbref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Jimenez-Guardeño
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Castaño-Rodriguez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Delgado
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Usera
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus virulence genes with main focus on SARS-CoV envelope gene
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         194
        </volume>
        <year>
         2014
        </year>
        <fpage>
         124
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="pmid">
         25093995
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <element-citation id="sbref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Desjardins
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         3097
        </fpage>
        <lpage>
         3107
        </lpage>
        <pub-id pub-id-type="pmid">
         23283955
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <element-citation id="sbref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Le Coupanec
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Stodola
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Meessen-Pinard
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         194
        </volume>
        <year>
         2014
        </year>
        <fpage>
         145
        </fpage>
        <lpage>
         158
        </lpage>
        <pub-id pub-id-type="pmid">
         25281913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <element-citation id="sbref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Günther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Werf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           van der, Brodt
          </surname>
          <given-names>
           H.-R.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rabenau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Panning
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Berger
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Burguière
          </surname>
          <given-names>
           A.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Eickmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Escriou
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Grywna
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kramme
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Manuguerra
          </surname>
          <given-names>
           J.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rickerts
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Stürmer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Simon Vieth
          </surname>
          <given-names>
           H.-D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Schmitz
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1967
        </fpage>
        <lpage>
         1976
        </lpage>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <element-citation id="sbref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Favreau
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Meessen-Pinard
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus-induced neuronal programmed cell death is cyclophilin D dependent and potentially caspase dispensable
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         86
        </volume>
        <year>
         2012
        </year>
        <fpage>
         81
        </fpage>
        <lpage>
         93
        </lpage>
        <pub-id pub-id-type="pmid">
         22013052
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <element-citation id="sbref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Organization and dynamics of PDZ-domain-related supramodules in the postsynaptic density
        </article-title>
        <source>
         Nat. Rev. Neurosci.
        </source>
        <volume>
         10
        </volume>
        <year>
         2009
        </year>
        <fpage>
         87
        </fpage>
        <lpage>
         99
        </lpage>
        <pub-id pub-id-type="pmid">
         19153575
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <element-citation id="sbref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Stegen
          </surname>
          <given-names>
           C.F.
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
         <name>
          <surname>
           Samsonoff
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of constructed E gene mutants of mouse hepatitis virus confirms a pivotal role for E protein in coronavirus assembly
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         72
        </volume>
        <year>
         1998
        </year>
        <fpage>
         7885
        </fpage>
        <lpage>
         7894
        </lpage>
        <pub-id pub-id-type="pmid">
         9733825
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <element-citation id="sbref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fronhoffs
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Totzke
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Stier
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wernert
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Rothe
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bruning
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Koch
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Sachinidis
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vetter
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A method for the rapid construction of cRNA standard curves in quantitative real-time reverse transcription polymerase chain reaction
        </article-title>
        <source>
         Mol. Cell Probes
        </source>
        <volume>
         16
        </volume>
        <year>
         2002
        </year>
        <fpage>
         99
        </fpage>
        <lpage>
         110
        </lpage>
        <pub-id pub-id-type="pmid">
         12030760
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <element-citation id="sbref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Godet
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           L’Haridon
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Vautherot
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Laude
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         TGEV corona virus ORF4 encodes a membrane protein that is incorporated into virions
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         188
        </volume>
        <year>
         1992
        </year>
        <fpage>
         666
        </fpage>
        <lpage>
         675
        </lpage>
        <pub-id pub-id-type="pmid">
         1316677
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <element-citation id="sbref21" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviridae
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           King
          </surname>
          <given-names>
           A.M.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Carstens
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
         <name>
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <source>
         Virus Taxonomy
        </source>
        <year>
         2012
        </year>
        <publisher-name>
         Elsevier
        </publisher-name>
        <publisher-loc>
         New York, NY
        </publisher-loc>
        <fpage>
         806
        </fpage>
        <lpage>
         828
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib22">
       <element-citation id="sbref22" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Shao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pei
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Leong
          </surname>
          <given-names>
           A.S.-Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multiple organ infection and the pathogenesis of SARS
        </article-title>
        <source>
         J. Exp. Med.
        </source>
        <volume>
         202
        </volume>
        <year>
         2005
        </year>
        <fpage>
         415
        </fpage>
        <lpage>
         424
        </lpage>
        <pub-id pub-id-type="pmid">
         16043521
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <element-citation id="sbref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differentiation of LA-N-5 neuroblastoma cells into cholinergic neurons: methods for differentiation, immunohistochemistry and reporter gene introduction
        </article-title>
        <source>
         Brain Res. Protoc.
        </source>
        <volume>
         2
        </volume>
        <year>
         1998
        </year>
        <fpage>
         183
        </fpage>
        <lpage>
         190
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib24">
       <element-citation id="sbref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vacuolating encephalitis in mice infected by human coronavirus OC43
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         315
        </volume>
        <year>
         2003
        </year>
        <fpage>
         20
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         14592756
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <element-citation id="sbref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Fragoso
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Almazan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Mushynski
          </surname>
          <given-names>
           W.E.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         349
        </volume>
        <year>
         2006
        </year>
        <fpage>
         335
        </fpage>
        <lpage>
         346
        </lpage>
        <pub-id pub-id-type="pmid">
         16527322
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <element-citation id="sbref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Javier
          </surname>
          <given-names>
           R.T.
          </given-names>
         </name>
         <name>
          <surname>
           Rice
          </surname>
          <given-names>
           A.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <year>
         2011
        </year>
        <fpage>
         11544
        </fpage>
        <lpage>
         11556
        </lpage>
        <pub-id pub-id-type="pmid">
         21775458
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <element-citation id="sbref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jimenez-Guardeño
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J. a.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Delgado
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Castaño-Rodriguez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         10
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e1004320
        </fpage>
        <pub-id pub-id-type="pmid">
         25122212
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <element-citation id="sbref28" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jimenez-Guardeño
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Castaño-Rodriguez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Delgado
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         11
        </volume>
        <year>
         2015
        </year>
        <fpage>
         e1005215
        </fpage>
        <pub-id pub-id-type="pmid">
         26513244
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <element-citation id="sbref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Peret
          </surname>
          <given-names>
           L.J.A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Emery
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Urbani
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Comer
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Dowell
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.-E.
          </given-names>
         </name>
         <name>
          <surname>
           Humphrey
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Wun
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           the SARS Working Group
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <element-citation id="sbref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuo
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The small envelope protein E is not essential for murine coronavirus replication
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         77
        </volume>
        <year>
         2003
        </year>
        <fpage>
         4597
        </fpage>
        <lpage>
         4608
        </lpage>
        <pub-id pub-id-type="pmid">
         12663766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <element-citation id="sbref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuo
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evolved variants of the membrane protein can partially replace the envelope protein in murine coronavirus assembly
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         84
        </volume>
        <year>
         2010
        </year>
        <fpage>
         12872
        </fpage>
        <lpage>
         12885
        </lpage>
        <pub-id pub-id-type="pmid">
         20926558
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <element-citation id="sbref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuo
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Hurst
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Exceptional flexibility in the sequence requirements for coronavirus small envelope protein function
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <year>
         2007
        </year>
        <fpage>
         2249
        </fpage>
        <lpage>
         2262
        </lpage>
        <pub-id pub-id-type="pmid">
         17182690
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <element-citation id="sbref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lambert
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Marceau
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Titration of human coronaviruses using an immunoperoxidase assay
        </article-title>
        <source>
         J. Vis. Exp.
        </source>
        <year>
         2008
        </year>
       </element-citation>
      </ref>
      <ref id="bib34">
       <element-citation id="sbref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Le Coupanec
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Meessen-Pinard
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dubé
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Seidah
          </surname>
          <given-names>
           N.G.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cleavage of a neuroinvasive human respiratory virus spike glycoprotein by proprotein convertases modulates neurovirulence and virus spread within the central nervous system
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         11
        </volume>
        <year>
         2015
        </year>
        <fpage>
         e1005261
        </fpage>
        <pub-id pub-id-type="pmid">
         26545254
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <element-citation id="sbref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.X.
          </given-names>
         </name>
         <name>
          <surname>
           Inglis
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Association of the infectious bronchitis virus 3c protein with the virion envelope
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         185
        </volume>
        <year>
         1991
        </year>
        <fpage>
         911
        </fpage>
        <lpage>
         917
        </lpage>
        <pub-id pub-id-type="pmid">
         1962461
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <element-citation id="sbref36" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morfopoulou
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Virasami
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Qasim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Chong
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Hubank
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Plagnol
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Jacques
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Breuer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus OC43 associated with fatal encephalitis
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         375
        </volume>
        <year>
         2016
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         498
        </lpage>
        <pub-id pub-id-type="pmid">
         27518687
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <element-citation id="sbref37" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dediego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Jiménez-Guardeño
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Llorente
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kremer
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shuo
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         415
        </volume>
        <year>
         2011
        </year>
        <fpage>
         69
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         21524776
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <element-citation id="sbref38" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Verdiá-Báguena
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Jimenez-Guardeño
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Delgado
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Castaño-Rodriguez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Alcaraz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Aguilella
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         10
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e1004077
        </fpage>
        <pub-id pub-id-type="pmid">
         24788150
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <element-citation id="sbref39" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nieva
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Madan
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Carrasco
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viroporins: structure and biological functions
        </article-title>
        <source>
         Nat. Rev. Microbiol
        </source>
        <volume>
         10
        </volume>
        <year>
         2012
        </year>
        <fpage>
         563
        </fpage>
        <lpage>
         574
        </lpage>
        <pub-id pub-id-type="pmid">
         22751485
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <element-citation id="sbref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ortego
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Escors
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Laude
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Generation of a replication-competent, propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus genome
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         76
        </volume>
        <year>
         2002
        </year>
        <fpage>
         11518
        </fpage>
        <lpage>
         11529
        </lpage>
        <pub-id pub-id-type="pmid">
         12388713
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <element-citation id="sbref41" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ortego
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ceriani
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Patiño
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Plana
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Absence of E protein arrests transmissible gastroenteritis coronavirus maturation in the secretory pathway
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         368
        </volume>
        <year>
         2007
        </year>
        <fpage>
         296
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         17692883
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <element-citation id="sbref42" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pervushin
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Parthasarathy
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           F.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Vararattanavech
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Soong
          </surname>
          <given-names>
           T.W.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.D.X.
          </given-names>
         </name>
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure and inhibition of the SARS coronavirus envelope protein ion channel
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         5
        </volume>
        <year>
         2009
        </year>
        <fpage>
         e1000511
        </fpage>
        <pub-id pub-id-type="pmid">
         19593379
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <element-citation id="sbref43" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Préhaud
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wolff
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Terrien
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Lafage
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Mégret
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Babault
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Cordier
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
         <name>
          <surname>
           Maitrepierre
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Ménager
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Chopy
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hoos
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           England
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Delepierre
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Schnell
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Buc
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lafon
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Attenuation of rabies virulence: takeover by the cytoplasmic domain of its envelope protein
        </article-title>
        <source>
         Sci. Signal.
        </source>
        <volume>
         3
        </volume>
        <year>
         2010
        </year>
        <fpage>
         ra5
        </fpage>
        <pub-id pub-id-type="pmid">
         20086240
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <element-citation id="sbref44" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Jimenez-Guardeño
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Delgado
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Castaño-Rodríguez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <year>
         2015
        </year>
        <fpage>
         3870
        </fpage>
        <lpage>
         3887
        </lpage>
        <pub-id pub-id-type="pmid">
         25609816
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <element-citation id="sbref45" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ruch
          </surname>
          <given-names>
           T.R.
          </given-names>
         </name>
         <name>
          <surname>
           Machamer
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The hydrophobic domain of infectious bronchitis virus E protein alters the host secretory pathway and is important for release of infectious virus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <year>
         2011
        </year>
        <fpage>
         675
        </fpage>
        <lpage>
         685
        </lpage>
        <pub-id pub-id-type="pmid">
         21047962
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <element-citation id="sbref46" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ruch
          </surname>
          <given-names>
           T.R.
          </given-names>
         </name>
         <name>
          <surname>
           Machamer
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A single polar residue and distinct membrane topologies impact the function of the infectious bronchitis coronavirus E protein
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         8
        </volume>
        <year>
         2012
        </year>
        <fpage>
         e1002674
        </fpage>
        <pub-id pub-id-type="pmid">
         22570613
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <element-citation id="sbref47" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Griffin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viroporins: structure, function and potential as antiviral targets
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <volume>
         96
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2000
        </fpage>
        <lpage>
         2027
        </lpage>
        <pub-id pub-id-type="pmid">
         26023149
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <element-citation id="sbref48" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           St-Jean
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Desforges
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Almazán
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jacomy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recovery of a neurovirulent human coronavirus OC43 from an infectious cDNA clone
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         80
        </volume>
        <year>
         2006
        </year>
        <fpage>
         3670
        </fpage>
        <lpage>
         3674
        </lpage>
        <pub-id pub-id-type="pmid">
         16537637
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <element-citation id="sbref49" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Surya
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Verdià-Bàguena
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Aguilella
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         201
        </volume>
        <year>
         2015
        </year>
        <fpage>
         61
        </fpage>
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="pmid">
         25733052
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <element-citation id="sbref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Teoh
          </surname>
          <given-names>
           K.-T.
          </given-names>
         </name>
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           Y.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           W.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Schlüter
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Bruzzone
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Margolis
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Nal
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis
        </article-title>
        <source>
         Mol. Biol. Cell
        </source>
        <volume>
         21
        </volume>
        <year>
         2010
        </year>
        <fpage>
         3838
        </fpage>
        <lpage>
         3852
        </lpage>
        <pub-id pub-id-type="pmid">
         20861307
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <element-citation id="sbref51" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Parthasarathy
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.X.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The transmembrane oligomers of coronavirus protein E
        </article-title>
        <source>
         Biophys. J.
        </source>
        <volume>
         88
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1283
        </fpage>
        <lpage>
         1290
        </lpage>
        <pub-id pub-id-type="pmid">
         15713601
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <element-citation id="sbref52" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Parthasarathy
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Saravanan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Kukol
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Model of a putative pore: the pentameric alpha-helical bundle of SARS coronavirus E protein in lipid bilayers
        </article-title>
        <source>
         Biophys. J.
        </source>
        <volume>
         91
        </volume>
        <year>
         2006
        </year>
        <fpage>
         938
        </fpage>
        <lpage>
         947
        </lpage>
        <pub-id pub-id-type="pmid">
         16698774
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib53">
       <element-citation id="sbref53" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Dina
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Brison
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Brouard
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Freymuth
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus humains (HCoV)
        </article-title>
        <source>
         Pathol. Biol.
        </source>
        <volume>
         57
        </volume>
        <year>
         2009
        </year>
        <fpage>
         149
        </fpage>
        <lpage>
         160
        </lpage>
        <pub-id pub-id-type="pmid">
         18456429
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <element-citation id="sbref54" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Venkatagopalan
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Daskalova
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lopez
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Dolezal
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hogue
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus envelope (E) protein remains at the site of assembly
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         478
        </volume>
        <year>
         2015
        </year>
        <fpage>
         75
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         25726972
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib55">
       <element-citation id="sbref55" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Verdiá-Báguena
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alcaraz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Torres
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Aguilella
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         432
        </volume>
        <year>
         2012
        </year>
        <fpage>
         485
        </fpage>
        <lpage>
         494
        </lpage>
        <pub-id pub-id-type="pmid">
         22832120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib56">
       <element-citation id="sbref56" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Verdiá-Báguena
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alcaraz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Dediego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Aguilella
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of SARS-CoV e protein ion channel activity by tuning the protein and lipid charge
        </article-title>
        <source>
         Biochim. Biophys. Acta - Biomembr.
        </source>
        <volume>
         1828
        </volume>
        <year>
         2013
        </year>
        <fpage>
         2026
        </fpage>
        <lpage>
         2031
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib57">
       <element-citation id="sbref57" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Moe
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Maes
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Duson
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ranst
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Van
          </surname>
         </name>
        </person-group>
        <article-title>
         Development of one-step, real-time, quantitative reverse transcriptase pcr assays for absolute quantitation
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         43
        </volume>
        <year>
         2005
        </year>
        <fpage>
         5452
        </fpage>
        <lpage>
         5456
        </lpage>
        <pub-id pub-id-type="pmid">
         16272469
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib58">
       <element-citation id="sbref58" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Westerbeck
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Machamer
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A coronavirus E protein is present in two distinct pools with different effects on assembly and the secretory pathway
        </article-title>
        <comment>
         (JVI.01237-15)
        </comment>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
       </element-citation>
      </ref>
      <ref id="bib59">
       <element-citation id="sbref59" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Mckinlay
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gage
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Ewart
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS coronavirus E protein forms cation-selective ion channels
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         330
        </volume>
        <year>
         2004
        </year>
        <fpage>
         322
        </fpage>
        <lpage>
         331
        </lpage>
        <pub-id pub-id-type="pmid">
         15527857
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <element-citation id="sbref60" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gage
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Ewart
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         353
        </volume>
        <year>
         2006
        </year>
        <fpage>
         294
        </fpage>
        <lpage>
         306
        </lpage>
        <pub-id pub-id-type="pmid">
         16815524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib61">
       <element-citation id="sbref61" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         41
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1089
        </fpage>
        <lpage>
         1096
        </lpage>
        <pub-id pub-id-type="pmid">
         16163626
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib62">
       <element-citation id="sbref62" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structures and target recognition modes of PDZ domains: recurring themes and emerging pictures
        </article-title>
        <source>
         Biochem. J.
        </source>
        <volume>
         455
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="pmid">
         24028161
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib63">
       <element-citation id="sbref63" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hogue
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of the coronavirus E viroporin protein transmembrane domain in virus assembly
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <year>
         2007
        </year>
        <fpage>
         3597
        </fpage>
        <lpage>
         3607
        </lpage>
        <pub-id pub-id-type="pmid">
         17229680
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib64">
       <element-citation id="sbref64" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeh
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Duffner
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Faden
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis
        </article-title>
        <source>
         Pediatrics
        </source>
        <volume>
         113
        </volume>
        <year>
         2004
        </year>
        <fpage>
         e73
        </fpage>
        <lpage>
         e76
        </lpage>
        <pub-id pub-id-type="pmid">
         14702500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <element-citation id="sbref65" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Bi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Leibowitz
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mouse hepatitis virus gene 5b protein is a new virion envelope protein
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         202
        </volume>
        <year>
         1994
        </year>
        <fpage>
         1018
        </fpage>
        <lpage>
         1023
        </lpage>
        <pub-id pub-id-type="pmid">
         8030202
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib66">
       <element-citation id="sbref66" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           van, Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         New Engl. J. Med.
        </source>
        <volume>
         367
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="s0145" sec-type="supplementary-material">
      <label>
       Appendix A
      </label>
      <title>
       Supplementary material
      </title>
      <p id="p0260">
       <fig id="f0045" position="anchor">
        <label>
         Sup. Figure 1
        </label>
        <caption>
         <p>
          <bold>
           HCoV-OC43 E protein transmembrane (TM) domain is important for its efficient propagation in human and murine neuronal cells.
          </bold>
          (A) Differentiated LA-N-5 and (B) mixed primary murine CNS cells were infected with either rOC/ATCC or rOC/E-TM
          <sub>
           Q17A
          </sub>
          at the same MOI and cells were fixed at several time points and HCoV-OC43 S protein (red) was revealed by immunofluorescence staining to follow viral propagation. Green represents the microtubule associated protein 2 (MAP2) staining in neurons of the mixed primary murine CNS cells. Nucleus were stained with DAPI (blue).
         </p>
        </caption>
        <alt-text id="at0050">
         Sup. Figure 1
        </alt-text>
        <graphic xlink:href="mmc1_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0265">
       <fig id="f0050" position="anchor">
        <label>
         Sup. Figure 2
        </label>
        <caption>
         <p>
          <bold>
           HCoV-OC43 E protein PBM motif greatly improves its propagation in human and murine neuronal cells.
          </bold>
          (A) Differentiated LA-N-5 and (B) mixed primary murine CNS cells were infected with either rOC/ATCC or rOC/E-TM
          <sub>
           D82A-V84A
          </sub>
          at the same MOI and cells were fixed at several time points and HCoV-OC43 S protein (red) was revealed by immunofluorescence staining to follow viral propagation. Green represents the microtubule associated protein 2 (MAP2) staining in neurons of the mixed primary murine CNS cells. Nucleus were stained with DAPI (blue).
         </p>
        </caption>
        <alt-text id="at0055">
         Sup. Figure 2
        </alt-text>
        <graphic xlink:href="mmc2_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0270">
       <fig id="f0055" position="anchor">
        <label>
         Sup. Figure 3
        </label>
        <caption>
         <p>
          <bold>
           HCoV-OC43 E protein is required for pathogenesis in the CNS.
          </bold>
          (A) Survival curves of mice in percentage over 21 days following the injection. (B) Infected mice were weighted every 2 days for a period of 21 days following infection. The weight gain is shown as percentage of j0 set at 100%. (C) Evaluation of the clinical scores (percentage of mice at each level of the scale) of mice infected by rOC/ATCC or rOC/Estop based on neurological symptoms described in clinical score scale between level 0 and 4 (see Materials and methods). (D) Viral RNA was detected and quantified by RT-qPCR in the brain of infected mice at 5 and 9 days post-infection. Representative of three different experiments. (** P&lt;0.01; *** P&lt;0.001).
         </p>
        </caption>
        <alt-text id="at0060">
         Sup. Figure 3
        </alt-text>
        <graphic xlink:href="mmc3_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0275">
       <fig id="f0060" position="anchor">
        <label>
         Sup. Figure 4
        </label>
        <caption>
         <p>
          <bold>
           rOC/E-PBM
          </bold>
          <sub>
           <bold>
            D82A-V84A
           </bold>
          </sub>
          <bold>
           is able to produce infectious virions in the brain and to propagate to the spinal cord after an infection at a higher dose.
          </bold>
          (A) Infectious viral particles were quantified in the brains of 22-day-old C57Bl/6 mice infected by the IC route by 10
          <sup>
           2.5
          </sup>
          TCID
          <sub>
           50
          </sub>
          /10 µL rOC/ATCC, or rOC/E-PBM-82–84 over 11 days post-infection. Viral RNA was detected and quantified by RT-qPCR in the (B) brain and (C) spinal cord of infected mice over 11 days post-infection. LOD, limit of detection.
         </p>
        </caption>
        <alt-text id="at0065">
         Sup. Figure 4
        </alt-text>
        <graphic xlink:href="mmc4_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <ack id="ack0005">
      <title>
       Acknowledgements
      </title>
      <p>
       We thank Jessie Tremblay for excellent technical assistance with confocal microscopy. J.K.S. and G.D. wishes to thank Mathieu Meessen-Pinard, Mathieu Dubé, and especially Marc Desforges and Pierre J. Talbot for their advice and support throughout the project. Additionally, J.K.S. and G.D. wishes to thank M.D. and P.J.T. for guidance in the preparation of this manuscript. This study was supported by Discovery grant 42619-2009 from the
       <funding-source id="gs1">
        National Sciences and Engineering Research Council of Canada
       </funding-source>
       and operating grant MT-9203 from the
       <funding-source id="gs2">
        Institute of Infection and Immunity of the Canadian Institutes for Health Research
       </funding-source>
       to P.J.T. who is the holder of the Tier-1 (Senior) Canada Research Chair in Neuroimmunovirology award. J.K.S. gratefully acknowledges a masters studentship from the
       <italic>
        Fondation Universitaire Armand-Frappier de l’INRS
       </italic>
       . The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
      </p>
     </ack>
     <ack id="ack0010">
      <sec id="s0130">
       <title>
        Funding
       </title>
       <p id="p0245">
        This study was supported by Discovery grant 42619-2009 from the National Sciences and Engineering Research Council of Canada and operating grant MT-9203 from the Institute of Infection and Immunity of the Canadian Institutes for Health Research to P.J.T. who is the holder of the Tier-1 (Senior) Canada Research Chair in Neuroimmunovirology award. J.K.S. gratefully acknowledges a masters studentship from the
        <italic>
         Fondation Universitaire Armand-Frappier de l’INRS
        </italic>
        . The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
       </p>
      </sec>
      <sec id="s0135">
       <title>
        Competing interests
       </title>
       <p id="p0250">
        The authors have declared that no competing interests exist.
       </p>
      </sec>
     </ack>
     <fn-group>
      <fn fn-type="supplementary-material" id="s0140">
       <label>
        Appendix A
       </label>
       <p id="p0255">
        Supplementary data associated with this article can be found in the online version at
        <ext-link ext-link-type="uri" id="ir0005" xlink:href="http://doi:10.1016/j.virol.2017.12.023">
         doi:10.1016/j.virol.2017.12.023
        </ext-link>
        .
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Nat Rev Microbiol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Nat. Rev. Microbiol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Nature Reviews. Microbiology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1740-1526
      </issn>
      <issn pub-type="epub">
       1740-1534
      </issn>
      <publisher>
       <publisher-name>
        Nature Publishing Group UK
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       27344959
      </article-id>
      <article-id pub-id-type="pmc">
       7097822
      </article-id>
      <article-id pub-id-type="publisher-id">
       BFnrmicro201681
      </article-id>
      <article-id pub-id-type="doi">
       10.1038/nrmicro.2016.81
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        SARS and MERS: recent insights into emerging coronaviruses
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          de Wit
         </surname>
         <given-names>
          Emmie
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <bio>
         <p id="Par1">
          Emmie de Wit is a staff scientist in the Disease Modelling and Transmission Section of the Laboratory of Virology at the Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA. She received her Ph.D. in virology from Erasmus University Rotterdam, The Netherlands, where she studied the molecular determinants of influenza A virus replication and pathogenesis. Her current research focuses on the pathogenesis and transmission of Ebola virus, Nipah virus and Middle East respiratory syndrome coronavirus (MERS-CoV), and the development of countermeasures against these viruses.
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          van Doremalen
         </surname>
         <given-names>
          Neeltje
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <bio>
         <p id="Par2">
          Neeltje van Doremalen is a visiting postdoctoral fellow in the Virus Ecology Unit of the Laboratory of Virology at the Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA. She received her B.Sc. in biochemistry from the Hogeschool of Arnhem and Nijmegen, Nijmegen, The Netherlands; her M.Sc. in biomedical science from Radboud University, Nijmegen; and her Ph.D. from Imperial College, London, UK, for her studies of the receptor-binding and transmission of influenza viruses. She currently studies the species tropism and transmission of Middle East respiratory syndrome coronavirus (MERS-CoV).
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Falzarano
         </surname>
         <given-names>
          Darryl
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
        <bio>
         <p id="Par3">
          Darryl Falzarano is a research scientist at the Vaccine and Infectious Disease Organization–International Vaccine Centre (VIDO–InterVac) and an adjunct professor in the Department of Veterinary Microbiology, both at the University of Saskatchewan, Saskatoon, Canada. He received his Ph.D. in medical microbiology from the University of Manitoba, Winnipeg, Canada, where he studied the relationship between protein structure and function of Ebola virus glycoproteins. As a visiting fellow at the Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA, he developed antiviral therapeutic strategies and animal models for MERS-CoV. His laboratory is currently focused on the development of vaccine strategies and large-animal models for Middle East respiratory syndrome coronavirus (MERS-CoV).
          <ext-link ext-link-type="uri" xlink:href="http://vido.org/team/project-leaders/darryl-falzarano">
           Darryl Falzarano's homepage
          </ext-link>
          .
         </p>
        </bio>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Munster
         </surname>
         <given-names>
          Vincent J.
         </given-names>
        </name>
        <address>
         <email>
          vincent.munster@nih.gov
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <bio>
         <p id="Par4">
          Vincent J. Munster is the chief of the Virus Ecology Unit of the Laboratory of Virology at the Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA. He received his Ph.D. in virology from Erasmus University Rotterdam, The Netherlands, where he studied the ecology, evolution and pathogenesis of avian influenza viruses. His laboratory focuses on the ecology of emerging viruses and drivers of zoonotic and cross-species transmission.
          <ext-link ext-link-type="uri" xlink:href="http://www.niaid.nih.gov/labsandresources/labs/aboutlabs/lv/virusecology/Pages/default.aspx">
           Vincent J. Munster's homepage
          </ext-link>
          .
         </p>
        </bio>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.419681.3
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 2164 9667
         </institution-id>
         <institution>
          Division of Intramural Research,
         </institution>
         <institution>
          Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories,
         </institution>
        </institution-wrap>
        Hamilton, 59840 Montana USA
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.25152.31
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 2154 235X
         </institution-id>
         <institution>
          Vaccine and Infectious Disease Organization – International Vaccine Centre and Department of Veterinary Microbiology,
         </institution>
         <institution>
          University of Saskatchewan,
         </institution>
        </institution-wrap>
        120 Veterinary Road, Saskatoon, S7N 5E3 Saskatchewan Canada
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        27
       </day>
       <month>
        6
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <year>
        2016
       </year>
      </pub-date>
      <volume>
       14
      </volume>
      <issue>
       8
      </issue>
      <fpage>
       523
      </fpage>
      <lpage>
       534
      </lpage>
      <permissions>
       <copyright-statement>
        © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2016
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="KeyPoints" id="Abs1">
       <title>
        Key Points
       </title>
       <p id="Par5">
        <list list-type="bullet">
         <list-item>
          <p id="Par6">
           Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are zoonotic pathogens that can cause severe respiratory disease in humans. Although disease progression is fairly similar for SARS and MERS, the case fatality rate of MERS is much higher than that of SARS.
          </p>
         </list-item>
         <list-item>
          <p id="Par7">
           Comorbidities have an important role in SARS and MERS. Several risk factors are associated with progression to acute respiratory distress syndrome (ARDS) in SARS and MERS cases, especially advanced age and male sex. For MERS, additional risk factors that are associated with severe disease include chronic conditions such as diabetes mellitus, hypertension, cancer, renal and lung disease, and co-infections.
          </p>
         </list-item>
         <list-item>
          <p id="Par8">
           Although the ancestors of SARS-CoV and MERS-CoV probably circulate in bats, zoonotic transmission of SARS-CoV required an incidental amplifying host. Dromedary camels are the MERS-CoV reservoir from which zoonotic transmission occurs; serological evidence indicates that MERS-CoV-like viruses have been circulating in dromedary camels for at least three decades.
          </p>
         </list-item>
         <list-item>
          <p id="Par9">
           Human-to-human transmission of SARS-CoV and MERS-CoV occurs mainly in health care settings. Patients do not shed large amounts of virus until well after the onset of symptoms, when patients are most probably already seeking medical care. Analysis of hospital surfaces after the treatment of patients with MERS showed the ubiquitous presence of infectious virus.
          </p>
         </list-item>
         <list-item>
          <p id="Par10">
           Our understanding of the pathogenesis of SARS-CoV and MERS-CoV is still incomplete, but the combination of viral replication in the lower respiratory tract and an aberrant immune response is thought to have a crucial role in the severity of both syndromes.
          </p>
         </list-item>
         <list-item>
          <p id="Par11">
           The severity of the diseases that are caused by emerging coronaviruses highlights the need to develop effective therapeutic measures against these viruses. Although several treatments for SARS and MERS (based on inhibition of viral replication with drugs or neutralizing antibodies, or on dampening the host response) have been identified in animal models and
           <italic>
            in vitro
           </italic>
           studies, efficacy data from human clinical trials are urgently required.
          </p>
         </list-item>
        </list>
       </p>
       <sec>
        <title>
         Supplementary information
        </title>
        <p>
         The online version of this article (doi:10.1038/nrmicro.2016.81) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <abstract abstract-type="web-summary" id="Abs2">
       <p id="Par12">
        Insights into coronavirus emergence, replication and pathogenesis gained from the SARS and MERS outbreaks have guided the development of preventive and therapeutic measures. In this Review, Munster and colleagues highlight recent achievements and areas that need to be addressed to combat novel coronaviruses.
       </p>
       <sec>
        <title>
         Supplementary information
        </title>
        <p>
         The online version of this article (doi:10.1038/nrmicro.2016.81) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <abstract id="Abs3">
       <p id="Par13">
        The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 marked the second introduction of a highly pathogenic coronavirus into the human population in the twenty-first century. The continuing introductions of MERS-CoV from dromedary camels, the subsequent travel-related viral spread, the unprecedented nosocomial outbreaks and the high case-fatality rates highlight the need for prophylactic and therapeutic measures. Scientific advancements since the 2002–2003 severe acute respiratory syndrome coronavirus (SARS-CoV) pandemic allowed for rapid progress in our understanding of the epidemiology and pathogenesis of MERS-CoV and the development of therapeutics. In this Review, we detail our present understanding of the transmission and pathogenesis of SARS-CoV and MERS-CoV, and discuss the current state of development of measures to combat emerging coronaviruses.
       </p>
       <sec>
        <title>
         Supplementary information
        </title>
        <p>
         The online version of this article (doi:10.1038/nrmicro.2016.81) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
       <title>
        Subject terms
       </title>
       <kwd>
        SARS virus
       </kwd>
       <kwd>
        Viral pathogenesis
       </kwd>
       <kwd>
        Antivirals
       </kwd>
       <kwd>
        Viral transmission
       </kwd>
       <kwd>
        Viral reservoirs
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer Nature Limited 2016
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Main
     </title>
     <p id="Par14">
      This century has seen the global spread of two previously unknown coronaviruses. In November 2002, the first known case of severe acute respiratory syndrome (SARS) occurred in Foshan, China
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
      </sup>
      . New cases emerged in mainland China, and by February 2003, more than 300 cases had been reported, around one-third of which were in health care workers
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
      </sup>
      . Individuals who were infected and subsequently travelled spread the outbreak to Hong Kong
      <sup>
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
      </sup>
      and from there to Vietnam, Canada and several other countries
      <sup>
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
      </sup>
      . In March 2003, the WHO established a network of laboratories to determine the causative agent of SARS. A remarkable global effort led to the identification of SARS coronavirus (SARS-CoV) in early April of that year
      <sup>
       <xref ref-type="bibr" rid="CR4">
        4
       </xref>
       ,
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
      </sup>
      . By July 2003 and after a total of 8,096 reported cases, including 774 deaths in 27 countries
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      , no more infections were detected, and the SARS pandemic was declared to be over. Five additional SARS cases, resulting from zoonotic transmission, occurred in December 2003–January 2004 (Ref.
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ), but no human SARS cases have been detected since. Measures of infection control, rather than medical interventions, ended the SARS pandemic. However, certain SARS-CoV-like viruses found in bats have recently been shown to be able to infect human cells without prior adaptation
      <sup>
       <xref ref-type="bibr" rid="CR9">
        9
       </xref>
       ,
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
      </sup>
      , which indicates that SARS could re-emerge.
     </p>
     <p id="Par15">
      In June 2012, 10 years after the first emergence of SARS-CoV, a man in Saudi Arabia died of acute pneumonia and renal failure. A novel coronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV), was isolated from his sputum
      <sup>
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
      </sup>
      . A cluster of cases of severe respiratory disease had occurred in April 2012 in a hospital in Jordan and was retrospectively diagnosed as MERS
      <sup>
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
      </sup>
      , and a cluster of three cases of MERS in the UK was identified in September 2012 (Ref.
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      ). MERS-CoV continued to emerge and spread to countries outside of the Arabian Peninsula as a result of travel of infected persons; often, these imported MERS cases resulted in
      <xref ref-type="list" rid="Glos1">
       nosocomial transmission
      </xref>
      . In May 2015, a single person returning from the Middle East started a nosocomial outbreak of MERS in South Korea that involved 16 hospitals and 186 patients
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
      </sup>
      . As of 26 April 2016, there have been 1,728 confirmed cases of MERS, including 624 deaths in 27 countries
      <sup>
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
      </sup>
      .
     </p>
     <p id="Par16">
      This Review highlights the pandemic and epidemic potential of emerging coronaviruses and discusses our current knowledge of the biology of SARS-CoV and MERS-CoV, including their transmission, their pathogenesis and the development of medical countermeasures. Key features of these viruses are the dominance of nosocomial transmission, and pathogenesis that is driven by a combination of viral replication in the lower respiratory tract and an aberrant host immune response. Several potential treatments for SARS and MERS have been identified in animal and
      <italic>
       in vitro
      </italic>
      models, including small-molecule protease inhibitors, neutralizing antibodies and inhibitors of the host immune response. However, efficacy data from human clinical trials are lacking but are needed to move these potential countermeasures forward.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Replication of SARS-CoV and MERS-CoV
     </title>
     <p id="Par17">
      SARS-CoV and MERS-CoV belong to the Coronavirus genus in the
      <italic>
       Coronaviridae
      </italic>
      family and have large, positive-sense RNA genomes of 27.9 kb and 30.1 kb, respectively (
      <xref ref-type="fig" rid="Fig1">
       Fig. 1a
      </xref>
      ). Similarly to all viruses in the order
      <italic>
       Nidovirales
      </italic>
      , SARS-CoV and MERS-CoV have a unique coding strategy: two-thirds of the viral RNA is translated into two large polyproteins, and the remainder of the viral genome is transcribed into a nested set of subgenomic mRNAs
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
      </sup>
      (
      <xref ref-type="fig" rid="Fig1">
       Fig. 1b
      </xref>
      ). The two polyproteins, pp1a and pp1ab, encode 16 non-structural proteins (nsp1–nsp16)
      <sup>
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
      </sup>
      that make up the viral replicase–transcriptase complex. The polyproteins are cleaved by two proteases, papain-like protease (PLpro; corresponding to nsp3) and a main protease, 3C-like protease (3CLpro; corresponding to nsp5). The nsps rearrange membranes that are derived from the rough endoplasmic reticulum (RER) into double-membrane vesicles, in which viral replication and transcription occur
      <sup>
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
      </sup>
      . One unique feature of coronaviruses is the exoribonuclease (ExoN) function of nsp14 (Ref.
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ), which provides the
      <xref ref-type="list" rid="Glos2">
       proofreading
      </xref>
      capability required to maintain a large RNA genome without the accumulation of detrimental mutations
      <sup>
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="CR22">
        22
       </xref>
      </sup>
      . SARS-CoV and MERS-CoV transcribe 12 and 9 subgenomic RNAs, respectively, and these encode the four structural proteins spike (S), envelope (E), membrane (M) and nucleocapsid (N), as well as several accessory proteins that are not involved in viral replication but interfere with the host innate immune response or are of unknown or poorly understood function.
      <fig id="Fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <title>
         SARS-CoV and MERS-CoV structure and replication.
        </title>
        <p>
         <bold>
          a
         </bold>
         | The single-stranded RNA (ssRNA) genomes of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) encode two large polyproteins, pp1a and pp1ab, which are proteolytically cleaved into 16 non-structural proteins (nsps), including papain-like protease (PLpro), 3C-like protease (3CLpro), RNA-dependent RNA polymerase (RdRp), helicase (Hel) and exonuclease (ExoN). An additional 9–12 ORFs are encoded through the transcription of a nested set of subgenomic RNAs. SARS-CoV and MERS-CoV form spherical particles that consist of four structural proteins. The envelope glycoprotein spike (S) forms a layer of glycoproteins that protrude from the envelope. Two additional transmembrane glycoproteins are incorporated in the virion: envelope (E) and membrane (M). Inside the viral envelope resides the helical nucleocapsid, which consists of the viral positive-sense RNA ((+)RNA) genome encapsidated by protein nucleocapsid (N).
         <bold>
          b
         </bold>
         | Following entry of the virus into the host cell, the viral RNA is uncoated in the cytoplasm. ORF1a and ORF1ab are translated to produce pp1a and pp1ab, which are cleaved by the proteases that are encoded by ORF1a to yield 16 nsps that form the RNA replicase–transcriptase complex. This complex localizes to modified intracellular membranes that are derived from the rough endoplasmic reticulum (ER) in the perinuclear region, and it drives the production of negative-sense RNAs ((−)RNAs) through both replication and transcription. During replication, full-length (−)RNA copies of the genome are produced and used as templates for full-length (+)RNA genomes. During transcription, a subset of 7–9 subgenomic RNAs, including those encoding all structural proteins, is produced through discontinuous transcription. In this process, subgenomic (−)RNAs are synthesized by combining varying lengths of the 3′ end of the genome with the 5′ leader sequence necessary for translation. These subgenomic (−)RNAs are then transcribed into subgenomic (+)mRNAs. Although the different subgenomic mRNAs may contain several ORFs, only the first ORF (that closest to the 5′ end) is translated. The resulting structural proteins are assembled into the nucleocapsid and viral envelope at the ER–Golgi intermediate compartment (ERGIC), followed by release of the nascent virion from the infected cell.
        </p>
        <p>
         <xref ref-type="media" rid="MOESM6">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <graphic id="d29e432" xlink:href="41579_2016_Article_BFnrmicro201681_Fig1_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par18">
      The envelope spike glycoprotein binds to its cellular receptor, angiotensin-converting enzyme 2 (ACE2) for SARS-CoV and dipeptidyl peptidase 4 (DPP4) for MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
      </sup>
      . After membrane fusion, either directly with the host cell membrane or with the endosome membrane, the viral RNA genome is released into the cytoplasm, and the RNA is uncoated to allow translation of the two polyproteins, transcription of the subgenomic RNAs and replication of the viral genome (
      <xref ref-type="fig" rid="Fig1">
       Fig. 1b
      </xref>
      ). Newly formed envelope glycoproteins are inserted in the RER or Golgi membranes; genomic RNA and nucleocapsid proteins combine to form nucleocapsids, and the viral particles bud into the
      <xref ref-type="list" rid="Glos3">
       ER–Golgi intermediate compartment
      </xref>
      (ERGIC). Virion-containing vesicles subsequently fuse with the plasma membrane to release the virus
      <sup>
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec3">
     <title>
      Reservoirs and transmission
     </title>
     <p id="Par19">
      The first indication of the source of SARS-CoV was the detection of the virus in masked palm civets and a raccoon dog and the detection of antibodies against the virus in Chinese ferret badgers in a live-animal market in Shenzhen, China
      <sup>
       <xref ref-type="bibr" rid="CR25">
        25
       </xref>
      </sup>
      . However, these animals were only incidental hosts, as there was no evidence for the circulation of SARS-CoV-like viruses in palm civets in the wild or in breeding facilities
      <sup>
       <xref ref-type="bibr" rid="CR26">
        26
       </xref>
      </sup>
      . Rather, bats are the reservoir of a wide variety of coronaviruses, including SARS-CoV-like and MERS-CoV-like viruses
      <sup>
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
      </sup>
      (
      <xref ref-type="fig" rid="Fig2">
       Fig. 2
      </xref>
      ).
      <fig id="Fig2">
       <label>
        Figure 2
       </label>
       <caption>
        <title>
         The emergence of SARS-CoV and MERS-CoV.
        </title>
        <p>
         Bats harbour a wide range of coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV)-like and Middle East respiratory syndrome coronavirus (MERS-CoV)-like viruses. SARS-CoV crossed the species barrier into masked palm civets and other animals in live-animal markets in China; genetic analysis suggests that this occurred in late 2002. Several people in close proximity to palm civets became infected with SARS-CoV. A MERS-CoV ancestral virus crossed the species barrier into dromedary camels; serological evidence suggests that this happened more than 30 years ago. Abundant circulation of MERS-CoV in dromedary camels results in frequent zoonotic transmission of this virus. SARS-CoV and MERS-CoV spread between humans mainly through nosocomial transmission, which results in the infection of health care workers and patients at a higher frequency than infection of their relatives.
        </p>
        <p>
         <xref ref-type="media" rid="MOESM7">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <graphic id="d29e484" xlink:href="41579_2016_Article_BFnrmicro201681_Fig2_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par20">
      Thus, the search for the reservoir of MERS-CoV initially focused on bats, but a serological survey in dromedary camels from Oman and the Canary Islands showed a high prevalence of MERS-CoV-neutralizing antibodies in these animals
      <sup>
       <xref ref-type="bibr" rid="CR28">
        28
       </xref>
      </sup>
      . In addition, MERS-CoV RNA was detected in swabs that were collected from dromedary camels at a farm in Qatar that was linked to two human cases of MERS, and infectious virus was isolated from dromedary camels in Saudi Arabia and Qatar
      <sup>
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
       ,
       <xref ref-type="bibr" rid="CR31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
      </sup>
      . Serological evidence for the circulation of a MERS-CoV-like virus in dromedary camels has been obtained in the Middle East, Eastern Africa and Northern Africa, dating back as far as 1983 (Ref.
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ). Dromedary camels in Saudi Arabia harbour several viral genetic lineages
      <sup>
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
      </sup>
      , including those that have caused human outbreaks. Taken together, these data strongly point to the role of dromedary camels as a reservoir for MERS-CoV. The ubiquity of infected dromedary camels close to humans and the resulting continuing zoonotic transmission may explain why MERS-CoV continues to cause infections in humans, whereas SARS-CoV, without the continuing presence of an infected intermediate host and with relatively infrequent human–bat interactions, has caused no more infections in humans.
     </p>
     <p id="Par21">
      Human-to-human transmission of SARS-CoV and MERS-CoV occurs mainly through nosocomial transmission; 43.5–100% of MERS cases in individual outbreaks were linked to hospitals, and very similar observations were made for some of the SARS clusters
      <sup>
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="CR36">
        36
       </xref>
      </sup>
      . Transmission between family members occurred in only 13–21% of MERS cases and 22–39% of SARS cases. Transmission of MERS-CoV between patients was the most common route of infection (62–79% of cases), whereas for SARS-CoV, infection of health care workers by infected patients was very frequent (33–42%)
      <sup>
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
      </sup>
      . The predominance of nosocomial transmission is probably due to the fact that substantial virus shedding occurs only after the onset of symptoms
      <sup>
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
      </sup>
      , when most patients are already seeking medical care
      <sup>
       <xref ref-type="bibr" rid="CR39">
        39
       </xref>
      </sup>
      . An analysis of hospital surfaces after the treatment of patients with MERS showed the ubiquitous presence of viral RNA in the environment for several days after patients no longer tested positive
      <sup>
       <xref ref-type="bibr" rid="CR40">
        40
       </xref>
      </sup>
      . Moreover, many patients with SARS or MERS were infected through
      <xref ref-type="list" rid="Glos4">
       super spreaders
      </xref>
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="CR41">
        41
       </xref>
       ,
       <xref ref-type="bibr" rid="CR42">
        42
       </xref>
       ,
       <xref ref-type="bibr" rid="CR43">
        43
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec4">
     <title>
      The pathogenesis of SARS-CoV and MERS-CoV
     </title>
     <p id="Par22">
      The clinical courses of SARS and MERS are remarkably similar, although there are subtle differences (
      <xref ref-type="sec" rid="Sec5">
       Box 1
      </xref>
      ). Owing to the current sparsity of data on human MERS-CoV infections
      <sup>
       <xref ref-type="bibr" rid="CR44">
        44
       </xref>
      </sup>
      , the pathogenesis of this virus is poorly understood; however, similar mechanisms may underlie the pathogenesis of both MERS and SARS.
     </p>
     <p id="Par23">
      The binding of spike protein to ACE2 and the subsequent downregulation of this receptor contribute to lung injury during SARS
      <sup>
       <xref ref-type="bibr" rid="CR45">
        45
       </xref>
      </sup>
      . Although it seems counterintuitive that receptor downregulation would increase pathology, it has been shown that ACE2 can protect against acute lung injury. The downregulation of ACE2 results in the excessive production of angiotensin II by the related enzyme ACE, and it has been suggested that the stimulation of type 1a angiotensin II receptor (AGTR1A) increases pulmonary vascular permeability, thus potentially explaining the increased lung pathology when the expression of ACE2 is decreased
      <sup>
       <xref ref-type="bibr" rid="CR46">
        46
       </xref>
      </sup>
      .
     </p>
     <p id="Par24">
      <bold>
       <italic>
        Immunopathology.
       </italic>
      </bold>
      The immune response is essential for the resolution of an infection, but it can also result in immunopathogenesis. One indication that immunopathogenesis may contribute to SARS was the observation that viral loads were found to be decreasing while disease severity increased
      <sup>
       <xref ref-type="bibr" rid="CR39">
        39
       </xref>
       ,
       <xref ref-type="bibr" rid="CR47">
        47
       </xref>
      </sup>
      . It is unclear whether a similar trend applies to MERS
      <sup>
       <xref ref-type="bibr" rid="CR48">
        48
       </xref>
       ,
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
      </sup>
      . Moreover, progression to
      <xref ref-type="list" rid="Glos5">
       acute respiratory distress syndrome
      </xref>
      (ARDS) is associated with the upregulation of pro-inflammatory cytokines and chemokines, particularly interleukin-1β (IL-1β), IL-8, IL-6, CXC-chemokine ligand 10 (CXCL10) and CC-chemokine ligand 2 (CCL2)
      <sup>
       <xref ref-type="bibr" rid="CR50">
        50
       </xref>
       ,
       <xref ref-type="bibr" rid="CR51">
        51
       </xref>
      </sup>
      ; increased plasma levels of these molecules have been detected in patients with SARS
      <sup>
       <xref ref-type="bibr" rid="CR52">
        52
       </xref>
       ,
       <xref ref-type="bibr" rid="CR53">
        53
       </xref>
       ,
       <xref ref-type="bibr" rid="CR54">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
      </sup>
      . Retrospective longitudinal studies in patients who recovered from SARS versus those who succumbed to the disease have shown an early expression of interferon-α (IFNα), IFNγ, CXCL10, CCL2 and proteins that are encoded by IFN-stimulated genes (ISGs) in all patients, but only patients who survived then had gene expression profiles that are indicative of the development of an adaptive immune response. By contrast, patients who succumbed maintained high levels of CXCL10, CCL2 and ISG-encoded proteins, whereas spike-specific antibodies were present at low levels or were absent
      <sup>
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
      </sup>
      , which suggests that severe disease is related to the lack of a switch from an innate immune response to an adaptive immune response.
     </p>
     <p id="Par25">
      Experiments using
      <xref ref-type="list" rid="Glos6">
       Collaborative Cross mouse
      </xref>
      lines and mouse-adapted SARS-CoV identified one host gene,
      <italic>
       Trim55
      </italic>
      , as important for SARS pathogenesis. Although there was no difference in clinical signs or viral replication in
      <italic>
       Trim55
      </italic>
      <sup>
       −/−
      </sup>
      mice compared with wild-type mice,
      <xref ref-type="list" rid="Glos7">
       perivascular cuffing
      </xref>
      and the number of inflammatory cells in the lungs were reduced in the
      <italic>
       Trim55
      </italic>
      <sup>
       −/−
      </sup>
      mice
      <sup>
       <xref ref-type="bibr" rid="CR57">
        57
       </xref>
      </sup>
      .
     </p>
     <p id="Par26">
      The involvement of the host immune response in the pathogenesis of SARS, and most likely also that of MERS, suggests that drugs which inhibit viral replication will need to be combined with treatments that control detrimental immune responses.
     </p>
     <p id="Par27">
      <bold>
       <italic>
        Immune evasion.
       </italic>
      </bold>
      SARS-CoV and MERS-CoV use several strategies to avoid the innate immune response. Viral pathogen-associated molecular patterns (PAMPs), such as double-stranded RNA (dsRNA) or uncapped mRNA, are detected by pattern recognition receptors (PRRs), such as retinoic acid-inducible gene I protein (RIG-I; also known as DDX58) or melanoma differentiation-associated protein 5 (MDA5; also known as IFIH1)
      <sup>
       <xref ref-type="bibr" rid="CR58">
        58
       </xref>
      </sup>
      . This triggers complex signalling cascades involving MYD88 that lead to the production of
      <xref ref-type="list" rid="Glos8">
       type I IFNs
      </xref>
      and the activation of the transcription factor nuclear factor-κB (NF-κB). In turn, active NF-κB induces the transcription of pro-inflammatory cytokines (
      <xref ref-type="fig" rid="Fig3">
       Fig. 3a
      </xref>
      ). Type I IFNs signal through IFNα/β receptor (IFNAR) and downstream molecules such as signal transducer and activator of transcription (STAT) proteins to stimulate the production of antiviral proteins that are encoded by ISGs, such as IFN-induced protein with tetratricopeptide repeats 1 (IFIT1;
      <xref ref-type="fig" rid="Fig3">
       Fig. 3b
      </xref>
      ). Collectively, this establishes an antiviral immune response that limits viral replication in infected and in neighbouring cells (
      <xref ref-type="fig" rid="Fig3">
       Fig. 3
      </xref>
      ).
      <fig id="Fig3">
       <label>
        Figure 3
       </label>
       <caption>
        <title>
         Evasion of the innate immune response by SARS-CoV and MERS-CoV.
        </title>
        <p>
         <bold>
          a
         </bold>
         | The innate immune response is activated by the detection of viral pathogen-associated molecular patterns (PAMPs), such as double-stranded RNA (dsRNA) or uncapped mRNA. This occurs via host pattern recognition receptors (PRRs), such as retinoic acid-inducible gene I protein (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), potentially via dsRNA-binding partners such as IFN-inducible dsRNA-dependent protein kinase activator A (PRKRA). Following PRR-mediated detection of a PAMP, the resulting interaction of PRRs with mitochondrial antiviral-signalling protein (MAVS) activates nuclear factor-κB (NF-κB) through a signalling cascade involving several kinases. Activated NF-κB translocates to the nucleus, where it induces the transcription of pro-inflammatory cytokines. The kinases also phosphorylate (P) IFN-regulatory factor 3 (IRF3) and IRF7, which form homodimers and heterodimers and enter the nucleus to initiate the transcription of type I interferons (type I IFNs). Both severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have developed mechanisms to interfere with these signalling pathways, as shown; these subversion strategies involve both structural proteins (membrane (M) and nucleocapsid (N)) and non-structural proteins (nsp1, nsp3b, nsp4a, nsp4b, nsp5, nsp6 and papain-like protease (PLpro); indicated in the figure by just their nsp numbers and letters).
         <bold>
          b
         </bold>
         | Binding of type I IFNs to their dimeric receptor, IFNα/β receptor (IFNAR), activates the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway, in which JAK1 and TYK2 kinases phosphorylate STAT1 and STAT2, which form complexes with IRF9. These complexes move into the nucleus to initiate the transcription of IFN-stimulated genes (ISGs) under the control of promoters that contain an IFN-stimulated response element (ISRE). Collectively, the expression of cytokines, IFNs and ISGs establishes an antiviral innate immune response that limits viral replication in infected and in neighbouring cells. Again, viral proteins have been shown to inhibit these host signalling pathways to evade this immune response. IκBα, NF-κB inhibitor-α.
        </p>
        <p>
         <xref ref-type="media" rid="MOESM8">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <graphic id="d29e698" xlink:href="41579_2016_Article_BFnrmicro201681_Fig3_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par28">
      Infection of knockout mice revealed the importance of innate immunity. Infection of
      <italic>
       Myd88
      </italic>
      <sup>
       −/−
      </sup>
      and
      <italic>
       Stat1
      </italic>
      <sup>
       −/−
      </sup>
      mice, but not mice that were deficient in IFN receptors, with a mouse-adapted strain of SARS-CoV resulted in more severe disease than infection with a non-adapted SARS-CoV strain
      <sup>
       <xref ref-type="bibr" rid="CR59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="CR60">
        60
       </xref>
      </sup>
      . Moreover, MERS-CoV infection of wild-type mice that were transduced with human DPP4 caused mild disease, but symptoms were more severe in
      <italic>
       Myd88
      </italic>
      <sup>
       −/−
      </sup>
      mice and
      <italic>
       Ifnar1
      </italic>
      <sup>
       −/−
      </sup>
      mice
      <sup>
       <xref ref-type="bibr" rid="CR61">
        61
       </xref>
      </sup>
      .
     </p>
     <p id="Par29">
      SARS-CoV and MERS-CoV avoid host detection of their dsRNA by replicating in virus-induced double-membrane vesicles that lack PRRs
      <sup>
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="CR62">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="CR63">
        63
       </xref>
      </sup>
      . Moreover, the recognition of SARS-CoV mRNAs, for example, by MDA5 and IFIT1 is prevented by capping of the viral mRNAs by nsp14 and the nsp10–nsp16 complex
      <sup>
       <xref ref-type="bibr" rid="CR64">
        64
       </xref>
      </sup>
      . Recombinant SARS-CoV that lacks the methylation activity of nsp16 is attenuated and exhibits increased sensitivity to type I IFNs. This effect is dependent on IFIT1 or MDA5, as the same virus is not attenuated in mice that are deficient in either molecule
      <sup>
       <xref ref-type="bibr" rid="CR65">
        65
       </xref>
      </sup>
      . Although mRNA capping has not yet been shown for MERS-CoV, structural similarity between the MERS-CoV nsp10–nsp16 complex and the SARS-CoV nsp10–nsp16 complex suggests that a similar mechanism exists to avoid host recognition of MERS-CoV mRNAs by cytosolic PRRs
      <sup>
       <xref ref-type="bibr" rid="CR66">
        66
       </xref>
      </sup>
      .
     </p>
     <p id="Par30">
      SARS-CoV encodes at least eight proteins that interact with the signalling cascades downstream of PRRs; in MERS-CoV, several proteins have been identified with similar functions (
      <xref ref-type="fig" rid="Fig3">
       Fig. 3
      </xref>
      ). The nucleocapsid protein of SARS-CoV has been associated with the suppression of
      <xref ref-type="list" rid="Glos9">
       RNAi
      </xref>
      in mammalian cells
      <sup>
       <xref ref-type="bibr" rid="CR67">
        67
       </xref>
      </sup>
      . Furthermore, this protein antagonizes IFN induction, probably early in the signalling cascade, as downstream signalling molecules relieve the inhibition
      <sup>
       <xref ref-type="bibr" rid="CR68">
        68
       </xref>
      </sup>
      . MERS-CoV ORF4a has a similar IFN-antagonistic function, involving the binding of dsRNA and subsequent inhibition of MDA5 activation
      <sup>
       <xref ref-type="bibr" rid="CR69">
        69
       </xref>
      </sup>
      , potentially through interaction with IFN-inducible dsRNA-dependent protein kinase activator A (PRKRA; also known as PACT), which interacts with MDA5 and RIG-I
      <sup>
       <xref ref-type="bibr" rid="CR70">
        70
       </xref>
      </sup>
      . Moreover, MERS-CoV ORF4a, ORF4b, ORF5 and membrane protein inhibit the nuclear trafficking of IFN-regulatory factor 3 (IRF3) and activation of the
      <italic>
       IFNB
      </italic>
      promoter
      <sup>
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
      </sup>
      . These viral proteins, except for ORF5, also inhibit the expression of genes that are under the control of an IFN-stimulated response element (ISRE), and ORF4a reduces the expression of genes that are stimulated by NF-κB
      <sup>
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
      </sup>
      . Finally, MERS-CoV ORF4b interacts with TBK1 and inhibitor of NF-κB kinase-ɛ (IKKɛ), thereby suppressing the interaction between IKKɛ and mitochondrial antiviral-signalling protein (MAVS) and inhibiting the phosphorylation of IRF3 (Ref.
      <xref ref-type="bibr" rid="CR72">
       72
      </xref>
      ).
     </p>
     <p id="Par31">
      The membrane protein of SARS-CoV inhibits the formation of a signalling complex that contains IKKɛ, thus repressing the activation of IRF3 and IRF7 and their induction of type I IFN expression. The membrane protein of MERS-CoV inhibits IRF3 function and the expression of genes that are regulated by an ISRE, including IFNβ
      <sup>
       <xref ref-type="bibr" rid="CR71">
        71
       </xref>
      </sup>
      , but whether this occurs through a mechanism similar to that of SARS-CoV is unclear.
     </p>
     <p id="Par32">
      SARS-CoV PLpro disrupts NF-κB signalling
      <sup>
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      and blocks the phosphorylation of IRF3 indirectly
      <sup>
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
       ,
       <xref ref-type="bibr" rid="CR74">
        74
       </xref>
      </sup>
      . Furthermore, SARS-CoV PLpro inhibits the induction of type I IFNs, potentially through the deubiquitylation of phosphorylated IRF3 (Refs
      <xref ref-type="bibr" rid="CR73">
       73
      </xref>
      ,
      <xref ref-type="bibr" rid="CR75">
       75
      </xref>
      ). Similar functions have been described for MERS-CoV PLpro
      <sup>
       <xref ref-type="bibr" rid="CR76">
        76
       </xref>
      </sup>
      .
     </p>
     <p id="Par33">
      Experiments involving recombinantly expressed proteins,
      <italic>
       in vitro
      </italic>
      translation, protein overexpression and
      <xref ref-type="list" rid="Glos10">
       minireplicon systems
      </xref>
      have shown that nsp1 of SARS-CoV blocks the IFN response through the inhibition of STAT1, degradation of host mRNAs and inactivation of the host translational machinery through a tight association with the 40S ribosomal subunit
      <sup>
       <xref ref-type="bibr" rid="CR77">
        77
       </xref>
       ,
       <xref ref-type="bibr" rid="CR78">
        78
       </xref>
       ,
       <xref ref-type="bibr" rid="CR79">
        79
       </xref>
       ,
       <xref ref-type="bibr" rid="CR80">
        80
       </xref>
      </sup>
      . Nsp1 of MERS-CoV also inhibits the translation of mRNAs and induces mRNA degradation, although the translational inhibition is achieved through a different mechanism than ribosome binding, which selectively targets the translation of nuclear mRNAs and thereby spares cytoplasmic viral mRNAs
      <sup>
       <xref ref-type="bibr" rid="CR81">
        81
       </xref>
      </sup>
      .
     </p>
     <p id="Par34">
      SARS-CoV ORF3b inhibits the production of type I IFN, the phosphorylation of IRF3 and gene expression from an ISRE promoter
      <sup>
       <xref ref-type="bibr" rid="CR82">
        82
       </xref>
       ,
       <xref ref-type="bibr" rid="CR83">
        83
       </xref>
      </sup>
      . SARS-CoV ORF6 also blocks the nuclear translocation of STAT1 (Ref.
      <xref ref-type="bibr" rid="CR83">
       83
      </xref>
      ).
     </p>
     <p id="Par35">
      Both nsp7 and nsp15 from SARS-CoV were also suggested to be IFN antagonists, but the underlying mechanism is unknown
      <sup>
       <xref ref-type="bibr" rid="CR73">
        73
       </xref>
      </sup>
      . nsp15 is an inhibitor of MAVS-induced apoptosis; however, this occurs through an IFN-independent mechanism
      <sup>
       <xref ref-type="bibr" rid="CR84">
        84
       </xref>
      </sup>
      . Finally, transcriptomic and proteomic analysis of human airway cell cultures showed that MERS-CoV but not SARS-CoV induces repressive histone modifications that downregulate the expression of certain ISGs
      <sup>
       <xref ref-type="bibr" rid="CR85">
        85
       </xref>
      </sup>
      .
     </p>
     <p id="Par36">
      It should be noted that most of the interactions of SARS-CoV and MERS-CoV proteins with innate immune pathways were established in
      <italic>
       in vitro
      </italic>
      systems, which rely on the overexpression of viral and, sometimes, cellular proteins, and these interactions have rarely been confirmed in the context of viral replication
      <italic>
       in vitro
      </italic>
      or
      <italic>
       in vivo
      </italic>
      .
     </p>
     <sec id="Sec5">
      <boxed-text>
       <label>
        Box 1: Clinical features of SARS and MERS
       </label>
       <p id="Par37">
        Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have an incubation period of ∼5 days, and 95% of patients develop disease within 13 days of exposure
        <sup>
         <xref ref-type="bibr" rid="CR14">
          14
         </xref>
         ,
         <xref ref-type="bibr" rid="CR38">
          38
         </xref>
         ,
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR145">
          145
         </xref>
         ,
         <xref ref-type="bibr" rid="CR146">
          146
         </xref>
        </sup>
        . Common early symptoms are fever, chills, coughing, malaise, myalgia and headache, and less common symptoms include diarrhoea, vomiting and nausea
        <sup>
         <xref ref-type="bibr" rid="CR2">
          2
         </xref>
         ,
         <xref ref-type="bibr" rid="CR6">
          6
         </xref>
         ,
         <xref ref-type="bibr" rid="CR39">
          39
         </xref>
         ,
         <xref ref-type="bibr" rid="CR89">
          89
         </xref>
         ,
         <xref ref-type="bibr" rid="CR90">
          90
         </xref>
         ,
         <xref ref-type="bibr" rid="CR92">
          92
         </xref>
         ,
         <xref ref-type="bibr" rid="CR95">
          95
         </xref>
         ,
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR146">
          146
         </xref>
         ,
         <xref ref-type="bibr" rid="CR147">
          147
         </xref>
         ,
         <xref ref-type="bibr" rid="CR148">
          148
         </xref>
        </sup>
        . Upper respiratory tract symptoms and viral shedding are rare, which explains difficulties in obtaining a laboratory diagnosis from nasal or nasopharyngeal swabs
        <sup>
         <xref ref-type="bibr" rid="CR149">
          149
         </xref>
        </sup>
        . Abnormal chest X-rays are more common in patients with MERS (90–100%)
        <sup>
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR148">
          148
         </xref>
        </sup>
        than in those with SARS (60–100%)
        <sup>
         <xref ref-type="bibr" rid="CR39">
          39
         </xref>
         ,
         <xref ref-type="bibr" rid="CR89">
          89
         </xref>
        </sup>
        . Accordingly, only 20–30% of patients with SARS require intensive care and subsequent mechanical ventilation, whereas 50–89% of patients with MERS require intensive care
        <sup>
         <xref ref-type="bibr" rid="CR2">
          2
         </xref>
         ,
         <xref ref-type="bibr" rid="CR39">
          39
         </xref>
         ,
         <xref ref-type="bibr" rid="CR89">
          89
         </xref>
         ,
         <xref ref-type="bibr" rid="CR90">
          90
         </xref>
         ,
         <xref ref-type="bibr" rid="CR95">
          95
         </xref>
         ,
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR147">
          147
         </xref>
         ,
         <xref ref-type="bibr" rid="CR148">
          148
         </xref>
        </sup>
        . The higher incidence of acute respiratory distress syndrome (ARDS) in individuals with MERS is reflected in the case fatality rate: this is ∼36% for MERS compared with ∼10% for SARS
        <sup>
         <xref ref-type="bibr" rid="CR15">
          15
         </xref>
         ,
         <xref ref-type="bibr" rid="CR145">
          145
         </xref>
        </sup>
        .
       </p>
       <p id="Par38">
        Comorbidities have an important role in both SARS and MERS. Several risk factors are associated with poor disease outcome, especially advanced age and male sex
        <sup>
         <xref ref-type="bibr" rid="CR2">
          2
         </xref>
         ,
         <xref ref-type="bibr" rid="CR14">
          14
         </xref>
         ,
         <xref ref-type="bibr" rid="CR39">
          39
         </xref>
         ,
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR146">
          146
         </xref>
         ,
         <xref ref-type="bibr" rid="CR148">
          148
         </xref>
         ,
         <xref ref-type="bibr" rid="CR150">
          150
         </xref>
         ,
         <xref ref-type="bibr" rid="CR151">
          151
         </xref>
        </sup>
        . For MERS, additional risk factors for a poor outcome include diabetes mellitus, hypertension, cancer, renal and lung disease, and co-infections
        <sup>
         <xref ref-type="bibr" rid="CR14">
          14
         </xref>
         ,
         <xref ref-type="bibr" rid="CR144">
          144
         </xref>
         ,
         <xref ref-type="bibr" rid="CR146">
          146
         </xref>
         ,
         <xref ref-type="bibr" rid="CR148">
          148
         </xref>
         ,
         <xref ref-type="bibr" rid="CR150">
          150
         </xref>
         ,
         <xref ref-type="bibr" rid="CR151">
          151
         </xref>
        </sup>
        .
       </p>
       <p id="Par39">
        Health care settings seem to increase the risk of viral transmission owing to aerosol-generating procedures such as intubation and bronchoscopy. Appropriate hospital hygiene practices and awareness are crucial to limit future nosocomial outbreaks.
       </p>
      </boxed-text>
     </sec>
    </sec>
    <sec id="Sec6">
     <title>
      Treatment of severe coronavirus infections
     </title>
     <p id="Par40">
      Several strategies are being considered to treat infections with MERS-CoV (
      <xref ref-type="table" rid="Tab1">
       Table 1
      </xref>
      ) and SARS-CoV, including the use of antibodies, IFNs, inhibitors of viral and host proteases, and host-directed therapies.
      <table-wrap id="Tab1">
       <label>
        Table 1
       </label>
       <caption>
        <title>
         Potential therapeutics for MERS
        </title>
        <p>
         <xref ref-type="media" rid="MOESM9">
          PowerPoint slide
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Treatment
          </th>
          <th>
           Stage of development
          </th>
          <th>
           References
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           Host protease inhibitors
          </td>
          <td>
           <italic>
            In vitro
           </italic>
           inhibition
          </td>
          <td>
           <xref ref-type="bibr" rid="CR132">
            132
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Viral protease inhibitors
          </td>
          <td>
           <italic>
            In vitro
           </italic>
           inhibition
          </td>
          <td>
           <xref ref-type="bibr" rid="CR97">
            97
           </xref>
           ,
           <xref ref-type="bibr" rid="CR99">
            99
           </xref>
           ,
           <xref ref-type="bibr" rid="CR112">
            112
           </xref>
           ,
           <xref ref-type="bibr" rid="CR113">
            113
           </xref>
           ,
           <xref ref-type="bibr" rid="CR114">
            114
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Repurposed FDA-approved drugs
          </td>
          <td>
           <italic>
            In vitro
           </italic>
           inhibition
          </td>
          <td>
           <xref ref-type="bibr" rid="CR62">
            62
           </xref>
           ,
           <xref ref-type="bibr" rid="CR99">
            99
           </xref>
           ,
           <xref ref-type="bibr" rid="CR113">
            113
           </xref>
           ,
           <xref ref-type="bibr" rid="CR115">
            115
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Monoclonal and polyclonal antibodies
          </td>
          <td>
           Effective in mouse, rabbit and non-human primate models
          </td>
          <td>
           <xref ref-type="bibr" rid="CR118">
            118
           </xref>
           ,
           <xref ref-type="bibr" rid="CR119">
            119
           </xref>
           ,
           <xref ref-type="bibr" rid="CR120">
            120
           </xref>
           ,
           <xref ref-type="bibr" rid="CR121">
            121
           </xref>
           ,
           <xref ref-type="bibr" rid="CR123">
            123
           </xref>
           ,
           <xref ref-type="bibr" rid="CR124">
            124
           </xref>
           ,
           <xref ref-type="bibr" rid="CR125">
            125
           </xref>
           ,
           <xref ref-type="bibr" rid="CR126">
            126
           </xref>
           ,
           <xref ref-type="bibr" rid="CR127">
            127
           </xref>
           ,
           <xref ref-type="bibr" rid="CR128">
            128
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Convalescent plasma
          </td>
          <td>
           Effective in a mouse model; clinical trial approved
          </td>
          <td>
           <xref ref-type="bibr" rid="CR122">
            122
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Interferons
          </td>
          <td>
           Effective in non-human primate models; off-label use in patients
          </td>
          <td>
           <xref ref-type="bibr" rid="CR87">
            87
           </xref>
           ,
           <xref ref-type="bibr" rid="CR97">
            97
           </xref>
           ,
           <xref ref-type="bibr" rid="CR98">
            98
           </xref>
           ,
           <xref ref-type="bibr" rid="CR99">
            99
           </xref>
           ,
           <xref ref-type="bibr" rid="CR101">
            101
           </xref>
           ,
           <xref ref-type="bibr" rid="CR102">
            102
           </xref>
           ,
           <xref ref-type="bibr" rid="CR103">
            103
           </xref>
           ,
           <xref ref-type="bibr" rid="CR104">
            104
           </xref>
           ,
           <xref ref-type="bibr" rid="CR105">
            105
           </xref>
           ,
           <xref ref-type="bibr" rid="CR108">
            108
           </xref>
           ,
           <xref ref-type="bibr" rid="CR109">
            109
           </xref>
           ,
           <xref ref-type="bibr" rid="CR110">
            110
           </xref>
           ,
           <xref ref-type="bibr" rid="CR111">
            111
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Ribavirin
          </td>
          <td>
           Effective in a non-human primate model; off-label use in patients
          </td>
          <td>
           <xref ref-type="bibr" rid="CR87">
            87
           </xref>
           ,
           <xref ref-type="bibr" rid="CR88">
            88
           </xref>
           ,
           <xref ref-type="bibr" rid="CR101">
            101
           </xref>
           ,
           <xref ref-type="bibr" rid="CR102">
            102
           </xref>
           ,
           <xref ref-type="bibr" rid="CR108">
            108
           </xref>
           ,
           <xref ref-type="bibr" rid="CR109">
            109
           </xref>
           ,
           <xref ref-type="bibr" rid="CR111">
            111
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Mycophenolic acid
          </td>
          <td>
           Failed to protect in a non-human primate model
          </td>
          <td>
           <xref ref-type="bibr" rid="CR97">
            97
           </xref>
           ,
           <xref ref-type="bibr" rid="CR99">
            99
           </xref>
           ,
           <xref ref-type="bibr" rid="CR105">
            105
           </xref>
           ,
           <xref ref-type="bibr" rid="CR113">
            113
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Lopinavir and ritonavir
          </td>
          <td>
           Effective in a non-human primate model; off-label use in patients
          </td>
          <td>
           <xref ref-type="bibr" rid="CR105">
            105
           </xref>
           ,
           <xref ref-type="bibr" rid="CR109">
            109
           </xref>
           ,
           <xref ref-type="bibr" rid="CR110">
            110
           </xref>
           ,
           <xref ref-type="bibr" rid="CR111">
            111
           </xref>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         MERS, Middle East respiratory syndrome.
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="Par41">
      <bold>
       <italic>
        Current therapies.
       </italic>
      </bold>
      In the absence of a clinically proven effective antiviral therapy against SARS-CoV and MERS-CoV, patients mainly receive supportive care, which is often supplemented by different combinations of drugs.
      <xref ref-type="list" rid="Glos11">
       Ribavirin
      </xref>
      <sup>
       <xref ref-type="bibr" rid="CR86">
        86
       </xref>
      </sup>
      and various types of IFN have been given to patients with MERS in Saudi Arabia
      <sup>
       <xref ref-type="bibr" rid="CR87">
        87
       </xref>
      </sup>
      and China
      <sup>
       <xref ref-type="bibr" rid="CR88">
        88
       </xref>
      </sup>
      , typically in combination with a broad-spectrum antibiotic and oxygen. The efficacy of treatments for SARS-CoV and MERS-CoV infection currently remains unclear. In addition, treatment for MERS is typically started only in a late disease stage, when immunopathology predominates and antiviral drugs are likely to provide little benefit.
     </p>
     <p id="Par42">
      Ribavirin was used most frequently during the SARS outbreak, often in combination with corticosteroids, which have an anti-inflammatory effect
      <sup>
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="CR89">
        89
       </xref>
       ,
       <xref ref-type="bibr" rid="CR90">
        90
       </xref>
       ,
       <xref ref-type="bibr" rid="CR91">
        91
       </xref>
       ,
       <xref ref-type="bibr" rid="CR92">
        92
       </xref>
      </sup>
      . IFNα was also given, usually in combination with immunoglobulins or thymosins, which stimulate the development of T cells, and in a small number of cases in combination with ribavirin
      <sup>
       <xref ref-type="bibr" rid="CR93">
        93
       </xref>
       ,
       <xref ref-type="bibr" rid="CR94">
        94
       </xref>
      </sup>
      . None of these treatments was tested in a clinical trial, which makes it difficult to assess their efficacy. In fact, retrospective analysis did not yield a treatment combination that was clearly effective. Moreover, the data from patients are contradictory about whether ribavirin, when used alone, provided a benefit or was possibly even detrimental
      <sup>
       <xref ref-type="bibr" rid="CR89">
        89
       </xref>
       ,
       <xref ref-type="bibr" rid="CR90">
        90
       </xref>
       ,
       <xref ref-type="bibr" rid="CR92">
        92
       </xref>
       ,
       <xref ref-type="bibr" rid="CR95">
        95
       </xref>
      </sup>
      .
      <italic>
       In vitro
      </italic>
      coronaviruses have a lower sensitivity to ribavirin than other viruses. Deletion of the nsp14-encoding sequence increases the sensitivity of coronaviruses to ribavirin; however, the underlying mechanism is unclear and is not related to the proofreading function of nsp14 (Ref.
      <xref ref-type="bibr" rid="CR96">
       96
      </xref>
      ). Therefore, ribavirin should be considered only in combination with other antiviral treatments.
     </p>
     <p id="Par43">
      Although IFNs are effective against MERS-CoV
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR97">
        97
       </xref>
       ,
       <xref ref-type="bibr" rid="CR98">
        98
       </xref>
       ,
       <xref ref-type="bibr" rid="CR99">
        99
       </xref>
      </sup>
      , their effect in humans has yet to be proved. The effectiveness of IFN is increased
      <italic>
       in vitro
      </italic>
      if ribavirin is added
      <sup>
       <xref ref-type="bibr" rid="CR98">
        98
       </xref>
       ,
       <xref ref-type="bibr" rid="CR100">
        100
       </xref>
      </sup>
      , and a combined use of the two drugs reduces disease severity in a rhesus macaque model of MERS
      <sup>
       <xref ref-type="bibr" rid="CR101">
        101
       </xref>
      </sup>
      . The potential side effects of these treatments, such as fatigue, depression and anaemia, have inhibited their use as a first-line treatment for MERS, and they are generally administered only after a patient's condition starts to deteriorate. For example, one study of five patients who were infected with MERS-CoV indicated no survival following ribavirin and IFNα2b therapy; however, therapy was not started until 10 days after admission
      <sup>
       <xref ref-type="bibr" rid="CR87">
        87
       </xref>
      </sup>
      . A separate study found an improvement in survival 14 days after MERS diagnosis and the start of treatment, but not 28 days after
      <sup>
       <xref ref-type="bibr" rid="CR102">
        102
       </xref>
      </sup>
      . In a third study, a combination of IFNα2a and ribavirin or IFNβ1a and ribavirin did not improve survival; however, some of the patients were more than 50 years old and had pre-existing renal failure
      <sup>
       <xref ref-type="bibr" rid="CR103">
        103
       </xref>
      </sup>
      . In a single case in which ribavirin and IFNα2b were started shortly after admission to hospital, the patient started to improve on day 6 after admission and made a complete recovery
      <sup>
       <xref ref-type="bibr" rid="CR104">
        104
       </xref>
      </sup>
      .
     </p>
     <p id="Par44">
      IFNβ1b is a more potent inhibitor of MERS-CoV replication
      <italic>
       in vitro
      </italic>
      than other types of IFN
      <sup>
       <xref ref-type="bibr" rid="CR97">
        97
       </xref>
       ,
       <xref ref-type="bibr" rid="CR99">
        99
       </xref>
      </sup>
      , and an improved outcome of disease was observed in common marmosets after challenge with MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR105">
        105
       </xref>
      </sup>
      . Thus, the type of IFN that is used for treatment in humans should be reconsidered (usually, IFNα is used). Furthermore, ribavirin and/or IFNs should be tested in clinical trials to determine their efficacy in MERS treatment and to establish treatment protocols.
     </p>
     <p id="Par45">
      <bold>
       <italic>
        Additional antiviral treatments.
       </italic>
      </bold>
      The protease inhibitors lopinavir and ritonavir, which are used in combination to treat infection with HIV, improved the outcome of patients with SARS when combined with ribavirin, compared with patients who were treated with ribavirin alone
      <sup>
       <xref ref-type="bibr" rid="CR106">
        106
       </xref>
       ,
       <xref ref-type="bibr" rid="CR107">
        107
       </xref>
      </sup>
      . Lopinavir showed no clear antiviral activity against MERS-CoV
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR97">
        97
       </xref>
      </sup>
      , and it is thus rarely used in patients with MERS. However, lopinavir and ritonavir improve the outcome in common marmosets when treatment is initiated 6 hours after infection with MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR105">
        105
       </xref>
      </sup>
      . Thus, the testing of lopinavir and ritonavir in clinical trials in patients with MERS should be reconsidered. One patient who received
      <xref ref-type="list" rid="Glos12">
       pegylated
      </xref>
      IFNα, ribavirin, lopinavir and ritonavir in combination had undetectable levels of MERS-CoV in the blood 2 days after the initiation of therapy; however, this patient did not survive
      <sup>
       <xref ref-type="bibr" rid="CR108">
        108
       </xref>
      </sup>
      . The combination of IFNα, ribavirin, lopinavir and ritonavir was also used for MERS treatment in South Korea, but efficacy data are not yet available. However, three case reports indicate recovery in five out of seven patients who were treated with this combination
      <sup>
       <xref ref-type="bibr" rid="CR109">
        109
       </xref>
       ,
       <xref ref-type="bibr" rid="CR110">
        110
       </xref>
       ,
       <xref ref-type="bibr" rid="CR111">
        111
       </xref>
      </sup>
      .
     </p>
     <p id="Par46">
      As 3CLpro and PLpro are essential for cleavage of the viral polyproteins and are distinct from cellular proteases, they are ideal drug targets, in particular PLpro, which is involved in both viral replication and IFN antagonism. Indeed, most antiviral drug-like molecules have been developed against 3CLpro and PLpro, which was aided by the rapid report of crystal structures of these proteases
      <sup>
       <xref ref-type="bibr" rid="CR112">
        112
       </xref>
      </sup>
      .
     </p>
     <p id="Par47">
      PLpro was initially identified as a drugable target for SARS-CoV; recently, it has been noted that some of the compounds that target PLpro from SARS-CoV are also active against PLpro from MERS-CoV. For example, both 6-mercaptopurine and 6-thioguanine inhibit MERS-CoV and SARS-CoV
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR113">
        113
       </xref>
      </sup>
      ; however, the efficacy of these molecules has not yet been tested
      <italic>
       in vivo
      </italic>
      . Mycophenolic acid also inhibits the replication of MERS-CoV
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR97">
        97
       </xref>
       ,
       <xref ref-type="bibr" rid="CR99">
        99
       </xref>
      </sup>
      through the inhibition of PLpro
      <sup>
       <xref ref-type="bibr" rid="CR113">
        113
       </xref>
      </sup>
      , but it had no effect in marmosets
      <sup>
       <xref ref-type="bibr" rid="CR105">
        105
       </xref>
      </sup>
      .
     </p>
     <p id="Par48">
      As new coronaviruses are likely to emerge from bats, protease inhibitors were designed against bat coronaviruses with the goal of developing a universal antiviral compound against emerging zoonotic coronaviruses. This approach yielded an inhibitor of Tylonycteris bat coronavirus HKU4 (HKU4-CoV), which is closely related to MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
      </sup>
      . This inhibitor, named SG85, indeed inhibits MERS-CoV replication
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR112">
        112
       </xref>
      </sup>
      . Similarly,
      <xref ref-type="list" rid="Glos13">
       peptidomimetics
      </xref>
      that target and inhibit 3CLpro of MERS-CoV, HKU4-CoV and Pipistrellus bat coronavirus HKU5 (HKU5-CoV) have also been identified, but have not yet progressed beyond the
      <italic>
       in vitro
      </italic>
      stage
      <sup>
       <xref ref-type="bibr" rid="CR114">
        114
       </xref>
      </sup>
      .
     </p>
     <p id="Par49">
      Several other drugs that were approved for use in humans were shown to inhibit the replication of MERS-CoV
      <italic>
       in vitro
      </italic>
      , notably chloroquine, chlorpromazine, loperamide and cyclosporine A
      <sup>
       <xref ref-type="bibr" rid="CR62">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="CR99">
        99
       </xref>
       ,
       <xref ref-type="bibr" rid="CR113">
        113
       </xref>
       ,
       <xref ref-type="bibr" rid="CR115">
        115
       </xref>
      </sup>
      , although their mechanisms of action are unknown, and the benefit of cyclosporine A in patients is debatable owing to the immunosuppressive effect of the drug. Although cyclophilin inhibitors that do not result in immunosuppression are available, their activity against MERS-CoV has not yet been tested.
     </p>
     <p id="Par50">
      <bold>
       <italic>
        Antibody and plasma therapy.
       </italic>
      </bold>
      Plasma from convalescent patients and/or antibody therapies have been the leading proposed treatment for MERS so far
      <sup>
       <xref ref-type="bibr" rid="CR116">
        116
       </xref>
      </sup>
      . There are several potential advantages to this approach. For example, as case numbers increase, the pool of survivors becomes larger; provided these individuals have sufficiently high antibody titres and are willing and able to donate plasma, this is a low-tech, reasonably safe treatment option. Furthermore, generation of monoclonal antibodies for use in humans is well established, with a fairly straightforward path to safety and efficacy testing. However, to date, there are very few reports on the use of convalescent plasma and none on the use of monoclonal antibodies as treatments for acute, severe respiratory disease in humans. A post hoc meta-analysis of 32 studies of either SARS or severe influenza found a significant reduction in the pooled odds of mortality when convalescent plasma was used
      <sup>
       <xref ref-type="bibr" rid="CR117">
        117
       </xref>
      </sup>
      . However, study design was rated as low or very low quality, as there were generally a lack of control groups and a moderate-to-high risk of bias, which suggests that a properly designed clinical trial of convalescent plasma use in severe respiratory infections is needed
      <sup>
       <xref ref-type="bibr" rid="CR117">
        117
       </xref>
      </sup>
      . Potent monoclonal antibodies that neutralize the MERS-COV spike protein
      <italic>
       in vitro
      </italic>
      have been developed
      <sup>
       <xref ref-type="bibr" rid="CR118">
        118
       </xref>
       ,
       <xref ref-type="bibr" rid="CR119">
        119
       </xref>
       ,
       <xref ref-type="bibr" rid="CR120">
        120
       </xref>
       ,
       <xref ref-type="bibr" rid="CR121">
        121
       </xref>
      </sup>
      . However, with a few exceptions,
      <italic>
       in vivo
      </italic>
      data relating to the use of convalescent plasma or monoclonal antibodies in the treatment of MERS are currently lacking. Serum from high-titre dromedary camels decreased MERS-CoV loads in the lungs of mice that had been transduced with human DPP4 (Ref.
      <xref ref-type="bibr" rid="CR122">
       122
      </xref>
      ). Human polyclonal antibodies against the spike protein were generated by vaccinating transchromosomic bovines, and treatment with these antibodies reduced viral titres in the lungs of DPP4-transduced mice when treatment was administered 24 or 48 hours after challenge with MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR123">
        123
       </xref>
      </sup>
      . DPP4-transduced mice were also treated with humanized neutralizing monoclonal antibody 4C2h, which is directed against the receptor-binding domain of the MERS-CoV spike protein, 1 day after MERS-CoV challenge, and this treatment also decreased viral titres in the lungs
      <sup>
       <xref ref-type="bibr" rid="CR124">
        124
       </xref>
      </sup>
      , as did the neutralizing antibody LCA60, which was obtained from a convalescent patient and produced recombinantly
      <sup>
       <xref ref-type="bibr" rid="CR125">
        125
       </xref>
      </sup>
      . Human neutralizing monoclonal antibodies REGN3048 and REGN3051 also provided a benefit in mice that expressed human DPP4 and were challenged with MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR126">
        126
       </xref>
      </sup>
      . The human neutralizing monoclonal antibody m332 reduced MERS-CoV replication in the lungs of rabbits following prophylactic, but not therapeutic, treatment
      <sup>
       <xref ref-type="bibr" rid="CR127">
        127
       </xref>
      </sup>
      . Treatment of rhesus macaques with the human monoclonal antibody 311B-N1 day after challenge resulted in reduced lung pathology
      <sup>
       <xref ref-type="bibr" rid="CR128">
        128
       </xref>
      </sup>
      . In all of these studies, viral replication was not completely inhibited, and there were some pathological alterations to the lungs, despite the therapy. Furthermore, none of the studies addressed the potential emergence of escape mutants
      <italic>
       in vivo
      </italic>
      .
     </p>
     <p id="Par51">
      Alternatively, antibodies that target the region of DPP4 that binds to the spike protein could be used to prevent entry of MERS-CoV; this approach was successful
      <italic>
       in vitro
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR129">
        129
       </xref>
      </sup>
      . However, whether such a treatment would be feasible and would not have substantial adverse effects in humans remains to be determined.
     </p>
     <p id="Par52">
      <bold>
       <italic>
        Host-directed therapies.
       </italic>
      </bold>
      Host-directed strategies can also limit viral replication. For example, the spike protein of SARS-CoV is cleaved by cathepsin B and cathepsin L, transmembrane protease serine 2 (TMPRSS2) and possibly other host proteases
      <sup>
       <xref ref-type="bibr" rid="CR130">
        130
       </xref>
       ,
       <xref ref-type="bibr" rid="CR131">
        131
       </xref>
      </sup>
      . Inhibition of host serine proteases by camostat reduced the entry of SARS-CoV and increased survival in a mouse model
      <sup>
       <xref ref-type="bibr" rid="CR132">
        132
       </xref>
      </sup>
      . However, the targeting of host proteases is more likely to result in undesirable side effects than the targeting of viral proteases.
     </p>
     <p id="Par53">
      Another underappreciated strategy is attenuation of detrimental host responses. The development of such treatments would require a thorough understanding of the host responses that are involved in acute lung injury and ARDS, processes that are unfortunately poorly understood at the moment. Nonetheless,
      <italic>
       in vitro
      </italic>
      studies and limited studies in animal models with other respiratory viruses have shown that
      <xref ref-type="list" rid="Glos14">
       anaphylatoxin C5a
      </xref>
      is important for the development of acute lung injury, and blocking anaphylatoxin C5a can reduce lung pathology
      <sup>
       <xref ref-type="bibr" rid="CR133">
        133
       </xref>
      </sup>
      .
     </p>
     <p id="Par54">
      Changes in gene expression during
      <italic>
       in vitro
      </italic>
      MERS-CoV infection were used to predict potential effective drugs. One of the drugs with predicted efficacy, the kinase inhibitor SB203580, modestly inhibited SARS-CoV and MERS-CoV replication following the treatment of cells prior to infection, but treatment after infection inhibited replication of only SARS-CoV and not MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR134">
        134
       </xref>
      </sup>
      .
     </p>
     <p id="Par55">
      <bold>
       <italic>
        Vaccines.
       </italic>
      </bold>
      Vaccination could be used to prevent infection or to reduce disease severity, viral shedding and thereby transmission, thus helping to control MERS outbreaks. Several vaccination strategies were developed against SARS-CoV and tested in animals, such as an inactivated virus, a live-attenuated virus, viral vectors,
      <xref ref-type="list" rid="Glos15">
       subunit vaccines
      </xref>
      , recombinant proteins and
      <xref ref-type="list" rid="Glos16">
       DNA vaccines
      </xref>
      <sup>
       <xref ref-type="bibr" rid="CR135">
        135
       </xref>
       ,
       <xref ref-type="bibr" rid="CR136">
        136
       </xref>
      </sup>
      . Similar approaches have been used for the development of experimental MERS-CoV vaccines
      <sup>
       <xref ref-type="bibr" rid="CR137">
        137
       </xref>
      </sup>
      . To date, three MERS-CoV vaccines have been evaluated in non-human primates. In one study, rhesus macaques were primed with DNA encoding the spike protein, followed by boosts with spike DNA and with recombinant protein consisting of the spike subunit containing the receptor-binding domain, or primed and boosted once with the subunit protein. Both approaches reduced pathological changes in lung function in animals that were infected with MERS-CoV 19 weeks after the last vaccination
      <sup>
       <xref ref-type="bibr" rid="CR138">
        138
       </xref>
      </sup>
      . Moreover, three vaccinations with a recombinantly expressed protein that contains the receptor-binding domain of the spike protein reduced viral loads and lung pathology in rhesus macaques that were infected 2 weeks after the last vaccination
      <sup>
       <xref ref-type="bibr" rid="CR139">
        139
       </xref>
      </sup>
      . Three DNA vaccinations with a construct encoding the full-length spike sequence reduced viral loads and pathology in the lungs after challenge with MERS-CoV 5 weeks after the last vaccination
      <sup>
       <xref ref-type="bibr" rid="CR140">
        140
       </xref>
      </sup>
      .
     </p>
     <p id="Par56">
      One concern of vaccination in humans is vaccine-mediated enhancement of disease, a process in which the disease following infection is more severe in vaccinated individuals than in unvaccinated individuals. Although this was observed in only a small subset of vaccine studies that were carried out for SARS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR136">
        136
       </xref>
      </sup>
      and has not yet been observed in any of the published MERS-CoV vaccine studies, it is an important concern. Moreover, it is unclear who to vaccinate against MERS-CoV, as healthy individuals seem to be at little risk of severe disease. Older patients or patients with underlying disease, who have the highest risk of severe MERS, would be important target populations. However, vaccination in such patients can be problematic owing to their poor immune responses, as has been established for influenza virus
      <sup>
       <xref ref-type="bibr" rid="CR141">
        141
       </xref>
      </sup>
      . In addition, vaccination of people with a high risk of exposure to MERS-CoV, such as health care workers, slaughterhouse workers and camel herders, is advisable
      <sup>
       <xref ref-type="bibr" rid="CR142">
        142
       </xref>
      </sup>
      .
     </p>
    </sec>
    <sec id="Sec7">
     <title>
      Outlook
     </title>
     <p id="Par57">
      As our understanding of the pathogenesis of emerging coronaviruses increases, so will the opportunities for the rational design of therapeutics that target viral replication or immunopathology. The rational design of new drugs and the repurposing of existing compounds have already resulted in the development of PLpro inhibitors and the identification of kinase inhibitors that inhibit the replication of SARS-CoV and MERS-CoV
      <italic>
       in vitro
      </italic>
      . However, only a few potential treatments have progressed past the identification of an effect
      <italic>
       in vitro
      </italic>
      , and
      <italic>
       in vivo
      </italic>
      studies to select the most promising treatment options are required. The development of several mouse models of MERS is thus an important step forward (
      <xref ref-type="sec" rid="Sec8">
       Box 2
      </xref>
      ). Owing to the acute nature of MERS and the important role of immunopathology, combination therapies aimed at simultaneously inhibiting viral replication, limiting viral dissemination and dampening the host response are likely to yield the best results. Furthermore, treatment should be started as early as possible, rather than waiting until the patient has already developed extensive lung damage.
     </p>
     <p id="Par58">
      The development of therapies against SARS and MERS needs to focus on testing in humans, in properly controlled clinical trials. The current non-standardized, uncontrolled approach to treatment is not informative and may not be beneficial to the patient. The recent Ebola outbreak has demonstrated that rapid clinical trial design and approval are possible and that exceptional situations call for deviations from normal procedures (
      <xref ref-type="sec" rid="Sec9">
       Box 3
      </xref>
      ).
     </p>
     <p id="Par59">
      While treatments are being developed and evaluated, the prevention of viral transmission is key to reducing the burden of MERS. The large proportion of nosocomial MERS-CoV infections indicates that preventive measures in hospitals are currently either not fully implemented or insufficient. Prevention of zoonotic transmission from dromedary camels is another possibility to decrease the number of MERS cases. The first vaccines against MERS-CoV have been tested in dromedary camels
      <sup>
       <xref ref-type="bibr" rid="CR140">
        140
       </xref>
       ,
       <xref ref-type="bibr" rid="CR143">
        143
       </xref>
      </sup>
      ; indeed, when camels were vaccinated with a modified vaccinia virus that expresses the MERS-CoV spike protein, subsequent challenge of these animals with MERS-CoV resulted in less viral shedding than in unvaccinated animals
      <sup>
       <xref ref-type="bibr" rid="CR143">
        143
       </xref>
      </sup>
      , thereby potentially limiting the transmission to naive animals or to humans. Certainly, there has been progress in the development of vaccines and therapies against emerging coronaviruses, but more research and rigorous testing is required if we are to successfully combat these novel pathogens.
     </p>
     <sec id="Sec8">
      <boxed-text>
       <label>
        Box 2: Animal models
       </label>
       <p id="Par60">
        Most of our understanding of the pathogenesis of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) comes from animal studies. Ideally, these models recapitulate all or specific aspects of human disease. Several mouse models have been established, for example by using mouse-adapted SARS coronavirus (SARS-CoV) or expressing human receptors in mice
        <sup>
         <xref ref-type="bibr" rid="CR152">
          152
         </xref>
        </sup>
        . Although it has been recognized that mice might poorly mimic specific human responses to infection, the availability of knockout and transgenic mice enables the targeted study of virus–host interactions. Several non-human primate models have been developed for SARS-CoV and MERS coronavirus (MERS-CoV)
        <sup>
         <xref ref-type="bibr" rid="CR152">
          152
         </xref>
        </sup>
        . The close relationship of non-human primates to humans often allows faithful recapitulation of a disease and the host response. However, these benefits are countered by the need for specialized husbandry, the sometimes limited availability of the animals and reagents, and high costs.
       </p>
       <p id="Par61">
        The pathogenesis of SARS-CoV and MERS-CoV in their respective reservoir hosts is not nearly as well studied as that in humans. Currently, only one experimental-infection study has been carried out in bats with MERS-CoV
        <sup>
         <xref ref-type="bibr" rid="CR153">
          153
         </xref>
        </sup>
        , and none has been carried out for other coronaviruses. Thus, data are mostly limited to the detection of coronaviruses in naturally infected bats. The detection of coronaviruses mainly in faecal samples from bats and not in oral swabs suggests that replication in bats occurs predominantly in the gastrointestinal tract
        <sup>
         <xref ref-type="bibr" rid="CR9">
          9
         </xref>
         ,
         <xref ref-type="bibr" rid="CR154">
          154
         </xref>
         ,
         <xref ref-type="bibr" rid="CR155">
          155
         </xref>
        </sup>
        . By contrast, a combination of intratracheal and intranasal inoculation of masked palm civets with SARS-CoV resulted in interstitial pneumonia, with oral and rectal viral shedding
        <sup>
         <xref ref-type="bibr" rid="CR156">
          156
         </xref>
        </sup>
        .
       </p>
       <p id="Par62">
        The pathogenesis of MERS-CoV in dromedary camels has been studied experimentally in a limited number of animals. These animals developed transient mild disease; however, large quantities of MERS-CoV were shed from the upper respiratory tract, in line with the predominant replication of MERS-CoV in the nasal turbinates and larynx in these animals, which explains the frequent zoonotic transmission
        <sup>
         <xref ref-type="bibr" rid="CR157">
          157
         </xref>
        </sup>
        .
       </p>
      </boxed-text>
     </sec>
     <sec id="Sec9">
      <boxed-text>
       <label>
        Box 3: Preparing for emerging viruses: lessons from SARS-CoV, MERS-CoV and Ebola virus
       </label>
       <p id="Par63">
        When the severe acute respiratory syndrome (SARS) outbreak developed into the first pandemic of the twenty-first century, it became clear that the medical and scientific communities were not adequately prepared for the emergence of highly pathogenic viruses. Whereas several months elapsed and several thousand cases of SARS were observed before the causative agent was identified as SARS coronavirus (SARS-CoV)
        <sup>
         <xref ref-type="bibr" rid="CR4">
          4
         </xref>
         ,
         <xref ref-type="bibr" rid="CR5">
          5
         </xref>
         ,
         <xref ref-type="bibr" rid="CR6">
          6
         </xref>
        </sup>
        , subsequent advances in molecular diagnostic tools, such as next generation sequencing, meant that Middle East respiratory syndrome coronavirus (MERS-CoV) was identified before it caused a large outbreak of MERS
        <sup>
         <xref ref-type="bibr" rid="CR11">
          11
         </xref>
        </sup>
        . The availability of the full-length genome of MERS-CoV enabled the rapid development and distribution of diagnostic assays. The first animal models of disease, several treatment efficacy studies and the identification of the reservoir followed soon after. Unfortunately, the SARS pandemic did not yield solid clinical data on the efficacy of treatment regimens. These data are urgently needed for the treatment of MERS, as well as to prepare for novel coronaviruses that may emerge. Several studies have used synthetic biology to study the zoonotic transmission potential of SARS-CoV-like viruses from bats
        <sup>
         <xref ref-type="bibr" rid="CR9">
          9
         </xref>
         ,
         <xref ref-type="bibr" rid="CR10">
          10
         </xref>
         ,
         <xref ref-type="bibr" rid="CR158">
          158
         </xref>
         ,
         <xref ref-type="bibr" rid="CR159">
          159
         </xref>
        </sup>
        .
       </p>
       <p id="Par64">
        The Ebola virus outbreak in West Africa has highlighted the need for fast-tracking of potential treatments, as several clinical trials were started only towards the end of the outbreak. The combined experiences of the outbreaks of SARS, MERS and Ebola provide a blueprint for the response to emerging pathogens: after the identification of the causative agent, diagnostic assays need to be developed and distributed rapidly, and simultaneously, awareness of the new syndrome and reporting of (suspected) cases must be increased. In addition, infection control measures in health care facilities are essential. Research needs to focus on understanding the epidemiology, including pathogen transmission and identification of the reservoir and/or intermediate hosts. Animal models need to be developed, as well as therapeutic and prophylactic measures. Finally, promising treatments need to be fast-tracked into clinical trials.
       </p>
      </boxed-text>
     </sec>
    </sec>
    <back>
     <app-group>
      <app id="App1">
       <sec id="Sec10">
        <title>
         PowerPoint slides
        </title>
        <p id="Par66">
         <media id="MOESM6" position="anchor" xlink:href="41579_2016_BFnrmicro201681_MOESM6_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 1
           </p>
          </caption>
         </media>
         <media id="MOESM7" position="anchor" xlink:href="41579_2016_BFnrmicro201681_MOESM7_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 2
           </p>
          </caption>
         </media>
         <media id="MOESM8" position="anchor" xlink:href="41579_2016_BFnrmicro201681_MOESM8_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Fig. 3
           </p>
          </caption>
         </media>
        </p>
        <p id="Par67">
         <media id="MOESM9" position="anchor" xlink:href="41579_2016_BFnrmicro201681_MOESM9_ESM.ppt">
          <caption>
           <p>
            PowerPoint slide for Table 1
           </p>
          </caption>
         </media>
        </p>
       </sec>
      </app>
     </app-group>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       The work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), US National Institutes of Health.
      </p>
     </ack>
     <notes notes-type="COI-statement">
      <title>
       Competing interests
      </title>
      <p id="Par65">
       The authors declare no competing financial interests.
      </p>
     </notes>
     <glossary>
      <title>
       Glossary
      </title>
      <def-list>
       <def-item id="Glos1">
        <term>
         Nosocomial transmission
        </term>
        <def>
         <p>
          Transmission of an infectious agent by staff, equipment or the environment in a health care setting.
         </p>
        </def>
       </def-item>
       <def-item id="Glos2">
        <term>
         Proofreading
        </term>
        <def>
         <p>
          The correction of errors that are acquired during the replication of DNA or RNA.
         </p>
        </def>
       </def-item>
       <def-item id="Glos3">
        <term>
         ER–Golgi intermediate compartment
        </term>
        <def>
         <p>
          (ERGIC). A cellular compartment that facilitates transport between the endoplasmic reticulum (ER) and the Golgi complex.
         </p>
        </def>
       </def-item>
       <def-item id="Glos4">
        <term>
         Super spreaders
        </term>
        <def>
         <p>
          Infected individuals who each infect a disproportionately large number of secondary cases.
         </p>
        </def>
       </def-item>
       <def-item id="Glos5">
        <term>
         Acute respiratory distress syndrome
        </term>
        <def>
         <p>
          (ARDS). A life-threatening condition in which the accumulation of fluid and inflammatory cells in the lungs decreases the exchange of oxygen and carbon dioxide to dangerously low levels.
         </p>
        </def>
       </def-item>
       <def-item id="Glos6">
        <term>
         Collaborative Cross mouse
        </term>
        <def>
         <p>
          One of a panel of recombinant inbred mouse strains derived from a genetically diverse set of founder strains and designed for the analysis of complex traits.
         </p>
        </def>
       </def-item>
       <def-item id="Glos7">
        <term>
         Perivascular cuffing
        </term>
        <def>
         <p>
          The aggregation of leukocytes around blood vessels.
         </p>
        </def>
       </def-item>
       <def-item id="Glos8">
        <term>
         Type I IFNs
        </term>
        <def>
         <p>
          (Type I interferons). A group of IFNs, including IFNα and IFNβ, with immune-modulating and antiviral functions.
         </p>
        </def>
       </def-item>
       <def-item id="Glos9">
        <term>
         RNAi
        </term>
        <def>
         <p>
          A biological process in which small RNA molecules induce the degradation of specific mRNA molecules, thereby inhibiting gene expression.
         </p>
        </def>
       </def-item>
       <def-item id="Glos10">
        <term>
         Minireplicon systems
        </term>
        <def>
         <p>
          Systems in which a DNA molecule is produced that contains the viral leader and trailer sequences, with an assayable reporter replacing the viral ORFs. When combined with the expression of viral proteins in
          <italic>
           trans
          </italic>
          , this system can be used to model the viral life cycle without the necessity of using infectious virus.
         </p>
        </def>
       </def-item>
       <def-item id="Glos11">
        <term>
         Ribavirin
        </term>
        <def>
         <p>
          A broadly active antiviral nucleoside analogue with several direct and indirect mechanisms of action; mainly used for the treatment of hepatitis C, in combination with interferon.
         </p>
        </def>
       </def-item>
       <def-item id="Glos12">
        <term>
         Pegylated
        </term>
        <def>
         <p>
          Having polyethylene glycol (PEG) attached, to a drug for example; this moiety improves the solubility, decreases the immunogenicity and increases the stability, of the drug of interest, thereby allowing a reduced dosing frequency to be used.
         </p>
        </def>
       </def-item>
       <def-item id="Glos13">
        <term>
         Peptidomimetics
        </term>
        <def>
         <p>
          Compounds that mimic biologically active peptides or proteins.
         </p>
        </def>
       </def-item>
       <def-item id="Glos14">
        <term>
         Anaphylatoxin C5a
        </term>
        <def>
         <p>
          A complement-activated molecule that is important for the recruitment to and activation of inflammatory cells in the lungs.
         </p>
        </def>
       </def-item>
       <def-item id="Glos15">
        <term>
         Subunit vaccines
        </term>
        <def>
         <p>
          Vaccines that contain immunogenic parts of a pathogen rather than the entire pathogen.
         </p>
        </def>
       </def-item>
       <def-item id="Glos16">
        <term>
         DNA vaccines
        </term>
        <def>
         <p>
          Vaccines based on the direct introduction of a plasmid encoding an antigen; following
          <italic>
           in situ
          </italic>
          production of this antigen, an immune response is mounted against it.
         </p>
        </def>
       </def-item>
      </def-list>
     </glossary>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           NS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         362
        </volume>
        <fpage>
         1353
        </fpage>
        <lpage>
         1358
        </lpage>
        <pub-id pub-id-type="pmid">
         14585636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A major outbreak of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1986
        </fpage>
        <lpage>
         1994
        </lpage>
        <pub-id pub-id-type="pmid">
         12682352
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2004
        </year>
        <volume>
         363
        </volume>
        <fpage>
         99
        </fpage>
        <lpage>
         104
        </lpage>
        <pub-id pub-id-type="pmid">
         14726162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1967
        </fpage>
        <lpage>
         1976
        </lpage>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         1319
        </fpage>
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7
       </label>
       <mixed-citation publication-type="other">
        WHO. Summary of probably SARS cases with onset of illness from 1 November 2002 to 31 July 2003.
        <italic>
         WHO
        </italic>
        ,
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/country/table2004_04_21/en/">
         http://www.who.int/csr/sars/country/table2004_04_21/en/
        </ext-link>
        (2004).
       </mixed-citation>
      </ref>
      <ref id="CR8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS-CoV infection in a restaurant from palm civet
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         1860
        </fpage>
        <lpage>
         1865
        </lpage>
        <pub-id pub-id-type="pmid">
         16485471
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           XY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         503
        </volume>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <fpage>
         1508
        </fpage>
        <lpage>
         1513
        </lpage>
        <pub-id pub-id-type="pmid">
         26552008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hijawi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation
        </article-title>
        <source>
         East. Mediterr. Health J.
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <issue>
         Suppl. 1
        </issue>
        <fpage>
         S12
        </fpage>
        <lpage>
         S18
        </lpage>
        <pub-id pub-id-type="pmid">
         23888790
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wise
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Patient with new strain of coronavirus is treated in intensive care at London hospital
        </article-title>
        <source>
         BMJ
        </source>
        <year>
         2012
        </year>
        <volume>
         345
        </volume>
        <fpage>
         e6455
        </fpage>
        <pub-id pub-id-type="pmid">
         23008211
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14
       </label>
       <mixed-citation publication-type="other">
        Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015.
        <italic>
         Osong Public Health Res. Perspect.
        </italic>
        <bold>
         6
        </bold>
        , 269–278 (2015).
       </mixed-citation>
      </ref>
      <ref id="CR15">
       <label>
        15
       </label>
       <mixed-citation publication-type="other">
        WHO. Coronavirus infections: disease outbreak news.
        <italic>
         WHO
        </italic>
        ,
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/26-april-2016-mers-saudi-arabia/en/">
         http://www.who.int/csr/don/26-april-2016-mers-saudi-arabia/en/
        </ext-link>
        (2016).
       </mixed-citation>
      </ref>
      <ref id="CR16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pasternak
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
         <name>
          <surname>
           Spaan
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nidovirus transcription: how to make sense...?
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         87
        </volume>
        <fpage>
         1403
        </fpage>
        <lpage>
         1421
        </lpage>
        <pub-id pub-id-type="pmid">
         16690906
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses post-SARS: update on replication and pathogenesis
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2009
        </year>
        <volume>
         7
        </volume>
        <fpage>
         439
        </fpage>
        <lpage>
         450
        </lpage>
        <pub-id pub-id-type="pmid">
         19430490
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: an overview of their replication and pathogenesis
        </article-title>
        <source>
         Methods Mol. Biol.
        </source>
        <year>
         2015
        </year>
        <volume>
         1282
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Knoops
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum
        </article-title>
        <source>
         PLoS Biol.
        </source>
        <year>
         2008
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e226
        </fpage>
        <pub-id pub-id-type="pmid">
         18798692
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage
        </article-title>
        <source>
         J. Mol. Biol.
        </source>
        <year>
         2003
        </year>
        <volume>
         331
        </volume>
        <fpage>
         991
        </fpage>
        <lpage>
         1004
        </lpage>
        <pub-id pub-id-type="pmid">
         12927536
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           LD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infidelity of SARS-CoV nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2010
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e1000896
        </fpage>
        <pub-id pub-id-type="pmid">
         20463816
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sevajol
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Subissi
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Decroly
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Canard
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Imbert
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2014
        </year>
        <volume>
         194
        </volume>
        <fpage>
         90
        </fpage>
        <lpage>
         99
        </lpage>
        <pub-id pub-id-type="pmid">
         25451065
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         495
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <source>
         Fields Virology
        </source>
        <year>
         2013
        </year>
        <fpage>
         825
        </fpage>
        <lpage>
         858
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
        </article-title>
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        <volume>
         302
        </volume>
        <fpage>
         276
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           LF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Review of bats and SARS
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2006
        </year>
        <volume>
         12
        </volume>
        <fpage>
         1834
        </fpage>
        <lpage>
         1840
        </lpage>
        <pub-id pub-id-type="pmid">
         17326933
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <year>
         2014
        </year>
        <volume>
         101
        </volume>
        <fpage>
         45
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         24184128
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus neutralizing serum antibodies in dromedary camels: a comparative serological study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         859
        </fpage>
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         14
        </volume>
        <fpage>
         140
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         370
        </volume>
        <fpage>
         2499
        </fpage>
        <lpage>
         2505
        </lpage>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS coronavirus in dromedary camel herd, Saudi Arabia
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1231
        </fpage>
        <lpage>
         1234
        </lpage>
        <pub-id pub-id-type="pmid">
         24964193
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1339
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="pmid">
         25075761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983–1997
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         2093
        </fpage>
        <lpage>
         2095
        </lpage>
        <pub-id pub-id-type="pmid">
         25425139
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sabir
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia
        </article-title>
        <source>
         Science
        </source>
        <year>
         2016
        </year>
        <volume>
         351
        </volume>
        <fpage>
         81
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         26678874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chowell
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study
        </article-title>
        <source>
         BMC Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         13
        </volume>
        <fpage>
         210
        </fpage>
        <pub-id pub-id-type="pmid">
         26336062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hunter
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         647
        </fpage>
        <lpage>
         656
        </lpage>
        <pub-id pub-id-type="pmid">
         26981708
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic
        </article-title>
        <source>
         Philos. Trans. R. Soc. Lond. B. Biol. Sci.
        </source>
        <year>
         2004
        </year>
        <volume>
         359
        </volume>
        <fpage>
         1091
        </fpage>
        <lpage>
         1105
        </lpage>
        <pub-id pub-id-type="pmid">
         15306395
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015
        </article-title>
        <source>
         Euro Surveill.
        </source>
        <year>
         2015
        </year>
        <volume>
         20
        </volume>
        <fpage>
         7
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="pmid">
         26132767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         1767
        </fpage>
        <lpage>
         1772
        </lpage>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bin
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         62
        </volume>
        <fpage>
         755
        </fpage>
        <lpage>
         760
        </lpage>
        <pub-id pub-id-type="pmid">
         26679623
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kucharski
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Althaus
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission
        </article-title>
        <source>
         Euro Surveill.
        </source>
        <year>
         2015
        </year>
        <volume>
         20
        </volume>
        <fpage>
         14
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="pmid">
         26132768
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus superspreading event involving 81 persons, Korea 2015
        </article-title>
        <source>
         J. Korean Med. Sci.
        </source>
        <year>
         2015
        </year>
        <volume>
         30
        </volume>
        <fpage>
         1701
        </fpage>
        <lpage>
         1705
        </lpage>
        <pub-id pub-id-type="pmid">
         26539018
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS, SARS, and Ebola: the role of super-spreaders in infectious disease
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <year>
         2015
        </year>
        <volume>
         18
        </volume>
        <fpage>
         398
        </fpage>
        <lpage>
         401
        </lpage>
        <pub-id pub-id-type="pmid">
         26468744
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2016
        </year>
        <volume>
         186
        </volume>
        <fpage>
         652
        </fpage>
        <lpage>
         658
        </lpage>
        <pub-id pub-id-type="pmid">
         26857507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 protects from severe acute lung failure
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2005
        </year>
        <volume>
         436
        </volume>
        <fpage>
         112
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="pmid">
         16001071
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           WK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         39
        </volume>
        <fpage>
         1071
        </fpage>
        <lpage>
         1075
        </lpage>
        <pub-id pub-id-type="pmid">
         15472864
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         745
        </fpage>
        <lpage>
         751
        </lpage>
        <pub-id pub-id-type="pmid">
         23782859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poissy
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         61
        </volume>
        <fpage>
         275
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         25073585
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Binnie
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           dos Santos
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Biomarkers in acute respiratory distress syndrome
        </article-title>
        <source>
         Curr. Opin. Crit. Care
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         47
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         24296379
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Chambers
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        <article-title>
         The mercurial nature of neutrophils: still an enigma in ARDS?
        </article-title>
        <source>
         Am. J. Physiol. Lung Cell. Mol. Physiol.
        </source>
        <year>
         2014
        </year>
        <volume>
         306
        </volume>
        <fpage>
         L217
        </fpage>
        <lpage>
         L230
        </lpage>
        <pub-id pub-id-type="pmid">
         24318116
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baas
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Taubenberger
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Chong
          </surname>
          <given-names>
           PY
          </given-names>
         </name>
         <name>
          <surname>
           Chui
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Katze
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV virus–host interactions and comparative etiologies of acute respiratory distress syndrome as determined by transcriptional and cytokine profiling of formalin-fixed paraffin-embedded tissues
        </article-title>
        <source>
         J. Interferon Cytokine Res.
        </source>
        <year>
         2006
        </year>
        <volume>
         26
        </volume>
        <fpage>
         309
        </fpage>
        <lpage>
         317
        </lpage>
        <pub-id pub-id-type="pmid">
         16689659
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Faure
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2014
        </year>
        <volume>
         9
        </volume>
        <fpage>
         e88716
        </fpage>
        <pub-id pub-id-type="pmid">
         24551142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Chui
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Salto-Tellez
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2009
        </year>
        <volume>
         145
        </volume>
        <fpage>
         260
        </fpage>
        <lpage>
         269
        </lpage>
        <pub-id pub-id-type="pmid">
         19635508
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           NL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Chem.
        </source>
        <year>
         2005
        </year>
        <volume>
         51
        </volume>
        <fpage>
         2333
        </fpage>
        <lpage>
         2340
        </lpage>
        <pub-id pub-id-type="pmid">
         16195357
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cameron
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         8692
        </fpage>
        <lpage>
         8706
        </lpage>
        <pub-id pub-id-type="pmid">
         17537853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genome wide identification of SARS-CoV susceptibility loci using the Collaborative Cross
        </article-title>
        <source>
         PLoS Genet.
        </source>
        <year>
         2015
        </year>
        <volume>
         11
        </volume>
        <fpage>
         e1005504
        </fpage>
        <pub-id pub-id-type="pmid">
         26452100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jensen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Thomsen
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <fpage>
         2900
        </fpage>
        <lpage>
         2910
        </lpage>
        <pub-id pub-id-type="pmid">
         22258243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2010
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e1000849
        </fpage>
        <pub-id pub-id-type="pmid">
         20386712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2008
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e1000240
        </fpage>
        <pub-id pub-id-type="pmid">
         19079579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rapid generation of a mouse model for Middle East respiratory syndrome
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2014
        </year>
        <volume>
         111
        </volume>
        <fpage>
         4970
        </fpage>
        <lpage>
         4975
        </lpage>
        <pub-id pub-id-type="pmid">
         24599590
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR62">
       <label>
        62
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS-coronavirus replication induces severe
         <italic>
          in vitro
         </italic>
         cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         94
        </volume>
        <fpage>
         1749
        </fpage>
        <lpage>
         1760
        </lpage>
        <pub-id pub-id-type="pmid">
         23620378
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         80
        </volume>
        <fpage>
         5927
        </fpage>
        <lpage>
         5940
        </lpage>
        <pub-id pub-id-type="pmid">
         16731931
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bouvet
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         <italic>
          In vitro
         </italic>
         reconstitution of SARS-coronavirus mRNA cap methylation
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2010
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e1000863
        </fpage>
        <pub-id pub-id-type="pmid">
         20421945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR65">
       <label>
        65
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2′-O-methyltransferase activity
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         4251
        </fpage>
        <lpage>
         4264
        </lpage>
        <pub-id pub-id-type="pmid">
         24478444
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR66">
       <label>
        66
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <name>
          <surname>
           Debbink
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus non-structural protein 16: evasion, attenuation, and possible treatments
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2014
        </year>
        <volume>
         194
        </volume>
        <fpage>
         191
        </fpage>
        <lpage>
         199
        </lpage>
        <pub-id pub-id-type="pmid">
         25278144
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR67">
       <label>
        67
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA silencing in mammalian cells
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         9029
        </fpage>
        <lpage>
         9043
        </lpage>
        <pub-id pub-id-type="pmid">
         26085159
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR68">
       <label>
        68
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism
        </article-title>
        <source>
         Virus Genes
        </source>
        <year>
         2011
        </year>
        <volume>
         42
        </volume>
        <fpage>
         37
        </fpage>
        <lpage>
         45
        </lpage>
        <pub-id pub-id-type="pmid">
         20976535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR69">
       <label>
        69
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Niemeyer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         12489
        </fpage>
        <lpage>
         12495
        </lpage>
        <pub-id pub-id-type="pmid">
         24027320
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR70">
       <label>
        70
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         4866
        </fpage>
        <lpage>
         4876
        </lpage>
        <pub-id pub-id-type="pmid">
         24522921
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR71">
       <label>
        71
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists
        </article-title>
        <source>
         Protein Cell
        </source>
        <year>
         2013
        </year>
        <volume>
         4
        </volume>
        <fpage>
         951
        </fpage>
        <lpage>
         961
        </lpage>
        <pub-id pub-id-type="pmid">
         24318862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR72">
       <label>
        72
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2015
        </year>
        <volume>
         5
        </volume>
        <fpage>
         17554
        </fpage>
        <pub-id pub-id-type="pmid">
         26631542
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR73">
       <label>
        73
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ratia
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name>
          <surname>
           Mesecar
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-κB signaling
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <fpage>
         6689
        </fpage>
        <lpage>
         6705
        </lpage>
        <pub-id pub-id-type="pmid">
         19369340
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR74">
       <label>
        74
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Devaraj
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2007
        </year>
        <volume>
         282
        </volume>
        <fpage>
         32208
        </fpage>
        <lpage>
         32221
        </lpage>
        <pub-id pub-id-type="pmid">
         17761676
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR75">
       <label>
        75
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Schafer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Pham
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS coronavirus papain like protease can inhibit IRF3 at a post activation step that requires deubiquitination activity
        </article-title>
        <source>
         Virol. J.
        </source>
        <year>
         2014
        </year>
        <volume>
         11
        </volume>
        <fpage>
         209
        </fpage>
        <pub-id pub-id-type="pmid">
         25481026
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR76">
       <label>
        76
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bailey-Elkin
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2014
        </year>
        <volume>
         289
        </volume>
        <fpage>
         34667
        </fpage>
        <lpage>
         34682
        </lpage>
        <pub-id pub-id-type="pmid">
         25320088
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR77">
       <label>
        77
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2011
        </year>
        <volume>
         7
        </volume>
        <fpage>
         e1002433
        </fpage>
        <pub-id pub-id-type="pmid">
         22174690
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR78">
       <label>
        78
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kamitani
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Lokugamage
          </surname>
          <given-names>
           KG
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         A two-pronged strategy to suppress host protein synthesis by SARS coronavirus nsp1 protein
        </article-title>
        <source>
         Nat. Struct. Mol. Biol.
        </source>
        <year>
         2009
        </year>
        <volume>
         16
        </volume>
        <fpage>
         1134
        </fpage>
        <lpage>
         1140
        </lpage>
        <pub-id pub-id-type="pmid">
         19838190
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR79">
       <label>
        79
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Kamitani
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Matsuura
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus nsp1 facilitates efficient propagation in cells through a specific translational shutoff of host mRNA
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <fpage>
         11128
        </fpage>
        <lpage>
         11137
        </lpage>
        <pub-id pub-id-type="pmid">
         22855488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR80">
       <label>
        80
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wathelet
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Orr
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         11620
        </fpage>
        <lpage>
         11633
        </lpage>
        <pub-id pub-id-type="pmid">
         17715225
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR81">
       <label>
        81
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lokugamage
          </surname>
          <given-names>
           KG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus nsp1 inhibits host gene expression by selectively targeting mRNAs transcribed in the nucleus while sparing mRNAs of cytoplasmic origin
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         10970
        </fpage>
        <lpage>
         10981
        </lpage>
        <pub-id pub-id-type="pmid">
         26311885
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR82">
       <label>
        82
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Freundt
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lenardo
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           XN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <fpage>
         6631
        </fpage>
        <lpage>
         6640
        </lpage>
        <pub-id pub-id-type="pmid">
         19403678
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR83">
       <label>
        83
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kopecky-Bromberg
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Martinez-Sobrido
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Palese
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         548
        </fpage>
        <lpage>
         557
        </lpage>
        <pub-id pub-id-type="pmid">
         17108024
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR84">
       <label>
        84
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MAVS-mediated apoptosis and its inhibition by viral proteins
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2009
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e5466
        </fpage>
        <pub-id pub-id-type="pmid">
         19404494
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR85">
       <label>
        85
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2014
        </year>
        <volume>
         5
        </volume>
        <fpage>
         e01174-14
        </fpage>
        <pub-id pub-id-type="pmid">
         24846384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR86">
       <label>
        86
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graci
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
         <name>
          <surname>
           Cameron
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanisms of action of ribavirin against distinct viruses
        </article-title>
        <source>
         Rev. Med. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         16
        </volume>
        <fpage>
         37
        </fpage>
        <lpage>
         48
        </lpage>
        <pub-id pub-id-type="pmid">
         16287208
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR87">
       <label>
        87
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Momattin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Dib
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         42
        </fpage>
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="pmid">
         24406736
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR88">
       <label>
        88
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical analysis of the first patient with imported Middle East respiratory syndrome in China
        </article-title>
        <source>
         Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
        </source>
        <year>
         2015
        </year>
        <volume>
         27
        </volume>
        <fpage>
         630
        </fpage>
        <lpage>
         634
        </lpage>
        <pub-id pub-id-type="pmid">
         26255008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR89">
       <label>
        89
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Booth
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2003
        </year>
        <volume>
         289
        </volume>
        <fpage>
         2801
        </fpage>
        <lpage>
         2809
        </lpage>
        <pub-id pub-id-type="pmid">
         12734147
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR90">
       <label>
        90
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poutanen
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of severe acute respiratory syndrome in Canada
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1995
        </fpage>
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="pmid">
         12671061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR91">
       <label>
        91
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           So
          </surname>
          <given-names>
           LK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development of a standard treatment protocol for severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         1615
        </fpage>
        <lpage>
         1617
        </lpage>
        <pub-id pub-id-type="pmid">
         12747883
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR92">
       <label>
        92
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A cluster of cases of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1977
        </fpage>
        <lpage>
         1985
        </lpage>
        <pub-id pub-id-type="pmid">
         12671062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR93">
       <label>
        93
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Loutfy
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2003
        </year>
        <volume>
         290
        </volume>
        <fpage>
         3222
        </fpage>
        <lpage>
         3228
        </lpage>
        <pub-id pub-id-type="pmid">
         14693875
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR94">
       <label>
        94
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
        </article-title>
        <source>
         J. Med. Microbiol.
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <fpage>
         715
        </fpage>
        <lpage>
         720
        </lpage>
        <pub-id pub-id-type="pmid">
         12867568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR95">
       <label>
        95
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           LY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2003
        </year>
        <volume>
         9
        </volume>
        <fpage>
         713
        </fpage>
        <lpage>
         717
        </lpage>
        <pub-id pub-id-type="pmid">
         12781012
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR96">
       <label>
        96
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Blanc
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Surdel
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Vignuzzi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Denison
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2013
        </year>
        <volume>
         9
        </volume>
        <fpage>
         e1003565
        </fpage>
        <pub-id pub-id-type="pmid">
         23966862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR97">
       <label>
        97
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Infect.
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <fpage>
         606
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR98">
       <label>
        98
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2013
        </year>
        <volume>
         3
        </volume>
        <fpage>
         1686
        </fpage>
        <pub-id pub-id-type="pmid">
         23594967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR99">
       <label>
        99
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR100">
       <label>
        100
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Michaelis
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Baer
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2005
        </year>
        <volume>
         326
        </volume>
        <fpage>
         905
        </fpage>
        <lpage>
         908
        </lpage>
        <pub-id pub-id-type="pmid">
         15607755
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR101">
       <label>
        101
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <fpage>
         1313
        </fpage>
        <lpage>
         1317
        </lpage>
        <pub-id pub-id-type="pmid">
         24013700
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR102">
       <label>
        102
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         14
        </volume>
        <fpage>
         1090
        </fpage>
        <lpage>
         1095
        </lpage>
        <pub-id pub-id-type="pmid">
         25278221
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR103">
       <label>
        103
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shalhoub
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study
        </article-title>
        <source>
         J. Antimicrob. Chemother.
        </source>
        <year>
         2015
        </year>
        <volume>
         70
        </volume>
        <fpage>
         2129
        </fpage>
        <lpage>
         2132
        </lpage>
        <pub-id pub-id-type="pmid">
         25900158
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR104">
       <label>
        104
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khalid
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases
        </article-title>
        <source>
         Antivir. Ther.
        </source>
        <year>
         2015
        </year>
        <volume>
         20
        </volume>
        <fpage>
         87
        </fpage>
        <lpage>
         91
        </lpage>
        <pub-id pub-id-type="pmid">
         24831606
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR105">
       <label>
        105
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR106">
       <label>
        106
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study
        </article-title>
        <source>
         Hong Kong Med. J.
        </source>
        <year>
         2003
        </year>
        <volume>
         9
        </volume>
        <fpage>
         399
        </fpage>
        <lpage>
         406
        </lpage>
        <pub-id pub-id-type="pmid">
         14660806
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR107">
       <label>
        107
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
        </article-title>
        <source>
         Thorax
        </source>
        <year>
         2004
        </year>
        <volume>
         59
        </volume>
        <fpage>
         252
        </fpage>
        <lpage>
         256
        </lpage>
        <pub-id pub-id-type="pmid">
         14985565
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR108">
       <label>
        108
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spanakis
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
        </article-title>
        <source>
         Int. J. Antimicrob. Agents
        </source>
        <year>
         2014
        </year>
        <volume>
         44
        </volume>
        <fpage>
         528
        </fpage>
        <lpage>
         532
        </lpage>
        <pub-id pub-id-type="pmid">
         25288266
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR109">
       <label>
        109
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           KN
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome-coronavirus infection: a case report of serial computed tomographic findings in a young male patient
        </article-title>
        <source>
         Korean J. Radiol
        </source>
        <year>
         2016
        </year>
        <volume>
         17
        </volume>
        <fpage>
         166
        </fpage>
        <lpage>
         170
        </lpage>
        <pub-id pub-id-type="pmid">
         26798230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR110">
       <label>
        110
       </label>
       <mixed-citation publication-type="other">
        Kim, U. J., Won, E. J., Kee, S. J., Jung, S. I. &amp; Jang, H. C. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome: a case report.
        <italic>
         Antivir. Ther.
        </italic>
        10.3851/IMP3002 (2015).
       </mixed-citation>
      </ref>
      <ref id="CR111">
       <label>
        111
       </label>
       <mixed-citation publication-type="other">
        Rhee, J. Y., Hong, G. &amp; Ryu, K. M. Clinical implications of five cases of Middle East respiratory syndrome coronavirus infection in South Korea Outbreak.
        <italic>
         Jpn J. Infect. Dis.
        </italic>
        10.7883/yoken.JJID.2015.445 (2016).
       </mixed-citation>
      </ref>
      <ref id="CR112">
       <label>
        112
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hilgenfeld
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
        </article-title>
        <source>
         FEBS J.
        </source>
        <year>
         2014
        </year>
        <volume>
         281
        </volume>
        <fpage>
         4085
        </fpage>
        <lpage>
         4096
        </lpage>
        <pub-id pub-id-type="pmid">
         25039866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR113">
       <label>
        113
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         115
        </volume>
        <fpage>
         9
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="pmid">
         25542975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR114">
       <label>
        114
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tomar
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease (3CL
         <sup>
          pro
         </sup>
         ): implications for nsp5 regulation and the development of antivirals
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2015
        </year>
        <volume>
         290
        </volume>
        <fpage>
         19403
        </fpage>
        <lpage>
         19422
        </lpage>
        <pub-id pub-id-type="pmid">
         26055715
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR115">
       <label>
        115
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture
        </article-title>
        <source>
         Antimicrob. Agents Chemother.
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <fpage>
         4875
        </fpage>
        <lpage>
         4884
        </lpage>
        <pub-id pub-id-type="pmid">
         24841269
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR116">
       <label>
        116
       </label>
       <mixed-citation publication-type="other">
        International Severe Acute Respiratory &amp; Emerging Infection Consortium. Treatment of MERS-CoV: decision support tool.
        <italic>
         International Severe Acute Respiratory &amp; Emerging Infection Consortium
        </italic>
        ,
        <ext-link ext-link-type="uri" xlink:href="https://isaric.tghn.org/site_media/media/articles/Decision_Support_Document_v1_1_20130729.pdf">
         https://isaric.tghn.org/site_media/media/articles/Decision_Support_Document_v1_1_20130729.pdf
        </ext-link>
        (updated 29 July 2013).
       </mixed-citation>
      </ref>
      <ref id="CR117">
       <label>
        117
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mair-Jenkins
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         211
        </volume>
        <fpage>
         80
        </fpage>
        <lpage>
         90
        </lpage>
        <pub-id pub-id-type="pmid">
         25030060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR118">
       <label>
        118
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         7045
        </fpage>
        <lpage>
         7053
        </lpage>
        <pub-id pub-id-type="pmid">
         24719424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR119">
       <label>
        119
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein
        </article-title>
        <source>
         Sci. Transl Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         6
        </volume>
        <fpage>
         234ra59
        </fpage>
        <pub-id pub-id-type="pmid">
         24778414
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR120">
       <label>
        120
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           XC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2014
        </year>
        <volume>
         111
        </volume>
        <fpage>
         E2018
        </fpage>
        <lpage>
         E2026
        </lpage>
        <pub-id pub-id-type="pmid">
         24778221
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR121">
       <label>
        121
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         7796
        </fpage>
        <lpage>
         7805
        </lpage>
        <pub-id pub-id-type="pmid">
         24789777
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR122">
       <label>
        122
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         6117
        </fpage>
        <lpage>
         6120
        </lpage>
        <pub-id pub-id-type="pmid">
         25787284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR123">
       <label>
        123
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luke
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV
         <italic>
          in vivo
         </italic>
        </article-title>
        <source>
         Sci. Transl Med.
        </source>
        <year>
         2016
        </year>
        <volume>
         8
        </volume>
        <fpage>
         326ra21
        </fpage>
        <pub-id pub-id-type="pmid">
         26888429
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR124">
       <label>
        124
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein
        </article-title>
        <source>
         Cell Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         25
        </volume>
        <fpage>
         1237
        </fpage>
        <lpage>
         1249
        </lpage>
        <pub-id pub-id-type="pmid">
         26391698
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR125">
       <label>
        125
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corti
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2015
        </year>
        <volume>
         112
        </volume>
        <fpage>
         10473
        </fpage>
        <lpage>
         10478
        </lpage>
        <pub-id pub-id-type="pmid">
         26216974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR126">
       <label>
        126
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pascal
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2015
        </year>
        <volume>
         112
        </volume>
        <fpage>
         8738
        </fpage>
        <lpage>
         8743
        </lpage>
        <pub-id pub-id-type="pmid">
         26124093
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR127">
       <label>
        127
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Houser
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prophylaxis with a MERS-CoV-specific human monoclonal antibody protects rabbits from MERS-CoV infection
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         213
        </volume>
        <fpage>
         1557
        </fpage>
        <lpage>
         1561
        </lpage>
        <pub-id pub-id-type="pmid">
         26941283
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR128">
       <label>
        128
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2016
        </year>
        <volume>
         490
        </volume>
        <fpage>
         49
        </fpage>
        <lpage>
         58
        </lpage>
        <pub-id pub-id-type="pmid">
         26828465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR129">
       <label>
        129
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ohnuma
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         13892
        </fpage>
        <lpage>
         13899
        </lpage>
        <pub-id pub-id-type="pmid">
         24067970
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR130">
       <label>
        130
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Elshabrawy
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         4353
        </fpage>
        <lpage>
         4365
        </lpage>
        <pub-id pub-id-type="pmid">
         24501399
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR131">
       <label>
        131
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glowacka
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         4122
        </fpage>
        <lpage>
         4134
        </lpage>
        <pub-id pub-id-type="pmid">
         21325420
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR132">
       <label>
        132
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protease inhibitors targeting coronavirus and filovirus entry
        </article-title>
        <source>
         Antiviral Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         116
        </volume>
        <fpage>
         76
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         25666761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR133">
       <label>
        133
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of C5a in acute lung injury induced by highly pathogenic viral infections
        </article-title>
        <source>
         Emerg. Microbes Infect.
        </source>
        <year>
         2015
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e28
        </fpage>
        <pub-id pub-id-type="pmid">
         26060601
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR134">
       <label>
        134
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Josset
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2013
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e00165
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="pmid">
         23631916
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR135">
       <label>
        135
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           EF
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         A decade after SARS: strategies for controlling emerging coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2013
        </year>
        <volume>
         11
        </volume>
        <fpage>
         836
        </fpage>
        <lpage>
         848
        </lpage>
        <pub-id pub-id-type="pmid">
         24217413
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR136">
       <label>
        136
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roper
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Rehm
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS vaccines: where are we?
        </article-title>
        <source>
         Expert Rev. Vaccines
        </source>
        <year>
         2009
        </year>
        <volume>
         8
        </volume>
        <fpage>
         887
        </fpage>
        <lpage>
         898
        </lpage>
        <pub-id pub-id-type="pmid">
         19538115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR137">
       <label>
        137
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome: current status and future prospects for vaccine development
        </article-title>
        <source>
         Expert Opin. Biol. Ther.
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <fpage>
         1647
        </fpage>
        <lpage>
         1651
        </lpage>
        <pub-id pub-id-type="pmid">
         26414077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR138">
       <label>
        138
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of candidate vaccine approaches for MERS-CoV
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <year>
         2015
        </year>
        <volume>
         6
        </volume>
        <fpage>
         7712
        </fpage>
        <pub-id pub-id-type="pmid">
         26218507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR139">
       <label>
        139
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge
        </article-title>
        <source>
         EBioMedicine
        </source>
        <year>
         2015
        </year>
        <volume>
         2
        </volume>
        <fpage>
         1438
        </fpage>
        <lpage>
         1446
        </lpage>
        <pub-id pub-id-type="pmid">
         26629538
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR140">
       <label>
        140
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muthumani
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates
        </article-title>
        <source>
         Sci. Transl Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         7
        </volume>
        <fpage>
         301ra132
        </fpage>
        <pub-id pub-id-type="pmid">
         26290414
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR141">
       <label>
        141
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mastalerz-Migas
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Bujnowska-Fedak
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Brydak
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immune efficacy of first and repeat trivalent influenza vaccine in healthy subjects and hemodialysis patients
        </article-title>
        <source>
         Adv. Exp. Med. Biol.
        </source>
        <year>
         2015
        </year>
        <volume>
         836
        </volume>
        <fpage>
         47
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         25248348
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR142">
       <label>
        142
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <fpage>
         629
        </fpage>
        <pub-id pub-id-type="pmid">
         26008827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR143">
       <label>
        143
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
        </article-title>
        <source>
         Science
        </source>
        <year>
         2016
        </year>
        <volume>
         351
        </volume>
        <fpage>
         77
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="pmid">
         26678878
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR144">
       <label>
        144
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         752
        </fpage>
        <lpage>
         761
        </lpage>
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR145">
       <label>
        145
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients
        </article-title>
        <source>
         Ann. Intern. Med.
        </source>
        <year>
         2004
        </year>
        <volume>
         141
        </volume>
        <fpage>
         662
        </fpage>
        <lpage>
         673
        </lpage>
        <pub-id pub-id-type="pmid">
         15520422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR146">
       <label>
        146
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2015
        </year>
        <volume>
         386
        </volume>
        <fpage>
         995
        </fpage>
        <lpage>
         1007
        </lpage>
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR147">
       <label>
        147
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Abdallat
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         59
        </volume>
        <fpage>
         1225
        </fpage>
        <lpage>
         1233
        </lpage>
        <pub-id pub-id-type="pmid">
         24829216
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR148">
       <label>
        148
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saad
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         29
        </volume>
        <fpage>
         301
        </fpage>
        <lpage>
         306
        </lpage>
        <pub-id pub-id-type="pmid">
         25303830
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR149">
       <label>
        149
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         210
        </volume>
        <fpage>
         1590
        </fpage>
        <lpage>
         1594
        </lpage>
        <pub-id pub-id-type="pmid">
         24837403
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR150">
       <label>
        150
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feikin
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Association of higher MERS-CoV virus load with severe disease and death, Saudi Arabia, 2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <fpage>
         2029
        </fpage>
        <lpage>
         2035
        </lpage>
        <pub-id pub-id-type="pmid">
         26488195
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR151">
       <label>
        151
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Kluberg
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Mekaru
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Brownstein
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mortality risk factors for Middle East respiratory syndrome outbreak, South Korea, 2015
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <fpage>
         2088
        </fpage>
        <lpage>
         2090
        </lpage>
        <pub-id pub-id-type="pmid">
         26488869
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR152">
       <label>
        152
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gretebeck
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Animal models for SARS and MERS coronaviruses
        </article-title>
        <source>
         Curr. Opin. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         13
        </volume>
        <fpage>
         123
        </fpage>
        <lpage>
         129
        </lpage>
        <pub-id pub-id-type="pmid">
         26184451
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR153">
       <label>
        153
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication and shedding of MERS-CoV in Jamaican fruit bats (
         <italic>
          Artibeus jamaicensis
         </italic>
         )
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2016
        </year>
        <volume>
         6
        </volume>
        <fpage>
         21878
        </fpage>
        <pub-id pub-id-type="pmid">
         26899616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR154">
       <label>
        154
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2005
        </year>
        <volume>
         102
        </volume>
        <fpage>
         14040
        </fpage>
        <lpage>
         14045
        </lpage>
        <pub-id pub-id-type="pmid">
         16169905
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR155">
       <label>
        155
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <year>
         2005
        </year>
        <volume>
         310
        </volume>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR156">
       <label>
        156
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         2620
        </fpage>
        <lpage>
         2625
        </lpage>
        <pub-id pub-id-type="pmid">
         15681462
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR157">
       <label>
        157
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1999
        </fpage>
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="pmid">
         25418529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR158">
       <label>
        158
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2008
        </year>
        <volume>
         105
        </volume>
        <fpage>
         19944
        </fpage>
        <lpage>
         19949
        </lpage>
        <pub-id pub-id-type="pmid">
         19036930
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR159">
       <label>
        159
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS-like WIV1-CoV poised for human emergence
        </article-title>
        <source>
         Proc. Natl Acad. Sci. USA
        </source>
        <year>
         2016
        </year>
        <volume>
         113
        </volume>
        <fpage>
         3048
        </fpage>
        <lpage>
         3053
        </lpage>
        <pub-id pub-id-type="pmid">
         26976607
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="other" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Viruses
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Viruses
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       viruses
      </journal-id>
      <journal-title-group>
       <journal-title>
        Viruses
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1999-4915
      </issn>
      <publisher>
       <publisher-name>
        MDPI
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32050635
      </article-id>
      <article-id pub-id-type="pmc">
       7077337
      </article-id>
      <article-id pub-id-type="doi">
       10.3390/v12020194
      </article-id>
      <article-id pub-id-type="publisher-id">
       viruses-12-00194
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Perspective
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Potential Maternal and Infant Outcomes from Coronavirus 2019-nCoV (SARS-CoV-2) Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0002-7486-8545
        </contrib-id>
        <name>
         <surname>
          Schwartz
         </surname>
         <given-names>
          David A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-12-00194">
         1
        </xref>
        <xref ref-type="corresp" rid="c1-viruses-12-00194">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0001-5855-9614
        </contrib-id>
        <name>
         <surname>
          Graham
         </surname>
         <given-names>
          Ashley L.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2-viruses-12-00194">
         2
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af1-viruses-12-00194">
       <label>
        1
       </label>
       Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
      </aff>
      <aff id="af2-viruses-12-00194">
       <label>
        2
       </label>
       Department of Anthropology, University of Connecticut, Storrs, CT 06269, USA;
       <email>
        ashley.graham@uconn.edu
       </email>
      </aff>
      <author-notes>
       <corresp id="c1-viruses-12-00194">
        <label>
         *
        </label>
        Correspondence:
        <email>
         davidalanschwartz@gmail.com
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        10
       </day>
       <month>
        2
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <month>
        2
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       12
      </volume>
      <issue>
       2
      </issue>
      <elocation-id>
       194
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         02
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         09
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 by the authors.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ).
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        In early December 2019 a cluster of cases of pneumonia of unknown cause was identified in Wuhan, a city of 11 million persons in the People’s Republic of China. Further investigation revealed these cases to result from infection with a newly identified coronavirus, initially termed 2019-nCoV and subsequently SARS-CoV-2. The infection moved rapidly through China, spread to Thailand and Japan, extended into adjacent countries through infected persons travelling by air, eventually reaching multiple countries and continents. Similar to such other coronaviruses as those causing the Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), the new coronavirus was reported to spread via natural aerosols from human-to-human. In the early stages of this epidemic the case fatality rate is estimated to be approximately 2%, with the majority of deaths occurring in special populations. Unfortunately, there is limited experience with coronavirus infections during pregnancy, and it now appears certain that pregnant women have become infected during the present 2019-nCoV epidemic. In order to assess the potential of the Wuhan 2019-nCoV to cause maternal, fetal and neonatal morbidity and other poor obstetrical outcomes, this communication reviews the published data addressing the epidemiological and clinical effects of SARS, MERS, and other coronavirus infections on pregnant women and their infants. Recommendations are also made for the consideration of pregnant women in the design, clinical trials, and implementation of future 2019-nCoV vaccines.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        Middle East respiratory syndrome
       </kwd>
       <kwd>
        severe acute respiratory syndrome
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        Wuhan coronavirus
       </kwd>
       <kwd>
        2019-nCoV
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        pregnancy
       </kwd>
       <kwd>
        maternal mortality
       </kwd>
       <kwd>
        maternal death
       </kwd>
       <kwd>
        pregnancy complications
       </kwd>
       <kwd>
        maternal morbidity
       </kwd>
       <kwd>
        pneumonia
       </kwd>
       <kwd>
        epidemic
       </kwd>
       <kwd>
        emerging infection
       </kwd>
       <kwd>
        China
       </kwd>
       <kwd>
        Wuhan coronavirus outbreak
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1-viruses-12-00194" sec-type="intro">
     <title>
      1. Introduction
     </title>
     <p>
      Coronaviruses are spherical, enveloped, and the largest of positive-strand RNA viruses. They have a wide host range, including birds, farm animals, pets, camels, and bats, in which they primarily cause respiratory and gastrointestinal disease. Belonging to the order
      <italic>
       Nidovirales
      </italic>
      , family
      <italic>
       Coronaviridae
      </italic>
      , and the subfamily
      <italic>
       Orthocoronaviridae
      </italic>
      there are four genera of coronaviruses—
      <italic>
       Alphacoronavirus
      </italic>
      ,
      <italic>
       Betacoronavirus
      </italic>
      ,
      <italic>
       Deltacorona
      </italic>
      virus, and
      <italic>
       Gammacoronavirus
      </italic>
      [
      <xref ref-type="bibr" rid="B1-viruses-12-00194">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="B2-viruses-12-00194">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B3-viruses-12-00194">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="B4-viruses-12-00194">
       4
      </xref>
      ].
     </p>
     <p>
      In humans, they are a cause of mild illnesses including the common colds occurring in children and adults, and were believed to be of modest medical importance. However, two zoonotic coronaviruses—including the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV)—can produce severe lower respiratory tract infections. Both the SARS-CoV and MERS-CoV have several features in common that are factors in producing nosocomial transmission, replication in the lower respiratory tract, and viral immunopathology. Both coronaviruses are zoonotic infections and constitute significant public health threats that have resulted in epidemics with significant loss of life [
      <xref ref-type="bibr" rid="B1-viruses-12-00194">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="B5-viruses-12-00194">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="B6-viruses-12-00194">
       6
      </xref>
      ]. When the SARS-CoV and MERS-CoV infect women who are pregnant, they can result in poor obstetric outcomes including maternal morbidity and death. There are currently no vaccines or specific treatments approved for coronavirus infections [
      <xref ref-type="bibr" rid="B2-viruses-12-00194">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B6-viruses-12-00194">
       6
      </xref>
      ].
     </p>
     <p>
      Prior to December 2019, there were a total of six coronavirus species that produced human infection: HCoV-229E and HCoV-NL63 belonging to the
      <italic>
       Alphacoronaviru
      </italic>
      s genus; and HCoV-OC43, HCoV-HKU1, MERS-CoV, and SARS-CoV, which belong to the
      <italic>
       Betacoronavirus
      </italic>
      genus [
      <xref ref-type="bibr" rid="B1-viruses-12-00194">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="B2-viruses-12-00194">
       2
      </xref>
      ]. As of December 2019, there are now seven species that infect humans.
     </p>
     <p>
      As the newly identified novel coronavirus, termed 2019-nCoV and subsequently named SARS-CoV-2, spreads rapidly throughout China and across to other countries, researchers scramble to understand transmission dynamics, virulence, and pathogenicity. Given the rapidly progressive spread of this current 2019 novel coronavirus it is reasonable to expect that pregnant women have already become infected. The effect of 2019-nCoV during pregnancy is, at the present, unknown. This communication reviews the medical and clinical findings from coronavirus infections in pregnant women in order to anticipate how the newly discovered 2019-nCoV might affect maternal and infant morbidity and mortality.
     </p>
    </sec>
    <sec id="sec2-viruses-12-00194">
     <title>
      2. The 2019 Coronavirus 2019-nCoV (SARS-CoV-2) Outbreak in Wuhan
     </title>
     <p>
      In the beginning of December 2019, a cluster of persons with a pneumonia of unknown cause was identified in Wuhan, the capital of Hubei Province and a large city of approximately 11 million persons located in the central region of the People’s Republic of China [
      <xref ref-type="bibr" rid="B7-viruses-12-00194">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B8-viruses-12-00194">
       8
      </xref>
      ]. Between 8 and 18 December 2019 there were 7 cases of pneumonia identified whose clinical features resembled that of a viral pneumonia. The outbreak was initially believed to be linked to the Wuhan Huanan (South China) Seafood Wholesale Market. This market, termed a “wet” market, sells a variety of seafood, cuts of meat, and both live and dead animals in over one thousand stalls in constant close contact; however, whether this market was the origin of the outbreak remains unknown [
      <xref ref-type="bibr" rid="B9-viruses-12-00194">
       9
      </xref>
      ]. On 31 December 2019, the Chinese Center for Disease Control and Prevention (China CDC) sent a rapid response team to Hubei to work alongside health personnel from the provincial and Wuhan city health departments to conduct an epidemiologic investigation. As the disease was spreading through secondary and tertiary cases, the World Health Organization (WHO) China Country Office was informed on 31 December 2019 of the occurrence of these cases of pneumonia of unknown etiology. During the period from 31 December 2019 to 3 January 2020, 44 patients with pneumonia of unknown etiology were reported by the Chinese authorities to the WHO. On 7 January 2020 investigators in China identified the etiological agent of the epidemic as a previously unknown coronavirus, and it was given the designation 2019-nCoV (for 2019 novel coronavirus) [
      <xref ref-type="bibr" rid="B8-viruses-12-00194">
       8
      </xref>
      ]. Analysis of the clinical features of 41 hospitalized patients with laboratory-confirmed 2019-nCoV infection revealed that 30 were men (73%); less than one-half had underlying co-morbid conditions (13; 32%) which included diabetes (8, 20%), hypertension (6, 15%), and cardiovascular disease (6; 15%); and the average age was 49.0 years old. The most common symptoms at the beginning of their illness included fever (40, 98%), cough (31, 76%), and fatigue or myalgia (18, 44%), sputum production (11, 28%), and headache (3, 8%) [
      <xref ref-type="bibr" rid="B10-viruses-12-00194">
       10
      </xref>
      ]. Among these 41 initial cases of 2019-nCoV infection there were 12 patients (32%) who developed acute respiratory distress syndrome (ARDS), 13 (32%) required intensive care and 6 (15%) died. During the first weeks of January the infection spread rapidly through China and extended to adjacent countries where cases began to appear—13 January in Thailand, 15 January in Japan, 20 January in the Republic of Korea, and Taiwan and the United States on 21 January [
      <xref ref-type="bibr" rid="B11-viruses-12-00194">
       11
      </xref>
      ]. Infected travelers, mostly via commercial air travel, are known to have been responsible for introducing the virus outside of Wuhan. The new coronavirus continued to spread throughout multiple countries and continents, and by 9 February 2020 the WHO reported 37,251 confirmed cases in China that resulted in 812 deaths, surpassing the number of deaths that occurred during the 2002–2003 SARS epidemic. An additional 307 cases of 2019-nCoV infection have occurred among 24 other countries outside of China [
      <xref ref-type="bibr" rid="B12-viruses-12-00194">
       12
      </xref>
      ]. (
      <xref ref-type="fig" rid="viruses-12-00194-f001">
       Figure 1
      </xref>
      ) At the meeting of the Emergency Committee of the WHO on 30 January, the novel coronavirus 2019 epidemic was declared a Public Health Emergency of International Concern (PHEIC) [
      <xref ref-type="bibr" rid="B11-viruses-12-00194">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="B13-viruses-12-00194">
       13
      </xref>
      ].
     </p>
     <p>
      This newly recognized coronavirus, producing a disease that has been termed COVID-19, is rapidly spreading throughout China, has crossed international borders to infect persons in neighboring countries, and humans infected by the virus are travelling via commercial airlines to other continents. It is certain that 2019-nCoV will infect women who are pregnant, leaving the question open as to whether the novel coronavirus will have a similar or different effect on them compared with SARS-CoV and MERS-CoV. In order to address the potential obstetrical outcomes of infection to both mother and infant, the present communication describes the current state of knowledge regarding the effects of other coronavirus infections in pregnancy.
     </p>
    </sec>
    <sec id="sec3-viruses-12-00194">
     <title>
      3. Pneumonia Occurring during Pregnancy
     </title>
     <p>
      Pneumonia arising from any infectious etiology is an important cause of morbidity and mortality among pregnant women. It is the most prevalent non-obstetric infectious condition that occurs during pregnancy [
      <xref ref-type="bibr" rid="B14-viruses-12-00194">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B15-viruses-12-00194">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="B16-viruses-12-00194">
       16
      </xref>
      ]. In one study pneumonia was the 3rd most common cause of indirect maternal death [
      <xref ref-type="bibr" rid="B17-viruses-12-00194">
       17
      </xref>
      ]. Approximately 25 percent of pregnant women who develop pneumonia will need to be hospitalized in critical care units and require ventilatory support [
      <xref ref-type="bibr" rid="B16-viruses-12-00194">
       16
      </xref>
      ]. Although bacterial pneumonia is a serious disease when it occurs in pregnant women, even when the agent(s) are susceptible to antibiotics, viral pneumonia has even higher levels of morbidity and mortality during pregnancy [
      <xref ref-type="bibr" rid="B18-viruses-12-00194">
       18
      </xref>
      ]. As with other infectious diseases, the normal maternal physiologic changes that accompany pregnancy—including altered cell-mediated immunity [
      <xref ref-type="bibr" rid="B19-viruses-12-00194">
       19
      </xref>
      ] and changes in pulmonary function—have been hypothesized to affect both susceptibility to and clinical severity of pneumonia [
      <xref ref-type="bibr" rid="B20-viruses-12-00194">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="B21-viruses-12-00194">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="B22-viruses-12-00194">
       22
      </xref>
      ]. This has been evident historically during previous epidemics. The case fatality rate (CFR) for pregnant women infected with influenza during the 1918–1919 pandemic was 27%—even higher when exposure occurred during the 3rd trimester and upwards of 50% if pneumonia supervened [
      <xref ref-type="bibr" rid="B23-viruses-12-00194">
       23
      </xref>
      ]. During the 1957–1958 Asian flu epidemic, 10% of all deaths occurred in pregnant women, and their CFR was twice as high as that of infected women who were not pregnant [
      <xref ref-type="bibr" rid="B24-viruses-12-00194">
       24
      </xref>
      ]. The most common adverse obstetrical outcomes associated with maternal pneumonias from all causes include premature rupture of membranes (PROM) and preterm labor (PTL), intrauterine fetal demise (IUFD), intrauterine growth restriction (IUGR), and neonatal death [
      <xref ref-type="bibr" rid="B14-viruses-12-00194">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="B15-viruses-12-00194">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="B16-viruses-12-00194">
       16
      </xref>
      ].
     </p>
    </sec>
    <sec id="sec4-viruses-12-00194">
     <title>
      4. The 2002–2003 Severe Acute Respiratory Syndrome (SARS) Epidemic
     </title>
     <p>
      The SARS epidemic began quietly at the turn of the 21st century. In November 2002, a cook in Guangdong Province, China, died from an unidentified illness. He had worked at a restaurant in which meat from wild animals was served. On 27 November 2002 Chinese-language media and internet reports were picked up by Canada’s Global Public Health Intelligence Network (GPHIN) that indicated a flu-like illness was occurring in China [
      <xref ref-type="bibr" rid="B25-viruses-12-00194">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="B26-viruses-12-00194">
       26
      </xref>
      ]. Unfortunately, the reports were not translated, and China failed to report the occurrence of this illness to the World Health Organization (WHO) until February 2003. The disease spread to other countries where it primarily infected healthcare workers. One of these was Dr. Carlo Urbani, a WHO physician investigating a patient with the new disease in Hanoi. He recognized that the pneumonia was probably caused by a new, highly infectious agent, and rapidly notified the WHO. He contracted the SARS-CoV while there, became febrile and later died after traveling to Thailand to attend a conference. On 12 March 2003, WHO issued a global alert regarding the disease that was occurring primarily among health care workers in Hanoi, Vietnam and Hong Kong. The disease continued to spread, and by 31 July 2003 there were 8422 probable cases, leading to 916 deaths in 29 countries, with the majority of cases occurring in mainland China and Hong Kong. Approximately 30% of infections occurred in healthcare workers. By the termination of the epidemic the global CFR was 11% [
      <xref ref-type="bibr" rid="B27-viruses-12-00194">
       27
      </xref>
      ].
     </p>
    </sec>
    <sec id="sec5-viruses-12-00194">
     <title>
      5. SARS and Pregnancy
     </title>
     <p>
      Although there were relatively few documented cases of SARS occurring during pregnancy, several case reports and small clinical studies have described the clinical effects in pregnant women and their infants. In reviewing these reports describing pregnant women with SARS in China it is possible, and perhaps even probable, that some of the same patients were included in more than one publication. However, even if this is the case, there is no doubt that SARS coronavirus infection was found to be associated with severe maternal illness, maternal death, and spontaneous abortion [
      <xref ref-type="bibr" rid="B19-viruses-12-00194">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="B28-viruses-12-00194">
       28
      </xref>
      ,
      <xref ref-type="bibr" rid="B29-viruses-12-00194">
       29
      </xref>
      ,
      <xref ref-type="bibr" rid="B30-viruses-12-00194">
       30
      </xref>
      ,
      <xref ref-type="bibr" rid="B31-viruses-12-00194">
       31
      </xref>
      ]. Martha Anker, an expert in statistics formerly with the WHO and the University of Massachusetts, estimated that more than 100 cases of SARS-CoV infection occurred in pregnant women, which warrants closer inspection [
      <xref ref-type="bibr" rid="B27-viruses-12-00194">
       27
      </xref>
      ].
     </p>
     <p>
      The clinical outcomes among pregnant women with SARS in Hong Kong were worse than those occurring in infected women who were not pregnant [
      <xref ref-type="bibr" rid="B32-viruses-12-00194">
       32
      </xref>
      ]. Wong et al. [
      <xref ref-type="bibr" rid="B29-viruses-12-00194">
       29
      </xref>
      ] evaluated the obstetrical outcomes from a cohort of pregnant women who developed SARS in Hong Kong during the period of 1 February to 31 July 2003. Four of the 7 women (57%) that presented during the 1st trimester sustained spontaneous miscarriages, likely a result of the hypoxia that was caused by SARS-related acute respiratory distress. Among the 5 women who presented after 24 weeks gestation, 4 had preterm deliveries (80%).
     </p>
     <p>
      A case-control study to determine the effects of SARS on pregnancy compared 10 pregnant and 40 non-pregnant women with the infection at the Princess Margaret Hospital in Hong Kong [
      <xref ref-type="bibr" rid="B27-viruses-12-00194">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="B33-viruses-12-00194">
       33
      </xref>
      ]. There were 3 deaths among the pregnant women with SARS (maternal mortality rate of 30%) and no deaths in the non-pregnant group of infected women (
      <italic>
       P
      </italic>
      = 0.006). Renal failure (
      <italic>
       P
      </italic>
      = 0.006) and disseminated intravascular coagulopathy (
      <italic>
       P
      </italic>
      = 0.006) developed more frequently in pregnant SARS patients when compared with the non-pregnant SARS group. Six pregnant women with SARS required admission to the intensive care unit (ICU) (60%) and 4 required endotracheal intubation (40%), compared with a 12.5% intubation rate (
      <italic>
       P
      </italic>
      = 0.065) and 17.5% ICU admission rate (
      <italic>
       P
      </italic>
      = 0.012) in the non-pregnant group.
     </p>
     <p>
      Maxwell et al. [
      <xref ref-type="bibr" rid="B32-viruses-12-00194">
       32
      </xref>
      ] reported 7 pregnant women infected with SARS-CoV who were followed at a designated SARS unit—2 of the 7 died (CFR of 28%), and 4 (57%) required ICU hospitalization and mechanical ventilation. In contrast, the mortality rate was less than 10% and mechanical ventilation rate less than 20% among non-pregnant, age-matched counterparts who were not infected with SARS-CoV. Two women with SARS recovered and maintained their pregnancy but had infants with IUGR. Among the live newborn infants, none had clinical or laboratory evidence for SARS-CoV infection. The new mothers who had developed SARS were advised not to breastfeed to prevent possible vertical transmission of the virus.
     </p>
     <p>
      Zhang et al. [
      <xref ref-type="bibr" rid="B34-viruses-12-00194">
       34
      </xref>
      ] described SARS-CoV infections in 5 primagravidas from Guangzhou, China at the height of the SARS epidemic. Two of the mothers became infected in the 2nd trimester, and 3 developed infection in the 3rd trimester. Two of the pregnant women had hospital-acquired SARS infections, and the other 3 were community-acquired. All 5 pregnant women had fever and abnormal chest radiographs; 4 had cough; 4 developed hypoalbuminemia; 3 had elevated alanine aminotransferase levels (ALT), 3 had chills or rigor, 2 had decreased lymphocytes, and 2 had decreased platelets. One pregnant woman required intensive care, but all recovered and there were no maternal deaths. The 5 infants were clinically evaluated, and none had evidence of SARS.
     </p>
     <p>
      Two pregnant women with SARS were reported from the United States. In a detailed case report, Robertson et al. [
      <xref ref-type="bibr" rid="B35-viruses-12-00194">
       35
      </xref>
      ] described a 36-year-old pregnant woman with an intermittent cough of approximately 10 days duration and no fever. While travelling in Hong Kong during the 2003 epidemic, she was exposed at her hotel to a person subsequently known to be infected with SARS-CoV. At 19 weeks gestation she developed fever, anorexia, headache, increasing cough, weakness, and shortness of breath. Upon returning to the United States she was hospitalized with pneumonia. Obstetrical ultrasounds revealed a low-lying placenta (placenta previa) but were otherwise normal. Following her discharge home and clinical recovery, she was found to have antibodies to SARS-CoV. She underwent cesarean section at 38 weeks gestation because of the placenta previa and a healthy baby girl was delivered [
      <xref ref-type="bibr" rid="B35-viruses-12-00194">
       35
      </xref>
      ,
      <xref ref-type="bibr" rid="B36-viruses-12-00194">
       36
      </xref>
      ]. The placenta was interpreted as being normal. At 130 days post-maternal illness, maternal serum and whole blood, swabs from maternal nasopharynx and rectum, post-delivery placenta, umbilical cord blood, amniotic fluid, and breast milk were collected for analysis—no viral RNA was detected in specimens tested by reverse transcriptase polymerase chain reaction (RT-PCR). Antibodies to SARS-CoV were detected from maternal serum, umbilical cord blood, and breast milk by enzyme immunoassay (EIA) and indirect immunofluorescence assay. No clinical specimens (except for cord blood) were available for testing from the infant. The second case in the USA occurred in a 38-year-old woman who had travelled to Hong Kong at 7 weeks gestation where she was exposed to SARS-CoV in the same hotel as the aforementioned American woman [
      <xref ref-type="bibr" rid="B37-viruses-12-00194">
       37
      </xref>
      ]. Following her return to the United States, her husband developed the clinical onset of SARS, and 6 days later she became ill with fever, myalgia, chills, headache, coryza, and a productive cough with shortness of breath and wheezing. Following her hospitalization for SARS she recovered, serum samples taken on days 28 and 64 post-onset of illness were positive for antibodies to SARS-CoV by enzyme immunoassay and immunofluorescent assays. Her pregnancy continued and was unremarkable except for developing elevated glucose levels. A cesarean section that was performed at 36 weeks gestation due to preterm rupture of membranes and fetal distress resulted in a healthy baby boy. At the time of delivery, the mother’s serum samples were positive for antibodies to SARS-CoV, but samples taken of umbilical cord blood and placenta were negative. Breast milk sampled 12 and 30 days after delivery were also negative for SARS-CoV antibodies. Specimens evaluated from maternal blood, stool, and nasopharynx samples, as well as umbilical cord blood of the infant, were all negative for coronavirus RNA by RT-PCR. Neonatal stool samples obtained on days-of-life 12 and 30 were also negative for viral RNA.
     </p>
     <p>
      From Canada, Yudin et al. [
      <xref ref-type="bibr" rid="B38-viruses-12-00194">
       38
      </xref>
      ] reported a 33-year-old pregnant woman who was admitted to the hospital at 31 weeks gestation with a fever, dry cough, and abnormal chest radiograph demonstrating patchy infiltrates. She had acquired SARS from contact with an infected family member. Following a 21-day stay in the hospital, during which she did not require ventilatory support, her convalescent antibody titers were positive for coronavirus infection. She had a normal labor and delivery and her newborn girl had no evidence of infection.
     </p>
     <p>
      In a study of 5 liveborn neonates who were delivered to women infected with SARS-CoV during the Hong Kong epidemic, results from multiple tests—including serial RT-PCR assays, viral culture, and paired neonatal serological titers—were negative for SARS-CoV [
      <xref ref-type="bibr" rid="B39-viruses-12-00194">
       39
      </xref>
      ]. None of the 5 neonates developed any clinical signs or symptoms of respiratory infection or compromise.
     </p>
     <p>
      Fortunately, there were no cases of vertical transmission identified among pregnant women infected with SARS-CoV during the 2002–2003 Asian epidemic [
      <xref ref-type="bibr" rid="B27-viruses-12-00194">
       27
      </xref>
      ,
      <xref ref-type="bibr" rid="B30-viruses-12-00194">
       30
      </xref>
      ,
      <xref ref-type="bibr" rid="B31-viruses-12-00194">
       31
      </xref>
      ,
      <xref ref-type="bibr" rid="B39-viruses-12-00194">
       39
      </xref>
      ,
      <xref ref-type="bibr" rid="B40-viruses-12-00194">
       40
      </xref>
      ], and with the exception of a small cluster of cases that recurred in late 2003, no new cases of SARS have occurred.
     </p>
    </sec>
    <sec id="sec6-viruses-12-00194">
     <title>
      6. Placental Pathology of SARS
     </title>
     <p>
      In the only reported study of the placental pathology of mothers with SARS, Ng et al. [
      <xref ref-type="bibr" rid="B41-viruses-12-00194">
       41
      </xref>
      ] reported the findings from 7 pregnant women infected with SARS-CoV. In the case of 2 women who were convalescing from SARS-CoV infection during the 1st trimester of pregnancy, the placentas were found to be normal. Three placentas were delivered from pregnancies in which the mothers had acute SARS-CoV infection—these were abnormal and demonstrated increased subchorionic and intervillous fibrin, a finding that can be associated with abnormal maternal blood flow to the placenta. In the placentas of 2 women who were convalescing from SARS-CoV infection in the 3rd trimester of pregnancy the placentas were highly abnormal. They showed extensive fetal thrombotic vasculopathy with areas of avascular chorionic villi—chronic findings of fetal vascular malperfusion. These 2 pregnancies also were complicated by oligohydramnios and had poor obstetrical outcomes—both infants had developed IUGR. It is interesting that villitis, the microscopic finding of inflammation of the chorionic villi that is the histologic hallmark of many maternal hematogenous infections that are transmitted through the placenta to the fetus, was not identified in any of these placentas.
     </p>
    </sec>
    <sec id="sec7-viruses-12-00194">
     <title>
      7. Safe Management of Pregnant Women with SARS
     </title>
     <p>
      Similar to other coronavirus infections, SARS-CoV is easily spread from person-to-person via respiratory droplets and secretions as well as through nosocomial contacts [
      <xref ref-type="bibr" rid="B42-viruses-12-00194">
       42
      </xref>
      ,
      <xref ref-type="bibr" rid="B43-viruses-12-00194">
       43
      </xref>
      ]. In addition to transmission of SARS-CoV through natural aerosols from infected patients, it was found that in Hong Kong the SARS-CoV could also be transmitted by mechanical aerosols [
      <xref ref-type="bibr" rid="B44-viruses-12-00194">
       44
      </xref>
      ]. Environmental factors had an important role when it was discovered that during the Amoy Gardens housing estate outbreak as many as two-thirds of infected persons had diarrhea, SARS-CoV was excreted in their stools, and that aerosols arising from the flushing of toilets could transmit the virus [
      <xref ref-type="bibr" rid="B44-viruses-12-00194">
       44
      </xref>
      ]. Healthcare facilities were also an important source of new SARS infections during the 2002–2003 epidemic, and healthcare workers were also at high risk for acquiring the infection.
     </p>
     <p>
      In order to address the safety issues for the obstetrical management and delivery of pregnant women with SARS, guidelines were prepared by the Canadian Task Force on Preventive Health Care and the Society of Obstetricians and Gynaecologists of Canada [
      <xref ref-type="bibr" rid="B45-viruses-12-00194">
       45
      </xref>
      ]. These recommendations include:
      <list list-type="order">
       <list-item>
        <p>
         “All hospitals should have infection control systems in place to ensure that alerts regarding changes in exposure risk factors for SARS or other potentially serious communicable diseases are conveyed promptly to clinical units, including the labour and delivery unit.
        </p>
       </list-item>
       <list-item>
        <p>
         At times of SARS outbreaks, all pregnant patients being assessed or admitted to the hospital should be screened for symptoms of and risk factors for SARS.
        </p>
       </list-item>
       <list-item>
        <p>
         Upon arrival in the labour triage unit, pregnant patients with suspected and probable SARS should be placed in a negative pressure isolation room with at least 6 air exchanges per hour. All labour and delivery units caring for suspected and probable SARS should have available at least one room in which patients can safely labour and deliver while in need of airborne isolation.
        </p>
       </list-item>
       <list-item>
        <p>
         If possible, labour and delivery (including operative delivery or Caesarean section) should be managed in a designated negative pressure isolation room, by designated personnel with specialized infection control preparation and protective gear.
        </p>
       </list-item>
       <list-item>
        <p>
         Either regional or general anaesthesia may be appropriate for delivery of patients with SARS.
        </p>
       </list-item>
       <list-item>
        <p>
         Neonates of mothers with SARS should be isolated in a designated unit until the infant has been well for 10 days, or until the mother’s period of isolation is complete. The mother should not breastfeed during this period.
        </p>
       </list-item>
       <list-item>
        <p>
         A multidisciplinary team, consisting of obstetricians, nurses, pediatricians, infection control specialists, respiratory therapists, and anaesthesiologists, should be identified in each unit and be responsible for the unit organization and implementation of SARS management protocols.
        </p>
       </list-item>
       <list-item>
        <p>
         Staff caring for pregnant SARS patients should not care for other pregnant patients. Staff caring for pregnant SARS patients should be actively monitored for fever and other symptoms of SARS. Such individuals should not work in the presence of any SARS symptoms within 10 days of exposure to a SARS patient.
        </p>
       </list-item>
       <list-item>
        <p>
         All health care personnel, trainees, and support staff should be trained in infection control management and containment to prevent spread of the SARS virus.
        </p>
       </list-item>
       <list-item>
        <p>
         Regional health authorities in conjunction with hospital staff should consider designating specific facilities or health care units, including primary, secondary, or tertiary health care centers, to care for patients with SARS or similar illnesses.”
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="sec8-viruses-12-00194">
     <title>
      8. Middle East Respiratory Syndrome (MERS)
     </title>
     <p>
      Middle East respiratory syndrome (MERS) was first reported in September 2012 in Saudi Arabia, following isolation of MERS-CoV from a male patient who died months earlier from severe pneumonia and multiple organ failure [
      <xref ref-type="bibr" rid="B1-viruses-12-00194">
       1
      </xref>
      ]. In the 8 years since then, there have been more than 2494 confirmed cases of MERS resulting in upwards of 858 deaths globally [
      <xref ref-type="bibr" rid="B46-viruses-12-00194">
       46
      </xref>
      ]. While 27 countries have reported cases of MERS, approximately 80% of confirmed cases originated in Saudi Arabia [
      <xref ref-type="bibr" rid="B47-viruses-12-00194">
       47
      </xref>
      ]. To date, all known cases of MERS can be linked to travel or residence in countries along the Arabian Peninsula—that is, Bahrain; Iraq; Iran; Israel, the West Bank, and Gaza; Jordan; Kuwait; Lebanon; Oman; Qatar, Saudi Arabia; Syria; the United Arab Emirates (UAE); and Yemen [
      <xref ref-type="bibr" rid="B48-viruses-12-00194">
       48
      </xref>
      ]. The largest documented outbreak outside of this region occurred in 2015 in the Republic of Korea, in which 186 infections occurred, resulting in 38 deaths [
      <xref ref-type="bibr" rid="B49-viruses-12-00194">
       49
      </xref>
      ]. The index case in this outbreak reportedly returned from the Arabian Peninsula just prior to onset of illness [
      <xref ref-type="bibr" rid="B50-viruses-12-00194">
       50
      </xref>
      ].
     </p>
     <p>
      MERS-CoV is characterized by sporadic zoonotic transmission events as well as spread between infected patients and close contacts (i.e., intra-familial transmission) [
      <xref ref-type="bibr" rid="B51-viruses-12-00194">
       51
      </xref>
      ]. Nosocomial outbreaks in health care settings—the result of poor infection control and prevention—are widely recognized as the hallmark of MERS [
      <xref ref-type="bibr" rid="B1-viruses-12-00194">
       1
      </xref>
      ]. Superspreading events have been recorded in healthcare settings in Jordan, Al Hasa, Jeddah, Abu Dhabi and South Korea [
      <xref ref-type="bibr" rid="B47-viruses-12-00194">
       47
      </xref>
      ,
      <xref ref-type="bibr" rid="B52-viruses-12-00194">
       52
      </xref>
      ,
      <xref ref-type="bibr" rid="B53-viruses-12-00194">
       53
      </xref>
      ,
      <xref ref-type="bibr" rid="B54-viruses-12-00194">
       54
      </xref>
      ,
      <xref ref-type="bibr" rid="B55-viruses-12-00194">
       55
      </xref>
      ]. Like other coronaviruses, MERS-CoV can be spread through person-to-person contact, likely via infected respiratory secretions [
      <xref ref-type="bibr" rid="B48-viruses-12-00194">
       48
      </xref>
      ]. Transmission dynamics, however, are otherwise poorly understood [
      <xref ref-type="bibr" rid="B1-viruses-12-00194">
       1
      </xref>
      ]. Bats are believed to be the natural reservoir of MERS-CoV, and dromedary camels can have the virus and have been suggested as possible intermediary hosts as well as a source of infection to humans [
      <xref ref-type="bibr" rid="B2-viruses-12-00194">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B56-viruses-12-00194">
       56
      </xref>
      ,
      <xref ref-type="bibr" rid="B57-viruses-12-00194">
       57
      </xref>
      ].
     </p>
     <p>
      There are no clinical or serological reports of perinatal transmission of MERS, though vertical transmission has been reported for non-coronavirus respiratory viruses including influenza and respiratory syncytial virus (RSV) [
      <xref ref-type="bibr" rid="B58-viruses-12-00194">
       58
      </xref>
      ]. Researchers have not yet discovered ongoing transmission of MERS-CoV within communities outside of health care settings.
     </p>
     <p>
      The clinical presentation of MERS varies from asymptomatic to severe pneumonia with acute respiratory distress syndrome (ARDS), septic shock, and multiple organ failure, often resulting in death. Most patients with MERS develop severe acute respiratory illness accompanied by fever, cough, and shortness of breath [
      <xref ref-type="bibr" rid="B50-viruses-12-00194">
       50
      </xref>
      ]. Progression to pneumonia is swift—usually within the first week —and at least one-third of patients also present with gastrointestinal symptoms [
      <xref ref-type="bibr" rid="B1-viruses-12-00194">
       1
      </xref>
      ]. MERS progresses much more rapidly to respiratory failure and has a higher case fatality rate than SARS [
      <xref ref-type="bibr" rid="B1-viruses-12-00194">
       1
      </xref>
      ]. Unlike SARS, however, infection with MERS-CoV is generally mild in healthy individuals but more severe in immunocompromised patients and people with underlying comorbidities [
      <xref ref-type="bibr" rid="B1-viruses-12-00194">
       1
      </xref>
      ]. The overall CFR of MERS is approximately 34.4% [
      <xref ref-type="bibr" rid="B46-viruses-12-00194">
       46
      </xref>
      ]. Most fatalities have been associated with pre-existing medical conditions like chronic lung disease, diabetes, and renal failure, as well as weakened immune systems [
      <xref ref-type="bibr" rid="B59-viruses-12-00194">
       59
      </xref>
      ], making such individuals high risk. As a result of the immunological changes that occur during pregnancy, women who are pregnant are included in this high-risk group. Pregnant women may develop severe disease and fatal maternal and/or fetal outcomes as a result of MERS-CoV infection; however, little is known of the pathophysiology of this infection during pregnancy.
     </p>
    </sec>
    <sec id="sec9-viruses-12-00194">
     <title>
      9. MERS and Pregnancy
     </title>
     <p>
      Limited data exists on the prevalence and clinical features of MERS during pregnancy, birth, and the postnatal period. It is likely, however, that the immunological changes that normally occur in pregnancy may alter susceptibility to the MERS-CoV and the severity of clinical illness [
      <xref ref-type="bibr" rid="B60-viruses-12-00194">
       60
      </xref>
      ]. Pregnant women infected with SARS-CoV, a related coronavirus, appear to have increased morbidity and mortality when compared to non-pregnant women, suggesting that MERS-CoV could also lead to severe clinical outcomes in pregnancy. To date, however, very few pregnancy-associated cases (
      <italic>
       n
      </italic>
      = 11) have been documented, with 91% having adverse clinical outcomes.
     </p>
     <p>
      Between November 2012 and February 2016, there were 1308 cases of MERS reported by the Saudi Arabia Ministry of Health (MoH). Of these, 5 patients were pregnant, according to a retrospective study by Assiri et al. [
      <xref ref-type="bibr" rid="B47-viruses-12-00194">
       47
      </xref>
      ], and all resulted in adverse outcomes. Patient ages ranged from 27 to 34 years, with occurrence of exposure in either the 2nd or 3rd trimester. All 5 cases received intensive care. Two women died and there were 2 cases of perinatal death— 1 stillbirth and 1 neonatal death shortly after emergency cesarean section. These instances of severe maternal and perinatal outcomes are consistent with other reports of MERS-CoV infection in pregnant women, as well as outcomes associated with SARS-CoV infection. The authors of the retrospectives study concede that unreported cases of MERS in pregnancy are likely due to lack of routine pregnancy testing [
      <xref ref-type="bibr" rid="B47-viruses-12-00194">
       47
      </xref>
      ]. They conclude that pregnancy testing for women of reproductive age should be considered for those who test positive for MERS-CoV, to contribute to overall understanding of pathogenesis and epidemiological risk. Additionally, 2 of the 5 patients were healthcare workers, which corresponds with existing knowledge of higher risk of exposure to MERS-CoV in healthcare settings.
     </p>
     <p>
      In a separate case report of MERS occurring in pregnancy, Alserehi et al. [
      <xref ref-type="bibr" rid="B58-viruses-12-00194">
       58
      </xref>
      ] described a 33-year-old critical care nurse who became infected during the 3rd trimester in the midst of a large hospital outbreak. In the days following hospital admission, she developed respiratory failure necessitating mechanical ventilation and administration of dexamethasone as prophylaxis for the fetus. Following an emergency cesarean section at 32 weeks gestation, she was transferred to the intensive care unit (ICU) and later recovered. The preterm but otherwise healthy infant was kept in the neonatal unit for observation and later released along with his mother. In contrast to other reported cases, this patient had a successful outcome, perhaps due to the timing of MERS-CoV exposure, her young age, the use of steroids, and differences in immune response.
     </p>
     <p>
      Alfaraj et al. [
      <xref ref-type="bibr" rid="B61-viruses-12-00194">
       61
      </xref>
      ] described 2 cases of maternal infection with MERS-CoV at the Prince Mohammed Bin Abdulaziz Hospital (PMAH) in Saudi Arabia. Maternal infection in both cases was confirmed by nasopharyngeal swab testing by RT-PCR. One patient was a 29-year-old woman at 6 weeks gestation with no underlying medical conditions. The second patient, a 39-year-old at 24 weeks gestation, had several comorbidities, including end stage renal disease, hypertension, and hemodialysis. This woman presented to the hospital after contact with a MERS-CoV-infected person during an active outbreak. Both patients later tested negative for MERS-CoV and were subsequently discharged. The younger patient delivered a healthy, full-term infant. The status of the other delivery is unknown. Neither fetus was tested for MERS-CoV.
     </p>
     <p>
      According to Payne et al. [
      <xref ref-type="bibr" rid="B62-viruses-12-00194">
       62
      </xref>
      ], epidemiologic investigation of the 2012 MERS outbreak in Zarqa, Jordan, revealed that a 2nd trimester stillbirth (5 months gestational age) had occurred as a result of maternal exposure to MERS-CoV. The mother experienced fever, fatigue, headache and cough, concurrently with vaginal bleeding and abdominal pain. On the 7th day of symptoms, she had a fetal death. The mother was confirmed to have antibody to MERS-CoV, and she self-reported having had unprotected contact with family members who later tested positive for the virus. This was the first documented occurrence of stillbirth during maternal infection with MERS-CoV.
     </p>
     <p>
      On 24 November 2013, a 32-year-old pregnant woman in the United Arab Emirates (UAE) developed ARDS following admission to the ICU after suspected community-acquired pneumonia advanced to respiratory failure and hypotension [
      <xref ref-type="bibr" rid="B60-viruses-12-00194">
       60
      </xref>
      ]. Later that day, her baby was delivered by caesarean section and subsequent Apgar scores were within healthy range. The next day, RT-PCR evaluation revealed that the mother was positive for MERS-CoV. Despite rigorous intervention, including oral ribavirin-peginterferon-α therapy and ventilator support, the woman continued to deteriorate, developed septic shock, and died. While the outcome for this mother was fatal, Malik et al. noted that virus shedding ceased during therapy with ribavirin and peginterferon-α and radiographic evidence indicated clinical improvement before her death [
      <xref ref-type="bibr" rid="B58-viruses-12-00194">
       58
      </xref>
      ]. More research is needed to determine safety, efficacy, and dosage of these therapies in the general population but also in pregnant women. While few data exist on the effects of these treatments in pregnant humans, ribavirin is generally contraindicated during pregnancy [
      <xref ref-type="bibr" rid="B58-viruses-12-00194">
       58
      </xref>
      ].
     </p>
     <p>
      Outside of the Middle East the only confirmed case of MERS in pregnancy occurred in 2015 in South Korea. Jeong et al. [
      <xref ref-type="bibr" rid="B49-viruses-12-00194">
       49
      </xref>
      ] reported that a 39-year-old patient was exposed during the 3rd trimester following contact with a patient having MERS. Despite abrupt vaginal bleeding and rupture of membranes, the patient recovered fully and delivered a healthy infant at 37 weeks and 5 days gestation. Subsequent testing of the infant’s blood did not detect any IgG, IgM, or IgA antibodies to MERS-CoV.
     </p>
     <p>
      The mean maternal age of the 11 confirmed maternal SARS cases described above was 33.2 years, with a mean gestational age of 26.3 weeks. The source of infection in 2 of the cases was attributed to contact with family members who tested positive for MERS-CoV, unknown in 3 cases, likely due to animal exposure in 1 case, and 6 were healthcare-associated (2 of these patients were healthcare workers). Six patients required intensive care and 3 died. Of those who died, 2 were exposed to MERS-CoV in the 3rd trimester, and 1 was exposed during the 2nd trimester. The infant death rate for all 11 cases was 27%. Fetal survival did not appear to correlate with the timing of maternal infection and gestational age; however, more data are needed to draw conclusions about this relationship. According to Alfaraj et al. [
      <xref ref-type="bibr" rid="B61-viruses-12-00194">
       61
      </xref>
      ], the CFR for the 11 infected women—also 27%—was not statistically different from the overall CFR of MERS in the general population (35%) (
      <italic>
       P
      </italic>
      = 0.75). Only 1 case resulted in both maternal and fetal death.
     </p>
     <p>
      Similar to SARS in pregnancy, more research is needed to understand the pathogenesis and epidemiology of MERS in pregnancy including the relationship between the timing of maternal infection, gestational age of the fetus, the effects of comorbid factors, and the occurrence of adverse outcomes. Few studies documented the presence of MERS-CoV antibodies in the umbilical cord or neonatal blood, making it difficult to assess perinatal transmission. As such, future studies should involve the collection of samples from relevant specimens including amniotic fluid, placenta, and umbilical cord [
      <xref ref-type="bibr" rid="B49-viruses-12-00194">
       49
      </xref>
      ].
     </p>
    </sec>
    <sec id="sec10-viruses-12-00194">
     <title>
      10. MERS Prevention and Treatment
     </title>
     <p>
      MERS prevention should be high priority for high-risk exposures such as healthcare workers, pregnant women and individuals working with camels, camel meat-milk processors and in abattoirs [
      <xref ref-type="bibr" rid="B57-viruses-12-00194">
       57
      </xref>
      ]. Since 2013, the Saudi Arabia MoH has recommended that pregnant women postpone travel to Saudi Arabia for the Hajj and Umrah [
      <xref ref-type="bibr" rid="B47-viruses-12-00194">
       47
      </xref>
      ]. To further reduce risk of exposure among pregnant women, additional measures such as avoiding contact with camels and sick persons—particularly in healthcare settings—are also recommended. Pregnant women who present with symptoms of pneumonia, influenza-like illness (ILI), or sepsis on the Arabian Peninsula may also benefit from MERS-CoV screening to expedite early diagnosis and improve disease management [
      <xref ref-type="bibr" rid="B60-viruses-12-00194">
       60
      </xref>
      ].
     </p>
     <p>
      While multiple agents have been used to treat MERS, none have been tested in large clinical studies. Available data are limited to the use of combination therapies of interferon and other agents in case reports and case series [
      <xref ref-type="bibr" rid="B63-viruses-12-00194">
       63
      </xref>
      ]. A prospective or randomized study may prove difficult given the sporadic nature of MERS-CoV outbreaks.
     </p>
     <p>
      Due to a gap in research on the treatment of MERS in pregnancy, there are no therapeutic options currently recommended for pregnant women [
      <xref ref-type="bibr" rid="B58-viruses-12-00194">
       58
      </xref>
      ]. Therapies under development and testing may be considered inappropriate for pregnant women due to the unknown potential for teratogenic effects. For example, during the 2003 SARS outbreak, ribavirin was administered to pregnant women with severe cases of the disease, but ribavirin therapy has been documented to increase the risk of teratogenic effects in newborns [
      <xref ref-type="bibr" rid="B58-viruses-12-00194">
       58
      </xref>
      ].
     </p>
    </sec>
    <sec id="sec11-viruses-12-00194">
     <title>
      11. Other Coronaviruses and Pregnancy
     </title>
     <p>
      The Alphacoronaviruses HCoV 229E and NL63, as well as the Betacoronaviruses HKU
      <sub>
       1
      </sub>
      and OC43, can infect humans and cause the common cold. In order to investigate the potential maternal-fetal transmission of human coronaviruses during pregnancy, Gagneur et al. [
      <xref ref-type="bibr" rid="B64-viruses-12-00194">
       64
      </xref>
      ,
      <xref ref-type="bibr" rid="B65-viruses-12-00194">
       65
      </xref>
      ] evaluated 3 types of maternal-infant paired specimens that included maternal vaginal and respiratory specimens that were obtained during labor, as well as gastric samples from the newborn infants. These specimens were evaluated for the presence of HCoV 229E, OC-43, NL63 and HKU
      <sub>
       1
      </sub>
      using RT-PCR methodology. Between the period from July 2003 to August 2005 the authors examined 159 mother-infant dyads. Human coronaviruses were identified in 12 samples (HCoV 229E: 11; HKU
      <sub>
       1
      </sub>
      : 1) from 7 mother-child pairs. In 3 mother-infant dyads only maternal respiratory samples were positive; in 2 other pairs all 3 of the samples tested positive for human coronavirus; in 1 case only the maternal vaginal and newborn gastric samples were positive; and in another case the maternal vaginal sample alone was positive. There were no signs of clinical infection in any of the 3 neonates that had positive gastric samples for human coronavirus.
     </p>
    </sec>
    <sec id="sec12-viruses-12-00194">
     <title>
      12. Participation of Pregnant Women in the Development of a Coronavirus Vaccine
     </title>
     <p>
      It is beyond the scope of this communication to discuss the various technical challenges inherent in developing a safe and efficacious vaccine for coronavirus infections in humans. There are clearly challenges to this endeavor—protective antibodies to coronaviruses are not long-lasting, tissue damage has been reported to occur as a result of exposure to SARS-CoV, development of animal models that closely resemble human infection are limited, and the extensive time and expense necessary to perform clinical trials in humans, to name a few [
      <xref ref-type="bibr" rid="B66-viruses-12-00194">
       66
      </xref>
      ,
      <xref ref-type="bibr" rid="B67-viruses-12-00194">
       67
      </xref>
      ,
      <xref ref-type="bibr" rid="B68-viruses-12-00194">
       68
      </xref>
      ].
     </p>
     <p>
      It is vitally important that pregnant women be considered in the design, clinical trial, and implementation of vaccine candidates for 2019-nCoV. In examining the history of vaccine design, it is clear that the needs of pregnant women have rarely been prioritized in either the preclinical development or the clinical trial phases of production. Today, pregnant women are usually excluded from experimental trial of drugs and vaccines that do not target obstetric conditions [
      <xref ref-type="bibr" rid="B69-viruses-12-00194">
       69
      </xref>
      ]. Excluding pregnant women and their infants from participation in vaccine development and implementation undermines ethical principles of justice—fairness, equity, and maximization of benefit—and potentially places their health at risk during outbreaks and other health emergencies [
      <xref ref-type="bibr" rid="B69-viruses-12-00194">
       69
      </xref>
      ,
      <xref ref-type="bibr" rid="B70-viruses-12-00194">
       70
      </xref>
      ,
      <xref ref-type="bibr" rid="B71-viruses-12-00194">
       71
      </xref>
      ].
     </p>
     <p>
      On 23 January 2020 the Coalition for Epidemic Preparedness Innovations (CEPI) announced three programs to develop a vaccine against the novel Wuhan coronavirus. The Chief Executive Officer of CEPI, Richard Hatchett, said [
      <xref ref-type="bibr" rid="B72-viruses-12-00194">
       72
      </xref>
      ]:
     </p>
     <disp-quote>
      <p>
       “Given the rapid global spread of the nCoV-2019 virus the world needs to act quickly and in unity to tackle this disease. Our intention with this work is to leverage our work on the MERS coronavirus and rapid response platforms to speed up vaccine development.”
      </p>
     </disp-quote>
     <p>
      The novel coronavirus is the first epidemic disease to emerge since the formation of CEPI in Davos in 2017. CEPI was created with the express intent to enable speedy research and development of vaccines against emerging pathogens. In May 2017, WHO released the Target Product Profile (TPP) for MERS-CoV vaccines, following the prioritization of MERS-CoV as one of eight priority pathogens for prevention of epidemics [
      <xref ref-type="bibr" rid="B73-viruses-12-00194">
       73
      </xref>
      ]. CEPI and partners aim to use existing platforms—that is, the existing “backbone” that can be adapted for use against new pathogens—that are currently in preclinical development for MERS-CoV vaccine candidates. Following the WHO declaration on 30 January that the current 2019-nCoV outbreak is a public health emergency of international concern (PHEIC), global health organizations and researchers will be further mobilized—bolstered by new mechanisms for action and greater resources—to stop the spread of disease.
     </p>
     <p>
      A critical question that must be answered at this stage—with a clear view of the potential deleterious effects of a new coronavirus in pregnancy—is will maternal immunization be a priority in research and development? As of the PHEIC declaration, 12 groups have announced that they are developing new vaccines against 2019-nCoV and seven others announced initiatives to develop new therapies [
      <xref ref-type="bibr" rid="B74-viruses-12-00194">
       74
      </xref>
      ]. Safe testing of experimental vaccines in a pregnant population is difficult and, as a result, vaccines are not typically developed with pregnant women in mind. To date, very few clinical trials for vaccines have proactively included pregnant women [
      <xref ref-type="bibr" rid="B75-viruses-12-00194">
       75
      </xref>
      ], and the exclusion of pregnant and lactating women from receiving the rVSV-ZEBOV vaccine through 3 Ebola virus epidemics serves as a recent example [
      <xref ref-type="bibr" rid="B69-viruses-12-00194">
       69
      </xref>
      ,
      <xref ref-type="bibr" rid="B70-viruses-12-00194">
       70
      </xref>
      ,
      <xref ref-type="bibr" rid="B71-viruses-12-00194">
       71
      </xref>
      ]. Given the potential severity in pregnancy, as demonstrated by this review of maternal infections of SARS and MERS, women who are pregnant should be considered a priority population in all efforts to prepare for and prevent infection by novel coronaviruses.
     </p>
    </sec>
    <sec id="sec13-viruses-12-00194">
     <title>
      13. Current Status of 2019-nCoV (SARS-CoV-2) Infection of Pregnant Women and Neonates
     </title>
     <p>
      On 5 February 2020 it was reported by multiple media outlets that a newborn infant delivered during the epidemic in Wuhan had tested positive for 2019-nCoV at the Wuhan Children’s Hospital in Hubei Province 30 hours following its birth. According to the official Xinhua news agency, the infant was delivered on 2 February to a mother who had tested positive for the virus. Reports have stated that the infant had stable vital signs, no fever or cough, but had shortness of breath together with abnormal chest radiographs and abnormalities of liver function [
      <xref ref-type="bibr" rid="B76-viruses-12-00194">
       76
      </xref>
      ,
      <xref ref-type="bibr" rid="B77-viruses-12-00194">
       77
      </xref>
      ,
      <xref ref-type="bibr" rid="B78-viruses-12-00194">
       78
      </xref>
      ]. Dr. Zeng Lingkong, Chief Physician at the Neonatal Medicine Department of the hospital, said [
      <xref ref-type="bibr" rid="B78-viruses-12-00194">
       78
      </xref>
      ],
     </p>
     <disp-quote>
      <p>
       “This reminds us to pay attention to mother-to-child being a possible route of coronavirus transmission”
      </p>
     </disp-quote>
     <p>
      The hospital also provided information about a previous case of a baby that had been delivered on 13 January 2020. Following its birth, the infant’s nanny was diagnosed with 2019-nCoV, and the mother was diagnosed days later [
      <xref ref-type="bibr" rid="B76-viruses-12-00194">
       76
      </xref>
      ]. On 29 January the baby began to develop symptoms. According to Dr. Zeng Lingkong [
      <xref ref-type="bibr" rid="B76-viruses-12-00194">
       76
      </xref>
      ],
     </p>
     <disp-quote>
      <p>
       “Whether it was the baby’s nanny who passed the virus to the mother who passed it to the baby, we cannot be sure at the moment. But we can confirm that the baby was in close contact with patients infected with the new coronavirus, which says newborns can also be infected”
      </p>
     </disp-quote>
     <p>
      In considering whether these and future cases of neonatal infection are acquired prior to delivery, it is important to remember that newborn infants can acquire an infection in other ways beyond intrauterine maternal-fetal transmission. In some cases, viral infection can be acquired when the infant passes through the birth canal during a vaginal delivery or through post-partum breast feeding, although these mechanisms would be highly unusual for a respiratory virus. Neonatal infection from respiratory viruses can occur after delivery through such mechanisms as inhalation of the agent through aerosols produced by coughing from the mother, relatives or healthcare workers or other sources in the hospital environment. Based upon past experience with pregnant women who developed MERS and SARS, and realizing that the numbers are limited, there has never been confirmed intrauterine coronavirus transmission from mother to fetus. Discussing the most recent baby to be diagnosed with the 2019-nCoV infection, Dr. Stephen Morse, an epidemiologist at the Mailman School of Public Health at Columbia University stated [
      <xref ref-type="bibr" rid="B77-viruses-12-00194">
       77
      </xref>
      ],
     </p>
     <disp-quote>
      <p>
       “It’s more likely that the baby contracted the virus from the hospital environment, the same way healthcare workers get infected by the patients they treat,”
      </p>
     </disp-quote>
     <disp-quote>
      <p>
       “It’s quite possible that the baby picked it up very conventionally—by inhaling virus droplets that came from the mother coughing.”
      </p>
     </disp-quote>
     <p>
      And according to Dr. Paul Hunter, Professor of Medicine at the University of East Anglia [
      <xref ref-type="bibr" rid="B79-viruses-12-00194">
       79
      </xref>
      ],
     </p>
     <disp-quote>
      <p>
       “As far as I am aware there is currently no evidence that the novel coronavirus can be transmitted in the womb. When a baby is born vaginally it is exposed to the mother’s gut microbiome, therefore if a baby does get infected with coronavirus a few days after birth we currently cannot tell if the baby was infected in the womb or during birth.”
      </p>
     </disp-quote>
    </sec>
    <sec id="sec14-viruses-12-00194" sec-type="conclusions">
     <title>
      14. Conclusions
     </title>
     <p>
      There is limited knowledge regarding coronavirus infections that occur during pregnancy—what is known has, for the most part, been the result of epidemics resulting from two different diseases, SARS and MERS. These previous experiences with coronavirus infections in pregnancy indicates that these agents are capable of causing adverse clinical outcomes including life-threatening maternal disease that in some cases requires hospitalization, intensive care and ventilatory support. Both of these coronaviruses can result in maternal death in a small but significant number of cases, but the specific risk factors for a fatal outcome during pregnancy have not been clarified. Coronaviruses can also result in adverse outcomes for the fetus and infant including intrauterine growth restriction, preterm delivery, admission to the ICU, spontaneous abortion and perinatal death. Unlike some viral infections, notably Ebola virus [
      <xref ref-type="bibr" rid="B70-viruses-12-00194">
       70
      </xref>
      ] and Zika virus [
      <xref ref-type="bibr" rid="B80-viruses-12-00194">
       80
      </xref>
      ], the likelihood of intrauterine maternal-fetal transmission of coronaviruses is low—there have been no documented cases of vertical transmission occurring with either SARS or MERS. It remains to be seen during the current Wuhan 2019-nCoV epidemic how this newly-emergent coronavirus affects pregnant women and their infants, as well as which factors may modulate obstetrical disease and outcomes including the timing of maternal coronavirus exposure by gestational age, the effects of medications or other treatment regimens, differences in host immune responses, occurrence of coexisting medical and obstetrical conditions, and other covariables. However, pregnant women should be considered to be at high risk for developing severe infection during this current outbreak of 2019-nCoV. Additional clinical research on the treatment of SARS, MERS, and the new coronavirus 2019-nCoV is necessary if we are to understand the potential risks and benefits of novel therapies and new vaccines in pregnancy. This research will be critical in improving the care, and even saving the lives, of pregnant women in the current as well as future outbreaks.
     </p>
    </sec>
    <back>
     <notes>
      <title>
       Funding
      </title>
      <p>
       This research received no external funding.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Conflicts of Interest
      </title>
      <p>
       The authors declare no conflict of interest.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1-viruses-12-00194">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemic and emerging coronaviruses (severe acute respiratory syndrome and Middle East respiratory syndrome)
        </article-title>
        <source>
         Clin. Chest Med.
        </source>
        <year>
         2017
        </year>
        <volume>
         38
        </volume>
        <fpage>
         71
        </fpage>
        <lpage>
         86
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ccm.2016.11.007
        </pub-id>
        <pub-id pub-id-type="pmid">
         28159163
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2-viruses-12-00194">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         From SARS to MERS, thrusting coronaviruses into the spotlight
        </article-title>
        <source>
         Viruses
        </source>
        <year>
         2019
        </year>
        <volume>
         11
        </volume>
        <elocation-id>
         59
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/v11010059
        </pub-id>
        <pub-id pub-id-type="pmid">
         30646565
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3-viruses-12-00194">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Origin and evolution of pathogenic coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2019
        </year>
        <volume>
         17
        </volume>
        <fpage>
         181
        </fpage>
        <lpage>
         192
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/s41579-018-0118-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         30531947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4-viruses-12-00194">
       <label>
        4.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          ICTV 9th Report (2011)
         </collab>
        </person-group>
        <article-title>
         Coronaviridae
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/222/coronaviridae">
          https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-rna-viruses-2011/w/posrna_viruses/222/coronaviridae
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-06">
         (accessed on 6 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B5-viruses-12-00194">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Another decade, another coronavirus
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1056/NEJMe2001126
        </pub-id>
        <pub-id pub-id-type="pmid">
         31978944
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6-viruses-12-00194">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: Historical, epidemiologic, and clinical features
        </article-title>
        <source>
         Infect. Dis. Clin. N. Am.
        </source>
        <year>
         2019
        </year>
        <volume>
         33
        </volume>
        <fpage>
         869
        </fpage>
        <lpage>
         889
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.idc.2019.07.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         31668196
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7-viruses-12-00194">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           E.H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001316
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8-viruses-12-00194">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001017
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9-viruses-12-00194">
       <label>
        9.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Wuhan Seafood Market May Not Be Source of Novel Virus Spreading Globally
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally">
          https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-31">
         (accessed on 31 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B10-viruses-12-00194">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30183-5
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11-viruses-12-00194">
       <label>
        11.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV)
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-nCoV)">
          https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-nCoV)
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-30">
         (accessed on 30 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B12-viruses-12-00194">
       <label>
        12.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Novel Coronavirus (2019-nCoV). Situation Report–20
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200209-sitrep-20-ncov.pdf?sfvrsn=6f80d1b9_2">
          https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200209-sitrep-20-ncov.pdf?sfvrsn=6f80d1b9_2
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-09">
         (accessed on 9 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B13-viruses-12-00194">
       <label>
        13.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wee
          </surname>
          <given-names>
           S.-L.
          </given-names>
         </name>
         <name>
          <surname>
           McNeil
          </surname>
          <given-names>
           D.G.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Hernández
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         W.H.O. Declares Global Emergency as Wuhan Coronavirus Spreads
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.nytimes.com/2020/01/30/health/coronavirus-world-health-organization.html">
          https://www.nytimes.com/2020/01/30/health/coronavirus-world-health-organization.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-31">
         (accessed on 31 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B14-viruses-12-00194">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benedetti
          </surname>
          <given-names>
           T.J.
          </given-names>
         </name>
         <name>
          <surname>
           Valle
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ledger
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antepartum pneumonia in pregnancy
        </article-title>
        <source>
         Obstet. Gynecol.
        </source>
        <year>
         1982
        </year>
        <volume>
         144
        </volume>
        <fpage>
         413
        </fpage>
        <lpage>
         417
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0002-9378(82)90246-0
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15-viruses-12-00194">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Berkowitz
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           LaSala
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors associated with the increasing prevalence of pneumonia during pregnancy
        </article-title>
        <source>
         Am. J. Obstet. Gynecol.
        </source>
        <year>
         1990
        </year>
        <volume>
         163
        </volume>
        <fpage>
         981
        </fpage>
        <lpage>
         985
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0002-9378(90)91109-P
        </pub-id>
        <pub-id pub-id-type="pmid">
         2403178
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B16-viruses-12-00194">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madinger
          </surname>
          <given-names>
           N.E.
          </given-names>
         </name>
         <name>
          <surname>
           Greenspoon
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Eilrodt
          </surname>
          <given-names>
           A.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pneumonia during pregnancy: Has modern technology improved maternal and fetal outcome?
        </article-title>
        <source>
         Am. J. Obstet. Gynecol.
        </source>
        <year>
         1989
        </year>
        <volume>
         161
        </volume>
        <fpage>
         657
        </fpage>
        <lpage>
         662
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0002-9378(89)90373-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         2782348
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B17-viruses-12-00194">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Visscher
          </surname>
          <given-names>
           H.C.
          </given-names>
         </name>
         <name>
          <surname>
           Visscher
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Indirect obstetric deaths in the state of Michigan 1960–1968
        </article-title>
        <source>
         Am. J. Obstet. Gynecol.
        </source>
        <year>
         1971
        </year>
        <volume>
         109
        </volume>
        <fpage>
         1187
        </fpage>
        <lpage>
         1196
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0002-9378(71)90664-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         5554850
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18-viruses-12-00194">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rigby
          </surname>
          <given-names>
           F.B.
          </given-names>
         </name>
         <name>
          <surname>
           Pastorek
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pneumonia during pregnancy
        </article-title>
        <source>
         Clin. Obstet. Gynecol.
        </source>
        <year>
         1996
        </year>
        <volume>
         39
        </volume>
        <fpage>
         107
        </fpage>
        <lpage>
         119
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/00003081-199603000-00011
        </pub-id>
        <pub-id pub-id-type="pmid">
         8635293
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19-viruses-12-00194">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jamieson
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Theiler
          </surname>
          <given-names>
           R.N.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging infections and pregnancy
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2006
        </year>
        <volume>
         12
        </volume>
        <fpage>
         1638
        </fpage>
        <lpage>
         1643
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1211.060152
        </pub-id>
        <pub-id pub-id-type="pmid">
         17283611
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20-viruses-12-00194">
       <label>
        20.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sargent
          </surname>
          <given-names>
           I.L.
          </given-names>
         </name>
         <name>
          <surname>
           Redman
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunobiologic adaptations of pregnancy
        </article-title>
        <source>
         Medicine of the Fetus and Mother
        </source>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Reece
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hobbins.
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Mahoney
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Petrie
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
        </person-group>
        <publisher-name>
         JB Lippincott Company
        </publisher-name>
        <publisher-loc>
         Philadelphia, PA, USA
        </publisher-loc>
        <year>
         1992
        </year>
        <fpage>
         317
        </fpage>
        <lpage>
         327
        </lpage>
       </element-citation>
      </ref>
      <ref id="B21-viruses-12-00194">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nyhan
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bredin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Quigley
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute respiratory failure in pregnancy due to staphylococcal pneumonia
        </article-title>
        <source>
         Ir. Med. J.
        </source>
        <year>
         1983
        </year>
        <volume>
         76
        </volume>
        <fpage>
         320
        </fpage>
        <lpage>
         321
        </lpage>
        <pub-id pub-id-type="pmid">
         6885332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22-viruses-12-00194">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weinberger
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pregnancy and the lung
        </article-title>
        <source>
         Am. Rev. Resp. Dis.
        </source>
        <year>
         1980
        </year>
        <volume>
         121
        </volume>
        <fpage>
         559
        </fpage>
        <lpage>
         581
        </lpage>
        <pub-id pub-id-type="doi">
         10.1164/arrd.1980.121.3.559
        </pub-id>
        <pub-id pub-id-type="pmid">
         6998334
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23-viruses-12-00194">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harris
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influenza occurring in pregnant women; a statistical study of thirteen hundred and fifty cases
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         1919
        </year>
        <volume>
         72
        </volume>
        <fpage>
         978
        </fpage>
        <lpage>
         980
        </lpage>
        <pub-id pub-id-type="doi">
         10.1001/jama.1919.02610140008002
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24-viruses-12-00194">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eickhoff
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Sherman
          </surname>
          <given-names>
           I.L.
          </given-names>
         </name>
         <name>
          <surname>
           Serfling
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Observations on excess mortality associated with epidemic influenza
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         1961
        </year>
        <volume>
         176
        </volume>
        <fpage>
         776
        </fpage>
        <lpage>
         782
        </lpage>
        <pub-id pub-id-type="doi">
         10.1001/jama.1961.03040220024005
        </pub-id>
        <pub-id pub-id-type="pmid">
         13726091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B25-viruses-12-00194">
       <label>
        25.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Government of Canada
         </collab>
        </person-group>
        <article-title>
         Learning from SARS: Renewal of Public Health in Canada—SARS in Canada: Anatomy of an Outbreak
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.canada.ca/en/public-health/services/reports-publications/learning-sars-renewal-public-health-canada/chapter-2-sars-canada-anatomy-outbreak.html">
          https://www.canada.ca/en/public-health/services/reports-publications/learning-sars-renewal-public-health-canada/chapter-2-sars-canada-anatomy-outbreak.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-02">
         (accessed on 2 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B26-viruses-12-00194">
       <label>
        26.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peterson
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reporting Incidence of Severe Acute Respiratory Syndrome (SARS) Appendix A: Chronology
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.umass.edu/sts/pdfs/SARS_AChrono.pdf">
          https://www.umass.edu/sts/pdfs/SARS_AChrono.pdf
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-02">
         (accessed on 2 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B27-viruses-12-00194">
       <label>
        27.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Consensus Document on the Epidemiology of Severe Acute Respiratory Syndrome (SARS)
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/en/WHOconsensus.pdf">
          https://www.who.int/csr/sars/en/WHOconsensus.pdf
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-30">
         (accessed on 30 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B28-viruses-12-00194">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Chow
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           de Swiet
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome and pregnancy
        </article-title>
        <source>
         BJOG
        </source>
        <year>
         2003
        </year>
        <volume>
         110
        </volume>
        <fpage>
         641
        </fpage>
        <lpage>
         642
        </lpage>
        <pub-id pub-id-type="doi">
         10.1046/j.1471-0528.2003.03008.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         12842052
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29-viruses-12-00194">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Chow
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           T.N.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           W.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           T.K.
          </given-names>
         </name>
         <name>
          <surname>
           Shek
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           P.W.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome
        </article-title>
        <source>
         Am. J. Obstet. Gynecol.
        </source>
        <year>
         2004
        </year>
        <volume>
         191
        </volume>
        <fpage>
         292
        </fpage>
        <lpage>
         297
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ajog.2003.11.019
        </pub-id>
        <pub-id pub-id-type="pmid">
         15295381
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30-viruses-12-00194">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           So
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           T.F.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           F.W.
          </given-names>
         </name>
         <name>
          <surname>
           Lyon
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infection control for SARS in a tertiary neonatal centre
        </article-title>
        <source>
         Arch. Dis. Child. Fetal Neonatal Ed.
        </source>
        <year>
         2003
        </year>
        <volume>
         88
        </volume>
        <fpage>
         F405
        </fpage>
        <lpage>
         F409
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/fn.88.5.F405
        </pub-id>
        <pub-id pub-id-type="pmid">
         12937045
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31-viruses-12-00194">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Hon
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS in newborns and children
        </article-title>
        <source>
         Biol. Neonate.
        </source>
        <year>
         2004
        </year>
        <volume>
         85
        </volume>
        <fpage>
         293
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="doi">
         10.1159/000078174
        </pub-id>
        <pub-id pub-id-type="pmid">
         15218286
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B32-viruses-12-00194">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maxwell
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           K.F.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sermer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         No. 225-Management guidelines for obstetric patients and neonates born to mothers with suspected or probable severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         J. Obstet. Gynaecol. Can.
        </source>
        <year>
         2017
        </year>
        <volume>
         39
        </volume>
        <fpage>
         e130
        </fpage>
        <lpage>
         e137
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jogc.2017.04.024
        </pub-id>
        <pub-id pub-id-type="pmid">
         28729104
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33-viruses-12-00194">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           T.N.
          </given-names>
         </name>
         <name>
          <surname>
           Chow
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome
        </article-title>
        <source>
         BJOG
        </source>
        <year>
         2004
        </year>
        <volume>
         111
        </volume>
        <fpage>
         771
        </fpage>
        <lpage>
         774
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1471-0528.2004.00199.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         15270922
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34-viruses-12-00194">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           Y.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical analysis of pregnancy in second and third trimesters complicated severe acute respiratory syndrome
        </article-title>
        <source>
         Zhonghua Fu Chan Ke Za Zhi
        </source>
        <year>
         2003
        </year>
        <volume>
         38
        </volume>
        <fpage>
         516
        </fpage>
        <lpage>
         520
        </lpage>
        <pub-id pub-id-type="pmid">
         14521763
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35-viruses-12-00194">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lowther
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Birch
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sorhage
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Stockman
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           McDonald
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lingappa
          </surname>
          <given-names>
           J.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bresnitz
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS and pregnancy: A case report
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         345
        </fpage>
        <lpage>
         348
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1002.030736
        </pub-id>
        <pub-id pub-id-type="pmid">
         15030710
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36-viruses-12-00194">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schneider
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Duncan
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Reiken
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Perry
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Messick
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sheedy
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Haase
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gorab
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS in pregnancy
        </article-title>
        <source>
         AWHONN Lifelines
        </source>
        <year>
         2004
        </year>
        <volume>
         8
        </volume>
        <fpage>
         122
        </fpage>
        <lpage>
         128
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/1091592304265557
        </pub-id>
        <pub-id pub-id-type="pmid">
         15137260
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B37-viruses-12-00194">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stockman
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lowther
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Coy
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Saw
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Parashar
          </surname>
          <given-names>
           U.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS during pregnancy, United States
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         1689
        </fpage>
        <lpage>
         1690
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1009.040244
        </pub-id>
        <pub-id pub-id-type="pmid">
         15503406
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B38-viruses-12-00194">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yudin
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Steele
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sgro
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Read
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kopplin
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gough
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome in pregnancy
        </article-title>
        <source>
         Obstet. Gynecol.
        </source>
        <year>
         2005
        </year>
        <volume>
         105
        </volume>
        <fpage>
         124
        </fpage>
        <lpage>
         127
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/01.AOG.0000151598.49129.de
        </pub-id>
        <pub-id pub-id-type="pmid">
         15625153
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B39-viruses-12-00194">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shek
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           G.P.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           F.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infants born to mothers with severe acute respiratory syndrome
        </article-title>
        <source>
         Pediatrics
        </source>
        <year>
         2003
        </year>
        <volume>
         112
        </volume>
        <fpage>
         e254
        </fpage>
        <pub-id pub-id-type="doi">
         10.1542/peds.112.4.e254
        </pub-id>
        <pub-id pub-id-type="pmid">
         14523207
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B40-viruses-12-00194">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) in neonates and children
        </article-title>
        <source>
         Arch. Dis. Child. Fetal Neonatal Ed.
        </source>
        <year>
         2005
        </year>
        <volume>
         90
        </volume>
        <fpage>
         F461
        </fpage>
        <lpage>
         F465
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/adc.2005.075309
        </pub-id>
        <pub-id pub-id-type="pmid">
         16244207
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B41-viruses-12-00194">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           W.F.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Mak
          </surname>
          <given-names>
           Y.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chow
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The placentas of patients with severe acute respiratory syndrome: A pathophysiological evaluation
        </article-title>
        <source>
         Pathology
        </source>
        <year>
         2006
        </year>
        <volume>
         38
        </volume>
        <fpage>
         210
        </fpage>
        <lpage>
         218
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/00313020600696280
        </pub-id>
        <pub-id pub-id-type="pmid">
         16753741
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B42-viruses-12-00194">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poutanen
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Henry
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Finkelstein
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Tellier
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Draker
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Adachi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ayers
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of severe acute respiratory syndrome in Canada
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1995
        </fpage>
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030634
        </pub-id>
        <pub-id pub-id-type="pmid">
         12671061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B43-viruses-12-00194">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seto
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Yung
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Ching
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           T.K.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
         <collab>
          Advisors of Expert SARS group of Hospital Authority
         </collab>
        </person-group>
        <article-title>
         Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <fpage>
         1519
        </fpage>
        <lpage>
         1520
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13168-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         12737864
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B44-viruses-12-00194">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS epidemic in Hong Kong: What lessons have we learned?
        </article-title>
        <source>
         J. R. Soc. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         96
        </volume>
        <fpage>
         374
        </fpage>
        <lpage>
         378
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/014107680309600803
        </pub-id>
        <pub-id pub-id-type="pmid">
         12893851
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B45-viruses-12-00194">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maxwell
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           K.F.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sermer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <collab>
          Maternal Fetal Medicine Committee
         </collab>
         <collab>
          Infectious Disease Committee
         </collab>
        </person-group>
        <article-title>
         Management guidelines for obstetric patients and neonates born to mothers with suspected or probable severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         J. Obstet. Gynaecol. Can.
        </source>
        <year>
         2009
        </year>
        <volume>
         31
        </volume>
        <fpage>
         358
        </fpage>
        <lpage>
         364
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1701-2163(16)34155-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         19497157
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B46-viruses-12-00194">
       <label>
        46.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome (MERS) Background
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/">
          https://www.who.int/emergencies/mers-cov/en/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-31">
         (accessed on 31 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B47-viruses-12-00194">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
         <name>
          <surname>
           Almasry
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bin Saeed
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           S.I.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection during pregnancy: A report of 5 cases from Saudi Arabia
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         63
        </volume>
        <fpage>
         951
        </fpage>
        <lpage>
         953
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/ciw412
        </pub-id>
        <pub-id pub-id-type="pmid">
         27358348
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B48-viruses-12-00194">
       <label>
        48.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Centers for Disease Control and Prevention (CDC)
         </collab>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome (MERS) Fact Sheet
        </article-title>
        <year>
         2015
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/mers/downloads/factsheet-mers_en.pdf">
          https://www.cdc.gov/coronavirus/mers/downloads/factsheet-mers_en.pdf
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-31">
         (accessed on 31 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B49-viruses-12-00194">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jeong
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           S.I.
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ahn
          </surname>
          <given-names>
           W.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           E.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           S.P.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV infection in pregnant woman in Korea
        </article-title>
        <source>
         J. Korean Med. Sci.
        </source>
        <year>
         2017
        </year>
        <volume>
         32
        </volume>
        <fpage>
         1717
        </fpage>
        <lpage>
         1720
        </lpage>
        <pub-id pub-id-type="doi">
         10.3346/jkms.2017.32.10.1717
        </pub-id>
        <pub-id pub-id-type="pmid">
         28875620
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B50-viruses-12-00194">
       <label>
        50.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome (MERS) Overview
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/mers/index.html">
          https://www.cdc.gov/coronavirus/mers/index.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-31">
         (accessed on 31 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B51-viruses-12-00194">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Sumla
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hakeem
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Stephens
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Family cluster of Middle East respiratory syndrome coronavirus infections
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2013
        </year>
        <volume>
         368
        </volume>
        <fpage>
         2487
        </fpage>
        <lpage>
         2494
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1303729
        </pub-id>
        <pub-id pub-id-type="pmid">
         23718156
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B52-viruses-12-00194">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hijawi
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Abdallat
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sayaydeh
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Haddadin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jaarour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Alsheikh
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Alsanouri
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel coronavirus infections in Jordan, April 2012: Epidemiological findings from a retrospective investigation
        </article-title>
        <source>
         East. Mediterr. Health J.
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <fpage>
         S12
        </fpage>
        <lpage>
         S18
        </lpage>
        <pub-id pub-id-type="doi">
         10.26719/2013.19.supp1.S12
        </pub-id>
        <pub-id pub-id-type="pmid">
         23888790
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B53-viruses-12-00194">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oboho
          </surname>
          <given-names>
           I.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tomczyk
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Asmari
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Banjar
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Mugti
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Aloraini
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Alkhaldi
          </surname>
          <given-names>
           K.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Almohammadi
          </surname>
          <given-names>
           E.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           S.I.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         2014 MERS-CoV outbreak in Jeddah—A link to health care facilities
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         372
        </volume>
        <fpage>
         846
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1408636
        </pub-id>
        <pub-id pub-id-type="pmid">
         25714162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B54-viruses-12-00194">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hunter
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Aden
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Al Bandar
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Al Dhaheri
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Abu Elkheir
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Khudair
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Mulla
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           El Saleh
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Imambaccus
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         647
        </fpage>
        <lpage>
         656
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2204.151615
        </pub-id>
        <pub-id pub-id-type="pmid">
         26981708
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B55-viruses-12-00194">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Bang
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           E.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           H.B.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome: What we learned from the 2015 outbreak in the Republic of Korea
        </article-title>
        <source>
         Korean J. Intern. Med.
        </source>
        <year>
         2018
        </year>
        <volume>
         33
        </volume>
        <fpage>
         233
        </fpage>
        <lpage>
         246
        </lpage>
        <pub-id pub-id-type="doi">
         10.3904/kjim.2018.031
        </pub-id>
        <pub-id pub-id-type="pmid">
         29506344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B56-viruses-12-00194">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mohd
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome Coronavirus (MERS-CoV) origin and animal reservoir
        </article-title>
        <source>
         Virol. J.
        </source>
        <year>
         2016
        </year>
        <volume>
         13
        </volume>
        <fpage>
         87
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12985-016-0544-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         27255185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B57-viruses-12-00194">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           H.G.
          </given-names>
         </name>
         <name>
          <surname>
           Elmoslemany
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hizab
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Alnaeem
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Almathen
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Faye
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dromedary camels and the transmission of Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <source>
         Transbound. Emerg. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         64
        </volume>
        <fpage>
         344
        </fpage>
        <lpage>
         353
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/tbed.12401
        </pub-id>
        <pub-id pub-id-type="pmid">
         26256102
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B58-viruses-12-00194">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alserehi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wali
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of Middle East respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome
        </article-title>
        <source>
         BMC Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         16
        </volume>
        <elocation-id>
         105
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1186/s12879-016-1437-y
        </pub-id>
        <pub-id pub-id-type="pmid">
         26936356
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B59-viruses-12-00194">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yadav
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rawal
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Baxi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An Overview of the latest infectious diseases around the world
        </article-title>
        <source>
         J. Comm. Health Manag.
        </source>
        <year>
         2016
        </year>
        <volume>
         3
        </volume>
        <fpage>
         41
        </fpage>
        <lpage>
         43
        </lpage>
       </element-citation>
      </ref>
      <ref id="B60-viruses-12-00194">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           El Masry
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ravi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sayed
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus during pregnancy, Abu Dhabi, United Arab Emirates 2013
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         515
        </fpage>
        <lpage>
         517
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2203.151049
        </pub-id>
        <pub-id pub-id-type="pmid">
         26890613
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B61-viruses-12-00194">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alfaraj
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) infection during pregnancy: Report of two cases &amp; review of literature
        </article-title>
        <source>
         J. Microbiol. Immunol. Infect.
        </source>
        <year>
         2019
        </year>
        <volume>
         52
        </volume>
        <fpage>
         501
        </fpage>
        <lpage>
         503
        </lpage>
        <pub-id pub-id-type="pmid">
         29907538
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B62-viruses-12-00194">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Iblan
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Al Nsour
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rha
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Tohme
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           N.H.
          </given-names>
         </name>
         <name>
          <surname>
           Haddadin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Sanhouri
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Stillbirth during infection with Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         209
        </volume>
        <fpage>
         1870
        </fpage>
        <lpage>
         1872
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiu068
        </pub-id>
        <pub-id pub-id-type="pmid">
         24474813
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B63-viruses-12-00194">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update on therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <source>
         Expert Rev. Anti-Infect. Ther.
        </source>
        <year>
         2017
        </year>
        <volume>
         15
        </volume>
        <fpage>
         269
        </fpage>
        <lpage>
         275
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/14787210.2017.1271712
        </pub-id>
        <pub-id pub-id-type="pmid">
         27937060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B64-viruses-12-00194">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gagneur
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Dirson
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Audebert
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Vallet
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Quillien
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Baron
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Laurent
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Collet
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Oger
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Vertical transmission of human coronavirus. Prospective pilot study
        </article-title>
        <source>
         Pathol. Biol.
        </source>
        <year>
         2007
        </year>
        <volume>
         55
        </volume>
        <fpage>
         525
        </fpage>
        <lpage>
         530
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.patbio.2007.07.013
        </pub-id>
        <pub-id pub-id-type="pmid">
         17889450
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B65-viruses-12-00194">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gagneur
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Dirson
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Audebert
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Vallet
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Legrand-Quillien
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Laurent
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Collet
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Oger
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Payan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Materno-fetal transmission of human coronaviruses: A prospective pilot study
        </article-title>
        <source>
         Eur. J. Clin. Microbiol. Infect. Dis.
        </source>
        <year>
         2008
        </year>
        <volume>
         27
        </volume>
        <fpage>
         863
        </fpage>
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s10096-008-0505-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         18373106
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B66-viruses-12-00194">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gillim-Ross
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging respiratory viruses: Challenges and vaccine strategies
        </article-title>
        <source>
         Clin. Microbiol. Rev.
        </source>
        <year>
         2006
        </year>
        <volume>
         19
        </volume>
        <fpage>
         614
        </fpage>
        <lpage>
         636
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CMR.00005-06
        </pub-id>
        <pub-id pub-id-type="pmid">
         17041137
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B67-viruses-12-00194">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           L.-P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           Y.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           X.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Na
          </surname>
          <given-names>
           D.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.-F.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           G.-D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Duration of antibody responses after severe acute respiratory syndrome
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2007
        </year>
        <volume>
         13
        </volume>
        <fpage>
         1562
        </fpage>
        <lpage>
         1564
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1310.070576
        </pub-id>
        <pub-id pub-id-type="pmid">
         18258008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B68-viruses-12-00194">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Sbrana
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Iwata-Yoshikawa
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Newman
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Garron
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Atmar
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Couch
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2012
        </year>
        <volume>
         7
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="doi">
         10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B69-viruses-12-00194">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical trials and administration of Zika virus vaccine in pregnant women: Lessons (that should have been) learned from excluding immunization with the Ebola vaccine during pregnancy and lactation
        </article-title>
        <source>
         Vaccines (Basel)
        </source>
        <year>
         2018
        </year>
        <volume>
         6
        </volume>
        <elocation-id>
         81
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/vaccines6040081
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B70-viruses-12-00194">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Being pregnant during the Kivu Ebola virus outbreak in DR Congo: The rVSV-ZEBOV vaccine and its accessibility by mothers and infants during humanitarian crises and in conflict areas
        </article-title>
        <source>
         Vaccines
        </source>
        <year>
         2020
        </year>
        <volume>
         8
        </volume>
        <elocation-id>
         38
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/vaccines8010038
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B71-viruses-12-00194">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Maternal and infant death and the rVSV-ZEBOV vaccine through three recent Ebola virus epidemics-West Africa, DRC Équateur and DRC Kivu: 4 years of excluding pregnant and lactating women and their infants from immunization
        </article-title>
        <source>
         Curr. Trop. Med. Rep.
        </source>
        <year>
         2019
        </year>
        <volume>
         6
        </volume>
        <fpage>
         213
        </fpage>
        <lpage>
         222
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s40475-019-00195-w
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B72-viruses-12-00194">
       <label>
        72.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Coalition for Epidemic Preparedness Innovations
         </collab>
        </person-group>
        <article-title>
         CEPI to Fund Three Programmes to Develop Vaccines against the Novel Coronavirus, nCoV-2019. 23 January 2020
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://cepi.net/news_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/">
          https://cepi.net/news_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-29">
         (accessed on 29 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B73-viruses-12-00194">
       <label>
        73.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A Dozen Vaccine Programs Underway as WHO Declares Coronavirus Public Health Emergency. Biocentury. 30 January 2020
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.biocentury.com/article/304328/industry-and-academic-centers-are-rushing-to-create-new-vaccines-and-therapeutics-targeting-coronavirus">
          https://www.biocentury.com/article/304328/industry-and-academic-centers-are-rushing-to-create-new-vaccines-and-therapeutics-targeting-coronavirus
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-02">
         (accessed on 2 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B74-viruses-12-00194">
       <label>
        74.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          WHO
         </collab>
        </person-group>
        <article-title>
         WHO Target Product Profiles for MERS-CoV Vaccines
        </article-title>
        <year>
         2017
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/what/research-development/MERS_CoV_TPP_15052017.pdf?ua=1">
          https://www.who.int/blueprint/what/research-development/MERS_CoV_TPP_15052017.pdf?ua=1
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-31">
         (accessed on 31 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B75-viruses-12-00194">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         When is it acceptable to vaccinate pregnant women? Risk, ethics, and politics of governance in epidemic crises
        </article-title>
        <source>
         Curr. Trop. Med. Rep.
        </source>
        <year>
         2019
        </year>
        <volume>
         6
        </volume>
        <fpage>
         205
        </fpage>
        <lpage>
         212
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s40475-019-00190-1
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B76-viruses-12-00194">
       <label>
        76.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Steinbuch
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chinese Baby Tests Positive for Coronavirus 30 Hours after Birth
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://nypost.com/2020/02/05/chinese-baby-tests-positive-for-coronavirus-30-hours-after-birth/">
          https://nypost.com/2020/02/05/chinese-baby-tests-positive-for-coronavirus-30-hours-after-birth/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-09">
         (accessed on 9 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B77-viruses-12-00194">
       <label>
        77.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woodward
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A Pregnant Mother Infected with the Coronavirus Gave Birth, and Her Baby Tested Positive 30 Hours Later
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.businessinsider.com/wuhan-coronavirus-in-infant-born-from-infected-mother-2020-2">
          https://www.businessinsider.com/wuhan-coronavirus-in-infant-born-from-infected-mother-2020-2
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-08">
         (accessed on 8 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B78-viruses-12-00194">
       <label>
        78.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gillespie
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus: Doctors Fear Pregnant Women Can Pass on Illness after Newborn Baby Is Diagnosed
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://news.sky.com/story/coronavirus-doctors-fear-pregnant-women-can-pass-on-illness-after-newborn-baby-is-diagnosed-11926968">
          https://news.sky.com/story/coronavirus-doctors-fear-pregnant-women-can-pass-on-illness-after-newborn-baby-is-diagnosed-11926968
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-08">
         (accessed on 8 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B79-viruses-12-00194">
       <label>
        79.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          Science Media Centre
         </collab>
        </person-group>
        <article-title>
         Expert Reaction to Newborn Baby Testing Positive for Coronavirus in Wuhan
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.sciencemediacentre.org/expert-reaction-to-newborn-baby-testing-positive-for-coronavirus-in-wuhan/">
          https://www.sciencemediacentre.org/expert-reaction-to-newborn-baby-testing-positive-for-coronavirus-in-wuhan/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-09">
         (accessed on 9 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B80-viruses-12-00194">
       <label>
        80.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alvarado
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Zika virus infection in pregnancy, microcephaly and maternal and fetal health—What we think, what we know, and what we think we know
        </article-title>
        <source>
         Arch. Pathol. Lab. Med.
        </source>
        <year>
         2017
        </year>
        <volume>
         141
        </volume>
        <fpage>
         26
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="doi">
         10.5858/arpa.2016-0382-RA
        </pub-id>
        <pub-id pub-id-type="pmid">
         27636525
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="viruses-12-00194-f001" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Distribution of countries with confirmed cases of the newly identified coronavirus 2019-nCoV (also termed SARS-CoV-2) infection as of 7 February 2020. Courtesy of the U.S. Centers for Disease Control and Prevention, Atlanta, GA.
       </p>
      </caption>
      <graphic xlink:href="viruses-12-00194-g001">
      </graphic>
     </fig>
    </floats-group>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Viruses
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Viruses
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       viruses
      </journal-id>
      <journal-title-group>
       <journal-title>
        Viruses
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1999-4915
      </issn>
      <publisher>
       <publisher-name>
        MDPI
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32098422
      </article-id>
      <article-id pub-id-type="pmc">
       7077191
      </article-id>
      <article-id pub-id-type="doi">
       10.3390/v12020244
      </article-id>
      <article-id pub-id-type="publisher-id">
       viruses-12-00244
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Communication
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          Jiabao
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-12-00244">
         1
        </xref>
        <xref ref-type="author-notes" rid="fn1-viruses-12-00244">
         †
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          Shizhe
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-12-00244">
         1
        </xref>
        <xref ref-type="author-notes" rid="fn1-viruses-12-00244">
         †
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0002-2150-0261
        </contrib-id>
        <name>
         <surname>
          Teng
         </surname>
         <given-names>
          Tieshan
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-12-00244">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Abdalla
         </surname>
         <given-names>
          Abualgasim Elgaili
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2-viruses-12-00244">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          Wan
         </given-names>
        </name>
        <xref ref-type="aff" rid="af3-viruses-12-00244">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         https://orcid.org/0000-0001-6825-9690
        </contrib-id>
        <name>
         <surname>
          Xie
         </surname>
         <given-names>
          Longxiang
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-12-00244">
         1
        </xref>
        <xref ref-type="corresp" rid="c1-viruses-12-00244">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Yunlong
         </given-names>
        </name>
        <xref ref-type="aff" rid="af4-viruses-12-00244">
         4
        </xref>
        <xref ref-type="corresp" rid="c1-viruses-12-00244">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Guo
         </surname>
         <given-names>
          Xiangqian
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-12-00244">
         1
        </xref>
        <xref ref-type="corresp" rid="c1-viruses-12-00244">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af1-viruses-12-00244">
       <label>
        1
       </label>
       Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng 475004, China;
       <email>
        xujiabao0907@126.com
       </email>
       (J.X.);
       <email>
        zhaoshizhe1126@126.com
       </email>
       (S.Z.);
       <email>
        xiaoshan1220@163.com
       </email>
       (T.T.)
      </aff>
      <aff id="af2-viruses-12-00244">
       <label>
        2
       </label>
       Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 2014, Saudi Arabia;
       <email>
        gasimmicro@gmail.com
       </email>
      </aff>
      <aff id="af3-viruses-12-00244">
       <label>
        3
       </label>
       Department of Anesthesia, Stanford University, Stanford, CA 94305, USA;
       <email>
        ms.wanzhu@gmail.com
       </email>
      </aff>
      <aff id="af4-viruses-12-00244">
       <label>
        4
       </label>
       Henan Bioengineering Research Center, Zhengzhou 450046, China
      </aff>
      <author-notes>
       <corresp id="c1-viruses-12-00244">
        <label>
         *
        </label>
        Correspondence:
        <email>
         xielongxiang123@126.com
        </email>
        (L.X.);
        <email>
         biowyl@126.com
        </email>
        (Y.W.);
        <email>
         xqguo@henu.edu.cn
        </email>
        (X.G.); Tel.: +86-0371-22892960 (L.X.); +86-0371-67999699 (Y.W.); +86-0371-22892960 (X.G.)
       </corresp>
       <fn id="fn1-viruses-12-00244">
        <label>
         †
        </label>
        <p>
         These authors contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        22
       </day>
       <month>
        2
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <month>
        2
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       12
      </volume>
      <issue>
       2
      </issue>
      <elocation-id>
       244
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         04
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         20
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 by the authors.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ).
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        After the outbreak of the severe acute respiratory syndrome (SARS) in the world in 2003, human coronaviruses (HCoVs) have been reported as pathogens that cause severe symptoms in respiratory tract infections. Recently, a new emerged HCoV isolated from the respiratory epithelium of unexplained pneumonia patients in the Wuhan seafood market caused a major disease outbreak and has been named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus causes acute lung symptoms, leading to a condition that has been named as “coronavirus disease 2019” (COVID-19). The emergence of SARS-CoV-2 and of SARS-CoV caused widespread fear and concern and has threatened global health security. There are some similarities and differences in the epidemiology and clinical features between these two viruses and diseases that are caused by these viruses. The goal of this work is to systematically review and compare between SARS-CoV and SARS-CoV-2 in the context of their virus incubation, originations, diagnosis and treatment methods, genomic and proteomic sequences, and pathogenic mechanisms.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        coronaviruses
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        genomic comparison
       </kwd>
       <kwd>
        proteomic comparison
       </kwd>
       <kwd>
        pathogenic mechanism
       </kwd>
       <kwd>
        clinical manifestations
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1-viruses-12-00244" sec-type="intro">
     <title>
      1. Introduction
     </title>
     <p>
      Coronaviruses (CoVs) are a group of viruses that co-infect humans and other vertebrate animals. CoV infections affect the respiratory, gastrointestinal, liver, and central nervous systems of humans, livestock, birds, bats, mice, and many other wild animals [
      <xref ref-type="bibr" rid="B1-viruses-12-00244">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="B2-viruses-12-00244">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B3-viruses-12-00244">
       3
      </xref>
      ]. For example, severe acute respiratory syndrome (SARS) in 2002 and the Middle East respiratory syndrome (MERS) in 2012 were both coronaviruses that transmitted from animals to humans [
      <xref ref-type="bibr" rid="B4-viruses-12-00244">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="B5-viruses-12-00244">
       5
      </xref>
      ]. The source of unexplained pneumonia was first discovered in Wuhan in Dec, 2019, and SARS-CoV-2, a new coronavirus, was isolated from the respiratory epithelium of patients. It belongs to a new evolutionary branch within the CoV. On Feb. 11th, 2020, the new coronavirus was officially renamed “SARS-CoV-2” from “2019-nCoV” [
      <xref ref-type="bibr" rid="B6-viruses-12-00244">
       6
      </xref>
      ]. The disease caused by SARS-CoV-2 was called “coronavirus disease 2019” (COVID-19) [
      <xref ref-type="bibr" rid="B7-viruses-12-00244">
       7
      </xref>
      ]. According to the data released by the National Health Commission of the People’s Republic of China, SARS-CoV-2 was most likely transmitted from wild bats to humans, and all the above three CoVs can transmit from person to person [
      <xref ref-type="bibr" rid="B8-viruses-12-00244">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="B9-viruses-12-00244">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="B10-viruses-12-00244">
       10
      </xref>
      ]. SARS-CoV-2 shares a highly similar gene sequence and behavior pattern with SARS-CoV [
      <xref ref-type="bibr" rid="B11-viruses-12-00244">
       11
      </xref>
      ]. This paper summarized the similarities and differences between SARS-CoV-2 and SARS-CoV, both of which cause major disease outbreaks in China and worldwide, which will provide comprehensive reference for epidemic prevention.
     </p>
    </sec>
    <sec id="sec2-viruses-12-00244">
     <title>
      2. Materials and Methods
     </title>
     <sec id="sec2dot1-viruses-12-00244">
      <title>
       2.1. Data Collection
      </title>
      <p>
       The complete genomic sequences of SARS-CoV-2 were obtained from 2019 Novel Coronavirus Resource (2019nCoVR) [
       <xref ref-type="bibr" rid="B12-viruses-12-00244">
        12
       </xref>
       ] and two databases, including the National Center for Biotechnology Information (NCBI) [
       <xref ref-type="bibr" rid="B13-viruses-12-00244">
        13
       </xref>
       ] and Global Initiative on Sharing All Influenza Data (GISAID) [
       <xref ref-type="bibr" rid="B14-viruses-12-00244">
        14
       </xref>
       ]. The DNA sequences of two other representative CoVs (SARS-CoV and MERS-CoV) were included for comparative analysis. The genomic information of latest SARS-CoV-2 strains is shown in
       <xref ref-type="app" rid="app1-viruses-12-00244">
        Table S1
       </xref>
       .
      </p>
     </sec>
     <sec id="sec2dot2-viruses-12-00244">
      <title>
       2.2. Homology Analysis
      </title>
      <p>
       The amino acid sequences of 28 proteins in SARS-CoV-2 were compared with those of SARS-CoV to analyze protein homology by using NCBI Blastp [
       <xref ref-type="bibr" rid="B15-viruses-12-00244">
        15
       </xref>
       ]. Proteins from SARS and SARS-CoV-2 were treated as homologous: identity value ≥ 65%, query coverage ≥ 95%.
      </p>
     </sec>
     <sec id="sec2dot3-viruses-12-00244">
      <title>
       2.3. Phylogenetic Analysis
      </title>
      <p>
       Comparative genomic analyses of SARS-CoV-2 and SARS-CoV were performed by zpicture for the global comparison [
       <xref ref-type="bibr" rid="B16-viruses-12-00244">
        16
       </xref>
       ]. Multiple sequence alignment and the construction of phylogenetic trees of 38 CoVs were conducted using MEGA7 [
       <xref ref-type="bibr" rid="B17-viruses-12-00244">
        17
       </xref>
       ]. The evolutionary distances were calculated using the Maximum Composite Likelihood method [
       <xref ref-type="bibr" rid="B18-viruses-12-00244">
        18
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec3-viruses-12-00244" sec-type="results">
     <title>
      3. Results
     </title>
     <p>
      The differences and similarities of clinical characteristics between COVID-19 and SARS were summarized in
      <xref ref-type="table" rid="viruses-12-00244-t001">
       Table 1
      </xref>
      .
     </p>
     <sec id="sec3dot1-viruses-12-00244">
      <title>
       3.1. COVID-19 and SARS—the Initial Events
      </title>
      <p>
       On Nov. 27th, 2002, a respiratory illness erupted in Guangdong Province, China [
       <xref ref-type="bibr" rid="B19-viruses-12-00244">
        19
       </xref>
       ]. In Feb, 2003, the Chinese Ministry of Health announced that this acute respiratory syndrome had thus far resulted in 305 cases and five deaths [
       <xref ref-type="bibr" rid="B20-viruses-12-00244">
        20
       </xref>
       ]. The following month, there were clusters of atypical pneumonia reported in other parts of mainland China, Hong Kong [
       <xref ref-type="bibr" rid="B21-viruses-12-00244">
        21
       </xref>
       ], Canada [
       <xref ref-type="bibr" rid="B22-viruses-12-00244">
        22
       </xref>
       ], and Singapore [
       <xref ref-type="bibr" rid="B23-viruses-12-00244">
        23
       </xref>
       ]. In Jul, 2003, SARS-CoV spread across 26 countries in six continents, and caused a cumulative 8,096 cases and 774 deaths (9.6%) [
       <xref ref-type="bibr" rid="B24-viruses-12-00244">
        24
       </xref>
       ]. In particular, a higher mortality (21%) was found in hospital personnel [
       <xref ref-type="bibr" rid="B25-viruses-12-00244">
        25
       </xref>
       ,
       <xref ref-type="bibr" rid="B26-viruses-12-00244">
        26
       </xref>
       ].
      </p>
      <p>
       On Dec. 29th, 2019, the health departments of Hubei Province received a report that four employees of the South China Seafood Wholesale Market were diagnosed with unknown-caused pneumonia in a local hospital, which was the first report of SARS-CoV-2 [
       <xref ref-type="bibr" rid="B27-viruses-12-00244">
        27
       </xref>
       ]. On Dec. 31st, 2019, the National Health Commission of People Republic of China and Chinese Center for Disease Control and Prevention (China CDC) participated in the investigation and case-searching work [
       <xref ref-type="bibr" rid="B27-viruses-12-00244">
        27
       </xref>
       ]. On the same day, the government of Wuhan released information about the disease outbreaks to society [
       <xref ref-type="bibr" rid="B28-viruses-12-00244">
        28
       </xref>
       ]. Nowadays, the number of patients infected with SARS-CoV-2 continues to climb worldwide. By the date of this paper’s submission, a cumulative 67,081 cases and 1,526 deaths (2.1%) were reported worldwide. In Wuhan, China, the number is 37,914. The main timeline of SARS and COVID-19 epidemic development were shown in
       <xref ref-type="fig" rid="viruses-12-00244-f001">
        Figure 1
       </xref>
       a,b, respectively.
      </p>
     </sec>
     <sec id="sec3dot2-viruses-12-00244">
      <title>
       3.2. Clinical Symptoms
      </title>
      <p>
       The initial symptoms of SARS patients were fever (100%), cough (61.8%), myalgia (48.7%), dyspnea (40.8%), and diarrhea (31.6%) [
       <xref ref-type="bibr" rid="B29-viruses-12-00244">
        29
       </xref>
       ], and the prognosis of patients was associated with host characteristics (including age, gender, etc.) [
       <xref ref-type="bibr" rid="B30-viruses-12-00244">
        30
       </xref>
       ]. During hospitalization, respiratory distress occurred in 90.8% of SARS patients [
       <xref ref-type="bibr" rid="B29-viruses-12-00244">
        29
       </xref>
       ]. The duration from disease onset to severe respiratory distress was an average of 9.8 ± 3.0 days [
       <xref ref-type="bibr" rid="B29-viruses-12-00244">
        29
       </xref>
       ]. During the disease course, some patients developed leukopenia, lymphopenia, and thrombocytopenia with an upregulation of aspartate transaminase (AST), alanine aminotransferase (ALT), lactic dehydrogenase (LDH), and C-reactive protein (CRP) [
       <xref ref-type="bibr" rid="B29-viruses-12-00244">
        29
       </xref>
       ].
      </p>
      <p>
       In comparison, COVID-19 showed similar trends with SARS patients [
       <xref ref-type="bibr" rid="B28-viruses-12-00244">
        28
       </xref>
       ]. Fever, fatigue, and dry cough are the main manifestations of the patients, while nasal congestion, runny nose, and other symptoms of the upper respiratory tract are rare. Beijing Centers for Diseases Control and Prevention indicated that the typical case of COVID-19 has a progressive aggravation process. COVID-19 can be classified into light, normal, severe, and critical types based on the severity of the disease [
       <xref ref-type="bibr" rid="B31-viruses-12-00244">
        31
       </xref>
       ]: (1) Mild cases—the clinical symptoms were mild, and no pneumonia was found on the chest computed tomography (CT); (2) normal cases—fever, respiratory symptoms, and patients found to have imaging manifestations of pneumonia; (3) severe cases—one of the following three conditions: Respiratory distress, respiratory rate ≥ 30 times/min (in resting state, refers to oxygen saturation ≤ 93%), partial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) ≤ 300 mmHg (1 mmHg = 0.133 kPa); (4) critical cases—one of the following three conditions: Respiratory failure and the need for mechanical ventilation, shock, or the associated failure of other organs requiring the intensive care unit [
       <xref ref-type="bibr" rid="B32-viruses-12-00244">
        32
       </xref>
       ]. The current clinical data shows that the majority of the deaths occurred in the older patients. However, severe cases have been documented in young adults who have unique factors, particularly those with chronic diseases, such as diabetes or hepatitis B. Those with a long-term use of hormones or immunosuppressants, and decreased immune function, are likely to get severely infected.
      </p>
     </sec>
     <sec id="sec3dot3-viruses-12-00244">
      <title>
       3.3. Virus Incubation
      </title>
      <p>
       The incubation period of SARS is 1–4 days [
       <xref ref-type="bibr" rid="B33-viruses-12-00244">
        33
       </xref>
       ]. However, in a small number of patients, the incubation period may be longer than 10 days [
       <xref ref-type="bibr" rid="B34-viruses-12-00244">
        34
       </xref>
       ]. It has been demonstrated that the latency of COVID-19 varies from 3–7 days on average, for up to 14 days [
       <xref ref-type="bibr" rid="B35-viruses-12-00244">
        35
       </xref>
       ]. During this incubation period, patients are contagious, and it has been reported that each case infected on average 3.77 other people (uncertainty range 2.23-4.82) [
       <xref ref-type="bibr" rid="B36-viruses-12-00244">
        36
       </xref>
       ]. By comparison, we found that the average latency of COVID-19 is slightly longer than that of SARS.
      </p>
     </sec>
     <sec id="sec3dot4-viruses-12-00244">
      <title>
       3.4. Susceptible Populations
      </title>
      <p>
       According to the demographic information of SARS patients, infection occurred in all age groups (the average age was ≦45) [
       <xref ref-type="bibr" rid="B37-viruses-12-00244">
        37
       </xref>
       ]. There was a proportional difference between male and female (female predominance) [
       <xref ref-type="bibr" rid="B37-viruses-12-00244">
        37
       </xref>
       ], with a male-to-female ratio of 1:1.25 [
       <xref ref-type="bibr" rid="B38-viruses-12-00244">
        38
       </xref>
       ]. In addition, hospital staff had a higher risk due to the proximal interactions with large numbers from the infected population. For example, hospital staff accounted for 22% of all cases in Hong Kong and 22.8% in Guangdong [
       <xref ref-type="bibr" rid="B37-viruses-12-00244">
        37
       </xref>
       ]. The mortality caused by SARS increased with age (&gt; 64 years) [
       <xref ref-type="bibr" rid="B37-viruses-12-00244">
        37
       </xref>
       ], and the overall mortality rate during the outbreak of SARS was estimated at 9.6% [
       <xref ref-type="bibr" rid="B39-viruses-12-00244">
        39
       </xref>
       ,
       <xref ref-type="bibr" rid="B40-viruses-12-00244">
        40
       </xref>
       ].
      </p>
      <p>
       Li et al. reported that people who have not been exposed to SARS-CoV-2 are all susceptible to COVID-19 [
       <xref ref-type="bibr" rid="B41-viruses-12-00244">
        41
       </xref>
       ]. Among the 8,866 patients who have been confirmed with COVID-19, nearly half of the patients have been aged 50 years or older (47.7%) [
       <xref ref-type="bibr" rid="B36-viruses-12-00244">
        36
       </xref>
       ]. The male-to-female ratio is about 2.7:1 [
       <xref ref-type="bibr" rid="B38-viruses-12-00244">
        38
       </xref>
       ] and the average incubation period is 5.2 days [
       <xref ref-type="bibr" rid="B42-viruses-12-00244">
        42
       </xref>
       ]. However, severe COVID-19 cases and deaths have mostly been in the middle-aged adults and the elderly with long smoking histories or other basic diseases, such as heart disease and hypertension [
       <xref ref-type="bibr" rid="B43-viruses-12-00244">
        43
       </xref>
       ,
       <xref ref-type="bibr" rid="B44-viruses-12-00244">
        44
       </xref>
       ]. At the time that this paper was been submitted, COVID-19 patients mortality rate was 2.1% [
       <xref ref-type="bibr" rid="B45-viruses-12-00244">
        45
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec3dot5-viruses-12-00244">
      <title>
       3.5. Animal Reservoirs
      </title>
      <p>
       In 2010, Shi et al. isolated a SARS-like coronavirus which was highly homologous to the SARS-CoV, confirming that
       <italic>
        Rhinolophus sinicus
       </italic>
       (Chinese rufous horseshoe bat) was a natural host of the SARS-CoV [
       <xref ref-type="bibr" rid="B46-viruses-12-00244">
        46
       </xref>
       ]. Bats are known to be hosts for 30 coronaviruses based on complete genomic sequences analysis [
       <xref ref-type="bibr" rid="B47-viruses-12-00244">
        47
       </xref>
       ]. Epidemiological investigations have shown that civet cats in the wildlife market were the direct source of SARS-CoV [
       <xref ref-type="bibr" rid="B48-viruses-12-00244">
        48
       </xref>
       ]. Among the four patients with SARS discovered during the winter of 2003-2004, two were waitresses at a restaurant in Guangzhou, China, and one was a customer who ate in the restaurant a short distance from a civet cage. All six civets in this cage were tested positive for SARS-CoV [
       <xref ref-type="bibr" rid="B48-viruses-12-00244">
        48
       </xref>
       ].
      </p>
      <p>
       The new emerging SARS-CoV-2 shares about 80% of the gene sequence of SARS-CoV, released by the Military Medical Research Institute of Nanjing Military Region in 2003 [
       <xref ref-type="bibr" rid="B28-viruses-12-00244">
        28
       </xref>
       ]. Recently, Shi et al. reported that the sequence similarity of coronavirus between SARS-CoV-2 and the coronavirus isolated from
       <italic>
        Rhinolophus affinis
       </italic>
       is 96.2%, and suggested that bats may be the source of the virus [
       <xref ref-type="bibr" rid="B49-viruses-12-00244">
        49
       </xref>
       ]. So far, the intermediate hosts of SARS-CoV-2 are elusive and have been reported to be snakes, minks, or variable others [
       <xref ref-type="bibr" rid="B50-viruses-12-00244">
        50
       </xref>
       ,
       <xref ref-type="bibr" rid="B51-viruses-12-00244">
        51
       </xref>
       ]. Recently, a research group of South China Agricultural University reported that pangolins may be one of the intermediate hosts for SARS-CoV-2, by analyzing more than 1,000 metagenomic samples, because they found that 70% of pangolins are positive for the coronavirus. Moreover, the virus isolate from pangolin shared 99% sequence similarity with the current infected human strain SARS-CoV-2 [
       <xref ref-type="bibr" rid="B52-viruses-12-00244">
        52
       </xref>
       ]. Taking this recent research into consideration, we agreed that pangolin is more likely to be one of intermediate hosts of SARS-CoV-2.
      </p>
     </sec>
     <sec id="sec3dot6-viruses-12-00244">
      <title>
       3.6. Regional Distribution
      </title>
      <p>
       According to the WHO data on Jul. 31th, 2003 [
       <xref ref-type="bibr" rid="B24-viruses-12-00244">
        24
       </xref>
       ], a total of 8,096 clinically diagnosed cases of SARS were reported worldwide, with 774 deaths and 26 countries and regions affected (
       <xref ref-type="fig" rid="viruses-12-00244-f002">
        Figure 2
       </xref>
       a). Most cases were in Asia, Europe, and America. The main countries in Asia were China (including mainland, Macao, Hong Kong, and Taiwan), Singapore, and so on. The total number of cases in mainland China was 5,327, with 349 deaths [
       <xref ref-type="bibr" rid="B53-viruses-12-00244">
        53
       </xref>
       ]. The cases were mainly concentrated in Beijing, Guangdong, and Shanxi (
       <xref ref-type="fig" rid="viruses-12-00244-f002">
        Figure 2
       </xref>
       b) [
       <xref ref-type="bibr" rid="B54-viruses-12-00244">
        54
       </xref>
       ]. In total, 2,102 patients were from Hong Kong, Macao, and Taiwan, with 336 deaths [
       <xref ref-type="bibr" rid="B24-viruses-12-00244">
        24
       </xref>
       ].
      </p>
      <p>
       According to the latest data on Feb. 14th, 2020 [
       <xref ref-type="bibr" rid="B55-viruses-12-00244">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="B56-viruses-12-00244">
        56
       </xref>
       ], there have been a total of 67,081 clinically diagnosed cases of COVID-19 in worldwide, with 1,526 deaths. A total of 25 countries and regions have infected people. Due to the Spring Festival transportation peak, the disease has been spread more rapidly across China (
       <xref ref-type="fig" rid="viruses-12-00244-f002">
        Figure 2
       </xref>
       c). As the origin area of COVID-19, Hubei province has been the most severely infected area, with 54,406 cumulative diagnosis cases. Wuhan city has 37,914 cases. Guangdong, Henan, and Zhejiang province have 1,294 cases, 1,212 cases, and 1,162 cases, respectively (
       <xref ref-type="fig" rid="viruses-12-00244-f002">
        Figure 2
       </xref>
       d). At present, the COVID-19 outbreak has been spread to all parts of China and around the world, including the United States, Thailand, and Japan. It has been noticed that most of these patients have ever been to Wuhan or contacted with people who had been in Wuhan. The distribution of COVID-2019 patients in China (including Hong Kong, Macao and Taiwan) and Hubei Province is shown in
       <xref ref-type="fig" rid="viruses-12-00244-f003">
        Figure 3
       </xref>
       .
      </p>
     </sec>
     <sec id="sec3dot7-viruses-12-00244">
      <title>
       3.7. Prevention, Diagnosis, and Treatment
      </title>
      <sec id="sec3dot7dot1-viruses-12-00244">
       <title>
        3.7.1. Prevention
       </title>
       <p>
        As the number of COVID-19 patients in China has been growing rapidly, preventing the spread of SARS-CoV-2 is the most important and urgent task [
        <xref ref-type="bibr" rid="B57-viruses-12-00244">
         57
        </xref>
        ]. It was shown that human-to-human transmission of SARS-CoV-2 has spread via droplets or close contacts [
        <xref ref-type="bibr" rid="B58-viruses-12-00244">
         58
        </xref>
        ,
        <xref ref-type="bibr" rid="B59-viruses-12-00244">
         59
        </xref>
        ], but aerosol and fecal-oral transmission still need further study [
        <xref ref-type="bibr" rid="B60-viruses-12-00244">
         60
        </xref>
        ,
        <xref ref-type="bibr" rid="B61-viruses-12-00244">
         61
        </xref>
        ]. To reduce virus transmission, early detection and isolation are essential. In addition, close monitoring in crowded places is also important [
        <xref ref-type="bibr" rid="B62-viruses-12-00244">
         62
        </xref>
        ]. The possible pathogens of SARS and COVID-19 are both derived from wild animals [
        <xref ref-type="bibr" rid="B63-viruses-12-00244">
         63
        </xref>
        ]. Therefore, hunting, selling, and eating wild animals not only seriously damage the ecosystem, but also lead to the spread of epidemic diseases [
        <xref ref-type="bibr" rid="B64-viruses-12-00244">
         64
        </xref>
        ]. Thus, banning all wildlife trade is an effective measure to prevent viral prevalence. Wearing level-D protective clothing can protect medical staff from infection of respiratory viruses [
        <xref ref-type="bibr" rid="B65-viruses-12-00244">
         65
        </xref>
        ]. A vaccine against SARS-CoV has not been described in any published articles [
        <xref ref-type="bibr" rid="B66-viruses-12-00244">
         66
        </xref>
        ]. However, on Jan. 26th, 2020, the China CDC started to develop a new vaccine for SARS-CoV-2. The virus has been successfully isolated and seed strains have been screened [
        <xref ref-type="bibr" rid="B67-viruses-12-00244">
         67
        </xref>
        ].
       </p>
      </sec>
      <sec id="sec3dot7dot2-viruses-12-00244">
       <title>
        3.7.2. Diagnosis
       </title>
       <p>
        The early symptoms of SARS and COVID-19 are very similar to winter influenza, and the most important way to distinguish flu and pneumonia is to take throat swabs for viral testing [
        <xref ref-type="bibr" rid="B68-viruses-12-00244">
         68
        </xref>
        ]. Current diagnostic tests for coronavirus include RT-PCR, real-time reverse transcription PCR (rRT-PCR), reverse transcription loop-mediated isothermal amplification, as well as real-time RT-LAMP [
        <xref ref-type="bibr" rid="B69-viruses-12-00244">
         69
        </xref>
        ,
        <xref ref-type="bibr" rid="B70-viruses-12-00244">
         70
        </xref>
        ,
        <xref ref-type="bibr" rid="B71-viruses-12-00244">
         71
        </xref>
        ,
        <xref ref-type="bibr" rid="B72-viruses-12-00244">
         72
        </xref>
        ]. National Medical Products Administration has approved seven new nucleic acid test reagents for coronavirus, which were developed based on fluorescence PCR by Feb. 1st, 2020 [
        <xref ref-type="bibr" rid="B73-viruses-12-00244">
         73
        </xref>
        ]. Suspected infections can be detected accurately and quickly for timely isolation and treatment to avoid infecting others by using these test reagents.
       </p>
      </sec>
      <sec id="sec3dot7dot3-viruses-12-00244">
       <title>
        3.7.3. Treatment
       </title>
       <p>
        Both SARS-CoV and SARS-CoV-2 are CoVs; hence, the treatment strategies of SARS could be relevant for COVID-19 [
        <xref ref-type="bibr" rid="B74-viruses-12-00244">
         74
        </xref>
        ]. In 2003, SARS was mainly treated by isolation of the patients, hormones treatment, antiviral and symptomatic treatments, and many drugs such as glucocorticoid [
        <xref ref-type="bibr" rid="B29-viruses-12-00244">
         29
        </xref>
        ] and interferon [
        <xref ref-type="bibr" rid="B75-viruses-12-00244">
         75
        </xref>
        ]. Now, isolation, antiviral, and symptomatic treatments are still mainly adopted for COVID-19 treatment. As effective drugs for SARS, hormones and interferons can also be used to treat COVID-19 [
        <xref ref-type="bibr" rid="B74-viruses-12-00244">
         74
        </xref>
        ]. Lopinavir is one kind of protease inhibitor used to treat HIV infection, with ritonavir as a booster. Lopinavir and/or ritonavir has anti coronavirus activity in vitro. Hong Kong scholars found that, compared with ribavirin alone, patients treated with lopinavir/ritonavir and ribavirin had lower risk of acute respiratory distress syndrome (ARDS) or death caused by SARS-CoV [
        <xref ref-type="bibr" rid="B76-viruses-12-00244">
         76
        </xref>
        ,
        <xref ref-type="bibr" rid="B77-viruses-12-00244">
         77
        </xref>
        ]. Lopinavir/ritonavir has also been clinically tested in treatment of COVID-19, and showed wonderfully effective treatment for some patients, but the general clinical effect has not been determined [
        <xref ref-type="bibr" rid="B78-viruses-12-00244">
         78
        </xref>
        ].
       </p>
       <p>
        More effective treatments are still under continuing exploration: On Jan. 25th, 2020, a joint research team from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Shanghai Tech University screened and identified 30 potential drugs that are reported to be effective against SARS-CoV-2 [
        <xref ref-type="bibr" rid="B79-viruses-12-00244">
         79
        </xref>
        ]. A high-resolution crystal structure of SARS-CoV-2 coronavirus 3CL hydrolase (Mpro) was announced after the outbreak of COVID-19 in the world [
        <xref ref-type="bibr" rid="B80-viruses-12-00244">
         80
        </xref>
        ], and human coronaviruses (HCoVs) have been treated as severe pathogens in respiratory tract infections. Nelfinavir was predicted to be a potential inhibitor of SARS-CoV-2 main protease [
        <xref ref-type="bibr" rid="B81-viruses-12-00244">
         81
        </xref>
        ]. The first patient in the US had been trial-treated with intravenous remdesivir (a novel nucleotide analogue prodrug in development) due to a severe infection [
        <xref ref-type="bibr" rid="B82-viruses-12-00244">
         82
        </xref>
        ,
        <xref ref-type="bibr" rid="B83-viruses-12-00244">
         83
        </xref>
        ]. No adverse reactions were observed during the administration, and the patient’s condition was effectively improved [
        <xref ref-type="bibr" rid="B84-viruses-12-00244">
         84
        </xref>
        ]. Clinical trials of remdesivir for treatment of COVID-19 just started on Feb. 5th and 12th, 2020 in Wuhan and Beijing, respectively, and the experimental results remain unclear [
        <xref ref-type="bibr" rid="B85-viruses-12-00244">
         85
        </xref>
        ,
        <xref ref-type="bibr" rid="B86-viruses-12-00244">
         86
        </xref>
        ].
       </p>
      </sec>
     </sec>
     <sec id="sec3dot8-viruses-12-00244">
      <title>
       3.8. Genomic Comparison
      </title>
      <p>
       CoVs are RNA viruses and contain the largest genomes of all RNA viruses [
       <xref ref-type="bibr" rid="B87-viruses-12-00244">
        87
       </xref>
       ]. CoVs belong to the subfamily Coronavirinae in the family of Coronaviridae of the order Nidovirales, and this subfamily includes four genera: α-coronavirus, β-coronavirus, γ-coronavirus, and δ-coronavirus [
       <xref ref-type="bibr" rid="B88-viruses-12-00244">
        88
       </xref>
       ]. Both SARS-CoV-2 and SARS-CoV are in the coronavirus family, β-coronavirus genera [
       <xref ref-type="bibr" rid="B89-viruses-12-00244">
        89
       </xref>
       ]. The genome of SARS-CoV-2 is more than 85% similar to the genome of the SARS-like virus ZC45 (bat-SL-CoVZC45, MG772933.1), and together these types of viruses form a unique Orthocoronavirinae subfamily with another SARS-like virus ZXC21 in the sarbecovirus subgenus [
       <xref ref-type="bibr" rid="B35-viruses-12-00244">
        35
       </xref>
       ]. All the three viruses show typical β-coronavirus gene structure. Human SARS-CoV and a genetically similar bat coronavirus (bat-SL-CoVZXC21, MG772934) from southwest of China have formed another clade within the sarbecovirus [
       <xref ref-type="bibr" rid="B35-viruses-12-00244">
        35
       </xref>
       ].
      </p>
      <p>
       We also performed comparative genomic analyses of SARS-CoV-2 and SARS-CoV by zpicture. The results showed that the genomic sequences of SARS-CoV-2 and SARS-CoV have extremely high homology at the nucleotide level (
       <xref ref-type="fig" rid="viruses-12-00244-f004">
        Figure 4
       </xref>
       a,b). There are six regions of difference (RD) in the genome sequence between SARS-CoV and SARS-CoV-2, and the RDs are named according to the order of discovery. RD1, RD2, and RD3 (448nt, 55nt, and 278nt, respectively) are partial coding sequences of the
       <italic>
        orf lab
       </italic>
       gene; RD4 and RD5 (315nt and 80nt, respectively) are partial coding sequences of the
       <italic>
        S
       </italic>
       gene; RD6 is 214nt in size and is part of the coding sequence of the
       <italic>
        orf7b
       </italic>
       and
       <italic>
        orf8
       </italic>
       genes. These RDs may provide new molecular markers for the identification of SARS-CoV-2 and SARS-CoV, and also help to develop new drugs against SARS-CoV-2.
      </p>
      <p>
       To analyze the homogeneity of SARS-CoV, MERS-CoV, and SARS-CoV-2, an evolutionary tree was constructed based on the genomes of 35 SARS-CoV-2 strains from different data submission units, one SARS-CoV strain, and two MERS-CoV strains (
       <xref ref-type="app" rid="app1-viruses-12-00244">
        Figure S1
       </xref>
       ). Phylogenetic analysis showed that the distance of SARS-CoV (AY274119) is closer to SARS-CoV-2 strains than MERS-CoV (KC164505, JX869059).
      </p>
     </sec>
     <sec id="sec3dot9-viruses-12-00244">
      <title>
       3.9. Proteomic Comparison
      </title>
      <p>
       To further explore whether all encoded proteins of SARS-CoV-2 are homologous to that of SARS-CoV, we performed a protein sequence alignment analysis using Blastp. The results showed that most of SARS-CoV-2 proteins are highly homologous (95%–100%) to the proteins of SARS-CoV virus, indicating the evolutionary similarity between SARS-CoV and SARS-CoV-2 (
       <xref ref-type="table" rid="viruses-12-00244-t002">
        Table 2
       </xref>
       ). However, two proteins (orf8 and orf10) in SARS-CoV-2 have no homologous proteins in SARS-CoV. The amino acid sequence of orf8 in SARS-CoV-2 is different from sequences of conserved orf8 or orf8b derived from human SARS-CoV [
       <xref ref-type="bibr" rid="B11-viruses-12-00244">
        11
       </xref>
       ]. Orf8 protein of SARS-CoV-2 does not contain known functional domain or motif. An aggregation motif VLVVL (amino acid 75–79) has been found in SARS-CoV orf8b which was shown to trigger intracellular stress pathways and activate NOD-like receptor family pyrin domain-containing-3 (NLRP3) inflammasomes [
       <xref ref-type="bibr" rid="B90-viruses-12-00244">
        90
       </xref>
       ]. Therefore, it will be clinically meaningful to analyze the biological function of these two specific proteins (orf8 and orf10) in SARS-CoV-2.
      </p>
      <p>
       As the most abundant protein in CoVs, nucleocapsid (N) protein is highly conserved across CoVs [
       <xref ref-type="bibr" rid="B91-viruses-12-00244">
        91
       </xref>
       ]. The N protein in SARS-CoV-2 shares ~90% amino acid identity with that in SARS-CoV [
       <xref ref-type="bibr" rid="B28-viruses-12-00244">
        28
       </xref>
       ], which indicates that antibodies against the N protein of SARS-CoV would likely recognize and bind the N protein of SARS-CoV-2 as well. N antibodies do not provide immunity to SARS-CoV-2 infection, but the antibodies have a cross reactivity with SARS-CoV N protein viruses, which would allow a serum-based assay to identify the asymptomatic SARS-CoV-2 infected-cases [
       <xref ref-type="bibr" rid="B28-viruses-12-00244">
        28
       </xref>
       ]. Although previous studies have found serum reactivity to group SARS-CoV N proteins in Chinese populations [
       <xref ref-type="bibr" rid="B92-viruses-12-00244">
        92
       </xref>
       ], exposure to SARS-CoV-2 should increase the dilution factor if the infection had occurred. This information has important implications for preventing the spread of asymptomatic infections.
      </p>
      <p>
       In addition, spike stalk S2 in SARS-CoV-2 is highly conserved and shares 99% identity with those of the two bat SARS-like CoVs (bat-SL-CoVZXC21 and bat-SL-CoVZC45) and human SARS-CoV [
       <xref ref-type="bibr" rid="B11-viruses-12-00244">
        11
       </xref>
       ]. Thus, the broad spectrum antiviral peptides against S2 has the potential to be effective treatment [
       <xref ref-type="bibr" rid="B93-viruses-12-00244">
        93
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec3dot10-viruses-12-00244">
      <title>
       3.10. Pathogenic Mechanisms
      </title>
      <p>
       Many studies have been performed to study the pathogenesis of SARS-CoV [
       <xref ref-type="bibr" rid="B94-viruses-12-00244">
        94
       </xref>
       ,
       <xref ref-type="bibr" rid="B95-viruses-12-00244">
        95
       </xref>
       ,
       <xref ref-type="bibr" rid="B96-viruses-12-00244">
        96
       </xref>
       ]. The spike (S) protein and N protein confer stability to the viral particle [
       <xref ref-type="bibr" rid="B97-viruses-12-00244">
        97
       </xref>
       ]. The N protein is a structural protein involved in virion assembly, and plays a pivotal role in virus transcription and assembly efficiency [
       <xref ref-type="bibr" rid="B97-viruses-12-00244">
        97
       </xref>
       ]. S protein can bind to the cellular receptors of sensitive cells and mediate infection of their target cells, after which it begins to replicate in the cytoplasm [
       <xref ref-type="bibr" rid="B98-viruses-12-00244">
        98
       </xref>
       ]. SARS-CoV mainly targets the lungs, immune organs, and small systemic blood vessels and causes systemic vasculitis and decrease of immune function [
       <xref ref-type="bibr" rid="B99-viruses-12-00244">
        99
       </xref>
       ]. More seriously, the infection leads to extensive pulmonary consolidation, diffuse alveolar damage, and the formation of a transparent membrane, finally deteriorating to respiratory distress [
       <xref ref-type="bibr" rid="B100-viruses-12-00244">
        100
       </xref>
       ].
      </p>
      <p>
       CoV can enter host cells through the interaction between CoV S protein and its host receptor angiotensin-converting enzyme 2 (ACE2), which is isolated from SARS-CoV–permissive Vero-E6 cells. The receptor-binding motif (RBM) of S protein can directly contact ACE2 [
       <xref ref-type="bibr" rid="B47-viruses-12-00244">
        47
       </xref>
       ,
       <xref ref-type="bibr" rid="B101-viruses-12-00244">
        101
       </xref>
       ,
       <xref ref-type="bibr" rid="B102-viruses-12-00244">
        102
       </xref>
       ]. AEC2 have been identified to be key binding residues and functional receptor for SARS-CoV, and it can also protect alveolar cells [
       <xref ref-type="bibr" rid="B103-viruses-12-00244">
        103
       </xref>
       ]. The binding of spike protein to ACE2 and the subsequent downregulation of this receptor contribute to severe alveolar injury during SARS [
       <xref ref-type="bibr" rid="B49-viruses-12-00244">
        49
       </xref>
       ]. The downregulation of ACE2 results in the excessive production of angiotensin II by the related enzyme ACE, and the stimulation of type 1A angiotensin II receptor (AGTR1A) can lead to the increase of pulmonary vascular permeability, which potentially explains the increased lung pathology when the expression of ACE2 is decreased [
       <xref ref-type="bibr" rid="B104-viruses-12-00244">
        104
       </xref>
       ]. ACE2-transfected T cells form multinucleated syncytia with cells expressing S protein. The virus was shown to replicate effectively in ACE2-transfected, but not in mock-transfected T cells. Antibodies targeting ACE2 can block viral replication in Vero-E6 cells [
       <xref ref-type="bibr" rid="B105-viruses-12-00244">
        105
       </xref>
       ].
      </p>
      <p>
       Recently, Ji et al. demonstrated that the receptor binding domain of SARS-CoV-2 was capable of binding ACE2 in the context of the SARS-CoV spike protein [
       <xref ref-type="bibr" rid="B51-viruses-12-00244">
        51
       </xref>
       ]. Among SRAS-CoV spike protein’s fourteen residues predicted to interact directly with human ACE2 as the receptor for SARS-CoV, eight amino acids are well conserved in homology SARS-CoV-2 spike protein [
       <xref ref-type="bibr" rid="B26-viruses-12-00244">
        26
       </xref>
       ,
       <xref ref-type="bibr" rid="B102-viruses-12-00244">
        102
       </xref>
       ]. At the same time, Wan et al. showed that SARS-CoV-2 uses ACE2 receptors to infect humans, bats, civets, monkeys, and swine, but not mice [
       <xref ref-type="bibr" rid="B106-viruses-12-00244">
        106
       </xref>
       ]. Compared to previously reported SARS-CoV strains, SARS-CoV-2 uses ACE2 receptors more efficiently than human SARS-CoV (year 2003), but less efficiently than human SARS-CoV (year 2002) [
       <xref ref-type="bibr" rid="B106-viruses-12-00244">
        106
       </xref>
       ]. The mutation of proteins determines two important characteristics of the SARS-CoV-2: A higher ability to infect and enhanced pathogenicity than the bat-like SARS-CoV, but a lower pathogenicity than SARS-CoV [
       <xref ref-type="bibr" rid="B43-viruses-12-00244">
        43
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec4-viruses-12-00244" sec-type="discussion">
     <title>
      4. Discussion
     </title>
     <p>
      As a large number of people have left Wuhan, the control of the epidemic situation is extremely urgent, and the treatments of COVID-19 are imminent. On Feb. 14th, 2020, there were more than 54,000 confirmed patients in Hubei province, China [
      <xref ref-type="bibr" rid="B55-viruses-12-00244">
       55
      </xref>
      ]. Due to the lack of effective antiviral drugs, the prognosis of patients solely depends on their age and physical condition [
      <xref ref-type="bibr" rid="B74-viruses-12-00244">
       74
      </xref>
      ]. Although it was reported that the clinically recovered patients exceed the number of dead, the majority of the patients are still not cured in hospital. In addition, the potential adaptive mutation of SARS-CoV-2 makes it difficult for vaccine development. Therefore, it is urgent for us to develop more sensitive inspection methods and effective drugs.
     </p>
     <p>
      Seven type of CoVs have been identified to cause human disease [
      <xref ref-type="bibr" rid="B107-viruses-12-00244">
       107
      </xref>
      ]. The two highly pathogenic viruses, SARS-CoV and MERS-CoV, cause severe respiratory syndrome in humans. The other four human CoVs (HCoV-NL63, HCoV-229E, HCoV-OC43 and HKU1) induce only mild upper respiratory diseases, although some of them can cause severe infections in infants, young children, and elderly individuals [
      <xref ref-type="bibr" rid="B4-viruses-12-00244">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="B108-viruses-12-00244">
       108
      </xref>
      ]. The latest one is SARS-CoV-2. It has been reported that SARS-CoV-2 shared almost 80% of the genome with SARS-CoV [
      <xref ref-type="bibr" rid="B11-viruses-12-00244">
       11
      </xref>
      ]. Our results also showed that almost all encoded proteins of SARS-CoV-2 are homologous to SARS-CoV proteins (
      <xref ref-type="table" rid="viruses-12-00244-t002">
       Table 2
      </xref>
      ). Hence, clinical drugs and therapies for treating SARS may be used as a reference for COVID-19 treatment [
      <xref ref-type="bibr" rid="B74-viruses-12-00244">
       74
      </xref>
      ].
     </p>
     <p>
      In addition to the well-known SARS-CoV, MERS-CoV, as one Merbecovirus subgenus of β-CoVs, is also extremely invasive. MERS-CoV is the pathogen of the Middle East Respiratory Syndrome, which can infect both humans and animals, and can be transmitted through camels [
      <xref ref-type="bibr" rid="B109-viruses-12-00244">
       109
      </xref>
      ]. It mainly occurs in Saudi Arabia and has a high mortality rate [
      <xref ref-type="bibr" rid="B66-viruses-12-00244">
       66
      </xref>
      ]. Studies had demonstrated that the clinical course of SARS and MERS was highly similar, and SARS and MERS may have similar pathogenesis [
      <xref ref-type="bibr" rid="B66-viruses-12-00244">
       66
      </xref>
      ]. The genome sequence of SARS-CoV-2 also shows some similarities to that of MERS-CoV. It will be very interesting to study the relationship among SARS-CoV, MERS-CoV, and SARS-CoV-2 that may be exploited for future developing broad-spectrum antiviral therapies.
     </p>
     <p>
      Although more and more studies for SARS-CoV-2 have sprung up since the outbreak of this epidemic COVID-19, based on our comparison, we propose some key questions to be clarified in future studies (
      <xref ref-type="table" rid="viruses-12-00244-t003">
       Table 3
      </xref>
      ). In-depth understanding the underlying pathogenic mechanisms of SARS-CoV-2 will reveal more targets for better therapy of COVID-19.
     </p>
    </sec>
    <back>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       All the genomic data of SARS-CoV-2 is from GISAID, NCBI/GenBank, NMDC, CNGB/CNGBdb and 2019nCoVR (
       <xref ref-type="app" rid="app1-viruses-12-00244">
        Table S1
       </xref>
       ). Here, we would like to express our gratitude to all units and individuals who are responsible for the sample collection and data submission.
      </p>
     </ack>
     <app-group>
      <app id="app1-viruses-12-00244">
       <title>
        Supplementary Materials
       </title>
       <supplementary-material content-type="local-data" id="viruses-12-00244-s001">
        <media xlink:href="viruses-12-00244-s001.zip">
         <caption>
          <p>
           Click here for additional data file.
          </p>
         </caption>
        </media>
       </supplementary-material>
       <p>
        The following are available online at
        <uri xlink:href="https://www.mdpi.com/1999-4915/12/2/244/s1">
         https://www.mdpi.com/1999-4915/12/2/244/s1
        </uri>
        , Figure S1: Phylogeny of SARS-CoV-2, SARS-CoV and MERS-CoV. Unrooted phylogenetic relationships are represented by constructing Neighbor-Joining tree. Table S1: The genomic information of latest SARS-CoV-2 strains
       </p>
      </app>
     </app-group>
     <notes>
      <title>
       Author Contributions
      </title>
      <p>
       Conceptualization, L.X., Y.W. and X.G.; methodology, J.X. and W.Z.; software, S.Z. and W.Z.; validation, J.X., S.Z. and T.T.; formal analysis, J.X. and S.Z.; writing—original draft preparation, J.X. and S.Z.; writing—review and editing, L.X., Y.W., W.Z. and X.G.; visualization, J.X., S.Z., and A.E.A.; funding acquisition, L.X., Y.W. and X.G. All authors have read and agreed to the published version of the manuscript.
      </p>
     </notes>
     <notes>
      <title>
       Funding
      </title>
      <p>
       This work was supported by the 2020 New Coronavirus Prevention and Control Emergency Project (grant no. 201100310300), the Program for Innovative Talents of Science and Technology in Henan Province (grant no. 18HASTIT048).
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Conflicts of Interest
      </title>
      <p>
       The authors declare no conflict of interest.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1-viruses-12-00244">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Field
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Daszak
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Eaton
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Review of bats and SARS
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2006
        </year>
        <volume>
         12
        </volume>
        <fpage>
         1834
        </fpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1212.060401
        </pub-id>
        <pub-id pub-id-type="pmid">
         17326933
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2-viruses-12-00244">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Chmura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Mazet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         503
        </volume>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12711
        </pub-id>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3-viruses-12-00244">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular mechanisms of coronavirus RNA capping and methylation
        </article-title>
        <source>
         Virol. Sin.
        </source>
        <year>
         2016
        </year>
        <volume>
         31
        </volume>
        <fpage>
         3
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s12250-016-3726-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         26847650
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4-viruses-12-00244">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Origin and evolution of pathogenic coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2019
        </year>
        <volume>
         17
        </volume>
        <fpage>
         181
        </fpage>
        <lpage>
         192
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/s41579-018-0118-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         30531947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5-viruses-12-00244">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Riley
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ferguson
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission scenarios for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and how to tell them apart
        </article-title>
        <source>
         Euro Surveill.
        </source>
        <year>
         2013
        </year>
        <volume>
         18
        </volume>
        <fpage>
         18
        </fpage>
       </element-citation>
      </ref>
      <ref id="B6-viruses-12-00244">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gulyaeva
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lauber
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Leontovich
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Neuman
          </surname>
          <given-names>
           B.W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome-related coronavirus: The species and its viruses—A statement of the Coronavirus Study Group
        </article-title>
        <source>
         bioRxiv
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1101/2020.02.07.937862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7-viruses-12-00244">
       <label>
        7.
       </label>
       <element-citation publication-type="web">
        <article-title>
         WHO Named the New Pneumonia “COVID-19”
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.xinhuanet.com/world/2020-02/12/c_1125561389.htm">
          http://www.xinhuanet.com/world/2020-02/12/c_1125561389.htm
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-12">
         (accessed on 12 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B8-viruses-12-00244">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           Z.X.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Butt
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
        </article-title>
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        <volume>
         302
        </volume>
        <fpage>
         276
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1087139
        </pub-id>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9-viruses-12-00244">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ki
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         2015 MERS outbreak in Korea: Hospital-to-hospital transmission
        </article-title>
        <source>
         Epidemiol. Health
        </source>
        <year>
         2015
        </year>
        <volume>
         37
        </volume>
        <fpage>
         37
        </fpage>
        <pub-id pub-id-type="doi">
         10.4178/epih/e2015033
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B10-viruses-12-00244">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           E.I.
          </given-names>
         </name>
         <name>
          <surname>
           El-Kafrawy
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Farraj
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Saeed
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         370
        </volume>
        <fpage>
         2499
        </fpage>
        <lpage>
         2505
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1401505
        </pub-id>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11-viruses-12-00244">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
        </article-title>
        <source>
         Emerg. Microbes. Infect.
        </source>
        <year>
         2020
        </year>
        <volume>
         9
        </volume>
        <fpage>
         221
        </fpage>
        <lpage>
         236
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/22221751.2020.1719902
        </pub-id>
        <pub-id pub-id-type="pmid">
         31987001
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B12-viruses-12-00244">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           W.M.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The 2019 Novel Coronavirus Resource
        </article-title>
        <source>
         Hereditas
        </source>
        <year>
         2020
        </year>
        <volume>
         36
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         9
        </lpage>
       </element-citation>
      </ref>
      <ref id="B13-viruses-12-00244">
       <label>
        13.
       </label>
       <element-citation publication-type="gov">
        <article-title>
         NCBI Database. 2019-nCoV
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/?term=2019-nCoV">
          https://www.ncbi.nlm.nih.gov/pubmed/?term=2019-nCoV
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-14">
         (accessed on 14 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B14-viruses-12-00244">
       <label>
        14.
       </label>
       <element-citation publication-type="web">
        <article-title>
         GSAID Database. 2020 Coronavirus
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://www.gisaid.org/CoV2020/">
          https://www.gisaid.org/CoV2020/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-14">
         (accessed on 14 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B15-viruses-12-00244">
       <label>
        15.
       </label>
       <element-citation publication-type="gov">
        <article-title>
         NCBI Blast
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://blast.ncbi.nlm.nih.gov/Blast.cgi">
          https://blast.ncbi.nlm.nih.gov/Blast.cgi
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-30">
         (accessed on 30 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B16-viruses-12-00244">
       <label>
        16.
       </label>
       <element-citation publication-type="web">
        <article-title>
         Zpicture
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://zpicture.dcode.org">
          https://zpicture.dcode.org
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-01">
         (accessed on 1 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B17-viruses-12-00244">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Tamura
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MEGA7: Molecular evolutionary genetics analysis version 7.0 for bigger datasets
        </article-title>
        <source>
         Mol. Biol. Evol.
        </source>
        <year>
         2016
        </year>
        <volume>
         33
        </volume>
        <fpage>
         1870
        </fpage>
        <lpage>
         1874
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/molbev/msw054
        </pub-id>
        <pub-id pub-id-type="pmid">
         27004904
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18-viruses-12-00244">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tamura
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Nei
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prospects for inferring very large phylogenies by using the neighbor-joining method
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         11030
        </fpage>
        <lpage>
         11035
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0404206101
        </pub-id>
        <pub-id pub-id-type="pmid">
         15258291
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19-viruses-12-00244">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
        </article-title>
        <source>
         Clin. Microbiol. Rev.
        </source>
        <year>
         2007
        </year>
        <volume>
         20
        </volume>
        <fpage>
         660
        </fpage>
        <lpage>
         694
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CMR.00023-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         17934078
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20-viruses-12-00244">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          World Health Organization
         </collab>
        </person-group>
        <article-title>
         Weekly Epidemiological Record, 2013, vol. 88, 35 [full issue]
        </article-title>
        <source>
         Wkly. Epidemiol. Rec.
        </source>
        <year>
         2013
        </year>
        <volume>
         88
        </volume>
        <fpage>
         365
        </fpage>
        <lpage>
         380
        </lpage>
        <pub-id pub-id-type="pmid">
         24040691
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21-viruses-12-00244">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Cameron
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Joynt
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Ahuja
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Yung
          </surname>
          <given-names>
           M.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A major outbreak of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1986
        </fpage>
        <lpage>
         1994
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030685
        </pub-id>
        <pub-id pub-id-type="pmid">
         12682352
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22-viruses-12-00244">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poutanen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           N.E.
          </given-names>
         </name>
         <name>
          <surname>
           Henry
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Finkelstein
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Tellier
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Draker
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Adachi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ayers
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of severe acute respiratory syndrome in Canada
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1995
        </fpage>
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030634
        </pub-id>
        <pub-id pub-id-type="pmid">
         12671061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23-viruses-12-00244">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leo
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Heng
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome-Singapore, 2003
        </article-title>
        <source>
         MMWR Morb. Mortal. Wkly. Rep.
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <fpage>
         405
        </fpage>
        <pub-id pub-id-type="pmid">
         12807088
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24-viruses-12-00244">
       <label>
        24.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          World Health Organization
         </collab>
        </person-group>
        <article-title>
         Summary of Probable SARS Cases with Onset of Illness from 1 November 2002 to 31 July 2003
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/country/table2004_04_21/en/index.html.">
          http://www.who.int/csr/sars/country/table2004_04_21/en/index.html.
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-27">
         (accessed on 27 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B25-viruses-12-00244">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nuttall
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Dye
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS wake-up call
        </article-title>
        <source>
         Science
        </source>
        <year>
         2013
        </year>
        <volume>
         339
        </volume>
        <fpage>
         1287
        </fpage>
        <lpage>
         1288
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1236434
        </pub-id>
        <pub-id pub-id-type="pmid">
         23493705
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26-viruses-12-00244">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Travel implications of emerging coronaviruses: SARS and MERS-CoV
        </article-title>
        <source>
         Travel. Med. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         12
        </volume>
        <fpage>
         422
        </fpage>
        <lpage>
         428
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tmaid.2014.06.007
        </pub-id>
        <pub-id pub-id-type="pmid">
         25047726
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B27-viruses-12-00244">
       <label>
        27.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Chinese Center for Disease Control and Prevention
         </collab>
        </person-group>
        <article-title>
         Epidemic Update and Risk Assessment of 2019 Novel Coronavirus
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.chinacdc.cn/yyrdgz/202001/P020200128523354919292.pdf">
          http://www.chinacdc.cn/yyrdgz/202001/P020200128523354919292.pdf
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B28-viruses-12-00244">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Return of the Coronavirus: 2019-nCoV
        </article-title>
        <source>
         Viruses
        </source>
        <year>
         2020
        </year>
        <volume>
         12
        </volume>
        <elocation-id>
         135
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/v12020135
        </pub-id>
        <pub-id pub-id-type="pmid">
         31991541
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29-viruses-12-00244">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Sheng
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         818
        </fpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1005.030640
        </pub-id>
        <pub-id pub-id-type="pmid">
         15200814
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30-viruses-12-00244">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome: Emergence of a pathogenic human coronavirus
        </article-title>
        <source>
         Annu. Rev. Med.
        </source>
        <year>
         2017
        </year>
        <volume>
         68
        </volume>
        <fpage>
         387
        </fpage>
        <lpage>
         399
        </lpage>
        <pub-id pub-id-type="doi">
         10.1146/annurev-med-051215-031152
        </pub-id>
        <pub-id pub-id-type="pmid">
         27576010
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31-viruses-12-00244">
       <label>
        31.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          National Health Commission of the People’s Republic of China
         </collab>
        </person-group>
        <article-title>
         Diagnosis and Treatment of Pneumonia Caused by 2019-nCoV (Trial Version 4)
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/jkj/s3577/202002/573340613ab243b3a7f61df260551dd4/files/c791e5a7ea5149f680fdcb34dac0f54e.pdf">
          http://www.nhc.gov.cn/jkj/s3577/202002/573340613ab243b3a7f61df260551dd4/files/c791e5a7ea5149f680fdcb34dac0f54e.pdf
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-06">
         (accessed on 6 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B32-viruses-12-00244">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pulmonary rehabilitation guidelines in the principle of 4S for patients infected with 2019 novel coronavirus (2019-nCoV)
        </article-title>
        <source>
         Zhonghua Jie He He Hu Xi Za Zhi
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <fpage>
         E004
        </fpage>
        <pub-id pub-id-type="pmid">
         32023687
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33-viruses-12-00244">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lessler
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Reich
          </surname>
          <given-names>
           N.G.
          </given-names>
         </name>
         <name>
          <surname>
           Brookmeyer
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
         <name>
          <surname>
           Cummings
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incubation periods of acute respiratory viral infections: A systematic review
        </article-title>
        <source>
         Lancet. Infect. Dis.
        </source>
        <year>
         2009
        </year>
        <volume>
         9
        </volume>
        <fpage>
         291
        </fpage>
        <lpage>
         300
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(09)70069-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         19393959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34-viruses-12-00244">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meltzer
          </surname>
          <given-names>
           M.I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multiple contact dates and SARS incubation periods
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         207
        </fpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1002.030426
        </pub-id>
        <pub-id pub-id-type="pmid">
         15030684
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35-viruses-12-00244">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
        <volume>
         382
        </volume>
        <fpage>
         727
        </fpage>
        <lpage>
         733
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001017
        </pub-id>
        <pub-id pub-id-type="pmid">
         31978945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36-viruses-12-00244">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jalali
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Dean
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Longini
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Halloran
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China
        </article-title>
        <source>
         medRxiv
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1101/2020.02.10.20021675
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B37-viruses-12-00244">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan-Yeung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: Epidemiology
        </article-title>
        <source>
         Respirology
        </source>
        <year>
         2003
        </year>
        <volume>
         8
        </volume>
        <fpage>
         S9
        </fpage>
        <lpage>
         S14
        </lpage>
        <pub-id pub-id-type="doi">
         10.1046/j.1440-1843.2003.00518.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         15018127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B38-viruses-12-00244">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Horby
          </surname>
          <given-names>
           P.W.
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           F.G.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus outbreak of global health concern
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         470
        </fpage>
        <lpage>
         473
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30185-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         31986257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B39-viruses-12-00244">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Stöhr
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         349
        </volume>
        <fpage>
         2431
        </fpage>
        <lpage>
         2441
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMra032498
        </pub-id>
        <pub-id pub-id-type="pmid">
         14681510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B40-viruses-12-00244">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hedley
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           L.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Chau
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           I.O.
          </given-names>
         </name>
         <name>
          <surname>
           Thach
          </surname>
          <given-names>
           T.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Ghani
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Riley
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: An analysis of all 1755 patients
        </article-title>
        <source>
         Ann. Intern. Med.
        </source>
        <year>
         2004
        </year>
        <volume>
         141
        </volume>
        <fpage>
         662
        </fpage>
        <lpage>
         673
        </lpage>
        <pub-id pub-id-type="doi">
         10.7326/0003-4819-141-9-200411020-00006
        </pub-id>
        <pub-id pub-id-type="pmid">
         15520422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B41-viruses-12-00244">
       <label>
        41.
       </label>
       <element-citation publication-type="web">
        <article-title>
         Infectious Disease Expert Li Lanjuan Responded to Six Questions of 2019-nCoV
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://m.news.cctv.com/2020/01/23/ARTIEw78LIxqpgx6Ilm7NkBo200123.shtml">
          http://m.news.cctv.com/2020/01/23/ARTIEw78LIxqpgx6Ilm7NkBo200123.shtml
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-23">
         (accessed on 23 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B42-viruses-12-00244">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           E.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001316
        </pub-id>
        <pub-id pub-id-type="pmid">
         31995857
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B43-viruses-12-00244">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30183-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B44-viruses-12-00244">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B45-viruses-12-00244">
       <label>
        45.
       </label>
       <element-citation publication-type="gov">
        <article-title>
         Press Conference of the National Health Commission of the People’s Republic of China on 3 February 2020
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/wjw/xwfbh/xwzb.shtml">
          http://www.nhc.gov.cn/wjw/xwfbh/xwzb.shtml
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-04">
         (accessed on 4 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B46-viruses-12-00244">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hon
          </surname>
          <given-names>
           C.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           T.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           F.C.-C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Intraspecies diversity of SARS-like coronaviruses in
         <italic>
          Rhinolophus sinicus
         </italic>
         and its implications for the origin of SARS coronaviruses in humans
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2010
        </year>
        <volume>
         91
        </volume>
        <fpage>
         1058
        </fpage>
        <lpage>
         1062
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.016378-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         20016037
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B47-viruses-12-00244">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Phan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel coronavirus: From discovery to clinical diagnostics
        </article-title>
        <source>
         Infect. Genet. Evol.
        </source>
        <year>
         2020
        </year>
        <volume>
         79
        </volume>
        <fpage>
         104211
        </fpage>
        <pub-id pub-id-type="doi">
         10.1016/j.meegid.2020.104211
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B48-viruses-12-00244">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Kan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS-CoV infection in a restaurant from palm civet
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         1860
        </fpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1112.041293
        </pub-id>
        <pub-id pub-id-type="pmid">
         16485471
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B49-viruses-12-00244">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.-G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Si
          </surname>
          <given-names>
           H.-R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.-L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin
        </article-title>
        <source>
         bioRxiv
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1101/2020.01.22.914952
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B50-viruses-12-00244">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host and infectivity prediction of Wuhan 2019 novel coronavirus using deep learning algorithm
        </article-title>
        <source>
         bioRxiv
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1101/2020.01.21.914044
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B51-viruses-12-00244">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ji
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2020
        </year>
        <volume>
         92
        </volume>
        <fpage>
         433
        </fpage>
        <lpage>
         440
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25682
        </pub-id>
        <pub-id pub-id-type="pmid">
         31967321
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B52-viruses-12-00244">
       <label>
        52.
       </label>
       <element-citation publication-type="web">
        <article-title>
         South China Agricultural University: Pangolin May Be a Potential Intermediate Host of New Coronavirus
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.chinanews.com/sh/2020/02-07/9082279.shtml">
          http://www.chinanews.com/sh/2020/02-07/9082279.shtml
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-07">
         (accessed on 7 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B53-viruses-12-00244">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chowell
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Castillo-Chavez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fenimore
          </surname>
          <given-names>
           P.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kribs-Zaleta
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Arriola
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Hyman
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Model parameters and outbreak control for SARS
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         1258
        </fpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1007.030647
        </pub-id>
        <pub-id pub-id-type="pmid">
         15324546
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B54-viruses-12-00244">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           E.H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hsiung
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           L.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           C.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A comparative epidemiologic analysis of SARS in Hong Kong, Beijing and Taiwan
        </article-title>
        <source>
         BMC Infect. Dis.
        </source>
        <year>
         2010
        </year>
        <volume>
         10
        </volume>
        <elocation-id>
         50
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1186/1471-2334-10-50
        </pub-id>
        <pub-id pub-id-type="pmid">
         20205928
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B55-viruses-12-00244">
       <label>
        55.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Chinese Center for Disease Control and Prevention
         </collab>
        </person-group>
        <article-title>
         Distribution of Pneumonia Infected by 2019-nCoV
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://2019ncov.chinacdc.cn/2019-nCoV/">
          http://2019ncov.chinacdc.cn/2019-nCoV/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-15">
         (accessed on 15 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B56-viruses-12-00244">
       <label>
        56.
       </label>
       <element-citation publication-type="web">
        <article-title>
         Real-time Updates of COVID-19 Epidemic in China
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="https://ncov.dxy.cn/ncovh5/view/pneumonia">
          https://ncov.dxy.cn/ncovh5/view/pneumonia
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-15">
         (accessed on 15 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B57-viruses-12-00244">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           S.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Linton
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Kinoshita
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hayashi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kobayashi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Akhmetzhanov
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The extent of transmission of novel coronavirus in Wuhan, China, 2020
        </article-title>
        <source>
         J. Clin. Med.
        </source>
        <year>
         2020
        </year>
        <volume>
         9
        </volume>
        <elocation-id>
         330
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/jcm9020330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B58-viruses-12-00244">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potential of large ‘first generation’ human-to-human transmission of 2019-nCoV
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2020
        </year>
        <volume>
         92
        </volume>
        <fpage>
         448
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25693
        </pub-id>
        <pub-id pub-id-type="pmid">
         31997390
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B59-viruses-12-00244">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carlos
          </surname>
          <given-names>
           W.G.
          </given-names>
         </name>
         <name>
          <surname>
           Dela Cruz
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Pasnick
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Jamil
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Novel Wuhan (2019-nCoV) Coronavirus
        </article-title>
        <source>
         Am. J. Respir. Crit. Care Med.
        </source>
        <year>
         2020
        </year>
        <volume>
         201
        </volume>
        <fpage>
         7
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="doi">
         10.1164/rccm.2014P7
        </pub-id>
        <pub-id pub-id-type="pmid">
         31658423
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B60-viruses-12-00244">
       <label>
        60.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          National Health Commission of the People’s Republic of China
         </collab>
        </person-group>
        <article-title>
         The Role of Fecal-Oral Transmission in All transmission Still Need Further Observation and Research
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://news.cctv.com/2020/02/13/ARTISJWExxLSLWoL8mtJos97200213.shtml">
          http://news.cctv.com/2020/02/13/ARTISJWExxLSLWoL8mtJos97200213.shtml
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-13">
         (accessed on 13 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B61-viruses-12-00244">
       <label>
        61.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Chinese Center for Disease Control and Prevention
         </collab>
        </person-group>
        <article-title>
         There Is No Evidence That the New Coronavirus Can Be Transmitted through Aerosol
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://news.cctv.com/2020/02/09/ARTIiVFnLC1ww5sTSMqbcXlz200209.shtml">
          http://news.cctv.com/2020/02/09/ARTIiVFnLC1ww5sTSMqbcXlz200209.shtml
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-09">
         (accessed on 9 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B62-viruses-12-00244">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Tsui
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS transmission, risk factors, and prevention in Hong Kong
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         587
        </fpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1004.030628
        </pub-id>
        <pub-id pub-id-type="pmid">
         15200846
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B63-viruses-12-00244">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Stratton
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreak of Pneumonia of Unknown Etiology in Wuhan China: The Mystery and the Miracle
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2020
        </year>
        <volume>
         92
        </volume>
        <fpage>
         401
        </fpage>
        <lpage>
         402
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25678
        </pub-id>
        <pub-id pub-id-type="pmid">
         31950516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B64-viruses-12-00244">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rouquet
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Froment
          </surname>
          <given-names>
           J.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Bermejo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kilbourn
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Karesh
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Reed
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kumulungui
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Yaba
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Delicat
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001–2003
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         283
        </fpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1102.040533
        </pub-id>
        <pub-id pub-id-type="pmid">
         15752448
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B65-viruses-12-00244">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yoo
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Fight against the 2019-nCoV Outbreak: An Arduous March Has Just Begun
        </article-title>
        <source>
         J. Korean Med. Sci.
        </source>
        <year>
         2020
        </year>
        <volume>
         35
        </volume>
        <fpage>
         e56
        </fpage>
        <pub-id pub-id-type="doi">
         10.3346/jkms.2020.35.e56
        </pub-id>
        <pub-id pub-id-type="pmid">
         31997618
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B66-viruses-12-00244">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS and MERS: Recent insights into emerging coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2016
        </year>
        <volume>
         14
        </volume>
        <fpage>
         523
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro.2016.81
        </pub-id>
        <pub-id pub-id-type="pmid">
         27344959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B67-viruses-12-00244">
       <label>
        67.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Chinese Center for Disease Control and Prevention
         </collab>
        </person-group>
        <article-title>
         The First New Coronavirus Species Information Was Published by the National Pathogen Microorganism Resource Bank
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.chinacdc.cn/yw_9324/202001/t20200124_211413.html">
          http://www.chinacdc.cn/yw_9324/202001/t20200124_211413.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-01">
         (accessed on 1 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B68-viruses-12-00244">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Khan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The utility of preemptive mass influenza vaccination in controlling a SARS outbreak during flu season
        </article-title>
        <source>
         Math. Biosci. Eng.
        </source>
        <year>
         2007
        </year>
        <volume>
         4
        </volume>
        <fpage>
         739
        </fpage>
        <pub-id pub-id-type="pmid">
         17924722
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B69-viruses-12-00244">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Characterization of a New Member of Alphacoronavirus with Unique Genomic Features in Rhinolophus Bats
        </article-title>
        <source>
         Viruses
        </source>
        <year>
         2019
        </year>
        <volume>
         11
        </volume>
        <elocation-id>
         379
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.3390/v11040379
        </pub-id>
        <pub-id pub-id-type="pmid">
         31022925
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B70-viruses-12-00244">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bhadra
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ellington
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2015
        </year>
        <volume>
         10
        </volume>
        <elocation-id>
         e0123126
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0123126
        </pub-id>
        <pub-id pub-id-type="pmid">
         25856093
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B71-viruses-12-00244">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           G.K.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Tee
          </surname>
          <given-names>
           K.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           H.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           C.C.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development and evaluation of novel real-time reverse transcription-PCR assays with locked nucleic acid probes targeting leader sequences of human-pathogenic coronaviruses
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <year>
         2015
        </year>
        <volume>
         53
        </volume>
        <fpage>
         2722
        </fpage>
        <lpage>
         2726
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JCM.01224-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         26019210
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B72-viruses-12-00244">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           E.H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020
        </article-title>
        <source>
         Euro. Surveill.
        </source>
        <year>
         2020
        </year>
        <volume>
         25
        </volume>
        <fpage>
         2000044
        </fpage>
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES.2020.25.3.2000044
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B73-viruses-12-00244">
       <label>
        73.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          National Medical Products Administration
         </collab>
        </person-group>
        <article-title>
         National Medical Products Administration Examined and Approved the New Nucleic Acid Test Reagent of Coronavirus Again
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.nmpa.gov.cn/WS04/CL2056/374398.html">
          http://www.nmpa.gov.cn/WS04/CL2056/374398.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-28">
         (accessed on 28 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B74-viruses-12-00244">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging coronaviruses: Genome structure, replication, and pathogenesis
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2020
        </year>
        <volume>
         92
        </volume>
        <fpage>
         418
        </fpage>
        <lpage>
         423
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25681
        </pub-id>
        <pub-id pub-id-type="pmid">
         31967327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B75-viruses-12-00244">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Bauer
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chandra
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rabenau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Doerr
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of SARS with human interferons
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         362
        </volume>
        <fpage>
         293
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13973-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         12892961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B76-viruses-12-00244">
       <label>
        76.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           I.F.N.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           M.M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           C.L.P.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings
        </article-title>
        <source>
         Thorax
        </source>
        <year>
         2004
        </year>
        <volume>
         59
        </volume>
        <fpage>
         252
        </fpage>
        <lpage>
         256
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/thorax.2003.012658
        </pub-id>
        <pub-id pub-id-type="pmid">
         14985565
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B77-viruses-12-00244">
       <label>
        77.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug treatment options for the 2019-new coronavirus (2019-nCoV)
        </article-title>
        <source>
         Biosci. Trends
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.5582/bst.2020.01020
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B78-viruses-12-00244">
       <label>
        78.
       </label>
       <element-citation publication-type="gov">
        <person-group person-group-type="author">
         <collab>
          Beijing Municipal Health Commission
         </collab>
        </person-group>
        <article-title>
         Explanation on the Situation that Drugs for AIDS Can Be Tried to Treat Pneumonia Caused by 2019-nCoV Infection
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://wjw.beijing.gov.cn/wjwh/ztzl/xxgzbd/202001/t20200126_1621354.html">
          http://wjw.beijing.gov.cn/wjwh/ztzl/xxgzbd/202001/t20200126_1621354.html
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-26">
         (accessed on 26 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B79-viruses-12-00244">
       <label>
        79.
       </label>
       <element-citation publication-type="web">
        <article-title>
         The Joint Research Team of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and ShanghaiTech University Discovered a Batch of Old Drugs and Traditional Chinese Medicines with Therapeutic Potential for COVID-19
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.shanghaitech.edu.cn/2020/0125/c1001a50141/page.htm">
          http://www.shanghaitech.edu.cn/2020/0125/c1001a50141/page.htm
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-25">
         (accessed on 25 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B80-viruses-12-00244">
       <label>
        80.
       </label>
       <element-citation publication-type="web">
        <article-title>
         High-Resolution Crystal Structure of 2019-nCoV Coronavirus 3CL Hydrolase (Mpro) was Announced by the Joint Research Team of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and ShanghaiTech University
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.shanghaitech.edu.cn/2020/0126/c1001a50145/page.htm">
          http://www.shanghaitech.edu.cn/2020/0126/c1001a50145/page.htm
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-01-26">
         (accessed on 26 January 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B81-viruses-12-00244">
       <label>
        81.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Mu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nelfinavir was predicted to be a potential inhibitor of 2019 nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation
        </article-title>
        <source>
         bioRxiv
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1101/2020.01.27.921627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B82-viruses-12-00244">
       <label>
        82.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Leist
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Schäfer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Won
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Montgomery
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hogg
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Babusis
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Clarke
          </surname>
          <given-names>
           M.O.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <year>
         2020
        </year>
        <volume>
         11
        </volume>
        <fpage>
         222
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41467-019-13940-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         31924756
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B83-viruses-12-00244">
       <label>
        83.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mulangu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Dodd
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Davey
          </surname>
          <given-names>
           R.T.
          </given-names>
         </name>
         <name>
          <surname>
           Mbaya
          </surname>
          <given-names>
           O.T.
          </given-names>
         </name>
         <name>
          <surname>
           Proschan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Mukadi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Manzo
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Nzolo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Oloma
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Ibanda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A randomized, controlled trial of Ebola virus disease therapeutics
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2019
        </year>
        <volume>
         381
        </volume>
        <fpage>
         2293
        </fpage>
        <lpage>
         2303
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1910993
        </pub-id>
        <pub-id pub-id-type="pmid">
         31774950
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B84-viruses-12-00244">
       <label>
        84.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holshue
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           DeBolt
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lindquist
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lofy
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wiesman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bruce
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Spitters
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ericson
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wilkerson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tural
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         First Case of 2019 Novel Coronavirus in the United States
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001191
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B85-viruses-12-00244">
       <label>
        85.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           M.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           X.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Research progress on novel coronavirus (2019-nCoV) related drugs in vitro/vivo
        </article-title>
        <source>
         Bing Du Xue Bao
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.13242/j.cnki.bingduxuebao.003646
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B86-viruses-12-00244">
       <label>
        86.
       </label>
       <element-citation publication-type="web">
        <article-title>
         China-Japan Friendship Hospital: Clinical Experimental Research Work Is Being Carried Out on Remdesivir
        </article-title>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.chinanews.com/sh/shipin/cns-d/2020/02-12/news847712.shtml">
          http://www.chinanews.com/sh/shipin/cns-d/2020/02-12/news847712.shtml
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2020-02-12">
         (accessed on 12 February 2020)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B87-viruses-12-00244">
       <label>
        87.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recombination in large RNA viruses: Coronaviruses
        </article-title>
        <source>
         Semin. Virol.
        </source>
        <year>
         1996
        </year>
        <volume>
         7
        </volume>
        <fpage>
         381
        </fpage>
        <lpage>
         388
        </lpage>
        <pub-id pub-id-type="doi">
         10.1006/smvy.1996.0046
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B88-viruses-12-00244">
       <label>
        88.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           J.H.N.
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Teng
          </surname>
          <given-names>
           J.L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           C.C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <fpage>
         3995
        </fpage>
        <lpage>
         4008
        </lpage>
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B89-viruses-12-00244">
       <label>
        89.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         565
        </fpage>
        <lpage>
         574
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30251-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007145
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B90-viruses-12-00244">
       <label>
        90.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Nabar
          </surname>
          <given-names>
           N.R.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           N.N.
          </given-names>
         </name>
         <name>
          <surname>
           Kehrl
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes
        </article-title>
        <source>
         Cell Death Discov.
        </source>
        <year>
         2019
        </year>
        <volume>
         5
        </volume>
        <fpage>
         101
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41420-019-0181-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         31231549
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B91-viruses-12-00244">
       <label>
        91.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Jumping species—A mechanism for coronavirus persistence and survival
        </article-title>
        <source>
         Curr. Opin. Virol.
        </source>
        <year>
         2017
        </year>
        <volume>
         23
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.coviro.2017.01.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         28214731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B92-viruses-12-00244">
       <label>
        92.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           H.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           C.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chmura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Serological evidence of bat SARS-related coronavirus infection in humans, China
        </article-title>
        <source>
         Virol. Sin.
        </source>
        <year>
         2018
        </year>
        <volume>
         33
        </volume>
        <fpage>
         104
        </fpage>
        <lpage>
         107
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s12250-018-0012-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         29500691
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B93-viruses-12-00244">
       <label>
        93.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Algaissi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C.-T.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           I.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
        </article-title>
        <source>
         Sci. Adv.
        </source>
        <year>
         2019
        </year>
        <volume>
         5
        </volume>
        <fpage>
         eaav4580
        </fpage>
        <pub-id pub-id-type="doi">
         10.1126/sciadv.aav4580
        </pub-id>
        <pub-id pub-id-type="pmid">
         30989115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B94-viruses-12-00244">
       <label>
        94.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           DONG
          </surname>
          <given-names>
           X.P.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: Clinical virology and pathogenesis
        </article-title>
        <source>
         Respirology
        </source>
        <year>
         2003
        </year>
        <volume>
         8
        </volume>
        <fpage>
         S6
        </fpage>
        <lpage>
         S8
        </lpage>
        <pub-id pub-id-type="doi">
         10.1046/j.1440-1843.2003.00517.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         15018126
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B95-viruses-12-00244">
       <label>
        95.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: Relation to the acute lung injury and pathogenesis of SARS
        </article-title>
        <source>
         J. Pathol.
        </source>
        <year>
         2006
        </year>
        <volume>
         210
        </volume>
        <fpage>
         288
        </fpage>
        <lpage>
         297
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/path.2067
        </pub-id>
        <pub-id pub-id-type="pmid">
         17031779
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B96-viruses-12-00244">
       <label>
        96.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamming
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Timens
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bulthuis
          </surname>
          <given-names>
           M.L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lely
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Navis
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           van Goor
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
        </article-title>
        <source>
         J. Pathol.
        </source>
        <year>
         2004
        </year>
        <volume>
         203
        </volume>
        <fpage>
         631
        </fpage>
        <lpage>
         637
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/path.1570
        </pub-id>
        <pub-id pub-id-type="pmid">
         15141377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B97-viruses-12-00244">
       <label>
        97.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses post-SARS: Update on replication and pathogenesis
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2009
        </year>
        <volume>
         7
        </volume>
        <fpage>
         439
        </fpage>
        <lpage>
         450
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro2147
        </pub-id>
        <pub-id pub-id-type="pmid">
         19430490
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B98-viruses-12-00244">
       <label>
        98.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Weng
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The clinical pathology of severe acute respiratory syndrome (SARS): A report from China
        </article-title>
        <source>
         J. Pathol.
        </source>
        <year>
         2003
        </year>
        <volume>
         200
        </volume>
        <fpage>
         282
        </fpage>
        <lpage>
         289
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/path.1440
        </pub-id>
        <pub-id pub-id-type="pmid">
         12845623
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B99-viruses-12-00244">
       <label>
        99.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           X.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           J.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications for pathogenesis and virus transmission pathways
        </article-title>
        <source>
         J. Pathol.
        </source>
        <year>
         2004
        </year>
        <volume>
         203
        </volume>
        <fpage>
         622
        </fpage>
        <lpage>
         630
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/path.1560
        </pub-id>
        <pub-id pub-id-type="pmid">
         15141376
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B100-viruses-12-00244">
       <label>
        100.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           HUI
          </surname>
          <given-names>
           D.S.C.
          </given-names>
         </name>
         <name>
          <surname>
           WONG
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: Clinical features and diagnosis
        </article-title>
        <source>
         Respirology
        </source>
        <year>
         2003
        </year>
        <volume>
         8
        </volume>
        <fpage>
         S20
        </fpage>
        <lpage>
         S24
        </lpage>
        <pub-id pub-id-type="doi">
         10.1046/j.1440-1843.2003.00520.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         15018129
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B101-viruses-12-00244">
       <label>
        101.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Millet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
        </article-title>
        <source>
         Virus. Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         202
        </volume>
        <fpage>
         120
        </fpage>
        <lpage>
         134
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2014.11.021
        </pub-id>
        <pub-id pub-id-type="pmid">
         25445340
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B102-viruses-12-00244">
       <label>
        102.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.-G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Si
          </surname>
          <given-names>
           H.-R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.-L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1038/s41586-020-2012-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32015507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B103-viruses-12-00244">
       <label>
        103.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1267
        </pub-id>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B104-viruses-12-00244">
       <label>
        104.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wada
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Leong-Poi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 protects from severe acute lung failure
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2005
        </year>
        <volume>
         436
        </volume>
        <fpage>
         112
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature03712
        </pub-id>
        <pub-id pub-id-type="pmid">
         16001071
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B105-viruses-12-00244">
       <label>
        105.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         426
        </volume>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature02145
        </pub-id>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B106-viruses-12-00244">
       <label>
        106.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00127-20
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B107-viruses-12-00244">
       <label>
        107.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bassetti
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Vena
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Roberto Giacobbe
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Novel Chinese Coronavirus (2019-nCoV) Infections: Challenges for fighting the storm
        </article-title>
        <source>
         Eur. J. Clin. Investig.
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1111/eci.13209
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B108-viruses-12-00244">
       <label>
        108.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bi
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology, genetic recombination, and pathogenesis of coronaviruses
        </article-title>
        <source>
         Trends. Microbiol.
        </source>
        <year>
         2016
        </year>
        <volume>
         24
        </volume>
        <fpage>
         490
        </fpage>
        <lpage>
         502
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tim.2016.03.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         27012512
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B109-viruses-12-00244">
       <label>
        109.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.W.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gomaa
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shehata
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Perera
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Abu Zeid
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           El Rifay
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           L.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Webby
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS coronaviruses in dromedary camels, Egypt
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1049
        </fpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2006.140299
        </pub-id>
        <pub-id pub-id-type="pmid">
         24856660
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="viruses-12-00244-f001" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Timeline of SARS (
        <bold>
         a
        </bold>
        ) and COVID-19 (
        <bold>
         b
        </bold>
        ) epidemic development.
       </p>
      </caption>
      <graphic xlink:href="viruses-12-00244-g001">
      </graphic>
     </fig>
     <fig id="viruses-12-00244-f002" orientation="portrait" position="float">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        (
        <bold>
         a
        </bold>
        ) Comparison of the number of SARS and COVID-19 patients in China (including Hong Kong, Macao and Taiwan) and other countries; (
        <bold>
         b
        </bold>
        ) the number of SARS patients in different provinces of China; (
        <bold>
         c
        </bold>
        ) an increased number of COVID-19 patients over time was showed in a histogram. On Feb. 11th, Hubei Province had added a “clinical diagnosis case” classification, and identified suspected cases with pneumonia imaging features as clinical diagnosis cases so that patients can receive standardized treatment as soon as possible. (
        <bold>
         d
        </bold>
        ) The number of COVID-19 patients in different provinces of China. The time period shown in the picture was in the Spring Festival transportation.
       </p>
      </caption>
      <graphic xlink:href="viruses-12-00244-g002">
      </graphic>
     </fig>
     <fig id="viruses-12-00244-f003" orientation="portrait" position="float">
      <label>
       Figure 3
      </label>
      <caption>
       <p>
        The distribution of COVID-2019 patients in China (
        <bold>
         a
        </bold>
        ) and Hubei Province (
        <bold>
         b
        </bold>
        ). XJ, Xinjiang; XZ, Xizang; GS, Gansu; QH, Qinghai; SC, Sichuan; YN, Yunnan; IM, Inner Mongolia; NX, Ningxia; SN, Shaanxi; CQ, Chongqing; GZ, Guizhou; GX, Guangxi; HI, Hainan; SX, Shanxi, HA, Henan; HB, Hubei; HN, Hunan; GD, Guangdong; HK, Hong Kong; HE, Hebei; BJ, Beijing; TJ, Tianjin; SD, Shandong; AH, Anhui; JX, Jiangxi; JS, Jiangsu; SH, Shanghai; ZJ, Zhejiang; FJ, Fujian; TW, Taiwan; HL, Heilongjiang; JL, Jilin; LN, Liaoning.
       </p>
      </caption>
      <graphic xlink:href="viruses-12-00244-g003">
      </graphic>
     </fig>
     <fig id="viruses-12-00244-f004" orientation="portrait" position="float">
      <label>
       Figure 4
      </label>
      <caption>
       <p>
        (
        <bold>
         a
        </bold>
        ) Genomic sequence alignment between SARS-CoV-2 and SARS-CoV; (
        <bold>
         b
        </bold>
        ) Dot plot matrix calculated for the complete genomes of SARS-CoV-2 and SARS-CoV.
       </p>
      </caption>
      <graphic xlink:href="viruses-12-00244-g004">
      </graphic>
     </fig>
     <table-wrap id="viruses-12-00244-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-12-00244-t001_Table 1
      </object-id>
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Comparison of SARS and COVID-19.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Items
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          SARS
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          COVID-19
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          First occurrence
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Nov. 16th, 2002 in Foshan, Guangdong
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Dec. 07th, 2019 in Wuhan,
          <break>
          </break>
          Hubei
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Pathogen
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS-CoV
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS-CoV-2
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Intermediate host
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <italic>
           Paguma larvata
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Pangolin, Mink (Possible)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Definitive host
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <italic>
           Rhinolophus sinicus
          </italic>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <italic>
           Rhinolophus affinis
          </italic>
          (Possible)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Virus type
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RNA virus
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RNA virus
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Species pathogen
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          β-coronavirus
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          β-coronavirus
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Total DNA sequence length of pathogen
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          29,751
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          29,903
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Latency
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1–4 days on average
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          3–7 days on average
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Susceptible people
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Young adults
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          People who have not been exposed to SARS-CoV-2
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Male–female patient ratio
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1:1.25
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2.70:1
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Mortality
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          9.60%
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2.10%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Clinical symptoms
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Fever, cough, myalgia, dyspnea, and diarrhea
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Fever, fatigue, and dry cough
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Propagation mode
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Droplets or close contacts
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Droplets or close contacts
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Major regional distribution
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Beijing, Guangdong, Shanxi in China
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Hubei, especially Wuhan in China
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Diagnostic methods
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RT-PCR, rRT-PCR, RT-LAMP, rRT-LAMP, Coronavirus detection kit
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          RT-PCR, rRT-PCR, RT-LAMP, rRT-LAMP, Coronavirus detection kit
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Treatment
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Glucocorticoid and interferon
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Lopinavir/ritonavir (in testing)
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="viruses-12-00244-t002" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-12-00244-t002_Table 2
      </object-id>
      <label>
       Table 2
      </label>
      <caption>
       <p>
        Comparison of protein sequences SARS-CoV-2 and SARS-CoV by Blastp.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin" valign="middle">
         </th>
         <th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          SARS-CoV-2
         </th>
         <th align="center" colspan="4" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          SARS-CoV
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Protein Name
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Accession Number
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Putative Function/Domain
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Accession Number
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Query Cover *
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Percent Identity
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725298.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nonstructural polyprotein pp1a
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          ABF65834.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          68.34%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725299.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          polyprotein orf1a
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          AFR58698.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          75.82%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp4
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725300.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          polyprotein 1a
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          ARO76381.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          80.80%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725302.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp6-pp1a/pp1ab (TM3)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828864.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          98%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          88.15%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp7
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725303.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Chain A, Replicase Polyprotein 1ab, Light Chain
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2AHM_A
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          98.80%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725304.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Chain E, Replicase Polyprotein 1ab, Heavy Chain
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2AHM_E
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          97.47%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          7
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp9
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725305.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp9-pp1a/pp1ab
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828867.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          97.35%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp10
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725306.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Chain A, Non-structural Protein 10
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5C8S_A
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          97.12%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          9
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp11
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725312.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp11-pp1a
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_904321.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          84.62%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          10
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          orf1a polyprotein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725295.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          orf1a polyprotein (pp1a)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828850.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          80.58%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          orf1ab polyprotein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009724389.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          orf1ab polyprotein (pp1ab)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828849.2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          86.26%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          12
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          orf3a protein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009724391.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          hypothetical protein sars3a
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828852.2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          72.04%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          orf6 protein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009724394.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          hypothetical protein sars6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828856.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          68.85%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          14
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          orf7a protein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009724395.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          protein 8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          ARO76387.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          87.70%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          15
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          orf7b protein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725296.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          hypothetical protein sars7b
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_849175.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          95%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          85.37%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          16
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          orf8 protein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009724396.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          -
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          -
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          -
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          -
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          17
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          orf10 protein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725255.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          -
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          -
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          -
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          -
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          18
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2’-O-ribose methyltransferase
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725311.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp16-pp1ab (2’-o-MT)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828873.2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          99%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          93.60%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          19
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3C-like proteinase
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725301.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          polyprotein 1a
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          ARO76381.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          96.08%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          20
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3’-to-5’ exonuclease
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725309.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp14-pp1ab (nuclease ExoN homolog)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828871.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          95.07%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          21
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          endoRNAse
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725310.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp15-pp1ab (endoRNAse)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828872.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          88.73%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          22
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          envelope protein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009724392.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          E protein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          APO40581.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          94.74%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          23
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          helicase
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725308.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp13-pp1ab (ZD, NTPase/HEL)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828870.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          99.83%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          24
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          leader protein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725297.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp1-pp1a/pp1ab
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828860.2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          84.44%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          25
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          membrane glycoprotein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009724393.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          matrix protein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828855.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          90.54%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          26
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nucleocapsid phosphoprotein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009724397.2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nucleocapsid protein
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          ARO76389.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          90.52%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          27
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          RNA-dependent RNA polymerase
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          YP_009725307.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          nsp12-pp1ab (RdRp)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          NP_828869.1
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          96.35%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          28
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          surface glycoprotein
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          YP_009724390.1
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          spike glycoprotein
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          ABD72985.1
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          100%
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          76.42%
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         “-” represents no homologous protein. Query cover represents the percentage of the protein sequences that are participating in the comparison. Percent identity indicates the homology.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <table-wrap id="viruses-12-00244-t003" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-12-00244-t003_Table 3
      </object-id>
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Proposed questions to study SARS-CoV-2 for future studies.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          What is the effect of the surface epitope and receptor binding domain of S protein of SARS-CoV-2 on the virus’ infectivity?
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Is there any effect of SARS-CoV vaccine designed according to S protein on SARS-CoV-2?
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Does SARS-CoV-2 orf8 and orf10 proteins, which have no homology proteins in SARS-CoV, play roles in the infectivity and pathogenicity of SARS-CoV-2?
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Can the susceptibility of asymptomatic carriers be judged by detecting the serum reactivity level of N protein?
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Apart from droplet transmission and contact transmission, are there other methods to transmit SARS-CoV-2?
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          What is the percentage of COVID-19 patients have been infected with SARS and produced antibodies?
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Is there an effective specific anti-SARS-CoV-2 solution?
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Does traditional Chinese medicine have any effect on the treatment of COVID-19 caused by SARS-CoV-2?
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Do ethnic differences affect the transmissibility and pathogenicity of SARS-CoV-2?
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Do any environmental factors, such as regional conditions or climate, affect SARS-CoV-2 transmission?
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Protein Sci
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Protein Sci
      </journal-id>
      <journal-id journal-id-type="doi">
       10.1002/(ISSN)1469-896X
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       PRO
      </journal-id>
      <journal-title-group>
       <journal-title>
        Protein Science : A Publication of the Protein Society
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0961-8368
      </issn>
      <issn pub-type="epub">
       1469-896X
      </issn>
      <publisher>
       <publisher-name>
        John Wiley and Sons Inc.
       </publisher-name>
       <publisher-loc>
        Hoboken
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       24519901
      </article-id>
      <article-id pub-id-type="pmc">
       4005712
      </article-id>
      <article-id pub-id-type="doi">
       10.1002/pro.2442
      </article-id>
      <article-id pub-id-type="publisher-id">
       PRO2442
      </article-id>
      <article-categories>
       <subj-group subj-group-type="overline">
        <subject>
         Article
        </subject>
       </subj-group>
       <subj-group subj-group-type="heading">
        <subject>
         Articles
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Influence of hydrophobic and electrostatic residues on SARS‐coronavirus S2 protein stability: Insights into mechanisms of general viral fusion and inhibitor design
       </article-title>
       <alt-title alt-title-type="right-running-head">
        Biophysical Characterization of the SARS S2 Helical Core
       </alt-title>
       <alt-title alt-title-type="left-running-head">
        Aydin et al.
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="pro2442-cr-0001">
        <name>
         <surname>
          Aydin
         </surname>
         <given-names>
          Halil
         </given-names>
        </name>
        <xref ref-type="aff" rid="pro2442-aff-0001">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" id="pro2442-cr-0002">
        <name>
         <surname>
          Al‐Khooly
         </surname>
         <given-names>
          Dina
         </given-names>
        </name>
        <xref ref-type="aff" rid="pro2442-aff-0001">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes" id="pro2442-cr-0003">
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          Jeffrey E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="pro2442-aff-0001">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
      </contrib-group>
      <aff id="pro2442-aff-0001">
       <label>
        <sup>
         1
        </sup>
       </label>
       <named-content content-type="organisation-division">
        Department of Laboratory Medicine and Pathobiology
       </named-content>
       <institution>
        Faculty of Medicine, University of Toronto
       </institution>
       <city>
        Toronto
       </city>
       <named-content content-type="country-part">
        Ontario
       </named-content>
       <postal-code>
        M5S 1A8
       </postal-code>
       <country country="CA">
        Canada
       </country>
      </aff>
      <author-notes>
       <corresp id="correspondenceTo">
        <label>
         *
        </label>
        <italic>
         Correspondence to
        </italic>
        : J. E. Lee, 1 King's College Circle, Room 6316, Medical Sciences Building, Toronto, ON M5S 1A8, Canada. E‐mail:
        <email>
         jeff.lee@utoronto.ca
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        5
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        19
       </day>
       <month>
        3
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <volume>
       23
      </volume>
      <issue>
       5
      </issue>
      <issue-id pub-id-type="doi">
       10.1002/pro.v23.5
      </issue-id>
      <fpage>
       603
      </fpage>
      <lpage>
       617
      </lpage>
      <history>
       <date date-type="received">
        <day>
         07
        </day>
        <month>
         12
        </month>
        <year>
         2013
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         09
        </day>
        <month>
         2
        </month>
        <year>
         2014
        </year>
       </date>
       <date date-type="accepted">
        <day>
         10
        </day>
        <month>
         2
        </month>
        <year>
         2014
        </year>
       </date>
      </history>
      <permissions>
       <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2014 The Protein Society <copyright-statement>-->
       <copyright-statement content-type="article-copyright">
        © 2014 The Protein Society
       </copyright-statement>
       <license>
        <license-p>
         This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
        </license-p>
       </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="file:PRO-23-603.pdf">
      </self-uri>
      <abstract>
       <title>
        Abstract
       </title>
       <p>
        Severe acute respiratory syndrome (SARS) is an acute respiratory disease caused by the SARS‐coronavirus (SARS‐CoV). SARS‐CoV entry is facilitated by the spike protein (S), which consists of an N‐terminal domain (S1) responsible for cellular attachment and a C‐terminal domain (S2) that mediates viral and host cell membrane fusion. The SARS‐CoV S2 is a potential drug target, as peptidomimetics against S2 act as potent fusion inhibitors. In this study, site‐directed mutagenesis and thermal stability experiments on electrostatic, hydrophobic, and polar residues to dissect their roles in stabilizing the S2 postfusion conformation was performed. It was shown that unlike the pH‐independent retroviral fusion proteins, SARS‐CoV S2 is stable over a wide pH range, supporting its ability to fuse at both the plasma membrane and endosome. A comprehensive SARS‐CoV S2 analysis showed that specific hydrophobic positions at the C‐terminal end of the HR2, rather than electrostatics are critical for fusion protein stabilization. Disruption of the conserved C‐terminal hydrophobic residues destabilized the fusion core and reduced the melting temperature by 30°C. The importance of the C‐terminal hydrophobic residues led us to identify a 42‐residue substructure on the central core that is structurally conserved in all existing CoV S2 fusion proteins (root mean squared deviation = 0.4 Å). This is the first study to identify such a conserved substructure and likely represents a common foundation to facilitate viral fusion. We have discussed the role of key residues in the design of fusion inhibitors and the potential of the substructure as a general target for the development of novel therapeutics against CoV infections.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
       <kwd id="pro2442-kwd-0001">
        viral entry
       </kwd>
       <kwd id="pro2442-kwd-0002">
        SARS‐CoV
       </kwd>
       <kwd id="pro2442-kwd-0003">
        viral fusion
       </kwd>
       <kwd id="pro2442-kwd-0004">
        coronavirus
       </kwd>
       <kwd id="pro2442-kwd-0005">
        MERS‐CoV
       </kwd>
       <kwd id="pro2442-kwd-0006">
        glycoprotein
       </kwd>
       <kwd id="pro2442-kwd-0007">
        S2
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group id="funding-0001">
        <funding-source>
         Canadian Institutes of Health Research (CIHR) Open Operating Grant
        </funding-source>
        <award-id>
         MOP‐115066
        </award-id>
       </award-group>
       <award-group id="funding-0002">
        <funding-source>
         Canada Research Chair in Structural Virology and a CIHR New Investigator Award
        </funding-source>
        <award-id>
         MSH‐113554
        </award-id>
       </award-group>
       <award-group id="funding-0003">
        <funding-source>
         HA was supported by a University of Toronto Graduate Fellowship
        </funding-source>
       </award-group>
      </funding-group>
      <counts>
       <page-count count="15">
       </page-count>
      </counts>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         source-schema-version-number
        </meta-name>
        <meta-value>
         2.0
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         cover-date
        </meta-name>
        <meta-value>
         May 2014
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         details-of-publishers-convertor
        </meta-name>
        <meta-value>
         Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.0 mode:remove_FC converted:15.04.2020
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <def-list id="pro2442-lp-0001" list-content="abbreviations">
     <title>
      Abbreviations
     </title>
     <def-item>
      <term id="pro2442-li-0001">
       ACE2
      </term>
      <def id="pro2442-li-0002">
       <p>
        angiotensin‐converting enzyme 2
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0003">
       APN
      </term>
      <def id="pro2442-li-0004">
       <p>
        aminopeptidase N
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0005">
       ASLV
      </term>
      <def id="pro2442-li-0006">
       <p>
        avian sarcoma leucosis virus
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0007">
       BtCoV
      </term>
      <def id="pro2442-li-0008">
       <p>
        bat coronavirus
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0009">
       CD
      </term>
      <def id="pro2442-li-0010">
       <p>
        circular dichroism
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0011">
       CAECAM1
      </term>
      <def id="pro2442-li-0012">
       <p>
        carcinoembryonic antigen adhesion molecule 1
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0013">
       CoV
      </term>
      <def id="pro2442-li-0014">
       <p>
        coronavirus
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0015">
       DPP4
      </term>
      <def id="pro2442-li-0016">
       <p>
        dipeptidyl peptidase 4
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0017">
       EBOV
      </term>
      <def id="pro2442-li-0018">
       <p>
        ebola virus
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0019">
       Env
      </term>
      <def id="pro2442-li-0020">
       <p>
        retroviral envelope glycoprotein
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0021">
       GP
      </term>
      <def id="pro2442-li-0022">
       <p>
        glycoprotein
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0023">
       GP
       <sub>
        1
       </sub>
      </term>
      <def id="pro2442-li-0024">
       <p>
        glycoprotein 1 attachment domain
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0025">
       GP
       <sub>
        2
       </sub>
      </term>
      <def id="pro2442-li-0026">
       <p>
        glycoprotein 2 fusion domain
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0027">
       HA
      </term>
      <def id="pro2442-li-0028">
       <p>
        hemagglutinin
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0029">
       HIV‐1
      </term>
      <def id="pro2442-li-0030">
       <p>
        human immunodeficiency virus type‐1
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0031">
       HKU
      </term>
      <def id="pro2442-li-0032">
       <p>
        Hong Kong university
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0033">
       HR1
      </term>
      <def id="pro2442-li-0034">
       <p>
        Heptad repeat region 1
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0035">
       HR2
      </term>
      <def id="pro2442-li-0036">
       <p>
        heptad repeat region 2
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0037">
       IAV
      </term>
      <def id="pro2442-li-0038">
       <p>
        influenza A virus
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0039">
       LCMV
      </term>
      <def id="pro2442-li-0040">
       <p>
        lymphocytic choriomeningitis virus
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0041">
       MERS‐CoV
      </term>
      <def id="pro2442-li-0042">
       <p>
        middle East respiratory syndrome‐coronavirus
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0043">
       MHV
      </term>
      <def id="pro2442-li-0044">
       <p>
        mouse hepatitis virus
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0045">
       RBD
      </term>
      <def id="pro2442-li-0046">
       <p>
        receptor‐binding domain
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0047">
       RBM
      </term>
      <def id="pro2442-li-0048">
       <p>
        receptor‐binding motif
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0049">
       RMSD
      </term>
      <def id="pro2442-li-0050">
       <p>
        root mean square deviation
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0051">
       S
      </term>
      <def id="pro2442-li-0052">
       <p>
        coronavirus spike glycoprotein
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0053">
       S1
      </term>
      <def id="pro2442-li-0054">
       <p>
        coronavirus spike glycoprotein attachment subunit
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0055">
       S2
      </term>
      <def id="pro2442-li-0056">
       <p>
        coronavirus spike glycoprotein fusion subunit
       </p>
      </def>
     </def-item>
     <def-item>
      <term id="pro2442-li-0057">
       SARS‐CoV
      </term>
      <def id="pro2442-li-0058">
       <p>
        severe acute respiratory syndrome‐coronavirus.
       </p>
      </def>
     </def-item>
    </def-list>
    <sec id="pro2442-sec-0001">
     <title>
      Introduction
     </title>
     <p>
      Coronaviruses (CoVs) are enveloped, positive‐strand RNA viruses responsible for enteric and respiratory diseases in avian and mammalian species.
      <xref ref-type="ref" rid="pro2442-bib-0001">
       1
      </xref>
      In 2002, the severe acute respiratory syndrome coronavirus (SARS‐CoV) emerged in Southeast Asia and rapidly spread worldwide, resulting in more than 8000 cases and almost 800 deaths.
      <xref ref-type="ref" rid="pro2442-bib-0002">
       2
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0003">
       3
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0004">
       4
      </xref>
      The unexpected emergence of the highly pathogenic human SARS‐CoV revealed the potential for cross‐species transmission from circulating strains of CoVs in zoonotic reservoirs.
      <xref ref-type="ref" rid="pro2442-bib-0005">
       5
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0006">
       6
      </xref>
      Recently, a novel beta‐coronavirus, termed Middle East respiratory syndrome (MERS) CoV, was discovered in the Arabian Peninsula.
      <xref ref-type="ref" rid="pro2442-bib-0007">
       7
      </xref>
      Since then, the virus has now migrated to the United Kingdom, France, Italy, and Africa through infected travelers, and is considered a threat to global health with 42.5% case fatality rate among infected individuals.
      <xref ref-type="ref" rid="pro2442-bib-0008">
       8
      </xref>
      Genetic sequence analyses show that MERS‐CoV belongs to the beta‐coronavirus genus, along with the bat coronaviruses (BtCoVs) HKU4 and HKU5.
      <sup>
       7
      </sup>
      Currently, bats host more than 60 CoV species and a number of other SARS‐like CoVs were identified from bats in Eurasia, Africa, and North America.
      <xref ref-type="ref" rid="pro2442-bib-0001">
       1
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0009">
       9
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0010">
       10
      </xref>
      Although much has been discovered in the 10 years since the SARS‐CoV discovery, emerging zoonotic CoVs continue to cause deadly outbreaks and threaten human health.
     </p>
     <p>
      CoV infection is initiated by the spike (S) protein on the viral surface.
      <xref ref-type="ref" rid="pro2442-bib-0011">
       11
      </xref>
      The SARS‐CoV S is synthesized as a 1255‐amino acid glycoprotein precursor and is classified as a class I viral fusion protein.
      <xref ref-type="ref" rid="pro2442-bib-0012">
       12
      </xref>
      Upon proteolytic activation,
      <xref ref-type="ref" rid="pro2442-bib-0012">
       12
      </xref>
      the S protein is cleaved into a S1 domain (residues 12–680) that is responsible for tropism and cellular attachment, and the S2 domain (residues 681–1255) that facilitates virus and host cell membrane fusion.
      <xref ref-type="ref" rid="pro2442-bib-0012">
       12
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0013">
       13
      </xref>
      The SARS‐CoV S1–S2 heterodimer assembles as a metastable trimer on the viral surface. Similar to other class I viral fusion proteins, such as human immunodeficiency virus type‐1 (HIV‐1) gp41, Ebola virus glycoprotein (GP
      <sub>
       2
      </sub>
      ), and influenza A hemagglutinin (HA
      <sub>
       2
      </sub>
      ), conformational changes in three functional elements of S2: the putative fusion peptide, heptad repeat 1 (HR1), and heptad repeat 2 (HR2) are critical for facilitating the fusion process.
      <xref ref-type="ref" rid="pro2442-bib-0012">
       12
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0014">
       14
      </xref>
      Upon activation, the fusion peptide unfolds and inserts into the target cell membrane forming the pre‐hairpin intermediate.
      <xref ref-type="ref" rid="pro2442-bib-0014">
       14
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0015">
       15
      </xref>
      Subsequently, the HR2 region that anchors the viral membrane folds back near the HR1 trimeric core and triggers the collapse of the pre‐hairpin intermediate state.
      <xref ref-type="ref" rid="pro2442-bib-0015">
       15
      </xref>
      These conformational changes in the HR1 and HR2 regions draw the viral and host cell membranes together and mediate the merger of the two outer leaflets into a hemifusion stalk intermediate.
      <xref ref-type="ref" rid="pro2442-bib-0014">
       14
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0015">
       15
      </xref>
      A final conformational step results in refolding of both HR1 and HR2 into a low energy postfusion state and allows the fusion pore to form.
      <xref ref-type="ref" rid="pro2442-bib-0014">
       14
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0015">
       15
      </xref>
      There is a high kinetic barrier for the fusion of the two bilayer membranes; the free energy released during conformational changes of the fusion protein S2 provides the energetics to overcome the kinetic barriers for fusion pore formation.
      <xref ref-type="ref" rid="pro2442-bib-0015">
       15
      </xref>
     </p>
     <p>
      For class I viral fusion proteins, there are three types of fusion triggers: low pH, receptor binding, and proteolytic cleavage.
      <xref ref-type="ref" rid="pro2442-bib-0016">
       16
      </xref>
      Some viruses, such as avian sarcoma leucosis virus,
      <xref ref-type="ref" rid="pro2442-bib-0017">
       17
      </xref>
      SARS‐CoV,
      <xref ref-type="ref" rid="pro2442-bib-0018">
       18
      </xref>
      and perhaps Ebola virus,
      <xref ref-type="ref" rid="pro2442-bib-0019">
       19
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0020">
       20
      </xref>
      utilize combinations of these triggers. The fusion of SARS‐CoV is complex but is thought to require both receptor binding and proteolytic cleavage.
      <xref ref-type="ref" rid="pro2442-bib-0011">
       11
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0012">
       12
      </xref>
      The proteolytic cleavage event that separates the receptor binding and fusion domains into non‐covalently associated fragments depends on the species of CoV. Some CoVs are proteolytically cleaved at the S1–S2 boundary,
      <xref ref-type="ref" rid="pro2442-bib-0021">
       21
      </xref>
      whereas others remain uncleaved, yet are still infectious.
      <xref ref-type="ref" rid="pro2442-bib-0011">
       11
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0022">
       22
      </xref>
      For SARS‐CoV, a primary proteolytic cleavage at the S1–S2 boundary, followed by a secondary cleavage at a S2′ position is often required to mediate membrane fusion.
      <xref ref-type="ref" rid="pro2442-bib-0022">
       22
      </xref>
      Protease activation by trypsin‐like, thermolysin, elastase, and factor Xa proteases on the plasma membrane
      <xref ref-type="ref" rid="pro2442-bib-0023">
       23
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0024">
       24
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0025">
       25
      </xref>
      and cathepsin L proteolytic cleavage in the low pH endosomes were shown to enhance the SARS‐CoV infection.
      <xref ref-type="ref" rid="pro2442-bib-0025">
       25
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0026">
       26
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0027">
       27
      </xref>
      Regardless of the route of entry, viral fusion proteins require structural rearrangements in the S2 domain to mediate the merger of the virus and host cell lipid bilayers.
      <xref ref-type="ref" rid="pro2442-bib-0024">
       24
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0028">
       28
      </xref>
     </p>
     <p>
      Recent studies have identified key features that contribute to the function of viral fusion proteins from viruses that enter either at the plasma membrane or low pH endosomes. Although the atomic resolution structures of the SARS‐CoV S1 domain and S2 fusion core in the postfusion hairpin conformation have been determined previously, characterization of specific residues involved in the stabilizing the SARS‐CoV S2 during membrane fusion remain unclear. Any functional information regarding the molecular identities of these residues is important for the development of novel antiviral therapeutics. In order to understand the structural determinants involved in stabilizing the SARS‐CoV S2 fusion protein, we performed site‐directed mutagenesis to investigate the roles of electrostatic, polar, and hydrophobic residues on the SARS‐CoV S2 extracellular fusion core and the key features necessary for pH‐dependent viral fusion. Our results revealed that the SARS‐CoV S2 fusion core is stable over a wide pH range and that specific hydrophobic residues at the HR1–HR2 interface play a major role in stabilizing the six‐helix bundle. In contrast, three ion‐pairs and chloride‐binding site residues were shown to play minor roles in stabilizing the postfusion conformation. Specifically, interhelix interactions between the trimeric coiled‐coil HR1 inner core and C‐terminal portion of the HR2 helices are important determinants of SARS‐CoV fusion, whereas those between the tether and inner HR1 core regions are less important in stabilizing the postfusion state. We also identified a 42‐residue conserved substructure within the central heptad repeat region of the SARS‐CoV S2 fusion core that we hypothesize will provide a structural foundation for fusion. Our biophysical thermal stability data now explains the inhibition profiles of an array of SARS‐CoV S2 peptidomimetics. The results presented here provide insights into the general mechanisms of viral fusion and identify an attractive site for coronavirus fusion inhibitor design.
     </p>
    </sec>
    <sec id="pro2442-sec-0002">
     <title>
      Results
     </title>
     <sec id="pro2442-sec-0003">
      <title>
       Generation and characterization of a linked HR1–HR2 trimeric SARS‐CoV S2
      </title>
      <p>
       The SARS‐CoV S2 domain contains an extramembrane helical region that transforms into a coiled‐coil six‐helix bundle structure in the postfusion state. The N‐terminus (residues 890–973) forms a long helical strand, often termed the HR1 region, with 22 helical turns. The HR1 region contains the typical heptad repeat motif of coiled‐coil structures. Each repeat consists of a seven‐residue
       <bold>
        <italic>
         <underline underline-style="single">
          a
         </underline>
        </italic>
       </bold>
       <italic>
        bc
       </italic>
       <bold>
        <italic>
         <underline underline-style="single">
          d
         </underline>
        </italic>
       </bold>
       <italic>
        efg
       </italic>
       motif, where hydrophobic residues (leucine, isoleucine, phenylalanine, and valine) are displayed in the
       <bold>
        <italic>
         <underline underline-style="single">
          a
         </underline>
        </italic>
       </bold>
       and
       <bold>
        <italic>
         <underline underline-style="single">
          d
         </underline>
        </italic>
       </bold>
       positions. The C‐terminal segment of each protomer extends alongside the inner core in an antiparallel manner. These residues first form the random coil tether (residues 1142–1160) and then second heptad repeat region (HR2) between residues 1161–1179. The HR2 helices make five full turns and pack into the central HR1 trimer to form a highly stable six‐helix bundle conformation that coordinates the fusogenic events between the virus and host cell membranes.
      </p>
      <p>
       Recombinant expression of the full‐length SARS‐CoV S2 for structural or biophysical studies is challenging. There are no existing structural models of the entire SARS‐CoV S2 protein. The SARS‐CoV S2 fusion core, consisting of only the HR1 and HR2 helical regions, has been crystallized, and the structure solved. Commonly, the SARS‐CoV S2 fusion core is reconstituted through the addition of synthesized peptides corresponding to HR1 and HR2 regions.
       <xref ref-type="ref" rid="pro2442-bib-0029">
        29
       </xref>
       ,
       <xref ref-type="ref" rid="pro2442-bib-0030">
        30
       </xref>
       ,
       <xref ref-type="ref" rid="pro2442-bib-0031">
        31
       </xref>
       Here, we designed a linked recombinant SARS‐CoV S2 fusion protein (SARS‐CoV S2 L2H) using N‐terminal residues 896–972 and C‐terminal residues 1142–1183, with a six‐residue glycine–serine linker (GGS–GGS) between the two regions [Fig.
       <xref ref-type="fig" rid="pro2442-fig-0001">
        1
       </xref>
       (A)]. This construct is similar to a previously designed construct.
       <xref ref-type="ref" rid="pro2442-bib-0032">
        32
       </xref>
       When expressed using an
       <italic>
        Escherichia coli
       </italic>
       SHuffle T7 expression system, we were able to obtain multi‐milligram quantities of protein. The SARS‐CoV S2 L2H is soluble and migrates as a stable trimer on size exclusion chromatography. Sedimentation equilibrium analytical ultracentrifugation confirmed the trimeric nature of the SARS‐CoV S2 L2H [Fig.
       <xref ref-type="fig" rid="pro2442-fig-0001">
        1
       </xref>
       (B)]. Furthermore, the circular dichroism (CD) spectrum of the protein was characterized by double minima at 208 and 222 nm, the typical CD signature for a predominantly α‐helical protein [Fig.
       <xref ref-type="fig" rid="pro2442-fig-0001">
        1
       </xref>
       (C)]. The CD wavelength scans for all SARS‐CoV S2 L2H mutants were similar (data not shown), suggesting that the relative α‐helical content did not change as a result of the mutations. Moreover, SARS‐CoV S2 L2H contains an estimated 50% α‐helical content, in line with the secondary structural composition seen in the X‐ray crystal structure of SARS‐CoV S2.
      </p>
      <fig fig-type="Figure" id="pro2442-fig-0001" orientation="portrait" position="float" xml:lang="en">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Structural description and biophysical characterization of the SARS‐CoV S2 L2H protein.
         <bold>
          (A)
         </bold>
         Schematic diagram of the SARS‐CoV S protein. The S protein exhibits the characteristic domain organization of class I viral proteins. Abbreviations are as follows: S1, CoV attachment subunit; S2, CoV fusion subunit; SP, signal peptide; RBD, receptor binding domain; RBM, receptor binding motif; FP, fusion peptide; HR1, heptad repeat 1 region; HR2, heptad repeat 2 region; T, tether region; TM, transmembrane domain; CT, cytoplasmic tail; L2H, linked two‐heptad construct. The positions of the S1 domain (residues 14–667), S2 domain (residues 668–1255), SP (residues 1–14), RBD (residues 306–527), RBM (residues 424–494), HR1 (residues 890–973), tether, and HR2 (residues 1142–1184), TM and CT (residues 1196–1255) are shown above the schematic.
         <italic>
          Red arrows
         </italic>
         indicate the S1–S2 and S′ proteolytic cleavage sites at residues R667 and R797, respectively. SARS‐CoV S2 L2H construct was generated by using HR1 residues 896–972 and tether/HR2 residues 1142–1183 connected by a six amino acid linker at the HR1 C‐terminal and HR2 N‐terminal ends (colored in
         <italic>
          orange
         </italic>
         ).
         <bold>
          (B)
         </bold>
         Sedimentation equilibrium data for a 20 μ
         <italic>
          M
         </italic>
         sample at 4°C and 22,000 rpm in TBS buffer. The curve indicates the distribution of a 48.4‐kDa protein. The data fit closely to a trimeric model for SARS‐CoV S2 L2H. The deviation in the data from the linear fit for a trimeric model is plotted in the upper panel.
         <bold>
          (C)
         </bold>
         Experimental CD wavelength scan of SARS‐CoV S2 L2H (
         <italic>
          blue
         </italic>
         ) at 25°C reveals minimas at 208 and 222 nm, indicative of strong α‐helical secondary structural characteristics. The SARS‐CoV S2 L2H is calculated to contain 50% α‐helical content. A reconstructed CD wavelength scan (
         <italic>
          red
         </italic>
         ) shows the quality of the fit used in the calculation of secondary structural content.
        </p>
       </caption>
       <graphic id="nlm-graphic-1" xlink:href="PRO-23-603-g001">
       </graphic>
      </fig>
     </sec>
     <sec id="pro2442-sec-0004">
      <title>
       SARS S2 fusion core is stable over a wide pH range
      </title>
      <p>
       Some CoV's such as hCoV‐229E enter cells via the low pH endosomal environment, whereas others, like mouse hepatitis virus (MHV)−4, directly fuse at the plasma membrane.
       <xref ref-type="ref" rid="pro2442-bib-0033">
        33
       </xref>
       ,
       <xref ref-type="ref" rid="pro2442-bib-0034">
        34
       </xref>
       Interestingly, SARS‐CoV can enter cells through either pH‐dependent or pH‐independent entry pathways depending on the presence of proteases.
       <xref ref-type="ref" rid="pro2442-bib-0023">
        23
       </xref>
       ,
       <xref ref-type="ref" rid="pro2442-bib-0024">
        24
       </xref>
       In order to investigate the pH dependence of the SARS‐CoV S2 fusion core structure, we performed CD thermal denaturation assays in buffers ranging from pH 4.0 to 8.5. The wild‐type (WT) SARS‐CoV S2 L2H denatured irreversibly with a melting temperature (
       <italic>
        T
       </italic>
       <sub>
        m
       </sub>
       ) of 97.0°C at neutral pH. This is consistent with the previously reported
       <italic>
        T
       </italic>
       <sub>
        m
       </sub>
       for SARS‐CoV S2 of &gt;90°C.
       <xref ref-type="ref" rid="pro2442-bib-0035">
        35
       </xref>
       The Gibbs free energy of unfolding cannot be calculated from an irreversible denaturation curve; however, the apparent melting temperature may provide a simple measure of protein stability. At all pH levels, the SARS‐CoV S2 L2H fusion core was highly stable [Fig. 2(A); Table
       <xref ref-type="table" rid="pro2442-tbl-0001">
        1
       </xref>
       ]. As pH was increased, the
       <italic>
        T
       </italic>
       <sub>
        m
       </sub>
       values remained unchanged (∼95°C). At lower pH conditions that correspond to early (6.0–6.5) and late (5.0–6.0) endosomal environments, slightly lower melting temperatures from 92.9°C to 94.6°C were observed. Varying pH did not appear to have drastic effects on protein stability [Fig.
       <xref ref-type="fig" rid="pro2442-fig-0002">
        2
       </xref>
       (B)]; the postfusion SARS‐CoV S2 L2H is stable from pH 4.0 to 8.5.
      </p>
      <table-wrap id="pro2442-tbl-0001" orientation="portrait" position="float" xml:lang="en">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Summary of SARS‐CoV Fusion Protein Stability Under Various pH Conditions
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <col span="1" style="border-bottom:solid 1px #000000; border-right:solid 1px #000000"/>
        <col span="1" style="border-bottom:solid 1px #000000; border-right:solid 1px #000000"/>
        <thead valign="bottom">
         <tr style="border-bottom:solid 1px #000000">
          <th align="left" colspan="1" rowspan="1" valign="bottom">
           <bold>
            Buffered pH
           </bold>
          </th>
          <th align="center" colspan="1" rowspan="1" valign="bottom">
           <bold>
            <italic>
             T
            </italic>
            <sub>
             m
            </sub>
            (°C)
           </bold>
           <xref ref-type="fn" rid="pro2442-note-0001">
            a
           </xref>
          </th>
         </tr>
        </thead>
        <tbody valign="top">
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           10 m
           <italic>
            M
           </italic>
           NaOAc, pH 4.0
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           90.6 ± 0.3
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           10 m
           <italic>
            M
           </italic>
           NaOAc, pH 4.5
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           92.7 ± 0.3
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           10 m
           <italic>
            M
           </italic>
           NaOAc, pH 5.0
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           92.9 ± 0.3
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           10 m
           <italic>
            M
           </italic>
           NaOAc, pH 5.5
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           93.4 ± 0.3
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           10 m
           <italic>
            M
           </italic>
           NaOAc, pH 6.0
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           93.5 ± 0.3
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           10 m
           <italic>
            M
           </italic>
           NaOAc, pH 6.5
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           94.6 ± 0.3
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           10 m
           <italic>
            M
           </italic>
           Tris‐HCl, pH 7.0
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           95.0 ± 0.5
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           10 m
           <italic>
            M
           </italic>
           Tris‐HCl, pH 7.5
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           97.0 ± 0.2
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           10 m
           <italic>
            M
           </italic>
           Tris‐HCl, pH 8.0
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           94.9 ± 0.2
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           10 m
           <italic>
            M
           </italic>
           Tris‐HCl, pH 8.5
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           95.3 ± 0.2
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="pro2442-note-0001">
         <label>
          a
         </label>
         <p>
          The midpoint thermal denaturation (
          <italic>
           T
          </italic>
          <sub>
           m
          </sub>
          ) value was estimated from fraction unfolded (
          <italic>
           F
          </italic>
          <sub>
           unf
          </sub>
          ) and plotted as a function of temperature. Error values indicate 95% confidence intervals from fitting to a non‐linear biphasic sigmoidal curve.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <fig fig-type="Figure" id="pro2442-fig-0002" orientation="portrait" position="float" xml:lang="en">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         SARS‐CoV S2 L2H stability at various pH values.
         <bold>
          (A)
         </bold>
         Thermal denaturation of SARS‐CoV S2 L2H monitored by CD molar ellipticity at 222 nm in sodium acetate buffer (between pH 4.0 and 6.5), and TBS buffer (between pH 7.0 and 8.5). The CD signal was baseline corrected, normalized between 0 (folded) and 1 (unfolded), and fit to a non‐linear biphasic sigmoidal curve. The
         <italic>
          T
         </italic>
         <sub>
          m
         </sub>
         values correspond to the temperature where 50% of the protein has unfolded.
         <bold>
          (B)
         </bold>
         Plot of SARS‐CoV S2 L2H stability as a function of pH. The trimeric SARS‐CoV S2 L2H is stable between pH values 4.0 and 8.5.
        </p>
       </caption>
       <graphic id="nlm-graphic-3" xlink:href="PRO-23-603-g002">
       </graphic>
      </fig>
     </sec>
     <sec id="pro2442-sec-0005">
      <title>
       Electrostatic interactions play a minor role in the stability of the fusion core
      </title>
      <p>
       Salt bridges are long‐range electrostatic interactions typically formed between an anionic carboxylate (—COO
       <sup>
        −
       </sup>
       ) functional group of aspartate or glutamate and the cationic ammonium of lysine (—NH
       <sub>
        3
       </sub>
       <sup>
        +
       </sup>
       ), the guanidinium group of arginine, or imidazole ring of histidine. Electrostatic interactions can contribute up to 10 kcal/mol in free energy,
       <xref ref-type="ref" rid="pro2442-bib-0036">
        36
       </xref>
       and thus are important factors for stabilizing protein structures. The free energy contribution of a salt bridge is pH‐dependent, as the ionization of the side chain is affected by the pH of the local environment.
       <xref ref-type="ref" rid="pro2442-bib-0036">
        36
       </xref>
       The SARS‐CoV S2 fusion core structure revealed three sets of electrostatic interactions clustered in two regions of the protein.
       <xref ref-type="ref" rid="pro2442-bib-0030">
        30
       </xref>
       The HR1–HR2 region contains two salt bridge pairs: between Arg1167 and Glu918 in the middle of the HR2, and between Glu1164 and Lys929 residues at the membrane‐distal end of the HR2 [Fig.
       <xref ref-type="fig" rid="pro2442-fig-0003">
        3
       </xref>
       (A)]. A third complex intersubunit electrostatic interaction is formed between Arg965, Asp967, and Glu970 at the base of the HR1 helical core. Alanine mutations to abrogate these salt bridges led to a modest decrease in melting temperatures (Δ
       <italic>
        T
       </italic>
       <sub>
        m
       </sub>
       &lt; 8°C) [Fig. 3(B); Table
       <xref ref-type="table" rid="pro2442-tbl-0002">
        2
       </xref>
       ]. Interestingly, charge reversal mutations (Lys929Glu, Arg965Glu, and Arg1167Glu) destabilized the SARS‐CoV S2 L2H six‐helix bundle to a similar extent (Δ
       <italic>
        T
       </italic>
       <sub>
        m
       </sub>
       &lt; 8°C). Double and triple charge reversal mutations (Lys929Glu–Arg965Glu, Arg965Glu–Arg1167Glu, and Lys929Glu–Arg965Glu–Arg1167Glu) resulted in an additive reduction in stability (Δ
       <italic>
        T
       </italic>
       <sub>
        m
       </sub>
       ∼ 13°C); however, the changes were still modest [Fig. 3(C); Table
       <xref ref-type="table" rid="pro2442-tbl-0002">
        2
       </xref>
       ]. In conclusion, our results demonstrated that salt bridges play a small role on the SARS‐CoV S2 fusion core stability.
      </p>
      <fig fig-type="Figure" id="pro2442-fig-0003" orientation="portrait" position="float" xml:lang="en">
       <label>
        Figure 3
       </label>
       <caption>
        <p>
         Biophysical characterization of SARS‐CoV S2 electrostatic interactions.
         <bold>
          (A)
         </bold>
         Ribbon diagram of SARS‐CoV S2 fusion core (PDB code: 2BEZ) shows electrostatic interactions between the HR1–HR1 and HR1–HR2 regions. The HR1 and tether/HR2 regions are depicted in
         <italic>
          gray
         </italic>
         and
         <italic>
          green
         </italic>
         , respectively. The side chains of the ion‐pair interactions are colored in
         <italic>
          magenta
         </italic>
         . The zoomed views of ion‐pairs are shown in the inset
         <italic>
          boxes
         </italic>
         and the distances between the residues are indicated in
         <italic>
          Ångstroms
         </italic>
         (Å).
         <bold>
          (B)
         </bold>
         Thermal denaturation profiles of wild‐type (WT), single,
         <bold>
          (C)
         </bold>
         double and triple mutant of electrostatic residues in the SARS‐CoV S2 fusion subunit. Thermal stability was recorded at 222 nm. All data were baseline corrected, normalized between 0 (folded) and 1 (unfolded) and plotted as a function of temperature. The
         <italic>
          T
         </italic>
         <sub>
          m
         </sub>
         values indicate the midpoint melting temperatures for WT and mutant proteins.
        </p>
       </caption>
       <graphic id="nlm-graphic-5" xlink:href="PRO-23-603-g003">
       </graphic>
      </fig>
      <table-wrap id="pro2442-tbl-0002" orientation="portrait" position="float" xml:lang="en">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Summary of Wild‐Type and Mutant SARS‐CoV Fusion Protein Stabilities
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <col span="1" style="border-bottom:solid 1px #000000; border-right:solid 1px #000000"/>
        <col span="1" style="border-bottom:solid 1px #000000; border-right:solid 1px #000000"/>
        <col span="1" style="border-bottom:solid 1px #000000; border-right:solid 1px #000000"/>
        <thead valign="bottom">
         <tr style="border-bottom:solid 1px #000000">
          <th align="left" colspan="1" rowspan="1" valign="bottom">
           <bold>
            SARS‐CoV S2 mutant
           </bold>
          </th>
          <th align="center" colspan="1" rowspan="1" valign="bottom">
           <bold>
            <italic>
             T
            </italic>
            <sub>
             m
            </sub>
            (°C)
           </bold>
           <xref ref-type="fn" rid="pro2442-note-0002">
            a
           </xref>
          </th>
          <th align="center" colspan="1" rowspan="1" valign="bottom">
           <bold>
            Location of mutation
           </bold>
          </th>
         </tr>
        </thead>
        <tbody valign="top">
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wild type
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           96.2 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           –
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Q902A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           89.0 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 top
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           E918A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           91.8 ± 0.4
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 top
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           K929A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           88.9 ± 0.3
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 top
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           K929E
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           88.7 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 top
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           N937A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           82.7 ± 0.3
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 central
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           N951A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           94.4 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 central
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           R965A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           92.3 ± 0.4
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 bottom
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           R965E
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           93.3 ± 0.8
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 bottom
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           D967A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           91.3 ± 0.3
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 bottom
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           E970A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           92.3 ± 0.1
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 bottom
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           L1148A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           88.2 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Tether region
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           I1151A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           86.4 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Tether region
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           I1161A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           79.5 ± 0.3
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR2 bottom
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           E1164A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           88.5 ± 0.3
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR2 bottom
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           R1167A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           92.5 ± 0.4
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR2 middle
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           R1167E
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           92.1 ± 0.3
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR2 middle
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           L1168A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           67.0 ± 0.3
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR2 top
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           L1175A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           66.0 ± 0.4
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR2 top
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Q902A‐N937A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           74.3 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 top and central
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           K929A‐R965A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           92.8 ± 0.3
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 top and bottom
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           K929E‐R965E
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           85.9 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 top and bottom
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           K929A‐R1167A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           91.7 ± 0.3
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 top and HR2 middle
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           K929E‐R1167E
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           84.0 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 top and HR2 middle
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           R965A‐R1167A
          </td>
          <td align="char" char="∼" colspan="1" rowspan="1" valign="top">
           ∼89.1
           <xref ref-type="fn" rid="pro2442-note-0003">
            b
           </xref>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 bottom and HR2 middle
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           R965E‐R1167E
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           88.1 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 bottom and HR2 middle
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           K929A‐R965A‐R1167A
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           90.5 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 top, HR1 bottom and HR2 middle
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           K929E‐R965E‐R1167E
          </td>
          <td align="char" char="±" colspan="1" rowspan="1" valign="top">
           83.1 ± 0.2
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HR1 top, HR1 bottom and HR2 middle
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="pro2442-note-0002">
         <label>
          a
         </label>
         <p>
          The midpoint thermal denaturation (
          <italic>
           T
          </italic>
          <sub>
           m
          </sub>
          ) value was estimated from fraction unfolded (
          <italic>
           F
          </italic>
          <sub>
           unf
          </sub>
          ) and plotted as a function of temperature. Error values indicate 95% confidence intervals from fitting to a non‐linear biphasic sigmoidal curve.
         </p>
        </fn>
        <fn id="pro2442-note-0003">
         <label>
          b
         </label>
         <p>
          The
          <italic>
           T
          </italic>
          <sub>
           m
          </sub>
          value for this double mutant is an estimate; errors were not calculated
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </sec>
     <sec id="pro2442-sec-0006">
      <title>
       Hydrophobic residues are important for postfusion stability
      </title>
      <p>
       Given our findings that electrostatic interactions play only a minor role in the stability of the SARS‐CoV S2 L2H fusion subunit, we focused on the role of the hydrophobic residues in maintaining structural integrity. The postfusion structure of SARS‐CoV S2 reveals a series of hydrophobic residues positioned at the interface of the HR1–tether (Leu1148 and Ile1151) and HR1–HR2 (Ile1161, Leu1168, and Leu1175) [Fig.
       <xref ref-type="fig" rid="pro2442-fig-0004">
        4
       </xref>
       (A)]. We hypothesized that the hydrophobic interactions between the HR1–tether and HR1–HR2 regions play an essential role in stabilizing the outer layer (HR2 and tether) to the inner core (HR1) in the postfusion state. To test our hypothesis, we mutated all five hydrophobic residues to an alanine residue and performed CD thermal denaturation assays. Mutations to hydrophobes at the HR1–tether interface (Leu1148Ala and Ile1151Ala) destabilized SARS‐CoV S2 L2H on the order of Δ
       <italic>
        T
       </italic>
       <sub>
        m
       </sub>
       ∼10°C [Fig. 4(B); Table
       <xref ref-type="table" rid="pro2442-tbl-0002">
        2
       </xref>
       ]. Strikingly, alanine mutations to the hydrophobic residues at the HR1–HR2 interface (Ile1161Ala, Leu1168Ala, and Leu1175Ala) had drastic effects on protein stability, with &gt;20°C decrease each on the apparent
       <italic>
        T
       </italic>
       <sub>
        m
       </sub>
       , as compared with WT SARS‐CoV S2 L2H. Specifically, a single alanine mutation to Leu1168 or Leu1175 residue led to a approximately 30°C decrease on the melting temperature of SARS‐CoV S2 L2H [Fig. 4(B); Table
       <xref ref-type="table" rid="pro2442-tbl-0002">
        2
       </xref>
       ]. Our results indicate that hydrophobic interactions between HR1 and HR2, specifically Leu1168 and Leu1175, are critical for the stability of postfusion SARS‐CoV S2. The hydrophobic HR2 residues involved in postfusion stability are well conserved across the coronavirus family (Fig.
       <xref ref-type="fig" rid="pro2442-fig-0005">
        5
       </xref>
       ).
      </p>
      <fig fig-type="Figure" id="pro2442-fig-0004" orientation="portrait" position="float" xml:lang="en">
       <label>
        Figure 4
       </label>
       <caption>
        <p>
         SARS‐CoV S2 hydrophobic and polar interactions.
         <bold>
          (A)
         </bold>
         Ribbon diagram of SARS‐CoV S2 fusion core structure (PDB Code: 2BEZ). The HR1 region forms a long helical strand with 22 helical turns (colored in
         <italic>
          gray
         </italic>
         ). The tether and HR2 regions extend alongside the HR1 inner core in an antiparallel manner (colored in
         <italic>
          green
         </italic>
         ). The hydrophobic residues at the HR1–tether and HR1–HR2 interface are depicted in
         <italic>
          orange
         </italic>
         . The inset boxes show the zoomed view of critical hydrophobic residues positioned at the interfaces.
         <bold>
          (B)
         </bold>
         Thermal denaturation of wild‐type (WT) and mutant hydrophobic residues in the SARS‐CoV fusion subunit.
         <bold>
          (C)
         </bold>
         Ribbon diagram of an extended SARS‐CoV S2 fusion core structure (PDB Code: 1WYY) displaying two putative chloride binding sites. Chloride ions observed in the crystal structure of the HR1 inner core are shown in
         <italic>
          red
         </italic>
         . The polar residues interacting with chloride ion (Q902 and N937) and a single polar residue (N951) at the HR1‐tether interface are shown as
         <italic>
          blue sticks
         </italic>
         . The HR1 and tether/HR2 regions are depicted in
         <italic>
          gray
         </italic>
         and
         <italic>
          green
         </italic>
         , respectively.
         <bold>
          (D)
         </bold>
         Thermal denaturation profiles of wild‐type (WT) and chloride binding site mutants. All thermal denaturation profiles are plotted as described in Figure
         <xref ref-type="fig" rid="pro2442-fig-0003">
          3
         </xref>
         .
        </p>
       </caption>
       <graphic id="nlm-graphic-7" xlink:href="PRO-23-603-g004">
       </graphic>
      </fig>
      <fig fig-type="Figure" id="pro2442-fig-0005" orientation="portrait" position="float" xml:lang="en">
       <label>
        Figure 5
       </label>
       <caption>
        <p>
         Primary sequence alignment of CoV S2 fusion cores. Multiple sequence alignment of various human and animal CoV fusion proteins. Abbreviations are as follows: SARS‐CoV, severe acute respiratory syndrome‐coronavirus; MERS‐CoV, middle east respiratory syndrome‐coronavirus; hCoV, human coronavirus; HKU, Hong Kong University strain; BCoV, bovine coronavirus; BtCoV, bat coronavirus; CCoV, canine coronavirus; FCoV, feline coronavirus; FIPV, feline infectious peritonitis virus; MHV, mouse hepatitis virus; MuCoV, munia coronavirus; PEDV, porcine epidemic bronchitis virus; PRCoV, porcine respiratory coronavirus; PHEV, porcine hemagglutinating encephalomyelitis virus; TGEV, transmissible gastroenteritis virus; RbCoV, rabbit coronavirus; RtCoV, rat coronavirus; SpCoV, sparrow coronavirus; ThCoV, thrush coronavirus. Sequence boundaries for HR1 and tether/HR2 regions are depicted with gray and green lines, respectively. Residue numbers corresponding to the SARS‐CoV S2 fusion subunit numbering are indicated above the alignment. Strictly conserved residues are outlined in
         <italic>
          red
         </italic>
         and residues that are important for the stability of the SARS‐CoV S2 fusion core are highlighted in
         <italic>
          yellow
         </italic>
         and marked with an asterisk (*). Residues (911–924) involved in the formation of the common HR1 substructure are shown in a
         <italic>
          black box
         </italic>
         . The heptad repeat register (
         <italic>
          a, b, c, d, e, f, g
         </italic>
         ) of the SARS‐CoV S2 fusion core is indicated below the alignment.
        </p>
       </caption>
       <graphic id="nlm-graphic-9" xlink:href="PRO-23-603-g005">
       </graphic>
      </fig>
     </sec>
     <sec id="pro2442-sec-0007">
      <title>
       Putative chloride binding site reinforces the structural stability of the postfusion core
      </title>
      <p>
       In many postfusion viral fusion proteins, the heptad repeats in the HR1 helix are broken up by a layer of aspargine or glutamine residues to coordinate a putative chloride ion.
       <xref ref-type="ref" rid="pro2442-bib-0037">
        37
       </xref>
       This phenomenon is seen in all CX
       <sub>
        6
       </sub>
       CC‐containing retrovirus and filovirus fusion proteins, and is suggested to be important as a conformational switch between the prefusion and postfusion states.
       <xref ref-type="ref" rid="pro2442-bib-0037">
        37
       </xref>
       ,
       <xref ref-type="ref" rid="pro2442-bib-0038">
        38
       </xref>
       ,
       <xref ref-type="ref" rid="pro2442-bib-0039">
        39
       </xref>
       The SARS‐CoV S2 extramembrane helical fusion core contains two chloride‐binding sites
       <xref ref-type="ref" rid="pro2442-bib-0030">
        30
       </xref>
       [Fig.
       <xref ref-type="fig" rid="pro2442-fig-0004">
        4
       </xref>
       (C)]. The first chloride‐binding site of HR1 is located at the membrane‐proximal end of the protein and is coordinated by Gln902, whereas the second site is at the center of the trimeric HR1 coiled coil and is coordinated by Asn937. In order to investigate the significance of these chloride‐binding sites, we mutated both Gln902 and Asn937 to an alanine residue and monitored the changes on the stability of the protein. Gln902Ala and Asn937Ala resulted in the decrease of the apparent
       <italic>
        T
       </italic>
       <sub>
        m
       </sub>
       values by 8°C and 14°C, respectively [Fig. 4(D); Table
       <xref ref-type="table" rid="pro2442-tbl-0002">
        2
       </xref>
       ]. Thermal unfolding of the Gln902Ala–Asn937Ala double mutant revealed an additive effect in the change of melting temperature (Δ
       <italic>
        T
       </italic>
       <sub>
        m
       </sub>
       = ∼23°C). As a control, we mutated an asparagine residue (Asn951) located outside of the chloride‐binding sites and assessed its contribution on postfusion stability. As expected, Asn951Ala did not result in a change on the apparent
       <italic>
        T
       </italic>
       <sub>
        m
       </sub>
       value [Fig. 4(D); Table
       <xref ref-type="table" rid="pro2442-tbl-0002">
        2
       </xref>
       ]. Taken together, this suggests that conserved polar interactions with the chloride ion, in particular the central chloride‐binding site, are important for the postfusion stability of the protein.
      </p>
     </sec>
    </sec>
    <sec id="pro2442-sec-0008">
     <title>
      Discussion
     </title>
     <p>
      All class I viral glycoproteins, including those from coronaviruses, utilize a similar mechanism of fusion, in which structural rearrangements of two highly conserved heptad repeats juxtapose the viral and host cell membranes to form the fusion pore. The conformational changes necessary for membrane fusion requires the formation of an energetically stable six‐helix bundle structure in the postfusion state. The transition from the higher energy metastable prefusion to the lower energy six‐helix bundle postfusion conformation provides the energetics for fusion. Recently, it was suggested that the stability of the postfusion subunit is highest at the pH of the environment of where fusion occurs.
      <xref ref-type="ref" rid="pro2442-bib-0040">
       40
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0041">
       41
      </xref>
      For example, human T‐lymphotropic virus‐1 (HTLV‐1) fuses at the host plasma membrane at neutral pH. The HTLV‐1 gp21 fusion subunit is most stable at pH values above 7.0 (61.0°C at pH 5.0 vs. &gt;99.0°C at pH 7.5).
      <xref ref-type="ref" rid="pro2442-bib-0041">
       41
      </xref>
      Ebola virus fusion occurs at the endolysosome, and its GP
      <sub>
       2
      </sub>
      subunit is most stable at pH values below 5.5 (86.8°C at pH 5.3 vs. 49.8°C at pH 6.1).
      <xref ref-type="ref" rid="pro2442-bib-0040">
       40
      </xref>
      The observation that the stability of the fusion subunit mimics the environment where they fuse also holds true for avian sarcoma leukosis virus (ASLV). ASLV is a retrovirus that undergoes a unique two‐step entry mechanism that involves first receptor‐binding at the plasma membrane, followed by low pH activation in the endosome.
      <xref ref-type="ref" rid="pro2442-bib-0017">
       17
      </xref>
      The ASLV TM fusion protein is stable over a broad range of pH values (67.0°C–73.8°C at pH values between 5.0 and 8.5).
      <xref ref-type="ref" rid="pro2442-bib-0041">
       41
      </xref>
      Although SARS‐CoV does not undergo a two‐step mechanism of entry, SARS‐CoV entry may be promiscuous as it is able to enter target cells through either a low pH endosomal route or direct fusion at the plasma membrane at neutral pH.
      <xref ref-type="ref" rid="pro2442-bib-0023">
       23
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0024">
       24
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0026">
       26
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0042">
       42
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0043">
       43
      </xref>
      Consistent with ASLV TM, the linked SARS‐CoV S2 is stable between pH 4.0 and 8.5. This provides further support that the SARS‐CoV S2 fusion subunit is able to maintain the core stability regardless of its route of entry and environments encountered.
     </p>
     <p>
      Structural and biophysical characterization of class I viral fusion subunits have identified general features required for stabilization of the postfusion structure. Mason‐Pfizer monkey virus (MPMV), HTLV‐1, and xenotropic murine leukemia virus‐related virus (XMRV) belong to the β‐, δ‐, and γ‐retrovirus genus, respectively, and fuse at the plasma membrane in a pH‐independent entry process.
      <xref ref-type="ref" rid="pro2442-bib-0044">
       44
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0045">
       45
      </xref>
      Crystal structures of HTLV‐1, MPMV, and XMRV transmembrane fusion protein domains identified a series of electrostatic and hydrophobic interactions between the HR1 and HR2 regions.
      <xref ref-type="ref" rid="pro2442-bib-0038">
       38
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0046">
       46
      </xref>
      Mutations to the negatively and positively charged residues result in a significant decrease in the stability of the postfusion glycoprotein structure and decrease viral infectivity, suggesting a major role for salt bridges in stabilizing the postfusion six‐helix bundle.
      <xref ref-type="ref" rid="pro2442-bib-0046">
       46
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0047">
       47
      </xref>
      Electrostatic interactions may be a common strategy used by viruses to stabilize the fusion protein at the plasma membrane. In ASLV, which has been used extensively as a model virus for both pH‐dependent and pH‐independent entry, the fusion domain crystal structure also revealed a lining of electrostatic salt bridges. However, these electrostatic interactions do not play a major role in stabilizing the six‐helix bundle, as they do in fusion proteins of retroviruses with pH‐independent entry. Instead, hydrophobic residues in the ASLV fusion protein play a large role in stabilizing the postfusion state.
      <xref ref-type="ref" rid="pro2442-bib-0041">
       41
      </xref>
      The use of hydrophobic residues for stabilization is consistent with ASLV's mode of entry requiring low pH,
      <xref ref-type="ref" rid="pro2442-bib-0041">
       41
      </xref>
      as the strength of hydrophobic interactions are not affected by pH changes in the environment. Other class I viruses such as influenza A virus (IAV) and lymphocytic choriomeningitis virus (LCMV), which solely enter host cells through low pH endosomes, also contain both ionic and hydrophobic interactions within their fusion core in the postfusion state.
      <xref ref-type="ref" rid="pro2442-bib-0048">
       48
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0049">
       49
      </xref>
      It is not clear whether the ionic residues are important for stability, as no studies have been performed on proteins from these viruses. Like ASLV, these viruses may utilize hydrophobic interactions as their primary mechanism for maintaining postfusion stability within the endosomes.
     </p>
     <p>
      Hydrophobic residues appear to play a greater role in stabilizing the fusion subunits from viruses that are pH‐dependent than do electrostatic interactions. On the flip side, electrostatic interactions are important to viruses that fuse at the plasma membrane at neutral pH. SARS‐CoV is able to enter through direct fusion at the plasma membrane and the low pH environment of the endosome; therefore, we expected that the fusion subunit would have structural features typical of both types of viral fusion proteins. Our biophysical study on the linked SARS‐CoV S2 now provides additional evidence to support this hypothesis. Salt bridge interactions in SARS‐CoV S2 play a minor role in stabilizing the six‐helix bundle. Moreover, the lack of a role for salt bridges is supported by the poor conservation of some salt bridge residues (i.e., Glu918–Arg1167) in all CoVs.
     </p>
     <p>
      Coronaviruses are capable of animal‐to‐human transition, and CoVs that infect pets or animals that frequent urban centers are human health threats due to the potential for mutations that will allow the virus to cross the interspecies barrier. The development of CoV inhibitors will provide a weapon against existing, emerging, or re‐emerging CoV outbreaks. The coronavirus S protein plays key roles in facilitating the attachment of the virus to the host receptor, and catalyzing the fusion of the virus and host lipid bilayers. While drugs have been developed against the attachment subunit (S1 equivalent) for other viruses, this may not be a good target for coronaviruses, as they utilize a diverse range of cellular receptors for host attachment. For example, SARS‐CoV and hCoV‐NL63 use angiotensin‐converting enzyme 2 (ACE2) as a receptor for infection of target cells,
      <xref ref-type="ref" rid="pro2442-bib-0050">
       50
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0051">
       51
      </xref>
      whereas MHV and hCoV‐229E utilize carcinoembryonic antigen adhesion molecule 1 (CAECAM1) and aminopeptidase N (APN) as receptors, respectively.
      <xref ref-type="ref" rid="pro2442-bib-0052">
       52
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0053">
       53
      </xref>
      Lastly, Raj
      <italic>
       et al
      </italic>
      . showed that the recently identified MERS‐CoV binds to an exopeptidase, dipeptidyl peptidase 4 (DPP4), as a functional receptor for entry.
      <xref ref-type="ref" rid="pro2442-bib-0054">
       54
      </xref>
      Studies conducted by Lu
      <italic>
       et al
      </italic>
      .,
      <xref ref-type="ref" rid="pro2442-bib-0055">
       55
      </xref>
      Du
      <italic>
       et al
      </italic>
      .,
      <xref ref-type="ref" rid="pro2442-bib-0056">
       56
      </xref>
      and Wang
      <italic>
       et al
      </italic>
      .
      <xref ref-type="ref" rid="pro2442-bib-0057">
       57
      </xref>
      revealed that a 286‐amino acid fragment within the S1 domain of MERS‐CoV interact with the DPP4 receptor. These analyses highlighted notable differences between coronavirus S1 protein‐receptor interactions. Furthermore, primary sequence analysis reveals that there is only a &lt;2% sequence identity between all the S1 domains of CoV. Antiviral therapeutics targeting this critical region will likely result in species‐specific drugs.
     </p>
     <p>
      In contrast, the CoV S2 protein is likely an excellent target for the design of more general CoV inhibitors. CoV S2 plays an indispensable role in catalyzing the fusion of the virus and host lipid bilayers and residues involved in fusion are relatively well conserved across all family members (Fig.
      <xref ref-type="fig" rid="pro2442-fig-0005">
       5
      </xref>
      ). Targeting the viral fusion subunit is a proven strategy, as demonstrated by the efficacy of the FDA‐approved HIV‐1 gp41 HR2 mimic enfuvirtide (T‐20).
      <xref ref-type="ref" rid="pro2442-bib-0058">
       58
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0059">
       59
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0060">
       60
      </xref>
      SARS‐CoV S2 HR2 peptides are also effective entry inhibitors based on pseudovirus and cell–cell fusion assays.
      <xref ref-type="ref" rid="pro2442-bib-0032">
       32
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0061">
       61
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0062">
       62
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0063">
       63
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0064">
       64
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0065">
       65
      </xref>
      The peptides have traditionally been designed blindly by systematic addition of residues to the core HR2 region. Based on our biophysical fusion protein stability data, we are able to rationalize the trends of effectiveness of peptides. Our thermal denaturation data clearly shows that Ile1161, Leu1168, and Leu1175 are critical to the stability of the postfusion six‐helix bundle structure, whereas hydrophobic residues that belong to the tether region have modest effects on stability. Hydrophobic residues at the C‐terminal end of the HR2 region are more critical to the stability of the postfusion state than those at the tether region. The importance of these residues correlates well with the SARS‐CoV HR2 peptide inhibition studies
      <xref ref-type="ref" rid="pro2442-bib-0035">
       35
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0043">
       43
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0061">
       61
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0064">
       64
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0065">
       65
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0066">
       66
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0067">
       67
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0068">
       68
      </xref>
      (Table
      <xref ref-type="table" rid="pro2442-tbl-0003">
       3
      </xref>
      ). Peptides that encompass the HR2 hydrophobic residues (Ile1161, Leu1168, and Leu1175) and those corresponding to the HR2 C‐terminal ends had better IC
      <sub>
       50
      </sub>
      values than other peptides tested. Peptides that contain residues from the N‐terminal tether region were less effective. Our data suggest that effective SARS‐CoV HR2 peptide inhibitors should encompass the HR2 region and residues C‐terminal to HR2.
     </p>
     <table-wrap id="pro2442-tbl-0003" orientation="portrait" position="float" xml:lang="en">
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Summary of SARS‐CoV S2 HR2 Peptide Mimics
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <col span="1" style="border-bottom:solid 1px #000000; border-right:solid 1px #000000"/>
       <col span="1" style="border-bottom:solid 1px #000000; border-right:solid 1px #000000"/>
       <col span="1" style="border-bottom:solid 1px #000000; border-right:solid 1px #000000"/>
       <col span="1" style="border-bottom:solid 1px #000000; border-right:solid 1px #000000"/>
       <col span="1" style="border-bottom:solid 1px #000000; border-right:solid 1px #000000"/>
       <thead valign="bottom">
        <tr style="border-bottom:solid 1px #000000">
         <th align="left" colspan="1" rowspan="1" valign="bottom">
          <bold>
           Peptide
          </bold>
         </th>
         <th align="center" colspan="1" rowspan="1" valign="bottom">
          <bold>
           Residue region
          </bold>
         </th>
         <th align="center" colspan="1" rowspan="1" valign="bottom">
          <bold>
           Number of residues
          </bold>
         </th>
         <th align="center" colspan="1" rowspan="1" valign="bottom">
          <bold>
           IC
           <sub>
            50
           </sub>
           (assay)
          </bold>
         </th>
         <th align="center" colspan="1" rowspan="1" valign="bottom">
          <bold>
           Reference
          </bold>
         </th>
        </tr>
       </thead>
       <tbody valign="top">
        <tr>
         <td align="left" colspan="5" rowspan="1" valign="top">
          <bold>
           N‐term HR2 extensions
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          sHR2‐1
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1126–1189
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          63
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          43 ± 6.4 µ
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Bosch
          <italic>
           et al
          </italic>
          ., 2004
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          sHR2‐2
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          1130–1189
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          60
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          24 ± 2.8 µ
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Bosch
          <italic>
           et al
          </italic>
          ., 2004
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          sHR2–8
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1126–1193
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          68
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          17 ± 3.0 µ
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Bosch
          <italic>
           et al
          </italic>
          ., 2004
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          sHR2–9
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1126–1185
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          60
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          34 ± 4.0 µ
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Bosch
          <italic>
           et al
          </italic>
          ., 2004
         </td>
        </tr>
        <tr>
         <td align="left" colspan="5" rowspan="1" valign="top">
          <bold>
           C‐term HR2 extensions
          </bold>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          HR2–18
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1161–1187
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          27
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          3.68 ± 1.5 µ
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Yuan
          <italic>
           et al
          </italic>
          ., 2004
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          CP‐1
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1153–1189
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          37
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          19 µ
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Liu
          <italic>
           et al
          </italic>
          ., 2004
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          HR2–38
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1149–1186
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          38
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          66.2 n
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Zhu
          <italic>
           et al
          </italic>
          ., 2004
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          HR2–38*
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1149–1186
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          38
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0.5–5 n
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Zhu
          <italic>
           et al
          </italic>
          ., 2004
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          HR2–44
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1149–1192
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          44
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          500 n
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Zhu
          <italic>
           et al
          </italic>
          ., 2004
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          HR2–38
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1149–1186
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          38
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          1.02 ± 0.02 µ
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Ni
          <italic>
           et al
          </italic>
          ., 2005
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          SR9
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1151–1185
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          35
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          100 n
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Ujike
          <italic>
           et al
          </italic>
          ., 2008
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          HR2
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1151–1185
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          35
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0.34 µ
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Chu
          <italic>
           et al
          </italic>
          ., 2008
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          P1
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1153–1189
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          37
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          3.04 µ
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Liu
          <italic>
           et al
          </italic>
          ., 2009
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          P4
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1153–1182
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          30
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          3.17 µ
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Liu
          <italic>
           et al
          </italic>
          ., 2009
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          P6
         </td>
         <td align="char" char="–" colspan="1" rowspan="1" valign="top">
          1153–1175
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          23
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2.28 µ
          <italic>
           M
          </italic>
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Liu
          <italic>
           et al
          </italic>
          ., 2009
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn id="pro2442-note-0011">
        <p>
         * = synthetic HR2 peptide.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <p>
      Recently, crystal structures of MERS‐CoV S2 fusion core have been determined at high atomic resolution
      <xref ref-type="ref" rid="pro2442-bib-0069">
       69
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0070">
       70
      </xref>
      and structural comparison between MERS‐CoV and SARS‐CoV fusion cores revealed a high degree of overall structural similarity with an root mean squared deviation (RMSD) of approximately 0.9 Å for 204 Cα atoms.
      <xref ref-type="ref" rid="pro2442-bib-0069">
       69
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0070">
       70
      </xref>
      We hypothesized that interacting residues on the HR1 may form a conserved interface to accommodate the HR2 hydrophobic residues for fusion. Analysis of available coronavirus S2 structures revealed strong structural conservation of the HR1 region that interacts with the key hydrophobic HR2 residues. Superimposition of a 42‐residue HR1 region surrounding the HR2 binding site reveals an average RMSD of 0.4 Å between the SARS‐CoV, MERS‐CoV, MHV, and hCoV‐NL63 S2 fusion subunits [Fig.
      <xref ref-type="fig" rid="pro2442-fig-0006">
       6
      </xref>
      (A)]. This is in contrast to an overall superimposition of the entire SARS‐CoV, hCoV‐NL63, and MERS‐CoV, MHV S2 inner HR1 trimeric structures which showed C
      <sub>
       α
      </sub>
      atom RMSDs of ∼1.3, ∼0.6, and ∼0.6 Å, respectively. The surface of the substructure has a long groove (16‐Å long × 9‐Å wide × 7‐Å deep) and a pocket (7‐Å long × 9‐Å wide × 7‐Å deep) at the HR2 interface. The rim of the pocket is surrounded with polar (glutamine and asparagine) and hydrophobic residues (leucine, isoleucine, serine, and alanine) whereas the bottom of the pocket is lined with isoleucine residues [Fig.
      <xref ref-type="fig" rid="pro2442-fig-0006">
       6
      </xref>
      (B)]. HR2 residues that pack into the HR1 pocket are conserved in all fusion core structures with the exception of a conservative isoleucine substitution (Ile1279) in the hCoV–NL63 fusion core for the leucine in MHV, MERS‐CoV, and SARS‐CoV S2 (Fig.
      <xref ref-type="fig" rid="pro2442-fig-0005">
       5
      </xref>
      ). The conservation of the 42‐residue substructure among coronavirus S2 fusion subunits may represent a common foundation to facilitate viral fusion.
     </p>
     <fig fig-type="Figure" id="pro2442-fig-0006" orientation="portrait" position="float" xml:lang="en">
      <label>
       Figure 6
      </label>
      <caption>
       <p>
        The common HR1 SARS‐CoV S2 substructure.
        <bold>
         (A)
        </bold>
        Ribbon diagram of the structural alignments of the HR1 substructure. The SARS‐CoV HR1 substructure (colored in
        <italic>
         green
        </italic>
        ) was superimposed with MHV (colored in
        <italic>
         purple
        </italic>
        ), MERS‐CoV (colored in
        <italic>
         magenta
        </italic>
        ), and hCoV‐NL63 (colored in
        <italic>
         orange
        </italic>
        ) HR1 substructures (RMSD = ∼0.4 Å). Conserved side chains within the HR1 substructure are shown for each virus. SARS‐CoV S2 residue numbering was used in both structural alignments.
        <bold>
         (B)
        </bold>
        Characterization of the groove on the surface of the HR1 inner core. The electrostatic surface potential of the HR1 region at the HR2 interface was depicted for the SARS‐CoV S2, MHV S2, MERS‐CoV S2, and hCoV‐NL63 S2 fusion cores. HR2 helical region residues extending alongside the HR1 inner core are shown as
        <italic>
         yellow sticks
        </italic>
        . Conserved HR2 residues interacting with the HR1 inner core are labeled accordingly. The structurally conserved HR1 core boundaries are indicated between the
        <italic>
         black dashed lines
        </italic>
        . Using computational solvent mapping, a hydrophobic pocket was identified, as shown by the green small molecules, on the HR1 substructure.
       </p>
      </caption>
      <graphic id="nlm-graphic-11" xlink:href="PRO-23-603-g006">
      </graphic>
     </fig>
     <p>
      Our discovery of a structurally conserved 42‐residue substructure on the HR1 region in SARS‐CoV, hCoV‐NL63, MERS‐CoV, and MHV S2 provides another target for drug development. The conserved HR1 substructure corresponds to the site of interaction for residues Leu1168 and Leu1175 from the HR2 helix [Fig.
      <xref ref-type="fig" rid="pro2442-fig-0006">
       6
      </xref>
      (A)]; these are the key HR2 hydrophobic residues involved in stabilizing the postfusion conformation. More importantly, a large amphipathic cavity with hydrophobic and polar character is present within the HR1 core substructure [Fig.
      <xref ref-type="fig" rid="pro2442-fig-0006">
       6
      </xref>
      (B)] that allows interaction with the critical Leu1175 hydrophobic residue. This HR1 substructure also coincides with the deep hydrophobic grooves previously identified on the HR1 coiled‐coil regions of the SARS‐CoV and MERS‐CoV S2 fusion core crystal structures.
      <xref ref-type="ref" rid="pro2442-bib-0031">
       31
      </xref>
      ,
      <xref ref-type="ref" rid="pro2442-bib-0070">
       70
      </xref>
      We rationalize that the conserved core maintains the structural integrity of the viral glycoprotein and acts as a foundation for conformational changes necessary for the fusion of the viral and host cell membranes. Inhibitors designed against this site have the potential to block formation of the fusion core complex of many coronaviruses.
     </p>
     <sec id="pro2442-sec-0009">
      <title>
       Conclusions
      </title>
      <p>
       SARS‐CoV entry requires binding to specific host cell receptors, and fusion of the viral and host cell membranes in a protease‐dependent manner. Biophysical and structural analyses of the S2 protein showed that hydrophobic amino acids occupying the “
       <italic>
        d
       </italic>
       ” position in the C‐terminal HR2 region are highly critical for the stability of the six‐helix bundle. These residues interact with a conserved substructure within the N‐terminal HR1 region and maintain the integrity of the fusion core in the postfusion state. The HR1 substructure is a common feature among many characterized CoV fusion proteins and provides a tangible target for small molecule and peptide fusion inhibitor design. A general strategy targeting this site could be used to combat disease caused by emerging or re‐emerging CoV's.
      </p>
     </sec>
    </sec>
    <sec id="pro2442-sec-0010">
     <title>
      Materials and Methods
     </title>
     <sec id="pro2442-sec-0011">
      <title>
       Cloning and site‐directed mutagenesis
      </title>
      <p>
       The gene sequence of SARS‐CoV S2 strain BJ302 clone 1 (GenBank accession: AY429072) was codon‐optimized and gene synthesized for expression in
       <italic>
        E. coli
       </italic>
       . The DNA corresponding to a linked two‐helix (L2H) SARS‐CoV S2 fusion core, containing HR1 residues 896–973 and HR2 residues 1142–1183 connected with a Gly–Gly–Ser–Gly–Gly–Ser linker, was cloned into pET‐46 Ek/LIC (EMD Millipore). A QuikChange site‐directed mutagenesis‐based protocol was used to generate the following single‐, double‐ and triple‐site SARS‐CoV S2 L2H mutants: Q902A, E918A, K929A, K929E, N937A, N942A, N951A, R965A, R965E, D967A, E970A, L1148A, I1151A, I1161A, E1164A, R1167A, R1167E, L1168A, L1175A, Q902A‐N937A, K929A‐R965A, K929E‐R965E, K929E‐R1167E, K929A‐R1167A, R965A‐R1167A, R965E‐R1167E, K929A‐R965A‐R1167A, and K929E‐R965E‐R1167E.
      </p>
     </sec>
     <sec id="pro2442-sec-0012">
      <title>
       Expression and purification of the SARS‐CoV S2 linked core
      </title>
      <p>
       Plasmids containing SARS‐CoV S2 L2H WT and mutants were transformed into the
       <italic>
        E. coli
       </italic>
       SHuffle T7 expression cell line (New England Biolabs). A single colony was inoculated into LB media supplemented with 100 μg/mL ampicillin and grown overnight at 37°C. About 20 mL of the overnight culture was then used to inoculate 1 L of LB media supplemented with 100 μg/mL ampicillin, and grown to OD
       <sub>
        600
       </sub>
       of 0.6 at 37°C. Protein expression was induced by the addition of isopropyl β‐
       <sc>
        d
       </sc>
       −1‐thiogalactopyranoside (IPTG) to a final concentration of 0.5 m
       <italic>
        M
       </italic>
       . The temperature was lowered to 18°C and harvested 18 hours post‐induction by centrifugation at 3000
       <italic>
        g
       </italic>
       . The bacterial cell pellet was resuspended in 25 mL 1× Ni‐NTA binding buffer (50 m
       <italic>
        M
       </italic>
       Tris‐HCl pH 7.5, 300 m
       <italic>
        M
       </italic>
       NaCl, and 20 m
       <italic>
        M
       </italic>
       imidazole) supplemented with 0.05% (w/v) CHAPS and 1× EDTA‐free protease inhibitor cocktail (Bioshop). A hydraulic cell disruption system (Constant Systems) was used to lyse the homogenized cell suspension at 30 kpsi, and the lysate was clarified by centrifugation at 36,500
       <italic>
        g
       </italic>
       for 45 min at 4°C. The supernatant was then loaded onto a 2 mL Ni‐NTA column (Thermo Pierce), and washed with 10 bed volumes of 1× Ni‐NTA binding buffer. The SARS‐CoV S2 L2H protein was eluted in sequential steps using increasing concentrations of imidazole (125 m
       <italic>
        M
       </italic>
       imidazole, 250 m
       <italic>
        M
       </italic>
       imidazole, 375 m
       <italic>
        M
       </italic>
       imidazole, or 500 m
       <italic>
        M
       </italic>
       imidazole in 1× Ni‐NTA buffer). The eluted SARS‐CoV S2 L2H protein was then concentrated and further purified by size exclusion chromatography on a prep grade Superdex‐75 10/300 column equilibrated with 10 m
       <italic>
        M
       </italic>
       K
       <sub>
        2
       </sub>
       HPO
       <sub>
        4
       </sub>
       /KH
       <sub>
        2
       </sub>
       PO
       <sub>
        4
       </sub>
       pH 7.5, 150 m
       <italic>
        M
       </italic>
       NaCl, and 0.05% (w/v) CHAPS. Protein concentration was quantified by absorbance at 280 nm, and protein purity was analyzed by SDS‐PAGE and electrospray mass spectrometry.
      </p>
     </sec>
     <sec id="pro2442-sec-0013">
      <title>
       Analytical ultracentrifugation (AUC)
      </title>
      <p>
       Sedimentation equilibrium experiments were performed in a Beckman Coulter Optima XL‐A analytical ultracentrifuge equipped with an An‐60 Ti rotor (Beckman‐Coulter, Palo Alto, CA) at the Analytical Ultracentrifugation Facility in the Department of Biochemistry at the University of Toronto. The experiments were carried out at 4°C using purified SARS‐CoV S2 L2H fusion core in 10 m
       <italic>
        M
       </italic>
       Tris‐HCl, 150 m
       <italic>
        M
       </italic>
       NaCl pH 7.5. About 20 μ
       <italic>
        M
       </italic>
       protein sample was centrifuged at three different speeds (18,000, 20,000, and 22,000 rpm) and migration of SARS‐CoV S2 L2H was monitored by absorbance at 230 and 280 nm over 60 hours. Data analysis was performed using the Origin MicroCal XL‐A/CL‐I Data Analysis Software Package Version 4.0.
      </p>
     </sec>
     <sec id="pro2442-sec-0014">
      <title>
       CD spectroscopy
      </title>
      <p>
       Purified SARS‐CoV S2 L2H proteins were characterized by CD spectroscopy on a Jasco J‐810 spectropolarimeter using 1 mm quartz cuvettes (Helma).
      </p>
      <sec id="pro2442-sec-0015">
       <title>
        Wavelength scans
       </title>
       <p>
        Wavelength spectra were recorded from 190 to 250 nm for wild‐type and mutant SARS‐CoV S2 L2H in 10 m
        <italic>
         M
        </italic>
        K
        <sub>
         2
        </sub>
        HPO
        <sub>
         4
        </sub>
        /KH
        <sub>
         2
        </sub>
        PO
        <sub>
         4
        </sub>
        pH 7.5, 150 m
        <italic>
         M
        </italic>
        NaCl, and 0.05% (w/v) CHAPS buffer at 20°C to determine overall protein secondary structural changes due to the mutation. Five spectra were acquired and averaged, with the results reported as molar ellipticity [
        <italic>
         θ
        </italic>
        ] (units of deg cm
        <sup>
         2
        </sup>
        dmol
        <sup>
         −1
        </sup>
        ). The α‐helical content of wild‐type SARS‐CoV S2 L2H was calculated from the experimental CD wavelength scans using the SELCON3 algorithm in the program DichroWeb.
        <xref ref-type="ref" rid="pro2442-bib-0071">
         71
        </xref>
       </p>
      </sec>
      <sec id="pro2442-sec-0016">
       <title>
        Thermal denaturation scans
       </title>
       <p>
        The relative thermal stabilities of SARS‐CoV S2 L2H mutants were performed by heating the sample from 20°C to 99°C at 0.2°C intervals and monitoring the loss of CD signal at 222 nm. Heating alone was insufficient to denature the predominantly helical SARS‐CoV S2 L2H fusion core. Similar to previous studies,
        <xref ref-type="ref" rid="pro2442-bib-0072">
         72
        </xref>
        4
        <italic>
         M
        </italic>
        guanidine hydrochloride was added to all samples to facilitate unfolding within a temperature range of 20°C–99°C. Ellipticity readings for thermal denaturation data were baseline corrected, normalized between 0 (folded) and 1 (unfolded) and fit to a non‐linear biphasic sigmoidal curve in Graphpad. Values of midpoint unfolding transitions (
        <italic>
         T
        </italic>
        <sub>
         m
        </sub>
        ) were calculated from thermal melt curves and they correspond to the temperature where 50% of the protein has unfolded.
       </p>
      </sec>
      <sec id="pro2442-sec-0017">
       <title>
        pH scans
       </title>
       <p>
        In order to study the effects of pH on the stability of the SARS‐CoV S2 L2H fusion core, the purified proteins were buffer exchanged using an Amicon Ultra‐0.5 centrifugal concentrator (10 kDa molecular weight cut off) into the following buffer conditions: pH 4.0–6.5, sodium acetate (NaOAc) buffer (10 m
        <italic>
         M
        </italic>
        NaOAc, 150 m
        <italic>
         M
        </italic>
        NaCl, and 0.05% (w/v) CHAPS); pH 7.0–8.5, Tris‐HCl buffer (10 m
        <italic>
         M
        </italic>
        Tris‐HCl, 150 m
        <italic>
         M
        </italic>
        NaCl, and 0.05% (w/v) CHAPS). CD wavelength scans and thermal melts as a function of pH were performed as described above. The pH may exhibit fluctuations within the buffering range during the CD thermal melt experiments due to temperature‐dependent phenomenon of the buffer.
       </p>
      </sec>
     </sec>
     <sec id="pro2442-sec-0018">
      <title>
       Structural comparison and analysis
      </title>
      <p>
       Coronavirus fusion protein structures used for structural comparisons were obtained from the Protein Data Bank (1WNC, 1WYY, 1ZV7, 1ZV8, 1ZVA, 1ZVB, 2BEQ, and 2BEZ for SARS‐CoV S2; 4MOD for MERS‐CoV S2; 1WDF and 1WDG for MHV S2; and 2IEQ for hCoV‐NL63 S2). Superimpositions of three‐dimensional structures and root mean squared deviation (RMSD) calculations were obtained using the pair‐wise alignment of the CLICK server.
       <xref ref-type="ref" rid="pro2442-bib-0073">
        73
       </xref>
       Identification of pockets on the surface of the SARS‐CoV conserved substructure was performed by computational solvent mapping using the FTMap server.
       <xref ref-type="ref" rid="pro2442-bib-0074">
        74
       </xref>
      </p>
     </sec>
    </sec>
    <back>
     <ack id="pro2442-sec-0019">
      <title>
       Acknowledgments
      </title>
      <p>
       The authors would like to thank the Molecular Structure &amp; Function program at the Hospital for Sick Children Research Institute (Toronto, ON) for access to the circular dichroism spectrometer, Drs. Walid Houry and Yoshito Kakihara for assistance with the sedimentation equilibrium ultracentrifugation experiments, and Dr. Karen Siu for critical reading of the manuscript.
      </p>
     </ack>
     <ref-list content-type="cited-references">
      <title>
       References
      </title>
      <ref id="pro2442-bib-0001">
       <label>
        1
       </label>
       <mixed-citation id="pro2442-cit-0001" publication-type="journal">
        <string-name>
         <surname>
          Perlman
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Netland
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Coronaviruses post‐SARS: update on replication and pathogenesis
        </article-title>
        .
        <source xml:lang="en">
         Nat Rev Microbiol
        </source>
        <volume>
         7
        </volume>
        :
        <fpage>
         439
        </fpage>
        –
        <lpage>
         450
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19430490
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0002">
       <label>
        2
       </label>
       <mixed-citation id="pro2442-cit-0002" publication-type="journal">
        <string-name>
         <surname>
          Ksiazek
         </surname>
         <given-names>
          TG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Erdman
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Goldsmith
         </surname>
         <given-names>
          CS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zaki
         </surname>
         <given-names>
          SR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Peret
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Emery
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tong
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Urbani
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Comer
         </surname>
         <given-names>
          JA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lim
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rollin
         </surname>
         <given-names>
          PE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dowell
         </surname>
         <given-names>
          SF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ling
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Humphrey
         </surname>
         <given-names>
          CD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shieh
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Guarner
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Paddock
         </surname>
         <given-names>
          CD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rota
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fields
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          DeRisi
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yang
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cox
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hughes
         </surname>
         <given-names>
          JM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          LeDuc
         </surname>
         <given-names>
          JW
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bellini
         </surname>
         <given-names>
          WJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Anderson
         </surname>
         <given-names>
          LJ
         </given-names>
        </string-name>
        , and the SARS Working Group (
        <year>
         2003
        </year>
        )
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        .
        <source xml:lang="en">
         N Engl J Med
        </source>
        <volume>
         348
        </volume>
        :
        <fpage>
         1953
        </fpage>
        –
        <lpage>
         1966
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0003">
       <label>
        3
       </label>
       <mixed-citation id="pro2442-cit-0003" publication-type="journal">
        <string-name>
         <surname>
          Rota
         </surname>
         <given-names>
          PA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Oberste
         </surname>
         <given-names>
          MS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Monroe
         </surname>
         <given-names>
          SS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Nix
         </surname>
         <given-names>
          WA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Campagnoli
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Icenogle
         </surname>
         <given-names>
          JP
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Peñaranda
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bankamp
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Maher
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chen
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tong
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tamin
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lowe
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Frace
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          DeRisi
         </surname>
         <given-names>
          JL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chen
         </surname>
         <given-names>
          Q
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Erdman
         </surname>
         <given-names>
          DD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Peret
         </surname>
         <given-names>
          TCT
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Burns
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ksiazek
         </surname>
         <given-names>
          TG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rollin
         </surname>
         <given-names>
          PE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sanchez
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liffick
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Holloway
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Limor
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          McCaustland
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Olsen‐Rasmussen
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fouchier
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Günther
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Osterhaus
         </surname>
         <given-names>
          ADME
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Drosten
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pallansch
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Anderson
         </surname>
         <given-names>
          LJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bellini
         </surname>
         <given-names>
          WJ
         </given-names>
        </string-name>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Characterization of a novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        .
        <source xml:lang="en">
         Science
        </source>
        <volume>
         300
        </volume>
        :
        <fpage>
         1394
        </fpage>
        –
        <lpage>
         1399
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12730500
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0004">
       <label>
        4
       </label>
       <mixed-citation id="pro2442-cit-0004" publication-type="journal">
        <string-name>
         <surname>
          Drosten
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Günther
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Preiser
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van der Werf
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Brodt
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Becker
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rabenau
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Panning
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kolesnikova
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fouchier
         </surname>
         <given-names>
          RAM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Berger
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Burguière
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cinatl
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Eickmann
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Escriou
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Grywna
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kramme
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Manuguerra
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Müller
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rickerts
         </surname>
         <given-names>
          V
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Stürmer
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Vieth
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Klenk
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Osterhaus
         </surname>
         <given-names>
          ADME
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Schmitz
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Doerr
         </surname>
         <given-names>
          HW
         </given-names>
        </string-name>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        .
        <source xml:lang="en">
         N Engl J Med
        </source>
        <volume>
         348
        </volume>
        :
        <fpage>
         1967
        </fpage>
        –
        <lpage>
         1976
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0005">
       <label>
        5
       </label>
       <mixed-citation id="pro2442-cit-0005" publication-type="journal">
        <string-name>
         <surname>
          Gerlier
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Emerging zoonotic viruses: new lessons on receptor and entry mechanisms
        </article-title>
        .
        <source xml:lang="en">
         Curr Opin Virol
        </source>
        <volume>
         1
        </volume>
        :
        <fpage>
         27
        </fpage>
        –
        <lpage>
         34
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22440564
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0006">
       <label>
        6
       </label>
       <mixed-citation id="pro2442-cit-0006" publication-type="journal">
        <string-name>
         <surname>
          Bolles
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Donaldson
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Baric
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         SARS‐CoV and emergent coronaviruses: viral determinants of interspecies transmission
        </article-title>
        .
        <source xml:lang="en">
         Curr Opin Virol
        </source>
        <volume>
         1
        </volume>
        :
        <fpage>
         624
        </fpage>
        –
        <lpage>
         634
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22180768
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0007">
       <label>
        7
       </label>
       <mixed-citation id="pro2442-cit-0007" publication-type="journal">
        <string-name>
         <surname>
          Zaki
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van Boheemen
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bestebroer
         </surname>
         <given-names>
          TM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Osterhaus
         </surname>
         <given-names>
          ADME
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fouchier
         </surname>
         <given-names>
          RAM
         </given-names>
        </string-name>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        .
        <source xml:lang="en">
         N Engl J Med
        </source>
        <volume>
         367
        </volume>
        :
        <fpage>
         1814
        </fpage>
        –
        <lpage>
         1820
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0008">
       <label>
        8
       </label>
       <mixed-citation id="pro2442-cit-0008" publication-type="miscellaneous">
        <collab collab-type="authors">
         Centers for Disease Control and Prevention
        </collab>
        (
        <year>
         2013
        </year>
        ) CDC ‐ Coronavirus ‐ Middle East Respiratory Syndrome ‐ MERS‐CoV.
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/coronavirus/mers/">
         http://www.cdc.gov/coronavirus/mers/
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0009">
       <label>
        9
       </label>
       <mixed-citation id="pro2442-cit-0009" publication-type="journal">
        <string-name>
         <surname>
          Tong
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Conrardy
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ruone
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kuzmin
         </surname>
         <given-names>
          IV
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Guo
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tao
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Niezgoda
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Haynes
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Agwanda
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Breiman
         </surname>
         <given-names>
          RF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Anderson
         </surname>
         <given-names>
          LJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rupprecht
         </surname>
         <given-names>
          CE
         </given-names>
        </string-name>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Detection of novel SARS‐like and other coronaviruses in bats from Kenya
        </article-title>
        .
        <source xml:lang="en">
         Emerg Infect Dis
        </source>
        <volume>
         15
        </volume>
        :
        <fpage>
         482
        </fpage>
        –
        <lpage>
         485
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19239771
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0010">
       <label>
        10
       </label>
       <mixed-citation id="pro2442-cit-0010" publication-type="journal">
        <string-name>
         <surname>
          Ge
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yang
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chmura
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhu
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Epstein
         </surname>
         <given-names>
          JH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mazet
         </surname>
         <given-names>
          JK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hu
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhang
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Peng
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Luo
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tan
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhu
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Crameri
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhang
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Daszak
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shi
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Isolation and characterization of a bat SARS‐like coronavirus that uses the ACE2 receptor
        </article-title>
        .
        <source xml:lang="en">
         Nature
        </source>
        <volume>
         503
        </volume>
        :
        <fpage>
         535
        </fpage>
        –
        <lpage>
         538
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0011">
       <label>
        11
       </label>
       <mixed-citation id="pro2442-cit-0011" publication-type="journal">
        <string-name>
         <surname>
          Heald‐Sargent
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gallagher
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence
        </article-title>
        .
        <source xml:lang="en">
         Viruses
        </source>
        <volume>
         4
        </volume>
        :
        <fpage>
         557
        </fpage>
        –
        <lpage>
         580
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22590686
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0012">
       <label>
        12
       </label>
       <mixed-citation id="pro2442-cit-0012" publication-type="journal">
        <string-name>
         <surname>
          Du
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          He
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zheng
         </surname>
         <given-names>
          B‐J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jiang
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         The spike protein of SARS‐CoV — a target for vaccine and therapeutic development
        </article-title>
        .
        <source xml:lang="en">
         Nat Rev Microbiol
        </source>
        <volume>
         7
        </volume>
        :
        <fpage>
         226
        </fpage>
        –
        <lpage>
         236
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0013">
       <label>
        13
       </label>
       <mixed-citation id="pro2442-cit-0013" publication-type="journal">
        <string-name>
         <surname>
          Hofmann
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pöhlmann
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Cellular entry of the SARS coronavirus
        </article-title>
        .
        <source xml:lang="en">
         Trends Microbiol
        </source>
        <volume>
         12
        </volume>
        :
        <fpage>
         466
        </fpage>
        –
        <lpage>
         472
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15381196
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0014">
       <label>
        14
       </label>
       <mixed-citation id="pro2442-cit-0014" publication-type="journal">
        <string-name>
         <surname>
          Bartlam
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yang
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rao
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Structural insights into SARS coronavirus proteins
        </article-title>
        .
        <source xml:lang="en">
         Curr Opin Struct Biol
        </source>
        <volume>
         15
        </volume>
        :
        <fpage>
         664
        </fpage>
        –
        <lpage>
         672
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16263266
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0015">
       <label>
        15
       </label>
       <mixed-citation id="pro2442-cit-0015" publication-type="journal">
        <string-name>
         <surname>
          Harrison
         </surname>
         <given-names>
          SC
         </given-names>
        </string-name>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Viral membrane fusion
        </article-title>
        .
        <source xml:lang="en">
         Nat Struct Mol Biol
        </source>
        <volume>
         15
        </volume>
        :
        <fpage>
         690
        </fpage>
        –
        <lpage>
         698
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18596815
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0016">
       <label>
        16
       </label>
       <mixed-citation id="pro2442-cit-0016" publication-type="journal">
        <string-name>
         <surname>
          White
         </surname>
         <given-names>
          JM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Delos
         </surname>
         <given-names>
          SE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Brecher
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Schornberg
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Structures and mechanisms of viral membrane fusion proteins
        </article-title>
        .
        <source xml:lang="en">
         Crit Rev Biochem Mol Biol
        </source>
        <volume>
         43
        </volume>
        :
        <fpage>
         189
        </fpage>
        –
        <lpage>
         219
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18568847
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0017">
       <label>
        17
       </label>
       <mixed-citation id="pro2442-cit-0017" publication-type="journal">
        <string-name>
         <surname>
          Mothes
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Boerger
         </surname>
         <given-names>
          AL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Narayan
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cunningham
         </surname>
         <given-names>
          JM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Young
         </surname>
         <given-names>
          JAT
         </given-names>
        </string-name>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein
        </article-title>
        .
        <source xml:lang="en">
         Cell
        </source>
        <volume>
         103
        </volume>
        :
        <fpage>
         679
        </fpage>
        –
        <lpage>
         689
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11106737
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0018">
       <label>
        18
       </label>
       <mixed-citation id="pro2442-cit-0018" publication-type="journal">
        <string-name>
         <surname>
          Matsuyama
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Taguchi
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Two‐step conformational changes in a coronavirus envelope glycoprotein mediated by receptor binding and proteolysis
        </article-title>
        .
        <source xml:lang="en">
         J Virol
        </source>
        <volume>
         83
        </volume>
        :
        <fpage>
         11133
        </fpage>
        –
        <lpage>
         11141
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19706706
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0019">
       <label>
        19
       </label>
       <mixed-citation id="pro2442-cit-0019" publication-type="journal">
        <string-name>
         <surname>
          Bale
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Abelson
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fusco
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Woods
         </surname>
         <given-names>
          VL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ollmann Saphire
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion
        </article-title>
        .
        <source xml:lang="en">
         PLoS Negl Trop Dis
        </source>
        <volume>
         5
        </volume>
        :
        <fpage>
         e1395
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         22102923
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0020">
       <label>
        20
       </label>
       <mixed-citation id="pro2442-cit-0020" publication-type="journal">
        <string-name>
         <surname>
          Brecher
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Schornberg
         </surname>
         <given-names>
          KL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Delos
         </surname>
         <given-names>
          SE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fusco
         </surname>
         <given-names>
          ML
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Saphire
         </surname>
         <given-names>
          EO
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          White
         </surname>
         <given-names>
          JM
         </given-names>
        </string-name>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion‐relevant conformational change
        </article-title>
        .
        <source xml:lang="en">
         J Virol
        </source>
        <volume>
         86
        </volume>
        :
        <fpage>
         364
        </fpage>
        –
        <lpage>
         372
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22031933
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0021">
       <label>
        21
       </label>
       <mixed-citation id="pro2442-cit-0021" publication-type="journal">
        <string-name>
         <surname>
          De Haan
         </surname>
         <given-names>
          CAM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Stadler
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Godeke
         </surname>
         <given-names>
          G‐J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bosch
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rottier
         </surname>
         <given-names>
          PJM
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Cleavage inhibition of the murine voronavirus spike protein by a furin‐like enzyme affects cell‐cell but not virus‐cell rusion
        </article-title>
        .
        <source xml:lang="en">
         J Virol
        </source>
        <volume>
         78
        </volume>
        :
        <fpage>
         6048
        </fpage>
        –
        <lpage>
         6054
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15141003
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0022">
       <label>
        22
       </label>
       <mixed-citation id="pro2442-cit-0022" publication-type="journal">
        <string-name>
         <surname>
          Belouzard
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chu
         </surname>
         <given-names>
          VC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Whittaker
         </surname>
         <given-names>
          GR
         </given-names>
        </string-name>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         106
        </volume>
        :
        <fpage>
         5871
        </fpage>
        –
        <lpage>
         5876
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19321428
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0023">
       <label>
        23
       </label>
       <mixed-citation id="pro2442-cit-0023" publication-type="journal">
        <string-name>
         <surname>
          Matsuyama
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ujike
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Morikawa
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tashiro
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Taguchi
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Protease‐mediated enhancement of severe acute respiratory syndrome coronavirus infection
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         102
        </volume>
        :
        <fpage>
         12543
        </fpage>
        –
        <lpage>
         12547
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16116101
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0024">
       <label>
        24
       </label>
       <mixed-citation id="pro2442-cit-0024" publication-type="journal">
        <string-name>
         <surname>
          Simmons
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Reeves
         </surname>
         <given-names>
          JD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rennekamp
         </surname>
         <given-names>
          AJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Amberg
         </surname>
         <given-names>
          SM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Piefer
         </surname>
         <given-names>
          AJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bates
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Characterization of severe acute respiratory syndrome‐associated coronavirus (SARS‐CoV) spike glycoprotein‐mediated viral entry
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         101
        </volume>
        :
        <fpage>
         4240
        </fpage>
        –
        <lpage>
         4245
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15010527
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0025">
       <label>
        25
       </label>
       <mixed-citation id="pro2442-cit-0025" publication-type="journal">
        <string-name>
         <surname>
          Simmons
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gosalia
         </surname>
         <given-names>
          DN
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rennekamp
         </surname>
         <given-names>
          AJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Reeves
         </surname>
         <given-names>
          JD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Diamond
         </surname>
         <given-names>
          SL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bates
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         102
        </volume>
        :
        <fpage>
         11876
        </fpage>
        –
        <lpage>
         11881
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16081529
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0026">
       <label>
        26
       </label>
       <mixed-citation id="pro2442-cit-0026" publication-type="journal">
        <string-name>
         <surname>
          Du
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kao
         </surname>
         <given-names>
          RY
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          He
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhao
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wong
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jiang
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yuen
         </surname>
         <given-names>
          K‐Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jin
         </surname>
         <given-names>
          D‐Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zheng
         </surname>
         <given-names>
          B‐J
         </given-names>
        </string-name>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity
        </article-title>
        .
        <source xml:lang="en">
         Biochem Biophys Res Commun
        </source>
        <volume>
         359
        </volume>
        :
        <fpage>
         174
        </fpage>
        –
        <lpage>
         179
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17533109
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0027">
       <label>
        27
       </label>
       <mixed-citation id="pro2442-cit-0027" publication-type="journal">
        <string-name>
         <surname>
          Bosch
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bartelink
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rottier
         </surname>
         <given-names>
          PJM
         </given-names>
        </string-name>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide
        </article-title>
        .
        <source xml:lang="en">
         J Virol
        </source>
        <volume>
         82
        </volume>
        :
        <fpage>
         8887
        </fpage>
        –
        <lpage>
         8890
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18562523
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0028">
       <label>
        28
       </label>
       <mixed-citation id="pro2442-cit-0028" publication-type="journal">
        <string-name>
         <surname>
          Bosch
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Martina
         </surname>
         <given-names>
          BEE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zee
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        <string-name>
         <surname>
          van der Lepault
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Haijema
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Versluis
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Heck
         </surname>
         <given-names>
          AJR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Groot
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        <string-name>
         <surname>
          de Osterhaus
         </surname>
         <given-names>
          ADME
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rottier
         </surname>
         <given-names>
          PJM
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Severe acute respiratory syndrome coronavirus (SARS‐CoV) infection inhibition using spike protein heptad repeat‐derived peptides
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         101
        </volume>
        :
        <fpage>
         8455
        </fpage>
        –
        <lpage>
         8460
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15150417
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0029">
       <label>
        29
       </label>
       <mixed-citation id="pro2442-cit-0029" publication-type="journal">
        <string-name>
         <surname>
          Supekar
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bruckmann
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ingallinella
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bianchi
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pessi
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Carfí
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci
        </source>
        <volume>
         101
        </volume>
        :
        <fpage>
         17958
        </fpage>
        –
        <lpage>
         17963
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15604146
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0030">
       <label>
        30
       </label>
       <mixed-citation id="pro2442-cit-0030" publication-type="journal">
        <string-name>
         <surname>
          Duquerroy
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Vigouroux
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rottier
         </surname>
         <given-names>
          PJM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rey
         </surname>
         <given-names>
          FA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bosch
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Central ions and lateral asparagine/glutamine zippers stabilize the post‐fusion hairpin conformation of the SARS coronavirus spike glycoprotein
        </article-title>
        .
        <source xml:lang="en">
         Virology
        </source>
        <volume>
         335
        </volume>
        :
        <fpage>
         276
        </fpage>
        –
        <lpage>
         285
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15840526
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0031">
       <label>
        31
       </label>
       <mixed-citation id="pro2442-cit-0031" publication-type="journal">
        <string-name>
         <surname>
          Xu
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lou
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pang
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tien
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gao
         </surname>
         <given-names>
          GF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rao
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core
        </article-title>
        .
        <source xml:lang="en">
         J Biol Chem
        </source>
        <volume>
         279
        </volume>
        :
        <fpage>
         49414
        </fpage>
        –
        <lpage>
         49419
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15345712
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0032">
       <label>
        32
       </label>
       <mixed-citation id="pro2442-cit-0032" publication-type="journal">
        <string-name>
         <surname>
          Xu
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhu
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lou
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yuan
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cole
         </surname>
         <given-names>
          DK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ni
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Su
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Qin
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bai
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bell
         </surname>
         <given-names>
          JI
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pang
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tien
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gao
         </surname>
         <given-names>
          GF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rao
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus
        </article-title>
        .
        <source xml:lang="en">
         Biochemistry
        </source>
        <volume>
         43
        </volume>
        :
        <fpage>
         14064
        </fpage>
        –
        <lpage>
         14071
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15518555
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0033">
       <label>
        33
       </label>
       <mixed-citation id="pro2442-cit-0033" publication-type="journal">
        <string-name>
         <surname>
          Nomura
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kiyota
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Suzaki
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kataoka
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ohe
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Miyamoto
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Senda
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fujimoto
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Human coronavirus 229E binds to CD13 in rafts and enters the cell through Caveolae
        </article-title>
        .
        <source xml:lang="en">
         J Virol
        </source>
        <volume>
         78
        </volume>
        :
        <fpage>
         8701
        </fpage>
        –
        <lpage>
         8708
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15280478
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0034">
       <label>
        34
       </label>
       <mixed-citation id="pro2442-cit-0034" publication-type="journal">
        <string-name>
         <surname>
          Nash
         </surname>
         <given-names>
          TC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Buchmeier
         </surname>
         <given-names>
          MJ
         </given-names>
        </string-name>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Entry of mouse hepatitis virus into cells by endosomal and nonendosomal pathways
        </article-title>
        .
        <source xml:lang="en">
         Virology
        </source>
        <volume>
         233
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9201212
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0035">
       <label>
        35
       </label>
       <mixed-citation id="pro2442-cit-0035" publication-type="journal">
        <string-name>
         <surname>
          Zhu
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Xiao
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Xu
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yuan
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zheng
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yan
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cole
         </surname>
         <given-names>
          DK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bell
         </surname>
         <given-names>
          JI
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rao
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tien
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gao
         </surname>
         <given-names>
          GF
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Following the rule: formation of the 6‐helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors
        </article-title>
        .
        <source xml:lang="en">
         Biochem Biophys Res Commun
        </source>
        <volume>
         319
        </volume>
        :
        <fpage>
         283
        </fpage>
        –
        <lpage>
         288
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15158473
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0036">
       <label>
        36
       </label>
       <mixed-citation id="pro2442-cit-0036" publication-type="journal">
        <string-name>
         <surname>
          Bosshard
         </surname>
         <given-names>
          HR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Marti
         </surname>
         <given-names>
          DN
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jelesarov
         </surname>
         <given-names>
          I
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Protein stabilization by salt bridges: concepts, experimental approaches and clarification of some misunderstandings
        </article-title>
        .
        <source xml:lang="en">
         J Mol Recognit
        </source>
        <volume>
         17
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         16
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14872533
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0037">
       <label>
        37
       </label>
       <mixed-citation id="pro2442-cit-0037" publication-type="journal">
        <string-name>
         <surname>
          Fass
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Harrison
         </surname>
         <given-names>
          SC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kim
         </surname>
         <given-names>
          PS
         </given-names>
        </string-name>
        (
        <year>
         1996
        </year>
        )
        <article-title>
         Retrovirus envelope domain at 1.7 Å resolution
        </article-title>
        .
        <source xml:lang="en">
         Nat Struct Mol Biol
        </source>
        <volume>
         3
        </volume>
        :
        <fpage>
         465
        </fpage>
        –
        <lpage>
         469
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0038">
       <label>
        38
       </label>
       <mixed-citation id="pro2442-cit-0038" publication-type="journal">
        <string-name>
         <surname>
          Kobe
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Center
         </surname>
         <given-names>
          RJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kemp
         </surname>
         <given-names>
          BE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Poumbourios
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        (
        <year>
         1999
        </year>
        )
        <article-title>
         Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose‐binding protein chimera reveals structural evolution of retroviral transmembrane proteins
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         96
        </volume>
        :
        <fpage>
         4319
        </fpage>
        –
        <lpage>
         4324
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10200260
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0039">
       <label>
        39
       </label>
       <mixed-citation id="pro2442-cit-0039" publication-type="journal">
        <string-name>
         <surname>
          Weissenhorn
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Carfí
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lee
         </surname>
         <given-names>
          K‐H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Skehel
         </surname>
         <given-names>
          JJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wiley
         </surname>
         <given-names>
          DC
         </given-names>
        </string-name>
        (
        <year>
         1998
        </year>
        )
        <article-title>
         Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain
        </article-title>
        .
        <source xml:lang="en">
         Mol Cell
        </source>
        <volume>
         2
        </volume>
        :
        <fpage>
         605
        </fpage>
        –
        <lpage>
         616
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9844633
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0040">
       <label>
        40
       </label>
       <mixed-citation id="pro2442-cit-0040" publication-type="journal">
        <string-name>
         <surname>
          Harrison
         </surname>
         <given-names>
          JS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Higgins
         </surname>
         <given-names>
          CD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chandran
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lai
         </surname>
         <given-names>
          JR
         </given-names>
        </string-name>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Designed protein mimics of the Ebola virus glycoprotein GP2 α‐helical bundle: stability and pH effects
        </article-title>
        .
        <source xml:lang="en">
         Protein Sci
        </source>
        <volume>
         20
        </volume>
        :
        <fpage>
         1587
        </fpage>
        –
        <lpage>
         1596
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21739501
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0041">
       <label>
        41
       </label>
       <mixed-citation id="pro2442-cit-0041" publication-type="journal">
        <string-name>
         <surname>
          Aydin
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Smrke
         </surname>
         <given-names>
          BM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lee
         </surname>
         <given-names>
          JE
         </given-names>
        </string-name>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Structural characterization of a fusion glycoprotein from a retrovirus that undergoes a hybrid 2‐step entry mechanism
        </article-title>
        .
        <source xml:lang="en">
         FASEB J
        </source>
        <volume>
         27
        </volume>
        :
        <fpage>
         5059
        </fpage>
        –
        <lpage>
         5071
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24036886
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0042">
       <label>
        42
       </label>
       <mixed-citation id="pro2442-cit-0042" publication-type="journal">
        <string-name>
         <surname>
          Yang
         </surname>
         <given-names>
          Z‐Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Huang
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ganesh
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Leung
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kong
         </surname>
         <given-names>
          W‐P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Schwartz
         </surname>
         <given-names>
          O
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Subbarao
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Nabel
         </surname>
         <given-names>
          GJ
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         pH‐dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC‐SIGN
        </article-title>
        .
        <source xml:lang="en">
         J Virol
        </source>
        <volume>
         78
        </volume>
        :
        <fpage>
         5642
        </fpage>
        –
        <lpage>
         5650
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15140961
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0043">
       <label>
        43
       </label>
       <mixed-citation id="pro2442-cit-0043" publication-type="journal">
        <string-name>
         <surname>
          Ujike
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Nishikawa
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Otaka
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yamamoto
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yamamoto
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Matsuoka
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kodama
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fujii
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Taguchi
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Heptad repeat‐derived peptides block protease‐mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway
        </article-title>
        .
        <source xml:lang="en">
         J Virol
        </source>
        <volume>
         82
        </volume>
        :
        <fpage>
         588
        </fpage>
        –
        <lpage>
         592
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17942557
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0044">
       <label>
        44
       </label>
       <mixed-citation id="pro2442-cit-0044" publication-type="journal">
        <string-name>
         <surname>
          McClure
         </surname>
         <given-names>
          MO
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sommerfelt
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Marsh
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Weiss
         </surname>
         <given-names>
          RA
         </given-names>
        </string-name>
        (
        <year>
         1990
        </year>
        )
        <article-title>
         The pH independence of mammalian retrovirus infection
        </article-title>
        .
        <source xml:lang="en">
         J Gen Virol
        </source>
        <volume>
         71
        </volume>
        :
        <fpage>
         767
        </fpage>
        –
        <lpage>
         773
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2157795
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0045">
       <label>
        45
       </label>
       <mixed-citation id="pro2442-cit-0045" publication-type="journal">
        <string-name>
         <surname>
          Côté
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zheng
         </surname>
         <given-names>
          Y‐M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          S‐L
         </given-names>
        </string-name>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Membrane fusion and cell entry of XMRV are pH‐independent and modulated by the envelope glycoprotein's cytoplasmic tail
        </article-title>
        .
        <source xml:lang="en">
         PLoS ONE
        </source>
        <volume>
         7
        </volume>
        :
        <fpage>
         e33734
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         22479434
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0046">
       <label>
        46
       </label>
       <mixed-citation id="pro2442-cit-0046" publication-type="journal">
        <string-name>
         <surname>
          Aydin
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cook
         </surname>
         <given-names>
          JD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lee
         </surname>
         <given-names>
          JE
         </given-names>
        </string-name>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Crystal structures of beta‐ and gamma retrovirus fusion proteins reveal a role for electrostatic stapling in viral entry
        </article-title>
        .
        <source xml:lang="en">
         J Virol
        </source>
        <volume>
         88
        </volume>
        :
        <fpage>
         143
        </fpage>
        –
        <lpage>
         153
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24131724
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0047">
       <label>
        47
       </label>
       <mixed-citation id="pro2442-cit-0047" publication-type="journal">
        <string-name>
         <surname>
          Maerz
         </surname>
         <given-names>
          AL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Center
         </surname>
         <given-names>
          RJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kemp
         </surname>
         <given-names>
          BE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kobe
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Poumbourios
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        (
        <year>
         2000
        </year>
        )
        <article-title>
         Functional implications of the human T‐lymphotropic virus type 1 transmembrane glycoprotein helical hairpin structure
        </article-title>
        .
        <source xml:lang="en">
         J Virol
        </source>
        <volume>
         74
        </volume>
        :
        <fpage>
         6614
        </fpage>
        –
        <lpage>
         6621
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10864675
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0048">
       <label>
        48
       </label>
       <mixed-citation id="pro2442-cit-0048" publication-type="journal">
        <string-name>
         <surname>
          Igonet
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Vaney
         </surname>
         <given-names>
          M‐C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Vonrhein
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bricogne
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Stura
         </surname>
         <given-names>
          EA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hengartner
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Eschli
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rey
         </surname>
         <given-names>
          FA
         </given-names>
        </string-name>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         X‐ray structure of the arenavirus glycoprotein GP2 in its postfusion hairpin conformation
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         108
        </volume>
        :
        <fpage>
         19967
        </fpage>
        –
        <lpage>
         19972
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22123988
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0049">
       <label>
        49
       </label>
       <mixed-citation id="pro2442-cit-0049" publication-type="journal">
        <string-name>
         <surname>
          Bullough
         </surname>
         <given-names>
          PA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hughson
         </surname>
         <given-names>
          FM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Skehel
         </surname>
         <given-names>
          JJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wiley
         </surname>
         <given-names>
          DC
         </given-names>
        </string-name>
        (
        <year>
         1994
        </year>
        )
        <article-title>
         Structure of influenza haemagglutinin at the pH of membrane fusion
        </article-title>
        .
        <source xml:lang="en">
         Nature
        </source>
        <volume>
         371
        </volume>
        :
        <fpage>
         37
        </fpage>
        –
        <lpage>
         43
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8072525
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0050">
       <label>
        50
       </label>
       <mixed-citation id="pro2442-cit-0050" publication-type="journal">
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Moore
         </surname>
         <given-names>
          MJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Vasilieva
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sui
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wong
         </surname>
         <given-names>
          SK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Berne
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Somasundaran
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sullivan
         </surname>
         <given-names>
          JL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Luzuriaga
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Greenough
         </surname>
         <given-names>
          TC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Choe
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Farzan
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        (
        <year>
         2003
        </year>
        )
        <article-title>
         Angiotensin‐converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        .
        <source xml:lang="en">
         Nature
        </source>
        <volume>
         426
        </volume>
        :
        <fpage>
         450
        </fpage>
        –
        <lpage>
         454
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0051">
       <label>
        51
       </label>
       <mixed-citation id="pro2442-cit-0051" publication-type="journal">
        <string-name>
         <surname>
          Hofmann
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pyrc
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hoek
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        <string-name>
         <surname>
          van der Geier
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Berkhout
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pöhlmann
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         102
        </volume>
        :
        <fpage>
         7988
        </fpage>
        –
        <lpage>
         7993
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15897467
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0052">
       <label>
        52
       </label>
       <mixed-citation id="pro2442-cit-0052" publication-type="journal">
        <string-name>
         <surname>
          Williams
         </surname>
         <given-names>
          RK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jiang
         </surname>
         <given-names>
          GS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Holmes
         </surname>
         <given-names>
          KV
         </given-names>
        </string-name>
        (
        <year>
         1991
        </year>
        )
        <article-title>
         Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         88
        </volume>
        :
        <fpage>
         5533
        </fpage>
        –
        <lpage>
         5536
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1648219
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0053">
       <label>
        53
       </label>
       <mixed-citation id="pro2442-cit-0053" publication-type="journal">
        <string-name>
         <surname>
          Yeager
         </surname>
         <given-names>
          CL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ashmun
         </surname>
         <given-names>
          RA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Williams
         </surname>
         <given-names>
          RK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cardellichio
         </surname>
         <given-names>
          CB
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shapiro
         </surname>
         <given-names>
          LH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Look
         </surname>
         <given-names>
          AT
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Holmes
         </surname>
         <given-names>
          KV
         </given-names>
        </string-name>
        (
        <year>
         1992
        </year>
        )
        <article-title>
         Human aminopeptidase N is a receptor for human coronavirus 229E
        </article-title>
        .
        <source xml:lang="en">
         Nature
        </source>
        <volume>
         357
        </volume>
        :
        <fpage>
         420
        </fpage>
        –
        <lpage>
         422
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         1350662
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0054">
       <label>
        54
       </label>
       <mixed-citation id="pro2442-cit-0054" publication-type="journal">
        <string-name>
         <surname>
          Raj
         </surname>
         <given-names>
          VS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mou
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Smits
         </surname>
         <given-names>
          SL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dekkers
         </surname>
         <given-names>
          DHW
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Müller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dijkman
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muth
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Demmers
         </surname>
         <given-names>
          JAA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zaki
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fouchier
         </surname>
         <given-names>
          RAM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Thiel
         </surname>
         <given-names>
          V
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Drosten
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rottier
         </surname>
         <given-names>
          PJM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Osterhaus
         </surname>
         <given-names>
          ADME
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bosch
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Haagmans
         </surname>
         <given-names>
          BL
         </given-names>
        </string-name>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus‐EMC
        </article-title>
        .
        <source xml:lang="en">
         Nature
        </source>
        <volume>
         495
        </volume>
        :
        <fpage>
         251
        </fpage>
        –
        <lpage>
         254
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0055">
       <label>
        55
       </label>
       <mixed-citation id="pro2442-cit-0055" publication-type="journal">
        <string-name>
         <surname>
          Lu
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hu
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          Q
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Qi
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gao
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhang
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yuan
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bao
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhang
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shi
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yan
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gao
         </surname>
         <given-names>
          GF
         </given-names>
        </string-name>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Molecular basis of binding between novel human coronavirus MERS‐CoV and its receptor CD26
        </article-title>
        .
        <source xml:lang="en">
         Nature
        </source>
        <volume>
         500
        </volume>
        :
        <fpage>
         227
        </fpage>
        –
        <lpage>
         231
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23831647
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0056">
       <label>
        56
       </label>
       <mixed-citation id="pro2442-cit-0056" publication-type="journal">
        <string-name>
         <surname>
          Du
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhao
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kou
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ma
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sun
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Poon
         </surname>
         <given-names>
          VKM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lu
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Debnath
         </surname>
         <given-names>
          AK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zheng
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jiang
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Identification of a receptor‐binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development
        </article-title>
        .
        <source xml:lang="en">
         J Virol
        </source>
        <volume>
         87
        </volume>
        :
        <fpage>
         9939
        </fpage>
        –
        <lpage>
         9942
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23824801
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0057">
       <label>
        57
       </label>
       <mixed-citation id="pro2442-cit-0057" publication-type="journal">
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shi
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jiang
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhang
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tong
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Guo
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fu
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cui
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Arledge
         </surname>
         <given-names>
          KC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chen
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhang
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Structure of MERS‐CoV spike receptor‐binding domain complexed with human receptor DPP4
        </article-title>
        .
        <source xml:lang="en">
         Cell Res
        </source>
        <volume>
         23
        </volume>
        :
        <fpage>
         986
        </fpage>
        –
        <lpage>
         993
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23835475
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0058">
       <label>
        58
       </label>
       <mixed-citation id="pro2442-cit-0058" publication-type="journal">
        <string-name>
         <surname>
          Jiang
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lin
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Strick
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Neurath
         </surname>
         <given-names>
          AR
         </given-names>
        </string-name>
        (
        <year>
         1993
        </year>
        )
        <article-title>
         HIV‐1 inhibition by a peptide
        </article-title>
        .
        <source xml:lang="en">
         Nature
        </source>
        <volume>
         365
        </volume>
        :
        <fpage>
         113
        </fpage>
        –
        <lpage>
         113
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8371754
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0059">
       <label>
        59
       </label>
       <mixed-citation id="pro2442-cit-0059" publication-type="journal">
        <string-name>
         <surname>
          Wild
         </surname>
         <given-names>
          CT
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shugars
         </surname>
         <given-names>
          DC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Greenwell
         </surname>
         <given-names>
          TK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          McDanal
         </surname>
         <given-names>
          CB
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Matthews
         </surname>
         <given-names>
          TJ
         </given-names>
        </string-name>
        (
        <year>
         1994
        </year>
        )
        <article-title>
         Peptides corresponding to a predictive alpha‐helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         91
        </volume>
        :
        <fpage>
         9770
        </fpage>
        –
        <lpage>
         9774
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7937889
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0060">
       <label>
        60
       </label>
       <mixed-citation id="pro2442-cit-0060" publication-type="journal">
        <string-name>
         <surname>
          Kilby
         </surname>
         <given-names>
          JM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hopkins
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Venetta
         </surname>
         <given-names>
          TM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          DiMassimo
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cloud
         </surname>
         <given-names>
          GA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lee
         </surname>
         <given-names>
          JY
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Alldredge
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hunter
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lambert
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bolognesi
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Matthews
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Johnson
         </surname>
         <given-names>
          MR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Nowak
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shaw
         </surname>
         <given-names>
          GM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Saag
         </surname>
         <given-names>
          MS
         </given-names>
        </string-name>
        (
        <year>
         1998
        </year>
        )
        <article-title>
         Potent suppression of HIV‐1 replication in humans by T‐20, a peptide inhibitor of gp41‐mediated virus entry
        </article-title>
        .
        <source xml:lang="en">
         Nat Med
        </source>
        <volume>
         4
        </volume>
        :
        <fpage>
         1302
        </fpage>
        –
        <lpage>
         1307
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9809555
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0061">
       <label>
        61
       </label>
       <mixed-citation id="pro2442-cit-0061" publication-type="journal">
        <string-name>
         <surname>
          Bosch
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Martina
         </surname>
         <given-names>
          BEE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zee
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        <string-name>
         <surname>
          van der Lepault
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Haijema
         </surname>
         <given-names>
          BJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Versluis
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Heck
         </surname>
         <given-names>
          AJR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Groot
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        <string-name>
         <surname>
          de Osterhaus
         </surname>
         <given-names>
          ADME
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rottier
         </surname>
         <given-names>
          PJM
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Severe acute respiratory syndrome coronavirus (SARS‐CoV) infection inhibition using spike protein heptad repeat‐derived peptides
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         101
        </volume>
        :
        <fpage>
         8455
        </fpage>
        –
        <lpage>
         8460
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15150417
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0062">
       <label>
        62
       </label>
       <mixed-citation id="pro2442-cit-0062" publication-type="journal">
        <string-name>
         <surname>
          Ingallinella
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bianchi
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Finotto
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cantoni
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Eckert
         </surname>
         <given-names>
          DM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Supekar
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bruckmann
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Carfi
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pessi
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Structural characterization of the fusion‐active complex of severe acute respiratory syndrome (SARS) coronavirus
        </article-title>
        .
        <source xml:lang="en">
         Proc Natl Acad Sci USA
        </source>
        <volume>
         101
        </volume>
        :
        <fpage>
         8709
        </fpage>
        –
        <lpage>
         8714
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15161975
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0063">
       <label>
        63
       </label>
       <mixed-citation id="pro2442-cit-0063" publication-type="journal">
        <string-name>
         <surname>
          Yan
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tripet
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hodges
         </surname>
         <given-names>
          RS
         </given-names>
        </string-name>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         Biophysical characterization of HRC peptide analogs interaction with heptad repeat regions of the SARS‐coronavirus Spike fusion protein core
        </article-title>
        .
        <source xml:lang="en">
         J Struct Biol
        </source>
        <volume>
         155
        </volume>
        :
        <fpage>
         162
        </fpage>
        –
        <lpage>
         175
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16765058
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0064">
       <label>
        64
       </label>
       <mixed-citation id="pro2442-cit-0064" publication-type="journal">
        <string-name>
         <surname>
          Chu
         </surname>
         <given-names>
          L‐HM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chan
         </surname>
         <given-names>
          S‐H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tsai
         </surname>
         <given-names>
          S‐N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cheng
         </surname>
         <given-names>
          CH‐K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wong
         </surname>
         <given-names>
          K‐B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Waye
         </surname>
         <given-names>
          MM‐Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ngai
         </surname>
         <given-names>
          S‐M
         </given-names>
        </string-name>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS‐CoV): in search of potent SARS‐CoV entry inhibitors
        </article-title>
        .
        <source xml:lang="en">
         J Cell Biochem
        </source>
        <volume>
         104
        </volume>
        :
        <fpage>
         2335
        </fpage>
        –
        <lpage>
         2347
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18442051
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0065">
       <label>
        65
       </label>
       <mixed-citation id="pro2442-cit-0065" publication-type="journal">
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          I‐J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kao
         </surname>
         <given-names>
          C‐L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hsieh
         </surname>
         <given-names>
          S‐C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wey
         </surname>
         <given-names>
          M‐T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kan
         </surname>
         <given-names>
          L‐S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          W‐K
         </given-names>
        </string-name>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS‐CoV and combination of HR1‐derived peptides as fusion inhibitors
        </article-title>
        .
        <source xml:lang="en">
         Antiviral Res
        </source>
        <volume>
         81
        </volume>
        :
        <fpage>
         82
        </fpage>
        –
        <lpage>
         87
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18983873
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0066">
       <label>
        66
       </label>
       <mixed-citation id="pro2442-cit-0066" publication-type="journal">
        <string-name>
         <surname>
          Yuan
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yi
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chen
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Qu
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Qing
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rao
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jiang
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hu
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Xiong
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Nie
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shi
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ling
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yin
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fan
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lai
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ding
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Deng
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Suppression of SARS‐CoV entry by peptides corresponding to heptad regions on spike glycoprotein
        </article-title>
        .
        <source xml:lang="en">
         Biochem Biophys Res Commun
        </source>
        <volume>
         319
        </volume>
        :
        <fpage>
         746
        </fpage>
        –
        <lpage>
         752
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15184046
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0067">
       <label>
        67
       </label>
       <mixed-citation id="pro2442-cit-0067" publication-type="journal">
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Xiao
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chen
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          He
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Niu
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Escalante
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Xiong
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Farmar
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Debnath
         </surname>
         <given-names>
          AK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tien
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jiang
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         Interaction between heptad repeat 1 and 2 regions in spike protein of SARS‐associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors
        </article-title>
        .
        <source xml:lang="en">
         Lancet
        </source>
        <volume>
         363
        </volume>
        :
        <fpage>
         938
        </fpage>
        –
        <lpage>
         947
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15043961
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0068">
       <label>
        68
       </label>
       <mixed-citation id="pro2442-cit-0068" publication-type="journal">
        <string-name>
         <surname>
          Ni
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhu
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhang
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yan
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gao
         </surname>
         <given-names>
          GF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tien
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Design of recombinant protein‐based SARS‐CoV entry inhibitors targeting the heptad‐repeat regions of the spike protein S2 domain
        </article-title>
        .
        <source xml:lang="en">
         Biochem Biophys Res Commun
        </source>
        <volume>
         330
        </volume>
        :
        <fpage>
         39
        </fpage>
        –
        <lpage>
         45
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15781229
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0069">
       <label>
        69
       </label>
       <mixed-citation id="pro2442-cit-0069" publication-type="journal">
        <string-name>
         <surname>
          Lu
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          Q
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhu
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chan
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Qin
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          Q
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chan
         </surname>
         <given-names>
          JF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Du
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yu
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ma
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ye
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yuen
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhang
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jiang
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Structure‐based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
        </article-title>
        .
        <source xml:lang="en">
         Nat Commun
        </source>
        <volume>
         5
        </volume>
        , article number 3067.
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0070">
       <label>
        70
       </label>
       <mixed-citation id="pro2442-cit-0070" publication-type="journal">
        <string-name>
         <surname>
          Gao
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lu
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Qi
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wu
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Deng
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Geng
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wang
         </surname>
         <given-names>
          Q
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Xiao
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tan
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yan
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gao
         </surname>
         <given-names>
          GF
         </given-names>
        </string-name>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus
        </article-title>
        .
        <source xml:lang="en">
         J Virol
        </source>
        <volume>
         87
        </volume>
        :
        <fpage>
         13134
        </fpage>
        –
        <lpage>
         13140
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24067982
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0071">
       <label>
        71
       </label>
       <mixed-citation id="pro2442-cit-0071" publication-type="journal">
        <string-name>
         <surname>
          Whitmore
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wallace
         </surname>
         <given-names>
          BA
         </given-names>
        </string-name>
        (
        <year>
         2004
        </year>
        )
        <article-title>
         DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data
        </article-title>
        .
        <source xml:lang="en">
         Nucleic Acids Res
        </source>
        <volume>
         32
        </volume>
        :
        <fpage>
         W668
        </fpage>
        –
        <lpage>
         W673
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15215473
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0072">
       <label>
        72
       </label>
       <mixed-citation id="pro2442-cit-0072" publication-type="journal">
        <string-name>
         <surname>
          Zheng
         </surname>
         <given-names>
          Q
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Deng
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Liu
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van der Hoek
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Berkhout
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lu
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         Core structure of S2 from the human coronavirus NL63 spike glycoprotein
        </article-title>
        .
        <source xml:lang="en">
         Biochemistry
        </source>
        <volume>
         45
        </volume>
        :
        <fpage>
         15205
        </fpage>
        –
        <lpage>
         15215
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17176042
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0073">
       <label>
        73
       </label>
       <mixed-citation id="pro2442-cit-0073" publication-type="journal">
        <string-name>
         <surname>
          Nguyen
         </surname>
         <given-names>
          MN
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tan
         </surname>
         <given-names>
          KP
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Madhusudhan
         </surname>
         <given-names>
          MS
         </given-names>
        </string-name>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         CLICK—topology‐independent comparison of biomolecular 3D structures
        </article-title>
        .
        <source xml:lang="en">
         Nucleic Acids Res
        </source>
        <volume>
         39
        </volume>
        :
        <fpage>
         W24
        </fpage>
        –
        <lpage>
         W28
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21602266
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pro2442-bib-0074">
       <label>
        74
       </label>
       <mixed-citation id="pro2442-cit-0074" publication-type="journal">
        <string-name>
         <surname>
          Brenke
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kozakov
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chuang
         </surname>
         <given-names>
          G‐Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Beglov
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hall
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Landon
         </surname>
         <given-names>
          MR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mattos
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Vajda
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Fragment‐based identification of druggable “hot spots” of proteins using Fourier domain correlation techniques
        </article-title>
        .
        <source xml:lang="en">
         Bioinformatics
        </source>
        <volume>
         25
        </volume>
        :
        <fpage>
         621
        </fpage>
        –
        <lpage>
         627
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19176554
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Sci Rep
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Sci Rep
      </journal-id>
      <journal-title-group>
       <journal-title>
        Scientific Reports
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2045-2322
      </issn>
      <publisher>
       <publisher-name>
        Nature Publishing Group UK
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30341341
      </article-id>
      <article-id pub-id-type="pmc">
       6195612
      </article-id>
      <article-id pub-id-type="publisher-id">
       33975
      </article-id>
      <article-id pub-id-type="doi">
       10.1038/s41598-018-33975-x
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        White-nose syndrome is associated with increased replication of a naturally persisting coronaviruses in bats
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" equal-contrib="yes">
        <name>
         <surname>
          Davy
         </surname>
         <given-names>
          Christina M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="yes">
        <name>
         <surname>
          Donaldson
         </surname>
         <given-names>
          Michael E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0002-5937-1880
        </contrib-id>
        <name>
         <surname>
          Subudhi
         </surname>
         <given-names>
          Sonu
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author" equal-contrib="yes">
        <name>
         <surname>
          Rapin
         </surname>
         <given-names>
          Noreen
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Warnecke
         </surname>
         <given-names>
          Lisa
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
        <xref ref-type="aff" rid="Aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Turner
         </surname>
         <given-names>
          James M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
        <xref ref-type="aff" rid="Aff6">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bollinger
         </surname>
         <given-names>
          Trent K.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff7">
         7
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kyle
         </surname>
         <given-names>
          Christopher J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff8">
         8
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Dorville
         </surname>
         <given-names>
          Nicole A. S.-Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kunkel
         </surname>
         <given-names>
          Emma L.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Norquay
         </surname>
         <given-names>
          Kaleigh J. O.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Dzal
         </surname>
         <given-names>
          Yvonne A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Willis
         </surname>
         <given-names>
          Craig K. R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0001-6818-7156
        </contrib-id>
        <name>
         <surname>
          Misra
         </surname>
         <given-names>
          Vikram
         </given-names>
        </name>
        <address>
         <email>
          vikram.misra@usask.ca
         </email>
        </address>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 1090 2022
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.52539.38
         </institution-id>
         <institution>
          Environmental and Life Sciences Graduate Program,
         </institution>
         <institution>
          Trent University,
         </institution>
        </institution-wrap>
        Peterborough, ON Canada
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 1090 2022
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.52539.38
         </institution-id>
         <institution>
          Ontario Ministry of Natural Resources and Forestry, Wildlife Research and Monitoring Section,
         </institution>
         <institution>
          Trent University,
         </institution>
        </institution-wrap>
        Peterborough, ON Canada
       </aff>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2154 235X
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.25152.31
         </institution-id>
         <institution>
          Department of Microbiology, Western College of Veterinary Medicine,
         </institution>
         <institution>
          University of Saskatchewan,
         </institution>
        </institution-wrap>
        Saskatoon, Saskatchewan Canada
       </aff>
       <aff id="Aff4">
        <label>
         4
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 1703 4731
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.267457.5
         </institution-id>
         <institution>
          Department of Biology,
         </institution>
         <institution>
          University of Winnipeg,
         </institution>
        </institution-wrap>
        Manitoba, Canada
       </aff>
       <aff id="Aff5">
        <label>
         5
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2287 2617
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.9026.d
         </institution-id>
         <institution>
          Present Address: Department of Animal Ecology and Conservation,
         </institution>
         <institution>
          University Hamburg, Hamburg,
         </institution>
        </institution-wrap>
        Hamburg, Germany
       </aff>
       <aff id="Aff6">
        <label>
         6
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0004 0368 0777
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.1037.5
         </institution-id>
         <institution>
          Present Address: Institute for Land Water and Society,
         </institution>
         <institution>
          Charles Sturt University,
         </institution>
        </institution-wrap>
        Albury, New South Wales Australia
       </aff>
       <aff id="Aff7">
        <label>
         7
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2154 235X
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.25152.31
         </institution-id>
         <institution>
          Canadian Wildlife Health Cooperative and Department of Pathology, Western College of Veterinary Medicine,
         </institution>
         <institution>
          University of Saskatchewan,
         </institution>
        </institution-wrap>
        Saskatoon, Saskatchewan Canada
       </aff>
       <aff id="Aff8">
        <label>
         8
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 1090 2022
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.52539.38
         </institution-id>
         <institution>
          Forensic Science Department,
         </institution>
         <institution>
          Trent University,
         </institution>
        </institution-wrap>
        Peterborough, ON Canada
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        19
       </day>
       <month>
        10
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        19
       </day>
       <month>
        10
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2018
       </year>
      </pub-date>
      <volume>
       8
      </volume>
      <elocation-id>
       15508
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         16
        </day>
        <month>
         7
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         9
        </day>
        <month>
         10
        </month>
        <year>
         2018
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author(s) 2018
       </copyright-statement>
       <license license-type="OpenAccess">
        <license-p>
         <bold>
          Open Access
         </bold>
         This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         .
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p id="Par1">
        Spillover of viruses from bats to other animals may be associated with increased contact between them, as well as increased shedding of viruses by bats. Here, we tested the prediction that little brown bats (
        <italic>
         Myotis lucifugus
        </italic>
        ) co-infected with the
        <italic>
         M. lucifugus
        </italic>
        coronavirus (
        <italic>
         Myl
        </italic>
        -CoV) and with
        <italic>
         Pseudogymnoascus destructans
        </italic>
        (
        <italic>
         Pd
        </italic>
        ), the fungus that causes bat white-nose syndrome (WNS), exhibit different disease severity, viral shedding and molecular responses than bats infected with only
        <italic>
         Myl
        </italic>
        -CoV or only
        <italic>
         P. destructans
        </italic>
        . We took advantage of the natural persistence of
        <italic>
         Myl
        </italic>
        -CoV in bats that were experimentally inoculated with
        <italic>
         P. destructans
        </italic>
        in a previous study. Here, we show that the intestines of virus-infected bats that were also infected with fungus contained on average 60-fold more viral RNA than bats with virus alone. Increased viral RNA in the intestines correlated with the severity of fungus-related pathology. Additionally, the intestines of bats infected with fungus exhibited different expression of mitogen-activated protein kinase pathway and cytokine related transcripts, irrespective of viral presence. Levels of coronavirus antibodies were also higher in fungal-infected bats. Our results suggest that the systemic effects of WNS may down-regulate anti-viral responses in bats persistently infected with
        <italic>
         M. lucifugus
        </italic>
        coronavirus and increase the potential of virus shedding.
       </p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
       <title>
        Subject terms
       </title>
       <kwd>
        Molecular ecology
       </kwd>
       <kwd>
        Fungal pathogenesis
       </kwd>
       <kwd>
        Virus-host interactions
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2018
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1" sec-type="introduction">
     <title>
      Introduction
     </title>
     <p id="Par2">
      Bats are hosts for many viruses and are thought to be the source of some viruses that have spilled over to humans and other mammals, causing fatal disease. These include coronaviruses causing severe acute respiratory syndrome (SARS
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
      </sup>
      ), Middle East respiratory syndrome (MERS
      <sup>
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       –
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
      </sup>
      ), porcine epidemic diarrhoea (PED
      <sup>
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
      </sup>
      ) and swine acute diarrhoea syndrome (SADS
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      ); paramyxoviruses such as Hendra
      <sup>
       <xref ref-type="bibr" rid="CR8">
        8
       </xref>
      </sup>
      and Nipah
      <sup>
       <xref ref-type="bibr" rid="CR9">
        9
       </xref>
      </sup>
      ; and filoviruses like Marburg
      <sup>
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
      </sup>
      and Ebola
      <sup>
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
      </sup>
      . Four families of viruses that are pathogenic for other mammalian species (
      <italic>
       Coronaviridae
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
      </sup>
      ,
      <italic>
       Paramyxoviridae
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
      </sup>
      ,
      <italic>
       Rhabdoviridae
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
      </sup>
      and
      <italic>
       Filoviridae
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
      </sup>
      ) may also have originated in bats. These viruses often cause serious disease in their secondary hosts, but most do not appear to cause clinical signs or pathology in bats
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       –
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
      </sup>
      , suggesting that uniquely benign relationships have co-evolved between the viruses and their primary bat hosts
      <sup>
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="CR20">
        20
       </xref>
      </sup>
      . While relatively little is known about the dynamics of viral infections in bats, these viruses may be maintained in bat populations as a result of either persistently infected individuals, reinfection after waning immunity, or spatial transmission dynamics
      <sup>
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="CR22">
        22
       </xref>
      </sup>
      .
     </p>
     <p id="Par3">
      The rare spill-over of bat viruses to other animals may require a “perfect storm” of conditions that include increased contact between bats or fomites and other mammals, possibly due to human impacts on habitat quality
      <sup>
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
      </sup>
      , and the ability of the virus to infect, replicate, and transmit in the secondary host. The rate of viral shedding and the amount of detectable virus associated with bat colonies fluctuates, with periodic increases often linked to parturition, waning maternal immunity, nutritional stress or increased energy consumption
      <sup>
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
       ,
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
       –
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
      </sup>
      . Increased shedding of virus by a colony of bats may reflect an increase in the proportion and number of susceptible individuals, or an increase in the replication of persistent or latent virus normally suppressed by the host. For herpesviruses, reactivation from latency is linked to perturbations caused by a variety of physiological, immunological and psychological stressors
      <sup>
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
      </sup>
      . The mechanisms that trigger the reactivation of latent or persistently infecting viruses are not clearly understood, but the increased shedding of viruses is correlated with some incidents of spill-over of bat viruses to other animals
      <sup>
       <xref ref-type="bibr" rid="CR31">
        31
       </xref>
      </sup>
      .
     </p>
     <p id="Par4">
      The Canadian prairies are home to three species of bats, including the little brown bat (
      <italic>
       Myotis lucifugus
      </italic>
      ), big brown bat (
      <italic>
       Eptesicus fuscus
      </italic>
      ), and northern long-eared bat
      <italic>
       (Myotis septentrionalis
      </italic>
      ). All three species hibernate from October to May, sometimes in shared hibernacula. We recently demonstrated that ~30% of hibernating
      <italic>
       M. lucifugus
      </italic>
      sampled over two years from hibernacula in Manitoba were infected with a coronavirus (
      <italic>
       Myl
      </italic>
      -CoV), which persisted at low levels in the intestine
      <sup>
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
      </sup>
      . A closely related coronavirus also infects
      <italic>
       E. fuscus
      </italic>
      <sup>
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
      </sup>
      .
     </p>
     <p id="Par5">
      Whereas bats appear to be relatively resistant to viral infections, a cold-adapted fungus that was recently introduced to North America has caused widespread mortality in some species of bats in eastern United States and Canada
      <sup>
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
       –
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
      </sup>
      . The fungus (
      <italic>
       Pseudogymnoascus destructans)
      </italic>
      causes white-nose syndrome (WNS) in hibernating bats, which is characterized by the growth of white fungal mycelia on the face and exposed skin of the wings and tail membranes. The visual and microscopic effects of
      <italic>
       P. destructans
      </italic>
      on the skin of the wings are associated with increased expression of several genes devoted to innate immunity and inflammation in wing tissue
      <sup>
       <xref ref-type="bibr" rid="CR38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="CR39">
        39
       </xref>
      </sup>
      . Profound systemic effects include dehydration, hypovolemia, metabolic acidosis, and fat depletion, which can lead to death
      <sup>
       <xref ref-type="bibr" rid="CR40">
        40
       </xref>
       –
       <xref ref-type="bibr" rid="CR42">
        42
       </xref>
      </sup>
      . Other systemic effects of bat WNS include an accumulation of neutrophils in the lungs, which is accompanied by an increase in the expression of several cytokine genes
      <sup>
       <xref ref-type="bibr" rid="CR43">
        43
       </xref>
      </sup>
      suggesting that even the most severely afflicted hibernating bats are capable of at least some systemic immune response to fungal infection.
     </p>
     <p id="Par6">
      Previous studies on other species have demonstrated that a fungus and a virus could interact during co-infection and affect each other
      <sup>
       <xref ref-type="bibr" rid="CR44">
        44
       </xref>
       ,
       <xref ref-type="bibr" rid="CR45">
        45
       </xref>
      </sup>
      . Similar interactive impacts of co-infection with
      <italic>
       P. destructans
      </italic>
      and viruses on bat immune responses are not known. We used
      <italic>
       M. lucifugus
      </italic>
      experimentally-infected with
      <italic>
       P. destructans
      </italic>
      and/or naturally infected with
      <italic>
       Myl
      </italic>
      -CoV as a model to understand how co-infections influence bat-virus interactions. This system allows us to avoid confounding factors of direct pathogen-pathogen interactions, because the fungus affects the skin, while the coronavirus infections occur internally, almost exclusively in the ileum and lungs
      <sup>
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
      </sup>
      . We hypothesized that co-infection would alter the molecular response of bats to a persistent viral infection, and that viral shedding would change as a result of the increased or disrupted host immune response. To test this prediction, we examined tissues collected from
      <italic>
       M. lucifugus
      </italic>
      at the termination of an earlier study that quantified the effects and pathogenesis of
      <italic>
       P. destructans
      </italic>
      in hibernating bats experimentally infected with the fungus
      <sup>
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
      </sup>
      , some of which were naturally infected with
      <italic>
       Myl-
      </italic>
      CoV
      <sup>
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
      </sup>
      . This combination of uninfected, virus-infected, fungus-infected and co-infected
      <italic>
       M. lucifugus
      </italic>
      allowed us to test our hypothesis that host responses to co-infection are synergistic and not simply additive.
     </p>
    </sec>
    <sec id="Sec2" sec-type="results">
     <title>
      Results
     </title>
     <p id="Par7">
      Quantitation of
      <italic>
       Myl-
      </italic>
      CoV and
      <italic>
       M. lucifugus
      </italic>
      RNA through reverse transcription quantitative PCR (RT-qPCR) and dual-RNA-sequencing indicated that co-infected bats had significantly higher levels of
      <italic>
       Myl
      </italic>
      -CoV RNA than bats infected with virus alone. The amount of
      <italic>
       Myl-
      </italic>
      CoV RNA correlated with the severity of WNS pathology in co-infected bats. This phenomenon was associated with specific molecular responses to co-infection, even in the intestines of bats where only one of the two pathogens was directly interacting with the host tissue. The levels of antibodies against
      <italic>
       Myl
      </italic>
      -CoV nucleocapsid (N) protein were also higher in co-infected bats. Each key result is discussed in detail below.
     </p>
     <sec id="Sec3">
      <title>
       Bats co-infected with the fungus
       <italic>
        P. destructans
       </italic>
       and the virus
       <italic>
        Myl
       </italic>
       -CoV contained higher levels of
       <italic>
        Myl
       </italic>
       -CoV RNA
      </title>
      <p id="Par8">
       <italic>
        Myl
       </italic>
       -CoV genomic RNA was detected in bats infected only with
       <italic>
        Myl-
       </italic>
       CoV (virus-infected; 7/18), co-infected bats (European
       <italic>
        P. destructans
       </italic>
       (3/13), or with North American
       <italic>
        P. destructans
       </italic>
       (7/16)
       <sup>
        <xref ref-type="bibr" rid="CR37">
         37
        </xref>
       </sup>
       ). There was no difference in the frequency of
       <italic>
        Myl
       </italic>
       -CoV detected among these treatments (
       <italic>
        p-value
       </italic>
       = 0.801). We pooled bats infected with the two
       <italic>
        P. destructans
       </italic>
       isolates for all further analyses and tested whether co-infection with
       <italic>
        P. destructans
       </italic>
       and
       <italic>
        Myl-
       </italic>
       CoV correlated with an increase in viral replication. Our RT-qPCR data showed that the co-infected bats contained 60-fold more
       <italic>
        Myl-
       </italic>
       CoV RNA on average than the virus-infected bats (Mann Whitney test;
       <italic>
        p-value
       </italic>
       =
       <italic>
        0.014
       </italic>
       ; Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       ).
       <fig id="Fig1">
        <label>
         Figure 1
        </label>
        <caption>
         <p>
          Effect of white-nose syndrome on level of
          <italic>
           Myotis lucifugus
          </italic>
          coronavirus (
          <italic>
           Myl
          </italic>
          -CoV) RNA in hibernating little brown bats (
          <italic>
           M. lucifugus
          </italic>
          ). Relative transcript levels for the coronavirus RNA polymerase gene for each bat are depicted as reciprocal of Cycle threshold (Ct) normalized separately (ΔCt) for levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcripts in each sample. The horizontal bar represents the mean while the vertical bar indicates standard deviation from the mean. Significance (
          <italic>
           p
          </italic>
          value) is as calculated with an independent Mann-Whitney test. Virus-infected bats had lower 1/ΔCt values for coronavirus RNA than co-infected bats. The average fold-differences between virus-infected and co-infected bats were calculated from the difference between the average ΔCt values.
         </p>
        </caption>
        <graphic id="d29e771" xlink:href="41598_2018_33975_Fig1_HTML">
        </graphic>
       </fig>
      </p>
      <p id="Par9">
       Relative quantities of
       <italic>
        Myl
       </italic>
       -CoV RNA detected in the ileum of the virus-infected bats were low and showed low variation (Standard Deviation of 1/ΔCT = 0.005), compared to the relative quantities of
       <italic>
        Myl
       </italic>
       -CoV RNA in the co-infected bats (Standard Deviation of 1/ΔCT = 0.108; Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       ). The severity of WNS fungal pathology varied in co-infected bats, and we therefore tested whether relative quantities of viral RNA in the ileum correlated with the severity of WNS symptoms. Levels of WNS severity were scored based on fungal hyphae on the wings, secondary bacteria in wing lesions, oedema, necrosis and inflammation in wing lesions, and levels of neutrophils in lung, spleen and liver interstitium. Severity scores for wing tissue, secondary bacteria in lesions, and neutrophils in the lung interstitium positively correlated with relative amounts of coronavirus RNA in hibernating bats (Table
       <xref ref-type="table" rid="Tab1">
        1
       </xref>
       ).
       <table-wrap id="Tab1">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Correlation between level of
          <italic>
           Myotis lucifugus
          </italic>
          coronavirus RNA and disease severity of white-nose syndrome (WNS) in co-infected
          <italic>
           M. lucifugus
          </italic>
          , based on three measures of WNS severity and pathology.
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th rowspan="2">
            Correlate
           </th>
           <th colspan="3">
            Level of coronavirus RNA
           </th>
          </tr>
          <tr>
           <th>
            Pearson Correlation
            <sup>
             a
            </sup>
           </th>
           <th>
            Significance
           </th>
           <th>
            N
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Virus-infected/Co-infected
           </td>
           <td>
            −0.610
           </td>
           <td>
            <bold>
             0.009
            </bold>
           </td>
           <td>
            17
           </td>
          </tr>
          <tr>
           <td>
            Average hyphae score
           </td>
           <td>
            −0.630
           </td>
           <td>
            <bold>
             0.016
            </bold>
           </td>
           <td>
            14
           </td>
          </tr>
          <tr>
           <td>
            Average bacterial score
           </td>
           <td>
            −0.680
           </td>
           <td>
            <bold>
             0.007
            </bold>
           </td>
           <td>
            14
           </td>
          </tr>
          <tr>
           <td>
            Lung interstitial neutrophils
           </td>
           <td>
            −0.618
           </td>
           <td>
            <bold>
             0.043
            </bold>
           </td>
           <td>
            11
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          <sup>
           a
          </sup>
          Pearson’s coefficients were calculated for the ∆Ct levels for cytokine transcripts for bats in each treatment class and lung interstitial neutrophil scores and mean bacterial and hyphae scores for 5 wing sections for each bat.
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Bat responses to co-infection exceed the sum of responses to virus or fungal infection alone
      </title>
      <p id="Par10">
       To determine the extent to which
       <italic>
        Myl
       </italic>
       -CoV and
       <italic>
        P. destructans
       </italic>
       infection interact to influence gene expression in bat intestines, we performed a transcriptomic analysis on bat intestines comparing gene expression among the uninfected, virus-infected, fungus-infected, and co-infected treatments (Fig.
       <xref ref-type="fig" rid="Fig2">
        2(A)
       </xref>
       ). RNA sequencing resulted in ~700 million paired-end reads passing filters, 65% of which aligned to the
       <italic>
        M. lucifugus
       </italic>
       genome (Table
       <xref ref-type="media" rid="MOESM1">
        S1
       </xref>
       ). Pairwise differential gene expression varied widely among the four treatments with relatively low overlap in differentially expressed transcripts (Fig.
       <xref ref-type="fig" rid="Fig2">
        2B,C)
       </xref>
       , Supplementary Fig.
       <xref ref-type="media" rid="MOESM1">
        1
       </xref>
       ). Similar transcript expression occurred between the uninfected and virus-infected bats, and between the fungus-infected and co-infected bats.
       <fig id="Fig2">
        <label>
         Figure 2
        </label>
        <caption>
         <p>
          Co-infection of little brown bats (
          <italic>
           Myotis lucifugus
          </italic>
          ) with
          <italic>
           M. lucifugus
          </italic>
          coronavirus (
          <italic>
           Myl-
          </italic>
          CoV) and
          <italic>
           Pseudogymnoascus destructans
          </italic>
          results in non-additive patterns of gene expression compared to sole infection with the virus or fungus. (
          <bold>
           A
          </bold>
          ) Experimental design, showing the four treatments of little brown bat (
          <italic>
           Myotis lucifugus
          </italic>
          ) established by experimental inoculation with
          <italic>
           Pseudogymnoascus destructans
          </italic>
          and by qPCR detection of persistent
          <italic>
           Myl
          </italic>
          -CoV infections: uninfected, virus-infected, fungus-infected and co-infected. (
          <bold>
           B
          </bold>
          ) Differential gene expression identified by DESeq2 among virus-infected, fungus-infected and Co-infected bats as compared to the change each exhibited relative to uninfected bats. (
          <bold>
           C
          </bold>
          ) Differential gene expression among the four treatments, detected by DESEQ2 and visualized in volcano plots. The log of the adjusted
          <italic>
           p
          </italic>
          -value is plotted as a function of the log ratio of differential expression. Colored data points represent different groups of genes based on fold change and false discovery rate (FDR) cutoff; red (&gt;2 fold change, FDR &lt;0.05), dark grey (&gt;2 fold change, FDR &gt; 0.05), light grey (&lt;2 fold change, FDR &lt; 0.05), black (&lt;2 fold change, FDR &gt; 0.05).
         </p>
        </caption>
        <graphic id="d29e963" xlink:href="41598_2018_33975_Fig2_HTML">
        </graphic>
       </fig>
      </p>
      <p id="Par11">
       The fungus-infected bats exhibited a much stronger response, differentially expressing 324 transcripts compared to the uninfected bats (Table
       <xref ref-type="media" rid="MOESM1">
        S3
       </xref>
       ). These transcripts were enriched for only two gene ontology (GO) terms (cell-cell junction and plasma membrane part; Table
       <xref ref-type="media" rid="MOESM1">
        S8
       </xref>
       ). The co-infected bats differentially expressed 634 transcripts relative to the uninfected bats (Table
       <xref ref-type="media" rid="MOESM1">
        S4
       </xref>
       ). These transcripts showed significant enrichment for 16 GO terms (Table
       <xref ref-type="media" rid="MOESM1">
        S8
       </xref>
       ). The co-infected and fungus-infected bats shared 108 similar differentially expressed transcripts and overlapped in one enriched GO term relative to the uninfected bats (plasma membrane part; Table
       <xref ref-type="media" rid="MOESM1">
        S8
       </xref>
       ).
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Effect of infection with the fungus
       <italic>
        P. destructans
       </italic>
       on the expression of genes linked to innate responses in the intestines of bats infected with the virus Myl-CoV
      </title>
      <p id="Par12">
       When we directly compared responses of bats among the four treatments, response of the virus-infected bats differed strongly from the responses of fungus-infected or co-infected bats (virus-infected vs. fungus-infected: 461 differentially expressed transcripts and 9 significantly enriched GO terms; virus-infected vs. co-infected: 473 transcripts and 43 enriched GO terms; Tables
       <xref ref-type="media" rid="MOESM1">
        S5
       </xref>
       ,
       <xref ref-type="media" rid="MOESM1">
        S6
       </xref>
       ,
       <xref ref-type="media" rid="MOESM1">
        S7
       </xref>
       ; Supplementary Fig.
       <xref ref-type="media" rid="MOESM1">
        1
       </xref>
       ). These differences in gene expression patterns included genes that clustered in two processes relevant to host-pathogen interactions – the mitogen-activated protein kinase (MAPK) pathways and cytokine and innate immune responses. Table
       <xref ref-type="table" rid="Tab2">
        2
       </xref>
       lists genes from the two processes that were significantly either up or down-regulated when virus-infected bats were compared to co-infected bats. For the MAPK pathway-related transcripts, genes such as RSU1 and RERG were up-regulated while those, such as STYK1, RRAD, MAP3K and SRC were down-regulated. For cytokine-related genes several transcripts were suppressed. When we compared the expression of the same genes for bats with WNS (combining fungus-infected and co-infected bats) and all bats without WNS (combining uninfected and virus-infected bats), we found similar differences (last two columns of Table
       <xref ref-type="table" rid="Tab2">
        2
       </xref>
       ). This suggested that superficial infection with fungus,
       <italic>
        P. destructans
       </italic>
       , was the driving factor for altered gene expression in the bat intestines.
       <table-wrap id="Tab2">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          RNA-sequencing identified differential expression of transcripts related to the MAPK pathway and to cytokine-related processes, comparing gene expression in the ileum of little brown bats (
          <italic>
           Myotis lucifugus
          </italic>
          ) infected only with the
          <italic>
           M. lucifugus
          </italic>
          coronavirus (
          <italic>
           Myl-
          </italic>
          CoV; virus-infected) or co-infected with
          <italic>
           Myl-
          </italic>
          CoV and
          <italic>
           Pseudogymnoascus destructans
          </italic>
          . The last 2 columns show the same comparisons made after grouping bats that were not exposed to the fungus, and bats that were exposed to the fungus and exhibiting symptoms of WNS (irrespective of their viral infection status).
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th rowspan="2">
            Ensembl Gene Name
           </th>
           <th rowspan="2">
            Ensembl Description
           </th>
           <th colspan="2">
            Virus-infected vs. Co-infected
           </th>
           <th colspan="2">
            All bats “without fungus” vs. all bats “with fungus”
            <sup>
             a
            </sup>
           </th>
          </tr>
          <tr>
           <th>
            Log
            <sub>
             2
            </sub>
            Fold Change
            <sup>
             b
            </sup>
           </th>
           <th>
            Padj
           </th>
           <th>
            Log
            <sub>
             2
            </sub>
            Fold Change
            <sup>
             b
            </sup>
           </th>
           <th>
            Padj
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td colspan="6">
            <italic>
             MAPK pathway-related transcripts
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            STYK1
           </td>
           <td>
            serine/threonine/tyrosine kinase 1
           </td>
           <td>
            −1.268
           </td>
           <td>
            0.025
           </td>
           <td>
            −1.516
           </td>
           <td>
            &lt;0.0001
           </td>
          </tr>
          <tr>
           <td>
            RSU1
           </td>
           <td>
            Ras suppressor protein 1
           </td>
           <td>
            1.102
           </td>
           <td>
            0.004
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            RRAD
           </td>
           <td>
            RRAD, Ras related glycolysis inhibitor and calcium channel regulator
           </td>
           <td>
            −1.297
           </td>
           <td>
            0.028
           </td>
           <td>
            −1.3
           </td>
           <td>
            0.025
           </td>
          </tr>
          <tr>
           <td>
            RERG
           </td>
           <td>
            RAS like estrogen regulated growth inhibitor
           </td>
           <td>
            1.562
           </td>
           <td>
            0.018
           </td>
           <td>
            1.416
           </td>
           <td>
            0.005
           </td>
          </tr>
          <tr>
           <td>
            MAP3K11
           </td>
           <td>
            mitogen-activated protein kinase 11
           </td>
           <td>
            −1.14
           </td>
           <td>
            0.040
           </td>
           <td>
            −1.13
           </td>
           <td>
            0.0002
           </td>
          </tr>
          <tr>
           <td>
            SRC
           </td>
           <td>
            SRC proto-oncogene, non-receptor tyrosine kinase
           </td>
           <td>
            −1.539
           </td>
           <td>
            0.013
           </td>
           <td>
            −1.297
           </td>
           <td>
            0.0037
           </td>
          </tr>
          <tr>
           <td colspan="6">
            <italic>
             Cytokine-related transcripts
            </italic>
           </td>
          </tr>
          <tr>
           <td>
            IRF1
           </td>
           <td>
            Interferon regulatory factor 1
           </td>
           <td>
            −1.551
           </td>
           <td>
            0.001
           </td>
           <td>
            −1.444
           </td>
           <td>
            0.0001
           </td>
          </tr>
          <tr>
           <td>
            IFI6
           </td>
           <td>
            Interferon alpha inducible protein 6
           </td>
           <td>
            −1.798
           </td>
           <td>
            0.014
           </td>
           <td>
            −1.352
           </td>
           <td>
            0.039
           </td>
          </tr>
          <tr>
           <td>
            IL22RA1
           </td>
           <td>
            Interleukin 22 receptor subunit alpha 1
           </td>
           <td>
            −1.411
           </td>
           <td>
            0.015
           </td>
           <td>
            −1.314
           </td>
           <td>
            0.002
           </td>
          </tr>
          <tr>
           <td>
            SOCS6
           </td>
           <td>
            Suppressor of cytokine signaling 6
           </td>
           <td>
            −1.278
           </td>
           <td>
            0.008
           </td>
           <td>
            −1.534
           </td>
           <td>
            &lt;0.0001
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          <sup>
           a
          </sup>
          (Uninfected + virus-infected) vs. (fungus-infected + co-infected)
         </p>
         <p>
          <sup>
           b
          </sup>
          Positive log2 fold-change values indicate higher expression in the second listed treatments relative to the first.
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p id="Par13">
       To confirm the results of the RNA-seq analysis, we selected 4 genes from Table
       <xref ref-type="table" rid="Tab2">
        2
       </xref>
       , namely IRF1, RERG, SRC and IL22RA1, to be verified by RT-qPCR. We also included interleukin 10 (IL10) due to its biological relevance to immune regulation and because we had previously observed an increase in its expression related to fungal infection
       <sup>
        <xref ref-type="bibr" rid="CR43">
         43
        </xref>
       </sup>
       . As we wanted to confirm whether WNS was driving gene expression in the intestines of bats, we performed a two-group analysis for the RT-qPCR data. We combined all the bats without WNS into a single group (uninfected + virus-infected) and all the bats with WNS into the other group (fungus-infected + co-infected; Fig.
       <xref ref-type="fig" rid="Fig3">
        3(A)
       </xref>
       ). Expression of Ras-like estrogen regulated growth inhibitor (RERG) increased while expression of Interleukin 22 receptor subunit alpha 1 (IL22 RA1) genes decreased in bats with WNS, irrespective of viral infection (Fig.
       <xref ref-type="fig" rid="Fig3">
        3C,E
       </xref>
       ). Expression of the immune modulatory cytokine IL10 tended to be higher in bats with WNS than in bats without WNS, but the difference was not statistically significant (
       <italic>
        p
       </italic>
       -value = 0.07) (Fig.
       <xref ref-type="fig" rid="Fig3">
        3(F)
       </xref>
       ).
       <fig id="Fig3">
        <label>
         Figure 3
        </label>
        <caption>
         <p>
          Effect of white-nose syndrome (WNS) on the levels of immune genes IRF1, RERG, SRC, IL22RA1 and IL10 expressed in the ileum of little brown bats (
          <italic>
           Myotis lucifugus
          </italic>
          ). (
          <bold>
           A
          </bold>
          ) Summary of the four treatments, with a red arrow indicating the two groups (“with fungus” and “without fungus”) that were compared. (
          <bold>
           B
          </bold>
          –
          <bold>
           F
          </bold>
          ) The relative transcript levels of each gene for bats with and without WNS, depicted as reciprocal of Cycle threshold (Ct) normalized separately (ΔCt) for levels of transcripts for GAPDH in each sample. Statistical significance was calculated based on the independent Mann Whitney test. The difference in the two groups was significant for RERG and IL22RA1 genes.
         </p>
        </caption>
        <graphic id="d29e1332" xlink:href="41598_2018_33975_Fig3_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       White-nose syndrome is associated with increased coronavirus antibody levels in the co-infected bats
      </title>
      <p id="Par14">
       In 2017, we performed a similar study, experimentally exposing 63
       <italic>
        M. lucifugus
       </italic>
       to
       <italic>
        P. destructans
       </italic>
       as described in Warnecke
       <italic>
        et al
       </italic>
       .
       <sup>
        <xref ref-type="bibr" rid="CR37">
         37
        </xref>
       </sup>
       . We performed IgG ELISA on blood plasma to detect
       <italic>
        Myl
       </italic>
       -CoV (coronavirus) N protein antibodies and found that 21/63 were positive for antibodies against the coronavirus. Of those 21 bats, 7 had detectable coronavirus RNA in their intestines suggesting an active infection, and 3 out of the 7 had been experimentally infected with
       <italic>
        P. destructans
       </italic>
       during the course of the study. We compared the ELISA optical density (O.D.) values of these virus-infected bats to co-infected bats (Fig.
       <xref ref-type="fig" rid="Fig4">
        4(A)
       </xref>
       ) and found that the presence of
       <italic>
        P. destructans
       </italic>
       was associated with increased levels of coronavirus antibodies (Mann Whitney test,
       <italic>
        p value
       </italic>
       = 0.03; Fig.
       <xref ref-type="fig" rid="Fig4">
        4(B)
       </xref>
       ).
       <fig id="Fig4">
        <label>
         Figure 4
        </label>
        <caption>
         <p>
          Little brown bats (
          <italic>
           Myotis lucifugus)
          </italic>
          coinfected with
          <italic>
           M. lucifugus
          </italic>
          coronavirus (
          <italic>
           Myl
          </italic>
          -CoV) and
          <italic>
           Pseudogymnoascus destructans
          </italic>
          produce more antibodies against
          <italic>
           Myl
          </italic>
          -CoV than bats infected only with
          <italic>
           Myl-
          </italic>
          CoV. (
          <bold>
           A
          </bold>
          ) Diagram summarizes the four treatments; the red arrow shows the two groups between which antibody levels were compared. (
          <bold>
           B
          </bold>
          ) Antibody levels against the
          <italic>
           Myl
          </italic>
          -CoV N protein detected by antibody capture ELISA expressed as optical density (O.D.) values at 405 nm. Co-infected bats had significantly higher antibody levels than bats infected only with
          <italic>
           Myl
          </italic>
          -CoV (independent Mann Whitney test;
          <italic>
           p value
          </italic>
          = 0.03).
         </p>
        </caption>
        <graphic id="d29e1412" xlink:href="41598_2018_33975_Fig4_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="Sec7" sec-type="discussion">
     <title>
      Discussion
     </title>
     <p id="Par15">
      Our findings suggest that systemic responses of bats to WNS results in increased coronavirus replication and consequently, increased viral shedding, which may lead to subsequent infection of susceptible animals. Coronavirus infection may in turn increase the severity of WNS pathology. This is the first study to examine the systemic effects of co-infection on either bat coronavirus or WNS, and our results raise important questions in regard to zoonotic spillover events. Although events of successful viral spillover to distantly related species are thought to be extremely rare, in recent years several coronaviruses have spilled over, including SARS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
      </sup>
      , MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       –
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
      </sup>
      , PEDV-CoV
      <sup>
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
      </sup>
      and SADS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      . These viruses are thought to have originated in bats. In addition, circumstantial evidence suggests that most alpha and beta coronaviruses that parasitize other mammals may have originated in bats as well
      <sup>
       <xref ref-type="bibr" rid="CR46">
        46
       </xref>
      </sup>
      . If so, then understanding host-pathogen interactions between bats and coronaviruses could inform our ability to predict or manage the risk of spillover. In this study, we showed that a coronavirus exhibits low activity in its natural host,
      <italic>
       M. lucifugus
      </italic>
      , but that co-infection with a fungus increases the quantity of viral RNA in the intestines. We have no reason to expect zoonotic transmission of the coronavirus i.e.
      <italic>
       Myl
      </italic>
      -CoV, but similar co-infection mechanisms may operate in tropical bat species harbouring potentially zoonotic viruses.
     </p>
     <p id="Par16">
      Our results suggest that secondary skin infection with the fungus,
      <italic>
       P. destructans
      </italic>
      , substantially increases the level of viral RNA in the intestine of hibernating bats. We showed that infection of the skin with
      <italic>
       P
      </italic>
      .
      <italic>
       destructans
      </italic>
      can cause profound changes in gene expression in the intestines, despite a lack of direct contact between intestinal tissue and the fungus. Infection with
      <italic>
       P. destructans
      </italic>
      causes modulation of a number of immune responses, including down-regulation of interleukin and cell proliferation genes which may compromise bats’ ability to suppress viral activity (Fig.
      <xref ref-type="fig" rid="Fig5">
       5
      </xref>
      ). Taken together, our results have implications for epidemiological studies of
      <italic>
       P. destructans
      </italic>
      , the WNS fungus and for research into viral spillovers, which should consider the potential implications of co-infections that increase viral shedding.
      <fig id="Fig5">
       <label>
        Figure 5
       </label>
       <caption>
        <p>
         Hypothesized model of pathways involved in increased coronavirus shedding and white-nose syndrome (WNS) severity in little brown bats (
         <italic>
          Myotis lucifugus
         </italic>
         ) co-infected with
         <italic>
          M. lucifugus
         </italic>
         coronavirus (
         <italic>
          Myl-
         </italic>
         CoV) and
         <italic>
          Pseudogymnoascus destructans
         </italic>
         . Diagram summarizes the changes observed by comparing co-infected bats with virus-infected bats. Bats with persistent
         <italic>
          Myl
         </italic>
         -CoV infection exhibit relatively low viral shedding. When bats are also infected with
         <italic>
          P. destructans
         </italic>
         (shown in yellow arrow) and develop WNS, the level of coronavirus increases. There is a change in the level of some immune genes, such as IL22, RERG and possibly IL10, which may have an effect on immune response and cell proliferation. The increase in coronavirus levels in co-infected bats is possibly due to the bats’ systemic response to WNS reducing innate anti-viral responses.
        </p>
       </caption>
       <graphic id="d29e1496" xlink:href="41598_2018_33975_Fig5_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par17">
      Complex strategies allow viruses to remain endemic in populations. These include a continuously replenished source of susceptible hosts for viruses that cause short-term acute infections with long-lasting immunity (e.g. measles virus), antigenic drift of virus (e.g. influenza virus) or waning immunity (e.g. respiratory syncytial virus) that allows reinfection, and long-lasting latent (e.g. herpesviruses) or persistent infections (e.g. pestiviruses) with sustained or periodic shedding. It is not yet clear how bat viruses are maintained in their natural host populations, or how they avoid extinction as host populations become immune and less susceptible. Persistent infections can be established in cultured cells with viruses that may have originated in bats, including Ebola virus
      <sup>
       <xref ref-type="bibr" rid="CR47">
        47
       </xref>
      </sup>
      and SARS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR48">
        48
       </xref>
       –
       <xref ref-type="bibr" rid="CR50">
        50
       </xref>
      </sup>
      , but whether these viruses persist in their primary hosts is not known. Studies of persistence of bat viruses in infected bats have produced equivocal results. The lack of direct evidence supporting specific models of persistence or transmission dynamics represents a major knowledge gap in bat-virus ecology
      <sup>
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
      </sup>
      .
     </p>
     <p id="Par18">
      We maintained
      <italic>
       M. lucifugus
      </italic>
      in controlled laboratory hibernation chambers for four months during these experiments, and we detected the coronavirus i.e.
      <italic>
       Myl
      </italic>
      -CoV, at the end of hibernation. These data imply that the coronavirus can persist in its host for at least the duration of hibernation, particularly as nucleotide variability among the detected coronavirus isolates showed that spread of coronavirus among bats within a chamber was unlikely
      <sup>
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
      </sup>
      . In an extensive study of New World alphacoronaviruses, no target viruses were detected in the rectal swabs of individual bats sampled over time
      <sup>
       <xref ref-type="bibr" rid="CR46">
        46
       </xref>
      </sup>
      , suggesting that persistence and intensity of shedding varies among species or viruses. The authors concluded that the targeted coronaviruses do not persist in their hosts but are maintained in populations by the introduction of new susceptible individuals. However, their results could also reflect viral persistence in individual animals, with low baseline levels of virus replication and undetectable shedding interspersed with periods of increased replication and shedding that did not occur during the sampling period.
     </p>
     <p id="Par19">
      Periodic or seasonal increases in virus shedding associated with parturition, lactation, nutritional deprivation or environmental stress
      <sup>
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
      </sup>
      suggest persistent or latent viruses may be activated by hormonal or other systemic cues. Direct evidence linking a specific trigger to increased shedding has not yet been found. However, viral replication in rodent and bat cells persistently infected with Ebola virus increased greatly following modulation of the Ras/MAPK pathway with lipopolysaccharides or phorbol esters, and with the resulting suppression of the cells’ interferon response
      <sup>
       <xref ref-type="bibr" rid="CR47">
        47
       </xref>
       –
       <xref ref-type="bibr" rid="CR49">
        49
       </xref>
      </sup>
      . In experimental systems, the immune modulatory cytokine IL10 also influences viral persistence and replication
      <sup>
       <xref ref-type="bibr" rid="CR51">
        51
       </xref>
       –
       <xref ref-type="bibr" rid="CR53">
        53
       </xref>
      </sup>
      , although more study is required to clarify the effects of circulating cytokines on the replication of persistently infecting viruses. Nevertheless, these results suggest that circumstances which induce anti-inflammatory cytokines or suppress anti-viral innate responses, may provide a trigger for increased shedding of persistently infecting virus.
     </p>
     <p id="Par20">
      We discovered that bats with WNS (fungus-infected and co-infected) had significantly lower intestinal levels of transcripts for IL22RA1 and other interferon-related genes as compared to uninfected bats, and we observed the same trend in IL10 (although it was not significant;
      <italic>
       p value
      </italic>
      = 0.07). IL22RA1 is the receptor present on host cells, including intestinal cells, which help in initiating cellular signalling in response to IL22 produced by T-cells
      <sup>
       <xref ref-type="bibr" rid="CR54">
        54
       </xref>
      </sup>
      . IL-22 leads to an increase in anti-microbial peptide production, cellular protection against damage and increases cellular proliferation
      <sup>
       <xref ref-type="bibr" rid="CR55">
        55
       </xref>
      </sup>
      . Therefore, reduced IL-22 signalling in the intestines of bats with WNS, might suppress the bat defences that control the coronavirus infection. Additionally, previous studies have shown that the anti-inflammatory gene, IL10, is expressed more in the lungs of bats with WNS than in bats without it
      <sup>
       <xref ref-type="bibr" rid="CR43">
        43
       </xref>
      </sup>
      . We saw a similar trend with the levels of IL10 in the intestines which might play a role in suppressing the immune response against the coronavirus. Another altered cytokine gene which was of interest was the suppressor of cytokine signalling-6 (SOCS6) gene. Fungal-infected bats showed lower levels of SOCS6 transcripts, lack of which has been implicated in mild growth retardation in mice
      <sup>
       <xref ref-type="bibr" rid="CR56">
        56
       </xref>
      </sup>
      . Overall, our results suggest that WNS triggers changes in gene expression in the ileum (Fig.
      <xref ref-type="fig" rid="Fig5">
       5
      </xref>
      ). These may influence expression of interferon-stimulated-genes (ISGs), thereby leading to increased viral replication at the site of viral persistence. Interferon-related transcripts were more highly expressed in the ileum of virus-infected bats that did not have WNS, suggesting that the bat’s response to WNS causes down-regulation of interferon activity. Interferons may control coronavirus replication, as seen in cases of SARS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR57">
        57
       </xref>
      </sup>
      and MERS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR58">
        58
       </xref>
      </sup>
      . Therefore, a decrease in interferon activity might cause an increase in coronavirus (
      <italic>
       Myl
      </italic>
      -CoV) replication. In addition to interferon-related genes, we also found that RERG, which is related to growth inhibition, was upregulated in the fungus-infected bats when compared to virus-infected bats. Upregulation of RERG could affect the rate of cell proliferation in the intestines
      <sup>
       <xref ref-type="bibr" rid="CR59">
        59
       </xref>
      </sup>
      . Finally, this cascade of responses is associated with increased severity of WNS symptoms.
     </p>
     <p id="Par21">
      Bats with WNS experience a range of systemic disturbances including dehydration, hypovolemia, metabolic acidosis and fat depletion
      <sup>
       <xref ref-type="bibr" rid="CR40">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="CR41">
        41
       </xref>
      </sup>
      , neutrophil infiltration of the lung interstitium, and increased expression of transcripts related to anti-microbial and pro- and anti-inflammatory cytokines
      <sup>
       <xref ref-type="bibr" rid="CR43">
        43
       </xref>
      </sup>
      . Taken together, this evidence suggests that hibernating bats respond systemically to superficial fungal infection, and this hypothesis is further supported by our observations of altered gene expression in the ileum of fungus-infected bats.
     </p>
     <p id="Par22">
      Based on our results, we propose a model for how secondary infections may increase the replication and subsequent shedding of persistently infecting virus (Fig.
      <xref ref-type="fig" rid="Fig5">
       5
      </xref>
      ). The establishment of WNS (or other secondary infection) impacts the tissue with which that pathogen interacts (in the case of
      <italic>
       P. destructans
      </italic>
      , the skin). Direct interactions between the host and the secondary pathogen are limited to the affected tissue, but the systemic response to the disease triggers a cascade of immune responses, including increased release of cytokines or neutrophils. Affected cells such as intra-alveolar macrophages in the lungs or cells lining the intestine, may produce pro- or anti-inflammatory molecules and influence cells that harbour viral genomes. This cascade of host responses disrupts the equilibrium between the persistently infecting virus and the cell’s innate immune response, leading to a dramatic increase in the expression of coronavirus (
      <italic>
       Myl-
      </italic>
      CoV) replication.
     </p>
     <p id="Par23">
      Our assays were unfortunately limited to analysing viral and cytokine transcripts rather than protein, because reagents for detecting bat viral and host proteins are not yet available. We were not able to perform serial dilutions of the plasma to precisely quantify anti-viral titre due to the limitation in the amount of plasma obtained from each bat. The sample size was also small for this assay, because only 7 of the sampled bats had detectable levels of coronavirus in their intestines and were positive for viral antibodies. Despite these limitations, we demonstrated higher antibodies against the coronavirus in the plasma of co-infected bats when compared with virus-infected bats. This increased antibody level in co-infected bats might reflect an adaptive immune response to increased coronavirus replication in the intestines.
     </p>
     <p id="Par24">
      Our proposed hypothesis for the mechanism driving increased viral replication following pathogenic co-infection was worth testing, but our results are also consistent with an alternative hypothesis. Increased viral replication or viral load may affect the severity and population-level impacts of WNS. Bat mortality following the arrival of WNS varies widely from site to site, with populations decreasing from 30% to 99%
      <sup>
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
      </sup>
      . Variation in the microclimate, and other ecological factors may drive some of this variation
      <sup>
       <xref ref-type="bibr" rid="CR60">
        60
       </xref>
      </sup>
      , but our data suggest that cryptic viral infections may also play a role in determining survival rates for bats hibernating in sites colonized by
      <italic>
       P. destructans
      </italic>
      . We recommend that future studies on population-wide impact of WNS incorporate viral sampling to help better understand the role of co-infections on bat populations in the wild.
     </p>
    </sec>
    <sec id="Sec8" sec-type="materials|methods">
     <title>
      Materials and Methods
     </title>
     <sec id="Sec9">
      <title>
       Sample acquisition
      </title>
      <p id="Par25">
       Fifty-four male
       <italic>
        M. lucifugus
       </italic>
       were collected from a WNS-free cave in Manitoba, Canada in November 2010. Details of the experimental design as well as protocols for collecting and transporting bats, infection with
       <italic>
        P. destructans
       </italic>
       , maintenance of bats in hibernation and sample collection have been described previously
       <sup>
        <xref ref-type="bibr" rid="CR37">
         37
        </xref>
        ,
        <xref ref-type="bibr" rid="CR43">
         43
        </xref>
       </sup>
       . Briefly, bats in groups of 18 were either sham-inoculated or inoculated with North American or European isolates of
       <italic>
        P. destructans
       </italic>
       . Bats were housed at 7 °C and &gt;97% relative humidity with
       <italic>
        ad libitum
       </italic>
       water. All bats were equipped with data loggers to monitor skin temperatures. Bats were euthanized during the experiment when humanely required or at the termination of the experiment 120 days after inoculation. Immediately following euthanasia samples from segments of wing as well as various tissues were preserved in RNAlater (Qiagen, 76016) or in formalin. Samples in RNAlater were kept at −20 °C until they were processed. North American and European isolates of
       <italic>
        P. destructans
       </italic>
       caused similar disease outcomes
       <sup>
        <xref ref-type="bibr" rid="CR37">
         37
        </xref>
       </sup>
       , so we did not differentiate between the strains in subsequent analysis. The procedures for care, handling and euthanasia of bats were approved by the University Committee on Animal Care and Supply of the University of Saskatchewan (Protocol #20100120). Bats were collected under the province of Manitoba Wildlife Scientific Permit WB11145.
      </p>
      <p id="Par26">
       In 2017, a further 129
       <italic>
        M. lucifugus
       </italic>
       were collected from a WNS-free cave in Manitoba, Canada in January under the Manitoba Sustainable Development Wildlife Scientific Permit No. SAR16009. Bats were euthanized during the experiment when humanely required or at the termination of the experiment 70 days after infection and a similar experiment was performed at the University of Winnipeg as described above (Protocol #AE08399).
      </p>
     </sec>
     <sec id="Sec10">
      <title>
       Histological classification
      </title>
      <p id="Par27">
       During necropsy, we collected representative samples for histopathology from all major organ systems. In addition, representative samples were taken from all areas of the wing and rolled on dental wax before placing in 10% neutral buffered formalin. Tissues were processed routinely for histology. Five µm sections were cut and stained with periodic acid-Schiff stain to highlight fungal hyphae. Liver and other tissues were processed routinely and stained with hematoxylin and eosin. Wings were scored on a scale of 0 to 5 with 5 being very severe with &gt;50% of wing covered in fungal hyphae. We used a bacterial score from 0 to 5, with 5 indicating wide-spread and abundant bacteria being present in many areas within the dermis and underlying connective tissues. Average scores from 5 sections of wing were used for analysis. Interstitial lung neutrophil assessment was similarly evaluated on a scale of 0 to 5, with 5 being very severe. Average scores from the 5 sections were used for analysis.
      </p>
     </sec>
     <sec id="Sec11">
      <title>
       RNA Extraction
      </title>
      <p id="Par28">
       Tissues preserved in RNAlater were homogenized in 2 ml sealed vials with a 5 mm stainless steel bead, 0.1 g of 0.1 mm zirconia/silica beads and 350 μl Buffer RLT Plus (with β-mercaptoethanol, RNeasy Plus Mini Kit, Qiagen, 74136) using a Retsch MM400 Oscillating Mill at 30 Hz for 4 min. Total RNA was extracted following the manufacturers protocol. RNA integrity was assessed using RNA 6000 Nano Kit (Agilent, 5067-1511) with the Agilent 2100 Bioanalyzer.
      </p>
     </sec>
     <sec id="Sec12">
      <title>
       cDNA Synthesis
      </title>
      <p id="Par29">
       cDNA was synthesized from 1 μg of RNA (or less if concentrations were too low) per reaction using QuantiTect Reverse Transcription Kit (Qiagen 205313). cDNA samples were stored at −80 °C until they were used for PCR.
      </p>
     </sec>
     <sec id="Sec13">
      <title>
       Polymerase Chain Reaction (PCR)
      </title>
      <p id="Par30">
       Tissue samples were identified by their submission numbers with no reference to treatment class prior to analysis with PCR, so that evaluation of the results could not be inadvertently biased by knowledge of the treatment. We used semi-nested PCR to detect
       <italic>
        Myl-
       </italic>
       CoV. Primers were designed from the partial sequence of Rocky Mountain bat coronavirus replicase (accession number EF544563) (Table
       <xref ref-type="media" rid="MOESM1">
        S9
       </xref>
       ). The primary reaction used primers MyCVF1 and MyCVR1 to yield a 441 bp product. The secondary or nested reaction used primers MyCVF2 and MyCV R1 to give a 273 bp product. PCR were performed in a MJ Research PTC-200 thermal cycler using TopTaq DNA Polymerase (Qiagen, 200205). Each reaction (50 μl) contained 2 μl cDNA (or 1 µl primary reaction), 200 nM of each primer, 200 µM of each dNTP (Invitrogen, 10297018), TopTaq PCR buffer and 0.25 μl TopTaq. The thermal profile for the primary reaction was: 94 °C for 3 min (denaturation), followed by 30 cycles of 94 °C for 30 sec, 45 °C for 30 sec (annealing), 72 °C for 1 min and finally 72 °C for 10 min. The thermal profile used for the secondary reaction was 94 °C for 3 min (denaturation), then 30 cycles of 94 °C for 30 sec, 55 °C for 30 sec (annealing), 72 °C for 1 min and finally 72 °C for 10 min. PCR products were analyzed on ethidium bromide stained 1.0% agarose gels (Invitrogen 15510-027 in 0.5X TBE). PCR products were purified using MinElute PCR Purification Kit (Qiagen, 28006) and verified by sequencing (Macrogen, Korea). If more than one DNA band was present, the appropriate size band was cut out and purified using QIAquick Gel Extraction Kit (Qiagen, 28706) before sequencing.
      </p>
     </sec>
     <sec id="Sec14">
      <title>
       Reverse-Transcription Quantitative PCR (RT-qPCR)
      </title>
      <p id="Par31">
       The Stratagene MX3005P qPCR System was used in conjunction with QuantiFast SYBR Green PCR Kit (Qiagen 204056). We quantified coronavirus with RNA primers MyCVF2 and MyCV R1 (Table
       <xref ref-type="media" rid="MOESM1">
        S9
       </xref>
       ). For initial experiments data were normalized to two transcripts – glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin
       <sup>
        <xref ref-type="bibr" rid="CR43">
         43
        </xref>
       </sup>
       . As there were no differences in results, all subsequent experiments used only GAPDH as a normalizer using primers GAPDH US and GAPDH DS (designed for use in humans but also amplify
       <italic>
        M. lucifugus
       </italic>
       transcripts – Table
       <xref ref-type="media" rid="MOESM1">
        S9
       </xref>
       ). As well, a no-template (negative) control was included with every set of primers. Each 25 μl reaction contained: 1 μM of each primer set, 12.5 μl SYBR Green Master Mix and 8.5 μl of diluted cDNA.
      </p>
      <p id="Par32">
       To verify the RNAseq data, cDNA from ileum samples in which coronavirus RNA had been detected via RT-qPCR were analysed using the following primers, IL22RA1, IRF1, RERG and SRC (for sequence of primers see Table
       <xref ref-type="media" rid="MOESM1">
        S9
       </xref>
       ). Primers were designed by aligning primers described for quantitating human cytokines (PrimerBank) with annotated transcripts of
       <italic>
        M. lucifugus
       </italic>
       genes: c-jun (Accession number: XM_006096110.1), cyclin D1 (XM_006098046.1), IL10 (XM_006094865.1) and TNF alpha (XM_006104644.1). The interferon beta primers were designed using the annotated transcript for the
       <italic>
        E. fuscus
       </italic>
       gene (XM_008145044.1), which also amplify transcripts from
       <italic>
        M. lucifugus
       </italic>
       . Primer efficiencies were determined from cycle threshold (Ct) values of purified PCR products serially diluted and re-amplified. Primers amplified targets with an efficiency of about 100% and in all cases the identities of the PCR products were confirmed by their specific dissociation temperature, specific sizes on agarose gels and by sequencing.
      </p>
      <p id="Par33">
       We observed primer-dimers in some reactions in addition to the PCR product. The dimers dissociated at 77 °C, while the specific coronavirus polymerase product dissociated at 83 °C. To avoid false positives due to primer-dimers, the thermocycler was programmed to read at 80 °C (in the cycle after the primer-dimer had dissociated, and before dissociation of the target product). The thermal profile used was 95 °C for 5 min followed by 40 cycles of 95 °C for 10 sec, 60 °C for 30 sec (readings taken at 80 °C), and a final cycle of dissociation of product 95 °C for 1 min, 55 °C for 30 sec and 95 °C for 30 sec (readings taken at every degree between 55 °C and 95 °C). Only results from reactions that yielded unambiguous results were used for analysis.
      </p>
     </sec>
     <sec id="Sec15">
      <title>
       RNA-seq Analysis
      </title>
      <p id="Par34">
       To explore the mechanisms driving high virus load in bats with WNS, we performed RNA-seq analysis which could potentially screen all targets in the bat intestinal cells. We targeted the ileum transcriptome because this is the tissue in which
       <italic>
        Myl
       </italic>
       -CoV is present in detectable concentrations
       <sup>
        <xref ref-type="bibr" rid="CR32">
         32
        </xref>
       </sup>
       . Extraction of RNA from ileum tissue, which includes the ileum and potential gut contents have been described in previous sections. Bats were screened for
       <italic>
        Myl
       </italic>
       -CoV using RT-qPCR, and bats were assigned post hoc to treatment groups representing four infection histories (Fig.
       <xref ref-type="fig" rid="Fig1">
        1(A)
       </xref>
       ): 1) Uninfected (bats were not infected with virus or fungus; n = 5), 2) Virus-infected (bats were naïve to the fungus but had a persistent
       <italic>
        Myl
       </italic>
       -CoV infection; n = 4), 3) Fungus-infected (bats were experimentally infected with
       <italic>
        P. destructans
       </italic>
       and no virus was detected
       <italic>
        ;
       </italic>
       n = 3), or 4) Co-infected (bats with persistent
       <italic>
        Myl
       </italic>
       -CoV infections that were also experimentally infected with
       <italic>
        P. destructans
       </italic>
       ; n = 4). All samples had adequate RNA quality for sequencing (i.e. RIN value &gt;7).
      </p>
     </sec>
     <sec id="Sec16">
      <title>
       RNA isolation
      </title>
      <p id="Par35">
       Tissues were homogenized in 2 ml sealed vials with a 5 mm steel bead, 0.1 g of 0.1 mm zirconium silica beads, 350 µL of RLT buffer (with β-mercaptoethanol) (RNeasy Plus Kit, Qiagen) using a Retsch MM400 tissue homogenizer at 30 Hz twice for 2 minutes each. Total RNA from tissues was extracted using the procedure provided with the RNeasy Plus Kit.
      </p>
     </sec>
     <sec id="Sec17">
      <title>
       cDNA library preparation and RNA-sequencing
      </title>
      <p id="Par36">
       Total RNA was sent to The Centre for Applied Genomics at The Hospital for Sick Children (Toronto, Canada). RNA quality was assessed using a Bioanalyzer (Agilent Technologies). We retained all samples with a DV200 (percentage of RNA fragments greater than 200 nt) greater than 85% (Table
       <xref ref-type="media" rid="MOESM1">
        S1
       </xref>
       ), discarding one Co-infected sample with a DV200 = 42%. Poly(A) mRNA was enriched using oligo dT-beads, and cDNA libraries were prepared using the NEBNext Ultra Directional RNA Library Prep Kit for Illumina (New England BioLabs). Barcoded libraries were pooled in equimolar quantities, and the sixteen libraries were sequenced on three lanes of a HiSeq. 2500 System (Illumina Inc.), which generated 126 bp paired-end reads.
      </p>
     </sec>
     <sec id="Sec18">
      <title>
       RNA-sequencing read alignment and analysis
      </title>
      <p id="Par37">
       We used FastQC v0.11.5
       <sup>
        <xref ref-type="bibr" rid="CR61">
         61
        </xref>
       </sup>
       to assess sequence quality and Trimmomatic v0.36
       <sup>
        <xref ref-type="bibr" rid="CR62">
         62
        </xref>
       </sup>
       to remove the adapter sequences and low-quality bases from reads with the following settings: Illumina clop:2:30:10, leading:3, tailing:3, slidingwindow:4:15, minlength:36. We used TopHat v2.1.1
       <sup>
        <xref ref-type="bibr" rid="CR63">
         63
        </xref>
       </sup>
       to align the trimmed paired-end reads from each library, separately, to the Ensembl
       <italic>
        M. lucifugus
       </italic>
       genome sequence (Myoluc2.0
       <sup>
        <xref ref-type="bibr" rid="CR64">
         64
        </xref>
       </sup>
       ) in strand-specific mode (fr-firststrand) with mate-inner-dist values specific for the insert size of each library. We used featureCounts
       <sup>
        <xref ref-type="bibr" rid="CR65">
         65
        </xref>
       </sup>
       to count reads mapped to the Myoluc2.0 genome annotation in strand-specific mode (reversely stranded), counting paired-end reads as fragments, counting only those fragments where both reads aligned successfully, counting multi-mapping fragments, and excluding chimeric fragments. We assessed the variability within and between the treatments using the R package SARTools v.1.3.0
       <sup>
        <xref ref-type="bibr" rid="CR66">
         66
        </xref>
       </sup>
       . The featureCount-estimated gene counts were transformed by a variance stabilizing method (VST) using SARTools.
      </p>
      <p id="Par38">
       We identified differentially expressed genes between each of the treatments using DESeq2 v.1.12.3, run in SARTools. Custom SARTools-based DESeq settings included: cooksCutoff = TRUE (perform outliers detection), independentFiltering = TRUE, alpha = 0.05 (threshold of statistical significance), pAdjustMethod = BH (benjamini hochberg
       <italic>
        p
       </italic>
       -value adjustment method), and locfunc = median (estimate size factors). Differentially expressed genes were identified as having a fold-change &gt;2 and false discovery rate (FDR)-corrected
       <italic>
        p
       </italic>
       -values &lt; 0.05
       <sup>
        <xref ref-type="bibr" rid="CR67">
         67
        </xref>
       </sup>
       . We produced volcano plots representing the differential expression comparisons by plotting the log of the adjusted p value as a function of the log ratio of differential expression. We used the Ensembl gene IDs identified by DESeq2 as input for the web-based g:Profiler
       <sup>
        <xref ref-type="bibr" rid="CR68">
         68
        </xref>
       </sup>
       to test for gene ontology (GO) term enrichment among the differentially expressed genes, using a FDR significance threshold &lt;0.05. These GO-terms and their corresponding
       <italic>
        p
       </italic>
       -values were used in REViGO
       <sup>
        <xref ref-type="bibr" rid="CR69">
         69
        </xref>
       </sup>
       to visualize significant enrichment of biological processes.
      </p>
     </sec>
     <sec id="Sec19">
      <title>
       IgG capture ELISA against
       <italic>
        Myl
       </italic>
       -CoV N protein
      </title>
      <p id="Par39">
       Purified, glutathione-s-transferase (GST)-tagged
       <italic>
        Myl
       </italic>
       -CoV N protein expressed in infected
       <italic>
        E. coli
       </italic>
       BL21 cells was used as positive antigen, and GST-tagged protein expressed in uninfected BL21 cells was used as negative antigen. 96-well Costar high-binding round-bottom assay plates were coated with 0.05 µg/well of either antigen diluted in 0.1 M phosphate buffered saline (pH 7.4) in a total volume of 100 µl. Plates were covered and incubated overnight at 4 °C and washed three times with 300 µl of PBS-Tween 20 (0.1%) immediately prior to use. Serum samples were diluted to 1:100 in PBS-Tween 20 (0.2%) supplemented with 5% fetal bovine serum (Gibco, Thermofisher). 100 µl of each sample was added in parallel to a positive and negative antigen plate and incubated at 37 °C for one hour and washed as above. A peroxidase-labelled goat anti-bat IgG secondary antibody (0.05 µg in 100 µl per well, Bethyl labs) was added, incubated for one hour at 37 °C and washed as above. Peroxidase substrate (2,2’-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid)) was added to each well and colour development was quantified 30 minutes later by measuring the optical density at 405 nm using an ELISA microplate reader. The ELISA cut-off value (0.39) was calculated as the [(mean bat plasma O.D. values for bats that were PCR-negative for
       <italic>
        Myl
       </italic>
       -CoV in the ileum) + (3x standard deviations of those O.D values)].
      </p>
     </sec>
     <sec id="Sec20">
      <title>
       Statistical analysis
      </title>
      <p id="Par40">
       Data from RT-qPCR and histopathological scores were analysed with SPSS Statistics version 23. The relative levels of a transcript for each bat were calculated as RT-qPCR Cycle threshold (Ct) normalized separately (ΔCt) to the “house-keeping” gene GAPDH. A ΔCt reduction of one (1) indicates an approximately two-fold higher concentration of RNA. The significance of differences of mean values of ΔCt between co-infected bats and virus-infected bats were determined using an independent-samples Mann-Whitney U test. We calculated Pearson’s coefficients to test the correlation between ΔCt levels for coronavirus polymerase cDNA for bats in each treatment class, and average scores for fungal hyphae, secondary bacteria, oedema, necrosis and inflammation in wing lesions, as well as bacteremia and levels of neutrophils in lung, spleen and liver interstitium.
      </p>
     </sec>
     <sec id="Sec21">
      <title>
       Ethical Statement
      </title>
      <p id="Par41">
       Bat studies were carried out in strict compliance with Canadian Council on Animal Care guidelines and the procedure for care, handling, and euthanasia of bats were approved by the University Committee on Animal Care and Supply of the University of Saskatchewan (protocol s#20100120).
      </p>
     </sec>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Electronic supplementary material
     </title>
     <sec id="Sec22">
      <p>
       <supplementary-material content-type="local-data" id="MOESM1">
        <media xlink:href="41598_2018_33975_MOESM1_ESM.pdf">
         <caption>
          <p>
           Supplementary Fig 1
          </p>
         </caption>
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="MOESM2">
        <media xlink:href="41598_2018_33975_MOESM2_ESM.xlsx">
         <caption>
          <p>
           Datasets S1-S9
          </p>
         </caption>
        </media>
       </supplementary-material>
      </p>
     </sec>
    </sec>
    <back>
     <fn-group>
      <fn>
       <p>
        <bold>
         Publisher’s note:
        </bold>
        Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
       </p>
      </fn>
      <fn>
       <p>
        Christina M. Davy, Michael E. Donaldson, Sonu Subudhi and Noreen Rapin contributed equally.
       </p>
      </fn>
     </fn-group>
     <sec>
      <title>
       Electronic supplementary material
      </title>
      <p>
       <bold>
        Supplementary information
       </bold>
       accompanies this paper at 10.1038/s41598-018-33975-x.
      </p>
     </sec>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       Funding for this study was provided by a United States Fish and Wildlife Service grant to Craig K.R. Willis, Trent K. Bollinger and Vikram Misra, Natural Sciences and Engineering Research Council (Discovery) grants to Christopher J. Kyle, Vikram Misra and Craig K.R. Willis, a University of Saskatchewan One Health Initiative grant to Vikram Misra and a fellowship within the Postdoc Programme of the Deutscher Akademischer Austausch Dienst (DAAD), German Academic Exchange Service to Lisa Warnecke. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
      </p>
     </ack>
     <notes notes-type="author-contribution">
      <title>
       Author Contributions
      </title>
      <p>
       C.M.D., M.E.D., S.S. and N.R. contributed equally to the work described in the manuscript: C.M.D., M.E.D. and C.K. analyzed the RNASeq data and contributed to the writing of the manuscript. S.S. and N.R. detected and quantitated viral and host transcripts, developed antisera against recombinant
       <italic>
        Myl
       </italic>
       -CoV N protein and optimized the ELISA assays for bat antibodies. S.S. prepared the initial draft of the manuscript and all authors were involved in editing and refining the manuscript. L.W., J.M.T., C.K.R.W. and V.M. conducted the WNS pathogenesis experiments in 2009 from which all tissue samples were obtained. N.D., E.K., K.N., Y.D., C.K.R.W. conducted the W.N.S. pathogenesis experiment in 2017 and provided samples for the serological analysis. T.K.B. conducted all pathological analyses.
      </p>
     </notes>
     <notes notes-type="data-availability">
      <title>
       Data Accessibility
      </title>
      <p>
       All RNA-seq fastq files have been submitted to the NCBI Sequence Read Archive database (accession number SRX3752319- SRX3752333). These data files will be released to the public upon acceptance of this manuscript for publication.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Competing Interests
      </title>
      <p id="Par42">
       The authors declare no competing interests.
      </p>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           XY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         503
        </volume>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12711
        </pub-id>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         11297
        </fpage>
        <lpage>
         11303
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01498-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25031349
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ithete
          </surname>
          <given-names>
           NL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <fpage>
         1697
        </fpage>
        <lpage>
         1699
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1910.130946
        </pub-id>
        <pub-id pub-id-type="pmid">
         24050621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS-related betacoronavirus in Vespertilio superans bats, China
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         1260
        </fpage>
        <lpage>
         1262
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2007.140318
        </pub-id>
        <pub-id pub-id-type="pmid">
         24960574
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="other">
        Anthony, S. J.
        <italic>
         et al
        </italic>
        . Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus.
        <italic>
         MBio
        </italic>
        <bold>
         8
        </bold>
        , 10.1128/mBio.00373-17 (2017).
       </mixed-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           YW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Origin, evolution, and genotyping of emergent porcine epidemic diarrhea virus strains in the United States
        </article-title>
        <source>
         MBio
        </source>
        <year>
         2013
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e00737
        </fpage>
        <lpage>
         00713
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00737-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24129257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2018
        </year>
        <volume>
         556
        </volume>
        <fpage>
         255
        </fpage>
        <lpage>
         258
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/s41586-018-0010-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         29618817
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Halpin
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Young
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
         <name>
          <surname>
           Field
          </surname>
          <given-names>
           HE
          </given-names>
         </name>
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of Hendra virus from pteropid bats: a natural reservoir of Hendra virus
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2000
        </year>
        <volume>
         81
        </volume>
        <fpage>
         1927
        </fpage>
        <lpage>
         1932
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/0022-1317-81-8-1927
        </pub-id>
        <pub-id pub-id-type="pmid">
         10900029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yob
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2001
        </year>
        <volume>
         7
        </volume>
        <fpage>
         439
        </fpage>
        <lpage>
         441
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid0703.010312
        </pub-id>
        <pub-id pub-id-type="pmid">
         11384522
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Towner
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation of genetically diverse Marburg viruses from Egyptian fruit bats
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <year>
         2009
        </year>
        <volume>
         5
        </volume>
        <fpage>
         e1000536
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1000536
        </pub-id>
        <pub-id pub-id-type="pmid">
         19649327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leroy
          </surname>
          <given-names>
           EM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Fruit bats as reservoirs of Ebola virus
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2005
        </year>
        <volume>
         438
        </volume>
        <fpage>
         575
        </fpage>
        <lpage>
         576
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/438575a
        </pub-id>
        <pub-id pub-id-type="pmid">
         16319873
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vijaykrishna
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evolutionary insights into the ecology of coronaviruses
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         4012
        </fpage>
        <lpage>
         4020
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02605-06
        </pub-id>
        <pub-id pub-id-type="pmid">
         17267506
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Bats host major mammalian paramyxoviruses
        </article-title>
        <source>
         Nat Commun
        </source>
        <year>
         2012
        </year>
        <volume>
         3
        </volume>
        <fpage>
         796
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/ncomms1796
        </pub-id>
        <pub-id pub-id-type="pmid">
         22531181
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Freuling
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Vos
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Fooks
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bat rabies–a Gordian knot?
        </article-title>
        <source>
         Berl Munch Tierarztl Wochenschr
        </source>
        <year>
         2009
        </year>
        <volume>
         122
        </volume>
        <fpage>
         425
        </fpage>
        <lpage>
         433
        </lpage>
        <pub-id pub-id-type="pmid">
         19999377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gonzalez
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Pourrut
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Leroy
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ebolavirus and other filoviruses
        </article-title>
        <source>
         Curr Top Microbiol Immunol
        </source>
        <year>
         2007
        </year>
        <volume>
         315
        </volume>
        <fpage>
         363
        </fpage>
        <lpage>
         387
        </lpage>
        <pub-id pub-id-type="pmid">
         17848072
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronaviruses in bent-winged bats (Miniopterus spp.)
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2006
        </year>
        <volume>
         87
        </volume>
        <fpage>
         2461
        </fpage>
        <lpage>
         2466
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.82203-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         16894183
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Halpin
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         946
        </fpage>
        <lpage>
         951
        </lpage>
        <pub-id pub-id-type="doi">
         10.4269/ajtmh.2011.10-0567
        </pub-id>
        <pub-id pub-id-type="pmid">
         22049055
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Middleton
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Experimental Nipah virus infection in pteropid bats (Pteropus poliocephalus)
        </article-title>
        <source>
         J Comp Pathol
        </source>
        <year>
         2007
        </year>
        <volume>
         136
        </volume>
        <fpage>
         266
        </fpage>
        <lpage>
         272
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jcpa.2007.03.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         17498518
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Schountz
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           LF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antiviral immune responses of bats: a review
        </article-title>
        <source>
         Zoonoses Public Health
        </source>
        <year>
         2013
        </year>
        <volume>
         60
        </volume>
        <fpage>
         104
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1863-2378.2012.01528.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         23302292
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O’Shea
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Bat flight and zoonotic viruses
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        <volume>
         20
        </volume>
        <fpage>
         741
        </fpage>
        <lpage>
         745
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2005.130539
        </pub-id>
        <pub-id pub-id-type="pmid">
         24750692
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Plowright
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ecological dynamics of emerging bat virus spillover
        </article-title>
        <source>
         Proc Biol Sci
        </source>
        <year>
         2015
        </year>
        <volume>
         282
        </volume>
        <fpage>
         20142124
        </fpage>
        <pub-id pub-id-type="doi">
         10.1098/rspb.2014.2124
        </pub-id>
        <pub-id pub-id-type="pmid">
         25392474
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Plowright
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Urban habituation, ecological connectivity and epidemic dampening: the emergence of Hendra virus from flying foxes (Pteropus spp.)
        </article-title>
        <source>
         Proc Biol Sci
        </source>
        <year>
         2011
        </year>
        <volume>
         278
        </volume>
        <fpage>
         3703
        </fpage>
        <lpage>
         3712
        </lpage>
        <pub-id pub-id-type="doi">
         10.1098/rspb.2011.0522
        </pub-id>
        <pub-id pub-id-type="pmid">
         21561971
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Webber
          </surname>
          <given-names>
           QMR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Social network characteristics and predicted pathogen transmission in summer colonies of female big brown bats (Eptesicus fuscus)
        </article-title>
        <source>
         Behavioral Ecology and Sociobiology
        </source>
        <year>
         2016
        </year>
        <volume>
         70
        </volume>
        <fpage>
         701
        </fpage>
        <lpage>
         712
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00265-016-2093-3
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Amplification of emerging viruses in a bat colony
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2011
        </year>
        <volume>
         17
        </volume>
        <fpage>
         449
        </fpage>
        <lpage>
         456
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1703.100526
        </pub-id>
        <pub-id pub-id-type="pmid">
         21392436
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Field
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hendra virus infection dynamics in Australian fruit bats
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e28678
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0028678
        </pub-id>
        <pub-id pub-id-type="pmid">
         22174865
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Plowright
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Reproduction and nutritional stress are risk factors for Hendra virus infection in little red flying foxes (Pteropus scapulatus)
        </article-title>
        <source>
         Proc Biol Sci
        </source>
        <year>
         2008
        </year>
        <volume>
         275
        </volume>
        <fpage>
         861
        </fpage>
        <lpage>
         869
        </lpage>
        <pub-id pub-id-type="doi">
         10.1098/rspb.2007.1260
        </pub-id>
        <pub-id pub-id-type="pmid">
         18198149
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pourrut
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2007
        </year>
        <volume>
         196
        </volume>
        <issue>
         Suppl 2
        </issue>
        <fpage>
         S176
        </fpage>
        <lpage>
         183
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/520541
        </pub-id>
        <pub-id pub-id-type="pmid">
         17940947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rahman
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Characterization of Nipah virus from naturally infected Pteropus vampyrus bats, Malaysia
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2010
        </year>
        <volume>
         16
        </volume>
        <fpage>
         1990
        </fpage>
        <lpage>
         1993
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1612.091790
        </pub-id>
        <pub-id pub-id-type="pmid">
         21122240
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McMichael
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Physiological stress and Hendra virus in flying-foxes (Pteropus spp.), Australia
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2017
        </year>
        <volume>
         12
        </volume>
        <fpage>
         e0182171
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0182171
        </pub-id>
        <pub-id pub-id-type="pmid">
         28767708
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="other">
        Roizman, B. &amp; Sears, A. E. In
        <italic>
         Fields Virology
        </italic>
        Vol. 2 (eds Fields, B. N., Knipe, D. M. &amp; Howley, P. M.) 2231–2295 (Lippincott-Raven (1996).
       </mixed-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amman
          </surname>
          <given-names>
           BR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <year>
         2012
        </year>
        <volume>
         8
        </volume>
        <fpage>
         e1002877
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1002877
        </pub-id>
        <pub-id pub-id-type="pmid">
         23055920
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Subudhi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A persistently infecting coronavirus in hibernating Myotis lucifugus, the North American little brown bat
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2017
        </year>
        <volume>
         98
        </volume>
        <fpage>
         2297
        </fpage>
        <lpage>
         2309
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jgv.0.000898
        </pub-id>
        <pub-id pub-id-type="pmid">
         28840816
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dominguez
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           O’Shea
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         <name>
          <surname>
           Oko
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
        </person-group>
        <article-title>
         1 coronaviruses in bats in North America
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2007
        </year>
        <volume>
         13
        </volume>
        <fpage>
         1295
        </fpage>
        <lpage>
         1300
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1309.070491
        </pub-id>
        <pub-id pub-id-type="pmid">
         18252098
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Blehert
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Bat white-nose syndrome: an emerging fungal pathogen?
        </article-title>
        <source>
         Science
        </source>
        <year>
         2009
        </year>
        <volume>
         323
        </volume>
        <fpage>
         227
        </fpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1163874
        </pub-id>
        <pub-id pub-id-type="pmid">
         18974316
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frick
          </surname>
          <given-names>
           WF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An emerging disease causes regional population collapse of a common North American bat species
        </article-title>
        <source>
         Science
        </source>
        <year>
         2010
        </year>
        <volume>
         329
        </volume>
        <fpage>
         679
        </fpage>
        <lpage>
         682
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1188594
        </pub-id>
        <pub-id pub-id-type="pmid">
         20689016
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lorch
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Experimental infection of bats with Geomyces destructans causes white-nose syndrome
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2011
        </year>
        <volume>
         480
        </volume>
        <fpage>
         376
        </fpage>
        <lpage>
         378
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature10590
        </pub-id>
        <pub-id pub-id-type="pmid">
         22031324
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Warnecke
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inoculation of bats with European Geomyces destructans supports the novel pathogen hypothesis for the origin of white-nose syndrome
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         2012
        </year>
        <volume>
         109
        </volume>
        <fpage>
         6999
        </fpage>
        <lpage>
         7003
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1200374109
        </pub-id>
        <pub-id pub-id-type="pmid">
         22493237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Field
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The White-Nose Syndrome Transcriptome: Activation of Anti-fungal Host Responses in Wing Tissue of Hibernating Little Brown Myotis
        </article-title>
        <source>
         PLoS Pathog
        </source>
        <year>
         2015
        </year>
        <volume>
         11
        </volume>
        <fpage>
         e1005168
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1005168
        </pub-id>
        <pub-id pub-id-type="pmid">
         26426272
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davy
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The other white-nose syndrome transcriptome: Tolerant and susceptible hosts respond differently to the pathogen
        </article-title>
        <source>
         Ecol Evol
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <fpage>
         7161
        </fpage>
        <lpage>
         7170
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/ece3.3234
        </pub-id>
        <pub-id pub-id-type="pmid">
         28944007
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Verant
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         White-nose syndrome initiates a cascade of physiologic disturbances in the hibernating bat host
        </article-title>
        <source>
         BMC Physiol
        </source>
        <year>
         2014
        </year>
        <volume>
         14
        </volume>
        <fpage>
         10
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12899-014-0010-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         25487871
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Warnecke
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pathophysiology of white-nose syndrome in bats: a mechanistic model linking wing damage to mortality
        </article-title>
        <source>
         Biol Lett
        </source>
        <year>
         2013
        </year>
        <volume>
         9
        </volume>
        <fpage>
         20130177
        </fpage>
        <pub-id pub-id-type="doi">
         10.1098/rsbl.2013.0177
        </pub-id>
        <pub-id pub-id-type="pmid">
         23720520
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McGuire
          </surname>
          <given-names>
           LP
          </given-names>
         </name>
         <name>
          <surname>
           Mayberry
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name>
          <surname>
           Willis
          </surname>
          <given-names>
           CKR
          </given-names>
         </name>
        </person-group>
        <article-title>
         White-nose syndrome increases torpid metabolic rate and evaporative water loss in hibernating bats
        </article-title>
        <source>
         Am J Physiol Regul Integr Comp Physiol
        </source>
        <year>
         2017
        </year>
        <volume>
         313
        </volume>
        <fpage>
         R680
        </fpage>
        <lpage>
         R686
        </lpage>
        <pub-id pub-id-type="doi">
         10.1152/ajpregu.00058.2017
        </pub-id>
        <pub-id pub-id-type="pmid">
         28835446
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rapin
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Activation of innate immune-response genes in little brown bats (Myotis lucifugus) infected with the fungus Pseudogymnoascus destructans
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2014
        </year>
        <volume>
         9
        </volume>
        <fpage>
         e112285
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0112285
        </pub-id>
        <pub-id pub-id-type="pmid">
         25391018
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pauli
          </surname>
          <given-names>
           Giuliano
          </given-names>
         </name>
         <name>
          <surname>
           Moura Mascarin
          </surname>
          <given-names>
           Gabriel
          </given-names>
         </name>
         <name>
          <surname>
           Eilenberg
          </surname>
          <given-names>
           Jørgen
          </given-names>
         </name>
         <name>
          <surname>
           Delalibera Júnior
          </surname>
          <given-names>
           Italo
          </given-names>
         </name>
        </person-group>
        <article-title>
         Within-Host Competition between Two Entomopathogenic Fungi and a Granulovirus in Diatraea saccharalis (Lepidoptera: Crambidae)
        </article-title>
        <source>
         Insects
        </source>
        <year>
         2018
        </year>
        <volume>
         9
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         64
        </fpage>
        <pub-id pub-id-type="doi">
         10.3390/insects9020064
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Whitfield
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infection and co-infection by the amphibian chytrid fungus and ranavirus in wild Costa Rican frogs
        </article-title>
        <source>
         Dis Aquat Organ
        </source>
        <year>
         2013
        </year>
        <volume>
         104
        </volume>
        <fpage>
         173
        </fpage>
        <lpage>
         178
        </lpage>
        <pub-id pub-id-type="doi">
         10.3354/dao02598
        </pub-id>
        <pub-id pub-id-type="pmid">
         23709470
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Osborne
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Alphacoronaviruses in New World bats: prevalence, persistence, phylogeny, and potential for interaction with humans
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e19156
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0019156
        </pub-id>
        <pub-id pub-id-type="pmid">
         21589915
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Strong
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         2008
        </year>
        <volume>
         105
        </volume>
        <fpage>
         17982
        </fpage>
        <lpage>
         17987
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0809698105
        </pub-id>
        <pub-id pub-id-type="pmid">
         18981410
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mizutani
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mechanisms of establishment of persistent SARS-CoV-infected cells
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <year>
         2006
        </year>
        <volume>
         347
        </volume>
        <fpage>
         261
        </fpage>
        <lpage>
         265
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2006.06.086
        </pub-id>
        <pub-id pub-id-type="pmid">
         16808902
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mizutani
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Fukushi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Saijo
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kurane
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of persistent SARS-CoV infection in Vero E6 cells
        </article-title>
        <source>
         Adv Exp Med Biol
        </source>
        <year>
         2006
        </year>
        <volume>
         581
        </volume>
        <fpage>
         323
        </fpage>
        <lpage>
         326
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/978-0-387-33012-9_57
        </pub-id>
        <pub-id pub-id-type="pmid">
         17037553
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Palacios
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Jabado
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Renwick
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Lipkin
          </surname>
          <given-names>
           WI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus persistence in Vero cells
        </article-title>
        <source>
         Chin Med J (Engl)
        </source>
        <year>
         2005
        </year>
        <volume>
         118
        </volume>
        <fpage>
         451
        </fpage>
        <lpage>
         459
        </lpage>
        <pub-id pub-id-type="pmid">
         15788125
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           CT
          </given-names>
         </name>
         <name>
          <surname>
           Oldstone
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
        </person-group>
        <article-title>
         IL-10: achieving balance during persistent viral infection
        </article-title>
        <source>
         Curr Top Microbiol Immunol
        </source>
        <year>
         2014
        </year>
        <volume>
         380
        </volume>
        <fpage>
         129
        </fpage>
        <lpage>
         144
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/978-3-662-43492-5_6
        </pub-id>
        <pub-id pub-id-type="pmid">
         25004816
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Puntambekar
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Shifting hierarchies of interleukin-10-producing T cell populations in the central nervous system during acute and persistent viral encephalomyelitis
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         6702
        </fpage>
        <lpage>
         6713
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00200-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         21525347
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           EB
          </given-names>
         </name>
         <name>
          <surname>
           Brooks
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of IL-10 in regulating immunity to persistent viral infections
        </article-title>
        <source>
         Curr Top Microbiol Immunol
        </source>
        <year>
         2011
        </year>
        <volume>
         350
        </volume>
        <fpage>
         39
        </fpage>
        <lpage>
         65
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/82_2010_96
        </pub-id>
        <pub-id pub-id-type="pmid">
         20703965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hernández
          </surname>
          <given-names>
           PP
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-λ and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection
        </article-title>
        <source>
         Nat Immunol
        </source>
        <year>
         2015
        </year>
        <volume>
         16
        </volume>
        <fpage>
         698
        </fpage>
        <lpage>
         707
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/ni.3180
        </pub-id>
        <pub-id pub-id-type="pmid">
         26006013
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wolk
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Sabat
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells
        </article-title>
        <source>
         Cytokine Growth Factor Rev
        </source>
        <year>
         2006
        </year>
        <volume>
         17
        </volume>
        <fpage>
         367
        </fpage>
        <lpage>
         380
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cytogfr.2006.09.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         17030002
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Krebs
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation
        </article-title>
        <source>
         Mol Cell Biol
        </source>
        <year>
         2002
        </year>
        <volume>
         22
        </volume>
        <fpage>
         4567
        </fpage>
        <lpage>
         4578
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/MCB.22.13.4567-4578.2002
        </pub-id>
        <pub-id pub-id-type="pmid">
         12052866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-beta 1a and SARS coronavirus replication
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         317
        </fpage>
        <lpage>
         319
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1002.030482
        </pub-id>
        <pub-id pub-id-type="pmid">
         15030704
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin
        </article-title>
        <source>
         Sci Rep
        </source>
        <year>
         2013
        </year>
        <volume>
         3
        </volume>
        <fpage>
         1686
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/srep01686
        </pub-id>
        <pub-id pub-id-type="pmid">
         23594967
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Finlin
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer
        </article-title>
        <source>
         J Biol Chem
        </source>
        <year>
         2001
        </year>
        <volume>
         276
        </volume>
        <fpage>
         42259
        </fpage>
        <lpage>
         42267
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M105888200
        </pub-id>
        <pub-id pub-id-type="pmid">
         11533059
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Langwig
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Sociality, density-dependence and microclimates determine the persistence of populations suffering from a novel fungal disease, white-nose syndrome
        </article-title>
        <source>
         Ecol Lett
        </source>
        <year>
         2012
        </year>
        <volume>
         15
        </volume>
        <fpage>
         1050
        </fpage>
        <lpage>
         1057
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1461-0248.2012.01829.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         22747672
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR61">
       <label>
        61.
       </label>
       <mixed-citation publication-type="other">
        Andrews, S. FastQC A Quality Control tool for High Throughput Sequence Data. http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ citeulike-article-id:11583827.
       </mixed-citation>
      </ref>
      <ref id="CR62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bolger
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Lohse
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Usadel
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Trimmomatic: a flexible trimmer for Illumina sequence data
        </article-title>
        <source>
         Bioinformatics
        </source>
        <year>
         2014
        </year>
        <volume>
         30
        </volume>
        <fpage>
         2114
        </fpage>
        <lpage>
         2120
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/bioinformatics/btu170
        </pub-id>
        <pub-id pub-id-type="pmid">
         24695404
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR63">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions
        </article-title>
        <source>
         Genome Biol
        </source>
        <year>
         2013
        </year>
        <volume>
         14
        </volume>
        <fpage>
         R36
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/gb-2013-14-4-r36
        </pub-id>
        <pub-id pub-id-type="pmid">
         23618408
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR64">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cunningham
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ensembl 2015
        </article-title>
        <source>
         Nucleic Acids Res
        </source>
        <year>
         2015
        </year>
        <volume>
         43
        </volume>
        <fpage>
         D662
        </fpage>
        <lpage>
         669
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/nar/gku1010
        </pub-id>
        <pub-id pub-id-type="pmid">
         25352552
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR65">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Smyth
          </surname>
          <given-names>
           GK
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
        </article-title>
        <source>
         Bioinformatics
        </source>
        <year>
         2014
        </year>
        <volume>
         30
        </volume>
        <fpage>
         923
        </fpage>
        <lpage>
         930
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/bioinformatics/btt656
        </pub-id>
        <pub-id pub-id-type="pmid">
         24227677
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR66">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Varet
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Brillet-Guéguen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Coppée
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Dillies
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARTools: A DESeq. 2- and EdgeR-Based R Pipeline for Comprehensive Differential Analysis of RNA-Seq Data
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2016
        </year>
        <volume>
         11
        </volume>
        <fpage>
         e0157022
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0157022
        </pub-id>
        <pub-id pub-id-type="pmid">
         27280887
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR67">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benjamini
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Hochberg
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing.
         <italic>
          Journal of the Royal Statistical Society
         </italic>
        </article-title>
        <source>
         Series B (Methodological)
        </source>
        <year>
         1995
        </year>
        <volume>
         57
        </volume>
        <fpage>
         289
        </fpage>
        <lpage>
         300
        </lpage>
        <pub-id pub-id-type="doi">
         10.2307/2346101
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR68">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reimand
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         g:Profiler-a web server for functional interpretation of gene lists (2016 update)
        </article-title>
        <source>
         Nucleic Acids Res
        </source>
        <year>
         2016
        </year>
        <volume>
         44
        </volume>
        <fpage>
         W83
        </fpage>
        <lpage>
         89
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/nar/gkw199
        </pub-id>
        <pub-id pub-id-type="pmid">
         27098042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR69">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Supek
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Bošnjak
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Škunca
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Šmuc
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         REVIGO summarizes and visualizes long lists of gene ontology terms
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e21800
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0021800
        </pub-id>
        <pub-id pub-id-type="pmid">
         21789182
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Autoimmun
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Autoimmun
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Autoimmunity
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0896-8411
      </issn>
      <issn pub-type="epub">
       1095-9157
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32143990
      </article-id>
      <article-id pub-id-type="pmc">
       7126544
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0896-8411(20)30047-0
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.jaut.2020.102434
      </article-id>
      <article-id pub-id-type="publisher-id">
       102434
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Yongshi
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Peng
         </surname>
         <given-names>
          Fujun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Runsheng
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Guan
         </surname>
         <given-names>
          Kai
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Jiang
         </surname>
         <given-names>
          Taijiao
         </given-names>
        </name>
        <email>
         taijiao@ibms.pumc.edu.cn
        </email>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
        <xref ref-type="corresp" rid="cor4">
         ∗∗∗∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au6">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          Guogang
         </given-names>
        </name>
        <email>
         guogang_xu@qq.com
        </email>
        <xref ref-type="aff" rid="aff5">
         e
        </xref>
        <xref ref-type="corresp" rid="cor3">
         ∗∗∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au7">
        <name>
         <surname>
          Sun
         </surname>
         <given-names>
          Jinlyu
         </given-names>
        </name>
        <email>
         sunjinlv@pumch.cn
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor2">
         ∗∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au8">
        <name>
         <surname>
          Chang
         </surname>
         <given-names>
          Christopher
         </given-names>
        </name>
        <email>
         chrchang@ucdavis.edu
        </email>
        <xref ref-type="aff" rid="aff6">
         f
        </xref>
        <xref ref-type="aff" rid="aff7">
         g
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Department of Allergy &amp; Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Sciences, National Clinical Research Center for Immunologic Diseases, Beijing, 100730, China
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, 100005, China
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       Department of Respiratory Diseases, The Second Medical Center &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China
      </aff>
      <aff id="aff5">
       <label>
        e
       </label>
       Department of Infection Prevention and Disease Control, The Second Medical Center &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China
      </aff>
      <aff id="aff6">
       <label>
        f
       </label>
       Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, Davis, CA, 95616, USA
      </aff>
      <aff id="aff7">
       <label>
        g
       </label>
       Division of Pediatric Immunology and Allergy, Joe DiMaggio Children's Hospital, Hollywood, FL, USA
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding authors. University of California, Davis, 451 Health Sciences Drive, Suite 6510, Davis, CA 95616, USA.
        <email>
         chrchang@ucdavis.edu
        </email>
       </corresp>
       <corresp id="cor2">
        <label>
         ∗∗
        </label>
        Corresponding author. No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China.
        <email>
         sunjinlv@pumch.cn
        </email>
       </corresp>
       <corresp id="cor3">
        <label>
         ∗∗∗
        </label>
        Corresponding authors. No.28 Fuxing Road, Beijing, 100853, China.
        <email>
         guogang_xu@qq.com
        </email>
       </corresp>
       <corresp id="cor4">
        <label>
         ∗∗∗∗
        </label>
        Corresponding author. No.9, Dongdan 3 rd, Dongcheng District, Beijing, 100005, China.
        <email>
         taijiao@ibms.pumc.edu.cn
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         1
        </label>
        <p id="ntpara0010">
         Yongshi Yang, Fujun Peng, Runsheng Wang contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        3
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        3
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       102434
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         19
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         22
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         22
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <p>
        The 2019-nCoV is officially called SARS-CoV-2 and the disease is named COVID-19. This viral epidemic in China has led to the deaths of over 1800 people, mostly elderly or those with an underlying chronic disease or immunosuppressed state. This is the third serious Coronavirus outbreak in less than 20 years, following SARS in 2002–2003 and MERS in 2012. While human strains of Coronavirus are associated with about 15% of cases of the common cold, the SARS-CoV-2 may present with varying degrees of severity, from flu-like symptoms to death. It is currently believed that this deadly Coronavirus strain originated from wild animals at the Huanan market in Wuhan, a city in Hubei province. Bats, snakes and pangolins have been cited as potential carriers based on the sequence homology of CoV isolated from these animals and the viral nucleic acids of the virus isolated from SARS-CoV-2 infected patients. Extreme quarantine measures, including sealing off large cities, closing borders and confining people to their homes, were instituted in January 2020 to prevent spread of the virus, but by that time much of the damage had been done, as human-human transmission became evident. While these quarantine measures are necessary and have prevented a historical disaster along the lines of the Spanish flu, earlier recognition and earlier implementation of quarantine measures may have been even more effective. Lessons learned from SARS resulted in faster determination of the nucleic acid sequence and a more robust quarantine strategy. However, it is clear that finding an effective antiviral and developing a vaccine are still significant challenges. The costs of the epidemic are not limited to medical aspects, as the virus has led to significant sociological, psychological and economic effects globally. Unfortunately, emergence of SARS-CoV-2 has led to numerous reports of Asians being subjected to racist behavior and hate crimes across the world.
       </p>
      </abstract>
      <abstract abstract-type="author-highlights" id="abs0015">
       <title>
        Highlights
       </title>
       <p>
        <list id="ulist0010" list-type="simple">
         <list-item id="u0010">
          <p id="p0010">
           •The 2019-nCoV is officially called SARS-CoV-2, and is the cause of the disease named COVID-19.
          </p>
         </list-item>
         <list-item id="u0015">
          <p id="p0015">
           •COVID-19 is the third severe epidemic caused by coronaviruses in the past 20 years.
          </p>
         </list-item>
         <list-item id="u0020">
          <p id="p0020">
           •It is believed that the SARS-CoV-2 virus originated from bats, based on genomic sequencing.
          </p>
         </list-item>
         <list-item id="u0025">
          <p id="p0025">
           •While human strains of Coronavirus are associated with about 15% of cases of the common cold, the SARS-CoV-2 is far more deadly, with a mortality rate around 2.3%.
          </p>
         </list-item>
         <list-item id="u0030">
          <p id="p0030">
           •As of February 19th, 2020, there have been 75,282 confirmed cases and 2012 deaths worldwide.
          </p>
         </list-item>
         <list-item id="u0035">
          <p id="p0035">
           •Lessons learned from SARS in 2003 resulted in faster determination of the nucleic acid sequence and a more robust quarantine strategy.
          </p>
         </list-item>
         <list-item id="u0040">
          <p id="p0040">
           •Extreme quarantine measures, including sealing off large cities, closing borders and confining people to their homes are critical to stemming spread of the virus.
          </p>
         </list-item>
         <list-item id="u0045">
          <p id="p0045">
           •Pyroptosis, a novel form of inflammatory cell death, is a possible mechanism for the increased virulence of the SARS-CoV-2.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        Epidemiology
       </kwd>
       <kwd>
        Pneumonia
       </kwd>
       <kwd>
        Flu
       </kwd>
       <kwd>
        Bats
       </kwd>
       <kwd>
        Human to human transmission
       </kwd>
       <kwd>
        Epidemic
       </kwd>
       <kwd>
        Pandemic
       </kwd>
       <kwd>
        Pyroptosis
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0050">
      Coronaviruses (CoVs) are named for the crown-like spikes on their surface and belong to the family Coronaviridae within the order Nidovirales. Coronaviruses broadly infect vertebrates including humans, birds, bats, snakes, mice and other wild animals [
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib2">
       2
      </xref>
      ]. Since the mid-1960s, seven known human coronaviruses (HCoVs) have been identified [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib4">
       4
      </xref>
      ]. Four commonly detected HCoVs are 229E, OC43, NL63 and HKU1. In one study, 229E and OC43 accounted for approximately 15–29% of respiratory pathogens with relatively low virulence in humans [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib5">
       5
      </xref>
      ]. Another epidemiological study in adults estimates that coronavirus causes about 15% of common colds [
      <xref ref-type="bibr" rid="bib6">
       6
      </xref>
      ]. Other significant causes of upper respiratory infections include influenza virus, rhinovirus, parainfluenza virus, Group A Streptococci, EBV and respiratory syncytial virus (RSV).
     </p>
     <p id="p0055">
      The three other strains of HCoVs, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have a different pathogenicity and lead to higher mortality rates in human populations. MERS-CoV was isolated from a male patient who died from acute pneumonia and renal failure in Saudi Arabia in 2012 [
      <xref ref-type="bibr" rid="bib7">
       7
      </xref>
      ], and was subsequently responsible for 2494 cases and 858 deaths from 27 different countries (case-fatality rate: 34.4%) [
      <xref ref-type="bibr" rid="bib8">
       8
      </xref>
      ]. Both SARS-CoV and SARS-CoV-2 were first recognized in China. SARS-CoV caused a total of 8422 probable SARS cases, 919 SARS-related deaths (case-fatality rate: 11%) and spread to 32 different countries or regions between November 2002 and August 2003 [
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ]. Since December 2019, the SARS-CoV-2 has infected 73,230 people and caused 1871 deaths (case-fatality rate: 2.6%) and has spread to 25 countries, according to the State Council Information Office in Beijing, China (updated as of Feb. 17, 2020) [
      <xref ref-type="bibr" rid="bib10">
       10
      </xref>
      ]. As of this date, the number of confirmed and suspected cases is still increasing, as is the number of deaths, although there is a significant increase in the number of recovered patients as well.
     </p>
     <p id="p0060">
      Coronaviruses were first identified in the 1960s. It is not known for how long they have existed. Most of the time they are associated with mild disease, but every few years a highly virulent strain appears. The pathogenesis of these deadly epidemics is unclear. An examination of the structure of the viruses and the mechanism of infection may help elucidate and provide information for the development of effective treatment and possibly vaccines. Our purpose of this review is to provide a brief summary of the epidemiology and history of SARS, as well as the lessons learned. The other aim is to review the epidemiology, pathogenesis, clinical characteristics, diagnosis and management of patients infected with SARS-CoV-2 to better understand this deadly coronavirus and suggest prevention, treatment and management strategies.
     </p>
    </sec>
    <sec id="sec2">
     <label>
      2
     </label>
     <title>
      Characteristics of coronaviruses and coronavirus infections
     </title>
     <sec id="sec2.1">
      <label>
       2.1
      </label>
      <title>
       Biology of the coronaviruses
      </title>
      <p id="p0065">
       CoVs are enveloped with a non-segmented, positive-sense, single-strand RNA, with size ranging from 26,000 to 37,000 bases. This is the largest known genome among RNA viruses [
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ]. The genomic structure of CoVs is as follows: 5′-leader-UTR-replicase-S (Spike)–E (Envelope)-M (Membrane)-N (Nucleocapsid)-3′UTRpoly (A) tail. There are accessory genes interspersed within the structural genes at the 3′ end of genome [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ], some of which have been shown to play an important roles in viral pathogenesis [
       <xref ref-type="bibr" rid="bib13">
        13
       </xref>
       ]. The S protein is responsible for receptor-binding and subsequent viral entry into host cells, the M and E proteins play important roles in viral assembly, and the N protein is necessary for RNA synthesis [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2.2">
      <label>
       2.2
      </label>
      <title>
       Coronavirus transmission
      </title>
      <p id="p0070">
       CoVs can transmit across species barriers. SARS-CoV originated from bats of the Hipposideridae family, using palm civets as intermediary hosts before dissemination to humans [
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="bib16">
        16
       </xref>
       ]. The earliest patients infected with SARS-CoV-2 in Wuhan ultimately caused the epidemic known as COronaVIrus Disease 2019 (COVID-2019). Some of these patients had a history of contact with a wholesale seafood market in the early stages, suggesting animal-to-person spread. Subsequently, a large number of patients reportedly did not have exposure to the markets, suggesting the development of person-to-person spread [
       <xref ref-type="bibr" rid="bib17">
        [17]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib18">
        [18]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib19">
        [19]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib20">
        [20]
       </xref>
       ].
      </p>
      <p id="p0075">
       There are three primary ways to transmit the virus, including close person-to-person contact, aerosol transmission, and transmission by touch [
       <xref ref-type="bibr" rid="bib21">
        [21]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        [22]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib23">
        [23]
       </xref>
       ]. The virus is thought to be transmitted to other people by respiratory droplets during coughing or sneezing. Droplet spread can occur when an infected person sneezes or coughs, whereupon virus containing droplets are propelled up to 3 feet through the air and are deposited on the mucous membranes of the mouth, nose, or eyes of persons who are nearby. A recent report suggests that transmission through the ocular surface is also possible [
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ]. The other avenues for the spread of the virus are shaking hands with an infected person, touching an infected object/surface, frequent touching of the nose or mouth or coming into contact with a patient's excreta. Another avenue is through “hidden transmission” [
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ], in which asymptomatic infected individuals or carriers unknowingly transmit the virus to unsuspecting contacts.
      </p>
     </sec>
     <sec id="sec2.3">
      <label>
       2.3
      </label>
      <title>
       Variability of clinical presentation
      </title>
      <p id="p0080">
       Before the first outbreak of SARS, a limited number of HCoVs such as HCoV-229E were frequently found to infect humans, and were widely circulating in human populations causing only mild illnesses like the common cold [
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
       ]. However, SARS, MERS and SARS-CoV-2 present with a spectrum of disease severity ranging from flu-like symptoms to acute respiratory distress syndrome [
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
       ,
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ]. Early on, these patients are usually treated with conventional medications which had no clinical benefit, resulting in spread to health care personnel. For those with flu-like symptoms or even more severe disease, it would not be immediately evident that this is an atypical and virulent form of a coronavirus. For comparison, influenza has an estimated mortality rate of 0.07%–0.2%. A high index of suspicion is helpful but not foolproof.
      </p>
     </sec>
     <sec id="sec2.4">
      <label>
       2.4
      </label>
      <title>
       Genetic diversity
      </title>
      <p id="p0085">
       The various CoVs of animal origin undergo evolution and genetic recombination, thereby resulting in mutated CoVs that may be highly pathogenic and potentially be more deadly to humans [
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="bib27">
        27
       </xref>
       ]. For SARS-CoV, the mutation rate in the SARS-CoV genome was estimated to be 0.80–2.38 × 10
       <sup>
        −3
       </sup>
       nucleotide substitutions per site per year, and the nonsynonymous and synonymous substitution rates were estimated to be 1.16–3.30 × 10
       <sup>
        −3
       </sup>
       and 1.67–4.67 × 10
       <sup>
        −3
       </sup>
       per site per year, respectively, which are similar to that of other RNA viruses [
       <xref ref-type="bibr" rid="bib28">
        28
       </xref>
       ]. The various CoVs of animal origin undergo evolution and genetic recombination either within the host species or upon jumping from one species to another. Such changes thus have the potential to lead to variants that have high pathogenic potential when transmitted to humans [
       <xref ref-type="bibr" rid="bib29">
        [29]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib30">
        [30]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib31">
        [31]
       </xref>
       ]. Recently, two mutations of the S protein and N protein SARS-CoV-2 may explain its zoonotic transmission [
       <xref ref-type="bibr" rid="bib32">
        32
       </xref>
       ]. Genomic alignment of 54 SARS-CoV-2 genomes identified two hotspots of hypervariability at positions 8789 (synonymous variant) and 28,151(Ser/Leu change), located in the polyprotein and ORF8 genes respectively [
       <xref ref-type="bibr" rid="bib33">
        33
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2.5">
      <label>
       2.5
      </label>
      <title>
       Comorbidities
      </title>
      <p id="p0090">
       Most patients who have died from the virus had other chronic medical conditions, were elderly patients or were immunocompromised. One study reported that 6.7% of SARS patients had acute renal impairment and 84.6% had proteinuria [
       <xref ref-type="bibr" rid="bib34">
        34
       </xref>
       ]. Hematological abnormalities such as thrombocytopenia and lymphopenia were frequently observed in SARS [
       <xref ref-type="bibr" rid="bib35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="bib36">
        36
       </xref>
       ]. Complications encountered for SARS-CoV-2 include acute respiratory distress syndrome (29%,12/41), anemia (15%, 6/41), acute cardiac injury (12%, 5/41) and secondary infection (10%, 4/41) [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ]. In a SARS-CoV-2 descriptive study, 11 of 99 patients died of multiple organ failure, and seven were older than 60 years [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2.6">
      <label>
       2.6
      </label>
      <title>
       Lack of effective treatment
      </title>
      <p id="p0095">
       To date, there is no anti-viral therapeutics that specifically targets human coronaviruses, so treatment is only supportive.
       <italic>
        In vitro
       </italic>
       , interferons (IFNs) are only partially effective against coronaviruses [
       <xref ref-type="bibr" rid="bib38">
        38
       </xref>
       ].
       <italic>
        In vivo
       </italic>
       , the effectiveness of IFNs combined with ribavirin requires further evaluation [
       <xref ref-type="bibr" rid="bib39">
        39
       </xref>
       ]. A variety of other agents, including antiviral peptides and corticosteroids have been shown to be effective
       <italic>
        in vitro
       </italic>
       and/or in animal models [
       <xref ref-type="bibr" rid="bib40">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="bib41">
        41
       </xref>
       ]. However, clinical evidence does not support the use of corticosteroid treatment for SARS-CoV-2 lung injury [
       <xref ref-type="bibr" rid="bib42">
        42
       </xref>
       ]. Vaccines that have been developed are either not effective, or in some cases have been reported to be involved in the selection of novel pathogenic CoVs via recombination of circulating strains [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="bib40">
        40
       </xref>
       ]. Vaccine development can be a challenge. It is noteworthy that almost 20 years after SARS, there is still no vaccine for coronavirus.
      </p>
     </sec>
    </sec>
    <sec id="sec3">
     <label>
      3
     </label>
     <title>
      A historical review of the epidemiology of SARS and how it was contained
     </title>
     <p id="p0100">
      It has been 17 years since the outbreak of severe acute respiratory syndrome (SARS) caused by the SARS coronavirus (SARS-CoV) [
      <xref ref-type="bibr" rid="bib43">
       43
      </xref>
      ]. This highly contagious atypical pneumonia first appeared in Guangdong Province, China, in November 2002. The initial cases were animal handlers in Guangzhou city having close contact with wild game food. It was suggested that civets could serve as an intermediate amplification host. Three months later, the SARS pandemic was rapidly and globally disseminated due to person-to-person transmission of the virus. On the February 21, 2003, a medical professor from Foshan in Guangdong province who was considered a “super-spreader” went to Hong Kong to visit his relatives. During his stay in Hong Kong, he transmitted the virus to 2 family members, 4 health care workers (HCWs) and 12 other nearby residents. Because of international travel and transmission to HCWs, these patients spread the SARS-CoV to Hong Kong and other countries including Vietnam, Singapore and Canada. Eventually, 8422 people were infected in 32 countries and 919 (11%) died [
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ]. In China, 5328 cases were reported and 349 (6.5%) perished between November 16, 2002 and June 3, 2003 [
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ].
     </p>
     <p id="p0105">
      At the beginning of the outbreaks in Hong Kong, mainland China and other areas, we were unfamiliar with the deadly SARS-CoV. It took about 3 months to complete the sequencing of this coronavirus [
      <xref ref-type="bibr" rid="bib44">
       44
      </xref>
      ]. The global success in the fight against SARS was partly based on epidemiological and biological characteristics of the infectious agent SARS-CoV. An understanding of transmission patterns and the ability to diagnose and confirm affected patients ultimately led to effective containment measures and a slowdown in the spread of the disease. Due to the lack of medications or a vaccine, the options for early intervention were limited to public health measures [
      <xref ref-type="bibr" rid="bib45">
       45
      </xref>
      ].
     </p>
     <p id="p0110">
      The steps that led to the containment of SARS can be illustrated by the events that occurred in Beijing. Beijing experienced the largest outbreak of SARS beginning on the March 5, 2003. The outbreak peaked within 6 weeks on the April 25, 2003 when 173 newly suspected SARS cases were hospitalized daily [
      <xref ref-type="bibr" rid="bib46">
       46
      </xref>
      ]. On the June 20, 2003, the last batch of 18 SARS patients recovered and were discharged from hospital, signaling the end of the pandemic in Beijing. The prompt resolution of the outbreak in Beijing was attributed to the rapid adoption of a series of effective control measures.
      <list id="olist0010" list-type="simple">
       <list-item id="o0010">
        <label>
         1.
        </label>
        <p id="p0115">
         Thousands of local and military health workers were deployed for emergency management of the outbreak. Large quantities of emergency supplies including personal protective equipment (PPE) and medical apparat were sent to front-line medical sectors. These people and materials were key to winning the war against SARS.
        </p>
       </list-item>
       <list-item id="o0015">
        <label>
         2.
        </label>
        <p id="p0120">
         More than 100 fever clinics were set up in all secondary and tertiary hospitals in Beijing. People visiting the fever clinics had a physical examination including body temperature, white blood cell count and chest radiograph. Fever clinics played an important role in screening and triage.
        </p>
       </list-item>
       <list-item id="o0020">
        <label>
         3.
        </label>
        <p id="p0125">
         All actively ill patients with SARS were concentrated in designated hospital wards. On the May 1, 2003, a new 1000-bed SARS hospital (Xiaotangshan Hospital, Beijing) was built and put into operation immediately. The advantages of having such a facility was that it was more conducive to the centralized management of SARS patients, and at the same time, it reduced transmission of the virus to healthy people.
        </p>
       </list-item>
       <list-item id="o0025">
        <label>
         4.
        </label>
        <p id="p0130">
         During the period of the SARS outbreak, more than 60,000 HCWs received medical training in the management of patients with SARS, infection control and the use of PPE.
        </p>
       </list-item>
       <list-item id="o0030">
        <label>
         5.
        </label>
        <p id="p0135">
         Multiple measures were taken to reduce person-to-person transmission, including isolation of patients with SARS, tracing and quarantine of close contacts, transit site surveillance and closing poorly maintained facilities that could enhance spread of the virus.
        </p>
       </list-item>
       <list-item id="o0035">
        <label>
         6.
        </label>
        <p id="p0140">
         Information dissemination was critical. Timely and accurate reporting of the status of the epidemic and scientific guidance on prevention and infection control played important roles in stabilizing people and overcoming the epidemic [
         <xref ref-type="bibr" rid="bib45">
          [45]
         </xref>
         ,
         <xref ref-type="bibr" rid="bib46">
          [46]
         </xref>
         ,
         <xref ref-type="bibr" rid="bib47">
          [47]
         </xref>
         ,
         <xref ref-type="bibr" rid="bib48">
          [48]
         </xref>
         ].
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="sec4">
     <label>
      4
     </label>
     <title>
      Lessons learned from the 2003 SARS pandemic
     </title>
     <p id="p0145">
      SARS was the very first coronavirus pandemic with the ability to spread from people to people mainly by droplets, but it would not be the last [
      <xref ref-type="bibr" rid="bib49">
       49
      </xref>
      ]. This section presents lessons learned from the SARS pandemic. Although the SARS-CoV rapidly spread throughout the world and caused great damages to human health, the global success in the fight against SARS ultimately demonstrated that containment was possible [
      <xref ref-type="bibr" rid="bib50">
       50
      </xref>
      ].
     </p>
     <sec id="sec4.1">
      <label>
       4.1
      </label>
      <title>
       Animal source containment
      </title>
      <p id="p0150">
       Early on, there were clues suggesting the link between SARS-CoV and civets, bred for food in China [
       <xref ref-type="bibr" rid="bib51">
        51
       </xref>
       ]. Strengthening the monitoring of these wild animal sources was an important factor in controlling emergence of these virus and their spread in humans. Some scholars advocated that the trading of wild animals in wet markets in Southern China should be banned [
       <xref ref-type="bibr" rid="bib52">
        52
       </xref>
       ]. In fact, the Chinese government had issued bans on rearing, trading, transporting and slaughtering wild animals for dietary purposes over 10 years ago [
       <xref ref-type="bibr" rid="bib53">
        53
       </xref>
       ]. This however, did not stop the practice of illegal trading of wild animals.
      </p>
     </sec>
     <sec id="sec4.2">
      <label>
       4.2
      </label>
      <title>
       Early detection and diagnosis
      </title>
      <p id="p0155">
       The nonspecific symptoms and signs of SARS and the long incubation period accentuated the transmission to HCWs and people in close communities [
       <xref ref-type="bibr" rid="bib54">
        54
       </xref>
       ]. Early identification of suspect cases is the key to inhibiting the spread of the virus. Rapid identification of the viral genome and the development of rapid diagnostic tests will facilitate the isolation of those who are confirmed as infected [
       <xref ref-type="bibr" rid="bib50">
        50
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec4.3">
      <label>
       4.3
      </label>
      <title>
       Rigorous infection control
      </title>
      <p id="p0160">
       <list id="olist0015" list-type="simple">
        <list-item id="o0040">
         <label>
          a)
         </label>
         <p id="p0165">
          Environmental hygiene in medical sectors and personal hygiene of health care workers should be maintained [
          <xref ref-type="bibr" rid="bib55">
           55
          </xref>
          ,
          <xref ref-type="bibr" rid="bib56">
           56
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0045">
         <label>
          b)
         </label>
         <p id="p0170">
          Contact tracing, strict isolation of actively ill patients and quarantine of close contacts should be implemented early [
          <xref ref-type="bibr" rid="bib54">
           54
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0050">
         <label>
          c)
         </label>
         <p id="p0175">
          Training in the use of personal protective equipment protects the safety of HCWs [
          <xref ref-type="bibr" rid="bib57">
           57
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0055">
         <label>
          d)
         </label>
         <p id="p0180">
          Establishing fever clinics, setting up designated hospital wards and SARS hospitals reduced human-to-human transmission [
          <xref ref-type="bibr" rid="bib58">
           58
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0060">
         <label>
          e)
         </label>
         <p id="p0185">
          Education of the public on communicable diseases and what measures to take on a personal basis to prevent spread.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="sec4.4">
      <label>
       4.4
      </label>
      <title>
       Timely case report and rapid information dissemination
      </title>
      <p id="p0190">
       A number of studies have shown that clear and timely dissemination of information is essential in handling an outbreak [
       <xref ref-type="bibr" rid="bib54">
        54
       </xref>
       ]. Infection control is based on rapid information dissemination. Since SARS in 2003, China has implemented legislation on the surveillance, reporting and early warning system of infectious diseases, requiring the regular release of information during public health emergencies. There is a clearly defined procedure and schedule for reporting public health emergencies which requires designated medical centers to submit relevant information online. If confirmed, reports on SARS and other infectious diseases can be submitted and received directly within two hours through the Internet [
       <xref ref-type="bibr" rid="bib53">
        53
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec4.5">
      <label>
       4.5
      </label>
      <title>
       Vaccine development
      </title>
      <p id="p0195">
       After SARS, development of a vaccine appeared to be the best approach to prevent future SARS-CoV epidemics. However, there were many obstacles in SARS vaccine development. Firstly, researchers did not have a comprehensive understanding of the pathogenic mechanism of SARS-CoV. Secondly, animal models of SARS-CoV infection could not simulate human disease because of an incongruent pathogenesis. Thirdly, in order to test the efficacy, many people must be tested in areas where the virus is endemic. Once the SARS epidemic ended, human trials were not possible [
       <xref ref-type="bibr" rid="bib59">
        59
       </xref>
       ]. Although several candidate vaccines against SARS-CoV have been produced and tested, at present, unfortunately, there is no FDA approved vaccine against SARS.
      </p>
     </sec>
    </sec>
    <sec id="sec5">
     <label>
      5
     </label>
     <title>
      The current SARS-CoV-2 infection in China
     </title>
     <sec id="sec5.1">
      <label>
       5.1
      </label>
      <title>
       The origin of SARS-CoV-2
      </title>
      <p id="p0200">
       A cluster of cases of viral pneumonia of unknown etiology, now known as SARS-CoV-2 pneumonia, occurred in Wuhan, Hubei Province and were reported to health authorities on the December 29, 2019 [
       <xref ref-type="bibr" rid="bib60">
        60
       </xref>
       ]. This outbreak was associated with a large seafood and animal market [
       <xref ref-type="bibr" rid="bib61">
        61
       </xref>
       ]. Further investigations are ongoing to determine the origin of the infection. To date, many reports have described possible original and intermediate hosts (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       ). Researchers found that the SARS-CoV-2 showed a higher sequence homology to Bat-CoV-RaTG13 that was previously detected in
       <italic>
        Rhinolophus affinis
       </italic>
       from Yunnan Province than Bat-SL-CoVZC21 and Bat-SL-CoVZC45, which suggested that the Chinese chrysanthemum bat is the origin of SARS-CoV-2. More recently, the pangolin was believed to be the likely intermediate host due to the fact that there appeared to be approximately 99% sequence homology between SARS-Co V-2 and the consensus sequence derived from &gt;1000 metagenomic samples from the pangolin species [
       <xref ref-type="bibr" rid="bib62">
        62
       </xref>
       ].
       <fig id="fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          The origin and inter-host timeline of SARS-CoV-2. All the information is derived from published data. Journal name: (a) Emerging Microbes &amp; Infections, (b) bioRvix, (c) J Med Virol, (d) The Lancet, (e) the New England Journal of Medicine, (f) J Virol, (g) Chin Med J (Engl), (h)
          <ext-link ext-link-type="uri" id="intref0115" xlink:href="https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm">
           https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm
          </ext-link>
          . Bat-ZC21: Bat-SL-CoVZC21, GenBank Accession MG772934; Bat-ZC45: Bat-SL-CoVZC45, GenBank Accession MG772933; Bat-RaTG13: yun-nan-Bat-CoV-RaTG13, GISAID accession EPI_ISL_402,131.
         </p>
        </caption>
        <alt-text id="alttext0010">
         Fig. 1
        </alt-text>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec5.2">
      <label>
       5.2
      </label>
      <title>
       New epidemiological developments
      </title>
      <p id="p0205">
       Currently, person to person transmission from patients with pneumonia or even asymptomatic patients during the incubation period are the main conduits for the spread of the infection [
       <xref ref-type="bibr" rid="bib63">
        63
       </xref>
       ]. Respiratory droplets are the main route of transmission, but the virus can also be transmitted through contact or through the fecal-oral route based on a study which demonstrated the presence of the virus in rectal swabs [
       <xref ref-type="bibr" rid="bib64">
        64
       </xref>
       ]. Fifteen health care workers in a Wuhan hospital were infected while caring for patients with confirmed or suspected infection [
       <xref ref-type="bibr" rid="bib65">
        65
       </xref>
       ,
       <xref ref-type="bibr" rid="bib66">
        66
       </xref>
       ]. As of February 11, 2020, a total of 1716 health care workers have become infected and 5 have died (0.3%) [
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
       ]. A study of a family cluster reported that five members of a family of six traveled to Wuhan, and four were infected with the SARS-CoV-2. The family member who did not travel became infected with the virus after several days of contact with the four infected members [
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ].
      </p>
      <p id="p0210">
       Li et al. [
       <xref ref-type="bibr" rid="bib65">
        65
       </xref>
       ] showed that human-to-human transmission among close contacts has been occurring since the middle of December 2019. Further dissemination has continued rapidly over the ensuing months. The authors estimated that the reproduction number (R
       <sub>
        0
       </sub>
       ) for SARS-CoV-2 is 2.2, meaning that every infected person can infect a mean of 2.2 people. In another study, the reproduction number of the SARS-CoV-2 was 2.68 with an epidemic doubling time of 6.4 days [
       <xref ref-type="bibr" rid="bib68">
        68
       </xref>
       ]. It is worth noting that a nucleic acid fragment of the SARS-CoV-2 was detected by Guangzhou Centers for Disease Control and Prevention (CDC) on a doorknob touched by a confirmed patient [
       <xref ref-type="bibr" rid="bib69">
        69
       </xref>
       ]. China Daily reported that scientists have discovered that stool samples from patients infected with the SARS-CoV-2 have also tested positive for the virus [
       <xref ref-type="bibr" rid="bib70">
        70
       </xref>
       ], and that the virus was also detected in the loose stool of the first patient in the US infected with the virus [
       <xref ref-type="bibr" rid="bib71">
        71
       </xref>
       ], meaning the virus has the potential to be spread through contaminated fecal material.
      </p>
      <p id="p0215">
       On the January 22, 2020, a member of the national expert panel on pneumonia reported that he was infected by SARS-CoV-2 during an inspection in Wuhan. He had worn an N95 mask but did not wear eye protection. Several days before the onset of pneumonia, he complained of redness of the eyes. Unprotected exposure of the eyes to SARS-CoV-2 in the Wuhan Fever Clinic may have allowed the virus to enter his body [
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ].
      </p>
      <p id="p0220">
       The situation with SARS-CoV-2 is evolving rapidly. According to the National Health Commission (NHC) of China update on February 17, 2020 [
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ], a total of 72,436 cases were confirmed in the Chinese mainland, including 11,741 severe cases and 1868 deaths. A total of 12,552 patients have recovered and have been discharged. An additional total of 6242 suspected cases remain. Most patients (59,989 cases) have been in Hubei province, where the outbreak began, including 10,970 severe cases and 1789 deaths. The Hong Kong and Macao Special Administrative Regions as well as Taiwan reported 92 confirmed cases of the disease, including 2 deaths and 9 patients who have recovered. There are significantly more SARS-CoV-2 cases than SARS cases during the 2003 outbreak. The current spread of the epidemic in China is shown in
       <xref ref-type="fig" rid="fig2">
        Fig. 2
       </xref>
       ,
       <xref ref-type="fig" rid="fig3">
        Fig. 3
       </xref>
       ,
       <xref ref-type="fig" rid="fig4">
        Fig. 4
       </xref>
       .
       <fig id="fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Confirmed cases of SARS-CoV-2, February 17, 2020. (Data from the government website of China's National Health Commission).
         </p>
        </caption>
        <alt-text id="alttext0015">
         Fig. 2
        </alt-text>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
       <fig id="fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Numbers of suspected, confirmed and severe cases of SARS-CoV-2 in China and Hubei province, February 17, 2020. (Data from the government website of China's National Health Commission. Since February 12, 2020, Hubei Province has included the number of clinical diagnosis cases into the number of confirmed cases).
         </p>
        </caption>
        <alt-text id="alttext0020">
         Fig. 3
        </alt-text>
        <graphic xlink:href="gr3_lrg">
        </graphic>
       </fig>
       <fig id="fig4">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          Numbers of deaths and recovered cases of SARS-CoV-2 in China and Hubei, February 17, 2020. (Data from the government website of China's National Health Commission).
         </p>
        </caption>
        <alt-text id="alttext0025">
         Fig. 4
        </alt-text>
        <graphic xlink:href="gr4_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0225">
       According to World Health Organization (WHO) SARS-CoV-2 Situation Report [
       <xref ref-type="bibr" rid="bib72">
        72
       </xref>
       ], additional cases have been identified in a growing number of other international locations, including 25 countries outside China (
       <xref ref-type="fig" rid="fig5">
        Fig. 5
       </xref>
       ). There are now three deaths that have been reported outside of China (one in the Philippines, one in Japan and one in France). The WHO declared the SARS-CoV-2 epidemic a Public Health Emergency of International Concern (PHEIC) on January 30, 2020, citing that human-to-human infections have been confirmed in multiple countries [
       <xref ref-type="bibr" rid="bib73">
        73
       </xref>
       ].
       <fig id="fig5">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          Countries, territories or areas with reported confirmed cases of SARS-CoV-2, February 17, 2020. (Data from the WHO Coronavirus disease 2019 (COVID-19) Situation Report-28).
         </p>
        </caption>
        <alt-text id="alttext0030">
         Fig. 5
        </alt-text>
        <graphic xlink:href="gr5_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0230">
       According to Fang et al. [
       <xref ref-type="bibr" rid="bib74">
        74
       </xref>
       ], fifteen cases of childhood infection had been identified as of January 30, 2020, including 8 boys and 7 girls, ranging in age from 8 months to 12 years. Of the 15 pediatric cases, 13 had a clear history of family clustering in Wuhan. At present, several confirmed pregnant women in Wuhan have given birth during the illness. On February 2, 2020, Wuhan local media reported that a confirmed pregnant woman gave birth to a newborn by cesarean section under strict level three protection, but the newborn's throat swab was positive for the nucleic acid virus test [
       <xref ref-type="bibr" rid="bib75">
        75
       </xref>
       ]. However, Chen et al. tested the SARS-CoV-2 in amniotic fluid, cord blood, neonatal throat swab, and breastmilk samples from six confirmed SARS-CoV-2 pregnant women, and all samples tested negative for the virus, which suggests that there is currently no evidence for intrauterine infection caused by vertical transmission in women who develop COVID-19 pneumonia in late pregnancy [
       <xref ref-type="bibr" rid="bib76">
        76
       </xref>
       ]. No cases of newborns or child deaths have been reported. The NHC has called for close monitoring of outbreaks in children and pregnant women [
       <xref ref-type="bibr" rid="bib77">
        77
       </xref>
       ].
      </p>
      <p id="p0235">
       The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team of the Chinese CDC reported the epidemiology characteristics of 44,672 confirmed cases as of February 11, 2020. Among the confirmed 44,672 cases (74.7% in Hubei Province), 51.4% were male, and 80.9% were mild or moderate cases. The majority of the cases were between 30 and 69 years old (77.8%), while 0-9 year-olds and 10-19 year-olds accounted for 0.9% and 1.2% respectively. Hypertension (12.8%), diabetes (5.3%), cardiovascular disease (4.2%) were the most common underlying diseases. A total of 1023 deaths occurred among confirmed cases for an overall case-fatality rate of 2.3%, and 81% of the deaths were over 60 years old. The mortality rates of those aged 60–69, 70–79 and over 80 years were 3.6%, 8.0%, and 14.8%, respectively. The mortality rate of critical cases was 49% [
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
       ].
      </p>
      <p id="p0240">
       Based on this evidence, the current SARS-CoV-2 is easily transmissible in humans, even in children and pregnant women. It should also be noted that most patients have a good prognosis. The symptoms in children are relatively mild, and only a minority are in critical condition. The death cases involved mostly the elderly and those with a chronic underlying disease. This fact, however, does not diminish the seriousness of the epidemic.
      </p>
      <p id="p0245">
       During the early stages of the epidemic, several hospitals, including Wuhan Union Hospital, Wuhan Tongji Hospital, and Peking Union Medical College Hospital, had created different diagnosis and treatment programs [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="bib78">
        [78]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib79">
        [79]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib80">
        [80]
       </xref>
       ]. The WHO and the NHC of China have since then published guidelines for the diagnosis and clinical management of SARS-CoV-2 pneumonia [
       <xref ref-type="bibr" rid="bib81">
        81
       </xref>
       ,
       <xref ref-type="bibr" rid="bib82">
        82
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec6">
     <label>
      6
     </label>
     <title>
      Clinical presentation
     </title>
     <sec id="sec6.1">
      <label>
       6.1
      </label>
      <title>
       Clinical manifestations
      </title>
      <p id="p0250">
       According to the guidelines published by the NHC and based on current epidemiological studies, the incubation period is typically 3–7 days, with a maximum of 14 days [
       <xref ref-type="bibr" rid="bib82">
        82
       </xref>
       ]. Common symptoms of COVID-19 include fever, fatigue, and dry cough. A few patients have symptoms such as nasal congestion, runny nose, sore throat, and diarrhea. Some patients only have a low fever, mild fatigue, and no pneumonia. In severe cases, the infection can cause pneumonia, shortness of breath and breathing difficulties occurring more than one week after infection. Critical patients may progress rapidly to acute respiratory distress syndrome (ARDS), septic shock, metabolic acidosis, coagulation dysfunction, and even death. It is worth noting that during the course of severe and critical patients, there can be moderate to low-grade fever or even no obvious fever.
      </p>
      <p id="p0255">
       Huang et al. provided first-hand data regarding COVID-19 [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ]. Their study reported the clinical features of the first 41 patients admitted to the designated hospital in Wuhan who were laboratory-confirmed COVID-19 by January 2, 2020. Twenty-seven (66%) of the 41 patients had been exposed to the Huanan seafood market. Common symptoms at the onset of illness were fever (98%), cough (76%), and myalgia or fatigue (44%). Less common symptoms were sputum production, headache, hemoptysis, and diarrhea. Dyspnea developed in 22 (55%) of 40 patients and 26 (63%) of 41 patients had lymphopenia. The median time from onset of symptoms to first hospital admission was 7.0 days, to shortness of breath was 8.0 days, and to ARDS was 9.0 days. Almost a third of patients developed ARDS requiring intensive care, 5 patients had acute cardiac injury, and 4 patients required assisted ventilation. Eventually 28 patients were discharged, 13 patients were admitted to the intensive care unit (ICU) and 6 patients died.
      </p>
      <p id="p0260">
       Chen et al. reported 99 patients with SARS-CoV-2 pneumonia admitted to the Jinyintan Hospital in Wuhan [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ]. Forty-nine (49%) patients had a history of exposure to the local Huanan seafood market and 50 patients (51%) had chronic underlying diseases. Patients had clinical manifestations of fever (83%), cough (82%), shortness of breath (31%), muscle aches (11%), confusion (9%), headache (8%), sore throat (5%), rhinorrhea (4%), chest pain (2%), and diarrhea (2%). Eighty-nine (90%) patients had more than one symptom. According to their study, many cases presented with organ function damage, including 17 cases with ARDS, 8 cases with acute respiratory injury, 3 cases with acute renal injury, 4 cases with septic shock, and 1 case with ventilator-associated pneumonia. Eventually 31 patients were discharged, 11 patients died, and the remaining 57 patients were still in hospital.
      </p>
      <p id="p0265">
       At Zhongnan Hospital of Wuhan University in Wuhan, Wang et al. [
       <xref ref-type="bibr" rid="bib83">
        83
       </xref>
       ] enrolled 138 hospitalized patients with SARS-CoV-2 pneumonia. Common symptoms included fever (98.6%), fatigue (69.6%), dry cough (59.4%), myalgia (34.8%), and dyspnea (31.2%). The median time from first symptom to dyspnea was 5.0 days, to hospital admission was 7.0 days, and to ARDS was 8.0 days. Major complications during hospitalization included ARDS, arrhythmia, and shock. Of the 138 hospitalized patients, 47 recovered and have been discharged, 36 patients were admitted to the ICU and 6 patients have died.
      </p>
      <p id="p0270">
       Chang et al. [
       <xref ref-type="bibr" rid="bib84">
        84
       </xref>
       ] reported 13 confirmed patients outside of Wuhan, including 2 children (aged 2 years and 15 years). Twelve patients (92%) had fever before hospitalization. Other symptoms included upper airway congestion (62%), cough (46%), myalgia (23%), and headache (23%). All the patients recovered.
      </p>
      <p id="p0275">
       Guan et al. [
       <xref ref-type="bibr" rid="bib85">
        85
       </xref>
       ] reported 1099 confirmed patients from 552 hospitals in the whole of China as of January 29, 2020. The most common symptoms including fever (87.9%) and cough (67.7%), whereas diarrhea (3.7%) and vomiting (5.0%) were rare. They also pointed out that only 43.8% of the patients had fever on presentation but 87.9% developed fever after being hospitalized. Moreover, compared with non-severe cases, any underlying diseases were significantly more common in severe cases. The most common complication was pneumonia (79.1%), ARDS (3.4%) and shock (1.0%). Of the 1099 patients, 55 patients were admitted to the ICU, and 15 patients died.
      </p>
      <p id="p0280">
       There were therefore a total of 41, 99 and 138 (total 278) cases of SARS-CoV pneumonia admitted in the 3 regional hospitals closest to the Huanan Seafood Market that resulted in 6, 11 and 6 deaths (23 deaths) or a case fatality rate of 0.82%.
      </p>
     </sec>
     <sec id="sec6.2">
      <label>
       6.2
      </label>
      <title>
       Laboratory tests
      </title>
      <p id="p0285">
       In the early stages of the disease, the total number of leukocytes in peripheral blood is normal or decreased, the lymphocyte count is decreased, and some patients show increases in liver enzymes, muscle enzymes, and myoglobin. The C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are increased in most patients, and procalcitonin is normal. In severe cases, D-dimer increases, and peripheral blood lymphocytes decrease progressively. Coronavirus nucleic acid can be detected in the throat, sputum, lower respiratory tract secretions, blood and tool.
      </p>
      <p id="p0290">
       In Huang's study [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ], the blood counts of patients on admission showed leucopenia and lymphopenia. Prothrombin time and D-dimer levels on admission were higher in ICU patients. Compared with non-ICU patients, ICU patients had higher plasma levels of IL-2, IL-7, IL-10, G-SCF, IP-10, MCP-1, MIP-1α, and TNFα. In Chen's study [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ], all patients were tested for nine respiratory pathogens and nucleic acids of influenza viruses A and B, as well as bacteria and fungi. No other respiratory viruses were detected, but 4 cases of fungal and 1 case of bacterial infection were found. The absolute number of leukocytes was decreased in 9 patients and increased in 24 patients. The absolute neutrophil count was increased in 38 patients and the absolute lymphocyte count was decreased in 35 patients. Forty-three patients had varying degrees of liver dysfunction, seven patients had varying degrees of renal dysfunction, and most patients had abnormal myocardial zymograms. Seventy-three patients were tested for C-reactive protein which was increased in 63 patients. In Guan's study, 82.1%, 36.2%, and 33.7% of the patients had lymphopenia, thrombocytopenia, and leukopenia, respectively. Compared with non-severe cases, severe cases had more prominent laboratory abnormalities [
       <xref ref-type="bibr" rid="bib85">
        85
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec6.3">
      <label>
       6.3
      </label>
      <title>
       Imaging studies
      </title>
      <p id="p0295">
       In Huang's study [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ], all 41 patients had pneumonia with abnormal findings on chest computed tomography (CT) and 40 (98%) had bilateral involvement. The ICU patients on admission had bilateral multiple lobular and subsegmental areas of consolidation. The non-ICU patients had bilateral ground-glass opacity and subsegmental areas of consolidation. Subsequent chest CT images showed bilateral ground-glass opacity, whereas the consolidation was resolved. In Chen's study [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ], imaging showed that 74 patients had bilateral pneumonia, 14 patients had multiple mottled and ground-glass opacities, and 1 patient had a pneumothorax. In Wang's study [
       <xref ref-type="bibr" rid="bib83">
        83
       </xref>
       ], imaging showed that 138 patients had bilateral patchy shadows or ground-glass opacity. In Guan's study, 840 of 1099 patients received chest CT on admission which showed that 76.4% had pneumonia, but 23.9% of severe cases had no radiologic abnormality on initial presentation. Ground-glass opacity (50.0%) and bilateral patchy shadow (46.0%) were the most common findings [
       <xref ref-type="bibr" rid="bib85">
        85
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec7">
     <label>
      7
     </label>
     <title>
      Diagnosis
     </title>
     <p id="p0300">
      The earliest cases of SARS-CoV-2 were identified as “pneumonia of unknown etiology”, which was defined as an illness of unknown etiology with 1. Fever with or without a recorded temperature 2. Radiographic evidence of pneumonia 3. Low or normal leukocyte count or low lymphocyte count during the early stage of disease and 4. No improvement or worsening symptoms after 3–5 days of antimicrobial treatment per standard clinical guidelines [
      <xref ref-type="bibr" rid="bib61">
       61
      </xref>
      ]. With increasing research and knowledge of the disease, diagnosis and treatment guidelines have been continuously updated. At present, the NHC has issued the fifth edition of the guidelines. However, because of a shortage of diagnostic reagents for SARS-CoV-2 detection, different guidelines or programs emphasized comprehensive analysis based on epidemiological history, clinical manifestations and imaging examinations in diagnosis.
     </p>
     <sec id="sec7.1">
      <label>
       7.1
      </label>
      <title>
       Diagnostic criteria [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="bib78">
        [78]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib79">
        [79]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib80">
        [80]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib81">
        [81]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib82">
        [82]
       </xref>
       ]
      </title>
      <p id="p0305">
       The diagnostic criteria of suspected and confirmed cases were summarized in
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       .
       <table-wrap id="tbl1" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          The diagnostic criteria for suspected and confirmed cases [
          <xref ref-type="bibr" rid="bib37">
           37
          </xref>
          ,
          <xref ref-type="bibr" rid="bib77">
           [77]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib78">
           [78]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib79">
           [79]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib80">
           [80]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib81">
           [81]
          </xref>
          ].
         </p>
        </caption>
        <alt-text id="alttext0060">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <tbody>
          <tr>
           <td align="left">
            Case
           </td>
           <td align="left">
            Diagnostic criteria
           </td>
          </tr>
          <tr>
           <td align="left" rowspan="3">
            Suspected case
           </td>
           <td align="left">
            Anyone with a history of epidemiology and any two of the clinical manifestations or anyone without epidemiological history and three of the clinical manifestations is considered to be a suspected case:
           </td>
          </tr>
          <tr>
           <td align="left">
            <list id="olist0020" list-type="simple">
             <list-item id="o0065">
              <label>
               (1)
              </label>
              <p id="p0540">
               Epidemiological history:
               <list id="olist0025" list-type="simple">
                <list-item id="o0070">
                 <label>
                  1)
                 </label>
                 <p id="p0545">
                  within 14 days before the disease onset, there is a travel history or living history in Wuhan or other areas with local cases
                 </p>
                </list-item>
                <list-item id="o0075">
                 <label>
                  2)
                 </label>
                 <p id="p0550">
                  within 14 days before the disease onset, there is contact with patients who had fever or respiratory symptoms from Wuhan or other areas with local cases
                 </p>
                </list-item>
                <list-item id="o0080">
                 <label>
                  3)
                 </label>
                 <p id="p0555">
                  a clustering of patients or a contact with patients infected with the SARS-CoV-2
                 </p>
                </list-item>
               </list>
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left">
            <list id="olist0030" list-type="simple">
             <list-item id="o0085">
              <label>
               (2)
              </label>
              <p id="p0560">
               Clinical manifestations:
               <list id="olist0035" list-type="simple">
                <list-item id="o0090">
                 <label>
                  1)
                 </label>
                 <p id="p0565">
                  fever and/or respiratory symptoms
                 </p>
                </list-item>
                <list-item id="o0095">
                 <label>
                  2)
                 </label>
                 <p id="p0570">
                  with the above-mentioned imaging characteristics of pneumonia
                 </p>
                </list-item>
                <list-item id="o0100">
                 <label>
                  3)
                 </label>
                 <p id="p0575">
                  the total number of leukocytes in the early stage of the disease is normal or decreased, or the lymphocyte count is decreased
                 </p>
                </list-item>
               </list>
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left" rowspan="2">
            Confirmed case
           </td>
           <td align="left">
            Any suspected case with one of the following pathogenic features is reclassified as a confirmed case:
           </td>
          </tr>
          <tr>
           <td align="left">
            <list id="olist0040" list-type="simple">
             <list-item id="o0105">
              <label>
               (1)
              </label>
              <p id="p0580">
               Positive results of SARS-CoV-2 nucleic acids by RT-PCR of respiratory or blood specimens
              </p>
             </list-item>
             <list-item id="o0110">
              <label>
               (2)
              </label>
              <p id="p0585">
               DNA highly homologous to SARS-CoV-2 by genetic sequencing of viral genes in respiratory or blood specimens
              </p>
             </list-item>
            </list>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           RT-PCR: real-time reverse-transcriptase polymerase-chain-reaction.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec7.2">
      <label>
       7.2
      </label>
      <title>
       Differential diagnosis
      </title>
      <p id="p0310">
       The SARS-CoV-2 needs to be distinguished from other known viral pneumonias including influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, SARS coronavirus, MERS coronavirus, as well as
       <italic>
        Mycoplasma pneumoniae
       </italic>
       , chlamydia pneumonia, and bacterial pneumonias. For patients with underlying diseases, attention should be paid to the detection of invasive fungal infections. The differential diagnosis also includes non-infectious diseases such as vasculitis, dermatomyositis, and organizing pneumonia. It should be noted that often patients with viral pneumonia may test positive to multiple viruses, and the potential lethality of a combined SARS-CoV-2/influenza virus infection should not be ignored.
      </p>
     </sec>
    </sec>
    <sec id="sec8">
     <label>
      8
     </label>
     <title>
      The effectiveness of SARS-CoV-2 rapid diagnosis in preventing spread of disease
     </title>
     <p id="p0315">
      Several rapid and sensitive detection tests have been developed for the prevention and control of the SARS-CoV-2 outbreak. At present, seven products including the SARS-CoV-2 nucleic acid detection kit (fluorescent PCR method) and the SARS-CoV-2 nucleic acid sequencing system have been approved on an emergency basis by the National Medical Products Administration. Biological product companies have expanded production of detection kits for the new coronavirus. The use of detection kits can accelerate accurate diagnosis of patients, help to determine quarantine and isolation requirements, assist in determining the treatment of patients and save limited medical resources. However, the rapidity of spread of the disease has led to an insufficient supply of detection kits.
     </p>
     <p id="p0320">
      It is worth noting that there have been confirmed patients whose viral nucleic acid tests are negative multiple times in the early stages, and there have also been confirmed cases whose throat swabs were negative for the viral nucleic acid test but positive in alveolar lavage fluid. Correlation of Chest CT and RT-PCR testing of 1014 cases showed that CT had a 88% had a positive CT scan but only 59% had positive RT-PCR. [
      <xref ref-type="bibr" rid="bib86">
       86
      </xref>
      ]. The poor sensitivity of the current tests makes diagnosis and epidemic control more challenging. Sampling techniques, extraction and detection of viral nucleic acids, and diagnostic reagents may affect the test results. More attention should be paid to the sensitivity and specificity of diagnostic reagents, and diagnostic decisions should rely on comprehensive judgment based on the clinical manifestations, laboratory results and imaging examinations of patients. According to the latest guideline of the NHC [
      <xref ref-type="bibr" rid="bib82">
       82
      </xref>
      ], if the suspected cases in Hubei Province have imaging characteristic of pneumonia, the CT image results can be used as a basis for “clinical diagnosis cases”.
     </p>
    </sec>
    <sec id="sec9">
     <label>
      9
     </label>
     <title>
      The pathogenesis of COVID-19
     </title>
     <p id="p0325">
      Current understanding of the pathogenesis of HCoVs infection is still limited, especially for SARS-CoV-2. Before 2019, there were six CoVs that could infect humans and cause respiratory disease. HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 are sometimes attributed to the “common cold”, but in rare cases can cause severe infections in infants, young children and elderly people. On the other hand, SARS-CoV and MERS-CoV can infect the lower respiratory tract and cause a severe respiratory syndrome in human [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ]. The new coronavirus SARS-CoV-2 is similar to SARS-CoV and MERS-CoV and can infect lower respiratory tract and cause severe pneumonia.
     </p>
     <p id="p0330">
      The origin of SARS-CoV-2 was thought to be wild animals in the Huanan Seafood Market in Wuhan. However, not all cases have an apparent connection with the Wuhan Huanan Seafood Wholesale Market. It is evident now that SARS-CoV-2 is capable of person-person transmission. We list the major pathogenic CoVs in
      <xref ref-type="table" rid="tbl2">
       Table 2
      </xref>
      for better understanding of the pathogenesis of HCoV [
      <xref ref-type="bibr" rid="bib87">
       87
      </xref>
      ].
      <table-wrap id="tbl2" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Partial list of important pathogenic human coronaviruses [
         <xref ref-type="bibr" rid="bib87">
          87
         </xref>
         ].
        </p>
       </caption>
       <alt-text id="alttext0065">
        Table 2
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Virus
          </th>
          <th>
           Genus
          </th>
          <th>
           Symptoms
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           HCoV-229E
          </td>
          <td align="left">
           <italic>
            alpha
           </italic>
          </td>
          <td align="left">
           mild respiratory tract infections
          </td>
         </tr>
         <tr>
          <td align="left">
           HCoV-NL63
          </td>
          <td align="left">
           <italic>
            alpha
           </italic>
          </td>
          <td align="left">
           mild respiratory tract infections
          </td>
         </tr>
         <tr>
          <td align="left">
           HCoV-OC43
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           mild respiratory tract infections
          </td>
         </tr>
         <tr>
          <td align="left">
           HCoV-HKU1
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           pneumonia
          </td>
         </tr>
         <tr>
          <td align="left">
           SARS-CoV
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           severe acute respiratory syndrome, 11% mortality rate
          </td>
         </tr>
         <tr>
          <td align="left">
           MERS-CoV
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           severe acute respiratory syndrome, 34% mortality rate
          </td>
         </tr>
         <tr>
          <td align="left">
           SARS-CoV-2
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           severe acute respiratory syndrome, 2.6% mortality rate
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
     <p id="p0335">
      The term “cell pyroptosis” was first proposed in 2001 [
      <xref ref-type="bibr" rid="bib88">
       88
      </xref>
      ]. In recent decades, there has been increasing evidence suggesting that “pyroptosis” is a novel inflammatory form of programmed cell death. In 2019, Chen et al. found that SARS-CoV Viroporin 3a triggered the activation of the NLRP3 inflammasome and the secretion of IL-1β in bone marrow-derived macrophages, suggesting SARS-CoV induced cell pyroptosis [
      <xref ref-type="bibr" rid="bib89">
       89
      </xref>
      ]. Studies have shown that patients infected with SARS-CoV-2 have increased IL-1β in the serum [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ]. As the rise of IL-1β is a downstream indicator of cell pyroptosis, this may suggest that cell pyroptotic activity is likely to be activated and involved in the pathogenesis of COVID-19 patients. Nevertheless, as both classical and non-classical pyroptosis signaling can induce the release of IL-1β, it is unclear which pathway is involved in COVID-19. Based on existing data, SARS-CoV-2 is likely to cause cell pyroptosis, especially in lymphocytes, through the activation of NLRP3 inflammasome. The pathways involved in the activation of the signaling between NLRP3m IL-1β, IL-18 and GSDMD are illustrated in
      <xref ref-type="fig" rid="fig6">
       Fig. 6
      </xref>
      and are a subject of study in samples from SARS-CoV-2 patients [
      <xref ref-type="bibr" rid="bib90">
       90
      </xref>
      ].
      <fig id="fig6">
       <label>
        Fig. 6
       </label>
       <caption>
        <p>
         A hypothesis of the relationship between SARS-CoV-2 and cell pyroptosis. The COVID-19 may be linked to cell pyroptosis, especially in lymphocytes through the activation of the NLRP3 inflammasome. Morphological changes in lymphocytes and macrophages, nucleic acid and protein levels in classical and non-classical cells, detection of NLRP3 and GSDMD, and the role of inflammatory cytokines IL-1β and IL-18 requires further research.
        </p>
       </caption>
       <alt-text id="alttext0035">
        Fig. 6
       </alt-text>
       <graphic xlink:href="gr6_lrg">
       </graphic>
      </fig>
     </p>
     <sec id="sec9.1">
      <label>
       9.1
      </label>
      <title>
       The genomic structure of SARS-CoV-2
      </title>
      <p id="p0340">
       The rapid sequencing of the nearly 30,000 nucleotide SARS-CoV-2 genome was accomplished in approximately 3 weeks from the time of the first hospitalized patient on the December 12, 2019 by Zhang's group and several others in China [
       <xref ref-type="bibr" rid="bib91">
        91
       </xref>
       ]. The genomic structure is shown in
       <xref ref-type="fig" rid="fig7">
        Fig. 7
       </xref>
       and shows greater than 99.9% consistency [
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="bib91">
        [91]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib92">
        [92]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib93">
        [93]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib94">
        [94]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib95">
        [95]
       </xref>
       ].
       <fig id="fig7">
        <label>
         Fig. 7
        </label>
        <caption>
         <p>
          Schematic diagram of the SARS-CoV-2 genome [
          <xref ref-type="bibr" rid="bib95">
           95
          </xref>
          ]. The genomic structure of SARS-CoV-2 is 5′-UTR-orf1a-orf1ab-S (Spike)–E (Envelope)-M (Membrane)-N (Nucleocapsid)-3′UTRpoly (A) tail. Accessory genes are interspersed within the structural genes at the 3′ end of genome. The pp1a protein encoded by the orf1a gene and the pp1ab protein encoded by the orf1ab gene contains 10 nsps (nsp1-nsp10). The pp1ab protein also includes nsp12-nsp16.
         </p>
        </caption>
        <alt-text id="alttext0040">
         Fig. 7
        </alt-text>
        <graphic xlink:href="gr7_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0345">
       The SARS-CoV-2 genome was found to possess 14 ORFs encoding 27 proteins. The orf1ab and orf1a genes are located at the 5′-terminus of the genome and encode 15 non-structural proteins (nsps) from nsp1 to nsp10, and from nsp12 to nsp16. The 3′-terminus of the genome contains 4 structural proteins (S, E, M and N) and 8 accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b and orf14). At the amino acid level, the SARS-CoV-2 is quite similar to that of SARS-CoV, but there are some notable differences. For example, the 8a protein is present in SARS-CoV and absent in SARS-CoV-2; the 3b protein is 154 amino acids in SARS-CoV but shorter in SARS-CoV-2 with only 22 amino acids. Further studies are needed to characterize how these differences affect the functionality and pathogenesis of SARS-CoV-2 [
       <xref ref-type="bibr" rid="bib95">
        95
       </xref>
       ].
      </p>
      <p id="p0350">
       The phylogenetic tree based on whole genomes showed that SARS-CoV-2 is most closely related to bat SARS-like coronavirus bat-SL-CoVZC21 (NCBI accession number MG772934) and bat-SL-CoVZC45 (NCBI accession number MG772933), which share ~89% sequence homology [
       <xref ref-type="bibr" rid="bib91">
        [91]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib92">
        [92]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib93">
        [93]
       </xref>
       ]. Their genomic organization is typical of a lineage B beta coronavirus. Further phylogenetic analysis has posited that SARS-CoV-2 is a product of recombination with previously identified bat coronaviruses, but a recent report has subsequently identified a bat CoVs sequence, RaTG13, with 92–96% sequence identity with the novel virus, demonstrating that RaTG13 is the closest relative of the SARS-CoV-2 and forms a distinct lineage from other SARS-CoVs. This rejects the hypothesis of emergence as a result of a recombination event [
       <xref ref-type="bibr" rid="bib94">
        94
       </xref>
       ,
       <xref ref-type="bibr" rid="bib96">
        96
       </xref>
       ]. Even though there are high similarities between SARS-CoV-2 S and RaTG13 S, there are two distinct differences: one is an “RRAR” furin recognition site formed by an insertion residues in the S1/S2 protease cleavage site in SARS-CoV-2, rather than the single Arginine in SARS-CoV [
       <xref ref-type="bibr" rid="bib97">
        [97]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib98">
        [98]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib99">
        [99]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib100">
        [100]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib101">
        [101]
       </xref>
       ]; the other difference is the presence of 29 variant residues between SARS-CoV-2 S and RaTG13 S, 17 of which mapped to the receptor binding domain (RBD) [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0355">
       The identities of 5′- and 3′-UTR sequences are more than 83.6% consistent between SARS-CoV-2 and other β-CoVs, such as SARS-CoV [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ]. The replicase polyproteins ppla and pp1ab encoded by the largest genes orf1ab are proteolytic and have been reported to function in the replication of CoVs by regulatory elements located within the non-structural proteins [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ]. Four structural proteins (S, E, M and N) contribute to virion assembly and infection of CoVs. The spike protein located on the surface of viral particles is made up of homotrimers of S proteins and is the key for the viral attachment to host receptors [
       <xref ref-type="bibr" rid="bib103">
        103
       </xref>
       ,
       <xref ref-type="bibr" rid="bib104">
        104
       </xref>
       ].
      </p>
      <p id="p0360">
       Spike glycoprotein consists of S1 and S2 subunits. The S1 subunit contains a signal peptide, an N-terminal domain (NTD) and RBD, while the S2 subunit includes the conserved fusion peptide (FP), heptad repeat 1 and 2 (HR1 and HR2), transmembrane domain (TM), and cytoplasmic domain (CP) [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ,
       <xref ref-type="bibr" rid="bib105">
        105
       </xref>
       ]. Furthermore, the S2 subunit of SARS-CoV-2 is highly conserved and shares 99% similarity with those of Bat-SL-CoVZC45, Bat-SL-CoVZC21 and human SARS-CoV [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ]. The S2 subunit is therefore targeted when screening broad spectrum antiviral peptides, which is an important piece of information that can be used to develop preventive and treatment measures. Most recently, the 3D structure of S protein was elucidated using Cryo-electron microscopy (Cryo-EM), and the RBD structure of the S protein is closer to the central location of SARS-CoV-2 compared to SARS-CoV [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0365">
       The E protein plays a role in virus assembly and release, and is required for pathogenesis [
       <xref ref-type="bibr" rid="bib106">
        106
       </xref>
       ,
       <xref ref-type="bibr" rid="bib107">
        107
       </xref>
       ]. The N protein contains two domains, both of which can bind virus RNA genomes via different mechanisms. It has been reported that the N protein can bind nsp3 protein to help tether the genome to replicase-transcriptase complex (RTC) and package the encapsulated genome into virions [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib108">
        108
       </xref>
       ,
       <xref ref-type="bibr" rid="bib109">
        109
       </xref>
       ]. The N protein is also an antagonist of interferon and viral encoded repressor (VSR) of RNA interference (RNAi), which benefits viral replication [
       <xref ref-type="bibr" rid="bib110">
        110
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec9.2">
      <label>
       9.2
      </label>
      <title>
       Entry into host cell
      </title>
      <p id="p0370">
       Cell entry is an essential component of cross-species transmission, especially for the β-CoVs. All CoVs encode a surface glycoprotein, spike, which binds to the host receptor and mediates viral entry [
       <xref ref-type="bibr" rid="bib111">
        111
       </xref>
       ]. For β-CoVs, the RBD of the spike protein mediates the interaction with host receptor. Upon binding the receptor, the spike protein is cleaved by nearby host proteases and releases the signal peptide to facilitate virus entry into host cells [
       <xref ref-type="bibr" rid="bib112">
        [112]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib113">
        [113]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib114">
        [114]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib115">
        [115]
       </xref>
       ].
      </p>
      <p id="p0375">
       Angiotensin converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4) are known host receptors for the β-CoVs SARS-CoV and MERS-CoV, respectively [
       <xref ref-type="bibr" rid="bib116">
        116
       </xref>
       ,
       <xref ref-type="bibr" rid="bib117">
        117
       </xref>
       ]. In similar fashion to SARS-CoV, SARS-CoV-2 also uses ACE2 to gain entry into host cells. Hoffmann et al. found that the cellular protease MPRSS2 blocks entry by cleaving the spike protein and may constitute a treatment option [
       <xref ref-type="bibr" rid="bib118">
        118
       </xref>
       ]. Zhou et al. also confirmed that SARS-CoV-2 is able to use all but mouse ACE2 as an entry receptor for ACE2-expressing cells, but not cells without ACE2, indicating that the cell receptor for SARS-CoV-2 could be ACE2, and not other coronavirus receptors such as aminopeptidase N and dipeptidyl peptidase 4 [
       <xref ref-type="bibr" rid="bib94">
        94
       </xref>
       ]. Huang also showed that the affinity of the SARS-CoV-2 S-RBD binding to ACE2 is less than that of SARS-CoV through Monte Carlo algorithm [
       <xref ref-type="bibr" rid="bib119">
        119
       </xref>
       ]. However, Wrapp et al. found that SARS-CoV-2 S binding to ACE2 has approximately 10- to 20- fold higher affinity than SARS-CoV S, which can provide one explanation why SARS-CoV-2 has more human-to human spread compared to SARS-CoV [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0380">
       The combination of SARS-CoV-2 S and ACE2 of host cells is similar to the combination of SARS-CoV and ACE2, indicating that they have the same mechanism to entry into host cells [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ]. The S protein of metastable prefusion conformation undergoes a series of structural rearrangements to combine with the viral membrane of host cells [
       <xref ref-type="bibr" rid="bib111">
        111
       </xref>
       ,
       <xref ref-type="bibr" rid="bib120">
        120
       </xref>
       ]. This process consists of the S1 subunit binding to the host cell receptor, triggering of the prefusion trimer's instability, and shedding of the S1 subunit, resulting in a highly stable post-fusion conformation of the S2 subunit [
       <xref ref-type="bibr" rid="bib121">
        121
       </xref>
       ]. During the binding of the subunit S1 to its cognate receptor, it is important to note that the S1 subunit exists in 2 different states, a “down” conformation and an “up” conformation state, which corresponds to a receptor-inaccessible state and an unstable receptor-accessible state, respectively [
       <xref ref-type="bibr" rid="bib122">
        [122]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib123">
        [123]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib124">
        [124]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib125">
        [125]
       </xref>
       ]. Unfortunately, there are significant conformational differences between SARS-CoV and SARS-CoV-2 such that the commercially available monoclonal antibodies against SARS-CoV do not react with SARS-CoV-2 [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0385">
       SARS-CoV-2 may directly bind to ACE2 positive cholangiocytes but not necessarily hepatocytes via specific expression of ACE2 in healthy liver tissues using cell RNA-seq data of two independent cohorts [
       <xref ref-type="bibr" rid="bib126">
        126
       </xref>
       ]. Though the respiratory systems is a primary target of SARS-CoV-2, bioinformatic analysis of single-cell transcriptomes datasets of lung, esophagus, gastric, ileum and colon reveal that the digestive system is also a potential route of entry for COVID-19, as ACE2 was not only highly expressed in lung AT2 cells, esophagus upper and stratified epithelial cells but also in absorptive enterocytes from the ileum and colon [
       <xref ref-type="bibr" rid="bib127">
        127
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec10">
     <label>
      10
     </label>
     <title>
      Recommendations
     </title>
     <sec id="sec10.1">
      <label>
       10.1
      </label>
      <title>
       Preventing the spread of disease
      </title>
      <p id="p0390">
       In response to the outbreak of pneumonia caused by the SARS-CoV-2, China has activated Level I public health emergency response for the entire country. This activates the most comprehensive and rigorous prevention and control measures for health and safety. A team of professionals from the NHC and China CDC was sent to conduct field investigations and implement disease control and prevention measures. The virus was quickly isolated and sequenced. On January 3, 2020, the first complete genome of the SARS-CoV-2 was determined and shared internationally, which led to the rapid development and deployment of diagnostic tests [
       <xref ref-type="bibr" rid="bib60">
        60
       </xref>
       ]. The NHC announced that preventive and control measures of category A infectious diseases would be implemented to effectively fight SARS-CoV-2 and has also introduced public education campaigns. At the same time, all medical expenses of confirmed patients would be covered by central and local financial institutions.
      </p>
     </sec>
     <sec id="sec10.2">
      <label>
       10.2
      </label>
      <title>
       Quarantine
      </title>
      <p id="p0395">
       Quarantine is a traditional but very effective measure to counter a deadly epidemic, but quarantine protocols can be hard to enforce. The local government in Wuhan announced the suspension of public transportation, with closure of airports, railway stations, and highways in the city, to prevent further disease transmission on January 23, 2020. Subsequently, the Chinese government imposed travel bans on several Chinese cities near Wuhan. At the same time, the Chinese government extended the Lunar New Year holidays and postponed the reopening of schools and factories to keep the nationwide migration of the population to a minimum. Travelers from Wuhan and other epidemic areas were advised to report their travel history and to self-quarantine for two weeks to prevent community transmission. In addition, most local governments required that all passengers must wear medical surgical masks or N95 masks when accessing public places, taxis or subways. Temperature screening checkpoints have been set up at subway stations, railway stations, high-speed rail exits and airports to screen passengers in an effort to curb the spread of the novel coronavirus.
      </p>
     </sec>
     <sec id="sec10.3">
      <label>
       10.3
      </label>
      <title>
       Mobilize resources
      </title>
      <p id="p0400">
       With the rapid spread of the epidemic, more designated treatment hospitals and health care workers were needed to meet the growing number of patients. On January 24, 2020, the local government in Wuhan announced the construction of a 1000-bed infirmary, named Huoshenshan hospital, and a 1500-bed infirmary, named Leishenshan hospital within 10 days, to ease the shortage of beds and treat people diagnosed with the SARS-CoV-2. These facilities are specialty hospitals for infectious diseases, rather than simply units to receive and quarantine patients. Wuhan has also been building 11 mobile Fangcang hospitals (a Chinese name which came from Noah's Ark) and creating tens of thousands of beds, to centralize quarantine and provide medical treatment for confirmed patients with mild symptoms, suspected patients and those who need observation. The new facilities further enhance the local public health capacities. Hospitals offer online consultants and medical services to symptomatic patients and suspected patients, which help reduce the frequency that patients go to hospitals and thereby reduce the risk of being infected. Health care workers, including military medical teams, from across the Chinese mainland arrived in Hubei to provide much needed assistance. At present, more than 30,000 health care workers have arrived in Hubei to help fight the novel coronavirus epidemic. In order to prevent health care workers from being infected, the NHC ensured enough supplies of isolation gowns, gloves and masks and issued a technical guideline for the prevention and control of infection caused by the novel coronavirus [
       <xref ref-type="bibr" rid="bib128">
        128
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec10.4">
      <label>
       10.4
      </label>
      <title>
       Disseminate information
      </title>
      <p id="p0405">
       The NHC also formulated a community prevention and control program for SARS-CoV-2 pneumonia to strengthen community-level epidemic prevention measures to control the spread of the outbreak [
       <xref ref-type="bibr" rid="bib129">
        129
       </xref>
       ]. All communities screen patients with fever within the community and monitor and report suspected cases with COVID-19. Various forms of health education have been carried out in the community to disseminate knowledge of epidemic prevention and control, such as using masks and washing hands correctly. The NHC issued guidelines for the protection of people at different levels of risk for COVID-19 [
       <xref ref-type="bibr" rid="bib130">
        130
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec11">
     <label>
      11
     </label>
     <title>
      Treatment and management
     </title>
     <p id="p0410">
      There is no clear, unified and effective treatment plan for COVID-19. Most guidelines emphasize early identification, early isolation, early diagnosis, and early treatment. The treatment and management of SARS-CoV-2 pneumonia mainly include the following aspects (
      <xref ref-type="fig" rid="fig8">
       Fig. 8
      </xref>
      ) [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ,
      <xref ref-type="bibr" rid="bib78">
       [78]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib79">
       [79]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib80">
       [80]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib81">
       [81]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib82">
       [82]
      </xref>
      ].
      <fig id="fig8">
       <label>
        Fig. 8
       </label>
       <caption>
        <p>
         The treatment and management of COVID-19 pneumonia. ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation.
        </p>
       </caption>
       <alt-text id="alttext0045">
        Fig. 8
       </alt-text>
       <graphic xlink:href="gr8_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0415">
      Suspected and confirmed cases should be isolated and treated in designated hospitals with effective isolation and protective conditions as soon as possible. Suspected cases should be isolated in a single room. WHO suggests that patients with mild symptoms and without underlying chronic diseases (such as lung or heart disease, renal failure, or immunodeficiency) may be cared for in the home environment in isolation [
      <xref ref-type="bibr" rid="bib131">
       131
      </xref>
      ]. However, severe cases should be hospitalized, and critical cases should be admitted to the ICU as soon as possible.
     </p>
     <p id="p0420">
      Supportive therapy includes bedrest, adequate nutrition, monitoring vital signs and oxygen saturation, prevention of dehydration and maintaining water, electrolyte, and acid-base balance. For severe cases, it may be necessary to proactively prevent complications and secondary infections, treat underlying diseases and provide organ function support according to the patients’ condition such as that reported by Chen et all that involved the administration of intravenous immunoglobulin therapy to 27 of such patients [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ].
     </p>
     <p id="p0425">
      Supplemental oxygen should be administered to patients with decreased oxygen saturation. In Huang's study [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ], four (10%) patients needed invasive mechanical ventilation, and two received extracorporeal membrane oxygenation (ECMO). In Chen's study [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ], 75 of 99 patients received oxygen therapy, 13 patients required non-invasive mechanical ventilation, four patients needed an invasive ventilator to assist ventilation, and three patients were treated with ECMO. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], of the 36 patients in the ICU, four patients received high-flow oxygen therapy, 15 patients received non-invasive ventilation, and 17 patients received invasive ventilation (four patients switched to ECMO). In Guan's study, 418 of 1099 patients received oxygen therapy, 67 patients received mechanical ventilation, and ECMO was adopted in 5 severe cases [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ].
     </p>
     <p id="p0430">
      Due to lack of valid evidence and possible adverse effects, routine use of corticosteroid should be avoided unless for specific reasons. Baillie JK et al. [
      <xref ref-type="bibr" rid="bib42">
       42
      </xref>
      ] suggested that corticosteroid should not be used for the treatment of SARS-CoV-2-induced lung injury or shock, because of the lack of evidence that patients with COVID-19 will benefit from corticosteroid. In the first 41 patients, only 22% (9/41) patients were given corticosteroid, with six of these in the ICU [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ]. Chen et al. reported that 19% (19/99) patients received corticosteroid treatment for 3–15 days [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ]. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], 45% (62/138) patients received corticosteroid treatment. In Guan's study, 18.6% (204/1099) of patients were given systemic corticosteroids [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ].
     </p>
     <p id="p0435">
      Indiscriminate or inappropriate antimicrobial treatment, especially the combination of broad-spectrum antibiotics, should be avoided. However, in Huang's study [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ], all his 41 patients received antibiotic therapy. In Chen's study [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ], 70 patients were given antibiotic treatment, among whom 25 patients were treated with a single antibiotic and 45 patients were given combination therapy. The duration of antibiotic treatment was 3–17 days. In addition, there were 15 patients who received antifungal treatment. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], the 138 hospitalized patients all received antibacterial therapy, including moxifloxacin (64.4%), ceftriaxone (24.6%), azithromycin (18.1%). In Guan's study, 632 patients were given intravenous antibiotics, and 30 patients were given antifungal medications [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ].
     </p>
     <p id="p0440">
      At present, there is no evidence-based medicine to support the effectiveness of antiviral drugs for COVID-19. The previous experience of treating SARS-CoV, MERS-CoV or influenza infections guides the selection of antiviral agents for COVID-19. The current guideline of the NHC recommends IFN-α, lopinavir/ritonavir, and ribavirin as antiviral therapy. In Huang's study [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ], 38 of 41 patients were given antiviral therapy. The Jinyintan hospital has launched a randomized, controlled trial of the anti-HIV drug combination of lopinavir and ritonavir. In Chen's study [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ], 75 patients received antiviral treatment, including oseltamivir, ganciclovir, and lopinavir/ritonavir, and the duration of antiviral treatment was 3–14 days. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], there were 89.9% (124/138) patients who received oseltamivir. And in Guan's study, 35.8% (393/1099) of patients received oseltamivir [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ]. The anti-viral drug remdesivir (Gilead®) is in clinical trials to treat COVID-19 in Wuhan [
      <xref ref-type="bibr" rid="bib132">
       132
      </xref>
      ]. Chloroquine phosphate has also been shown to be effective in some patients.
     </p>
     <p id="p0445">
      Identifying or developing novel drug treatment options as soon as possible is critical for the response to the SARS-CoV-2 outbreak. Based on the structural information of clinical effective medicines for SARS-CoV-2, Liu et al. predicted 10 commercial medicines which may function as inhibitors of SARS-CoV-2, including colistin, valrubicin, icatibant, bepotastine, epirubicin, etc. Some of these may be more resistant to viral mutation than lopinavir/ritonavir [
      <xref ref-type="bibr" rid="bib133">
       133
      </xref>
      ]. Stebbing et al. suggested that baricitinib may reduce both the viral entry and inflammation [
      <xref ref-type="bibr" rid="bib134">
       134
      </xref>
      ].
     </p>
     <p id="p0450">
      Lu reported that remdesivir may have the greatest potential for the successful treatment of SARS-CoV-2, but the efficacy and safety of remdesivir in COVID-19 needs further evaluation [
      <xref ref-type="bibr" rid="bib135">
       135
      </xref>
      ]. The antiviral efficiency of five FAD-approved drugs and two well-known broad-spectrum antiviral drugs have been studied and it has been found that remdesivir and chloroquine effectively inhibit SARS-CoV-2
      <italic>
       in vitro
      </italic>
      [
      <xref ref-type="bibr" rid="bib136">
       136
      </xref>
      ]. The New England Journal of Medicine reported that the first case of COVID-19 confirmed in the United States was treated with intravenous remdesivir and demonstrated clinical improvement [
      <xref ref-type="bibr" rid="bib71">
       71
      </xref>
      ]. At present, a randomized, double-blind, placebo-controlled phase III clinical trial of remdesivir has been launched and already 761 confirmed cases have been enrolled [
      <xref ref-type="bibr" rid="bib132">
       132
      </xref>
      ]. Lu also pointed out that there is no direct evidence that oseltamivir is effective in the treatment of SARS-CoV-2 [
      <xref ref-type="bibr" rid="bib135">
       135
      </xref>
      ]. However, we found that oral oseltamivir or abidol has been used for suspected or confirmed SARS-CoV-2 cases.
     </p>
     <p id="p0455">
      Favilavir, formerly known as Fapilavir, was the first anti-novel coronavirus drug that has been approved for marketing by the National Medical Products Administration since the outbreak. The drug was developed by Zhejiang Hisun Pharmaceutical Company and is expected to play an important role in preventing and treating the epidemic [
      <xref ref-type="bibr" rid="bib137">
       137
      </xref>
      ].
     </p>
     <p id="p0460">
      The role of intestinal microecological regulators that can be used to maintain intestinal microecological balance and prevent secondary bacterial infections is unclear. Chinese traditional medicine suggests Shufengjiedu and Lianhuaqingwen, which have played a role in the prevention and treatment of new infectious respiratory diseases, may be of benefit [
      <xref ref-type="bibr" rid="bib138">
       138
      </xref>
      ,
      <xref ref-type="bibr" rid="bib139">
       139
      </xref>
      ].
     </p>
     <p id="p0465">
      Anxiety and fear often exist in suspected or confirmed patients. Emergency psychological crisis intervention [
      <xref ref-type="bibr" rid="bib140">
       140
      </xref>
      ], and the implementation of classified intervention for different groups of people, is helpful in order to strengthen psychological counseling and reduce the psychological damage caused by the epidemic. Mass hysteria has also led to incidences of racial discrimination against Asians, particularly in non-Asian countries.
     </p>
    </sec>
    <sec id="sec12">
     <label>
      12
     </label>
     <title>
      Development of vaccines for coronavirus
     </title>
     <p id="p0470">
      Research institutions and pharmaceutical companies worldwide are stepping up research and development for a coronavirus vaccine. Virus strains have been isolated from patients’ samples and provide the basis for research and development of a vaccine for the novel coronavirus. Although vaccines have been developed for SARS-CoV and MERS-CoV, these are not commercially available [
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bib14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="bib141">
       141
      </xref>
      ]. Since the emergence of SARS-CoV and MERS-CoV, basic research on coronaviruses and advances in vaccine preparation technology can significantly shorten the development time of new coronavirus vaccines. However, the difficulties and challenges of developing an effective vaccine have been discussed earlier, and the key to a successful vaccine program is to vaccinate people before an outbreak occurs, not begin to develop the vaccine during the outbreak. Development of animal models that faithfully mimic SARS-CoV-2 infection in humans is critical not only in providing a more refined understanding of the pathogenic mechanisms involved but also to serve as a screening model for potential chemotherapeutic agents and vaccines.
     </p>
    </sec>
    <sec id="sec13">
     <label>
      13
     </label>
     <title>
      Guidelines for the future
     </title>
     <p id="p0475">
      Recommendations for the prevention and management of coronavirus epidemics are summarized in
      <xref ref-type="fig" rid="fig9">
       Fig. 9
      </xref>
      . Since both SARS and SARS-CoV-2 appear to have an exotic animal origin, the purchase, trafficking, and sale of wild animals should be banned, and illegal activities should be prosecuted. Early recognition of the problem, early identification of infected patients and early mobilization of healthcare resources are critical in limiting morbidity and mortality. When an outbreak occurs, it is very important to rapidly identify and characterize the pathogen, in order to be able to develop diagnostic assays. In the early stage of the disease epidemic, summarizing the clinical characteristics and treatment efficacy, formulating the diagnosis procedures, defining suspected cases and locations, determining transmission patterns, isolating contagious patients and formulating the appropriate quarantine strategy are all necessary and need to be implemented promptly.
      <fig id="fig9">
       <label>
        Fig. 9
       </label>
       <caption>
        <p>
         Keys to the control of future hCoV epidemics. Lessons learned from both the SARS and SARS-CoV-2 epidemics.
        </p>
       </caption>
       <alt-text id="alttext0050">
        Fig. 9
       </alt-text>
       <graphic xlink:href="gr9_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0480">
      The strict control of cross-infection in medical institutions is also key to preventing the further spread of the epidemic. In addition, actively mobilizing the population to participate in epidemic prevention and control is critical, and this can be achieved by accurate information dissemination and ongoing updates. Real-time updating the information of the epidemic situation can help to alleviate panic and reduce societal anxiety. A strong public health surveillance system to guide the response to the outbreak is important in the face of a lack of effective therapeutics or vaccines. Big data and artificial intelligence systems are tools that can be used to fully integrate the information, conduct comprehensive research and analyze public health risks. Last but not least, use of the Internet and the media to conduct health education for the people, publicize the correct knowledge of prevention, and offer online consultation to guide patients to seek medical treatment correctly are additional strategies that can be implemented to achieve viral containment.
     </p>
    </sec>
    <sec id="sec14">
     <label>
      14
     </label>
     <title>
      Discussion
     </title>
     <sec id="sec14.1">
      <label>
       14.1
      </label>
      <title>
       <italic>
        The differences between SARS and
       </italic>
       SARS-CoV-2
      </title>
      <p id="p0485">
       Although SARS-CoV-2 and SARS-CoV have certain similarities in biological, epidemiological and pathological characteristics, there are some important differences. First, the most fundamental difference between the two viruses lies in their gene sequence. Second, during the SARS epidemic, a total of 8422 patients worldwide were infected with SARS-CoV, of whom 919 died, with a mortality rate of 9.5% [
       <xref ref-type="bibr" rid="bib9">
        9
       </xref>
       ]. A total of 5328 patients in China were infected with SARS-CoV, of whom 349 died, with a mortality rate of 6.5% [
       <xref ref-type="bibr" rid="bib9">
        9
       </xref>
       ]. As of February 17, 2020, there were 72,436 confirmed cases of 2019-nCoV in China, of whom 1868 have died, with a mortality rate of 2.6% [
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ]. Compared to SARS, there are more confirmed cases, suspected cases and deaths of SARS-CoV-2, but the mortality rate is lower than that of SARS.
      </p>
      <p id="p0490">
       From 2017 to 2018, influenza ravaged the world, affecting up to 45 million people and killing about 95,000 people, with a reported mortality rate of about 0.2%. Every year millions of people are infected by influenza despite the existence of a yearly vaccine. According to the United States CDC weekly report, the number of childhood deaths in the United States so far from influenza during this flu season alone is 105. Compared with influenza, the number of patients who have died of coronavirus infection is less, but the virulence and mortality rate of coronavirus is significantly higher.
      </p>
      <p id="p0495">
       Clinically, the patients with COVID-19 have no upper respiratory symptoms (such as runny nose, sneezing, sore throat). In 2003, a large number of medical personnel were infected, and iatrogenic transmission occurred in SARS. In contrast, although there are cases of nosocomial infection in SARS-CoV-2, most of them are out-of-hospital infections.
      </p>
     </sec>
     <sec id="sec14.2">
      <label>
       14.2
      </label>
      <title>
       What can we learn from the 2020 nCoV epidemic in China?
      </title>
      <p id="p0500">
       The SARS-CoV-2 epidemic of 2020 in China is an international crisis, affecting human lives, the global economy, societal views and lifestyle. During times of crisis, misinformation, blame and conspiracy theories abound. It is probably prudent to not entirely trust the media, whether local, regional or international, as each most likely has their own agenda. On the other hand, it is the responsibility of doctors and scientists to evaluate the events to ascertain whether or not more effective management of the crisis could have been attained. This comes with its own set of challenges, as hindsight is always 20/20.
      </p>
      <p id="p0505">
       The quarantining of an entire country has been extreme, astounding and unprecedented. This not only involves quarantining measures within China but also internationally, as countries canceled flights into China, quarantined their own nationals as they returned from China and installed thermal scanners to detect ill people. But the quarantine measures inside China are certainly eye-opening. The entire city of Wuhan was shut off, and this was extended to every other city in China. In effect, the entire country was told to stay home, creating an enormous impact on the economy and on people's daily lives. Roads and stores became deserted (
       <xref ref-type="fig" rid="fig10">
        Fig. 10
       </xref>
       ). In Ningbo, each household was only permitted to send one person out for groceries every other day. Schools were closed till the end of March. Everyone wears masks. The objective was to starve the virus, to eliminate hosts. Yet even with these measures, new cases continued to appear. The quarantine measures in China have obviously come under a great deal of scrutiny, with so called “experts” weighing in, some saying that it will not work, that isolating a city deprives it of medical resources. Whatever the criticism, it is humbling to think of what may have happened without these draconian measures. It is also difficult to comprehend if such measures could actually take place in other parts of the world, or if the implementation of these changes could have taken place as quickly. For example, hand shaking is not part of Chinese culture, but it is almost automatic in other parts of the world, and it is normally done without even thinking. This is the first thing that would have to stop to help contain the virus.
       <fig id="fig10">
        <label>
         Fig. 10
        </label>
        <caption>
         <p>
          Life in China in Beijing and Hubei during quarantine measures. Quarantine measures have led to empty streets and shopping centers.
         </p>
        </caption>
        <alt-text id="alttext0055">
         Fig. 10
        </alt-text>
        <graphic xlink:href="gr10_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0510">
       Then there is the matter of the ophthalmologist and others who voiced concerns in the media about a cluster of cases of a flu-like illness near the end of December. At the present time, it is difficult to say whether or not the response could have been faster than it actually was, as this corresponds to the time when work began on viral sequencing. It is possible that medical teams were already working on the sequence at that time. It is also quite possible that officials did not initially sound the alarm publicly because they did not want to cause a panic. Perhaps this was the wrong decision, but these decisions are difficult in times of crisis and it is of course easy to second guess. It is easy to understand that this can be perceived as withholding information and why the public would be frustrated. The lesson here is that dissemination of accurate and validated information and establishing guidelines to prevent the spread of infections is critical.
      </p>
      <p id="p0515">
       There are many “heroes” in these crises, people who have risked their lives and made incredible sacrifices to help society rid itself of this scourge, including those who work on the front lines, epidemiologists, scientists, doctors, first responders, and members of the public. Unfortunately, these events also bring out the worst in people. Numerous accounts of racial discrimination have been perpetrated against Asians across the world, many rising to the level of hate crimes. One must not forget the psychological impact of an infection such as this on people who are not even infected or who will never encounter an infected person.
      </p>
      <p id="p0520">
       The emergence of SARS-CoV, MERS-CoV, and now SARS-CoV-2, suggests that coronavirus will pose a lasting threat to human beings. The epidemic will eventually be contained, and people's memory of the coronavirus may gradually blur. But we must not forget the lessons learned from this crisis, and already begin to take measures to prevent the next new outbreak of Coronavirus or some other virus from appearing in the future. If it does appear, how will we respond to it? What if it does not happen in China? Will other countries have the fortitude to implement even more drastic measures and mobilize resources to prevent the spread of the virus and to care for the sick?
      </p>
      <p id="p0525">
       We can always improve on the handling of global pandemics or epidemics. From the lessons learned during the SARS and now the SARS-CoV-2 epidemics, we can nearly provide a roadmap for the response to future outbreaks. The development of a vaccine for coronavirus is a critical step in prevention, but it may not be effective for future strains, and we must be ready for the next epidemic.
      </p>
     </sec>
    </sec>
    <sec id="sec15">
     <title>
      Funding
     </title>
     <p id="p0530">
      <funding-source id="gs1">
       Beijing Municipal Natural Science Foundation
      </funding-source>
      General Program (7,192,197).
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of competing interest
     </title>
     <p id="p0535">
      The authors declare no conflict of interest.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Leibowitz
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pathogenesis
        </article-title>
        <source>
         Adv. Virus Res.
        </source>
        <volume>
         81
        </volume>
        <year>
         2011
        </year>
        <fpage>
         85
        </fpage>
        <lpage>
         164
        </lpage>
        <pub-id pub-id-type="pmid">
         22094080
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sref2" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balasuriya
          </surname>
          <given-names>
           U.B.R.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         List of contributors
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           MacLachlan
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dubovi
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <source>
         Fenner's Veterinary Virology
        </source>
        <edition>
         fifth ed.
        </edition>
        <year>
         2017
        </year>
        <publisher-name>
         Academic Press
        </publisher-name>
        <publisher-loc>
         Boston
        </publisher-loc>
        <fpage>
         xvii
        </fpage>
        <lpage>
         xviii
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology, genetic recombination, and pathogenesis of coronaviruses
        </article-title>
        <source>
         Trends Microbiol.
        </source>
        <volume>
         24
        </volume>
        <issue>
         6
        </issue>
        <year>
         2016
        </year>
        <fpage>
         490
        </fpage>
        <lpage>
         502
        </lpage>
        <pub-id pub-id-type="pmid">
         27012512
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         N Engl J Med
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Isaacs
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology of coronavirus respiratory infections
        </article-title>
        <source>
         Arch. Dis. Child.
        </source>
        <volume>
         58
        </volume>
        <issue>
         7
        </issue>
        <year>
         1983
        </year>
        <fpage>
         500
        </fpage>
        <lpage>
         503
        </lpage>
        <pub-id pub-id-type="pmid">
         6307189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenberg
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update on human rhinovirus and coronavirus infections
        </article-title>
        <source>
         Semin. Respir. Crit. Care Med.
        </source>
        <volume>
         37
        </volume>
        <issue>
         4
        </issue>
        <year>
         2016
        </year>
        <fpage>
         555
        </fpage>
        <lpage>
         571
        </lpage>
        <pub-id pub-id-type="pmid">
         27486736
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         367
        </volume>
        <issue>
         19
        </issue>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <comment>
         [cited Jan 30, 2020; Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0010" xlink:href="http://www.who.int/emergencies/mers-cov/en/">
         http://www.who.int/emergencies/mers-cov/en/
        </ext-link>
        <year>
         2019 Jan 30
        </year>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Summary table of SARS cases by country, November 1, 2002-August 7, 2003
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0015" xlink:href="http://www.who.int/csr/sars/country/2003_08_15/en/">
         http://www.who.int/csr/sars/country/2003_08_15/en/
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Update on the Novel Coronavirus Pneumonia Outbreak
        </chapter-title>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0020" xlink:href="http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml">
         http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Navas-Martin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         Microbiol. Mol. Biol. Rev.
        </source>
        <volume>
         69
        </volume>
        <issue>
         4
        </issue>
        <year>
         2005
        </year>
        <fpage>
         635
        </fpage>
        <lpage>
         664
        </lpage>
        <pub-id pub-id-type="pmid">
         16339739
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: an overview of their replication and pathogenesis
        </article-title>
        <source>
         Methods Mol. Biol.
        </source>
        <volume>
         1282
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <volume>
         11
        </volume>
        <issue>
         6
        </issue>
        <year>
         2012
        </year>
        <fpage>
         607
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="pmid">
         22704621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         From SARS to MERS, thrusting coronaviruses into the spotlight
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         11
        </volume>
        <issue>
         1
        </issue>
        <year>
         2019
        </year>
        <fpage>
         59
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ecoepidemiology and complete genome comparison of different strains of severe acute respiratory syndrome-related Rhinolophus bat coronavirus in China reveal bats as a reservoir for acute, self-limiting infection that allows recombination events
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         84
        </volume>
        <issue>
         6
        </issue>
        <year>
         2010
        </year>
        <fpage>
         2808
        </fpage>
        <lpage>
         2819
        </lpage>
        <pub-id pub-id-type="pmid">
         20071579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <volume>
         310
        </volume>
        <issue>
         5748
        </issue>
        <year>
         2005
        </year>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Stratton
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreak of pneumonia of unknown etiology in wuhan China: the mystery and the miracle
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         401
        </fpage>
        <lpage>
         402
        </lpage>
        <comment>
         Epub 2020 Feb 12
        </comment>
        <pub-id pub-id-type="pmid">
         31950516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ji
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cross-species transmission of the newly identified coronavirus 2019-nCoV
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         433
        </fpage>
        <lpage>
         440
        </lpage>
        <pub-id pub-id-type="pmid">
         31967321
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020 Feb 15
        </year>
        <fpage>
         514
        </fpage>
        <lpage>
         523
        </lpage>
        <comment>
         Epub 2020 Jan 24
        </comment>
        <pub-id pub-id-type="pmid">
         31986261
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Linton
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Akhmetzhanov
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Initial cluster of novel coronavirus (2019-nCoV) infections in wuhan, China is consistent with substantial human-to-human transmission
        </article-title>
        <source>
         J. Clin. Med.
        </source>
        <volume>
         9
        </volume>
        <issue>
         2
        </issue>
        <year>
         2020
        </year>
        <fpage>
         E488
        </fpage>
        <pub-id pub-id-type="pmid">
         32054045
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <mixed-citation id="sref21" publication-type="other">
        Organization, W.H., Consensus Document on the Epidemiology of Severe Acute Respiratory Syndrome (SARS). 2003, World Health Organization: Geneva.
       </mixed-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sref22" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maier
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Bickerton
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Britton
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviruses: Methods and Protocols
        </chapter-title>
        <year>
         2015
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         282
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: current knowledge and future considerations
        </article-title>
        <source>
         EMHJ-Eastern Mediterranean Health J.
        </source>
        <volume>
         22
        </volume>
        <issue>
         7
        </issue>
        <year>
         2016
        </year>
        <fpage>
         533
        </fpage>
        <lpage>
         542
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         2019-nCoV transmission through the ocular surface must not be ignored
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10224
        </issue>
        <year>
         2020 Feb 22
        </year>
        <fpage>
         e39
        </fpage>
        <comment>
         Epub 2020 Feb 6
        </comment>
        <pub-id pub-id-type="pmid">
         32035510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wunderink
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS, SARS and other coronaviruses as causes of pneumonia
        </article-title>
        <source>
         Respirology
        </source>
        <volume>
         23
        </volume>
        <issue>
         2
        </issue>
        <year>
         2018
        </year>
        <fpage>
         130
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="pmid">
         29052924
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020 Feb 15
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <comment>
         Epub 2020 Jan 24
        </comment>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sabir
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia
        </article-title>
        <source>
         Science
        </source>
        <volume>
         351
        </volume>
        <issue>
         6268
        </issue>
        <year>
         2016
        </year>
        <fpage>
         81
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         26678874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sref28" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Moderate mutation rate in the SARS coronavirus genome and its implications
        </article-title>
        <source>
         BMC Evol. Biol.
        </source>
        <volume>
         4
        </volume>
        <year>
         2004
        </year>
        <fpage>
         21
        </fpage>
        <pub-id pub-id-type="pmid">
         15222897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious diseases emerging from Chinese wet-markets: zoonotic origins of severe respiratory viral infections
        </article-title>
        <source>
         Curr. Opin. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <issue>
         5
        </issue>
        <year>
         2006
        </year>
        <fpage>
         401
        </fpage>
        <lpage>
         407
        </lpage>
        <pub-id pub-id-type="pmid">
         16940861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus diversity, phylogeny and interspecies jumping
        </article-title>
        <source>
         Exp. Biol. Med.
        </source>
        <volume>
         234
        </volume>
        <issue>
         10
        </issue>
        <year>
         2009
        </year>
        <fpage>
         1117
        </fpage>
        <lpage>
         1127
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative analysis of 22 coronavirus HKU1 genomes reveals a novel genotype and evidence of natural recombination in coronavirus HKU1
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         80
        </volume>
        <issue>
         14
        </issue>
        <year>
         2006
        </year>
        <fpage>
         7136
        </fpage>
        <lpage>
         7145
        </lpage>
        <pub-id pub-id-type="pmid">
         16809319
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benvenuto
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The 2019-new coronavirus epidemic: evidence for virus evolution
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         455
        </fpage>
        <lpage>
         459
        </lpage>
        <comment>
         Epub 2020 Feb 7
        </comment>
        <pub-id pub-id-type="pmid">
         31994738
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ceraolo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Giorgi
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic variance of the 2019-nCoV coronavirus
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute renal impairment in coronavirus-associated severe acute respiratory syndrome
        </article-title>
        <source>
         Kidney Int.
        </source>
        <volume>
         67
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         698
        </fpage>
        <lpage>
         705
        </lpage>
        <pub-id pub-id-type="pmid">
         15673319
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <issue>
         9371
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1767
        </fpage>
        <lpage>
         1772
        </lpage>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sref36" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Booth
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <volume>
         289
        </volume>
        <issue>
         21
        </issue>
        <year>
         2003
        </year>
        <fpage>
         2801
        </fpage>
        <lpage>
         2809
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sref37" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: a Descriptive Study
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Lancet
        </publisher-name>
        <publisher-loc>
         London, England)
        </publisher-loc>
        <comment>
         S0140-6736(20)30211-7
        </comment>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sref38" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of SARS with human interferons
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         362
        </volume>
        <issue>
         9380
        </issue>
        <year>
         2003
        </year>
        <fpage>
         293
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="pmid">
         12892961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sref39" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stockman
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bellamy
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Garner
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: systematic review of treatment effects
        </article-title>
        <source>
         PLoS Med.
        </source>
        <volume>
         3
        </volume>
        <issue>
         9
        </issue>
        <year>
         2006
        </year>
        <fpage>
         e343
        </fpage>
        <pub-id pub-id-type="pmid">
         16968120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses - drug discovery and therapeutic options
        </article-title>
        <source>
         Nat. Rev. Drug Discov.
        </source>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <year>
         2016
        </year>
        <fpage>
         327
        </fpage>
        <lpage>
         347
        </lpage>
        <pub-id pub-id-type="pmid">
         26868298
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sref41" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <volume>
         31
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         304
        </fpage>
        <lpage>
         309
        </lpage>
        <pub-id pub-id-type="pmid">
         15494274
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation id="sref42" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Millar
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Baillie
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         The Lancet
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation id="sref43" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <issue>
         9366
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1319
        </fpage>
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation id="sref44" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           NS
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           GQ
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Our strategies for fighting severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         Am. J. Respir. Crit. Care Med.
        </source>
        <volume>
         168
        </volume>
        <issue>
         1
        </issue>
        <year>
         2003
        </year>
        <fpage>
         7
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         12773318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation id="sref45" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic
        </article-title>
        <source>
         Phil. Trans. Roy. Soc. Lond. B Biol. Sci.
        </source>
        <volume>
         359
        </volume>
        <issue>
         1447
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1091
        </fpage>
        <lpage>
         1105
        </lpage>
        <pub-id pub-id-type="pmid">
         15306395
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation id="sref46" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing
        </article-title>
        <source>
         JAMA, 2003
        </source>
        <volume>
         290
        </volume>
        <issue>
         24
        </issue>
        <year>
         2003
        </year>
        <fpage>
         3215
        </fpage>
        <lpage>
         3221
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation id="sref47" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Centers for Disease
          </surname>
         </name>
        </person-group>
        <article-title>
         C. and Prevention, Efficiency of quarantine during an epidemic of severe acute respiratory syndrome-Beijing, China
        </article-title>
        <source>
         MMWR. Morbidity Mortality Weekly Rep.
        </source>
        <volume>
         52
        </volume>
        <issue>
         43
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1037
        </fpage>
        <lpage>
         1040
        </lpage>
        <comment>
         2003
        </comment>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation id="sref48" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Breiman
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of China in the quest to define and control severe acute respiratory syndrome
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         9
        </volume>
        <issue>
         9
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1037
        </fpage>
        <lpage>
         1041
        </lpage>
        <pub-id pub-id-type="pmid">
         14519236
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation id="sref49" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sampathkumar
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: epidemiology, clinical presentation, management, and infection control measures
        </article-title>
        <source>
         Mayo Clin. Proc.
        </source>
        <volume>
         78
        </volume>
        <issue>
         7
        </issue>
        <year>
         2003
        </year>
        <fpage>
         882
        </fpage>
        <lpage>
         890
        </lpage>
        <pub-id pub-id-type="pmid">
         12839084
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation id="sref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Christian
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         38
        </volume>
        <issue>
         10
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1420
        </fpage>
        <lpage>
         1427
        </lpage>
        <pub-id pub-id-type="pmid">
         15156481
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation id="sref51" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           N
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Learning from the sars outbreak
        </article-title>
        <source>
         Curr. Biol. : CB
        </source>
        <volume>
         14
        </volume>
        <issue>
         3
        </issue>
        <year>
         2004
        </year>
        <fpage>
         R91
        </fpage>
        <lpage>
         R93
        </lpage>
        <pub-id pub-id-type="pmid">
         14986624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation id="sref52" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome and coronavirus
        </article-title>
        <source>
         Infect. Dis. Clin.
        </source>
        <volume>
         24
        </volume>
        <issue>
         3
        </issue>
        <year>
         2010
        </year>
        <fpage>
         619
        </fpage>
        <lpage>
         638
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation id="sref53" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           NS
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           GQ
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pandemic planning in China: applying lessons from severe acute respiratory syndrome
        </article-title>
        <source>
         Respirology
        </source>
        <year>
         2008
        </year>
        <fpage>
         S33
        </fpage>
        <lpage>
         S35
        </lpage>
        <pub-id pub-id-type="pmid">
         18366527
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation id="sref54" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AS
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lessons from the severe acute respiratory syndrome outbreak in Hong Kong
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         9
        </volume>
        <issue>
         9
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1042
        </fpage>
        <lpage>
         1045
        </lpage>
        <pub-id pub-id-type="pmid">
         14519237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation id="sref55" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           RP
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           MB
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Listening to SARS: lessons for infection control
        </article-title>
        <source>
         Ann. Intern. Med.
        </source>
        <volume>
         139
        </volume>
        <issue>
         7
        </issue>
        <year>
         2003
        </year>
        <fpage>
         592
        </fpage>
        <lpage>
         593
        </lpage>
        <pub-id pub-id-type="pmid">
         14530231
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation id="sref56" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical management and infection control of SARS: lessons learned
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <volume>
         100
        </volume>
        <issue>
         2
        </issue>
        <year>
         2013
        </year>
        <fpage>
         407
        </fpage>
        <lpage>
         419
        </lpage>
        <pub-id pub-id-type="pmid">
         23994190
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation id="sref57" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parashar
          </surname>
          <given-names>
           U.D.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: review and lessons of the 2003 outbreak
        </article-title>
        <source>
         Int. J. Epidemiol.
        </source>
        <volume>
         33
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         628
        </fpage>
        <lpage>
         634
        </lpage>
        <pub-id pub-id-type="pmid">
         15155694
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation id="sref58" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing
        </article-title>
        <source>
         JAMA, 2003
        </source>
        <volume>
         290
        </volume>
        <issue>
         24
        </issue>
        <year>
         2003
        </year>
        <fpage>
         3215
        </fpage>
        <lpage>
         3221
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation id="sref59" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DR
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Obstacles and advances in SARS vaccine development
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         24
        </volume>
        <issue>
         7
        </issue>
        <year>
         2006
        </year>
        <fpage>
         863
        </fpage>
        <lpage>
         871
        </lpage>
        <pub-id pub-id-type="pmid">
         16191455
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation id="sref60" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wenjie
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus genome identified in a cluster of pneumonia cases — wuhan, China 2019−2020
        </article-title>
        <source>
         China CDC Weekly
        </source>
        <volume>
         2
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020
        </year>
        <fpage>
         61
        </fpage>
        <lpage>
         62
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation id="sref61" publication-type="journal">
        <comment>
         The -nCo, V.O.J.F.E.I.T.
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Qun
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An outbreak of NCIP (2019-nCoV) infection in China — wuhan, Hubei province, 2019−2020
        </article-title>
        <source>
         China CDC Weekly
        </source>
        <volume>
         2
        </volume>
        <issue>
         5
        </issue>
        <year>
         2020
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         80
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation id="sref62" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           University
          </surname>
          <given-names>
           S.C.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pangolin was found to be a potential intermediate-host of new coronavirus
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0025" xlink:href="https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm">
         https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <element-citation id="sref63" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rothe
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission of 2019-nCoV infection from an asymptomatic contact in Germany
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020 Jan 30
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib64">
       <label>
        64
       </label>
       <element-citation id="sref64" publication-type="journal">
        <article-title>
         Clinical updates in women's health care summary: liver disease: reproductive considerations
        </article-title>
        <source>
         Obstet. Gynecol.
        </source>
        <volume>
         129
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <fpage>
         236
        </fpage>
        <pub-id pub-id-type="pmid">
         28002308
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <label>
        65
       </label>
       <element-citation id="sref65" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib66">
       <label>
        66
       </label>
       <element-citation id="sref66" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paules
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Marston
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fauci
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus infections-more than just the common cold
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib67">
       <label>
        67
       </label>
       <element-citation id="sref67" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Novel Coronavirus Pneumonia Emergency Response Epidemiology
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China
        </article-title>
        <source>
         Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
        </source>
        <volume>
         41
        </volume>
        <issue>
         2
        </issue>
        <year>
         2020
        </year>
        <fpage>
         145
        </fpage>
        <lpage>
         151
        </lpage>
        <pub-id pub-id-type="pmid">
         32064853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib68">
       <label>
        68
       </label>
       <element-citation id="sref68" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Nowcasting and Forecasting the Potential Domestic and International Spread of the 2019-nCoV Outbreak Originating in Wuhan, China: a Modelling Study
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Lancet
        </publisher-name>
        <publisher-loc>
         London, England)
        </publisher-loc>
        <comment>
         S0140-6736(20)30260-9
        </comment>
       </element-citation>
      </ref>
      <ref id="bib69">
       <label>
        69
       </label>
       <element-citation id="sref69" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prevention
          </surname>
         </name>
        </person-group>
        <article-title>
         G.C.f.D.C.a. The virus on the doorknob is not a live virus
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0030" xlink:href="http://www.gd.xinhuanet.com/newscenter/2020-02/04/c_1125528591.htm">
         http://www.gd.xinhuanet.com/newscenter/2020-02/04/c_1125528591.htm
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib70">
       <label>
        70
       </label>
       <element-citation id="sref70" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           ZH
          </surname>
         </name>
        </person-group>
        <article-title>
         Z. Fecal matter of patients tests positive for coronavirus
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0035" xlink:href="https://www.chinadaily.com.cn/a/202002/02/WS5e35b026a310128217274206.html">
         https://www.chinadaily.com.cn/a/202002/02/WS5e35b026a310128217274206.html
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib71">
       <label>
        71
       </label>
       <element-citation id="sref71" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holshue
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First case of 2019 novel coronavirus in the United States
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib72">
       <label>
        72
       </label>
       <element-citation id="sref72" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Organization, W.H. Novel Coronavirus
         </collab>
        </person-group>
        <article-title>
         (2019-nCoV) situation reports to data
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0040" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/">
         https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib73">
       <label>
        73
       </label>
       <element-citation id="sref73" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         W.H. Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV). . 2020
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         World Health Organization
        </publisher-name>
        <publisher-loc>
         Geneva
        </publisher-loc>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0045" xlink:href="https://www.who.int/newsroom/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-healthregulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov">
         https://www.who.int/newsroom/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-healthregulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib74">
       <label>
        74
       </label>
       <element-citation id="sref74" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           Z.D.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diagnosis and prevention of 2019-nCoV virus infection/pneumonia in children
        </article-title>
        <comment>
         (in Chinese) Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0050" xlink:href="https://www.cma.org.cn/art/2020/1/29/art_1822_32177.html">
         https://www.cma.org.cn/art/2020/1/29/art_1822_32177.html
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib75">
       <label>
        75
       </label>
       <element-citation id="sref75" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Technology
          </surname>
         </name>
        </person-group>
        <chapter-title>
         T.H.T.M.C.H.U.o.S.a. Be Alert to the Risk of Mother-To-Child Vertical Transmission and the First New Coronavirus Infection of a Newborn Was Diagnosed in Tongji Hospital
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         ChuTian Metropolis Daily
        </publisher-name>
        <fpage>
         2020
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib76">
       <label>
        76
       </label>
       <element-citation id="sref76" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         The Lancet
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib77">
       <label>
        77
       </label>
       <element-citation id="sref77" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Notice on prevention and control of pneumonia in children and pregnant women with new coronavirus infection
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0055" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202002/de2d62a5711c41ef9b2c4b6f4d1f2136.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202002/de2d62a5711c41ef9b2c4b6f4d1f2136.shtml
        </ext-link>
        <comment>
         2020; Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib78">
       <label>
        78
       </label>
       <mixed-citation id="sref78" publication-type="other">
        Technology, M.e.g.o.T.h.a.t.T.M.C.o.H.U.o.S.a. A rapid guideline for the diagnosis and treatment of pneumonia with new coronavirus infection (Third edition). . Herald of Medicine 2020 1004-0781,CN 42-1293/R]; Available from:
        <ext-link ext-link-type="uri" id="intref0060" xlink:href="http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html">
         http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib79">
       <label>
        79
       </label>
       <element-citation id="sref79" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Union Hospital
          </surname>
         </name>
        </person-group>
        <article-title>
         T.M.C., Huazhong University of Science and Technology., Wuhan union hospital manage the 2019 new coronavirus infection strategies and instructions
        </article-title>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0065" xlink:href="https://mp.weixin.qq.com/s/d7btF9g1wMhNgFnHy5vY1Q">
         https://mp.weixin.qq.com/s/d7btF9g1wMhNgFnHy5vY1Q
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib80">
       <label>
        80
       </label>
       <element-citation id="sref80" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yinghui Jing
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Zhenshui
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Hong
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Diagnosis and Clinical Management of 2019 Novel Coronavirus (2019-nCoV) Infection: an Operational Recommendation of Peking Union Medical College Hospital. (In Chinese)
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Medical Journal of Chinese People's Liberation Army
        </publisher-name>
        <comment>
         0577-7402,CN 11-1056/R
        </comment>
       </element-citation>
      </ref>
      <ref id="bib81">
       <label>
        81
       </label>
       <element-citation id="sref81" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         W.H., Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection Is Suspected
        </chapter-title>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib82">
       <label>
        82
       </label>
       <element-citation id="sref82" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         New Coronavirus Pneumonia Prevention and Control Program
        </chapter-title>
        <edition>
         fifth ed.
        </edition>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission, 2020
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0070" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib83">
       <label>
        83
       </label>
       <element-citation id="sref83" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib84">
       <label>
        84
       </label>
       <element-citation id="sref84" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside wuhan, China
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib85">
       <label>
        85
       </label>
       <element-citation id="sref85" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           W.-j.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Clinical Characteristics of 2019 Novel Coronavirus Infection in China
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         medRxiv
        </publisher-name>
        <comment>
         2020.02.06.20020974
        </comment>
       </element-citation>
      </ref>
      <ref id="bib86">
       <label>
        86
       </label>
       <element-citation id="sref86" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ai
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of
         <bold>
          1014
         </bold>
         Cases.
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020 Feb 26
        </year>
        <object-id pub-id-type="publisher-id">
         200642
        </object-id>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib87">
       <label>
        87
       </label>
       <element-citation id="sref87" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging coronaviruses: genome structure, replication, and pathogenesis
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         418
        </fpage>
        <lpage>
         423
        </lpage>
        <comment>
         Epub 2020 Feb 7. Review
        </comment>
        <pub-id pub-id-type="pmid">
         31967327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib88">
       <label>
        88
       </label>
       <element-citation id="sref88" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cookson
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Brennan
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pro-inflammatory programmed cell death
        </article-title>
        <source>
         Trends Microbiol.
        </source>
        <volume>
         9
        </volume>
        <issue>
         3
        </issue>
        <year>
         2001
        </year>
        <fpage>
         113
        </fpage>
        <lpage>
         114
        </lpage>
        <pub-id pub-id-type="pmid">
         11303500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib89">
       <label>
        89
       </label>
       <element-citation id="sref89" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           I.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus Viroporin 3a activates the NLRP3 inflammasome
        </article-title>
        <source>
         Front. Microbiol.
        </source>
        <volume>
         10
        </volume>
        <year>
         2019
        </year>
        <fpage>
         50
        </fpage>
        <pub-id pub-id-type="pmid">
         30761102
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib90">
       <label>
        90
       </label>
       <element-citation id="sref90" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Cell Pyroptosis, a Potential Pathogenic Mechanismof 2019 nCoV Infection
        </chapter-title>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib91">
       <label>
        91
       </label>
       <element-citation id="sref91" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Return of the coronavirus: 2019-nCoV
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         12
        </volume>
        <issue>
         2
        </issue>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib92">
       <label>
        92
       </label>
       <element-citation id="sref92" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10224
        </issue>
        <year>
         2020
        </year>
        <fpage>
         565
        </fpage>
        <lpage>
         574
        </lpage>
        <comment>
         Epub 2020 Jan 30
        </comment>
        <pub-id pub-id-type="pmid">
         32007145
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib93">
       <label>
        93
       </label>
       <element-citation id="sref93" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new coronavirus associated with human respiratory disease in China
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2020 Feb 3
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib94">
       <label>
        94
       </label>
       <element-citation id="sref94" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib95">
       <label>
        95
       </label>
       <element-citation id="sref95" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <year>
         2020 Feb 7
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib96">
       <label>
        96
       </label>
       <element-citation id="sref96" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paraskevis
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event
        </article-title>
        <source>
         Infect. Genet. Evol.
        </source>
        <volume>
         79
        </volume>
        <year>
         2020
        </year>
        <fpage>
         104212
        </fpage>
        <pub-id pub-id-type="pmid">
         32004758
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib97">
       <label>
        97
       </label>
       <element-citation id="sref97" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.02.11.944462
        </comment>
       </element-citation>
      </ref>
      <ref id="bib98">
       <label>
        98
       </label>
       <element-citation id="sref98" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <issue>
         6965
        </issue>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib99">
       <label>
        99
       </label>
       <element-citation id="sref99" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bartelink
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         82
        </volume>
        <issue>
         17
        </issue>
        <year>
         2008
        </year>
        <fpage>
         8887
        </fpage>
        <lpage>
         8890
        </lpage>
        <pub-id pub-id-type="pmid">
         18562523
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib100">
       <label>
        100
       </label>
       <element-citation id="sref100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belouzard
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A
        </source>
        <volume>
         106
        </volume>
        <issue>
         14
        </issue>
        <year>
         2009
        </year>
        <fpage>
         5871
        </fpage>
        <lpage>
         5876
        </lpage>
        <pub-id pub-id-type="pmid">
         19321428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib101">
       <label>
        101
       </label>
       <element-citation id="sref101" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glowacka
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <issue>
         9
        </issue>
        <year>
         2011
        </year>
        <fpage>
         4122
        </fpage>
        <lpage>
         4134
        </lpage>
        <pub-id pub-id-type="pmid">
         21325420
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib102">
       <label>
        102
       </label>
       <element-citation id="sref102" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
        </article-title>
        <source>
         Emerg. Microb. Infect.
        </source>
        <volume>
         9
        </volume>
        <issue>
         1
        </issue>
        <year>
         2020
        </year>
        <fpage>
         221
        </fpage>
        <lpage>
         236
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib103">
       <label>
        103
       </label>
       <element-citation id="sref103" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delmas
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Laude
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assembly of coronavirus spike protein into trimers and its role in epitope expression
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         64
        </volume>
        <issue>
         11
        </issue>
        <year>
         1990
        </year>
        <fpage>
         5367
        </fpage>
        <lpage>
         5375
        </lpage>
        <pub-id pub-id-type="pmid">
         2170676
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib104">
       <label>
        104
       </label>
       <element-citation id="sref104" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beniac
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Architecture of the SARS coronavirus prefusion spike
        </article-title>
        <source>
         Nat. Struct. Mol. Biol.
        </source>
        <volume>
         13
        </volume>
        <issue>
         8
        </issue>
        <year>
         2006
        </year>
        <fpage>
         751
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="pmid">
         16845391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib105">
       <label>
        105
       </label>
       <element-citation id="sref105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
        </article-title>
        <source>
         Cell. Mol. Immunol.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib106">
       <label>
        106
       </label>
       <element-citation id="sref106" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <issue>
         4
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1701
        </fpage>
        <lpage>
         1713
        </lpage>
        <pub-id pub-id-type="pmid">
         17108030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib107">
       <label>
        107
       </label>
       <element-citation id="sref107" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         10
        </volume>
        <issue>
         5
        </issue>
        <year>
         2014
        </year>
        <object-id pub-id-type="publisher-id">
         e1004077
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib108">
       <label>
        108
       </label>
       <element-citation id="sref108" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Modular organization of SARS coronavirus nucleocapsid protein
        </article-title>
        <source>
         J. Biomed. Sci.
        </source>
        <volume>
         13
        </volume>
        <issue>
         1
        </issue>
        <year>
         2006
        </year>
        <fpage>
         59
        </fpage>
        <lpage>
         72
        </lpage>
        <pub-id pub-id-type="pmid">
         16228284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib109">
       <label>
        109
       </label>
       <element-citation id="sref109" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hurst
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Koetzner
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         83
        </volume>
        <issue>
         14
        </issue>
        <year>
         2009
        </year>
        <fpage>
         7221
        </fpage>
        <lpage>
         7234
        </lpage>
        <pub-id pub-id-type="pmid">
         19420077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib110">
       <label>
        110
       </label>
       <element-citation id="sref110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA silencing in mammalian cells
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <issue>
         17
        </issue>
        <year>
         2015
        </year>
        <fpage>
         9029
        </fpage>
        <lpage>
         9043
        </lpage>
        <pub-id pub-id-type="pmid">
         26085159
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib111">
       <label>
        111
       </label>
       <element-citation id="sref111" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure, function, and evolution of coronavirus spike proteins
        </article-title>
        <source>
         Annu. Rev. Virol.
        </source>
        <volume>
         3
        </volume>
        <issue>
         1
        </issue>
        <year>
         2016
        </year>
        <fpage>
         237
        </fpage>
        <lpage>
         261
        </lpage>
        <pub-id pub-id-type="pmid">
         27578435
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib112">
       <label>
        112
       </label>
       <element-citation id="sref112" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belouzard
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A.
        </source>
        <volume>
         106
        </volume>
        <issue>
         14
        </issue>
        <year>
         2009
        </year>
        <fpage>
         5871
        </fpage>
        <lpage>
         5876
        </lpage>
        <pub-id pub-id-type="pmid">
         19321428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib113">
       <label>
        113
       </label>
       <element-citation id="sref113" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         84
        </volume>
        <issue>
         24
        </issue>
        <year>
         2010
        </year>
        <fpage>
         12658
        </fpage>
        <lpage>
         12664
        </lpage>
        <pub-id pub-id-type="pmid">
         20926566
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib114">
       <label>
        114
       </label>
       <element-citation id="sref114" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <issue>
         24
        </issue>
        <year>
         2011
        </year>
        <fpage>
         13363
        </fpage>
        <lpage>
         13372
        </lpage>
        <pub-id pub-id-type="pmid">
         21994442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib115">
       <label>
        115
       </label>
       <element-citation id="sref115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <volume>
         100
        </volume>
        <issue>
         3
        </issue>
        <year>
         2013
        </year>
        <fpage>
         605
        </fpage>
        <lpage>
         614
        </lpage>
        <pub-id pub-id-type="pmid">
         24121034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib116">
       <label>
        116
       </label>
       <element-citation id="sref116" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus
        </article-title>
        <source>
         Cell. Mol. Life Sci. : CMLS
        </source>
        <volume>
         61
        </volume>
        <issue>
         21
        </issue>
        <year>
         2004
        </year>
        <fpage>
         2738
        </fpage>
        <lpage>
         2743
        </lpage>
        <pub-id pub-id-type="pmid">
         15549175
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib117">
       <label>
        117
       </label>
       <element-citation id="sref117" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         495
        </volume>
        <issue>
         7440
        </issue>
        <year>
         2013
        </year>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib118">
       <label>
        118
       </label>
       <element-citation id="sref118" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The Novel Coronavirus 2019 (2019-nCoV) Uses the SARS-Coronavirus Receptor ACE2 and the Cellular Protease TMPRSS2 for Entry into Target Cells
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.01.31.929042
        </comment>
       </element-citation>
      </ref>
      <ref id="bib119">
       <label>
        119
       </label>
       <element-citation id="sref119" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Herrmann
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Fast Assessment of Human Receptor-Binding Capability of 2019 Novel Coronavirus (2019-nCoV)
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.02.01.930537
        </comment>
       </element-citation>
      </ref>
      <ref id="bib120">
       <label>
        120
       </label>
       <element-citation id="sref120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         77
        </volume>
        <issue>
         16
        </issue>
        <year>
         2003
        </year>
        <fpage>
         8801
        </fpage>
        <lpage>
         8811
        </lpage>
        <pub-id pub-id-type="pmid">
         12885899
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib121">
       <label>
        121
       </label>
       <element-citation id="sref121" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A
        </source>
        <volume>
         114
        </volume>
        <issue>
         42
        </issue>
        <year>
         2017
        </year>
        <fpage>
         11157
        </fpage>
        <lpage>
         11162
        </lpage>
        <pub-id pub-id-type="pmid">
         29073020
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib122">
       <label>
        122
       </label>
       <element-citation id="sref122" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gui
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding
        </article-title>
        <source>
         Cell Res.
        </source>
        <volume>
         27
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <fpage>
         119
        </fpage>
        <lpage>
         129
        </lpage>
        <pub-id pub-id-type="pmid">
         28008928
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib123">
       <label>
        123
       </label>
       <element-citation id="sref123" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pallesen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A
        </source>
        <volume>
         114
        </volume>
        <issue>
         35
        </issue>
        <year>
         2017
        </year>
        <fpage>
         E7348
        </fpage>
        <lpage>
         E7357
        </lpage>
        <pub-id pub-id-type="pmid">
         28807998
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib124">
       <label>
        124
       </label>
       <element-citation id="sref124" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <volume>
         8
        </volume>
        <year>
         2017
        </year>
        <comment>
         15092-15092
        </comment>
       </element-citation>
      </ref>
      <ref id="bib125">
       <label>
        125
       </label>
       <element-citation id="sref125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unexpected receptor functional mimicry elucidates activation of coronavirus fusion
        </article-title>
        <source>
         Cell
        </source>
        <volume>
         176
        </volume>
        <issue>
         5
        </issue>
        <year>
         2019
        </year>
        <comment>
         1026-1039.e15
        </comment>
       </element-citation>
      </ref>
      <ref id="bib126">
       <label>
        126
       </label>
       <element-citation id="sref126" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chai
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage after 2019-nCoV Infection
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.02.03.931766
        </comment>
       </element-citation>
      </ref>
      <ref id="bib127">
       <label>
        127
       </label>
       <element-citation id="sref127" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The Digestive System Is a Potential Route of 2019-nCov Infection: a Bioinformatics Analysis Based on Single-Cell Transcriptomes
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.01.30.927806
        </comment>
       </element-citation>
      </ref>
      <ref id="bib128">
       <label>
        128
       </label>
       <element-citation id="sref128" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Technical Guideline in Medical Institutions for the Prevention and Control of Infection with the Novel Coronavirus
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0080" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/b91fdab7c304431eb082d67847d27e14.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/b91fdab7c304431eb082d67847d27e14.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib129">
       <label>
        129
       </label>
       <element-citation id="sref129" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Community Prevention and Control Program for the 2019-nCoV Infected Pneumonia
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0085" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/dd1e502534004a8d88b6a10f329a3369.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/dd1e502534004a8d88b6a10f329a3369.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib130">
       <label>
        130
       </label>
       <element-citation id="sref130" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         A Guideline for the Protection of People at Different Risk of New Coronavirus Infection
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0090" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/a3a261dabfcf4c3fa365d4eb07ddab34.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/a3a261dabfcf4c3fa365d4eb07ddab34.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib131">
       <label>
        131
       </label>
       <element-citation id="sref131" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts: interim Guidance
        </article-title>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0095" xlink:href="https://www.who.int/publications-detail/home-carefor-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-withmild-symptoms-and-management-of-contacts">
         https://www.who.int/publications-detail/home-carefor-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-withmild-symptoms-and-management-of-contacts
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib132">
       <label>
        132
       </label>
       <element-citation id="sref132" publication-type="other">
        <comment>
         China., M.o.S.a.T.o.t.P.s.R.o. Clinical trial of antiviral drug remdesivir starts in Wuhan. (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0100" xlink:href="http://www.most.gov.cn/kjbgz/202002/t20200206_151440.htm">
         http://www.most.gov.cn/kjbgz/202002/t20200206_151440.htm
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib133">
       <label>
        133
       </label>
       <element-citation id="sref133" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.-J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Potential Inhibitors for 2019-nCoV Coronavirus M Protease from Clinically Approved Medicines
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.01.29.924100
        </comment>
       </element-citation>
      </ref>
      <ref id="bib134">
       <label>
        134
       </label>
       <element-citation id="sref134" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020 Feb 15
        </year>
        <fpage>
         e30
        </fpage>
        <lpage>
         e31
        </lpage>
        <comment>
         Epub 2020 Feb 4
        </comment>
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib135">
       <label>
        135
       </label>
       <element-citation id="sref135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug treatment options for the 2019-new coronavirus (2019-nCoV)
        </article-title>
        <source>
         Biosci. Trends
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib136">
       <label>
        136
       </label>
       <element-citation id="sref136" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Cell research
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib137">
       <label>
        137
       </label>
       <element-citation id="sref137" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Daily
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First antiviral drug approved to fight coronavirus
        </article-title>
        <comment>
         Feb.17,2002]
        </comment>
        <ext-link ext-link-type="uri" id="intref0105" xlink:href="http://global.chinadaily.com.cn/a/202002/17/WS5e49efc2a310128217277fa3.html">
         http://global.chinadaily.com.cn/a/202002/17/WS5e49efc2a310128217277fa3.html
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib138">
       <label>
        138
       </label>
       <element-citation id="sref138" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ji
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease
        </article-title>
        <source>
         Biomed. Pharmacotherapy = Biomed. Pharmacotherapie
        </source>
        <volume>
         121
        </volume>
        <year>
         2020
        </year>
        <comment>
         109652-109652
        </comment>
       </element-citation>
      </ref>
      <ref id="bib139">
       <label>
        139
       </label>
       <element-citation id="sref139" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function
        </article-title>
        <source>
         BMC Compl. Alternative Med.
        </source>
        <volume>
         17
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <comment>
         130-130
        </comment>
       </element-citation>
      </ref>
      <ref id="bib140">
       <label>
        140
       </label>
       <element-citation id="sref140" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          Commission, C.N.H
         </collab>
        </person-group>
        <chapter-title>
         Guiding Principles for the Intervention of Acute Psychological Crisis in Pneumonia Cases with New Coronavirus Infection. (In Chinese)
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0110" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/6adc08b966594253b2b791be5c3b9467.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/6adc08b966594253b2b791be5c3b9467.shtml
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib141">
       <label>
        141
       </label>
       <element-citation id="sref141" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses - drug discovery and therapeutic options
        </article-title>
        <source>
         Nat. Rev. Drug Discov.
        </source>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <year>
         2016
        </year>
        <fpage>
         327
        </fpage>
        <lpage>
         347
        </lpage>
        <pub-id pub-id-type="pmid">
         26868298
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Sci Rep
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Sci Rep
      </journal-id>
      <journal-title-group>
       <journal-title>
        Scientific Reports
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2045-2322
      </issn>
      <publisher>
       <publisher-name>
        Nature Publishing Group UK
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30976080
      </article-id>
      <article-id pub-id-type="pmc">
       6459860
      </article-id>
      <article-id pub-id-type="publisher-id">
       42355
      </article-id>
      <article-id pub-id-type="doi">
       10.1038/s41598-019-42355-y
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Genome Organization of Canada Goose Coronavirus, A Novel Species Identified in a Mass Die-off of Canada Geese
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Papineau
         </surname>
         <given-names>
          Amber
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Berhane
         </surname>
         <given-names>
          Yohannes
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wylie
         </surname>
         <given-names>
          Todd N.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wylie
         </surname>
         <given-names>
          Kristine M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sharpe
         </surname>
         <given-names>
          Samuel
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0002-0494-1620
        </contrib-id>
        <name>
         <surname>
          Lung
         </surname>
         <given-names>
          Oliver
         </given-names>
        </name>
        <address>
         <email>
          Oliver.Lung@canada.ca
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2177 1232
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.418040.9
         </institution-id>
         <institution>
          National Centre for Foreign Animal Disease,
         </institution>
         <institution>
          Canadian Food Inspection Agency,
         </institution>
        </institution-wrap>
        Winnipeg, MB Canada
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0004 1936 9609
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.21613.37
         </institution-id>
         <institution>
          Department of Biological Sciences,
         </institution>
         <institution>
          University of Manitoba,
         </institution>
        </institution-wrap>
        Winnipeg, MB Canada
       </aff>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2355 7002
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.4367.6
         </institution-id>
         <institution>
          Department of Pediatrics,
         </institution>
         <institution>
          Washington University School of Medicine, St. Louis,
         </institution>
        </institution-wrap>
        St. Louis, MO USA
       </aff>
       <aff id="Aff4">
        <label>
         4
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 2355 7002
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.4367.6
         </institution-id>
         <institution>
          McDonnell Genome Institute,
         </institution>
         <institution>
          Washington University School of Medicine in St. Louis,
         </institution>
        </institution-wrap>
        St. Louis, MO USA
       </aff>
       <aff id="Aff5">
        <label>
         5
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0004 1936 7697
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.22072.35
         </institution-id>
         <institution>
          Faculty of Veterinary Medicine,
         </institution>
         <institution>
          University of Calgary,
         </institution>
        </institution-wrap>
        Calgary, AB Canada
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        11
       </day>
       <month>
        4
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        11
       </day>
       <month>
        4
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       9
      </volume>
      <elocation-id>
       5954
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         14
        </day>
        <month>
         1
        </month>
        <year>
         2019
        </year>
       </date>
       <date date-type="accepted">
        <day>
         25
        </day>
        <month>
         3
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author(s) 2019
       </copyright-statement>
       <license license-type="OpenAccess">
        <license-p>
         <bold>
          Open Access
         </bold>
         This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         .
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p id="Par1">
        The complete genome of a novel coronavirus was sequenced directly from the cloacal swab of a Canada goose that perished in a die-off of Canada and Snow geese in Cambridge Bay, Nunavut, Canada. Comparative genomics and phylogenetic analysis indicate it is a new species of
        <italic>
         Gammacoronavirus
        </italic>
        , as it falls below the threshold of 90% amino acid similarity in the protein domains used to demarcate
        <italic>
         Coronaviridae
        </italic>
        . Additional features that distinguish the genome of Canada goose coronavirus include 6 novel ORFs, a partial duplication of the 4 gene and a presumptive change in the proteolytic processing of polyproteins 1a and 1ab.
       </p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
       <title>
        Subject terms
       </title>
       <kwd>
        Metagenomics
       </kwd>
       <kwd>
        Next-generation sequencing
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution-wrap>
          <institution-id institution-id-type="FundRef">
           https://doi.org/10.13039/100009837
          </institution-id>
          <institution>
           Canadian Food Inspection Agency (Agence Canadienne d&amp;apos;Inspection des Aliments)
          </institution>
         </institution-wrap>
        </funding-source>
        <award-id>
         WIN-A-1408
        </award-id>
        <award-id>
         WIN-A-1408
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Papineau
          </surname>
          <given-names>
           Amber
          </given-names>
         </name>
         <name>
          <surname>
           Lung
          </surname>
          <given-names>
           Oliver
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2019
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1" sec-type="introduction">
     <title>
      Introduction
     </title>
     <p id="Par2">
      Viruses belonging to the
      <italic>
       Coronaviridae
      </italic>
      family have a single stranded positive sense RNA genome of 26–31 kb. Members of this family include both human pathogens, such as severe acute respiratory syndrome virus (SARS-CoV)
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
      </sup>
      , and animal pathogens, such as porcine epidemic diarrhea virus
      <sup>
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
      </sup>
      . Currently, the International Committee on the Taxonomy of Viruses (ICTV) recognizes four genera in the
      <italic>
       Coronaviridae
      </italic>
      family:
      <italic>
       Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Deltacoronavirus
      </italic>
      . While the reservoirs of the
      <italic>
       Alphacoronavirus
      </italic>
      and
      <italic>
       Betacoronavirus
      </italic>
      genera are believed to be bats, the
      <italic>
       Gammacoronavirus
      </italic>
      and
      <italic>
       Deltacoronavirus
      </italic>
      genera have been shown to spread primarily through birds
      <sup>
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
      </sup>
      . The first three species of the
      <italic>
       Deltacoronavirus
      </italic>
      genus were discovered in 2009
      <sup>
       <xref ref-type="bibr" rid="CR4">
        4
       </xref>
      </sup>
      and recent work has vastly expanded the
      <italic>
       Deltacoronavirus
      </italic>
      genus, adding seven additional species
      <sup>
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
      </sup>
      .
     </p>
     <p id="Par3">
      By contrast relatively few species within the
      <italic>
       Gammacoronavirus
      </italic>
      genus have been identified. There are currently two recognized species in the
      <italic>
       Gammacoronavirus
      </italic>
      genus: avian coronavirus (ACoV) and beluga whale coronavirus SW1 (SW1). ACoVs infect multiple avian hosts and include several important poultry pathogens, such as infectious bronchitis virus (IBV) and turkey coronavirus (TCoV)
      <sup>
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
      </sup>
      . IBV was first described in the United States
      <sup>
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
      </sup>
      but has since been described around the globe
      <sup>
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      . Turkey Coronavirus is the cause of acute enteritis in domestic turkeys
      <sup>
       <xref ref-type="bibr" rid="CR8">
        8
       </xref>
      </sup>
      . The second species in the
      <italic>
       Gammacornavirus
      </italic>
      genus SW1 was first discovered in beluga whales
      <sup>
       <xref ref-type="bibr" rid="CR9">
        9
       </xref>
      </sup>
      but has since been detected in other cetaceans, such as Indo-Pacific bottlenose dolphins
      <sup>
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
      </sup>
      . Despite IBV being the first discovered coronavirus and the impact it has on the poultry industry
      <sup>
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
      </sup>
      , the number of identified species within the
      <italic>
       Gammacoronavirus
      </italic>
      genus remains small in comparison to the other coronavirus genera. Coronaviruses from several other avian hosts for which partial sequences are available suggest relatedness to IBV and TCoV. These viruses, which include goose coronavirus (GCoV), were tentatively classified as part of the ACoV species. An approximately 3 kb region, including the nucleocapsid gene and several accessory genes, of GCoV were previously sequenced from a greylag goose in Norway
      <sup>
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
      </sup>
      .
     </p>
     <p id="Par4">
      Here we present the full genome of Canada goose coronavirus (CGCoV) sequenced directly from the cloacal swab of a Canada goose, which expired in a mass die-off in a remote region near the arctic in Nunavut, Canada. Our analyses demonstrate that it should be classified as a novel species in the
      <italic>
       Gammacoronavirus
      </italic>
      genus.
     </p>
    </sec>
    <sec id="Sec2" sec-type="results">
     <title>
      Results and Discussion
     </title>
     <p id="Par5">
      Due to the remote location of the die off, samples from the dead birds were not collected immediately and sent to a diagnostic laboratory until severe predation and decomposition had occurred. The poor sample quality, in addition to the difficulty of coronavirus isolation, led to the failure to isolate infectious virus using standard methods. However, the complete genome of a novel gammacoronavirus was assembled from high throughput sequencing reads derived from the cloacal swab of a single Canada goose. The assembled genome of the novel Canada goose coronavirus (CGCoV) is 28,539 nts in length (excluding the poly(A) tail) and has 38.4% GC-content. The genome of CGCoV is approximately 1000 nts longer than the reference genomes for ACoV available in GenBank. The genome organization of CGCoV is presented in Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      . The 5′ UTR of CGCoV is 553 nt in length and contains a higher GC content (48.3%) relative to the genome as a whole. The 5′ UTR of CGCoV shares only 68% pairwise identity with that of duck coronavirus (DCoV) and 47.5% pairwise identity to that of SW1. Like all coronavirus genomes reported to date, CGCoV’s genome is dominated by the coding regions for the large polyproteins 1a and 1ab, followed by the structural and accessory genes. The heptanucleotide slippery sequence UUUAAAC, associated with the ribosomal slippage that produces polyprotein 1ab, was present at nt positon 11,995. CGCoV’s genome contains genes for all four structural proteins common to coronaviruses; spike (S), envelope (E), membrane (M) and nucleocapsid (N). In addition, CGCoV contains 10 open reading frames (ORFs) predicted to encode accessory proteins. The order of the structural and accessory protein-coding ORFs in CGCoV resembles that of ACoV, but there are notable differences. The general genome organization of ACoV is 1ab-S-3a-3b-E-M-4b-4c-5a-5b-N-6b
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
      </sup>
      . However, there is some variance in the genome organization within the ACoV species. For example, Australian IBV strains lack ORFs 4a, 4b and 5b
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
      </sup>
      . Overall, CGCoV contains a larger number (n = 14) of ORFs coding for predicted accessory and structural proteins downstream of the polyprotein 1ab coding region. Two additional ORFs (7a and 7b) are found between the CGCoV M and N ORFs. There are also two additional ORFs (10 and 11) following the N gene. While some ACoVs do have ORFs following the N gene, ORFs 10 and 11 in CGCoV do not share obvious homology to those of IBV and TCoV. The 3′ UTR of CGCoV is 301 nucleotides in length and contains the stem loop-like motif 113 bp upstream from the poly(A) tail. This stem loop-like motif was first identified in astroviruses
      <sup>
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
      </sup>
      but is also present in ACoVs and SARS-CoV
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
      </sup>
      . Further downstream in the 3′ UTR, the octanucleotide motif (GGAAGAGC) is found 71 bp upstream of the poly(A) tail. The 3′ UTR of CGCoV shares 98% pairwise identity to the partially sequenced GCoV and 84% pairwise identity to IBV.
      <fig id="Fig1">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Genome organization of Canada goose coronavirus. Purple indicates untranslated regions, blue indicates putative proteins, green indicates coding region of mature non-structural proteins (NSP) and red indicates transcription regulatory sequences (TRS). The stem loop-like motif and octamer motif are contained within the 3′ UTR. Genome organization figure was constructed using Geneious
         <sup>
          TM
         </sup>
         (Biomatters, v 9.1.8). *Indicate ACoV 4b homologues. Proteins are named numerically from the 5′ end of the genome, with the exception of the structural genes, which are denoted by their common names.
        </p>
       </caption>
       <graphic id="d29e440" xlink:href="41598_2019_42355_Fig1_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par6">
      A trait suggesting common ancestry between CGCoV and ACoV is the canonical ACoV transcription regulatory sequence (TRS) found at the end of the leader sequence in CGCoV. The TRS of CGCoV is identical to that identified by Cao
      <italic>
       et al
      </italic>
      . (2008) as the TRS of TCoV (CTTAACAAA). Body TRS’s regulate viral gene expression by forming a complex with the leader TRS, causing discontinuous transcription of mRNA
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
      </sup>
      . Ten putative body TRSs were found in the 3′ end of the CGCoV genome (Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ). Four of the ten putative TRSs (4, 6, 8, 9) were exact matches to the canonical leader TRS. Three TRSs (2, 7, 11) contained one mismatch and the remaining three TRSs (3, 5, 10) contained two mismatches to the leader TRS. The functionality of these TRSs would need to be experimentally determined; however, previous studies have shown that TRSs of ACoVs are subject to some variation
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
      </sup>
      . CGCoV contains twice the number of TRS’s as ACoVs and a similar number compared to the nine contained in SW1
      <sup>
       <xref ref-type="bibr" rid="CR9">
        9
       </xref>
      </sup>
      . Table
      <xref ref-type="table" rid="Tab1">
       1
      </xref>
      demonstrates the nucleotide distances between the TRS and the start codon of ORFs found in CGCoV’s, which are comparable to those of TCoV
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
      </sup>
      .
      <table-wrap id="Tab1">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Putative viral proteins of Canada goose coronavirus.
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Protein
          </th>
          <th>
           Top Match in NCBI
          </th>
          <th>
           Top match - aa % identity*
          </th>
          <th>
           Size (aa)
          </th>
          <th>
           Distance between TRS and start codon (nt)
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           1a
          </td>
          <td>
           1a-Infectious bronchitis virus strain B1648
          </td>
          <td>
           43
          </td>
          <td>
           3825
          </td>
          <td>
           480
          </td>
         </tr>
         <tr>
          <td>
           1ab
          </td>
          <td>
           1ab-Infectious bronchitis virus strain ck/CH/LJL/05I
          </td>
          <td>
           57
          </td>
          <td>
           6510
          </td>
          <td>
           480
          </td>
         </tr>
         <tr>
          <td>
           Spike
          </td>
          <td>
           Spike-Infectious bronchitis virus strain N2-75
          </td>
          <td>
           53
          </td>
          <td>
           1184
          </td>
          <td>
           82
          </td>
         </tr>
         <tr>
          <td>
           3
          </td>
          <td>
           n/a
          </td>
          <td>
           n/a
          </td>
          <td>
           53
          </td>
          <td>
           0
          </td>
         </tr>
         <tr>
          <td>
           4a
          </td>
          <td>
           n/a
          </td>
          <td>
           n/a
          </td>
          <td>
           55
          </td>
          <td>
           3
          </td>
         </tr>
         <tr>
          <td>
           Envelope
          </td>
          <td>
           Envelope-Infectious bronchitis virus strain IS-1494
          </td>
          <td>
           69
          </td>
          <td>
           100
          </td>
          <td>
           n/a
          </td>
         </tr>
         <tr>
          <td>
           Membrane
          </td>
          <td>
           Membrane-Duck Coronavirus isolate DK/GD/2014
          </td>
          <td>
           72
          </td>
          <td>
           235
          </td>
          <td>
           74
          </td>
         </tr>
         <tr>
          <td>
           5b
          </td>
          <td>
           4b-Infectious bronchitis virus strain Georgia 1998 Vaccine
          </td>
          <td>
           41
          </td>
          <td>
           88
          </td>
          <td>
           n/a
          </td>
         </tr>
         <tr>
          <td>
           6
          </td>
          <td>
           n/a
          </td>
          <td>
           n/a
          </td>
          <td>
           63
          </td>
          <td>
           5
          </td>
         </tr>
         <tr>
          <td>
           7a
          </td>
          <td>
           4b-Duck Coronavirus isolate DK/GD/2014
          </td>
          <td>
           23
          </td>
          <td>
           92
          </td>
          <td>
           3
          </td>
         </tr>
         <tr>
          <td>
           7b
          </td>
          <td>
           n/a
          </td>
          <td>
           n/a
          </td>
          <td>
           69
          </td>
          <td>
           n/a
          </td>
         </tr>
         <tr>
          <td>
           8a
          </td>
          <td>
           5a-Duck Coronavirus isolate DK/GD/2014
          </td>
          <td>
           37
          </td>
          <td>
           65
          </td>
          <td>
           4
          </td>
         </tr>
         <tr>
          <td>
           8b
          </td>
          <td>
           5b-Duck Coronavirus isolate DK/GD/2014
          </td>
          <td>
           46
          </td>
          <td>
           85
          </td>
          <td>
           n/a
          </td>
         </tr>
         <tr>
          <td>
           Nucleocapsid
          </td>
          <td>
           Nucleocapsid-Goose Coronavirus
          </td>
          <td>
           94
          </td>
          <td>
           414
          </td>
          <td>
           94
          </td>
         </tr>
         <tr>
          <td>
           10
          </td>
          <td>
           ORFxg-Goose Coronavirus
          </td>
          <td>
           92
          </td>
          <td>
           97
          </td>
          <td>
           0
          </td>
         </tr>
         <tr>
          <td>
           11
          </td>
          <td>
           ORFyg-Goose Coronavirus
          </td>
          <td>
           81
          </td>
          <td>
           180
          </td>
          <td>
           91
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         *Matches below 20% coverage not shown.
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="Par7">
      The start codon of CGCoV’s polyprotein 1ab is located 567 nucleotides downstream of the leader TRS. The coronavirus polyprotein 1ab is cleaved into 15–16 non-structural proteins (NSPs) by two viral proteases
      <sup>
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
      </sup>
      . Putative cleavage sites for these proteases are present in CGCoV’s 1a and 1ab polyproteins, with the exception of the NSP 10/11 (polyprotein 1a) and NSP 10/12 (polyprotein 1ab) cleavage sites. The missing cleavage site would be located near the end of polyprotein 1a, producing the NSPs 10 and 11, and also in the alternatively transcribed polyprotein 1ab, producing NSPs 10 and 12. The absence of the NSP10/11 and 10/12 protease recognition site was confirmed with Sanger sequencing. With the exception of the missing cleavage sites, the putative cleavage sites would produce NSPs of sizes congruent with other
      <italic>
       Gammacoronavirus
      </italic>
      species (Table
      <xref ref-type="table" rid="Tab2">
       2
      </xref>
      ). No
      <italic>
       Gammacoronavirus
      </italic>
      species to date, including CGCoV, have a papain-like protease cleavage site between NSP 1-2
      <sup>
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
      </sup>
      .
      <table-wrap id="Tab2">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Non-structural proteins size and cleavage site of gammacoronaviruses.
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th rowspan="2">
           Protein
          </th>
          <th colspan="2">
           CGCoV
          </th>
          <th colspan="2">
           TCoV
          </th>
          <th colspan="2">
           IBV
          </th>
          <th colspan="2">
           SW1
          </th>
         </tr>
         <tr>
          <th>
           Cleavage site
          </th>
          <th>
           Size aa
          </th>
          <th>
           Cleavage site
          </th>
          <th>
           Size aa
          </th>
          <th>
           Cleavage site
          </th>
          <th>
           Size aa
          </th>
          <th>
           Cleavage site
          </th>
          <th>
           Size aa
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           NSP1/2
          </td>
          <td>
           AG^GH
          </td>
          <td>
           609
          </td>
          <td>
           AG^GK
          </td>
          <td>
           673
          </td>
          <td>
           AG^GK
          </td>
          <td>
           673
          </td>
          <td>
           VD^GD
          </td>
          <td>
           636
          </td>
         </tr>
         <tr>
          <td>
           NSP3
          </td>
          <td>
           AG^GV
          </td>
          <td>
           1532
          </td>
          <td>
           AG^GV
          </td>
          <td>
           1594
          </td>
          <td>
           AG^GI
          </td>
          <td>
           1592
          </td>
          <td>
           LG^GV
          </td>
          <td>
           1586
          </td>
         </tr>
         <tr>
          <td>
           NSP4
          </td>
          <td>
           LQ^AG
          </td>
          <td>
           503
          </td>
          <td>
           LQ^AG
          </td>
          <td>
           514
          </td>
          <td>
           LQ^SG
          </td>
          <td>
           514
          </td>
          <td>
           LQ^AG
          </td>
          <td>
           537
          </td>
         </tr>
         <tr>
          <td>
           NSP5
          </td>
          <td>
           LQ^SN
          </td>
          <td>
           307
          </td>
          <td>
           LQ^SS
          </td>
          <td>
           307
          </td>
          <td>
           LQ^SS
          </td>
          <td>
           307
          </td>
          <td>
           LQ^SN
          </td>
          <td>
           303
          </td>
         </tr>
         <tr>
          <td>
           NSP6
          </td>
          <td>
           VQ^SK
          </td>
          <td>
           295
          </td>
          <td>
           VQ^SK
          </td>
          <td>
           297
          </td>
          <td>
           VQ^AK
          </td>
          <td>
           293
          </td>
          <td>
           VQ^SK
          </td>
          <td>
           303
          </td>
         </tr>
         <tr>
          <td>
           NSP7
          </td>
          <td>
           LQ^AV
          </td>
          <td>
           83
          </td>
          <td>
           LQ^SV
          </td>
          <td>
           83
          </td>
          <td>
           LQ^SV
          </td>
          <td>
           83
          </td>
          <td>
           LQ^AV
          </td>
          <td>
           83
          </td>
         </tr>
         <tr>
          <td>
           NSP8
          </td>
          <td>
           LQ^NN
          </td>
          <td>
           212
          </td>
          <td>
           LQ^NN
          </td>
          <td>
           210
          </td>
          <td>
           LQ^NN
          </td>
          <td>
           210
          </td>
          <td>
           LQ^NN
          </td>
          <td>
           198
          </td>
         </tr>
         <tr>
          <td>
           NSP9
          </td>
          <td>
           LQ^GK
          </td>
          <td>
           111
          </td>
          <td>
           LQ^SK
          </td>
          <td>
           111
          </td>
          <td>
           LQ^SK
          </td>
          <td>
           111
          </td>
          <td>
           LQ^HG
          </td>
          <td>
           112
          </td>
         </tr>
         <tr>
          <td>
           NSP10
          </td>
          <td>
           <bold>
            SRFV*
           </bold>
          </td>
          <td>
           <bold>
            173
           </bold>
          </td>
          <td>
           <bold>
            VQ^SA
           </bold>
          </td>
          <td>
           <bold>
            145
           </bold>
          </td>
          <td>
           <bold>
            VQ^SV
           </bold>
          </td>
          <td>
           <bold>
            145
           </bold>
          </td>
          <td>
           <bold>
            LQ^SV
           </bold>
          </td>
          <td>
           <bold>
            189
           </bold>
          </td>
         </tr>
         <tr>
          <td>
           NSP11
          </td>
          <td>
           <bold>
            —
           </bold>
          </td>
          <td>
           <bold>
            —
           </bold>
          </td>
          <td>
           <bold>
            —
           </bold>
          </td>
          <td>
           <bold>
            23
           </bold>
          </td>
          <td>
           <bold>
            —
           </bold>
          </td>
          <td>
           <bold>
            23
           </bold>
          </td>
          <td>
           <bold>
            —
           </bold>
          </td>
          <td>
           <bold>
            17
           </bold>
          </td>
         </tr>
         <tr>
          <td>
           NSP12
          </td>
          <td>
           <bold>
            SRFV*
           </bold>
          </td>
          <td>
           <bold>
            1101
           </bold>
          </td>
          <td>
           <bold>
            VQ^SA
           </bold>
          </td>
          <td>
           <bold>
            941
           </bold>
          </td>
          <td>
           <bold>
            VQ^SV
           </bold>
          </td>
          <td>
           <bold>
            940
           </bold>
          </td>
          <td>
           <bold>
            LQ^SV
           </bold>
          </td>
          <td>
           <bold>
            926
           </bold>
          </td>
         </tr>
         <tr>
          <td>
           NSP13
          </td>
          <td>
           LQ^SC
          </td>
          <td>
           599
          </td>
          <td>
           LQ^SC
          </td>
          <td>
           601
          </td>
          <td>
           LQ^SC
          </td>
          <td>
           600
          </td>
          <td>
           LQ^AS
          </td>
          <td>
           601
          </td>
         </tr>
         <tr>
          <td>
           NSP14
          </td>
          <td>
           LQ^SN
          </td>
          <td>
           522
          </td>
          <td>
           LQ^GT
          </td>
          <td>
           521
          </td>
          <td>
           LQ^GT
          </td>
          <td>
           514
          </td>
          <td>
           LQ^SQ
          </td>
          <td>
           528
          </td>
         </tr>
         <tr>
          <td>
           NSP15
          </td>
          <td>
           LQ^SI
          </td>
          <td>
           338
          </td>
          <td>
           LQ^SI
          </td>
          <td>
           338
          </td>
          <td>
           LQ^SI
          </td>
          <td>
           338
          </td>
          <td>
           LQ^SL
          </td>
          <td>
           349
          </td>
         </tr>
         <tr>
          <td>
           NSP16
          </td>
          <td>
           LQ^SG
          </td>
          <td>
           298
          </td>
          <td>
           LQ^SA
          </td>
          <td>
           302
          </td>
          <td>
           LQ^SA
          </td>
          <td>
           302
          </td>
          <td>
           LQ^SD
          </td>
          <td>
           312
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <p>
         *Amino acids present in CGCoV where putative protease cleavage sites were observed in TCoV, IBV and SW1.
        </p>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="Par8">
      While the genome structure of CGCoV resembles that of ACoV, there are some notable differences. For example, there are no homologues to ACoV’s 3a or 3b accessory proteins in CGCoV, a trait shared with SW1. Furthermore, CGCoV has a number of ORFs that do not appear to have homologues in other sequenced
      <italic>
       Gammacoronavirus
      </italic>
      species, such as the ORFs for putative proteins 3 and 4a (Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ). These two ORFs are found in CGCoV in the corresponding location of ACoV’s 3a and 3b ORFs (between the S and E ORFs) and are also similar in size to ACoV’s 3a and 3b proteins. However, they share no obvious sequence similarity with any 3a or 3b gene, or any other entry in NCBI (Table
      <xref ref-type="table" rid="Tab1">
       1
      </xref>
      ). ACoV’s 3a and 3b proteins have been shown to be unnecessary for replication
      <sup>
       <xref ref-type="bibr" rid="CR20">
        20
       </xref>
      </sup>
      , however knock-out mutants for these accessory genes are attenuated
      <sup>
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
      </sup>
      . The IBV’s 3 gene is functionally tricistronic, meaning the 3a, 3b and E proteins are under the control of a single TRS
      <sup>
       <xref ref-type="bibr" rid="CR22">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
      </sup>
      . This is not the case in CGCoV, as the E ORF of CGCoV shares a TRS with only the 4a ORF in CGCoV and 3 ORF is preceded by a separate TRS (Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ).
     </p>
     <p id="Par9">
      An additional TRS is also found in between CGCoV’s M and N ORFs, preceding the proteins 7a and 7b (Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ). Commonly ACoV’s have two ORFs between the M and 5 genes, coding for the 4b and 4c accessory proteins. CGCoV contains 4 ORFs between the M and 8 gene (ACoV 5 gene homologue). Two of these ORFs (5b and 7a) are ACoV 4b homologues, likely the result of gene duplication. This area in IBV has been identified as a hotspot for recombination
      <sup>
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
      </sup>
      . The region between the ACoV M and 5 gene was formally called the intergenic region because of the lack of a TRS. However, it was later shown that gene 4 is expressed using an alternative TRS in IBV
      <sup>
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
      </sup>
      . Notably, one of the 4b homologs (i.e. 5b) in CGCoV does have a TRS (Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ). The use of template switching at TRSs is thought to lend to recombination in coronaviruses
      <sup>
       <xref ref-type="bibr" rid="CR25">
        25
       </xref>
      </sup>
      . The two CGCoV 4b homologs are not identical to each other (Table
      <xref ref-type="table" rid="Tab1">
       1
      </xref>
      ). Amino acid sequence identity to other 4b proteins is low for both CGCoV 4b homologues, 41% to IBV and 23% to DCoV respectively. The gene 4 duplication was also confirmed by Sanger sequencing of the genomic region between the M ORF to the 8 gene.
     </p>
     <p id="Par10">
      The ACoV 5a and 5b accessory proteins (8a and 8b in CGCoV) appear to be the only accessory proteins conserved in all 3
      <italic>
       Gammacoronavirus
      </italic>
      species, although gene order differs. ORFs encoding putitive proteins 5a and 5b belong to the bicistronic gene 5 of ACoVs and are also unnecessary for replication
      <sup>
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
      </sup>
      . To date, all publically available sequence information suggest that
      <italic>
       Gammacoronavirus
      </italic>
      species have lost the NSP1 cleavage site. The function of NSP1 in alphacoronaviruses and betacoronaviruses is the inhibition of host protein production. Accessory protein 5a is shown to have adopted this function in place of NSP1 in IBV
      <sup>
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
      </sup>
      .
     </p>
     <p id="Par11">
      The majority of structural proteins of CGCoV also share low amino acid sequence identity (53–72%) with IBV and DCoV. Phylogenetic analysis of the spike gene show that the CGCoV spike gene clusters with the IBV spike gene, separate from the TCoV cluster (Fig.
      <xref ref-type="fig" rid="Fig2">
       2a
      </xref>
      ). Figure
      <xref ref-type="fig" rid="Fig2">
       2b
      </xref>
      also demonstrates the nucleocapsid gene of CGCoV is distantly related to those of ACoVs. However the CGCoV nucleocapid protein does share 94% amino acid sequence identity with the nucleocapsid protein encoded in the partially sequenced graylag GCoV genome
      <sup>
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
      </sup>
      . In addition, ORFs 10 and 11, which are preceded by the nucleocapsid gene, also share high amino acid identity with graylag GCoV proteins, 92% and 81% respectively. It should be noted that, among full and partial genomes of gammacoronaviruses sequenced to date, ORFs 10 and 11 seem to be unique to CGCoV and GCoV and are both preceded by a TRS, suggesting that these ORFs are very likely expressed. The fact that some CGCoV proteins share higher amino acid sequence similarity with the partial GCoV sequences available suggest these two viruses are more closely related to each other than to other gammacoronaviruses known to date.
      <fig id="Fig2">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         The phylogeny of gammacoronavirus spike and nucleocapsid proteins. A maximum likelihood tree built, using the amino acid sequences of the spike protein (
         <bold>
          a
         </bold>
         ) and nucleocapsid protein (
         <bold>
          b
         </bold>
         ) domains aligned with ClustalW
         <sup>
          <xref ref-type="bibr" rid="CR31">
           31
          </xref>
         </sup>
         , in MEGA X using the Jones-Taylor-Thornton (JTT) substitution model and 1000 bootstraps
         <sup>
          <xref ref-type="bibr" rid="CR32">
           32
          </xref>
         </sup>
         . IBV Infectious Bronchitis virus, TCoV Turkey Coronavavirus, PCoV Pigeon Coronavirus, DCoV Duck Coronavirus.
        </p>
       </caption>
       <graphic id="d29e1443" xlink:href="41598_2019_42355_Fig2_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par12">
      The phylogenetic tree built using the coding regions for the conserved replicase and helicase domains demonstrates that CGCoV clusters with gammacoronaviruses and shares a more recent common ancestor with ACoV than with the cetacean gammacoronaviruses (Fig.
      <xref ref-type="fig" rid="Fig3">
       3
      </xref>
      ). Further comparisons suggest that CGCoV is a separate species from ACoV. Current taxonomy of
      <italic>
       Coronaviridae
      </italic>
      is determined using pairwise comparisons of the amino acid sequence of seven conserved domains in the 1ab polyprotein. Members of the same species share over 90% amino acid identity in these seven conserved domains
      <sup>
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
      </sup>
      . Percent identity of CGCoV falls well below the 90% threshold set by ICTV with ACoV and SW1, suggesting CGCoV is a separate species (Table
      <xref ref-type="table" rid="Tab3">
       3
      </xref>
      ). Within
      <italic>
       Coronaviridae
      </italic>
      , CGCoV shares the highest homology (68%) in the 7 conserved domains to the gammacoronaviruses TCoV and DCoV.
      <fig id="Fig3">
       <label>
        Figure 3
       </label>
       <caption>
        <p>
         The phylogeny of Canada goose coronavirus. A maximum likelihood tree built, using the concatenated amino acid sequences of the replicase and helicase protein domains aligned with ClustalW
         <sup>
          <xref ref-type="bibr" rid="CR31">
           31
          </xref>
         </sup>
         , in MEGA X using the Jones-Taylor-Thornton (JTT) substitution model and 1000 bootstraps
         <sup>
          <xref ref-type="bibr" rid="CR32">
           32
          </xref>
         </sup>
         . Numbers at nodes indicate the bootstrap value.
        </p>
       </caption>
       <graphic id="d29e1479" xlink:href="41598_2019_42355_Fig3_HTML">
       </graphic>
      </fig>
      <table-wrap id="Tab3">
       <label>
        Table 3
       </label>
       <caption>
        <p>
         Comparison of the amino acid pairwise identity of 7 conserved coronavirus domains in the poly1ab protein of Canada goose coronavirus to other gammacoronaviruses.
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Domain
          </th>
          <th>
           aa % identity to IBV
          </th>
          <th>
           aa % identity to TCoV
          </th>
          <th>
           aa % identity to DCoV
          </th>
          <th>
           aa % Identity to SW1
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           ADP-ribose-1″-phosphatase
          </td>
          <td>
           42
          </td>
          <td>
           43
          </td>
          <td>
           38
          </td>
          <td>
           23
          </td>
         </tr>
         <tr>
          <td>
           3C-like Protease
          </td>
          <td>
           56
          </td>
          <td>
           58
          </td>
          <td>
           57
          </td>
          <td>
           49
          </td>
         </tr>
         <tr>
          <td>
           RdRp
          </td>
          <td>
           80
          </td>
          <td>
           80
          </td>
          <td>
           83
          </td>
          <td>
           69
          </td>
         </tr>
         <tr>
          <td>
           Helicase 1
          </td>
          <td>
           89
          </td>
          <td>
           90
          </td>
          <td>
           92
          </td>
          <td>
           78
          </td>
         </tr>
         <tr>
          <td>
           Exonuclease
          </td>
          <td>
           78
          </td>
          <td>
           72
          </td>
          <td>
           77
          </td>
          <td>
           56
          </td>
         </tr>
         <tr>
          <td>
           Endoribonuclease
          </td>
          <td>
           53
          </td>
          <td>
           53
          </td>
          <td>
           54
          </td>
          <td>
           41
          </td>
         </tr>
         <tr>
          <td>
           Ribose-2′-O methyltransferase
          </td>
          <td>
           74
          </td>
          <td>
           77
          </td>
          <td>
           76
          </td>
          <td>
           65
          </td>
         </tr>
         <tr>
          <td>
           Average
          </td>
          <td>
           67
          </td>
          <td>
           68
          </td>
          <td>
           68
          </td>
          <td>
           54
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
     <p id="Par13">
      As the full genome was sequenced from only the cloacal swab of a single Canada goose, a screening PCR was designed based on the 4b duplication region unique to CGCoV and performed on all samples. The Sanger sequencing primers of the region between the M and 8 gene were used, as this area of the genome is specific to CGCoV. All samples were found to be positive, with the exception of the pharyngeal swab of the snow goose and the lung tissue of the second Canada goose which could not be tested as the sample was exhausted. Amplicons were Sanger sequenced and confirmed to match the CGCoV genome. High throughput sequencing conducted on RNA extracted from cloacal swabs from the second Canada goose and the snow goose also resulted in partial (64 and 18%) genomes of the CGCoV. While this does not confirm the virus’s presence in all animals that perished in the die off, this shows CGCoV was present in all birds that were available for testing. Further studies will require the availability of an infectious virus to determine the pathogenicity of CGCoV and its ability to cause mortality in Canada geese and snow geese.
     </p>
     <p id="Par14">
      To summarize, the complete genome of CGCoV, a novel
      <italic>
       Gammacoronavirus
      </italic>
      species was sequenced directly from the cloacal swab of a Canada goose associated with a mass die-off. The CGCoV genome was also detected in samples derived from a second Canada goose and a snow goose that perished in the die-off, using PCR, Sanger and high throughput sequencing. Comparative genomics and phylogenetic analysis indicate CGCoV clusters with ACoV but is a distinct
      <italic>
       Gammacoronavirus
      </italic>
      species. Interesting features of this new species include the presence of two 4b homologues, a putative change in the proteolytic processing of the polyproteins 1a and 1ab, and six novel accessory genes.
     </p>
    </sec>
    <sec id="Sec3">
     <title>
      Methods
     </title>
     <sec id="Sec4">
      <title>
       Source of samples
      </title>
      <p id="Par15">
       A large die off of Canada and snow geese occurred in the fall of 2017 near the arctic in Cambridge Bay, Nunavut, Canada. Due to poor carcass quality and remote location, samples were only collected from two dead Canada geese and one Snow goose, all of which had undergone predation and decomposition. Cloacal and pharygenal swabs were collected from all three birds, lung tissue was collected from one Canada goose. Other organs were not present or were in extremely poor condition. Detection of both common avian pathogens, such as avian influenza and avian paramyxovirus by the National Reference Laboratory, by routine laboratory testing gave negative results. Virus isolation was performed by two serial passages in SPF chicken eggs using protocols prescribed by the World Organization for Animal Health (OIE) for the most closely related gammacoronavirus, infectious bronchitis virus (IBV). Samples were then subjected to targeted sequence enrichment
       <sup>
        <xref ref-type="bibr" rid="CR26">
         26
        </xref>
       </sup>
       and next-generation sequencing on an Illumina MiSeq platform.
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Sample pre-treatment
      </title>
      <p id="Par16">
       Tissues were homogenized using a Precellys Evolution homogenizer (Bertin Instruments) according to the manufacturer’s instructions. Following a clarification by centrifugation at 3000 rpm for 10 minutes, nucleic acids were extracted using the MagMAX Pathogen RNA/DNA Kit (Ambion) according to the manufacturer’s instructions.
      </p>
      <p id="Par17">
       cDNA synthesis was then performed using SuperScript™ IV First-Strand Synthesis System (SSIV) (ThermoFisher) according to the manufacturer’s recommendation. A total of 11 uL of extracted total nucleic acid was mixed with dNTPS (10 mM) and a tagged random nonamer primer (40 uM) (GTT TCC CAG TCA CGA TAN NNN NNN NN). Samples were incubated at 65 °C for 5 minutes, and then placed on ice for 1 minute. A reagent mixture of 5x SSIV Buffer, Ribonuclease Inhibitor (40 U/μL), DTT (100 mM) and SuperScript™ IV Reverse Transcriptase was then added. The samples were incubated for 10 minutes at 23 °C, 10 minutes at 50 °C and 10 minutes at 80 °C.
      </p>
      <p id="Par18">
       Second strand synthesis was performed using Sequenase Version 2.0 DNA Polymerase (ThermoFisher) according to the manufacturer’s recommendation. The first strand synthesis product was incubated with 10 uL of Sequenase Version 2.0 DNA Polymerase diluted in 5x reaction buffer and nuclease free water. Samples were then heated to 37 °C over five minutes and incubated at 37 °C for 12 minutes, followed by 2 minutes at 95 °C. Samples were then cooled to 10 °C and 1.2 uL of Sequenase DNA polymerase in dilution buffer was added. Samples were again ramped to 37 °C over five minutes and incubated at 37 °C for 12 minutes, followed by 8 minutes at 95 °C. A total of 6 uL of the second strand synthesis product was then used as template for amplification. AccuPrime™
       <italic>
        Taq
       </italic>
       DNA Polymerase (Thermofisher) was mixed with 10X AccuPrime™ PCR Buffer I, nuclease free water and a primer for the nonomer’s tag (100 uM). 30 cycles of PCR were then performed with the following parameters: 30 seconds at 94 °C, 30 seconds at 40 °C, 30 seconds at 50 °C and 1 minute at 72 °C. cDNA/DNA mixtures were then cleaned with Genomic DNA Clean &amp; Concentrator columns (Zymo Research) and eluted in 20 mM Tris (ThermoFisher).
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       Library preparation and sequencing
      </title>
      <p id="Par19">
       Sequence libraries were prepared with the KAPA HyperPlus library kit (Roche). Sequence library construction and capture were carried out according to Nimblegen’s SeqCap EZ HyperCap Workflow User’s Guide v1. Samples were pooled in equal amounts by weight prior to capture. Sequencing was performed on an Illumina Miseq instrument in the National Centre for Foreign Animal Disease biocontainment level 3 sequencing facility. A V2 flow cell was used with a 500 cycle reagent cartridge (Illumina).
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       5′ Race and Sanger sequencing
      </title>
      <p id="Par20">
       5′ RACE was used to obtain the missing leader sequence (52 bp). The SMARTer 5′ RACE and 3′ RACE kit (Takarabio) was used according to the kit instructions. The gene specific primer used for 5′ RACE was TCAGCTACAGTAGAGGGAGATGTCATAGGTGC. For Sanger sequencing, amplicons was performed using KAPA HiFi HotStart ReadyMixPCR Kit (KAPABiosystems). The primers CTAAAGAGAAGGTGGACACTGGT and CTAAGAATGCGAACTTCACAGAGC were used to amplify the gene 4b homologue region. The primers GTTGTTGTGTTACAAGGCAAGGG and GGATTATGATCAAACCATGAACCTGG were used to amplify the NSP 10/12 region. Cycling conditions used to generate amplicon for Sanger sequencing were: 1 cycle: 95 °C for 3 minutes, 40 cycles: 98 °C for 20 seconds, 65 °C for 15 seconds, 72 °C for 2.5 minutes, and 1 cycle: 72 °C for 3 minutes. Amplicons were cleaned using AMPure XP beads (Beckman Coulter) according to the manufacturer’s directions. Sanger sequencing was performed on the ABI Genetic Analyzer 3130XL platform using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) according to the user manual.
      </p>
     </sec>
     <sec id="Sec8">
      <title>
       Bioinformatics
      </title>
      <p id="Par21">
       Read quality was assessed using FastQC and trimmed using Trimmamatic
       <sup>
        <xref ref-type="bibr" rid="CR27">
         27
        </xref>
       </sup>
       (Version 0.36). Host reads were then filtered with RAMBO- K, using the only complete genome of a goose species (
       <italic>
        Anser cygnoides
       </italic>
       ) currently available and DCoV
       <sup>
        <xref ref-type="bibr" rid="CR28">
         28
        </xref>
       </sup>
       . The near complete genome sequence of CGCoV was assembled from NGS derived sequences from a cloacal swab of one Canada goose using SPAdes
       <sup>
        <xref ref-type="bibr" rid="CR29">
         29
        </xref>
       </sup>
       . Sanger reads were aligned to the draft genome in Geneious
       <sup>
        TM
       </sup>
       (Biomatters, v 9.1.8). Annotations were performed using Geneious and protein domains were identified using PFAM
       <sup>
        <xref ref-type="bibr" rid="CR30">
         30
        </xref>
       </sup>
       . The Canada goose coronavirus genome is available under accession number MK359255 on NCBI.
      </p>
     </sec>
    </sec>
    <back>
     <fn-group>
      <fn>
       <p>
        <bold>
         Publisher’s note:
        </bold>
        Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
       </p>
      </fn>
     </fn-group>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       The authors acknowledge funding from Canadian Food Inspection Agency (CFIA) project WIN-A-1408 and Canadian Safety and Security Program project TI-2222 for the student stipend of A.P. The authors would also like to acknowledge Michelle Nebroski and Mathew Fisher for review of the manuscript and technical assistance.
      </p>
     </ack>
     <notes notes-type="author-contribution">
      <title>
       Author Contributions
      </title>
      <p>
       A.P. and O.L. designed the experiment and wrote the main manuscript text. Y.B. and S.S. performed sample collection and routine testing. T.W. and K.W. designed the targeted sequence capture method used for enrichment of viral sequences. A.P. performed the experimental work and performed the analysis. All authors reviewed and approved the manuscript.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Competing Interests
      </title>
      <p id="Par22">
       The authors declare no competing interests.
      </p>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A cluster of cases of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1977
        </fpage>
        <lpage>
         1985
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030666
        </pub-id>
        <pub-id pub-id-type="pmid">
         12671062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wood
          </surname>
          <given-names>
           EN
          </given-names>
         </name>
        </person-group>
        <article-title>
         An apparently new syndrome of porcine epidemic diarrhoea
        </article-title>
        <source>
         Vet. Rec.
        </source>
        <year>
         1977
        </year>
        <volume>
         100
        </volume>
        <fpage>
         243
        </fpage>
        <lpage>
         244
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/vr.100.12.243
        </pub-id>
        <pub-id pub-id-type="pmid">
         888300
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PCY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <fpage>
         3995
        </fpage>
        <lpage>
         4008
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.06540-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PCY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparative analysis of complete genome sequences of three avian coronaviruses reveals a novel group 3c coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <fpage>
         908
        </fpage>
        <lpage>
         917
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01977-08
        </pub-id>
        <pub-id pub-id-type="pmid">
         18971277
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="other">
        de Groot, R. J.
        <italic>
         et al
        </italic>
        . Revision of the family Coronaviridae.
        <italic>
         Taxonomic proposal to the ICTV Executive Committee
        </italic>
        , 1–37 (2008).
       </mixed-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fabricant
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         The early history of infectious bronchitis
        </article-title>
        <source>
         Avian Dis.
        </source>
        <year>
         1998
        </year>
        <volume>
         42
        </volume>
        <fpage>
         648
        </fpage>
        <lpage>
         650
        </lpage>
        <pub-id pub-id-type="doi">
         10.2307/1592697
        </pub-id>
        <pub-id pub-id-type="pmid">
         9876830
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bande
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Global distributions and strain diversity of avian infectious bronchitis virus: a review
        </article-title>
        <source>
         Anim. Health Res. Rev.
        </source>
        <year>
         2017
        </year>
        <volume>
         18
        </volume>
        <fpage>
         70
        </fpage>
        <lpage>
         83
        </lpage>
        <pub-id pub-id-type="doi">
         10.1017/S1466252317000044
        </pub-id>
        <pub-id pub-id-type="pmid">
         28776490
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Characterization of turkey coronavirus from turkey poults with acute enteritis
        </article-title>
        <source>
         Vet. Microbiol.
        </source>
        <year>
         2002
        </year>
        <volume>
         84
        </volume>
        <fpage>
         179
        </fpage>
        <lpage>
         186
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0378-1135(01)00447-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         11731170
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mihindukulasuriya
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           St Leger
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Nordhausen
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a novel coronavirus from a beluga whale by using a panviral microarray
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         5084
        </fpage>
        <lpage>
         5088
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02722-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         18353961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PCY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of a novel bottlenose dolphin coronavirus reveals a distinct species of marine mammal coronavirus in Gammacoronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         1318
        </fpage>
        <lpage>
         1331
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02351-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24227844
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral respiratory diseases (ILT, aMPV infections, IB): are they ever under control?
        </article-title>
        <source>
         Br. Poult. Sci.
        </source>
        <year>
         2010
        </year>
        <volume>
         51
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/00071660903541378
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jonassen
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular identification and characterization of novel coronaviruses infecting graylag geese (Anser anser), feral pigeons (Columbia livia) and mallards (Anas platyrhynchos)
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         86
        </volume>
        <fpage>
         1597
        </fpage>
        <lpage>
         1607
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.80927-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         15914837
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           C-C
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complete nucleotide sequence of polyprotein gene 1 and genome organization of turkey coronavirus
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2008
        </year>
        <volume>
         136
        </volume>
        <fpage>
         43
        </fpage>
        <lpage>
         49
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2008.04.015
        </pub-id>
        <pub-id pub-id-type="pmid">
         18514348
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mardani
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Noormohammadi
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Ignjatovic
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Browning
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious bronchitis viruses with a novel genomic organization
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         2013
        </fpage>
        <lpage>
         2024
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01694-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         18045937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jonassen
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Jonassen
          </surname>
          <given-names>
           TO
          </given-names>
         </name>
         <name>
          <surname>
           Grinde
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         A common RNA motif in the 3′ end of the genomes of astroviruses, avian infectious bronchitis virus and an equine rhinovirus
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         1998
        </year>
        <volume>
         79
        </volume>
        <issue>
         Pt 4
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         718
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/0022-1317-79-4-715
        </pub-id>
        <pub-id pub-id-type="pmid">
         9568965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dufour
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Mateos-Gomez
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Gallego
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure and functional relevance of a transcription-regulating sequence involved in coronavirus discontinuous RNA synthesis
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         4963
        </fpage>
        <lpage>
         4973
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02317-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         21389138
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bentley
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Keep
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Armesto
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Britton
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a noncanonically transcribed subgenomic mRNA of infectious bronchitis virus and other gammacoronaviruses
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         2128
        </fpage>
        <lpage>
         2136
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02967-12
        </pub-id>
        <pub-id pub-id-type="pmid">
         23221558
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ziebuhr
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Snijder
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Virus-encoded proteinases and proteolytic processing in the Nidovirales
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2000
        </year>
        <volume>
         81
        </volume>
        <fpage>
         853
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/0022-1317-81-4-853
        </pub-id>
        <pub-id pub-id-type="pmid">
         10725411
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kint
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infectious bronchitis coronavirus limits interferon production by inducing a host shutoff that requires accessory protein 5b
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2016
        </year>
        <volume>
         90
        </volume>
        <fpage>
         7519
        </fpage>
        <lpage>
         7528
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00627-16
        </pub-id>
        <pub-id pub-id-type="pmid">
         27279618
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hodgson
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Britton
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neither the RNA nor the proteins of open reading frames 3a and 3b of the coronavirus infectious bronchitis virus are essential for replication
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         80
        </volume>
        <fpage>
         296
        </fpage>
        <lpage>
         305
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.80.1.296-305.2006
        </pub-id>
        <pub-id pub-id-type="pmid">
         16352554
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Laconi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Deletion of accessory genes 3a, 3b, 5a or 5b from avian coronavirus infectious bronchitis virus induces an attenuated phenotype both
         <italic>
          in vitro
         </italic>
         and
         <italic>
          in vivo
         </italic>
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2018
        </year>
        <volume>
         99
        </volume>
        <fpage>
         1381
        </fpage>
        <lpage>
         1390
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jgv.0.001130
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           DX
          </given-names>
         </name>
         <name>
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Inglis
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
        </person-group>
        <article-title>
         A polycistronic mRNA specified by the coronavirus infectious bronchitis virus
        </article-title>
        <source>
         Virology
        </source>
        <year>
         1991
        </year>
        <volume>
         184
        </volume>
        <fpage>
         531
        </fpage>
        <lpage>
         544
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/0042-6822(91)90423-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         1653486
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brooks
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparisons of envelope through 5B sequences of infectious bronchitis coronaviruses indicates recombination occurs in the envelope and membrane genes
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2004
        </year>
        <volume>
         100
        </volume>
        <fpage>
         191
        </fpage>
        <lpage>
         198
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2003.11.016
        </pub-id>
        <pub-id pub-id-type="pmid">
         15019237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hewson
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Ignjatovic
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Browning
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
         <name>
          <surname>
           Devlin
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Noormohammadi
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious bronchitis viruses with naturally occurring genomic rearrangement and gene deletion
        </article-title>
        <source>
         Arch. Virol.
        </source>
        <year>
         2011
        </year>
        <volume>
         156
        </volume>
        <fpage>
         245
        </fpage>
        <lpage>
         252
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00705-010-0850-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         21049275
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simon-Loriere
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Why do RNA viruses recombine?
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2011
        </year>
        <volume>
         9
        </volume>
        <fpage>
         617
        </fpage>
        <lpage>
         626
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro2614
        </pub-id>
        <pub-id pub-id-type="pmid">
         21725337
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wylie
          </surname>
          <given-names>
           TN
          </given-names>
         </name>
         <name>
          <surname>
           Wylie
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Herter
          </surname>
          <given-names>
           BN
          </given-names>
         </name>
         <name>
          <surname>
           Storch
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enhanced virome sequencing using targeted sequence capture
        </article-title>
        <source>
         Genome Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         25
        </volume>
        <fpage>
         1910
        </fpage>
        <lpage>
         1920
        </lpage>
        <pub-id pub-id-type="doi">
         10.1101/gr.191049.115
        </pub-id>
        <pub-id pub-id-type="pmid">
         26395152
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bolger
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Lohse
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Usadel
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Trimmomatic: a flexible trimmer for Illumina sequence data
        </article-title>
        <source>
         Bioinformatics
        </source>
        <year>
         2014
        </year>
        <volume>
         30
        </volume>
        <fpage>
         2114
        </fpage>
        <lpage>
         2120
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/bioinformatics/btu170
        </pub-id>
        <pub-id pub-id-type="pmid">
         24695404
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tausch
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Renard
          </surname>
          <given-names>
           BY
          </given-names>
         </name>
         <name>
          <surname>
           Nitsche
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dabrowski
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
        </person-group>
        <article-title>
         RAMBO-K: Rapid and Sensitive Removal of Background Sequences from Next Generation Sequencing Data
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2015
        </year>
        <volume>
         10
        </volume>
        <fpage>
         e0137896
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0137896
        </pub-id>
        <pub-id pub-id-type="pmid">
         26379285
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bankevich
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing
        </article-title>
        <source>
         J. Comput. Biol.
        </source>
        <year>
         2012
        </year>
        <volume>
         19
        </volume>
        <fpage>
         455
        </fpage>
        <lpage>
         477
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/cmb.2012.0021
        </pub-id>
        <pub-id pub-id-type="pmid">
         22506599
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           El-Gebali
          </surname>
          <given-names>
           Sara
          </given-names>
         </name>
         <name>
          <surname>
           Mistry
          </surname>
          <given-names>
           Jaina
          </given-names>
         </name>
         <name>
          <surname>
           Bateman
          </surname>
          <given-names>
           Alex
          </given-names>
         </name>
         <name>
          <surname>
           Eddy
          </surname>
          <given-names>
           Sean R
          </given-names>
         </name>
         <name>
          <surname>
           Luciani
          </surname>
          <given-names>
           Aurélien
          </given-names>
         </name>
         <name>
          <surname>
           Potter
          </surname>
          <given-names>
           Simon C
          </given-names>
         </name>
         <name>
          <surname>
           Qureshi
          </surname>
          <given-names>
           Matloob
          </given-names>
         </name>
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           Lorna J
          </given-names>
         </name>
         <name>
          <surname>
           Salazar
          </surname>
          <given-names>
           Gustavo A
          </given-names>
         </name>
         <name>
          <surname>
           Smart
          </surname>
          <given-names>
           Alfredo
          </given-names>
         </name>
         <name>
          <surname>
           Sonnhammer
          </surname>
          <given-names>
           Erik L L
          </given-names>
         </name>
         <name>
          <surname>
           Hirsh
          </surname>
          <given-names>
           Layla
          </given-names>
         </name>
         <name>
          <surname>
           Paladin
          </surname>
          <given-names>
           Lisanna
          </given-names>
         </name>
         <name>
          <surname>
           Piovesan
          </surname>
          <given-names>
           Damiano
          </given-names>
         </name>
         <name>
          <surname>
           Tosatto
          </surname>
          <given-names>
           Silvio C E
          </given-names>
         </name>
         <name>
          <surname>
           Finn
          </surname>
          <given-names>
           Robert D
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Pfam protein families database in 2019
        </article-title>
        <source>
         Nucleic Acids Research
        </source>
        <year>
         2018
        </year>
        <volume>
         47
        </volume>
        <issue>
         D1
        </issue>
        <fpage>
         D427
        </fpage>
        <lpage>
         D432
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/nar/gky995
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Larkin
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clustal W and Clustal X version 2.0
        </article-title>
        <source>
         Bioinformatics
        </source>
        <year>
         2007
        </year>
        <volume>
         23
        </volume>
        <fpage>
         2947
        </fpage>
        <lpage>
         2948
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/bioinformatics/btm404
        </pub-id>
        <pub-id pub-id-type="pmid">
         17846036
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Knyaz
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Tamura
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms
        </article-title>
        <source>
         Mol. Biol. Evol.
        </source>
        <year>
         2018
        </year>
        <volume>
         35
        </volume>
        <fpage>
         1547
        </fpage>
        <lpage>
         1549
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/molbev/msy096
        </pub-id>
        <pub-id pub-id-type="pmid">
         29722887
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Trends Microbiol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Trends Microbiol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Trends in Microbiology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0966-842X
      </issn>
      <issn pub-type="epub">
       1878-4380
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       27012512
      </article-id>
      <article-id pub-id-type="pmc">
       7125511
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0966-842X(16)00071-8
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.tim.2016.03.003
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="aut0005">
        <name>
         <surname>
          Su
         </surname>
         <given-names>
          Shuo
         </given-names>
        </name>
        <email>
         shuosu@njau.edu.cn
        </email>
        <xref ref-type="aff" rid="aff0005">
         1
        </xref>
        <xref ref-type="corresp" rid="cor0005">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0010">
        <name>
         <surname>
          Wong
         </surname>
         <given-names>
          Gary
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0010">
         2
        </xref>
        <xref ref-type="aff" rid="aff0015">
         3
        </xref>
        <xref ref-type="aff" rid="aff0020">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0015">
        <name>
         <surname>
          Shi
         </surname>
         <given-names>
          Weifeng
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0025">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0020">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          Jun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0020">
         4
        </xref>
        <xref ref-type="aff" rid="aff0030">
         6
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0025">
        <name>
         <surname>
          Lai
         </surname>
         <given-names>
          Alexander C.K.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0035">
         7
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0030">
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Jiyong
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0005">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0035">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          Wenjun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0015">
         3
        </xref>
        <xref ref-type="aff" rid="aff0020">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0040">
        <name>
         <surname>
          Bi
         </surname>
         <given-names>
          Yuhai
         </given-names>
        </name>
        <email>
         beeyh@im.ac.cn
        </email>
        <xref ref-type="aff" rid="aff0010">
         2
        </xref>
        <xref ref-type="aff" rid="aff0015">
         3
        </xref>
        <xref ref-type="aff" rid="aff0020">
         4
        </xref>
        <xref ref-type="corresp" rid="cor0005">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0045">
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          George F.
         </given-names>
        </name>
        <email>
         gaof@im.ac.cn
        </email>
        <xref ref-type="aff" rid="aff0010">
         2
        </xref>
        <xref ref-type="aff" rid="aff0015">
         3
        </xref>
        <xref ref-type="aff" rid="aff0020">
         4
        </xref>
        <xref ref-type="aff" rid="aff0030">
         6
        </xref>
        <xref ref-type="aff" rid="aff0040">
         8
        </xref>
        <xref ref-type="aff" rid="aff0045">
         9
        </xref>
        <xref ref-type="corresp" rid="cor0005">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0005">
       <label>
        1
       </label>
       Engineering Laboratory of Animal Immunity of Jiangsu Province, Institute of immunology and College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China
      </aff>
      <aff id="aff0010">
       <label>
        2
       </label>
       Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Shenzhen, China
      </aff>
      <aff id="aff0015">
       <label>
        3
       </label>
       CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
      </aff>
      <aff id="aff0020">
       <label>
        4
       </label>
       CAS Center for Influenza Research and Early-Warning (CASCIRE), Chinese Academy of Sciences, Beijing, China
      </aff>
      <aff id="aff0025">
       <label>
        5
       </label>
       Institute of Pathogen Biology, Taishan Medical College, Taian, China
      </aff>
      <aff id="aff0030">
       <label>
        6
       </label>
       National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
      </aff>
      <aff id="aff0035">
       <label>
        7
       </label>
       Kentucky State University, Frankfort, Kentucky, USA
      </aff>
      <aff id="aff0040">
       <label>
        8
       </label>
       Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, Zhejiang University, Hangzhou, China
      </aff>
      <aff id="aff0045">
       <label>
        9
       </label>
       University of Chinese Academy of Sciences Medical School, Chinese Academy of Sciences, Beijing, China
      </aff>
      <author-notes>
       <corresp id="cor0005">
        <label>
         ⁎
        </label>
        Correspondence:
        <email>
         shuosu@njau.edu.cn
        </email>
        <email>
         beeyh@im.ac.cn
        </email>
        <email>
         gaof@im.ac.cn
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        21
       </day>
       <month>
        3
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        6
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        21
       </day>
       <month>
        3
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <volume>
       24
      </volume>
      <issue>
       6
      </issue>
      <fpage>
       490
      </fpage>
      <lpage>
       502
      </lpage>
      <permissions>
       <copyright-statement>
        © 2016 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2016
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0005">
       <p>
        Human coronaviruses (HCoVs) were first described in the 1960s for patients with the common cold. Since then, more HCoVs have been discovered, including those that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), two pathogens that, upon infection, can cause fatal respiratory disease in humans. It was recently discovered that dromedary camels in Saudi Arabia harbor three different HCoV species, including a dominant MERS HCoV lineage that was responsible for the outbreaks in the Middle East and South Korea during 2015. In this review we aim to compare and contrast the different HCoVs with regard to epidemiology and pathogenesis, in addition to the virus evolution and recombination events which have, on occasion, resulted in outbreaks amongst humans.
       </p>
      </abstract>
      <abstract abstract-type="author-highlights" id="abs0010">
       <title>
        Trends
       </title>
       <p>
        Six coronaviruses (CoVs) are known to infect humans: 229E, OC43, SARS-CoV, NL63, HKU1, and MERS-CoV.
       </p>
       <p>
        Many CoVs are simultaneously maintained in nature, allowing for genetic recombination, resulting in novel viruses.
       </p>
       <p>
        Recombination of CoV in camels has resulted in a dominant MERS lineage that caused human outbreaks in 2015.
       </p>
      </abstract>
      <kwd-group id="kwd0005">
       <title>
        Keywords
       </title>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        MERS
       </kwd>
       <kwd>
        SARS
       </kwd>
       <kwd>
        evolution
       </kwd>
       <kwd>
        recombination
       </kwd>
       <kwd>
        pathogenesis
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec0005">
     <title>
      A Brief Introduction to Human and Animal Coronaviruses
     </title>
     <p id="par0005">
      Coronaviruses (CoVs), of the family Coronaviridae, are enveloped viruses with a single-strand, positive-sense RNA genome approximately 26–32 kilobases in size, which is the largest known genome for an RNA virus
      <xref ref-type="bibr" rid="bib0005">
       [1]
      </xref>
      . The term ‘coronavirus’ refers to the appearance of CoV virions when observed under electron microscopy, in which spike projections from the virus membrane give the semblance of a crown, or
      <italic>
       corona
      </italic>
      in Latin
      <xref ref-type="bibr" rid="bib0010">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0015">
       3
      </xref>
      . All coronaviruses share similarities in the organization and expression of their genome, in which 16 nonstructural proteins (nsp1 through nsp16), encoded by open reading frame (ORF) 1a/b at the 5′ end, are followed by the structural proteins spike (S), envelope (E), membrane (M), and nucleocapsid (N), which are encoded by other ORFs at the 3′ end. CoVs are separated into four genera based on phylogeny: alpha-CoV (group 1), beta-CoV (group 2), gamma-CoV (group 3) and delta-CoV (group 4) (
      <ext-link ext-link-type="uri" id="intr0005" xlink:href="http://ictvonline.org/proposals/2008.085-122%20V.v4.Coronaviridae.pdf">
       http://ictvonline.org/proposals/2008.085-122 V.v4.Coronaviridae.pdf
      </ext-link>
      ). Within the beta-CoV genus, four lineages (A, B, C, and D) are recognized. Distinct from other beta-CoV lineages, lineage A viruses also encode a smaller protein called hemagglutinin esterase (HE), which is functionally similar to the S protein
      <xref ref-type="bibr" rid="bib0020">
       [4]
      </xref>
      .
     </p>
     <p id="par0010">
      Since the early 1970s, a variety of pathological conditions in domestic animals have been attributed to CoV infections
      <xref ref-type="bibr" rid="bib0025">
       [5]
      </xref>
      . With the exception of infectious bronchitis virus (IBV), which causes avian infectious bronchitis in chickens
      <xref ref-type="bibr" rid="bib0030">
       [6]
      </xref>
      , canine respiratory coronavirus (CRCoV), which causes respiratory disease in dogs
      <xref ref-type="bibr" rid="bib0035">
       [7]
      </xref>
      , and mouse hepatitis virus (MHV), which can cause a progressive demyelinating encephalitis in mice
      <xref ref-type="bibr" rid="bib0015">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0040">
       8
      </xref>
      , other CoV infections typically result in gastrointestinal symptoms. For instance, transmissible gastroenteritis coronavirus (TGEV)
      <xref ref-type="bibr" rid="bib0045">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0050">
       10
      </xref>
      , bovine coronavirus (BCV)
      <xref ref-type="bibr" rid="bib0055">
       [11]
      </xref>
      , feline coronavirus (FCoV)
      <xref ref-type="bibr" rid="bib0060">
       [12]
      </xref>
      , canine coronavirus (CCoV)
      <xref ref-type="bibr" rid="bib0065">
       [13]
      </xref>
      , and turkey coronavirus (TCV)
      <xref ref-type="bibr" rid="bib0070">
       [14]
      </xref>
      are known to cause enteritis in their respective hosts
      <xref ref-type="bibr" rid="bib0005">
       [1]
      </xref>
      .
     </p>
     <p id="par0015">
      In humans, CoV infections primarily involve the upper respiratory tract and the gastrointestinal tract, and vary from mild, self-limiting disease, such as the common cold, to more severe manifestations, such as bronchitis and pneumonia with renal involvement
      <xref ref-type="bibr" rid="bib0075">
       [15]
      </xref>
      . The first human coronavirus (HCoV) was isolated during 1965 from the nasal discharge of patients with the common cold and termed B814
      <xref ref-type="bibr" rid="bib0080">
       [16]
      </xref>
      . Currently, six different CoV strains are known to infect humans. These include: HCoV-229E (229E), HCoV-OC43 (OC43), severe acute respiratory syndrome coronavirus (SARS-CoV), HCoV-NL63 (NL63), HCoV-HKU1 (HKU1), and Middle East respiratory syndrome coronavirus (MERS-CoV)
      <xref ref-type="bibr" rid="bib0085">
       [17]
      </xref>
      . 229E and OC43 are the prototype viruses from the two main HCoV lineages (Alpha and Beta, respectively) that cause 15–29% of all common colds, and are the best characterized
      <xref ref-type="bibr" rid="bib0090">
       [18]
      </xref>
      . SARS-CoV is the aetiological agent that was behind an outbreak of severe respiratory disease through China during 2002–2003
      <xref ref-type="bibr" rid="bib0095">
       [19]
      </xref>
      , and MERS-CoV is the pathogen responsible for an ongoing outbreak of severe respiratory disease centered in the Middle East since 2012
      <xref ref-type="bibr" rid="bib0100">
       [20]
      </xref>
      . In this review, we first compare and contrast the epidemiology and pathogenesis of the known CoVs infecting humans, in which CoVs that cause mild to severe disease in humans are newly emerged from a zoonotic source. Second, we describe the ecology of CoVs, and highlight evidence for viral recombination between the different CoVs within animal populations, which may result in the generation of novel CoVs that are transmissible and lethal to humans. Finally, we summarize the phylogeny, evolution, and genetic recombination of CoVs in detail.
     </p>
    </sec>
    <sec id="sec0010">
     <title>
      Epidemiology and Pathogenesis of HCoV
     </title>
     <p id="par0020">
      The epidemiology and pathogenesis of each HCoV are discussed within the following sections and summarized in
      <xref ref-type="table" rid="tbl0005">
       Table 1
      </xref>
      and
      <xref ref-type="fig" rid="fig0005">
       Figure 1
      </xref>
      , respectively. In general, 229E, OC43, and NL63 are distributed globally (
      <xref ref-type="fig" rid="fig0005">
       Figure 1
      </xref>
      A) and tend to be transmitted predominantly during the winter season in temperate-climate countries
      <xref ref-type="bibr" rid="bib0105">
       [21]
      </xref>
      , while NL63 showed a spring–summer peak of activity from a study in Hong Kong
      <xref ref-type="bibr" rid="bib0110">
       [22]
      </xref>
      .
      <table-wrap id="tbl0005" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Comparison of Clinical Symptoms, Incubation Time, Median Time to Death, and Case Fatality Rates of Human Coronaviruses
        </p>
       </caption>
       <alt-text id="at1">
        Table 1
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           HCoV
          </th>
          <th align="left">
           Clinical Symptoms
          </th>
          <th align="left">
           Case Fatality Rate
          </th>
          <th align="left">
           Incubation Period
          </th>
          <th align="left">
           Median Time to Death
          </th>
          <th align="left">
           Refs
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           229E
          </td>
          <td align="left">
           General malaise
           <break>
           </break>
           Headache
           <break>
           </break>
           Nasal discharge
           <break>
           </break>
           Sneezing
           <break>
           </break>
           Sore throat
           <break>
           </break>
           Fever and cough (10–20% of patients)
          </td>
          <td align="left">
           N/A
           <xref ref-type="table-fn" rid="tblfn0005">
            a
           </xref>
          </td>
          <td align="left">
           2–5 days
          </td>
          <td align="left">
           —
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0090">
            18
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0405">
            81
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0410">
            82
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           OC43
          </td>
          <td align="left">
           General malaise
           <break>
           </break>
           Headache
           <break>
           </break>
           Nasal discharge
           <break>
           </break>
           Sneezing
           <break>
           </break>
           Sore throat
           <break>
           </break>
           Fever and cough (10–20% of patients)
          </td>
          <td align="left">
           N/A
          </td>
          <td align="left">
           2–5 days
          </td>
          <td align="left">
           —
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0090">
            18
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0410">
            82
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0415">
            83
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0420">
            84
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           SARS-CoV
          </td>
          <td align="left">
           Fever
           <break>
           </break>
           Myalgia
           <break>
           </break>
           Headache
           <break>
           </break>
           Malaise
           <break>
           </break>
           Chills
           <break>
           </break>
           Nonproductive cough
           <break>
           </break>
           Dyspnea
           <break>
           </break>
           Respiratory distress
           <break>
           </break>
           Diarrhea (30–40% of patients)
          </td>
          <td align="left">
           9%
          </td>
          <td align="left">
           2–11 days
          </td>
          <td align="left">
           23 days
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0095">
            19
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0210">
            42
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0425">
            85
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0430">
            86
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0435">
            87
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0440">
            88
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           NL63
          </td>
          <td align="left">
           Cough, Rhinorrhea
           <break>
           </break>
           Tachypnea
           <break>
           </break>
           Fever
           <break>
           </break>
           Hypoxia
           <break>
           </break>
           Obstructive laryngitis (croup)
          </td>
          <td align="left">
           N/A
          </td>
          <td align="left">
           2–4 days
          </td>
          <td align="left">
           —
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0445">
            89
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0450">
            90
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0455">
            91
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0460">
            92
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           HKU1
          </td>
          <td align="left">
           Fever
           <break>
           </break>
           Running nose
           <break>
           </break>
           Cough
           <break>
           </break>
           Dyspnea
          </td>
          <td align="left">
           N/A
          </td>
          <td align="left">
           2–4 days
          </td>
          <td align="left">
           —
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0010">
            2
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0160">
            32
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0165">
            33
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0170">
            34
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0465">
            93
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0470">
            94
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           MERS-CoV
          </td>
          <td align="left">
           Fever
           <break>
           </break>
           Cough
           <break>
           </break>
           Chills
           <break>
           </break>
           Sore throat
           <break>
           </break>
           Myalgia
           <break>
           </break>
           Arthralgia
           <break>
           </break>
           Dyspnea
           <break>
           </break>
           Pneumonia
           <break>
           </break>
           Diarrhea and vomiting (one-third of patients)
           <break>
           </break>
           Acute renal impairment
          </td>
          <td align="left">
           36%
          </td>
          <td align="left">
           2–13 days
          </td>
          <td align="left">
           14 days
          </td>
          <td align="left">
           <xref ref-type="bibr" rid="bib0205">
            41
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0210">
            42
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0215">
            43
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0475">
            95
           </xref>
           ,
           <xref ref-type="bibr" rid="bib0480">
            96
           </xref>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="tblfn0005">
         <label>
          a
         </label>
         <p id="npar0005">
          N/A, not applicable.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <fig id="fig0005">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Global Distribution of Human Coronaviruses. (A) Green, blue, brown, and purple represent the global distribution of the NL63, HKU1, OC43, and 229E human coronaviruses, respectively. (B) Red and yellow represent the global distribution of MERS-CoV and SARS-CoV, respectively.
        </p>
       </caption>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
     <sec id="sec0015">
      <title>
       Human Coronavirus 229E (alphacoronavirus)
      </title>
      <p id="par0025">
       Strain 229E was discovered during 1966, when researchers were characterizing five novel agents that were isolated from the respiratory tract of humans who had contracted the common cold
       <xref ref-type="bibr" rid="bib0115">
        [23]
       </xref>
       . 229E was adapted to grow in WI-38 lung fibroblast cell lines, and was later shown to be morphologically identical to IBV and MHV
       <xref ref-type="bibr" rid="bib0120">
        [24]
       </xref>
       . Symptoms of 229E infection include general malaise, headache, nasal discharge, sneezing, and a sore throat
       <xref ref-type="bibr" rid="bib0125">
        [25]
       </xref>
       . A small portion of patients (10–20%) will also exhibit fever and cough. The incubation time is approximately 2–5 days, followed by illness lasting between 2 and 18 days, and clinically indistinguishable from respiratory tract infections caused by other pathogens, such as rhinovirus and influenza A
       <xref ref-type="bibr" rid="bib0090">
        [18]
       </xref>
       . 229E is distributed globally (
       <xref ref-type="fig" rid="fig0005">
        Figure 1
       </xref>
       A).
      </p>
     </sec>
     <sec id="sec0020">
      <title>
       Human Coronavirus OC43 (betacoronavirus, lineage A)
      </title>
      <p id="par0030">
       Strain OC43 was discovered, during 1967, in the nasopharyngeal wash of a patient with the common cold, and is adapted to grow in organ cultures containing suckling mouse brains. Similar to 229E, OC43 is morphologically indistinguishable from IBV and MHV
       <xref ref-type="bibr" rid="bib0120">
        [24]
       </xref>
       , and patients infected with OC43 present the same clinical symptoms as that of 229E
       <xref ref-type="bibr" rid="bib0120">
        [24]
       </xref>
       . However, there is no serological cross-reactivity between 229E and OC43
       <xref ref-type="bibr" rid="bib0120">
        [24]
       </xref>
       . OC43 is also distributed globally (
       <xref ref-type="fig" rid="fig0005">
        Figure 1
       </xref>
       A).
      </p>
     </sec>
     <sec id="sec0025">
      <title>
       SARS-CoV (betacoronavirus, lineage B)
      </title>
      <p id="par0035">
       Patients infected with SARS-CoV initially present with fever, myalgia, headache, malaise, and chills, followed by a nonproductive cough, dyspnea, and respiratory distress generally 5 to 7 days later, which may result in death (
       <ext-link ext-link-type="uri" id="intr0010" xlink:href="http://www.who.int/csr/sars/en/WHOconsensus.pdf?ua=1">
        http://www.who.int/csr/sars/en/WHOconsensus.pdf?ua=1
       </ext-link>
       ). Other notable features in some cases include infection of the gastrointestinal tract, liver, kidney, and brain. Diffuse alveolar damage, epithelial cell proliferation, and an increase in macrophages is seen in SARS-CoV infection of the lung. Lymphopenia, hemophagocytosis in the lung, in addition to white-pulp atrophy of the spleen observed in SARS patients, are similar to fatal H5N1 influenza virus infections
       <xref ref-type="bibr" rid="bib0005">
        [1]
       </xref>
       . Diarrhea is observed in approximately 30–40% of SARS infections (
       <ext-link ext-link-type="uri" id="intr0015" xlink:href="http://www.cdc.gov/sars/about/faq.html">
        http://www.cdc.gov/sars/about/faq.html
       </ext-link>
       ).
      </p>
      <p id="par0040">
       An outbreak of disease caused by SARS-CoV, originating from Guangdong Province in southern China during November 2002, eventually spread to other countries in Asia, in addition to North America and Europe (37 countries/regions in total) over 9 months (
       <ext-link ext-link-type="uri" id="intr0020" xlink:href="http://www.who.int/ith/diseases/sars/en/">
        http://www.who.int/ith/diseases/sars/en/
       </ext-link>
       ) (
       <xref ref-type="fig" rid="fig0005">
        Figure 1
       </xref>
       B). An eventual 8273 cases were reported, with 775 deaths for a case fatality rate (CFR) of 9%, and the majority of cases and deaths occurred in mainland China and in Hong Kong
       <xref ref-type="bibr" rid="bib0095">
        [19]
       </xref>
       . The elderly were more susceptible to SARS disease, with a mortality rate of over 50% (
       <ext-link ext-link-type="uri" id="intr0025" xlink:href="http://www.cdc.gov/sars/surveillance/absence.html">
        http://www.cdc.gov/sars/surveillance/absence.html
       </ext-link>
       ).
      </p>
     </sec>
     <sec id="sec0030">
      <title>
       Human Coronavirus NL63 (alphacoronavirus)
      </title>
      <p id="par0045">
       NL63 is primarily associated with young children, the elderly, and immunocompromised patients with respiratory illnesses
       <xref ref-type="bibr" rid="bib0130">
        [26]
       </xref>
       . NL63 was a novel HCoV isolated from a 7-month-old child with coryza, conjunctivitis, fever, and bronchiolitis in the Netherlands during late 2004
       <xref ref-type="bibr" rid="bib0130">
        [26]
       </xref>
       , and an independent investigation described the isolation of virtually the same virus from a nasal sample collected from an 8-month-old boy suffering from pneumonia in the Netherlands
       <xref ref-type="bibr" rid="bib0135">
        [27]
       </xref>
       . NL63 was also detected in New Haven, USA, during 2005 amongst 79 of 895 children, and was initially called HCoV-NH (NH), but genetic and phylogenetic analyses showed that NH and HKU1 likely are the same species
       <xref ref-type="bibr" rid="bib0130">
        26
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0140">
        28
       </xref>
       . Infections with NL63 typically result in mild respiratory disease similar to the common cold, characterized by cough, rhinorrhea, tachypnea, fever, and hypoxia, and resolve on their own
       <xref ref-type="bibr" rid="bib0145">
        [29]
       </xref>
       . Obstructive laryngitis, also known as croup, is frequently observed with NL63 infections. A study estimated that NL63 accounts for an estimated 4.7% of common respiratory diseases
       <xref ref-type="bibr" rid="bib0130">
        [26]
       </xref>
       . NL63 is distributed globally (
       <xref ref-type="fig" rid="fig0005">
        Figure 1
       </xref>
       A).
      </p>
     </sec>
     <sec id="sec0035">
      <title>
       Human Coronavirus HKU1 (betacoronavirus, lineage A)
      </title>
      <p id="par0050">
       HKU1 was first discovered during January 2005 in a 71-year-old patient from Hong Kong who had been hospitalized with pneumonia and bronchiolitis
       <xref ref-type="bibr" rid="bib0150">
        [30]
       </xref>
       . The symptoms of HKU1 respiratory tract infections are not able to be separated from those caused by other respiratory viruses. Most patients present with fever, running nose, and cough for infections in the upper respiratory tract, whereas a fever, productive cough, and dyspnea are the common symptoms presenting for infections in the lower respiratory tract
       <xref ref-type="bibr" rid="bib0155">
        [31]
       </xref>
       . Most HKU1 infections are self-limiting, with only two deaths reported in patients with pneumonia due to HKU1
       <xref ref-type="bibr" rid="bib0160">
        [32]
       </xref>
       . Although HKU1 is clinically relatively mild in children, HKU1 infection is associated with a high incidence of seizures, and was found in a patient with meningitis
       <xref ref-type="bibr" rid="bib0165">
        33
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        34
       </xref>
       . HKU1 cases outside Asia were detected in New Haven, USA, in 2 out of 851 children
       <xref ref-type="bibr" rid="bib0175">
        [35]
       </xref>
       , and also in Australia
       <xref ref-type="bibr" rid="bib0180">
        [36]
       </xref>
       , France
       <xref ref-type="bibr" rid="bib0185">
        [37]
       </xref>
       , and Brazil
       <xref ref-type="bibr" rid="bib0190">
        [38]
       </xref>
       , indicating a global distribution for the virus (
       <xref ref-type="fig" rid="fig0005">
        Figure 1
       </xref>
       A).
      </p>
     </sec>
     <sec id="sec0040">
      <title>
       MERS-CoV (betacoronavirus, lineage C)
      </title>
      <p id="par0055">
       MERS-CoV was first isolated from the lungs of a 60-year-old patient who had died from a severe respiratory illness in Jeddah, Saudi Arabia, 2012
       <xref ref-type="bibr" rid="bib0195">
        [39]
       </xref>
       . Clinical manifestations of MERS-CoV infection range from asymptomatic to severe pneumonia with acute respiratory distress, septic shock, and renal failure resulting in death
       <xref ref-type="bibr" rid="bib0200">
        [40]
       </xref>
       . A typical disease course begins with fever, cough, chills, sore throat, myalgia, and arthralgia, followed by dyspnea and rapid progression to pneumonia
       <xref ref-type="bibr" rid="bib0200">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0205">
        41
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0210">
        42
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0215">
        43
       </xref>
       . Approximately one-third of patients present with gastrointestinal symptoms, such as diarrhea and vomiting. Acute renal impairment was the most striking feature of disease caused by MERS-CoV, which is thus far unique for human CoV infections
       <xref ref-type="bibr" rid="bib0200">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0220">
        44
       </xref>
       . Seventy-five percent of patients with MERS disease also had at least one other comorbidity, and patients who died were more likely to have a pre-existing/underlying condition
       <xref ref-type="bibr" rid="bib0200">
        [40]
       </xref>
       . Countries around the Arabian Peninsula are known to be endemic for MERS-CoV, and Saudi Arabia has reported the most cases, but since its discovery in 2012, cases have been occasionally exported to other countries through travel, sometimes causing clusters of secondary outbreaks (
       <xref ref-type="fig" rid="fig0005">
        Figure 1
       </xref>
       B)
       <xref ref-type="bibr" rid="bib0225">
        [45]
       </xref>
       . As of December 31, 2015, a total of 1621 laboratory-confirmed infections have been reported, with 584 deaths (CFR = 36.0%) over 26 countries (
       <ext-link ext-link-type="uri" id="intr0030" xlink:href="http://www.who.int/csr/disease/coronavirus_infections/en">
        http://www.who.int/csr/disease/coronavirus_infections/en
       </ext-link>
       ), making MERS-CoV one of the most dangerous viruses known to humans.
      </p>
     </sec>
    </sec>
    <sec id="sec0045">
     <title>
      Ecology of Human Coronaviruses
     </title>
     <p id="par0060">
      Based on currently available evidence, 229E, OC43, NL63, and HKU1 are well adapted to humans, and the viruses widely circulate in the human population (
      <xref ref-type="fig" rid="fig0010">
       Figure 2
      </xref>
      ), with most cases causing mild disease in immunocompetent adults, and none of these viruses have been found to be maintained within an animal reservoir. However, in the case of SARS-CoV and MERS-CoV, the viruses are not as well adapted to being maintained in humans, and thus are likely spread mainly in zoonotic reservoir(s), with occasional spillover into the susceptible human population, possibly via an intermediate host species.
      <fig id="fig0010">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Intra- and Inter-Species Transmission of Human Coronaviruses. Red, yellow, green, blue, brown, and purple arrows represent transmission of MERS-CoV, SARS-CoV, NL63, HKU1, OC43, and 229E, respectively, between bats, camels, cows, humans, and masked palm civets (shown in a legend on the side of the figure). Unbroken arrows represent confirmed transmission between the two species in question, and broken arrows represent suspected transmission.
        </p>
       </caption>
       <graphic xlink:href="gr2_lrg">
       </graphic>
      </fig>
     </p>
     <p id="par0065">
      Regarding SARS-CoV, epidemiology data implicated masked palm civets (
      <italic>
       Paguma larvata
      </italic>
      ) from live animal markets (LAM) in Guangdong Province, China, as a route of exposure to SARS-CoV
      <xref ref-type="bibr" rid="bib0230">
       [46]
      </xref>
      . However, masked palm civets from the wild or from farms without LAM exposure were largely negative for SARS-CoV
      <xref ref-type="bibr" rid="bib0235">
       [47]
      </xref>
      . This suggests that palm civets were an intermediate host, but not a reservoir for SARS-CoV
      <xref ref-type="bibr" rid="bib0240">
       [48]
      </xref>
      . Subsequent studies have shown that wild horseshoe bats (Rhinolophidae family), which can also be found in LAM in China and served in some Chinese restaurants in Guangdong, China, have detectable levels of antibodies against SARS-CoV and a SARS-CoV-like virus (SARSr-Rh-Bat CoV)
      <xref ref-type="bibr" rid="bib0245">
       49
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0250">
       50
      </xref>
      , suggesting a bat origin for SARS-CoV. An evolutionary relationship between coronaviruses and bats was proposed, in which the ancestor for SARS-CoV first spread to bats of the Hipposideridae family, then Rhinolophidae, then masked palm civets and eventually humans
      <xref ref-type="bibr" rid="bib0255">
       [51]
      </xref>
      . Recently, two new SARS-like CoVs were isolated in horseshoe bats, and these viruses showed the highest relationship to SARS-CoV from all known bat coronaviruses
      <xref ref-type="bibr" rid="bib0260">
       [52]
      </xref>
      . ORF8 analysis of the SARS-like CoVs in bats suggests that Chinese horseshoe bats are the natural reservoirs of SARS-CoV
      <xref ref-type="bibr" rid="bib0260">
       52
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0265">
       53
      </xref>
      , and that intermediate hosts might not be needed for direct human infection, particularly for some bat SARS-CoV-like viruses
      <xref ref-type="bibr" rid="bib0260">
       [52]
      </xref>
      .
     </p>
     <p id="par0070">
      In the case of MERS-CoV, studies in Oman, Saudi Arabia, Qatar, United Arab Emirates, and Jordan have shown that dromedary camels are seropositive for neutralizing antibodies against MERS-CoV
      <xref ref-type="bibr" rid="bib0270">
       [54]
      </xref>
      , as well as camels of Middle East origin in Africa, including Egypt, Kenya, Nigeria, Ethiopia, Tunisia, Somalia, and Sudan
      <xref ref-type="bibr" rid="bib0275">
       [55]
      </xref>
      . Subsequent studies on dromedary camels in Saudi Arabia
      <xref ref-type="bibr" rid="bib0280">
       [56]
      </xref>
      , Qatar
      <xref ref-type="bibr" rid="bib0285">
       [57]
      </xref>
      , and Egypt
      <xref ref-type="bibr" rid="bib0290">
       [58]
      </xref>
      show that live MERS-CoV can be isolated primarily from the nasal swabs of camels, showing that camels are potential source of MERS-CoV infection. However, many confirmed cases lack contact history with camels
      <xref ref-type="bibr" rid="bib0295">
       [59]
      </xref>
      , suggesting direct human-to-human transmission, or through contact with a yet-to-be-identified animal species that is maintaining MERS-CoV. Studies on HKU4, a coronavirus of bat origin and the most phylogenically closely related to MERS-CoV, had shown that HKU4 is able to utilize the CD26 receptor for virus entry
      <xref ref-type="bibr" rid="bib0300">
       [60]
      </xref>
      . As CD26 is a known receptor for MERS-CoV
      <xref ref-type="bibr" rid="bib0305">
       [61]
      </xref>
      , the similarity in receptor specificity of these two CoVs supports the hypothesis that MERS-CoVs is also a bat-originated CoV. However, live MERS-CoV has not been isolated from wild bats, nor have viral sequences been detected.
     </p>
     <p id="par0075">
      A recent investigation discovered that multiple HCoV species, including MERS-CoV, beta-CoV group A, and a 229E-like virus, circulate amongst dromedary camels in Saudi Arabia
      <xref ref-type="bibr" rid="bib0310">
       [62]
      </xref>
      . Furthermore, multiple lineages of circulating MERS-CoV in these camels had resulted in a dominant, recombinant MERS-CoV strain that was responsible for the MERS-CoV outbreaks during 2015
      <xref ref-type="bibr" rid="bib0310">
       [62]
      </xref>
      . These results show that various CoVs of human and animal origin are currently circulating in the wild, providing ample opportunity for CoVs to undergo evolution and genetic recombination, thereby resulting in recombinant CoVs that may potentially be more deadly to humans. In the following sections, we summarize the evolution and genetic recombination of the current HCoVs.
     </p>
    </sec>
    <sec id="sec0050">
     <title>
      Phylogeny, Evolution and Genetic Recombination in Human Coronaviruses
     </title>
     <sec id="sec0055">
      <title>
       Phylogenetic Analysis
      </title>
      <p id="par0080">
       The phylogenetic tree for the CoVs of zoonotic and human origin was constructed based on the full genome. It can be observed that 229E and NL63 belong to the alpha-CoV genus and are grouped together with porcine epidemic diarrhea virus (PEDV), TGEV, porcine respiratory coronavirus (PRCV), feline infectious peritonitis virus (FIPV), and some bat-derived coronaviruses (
       <xref ref-type="fig" rid="fig0015">
        Figure 3
       </xref>
       ). The topology of the phylogeny is similar to the tree constructed based on the RNA-dependent RNA polymerase gene
       <xref ref-type="bibr" rid="bib0275">
        [55]
       </xref>
       .
       <fig id="fig0015">
        <label>
         Figure 3
        </label>
        <caption>
         <p>
          Phylogenetic Tree of Known Animal and Human Coronaviruses. Phylogenetic analysis of the full-length genome sequences of coronaviruses publicly available in GenBank was performed using RAxML, with 1000 bootstrap replicates. Lines with different colors represent different coronavirus species, Alpha-coronaviruses (blue lines), Beta-coronaviruses (red lines for Beta-coronavirus C, and black lines for Beta-coronavirus A, B, and D), Gamma-coronaviruses (green lines), and Delta-coronaviruses (purple lines). Human isolates are highlighted with different colors, whereas strains from other hosts are shown in black. Numbers at the branches represent bootstrap values obtained in the phylogenetic analysis.
         </p>
        </caption>
        <graphic xlink:href="gr3_lrg">
        </graphic>
       </fig>
      </p>
      <p id="par0085">
       OC43, HKU1, SARS-CoV, and MERS-CoV belong to the beta-CoV genus. Lineage A includes OC43 and HKU1, MHV, porcine hemagglutinating encephalomyelitis virus (PHEV), in addition to equine, rabbit, camel, bovine, antelope-derived animal coronaviruses. Lineage B includes SARS-CoV, SARS-like viruses of bat and palm civet origin, and some bat-derived CoVs. Lineage C includes MERS-CoV and some bat-derived viruses. Lineage D contains only bat-derived coronavirus (
       <xref ref-type="fig" rid="fig0015">
        Figure 3
       </xref>
       ). In contrast to alpha- and beta-CoVs, gamma-CoVs consist mainly of avian coronaviruses (such as IBV), as well as CoVs isolated from aquatic animals, whales, and dolphins. CoVs of wild-bird origin are clustered into the delta-CoV, which also contains some swine-derived CoVs (
       <xref ref-type="fig" rid="fig0015">
        Figure 3
       </xref>
       ).
      </p>
      <p id="par0090">
       In general, alpha- and beta-CoVs primarily include CoVs from mammals, whereas gamma- and delta-CoVs mostly include CoVs of avian origin. Notably, all currently known HCoVs belong to either the alpha- or betacoronavirus genera, which also contain CoVs of mainly bat origin.
      </p>
     </sec>
     <sec id="sec0060">
      <title>
       Mutation and Genetic Recombination in Coronaviruses
      </title>
      <p id="par0095">
       The estimated mutation rates in CoV are moderate to high compared to other single-stranded RNA (ssRNA) viruses, and the average substitution rate for CoVs was ∼10
       <sup>
        −4
       </sup>
       substitutions per year per site
       <xref ref-type="bibr" rid="bib0315">
        [63]
       </xref>
       . The nucleotide mutation rate of IBV for the hypervariable region in the S gene was estimated to be 0.3–0.6 × 10
       <sup>
        –2
       </sup>
       per site per year
       <xref ref-type="bibr" rid="bib0320">
        [64]
       </xref>
       . The S gene of OC43 possessed an average rate of 6.410.58 × 10
       <sup>
        –4
       </sup>
       substitution rates per site per year
       <xref ref-type="bibr" rid="bib0325">
        [65]
       </xref>
       . Additionally, the S gene of 229E possessed a rate of ∼3 × 10
       <sup>
        − 4
       </sup>
       substitutions per site per year
       <xref ref-type="bibr" rid="bib0315">
        [63]
       </xref>
       . For SARS-CoV, the mutation rate in the whole genome was estimated to be 0.80–2.38 × 1
       <sup>
        –3
       </sup>
       nucleotide substitutions per site per year, and the nonsynonymous and synonymous substitution rates were estimated to be 1.16–3.30 × 10
       <sup>
        –3
       </sup>
       and 1.67–4.67 × 10
       <sup>
        –3
       </sup>
       per site per year, respectively, which is similar to other RNA viruses
       <xref ref-type="bibr" rid="bib0330">
        [66]
       </xref>
       . The evolutionary rate for MERS-CoV genomes was estimated as 1.12 × 10
       <sup>
        −3
       </sup>
       substitutions per site per year (95% credible interval [95% CI], 8.76 × 10
       <sup>
        −4
       </sup>
       ; 1.37 × 10
       <sup>
        −3
       </sup>
       )
       <xref ref-type="bibr" rid="bib0335">
        [67]
       </xref>
       . Furthermore, the large RNA genome in CoV allows for extra plasticity in genome modification by mutations and recombinations, thereby increasing the probability for intraspecies variability, interspecies ‘host jump’, and novel CoVs to emerge under the right conditions
       <xref ref-type="bibr" rid="bib0340">
        68
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0345">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0350">
        70
       </xref>
       .
      </p>
      <p id="par0100">
       The major reason for recombination may be at the replication step in the virus life cycle. During replication, a set of subgenomic RNAs is generated, increasing the homologous recombination rate among closely related genes from different lineages of CoVs or other viruses by template switching
       <xref ref-type="bibr" rid="bib0165">
        [33]
       </xref>
       . Concurrently, circulating CoVs in multiple host species likely contribute to increases in the rate of recombination events. However, the exact mechanism of genetic recombination in CoVs remains unclear: recombination site ‘breakpoints’ in the viral genome – the crossing point of the recombinant genes between two distinct viral strains or genotypes – appear to be random, as different recombinant strains have different breakpoints.
      </p>
      <p id="par0105">
       Genetic recombination has been previously documented for animal CoVs, for instance: MHV
       <xref ref-type="bibr" rid="bib0355">
        [71]
       </xref>
       , TGEV
       <xref ref-type="bibr" rid="bib0360">
        [72]
       </xref>
       , as well as feline and canine coronaviruses
       <xref ref-type="bibr" rid="bib0365">
        73
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0370">
        74
       </xref>
       . Genetic recombination for other HCoVs including OC43, NL63, HKU1, SARS-CoV
       <xref ref-type="bibr" rid="bib0255">
        [51]
       </xref>
       , and MERS-CoV have also been documented and are discussed in detail below.
      </p>
      <p id="par0110">
       OC43 has diverged into five distinct genotypes (A to E). Genotype A is typified by the prototype VR759 strain that was isolated in 1967
       <xref ref-type="bibr" rid="bib0375">
        [75]
       </xref>
       . Genotypes B and C are two naturally circulating viruses. Genotype D emerged via recombination between genotypes B and C viruses at the breakpoint of 2500–5000 bp in the NSP2–NSP3 gene and 15500 bp-3′end in NSP12-N genes
       <xref ref-type="bibr" rid="bib0375">
        [75]
       </xref>
       (
       <xref ref-type="fig" rid="fig0020">
        Figure 4
       </xref>
       , Key Figure). Genotype E, identified in 2014, emerged by recombination amongst the genotype B, C, and D viruses with different breakpoints in the genes compared to the generation of genotype D
       <xref ref-type="bibr" rid="bib0380">
        [76]
       </xref>
       (
       <xref ref-type="fig" rid="fig0020">
        Figure 4
       </xref>
       ). A study in France, between 2001 and 2013, demonstrated that OC43 strains have more recombination patterns in Lower Normandy, and circulating OC43 viruses have a high genetic diversity
       <xref ref-type="bibr" rid="bib0085">
        [17]
       </xref>
       .
       <fig id="fig0020">
        <label>
         Figure 4
        </label>
        <caption>
         <p>
          Key Figure: Genetic Recombination in Human Coronaviruses
         </p>
        </caption>
        <caption>
         <p>
          The colored regions of each human coronavirus indicate genetic recombination at the genomic sites with coronaviruses of zoonotic origin. Specific nucleotide locations where recombination occurred are also shown in broken lines.
         </p>
        </caption>
        <graphic xlink:href="gr4_lrg">
        </graphic>
       </fig>
      </p>
      <p id="par0115">
       NL63 also has the potential for genetic recombination, and one such example is between the Amsterdam 1 and 496 strains. Recombination site breakpoints were identified in two parts of the S gene
       <xref ref-type="bibr" rid="bib0315">
        [63]
       </xref>
       (
       <xref ref-type="fig" rid="fig0020">
        Figure 4
       </xref>
       ).
      </p>
      <p id="par0120">
       Recombination events have been observed for different genotypes of HKU1, in which recombination breakpoints were found on genotypes B and C in the nsp6-nsp7 and nsp16-HE genes, respectively
       <xref ref-type="bibr" rid="bib0350">
        [70]
       </xref>
       (
       <xref ref-type="fig" rid="fig0020">
        Figure 4
       </xref>
       ). HKU1 was also shown to be able to recombine with other animal beta-CoVs, such as MHV, at the nsp3, nsp4, nsp6, nsp7, nps9, and nsp10 genes
       <xref ref-type="bibr" rid="bib0385">
        [77]
       </xref>
       (
       <xref ref-type="fig" rid="fig0020">
        Figure 4
       </xref>
       ).
      </p>
      <p id="par0125">
       SARS-CoV has a possible recombinant history with lineages of alpha- and gamma-CoV
       <xref ref-type="bibr" rid="bib0390">
        [78]
       </xref>
       . Many specific breakpoints and a large number of smaller recombinant regions had been identified in the RNA-dependent RNA polymerase (RDRP, nsp12 gene) at the following locations: nucleotides 13 392–13 610, 15 259–15 342, and 15 974–16 108 based on the sequence of the SARS-CoV TOR2 strain
       <xref ref-type="bibr" rid="bib0390">
        [78]
       </xref>
       . Recombination locations were also identified in the nsp9 and most of nsp10 gene located at 12 613–13 344, and parts of nsp14 (18 117–18 980)
       <xref ref-type="bibr" rid="bib0390">
        [78]
       </xref>
       . Another study analyzing the genome of the SARS-CoV CV7 strain had shown that seven putative recombination locations were found between SARS-CoV and six other coronaviruses: PEDV, TGEV, BCV, 229E, MHV, and IBV (
       <xref ref-type="fig" rid="fig0020">
        Figure 4
       </xref>
       ). This further suggests that SARS-CoV emerged via serial horizontal transmission and by genetic recombination, enhancing the adaptation process to its new host
       <xref ref-type="bibr" rid="bib0395">
        [79]
       </xref>
       .
      </p>
      <p id="par0130">
       Recombination was also detected between the SARS-related bat-associated CoV (SARSr-Bat CoVs), in which recombination between the Rp3 strain from Guangxi Province and Rf1 strain from Hubei Province, China, generated a new strain (SARSr-Civet CoV SZ3) in civets, with a breakpoint at the nsp16/spike and S2 region
       <xref ref-type="bibr" rid="bib0255">
        [51]
       </xref>
       (
       <xref ref-type="fig" rid="fig0020">
        Figure 4
       </xref>
       ). Furthermore, the SARS-CoV Rf1/2004 strain is itself a recombinant from the bat CoV 279/2004, bat CoV Rm1/2004 and civet CoV SZ3/2003
       <xref ref-type="bibr" rid="bib0255">
        [51]
       </xref>
       (
       <xref ref-type="fig" rid="fig0020">
        Figure 4
       </xref>
       ).
      </p>
      <p id="par0135">
       A recent study showed that the epidemic MERS-CoV experienced recombination events between the different lineages, which occurred in dromedary camels in Saudi Arabia
       <xref ref-type="bibr" rid="bib0310">
        [62]
       </xref>
       . Lineages 3 and 5 viruses were predominant during July and December 2014; however, lineage 5 became dominant within the camel population by 2015. Lineage 5, which is closely associated with the MERS-CoV causing the outbreak in South Korea in 2015, as well as recent human infections in Riyadh, Saudi Arabia, is a recombinant virus between lineages 3 and 4, or groups 3 and 5 of clade B (
       <xref ref-type="fig" rid="fig0020">
        Figure 4
       </xref>
       )
       <xref ref-type="bibr" rid="bib0310">
        62
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0400">
        80
       </xref>
       .
      </p>
     </sec>
    </sec>
    <sec id="sec0065">
     <title>
      Concluding Remarks
     </title>
     <p id="par0140">
      The result from a high frequency of recombination events in CoVs is the generation of novel viruses with a high genetic diversity, with unpredictable changes in virulence during human infections. With multiple species of CoVs circulating in the wild amongst different animal species that may constantly interact with one another, it is likely not a matter of if, but when, the next recombinant CoV will emerge and cause another outbreak in the human population. As such, some crucial future areas of investigation include: (i) the prevalence of HCoVs already circulating within the animal population, (ii) the commonality of coronavirus recombination in animals, (iii) animals which may potentially serve as mixing vessels for the generation of novel recombinant CoVs, and (iv) a surveillance network to monitor and predict the potential emergence of a highly virulent, recombinant CoV from animals (see Outstanding Questions). Furthermore, lessons from the SARS-CoV and MERS-CoV outbreaks must be urgently learned in advance to effectively prepare for the next CoV outbreak.
      <boxed-text id="tb0005">
       <label>
        Outstanding Questions
       </label>
       <p id="par0145">
        How common is coronavirus recombination in animals?
       </p>
       <p id="par0150">
        Can coronavirus undergo recombination in animal hosts other than camels?
       </p>
       <p id="par0155">
        Is there a way to predict the potential emergence of a novel recombinant coronavirus in the human population?
       </p>
      </boxed-text>
     </p>
    </sec>
    <sec id="sec0070">
     <title>
      Author Contributions
     </title>
     <p id="par0160">
      Shuo Su and Gary Wong contributed equally to this manuscript.
     </p>
    </sec>
    <back>
     <ref-list id="bibl0005">
      <title>
       References
      </title>
      <ref id="bib0005">
       <label>
        1
       </label>
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Navas-Martin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         Microbiol. Mol. Biol. Rev.
        </source>
        <volume>
         69
        </volume>
        <year>
         2005
        </year>
        <fpage>
         635
        </fpage>
        <lpage>
         664
        </lpage>
        <pub-id pub-id-type="pmid">
         16339739
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <label>
        2
       </label>
       <element-citation id="sbref0010" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviridae
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Knipe
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Howley
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
        </person-group>
        <source>
         Fields Virology
        </source>
        <edition>
         5th edn
        </edition>
        <year>
         2007
        </year>
        <publisher-name>
         Lippincott Williams &amp; Wilkins
        </publisher-name>
        <fpage>
         1305
        </fpage>
        <lpage>
         1335
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <label>
        3
       </label>
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The molecular biology of coronaviruses
        </article-title>
        <source>
         Adv. Vir. Res.
        </source>
        <volume>
         48
        </volume>
        <year>
         1997
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         100
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <label>
        4
       </label>
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Langereis
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Attachment of mouse hepatitis virus to O-acetylated sialic acid is mediated by hemagglutinin-esterase and not by the spike protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         84
        </volume>
        <year>
         2010
        </year>
        <fpage>
         8970
        </fpage>
        <lpage>
         8974
        </lpage>
        <pub-id pub-id-type="pmid">
         20538854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <label>
        5
       </label>
       <element-citation id="sbref0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Durham
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rotavirus and coronavirus associated diarrhoea in domestic animals
        </article-title>
        <source>
         N. Zealand Vet. J.
        </source>
        <volume>
         27
        </volume>
        <year>
         1979
        </year>
        <fpage>
         30
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="pmid">
         221870
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <label>
        6
       </label>
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus avian infectious bronchitis virus
        </article-title>
        <source>
         Vet. Res.
        </source>
        <volume>
         38
        </volume>
        <year>
         2007
        </year>
        <fpage>
         281
        </fpage>
        <lpage>
         297
        </lpage>
        <pub-id pub-id-type="pmid">
         17296157
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0035">
       <label>
        7
       </label>
       <element-citation id="sbref0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Erles
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of a group 2 coronavirus in dogs with canine infectious respiratory disease
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         310
        </volume>
        <year>
         2003
        </year>
        <fpage>
         216
        </fpage>
        <lpage>
         223
        </lpage>
        <pub-id pub-id-type="pmid">
         12781709
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <label>
        8
       </label>
       <element-citation id="sbref0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiner
          </surname>
          <given-names>
           L.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenesis of demyelination induced by a mouse hepatitis
        </article-title>
        <source>
         Arch. Neurol.
        </source>
        <volume>
         28
        </volume>
        <year>
         1973
        </year>
        <fpage>
         298
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="pmid">
         4348723
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0045">
       <label>
        9
       </label>
       <element-citation id="sbref0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pensaert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmissible gastroenteritis of swine: virus–intestinal cell interactions. II. Electron microscopy of the epithelium in isolated jejunal loops
        </article-title>
        <source>
         Arch. Gesamte Virusforsch.
        </source>
        <volume>
         31
        </volume>
        <year>
         1970
        </year>
        <fpage>
         335
        </fpage>
        <lpage>
         351
        </lpage>
        <pub-id pub-id-type="pmid">
         4992469
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <label>
        10
       </label>
       <element-citation id="sbref0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pensaert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmissible gastroenteritis of swine: virus-intestinal cell interactions. I. Immunofluorescence, histopathology and virus production in the small intestine through the course of infection
        </article-title>
        <source>
         Arch. Gesamte Virusforsch.
        </source>
        <volume>
         31
        </volume>
        <year>
         1970
        </year>
        <fpage>
         321
        </fpage>
        <lpage>
         334
        </lpage>
        <pub-id pub-id-type="pmid">
         4992468
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <label>
        11
       </label>
       <element-citation id="sbref0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bridger
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Replication of an enteric bovine coronavirus in intestinal organ cultures
        </article-title>
        <source>
         Arch. Virol.
        </source>
        <volume>
         57
        </volume>
        <year>
         1978
        </year>
        <fpage>
         43
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="pmid">
         655865
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <label>
        12
       </label>
       <element-citation id="sbref0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pedersen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenicity studies of feline coronavirus isolates 79-1146 and 79-1683
        </article-title>
        <source>
         Am. J. Vet. Res.
        </source>
        <volume>
         45
        </volume>
        <year>
         1984
        </year>
        <fpage>
         2580
        </fpage>
        <lpage>
         2585
        </lpage>
        <pub-id pub-id-type="pmid">
         6084432
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <label>
        13
       </label>
       <element-citation id="sbref0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Binn
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recovery and Characterization of a Coronavirus from Military Dogs with Diarrhea
        </article-title>
        <source>
         Proc. Annu. Meet. U.S. Anim Health Assoc.
        </source>
        <year>
         1974
        </year>
        <fpage>
         359
        </fpage>
        <lpage>
         366
        </lpage>
        <pub-id pub-id-type="pmid">
         4377955
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <label>
        14
       </label>
       <element-citation id="sbref0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ismail
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenicity of turkey coronavirus in turkeys and chickens
        </article-title>
        <source>
         Avian Dis.
        </source>
        <volume>
         47
        </volume>
        <year>
         2003
        </year>
        <fpage>
         515
        </fpage>
        <lpage>
         522
        </lpage>
        <pub-id pub-id-type="pmid">
         14562877
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0075">
       <label>
        15
       </label>
       <element-citation id="sbref0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wevers
          </surname>
          <given-names>
           B.A.
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recently discovered human coronaviruses
        </article-title>
        <source>
         Clin. Lab. Med.
        </source>
        <volume>
         29
        </volume>
        <year>
         2009
        </year>
        <fpage>
         715
        </fpage>
        <lpage>
         724
        </lpage>
        <pub-id pub-id-type="pmid">
         19892230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0080">
       <label>
        16
       </label>
       <element-citation id="sbref0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tyrrell
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bynoe
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cultivation of a novel type of common-cold virus in organ cultures
        </article-title>
        <source>
         Br. Med. J.
        </source>
        <volume>
         1
        </volume>
        <year>
         1965
        </year>
        <fpage>
         1467
        </fpage>
        <lpage>
         1470
        </lpage>
        <pub-id pub-id-type="pmid">
         14288084
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0085">
       <label>
        17
       </label>
       <element-citation id="sbref0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kin
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic analysis of 15 human coronaviruses OC43 (HCoV-OC43s) circulating in France from 2001 to 2013 reveals a high intra-specific diversity with new recombinant genotypes
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         7
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2358
        </fpage>
        <lpage>
         2377
        </lpage>
        <pub-id pub-id-type="pmid">
         26008694
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0090">
       <label>
        18
       </label>
       <element-citation id="sbref0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Monto
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Medical reviews. Coronaviruses
        </article-title>
        <source>
         Yale J. Biol. Med.
        </source>
        <volume>
         47
        </volume>
        <year>
         1974
        </year>
        <fpage>
         234
        </fpage>
        <lpage>
         251
        </lpage>
        <pub-id pub-id-type="pmid">
         4617423
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0095">
       <label>
        19
       </label>
       <element-citation id="sbref0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1319
        </fpage>
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0100">
       <label>
        20
       </label>
       <element-citation id="sbref0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS: emergence of a novel human coronavirus
        </article-title>
        <source>
         Curr. Opin. Virol.
        </source>
        <volume>
         5
        </volume>
        <year>
         2014
        </year>
        <fpage>
         58
        </fpage>
        <lpage>
         62
        </lpage>
        <pub-id pub-id-type="pmid">
         24584035
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0105">
       <label>
        21
       </label>
       <element-citation id="sbref0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hendley
          </surname>
          <given-names>
           J.O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus infections in working adults. Eight-year study with 229 E and OC 43
        </article-title>
        <source>
         Am. Rev. Respir. Dis.
        </source>
        <volume>
         105
        </volume>
        <year>
         1972
        </year>
        <fpage>
         805
        </fpage>
        <lpage>
         811
        </lpage>
        <pub-id pub-id-type="pmid">
         5020629
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0110">
       <label>
        22
       </label>
       <element-citation id="sbref0110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong
        </article-title>
        <source>
         China. Clin. Infect. Dis.
        </source>
        <volume>
         40
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1721
        </fpage>
        <lpage>
         1729
        </lpage>
        <pub-id pub-id-type="pmid">
         15909257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0115">
       <label>
        23
       </label>
       <element-citation id="sbref0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamre
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Procknow
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new virus isolated from the human respiratory tract
        </article-title>
        <source>
         Proc. Soc. Exp. Biol. Med.
        </source>
        <volume>
         121
        </volume>
        <year>
         1966
        </year>
        <fpage>
         190
        </fpage>
        <lpage>
         193
        </lpage>
        <pub-id pub-id-type="pmid">
         4285768
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0120">
       <label>
        24
       </label>
       <element-citation id="sbref0120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McIntosh
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U.S.A.
        </source>
        <volume>
         57
        </volume>
        <year>
         1967
        </year>
        <fpage>
         933
        </fpage>
        <lpage>
         940
        </lpage>
        <pub-id pub-id-type="pmid">
         5231356
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0125">
       <label>
        25
       </label>
       <element-citation id="sbref0125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tyrrell
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Signs and symptoms in common colds
        </article-title>
        <source>
         Epidem. Infect.
        </source>
        <volume>
         111
        </volume>
        <year>
         1993
        </year>
        <fpage>
         143
        </fpage>
        <lpage>
         156
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0130">
       <label>
        26
       </label>
       <element-citation id="sbref0130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus NL63, a new respiratory virus
        </article-title>
        <source>
         FEMS Microbiol. Rev.
        </source>
        <volume>
         30
        </volume>
        <year>
         2006
        </year>
        <fpage>
         760
        </fpage>
        <lpage>
         773
        </lpage>
        <pub-id pub-id-type="pmid">
         16911043
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0135">
       <label>
        27
       </label>
       <element-citation id="sbref0135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A previously undescribed coronavirus associated with respiratory disease in humans
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U.S.A.
        </source>
        <volume>
         101
        </volume>
        <year>
         2004
        </year>
        <fpage>
         6212
        </fpage>
        <lpage>
         6216
        </lpage>
        <pub-id pub-id-type="pmid">
         15073334
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0140">
       <label>
        28
       </label>
       <element-citation id="sbref0140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Esper
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         191
        </volume>
        <year>
         2005
        </year>
        <fpage>
         492
        </fpage>
        <lpage>
         498
        </lpage>
        <pub-id pub-id-type="pmid">
         15655770
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0145">
       <label>
        29
       </label>
       <element-citation id="sbref0145" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abdul-Rasool
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Fielding
          </surname>
          <given-names>
           B.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Understanding human coronavirus HCoV-NL63
        </article-title>
        <source>
         Open Virol. J.
        </source>
        <volume>
         4
        </volume>
        <year>
         2010
        </year>
        <fpage>
         76
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         20700397
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0150">
       <label>
        30
       </label>
       <element-citation id="sbref0150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         79
        </volume>
        <year>
         2005
        </year>
        <fpage>
         884
        </fpage>
        <lpage>
         895
        </lpage>
        <pub-id pub-id-type="pmid">
         15613317
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0155">
       <label>
        31
       </label>
       <element-citation id="sbref0155" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         More and more coronaviruses: human coronavirus HKU1
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         1
        </volume>
        <year>
         2009
        </year>
        <fpage>
         57
        </fpage>
        <lpage>
         71
        </lpage>
        <pub-id pub-id-type="pmid">
         21994538
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0160">
       <label>
        32
       </label>
       <element-citation id="sbref0160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia
        </article-title>
        <source>
         J. Infect Dis.
        </source>
        <volume>
         192
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1898
        </fpage>
        <lpage>
         1907
        </lpage>
        <pub-id pub-id-type="pmid">
         16267760
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0165">
       <label>
        33
       </label>
       <element-citation id="sbref0165" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus HKU1 and other coronavirus infections in Hong Kong
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         44
        </volume>
        <year>
         2006
        </year>
        <fpage>
         2063
        </fpage>
        <lpage>
         2071
        </lpage>
        <pub-id pub-id-type="pmid">
         16757599
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0170">
       <label>
        34
       </label>
       <element-citation id="sbref0170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gaunt
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         48
        </volume>
        <year>
         2010
        </year>
        <fpage>
         2940
        </fpage>
        <lpage>
         2947
        </lpage>
        <pub-id pub-id-type="pmid">
         20554810
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0175">
       <label>
        35
       </label>
       <element-citation id="sbref0175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Esper
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus HKU1 infection in the United States
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         12
        </volume>
        <year>
         2006
        </year>
        <fpage>
         775
        </fpage>
        <lpage>
         779
        </lpage>
        <pub-id pub-id-type="pmid">
         16704837
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0180">
       <label>
        36
       </label>
       <element-citation id="sbref0180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sloots
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence of human coronavirus HKU1 and human bocavirus in Australian children
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <volume>
         35
        </volume>
        <year>
         2006
        </year>
        <fpage>
         99
        </fpage>
        <lpage>
         102
        </lpage>
        <pub-id pub-id-type="pmid">
         16257260
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0185">
       <label>
        37
       </label>
       <element-citation id="sbref0185" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of the new human coronavirus HKU1: a report of 6 cases
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         42
        </volume>
        <year>
         2006
        </year>
        <fpage>
         634
        </fpage>
        <lpage>
         639
        </lpage>
        <pub-id pub-id-type="pmid">
         16447108
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0190">
       <label>
        38
       </label>
       <element-citation id="sbref0190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goes
          </surname>
          <given-names>
           L.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus HKU1 in children, Brazil, 1995
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         17
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1147
        </fpage>
        <lpage>
         1148
        </lpage>
        <pub-id pub-id-type="pmid">
         21749800
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0195">
       <label>
        39
       </label>
       <element-citation id="sbref0195" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         367
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0200">
       <label>
        40
       </label>
       <element-citation id="sbref0200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         386
        </volume>
        <year>
         2015
        </year>
        <fpage>
         995
        </fpage>
        <lpage>
         1007
        </lpage>
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0205">
       <label>
        41
       </label>
       <element-citation id="sbref0205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: a case–control study of hospitalized patients
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         59
        </volume>
        <year>
         2014
        </year>
        <fpage>
         160
        </fpage>
        <lpage>
         165
        </lpage>
        <pub-id pub-id-type="pmid">
         24723278
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0210">
       <label>
        42
       </label>
       <element-citation id="sbref0210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         13
        </volume>
        <year>
         2013
        </year>
        <fpage>
         752
        </fpage>
        <lpage>
         761
        </lpage>
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0215">
       <label>
        43
       </label>
       <element-citation id="sbref0215" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Ann. Intern. Med.
        </source>
        <volume>
         160
        </volume>
        <year>
         2014
        </year>
        <fpage>
         389
        </fpage>
        <lpage>
         397
        </lpage>
        <pub-id pub-id-type="pmid">
         24474051
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0220">
       <label>
        44
       </label>
       <element-citation id="sbref0220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Lancet. Infect. Dis.
        </source>
        <volume>
         13
        </volume>
        <year>
         2013
        </year>
        <fpage>
         745
        </fpage>
        <lpage>
         751
        </lpage>
        <pub-id pub-id-type="pmid">
         23782859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0225">
       <label>
        45
       </label>
       <element-citation id="sbref0225" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS in South Korea and China: a potential outbreak threat?
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         385
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2349
        </fpage>
        <lpage>
         2350
        </lpage>
        <pub-id pub-id-type="pmid">
         26088634
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0230">
       <label>
        46
       </label>
       <element-citation id="sbref0230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
        </article-title>
        <source>
         Science
        </source>
        <volume>
         302
        </volume>
        <year>
         2003
        </year>
        <fpage>
         276
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0235">
       <label>
        47
       </label>
       <element-citation id="sbref0235" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in bats
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         79
        </volume>
        <year>
         2005
        </year>
        <fpage>
         2001
        </fpage>
        <lpage>
         2009
        </lpage>
        <pub-id pub-id-type="pmid">
         15681402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0240">
       <label>
        48
       </label>
       <element-citation id="sbref0240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Netland
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses post-SARS: update on replication and pathogenesis
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <volume>
         7
        </volume>
        <year>
         2009
        </year>
        <fpage>
         439
        </fpage>
        <lpage>
         450
        </lpage>
        <pub-id pub-id-type="pmid">
         19430490
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0245">
       <label>
        49
       </label>
       <element-citation id="sbref0245" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibodies to SARS coronavirus in civets
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         2244
        </fpage>
        <lpage>
         2248
        </lpage>
        <pub-id pub-id-type="pmid">
         15663874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0250">
       <label>
        50
       </label>
       <element-citation id="sbref0250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         79
        </volume>
        <year>
         2005
        </year>
        <fpage>
         11892
        </fpage>
        <lpage>
         11900
        </lpage>
        <pub-id pub-id-type="pmid">
         16140765
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0255">
       <label>
        51
       </label>
       <element-citation id="sbref0255" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ecoepidemiology and complete genome comparison of different strains of severe acute respiratory syndrome-related Rhinolophus bat coronavirus in China reveal bats as a reservoir for acute, self-limiting infection that allows recombination events
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         84
        </volume>
        <year>
         2010
        </year>
        <fpage>
         2808
        </fpage>
        <lpage>
         2819
        </lpage>
        <pub-id pub-id-type="pmid">
         20071579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0260">
       <label>
        52
       </label>
       <element-citation id="sbref0260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         503
        </volume>
        <year>
         2013
        </year>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0265">
       <label>
        53
       </label>
       <element-citation id="sbref0265" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         ORF8-related genetic evidence for Chinese horseshoe bats as the source of human severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         213
        </volume>
        <year>
         2016
        </year>
        <fpage>
         579
        </fpage>
        <lpage>
         583
        </lpage>
        <pub-id pub-id-type="pmid">
         26433221
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0270">
       <label>
        54
       </label>
       <element-citation id="sbref0270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
        </article-title>
        <source>
         Lancet. Infect. Dis.
        </source>
        <volume>
         13
        </volume>
        <year>
         2013
        </year>
        <fpage>
         859
        </fpage>
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0275">
       <label>
        55
       </label>
       <element-citation id="sbref0275" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease
        </article-title>
        <source>
         Clin. Microbiol. Rev.
        </source>
        <volume>
         28
        </volume>
        <year>
         2015
        </year>
        <fpage>
         465
        </fpage>
        <lpage>
         522
        </lpage>
        <pub-id pub-id-type="pmid">
         25810418
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0280">
       <label>
        56
       </label>
       <element-citation id="sbref0280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronavirus in dromedary camel herd, Saudi Arabia
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1231
        </fpage>
        <lpage>
         1234
        </lpage>
        <pub-id pub-id-type="pmid">
         24964193
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0285">
       <label>
        57
       </label>
       <element-citation id="sbref0285" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1339
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="pmid">
         25075761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0290">
       <label>
        58
       </label>
       <element-citation id="sbref0290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronaviruses in dromedary camels, Egypt
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1049
        </fpage>
        <lpage>
         1053
        </lpage>
        <pub-id pub-id-type="pmid">
         24856660
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0295">
       <label>
        59
       </label>
       <element-citation id="sbref0295" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Samara
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Abdoun
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Concerns about misinterpretation of recent scientific data implicating dromedary camels in epidemiology of Middle East respiratory syndrome (MERS)
        </article-title>
        <source>
         Mbio
        </source>
        <volume>
         5
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e01430
        </fpage>
        <lpage>
         e1514
        </lpage>
        <pub-id pub-id-type="pmid">
         25006231
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0300">
       <label>
        60
       </label>
       <element-citation id="sbref0300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <volume>
         16
        </volume>
        <year>
         2014
        </year>
        <fpage>
         328
        </fpage>
        <lpage>
         337
        </lpage>
        <pub-id pub-id-type="pmid">
         25211075
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0305">
       <label>
        61
       </label>
       <element-citation id="sbref0305" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         500
        </volume>
        <year>
         2013
        </year>
        <fpage>
         227
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="pmid">
         23831647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0310">
       <label>
        62
       </label>
       <element-citation id="sbref0310" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sabir
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia
        </article-title>
        <source>
         Science
        </source>
        <volume>
         351
        </volume>
        <year>
         2016
        </year>
        <fpage>
         81
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         26678874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0315">
       <label>
        63
       </label>
       <element-citation id="sbref0315" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mosaic structure of human coronavirus NL63, one thousand years of evolution
        </article-title>
        <source>
         J. Mol. Biol.
        </source>
        <volume>
         364
        </volume>
        <year>
         2006
        </year>
        <fpage>
         964
        </fpage>
        <lpage>
         973
        </lpage>
        <pub-id pub-id-type="pmid">
         17054987
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0320">
       <label>
        64
       </label>
       <element-citation id="sbref0320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Does IBV change slowly despite the capacity of the spike protein to vary greatly?
        </article-title>
        <source>
         Adv. Exp. Med. Biol.
        </source>
        <volume>
         440
        </volume>
        <year>
         1998
        </year>
        <fpage>
         729
        </fpage>
        <lpage>
         734
        </lpage>
        <pub-id pub-id-type="pmid">
         9782351
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0325">
       <label>
        65
       </label>
       <element-citation id="sbref0325" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic drift of human coronavirus OC43 spike gene during adaptive evolution
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <volume>
         5
        </volume>
        <year>
         2015
        </year>
        <fpage>
         11451
        </fpage>
        <pub-id pub-id-type="pmid">
         26099036
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0330">
       <label>
        66
       </label>
       <element-citation id="sbref0330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Moderate mutation rate in the SARS coronavirus genome and its implications
        </article-title>
        <source>
         BMC Evol. Biol.
        </source>
        <volume>
         4
        </volume>
        <year>
         2004
        </year>
        <fpage>
         21
        </fpage>
        <pub-id pub-id-type="pmid">
         15222897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0335">
       <label>
        67
       </label>
       <element-citation id="sbref0335" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cotten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Mbio
        </source>
        <volume>
         5
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e01062
        </fpage>
        <lpage>
         e1113
        </lpage>
        <pub-id pub-id-type="pmid">
         24549846
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0340">
       <label>
        68
       </label>
       <element-citation id="sbref0340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus diversity, phylogeny and interspecies jumping
        </article-title>
        <source>
         Exp. Biol. Med. (Maywood)
        </source>
        <volume>
         234
        </volume>
        <year>
         2009
        </year>
        <fpage>
         1117
        </fpage>
        <lpage>
         1127
        </lpage>
        <pub-id pub-id-type="pmid">
         19546349
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0345">
       <label>
        69
       </label>
       <element-citation id="sbref0345" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious diseases emerging from Chinese wet-markets: zoonotic origins of severe respiratory viral infections
        </article-title>
        <source>
         Curr. Opin. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <year>
         2006
        </year>
        <fpage>
         401
        </fpage>
        <lpage>
         407
        </lpage>
        <pub-id pub-id-type="pmid">
         16940861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0350">
       <label>
        70
       </label>
       <element-citation id="sbref0350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative analysis of 22 coronavirus HKU1 genomes reveals a novel genotype and evidence of natural recombination in coronavirus HKU1
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         80
        </volume>
        <year>
         2006
        </year>
        <fpage>
         7136
        </fpage>
        <lpage>
         7145
        </lpage>
        <pub-id pub-id-type="pmid">
         16809319
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0355">
       <label>
        71
       </label>
       <element-citation id="sbref0355" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recombination between nonsegmented RNA genomes of murine coronaviruses
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         56
        </volume>
        <year>
         1985
        </year>
        <fpage>
         449
        </fpage>
        <lpage>
         456
        </lpage>
        <pub-id pub-id-type="pmid">
         2997467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0360">
       <label>
        72
       </label>
       <element-citation id="sbref0360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           P.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence of recombinant strains of porcine epidemic diarrhea virus, United States, 2013
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1735
        </fpage>
        <lpage>
         1738
        </lpage>
        <pub-id pub-id-type="pmid">
         25272273
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0365">
       <label>
        73
       </label>
       <element-citation id="sbref0365" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Terada
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emergence of pathogenic coronaviruses in cats by homologous recombination between feline and canine coronaviruses
        </article-title>
        <source>
         PLoS ONE
        </source>
        <volume>
         9
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e106534
        </fpage>
        <pub-id pub-id-type="pmid">
         25180686
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0370">
       <label>
        74
       </label>
       <element-citation id="sbref0370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Decaro
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recombinant canine coronaviruses related to transmissible gastroenteritis virus of Swine are circulating in dogs
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         83
        </volume>
        <year>
         2009
        </year>
        <fpage>
         1532
        </fpage>
        <lpage>
         1537
        </lpage>
        <pub-id pub-id-type="pmid">
         19036814
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0375">
       <label>
        75
       </label>
       <element-citation id="sbref0375" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular epidemiology of human coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <year>
         2011
        </year>
        <fpage>
         11325
        </fpage>
        <lpage>
         11337
        </lpage>
        <pub-id pub-id-type="pmid">
         21849456
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0380">
       <label>
        76
       </label>
       <element-citation id="sbref0380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genotype shift in human coronavirus OC43 and emergence of a novel genotype by natural recombination
        </article-title>
        <source>
         J. Infect.
        </source>
        <volume>
         70
        </volume>
        <year>
         2015
        </year>
        <fpage>
         641
        </fpage>
        <lpage>
         650
        </lpage>
        <pub-id pub-id-type="pmid">
         25530469
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0385">
       <label>
        77
       </label>
       <element-citation id="sbref0385" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Phylogenetic and recombination analysis of coronavirus HKU1, a novel coronavirus from patients with pneumonia
        </article-title>
        <source>
         Arch. Virol.
        </source>
        <volume>
         150
        </volume>
        <year>
         2005
        </year>
        <fpage>
         2299
        </fpage>
        <lpage>
         2311
        </lpage>
        <pub-id pub-id-type="pmid">
         15986174
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0390">
       <label>
        78
       </label>
       <element-citation id="sbref0390" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stanhope
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence from the evolutionary analysis of nucleotide sequences for a recombinant history of SARS-CoV
        </article-title>
        <source>
         Infect. Genet. Evol.
        </source>
        <volume>
         4
        </volume>
        <year>
         2004
        </year>
        <fpage>
         15
        </fpage>
        <lpage>
         19
        </lpage>
        <pub-id pub-id-type="pmid">
         15019585
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0395">
       <label>
        79
       </label>
       <element-citation id="sbref0395" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Testing the hypothesis of a recombinant origin of the SARS-associated coronavirus
        </article-title>
        <source>
         Arch. Virol.
        </source>
        <volume>
         150
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="pmid">
         15480857
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0400">
       <label>
        80
       </label>
       <element-citation id="sbref0400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Origin and possible genetic recombination of the Middle East respiratory syndrome coronavirus from the first imported case in China: phylogenetics and coalescence analysis
        </article-title>
        <source>
         Mbio
        </source>
        <volume>
         6
        </volume>
        <year>
         2015
        </year>
        <fpage>
         e01280
        </fpage>
        <lpage>
         01215
        </lpage>
        <pub-id pub-id-type="pmid">
         26350969
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0405">
       <label>
        81
       </label>
       <element-citation id="sbref0405" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pene
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus 229E-related pneumonia in immunocompromised patients
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         37
        </volume>
        <year>
         2003
        </year>
        <fpage>
         929
        </fpage>
        <lpage>
         932
        </lpage>
        <pub-id pub-id-type="pmid">
         13130404
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0410">
       <label>
        82
       </label>
       <element-citation id="sbref0410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Papa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses in children, Greece
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         13
        </volume>
        <year>
         2007
        </year>
        <fpage>
         947
        </fpage>
        <lpage>
         949
        </lpage>
        <pub-id pub-id-type="pmid">
         17582904
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0415">
       <label>
        83
       </label>
       <element-citation id="sbref0415" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cabeca
          </surname>
          <given-names>
           T.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical features of human coronavirus infections among different subsets of patients
        </article-title>
        <source>
         Influenza Other Respir. Virus.
        </source>
        <volume>
         7
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1040
        </fpage>
        <lpage>
         1047
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0420">
       <label>
        84
       </label>
       <element-citation id="sbref0420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         87
        </volume>
        <year>
         2013
        </year>
        <fpage>
         6081
        </fpage>
        <lpage>
         6090
        </lpage>
        <pub-id pub-id-type="pmid">
         23427150
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0425">
       <label>
        85
       </label>
       <element-citation id="sbref0425" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cleri
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe Acute Respiratory Syndrome (SARS)
        </article-title>
        <source>
         Infect. Dis. Clin. N. Am.
        </source>
        <volume>
         24
        </volume>
        <year>
         2010
        </year>
        <fpage>
         175
        </fpage>
        <lpage>
         202
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0430">
       <label>
        86
       </label>
       <element-citation id="sbref0430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multiple organ infection and the pathogenesis of SARS
        </article-title>
        <source>
         J. Exp. Med.
        </source>
        <volume>
         202
        </volume>
        <year>
         2005
        </year>
        <fpage>
         415
        </fpage>
        <lpage>
         424
        </lpage>
        <pub-id pub-id-type="pmid">
         16043521
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0435">
       <label>
        87
       </label>
       <element-citation id="sbref0435" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           K.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A cluster of cases of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         348
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1977
        </fpage>
        <lpage>
         1985
        </lpage>
        <pub-id pub-id-type="pmid">
         12671062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0440">
       <label>
        88
       </label>
       <element-citation id="sbref0440" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1767
        </fpage>
        <lpage>
         1772
        </lpage>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0445">
       <label>
        89
       </label>
       <element-citation id="sbref0445" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moes
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium
        </article-title>
        <source>
         BMC Infect. Dis.
        </source>
        <volume>
         5
        </volume>
        <year>
         2005
        </year>
        <fpage>
         6
        </fpage>
        <pub-id pub-id-type="pmid">
         15686594
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0450">
       <label>
        90
       </label>
       <element-citation id="sbref0450" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bastien
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus NL63 infection in Canada
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         191
        </volume>
        <year>
         2005
        </year>
        <fpage>
         503
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         15655772
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0455">
       <label>
        91
       </label>
       <element-citation id="sbref0455" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Croup is associated with the novel coronavirus NL63
        </article-title>
        <source>
         PLoS Med.
        </source>
        <volume>
         2
        </volume>
        <year>
         2005
        </year>
        <fpage>
         764
        </fpage>
        <lpage>
         770
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0460">
       <label>
        92
       </label>
       <element-citation id="sbref0460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         40
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1721
        </fpage>
        <lpage>
         1729
        </lpage>
        <pub-id pub-id-type="pmid">
         15909257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0465">
       <label>
        93
       </label>
       <element-citation id="sbref0465" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wat
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The common cold: a review of the literature
        </article-title>
        <source>
         Eur. J. Intern. Med.
        </source>
        <volume>
         15
        </volume>
        <year>
         2004
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         88
        </lpage>
        <pub-id pub-id-type="pmid">
         15172021
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0470">
       <label>
        94
       </label>
       <element-citation id="sbref0470" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of viruses identified recently in children with acute wheezing
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         79
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1238
        </fpage>
        <lpage>
         1243
        </lpage>
        <pub-id pub-id-type="pmid">
         17597481
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0475">
       <label>
        95
       </label>
       <element-citation id="sbref0475" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          WHO Mers-Cov Research Group
         </collab>
        </person-group>
        <article-title>
         State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans
        </article-title>
        <source>
         PLoS Curr. Outbreaks
        </source>
        <year>
         2013
        </year>
        <comment>
         Published online November 12, 2013
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0480">
       <label>
        96
       </label>
       <element-citation id="sbref0480" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral Shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         62
        </volume>
        <year>
         2016
        </year>
        <fpage>
         477
        </fpage>
        <lpage>
         483
        </lpage>
        <pub-id pub-id-type="pmid">
         26565003
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0005">
      <title>
       Acknowledgments
      </title>
      <p>
       This work was supported by the National Natural Science Foundation of China (81461168030), the China National Grand S&amp;T Special Project (2014ZX10004-001-006), and the National Key Program for Infectious Disease of China (2016ZX10004222). G.F.G. is a leading principal investigator of the NSFC Innovative Research Group (grant number 81321063). J.Z and S.S are supported by the Priority Academic Program Development of Jiangsu Higher Education Institution. G.W. is the recipient of a Banting Postdoctoral Fellowship from the Canadian Institutes of Health Research (CIHR), and a President's International Fellowship Initiative from the Chinese Academy of Sciences (CAS). All authors declare no competing interests.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Emerg Microbes Infect
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Emerg Microbes Infect
      </journal-id>
      <journal-title-group>
       <journal-title>
        Emerging Microbes &amp; Infections
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2222-1751
      </issn>
      <publisher>
       <publisher-name>
        Nature Publishing Group
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       28634353
      </article-id>
      <article-id pub-id-type="pmc">
       5584481
      </article-id>
      <article-id pub-id-type="pii">
       emi201737
      </article-id>
      <article-id pub-id-type="doi">
       10.1038/emi.2017.37
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Original Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        <italic>
         Coronavirus HKU15
        </italic>
        in respiratory tract of pigs and first discovery of coronavirus quasispecies in 5′-untranslated region
       </article-title>
       <alt-title alt-title-type="running">
        <italic>
         Coronavirus HKU15
        </italic>
        in porcine respiratory tract
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Woo
         </surname>
         <given-names>
          Patrick CY
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
        <xref ref-type="aff" rid="aff5">
         5
        </xref>
        <xref ref-type="author-notes" rid="note1">
         <sup>
          ✝
         </sup>
        </xref>
        <xref ref-type="corresp" rid="caf1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lau
         </surname>
         <given-names>
          Susanna KP
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
        <xref ref-type="aff" rid="aff5">
         5
        </xref>
        <xref ref-type="author-notes" rid="note1">
         <sup>
          ✝
         </sup>
        </xref>
        <xref ref-type="corresp" rid="caf2">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tsang
         </surname>
         <given-names>
          Chi-Ching
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0001-6705-2866
        </contrib-id>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lau
         </surname>
         <given-names>
          Candy CY
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wong
         </surname>
         <given-names>
          Po-Chun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chow
         </surname>
         <given-names>
          Franklin WN
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Fong
         </surname>
         <given-names>
          Jordan YH
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          Kwok-Yung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
        <xref ref-type="aff" rid="aff5">
         5
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         1
        </label>
        <institution>
         Department of Microbiology, The University of Hong Kong, Hong Kong
        </institution>
        ,
        <country>
         China
        </country>
       </aff>
       <aff id="aff2">
        <label>
         2
        </label>
        <institution>
         Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong
        </institution>
        ,
        <country>
         China
        </country>
       </aff>
       <aff id="aff3">
        <label>
         3
        </label>
        <institution>
         State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong
        </institution>
        ,
        <country>
         China
        </country>
       </aff>
       <aff id="aff4">
        <label>
         4
        </label>
        <institution>
         Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong
        </institution>
        ,
        <country>
         China
        </country>
       </aff>
       <aff id="aff5">
        <label>
         5
        </label>
        <institution>
         Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, The University of Hong Kong, Hong Kong
        </institution>
        ,
        <country>
         China
        </country>
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="caf1">
        <label>
         *
        </label>
        E-mail:
        <email>
         pcywoo@hku.hk
        </email>
       </corresp>
       <corresp id="caf2">
        <label>
         *
        </label>
        E-mail:
        <email>
         skplau@hku.hk
        </email>
       </corresp>
       <fn fn-type="equal" id="note1">
        <label>
         ✝
        </label>
        <p>
         These authors contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        06
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        21
       </day>
       <month>
        06
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        1
       </day>
       <month>
        6
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <volume>
       6
      </volume>
      <issue>
       6
      </issue>
      <fpage>
       e53
      </fpage>
      <lpage>
      </lpage>
      <history>
       <date date-type="received">
        <day>
         13
        </day>
        <month>
         12
        </month>
        <year>
         2016
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         13
        </day>
        <month>
         03
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="accepted">
        <day>
         09
        </day>
        <month>
         04
        </month>
        <year>
         2017
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2017 The Author(s)
       </copyright-statement>
       <copyright-year>
        2017
       </copyright-year>
       <copyright-holder>
        The Author(s)
       </copyright-holder>
       <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">
        <!--author-paid-->
        <license-p>
         This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        <italic>
         Coronavirus HKU15
        </italic>
        is a deltacoronavirus that was discovered in fecal samples of pigs in Hong Kong in 2012. Over the past three years,
        <italic>
         Coronavirus HKU15
        </italic>
        has been widely detected in pigs in East/Southeast Asia and North America and has been associated with fatal outbreaks. In all such epidemiological studies, the virus was generally only detected in fecal/intestinal samples. In this molecular epidemiology study, we detected
        <italic>
         Coronavirus HKU15
        </italic>
        in 9.6% of the nasopharyngeal samples obtained from 249 pigs in Hong Kong. Samples that tested positive were mostly collected during winter. Complete genome sequencing of the
        <italic>
         Coronavirus HKU15
        </italic>
        in two nasopharyngeal samples revealed quasispecies in one of the samples. Two of the polymorphic sites involved indels, but the other two involved transition substitutions. Phylogenetic analysis showed that the two nasopharyngeal strains in the present study were most closely related to the strains PDCoV/CHJXNI2/2015 from Jiangxi, China, and CH/Sichuan/S27/2012 from Sichuan, China. The outbreak strains in the United States possessed highly similar genome sequences and were clustered monophyletically, whereas the Asian strains were more diverse and paraphyletic. The detection of
        <italic>
         Coronavirus HKU15
        </italic>
        in respiratory tracts of pigs implies that in addition to enteric infections,
        <italic>
         Coronavirus HKU15
        </italic>
        may be able to cause respiratory infections in pigs and that in addition to fecal-oral transmission, the virus could possibly spread through the respiratory route. The presence of the virus in respiratory samples provides an alternative clinical sample to confirm the diagnosis of
        <italic>
         Coronavirus HKU15
        </italic>
        infection. Quasispecies were unprecedentedly observed in the 5′-untranslated region of coronavirus genomes.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        infection
       </kwd>
       <kwd>
        pig
       </kwd>
       <kwd>
        respiratory tract
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec>
     <title>
      INTRODUCTION
     </title>
     <p>
      Coronaviruses (CoVs) are found in a wide variety of animals, in which they can lead to enteric, hepatic, neurological and respiratory illnesses of differing severity. On the basis of genotypic and serological characterization, CoVs were traditionally divided into three distinct groups. In 2009, the Coronavirus Study Group of the International Committee for Taxonomy of Viruses replaced the traditional CoV groups 1, 2 and 3 with three genera,
      <italic>
       Alphacoronavirus
      </italic>
      ,
      <italic>
       Betacoronavirus
      </italic>
      and
      <italic>
       Gammacoronavirus
      </italic>
      , respectively.
      <sup>
       <xref ref-type="bibr" rid="bib1">
        1
       </xref>
      </sup>
      In the same year, we discovered three novel CoVs in avian cloacal swabs.
      <sup>
       <xref ref-type="bibr" rid="bib2">
        2
       </xref>
      </sup>
      These CoVs formed a distinct novel CoV genus, named
      <italic>
       Deltacoronavirus.
      </italic>
      <sup>
       <xref ref-type="bibr" rid="bib1">
        1
       </xref>
      </sup>
      Subsequently, in a large epidemiological study, we discovered seven additional deltacoronaviruses.
      <sup>
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
      </sup>
      Interestingly, one of these deltacoronaviruses, which was originally named porcine CoV HKU15, was found in fecal samples of pigs in Hong Kong, and it is the only mammalian deltacoronavirus.
      <sup>
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
      </sup>
      In 2016, the Coronavirus Study Group of the International Committee for Taxonomy of Viruses rectified the species name for this virus to
      <italic>
       Coronavirus HKU15.
      </italic>
      <sup>
       <xref ref-type="bibr" rid="bib4">
        4
       </xref>
      </sup>
     </p>
     <p>
      Over the past three years,
      <italic>
       Coronavirus HKU15
      </italic>
      has been widely detected in pigs in East/Southeast Asia and North America and was found to be associated with fatal outbreaks.
      <sup>
       <xref ref-type="bibr" rid="bib5">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="bib6">
        6
       </xref>
       ,
       <xref ref-type="bibr" rid="bib7">
        7
       </xref>
       ,
       <xref ref-type="bibr" rid="bib8">
        8
       </xref>
       ,
       <xref ref-type="bibr" rid="bib9">
        9
       </xref>
       ,
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib13">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="bib16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="bib17">
        17
       </xref>
       ,
       <xref ref-type="bibr" rid="bib18">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="bib20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
      </sup>
      In these epidemiological studies,
      <italic>
       Coronavirus HKU15
      </italic>
      was generally only detected in fecal/intestinal samples. However, some CoVs, such as transmissible gastroenteritis CoV (TGEV)/porcine respiratory CoV (PRCV) of
      <italic>
       Alphacoronavirus 1
      </italic>
      and bovine CoV of
      <italic>
       Betacoronavirus 1
      </italic>
      , could be detected consistently in both fecal and respiratory samples.
      <sup>
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
      </sup>
      Therefore, we hypothesized that
      <italic>
       Coronavirus HKU15
      </italic>
      may also be present in respiratory samples of pigs, which has implications for its transmission and potential role in respiratory diseases and for the use of nasopharyngeal sampling as an alternative method of identifying infected pigs. To test this hypothesis, we performed a molecular epidemiology study on nasopharyngeal samples collected from pigs in Hong Kong. Two complete genomes of the ‘respiratory’
      <italic>
       Coronavirus HKU15
      </italic>
      were sequenced, and comparative genomic and phylogenetic studies were performed. The implications of the presence of
      <italic>
       Coronavirus HKU15
      </italic>
      in respiratory samples are also discussed.
     </p>
    </sec>
    <sec>
     <title>
      MATERIALS AND METHODS
     </title>
     <sec>
      <title>
       Sample collection
      </title>
      <p>
       Nasopharyngeal samples from pigs were collected in Hong Kong over a 26-month period (January 2012–February 2014). These samples were obtained from slaughterhouses and pig farms in Hong Kong with the assistance of the Veterinary Public Health Section, Food and Environmental Hygiene Department; and the Agriculture, Fisheries and Conservation Department of the Government of Hong Kong. Immediately after sample collection, each nasopharyngeal swab was submerged in viral transport medium for viral transport and maintenance.
      </p>
     </sec>
     <sec>
      <title>
       RNA extraction and reverse transcription
      </title>
      <p>
       Viral RNAs were extracted from the nasopharyngeal samples of pigs by using 200 μL of inoculated viral transport medium for each sample and by utilizing the EZ1 Advanced XL system (Qiagen, Hilden, Germany) and EZ1 Virus Mini Kit v2.0 (Qiagen) according to the manufacturer’s protocol with RNase-free water as the eluent. Reverse transcription (RT) was performed using the SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol by random priming.
      </p>
     </sec>
     <sec>
      <title>
       <italic>
        Coronavirus
       </italic>
       HKU15 screening
      </title>
      <p>
       Detection of
       <italic>
        Coronavirus HKU15
       </italic>
       was performed by polymerase chain reaction (PCR) amplifying a 289-bp fragment of the RNA-dependent RNA polymerase (RdRp) gene, using the specific primer pair LPW14077 (5′-ACA CAC TTG CTG TAA CCA AA-3′) and LPW14080 (5′-ATC ATT AGA GTC ACC ACG AT-3′). PCR and DNA sequencing were carried out following our previous publications with slight modification.
       <sup>
        <xref ref-type="bibr" rid="bib26">
         26
        </xref>
        ,
        <xref ref-type="bibr" rid="bib27">
         27
        </xref>
       </sup>
       Briefly, each PCR mixture contained PCR buffer (50 mM of KCl, 10 mM of Tris-HCl at pH 8.3 and 3 mM of MgCl
       <sub>
        2
       </sub>
       ; Applied Biosystems, Foster City, CA, USA), 200 μM of each deoxynucleoside triphosphate (Roche Diagnostics, Basel, Switzerland), 1 μM of each primer (Invitrogen), 1.0 U of AmpliTag Gold DNA polymerase (Applied Biosystems) and cDNA. The mixtures were subjected to 60 thermocycles of 94 °C for 1 min, 50 °C for 1 min and 72 °C for 1 min, with an initial denaturation at 95 °C for 10 min and a final extension at 72 °C for 10 min for DNA amplification using the GeneAmp PCR System 9700 automated thermal cycler (Applied Biosystems). Standard precautions were taken to avoid contamination, and no false-positive result was observed for the negative controls. PCR products were agarose gel-purified using the QIAquick Gel Extraction kit (Qiagen). Both strands of the PCR products were sequenced twice by the ABI Prism 3130
       <italic>
        xl
       </italic>
       Genetic Analyzer (Applied Biosystems) using the two PCR primers.
      </p>
     </sec>
     <sec>
      <title>
       Complete genome sequencing
      </title>
      <p>
       The genomes of two
       <italic>
        Coronavirus HKU15
       </italic>
       strains detected in the nasopharyngeal samples of two different pigs were sequenced following our previous publications
       <sup>
        <xref ref-type="bibr" rid="bib26">
         26
        </xref>
        ,
        <xref ref-type="bibr" rid="bib27">
         27
        </xref>
       </sup>
       with modifications. Briefly, viral RNAs were converted to cDNAs using SuperScript III reverse transcriptase with a combined random priming and oligo(dT) priming strategy. The cDNAs were PCR-amplified by primers (
       <xref ref-type="supplementary-material" rid="sup1">
        Supplementary Tables S1 and S2
       </xref>
       ) that were designed by multiple alignment of the genome sequences of other
       <italic>
        Coronavirus HKU15
       </italic>
       strains with complete genomes available or from the results of the first and subsequent rounds of PCR–sequencing. PCRs were performed using the iProof High-Fidelity PCR kit (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s protocol, and DNA sequencing was performed as mentioned above. When ambiguous peaks were observed consistently in the electropherograms after several attempts of PCR-sequencing for certain genomic regions, cloning followed by plasmid sequencing was performed according to our previous publication,
       <sup>
        <xref ref-type="bibr" rid="bib28">
         28
        </xref>
       </sup>
       except the Zero Blunt TOPO PCR Cloning kit (Invitrogen) was used to resolve the sequence ambiguities. PCRs using recombinant plasmids as templates were also performed to confirm that indels at mononucleotide polymeric regions were not the result of polymerase slippage. The 5′ ends of the viral genomes were amplified and sequenced by the rapid amplification of cDNA ends (RACE) using the SMARTer RACE 5′/3′ kit (Clontech Laboratories, Mountain View, CA, USA) according to the manufacturer’s protocol with the reverse primers LPW15379 (5′-TGG GTA ATG TGT CCG CTG ACG GGC GGT G-3′), LPW15380 (5′-AGA AGT GGT GGA TGG TCA GAG GAA CGG T-3′) and LPW16265 (5′-GTG GCT GGT TTC CAG GTA ATC TA-3′). The sequences of the PCR products were then assembled manually to obtain the genomes of the two nasopharyngeal strains.
      </p>
     </sec>
     <sec>
      <title>
       Phylogenetic characterization
      </title>
      <p>
       Pairwise alignment was performed using BioEdit 7.2.5 (optimal GLOBAL alignment)
       <sup>
        <xref ref-type="bibr" rid="bib29">
         29
        </xref>
       </sup>
       or EMBOSS Stretcher (Nucleotide Alignment);
       <sup>
        <xref ref-type="bibr" rid="bib30">
         30
        </xref>
       </sup>
       whereas multiple sequence alignment was performed using MUSCLE 3.8,
       <sup>
        <xref ref-type="bibr" rid="bib31">
         31
        </xref>
       </sup>
       where the aligned sequences were further manually inspected and edited. Tests for substitution models and phylogenetic analysis by the maximum likelihood method were performed using MEGA 6.0.6.
       <sup>
        <xref ref-type="bibr" rid="bib32">
         32
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       Estimation of divergence times
      </title>
      <p>
       Divergence times for the
       <italic>
        Coronavirus HKU15
       </italic>
       strains were calculated based on the complete genome sequence data, utilizing the Bayesian Markov chain Monte Carlo method using BEAST 1.8.0
       <sup>
        <xref ref-type="bibr" rid="bib33">
         33
        </xref>
       </sup>
       with the substitution model GTR (general time-reversible model)+G (gamma-distributed rate variation)+I (estimated proportion of invariable sites), a strict molecular clock, and a constant coalescent. Fifty million generations were run with trees sampled every 1000th generation to yield 50 000 trees. Convergence was assessed based on the effective sampling size after a 10% burn-in using Tracer 1.6.0. The mean time to the most recent common ancestor (tMRCA) and the highest posterior density (HPD) regions at 95% were calculated. The trees, after a 10% burn-in, were summarized as a single tree using TreeAnnotator 1.8.0 by choosing the tree with the maximum sum of posterior probabilities (maximum clade credibility) and viewed using FigTree 1.4.0.
      </p>
     </sec>
     <sec>
      <title>
       Nucleotide sequence accession number
      </title>
      <p>
       The complete genome sequences of the two nasopharyngeal
       <italic>
        Coronavirus HKU15
       </italic>
       strains were deposited into the International Nucleotide Sequence Databases with accession numbers LC216914 and LC216915.
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      RESULTS
     </title>
     <sec>
      <title>
       Animal surveillance
      </title>
      <p>
       A total of 249 nasopharyngeal samples from 249 pigs were tested. RT-PCR for a 289-bp fragment of the RdRp gene of
       <italic>
        Coronavirus HKU15
       </italic>
       was positive in 24 (9.6%) of the 249 nasopharyngeal samples. The samples that tested positive were mostly collected during winter (December–March) (
       <xref ref-type="fig" rid="fig1">
        Figure 1
       </xref>
       ). DNA sequencing showed that seven sequence variants were detected among the 24 positive samples, and pairwise alignment showed that these seven sequence variants possessed 98.7%–100% sequence identity to the corresponding region in the RdRp gene of
       <italic>
        Coronavirus HKU15
       </italic>
       strain HKU15-155 that we previously found in fecal samples of pigs in Hong Kong
       <sup>
        <xref ref-type="bibr" rid="bib3">
         3
        </xref>
       </sup>
       (
       <xref ref-type="supplementary-material" rid="sup1">
        Supplementary Figure S1
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Complete genome sequencing and genome analysis
      </title>
      <p>
       Complete genome sequencing was performed for the
       <italic>
        Coronavirus HKU15
       </italic>
       found in two of the positive nasopharyngeal samples (S579N and S582N). Excluding the 3′ poly(A) tail, the genomes of S579N and S582N were 25 411–25 413 and 25 397 nucleotides long, respectively. The genome organization of the two strains was the same as that of other
       <italic>
        Coronavirus HKU15
       </italic>
       strains. The lengths of the seven open reading frames (ORFs) of the two strains S579N/S582N were 18 803/18 788, 3480, 252, 654, 285, 1029 and 603 bp, respectively. The genomes of the two strains possessed 98.9%–99.2% sequence identity to that of the representative isolate HKU15-155. Quasispecies were detected in one of the samples (S579N) at the 5′ genomic region via two independent nested PCRs targeting the 122nd–505th bases of the genome using two different primer pairs for the first round and the same primer pair for the second round of reaction. For S579N, direct sequencing of the PCR products yielded ambiguous peaks in the sequencing electropherograms, which could only be resolved after cloning (
       <xref ref-type="fig" rid="fig2">
        Figure 2
       </xref>
       ). Post-cloning DNA sequencing revealed that there were six sequence variants, with four polymorphic sites, for this genomic region (
       <xref ref-type="fig" rid="fig2">
        Figure 2
       </xref>
       ). Two of the polymorphic sites, located at the 189th and 376th nucleotide positions, involved indels (ΔT and ΔA/C, respectively), whereas the other two polymorphic sites, located at the 292nd and 296th nucleotide positions, involved transition substitutions (T→C and G→A, respectively). Additionally, PCR–DNA sequencing using the recombinant plasmids as amplification templates did not generate the same sequence ambiguities observed in the pre-cloning experiment.
      </p>
     </sec>
     <sec>
      <title>
       Phylogenetic characterization
      </title>
      <p>
       Phylogenetic analysis of the complete genomes of the two nasopharyngeal strains and other
       <italic>
        Coronavirus HKU15
       </italic>
       strains showed that the outbreak strains in the United States possessed highly similar genome sequences and that they were all clustered together monophyletically, whereas the Asian strains were more diverse and paraphyletic, with the Lao and Thai strains occupying the basal lineage; however, the South Korean strain KNU14-04 was more similar to the US strains than to the other Asian strains (
       <xref ref-type="fig" rid="fig3">
        Figure 3
       </xref>
       and
       <xref ref-type="supplementary-material" rid="sup1">
        Supplementary Figure S2
       </xref>
       ). The two nasopharyngeal strains S579N and S582N in the present study were most closely related to strains PDCoV/CHJXNI2/2015 from Jiangxi, China and CH/Sichuan/S27/2012 from Sichuan, China (
       <xref ref-type="fig" rid="fig3">
        Figure 3
       </xref>
       and
       <xref ref-type="supplementary-material" rid="sup1">
        Supplementary Figure S2
       </xref>
       ). Similar to other Chinese and Hong Kong strains (except CHN-AH-2004 and HKU15-44) and a Thai strain (P23_15_TT_1115), there was a deletion of an asparagine residue of the asparagine trimer located at the 50th–52nd amino-acid positions in the S protein compared with the other strains from South Korea, Laos and United States and to two other strains from Thailand. The deletion of this codon has been proposed as a genetic marker for the differentiation of China and Hong Kong strains from US and South Korean strains.
       <sup>
        <xref ref-type="bibr" rid="bib12">
         12
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       Estimation of divergence dates
      </title>
      <p>
       The estimated mean evolutionary rate of the complete genome sequence data set was 6.549 × 10
       <sup>
        −4
       </sup>
       (95% HPD: 5.632–7.476 × 10
       <sup>
        −4
       </sup>
       ) substitutions per site per year, which is approximately 1.7-fold higher than that estimated in a previous study.
       <sup>
        <xref ref-type="bibr" rid="bib19">
         19
        </xref>
       </sup>
       The root of the tree was September 1638 (95% HPD: June 1570–March 1698). The tMRCA of the diversity of
       <italic>
        Coronavirus HKU15
       </italic>
       was dated to June 1991 (95% HPD: November 1987–June 1994); and the tMRCA of the Thai/Laos strains was traced back to September 2014 (95% HPD: May 2014–January 2015). The tMRCAs for the clade containing US/Korean strains was estimated to be October 2012 (95% HPD: June 2012–January 2013), which is slightly delayed compared with that estimated in a previous study.
       <sup>
        <xref ref-type="bibr" rid="bib19">
         19
        </xref>
       </sup>
       For the two nasopharyngeal strains characterized in this study (S579N and S582N), they were estimated to have diverged from their respective MRCAs in December 2011 (95% HPD: May 2011–July 2012) and August 2009 (95% HPD: November 2008–April 2010), respectively (
       <xref ref-type="fig" rid="fig4">
        Figure 4
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      DISCUSSION
     </title>
     <p>
      <italic>
       Coronavirus HKU15
      </italic>
      was detected in nasopharyngeal samples of pigs. Although
      <italic>
       Coronavirus HKU15
      </italic>
      has been widely detected in various locations around the Pacific Ocean, including Canada,
      <sup>
       <xref ref-type="bibr" rid="bib7">
        7
       </xref>
      </sup>
      China,
      <sup>
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib13">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="bib16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="bib17">
        17
       </xref>
      </sup>
      Hong Kong,
      <sup>
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
      </sup>
      Laos,
      <sup>
       <xref ref-type="bibr" rid="bib22">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
      </sup>
      Mexico,
      <sup>
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
      </sup>
      South Korea,
      <sup>
       <xref ref-type="bibr" rid="bib5">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="bib21">
        21
       </xref>
      </sup>
      Thailand,
      <sup>
       <xref ref-type="bibr" rid="bib20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
      </sup>
      Vietnam
      <sup>
       <xref ref-type="bibr" rid="bib23">
        23
       </xref>
      </sup>
      and the United States,
      <sup>
       <xref ref-type="bibr" rid="bib6">
        6
       </xref>
       ,
       <xref ref-type="bibr" rid="bib7">
        7
       </xref>
       ,
       <xref ref-type="bibr" rid="bib8">
        8
       </xref>
       ,
       <xref ref-type="bibr" rid="bib9">
        9
       </xref>
       ,
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="bib18">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
      </sup>
      the virus has principally been found in fecal or intestinal specimens. There have been a few exceptional circumstances; in one study, the presence of
      <italic>
       Coronavirus HKU15
      </italic>
      was reported in the blood, liver, lung and kidney of one pig,
      <sup>
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
      </sup>
      and in a few other studies,
      <italic>
       Coronavirus HKU15
      </italic>
      was found to exist in the blood (
      <italic>
       n
      </italic>
      =10), mesenteric lymph node (
      <italic>
       n
      </italic>
      =2) and saliva (
      <italic>
       n
      </italic>
      =10)/oral fluid (
      <italic>
       n
      </italic>
      =73) of pigs,
      <sup>
       <xref ref-type="bibr" rid="bib7">
        7
       </xref>
       ,
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="bib20">
        20
       </xref>
      </sup>
      implying that
      <italic>
       Coronavirus HKU15
      </italic>
      can cause systemic infections in occasional cases. In this study,
      <italic>
       Coronavirus HKU15
      </italic>
      was found in 9.6% of the nasopharyngeal samples of pigs, which is similar to the 10.1% positive rate of
      <italic>
       Coronavirus HKU15
      </italic>
      in fecal samples of pigs that we reported previously.
      <sup>
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
      </sup>
      Seasonal variation in the detection rate of
      <italic>
       Coronavirus HKU15
      </italic>
      from pigs was noted, where most of the positive samples were collected in winter. This is similar to the pattern of seasonal variation in a surveillance study carried out in the United States, where the detection rate for
      <italic>
       Coronavirus HKU15
      </italic>
      was much lower during summer.
      <sup>
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
      </sup>
      It has recently been confirmed that
      <italic>
       Coronavirus HKU15
      </italic>
      is able to cause swine enteric infections by infecting gnotobiotic and conventional pigs with
      <italic>
       Coronavirus HKU15
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
      </sup>
      The detection of
      <italic>
       Coronavirus HKU15
      </italic>
      in respiratory tracts of pigs has the following implications. First, in addition to enteric infections,
      <italic>
       Coronavirus HKU15
      </italic>
      may be able to cause respiratory infections in pigs. Second, in addition to fecal-oral transmission, the virus may be able to spread through the respiratory route. Third, the presence of the virus in respiratory samples provides an alternative clinical sample to confirm the diagnosis of
      <italic>
       Coronavirus HKU15
      </italic>
      infection. Further studies will determine the full spectrum of clinical diseases and pathologies associated with
      <italic>
       Coronavirus HKU15.
      </italic>
     </p>
     <p>
      From the data of the present study, both the ‘enteric’ and ‘respiratory’
      <italic>
       Coronavirus HKU15
      </italic>
      may possess similar properties. A number of animal CoVs possess dual or multiple tissue tropisms. For example, TGEV, which is another enteropathogenic CoV that infects pigs, could also be found in the nasopharynx of pigs as PRCV, which is a deletion mutant of TGEV.
      <sup>
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
      </sup>
      Moreover, bovine CoV is both an enteric and a respiratory pathogen in cattle.
      <sup>
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
      </sup>
      Similar to TGEV/PRCV,
      <italic>
       Coronavirus HKU15
      </italic>
      is recovered from both respiratory and gastrointestinal samples. However, unlike TGEV/PRCV, in which there is a 621–681 nucleotide deletion at the 5′ end of the spike (S) gene leading to a loss of 1–2 antigenic sites in PRCV,
      <sup>
       <xref ref-type="bibr" rid="bib34">
        34
       </xref>
      </sup>
      comparative genome analysis of
      <italic>
       Coronavirus HKU15
      </italic>
      from respiratory and fecal samples did not show any obvious difference in their S proteins or other parts of their genomes. Phylogenetic analysis also did not reveal a separate clustering of fecal/intestinal and nasopharyngeal isolates (
      <xref ref-type="fig" rid="fig2">
       Figure 2
      </xref>
      ). Further cell culture experiments are required to confirm whether all strains of this species possess intrinsic tropism to both enteric and respiratory tissues.
     </p>
     <p>
      This is also the first report of CoV quasispecies in the 5′-untranslated region (UTR). In one (S579N) of the two
      <italic>
       Coronavirus HKU15
      </italic>
      genomes that we sequenced in this study, variant sites were observed at four positions; two of them were due to nucleotide substitutions, and the other two were results of indels at mononucleotide polymeric regions (189th and 376th bases). These two indels were genuine variant sites instead of being due to polymerase slippage during the amplification process because recombinant plasmid-dependent PCR–sequencing no longer resulted in sequence ambiguities in the electropherograms. Although the existence of quasispecies has been reported in CoVs, the variant sites were found in coding regions or 3′-UTR.
      <sup>
       <xref ref-type="bibr" rid="bib35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="bib36">
        36
       </xref>
       ,
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="bib38">
        38
       </xref>
      </sup>
      In the case of severe acute respiratory syndrome-related coronavirus, all of the variant sites observed in the quasispecies were located at the S gene.
      <sup>
       <xref ref-type="bibr" rid="bib35">
        35
       </xref>
      </sup>
      For bovine CoV, one of the two strains with naturally occurring intra-isolate quasispecies had all seven variant sites located at ORF1a, whereas for the other strain with naturally occurring intra-isolate quasispecies, there were 85 polymorphic sites scattered across ORF1a (
      <italic>
       n
      </italic>
      =28), ORF1b (
      <italic>
       n
      </italic>
      =19), 32 kDa-non-structural protein (NSP) gene (
      <italic>
       n
      </italic>
      =6), hemagglutinin esterase (HE) gene (
      <italic>
       n
      </italic>
      =2), S gene (
      <italic>
       n
      </italic>
      =18), 4.9 kDa-NSP gene (
      <italic>
       n
      </italic>
      =2), 4.8 kDa-NSP gene (
      <italic>
       n
      </italic>
      =2), membrane (M) gene (
      <italic>
       n
      </italic>
      =2), nucleocapsid (N) gene (
      <italic>
       n
      </italic>
      =5) and 3′-UTR (
      <italic>
       n
      </italic>
      =1).
      <sup>
       <xref ref-type="bibr" rid="bib36">
        36
       </xref>
      </sup>
      Similar to bovine CoV, Middle East respiratory syndrome-related coronavirus also possessed all the intra-host single nucleotide variations throughout its genome except the 5′-UTR.
      <sup>
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="bib38">
        38
       </xref>
      </sup>
      In this study, all four variant sites (189 ΔT, 292 T→C, 296 G→A and 376 ΔA/C) were present in the 5′-UTR and were not located in the leader sequence or the transcription regulatory sequence. We speculate that the existence of quasispecies in CoVs may play a role in CoV evolution, in addition to the more well-known high-recombination and mutation rates in CoV genomes.
      <sup>
       <xref ref-type="bibr" rid="bib39">
        39
       </xref>
      </sup>
     </p>
    </sec>
    <back>
     <ack>
      <p>
       This work was partly supported by the Consultancy Service for Enhancing Laboratory Surveillance of Emerging Infectious Disease for the Department of Health, Government of the Hong Kong Special Administrative Region; Theme-based Research Scheme (Project No. T11/707/15), University Grants Committee, Hong Kong; Strategic Research Theme Fund, Mary Sun Medical Scholarship, University Postgraduate Scholarship, Wong Ching Yee Medical Postgraduate Scholarship, and YS and Christabel Lung Postgraduate Scholarship, The University of Hong Kong, Hong Kong; and Croucher Senior Medical Research Fellowship, Croucher Foundation, Hong Kong. The funding sources had no role in study design, data collection, analysis, interpretation, or writing of the report. The authors alone are responsible for the content and the writing of the manuscript. The authors thank the staff from the Veterinary Public Health Section, Food and Environmental Hygiene Department as well as the Agriculture, Fisheries and Conservation Department of the Hong Kong Government for their help in collecting the porcine nasopharyngeal samples.
      </p>
     </ack>
     <fn-group>
      <fn>
       <p>
        <xref ref-type="supplementary-material" rid="sup1">
         Supplementary Information
        </xref>
        for this article can be found on the
        <italic>
         Emerging Microbes
        </italic>
        &amp;
        <italic>
         Infections
        </italic>
        website (http://www.nature.com/emi)
       </p>
      </fn>
     </fn-group>
     <ref-list>
      <ref id="bib1">
       <mixed-citation publication-type="other">
        de Groot RJ, Baker SC, Baric R et al. Family—Coronaviridae. In: Adams MJ, Carstens EB, Lefkowitz EJ (eds). Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses, International Union of Microbiological Societies, Virology Division. San Diego, CA: Elsevier,
        <year>
         2012
        </year>
        :
        <fpage>
         806
        </fpage>
        –828.
       </mixed-citation>
      </ref>
      <ref id="bib2">
       <mixed-citation publication-type="journal">
        Woo PCY, Lau SKP, Lam CSF et al.
        <article-title>
         Comparative analysis of complete genome sequences of three avian coronaviruses reveals a novel group 3c coronavirus
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        ;
        <volume>
         83
        </volume>
        :
        <fpage>
         908
        </fpage>
        –917.
        <pub-id pub-id-type="pmid">
         18971277
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib3">
       <mixed-citation publication-type="journal">
        Woo PCY, Lau SKP, Lam CSF et al.
        <article-title>
         Discovery of seven novel mammalian and avian coronaviruses in the genus
         <italic>
          Deltacoronavirus
         </italic>
         supports bat coronaviruses as the gene source of
         <italic>
          Alphacoronavirus
         </italic>
         and
         <italic>
          Betacoronavirus
         </italic>
         and avian coronaviruses as the gene source of
         <italic>
          Gammacoronavirus
         </italic>
         and
         <italic>
          Deltacoronavirus
         </italic>
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        :
        <fpage>
         3995
        </fpage>
        –4008.
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib4">
       <mixed-citation publication-type="other">
        International Committee on Taxonomy of Viruses (ICTV). Create 12 new species in the family Coronaviridae. Glasgow: ICTV; 2015. Available at https://talk.ictvonline.org/files/ictv_official_taxonomy_updates_since_the_8th_report/m/animal-ssrna-viruses/5879 (accessed 13 December 2016).
       </mixed-citation>
      </ref>
      <ref id="bib5">
       <mixed-citation publication-type="journal">
        Lee S, Lee C.
        <article-title>
         Complete genome characterization of Korean porcine deltacoronavirus strain KOR/KNU14-04/2014
        </article-title>
        .
        <source>
         Genome Announc
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         e01191
        </fpage>
        -14.
        <pub-id pub-id-type="pmid">
         25428966
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib6">
       <mixed-citation publication-type="journal">
        Li G, Chen Q, Harmon KM et al.
        <article-title>
         Full-length genome sequence of porcine deltacoronavirus strain USA/IA/2014/8734
        </article-title>
        .
        <source>
         Genome Announc
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         e00278
        </fpage>
        -14.
        <pub-id pub-id-type="pmid">
         24723718
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib7">
       <mixed-citation publication-type="journal">
        Marthaler D, Raymond L, Jiang Y, Collins J, Rossow K, Rovira A.
        <article-title>
         Rapid detection, complete genome sequencing, and phylogenetic analysis of porcine deltacoronavirus
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1347
        </fpage>
        –1350.
        <pub-id pub-id-type="pmid">
         25075556
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib8">
       <mixed-citation publication-type="journal">
        Marthaler D, Jiang Y, Collins J, Rossow K.
        <article-title>
         Complete genome sequence of strain SDCV/USA/Illinois121/2014, a porcine deltacoronavirus from the United States
        </article-title>
        .
        <source>
         Genome Announc
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         e00218
        </fpage>
        -14.
        <pub-id pub-id-type="pmid">
         24723704
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib9">
       <mixed-citation publication-type="journal">
        Wang L, Byrum B, Zhang Y.
        <article-title>
         Detection and genetic characterization of deltacoronavirus in pigs, Ohio, USA, 2014
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1227
        </fpage>
        –1230.
        <pub-id pub-id-type="pmid">
         24964136
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib10">
       <mixed-citation publication-type="journal">
        Wang L, Byrum B, Zhang Y.
        <article-title>
         Porcine coronavirus HKU15 detected in 9 US states, 2014
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1594
        </fpage>
        –1595.
        <pub-id pub-id-type="pmid">
         25153521
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib11">
       <mixed-citation publication-type="journal">
        Wang L, Zhang Y, Byrum B.
        <article-title>
         Complete genome sequence of porcine coronavirus HKU15 strain IN2847 from the United States
        </article-title>
        .
        <source>
         Genome Announc
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         e00291
        </fpage>
        -14.
        <pub-id pub-id-type="pmid">
         24744332
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib12">
       <mixed-citation publication-type="journal">
        Chen F, Zhu Y, Wu M, Ku X, Yao L, He Q.
        <article-title>
         Full-length genome characterization of chinese porcine deltacoronavirus strain CH/SXD1/2015
        </article-title>
        .
        <source>
         Genome Announc
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e01284
        </fpage>
        -15.
        <pub-id pub-id-type="pmid">
         26514769
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib13">
       <mixed-citation publication-type="journal">
        Dong N, Fang L, Zeng S, Sun Q, Chen H, Xiao S.
        <article-title>
         Porcine deltacoronavirus in mainland China
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         2254
        </fpage>
        –2255.
        <pub-id pub-id-type="pmid">
         26584185
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib14">
       <mixed-citation publication-type="journal">
        Hu H, Jung K, Vlasova AN et al.
        <article-title>
         Isolation and characterization of porcine deltacoronavirus from pigs with diarrhea in the United States
        </article-title>
        .
        <source>
         J Clin Microbiol
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         53
        </volume>
        :
        <fpage>
         1537
        </fpage>
        –1548.
        <pub-id pub-id-type="pmid">
         25740769
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib15">
       <mixed-citation publication-type="journal">
        Ma Y, Zhang Y, Liang X et al.
        <article-title>
         Origin, evolution, and virulence of porcine deltacoronaviruses in the United States
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         e00064
        </fpage>
        -15.
        <pub-id pub-id-type="pmid">
         25759498
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib16">
       <mixed-citation publication-type="journal">
        Song D, Zhou X, Peng Q et al.
        <article-title>
         Newly emerged porcine deltacoronavirus associated with diarrhoea in swine in China: identification, prevalence and full-length genome sequence analysis
        </article-title>
        .
        <source>
         Transbound Emerg Dis
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         62
        </volume>
        :
        <fpage>
         575
        </fpage>
        –580.
        <pub-id pub-id-type="pmid">
         26250097
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib17">
       <mixed-citation publication-type="journal">
        Wang Y-W, Yue H, Fang W, Huang Y-W.
        <article-title>
         Complete genome sequence of porcine deltacoronavirus strain CH/Sichuan/S27/2012 from mainland China
        </article-title>
        .
        <source>
         Genome Announc
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e00945
        </fpage>
        -15.
        <pub-id pub-id-type="pmid">
         26337879
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib18">
       <mixed-citation publication-type="journal">
        Wang L, Hayes J, Sarver C, Byrum B, Zhang Y.
        <article-title>
         Porcine deltacoronavirus: histological lesions and genetic characterization
        </article-title>
        .
        <source>
         Arch Virol
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         161
        </volume>
        :
        <fpage>
         171
        </fpage>
        –175.
        <pub-id pub-id-type="pmid">
         26475155
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib19">
       <mixed-citation publication-type="journal">
        Homwong N, Jarvis MC, Lam HC et al.
        <article-title>
         Characterization and evolution of porcine deltacoronavirus in the United States
        </article-title>
        .
        <source>
         Prev Vet Med
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         123
        </volume>
        :
        <fpage>
         168
        </fpage>
        –174.
        <pub-id pub-id-type="pmid">
         26611652
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib20">
       <mixed-citation publication-type="journal">
        Janetanakit T, Lumyai M, Bunpapong N et al.
        <article-title>
         Porcine deltacoronavirus, Thailand, 2015
        </article-title>
        .
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         757
        </fpage>
        –759.
       </mixed-citation>
      </ref>
      <ref id="bib21">
       <mixed-citation publication-type="journal">
        Lee JH, Chung HC, Nguyen VG et al.
        <article-title>
         Detection and phylogenetic analysis of porcine deltacoronavirus in Korean swine farms, 2015
        </article-title>
        .
        <source>
         Transbound Emerg Dis
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         63
        </volume>
        :
        <fpage>
         248
        </fpage>
        –252.
        <pub-id pub-id-type="pmid">
         26968326
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib22">
       <mixed-citation publication-type="journal">
        Lorsirigool A, Saeng-chuto K, Temeeyasen G et al.
        <article-title>
         The first detection and full-length genome sequence of porcine deltacoronavirus isolated in Lao PDR
        </article-title>
        .
        <source>
         Arch Virol
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         161
        </volume>
        :
        <fpage>
         2909
        </fpage>
        –2911.
        <pub-id pub-id-type="pmid">
         27424024
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib23">
       <mixed-citation publication-type="journal">
        Saeng-chuto K, Lorsirigool A, Temeeyasen G et al.
        <article-title>
         Different lineage of porcine deltacoronavirus in Thailand, Vietnam and Lao PDR in 2015
        </article-title>
        .
        <source>
         Transbound Emerg Dis
        </source>
        <year>
         2017
        </year>
        ;
        <volume>
         64
        </volume>
        :
        <fpage>
         3
        </fpage>
        –10.
        <pub-id pub-id-type="pmid">
         27718337
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib24">
       <mixed-citation publication-type="journal">
        Reynolds DJ, Debney TG, Hall GA, Thomas LH, Parsons KR.
        <article-title>
         Studies on the relationship between coronaviruses from the intestinal and respiratory tracts of calves
        </article-title>
        .
        <source>
         Arch Virol
        </source>
        <year>
         1985
        </year>
        ;
        <volume>
         85
        </volume>
        :
        <fpage>
         71
        </fpage>
        –83.
        <pub-id pub-id-type="pmid">
         2990390
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib25">
       <mixed-citation publication-type="journal">
        Laude H, Van Reeth K, Pensaert M.
        <article-title>
         Porcine respiratory coronavirus: molecular features and virus-host interactions
        </article-title>
        .
        <source>
         Vet Res
        </source>
        <year>
         1993
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         125
        </fpage>
        –150.
        <pub-id pub-id-type="pmid">
         8393722
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib26">
       <mixed-citation publication-type="journal">
        Lau SKP, Woo PCY, Li KSM et al.
        <article-title>
         Discovery of a novel coronavirus, China
         <italic>
          Rattus
         </italic>
         coronavirus HKU24, from Norway rats supports the murine origin of
         <italic>
          Betacoronavirus 1
         </italic>
         and has implications for the ancestor of
         <italic>
          Betacoronavirus
         </italic>
         lineage A
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         3076
        </fpage>
        –3092.
        <pub-id pub-id-type="pmid">
         25552712
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib27">
       <mixed-citation publication-type="journal">
        Woo PCY, Lau SKP, Lam CSF et al.
        <article-title>
         Discovery of a novel bottlenose dolphin coronavirus reveals a distinct species of marine mammal coronavirus in
         <italic>
          Gammacoronavirus
         </italic>
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         1318
        </fpage>
        –1331.
        <pub-id pub-id-type="pmid">
         24227844
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib28">
       <mixed-citation publication-type="journal">
        Zhao Y, Tsang C-C, Xiao M et al.
        <article-title>
         Intra-genomic internal transcribed spacer region sequence heterogeneity and molecular diagnosis in clinical microbiology
        </article-title>
        .
        <source>
         Int J Mol Sci
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         25067
        </fpage>
        –25079.
        <pub-id pub-id-type="pmid">
         26506340
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib29">
       <mixed-citation publication-type="journal">
        Hall TA.
        <article-title>
         BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT
        </article-title>
        .
        <source>
         Nucleic Acids Symp Ser
        </source>
        <year>
         1999
        </year>
        ;
        <volume>
         41
        </volume>
        :
        <fpage>
         95
        </fpage>
        –98.
       </mixed-citation>
      </ref>
      <ref id="bib30">
       <mixed-citation publication-type="journal">
        Li W, Cowley A, Uludag M et al.
        <article-title>
         The EMBL-EBI bioinformatics web and programmatic tools framework
        </article-title>
        .
        <source>
         Nucleic Acids Res
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         43
        </volume>
        :
        <fpage>
         W580
        </fpage>
        –W584.
        <pub-id pub-id-type="pmid">
         25845596
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib31">
       <mixed-citation publication-type="journal">
        Edgar RC.
        <article-title>
         MUSCLE: multiple sequence alignment with high accuracy and high throughput
        </article-title>
        .
        <source>
         Nucleic Acids Res
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         32
        </volume>
        :
        <fpage>
         1792
        </fpage>
        –1797.
        <pub-id pub-id-type="pmid">
         15034147
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib32">
       <mixed-citation publication-type="journal">
        Tamura K, Stecher G, Peterson D, Filipski A, Kumar S.
        <article-title>
         MEGA6: molecular evolutionary genetics analysis version 6.0
        </article-title>
        .
        <source>
         Mol Biol Evol
        </source>
        <year>
         2013
        </year>
        ;
        <volume>
         30
        </volume>
        :
        <fpage>
         2725
        </fpage>
        –2729.
        <pub-id pub-id-type="pmid">
         24132122
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib33">
       <mixed-citation publication-type="journal">
        Drummond AJ, Suchard MA, Xie D, Rambaut A.
        <article-title>
         Bayesian phylogenetics with BEAUti and the BEAST 1.7
        </article-title>
        .
        <source>
         Mol Biol Evol
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         29
        </volume>
        :
        <fpage>
         1969
        </fpage>
        –1973.
        <pub-id pub-id-type="pmid">
         22367748
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib34">
       <mixed-citation publication-type="journal">
        Costantini V, Lewis P, Alsop J, Templeton C, Saif LJ.
        <article-title>
         Respiratory and fecal shedding of Porcine respiratory coronavirus (PRCV) in sentinel weaned pigs and sequence of the partial S-gene of the PRCV isolates
        </article-title>
        .
        <source>
         Arch Virol
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         149
        </volume>
        :
        <fpage>
         957
        </fpage>
        –974.
        <pub-id pub-id-type="pmid">
         15098110
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib35">
       <mixed-citation publication-type="journal">
        Xu D, Zhang Z, Wang F-S.
        <article-title>
         SARS-associated coronavirus quasispecies in individual patients
        </article-title>
        .
        <source>
         N Engl J Med
        </source>
        <year>
         2004
        </year>
        ;
        <volume>
         350
        </volume>
        :
        <fpage>
         1366
        </fpage>
        –1367.
        <pub-id pub-id-type="pmid">
         15044654
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib36">
       <mixed-citation publication-type="journal">
        Zhang X, Hasoksuz M, Spiro D et al.
        <article-title>
         Quasispecies of bovine enteric and respiratory coronaviruses based on complete genome sequences and genetic changes after tissue culture adaptation
        </article-title>
        .
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        ;
        <volume>
         363
        </volume>
        :
        <fpage>
         1
        </fpage>
        –10.
        <pub-id pub-id-type="pmid">
         17434558
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib37">
       <mixed-citation publication-type="journal">
        Briese T, Mishra N, Jain K et al.
        <article-title>
         Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia
        </article-title>
        .
        <source>
         MBio
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e01146
        </fpage>
        -14.
        <pub-id pub-id-type="pmid">
         24781747
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib38">
       <mixed-citation publication-type="journal">
        Borucki MK, Lao V, Hwang M et al.
        <article-title>
         Middle East respiratory syndrome coronavirus intra-host populations are characterized by numerous high frequency variants
        </article-title>
        .
        <source>
         PLoS ONE
        </source>
        <year>
         2016
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         e0146251
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26790002
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="bib39">
       <mixed-citation publication-type="journal">
        Woo PCY, Lau SKP, Yip CCY et al.
        <article-title>
         Comparative analysis of 22 coronavirus HKU1 genomes reveals a novel genotype and evidence of natural recombination in coronavirus HKU1
        </article-title>
        .
        <source>
         J Virol
        </source>
        <year>
         2006
        </year>
        ;
        <volume>
         80
        </volume>
        :
        <fpage>
         7136
        </fpage>
        –7145.
        <pub-id pub-id-type="pmid">
         16809319
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
     <sec id="sup1" sec-type="supplementary-material">
      <title>
       Supplementary Material
      </title>
      <supplementary-material content-type="local-data" id="xob1">
       <label>
        Supplementary Figure S1
       </label>
       <media xlink:href="emi201737x1.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
        <caption>
         <p>
          Click here for additional data file.
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="xob2">
       <label>
        Supplementary Figure S2
       </label>
       <media xlink:href="emi201737x2.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
        <caption>
         <p>
          Click here for additional data file.
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="xob3">
       <label>
        Supplementary Table S1
       </label>
       <media xlink:href="emi201737x3.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
        <caption>
         <p>
          Click here for additional data file.
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="xob4">
       <label>
        Supplementary Table S2
       </label>
       <media xlink:href="emi201737x4.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
        <caption>
         <p>
          Click here for additional data file.
         </p>
        </caption>
       </media>
      </supplementary-material>
     </sec>
    </back>
    <floats-group>
     <fig id="fig1">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Seasonal variation in the detection rate of
        <italic>
         Coronavirus HKU15
        </italic>
        in swine nasopharynx during January 2012–February 2014.
       </p>
      </caption>
      <graphic xlink:href="emi201737f1" xmlns:xlink="http://www.w3.org/1999/xlink">
      </graphic>
     </fig>
     <fig id="fig2">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        Resolution of sequence ambiguities by cloning. RT, reverse transcription; PCR, polymerase chain reaction. Numbers above nucleotides indicate the respective nucleotide positions with respect to the complete genome sequence of
        <italic>
         Coronavirus HKU15
        </italic>
        strain S579N quasispecies 1 (International Nucleotide Sequence Databases LC216914). Six intra-strain quasispecies were found. Post-cloning plasmid-dependent PCR-sequencing confirmed that the presence of indels at positions 189 and 376 was not due to polymerase slippage. Quasispecies 1 and 3 were detected in both nested PCR using first round primers LPW18323/LPW30836 and second round primers LPW33264/LPW6975 as well as nested PCR using first round primers LPW33199/LPW33200 and second round primers LPW33264/LPW6975. However, quasispecies 2 and 4 were only detected in nested PCR using first round primers LPW33199/LPW33200 and second round primers LPW33264/LPW6975, whereas quasispecies 5 and 6 were only detected in nested PCR using first round primers LPW18323/LPW30836 and second round primers LPW33264/LPW6975.
       </p>
      </caption>
      <graphic xlink:href="emi201737f2" xmlns:xlink="http://www.w3.org/1999/xlink">
      </graphic>
     </fig>
     <fig id="fig3">
      <label>
       Figure 3
      </label>
      <caption>
       <p>
        Phylogenetic tree showing the relationship of the two
        <italic>
         Coronavirus HKU15
        </italic>
        nasopharyngeal strains to other
        <italic>
         Coronavirus HKU15
        </italic>
        strains. The trees were inferred from the almost complete genome sequence data by the maximum likelihood method with the substitution model TN93 (Tamura–Nei model)+G (gamma-distributed rate variation)+I (estimated proportion of invariable sites). The scale bar indicates the estimated number of substitutions per base. Numbers at nodes (expressed in percentage) indicate the levels of bootstrap support calculated from 1 000 replicates, and values lower than 70 are not shown. The two nasopharyngeal strains sequenced in this study are highlighted in bold. All names and accession numbers are given as cited in the International Nucleotide Sequence Databases.
       </p>
      </caption>
      <graphic xlink:href="emi201737f3" xmlns:xlink="http://www.w3.org/1999/xlink">
      </graphic>
     </fig>
     <fig id="fig4">
      <label>
       Figure 4
      </label>
      <caption>
       <p>
        Estimation of tMRCA for
        <italic>
         Coronavirus HKU15
        </italic>
        . The timescaled phylogeny was inferred from complete
        <italic>
         Coronavirus HKU15
        </italic>
        genomes. The two nasopharyngeal strains sequenced in this study are highlighted in bold. All names and accession numbers are given as cited in the International Nucleotide Sequence Databases.
       </p>
      </caption>
      <graphic xlink:href="emi201737f4" xmlns:xlink="http://www.w3.org/1999/xlink">
      </graphic>
     </fig>
    </floats-group>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Emerg Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Emerging Infect. Dis
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       EID
      </journal-id>
      <journal-title-group>
       <journal-title>
        Emerging Infectious Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1080-6040
      </issn>
      <issn pub-type="epub">
       1080-6059
      </issn>
      <publisher>
       <publisher-name>
        Centers for Disease Control and Prevention
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       15078592
      </article-id>
      <article-id pub-id-type="pmc">
       3322746
      </article-id>
      <article-id pub-id-type="publisher-id">
       03-0404
      </article-id>
      <article-id pub-id-type="doi">
       10.3201/eid1001.030404
      </article-id>
      <article-categories>
       <subj-group subj-group-type="second-type">
        <subject>
         Expedited
        </subject>
       </subj-group>
       <subj-group subj-group-type="heading">
        <subject>
         Research
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Severe Acute Respiratory Syndrome–associated Coronavirus in Lung Tissue
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mazzulli
         </surname>
         <given-names>
          Tony
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
        <xref ref-type="aff" rid="aff2">
         †
        </xref>
        <xref ref-type="aff" rid="aff3">
         ‡
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Farcas
         </surname>
         <given-names>
          Gabriella A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         ‡
        </xref>
        <xref ref-type="aff" rid="aff4">
         §
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Poutanen
         </surname>
         <given-names>
          Susan M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
        <xref ref-type="aff" rid="aff2">
         †
        </xref>
        <xref ref-type="aff" rid="aff3">
         ‡
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Willey
         </surname>
         <given-names>
          Barbara M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
        <xref ref-type="aff" rid="aff2">
         †
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Low
         </surname>
         <given-names>
          Donald E.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
        <xref ref-type="aff" rid="aff2">
         †
        </xref>
        <xref ref-type="aff" rid="aff3">
         ‡
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Butany
         </surname>
         <given-names>
          Jagdish
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         †
        </xref>
        <xref ref-type="aff" rid="aff3">
         ‡
        </xref>
        <xref ref-type="aff" rid="aff5">
         ¶
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Asa
         </surname>
         <given-names>
          Sylvia L.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         †
        </xref>
        <xref ref-type="aff" rid="aff3">
         ‡
        </xref>
        <xref ref-type="aff" rid="aff5">
         ¶
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Kain
         </surname>
         <given-names>
          Kevin C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         ‡
        </xref>
        <xref ref-type="aff" rid="aff4">
         §
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         *
        </label>
        Mount Sinai Hospital, Toronto, Ontario, Canada
       </aff>
       <aff id="aff2">
        <label>
         †
        </label>
        Toronto Medical Laboratories, Toronto Ontario, Canada
       </aff>
       <aff id="aff3">
        <label>
         ‡
        </label>
        University of Toronto, Toronto, Ontario, Canada
       </aff>
       <aff id="aff4">
        <label>
         §
        </label>
        Toronto General Hospital, Toronto, Ontario, Canada
       </aff>
       <aff id="aff5">
        <label>
         ¶
        </label>
        University Health Network, Toronto, Ontario, Canada
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address for correspondence: Kevin Kain, Tropical Disease Unit, EN G-224, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada; fax: 416-595-5826; email:
        <email xlink:href="kevin.kain@uhn.on.ca">
         kevin.kain@uhn.on.ca
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        1
       </month>
       <year>
        2004
       </year>
      </pub-date>
      <volume>
       10
      </volume>
      <issue>
       1
      </issue>
      <fpage>
       20
      </fpage>
      <lpage>
       24
      </lpage>
      <abstract>
       <p>
        Efforts to contain severe acute respiratory syndrome (SARS) have been limited by the lack of a standardized, sensitive, and specific test for SARS-associated coronavirus (CoV). We used a standardized reverse transcription-polymerase chain reaction assay to detect SARS-CoV in lung samples obtained from well-characterized patients who died of SARS and from those who died of other reasons. SARS-CoV was detected in all 22 postmortem lung tissues (to 10
        <sup>
         9
        </sup>
        viral copies/g) from 11 patients with probable SARS but was not detected in any of the 23 lung control samples (sample analysis was blinded). The sensitivity and specificity (95% confidence interval) were 100% (84.6% to 100%) and 100% (85.1% to 100%), respectively. Viral loads were significantly associated with a shorter course of illness but not with the use of ribavirin or steroids. CoV was consistently identified in the lungs of all patients who died of SARS but not in control patients, supporting a primary role for CoV in deaths.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <title>
        Keywords:
       </title>
       <kwd>
        SARS
       </kwd>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        lung tissue
       </kwd>
       <kwd>
        Canada
       </kwd>
       <kwd>
        RT-PCR
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p>
     From its origins in November 2002 in Guangdong Province, China, severe acute respiratory syndrome (SARS) has become an emerging infectious disease that has spread to areas throughout the world, including Hong Kong, Vietnam, Singapore, Taiwan, and Canada
     <xref ref-type="bibr" rid="R1">
      (
      <italic>
       1
      </italic>
      )
     </xref>
     . Although controversy remains over the etiology of SARS, the World Health Organization has declared a newly described virus known as the SARS-associated coronavirus (SARS-CoV) as the cause
     <xref ref-type="bibr" rid="R2">
      (
      <italic>
       2
      </italic>
      )
     </xref>
     . This announcement has led to a rapid proliferation of different in-house laboratory tests aimed at detecting either SARS-CoV–specific antibodies or SARS-CoV nucleic acid in clinical specimens. The Centers for Disease Control and Prevention definition for a confirmed case of SARS includes the results of these laboratory tests
     <xref ref-type="bibr" rid="R3">
      (
      <italic>
       3
      </italic>
      )
     </xref>
     . However, because different assays are being used, comparing results from different centers has been difficult. In addition, the inability of these nonstandardized tests to detect SARS-CoV in all cases has led to speculation that other agents may be associated with SARS. Some researchers have suggested that illnesses that progress to respiratory failure and death may not be caused by uncontrolled viral replication but rather are the result of an immunopathologic process
     <xref ref-type="bibr" rid="R4">
      (
      <italic>
       4
      </italic>
      )
     </xref>
     . In a recent report of six fatal cases of SARS, SARS-CoV was detected by reverse transcriptase-polymerase chain reaction (RT-PCR) in postmortem lung tissue in only four patients
     <xref ref-type="bibr" rid="R5">
      (
      <italic>
       5
      </italic>
      )
     </xref>
     .
    </p>
    <p>
     The purpose of this study was to use a standardized, commercially available, RT-PCR assay to test for the presence of SARS-CoV RNA. Lung tissue obtained at autopsy from well-characterized patients with SARS who died during the outbreak in Canada were compared to lung samples obtained at autopsy from patients without SARS who died during the outbreak and lung samples from patients who died before the outbreak.
    </p>
    <sec sec-type="methods">
     <title>
      Methods
     </title>
     <sec>
      <title>
       Patients
      </title>
      <p>
       All patients who met the current World Health Organization case definition of probable SARS and who underwent a postmortem examination in Canada during the March–April 2003 outbreak were included in this study. Clinical details were extracted retrospectively from hospital records. Clinical descriptions of some of these cases have been published separately (
       <xref ref-type="bibr" rid="R6">
        <italic>
         6
        </italic>
       </xref>
       <italic>
        ,
       </italic>
       <xref ref-type="bibr" rid="R7">
        <italic>
         7
        </italic>
       </xref>
       ). As of May 14, 2003, a total of 24 patients died of SARS in Canada; all died in Toronto. Of the 24 patients, autopsies were performed on 11 patients. Results of ante- and postmortem examination for routine bacterial and viral respiratory pathogens from these 11 patients, as described elsewhere, were negative
       <xref ref-type="bibr" rid="R6">
        (
        <italic>
         6
        </italic>
        )
       </xref>
       .
      </p>
     </sec>
     <sec>
      <title>
       Lung Tissue Samples
      </title>
      <p>
       A total of 22 discrete postmortem lung samples collected from these 11 patients were included in this analysis. An additional 13 postmortem lung samples from 7 patients who died during the SARS outbreak but whose deaths were attributed to other causes were also included. The attributed cause of death in these patients was as follows: a 46-year-old woman died of invasive group A streptococcal infection; a 93-year-old man died of congestive heart failure; a 37-year-old man died of sudden death cardiovascular disease; a 74-year-old man died of amiodarone pulmonary toxicity; a 78-year-old woman died of dementia and aspiration pneumonia; a 47-year-old woman died of diabetes and congestive heart failure; and an 81-year-old man died of bladder cancer and aspiration pneumonia. In addition, 10 lung samples collected in 1998 from 10 patients (4 women and 6 men; age range 54–75 years) with lung cancer were also included as negative controls. All samples collected at the time of autopsy were snap frozen in a mixture of absolute ethanol and dry ice and subsequently stored at –70°C until tested. The samples were coded and then processed, subjected to RT-PCR analysis, and interpreted before the identity of the samples was divulged. This study was approved by the research ethics boards at Mount Sinai Hospital and the University Health Network.
      </p>
     </sec>
     <sec>
      <title>
       RT-PCR
      </title>
      <p>
       Lung tissue samples were thawed and immediately homogenized in lysis buffer (QIAGEN, Mississauga, Canada) with disposable tissue grinders (Kendall Precision, Mansfield, MA). The homogenate was passed through QIAshredder columns (QIAGEN) before RNA isolation by using the RNeasy Mini Kit (QIAGEN). The sample was eluted in 30 μL of RNAse free water. The RT-PCR was carried out by using the RealArt HPA-Coronavirus LightCycler RT Reagents Assay (Artus GmbH, Hamburg, Germany) with a LightCycler real-time platform (Roche Diagnostics, Laval, Canada). The HPA-Coronavirus Master Mix contains reagents and enzymes for the specific amplification of an 80-bp region of the SARS-CoV polymerase gene from 5 μL of RNA with the primer pairs published by the Bernhard-Nocht Institute (Hamburg, Germany) as posted on the World Health Organization Web site (available from: URL:
       <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/primers/en/">
        http://www.who.int/csr/sars/primers/en/
       </ext-link>
       ).
      </p>
      <p>
       Viral load was calculated from a standard curve based on four external positive controls (quantification standards) included in the RealArt HPA-Coronavirus LightCycler RT Reagents Assay kit (
       <xref ref-type="fig" rid="F1">
        Figure
       </xref>
       A and B). The standards were treated as previously purified samples, and the same 5-μL volume was added per capillary. A standard preparation of SARS-CoV isolated from cell culture supernatants of VeroE6 cells was used as a calibrator in each run. In addition, the kit contains a second heterologous amplification system (i.e., an internal control) to identify either PCR inhibition exclusively, if added to the extracted RNA, or RNA isolation quality as well as PCR inhibition, if added during the RNA isolation procedure (
       <xref ref-type="fig" rid="F1">
        Figure
       </xref>
       C). Although the assay insert states that the primers and probes used in the assay were checked for possible similarity to other pathogens by means of sequence comparison, 25 randomly chosen amplicons from our sample pool were independently sequenced to confirm SARS-CoV–specific amplification and detection. Univariate analysis comparing potential predictors of viral load (e.g., duration of illness, the use of ribavirin, the use of steroids) was completed by using Fisher exact test. Two-sided p values
       <underline>
        &lt;
       </underline>
       0.05 were considered significant.
      </p>
      <fig fig-type="figure" id="F1" position="float">
       <label>
        Figure
       </label>
       <caption>
        <p>
         RealArt HPA-Coronavirus LightCycler (RealArt HPA Coronavirus RT-PCR) reverse transcription-polymerase chain reaction (PCR) Assay results. PCR results from 5 μL RNA are displayed in channel F1/F2 of the LightCycler instrument (A). Four quantification standards are included in the assay to generate a standard curve (B). An internal control, added at the RNA isolation stage, is used to monitor both the quality of the RNA isolation as well as possible PCR inhibition (C).
        </p>
       </caption>
       <graphic xlink:href="03-0404-F">
       </graphic>
      </fig>
     </sec>
    </sec>
    <sec>
     <title>
      Results
     </title>
     <p>
      The clinical description and RT-PCR results for the 11 patients with probable SARS from whom postmortem lung tissue samples were examined are summarized in
      <xref ref-type="table" rid="T1">
       Table 1
      </xref>
      . The mean age of the 11 patients was 70 years (range 43–99). Six of the 11 patients were men. All but 1 of the 11 patients had underlying coexisting conditions, the most common of which was diabetes mellitus in 6 patients. The mean duration of illness was 20 days (range 8–32). Seven patients had been intubated and mechanically ventilated before death. Three patients had requested not to be intubated (information on ventilation was not available for one patient). Ten of the 11 patients were treated with ribavirin; 6 of the 11 patients were treated with steroids.
     </p>
     <table-wrap id="T1" position="float">
      <label>
       Table 1
      </label>
      <caption>
       <title>
        Clinical description and SARS-CoV RT-PCR results for 11 patients who died with probable SARS
        <sup>
         a
        </sup>
       </title>
      </caption>
      <table frame="above" rules="groups">
       <col span="1" width="42"/>
       <col span="1" width="96"/>
       <col span="1" width="48"/>
       <col span="1" width="54"/>
       <col span="1" width="84"/>
       <col span="1" width="72"/>
       <col span="1" width="102"/>
       <col span="1" width="96"/>
       <col span="1" width="96"/>
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="2" scope="col" valign="bottom">
          Sex/age
         </th>
         <th align="center" colspan="1" rowspan="2" scope="col" valign="bottom">
          Coexisting conditions
         </th>
         <th align="center" colspan="4" rowspan="1" scope="colgroup" valign="bottom">
          Illness and treatment duration (days)
         </th>
         <th align="center" colspan="1" rowspan="2" scope="col" valign="bottom">
          Postmortem lung tissue description
         </th>
         <th align="center" colspan="2" rowspan="1" scope="colgroup" valign="bottom">
          RealArt HPA Coronavirus RT-PCR
          <sup>
           b
          </sup>
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
          Illness
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          Ventilation
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          Ribavirin
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          Steroids
         </th>
         <th align="center" colspan="1" rowspan="1" scope="colgroup" valign="bottom">
          Results
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          Copies of CoV/ gram tissue
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="5" scope="row" valign="top">
          M/43
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          Type II DM, HTN
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          15
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          4
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0
         </td>
         <td align="center" colspan="1" rowspan="5" valign="middle">
          0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          RUL
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.5 x 10
          <sup>
           8
          </sup>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" scope="row" valign="middle">
          RML (#1)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5.4 x 10
          <sup>
           7
          </sup>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" scope="row" valign="middle">
          RML (#2)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.8 x 10
          <sup>
           7
          </sup>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" scope="row" valign="middle">
          RML (#3)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          7.4 x 10
          <sup>
           6
          </sup>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" scope="row" valign="middle">
          RML (#4)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6.4 x 10
          <sup>
           8
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          M/76
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Type II DM, CAD, HTN
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          11
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6 (started on day 6 of illness)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Lung
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.8 x 10
          <sup>
           9
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
          F/78
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          Type II DM, CAD, hypercholesterolemia, chronic obstructive pulmonary disease
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          8
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          5
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          <underline>
           &gt;
          </underline>
          5 (started on day 4 of illness)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          RT lung
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1.0 x 10
          <sup>
           9
          </sup>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" scope="row" valign="middle">
          LUL
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          9.4 x 10
          <sup>
           7
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          M/62
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Rectal cancer; HTN, hypercholesterolemia
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          8
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          N/A
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          <underline>
           &gt;
          </underline>
          5 (started on day 4 of illness)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LT lung
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5.3 x 10
          <sup>
           7
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
          F/73
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          HTN, hypercholesterolemia
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          28
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          DNI
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          14 (started on day 5 of illness)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          12 (stated on day 14 of illness)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LT lung
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.0x 10
          <sup>
           4
          </sup>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" scope="row" valign="middle">
          RT lung
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.6 x10
          <sup>
           5
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="top">
          F/99
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Osteoarthritis
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          26
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          DNI
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          13 (started on day 1 of illness)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Lung
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5.0 x 10
          <sup>
           4
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
          M/63
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          Hypercholesterolemia, cerebral vascular disease
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          20
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          12
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          16 (started on day 4 of illness)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          16(started on day 6 of illness)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          RUL lung
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          3.2 x 10
          <sup>
           6
          </sup>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" scope="row" valign="middle">
          LLL
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.5 x10
          <sup>
           7
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
          F/78
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          Type II DM, HTN, hypercholesterolemia
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          24
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          18
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          10 (started on day 3 of illness)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          18 (started on day 5 of illness)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LT lung
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4.1 x 10
          <sup>
           5
          </sup>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" scope="row" valign="middle">
          RUL
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4.9x10
          <sup>
           5
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
          M/44
         </td>
         <td align="left" colspan="1" rowspan="2" valign="middle">
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          29
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          18
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          18 (started on day 8 of illness)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          17 (started on day 12 of illness)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          RT lung
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          7.6 x 10
          <sup>
           4
          </sup>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" scope="row" valign="middle">
          LT lung
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4.1 x 10
          <sup>
           4
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
          M/77
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          Type II DM, HTN, hypercholesterolemia
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          <underline>
           &gt;
          </underline>
          18
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          <underline>
           &gt;
          </underline>
          1
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          <underline>
           &gt;
          </underline>
          1 (started on day 10 of illness)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          <underline>
           &gt;
          </underline>
          7 (started on day 10 of illness)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LLL
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5.6 x 10
          <sup>
           5
          </sup>
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" scope="row" valign="middle">
          LUL
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5.7 x 10
          <sup>
           5
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="2" scope="row" valign="top">
          F/79
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          Type II DM, HTN, hypercholesterolemia
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          32
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          DNI
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          11 (started on day 2 of illness)
         </td>
         <td align="center" colspan="1" rowspan="2" valign="middle">
          <underline>
           &gt;
          </underline>
          4 (started on day 12 of illness)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          LT lung
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          Positive
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          2.7 x 10
          <sup>
           4
          </sup>
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="bottom">
          Lung
         </td>
         <td align="left" colspan="1" rowspan="1" valign="bottom">
          Positive
         </td>
         <td align="left" colspan="1" rowspan="1" valign="bottom">
          2.1 x 10
          <sup>
           5
          </sup>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        <sup>
         a
        </sup>
        SARS, severe acute respiratory syndrome; CoV, coronavirus; RT-PCR, reverse transcription polymerase chain reaction; F, female; M, male; DM, diabetes mellitus; HTN, hypertension; RUL, right upper lobe; RML, right middle lobe; CAD, coronary artery disease; RT, right; LT, left; LUL, left upper lobe; LLL, left lower lobe; N/A, not available; DNI, “Do not intubate” order written.
        <sup>
         b
        </sup>
        RealArt HPA Coronavirus RT-PCR (Artus GmbH, Hamburg, Germany).
       </p>
      </table-wrap-foot>
     </table-wrap>
     <p>
      SARS-CoV was detected in all 22 postmortem lung tissue samples collected from all 11 patients who died with a diagnosis of probable SARS. All 13 postmortem lung samples from the seven non-SARS fatalities that occurred during the SARS outbreak were negative for SARS-CoV, as were all 10 lung-tissue samples collected from patients with lung cancer 5 years before the outbreak (Table 2)
      <xref ref-type="table" rid="T1">
      </xref>
      . The corresponding sensitivity and specificity of the RealArt HPA-Coronavirus LightCycler RT Reagent assay are both 100% (95% confidence interval [CI] for sensitivity 84.6% to 100%; 95% CI for specificity 85.1% to 100%) for the detection of SARS-CoV.
     </p>
     <table-wrap id="T2" position="float">
      <label>
       Table 2
      </label>
      <caption>
       <title>
        Univariate analysis of predictors of high viral loads in postmortem lung tissue
       </title>
      </caption>
      <table frame="hsides" rules="groups">
       <col span="1" width="117"/>
       <col span="1" width="117"/>
       <col span="1" width="112"/>
       <col span="1" width="89"/>
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1" scope="col" valign="bottom">
          Predictor
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          Viral load
          <underline>
           &gt;
          </underline>
          10
          <sup>
           6
          </sup>
          copies/g lung tissue
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          Viral load &lt;10
          <sup>
           6
          </sup>
          copies/g lung tissue
         </th>
         <th align="center" colspan="1" rowspan="1" scope="col" valign="bottom">
          Fisher exact test
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="bottom">
          Short duration of illness (
          <underline>
           &lt;
          </underline>
          21 d)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5/5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          0/6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          p=0.002
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="bottom">
          Use of ribavirin
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          4/5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          6/6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          p=0.45
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" scope="row" valign="bottom">
          Use of steroids
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          1/5
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          5/6
         </td>
         <td align="center" colspan="1" rowspan="1" valign="middle">
          p=0.08
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <p>
      The SARS-CoV viral load in postmortem lung tissue ranged from 2.7 x 10
      <sup>
       4
      </sup>
      copies/g tissue to 3.8 x 10
      <sup>
       9
      </sup>
      copies/g tissue. Higher viral loads (
      <underline>
       &gt;
      </underline>
      10
      <sup>
       6
      </sup>
      copies/g tissue) were associated with patients who had a shorter duration of illness (
      <underline>
       &lt;
      </underline>
      21 days) (p=0.002, Fisher exact test). The use of ribavirin or steroids was not significantly associated with viral load levels (Table 2)
      <xref ref-type="table" rid="T1">
      </xref>
      .
     </p>
     <p>
      Twenty-five randomly selected amplicons from the sample pool were sequenced to assess specificity and possible cross-reactivity to other pathogens. A BLAST (available from: URL:
      <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/BLAST/">
       http://www.ncbi.nlm.nih.gov/BLAST/
      </ext-link>
      ) search performed against the SARS-CoV genomes in GenBank, European Molecular Biology Laboratory, DNA Data Bank of Japan, and Protein Data Bank on the National Center for Biotechnology Information Web site (available from: URL:
      <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/">
       http://www.ncbi.nlm.nih.gov/
      </ext-link>
      ), indicated that all amplicon samples contained SARS-CoV polymerase gene sequence.
     </p>
    </sec>
    <sec>
     <title>
      Discussion
     </title>
     <p>
      By using a standardized RT-PCR assay, SARS-CoV has been unequivocally identified in the lung tissue of all patients who died with probable SARS but not in any of the controls. These observations support a primary role for this virus in patients with SARS who have fatal outcomes and provide additional, strong evidence to fulfill Koch’s postulates regarding SARS-CoV as the cause of SARS
      <xref ref-type="bibr" rid="R8">
       (
       <italic>
        8
       </italic>
       )
      </xref>
      . SARS-CoV was found in different lung samples from the same patient, suggesting that the virus is widely disseminated throughout the lung at the time of death. Previous studies suggested that progression of disease to respiratory failure may be primarily mediated by host immune response rather than viral replication
      <xref ref-type="bibr" rid="R4">
       (
       <italic>
        4
       </italic>
       )
      </xref>
      . Although viral RNA in lung tissue does not necessarily indicate replicating virus, virus in multiple lung lobes, often in high copy number, at the time of death suggests that SARS-CoV may also be contributing to disease progression. The fact that higher viral loads were significantly associated with patients with a shorter duration from onset of illness to death supports the role of viral replication as a contributor to death. Ten of the 11 patients had received therapy with ribavirin, and 6 patients were treated with steroids. The failure to eradicate SARS-CoV despite ribavirin therapy and the lack of association between the use of ribavirin and SARS-CoV viral load are consistent with in vitro data showing that ribavirin has no activity against this agent
      <xref ref-type="bibr" rid="R9">
       (
       <italic>
        9
       </italic>
       )
      </xref>
      .
     </p>
     <p>
      Global efforts to contain SARS have been severely impeded by the lack of a standardized, sensitive, and specific diagnostic test for SARS-CoV. Different diagnostic strategies, including culture, serologic assays, and molecular detection methods, have been described, but each of these tests has limitations. In-house RT-PCR assays have been associated with sensitivities as low as 50% in patients with SARS
      <xref ref-type="bibr" rid="R10">
       (
       <italic>
        10
       </italic>
       )
      </xref>
      , which raises uncertainty about the role of CoV versus co-pathogens in mediating severe or fatal SARS. By contrast, the sensitivity and specificity of the RealArt HPA-Coronavirus RT-PCR assay for detecting CoV in lung tissue samples appear to be excellent. In addition, with the real-time LightCycler system, the assay generates quantitative results within 1 hour, which is much shorter than traditional PCR reactions.
     </p>
     <p>
      The type of specimen tested, the timing of sample collection, (i.e., acute versus convalescent phase) the method of specimen collection, as well as the method of sample preservation may have substantial impact on the results obtained from a diagnostic test. The lower sensitivity of SARS-CoV detection reported by Peiris et al.
      <xref ref-type="bibr" rid="R10">
       (
       <italic>
        10
       </italic>
       )
      </xref>
      may be a consequence of these confounding factors. Our study design of examining lung biopsies from clearly defined patient populations overcame confounding issues, such as sampling technique, nonspecific case definitions, and possible undocumented exposure to SARS. Given the predominance of respiratory symptoms in patients with SARS, lung samples have perhaps the highest viral titers of all specimen types; yet in nonfatal cases, obtaining routine lung biopsies is not practical. Other respiratory tract specimens may be satisfactory substitutes for biopsies, but further studies examining the prevalence of SARS-CoV in these other specimen types and in a larger population are needed. With the use of standardized commercially available assays, comparison of results from different centers may be facilitated.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn fn-type="citation">
       <p>
        <italic>
         Suggested citation for this article:
        </italic>
        Mazzulli T, Farcas GA, Poutanen SM, Willey BM, Low DE, Butany J, et al. Severe acute respiratory syndrome–associated coronavirus in lung tissue. Emerg Infect Dis [serial online] 2004 Jan [
        <italic>
         date cited
        </italic>
        ]. Available from: URL:
        <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/ncidod/EID/vol10no1/03-0404.htm">
         http://www.cdc.gov/ncidod/EID/vol10no1/03-0404.htm
        </ext-link>
       </p>
      </fn>
     </fn-group>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       We thank Allison McGeer, Karen Green, Poolak Akhavan, Sylvia Pong-Porter, Peter Faure, Wayne Gold, the Ontario Coroner’s Office; Brendan Mullen for generously providing 10 control lung samples; H.W. Doerr and M. Niedrig for generously providing supernatants of VeroE6 cells; and all of the clinicians who were involved in courageously caring for the patients described in this paper who lost their lives to severe acute respiratory syndrome.
      </p>
      <p>
       This study is supported by a grant from the Canadian Institute of Health Research (MT-13721 to K.C.K). K.C.K. is supported by a Career Scientist Award from the Ontario Ministry of Health and a Canada Research Chair. Artus GmbH provided assays for this study, but neither they nor the sponsors of the study had any role in the study design, data collection, data analysis, data interpretation, or writing of the report. None of the authors has a conflict of interest in relationship to this study.
      </p>
     </ack>
     <fn-group>
      <fn id="FN1">
       <p>
        1Drs. Mazzulli and Farcas contributed equally to the manuscript. All authors jointly conceived and designed the study and wrote the report. Gabriella A. Farcas performed the majority of the reverse transcription-polymerase chain reaction assays.
       </p>
      </fn>
     </fn-group>
     <bio>
      <p>
       Ms. Farcas is a Ph.D. student at the University of Toronto under Dr. Kain’s supervision. She is studying molecular diagnostics for emerging infectious diseases.
      </p>
     </bio>
     <ref-list>
      <title>
       References
      </title>
      <ref id="R1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <article-title>
         Update: outbreak of severe acute respiratory syndrome—worldwide, 2003.
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         52
        </volume>
        :
        <fpage>
         241
        </fpage>
        –
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         12680518
        </pub-id>
        <pub-id pub-id-type="pmid">
         12680518
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="book">
        <collab>
         World Health Organization
        </collab>
        Coronavirus never before seen in humans is the cause of SARS—update 31. Geneva: The Organization;
        <year>
         2003
        </year>
       </mixed-citation>
      </ref>
      <ref id="R3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="journal">
        <article-title>
         Updated interim surveillance case definition for severe acute respiratory syndrome (SARS)—United States, April 29, 2003.
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         52
        </volume>
        :
        <fpage>
         391
        </fpage>
        –
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         12765204
        </pub-id>
        <pub-id pub-id-type="pmid">
         12765204
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Peiris
         </surname>
         <given-names>
          JSM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chu
         </surname>
         <given-names>
          CM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cheng
         </surname>
         <given-names>
          VCC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chan
         </surname>
         <given-names>
          KS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hung
         </surname>
         <given-names>
          IFN
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Poon
         </surname>
         <given-names>
          LLM
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1767
        </fpage>
        –
        <lpage>
         72
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13412-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Nicholls
         </surname>
         <given-names>
          JM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Poon
         </surname>
         <given-names>
          LLM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lee
         </surname>
         <given-names>
          KC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ng
         </surname>
         <given-names>
          WF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lai
         </surname>
         <given-names>
          ST
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Leung
         </surname>
         <given-names>
          CY
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Lung pathology of fatal severe acute respiratory syndrome.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1773
        </fpage>
        –
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13413-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         12781536
        </pub-id>
        <pub-id pub-id-type="pmid">
         12781536
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Poutanen
         </surname>
         <given-names>
          SM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Low
         </surname>
         <given-names>
          DE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Henry
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Finkelstein
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rose
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Green
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Identification of severe acute respiratory syndrome in Canada.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         348
        </volume>
        :
        <fpage>
         1995
        </fpage>
        –
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030634
        </pub-id>
        <pub-id pub-id-type="pmid">
         12671061
        </pub-id>
        <pub-id pub-id-type="pmid">
         12671061
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Booth
         </surname>
         <given-names>
          CM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Matukas
         </surname>
         <given-names>
          LM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tomlinson
         </surname>
         <given-names>
          GA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rachlis
         </surname>
         <given-names>
          AR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rose
         </surname>
         <given-names>
          DB
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dwosh
         </surname>
         <given-names>
          HA
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.
        </article-title>
        <source>
         JAMA
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         289
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1001/jama.289.21.JOC30885
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Fouchier
         </surname>
         <given-names>
          RA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kuiken
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Schutten
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van Amerongen
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Van Doornum
         </surname>
         <given-names>
          GJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van den Hoogen
         </surname>
         <given-names>
          BG
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Aetiology: Koch’s postulates fulfilled for SARS virus.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         423
        </volume>
        :
        <fpage>
         240
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/423240a
        </pub-id>
        <pub-id pub-id-type="pmid">
         12748632
        </pub-id>
        <pub-id pub-id-type="pmid">
         12748632
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <article-title>
         Severe acute respiratory syndrome (SARS) and coronavirus testing—United States, 2003.
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         52
        </volume>
        :
        <fpage>
         297
        </fpage>
        –
        <lpage>
         302
        </lpage>
        <pub-id pub-id-type="pmid">
         12731699
        </pub-id>
        <pub-id pub-id-type="pmid">
         12731699
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Peiris
         </surname>
         <given-names>
          JS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lai
         </surname>
         <given-names>
          ST
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Poon
         </surname>
         <given-names>
          LL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Guan
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yam
         </surname>
         <given-names>
          LY
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lim
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <etal>
        </etal>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1319
        </fpage>
        –
        <lpage>
         25
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13077-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Virol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Virol
      </journal-id>
      <journal-id journal-id-type="hwp">
       jvi
      </journal-id>
      <journal-id journal-id-type="pmc">
       jvi
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JVI
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Virology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0022-538X
      </issn>
      <issn pub-type="epub">
       1098-5514
      </issn>
      <publisher>
       <publisher-name>
        American Society for Microbiology
       </publisher-name>
       <publisher-loc>
        1752 N St., N.W., Washington, DC
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       24648452
      </article-id>
      <article-id pub-id-type="pmc">
       4093886
      </article-id>
      <article-id pub-id-type="publisher-id">
       03801-13
      </article-id>
      <article-id pub-id-type="doi">
       10.1128/JVI.03801-13
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Pathogenesis and Immunity
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Protein Interferon-Stimulated Gene 15 Conjugation Delays but Does Not Overcome Coronavirus Proliferation in a Model of Fulminant Hepatitis
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ma
         </surname>
         <given-names>
          Xue-Zhong
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bartczak
         </surname>
         <given-names>
          Agata
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Jianhua
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          He
         </surname>
         <given-names>
          Wei
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Shalev
         </surname>
         <given-names>
          Itay
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Smil
         </surname>
         <given-names>
          David
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          Limin
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Phillips
         </surname>
         <given-names>
          Jim
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Feld
         </surname>
         <given-names>
          Jordan J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          c
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Selzner
         </surname>
         <given-names>
          Nazia
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Levy
         </surname>
         <given-names>
          Gary
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          McGilvray
         </surname>
         <given-names>
          Ian
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         a
        </label>
        Multi-Organ Transplant Program, University Health Network, University of Toronto, Toronto, Ontario, Canada
       </aff>
       <aff id="aff2">
        <label>
         b
        </label>
        Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada
       </aff>
       <aff id="aff3">
        <label>
         c
        </label>
        Toronto Centre for Liver Disease, McLaughlin-Rotman Centre for Global Health, University of Toronto, Toronto, Canada
       </aff>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Perlman
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        <role>
         Editor
        </role>
       </contrib>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address correspondence to Ian McGilvray,
        <email>
         ian.mcgilvray@uhn.ca
        </email>
        .
       </corresp>
       <fn fn-type="equal">
        <p>
         X.-Z.M. and A.B. contributed equally to this article.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        6
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <volume>
       88
      </volume>
      <issue>
       11
      </issue>
      <fpage>
       6195
      </fpage>
      <lpage>
       6204
      </lpage>
      <history>
       <date date-type="received">
        <day>
         28
        </day>
        <month>
         1
        </month>
        <year>
         2014
        </year>
       </date>
       <date date-type="accepted">
        <day>
         11
        </day>
        <month>
         3
        </month>
        <year>
         2014
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2014, American Society for Microbiology. All Rights Reserved.
       </copyright-statement>
       <copyright-year>
        2014
       </copyright-year>
       <copyright-holder>
        American Society for Microbiology
       </copyright-holder>
      </permissions>
      <self-uri xlink:href="zjv01114006195.pdf" xlink:title="pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <title>
        ABSTRACT
       </title>
       <p>
        Coronaviruses express a deubiquitinating protein, the papain-like protease-2 (PLP2), that removes both ubiquitin and the ubiquitin-like interferon (IFN)-stimulated gene 15 (ISG15) protein from target proteins. ISG15 has antiviral activity against a number of viruses; therefore, we examined the effect of ISG15 conjugation (ISGylation) in a model of acute viral hepatitis induced by the murine hepatitis virus strain 3 (MHV-3) coronavirus. Mice deficient in the ISG15 deconjugating enzyme, ubiquitin-specific peptidase-18 (USP18), accumulate high levels of ISG15-conjugated proteins and are hypersensitive to type I IFN. Infecting USP18
        <sup>
         −/−
        </sup>
        mice with MHV-3 resulted in extended survival (8 ± 1.2 versus 4 days) and in improved liver histology, a decreased inflammatory response, and viral titers 1 to 2 logs lower than in USP18
        <sup>
         +/+
        </sup>
        mice. The suppression of viral replication was not due to increased IFN since infected USP18
        <sup>
         −/−
        </sup>
        mice had neither increased hepatic IFN-α, -β, or -γ mRNA nor circulating protein. Instead, delayed MHV-3 replication coincided with high levels of cellular ISGylation. Decreasing ISGylation by knockdown of the ISG15 E1 enzyme, Ube1L, in primary USP18
        <sup>
         +/+
        </sup>
        and USP18
        <sup>
         −/−
        </sup>
        hepatocytes led to increased MHV-3 replication. Both
        <italic>
         in vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        , increasing MHV-3 titers were coincident with increased PLP2 mRNA and decreased ISGylation over the course of infection. The pharmacologic inhibition of the PLP2 enzyme
        <italic>
         in vitro
        </italic>
        led to decreased MHV-3 replication. Overall, these results demonstrate the antiviral effect of ISGylation in an
        <italic>
         in vivo
        </italic>
        model of coronavirus-induced mouse hepatitis and illustrate that PLP2 manipulates the host innate immune response through the ISG15/USP18 pathway.
       </p>
       <p>
        <bold>
         IMPORTANCE
        </bold>
        There have been a number of serious worldwide pandemics due to widespread infections by coronavirus. This virus (in its many forms) is difficult to treat, in part because it is very good at finding “holes” in the way that the host (the infected individual) tries to control and eliminate the virus. In this study, we demonstrate that an important host viral defense—the ISG15 pathway—is only partially effective in controlling severe coronavirus infection. Activation of the pathway is very good at suppressing viral production, but over time the virus overwhelms the host response and the effects of the ISG15 pathway. These data provide insight into host-virus interactions during coronavirus infection and suggest that the ISG15 pathway is a reasonable target for controlling severe coronavirus infection although the best treatment will likely involve multiple pathways and targets.
       </p>
      </abstract>
     </article-meta>
    </front>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Viruses
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Viruses
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       viruses
      </journal-id>
      <journal-title-group>
       <journal-title>
        Viruses
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1999-4915
      </issn>
      <publisher>
       <publisher-name>
        MDPI
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       30646565
      </article-id>
      <article-id pub-id-type="pmc">
       6357155
      </article-id>
      <article-id pub-id-type="doi">
       10.3390/v11010059
      </article-id>
      <article-id pub-id-type="publisher-id">
       viruses-11-00059
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        From SARS to MERS, Thrusting Coronaviruses into the Spotlight
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Song
         </surname>
         <given-names>
          Zhiqi
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          Yanfeng
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bao
         </surname>
         <given-names>
          Linlin
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Ling
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yu
         </surname>
         <given-names>
          Pin
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Qu
         </surname>
         <given-names>
          Yajin
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          Hua
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          Wenjie
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Han
         </surname>
         <given-names>
          Yunlin
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Qin
         </surname>
         <given-names>
          Chuan
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1-viruses-11-00059">
         1
        </xref>
        <xref ref-type="aff" rid="af2-viruses-11-00059">
         2
        </xref>
        <xref ref-type="aff" rid="af3-viruses-11-00059">
         3
        </xref>
        <xref ref-type="corresp" rid="c1-viruses-11-00059">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af1-viruses-11-00059">
       <label>
        1
       </label>
       Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) &amp; Comparative Medicine Centre, Peking Union Medical Collage (PUMC), Beijing 100021, China;
       <email>
        songzhiqi1989@foxmail.com
       </email>
       (Z.S.);
       <email>
        xuyanf2009@163.com
       </email>
       (Y.X.);
       <email>
        bllmsl@aliyun.com
       </email>
       (L.B.);
       <email>
        zhangling@cnilas.org
       </email>
       (L.Z.);
       <email>
        pinyucau@gmail.com
       </email>
       (P.Y.);
       <email>
        quyj@cnilas.org
       </email>
       (Y.Q.);
       <email>
        zhuh@cnilas.org
       </email>
       (H.Z.);
       <email>
        hnndwenjiezhao@163.com
       </email>
       (W.Z.);
       <email>
        18510165683@163.com
       </email>
       (Y.H.)
      </aff>
      <aff id="af2-viruses-11-00059">
       <label>
        2
       </label>
       NHC Key Laboratory of Human Disease Comparative Medicine, the Institute of Laboratory Animal Sciences, CAMS&amp;PUMC, Beijing 100021, China
      </aff>
      <aff id="af3-viruses-11-00059">
       <label>
        3
       </label>
       Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious, Beijing 100021, China
      </aff>
      <author-notes>
       <corresp id="c1-viruses-11-00059">
        <label>
         *
        </label>
        Correspondence:
        <email>
         qinchuan@pumc.edu.cn
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        14
       </day>
       <month>
        1
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <month>
        1
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <volume>
       11
      </volume>
      <issue>
       1
      </issue>
      <elocation-id>
       59
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         16
        </day>
        <month>
         12
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         09
        </day>
        <month>
         1
        </month>
        <year>
         2019
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2019 by the authors.
       </copyright-statement>
       <copyright-year>
        2019
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         ).
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Coronaviruses (CoVs) have formerly been regarded as relatively harmless respiratory pathogens to humans. However, two outbreaks of severe respiratory tract infection, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), as a result of zoonotic CoVs crossing the species barrier, caused high pathogenicity and mortality rates in human populations. This brought CoVs global attention and highlighted the importance of controlling infectious pathogens at international borders. In this review, we focus on our current understanding of the epidemiology, pathogenesis, prevention, and treatment of SARS-CoV and MERS-CoV, as well as provides details on the pivotal structure and function of the spike proteins (S proteins) on the surface of each of these viruses. For building up more suitable animal models, we compare the current animal models recapitulating pathogenesis and summarize the potential role of host receptors contributing to diverse host affinity in various species. We outline the research still needed to fully elucidate the pathogenic mechanism of these viruses, to construct reproducible animal models, and ultimately develop countermeasures to conquer not only SARS-CoV and MERS-CoV, but also these emerging coronaviral diseases.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        coronaviruses
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        spike proteins
       </kwd>
       <kwd>
        animal model
       </kwd>
       <kwd>
        prevention and treatment
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1-viruses-11-00059">
     <title>
      1. Introduction
     </title>
     <p>
      Before the first outbreak of severe acute respiratory syndrome (SARS), a limited number of coronaviruses were known to be circulating in humans, causing only mild illnesses, such as the common cold [
      <xref ref-type="bibr" rid="B1-viruses-11-00059">
       1
      </xref>
      ]. Following the 2003 SARS pandemic [
      <xref ref-type="bibr" rid="B2-viruses-11-00059">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B3-viruses-11-00059">
       3
      </xref>
      ], it became apparent that coronaviruses could cross the species barrier and cause life-threatening infections in humans. Therefore, further attention needs to be paid to these new coronaviruses.
     </p>
     <p>
      The 21st century has seen the worldwide spread of two previously unrecognized coronaviruses, the severe acute respiratory syndrome coronavirus (SARS-CoV) [
      <xref ref-type="bibr" rid="B4-viruses-11-00059">
       4
      </xref>
      ] and Middle East respiratory syndrome coronavirus (MERS-CoV), both of which are highly pathogenic. Starting from November 2002 in China [
      <xref ref-type="bibr" rid="B5-viruses-11-00059">
       5
      </xref>
      ], there have been unprecedented nosocomial transmissions from person to person of SARS-CoV, accompanied by high fatality rates. A united global effort led to the rapid identification of the SARS coronavirus and remarkable scientific advancements in epidemic prevention. Additionally, the zoonotic transmission of SARS from December 2003 to January 2004 [
      <xref ref-type="bibr" rid="B6-viruses-11-00059">
       6
      </xref>
      ] provided insight for researchers into the origin of this novel coronavirus. Notably, the SARS pandemic was declared to be over in 2004 when no more infections in patients were being detected. Subsequently, certain SARS-CoV-like viruses found in bats demonstrated the ability to infect human cells without prior adaptation [
      <xref ref-type="bibr" rid="B7-viruses-11-00059">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="B8-viruses-11-00059">
       8
      </xref>
      ] which indicates the possibility of the re-emergence of SARS-CoV or SARS-CoV-like viruses.
     </p>
     <p>
      A decade later in June 2012, another highly pathogenic and novel coronavirus, MERS-CoV, was isolated from the sputum of a male patient who died from acute pneumonia and renal failure in Saudi Arabia [
      <xref ref-type="bibr" rid="B9-viruses-11-00059">
       9
      </xref>
      ]. Nosocomial infections were reported, and international travel led to the transmission of MERS-CoV to countries outside of the Arabian Peninsula, causing it to become a global pathophoresis. In May 2015, an outbreak of MERS occurred in South Korea due to an individual returning from the Middle East [
      <xref ref-type="bibr" rid="B10-viruses-11-00059">
       10
      </xref>
      ]. Based on the lessons learned from managing SARS-CoV prevalence over the last decade, tremendous progress toward unraveling the biological characteristics of MERS-CoV has been achieved at an unprecedented speed. Scientific advancements have allowed for rapid and systemic progress in our understanding of the epidemiology and pathogenesis of MERS-CoV.
     </p>
     <p>
      SARS-CoV and MERS-CoV share several important common features that contribute to nosocomial transmission, preferential viral replication in the lower respiratory tract, and viral immunopathology. This review highlights the epidemiology and pathogenesis of these viruses, including our current understanding of their biological characteristics, their transmission, and their replication in the host. The spike proteins (S proteins) of CoVs play pivotal roles in viral infection and pathogenesis. As critical surface-located trimeric glycoproteins of CoVs, they guide entry into host cells. In this review, we summarize the structure and function of the S proteins and therapeutics designed to target them. Moreover, we will explore how CoV–host interactions cause pathogenic outcomes and discuss potential treatment options, as well as describe recent mammalian models that closely recapitulate the pathogenic process and have contributed to the development of prevention and treatment strategies for SARS-CoV and MERS-CoV. Although several potential therapies have been identified with SARS and MERS in animal and in vitro models, human clinical trials remain lacking, hindering the advancement of these potential countermeasures.
     </p>
    </sec>
    <sec id="sec2-viruses-11-00059">
     <title>
      2. Epidemiology of SARS-CoV and MERS-CoV
     </title>
     <p>
      Prior to the outbreaks of SARS and MERS [
      <xref ref-type="bibr" rid="B2-viruses-11-00059">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="B9-viruses-11-00059">
       9
      </xref>
      ], the clinical importance and epidemic possibility of CoVs had been recognized by researchers, (
      <xref ref-type="table" rid="viruses-11-00059-t001">
       Table 1
      </xref>
      ). In 2002, a SARS epidemic that originated in Guangdong Province in China resulted in 916 deaths among more than 8098 patients in 29 countries [
      <xref ref-type="bibr" rid="B11-viruses-11-00059">
       11
      </xref>
      ], identifying SARS as the first new infectious disease of the 21st century. Ten years later, the World Health Organization (WHO) published 2254 laboratory-confirmed cases of MERS-CoV that occurred from 2012 to 16 September 2018, with at least 800 deaths in 27 countries. Remarkably, more than 80% of recent research into the virology and genetics of this infection indicated that bats could be the possible natural reservoirs of both SARS and MERS-CoV. Palm civets [
      <xref ref-type="bibr" rid="B12-viruses-11-00059">
       12
      </xref>
      ] and dromedary camels [
      <xref ref-type="bibr" rid="B13-viruses-11-00059">
       13
      </xref>
      ] are also possible intermediary hosts of SARS and MERS, respectively, before dissemination to humans [
      <xref ref-type="bibr" rid="B14-viruses-11-00059">
       14
      </xref>
      ].
     </p>
     <p>
      The transmission mechanism of SARS-CoV and MERS-CoV has yet to be fully understood. For transmission from animals to humans, direct contact with the intermediary host might be one route. Recent reports demonstrated that camel workers in Saudi Arabia with high prevalence of MERS-CoV infection may contribute to the transmission of MERS [
      <xref ref-type="bibr" rid="B15-viruses-11-00059">
       15
      </xref>
      ]. Some customs and habits may also be conducive to transmission, such as the consumption of milk, urine, or uncooked meat. In this way, MERS-CoV was transmitted from dromedary camels directly to humans, principally in the Arabian Peninsula, and this is considered to be the main route of transmission from animals to humans, causing significant morbidity and mortality [
      <xref ref-type="bibr" rid="B16-viruses-11-00059">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="B17-viruses-11-00059">
       17
      </xref>
      ]. Human-to-human spread has also been detected, especially through nosocomial transmission. Delays in diagnosis in hospitals might lead to secondary cases among healthcare workers, family members, or other patients sharing rooms [
      <xref ref-type="bibr" rid="B18-viruses-11-00059">
       18
      </xref>
      ,
      <xref ref-type="bibr" rid="B19-viruses-11-00059">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="B20-viruses-11-00059">
       20
      </xref>
      ,
      <xref ref-type="bibr" rid="B21-viruses-11-00059">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="B22-viruses-11-00059">
       22
      </xref>
      ]. Among the reported cases of SARS, 22% were healthcare workers in China and more than 40% were healthcare workers in Canada [
      <xref ref-type="bibr" rid="B23-viruses-11-00059">
       23
      </xref>
      ]. Nosocomial transmission for MERS has similarly been seen in the Middle East [
      <xref ref-type="bibr" rid="B16-viruses-11-00059">
       16
      </xref>
      ] and in the Republic of Korea [
      <xref ref-type="bibr" rid="B22-viruses-11-00059">
       22
      </xref>
      ]. Outbreaks in other countries all resulted from the reported cases in the Middle East or North Africa, and transmission was the result of international travel. Both SARS and MERS caused large outbreaks with significant public health and economic consequences.
     </p>
    </sec>
    <sec id="sec3-viruses-11-00059">
     <title>
      3. Pathogenesis of SARS-CoV and MERS-CoV
     </title>
     <p>
      Although our current understanding of the pathogenesis of the SARS-CoV and MERS-CoV infection remains unclear, we summarize what is presently known (
      <xref ref-type="table" rid="viruses-11-00059-t002">
       Table 2
      </xref>
      ).
     </p>
     <p>
      Coronaviruses are the largest kind of positive-strand RNA viruses (26–32 kb) as they are about 125 nm in diameter [
      <xref ref-type="bibr" rid="B24-viruses-11-00059">
       24
      </xref>
      ], and comprise four genera (alpha-, beta-, gamma-, and delta-coronavirus) [
      <xref ref-type="bibr" rid="B25-viruses-11-00059">
       25
      </xref>
      ]. Currently, six human CoVs (HCoVs) have been confirmed: HCoV-NL63 and HCoV-229E, which belong to the alpha-coronavirus genus; and HCoV-OC43, HCoV-HKU1, SARS-CoV, and MERS-CoV, which belong to the beta-coronavirus genus. SARS-CoV and MERS-CoV are the two major causes of severe pneumonia in humans and share some common coronavirus structural characteristics. Similarly, their genomic organization is typical of coronaviruses, having an enveloped, single, positive-stranded RNA genome that encodes four major viral structural proteins, namely spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins 3–5, that follow the characteristic gene order [5′-replicase (
      <italic>
       rep
      </italic>
      gene), spike (S), envelope (E), membrane (M), nucleocapsid (N)-3′] with short untranslated regions at both termini (
      <xref ref-type="fig" rid="viruses-11-00059-f001">
       Figure 1
      </xref>
      ). The viral membrane contains S, E, and M proteins, and the spike protein plays a vital functional role in viral entry. The
      <italic>
       rep
      </italic>
      gene encodes the non-structural protein and constitutes approximately two-thirds of the genome at the 5′ end. In detail, the S protein is in charge of receptor-binding and subsequent viral entry into host cells, and is therefore a major therapeutic target [
      <xref ref-type="bibr" rid="B26-viruses-11-00059">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="B27-viruses-11-00059">
       27
      </xref>
      ]. The M and E proteins play important roles in viral assembly, and the N protein is necessary for RNA synthesis.
     </p>
     <p>
      The SARS-CoV genome has 29,727 nucleotides in length, including 11 open reading frames (ORFs). The SARS-CoV
      <italic>
       rep
      </italic>
      gene, containing about two-thirds of the genome, encodes at least two polyproteins (encoded by ORF1a and ORF1b) that undergo the process of cotranslational proteolysis. Between ORF1b and S of group 2 and some group 3 coronaviruses, there is a gene that encodes hemagglutinin-esterase [
      <xref ref-type="bibr" rid="B4-viruses-11-00059">
       4
      </xref>
      ], while this was not detected in SARS-CoV. This virus is significantly different from previously reported coronaviruses for many reasons, such as the short anchor of the S protein, the specific number and location of small ORFs, and the presence of only one copy of PLP
      <sup>
       pro
      </sup>
      .
     </p>
     <p>
      The MERS-CoV genome is larger than that of SARS-CoV at 30,119 nucleotides in length, and comprises a 5′ terminal cap structure, along with a poly (A) tail at the 3′ end, as well as the
      <italic>
       rep
      </italic>
      gene containing 16 non-structural proteins (nsp1–16) at the 5′ end of the genome. Four structural proteins (S, E, M, and N) and five accessory proteins (ORF3, ORF4a, ORF4b, ORF5, and ORF8) constitute about 10 kb at the 3′ end of the genome. Unlike some other beta-coronaviruses, the MERS-CoV genome does not encode a hemagglutinin-esterase (HE) protein [
      <xref ref-type="bibr" rid="B1-viruses-11-00059">
       1
      </xref>
      ]. Genomic analysis of MERS-CoV implies the potential for genetic recombination during a MERS-CoV outbreak [
      <xref ref-type="bibr" rid="B9-viruses-11-00059">
       9
      </xref>
      ]. MERS-CoV and SARS-CoV possess five and eight accessory proteins, respectively, which might help the virus evade the immune system by being harmful to the innate immune response. These differences might lead to greater sensitivity to the effects of induction and signaling of type 1 interferons (IFNs) in MERS-CoV than SARS-CoV.
     </p>
    </sec>
    <sec id="sec4-viruses-11-00059">
     <title>
      4. Comparative Pathology and Life Cycles of SARS-CoV and MERS-CoV
     </title>
     <p>
      Both SARS and MERS cause severe pneumonia resulting from these novel coronaviruses, sharing some similarities in their pathogenesis (
      <xref ref-type="fig" rid="viruses-11-00059-f002">
       Figure 2
      </xref>
      ) [
      <xref ref-type="bibr" rid="B28-viruses-11-00059">
       28
      </xref>
      ].
     </p>
     <p>
      SARS is an emerging infectious viral disease characterized by severe clinical manifestations of the lower respiratory tract, resulting in diffuse alveolar damage. SARS-CoV spreads through respiratory secretions, such as droplets, via direct person-to-person contact. Upon exposure of the host to the virus, the virus binds to cells expressing the virus receptors, of which the angiotensin-converting enzyme 2 (ACE2) is one of the main receptors, and CD209L is an alternative receptor with a much lower affinity [
      <xref ref-type="bibr" rid="B29-viruses-11-00059">
       29
      </xref>
      ]. In the respiratory tract, ACE2 is widely expressed on the epithelial cells of alveoli, trachea, bronchi, bronchial serous glands [
      <xref ref-type="bibr" rid="B30-viruses-11-00059">
       30
      </xref>
      ], and alveolar monocytes and macrophages [
      <xref ref-type="bibr" rid="B31-viruses-11-00059">
       31
      </xref>
      ]. The virus enters and replicates in these target cells. The mature virions are then released from primary cells and infect new target cells [
      <xref ref-type="bibr" rid="B32-viruses-11-00059">
       32
      </xref>
      ]. Furthermore, as a surface molecule, ACE2 is also diffusely localized on the endothelial cells of arteries and veins, the mucosal cells of the intestines, tubular epithelial cells of the kidneys, epithelial cells of the renal tubules, and cerebral neurons and immune cells, providing a variety of susceptible cells to SARS-CoV [
      <xref ref-type="bibr" rid="B33-viruses-11-00059">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="B34-viruses-11-00059">
       34
      </xref>
      ]. Respiratory secretions, urine, stools, and sweat from patients with SARS contain infective viral particles, which may be excreted into and contaminate the environment. Atypical pneumonia with rapid respiratory deterioration and failure can be induced by SARS-CoV infection because of increased levels of activated proinflammatory chemokines and cytokines [
      <xref ref-type="bibr" rid="B35-viruses-11-00059">
       35
      </xref>
      ].
     </p>
     <p>
      For MERS-CoV infection of humans, the primary receptor is a multifunctional cell surface protein, dipeptidyl peptidase 4 (DPP4, also known as CD26) [
      <xref ref-type="bibr" rid="B36-viruses-11-00059">
       36
      </xref>
      ], which is widely expressed on epithelial cells in the kidney, alveoli, small intestine, liver, and prostate, and on activated leukocytes [
      <xref ref-type="bibr" rid="B37-viruses-11-00059">
       37
      </xref>
      ]. Consistent with this, MERS-CoV can infect several human cell lines, including lower respiratory, kidney, intestinal, and liver cells, as well as histiocytes, as shown by a cell-line susceptibility study [
      <xref ref-type="bibr" rid="B38-viruses-11-00059">
       38
      </xref>
      ], indicating that the range of MERS-CoV tissue tropism in vitro was broader than that of any other CoV. MERS-CoV causes acute, highly lethal pneumonia and renal dysfunction with various clinical symptoms, including—but not restricted to—fever, cough, sore throat, myalgia, chest pain, diarrhea, vomiting, and abdominal pain [
      <xref ref-type="bibr" rid="B39-viruses-11-00059">
       39
      </xref>
      ,
      <xref ref-type="bibr" rid="B40-viruses-11-00059">
       40
      </xref>
      ]. Lung infection in the MERS animal model demonstrated infiltration of neutrophils and macrophages and alveolar edema [
      <xref ref-type="bibr" rid="B41-viruses-11-00059">
       41
      </xref>
      ]. The entry receptor (DPP4) for MERS-CoV is also highly expressed in the kidney, causing renal dysfunctions by either hypoxic damage or direct infection of the epithelia [
      <xref ref-type="bibr" rid="B42-viruses-11-00059">
       42
      </xref>
      ]. Remarkably, unlike SARS-CoV, MERS-CoV has the ability to infect human dendritic cells [
      <xref ref-type="bibr" rid="B43-viruses-11-00059">
       43
      </xref>
      ] and macrophages [
      <xref ref-type="bibr" rid="B44-viruses-11-00059">
       44
      </xref>
      ] in vitro, thus helping the virus to disrupt the immune system. T cells are another target for MERS-CoV because of their high amounts of CD26 [
      <xref ref-type="bibr" rid="B45-viruses-11-00059">
       45
      </xref>
      ]. This virus might deregulate antiviral T-cell responses due to the stimulation of T-cell apoptosis [
      <xref ref-type="bibr" rid="B45-viruses-11-00059">
       45
      </xref>
      ,
      <xref ref-type="bibr" rid="B46-viruses-11-00059">
       46
      </xref>
      ]. MERS-CoV might also lead to immune dysregulation [
      <xref ref-type="bibr" rid="B47-viruses-11-00059">
       47
      </xref>
      ] by stimulating attenuated innate immune responses, with delayed proinflammatory cytokine induction in vitro and in vivo [
      <xref ref-type="bibr" rid="B44-viruses-11-00059">
       44
      </xref>
      ,
      <xref ref-type="bibr" rid="B48-viruses-11-00059">
       48
      </xref>
      ,
      <xref ref-type="bibr" rid="B49-viruses-11-00059">
       49
      </xref>
      ].
     </p>
    </sec>
    <sec id="sec5-viruses-11-00059">
     <title>
      5. SARS and MERS-CoV Spike Protein: A Key Target for Antivirals
     </title>
     <sec id="sec5dot1-viruses-11-00059">
      <title>
       5.1. Structure of the SARS-CoV and MERS-CoV Spike Protein
      </title>
      <p>
       Trimers of the S protein make up the spikes of SARS-CoV and provide the formation of a 1255-amino-acids-length surface glycoprotein precursor. Most of the protein and the amino terminus are situated on the outside of the virus particle or the cell surface [
       <xref ref-type="bibr" rid="B50-viruses-11-00059">
        50
       </xref>
       ]. The expected structure of the S protein comprises four parts: a signal peptide located at the N terminus from amino acids 1 to 12, an extracellular domain from amino acids 13 to 1195, a transmembrane domain from amino acids 1196 to 1215, and an intracellular domain from amino acids 1216 to 1255. Proteases such as factor Xa, trypsin, and cathepsin L cleave the SARS-CoV S protein into two subunits, the S1 and S2 subunits. A minimal receptor-binding domain (RBD) located in the S1 subunit (amino acids 318–510) can combine with the host cell receptor, ACE2. The RBD displays a concave surface during interaction with the receptor. The entire receptor-binding loop, known as the receptor-binding motif (RBM) (amino acids 424–494), is located on the RBD and is responsible for complete contact with ACE2. Importantly, two residues in the RBM at positions 479 and 487 determine the progression of the SARS disease and the tropism of SARS-CoV [
       <xref ref-type="bibr" rid="B51-viruses-11-00059">
        51
       </xref>
       ,
       <xref ref-type="bibr" rid="B52-viruses-11-00059">
        52
       </xref>
       ]. Recent studies using civets, mice, and rats demonstrated that any change in these two residues might improve animal-to-human or human-to-human transmission and facilitate efficient cross-species infection [
       <xref ref-type="bibr" rid="B53-viruses-11-00059">
        53
       </xref>
       ]. The S2 subunit mediates the fusion between SARS-CoV and target cells, and includes the heptad repeat 1 (HR1) and HR2 domains, whose HR1 region is longer than the HR2 region.
      </p>
      <p>
       Similar to SARS-CoV, during the infection process, the S protein of MERS-CoV is cleaved into a receptor-binding subunit S1 and a membrane-fusion subunit S2 [
       <xref ref-type="bibr" rid="B54-viruses-11-00059">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="B55-viruses-11-00059">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="B56-viruses-11-00059">
        56
       </xref>
       ,
       <xref ref-type="bibr" rid="B57-viruses-11-00059">
        57
       </xref>
       ]. The MERS-CoV S1 subunit also includes an RBD, mediating the attachment between virus and target cells [
       <xref ref-type="bibr" rid="B54-viruses-11-00059">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="B55-viruses-11-00059">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="B58-viruses-11-00059">
        58
       </xref>
       ,
       <xref ref-type="bibr" rid="B59-viruses-11-00059">
        59
       </xref>
       ]. Unlike SARS-CoV, MERS-CoV requires DPP4 (also known as CD26) as its cellular receptor [
       <xref ref-type="bibr" rid="B60-viruses-11-00059">
        60
       </xref>
       ,
       <xref ref-type="bibr" rid="B61-viruses-11-00059">
        61
       </xref>
       ] but not ACE2. The RBDs of MERS-CoV and SARS-CoV differ, although they share a high degree of structural similarity in their core subdomains, explaining the different critical receptors noted above [
       <xref ref-type="bibr" rid="B57-viruses-11-00059">
        57
       </xref>
       ,
       <xref ref-type="bibr" rid="B62-viruses-11-00059">
        62
       </xref>
       ]. The core subdomain of RBD is stabilized by three disulfide bonds, and includes a five-stranded antiparallel β-sheet and several connecting helices. The RBM comprises a four-stranded antiparallel β-sheet for connecting to the core via loops [
       <xref ref-type="bibr" rid="B57-viruses-11-00059">
        57
       </xref>
       ,
       <xref ref-type="bibr" rid="B62-viruses-11-00059">
        62
       </xref>
       ]. Two N-linked glycans, N410 and N487, are seated in the core and RBM, respectively. Particularly, the residues 484–567 of RBM take charge of interacting with the extracellular β-propeller domain of DPP4. The fusion core formation of MERS-CoV resembles that of SARS-CoV; however, it is different from that of other coronaviruses, such as the mouse hepatitis virus (MHV) and HCoV-NL63 [
       <xref ref-type="bibr" rid="B63-viruses-11-00059">
        63
       </xref>
       ,
       <xref ref-type="bibr" rid="B64-viruses-11-00059">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="B65-viruses-11-00059">
        65
       </xref>
       ,
       <xref ref-type="bibr" rid="B66-viruses-11-00059">
        66
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec5dot2-viruses-11-00059">
      <title>
       5.2. Functions of the SARS-CoV and MERS-CoV S Protein
      </title>
      <p>
       The SARS-CoV S protein plays pivotal roles in viral infection and pathogenesis [
       <xref ref-type="bibr" rid="B67-viruses-11-00059">
        67
       </xref>
       ,
       <xref ref-type="bibr" rid="B68-viruses-11-00059">
        68
       </xref>
       ]. The S1 subunit recognizes and binds to host receptors, and the subsequent conformational changes in the S2 subunit mediate fusion between the viral envelope and the host cell membrane [
       <xref ref-type="bibr" rid="B69-viruses-11-00059">
        69
       </xref>
       ,
       <xref ref-type="bibr" rid="B70-viruses-11-00059">
        70
       </xref>
       ]. The RBD in the S1 subunit is responsible for virus binding to host cell receptors [
       <xref ref-type="bibr" rid="B61-viruses-11-00059">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="B70-viruses-11-00059">
        70
       </xref>
       ,
       <xref ref-type="bibr" rid="B71-viruses-11-00059">
        71
       </xref>
       ]. ACE2 is a functional receptor for SARS-CoV that makes contact with 14 amino acids in the RBD of SARS-CoV among its 18 residues [
       <xref ref-type="bibr" rid="B53-viruses-11-00059">
        53
       </xref>
       ]. The RBD in the S1 subunit is responsible for virus binding to host cell receptors [
       <xref ref-type="bibr" rid="B61-viruses-11-00059">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="B70-viruses-11-00059">
        70
       </xref>
       ,
       <xref ref-type="bibr" rid="B71-viruses-11-00059">
        71
       </xref>
       ]. Position R453 in the RBD and position K341 in ACE2 play indispensable roles in complex formation [
       <xref ref-type="bibr" rid="B72-viruses-11-00059">
        72
       </xref>
       ]. Furthermore, the N479 and T487 in the RBD of the S protein are pivotal positions for the affinity with ACE2 [
       <xref ref-type="bibr" rid="B52-viruses-11-00059">
        52
       </xref>
       ], and R441 or D454 in the RBD influences the antigenic structure and binding activity between RBD and ACE2 [
       <xref ref-type="bibr" rid="B73-viruses-11-00059">
        73
       </xref>
       ]. From a pre-fusion structure to a post-fusion structure, binding of the RBD in the S1 subunit to the receptor ACE2 stimulates a conformational change in S2. Accordingly, the supposed fusion peptide (amino acids 770–788) [
       <xref ref-type="bibr" rid="B74-viruses-11-00059">
        74
       </xref>
       ] builds in the target cell membrane of the host. Meanwhile, a six-helix bundle fusion core structure is made up by the HR1 and HR2 domains for bringing the viral envelope and the target cell membrane into close proximity and contributing to fusion [
       <xref ref-type="bibr" rid="B74-viruses-11-00059">
        74
       </xref>
       ]. Resembling the S2 subunit of SARS-CoV, the MERS-CoV S2 subunit is in charge of membrane fusion. The HR1 and HR2 regions in S2 play essential and complementary roles [
       <xref ref-type="bibr" rid="B56-viruses-11-00059">
        56
       </xref>
       ,
       <xref ref-type="bibr" rid="B63-viruses-11-00059">
        63
       </xref>
       ]. Furthermore, SARS-CoV displays an alternative method of binding to the host cell via other potential receptors. Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and/or liver/lymph node-SIGN (L-SIGN) are two examples of such receptors [
       <xref ref-type="bibr" rid="B29-viruses-11-00059">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="B75-viruses-11-00059">
        75
       </xref>
       ]. Seven residue sites, at positions 109, 118, 119, 158, 227, 589, and 699 of the S protein displaying asparagine-linked glycosylation are crucial for DC-SIGN or L-SIGN-mediated virus entry. These residues, unlike those of the ACE2-binding domain, function independently of ACE2 [
       <xref ref-type="bibr" rid="B76-viruses-11-00059">
        76
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec5dot3-viruses-11-00059">
      <title>
       5.3. Vaccines Based on the SARS-CoV and MERS-CoV S Protein
      </title>
      <p>
       In order to control the outbreak of viruses, vaccinations were developed against SARS-CoV and MERS-CoV. There are various approaches of different vaccines, and the development and advantages/disadvantages of these are listed in
       <xref ref-type="table" rid="viruses-11-00059-t003">
        Table 3
       </xref>
       (this table includes updates about SARS-CoV and MERS-CoV since 2013; SARS-CoV-related parts were modified by Graham et al. in Nature Reviews Microbiology, 2013 [
       <xref ref-type="bibr" rid="B77-viruses-11-00059">
        77
       </xref>
       ]).
      </p>
      <p>
       Importantly, among all the functional/non-functional structural proteins of SARS-CoV and MERS-CoV, the S protein is the principal antigenic component that induces antibodies to block virus-binding, stimulate host immune responses, fuse or neutralize antibodies and/or protect the immune system against virus infection. Therefore, the S protein has been selected as a significant target for the development of vaccines. It has been noted that antibodies raised against subunit S1 (amino acids 485–625) or S2 (amino acids 1029–1192) neutralize infection by SARS-CoV strains in Vero E6 cells [
       <xref ref-type="bibr" rid="B78-viruses-11-00059">
        78
       </xref>
       ,
       <xref ref-type="bibr" rid="B79-viruses-11-00059">
        79
       </xref>
       ]. Researchers have constructed an attenuated parainfluenza virus encoding the full-length S protein of the SARS-CoV Urbani strain for the vaccination of African green monkeys. This vaccine could protect monkeys from subsequent homologous SARS-CoV infection, demonstrating highly effective immunization with the S protein [
       <xref ref-type="bibr" rid="B80-viruses-11-00059">
        80
       </xref>
       ]. Other studies in a mouse model structured a DNA vaccine encoding the full-length S protein of the SARS-CoV Urbani strain that not only induced T-cell and neutralizing-antibody responses, but also stimulated protective immunity [
       <xref ref-type="bibr" rid="B81-viruses-11-00059">
        81
       </xref>
       ]. Furthermore, monkeys or mice were vaccinated with a highly attenuated, modified vaccine virus, Ankara, encoding the full-length S protein of the SARS-CoV strain HKU39849 or Urbani [
       <xref ref-type="bibr" rid="B82-viruses-11-00059">
        82
       </xref>
       ]. However, full-length S protein-based SARS vaccines may induce harmful immune responses, causing liver damage in the vaccinated animals or enhancing infection after being challenged with homologous SARS-CoV [
       <xref ref-type="bibr" rid="B83-viruses-11-00059">
        83
       </xref>
       ,
       <xref ref-type="bibr" rid="B84-viruses-11-00059">
        84
       </xref>
       ]. Researchers are thus concerned about the safety and ultimate protective efficacy of vaccines that include the full-length SARS-CoV S protein.
      </p>
      <p>
       There are still no commercial vaccines available against MERS-CoV [
       <xref ref-type="bibr" rid="B26-viruses-11-00059">
        26
       </xref>
       ]. Multiple vaccine candidates targeting the S protein, which is responsible for viral entry, have been developed, including subunit vaccines [
       <xref ref-type="bibr" rid="B85-viruses-11-00059">
        85
       </xref>
       ,
       <xref ref-type="bibr" rid="B86-viruses-11-00059">
        86
       </xref>
       ], recombinant vector vaccines [
       <xref ref-type="bibr" rid="B87-viruses-11-00059">
        87
       </xref>
       ,
       <xref ref-type="bibr" rid="B88-viruses-11-00059">
        88
       </xref>
       ], and DNA vaccines [
       <xref ref-type="bibr" rid="B89-viruses-11-00059">
        89
       </xref>
       ,
       <xref ref-type="bibr" rid="B90-viruses-11-00059">
        90
       </xref>
       ]. Importantly, compared with other regions of the S protein, the RBD fragment induced the highest-titer IgG antibodies in mice [
       <xref ref-type="bibr" rid="B85-viruses-11-00059">
        85
       </xref>
       ]. Modified vaccines, including recombinant vectors of Ankara and adenoviruses expressing the MERS-CoV S glycoprotein, showed immunogenicity in mice [
       <xref ref-type="bibr" rid="B25-viruses-11-00059">
        25
       </xref>
       ]. Attenuated live vaccines also showed a protective function, but there were concerns regarding the degree of attenuation [
       <xref ref-type="bibr" rid="B91-viruses-11-00059">
        91
       </xref>
       ]. After intranasal vaccination with the CoV N protein, airway memory CD4 T cells were generated and mediated the protection following a CoV challenge [
       <xref ref-type="bibr" rid="B92-viruses-11-00059">
        92
       </xref>
       ]. These cells could induce anti-viral innate responses at an early stage of infection, and facilitated CD8 T-cell responses by stimulating recombinant dendritic cell migration and CD8 T-cell mobilization [
       <xref ref-type="bibr" rid="B92-viruses-11-00059">
        92
       </xref>
       ]. The stimulation of airway memory CD4 T cells should be regarded as an essential part of any HCoV vaccine strategy, because these CD4 T cells target a conserved epitope within the N protein that cross-reacts with several other CoVs [
       <xref ref-type="bibr" rid="B92-viruses-11-00059">
        92
       </xref>
       ]. Furthermore, DNA vaccines expressing the MERS-CoV S1 gene produced antigen-specific humoral and cellular immune responses in mice [
       <xref ref-type="bibr" rid="B89-viruses-11-00059">
        89
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec5dot4-viruses-11-00059">
      <title>
       5.4. S Protein-Based Therapeutics for SARS-CoV and MERS-CoV
      </title>
      <p>
       Despite the presence of extensive research reporting on SARS-CoV and MERS-CoV therapies, it was not possible to establish whether treatments benefited patients during their outbreak. In the absence of fundamental, clinically proven, effective antiviral therapy against SARS-CoV and MERS-CoV, patients mainly receive supportive care supplemented by diverse combinations of drugs. Several approaches are being considered to treat infections of SARS-CoV [
       <xref ref-type="bibr" rid="B113-viruses-11-00059">
        113
       </xref>
       ] and MERS-CoV (
       <xref ref-type="table" rid="viruses-11-00059-t004">
        Table 4
       </xref>
       , MERS-CoV-related table previously reviewed by de Wit et al. in Nature Reviews Microbiology, 2016 [
       <xref ref-type="bibr" rid="B10-viruses-11-00059">
        10
       </xref>
       ]), including the use of antibodies, IFNs, and inhibitors of viral and host proteases.
      </p>
      <p>
       The vital role of the S protein of SARS-CoV makes this protein an important therapeutic target, and numerous studies have explored potential therapeutics. Firstly, peptides that block RBD–ACE2-binding derived from both RBD [
       <xref ref-type="bibr" rid="B114-viruses-11-00059">
        114
       </xref>
       ] and ACE2 [
       <xref ref-type="bibr" rid="B76-viruses-11-00059">
        76
       </xref>
       ] could be developed as novel therapeutics against SARS-CoV infection. Secondly, peptides binding to the S protein interfere with the cleavage of S1 and S2. This step inhibits the production of functional S1 and S2 subunits and the consequent fusion of the viral envelope with the host cell membrane. Thirdly, anti-SARS-CoV peptides blocking the HR1–HR2 interaction by forming a fusion-active core have viral fusion inhibitory activity at the micromolar level [
       <xref ref-type="bibr" rid="B115-viruses-11-00059">
        115
       </xref>
       ,
       <xref ref-type="bibr" rid="B116-viruses-11-00059">
        116
       </xref>
       ,
       <xref ref-type="bibr" rid="B117-viruses-11-00059">
        117
       </xref>
       ]. However, the potential selection of escape mutants with altered host range phenotypes is one of the disadvantages of this strategy that needs further modification [
       <xref ref-type="bibr" rid="B118-viruses-11-00059">
        118
       </xref>
       ]. Furthermore, mouse monoclonal antibodies (mAbs) targeting assorted fragments of the SARS-CoV S protein have effectively inhibited SARS-CoV infection [
       <xref ref-type="bibr" rid="B79-viruses-11-00059">
        79
       </xref>
       ,
       <xref ref-type="bibr" rid="B119-viruses-11-00059">
        119
       </xref>
       ,
       <xref ref-type="bibr" rid="B120-viruses-11-00059">
        120
       </xref>
       ,
       <xref ref-type="bibr" rid="B121-viruses-11-00059">
        121
       </xref>
       ,
       <xref ref-type="bibr" rid="B122-viruses-11-00059">
        122
       </xref>
       ]. A series of neutralizing human mAbs were generated from the B cells of patients infected with SARS-CoV [
       <xref ref-type="bibr" rid="B123-viruses-11-00059">
        123
       </xref>
       ,
       <xref ref-type="bibr" rid="B124-viruses-11-00059">
        124
       </xref>
       ]. Another strategy used human immunoglobulin transgenic mice immunized with full-length SARS-CoV S proteins [
       <xref ref-type="bibr" rid="B125-viruses-11-00059">
        125
       </xref>
       ,
       <xref ref-type="bibr" rid="B126-viruses-11-00059">
        126
       </xref>
       ,
       <xref ref-type="bibr" rid="B127-viruses-11-00059">
        127
       </xref>
       ]. 80R and CR3014 binding to the ACE2 receptor are examples of S-specific mAbs [
       <xref ref-type="bibr" rid="B128-viruses-11-00059">
        128
       </xref>
       ,
       <xref ref-type="bibr" rid="B129-viruses-11-00059">
        129
       </xref>
       ].
      </p>
      <p>
       Similarly, the therapeutic agents that have been developed against MERS-CoV are based on the S protein and basically restrain the binding of receptors or the fusion of membrane proteins, thereby leading to the inhibition of MERS-CoV infection. These methods mainly involve peptidic fusion inhibitors [
       <xref ref-type="bibr" rid="B56-viruses-11-00059">
        56
       </xref>
       ,
       <xref ref-type="bibr" rid="B63-viruses-11-00059">
        63
       </xref>
       ,
       <xref ref-type="bibr" rid="B116-viruses-11-00059">
        116
       </xref>
       ,
       <xref ref-type="bibr" rid="B130-viruses-11-00059">
        130
       </xref>
       ], anti-MERS-CoV neutralizing mAbs [
       <xref ref-type="bibr" rid="B86-viruses-11-00059">
        86
       </xref>
       ,
       <xref ref-type="bibr" rid="B131-viruses-11-00059">
        131
       </xref>
       ], anti-DPP4 mAbs [
       <xref ref-type="bibr" rid="B86-viruses-11-00059">
        86
       </xref>
       ,
       <xref ref-type="bibr" rid="B132-viruses-11-00059">
        132
       </xref>
       ,
       <xref ref-type="bibr" rid="B133-viruses-11-00059">
        133
       </xref>
       ], DPP4 antagonists [
       <xref ref-type="bibr" rid="B134-viruses-11-00059">
        134
       </xref>
       ], and protease inhibitors [
       <xref ref-type="bibr" rid="B135-viruses-11-00059">
        135
       </xref>
       ,
       <xref ref-type="bibr" rid="B136-viruses-11-00059">
        136
       </xref>
       ,
       <xref ref-type="bibr" rid="B137-viruses-11-00059">
        137
       </xref>
       ]. However, none of these anti-MERS-CoV curative agents are approved for commercial use in humans.
      </p>
     </sec>
    </sec>
    <sec id="sec6-viruses-11-00059">
     <title>
      6. The Animal Models of SARS and MERS-CoV
     </title>
     <p>
      International coordination and cooperation led to the rapid identification of SARS-CoV and MERS-CoV. Emergency control measures and laboratory detection systems which were put in place in response to SARS-CoV and MERS-CoV outbreaks were both exemplary. To establish optimal prevention and control strategies for SARS and MERS, numerous efforts to develop animal models were undertaken in several laboratories, despite the fact that some conflicting results have been reported. It is therefore necessary to compare and document the features and disadvantages of different animal models to better understand viral replication, transmission, pathogenesis, prevention, and treatment. Notably, several animal species were suggested as suitable disease models of SARS-CoV, but most laboratory animals are refractory or only semi-permissive to MERS-CoV infection.
     </p>
     <sec id="sec6dot1-viruses-11-00059">
      <title>
       6.1. Animal Models of SARS-CoV
      </title>
      <p>
       SARS-CoV replication has been studied in mice, Syrian golden and Chinese hamsters, civet cats, and non-human primates. The most severe symptoms of SARS were observed in aged animals. To develop epidemiological symptoms that advanced age resulted in increased mortality, aged mouse model of SARS-CoV has been generated. Transgenic mice expressing human ACE2 were also developed to closely mimic SARS-CoV infection in humans. Some animal models have been tested and analyzed on the genomic and proteomics level to study the pathogenesis of SARS.
      </p>
      <sec id="sec6dot1dot1-viruses-11-00059">
       <title>
        6.1.1. Mouse Models
       </title>
       <p>
        Mouse species that have been used as SARS-CoV-infected animal models include BALB/c [
        <xref ref-type="bibr" rid="B149-viruses-11-00059">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="B150-viruses-11-00059">
         150
        </xref>
        ], C57BL6 (B6) [
        <xref ref-type="bibr" rid="B151-viruses-11-00059">
         151
        </xref>
        ], and 129SvEv-lineage mice. The most relevant transgenic and knockout lines are accessible based on these susceptible animals [
        <xref ref-type="bibr" rid="B152-viruses-11-00059">
         152
        </xref>
        ]. Signal transducers and activators of transcription 1 (STAT1)-knockout and myeloid differentiation primary response 88 (MYD88)-knockout mice [
        <xref ref-type="bibr" rid="B149-viruses-11-00059">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="B151-viruses-11-00059">
         151
        </xref>
        ,
        <xref ref-type="bibr" rid="B153-viruses-11-00059">
         153
        </xref>
        ,
        <xref ref-type="bibr" rid="B154-viruses-11-00059">
         154
        </xref>
        ] are examples of mouse models with innate immune deficiency, and such animals display severe effects of the disease, such as pneumonitis, bronchiolitis, and weight loss, and often die within 9 days of infection. Notably, young mice require more mutations and passages than aged mice to produce SARS-CoV mouse-adapted strains. More severe pathological lesions and increased mortality were observed in one-year-old animals, along with fewer mutations at miscellaneous locations throughout the genome [
        <xref ref-type="bibr" rid="B98-viruses-11-00059">
         98
        </xref>
        ,
        <xref ref-type="bibr" rid="B155-viruses-11-00059">
         155
        </xref>
        ,
        <xref ref-type="bibr" rid="B156-viruses-11-00059">
         156
        </xref>
        ,
        <xref ref-type="bibr" rid="B157-viruses-11-00059">
         157
        </xref>
        ,
        <xref ref-type="bibr" rid="B158-viruses-11-00059">
         158
        </xref>
        ,
        <xref ref-type="bibr" rid="B159-viruses-11-00059">
         159
        </xref>
        ]. Intranasal inoculation of four- to eight-week-old BALB/c or B6 mice with SARS-CoV resulted in nasal turbinate in the upper respiratory tract and a high titer of virus replication in the lungs of the lower respiratory tract, and this model was highly reproducible without any signs of morbidity or mortality [
        <xref ref-type="bibr" rid="B149-viruses-11-00059">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="B151-viruses-11-00059">
         151
        </xref>
        ]. Neutralizing antibody responses could be generated in sub-lethally infected mice protecting recipients from subsequent lethal challenges, which probably reflected the situation in infected humans during an epidemic [
        <xref ref-type="bibr" rid="B160-viruses-11-00059">
         160
        </xref>
        ]. However, on day 2–3 post-infection (pi), virus replication in the respiratory tract peaked but was not accompanied by massive pulmonary inflammation or pneumonitis. By day 5–7 pi, the virus had been eliminated from the lungs [
        <xref ref-type="bibr" rid="B149-viruses-11-00059">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="B151-viruses-11-00059">
         151
        </xref>
        ]. It was obvious that viremia is common and long-lasting in patients, while it is rare and transient in mouse models [
        <xref ref-type="bibr" rid="B161-viruses-11-00059">
         161
        </xref>
        ]. Mice could therefore be used as a stable and reproducible animal model for the evaluation of vaccines, immune-prophylaxis, and antiviral drugs against SARS-CoV [
        <xref ref-type="bibr" rid="B81-viruses-11-00059">
         81
        </xref>
        ,
        <xref ref-type="bibr" rid="B96-viruses-11-00059">
         96
        </xref>
        ,
        <xref ref-type="bibr" rid="B109-viruses-11-00059">
         109
        </xref>
        ,
        <xref ref-type="bibr" rid="B124-viruses-11-00059">
         124
        </xref>
        ,
        <xref ref-type="bibr" rid="B149-viruses-11-00059">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="B162-viruses-11-00059">
         162
        </xref>
        ,
        <xref ref-type="bibr" rid="B163-viruses-11-00059">
         163
        </xref>
        ,
        <xref ref-type="bibr" rid="B164-viruses-11-00059">
         164
        </xref>
        ,
        <xref ref-type="bibr" rid="B165-viruses-11-00059">
         165
        </xref>
        ,
        <xref ref-type="bibr" rid="B166-viruses-11-00059">
         166
        </xref>
        ].
       </p>
      </sec>
      <sec id="sec6dot1dot2-viruses-11-00059">
       <title>
        6.1.2. Hamster Model
       </title>
       <p>
        Golden Syrian and Chinese hamsters have also been evaluated and shown to be excellent models of SARS-CoV infection, owing to their high titer of virus replication in the respiratory tract, associated with diffuse alveolar damage, interstitial pneumonitis, and pulmonary consolidation [
        <xref ref-type="bibr" rid="B104-viruses-11-00059">
         104
        </xref>
        ,
        <xref ref-type="bibr" rid="B167-viruses-11-00059">
         167
        </xref>
        ,
        <xref ref-type="bibr" rid="B168-viruses-11-00059">
         168
        </xref>
        ,
        <xref ref-type="bibr" rid="B169-viruses-11-00059">
         169
        </xref>
        ]. On day 2 pi, peak levels of viral replication were detected in the lower respiratory tract, and the virus was cleared without obvious clinical illness 7–10 days after infection. Similarly to mice, infected hamsters also produced a protective neutralizing-antibody response to subsequent SARS-CoV challenges [
        <xref ref-type="bibr" rid="B104-viruses-11-00059">
         104
        </xref>
        ,
        <xref ref-type="bibr" rid="B170-viruses-11-00059">
         170
        </xref>
        ]. Resulting from the extremely high titers and reproducible pulmonary pathological lesions in SARS-CoV-infected hamsters, this animal model is ideal for studies on the immunoprophylaxis and treatment of SARS [
        <xref ref-type="bibr" rid="B104-viruses-11-00059">
         104
        </xref>
        ,
        <xref ref-type="bibr" rid="B170-viruses-11-00059">
         170
        </xref>
        ]. However, there are still limited resources in terms of genetically established animal lines and accurate immunological and cellular biomarkers for hamster models.
       </p>
      </sec>
      <sec id="sec6dot1dot3-viruses-11-00059">
       <title>
        6.1.3. Ferret Model
       </title>
       <p>
        Ferrets were found to be susceptible to SARS-CoV infection [
        <xref ref-type="bibr" rid="B171-viruses-11-00059">
         171
        </xref>
        ] but could also transmit the virus at low levels by direct contact [
        <xref ref-type="bibr" rid="B84-viruses-11-00059">
         84
        </xref>
        ,
        <xref ref-type="bibr" rid="B172-viruses-11-00059">
         172
        </xref>
        ,
        <xref ref-type="bibr" rid="B173-viruses-11-00059">
         173
        </xref>
        ,
        <xref ref-type="bibr" rid="B174-viruses-11-00059">
         174
        </xref>
        ]. They showed diverse clinical symptoms in different studies [
        <xref ref-type="bibr" rid="B171-viruses-11-00059">
         171
        </xref>
        ,
        <xref ref-type="bibr" rid="B174-viruses-11-00059">
         174
        </xref>
        ]. Importantly, ferrets could develop fever, which is a characteristic clinical symptom of SARS-CoV-infected patients [
        <xref ref-type="bibr" rid="B93-viruses-11-00059">
         93
        </xref>
        ,
        <xref ref-type="bibr" rid="B175-viruses-11-00059">
         175
        </xref>
        ]. Similar to rodent models, infection of ferrets with SARS-CoV did not result in significant mortality. However, there are still some conflicting reports regarding the histopathological lesions and severity of clinical observations in the ferret model that require further investigation.
       </p>
      </sec>
      <sec id="sec6dot1dot4-viruses-11-00059">
       <title>
        6.1.4. Non-Human Primate Models
       </title>
       <p>
        Several species of non-human primates (NHP) were evaluated as animal models for SARS. At least six NHP species were tested including three Old World monkeys: rhesus macaques [
        <xref ref-type="bibr" rid="B176-viruses-11-00059">
         176
        </xref>
        ,
        <xref ref-type="bibr" rid="B177-viruses-11-00059">
         177
        </xref>
        ,
        <xref ref-type="bibr" rid="B178-viruses-11-00059">
         178
        </xref>
        ,
        <xref ref-type="bibr" rid="B179-viruses-11-00059">
         179
        </xref>
        ,
        <xref ref-type="bibr" rid="B180-viruses-11-00059">
         180
        </xref>
        ], cynomolgus macaques [
        <xref ref-type="bibr" rid="B177-viruses-11-00059">
         177
        </xref>
        ,
        <xref ref-type="bibr" rid="B181-viruses-11-00059">
         181
        </xref>
        ,
        <xref ref-type="bibr" rid="B182-viruses-11-00059">
         182
        </xref>
        ], and African green monkeys [
        <xref ref-type="bibr" rid="B177-viruses-11-00059">
         177
        </xref>
        ]; and three New World monkeys: the common marmoset [
        <xref ref-type="bibr" rid="B183-viruses-11-00059">
         183
        </xref>
        ], squirrel monkeys, and mustached tamarins [
        <xref ref-type="bibr" rid="B176-viruses-11-00059">
         176
        </xref>
        ,
        <xref ref-type="bibr" rid="B177-viruses-11-00059">
         177
        </xref>
        ,
        <xref ref-type="bibr" rid="B178-viruses-11-00059">
         178
        </xref>
        ,
        <xref ref-type="bibr" rid="B181-viruses-11-00059">
         181
        </xref>
        ,
        <xref ref-type="bibr" rid="B182-viruses-11-00059">
         182
        </xref>
        ,
        <xref ref-type="bibr" rid="B183-viruses-11-00059">
         183
        </xref>
        ,
        <xref ref-type="bibr" rid="B184-viruses-11-00059">
         184
        </xref>
        ]. Except for squirrel monkeys and mustached tamarins [
        <xref ref-type="bibr" rid="B185-viruses-11-00059">
         185
        </xref>
        ], all of the evaluated NHP species facilitated the replication of SARS-CoV [
        <xref ref-type="bibr" rid="B186-viruses-11-00059">
         186
        </xref>
        ]. Virus replication was detected in the respiratory tract of rhesus macaques, cynomolgus macaques, and African green monkeys. Pneumonitis was observed in each of these species in different studies [
        <xref ref-type="bibr" rid="B176-viruses-11-00059">
         176
        </xref>
        ,
        <xref ref-type="bibr" rid="B177-viruses-11-00059">
         177
        </xref>
        ,
        <xref ref-type="bibr" rid="B178-viruses-11-00059">
         178
        </xref>
        ,
        <xref ref-type="bibr" rid="B182-viruses-11-00059">
         182
        </xref>
        ]. SARS-infected common marmosets displayed a fever, watery diarrhea, pneumonitis, and hepatitis [
        <xref ref-type="bibr" rid="B183-viruses-11-00059">
         183
        </xref>
        ]. Unfortunately, research into the clinical signs of disease in cynomolgus and rhesus macaques gave conflicting results and therefore needs further investigation. The main reason for the lack of reproducibility in such studies may be the limited sample size.
       </p>
      </sec>
     </sec>
     <sec id="sec6dot2-viruses-11-00059">
      <title>
       6.2. Animal Models of MERS-CoV
      </title>
      <p>
       Small animal models of MERS infection are urgently needed to elucidate MERS pathogenesis and explore potential vaccines and antiviral drugs. Previous studies have demonstrated the difficulties in developing such a model, such as that mice [
       <xref ref-type="bibr" rid="B187-viruses-11-00059">
        187
       </xref>
       ,
       <xref ref-type="bibr" rid="B188-viruses-11-00059">
        188
       </xref>
       ], ferrets [
       <xref ref-type="bibr" rid="B134-viruses-11-00059">
        134
       </xref>
       ], guinea pigs [
       <xref ref-type="bibr" rid="B189-viruses-11-00059">
        189
       </xref>
       ], and hamsters [
       <xref ref-type="bibr" rid="B189-viruses-11-00059">
        189
       </xref>
       ] are not susceptible to experimental MERS-CoV infection mainly because their homologous DPP4 molecules do not function as receptors for MERS-CoV entry. After administering a high dose of MERS-CoV, no viral replication could be detected in these animals [
       <xref ref-type="bibr" rid="B190-viruses-11-00059">
        190
       </xref>
       ]. In an animal model using New Zealand white rabbits, regardless of the fact that detectable viral RNA existed in the respiratory tract and moderate necrosis was observed in nasal turbinates, the animals showed no clinical symptoms of disease [
       <xref ref-type="bibr" rid="B191-viruses-11-00059">
        191
       </xref>
       ]. In another study, attempts to infect hamsters with MERS-CoV were not successful [
       <xref ref-type="bibr" rid="B192-viruses-11-00059">
        192
       </xref>
       ]. However, despite this, MERS-CoV is a broad host-range virus in vitro [
       <xref ref-type="bibr" rid="B25-viruses-11-00059">
        25
       </xref>
       ], and there is hope that a reproducible and stable animal model for human MERS-CoV infection can be improved in the near future.
      </p>
      <sec id="sec6dot2dot1-viruses-11-00059">
       <title>
        6.2.1. Mouse Model for MERS Infection
       </title>
       <p>
        Despite the fact that wild-type rodents are not susceptible to MERS-CoV infection [
        <xref ref-type="bibr" rid="B188-viruses-11-00059">
         188
        </xref>
        ], researchers have developed several models in which mice are susceptible to MERS-CoV infection [
        <xref ref-type="bibr" rid="B193-viruses-11-00059">
         193
        </xref>
        ,
        <xref ref-type="bibr" rid="B194-viruses-11-00059">
         194
        </xref>
        ,
        <xref ref-type="bibr" rid="B195-viruses-11-00059">
         195
        </xref>
        ]. The first mouse model of MERS infection reported in 2014 involved transducing animals with recombinant adenovirus 5 encoding human DPP4 (hDPP4) molecules intranasally, and this resulted in replication of MERS-CoV in the lungs. This mouse model also showed clinical symptoms of interstitial pneumonia, including inflammatory cell infiltration, and thickened alveolar and mild edema [
        <xref ref-type="bibr" rid="B195-viruses-11-00059">
         195
        </xref>
        ]. However, there are certain limitations to this model, such as the uncontrolled expression and distribution of hDPP4. In 2015, the establishment of hDPP4 transgenic mice was reported [
        <xref ref-type="bibr" rid="B194-viruses-11-00059">
         194
        </xref>
        ]. MERS-CoV could infect this mouse model effectively. However, similarly to SARS-CoV-infected ACE2 transgenic mice [
        <xref ref-type="bibr" rid="B196-viruses-11-00059">
         196
        </xref>
        ], systemic expressions led to multiple organ lesions [
        <xref ref-type="bibr" rid="B194-viruses-11-00059">
         194
        </xref>
        ], resulting in the death of the animals. Most recently, the homologous hDPP4 gene was used in several MERS transgenic mouse models [
        <xref ref-type="bibr" rid="B193-viruses-11-00059">
         193
        </xref>
        ,
        <xref ref-type="bibr" rid="B197-viruses-11-00059">
         197
        </xref>
        ]. Remarkably, hDPP4 knockin (KI) mice, where mouse DPP4 gene fragments had been displaced by homologous human DPP4 fragments, showed effective receptor binding. Furthermore, a mouse-adapted MERS-CoV strain (MERS
        <sub>
         MA
        </sub>
        ) including 13–22 mutations was produced in the lungs of hDPP4-KI mice after 30 serial passages, causing effective weight loss and mortality in this mouse model [
        <xref ref-type="bibr" rid="B193-viruses-11-00059">
         193
        </xref>
        ]. Both this hDPP4-KI mouse and the MERS
        <sub>
         MA
        </sub>
        strain provide better tools to explore the pathogenesis of MERS and potential novel treatments.
       </p>
      </sec>
      <sec id="sec6dot2dot2-viruses-11-00059">
       <title>
        6.2.2. Camelidae
       </title>
       <p>
        As a reservoir of MERS-CoV, dromedary camels showed mild upper respiratory infections after the administration of MERS-CoV [
        <xref ref-type="bibr" rid="B198-viruses-11-00059">
         198
        </xref>
        ]. Oronasal infection of MERS-CoV in alpacas, a close relative within the Camelidae family, resulted in an asymptomatic infection with no signs of upper or lower respiratory tract disease [
        <xref ref-type="bibr" rid="B199-viruses-11-00059">
         199
        </xref>
        ,
        <xref ref-type="bibr" rid="B200-viruses-11-00059">
         200
        </xref>
        ]. Additionally, owing to their high cost and relatively large size, these animal models are not available for high-throughput studies of MERS.
       </p>
      </sec>
      <sec id="sec6dot2dot3-viruses-11-00059">
       <title>
        6.2.3. Non-Human Primates
       </title>
       <p>
        NHPs, such as the rhesus macaques [
        <xref ref-type="bibr" rid="B201-viruses-11-00059">
         201
        </xref>
        ] and common marmosets [
        <xref ref-type="bibr" rid="B202-viruses-11-00059">
         202
        </xref>
        ], are useful models for studying the pathogenesis of mild MERS-CoV infection and evaluating novel therapies for humans, although the degree of replication and disease severity vary [
        <xref ref-type="bibr" rid="B192-viruses-11-00059">
         192
        </xref>
        ,
        <xref ref-type="bibr" rid="B201-viruses-11-00059">
         201
        </xref>
        ,
        <xref ref-type="bibr" rid="B203-viruses-11-00059">
         203
        </xref>
        ,
        <xref ref-type="bibr" rid="B204-viruses-11-00059">
         204
        </xref>
        ]. MERS-CoV caused transient lower respiratory tract infection in rhesus macaques, with associated pneumonia. Clinical signs were observed by day 1 pi and resolved as early as day 4 pi [
        <xref ref-type="bibr" rid="B201-viruses-11-00059">
         201
        </xref>
        ]. Relatively mild clinical symptoms were observed early on in infection without fatalities, indicating that rhesus macaques do not recapitulate the severe infections observed in human cases; however, treatment of MERS-CoV-infected rhesus macaques with IFN-α and ribavirin decreased virus replication, alleviated the host response, and improved the clinical outcome [
        <xref ref-type="bibr" rid="B205-viruses-11-00059">
         205
        </xref>
        ]. Infection of MERS-CoV in common marmosets demonstrated various extents of damage depending on the study, but successfully reproduced several features of MERS-CoV infection in humans. Importantly, one study indicated that the infection became progressive severe pneumonia [
        <xref ref-type="bibr" rid="B203-viruses-11-00059">
         203
        </xref>
        ], while other groups found that MERS-CoV-infected common marmosets only developed mild to moderate nonlethal respiratory diseases by intratracheal administration [
        <xref ref-type="bibr" rid="B206-viruses-11-00059">
         206
        </xref>
        ].
       </p>
      </sec>
     </sec>
    </sec>
    <sec id="sec7-viruses-11-00059">
     <title>
      7. Role of Host Receptors in Animal Models of SARS-CoV and MERS-CoV
     </title>
     <p>
      The reasons for host restriction, none or limited clinical symptoms observed in varies animal models are complexity. The interaction between the host receptor and functional proteins of SARS and MERS, respectively, plays an important and predominant role. In the context of animal models of SARS-CoV infection, researchers have compared the ACE2 amino acids that interact with the S protein RBD from several species. In agreement with the permissive nature of these species, the ACE2 residues of marmoset and hamster are similar to those of hACE2 [
      <xref ref-type="bibr" rid="B53-viruses-11-00059">
       53
      </xref>
      ]. By comparison, many residues of mouse ACE2 are different from those of hACE2, and this meets with decreased replication of SARS-CoV in mouse cells [
      <xref ref-type="bibr" rid="B207-viruses-11-00059">
       207
      </xref>
      ] and the lungs of young mice [
      <xref ref-type="bibr" rid="B149-viruses-11-00059">
       149
      </xref>
      ]. The changes at positions 353 (histidine) and 82 (asparagine) of rat ACE2 relative to hACE2 partially disrupt the S protein-DPP4 interaction and contribute to abrogation of binding. Interestingly, ferrets are permissive to SARS-CoV infection, but most of their ACE2 interaction residues are different from those of hACE2 [
      <xref ref-type="bibr" rid="B53-viruses-11-00059">
       53
      </xref>
      ], while many of the ACE2 residues between civet and ferret are the same, which may result in similar affinity [
      <xref ref-type="bibr" rid="B208-viruses-11-00059">
       208
      </xref>
      ]. For MERS-CoV, 14 residues of the S protein RBD have direct contact with 15 residues of hDPP4 [
      <xref ref-type="bibr" rid="B57-viruses-11-00059">
       57
      </xref>
      ]. Comparisons of human DPP4 binding affinity to that of other species indicated that human DPP4 had the highest affinity to the S protein of MERS-CoV, where the decreasing order of affinity is as follows: human &gt; horses &gt; camels &gt; goats &gt; bats [
      <xref ref-type="bibr" rid="B209-viruses-11-00059">
       209
      </xref>
      ]. Further evidence demonstrates that the host restriction of MERS-CoV remarkably depends on the sequence of DPP4, such as the characterization of amino acid residues at the connector of DPP4 with the RBD of S proteins in mice [
      <xref ref-type="bibr" rid="B187-viruses-11-00059">
       187
      </xref>
      ,
      <xref ref-type="bibr" rid="B210-viruses-11-00059">
       210
      </xref>
      ], hamsters, and cotton rats [
      <xref ref-type="bibr" rid="B210-viruses-11-00059">
       210
      </xref>
      ]. However, the multiplicity in severity of disease between rhesus macaques and common marmosets indicate that other host factors can perhaps affect the infection and replication of the virus, such as the presence of S-cleaving proteases [
      <xref ref-type="bibr" rid="B187-viruses-11-00059">
       187
      </xref>
      ]. In general, although the structural analysis of receptors-S protein interactions cannot fully explain all the observations for host restriction, they agree with the improved replication in several animal models and that it should be the premier and remarkable focus of small-animal model development. These special residues for host affinity are important to build up transgenic animal models enhancing the permissiveness and infection of SARS and MERS.
     </p>
    </sec>
    <sec id="sec8-viruses-11-00059">
     <title>
      8. Outlook and Summary
     </title>
     <p>
      Unlike SARS-CoV, which resolved without more reported cases, continued outbreaks of MERS-CoV present an ongoing threat to public health. It should be noted that no specific treatment is currently available for HCoVs, and further research into the pathogenesis of HCoV infection is therefore imperative to identify appropriate therapeutic targets. Accordingly, at present, the prevention of viral transmission is of utmost importance to limit the spread of MERS. The enormous ratio of nosocomial infections indicates that preventive measures in hospitals have not been sufficiently implemented. Additionally, as an emerging zoonotic virus, prevention of transmission from dromedary camels is another possibility to reduce the quantity of MERS cases. Regarding clinical therapies, a combination of treatment administered as early as possible and aimed at synchronously disrupting viral replication, inhibiting viral dissemination, and restraining the host response is likely to be most suitable, due to the acute clinical features of MERS with diffuse lung damage and the important role of immunopathology.
     </p>
     <p>
      Potential treatments must undergo in vitro and in vivo studies to select the most promising options. The development of stable and reproducible animal models of MERS, especially in NHPs, is therefore a decisive step forward. The next step in the development of standardized and controllable therapies against SARS and MERS will be clinical trials in humans, validating a standard protocol for dosage and timing, and accruing data in real time during future outbreaks to monitor specific adverse effects and help inform treatment.
     </p>
     <p>
      The comprehensive lessons and experiences that have resulted from the outbreaks of SARS and MERS provide valuable insight and advancements in how to react to future emerging and re-emerging infectious agents. Rapid identification of the pathogen via effective diagnostic assays is the first step, followed by the implementation of preventive measures, including raising awareness of the new agent, reporting and recording (suspected) cases, and infection control management in medical facilities. Studies are currently needed that focus on the epidemiology of these organisms, especially in terms of pathogen transmission and potential reservoirs and/or intermediate hosts. Animal models and prophylactic and therapeutic approaches should be promoted, followed by fast-tracked clinical trials.
     </p>
     <p>
      Our increasing understanding of novel emerging coronaviruses will be accompanied by increasing opportunities for the reasonable design of therapeutics. Importantly, understanding this basic information will not only aid our public health preparedness against SARS-CoV and MERS-CoV, but also help prepare for novel coronaviruses that may emerge.
     </p>
    </sec>
    <back>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       We thank Kate Fox, DPhil, from Liwen Bianji, Edanz Group China (
       <uri xlink:href="www.liwenbianji.cn/ac">
        www.liwenbianji.cn/ac
       </uri>
       ), for editing the English text of a draft of this manuscript.
      </p>
     </ack>
     <notes>
      <title>
       Funding
      </title>
      <p>
       This research was funded by CAMS Innovation Fund for Medical Science (CIFMS), grant number 2016-12M-2-006.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Conflicts of Interest
      </title>
      <p>
       The authors declare no conflict of interest.
      </p>
     </notes>
     <ref-list>
      <title>
       References
      </title>
      <ref id="B1-viruses-11-00059">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wunderink
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS, SARS and other coronaviruses as causes of pneumonia
        </article-title>
        <source>
         Respirology
        </source>
        <year>
         2018
        </year>
        <volume>
         23
        </volume>
        <fpage>
         130
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/resp.13196
        </pub-id>
        <pub-id pub-id-type="pmid">
         29052924
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2-viruses-11-00059">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gunther
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           van der Werf
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Brodt
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rabenau
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Panning
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1967
        </fpage>
        <lpage>
         1976
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030747
        </pub-id>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B3-viruses-11-00059">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Peret
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Emery
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Urbani
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Comer
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030781
        </pub-id>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4-viruses-11-00059">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
        </article-title>
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        <volume>
         300
        </volume>
        <fpage>
         1394
        </fpage>
        <lpage>
         1399
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1085952
        </pub-id>
        <pub-id pub-id-type="pmid">
         12730500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5-viruses-11-00059">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           Z.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         362
        </volume>
        <fpage>
         1353
        </fpage>
        <lpage>
         1358
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)14630-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         14585636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6-viruses-11-00059">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Cameron
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Joynt
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ahuja
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yung
          </surname>
          <given-names>
           M.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A major outbreak of severe acute respiratory syndrome in Hong Kong
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1986
        </fpage>
        <lpage>
         1994
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030685
        </pub-id>
        <pub-id pub-id-type="pmid">
         12682352
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7-viruses-11-00059">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chmura
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Mazet
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         503
        </volume>
        <fpage>
         535
        </fpage>
        <lpage>
         538
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12711
        </pub-id>
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8-viruses-11-00059">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Debbink
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Plante
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         21
        </volume>
        <fpage>
         1508
        </fpage>
        <lpage>
         1513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm.3985
        </pub-id>
        <pub-id pub-id-type="pmid">
         26552008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9-viruses-11-00059">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B10-viruses-11-00059">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS and MERS: Recent insights into emerging coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2016
        </year>
        <volume>
         14
        </volume>
        <fpage>
         523
        </fpage>
        <lpage>
         534
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro.2016.81
        </pub-id>
        <pub-id pub-id-type="pmid">
         27344959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11-viruses-11-00059">
       <label>
        11.
       </label>
       <element-citation publication-type="web">
        <person-group person-group-type="author">
         <collab>
          World Health Organization
         </collab>
        </person-group>
        <article-title>
         WHO Guidelines for the Global Surveillance of Severe Acute Respiratory Syndrome (SARS)
        </article-title>
        <comment>
         Updated Recommendations
        </comment>
        <month>
         10
        </month>
        <year>
         2004
        </year>
        <comment>
         Available online:
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/mers-cov/en/">
          http://www.who.int/mediacentre/factsheets/mers-cov/en/
         </ext-link>
        </comment>
        <date-in-citation content-type="access-date" iso-8601-date="2018-10-08">
         (accessed on 8 October 2018)
        </date-in-citation>
       </element-citation>
      </ref>
      <ref id="B12-viruses-11-00059">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           Z.X.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           S.W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
        </article-title>
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        <volume>
         302
        </volume>
        <fpage>
         276
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1087139
        </pub-id>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B13-viruses-11-00059">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           E.I.
          </given-names>
         </name>
         <name>
          <surname>
           El-Kafrawy
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Farraj
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hassan
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Saeed
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Madani
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         370
        </volume>
        <fpage>
         2499
        </fpage>
        <lpage>
         2505
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1401505
        </pub-id>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14-viruses-11-00059">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Origin and evolution of pathogenic coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2018
        </year>
        <pub-id pub-id-type="doi">
         10.1038/s41579-018-0118-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         30531947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B15-viruses-11-00059">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Nehdi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baharoon
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Layqah
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bokhari
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Samman
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Boudjelal
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High Prevalence of MERS-CoV Infection in Camel Workers in Saudi Arabia
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2018
        </year>
        <volume>
         9
        </volume>
        <fpage>
         e01985-18
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.01985-18
        </pub-id>
        <pub-id pub-id-type="pmid">
         30377284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B16-viruses-11-00059">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabiah
          </surname>
          <given-names>
           F.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hajjar
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Barrak
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Flemban
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Nassir
          </surname>
          <given-names>
           W.N.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hakeem
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         13
        </volume>
        <fpage>
         752
        </fpage>
        <lpage>
         761
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70204-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B17-viruses-11-00059">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Arifi
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Najm
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Aldawood
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ghabashi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hawa
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alothman
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Khaldi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Ann. Intern. Med.
        </source>
        <year>
         2014
        </year>
        <volume>
         160
        </volume>
        <fpage>
         389
        </fpage>
        <lpage>
         397
        </lpage>
        <pub-id pub-id-type="doi">
         10.7326/M13-2486
        </pub-id>
        <pub-id pub-id-type="pmid">
         24474051
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B18-viruses-11-00059">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Abdallat
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rha
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Tohme
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Iblan
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Jarour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           N.H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: A serologic, epidemiologic, and clinical description
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         59
        </volume>
        <fpage>
         1225
        </fpage>
        <lpage>
         1233
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/ciu359
        </pub-id>
        <pub-id pub-id-type="pmid">
         24829216
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B19-viruses-11-00059">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           H.F.
          </given-names>
         </name>
         <name>
          <surname>
           Pringle
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pham
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Alami
          </surname>
          <given-names>
           N.N.
          </given-names>
         </name>
         <name>
          <surname>
           Khudhair
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Aden
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           El
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Response to Emergence of Middle East Respiratory Syndrome Coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1162
        </fpage>
        <lpage>
         1168
        </lpage>
        <pub-id pub-id-type="pmid">
         27314227
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B20-viruses-11-00059">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           McGeer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Price
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cummings
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alabdullatif
          </surname>
          <given-names>
           Z.N.
          </given-names>
         </name>
         <name>
          <surname>
           Assad
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Almulhim
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Hospital outbreak of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2013
        </year>
        <volume>
         369
        </volume>
        <fpage>
         407
        </fpage>
        <lpage>
         416
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1306742
        </pub-id>
        <pub-id pub-id-type="pmid">
         23782161
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B21-viruses-11-00059">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hussain
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           HajOmar
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Landt
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         60
        </volume>
        <fpage>
         369
        </fpage>
        <lpage>
         377
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/ciu812
        </pub-id>
        <pub-id pub-id-type="pmid">
         25323704
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B22-viruses-11-00059">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ryu
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015
        </article-title>
        <source>
         Eurosurveillance
        </source>
        <year>
         2015
        </year>
        <volume>
         20
        </volume>
        <fpage>
         21169
        </fpage>
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES2015.20.25.21169
        </pub-id>
        <pub-id pub-id-type="pmid">
         26132766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B23-viruses-11-00059">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Skowronski
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Astell
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Brunham
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Roper
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Babiuk
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS): A year in review
        </article-title>
        <source>
         Annu. Rev. Med.
        </source>
        <year>
         2005
        </year>
        <volume>
         56
        </volume>
        <fpage>
         357
        </fpage>
        <lpage>
         381
        </lpage>
        <pub-id pub-id-type="doi">
         10.1146/annurev.med.56.091103.134135
        </pub-id>
        <pub-id pub-id-type="pmid">
         15660517
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B24-viruses-11-00059">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: An overview of their replication and pathogenesis
        </article-title>
        <source>
         Methods Mol. Biol.
        </source>
        <year>
         2015
        </year>
        <volume>
         1282
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B25-viruses-11-00059">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models
        </article-title>
        <source>
         J. Thorac. Dis.
        </source>
        <year>
         2018
        </year>
        <volume>
         10
        </volume>
        <fpage>
         S2260
        </fpage>
        <lpage>
         S2271
        </lpage>
        <pub-id pub-id-type="doi">
         10.21037/jtd.2018.03.80
        </pub-id>
        <pub-id pub-id-type="pmid">
         30116605
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B26-viruses-11-00059">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV spike protein: A key target for antivirals
        </article-title>
        <source>
         Expert Opin. Ther. Targets
        </source>
        <year>
         2017
        </year>
        <volume>
         21
        </volume>
        <fpage>
         131
        </fpage>
        <lpage>
         143
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/14728222.2017.1271415
        </pub-id>
        <pub-id pub-id-type="pmid">
         27936982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B27-viruses-11-00059">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The spike protein of SARS-CoV—A target for vaccine and therapeutic development
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2009
        </year>
        <volume>
         7
        </volume>
        <fpage>
         226
        </fpage>
        <lpage>
         236
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro2090
        </pub-id>
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B28-viruses-11-00059">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2015
        </year>
        <volume>
         386
        </volume>
        <fpage>
         995
        </fpage>
        <lpage>
         1007
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(15)60454-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B29-viruses-11-00059">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jeffers
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Tusell
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gillim-Ross
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Hemmila
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Achenbach
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Babcock
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Thackray
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           Young
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Mason
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         15748
        </fpage>
        <lpage>
         15753
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0403812101
        </pub-id>
        <pub-id pub-id-type="pmid">
         15496474
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B30-viruses-11-00059">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the Upper Respiratory Tracts of Rhesus Macaques
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         4025
        </fpage>
        <lpage>
         4030
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02292-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         21289121
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B31-viruses-11-00059">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1267
        </pub-id>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B32-viruses-11-00059">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qinfen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Jinming
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xiaojun
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Huanying
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Jicheng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Kunpeng
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jingqiang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The life cycle of SARS coronavirus in Vero E6 cells
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         73
        </volume>
        <fpage>
         332
        </fpage>
        <lpage>
         337
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20095
        </pub-id>
        <pub-id pub-id-type="pmid">
         15170625
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B33-viruses-11-00059">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Korteweg
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           McNutt
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenetic mechanisms of severe acute respiratory syndrome
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2008
        </year>
        <volume>
         133
        </volume>
        <fpage>
         4
        </fpage>
        <lpage>
         12
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2007.01.022
        </pub-id>
        <pub-id pub-id-type="pmid">
         17825937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B34-viruses-11-00059">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Korteweg
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathology and pathogenesis of severe acute respiratory syndrome
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2007
        </year>
        <volume>
         170
        </volume>
        <fpage>
         1136
        </fpage>
        <lpage>
         1147
        </lpage>
        <pub-id pub-id-type="doi">
         10.2353/ajpath.2007.061088
        </pub-id>
        <pub-id pub-id-type="pmid">
         17392154
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B35-viruses-11-00059">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: Implications for pathogenesis and virus transmission pathways
        </article-title>
        <source>
         J. Pathol.
        </source>
        <year>
         2004
        </year>
        <volume>
         203
        </volume>
        <fpage>
         622
        </fpage>
        <lpage>
         630
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/path.1560
        </pub-id>
        <pub-id pub-id-type="pmid">
         15141376
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B36-viruses-11-00059">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lambertz
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2016
        </year>
        <volume>
         186
        </volume>
        <fpage>
         78
        </fpage>
        <lpage>
         86
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ajpath.2015.09.014
        </pub-id>
        <pub-id pub-id-type="pmid">
         26597880
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B37-viruses-11-00059">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Schipper
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kolijn
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           van Leenders
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bensaid
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Segales
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baumgartner
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2016
        </year>
        <volume>
         90
        </volume>
        <fpage>
         4838
        </fpage>
        <lpage>
         4842
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02994-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         26889022
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B38-viruses-11-00059">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oboho
          </surname>
          <given-names>
           I.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tomczyk
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Asmari
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Banjar
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Mugti
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Aloraini
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Alkhaldi
          </surname>
          <given-names>
           K.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Almohammadi
          </surname>
          <given-names>
           E.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           S.I.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         2014 MERS-CoV outbreak in Jeddah—A link to health care facilities
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2015
        </year>
        <volume>
         372
        </volume>
        <fpage>
         846
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1408636
        </pub-id>
        <pub-id pub-id-type="pmid">
         25714162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B39-viruses-11-00059">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           W.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           H.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Acute renal impairment in coronavirus-associated severe acute respiratory syndrome
        </article-title>
        <source>
         Kidney Int.
        </source>
        <year>
         2005
        </year>
        <volume>
         67
        </volume>
        <fpage>
         698
        </fpage>
        <lpage>
         705
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1523-1755.2005.67130.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         15673319
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B40-viruses-11-00059">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saad
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Baig
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Bahloul
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Elzein
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Matin
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Selim
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           N.D.
          </given-names>
         </name>
         <name>
          <surname>
           Al
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: A single-center experience in Saudi Arabia
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         29
        </volume>
        <fpage>
         301
        </fpage>
        <lpage>
         306
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2014.09.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         25303830
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B41-viruses-11-00059">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alagaili
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Briese
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Sameroff
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Burbelo
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Zalmout
          </surname>
          <given-names>
           I.S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2014
        </year>
        <volume>
         5
        </volume>
        <fpage>
         e814
        </fpage>
        <lpage>
         e884
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00884-14
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B42-viruses-11-00059">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lambeir
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Durinx
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Scharpe
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           De Meester
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV
        </article-title>
        <source>
         Crit. Rev. Clin. Lab. Sci.
        </source>
        <year>
         2003
        </year>
        <volume>
         40
        </volume>
        <fpage>
         209
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/713609354
        </pub-id>
        <pub-id pub-id-type="pmid">
         12892317
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B43-viruses-11-00059">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2014
        </year>
        <volume>
         454–455
        </volume>
        <fpage>
         197
        </fpage>
        <lpage>
         205
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2014.02.018
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B44-viruses-11-00059">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: Implications for pathogenesis
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         209
        </volume>
        <fpage>
         1331
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit504
        </pub-id>
        <pub-id pub-id-type="pmid">
         24065148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B45-viruses-11-00059">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         213
        </volume>
        <fpage>
         904
        </fpage>
        <lpage>
         914
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv380
        </pub-id>
        <pub-id pub-id-type="pmid">
         26203058
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B46-viruses-11-00059">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V.K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.L.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2
        </article-title>
        <source>
         Nat. Microbiol.
        </source>
        <year>
         2016
        </year>
        <volume>
         1
        </volume>
        <fpage>
         16004
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/nmicrobiol.2016.4
        </pub-id>
        <pub-id pub-id-type="pmid">
         27572168
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B47-viruses-11-00059">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protective T Cell Res.ponses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus-Derived CD8+ T Cell Epitopes and Host MHC
        </article-title>
        <source>
         J. Immunol.
        </source>
        <year>
         2017
        </year>
        <volume>
         198
        </volume>
        <fpage>
         873
        </fpage>
        <lpage>
         882
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.1601542
        </pub-id>
        <pub-id pub-id-type="pmid">
         27903740
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B48-viruses-11-00059">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Kuok
          </surname>
          <given-names>
           D.I.
          </given-names>
         </name>
         <name>
          <surname>
           Fong
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Nicholls
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         6604
        </fpage>
        <lpage>
         6614
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00009-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23552422
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B49-viruses-11-00059">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: Implications for pathogenesis and treatment
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         94
        </volume>
        <fpage>
         2679
        </fpage>
        <lpage>
         2690
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.055533-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24077366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B50-viruses-11-00059">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marra
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Astell
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Holt
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brooks-Wilson
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Butterfield
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Khattra
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Asano
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Barber
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The Genome sequence of the SARS-associated coronavirus
        </article-title>
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        <volume>
         300
        </volume>
        <fpage>
         1399
        </fpage>
        <lpage>
         1404
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1085953
        </pub-id>
        <pub-id pub-id-type="pmid">
         12730501
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B51-viruses-11-00059">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           X.X.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           X.J.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zuo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2005
        </year>
        <volume>
         280
        </volume>
        <fpage>
         29588
        </fpage>
        <lpage>
         29595
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M500662200
        </pub-id>
        <pub-id pub-id-type="pmid">
         15980414
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B52-viruses-11-00059">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           I.C.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2
        </article-title>
        <source>
         EMBO J.
        </source>
        <year>
         2005
        </year>
        <volume>
         24
        </volume>
        <fpage>
         1634
        </fpage>
        <lpage>
         1643
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/sj.emboj.7600640
        </pub-id>
        <pub-id pub-id-type="pmid">
         15791205
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B53-viruses-11-00059">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
        </article-title>
        <source>
         Science
        </source>
        <year>
         2005
        </year>
        <volume>
         309
        </volume>
        <fpage>
         1864
        </fpage>
        <lpage>
         1868
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1116480
        </pub-id>
        <pub-id pub-id-type="pmid">
         16166518
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B54-viruses-11-00059">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor recognition mechanisms of coronaviruses: A decade of structural studies
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         1954
        </fpage>
        <lpage>
         1964
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02615-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25428871
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B55-viruses-11-00059">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         500
        </volume>
        <fpage>
         227
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12328
        </pub-id>
        <pub-id pub-id-type="pmid">
         23831647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B56-viruses-11-00059">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         13134
        </fpage>
        <lpage>
         13140
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02433-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24067982
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B57-viruses-11-00059">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
        </article-title>
        <source>
         Cell Res.
        </source>
        <year>
         2013
        </year>
        <volume>
         23
        </volume>
        <fpage>
         986
        </fpage>
        <lpage>
         993
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/cr.2013.92
        </pub-id>
        <pub-id pub-id-type="pmid">
         23835475
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B58-viruses-11-00059">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current advancements and potential strategies in the development of MERS-CoV vaccines
        </article-title>
        <source>
         Expert Rev. Vaccines
        </source>
        <year>
         2014
        </year>
        <volume>
         13
        </volume>
        <fpage>
         761
        </fpage>
        <lpage>
         774
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/14760584.2014.912134
        </pub-id>
        <pub-id pub-id-type="pmid">
         24766432
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B59-viruses-11-00059">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Kou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Debnath
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         9939
        </fpage>
        <lpage>
         9942
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01048-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23824801
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B60-viruses-11-00059">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dekkers
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Muth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Demmers
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2013
        </year>
        <volume>
         495
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature12005
        </pub-id>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B61-viruses-11-00059">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Berne
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         426
        </volume>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature02145
        </pub-id>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B62-viruses-11-00059">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rajashankar
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         10777
        </fpage>
        <lpage>
         10783
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01756-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23903833
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B63-viruses-11-00059">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <year>
         2014
        </year>
        <volume>
         5
        </volume>
        <fpage>
         3067
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/ncomms4067
        </pub-id>
        <pub-id pub-id-type="pmid">
         24473083
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B64-viruses-11-00059">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Core structure of S2 from the human coronavirus NL63 spike glycoprotein
        </article-title>
        <source>
         Biochemistry
        </source>
        <year>
         2006
        </year>
        <volume>
         45
        </volume>
        <fpage>
         15205
        </fpage>
        <lpage>
         15215
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/bi061686w
        </pub-id>
        <pub-id pub-id-type="pmid">
         17176042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B65-viruses-11-00059">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tien
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2004
        </year>
        <volume>
         279
        </volume>
        <fpage>
         49414
        </fpage>
        <lpage>
         49419
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M408782200
        </pub-id>
        <pub-id pub-id-type="pmid">
         15345712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B66-viruses-11-00059">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tien
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2004
        </year>
        <volume>
         279
        </volume>
        <fpage>
         30514
        </fpage>
        <lpage>
         30522
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M403760200
        </pub-id>
        <pub-id pub-id-type="pmid">
         15123674
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B67-viruses-11-00059">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hattermann
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Marzi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gramberg
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Geier
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Krumbiegel
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kuate
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Uberla
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Niedrig
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         6134
        </fpage>
        <lpage>
         6142
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.12.6134-6142.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15163706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B68-viruses-11-00059">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-associated coronavirus
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1948
        </fpage>
        <lpage>
         1951
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMp030078
        </pub-id>
        <pub-id pub-id-type="pmid">
         12748314
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B69-viruses-11-00059">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Berardi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dormitzer
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         80
        </volume>
        <fpage>
         6794
        </fpage>
        <lpage>
         6800
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02744-05
        </pub-id>
        <pub-id pub-id-type="pmid">
         16809285
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B70-viruses-11-00059">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2004
        </year>
        <volume>
         279
        </volume>
        <fpage>
         3197
        </fpage>
        <lpage>
         3201
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.C300520200
        </pub-id>
        <pub-id pub-id-type="pmid">
         14670965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B71-viruses-11-00059">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chakraborti
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Dimitrov
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Gramatikoff
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Dimitrov
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS-CoV S glycoprotein: Expression and functional characterization
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2003
        </year>
        <volume>
         312
        </volume>
        <fpage>
         1159
        </fpage>
        <lpage>
         1164
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2003.11.054
        </pub-id>
        <pub-id pub-id-type="pmid">
         14651994
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B72-viruses-11-00059">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2
        </article-title>
        <source>
         Comput. Biol. Chem.
        </source>
        <year>
         2005
        </year>
        <volume>
         29
        </volume>
        <fpage>
         254
        </fpage>
        <lpage>
         257
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.compbiolchem.2005.04.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         15979045
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B73-viruses-11-00059">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2006
        </year>
        <volume>
         344
        </volume>
        <fpage>
         106
        </fpage>
        <lpage>
         113
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2006.03.139
        </pub-id>
        <pub-id pub-id-type="pmid">
         16615996
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B74-viruses-11-00059">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sainz
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Rausch
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gallaher
          </surname>
          <given-names>
           W.R.
          </given-names>
         </name>
         <name>
          <surname>
           Garry
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Wimley
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         7195
        </fpage>
        <lpage>
         7206
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.11.7195-7206.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15890958
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B75-viruses-11-00059">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ganesh
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           W.P.
          </given-names>
         </name>
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Nabel
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         5642
        </fpage>
        <lpage>
         5650
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.11.5642-5650.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15140961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B76-viruses-11-00059">
       <label>
        76.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Lohani
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           M.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         12029
        </fpage>
        <lpage>
         12039
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00315-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         17715238
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B77-viruses-11-00059">
       <label>
        77.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A decade after SARS: Strategies for controlling emerging coronaviruses
        </article-title>
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2013
        </year>
        <volume>
         11
        </volume>
        <fpage>
         836
        </fpage>
        <lpage>
         848
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrmicro3143
        </pub-id>
        <pub-id pub-id-type="pmid">
         24217413
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B78-viruses-11-00059">
       <label>
        78.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keng
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lip
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Fielding
          </surname>
          <given-names>
           B.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           C.F.
          </given-names>
         </name>
         <name>
          <surname>
           Loh
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: Implications for the development of vaccines and antiviral agents
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         3289
        </fpage>
        <lpage>
         3296
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.6.3289-3296.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15731223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B79-viruses-11-00059">
       <label>
        79.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hogan
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bunzel
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         7217
        </fpage>
        <lpage>
         7226
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.13.7217-7226.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15194798
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B80-viruses-11-00059">
       <label>
        80.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bukreyev
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E.W.
          </given-names>
         </name>
         <name>
          <surname>
           Buchholz
          </surname>
          <given-names>
           U.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
         <name>
          <surname>
           Elkins
          </surname>
          <given-names>
           W.R.
          </given-names>
         </name>
         <name>
          <surname>
           St
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mucosal immunisation of African green monkeys (
         <italic>
          Cercopithecus aethiops
         </italic>
         ) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2004
        </year>
        <volume>
         363
        </volume>
        <fpage>
         2122
        </fpage>
        <lpage>
         2127
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(04)16501-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         15220033
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B81-viruses-11-00059">
       <label>
        81.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           W.P.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Nabel
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2004
        </year>
        <volume>
         428
        </volume>
        <fpage>
         561
        </fpage>
        <lpage>
         564
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature02463
        </pub-id>
        <pub-id pub-id-type="pmid">
         15024391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B82-viruses-11-00059">
       <label>
        82.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kam
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
         <name>
          <surname>
           Kien
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           Y.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E.W.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Guarner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2007
        </year>
        <volume>
         25
        </volume>
        <fpage>
         729
        </fpage>
        <lpage>
         740
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2006.08.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         17049691
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B83-viruses-11-00059">
       <label>
        83.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Weingartl
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2005
        </year>
        <volume>
         23
        </volume>
        <fpage>
         2273
        </fpage>
        <lpage>
         2279
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2005.01.033
        </pub-id>
        <pub-id pub-id-type="pmid">
         15755610
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B84-viruses-11-00059">
       <label>
        84.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weingartl
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Neufeld
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Marszal
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Gren
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Proulx
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Deschambault
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         12672
        </fpage>
        <lpage>
         12676
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.22.12672-12676.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15507655
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B85-viruses-11-00059">
       <label>
        85.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2017
        </year>
        <volume>
         91
        </volume>
        <fpage>
         e01651-16
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01651-16
        </pub-id>
        <pub-id pub-id-type="pmid">
         27795425
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B86-viruses-11-00059">
       <label>
        86.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Joyce
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Modjarrad
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Lees
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yassine
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kanekiyo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of candidate vaccine approaches for MERS-CoV
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <year>
         2015
        </year>
        <volume>
         6
        </volume>
        <fpage>
         7712
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/ncomms8712
        </pub-id>
        <pub-id pub-id-type="pmid">
         26218507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B87-viruses-11-00059">
       <label>
        87.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gilbert
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Warimwe
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2017
        </year>
        <volume>
         35
        </volume>
        <fpage>
         4461
        </fpage>
        <lpage>
         4464
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2017.04.085
        </pub-id>
        <pub-id pub-id-type="pmid">
         28576573
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B88-viruses-11-00059">
       <label>
        88.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Okada
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kenniston
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           AlHajri
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           AlHajri
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Gambotto
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2014
        </year>
        <volume>
         32
        </volume>
        <fpage>
         5975
        </fpage>
        <lpage>
         5982
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2014.08.058
        </pub-id>
        <pub-id pub-id-type="pmid">
         25192975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B89-viruses-11-00059">
       <label>
        89.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2017
        </year>
        <volume>
         35
        </volume>
        <fpage>
         2069
        </fpage>
        <lpage>
         2075
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2017.02.063
        </pub-id>
        <pub-id pub-id-type="pmid">
         28314561
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B90-viruses-11-00059">
       <label>
        90.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Amri
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Abbas
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Siddiq
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sanki
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Muhanna
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Alhabbab
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           E.I.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <fpage>
         44875
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/srep44875
        </pub-id>
        <pub-id pub-id-type="pmid">
         28332568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B91-viruses-11-00059">
       <label>
        91.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Modjarrad
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV vaccine candidates in development: The current landscape
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2016
        </year>
        <volume>
         34
        </volume>
        <fpage>
         2982
        </fpage>
        <lpage>
         2987
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2016.03.104
        </pub-id>
        <pub-id pub-id-type="pmid">
         27083424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B92-viruses-11-00059">
       <label>
        92.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Mangalam
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Meyerholz
          </surname>
          <given-names>
           D.K.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           David
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Airway Memory CD4
         <sup>
          +
         </sup>
         T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses
        </article-title>
        <source>
         Immunity
        </source>
        <year>
         2016
        </year>
        <volume>
         44
        </volume>
        <fpage>
         1379
        </fpage>
        <lpage>
         1391
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.immuni.2016.05.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         27287409
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B93-viruses-11-00059">
       <label>
        93.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roper
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Rehm
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS vaccines: Where are we?
        </article-title>
        <source>
         Expert Rev. Vaccines
        </source>
        <year>
         2009
        </year>
        <volume>
         8
        </volume>
        <fpage>
         887
        </fpage>
        <lpage>
         898
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/erv.09.43
        </pub-id>
        <pub-id pub-id-type="pmid">
         19538115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B94-viruses-11-00059">
       <label>
        94.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine
        </article-title>
        <source>
         Antivir. Ther.
        </source>
        <year>
         2007
        </year>
        <volume>
         12
        </volume>
        <fpage>
         1107
        </fpage>
        <lpage>
         1113
        </lpage>
        <pub-id pub-id-type="pmid">
         18018769
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B95-viruses-11-00059">
       <label>
        95.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus
        </article-title>
        <source>
         Emerg. Microbes Infect.
        </source>
        <year>
         2018
        </year>
        <volume>
         7
        </volume>
        <fpage>
         60
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41426-018-0056-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         29618723
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B96-viruses-11-00059">
       <label>
        96.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           See
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zakhartchouk
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lawrence
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mok
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Hogan
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zitzow
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Karunakaran
          </surname>
          <given-names>
           K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Hitt
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         87
        </volume>
        <fpage>
         641
        </fpage>
        <lpage>
         650
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.81579-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         16476986
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B97-viruses-11-00059">
       <label>
        97.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Dediego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Deming
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2008
        </year>
        <volume>
         133
        </volume>
        <fpage>
         45
        </fpage>
        <lpage>
         62
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2007.01.021
        </pub-id>
        <pub-id pub-id-type="pmid">
         17416434
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B98-viruses-11-00059">
       <label>
        98.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bolles
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Deming
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Long
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Whitmore
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ferris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Funkhouser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Totura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         12201
        </fpage>
        <lpage>
         12215
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.06048-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         21937658
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B99-viruses-11-00059">
       <label>
        99.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ishioka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kimura
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kita
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Obuchi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hoshino
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Noda
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nishina
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kozawa
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kato
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of respiratory syncytial virus infection and major basic protein derived from eosinophils in pulmonary alveolar epithelial cells (A549)
        </article-title>
        <source>
         Cell Biol. Int.
        </source>
        <year>
         2011
        </year>
        <volume>
         35
        </volume>
        <fpage>
         467
        </fpage>
        <lpage>
         474
        </lpage>
        <pub-id pub-id-type="doi">
         10.1042/CBI20100255
        </pub-id>
        <pub-id pub-id-type="pmid">
         20977431
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B100-viruses-11-00059">
       <label>
        100.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Regla-Nava
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         6551
        </fpage>
        <lpage>
         6559
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00087-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23576515
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B101-viruses-11-00059">
       <label>
        101.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           L.D.
          </given-names>
         </name>
         <name>
          <surname>
           Bolles
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Denison
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2012
        </year>
        <volume>
         18
        </volume>
        <fpage>
         1820
        </fpage>
        <lpage>
         1826
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm.2972
        </pub-id>
        <pub-id pub-id-type="pmid">
         23142821
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B102-viruses-11-00059">
       <label>
        102.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Almazan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Zuniga
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Marquez-Jurado
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Andres
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate
        </article-title>
        <source>
         mBio
        </source>
        <year>
         2013
        </year>
        <volume>
         4
        </volume>
        <fpage>
         e613
        </fpage>
        <lpage>
         e650
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/mBio.00650-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24023385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B103-viruses-11-00059">
       <label>
        103.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vignuzzi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wendt
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Andino
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Engineering attenuated virus vaccines by controlling replication fidelity
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2008
        </year>
        <volume>
         14
        </volume>
        <fpage>
         154
        </fpage>
        <lpage>
         161
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1726
        </pub-id>
        <pub-id pub-id-type="pmid">
         18246077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B104-viruses-11-00059">
       <label>
        104.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Guarner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hayes
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         503
        </fpage>
        <lpage>
         511
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.1.503-511.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15596843
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B105-viruses-11-00059">
       <label>
        105.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deming
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Suthar
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Harkema
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Whitmore
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Pickles
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants
        </article-title>
        <source>
         PLoS Med.
        </source>
        <year>
         2006
        </year>
        <volume>
         3
        </volume>
        <elocation-id>
         e525
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pmed.0030525
        </pub-id>
        <pub-id pub-id-type="pmid">
         17194199
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B106-viruses-11-00059">
       <label>
        106.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ba
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         2678
        </fpage>
        <lpage>
         2688
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.5.2678-2688.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15708987
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B107-viruses-11-00059">
       <label>
        107.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge
        </article-title>
        <source>
         EBioMedicine
        </source>
        <year>
         2015
        </year>
        <volume>
         2
        </volume>
        <fpage>
         1438
        </fpage>
        <lpage>
         1446
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ebiom.2015.08.031
        </pub-id>
        <pub-id pub-id-type="pmid">
         26629538
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B108-viruses-11-00059">
       <label>
        108.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiaming
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yanfeng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Yawei
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Linlin
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Baoying
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jinghua
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Chuan
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wenjie
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2017
        </year>
        <volume>
         35
        </volume>
        <fpage>
         10
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2016.11.064
        </pub-id>
        <pub-id pub-id-type="pmid">
         27899228
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B109-viruses-11-00059">
       <label>
        109.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bisht
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Moss
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2005
        </year>
        <volume>
         334
        </volume>
        <fpage>
         160
        </fpage>
        <lpage>
         165
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2005.01.042
        </pub-id>
        <pub-id pub-id-type="pmid">
         15780866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B110-viruses-11-00059">
       <label>
        110.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           L.P.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2005
        </year>
        <volume>
         23
        </volume>
        <fpage>
         4959
        </fpage>
        <lpage>
         4968
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2005.05.023
        </pub-id>
        <pub-id pub-id-type="pmid">
         15993989
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B111-viruses-11-00059">
       <label>
        111.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization
        </article-title>
        <source>
         Mol. Immunol.
        </source>
        <year>
         2006
        </year>
        <volume>
         43
        </volume>
        <fpage>
         1791
        </fpage>
        <lpage>
         1798
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.molimm.2005.11.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         16423399
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B112-viruses-11-00059">
       <label>
        112.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gupta
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Tabiin
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chandrasekaran
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Anwar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chikhlikar
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Salmon
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Brusic
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Marques
          </surname>
          <given-names>
           E.T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2006
        </year>
        <volume>
         347
        </volume>
        <fpage>
         127
        </fpage>
        <lpage>
         139
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2005.11.042
        </pub-id>
        <pub-id pub-id-type="pmid">
         16387339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B113-viruses-11-00059">
       <label>
        113.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Saitoh
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <year>
         2009
        </year>
        <volume>
         82
        </volume>
        <fpage>
         73
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2009.02.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         19428598
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B114-viruses-11-00059">
       <label>
        114.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           R.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kou
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Tsui
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library
        </article-title>
        <source>
         J. Comb. Chem.
        </source>
        <year>
         2005
        </year>
        <volume>
         7
        </volume>
        <fpage>
         648
        </fpage>
        <lpage>
         656
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/cc0500607
        </pub-id>
        <pub-id pub-id-type="pmid">
         16153058
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B115-viruses-11-00059">
       <label>
        115.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hez
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus
        </article-title>
        <source>
         Antivir. Ther.
        </source>
        <year>
         2005
        </year>
        <volume>
         10
        </volume>
        <fpage>
         393
        </fpage>
        <lpage>
         403
        </lpage>
        <pub-id pub-id-type="pmid">
         15918330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B116-viruses-11-00059">
       <label>
        116.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Martina
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <name>
          <surname>
           Van Der Zee
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Lepault
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Haijema
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Versluis
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Heck
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           De Groot
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         8455
        </fpage>
        <lpage>
         8460
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0400576101
        </pub-id>
        <pub-id pub-id-type="pmid">
         15150417
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B117-viruses-11-00059">
       <label>
        117.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qing
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein
        </article-title>
        <source>
         Biochem. Biophys. Res. Commun.
        </source>
        <year>
         2004
        </year>
        <volume>
         319
        </volume>
        <fpage>
         746
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2004.05.046
        </pub-id>
        <pub-id pub-id-type="pmid">
         15184046
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B118-viruses-11-00059">
       <label>
        118.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McRoy
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Amino acid substitutions in the S2 subunit of mouse hepatitis virus variant V51 encode determinants of host range expansion
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         1414
        </fpage>
        <lpage>
         1424
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01674-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         18032498
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B119-viruses-11-00059">
       <label>
        119.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Heck
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lustigman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: Implication for vaccine design
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         80
        </volume>
        <fpage>
         5757
        </fpage>
        <lpage>
         5767
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00083-06
        </pub-id>
        <pub-id pub-id-type="pmid">
         16731915
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B120-viruses-11-00059">
       <label>
        120.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Lustigman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein
        </article-title>
        <source>
         J. Immunol.
        </source>
        <year>
         2006
        </year>
        <volume>
         176
        </volume>
        <fpage>
         6085
        </fpage>
        <lpage>
         6092
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.176.10.6085
        </pub-id>
        <pub-id pub-id-type="pmid">
         16670317
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B121-viruses-11-00059">
       <label>
        121.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: Importance for designing SARS vaccines
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2005
        </year>
        <volume>
         334
        </volume>
        <fpage>
         74
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2005.01.034
        </pub-id>
        <pub-id pub-id-type="pmid">
         15749124
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B122-viruses-11-00059">
       <label>
        122.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chong
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yeh
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jan
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Chi
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV)
        </article-title>
        <source>
         J. Biomed. Sci.
        </source>
        <year>
         2005
        </year>
        <volume>
         12
        </volume>
        <fpage>
         711
        </fpage>
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s11373-005-9004-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         16132115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B123-viruses-11-00059">
       <label>
        123.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Lian
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         190
        </volume>
        <fpage>
         1119
        </fpage>
        <lpage>
         1126
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/423286
        </pub-id>
        <pub-id pub-id-type="pmid">
         15319862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B124-viruses-11-00059">
       <label>
        124.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Traggiai
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Uematsu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gismondo
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rappuoli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Lanzavecchia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         871
        </fpage>
        <lpage>
         875
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1080
        </pub-id>
        <pub-id pub-id-type="pmid">
         15247913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B125-viruses-11-00059">
       <label>
        125.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rockx
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Corti
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Stadler
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Lanzavecchia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <fpage>
         3220
        </fpage>
        <lpage>
         3235
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02377-07
        </pub-id>
        <pub-id pub-id-type="pmid">
         18199635
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B126-viruses-11-00059">
       <label>
        126.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Chakraborti
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Prabakaran
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rockx
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Sidorov
          </surname>
          <given-names>
           I.A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2007
        </year>
        <volume>
         104
        </volume>
        <fpage>
         12123
        </fpage>
        <lpage>
         12128
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0701000104
        </pub-id>
        <pub-id pub-id-type="pmid">
         17620608
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B127-viruses-11-00059">
       <label>
        127.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coughlin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Martinez
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Masterman
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Olsen
          </surname>
          <given-names>
           O.A.
          </given-names>
         </name>
         <name>
          <surname>
           Moksa
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Babcook
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Prabhakar
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         361
        </volume>
        <fpage>
         93
        </fpage>
        <lpage>
         102
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2006.09.029
        </pub-id>
        <pub-id pub-id-type="pmid">
         17161858
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B128-viruses-11-00059">
       <label>
        128.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van den Brink
          </surname>
          <given-names>
           E.N.
          </given-names>
         </name>
         <name>
          <surname>
           Ter Meulen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Jongeneelen
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Thijsse
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Throsby
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Marissen
          </surname>
          <given-names>
           W.E.
          </given-names>
         </name>
         <name>
          <surname>
           Rood
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
         <name>
          <surname>
           Bakker
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
         <name>
          <surname>
           Gelderblom
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         1635
        </fpage>
        <lpage>
         1644
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.3.1635-1644.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15650189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B129-viruses-11-00059">
       <label>
        129.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Murakami
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tallarico
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Olurinde
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         2536
        </fpage>
        <lpage>
         2541
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0307140101
        </pub-id>
        <pub-id pub-id-type="pmid">
         14983044
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B130-viruses-11-00059">
       <label>
        130.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Escalante
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Farmar
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Debnath
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tien
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2004
        </year>
        <volume>
         363
        </volume>
        <fpage>
         938
        </fpage>
        <lpage>
         947
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(04)15788-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         15043961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B131-viruses-11-00059">
       <label>
        131.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corti
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pedotti
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Simonelli
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Rodriguez
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Foglierini
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Agatic
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Vanzetta
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2015
        </year>
        <volume>
         112
        </volume>
        <fpage>
         10473
        </fpage>
        <lpage>
         10478
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1510199112
        </pub-id>
        <pub-id pub-id-type="pmid">
         26216974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B132-viruses-11-00059">
       <label>
        132.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein
        </article-title>
        <source>
         Cell Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         25
        </volume>
        <fpage>
         1237
        </fpage>
        <lpage>
         1249
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/cr.2015.113
        </pub-id>
        <pub-id pub-id-type="pmid">
         26391698
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B133-viruses-11-00059">
       <label>
        133.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Kou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         7045
        </fpage>
        <lpage>
         7053
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00433-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24719424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B134-viruses-11-00059">
       <label>
        134.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Provacia
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wiersma
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ouwendijk
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Spronken
          </surname>
          <given-names>
           M.I.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         1834
        </fpage>
        <lpage>
         1838
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02935-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24257613
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B135-viruses-11-00059">
       <label>
        135.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
        </article-title>
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2016
        </year>
        <volume>
         291
        </volume>
        <fpage>
         9218
        </fpage>
        <lpage>
         9232
        </lpage>
        <pub-id pub-id-type="doi">
         10.1074/jbc.M116.716100
        </pub-id>
        <pub-id pub-id-type="pmid">
         26953343
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B136-viruses-11-00059">
       <label>
        136.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gierer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kaup
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Wrensch
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Heurich
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kramer-Kuhl
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Welsch
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Winkler
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         5502
        </fpage>
        <lpage>
         5511
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00128-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23468491
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B137-viruses-11-00059">
       <label>
        137.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kawase
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2013
        </year>
        <volume>
         87
        </volume>
        <fpage>
         12552
        </fpage>
        <lpage>
         12561
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01890-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24027332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B138-viruses-11-00059">
       <label>
        138.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Vedantham
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Agudelo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Carrion
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Nunneley
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pöhlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           McKerrow
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Renslo
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protease inhibitors targeting coronavirus and filovirus entry
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         116
        </volume>
        <fpage>
         76
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2015.01.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         25666761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B139-viruses-11-00059">
       <label>
        139.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Momattin
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Mohammed
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)–possible lessons from a systematic review of SARS-CoV therapy
        </article-title>
        <source>
         Int. J. Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         17
        </volume>
        <fpage>
         e792
        </fpage>
        <lpage>
         e798
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ijid.2013.07.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         23993766
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B140-viruses-11-00059">
       <label>
        140.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Kindrachuk
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Olinger
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
         <name>
          <surname>
           Holbrook
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Jahrling
          </surname>
          <given-names>
           P.B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.061911-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B141-viruses-11-00059">
       <label>
        141.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           ter Meulen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brink
          </surname>
          <given-names>
           E.N.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Marissen
          </surname>
          <given-names>
           W.E.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bakker
          </surname>
          <given-names>
           A.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Bogaards
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           van Deventer
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants
        </article-title>
        <source>
         PLoS Med.
        </source>
        <year>
         2006
        </year>
        <volume>
         3
        </volume>
        <elocation-id>
         e237
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pmed.0030237
        </pub-id>
        <pub-id pub-id-type="pmid">
         16796401
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B142-viruses-11-00059">
       <label>
        142.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ning
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.F.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A serological survey on neutralizing antibody titer of SARS convalescent sera
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         77
        </volume>
        <fpage>
         147
        </fpage>
        <lpage>
         150
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20431
        </pub-id>
        <pub-id pub-id-type="pmid">
         16121363
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B143-viruses-11-00059">
       <label>
        143.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miyoshi-Akiyama
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ishida
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Fukushi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yamaguchi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Matsuoka
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ishihara
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tsukahara
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hatakeyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Itoh
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Morisawa
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Fully Human Monoclonal Antibody Directed to Proteolytic Cleavage Site in Severe Acute Respiratory Syndrome (SARS) Coronavirus S Protein Neutralizes the Virus in a Rhesus Macaque SARS Model
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2011
        </year>
        <volume>
         203
        </volume>
        <fpage>
         1574
        </fpage>
        <lpage>
         1581
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jir084
        </pub-id>
        <pub-id pub-id-type="pmid">
         21592986
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B144-viruses-11-00059">
       <label>
        144.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Kuwahara
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates
        </article-title>
        <source>
         ACS Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         2
        </volume>
        <fpage>
         361
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/acsinfecdis.6b00006
        </pub-id>
        <pub-id pub-id-type="pmid">
         27627203
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B145-viruses-11-00059">
       <label>
        145.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         215
        </volume>
        <fpage>
         1807
        </fpage>
        <lpage>
         1815
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jix209
        </pub-id>
        <pub-id pub-id-type="pmid">
         28472421
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B146-viruses-11-00059">
       <label>
        146.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stockman
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bellamy
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Garner
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: Systematic Review of Treatment Effects
        </article-title>
        <source>
         PLoS Med.
        </source>
        <year>
         2006
        </year>
        <volume>
         3
        </volume>
        <elocation-id>
         e343
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pmed.0030343
        </pub-id>
        <pub-id pub-id-type="pmid">
         16968120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B147-viruses-11-00059">
       <label>
        147.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: Clinical presentation, transmission, pathogenesis and treatment options
        </article-title>
        <source>
         Clin. Sci.
        </source>
        <year>
         2006
        </year>
        <volume>
         110
        </volume>
        <fpage>
         193
        </fpage>
        <lpage>
         204
        </lpage>
        <pub-id pub-id-type="doi">
         10.1042/CS20050188
        </pub-id>
        <pub-id pub-id-type="pmid">
         16411895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B148-viruses-11-00059">
       <label>
        148.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv392
        </pub-id>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B149-viruses-11-00059">
       <label>
        149.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           McAuliffe
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fahle
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tatti
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Packard
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shieh
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         3572
        </fpage>
        <lpage>
         3577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.7.3572-3577.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15016880
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B150-viruses-11-00059">
       <label>
        150.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wentworth
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Gillim-Ross
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Espina
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bernard
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mice susceptible to SARS coronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         1293
        </fpage>
        <lpage>
         1296
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1007.031119
        </pub-id>
        <pub-id pub-id-type="pmid">
         15324552
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B151-viruses-11-00059">
       <label>
        151.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glass
          </surname>
          <given-names>
           W.G.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           P.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice
        </article-title>
        <source>
         J. Immunol.
        </source>
        <year>
         2004
        </year>
        <volume>
         173
        </volume>
        <fpage>
         4030
        </fpage>
        <lpage>
         4039
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.173.6.4030
        </pub-id>
        <pub-id pub-id-type="pmid">
         15356152
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B152-viruses-11-00059">
       <label>
        152.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.H.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection
        </article-title>
        <source>
         Comp. Med.
        </source>
        <year>
         2007
        </year>
        <volume>
         57
        </volume>
        <fpage>
         450
        </fpage>
        <lpage>
         459
        </lpage>
        <pub-id pub-id-type="pmid">
         17974127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B153-viruses-11-00059">
       <label>
        153.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Paddock
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Butler
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         5833
        </fpage>
        <lpage>
         5838
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.9.5833-5838.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15827197
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B154-viruses-11-00059">
       <label>
        154.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hogan
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Flieder
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Paragas
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kobinger
          </surname>
          <given-names>
           G.P.
          </given-names>
         </name>
         <name>
          <surname>
           Wivel
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Crystal
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Boyer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         11416
        </fpage>
        <lpage>
         11421
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.20.11416-11421.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15452265
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B155-viruses-11-00059">
       <label>
        155.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Page
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Woodruff
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Scorpio
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2012
        </year>
        <volume>
         86
        </volume>
        <fpage>
         884
        </fpage>
        <lpage>
         897
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.05957-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         22072787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B156-viruses-11-00059">
       <label>
        156.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Legge
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice
        </article-title>
        <source>
         J. Clin. Investig.
        </source>
        <year>
         2011
        </year>
        <volume>
         121
        </volume>
        <fpage>
         4921
        </fpage>
        <lpage>
         4930
        </lpage>
        <pub-id pub-id-type="doi">
         10.1172/JCI59777
        </pub-id>
        <pub-id pub-id-type="pmid">
         22105170
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B157-viruses-11-00059">
       <label>
        157.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2010
        </year>
        <volume>
         84
        </volume>
        <fpage>
         9318
        </fpage>
        <lpage>
         9325
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01049-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         20610717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B158-viruses-11-00059">
       <label>
        158.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Van Rooijen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evasion by stealth: Inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2009
        </year>
        <volume>
         5
        </volume>
        <elocation-id>
         e1000636
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1000636
        </pub-id>
        <pub-id pub-id-type="pmid">
         19851468
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B159-viruses-11-00059">
       <label>
        159.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Morrison
          </surname>
          <given-names>
           T.E.
          </given-names>
         </name>
         <name>
          <surname>
           Funkhouser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Uematsu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Akira
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2008
        </year>
        <volume>
         4
        </volume>
        <elocation-id>
         e1000240
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1000240
        </pub-id>
        <pub-id pub-id-type="pmid">
         19079579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B160-viruses-11-00059">
       <label>
        160.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Temperton
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brenchley
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         T cell responses to whole SARS coronavirus in humans
        </article-title>
        <source>
         J. Immunol.
        </source>
        <year>
         2008
        </year>
        <volume>
         181
        </volume>
        <fpage>
         5490
        </fpage>
        <lpage>
         5500
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.181.8.5490
        </pub-id>
        <pub-id pub-id-type="pmid">
         18832706
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B161-viruses-11-00059">
       <label>
        161.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Mu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Mu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           You
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection
        </article-title>
        <source>
         J. Med. Microbiol.
        </source>
        <year>
         2004
        </year>
        <volume>
         53
        </volume>
        <fpage>
         435
        </fpage>
        <lpage>
         438
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.45561-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         15096554
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B162-viruses-11-00059">
       <label>
        162.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spruth
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kistner
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Savidis-Dacho
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hitter
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Crowe
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Gerencer
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bruhl
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Grillberger
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Reiter
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tauer
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses
        </article-title>
        <source>
         Vaccine
        </source>
        <year>
         2006
        </year>
        <volume>
         24
        </volume>
        <fpage>
         652
        </fpage>
        <lpage>
         661
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vaccine.2005.08.055
        </pub-id>
        <pub-id pub-id-type="pmid">
         16214268
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B163-viruses-11-00059">
       <label>
        163.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Babcock
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Hernandez
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Coccia
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Graziano
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Srinivasan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lowy
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Finberg
          </surname>
          <given-names>
           R.W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2005
        </year>
        <volume>
         191
        </volume>
        <fpage>
         507
        </fpage>
        <lpage>
         514
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/427242
        </pub-id>
        <pub-id pub-id-type="pmid">
         15655773
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B164-viruses-11-00059">
       <label>
        164.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kapadia
          </surname>
          <given-names>
           S.U.
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2005
        </year>
        <volume>
         340
        </volume>
        <fpage>
         174
        </fpage>
        <lpage>
         182
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2005.06.016
        </pub-id>
        <pub-id pub-id-type="pmid">
         16043204
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B165-viruses-11-00059">
       <label>
        165.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stadler
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Eickmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kolesnikova
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Klenk
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Rappuoli
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Abrignani
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS vaccine protective in mice
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         1312
        </fpage>
        <lpage>
         1314
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1108.041003
        </pub-id>
        <pub-id pub-id-type="pmid">
         16110580
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B166-viruses-11-00059">
       <label>
        166.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bisht
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bukreyev
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Moss
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         6641
        </fpage>
        <lpage>
         6646
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0401939101
        </pub-id>
        <pub-id pub-id-type="pmid">
         15096611
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B167-viruses-11-00059">
       <label>
        167.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schaecher
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Stabenow
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Oberle
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Schriewer
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Buller
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Sagartz
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Pekosz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An immunosuppressed Syrian golden hamster model for SARS-CoV infection
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2008
        </year>
        <volume>
         380
        </volume>
        <fpage>
         312
        </fpage>
        <lpage>
         321
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2008.07.026
        </pub-id>
        <pub-id pub-id-type="pmid">
         18760437
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B168-viruses-11-00059">
       <label>
        168.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Pacal
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xing
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab’)2
        </article-title>
        <source>
         Viral Immunol.
        </source>
        <year>
         2007
        </year>
        <volume>
         20
        </volume>
        <fpage>
         495
        </fpage>
        <lpage>
         502
        </lpage>
        <pub-id pub-id-type="doi">
         10.1089/vim.2007.0038
        </pub-id>
        <pub-id pub-id-type="pmid">
         17931120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B169-viruses-11-00059">
       <label>
        169.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Is there an ideal animal model for SARS?
        </article-title>
        <source>
         Trends Microbiol.
        </source>
        <year>
         2006
        </year>
        <volume>
         14
        </volume>
        <fpage>
         299
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tim.2006.05.007
        </pub-id>
        <pub-id pub-id-type="pmid">
         16759866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B170-viruses-11-00059">
       <label>
        170.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           W.D.
          </given-names>
         </name>
         <name>
          <surname>
           Guarner
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           E.W.
          </given-names>
         </name>
         <name>
          <surname>
           Babcock
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Hayes
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2006
        </year>
        <volume>
         193
        </volume>
        <fpage>
         685
        </fpage>
        <lpage>
         692
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/500143
        </pub-id>
        <pub-id pub-id-type="pmid">
         16453264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B171-viruses-11-00059">
       <label>
        171.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martina
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Rimmelzwaan
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Virology: SARS virus infection of cats and ferrets
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         425
        </volume>
        <fpage>
         915
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/425915a
        </pub-id>
        <pub-id pub-id-type="pmid">
         14586458
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B172-viruses-11-00059">
       <label>
        172.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Leijten
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           van Riel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Martina
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathology of experimental SARS coronavirus infection in cats and ferrets
        </article-title>
        <source>
         Vet. Pathol.
        </source>
        <year>
         2008
        </year>
        <volume>
         45
        </volume>
        <fpage>
         551
        </fpage>
        <lpage>
         562
        </lpage>
        <pub-id pub-id-type="doi">
         10.1354/vp.45-4-551
        </pub-id>
        <pub-id pub-id-type="pmid">
         18587105
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B173-viruses-11-00059">
       <label>
        173.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Darnell
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Plant
          </surname>
          <given-names>
           E.P.
          </given-names>
         </name>
         <name>
          <surname>
           Watanabe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Byrum
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           St
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2007
        </year>
        <volume>
         196
        </volume>
        <fpage>
         1329
        </fpage>
        <lpage>
         1338
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/522431
        </pub-id>
        <pub-id pub-id-type="pmid">
         17922397
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B174-viruses-11-00059">
       <label>
        174.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           ter Meulen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bakker
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brink
          </surname>
          <given-names>
           E.N.
          </given-names>
         </name>
         <name>
          <surname>
           Weverling
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Martina
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           de Kruif
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Spaan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2004
        </year>
        <volume>
         363
        </volume>
        <fpage>
         2139
        </fpage>
        <lpage>
         2141
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(04)16506-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         15220038
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B175-viruses-11-00059">
       <label>
        175.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           See
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lawrence
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mok
          </surname>
          <given-names>
           C.P.
          </given-names>
         </name>
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zitzow
          </surname>
          <given-names>
           L.A.
          </given-names>
         </name>
         <name>
          <surname>
           Karunakaran
          </surname>
          <given-names>
           K.P.
          </given-names>
         </name>
         <name>
          <surname>
           Voss
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Brunham
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Gauldie
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome vaccine efficacy in ferrets: Whole killed virus and adenovirus-vectored vaccines
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2008
        </year>
        <volume>
         89
        </volume>
        <fpage>
         2136
        </fpage>
        <lpage>
         2146
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.2008/001891-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         18753223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B176-viruses-11-00059">
       <label>
        176.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           She
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Marasco
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus
        </article-title>
        <source>
         J. Pathol.
        </source>
        <year>
         2005
        </year>
        <volume>
         206
        </volume>
        <fpage>
         251
        </fpage>
        <lpage>
         259
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/path.1769
        </pub-id>
        <pub-id pub-id-type="pmid">
         15892035
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B177-viruses-11-00059">
       <label>
        177.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McAuliffe
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fahle
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Fischer
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shieh
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Butler
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           St
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2004
        </year>
        <volume>
         330
        </volume>
        <fpage>
         8
        </fpage>
        <lpage>
         15
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2004.09.030
        </pub-id>
        <pub-id pub-id-type="pmid">
         15527829
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B178-viruses-11-00059">
       <label>
        178.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Hogan
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Crystal
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Voss
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kobinger
          </surname>
          <given-names>
           G.P.
          </given-names>
         </name>
         <name>
          <surname>
           Wivel
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Macaque model for severe acute respiratory syndrome
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         11401
        </fpage>
        <lpage>
         11404
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.20.11401-11404.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15452262
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B179-viruses-11-00059">
       <label>
        179.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           F.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Woodle
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         944
        </fpage>
        <lpage>
         951
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1280
        </pub-id>
        <pub-id pub-id-type="pmid">
         16116432
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B180-viruses-11-00059">
       <label>
        180.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Midkiff
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lackner
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques
        </article-title>
        <source>
         Mucosal Immunol.
        </source>
        <year>
         2016
        </year>
        <volume>
         9
        </volume>
        <fpage>
         1089
        </fpage>
        <lpage>
         1101
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/mi.2015.127
        </pub-id>
        <pub-id pub-id-type="pmid">
         26647718
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B181-viruses-11-00059">
       <label>
        181.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Schutten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           van Doornum
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           van den Hoogen
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Stohr
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aetiology: Koch’s postulates fulfilled for SARS virus
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         423
        </volume>
        <fpage>
         240
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/423240a
        </pub-id>
        <pub-id pub-id-type="pmid">
         12748632
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B182-viruses-11-00059">
       <label>
        182.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuiken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Schutten
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Rimmelzwaan
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           van Riel
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Laman
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           de Jong
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           van Doornum
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         362
        </volume>
        <fpage>
         263
        </fpage>
        <lpage>
         270
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13967-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         12892955
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B183-viruses-11-00059">
       <label>
        183.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Carville
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Coderre
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Luzuriaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Mansfield
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pneumonitis and multi-organ system disease in common marmosets (
         <italic>
          Callithrix jacchus
         </italic>
         ) infected with the severe acute respiratory syndrome-associated coronavirus
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <year>
         2005
        </year>
        <volume>
         167
        </volume>
        <fpage>
         455
        </fpage>
        <lpage>
         463
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0002-9440(10)62989-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         16049331
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B184-viruses-11-00059">
       <label>
        184.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lawler
          </surname>
          <given-names>
           J.V.
          </given-names>
         </name>
         <name>
          <surname>
           Endy
          </surname>
          <given-names>
           T.P.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Garrison
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fritz
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lesar
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kulesh
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Norwood
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wasieloski
          </surname>
          <given-names>
           L.P.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cynomolgus macaque as an animal model for severe acute respiratory syndrome
        </article-title>
        <source>
         PLoS Med.
        </source>
        <year>
         2006
        </year>
        <volume>
         3
        </volume>
        <elocation-id>
         e149
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pmed.0030149
        </pub-id>
        <pub-id pub-id-type="pmid">
         16605302
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B185-viruses-11-00059">
       <label>
        185.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Animal models for SARS
        </article-title>
        <source>
         Adv. Exp. Med. Biol.
        </source>
        <year>
         2006
        </year>
        <volume>
         581
        </volume>
        <fpage>
         463
        </fpage>
        <lpage>
         471
        </lpage>
        <pub-id pub-id-type="pmid">
         17037579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B186-viruses-11-00059">
       <label>
        186.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rhesus angiotensin converting enzyme 2 supports entry of severe acute respiratory syndrome coronavirus in Chinese macaques
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2008
        </year>
        <volume>
         381
        </volume>
        <fpage>
         89
        </fpage>
        <lpage>
         97
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2008.08.016
        </pub-id>
        <pub-id pub-id-type="pmid">
         18801550
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B187-viruses-11-00059">
       <label>
        187.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Curnes
          </surname>
          <given-names>
           N.R.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         5195
        </fpage>
        <lpage>
         5199
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.03764-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24574399
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B188-viruses-11-00059">
       <label>
        188.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Goicochea
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <fpage>
         408
        </fpage>
        <lpage>
         412
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.060640-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24197535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B189-viruses-11-00059">
       <label>
        189.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Horne
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Martellaro
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Haddock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenke
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenke
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Saturday
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Domestic Pig Unlikely Reservoir for MERS-CoV
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2017
        </year>
        <volume>
         23
        </volume>
        <fpage>
         985
        </fpage>
        <lpage>
         988
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2306.170096
        </pub-id>
        <pub-id pub-id-type="pmid">
         28318484
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B190-viruses-11-00059">
       <label>
        190.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Swanstrom
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Jensen
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Burch
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Permissivity of Dipeptidyl Peptidase 4 Orthologs to Middle East Respiratory Syndrome Coronavirus Is Governed by Glycosylation and Other Complex Determinants
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2017
        </year>
        <volume>
         91
        </volume>
        <fpage>
         e00534-17
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00534-17
        </pub-id>
        <pub-id pub-id-type="pmid">
         28747502
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B191-viruses-11-00059">
       <label>
        191.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Provacia
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Stittelaar
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Getu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           de Waal
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           van Amerongen
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Verjans
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2015
        </year>
        <volume>
         89
        </volume>
        <fpage>
         6131
        </fpage>
        <lpage>
         6135
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00661-15
        </pub-id>
        <pub-id pub-id-type="pmid">
         25810539
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B192-viruses-11-00059">
       <label>
        192.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Prescott
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baseler
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lackemeyer
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Martellaro
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Milne-Price
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Haddock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2013
        </year>
        <volume>
         8
        </volume>
        <elocation-id>
         e69127
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0069127
        </pub-id>
        <pub-id pub-id-type="pmid">
         23844250
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B193-viruses-11-00059">
       <label>
        193.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Earnest
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Bair
          </surname>
          <given-names>
           T.B.
          </given-names>
         </name>
         <name>
          <surname>
           Bates
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Brogden
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Flaherty
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2017
        </year>
        <volume>
         114
        </volume>
        <fpage>
         E3119
        </fpage>
        <lpage>
         E3128
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1619109114
        </pub-id>
        <pub-id pub-id-type="pmid">
         28348219
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B194-viruses-11-00059">
       <label>
        194.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2015
        </year>
        <volume>
         10
        </volume>
        <elocation-id>
         e145561
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0145561
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B195-viruses-11-00059">
       <label>
        195.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gale
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rapid generation of a mouse model for Middle East respiratory syndrome
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. USA
        </source>
        <year>
         2014
        </year>
        <volume>
         111
        </volume>
        <fpage>
         4970
        </fpage>
        <lpage>
         4975
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1323279111
        </pub-id>
        <pub-id pub-id-type="pmid">
         24599590
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B196-viruses-11-00059">
       <label>
        196.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Newman
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Watts
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Packard
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <fpage>
         1162
        </fpage>
        <lpage>
         1173
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01702-06
        </pub-id>
        <pub-id pub-id-type="pmid">
         17108019
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B197-viruses-11-00059">
       <label>
        197.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Jensen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Douglas
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Beall
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X.C.
          </given-names>
         </name>
         <name>
          <surname>
           Marasco
          </surname>
          <given-names>
           W.A.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A mouse model for MERS coronavirus-induced acute respiratory distress syndrome
        </article-title>
        <source>
         Nat. Microbiol.
        </source>
        <year>
         2016
        </year>
        <volume>
         2
        </volume>
        <fpage>
         16226
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/nmicrobiol.2016.226
        </pub-id>
        <pub-id pub-id-type="pmid">
         27892925
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B198-viruses-11-00059">
       <label>
        198.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Volz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlsein
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Schipper
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Okba
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fux
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
        </article-title>
        <source>
         Science
        </source>
        <year>
         2016
        </year>
        <volume>
         351
        </volume>
        <fpage>
         77
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.aad1283
        </pub-id>
        <pub-id pub-id-type="pmid">
         26678878
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B199-viruses-11-00059">
       <label>
        199.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bielefeldt-Ohmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hartwig
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Bowen
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection, Replication, and Transmission of Middle East Respiratory Syndrome Coronavirus in Alpacas
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1031
        </fpage>
        <lpage>
         1037
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2206.160192
        </pub-id>
        <pub-id pub-id-type="pmid">
         27070385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B200-viruses-11-00059">
       <label>
        200.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Durr
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Klein
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Foord
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Riddell
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Haining
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hemida
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Barr
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Experimental Infection and Response to Rechallenge of Alpacas with Middle East Respiratory Syndrome Coronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2016
        </year>
        <volume>
         22
        </volume>
        <fpage>
         1071
        </fpage>
        <lpage>
         1074
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid2206.160007
        </pub-id>
        <pub-id pub-id-type="pmid">
         27070733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B201-viruses-11-00059">
       <label>
        201.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An Animal Model of MERS Produced by Infection of Rhesus Macaques with MERS Coronavirus
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <year>
         2013
        </year>
        <volume>
         209
        </volume>
        <fpage>
         236
        </fpage>
        <lpage>
         242
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jit590
        </pub-id>
        <pub-id pub-id-type="pmid">
         24218506
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B202-viruses-11-00059">
       <label>
        202.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         PLoS ONE
        </source>
        <year>
         2017
        </year>
        <volume>
         12
        </volume>
        <elocation-id>
         e172093
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0172093
        </pub-id>
        <pub-id pub-id-type="pmid">
         28234937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B203-viruses-11-00059">
       <label>
        203.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Haddock
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Nagy
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infection with MERS-CoV causes lethal pneumonia in the common marmoset
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <year>
         2014
        </year>
        <volume>
         10
        </volume>
        <elocation-id>
         e1004250
        </elocation-id>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1004250
        </pub-id>
        <pub-id pub-id-type="pmid">
         25144235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B204-viruses-11-00059">
       <label>
        204.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pneumonia from human coronavirus in a macaque model
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2013
        </year>
        <volume>
         368
        </volume>
        <fpage>
         1560
        </fpage>
        <lpage>
         1562
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMc1215691
        </pub-id>
        <pub-id pub-id-type="pmid">
         23550601
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B205-viruses-11-00059">
       <label>
        205.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Brining
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Martellaro
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Baseler
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques
        </article-title>
        <source>
         Nat. Med.
        </source>
        <year>
         2013
        </year>
        <volume>
         19
        </volume>
        <fpage>
         1313
        </fpage>
        <lpage>
         1317
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm.3362
        </pub-id>
        <pub-id pub-id-type="pmid">
         24013700
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B206-viruses-11-00059">
       <label>
        206.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Via
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Cornish
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Yellayi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huzella
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Oberlander
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bartos
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ork
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2015
        </year>
        <volume>
         485
        </volume>
        <fpage>
         422
        </fpage>
        <lpage>
         430
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2015.07.013
        </pub-id>
        <pub-id pub-id-type="pmid">
         26342468
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B207-viruses-11-00059">
       <label>
        207.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Greenough
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Somasundaran
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         11429
        </fpage>
        <lpage>
         11433
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.20.11429-11433.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15452268
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B208-viruses-11-00059">
       <label>
        208.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xuan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         2620
        </fpage>
        <lpage>
         2625
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.4.2620-2625.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15681462
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B209-viruses-11-00059">
       <label>
        209.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barlan
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sarkar
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           McCray
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         4953
        </fpage>
        <lpage>
         4961
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00161-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24554656
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B210-viruses-11-00059">
       <label>
        210.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Miazgowicz
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Milne-Price
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Kinne
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           McLellan
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2014
        </year>
        <volume>
         88
        </volume>
        <fpage>
         9220
        </fpage>
        <lpage>
         9232
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00676-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24899185
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <fig id="viruses-11-00059-f001" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Schematic representation of the genome organization and functional domains of S protein for SARS-CoV and MERS-CoV. The single-stranded RNA genomes of SARS-CoV and MERS-CoV encode two large genes, the ORF1a and ORF1b genes, which encode 16 non-structural proteins (nsp1–nsp16) that are highly conserved throughout coronaviruses. The structural genes encode the structural proteins, spike (S), envelope (E), membrane (M), and nucleocapsid (N), which are common features to all coronaviruses. The accessory genes (shades of green) are unique to different coronaviruses in terms of number, genomic organization, sequence, and function. The structure of each S protein is shown beneath the genome organization. The S protein mainly contains the S1 and S2 subunits. The residue numbers in each region represent their positions in the S protein of SARS and MERS, respectively. The S1/S2 cleavage sites are highlighted by dotted lines. SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; CP, cytoplasm domain; FP, fusion peptide; HR, heptad repeat; RBD, receptor-binding domain; RBM, receptor-binding motif; SP, signal peptide; TM, transmembrane domain.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00059-g001">
      </graphic>
     </fig>
     <fig id="viruses-11-00059-f002" orientation="portrait" position="float">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        The life cycle of SARS-CoV and MERS-CoV in host cells. SARS-CoV and MERS-CoV enter target cells through an endosomal pathway. The S proteins of SARS and MERS bind to cellular receptor angiotensin-converting enzyme 2 (ACE2) and cellular receptor dipeptidyl peptidase 4 (DPP4), respectively. Following entry of the virus into the host cell, the viral RNA is unveiled in the cytoplasm. ORF1a and ORF1ab are translated to produce pp1a and pp1ab polyproteins, which are cleaved by the proteases that are encoded by ORF1a to yield 16 non-structural proteins that form the RNA replicase–transcriptase complex. This complex drives the production of negative-sense RNAs [(−) RNA] through both replication and transcription. During replication, full-length (−) RNA copies of the genome are produced and used as templates for full-length (+) RNA genomes. During transcription, a subset of 7–9 sub-genomic RNAs, including those encoding all structural proteins, is produced through discontinuous transcription. Although the different sub-genomic mRNAs may contain several open reading frames (ORFs), only the first ORF (that closest to the 5′ end) is translated. Viral nucleocapsids are assembled from genomic RNA and N protein in the cytoplasm, followed by budding into the lumen of the ERGIC (endoplasmic reticulum (ER)–Golgi intermediate compartment). Virions are then released from the infected cell through exocytosis. SARS-CoV, severe acute respiratory syndrome coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; S, spike; E, envelope; M, membrane; N, nucleocapsid.
       </p>
      </caption>
      <graphic xlink:href="viruses-11-00059-g002">
      </graphic>
     </fig>
     <table-wrap id="viruses-11-00059-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-11-00059-t001_Table 1
      </object-id>
      <label>
       Table 1
      </label>
      <caption>
       <p>
        Epidemiology and biological characteristics of the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV).
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          SARS-CoV
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          MERS-CoV
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Genus
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Beta-CoVs, lineage B
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Beta-CoVs, lineage C
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Possible Natural Reservoir
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Bat
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Bat
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Possible Intermediary Host
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Palm civet
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Dromedary camel
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Origin
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Guangdong province, China
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Arabian Peninsula
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
          <bold>
           Clinical Epidemiology
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Total global number reported to WHO
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          More than 8098 people
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          2254 (from 2012 through 16 September 2018)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Affected countries
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          29
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          27
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Number of deaths
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          916
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          800
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Mortality
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          More than 10%
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          More than 35%
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Transmission region
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Globally
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Regionally
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Transmission patterns
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          From animal to human;
          <break>
          </break>
          from human to human
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           The predominant receptor
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Human angiotensin-converting enzyme 2 (ACE2)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Human dipeptidyl peptidase 4 (DPP4 or CD26)
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Receptor
          </bold>
          <break>
          </break>
          <bold>
           distribution
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Arterial and venous endothelium; arterial smooth muscle; small intestine; respiratory tract epithelium; alveolar monocytes and macrophages
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Respiratory tract epithelium; kidney; small intestine; liver and prostate; activated leukocytes
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Cell line susceptibility
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Respiratory tract;
          <break>
          </break>
          kidney; liver
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Respiratory tract;
          <break>
          </break>
          intestinal tract;
          <break>
          </break>
          genitourinary tract;
          <break>
          </break>
          liver, kidney,
          <break>
          </break>
          neurons;
          <break>
          </break>
          monocyte;
          <break>
          </break>
          Tlymphocyte; and
          <break>
          </break>
          histiocytic cell lines
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Viral replication efficiency
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          High
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Higher
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Ability to inhibit IFN production
          </bold>
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Delayed recognition and proinflammatory response
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Delayed recognition and proinflammatory response
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="viruses-11-00059-t002" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-11-00059-t002_Table 2
      </object-id>
      <label>
       Table 2
      </label>
      <caption>
       <p>
        The genomic characterization of SARS-CoV and MERS-CoV.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          SARS-CoV
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          MERS-CoV
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Length of nucleotides
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          29,727
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          30,119
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Open reading frames (ORFs)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          11
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          11
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Structural protein
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          4
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike protein (length of amino acids)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1255
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1353
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          S1 subunit
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Receptor-binding domain (RBD)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          318–510
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          367–588
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Receptor-binding motif (RBM)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          424–494
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          484–567
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
          S2 subunit
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Heptad repeat 1 (HR1) domains
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          892–1013
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          984–1104
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Heptad repeat 2 (HR2) domains
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1145–1195
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          1246–1295
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Non-structural proteins (NSPs)
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          At least 5
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          16
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Accessory proteins
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          8
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          5
         </td>
        </tr>
        <tr>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          A characteristic gene order
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          5′-replicase ORF1ab, spike (S), envelope (E), membrane (M), and nucleocapsid (N)-3′
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="viruses-11-00059-t003" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-11-00059-t003_Table 3
      </object-id>
      <label>
       Table 3
      </label>
      <caption>
       <p>
        Vaccine strategies of SARS-CoV and MERS-CoV.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Vaccine Strategy
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Process of Production
         </th>
         <th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          References
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Advantages
         </th>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Disadvantages
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          MERS
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Inactivated virus vaccines
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Virus particles are inactivated by heat, chemicals, or radiation
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Whole virus, with or without adjuvant (promote an effective immune response against the inactivated pathogen) [
          <xref ref-type="bibr" rid="B93-viruses-11-00059">
           93
          </xref>
          ,
          <xref ref-type="bibr" rid="B94-viruses-11-00059">
           94
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Whole virus, with or without adjuvant (promote an effective immune response against the inactivated pathogen) [
          <xref ref-type="bibr" rid="B91-viruses-11-00059">
           91
          </xref>
          ,
          <xref ref-type="bibr" rid="B95-viruses-11-00059">
           95
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Maintained virus particles structure; rapidly develop; easy to prepare; safety; high-titer neutralizing antibodies [
          <xref ref-type="bibr" rid="B93-viruses-11-00059">
           93
          </xref>
          ]; protection with adjuvant [
          <xref ref-type="bibr" rid="B96-viruses-11-00059">
           96
          </xref>
          ,
          <xref ref-type="bibr" rid="B97-viruses-11-00059">
           97
          </xref>
          ].
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Potential inappropriate for highly immunosuppressed individuals; possible T
          <sub>
           H
          </sub>
          2 cell-distortive immune response [
          <xref ref-type="bibr" rid="B98-viruses-11-00059">
           98
          </xref>
          ,
          <xref ref-type="bibr" rid="B99-viruses-11-00059">
           99
          </xref>
          ].
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Live-attenuated virus vaccines
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Attenuated the virulence, but still keeping it viable by mutagenesis or targeted deletions
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Envelope protein deletion [
          <xref ref-type="bibr" rid="B100-viruses-11-00059">
           100
          </xref>
          ]; non-structural protein 14 (nsp14) and exonuclease (ExoN) inactivation [
          <xref ref-type="bibr" rid="B101-viruses-11-00059">
           101
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Full-length infectious cDNA clone or mutant viruses [
          <xref ref-type="bibr" rid="B102-viruses-11-00059">
           102
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Inexpensive; quick immunity; less adverse effect; activates all phases of the immune system [
          <xref ref-type="bibr" rid="B103-viruses-11-00059">
           103
          </xref>
          ]; more durable immunity; more targeted [
          <xref ref-type="bibr" rid="B77-viruses-11-00059">
           77
          </xref>
          ].
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Phenotypic or genotypic reversion possible; need sufficient viral replication [
          <xref ref-type="bibr" rid="B77-viruses-11-00059">
           77
          </xref>
          ].
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Viral vector vaccines
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Genetically engineered unrelated viral genome with deficient packaging elements for encoding targeted gene
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B100-viruses-11-00059">
           100
          </xref>
          ,
          <xref ref-type="bibr" rid="B104-viruses-11-00059">
           104
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B87-viruses-11-00059">
           87
          </xref>
          ,
          <xref ref-type="bibr" rid="B88-viruses-11-00059">
           88
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Safety; stronger and specific cellular and humoral immune responses [
          <xref ref-type="bibr" rid="B77-viruses-11-00059">
           77
          </xref>
          ].
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Varies inoculation routes may produce different immune responses [
          <xref ref-type="bibr" rid="B96-viruses-11-00059">
           96
          </xref>
          ]; possibly incomplete protection; may fail in aged vaccinees; possible T
          <sub>
           H
          </sub>
          2 cell-distortive immune response [
          <xref ref-type="bibr" rid="B105-viruses-11-00059">
           105
          </xref>
          ].
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Subunit vaccines
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Antigenic components inducing the immune system without introducing viral particles, whole or otherwise.
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B53-viruses-11-00059">
           53
          </xref>
          ,
          <xref ref-type="bibr" rid="B59-viruses-11-00059">
           59
          </xref>
          ,
          <xref ref-type="bibr" rid="B106-viruses-11-00059">
           106
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B85-viruses-11-00059">
           85
          </xref>
          ,
          <xref ref-type="bibr" rid="B86-viruses-11-00059">
           86
          </xref>
          ,
          <xref ref-type="bibr" rid="B107-viruses-11-00059">
           107
          </xref>
          ,
          <xref ref-type="bibr" rid="B108-viruses-11-00059">
           108
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          High safety; consistent production; can induce cellular and humoral immune responses; high-titer neutralizing antibodies [
          <xref ref-type="bibr" rid="B109-viruses-11-00059">
           109
          </xref>
          ].
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Uncertain cost-effectiveness; relatively lower immunogenicity; need appropriate adjuvants [
          <xref ref-type="bibr" rid="B77-viruses-11-00059">
           77
          </xref>
          ].
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          DNA vaccines
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Genetically engineered DNA for directly producing an antigen
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B110-viruses-11-00059">
           110
          </xref>
          ,
          <xref ref-type="bibr" rid="B111-viruses-11-00059">
           111
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Spike and nucleocapsid proteins [
          <xref ref-type="bibr" rid="B89-viruses-11-00059">
           89
          </xref>
          ,
          <xref ref-type="bibr" rid="B90-viruses-11-00059">
           90
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Easier to design; high safety; high-titer neutralizing antibodies [
          <xref ref-type="bibr" rid="B110-viruses-11-00059">
           110
          </xref>
          ].
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Lower immune responses; potential T
          <sub>
           H
          </sub>
          2 cell-distortive immune response results; potential ineffective; possibly delayed-type hypersensitivity [
          <xref ref-type="bibr" rid="B112-viruses-11-00059">
           112
          </xref>
          ].
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <table-wrap id="viruses-11-00059-t004" orientation="portrait" position="float">
      <object-id pub-id-type="pii">
       viruses-11-00059-t004_Table 4
      </object-id>
      <label>
       Table 4
      </label>
      <caption>
       <p>
        Potential therapeutics for severe acute respiratory syndrome (SARS) and MERS.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Treatment
         </th>
         <th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">
          Stage of Development
         </th>
        </tr>
        <tr>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          SARS (Notes)
         </th>
         <th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          MERS (Notes)
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Host protease inhibitors
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in mouse models [
          <xref ref-type="bibr" rid="B138-viruses-11-00059">
           138
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          In vitro inhibition [
          <xref ref-type="bibr" rid="B138-viruses-11-00059">
           138
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Viral protease inhibitors
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          In vitro inhibition [
          <xref ref-type="bibr" rid="B139-viruses-11-00059">
           139
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          In vitro inhibition [
          <xref ref-type="bibr" rid="B140-viruses-11-00059">
           140
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Monoclonal and polyclonal antibodies
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in mouse, ferrets, golden Syrian hamster [
          <xref ref-type="bibr" rid="B124-viruses-11-00059">
           124
          </xref>
          ,
          <xref ref-type="bibr" rid="B141-viruses-11-00059">
           141
          </xref>
          ,
          <xref ref-type="bibr" rid="B142-viruses-11-00059">
           142
          </xref>
          ] and non-human primate models [
          <xref ref-type="bibr" rid="B143-viruses-11-00059">
           143
          </xref>
          ,
          <xref ref-type="bibr" rid="B144-viruses-11-00059">
           144
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in mouse, rabbit, and non-human primate models [
          <xref ref-type="bibr" rid="B10-viruses-11-00059">
           10
          </xref>
          ,
          <xref ref-type="bibr" rid="B145-viruses-11-00059">
           145
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Convalescent plasma
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Off-label use in patients [
          <xref ref-type="bibr" rid="B146-viruses-11-00059">
           146
          </xref>
          ,
          <xref ref-type="bibr" rid="B147-viruses-11-00059">
           147
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in a mouse model; clinical trial approved [
          <xref ref-type="bibr" rid="B10-viruses-11-00059">
           10
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Interferons
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Off-label use in patients (often in combination with immunoglobulins or thymosins) [
          <xref ref-type="bibr" rid="B146-viruses-11-00059">
           146
          </xref>
          ,
          <xref ref-type="bibr" rid="B147-viruses-11-00059">
           147
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in non-human primate models; off-label use in patients (often in combination with a broad-spectrum antibiotic and oxygen) [
          <xref ref-type="bibr" rid="B10-viruses-11-00059">
           10
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Ribavirin
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Off-label use in patients (often in combination with corticosteroids) [
          <xref ref-type="bibr" rid="B146-viruses-11-00059">
           146
          </xref>
          ,
          <xref ref-type="bibr" rid="B147-viruses-11-00059">
           147
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in a non-human primate model; off-label use in patients (often in combination with a broad-spectrum antibiotic and oxygen) [
          <xref ref-type="bibr" rid="B10-viruses-11-00059">
           10
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Lopinavir and ritonavir
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Off-label use in patients (improved the outcome in combination with ribavirin) [
          <xref ref-type="bibr" rid="B146-viruses-11-00059">
           146
          </xref>
          ,
          <xref ref-type="bibr" rid="B147-viruses-11-00059">
           147
          </xref>
          ]
         </td>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          Effective in a non-human primate model; off-label use in patients [
          <xref ref-type="bibr" rid="B10-viruses-11-00059">
           10
          </xref>
          ,
          <xref ref-type="bibr" rid="B148-viruses-11-00059">
           148
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
          <bold>
           Common Feature
          </bold>
         </td>
         <td align="center" colspan="2" rowspan="1" style="border-bottom:solid thin" valign="middle">
          None of these therapeutic agents are approved for commercial use in humans
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="research-article" xml:lang="fr" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Arch Pediatr
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Arch Pediatr
      </journal-id>
      <journal-title-group>
       <journal-title>
        Archives De Pediatrie
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0929-693X
      </issn>
      <issn pub-type="epub">
       1769-664X
      </issn>
      <publisher>
       <publisher-name>
        Éditions scientifiques et médicales Elsevier SAS.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       11865552
      </article-id>
      <article-id pub-id-type="pmc">
       7126531
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0929-693X(01)00696-0
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/S0929-693X(01)00696-0
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Infections nosocomiales à coronavirus humains chez le nouveau-né
        <xref ref-type="fn" rid="FTR1">
         1Travail financé en partie par la Société française de pédiatrie (bourse de DEA), le ministère de la santé (PHRC 97) et le CCLIN–Ouest. A. Gagneur est boursier de la Société française de pédiatrie.
        </xref>
       </article-title>
       <trans-title-group xml:lang="en">
        <trans-title>
         Nosocomial infection by human coronaviruses in neonates.
        </trans-title>
       </trans-title-group>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gagneur
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="ADR1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Legrand
         </surname>
         <given-names>
          M.C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="ADR2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Picard
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        <xref ref-type="aff" rid="ADR2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Baron
         </surname>
         <given-names>
          R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="ADR3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Talbot
         </surname>
         <given-names>
          P.J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="ADR4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          de Parscau
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        <xref ref-type="aff" rid="ADR1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sizun
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        <email>
         jacques.sizun@chu-brest.fr
        </email>
        <xref ref-type="aff" rid="ADR1">
         1
        </xref>
        <xref ref-type="corresp" rid="COR1">
         *
        </xref>
       </contrib>
      </contrib-group>
      <aff id="ADR1">
       <label>
        1
       </label>
       Unité de réanimation pédiatrique, département de pédiatrie, CHU, 29609 Brest, France
      </aff>
      <aff id="ADR2">
       <label>
        2
       </label>
       unité de virologie, département de microbiologie, CHU, 29609 Brest, France
      </aff>
      <aff id="ADR3">
       <label>
        3
       </label>
       unité d’hygiène hospitalière, CHU, 29609 Brest, France
      </aff>
      <aff id="ADR4">
       <label>
        4
       </label>
       laboratoire de neuro-immunovirologie, INRS-institut Armand-Frappier, université du Québec, Laval, Québec, Canada
      </aff>
      <author-notes>
       <corresp id="COR1">
        <label>
         *
        </label>
        Correspondance et tirés à part
        <email>
         jacques.sizun@chu-brest.fr
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        15
       </day>
       <month>
        2
       </month>
       <year>
        2002
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        1
       </month>
       <year>
        2002
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        15
       </day>
       <month>
        2
       </month>
       <year>
        2002
       </year>
      </pub-date>
      <volume>
       9
      </volume>
      <issue>
       1
      </issue>
      <fpage>
       61
      </fpage>
      <lpage>
       69
      </lpage>
      <history>
       <date date-type="received">
        <day>
         29
        </day>
        <month>
         1
        </month>
        <year>
         2001
        </year>
       </date>
       <date date-type="accepted">
        <day>
         10
        </day>
        <month>
         9
        </month>
        <year>
         2001
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2002 Éditions scientifiques et médicales Elsevier SAS. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2002
       </copyright-year>
       <copyright-holder>
        Éditions scientifiques et médicales Elsevier SAS
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <title>
        Résumé
       </title>
       <p>
        Les coronavirus humains sont des virus enveloppés à ARN de la famille des
        <italic>
         Coronaviridae
        </italic>
        avec deux sérogroupes identifiés : 229-E et OC-43. Ces virus possèdent le plus grand ARN viral connu. Ce génome est un ARN simple brin positif associé à une protéine phosphorylée de la nucléocapside, la protéine N. L’enveloppe des coronavirus humains contient deux ou trois glycoprotéines membranaires : S ou
        <italic>
         spike protein
        </italic>
        , M ou protéine de membrane et HE ou hémagglutine-estérase. Le rôle pathogène de ces virus est mal connu en raison des difficultés diagnostiques. Cependant la mise au point de l’immunofluorescence avec anticorps monoclonaux et des techniques d’amplification génique permet de nouvelles recherches épidémiologiques. Les coronavirus peuvent survivre jusqu’à six jours en suspension et trois heures après séchage, ce qui suggère un rôle nosocomial potentiel. Deux études prospectives réalisées dans une unité de réanimation néonatale et pédiatrique ont révélé une relation significative entre l’existence de prélèvement nasopharyngés positifs et la survenue de symptômes respiratoires. Des prélèvements positifs chez le personnel suggèrent une contamination patient-personnel ou personnel–patient. En raison de leur survie possible sur les surfaces et de l’efficacité démontrée des agents désinfectants, des mesures universelles de prévention associant lavage des mains et désinfection des surfaces peuvent être proposées.
       </p>
      </abstract>
      <trans-abstract xml:lang="en">
       <p>
        Human coronaviruses, with two known serogroups named 229-E and OC-43, are enveloped positive-stranded RNA viruses. The large RNA is surrounded by a nucleoprotein (protein N). The envelop contains 2 or 3 glycoproteins: spike protein (or protein S), matrix protein (or protein M) and a hemagglutinin (or protein HE). Their pathogen role remains unclear because their isolation is difficult. Reliable and rapid methods as immunofluorescence with monoclonal antibodies and reverse transcription-polymerase chain reaction allow new researches on epidemiology. Human coronaviruses can survive for as long as 6 days in suspension and 3 hours after drying on surfaces, suggesting that they could be a source of hospital-acquired infections. Two prospective studies conducted in a neonatal and paediatric intensive care unit demonstrated a significant association of coronavirus-positive naso-pharyngal samples with respiratory illness in hospitalised preterm neonates. Positive samples from staff suggested either a patient-to-staff or a staff-to-patient transmission. No cross-infection were observed from community-acquired respiratory-syncitial virus or influenza-infected children to neonates. Universal precautions with hand washing and surface desinfection could be proposed to prevent coronavirus transmission.
       </p>
      </trans-abstract>
      <kwd-group>
       <title>
        Mots-clé
       </title>
       <kwd>
        infection nosocomiale
       </kwd>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        nouveau-né
       </kwd>
      </kwd-group>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        cross infection
       </kwd>
       <kwd>
        infant, newborn
       </kwd>
       <kwd>
        coronavirus
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p>
     Les infections nosocomiales représentent un problème important de santé publique en raison de leurs conséquences médicales et économiques. La fréquence des infections d’origine virale est habituellement évaluée à 5 % de l’ensemble des infections nosocomiales, avec un tropisme essentiellement pulmonaire et digestif. Dans les hôpitaux pédiatriques, ces infections virales respiratoires se rencontrent avec prédilection en période épidémique, avec une incidence pouvant atteindre 23 à 35 % des infections nosocomiales
     <xref ref-type="bibr" rid="BIB1">
      1
     </xref>
     ,
     <xref ref-type="bibr" rid="BIB2">
      2
     </xref>
     ,
     <xref ref-type="bibr" rid="BIB3">
      3
     </xref>
     .
    </p>
    <p>
     Les facteurs de risque de survenue d’une infection respiratoire virale sévère sont le jeune âge (inférieur à 3 mois), les antécédents de prématurité, l’existence d’une pathologie chronique respiratoire (dysplasie bronchopulmonaire par exemple) ou cardiaque ou d’un déficit immunitaire. Les nouveau-nés hospitalisés dans les unités de médecine néonatale présentent un ou plusieurs de ces facteurs de risque. Cependant, la fréquence, le type, et les conséquences des infections virales respiratoires survenant dans les unités de néonatalogie sont mal connus. Seules des descriptions ponctuelles d’épidémies sont disponibles dans la littérature
     <xref ref-type="bibr" rid="BIB4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="BIB5">
      5
     </xref>
     .
    </p>
    <p>
     Les agents pathogènes les plus fréquemment incriminés sont le virus respiratoire syncytial (VRS), les virus
     <italic>
      Influenza
     </italic>
     et
     <italic>
      Parainfluenza
     </italic>
     , l’adénovirus et les rhinovirus
     <xref ref-type="bibr" rid="BIB1">
      〚1〛
     </xref>
     . Des recherches récentes évoquent également la responsabilité potentielle des coronavirus humains (HCoV) dans la survenue d’infections virales respiratoires chez le nouveau-né prématuré
     <xref ref-type="bibr" rid="BIB6">
      〚6〛
     </xref>
     . Le pouvoir pathogène réel des HCoV reste cependant mal connu.
    </p>
    <sec>
     <title>
      Virologie
     </title>
     <p>
      Isolés pour la première fois en 1965–1967
      <xref ref-type="bibr" rid="BIB7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB9">
       9
      </xref>
      chez des patients atteints de rhinite, les coronavirus humains sont des virus enveloppés à ARN de la famille des
      <italic>
       Coronaviridae
      </italic>
      , leur appartenance aux
      <italic>
       Coronaviridae
      </italic>
      étant basée sur leur morphologie, l’organisation de leur génome (homologie des séquences nucléotidiques et propriétés des protéines structurales), et leur stratégie de réplication et de maturation. Il existe de nombreux coronavirus animaux bien connus en médecine vétérinaire (
      <italic>
       bovine coronavirus, feline enteric coronavirus
      </italic>
      ,
      <italic>
       mouse hepatitis virus
      </italic>
      …)
      <xref ref-type="bibr" rid="BIB10">
       〚10〛
      </xref>
      . Seuls deux sérogroupes humains ont été identifiés : 229-E
      <xref ref-type="bibr" rid="BIB8">
       〚8〛
      </xref>
      et OC-43
      <xref ref-type="bibr" rid="BIB9">
       〚9〛
      </xref>
      .
     </p>
     <p>
      Les HCoV ont un aspect arrondi de 100 à 160 nm de diamètre, avec en surface des péplomères d’une longueur de 20 nm en forme de massue correspondant à des glycoprotéines de surface (telle que la glycoprotéine S). Ces péplomères sont à l’origine de l’aspect caractéristique en couronne noté en microscopie électronique
      <xref ref-type="fig" rid="FIG1">
       (figure 1)
      </xref>
      . Les HCoV possèdent le plus grand ARN viral connu, d’une taille de 27 à 32 kb ; ce génome est un ARN simple brin positif associé à une protéine phosphorylée de la nucléocapside, la protéine N
      <xref ref-type="bibr" rid="BIB10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB11">
       11
      </xref>
      . Leur enveloppe contient deux ou trois glycoprotéines membranaires
      <xref ref-type="fig" rid="FIG2">
       (figure 2)
      </xref>
      : S, M et HE, cette dernière étant spécifique du sérogroupe II (dont le HCoV OC-43). La protéine S ou
      <italic>
       spike protein
      </italic>
      est une protéine multifonctionnelle jouant un rôle complexe dans la pathogénie des infections à coronavirus : liaison à des récepteurs cellulaires spécifiques de la cellule hôte, fusion de l’enveloppe virale et de la membrane cellulaire, induction de la production d’anticorps neutralisants. La protéine de membrane ou protéine M possède un domaine cytoplasmique qui interagirait avec la nucléocapside virale
      <xref ref-type="bibr" rid="BIB12">
       〚12〛
      </xref>
      .
      <fig id="FIG1">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Aspect du coronavirus humain OC43 en microscopie électronique (cliché P.J. Talbot, INRS-Institut Armand-Frappier, Canada).
        </p>
       </caption>
       <graphic xlink:href="fx1">
       </graphic>
      </fig>
      <fig id="FIG2">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Structure des coronavirus. N : protéine de la nucléocapside. Glycoprotéines membranaires : S :
         <italic>
          spike protein
         </italic>
         ou protéine de surface ; M : protéine de membrane ; E : petite protéine d’enveloppe ; HE : hémagglutine-estérase.
        </p>
       </caption>
       <graphic xlink:href="fx2">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec>
     <title>
      Méthodes diagnostiques
     </title>
     <p>
      Si certaines souches de HCoV sélectionnées en laboratoire peuvent être cultivées sur des lignées cellulaires spécifiques (
      <italic>
       human embryonic lung fibroblast
      </italic>
      L132,
      <italic>
       human rectal tumor
      </italic>
      HRT-18), en revanche la culture n’est pas possible sur les lignées cellulaires utilisées en routine pour le diagnostic des infections respiratoires virales
      <xref ref-type="bibr" rid="BIB10">
       〚10〛
      </xref>
      . Les techniques sérologiques, principalement basées sur l’Elisa, ont été utilisées dans des études pédiatriques déjà anciennes
      <xref ref-type="bibr" rid="BIB13">
       〚13〛
      </xref>
      . Cependant, ces méthodes manquent de sensibilité et sont peu utiles pour le diagnostic d’infections respiratoires car nécessitant deux prélèvements sanguins successifs.
     </p>
     <p>
      L’immunofluorescence est la méthode de référence pour le diagnostic des infections virales respiratoires en raison de sa simplicité, de sa rapidité et de son coût. Mettant en évidence les particules virales dans la cellule du tractus respiratoire, elle permet de s’assurer de la réalité de l’infection. Le seul anticorps monoclonal commercialisé (Argène, France) ne reconnaît que le groupe sérologique 229-E et n’est plus actuellement disponible. Sa sensibilité n’est pas précisée par le fabricant. La sensibilité et la spécificité de deux anticorps monoclonaux (5-11H6 pour 229-E et 1-10C1 pour OC-43) produits par hybridome au Centre de recherche INRS-Armand-Frappier (Laval, Québec) ont été testées sur un modèle expérimental d’infection cellulaire. Ils reconnaissent la protéine S de chaque sérogroupe considéré, et permettent la détection du virus en culture cellulaire pour une multiplicité d’infection (MOI) de 10
      <sup>
       -2
      </sup>
      soit un titre infectieux en culture cellulaire (TCID 50/mL) de 10
      <sup>
       -4,25
      </sup>
      pour 229-E et 10
      <sup>
       -2
      </sup>
      pour OC-43
      <xref ref-type="fig" rid="FIG3">
       (figure 3)
      </xref>
      . Chacun de ces deux anticorps monoclonaux est spécifique du sérogroupe considéré et ne présente pas de faux positif pour les virus
      <italic>
       influenza
      </italic>
      , VRS et adénovirus
      <xref ref-type="bibr" rid="BIB14">
       〚14〛
      </xref>
      .
      <fig id="FIG3">
       <label>
        Figure 3
       </label>
       <caption>
        <p>
         HCoV 229-E en immunofluorescence après culture sur lignées L132 (× 250). Cliché M.C. Legrand, virologie, Brest.
        </p>
       </caption>
       <graphic xlink:href="fx3">
       </graphic>
      </fig>
     </p>
     <p>
      La microscopie électronique a été utilisée essentiellement pour l’étude des particules coronaviriformes
      <italic>
       (coronavirus-like particles)
      </italic>
      dans les prélèvements digestifs. De réalisation délicate, elle ne peut être utilisée en routine pour l’analyse de prélèvements d’origine respiratoire.
     </p>
     <p>
      Les techniques de biologie moléculaire apparaissent prometteuses pour l’étude des agents pathogènes difficiles à mettre en évidence par les techniques usuelles tant en recherche fondamentale
      <xref ref-type="bibr" rid="BIB15">
       〚15〛
      </xref>
      que clinique
      <xref ref-type="bibr" rid="BIB16">
       〚16〛
      </xref>
      . L’amplification de l’ARN par les techniques de RT-PCR permet ainsi la détection du génome viral en culture cellulaire pour une multiplicité d’infection (MOI) de 10
      <sup>
       -4
      </sup>
      soit un titre infectieux en culture cellulaire (TCID50/mL) de 1,75 pour 229-E et 1,5 pour OC-43 (log PFU/mL = 2,3 pour HCoV 229-E et 1,34 pour OC-43) avec une bonne spécificité de groupe
      <xref ref-type="bibr" rid="BIB14">
       〚14〛
      </xref>
      .
     </p>
     <p>
      Il reste que la mise en évidence de matériel génomique viral dans un prélèvement de sécrétions respiratoires pose le difficile problème d’un lien de causalité avec des signes d’infection pulmonaire
      <xref ref-type="bibr" rid="BIB16">
       〚16〛
      </xref>
      .
     </p>
    </sec>
    <sec>
     <title>
      Épidémiologie
     </title>
     <p>
      La majorité des études épidémiologiques concernant les HCoV sont basées sur la sérologie, et montrent la présence d’anticorps spécifique chez près de 100 % des adultes de plus de 30 ans, la prévalence variant cependant selon les pays et les techniques sérologiques utilisées
      <xref ref-type="bibr" rid="BIB17">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB18">
       18
      </xref>
      . Dans une étude de bassin de population réalisée en 1968–1969, Monto et al. rapportent une incidence d’infection récente de 29 % chez l’enfant âgé de moins de quatre ans, incidence diminuant progressivement avec l’âge (22 % chez l’adulte)
      <xref ref-type="bibr" rid="BIB19">
       〚19〛
      </xref>
      . Les infections à HCoV surviennent essentiellement pendant l’hiver et le printemps, avec des variations de sérotypes suivant les années ce qui justifie la réalisation d’études longitudinales pluriannuelles. Les techniques sérologiques manquant de sensibilité, il est probable que la prévalence des infections à HCoV est sous-estimée
      <xref ref-type="bibr" rid="BIB20">
       〚20〛
      </xref>
      . L’absence de réactifs commerciaux ne fait qu’amplifier cette situation.
     </p>
    </sec>
    <sec>
     <title>
      Pouvoir pathogène chez l’enfant
     </title>
     <p>
      Le pouvoir pathogène réel des HCoV est mal connu en raison des difficultés diagnostiques. D’autre part, la majorité des études publiées présentent des biais de recrutement importants. L’évaluation du rôle pathogène d’un agent infectieux repose sur des études en cohorte ou des comparaisons avec des groupes témoins
      <xref ref-type="bibr" rid="BIB21">
       〚21〛
      </xref>
      . Dans une évaluation systématique de la littérature réalisée en 1999 selon la méthodologie préconisée par l’Agence nationale d’accréditation et d’évaluation en santé (ANAES), aucune étude pédiatrique publiée entre 1966 et 1999 ne présentait un niveau de preuve de grade III
      <xref ref-type="bibr" rid="BIB22">
       〚22〛
      </xref>
      . Aucune de ces études ne permet d’affirmer la responsabilité des HCoV dans les pathologies observées, soit du fait de limites méthodologiques (études rétrospectives, absence de groupe témoins), soit par manque de puissance. Enfin la fréquence potentielle des coinfections virales rend difficile l’établissement du lien entre un agent pathogène et la survenue d’une maladie
      <xref ref-type="bibr" rid="BIB23">
       〚23〛
      </xref>
      .
     </p>
     <p>
      Le tropisme des HCoV est essentiellement respiratoire. Leur rôle dans la survenue d’une rhinite a été évoqué par leur mise en évidence dans les sécrétions nasales de sujets malades
      <xref ref-type="bibr" rid="BIB5">
       〚5〛
      </xref>
      et confirmé expérimentalement par inoculation intranasale chez des volontaires sains
      <xref ref-type="bibr" rid="BIB20">
       〚20〛
      </xref>
      . En revanche, leur responsabilité dans la survenue d’une infection respiratoire basse est moins bien documentée, les résultats des différentes études publiées étant contradictoires. Dans une étude réalisée par immunofluorescence dans la région lyonnaise pendant l’hiver 1994–1995, Lina et al. ont mis en évidence une prévalence des infections communautaires à HCoV de 18,4 % chez les sujets consultant pour syndrome grippal ; la prévalence chez des sujets témoins asymptomatique n’a cependant pas été précisée
      <xref ref-type="bibr" rid="BIB24">
       〚24〛
      </xref>
      . Le rôle déclenchant des infections respiratoires à HCoV dans la survenue d’une crise d’asthme ou d’une bronchite avec
      <italic>
       wheezing
      </italic>
      est diversement évalué selon les conditions d’inclusion (âge, type de recrutement, antécédents des patients) et les techniques virologiques utilisées
      <xref ref-type="bibr" rid="BIB25">
       25
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB26">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB27">
       27
      </xref>
      . Le taux élevé de co-infections (20 % dans l’étude de Freymuth et al.)
      <xref ref-type="bibr" rid="BIB26">
       〚26〛
      </xref>
      ne permet pas de conclure de façon certaine à la responsabilité des HCoV. Le mécanisme d’atteinte respiratoire pourrait être, non pas une infection directe de l’arbre bronchique, mais une réaction en cascade impliquant les médiateurs de l’inflammation (cytokines…) comme cela a été évoqué pour le rhinovirus
      <xref ref-type="bibr" rid="BIB28">
       〚28〛
      </xref>
      . Une étude a mis en évidence des HCoV par PCR sur produit de paracentèse chez des enfants atteints d’otite moyenne aiguë
      <xref ref-type="bibr" rid="BIB29">
       〚29〛
      </xref>
      ; aucune population témoin n’était cependant décrite.
     </p>
     <p>
      Le tropisme digestif des HCoV a été essentiellement exploré par microscopie électronique, permettant la mise en évidence des particules virales
      <italic>
       Corona-like
      </italic>
      . Une étude a démontré l’isolement d’un coronavirus entérique
      <xref ref-type="bibr" rid="BIB30">
       〚30〛
      </xref>
      . Le lien entre gastroentérite de l’enfant et HCoV est contesté, en raison de la fréquence importante des prélèvements positifs dans la population saine
      <xref ref-type="bibr" rid="BIB31">
       〚31〛
      </xref>
      . Des observations isolées de pancréatite et de péricardites ont également été rapportées
      <xref ref-type="bibr" rid="BIB32">
       〚32〛
      </xref>
      . La relation entre entérocolite du nouveau-né et HCoV est analysée plus loin.
     </p>
     <p>
      Les coronavirus présenteraient également un tropisme neurologique évoqué par des résultats de recherche clinique (mise en évidence de matériel génomique viral dans le cerveau de patient atteint de sclérose en plaque) et expérimentale (infectabilité de lignées cellulaires cérébrales humaines par les HCoV)
      <xref ref-type="bibr" rid="BIB33">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB34">
       34
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB35">
       35
      </xref>
      . Aucune donnée n’est cependant disponible chez l’enfant à l’exception d’observations isolées de méningite et de radiculite
      <xref ref-type="bibr" rid="BIB32">
       〚32〛
      </xref>
      .
     </p>
    </sec>
    <sec>
     <title>
      Mode de transmission et porte d’entrée
     </title>
     <p>
      Les virus à tropisme respiratoire sont classiquement transmis selon trois mécanismes parfois associés : aérosols de particules aériennes de diamètre inférieur à 5 μ pouvant diffuser à distance (virus influenza), aérosols de particules aériennes de plus grande taille dont la transmission nécessite un contact étroit (VRS), transmission directe par les mains ou par l’intermédiaire de surfaces
      <xref ref-type="bibr" rid="BIB36">
       〚36〛
      </xref>
      . Ijaz et al ont démontré la possibilité d’une survie des HCoV 229-E en aérosol pendant 86 heures sous certaines conditions d’hygrométrie et de température
      <xref ref-type="bibr" rid="BIB37">
       〚37〛
      </xref>
      . Expérimentalement, les HCoV 229-E et OC-43 en suspension peuvent survivre à température ambiante jusqu’à 6 jours, avec une demi-vie de 5 jours dans le tampon PBS et deux à trois jours dans un milieu de culture. La survie après séchage sur une surface (compresse, gant chirurgical ou aluminium) est plus courte mais la contagiosité du 229-E est détectable pendant une période de 3 heures
      <xref ref-type="bibr" rid="BIB38">
       〚38〛
      </xref>
      . La survie possible des HCoV en aérosol et en suspension plaide en faveur de la possibilité de transmission par particules aériennes et/ou par voie manuportée.
     </p>
     <p>
      La porte d’entrée des HCoV dans l’organisme est nasale
      <xref ref-type="bibr" rid="BIB20">
       〚20〛
      </xref>
      . Leur contamination par voie conjonctivale, démontrée pour le VRS, n’a pas été documentée.
     </p>
    </sec>
    <sec>
     <title>
      Les coronavirus, agents d’infections nosocomiales ?
     </title>
     <sec>
      <title>
       Travaux personnels
      </title>
      <sec>
       <title>
        Observations d’apnées sévères du prématuré associées à une colonisation nasale par HCoV
       </title>
       <p>
        En 1991, nous avons rapporté quatre cas d’infections respiratoires à HCoV chez des nouveau-nés prématurés hospitalisés en unité de réanimation pédiatrique polyvalente
        <xref ref-type="bibr" rid="BIB39">
         〚39〛
        </xref>
        . Ces enfants présentaient des épisodes d’apnées sévères, de survenue brutale, résistant aux méthylxanthines, associés à des bradycardies, sans cause neurologique, digestive, ou cardiaque. Une ventilation assistée a été nécessaire dans deux cas. L’évolution a été spontanément favorable sous dix jours. Les prélèvements bactériologiques étaient négatifs. L’analyse des sécrétions nasopharyngées par immunofluorescence était négative pour l’adénovirus, le VRS et les virus
        <italic>
         Influenza
        </italic>
        et
        <italic>
         Parainfluenza
        </italic>
        , mais positive pour le HCoV 229-E (anticorps monoclonal Biosoft, Clonatec).
       </p>
      </sec>
      <sec>
       <title>
        Étude prospective chez les nouveau-nés en unité de réanimation
       </title>
       <p>
        Ceci nous a conduit à réaliser une étude prospective dans la même unité de réanimation sur une période de 18 mois comprenant deux hivers
        <xref ref-type="bibr" rid="BIB40">
         〚40〛
        </xref>
        , chez les nouveau-nés d’âge gestationnel inférieur ou égal à 32 semaines et admis dans l’unité avant l’âge de trois jours. Un prélèvement nasal était fait par aspiration à l’admission puis de façon hebdomadaire. Les prélèvements étaient analysés par immunofluorescence indirecte avec une série d’anticorps monoclonaux (Clonatec, France) spécifiques des virus influenza A et B,
        <italic>
         Parainfluenza
        </italic>
        1, 2 et 3, adénovirus, VRS et HCoV 229-E. Quarante enfants ont été inclus. Treize prélèvements se sont révélés positifs chez dix nouveau-nés : dix pour le HCoV 229-E, 2 pour le virus
        <italic>
         Influenza
        </italic>
        type A et un pour l’adénovirus. Aucun prélèvement n’était positif à l’admission. Tous les enfants infectés par le HCoV 229-E étaient symptomatiques à la date d’infection, avec une symptomatologie dominée par les apnées, les bradycardies et une distension abdominale. Le nombre de jours d’hospitalisation avec apnées, avec bradycardie, et avec oxygène, était plus important chez les enfants infectés par HCoV comparés aux enfants non infectés, sans que toutefois la différence soit statistiquement significative, peut être en raison de la petite taille des groupes ou de la dispersion des valeurs.
       </p>
      </sec>
      <sec>
       <title>
        Étude de l’incidence des infections nosocomiales et communautaires à HCoV en unité de réanimation
       </title>
       <p>
        L’infection nosocomiale symptomatique par HCoV semblait donc possible et non exceptionnelle. Cependant plusieurs points restaient à explorer :
       </p>
       <p>
        <list list-type="simple">
         <list-item>
          <label>
           •
          </label>
          <p>
           ces résultats pouvaient-ils être confirmés par l’utilisation d’autres techniques diagnostiques notamment de PCR ?
          </p>
         </list-item>
         <list-item>
          <label>
           •
          </label>
          <p>
           Ces virus étaient-ils introduits dans l’unité de réanimation polyvalente par les personnels soignants ou par les nourrissons ou les enfants hospitalisés ?
          </p>
         </list-item>
         <list-item>
          <label>
           •
          </label>
          <p>
           L’épidémiologie était-elle variable en fonction des années ? Pour répondre à ces questions, nous avons entrepris à partir de novembre 1997 une nouvelle étude prospective. L’objectif était de déterminer l’incidence des infections nosocomiales et communautaires à HCoV chez les nouveau-nés (définis par un âge inférieur ou égal à 28 jours) et les enfants (âge &gt; 28 jours) hospitalisés dans l’unité de réanimation, ainsi que la prévalence des infections respiratoires chez le personnel soignant. Tous les patients hospitalisés dans l’unité pendant l’hiver 1997–1998 (décembre 1997 à avril 1998) ont été inclus. Les prélèvements nasals faits à l’admission et de façon hebdomadaire ont été analysés par culture virale et immunofluorescence indirecte. Les cultures virales ont été réalisées sur lignées cellulaires MDCK, HEp-2 et MRC5, avec lecture de j2 à j10 suivant les lignées par immunofluorescence ou par recherche d’effet cytopathique. L’immunofluorescence a été réalisée avec les anticorps monoclonaux spécifiques pour les virus VRS, virus
           <italic>
            Influenza
           </italic>
           type A et B,
           <italic>
            Parainfluenza
           </italic>
           type 1, 2 et 3, et adénovirus (Argène, France), et avec des anticorps commerciaux (Argène, France) et les anticorps 5-11H6 pour 229-E et 1-10C1 pour OC-43 du Centre de recherche INRS-Armand-Frappier (Laval, Québec, Canada pour les HCoV)
           <xref ref-type="bibr" rid="BIB14">
            〚14〛
           </xref>
           . Une infection communautaire était définie par un prélèvement positif à l’admission, et une infection nosocomiale par un prélèvement négatif à l’admission et positif ultérieurement. Des prélèvements nasals ont été réalisés chez le personnel médical et infirmier un jour par mois (point de prévalence) et analysés de façon anonyme.
          </p>
         </list-item>
        </list>
       </p>
       <p>
        Durant le premier hiver, 120 patients ont été inclus : 64 nouveau-nés et 56 enfants (âge moyen : 3,8 ans ;
        <italic>
         sex-ratio
        </italic>
        M/F : 1,6). Chez les 56 enfants, aucun cas d’infection virale nosocomiale n’a été mis en évidence. Par contre 15 prélèvements chez 13 enfants (deux coinfections) étaient positifs à l’admission, témoin d’une infection communautaire (incidence : 23 %) : sept VRS, cinq
        <italic>
         Influenza
        </italic>
        , et trois adénovirus
        <xref ref-type="fig" rid="FIG4">
         (figure 4)
        </xref>
        . Chez les nouveau-nés, sept prélèvements ont été positifs durant l’hospitalisation, tous pour le HCoV (incidence des infections nosocomiales à HCoV chez les nouveau-nés : 11 %). Les nouveau-nés étaient tous symptomatiques au moment de l’infection (bradycardies, apnées ou augmentation des besoins en oxygène). Les facteurs de risque d’infection virale nosocomiale, en analyse univariée, étaient les durées d’hospitalisation, de traitement antibiotique, et de nutrition parentérale
        <xref ref-type="table" rid="TABI">
         (tableau I)
        </xref>
        .
        <fig id="FIG4">
         <label>
          Figure 4
         </label>
         <caption>
          <p>
           Répartition mensuelle du nombre de virus détectés chez les nouveau-nés (infections nosocomiales à HCcoV : colonnes noires), chez les enfants (infections communautaires à VRS, influenza et adénovirus : colonnes grises), et chez le personnel (infections à HCoV sauf le mois d’avril avec une infection grippale et une infection à HCoV : colonnes blanches). Il n’est pas trouvé de transmission croisée entre les infections communautaires chez les enfants et les infections nosocomiales chez les nouveau-nés. Par contre, à l’exception du mois de février (fév), des infections à HCoV sont détectées chez le personnel et les nouveau-nés en décembre (déc), janvier (jan), mars (mar), et avril (avr).
          </p>
         </caption>
         <graphic xlink:href="fx4">
         </graphic>
        </fig>
        <table-wrap id="TABI" position="float">
         <label>
          Tableau I
         </label>
         <caption>
          <p>
           Facteurs de risque d’IRVN à HCoV chez les nouveau-nés.
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <thead>
           <tr>
            <th>
            </th>
            <th>
             <italic>
              HCoV+ (n = 7)
             </italic>
            </th>
            <th>
             <italic>
              HCoV- (n = 57)
             </italic>
            </th>
            <th>
             <italic>
              p
             </italic>
            </th>
           </tr>
          </thead>
          <tbody>
           <tr>
            <td>
             Age gestationnel (SA)
            </td>
            <td>
             32,8 ± 6,1
            </td>
            <td>
             33,9 ± 4,2
            </td>
            <td>
             ns
            </td>
           </tr>
           <tr>
            <td>
             Poids de naissance (g)
            </td>
            <td>
             1895 ± 1320
            </td>
            <td>
             2164 ± 920
            </td>
            <td>
             ns
            </td>
           </tr>
           <tr>
            <td>
             Durée de ventilation (j)
            </td>
            <td>
             9,1 ± 7,9
            </td>
            <td>
             4,9 ± 10,2
            </td>
            <td>
             0,052
            </td>
           </tr>
           <tr>
            <td>
             Durée d’oxygénation (j)
            </td>
            <td>
             14 ± 13,4
            </td>
            <td>
             7 ± 15,9
            </td>
            <td>
             ns
            </td>
           </tr>
           <tr>
            <td>
             Durée de cathéter central (j)
            </td>
            <td>
             23,8 ± 23,8
            </td>
            <td>
             9,1 ± 15,7
            </td>
            <td>
             &lt; 0,01
            </td>
           </tr>
           <tr>
            <td>
             Durée de nutrition parentérale (j)
            </td>
            <td>
             26 ± 24,6
            </td>
            <td>
             11,5 ± 17,5
            </td>
            <td>
             &lt; 0,01
            </td>
           </tr>
           <tr>
            <td>
             Durée d’antibiothérapie (j)
            </td>
            <td>
             17,9 ± 15,7
            </td>
            <td>
             5,1 ± 6,5
            </td>
            <td>
             &lt; 0,001
            </td>
           </tr>
           <tr>
            <td>
             Durée d’hospitalisation (j)
            </td>
            <td>
             27,1 ± 24,4
            </td>
            <td>
             12,8 ± 17,8
            </td>
            <td>
             &lt; 0,01
            </td>
           </tr>
          </tbody>
         </table>
         <table-wrap-foot>
          <fn>
           <p>
            ns : non significatif ; SA : semaines d’aménorrhée.
           </p>
          </fn>
         </table-wrap-foot>
        </table-wrap>
       </p>
       <p>
        Chez le personnel, cinq points de prévalence ont été réalisés, incluant 19 à 24 soignants selon les mois. Un ou deux prélèvements ont été positifs à HCoV chaque mois, sauf le dernier mois de l’étude avec un prélèvement positif à
        <italic>
         Influenza
        </italic>
        également
        <xref ref-type="bibr" rid="BIB41">
         〚41〛
        </xref>
        .
       </p>
       <p>
        Les conclusions de l’analyse des premiers mois de cette étude sont les suivantes :
       </p>
       <p>
        <list list-type="simple">
         <list-item>
          <label>
           •
          </label>
          <p>
           les infections respiratoires d’origine communautaire sont fréquentes chez les enfants hospitalisés en unité de réanimation, quel que soit le motif d’hospitalisation
           <xref ref-type="bibr" rid="BIB42">
            〚42〛
           </xref>
           . Cependant, les virus incriminés, en particulier le VRS, ne paraissent pas transmis aux nouveau-nés hospitalisés dans la même unité ;
          </p>
         </list-item>
         <list-item>
          <label>
           •
          </label>
          <p>
           les infections des voies aériennes respiratoires par HCoV semblent fréquentes et sont généralement asymptomatiques chez le personnel soignant.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       La réalité des infections nosocomiales par ces HCoV semble confirmée
      </title>
      <p>
       Les prélèvements réalisés pendant les hivers 1998 et 1999 sont en cours d’analyse, notamment par de nouvelles techniques de RT-PCR. Ceci permettra également de mieux appréhender les variations épidémiologiques inter annuelles.
      </p>
     </sec>
     <sec>
      <title>
       Données de la littérature
      </title>
      <p>
       La responsabilité des HCoV dans la survenue d’infections nosocomiales digestives ou respiratoires chez l’enfant ou l’adulte a été rapportée par d’autres auteurs. Chez le nouveau-né, des particules virales coronaviriformes ont été mises en évidence par microscopie électronique chez des enfants présentant des diarrhées aiguës ainsi que chez des nouveau-nés à terme atteint d’entérocolite ulcéronécrosante
       <xref ref-type="bibr" rid="BIB43">
        〚43〛
       </xref>
       . Vabret et al. ont trouvé 17 prélèvements positifs à HCoV 229-E dans l’analyse par immunofluorescence de 107 échantillons de lavages bronchoalvéolaires réalisés chez des sujets immunodéprimés ; l’utilisation de techniques d’amplification génique leur a ensuite permis de détecter la positivité de 7 prélèvements supplémentaires
       <xref ref-type="bibr" rid="BIB44">
        〚44〛
       </xref>
       . Dans une étude prospective concernant des personnes âgées fréquentant un hôpital de jour, le HCoV 229-E apparaît comme un agent nosocomial non négligeable, responsable de 8 % des infections respiratoires
       <xref ref-type="bibr" rid="BIB45">
        〚45〛
       </xref>
       .
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Prévention
     </title>
     <p>
      La connaissance de l’épidémiologie et des voies de transmission permettent de définir des mesures de préventions des infections nosocomiales. La prévention de la transmission des HCoV est identique à celle des VRS dans les services de néonatalogie
      <xref ref-type="bibr" rid="BIB46">
       46
      </xref>
      ,
      <xref ref-type="bibr" rid="BIB47">
       47
      </xref>
      . En raison de leur survie prolongée possible sur différentes surfaces et de l’efficacité des agents antiseptiques habituels (alcool, eau de javel domestique, polyvidone iodée)
      <xref ref-type="bibr" rid="BIB38">
       〚38〛
      </xref>
      , les mesures habituelles de prévention peuvent être proposées : lavage des mains et désinfection des surfaces. L’éviction du personnel soignant atteint d’affection aiguë du tractus respiratoire paraît difficile à mettre en œuvre et d’efficacité limitée en raison de la fréquence des porteurs sains. Le regroupement géographique des enfants atteints en « cohorte » n’a pas été validé.
     </p>
    </sec>
    <sec>
     <title>
      Conclusion
     </title>
     <p>
      Les données fondamentales disponibles et les données épidémiologiques suggèrent que les HCoV sont à l’origine d’infections nosocomiales respiratoires dans les services de néonatalogie. L’utilisation en diagnostic de routine de l’immunofluorescence avec anticorps monoclonaux spécifiques en cas de symptomatologie évocatrice (apnée, bradycardie) pourrait permettre de conforter cette hypothèse.
     </p>
     <p>
      Cependant de nombreux aspects restent mal connus et justifient la réalisation de nouvelles études prospectives. Ces travaux à venir, de préférence multicentriques et pluriannuels, pourront préciser la prévalence et les conséquences à long terme en particulier sur la fonction pulmonaire. Le tropisme digestif, en particulier le lien avec l’entérocolite, méritera également d’être étudié.
     </p>
    </sec>
    <back>
     <ref-list>
      <title>
       Références
      </title>
      <ref id="BIB1">
       <label>
        1
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Nosocomial viral respiratory infections in pediatric patients
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Mayhall
          </surname>
          <given-names>
           C.G
          </given-names>
         </name>
        </person-group>
        <source>
         Hospital epidemiology and infection control
        </source>
        <year>
         1996
        </year>
        <publisher-name>
         Williams and Wilkins
        </publisher-name>
        <publisher-loc>
         Baltimore
        </publisher-loc>
        <fpage>
         485
        </fpage>
        <lpage>
         493
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee Ford-Jones
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Mindorff
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Langley
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Navas
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Patrick
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiologic study of 4 684 hospital-acquired infections in pediatric patients
        </article-title>
        <source>
         Pediatr Infect Dis J
        </source>
        <volume>
         8
        </volume>
        <year>
         1989
        </year>
        <fpage>
         668
        </fpage>
        <lpage>
         675
        </lpage>
        <pub-id pub-id-type="pmid">
         2812911
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB3">
       <label>
        3
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee Ford-Jones
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The special problems of nosocomial infection in the pediatric patient
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Wenzel
          </surname>
          <given-names>
           R.P
          </given-names>
         </name>
        </person-group>
        <source>
         Prevention and control of nosocomial infections
        </source>
        <year>
         1993
        </year>
        <publisher-name>
         Wiliams and Wilkins
        </publisher-name>
        <publisher-loc>
         Baltimore
        </publisher-loc>
        <fpage>
         812
        </fpage>
        <lpage>
         896
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moisiuk
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Robson
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Klass
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Kliewer
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wasyliuk
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Davi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreak of
         <italic>
          Parainfluenza
         </italic>
         virus type 3 in an intermediate care neonatal nursery
        </article-title>
        <source>
         Pediatr Infect Dis J
        </source>
        <volume>
         17
        </volume>
        <year>
         1998
        </year>
        <fpage>
         49
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="pmid">
         9469395
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Valenti
          </surname>
          <given-names>
           W.M.
          </given-names>
         </name>
         <name>
          <surname>
           Clarke
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Menegus
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Shapiro
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Concurrent outbreaks of rhinovirus and respiratory syncytial virus in an intensive care nursery : epidemiology and associated risk factors
        </article-title>
        <source>
         J Pediatr
        </source>
        <volume>
         100
        </volume>
        <year>
         1982
        </year>
        <fpage>
         722
        </fpage>
        <lpage>
         726
        </lpage>
        <pub-id pub-id-type="pmid">
         6279812
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gagneur
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Legrand
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nosocomial viral respiratory tract infections in a NPICU
        </article-title>
        <source>
         Pediatr Crit Care M
        </source>
        <volume>
         17
        </volume>
        <year>
         2000
        </year>
        <fpage>
         16
        </fpage>
        <lpage>
         16
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tyrrell
          </surname>
          <given-names>
           D.A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bynoe
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cultivation of a novel type of common-cold virus in organ cultures
        </article-title>
        <source>
         Br Med J
        </source>
        <volume>
         1
        </volume>
        <year>
         1965
        </year>
        <fpage>
         1467
        </fpage>
        <lpage>
         1470
        </lpage>
        <pub-id pub-id-type="pmid">
         14288084
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamre
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Procknow
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new virus isolated from the human respiratory tract
        </article-title>
        <source>
         Proc Soc Exp Biol M
        </source>
        <volume>
         121
        </volume>
        <year>
         1966
        </year>
        <fpage>
         190
        </fpage>
        <lpage>
         193
        </lpage>
        <pub-id pub-id-type="pmid">
         4285768
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McIntosh
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
         <name>
          <surname>
           Chanock
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Growth in suckling mouse brain of “IBV-like” viruses from patients with upper respiratory tract disease
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <volume>
         58
        </volume>
        <year>
         1967
        </year>
        <fpage>
         2268
        </fpage>
        <lpage>
         2273
        </lpage>
        <pub-id pub-id-type="pmid">
         4298953
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB10">
       <label>
        10
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           M.M.C.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviruses
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Fields
          </surname>
          <given-names>
           B.N
          </given-names>
         </name>
         <name>
          <surname>
           Knipe
          </surname>
          <given-names>
           D.M
          </given-names>
         </name>
         <name>
          <surname>
           Howley
          </surname>
          <given-names>
           P.M
          </given-names>
         </name>
        </person-group>
        <source>
         Fields Virology
        </source>
        <year>
         1996
        </year>
        <publisher-name>
         Lippincott-Raven
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         1075
        </fpage>
        <lpage>
         1093
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB11">
       <label>
        11
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Enjuanes
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Brian
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           K.V.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviridae
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           F.A
          </given-names>
         </name>
         <name>
          <surname>
           Fauquet
          </surname>
          <given-names>
           C.M
          </given-names>
         </name>
         <name>
          <surname>
           Bishop
          </surname>
          <given-names>
           D.H.L
          </given-names>
         </name>
         <name>
          <surname>
           Ghabrial
          </surname>
          <given-names>
           S.A
          </given-names>
         </name>
         <name>
          <surname>
           Jarvis
          </surname>
          <given-names>
           A.W
          </given-names>
         </name>
         <name>
          <surname>
           Martelli
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <source>
         Virus taxonomy, Seventh report of the International Committee on Taxonomy of Viruses
        </source>
        <year>
         1999
        </year>
        <publisher-name>
         Academic Press
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
        <fpage>
         835
        </fpage>
        <lpage>
         849
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           M.M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The molecular biology of coronaviruses
        </article-title>
        <source>
         Adv Vir Res
        </source>
        <volume>
         48
        </volume>
        <year>
         1997
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         100
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McNaughton
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Flowers
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Isaacs
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diagnosis of human coronavirus infections in children using aenzyme-linked immunosorbent assay
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         11
        </volume>
        <year>
         1983
        </year>
        <fpage>
         319
        </fpage>
        <lpage>
         325
        </lpage>
        <pub-id pub-id-type="pmid">
         6308142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Arbour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of human coronaviruses by fluorescent monoclonal antibody staining and reverse transcription-PCR in cell cultures
        </article-title>
        <source>
         J Virol Methods
        </source>
        <volume>
         72
        </volume>
        <year>
         1998
        </year>
        <fpage>
         145
        </fpage>
        <lpage>
         152
        </lpage>
        <pub-id pub-id-type="pmid">
         9694322
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB15">
       <label>
        15
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stewart
          </surname>
          <given-names>
           J.N.
          </given-names>
         </name>
         <name>
          <surname>
           Mounir
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Detection of conaviruses by the polymerase chain reaction
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Daraï
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <source>
         Diagnosis of human viruses by polymerase chain reaction technology
        </source>
        <year>
         1995
        </year>
        <publisher-name>
         Springer Verlag
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
        <fpage>
         316
        </fpage>
        <lpage>
         327
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ieven
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Goossens
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <volume>
         2
        </volume>
        <year>
         1997
        </year>
        <fpage>
         242
        </fpage>
        <lpage>
         256
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB17">
       <label>
        17
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dick
          </surname>
          <given-names>
           E.C.
          </given-names>
         </name>
         <name>
          <surname>
           Inhorn
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviruses
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Feigin
          </surname>
          <given-names>
           R.P
          </given-names>
         </name>
         <name>
          <surname>
           Cherry
          </surname>
          <given-names>
           J.D
          </given-names>
         </name>
        </person-group>
        <source>
         Textbook of pediatric infectious diseases
        </source>
        <year>
         1992
        </year>
        <publisher-name>
         WB Saunders Company
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         1498
        </fpage>
        <lpage>
         1506
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Myint
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronaviruses. A brief review
        </article-title>
        <source>
         Rev Med Viol
        </source>
        <volume>
         4
        </volume>
        <year>
         1994
        </year>
        <fpage>
         35
        </fpage>
        <lpage>
         46
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Monto
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The tecumseh study of respiratory illness. VI. Frequency of and relationship between outbreaks of coronavirus infections
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         129
        </volume>
        <year>
         1974
        </year>
        <fpage>
         271
        </fpage>
        <lpage>
         271
        </lpage>
        <pub-id pub-id-type="pmid">
         4816305
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB20">
       <label>
        20
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Myint
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Human coronavirus infections
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Siddell
          </surname>
          <given-names>
           S.G
          </given-names>
         </name>
        </person-group>
        <source>
         The
         <italic>
          Coronaviridae
         </italic>
        </source>
        <year>
         1995
        </year>
        <publisher-name>
         Plenum Press
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
        <fpage>
         389
        </fpage>
        <lpage>
         401
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB21">
       <label>
        21
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mortimer
          </surname>
          <given-names>
           E.A.
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Fox
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Epideliology of infectious disease
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Feigin
          </surname>
          <given-names>
           R.P
          </given-names>
         </name>
         <name>
          <surname>
           Cherry
          </surname>
          <given-names>
           J.D
          </given-names>
         </name>
        </person-group>
        <source>
         Textbook of pediatric infectious disease
        </source>
        <year>
         1992
        </year>
        <publisher-name>
         WB Saunders Company
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         67
        </fpage>
        <lpage>
         90
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vernotte
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Gagneur
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Salmon
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Legrand
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Parscau
          </surname>
          <given-names>
           L.
          </given-names>
          <suffix>
           de
          </suffix>
         </name>
        </person-group>
        <article-title>
         Rôle pathogène des coronavirus humains chez l'enfant. Analyse systématique de la littérature
        </article-title>
        <source>
         Arch Pédiatr
        </source>
        <volume>
         6
        </volume>
        <issue>
         Suppl 2
        </issue>
        <year>
         1999
        </year>
        <fpage>
         533
        </fpage>
        <lpage>
         533
        </lpage>
        <pub-id pub-id-type="pmid">
         10370809
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brouard
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Freymuth
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jokic
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Guillois
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Duhamel
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Co-infections virales lors des bronchiolites du nourrisson immunocompétent : étude prospective épidémiologique
        </article-title>
        <source>
         Arch Pediatr
        </source>
        <volume>
         7
        </volume>
        <issue>
         Suppl 3
        </issue>
        <year>
         2000
        </year>
        <fpage>
         531
        </fpage>
        <lpage>
         535
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lina
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Valette
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Foray
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Luciani
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Stagnara
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           See
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Surveillance of community-acquired viral infections due to respiratory viruses in Rhone-Alpes (France) during winter 1994 to 1995
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         34
        </volume>
        <year>
         1996
        </year>
        <fpage>
         3007
        </fpage>
        <lpage>
         3011
        </lpage>
        <pub-id pub-id-type="pmid">
         8940439
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mertsola
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ziegler
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ruuskanen
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Vanto
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Koivikko
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Halonen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recurrent wheezy bronchitis and viral respiratory infections
        </article-title>
        <source>
         Arch Dis Child
        </source>
        <volume>
         66
        </volume>
        <year>
         1991
        </year>
        <fpage>
         124
        </fpage>
        <lpage>
         129
        </lpage>
        <pub-id pub-id-type="pmid">
         1847281
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Freymuth
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Brouard
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Toutain
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Verdon
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Petitjean
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of viral,
         <italic>
          Chlamydia pneumoniae
         </italic>
         and
         <italic>
          Mycoplasma pneumoniae
         </italic>
         infections in exacerbations of asthma in children
        </article-title>
        <source>
         J Clin Virol
        </source>
        <volume>
         13
        </volume>
        <year>
         1999
        </year>
        <fpage>
         131
        </fpage>
        <lpage>
         139
        </lpage>
        <pub-id pub-id-type="pmid">
         10443789
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vernotte
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Legrand
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Gagneur
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Salmon
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Parscau
          </surname>
          <given-names>
           L.
          </given-names>
          <suffix>
           de
          </suffix>
         </name>
        </person-group>
        <article-title>
         Exacerbation de l'asthme : le rôle déclenchant des coronavirus humains n'est pas confirmé
        </article-title>
        <source>
         Arch Pédiatr
        </source>
        <volume>
         6
        </volume>
        <issue>
         Suppl 2
        </issue>
        <year>
         1999
        </year>
        <fpage>
         583
        </fpage>
        <lpage>
         583
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Natural and experimental rhinovirus infections of the lower respiratory tract
        </article-title>
        <source>
         Am J Respir Crit Care M
        </source>
        <volume>
         152
        </volume>
        <issue>
         Suppl
        </issue>
        <year>
         1995
        </year>
        <fpage>
         46
        </fpage>
        <lpage>
         52
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pitkaranta
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Virolainen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Jero
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Arruda
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           F.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of rhinovirus, RSV and coronavirus infections in acute otitis media by RT-PCR
        </article-title>
        <source>
         Pediatrics
        </source>
        <volume>
         102
        </volume>
        <year>
         1998
        </year>
        <fpage>
         291
        </fpage>
        <lpage>
         295
        </lpage>
        <pub-id pub-id-type="pmid">
         9685428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Resta
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Luby
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenfeld
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Siegel
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and propagation of a human enteric coronavirus
        </article-title>
        <source>
         Science
        </source>
        <volume>
         229
        </volume>
        <year>
         1985
        </year>
        <fpage>
         978
        </fpage>
        <lpage>
         981
        </lpage>
        <pub-id pub-id-type="pmid">
         2992091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kidd
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Esrey
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ujfalusi
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Shedding of coronavirus-like particles by children in Lesotho
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         27
        </volume>
        <year>
         1989
        </year>
        <fpage>
         164
        </fpage>
        <lpage>
         169
        </lpage>
        <pub-id pub-id-type="pmid">
         2921603
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riski
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hovi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus infections in man associated with diseases other than the common cold
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         6
        </volume>
        <year>
         1980
        </year>
        <fpage>
         259
        </fpage>
        <lpage>
         265
        </lpage>
        <pub-id pub-id-type="pmid">
         6262459
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arbour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Cote
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Lachance
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tardieu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cashman
          </surname>
          <given-names>
           N.R.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute and persistent infection of human neural cell lines by human coronavirus OC43
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         73
        </volume>
        <year>
         1999
        </year>
        <fpage>
         3338
        </fpage>
        <lpage>
         3350
        </lpage>
        <pub-id pub-id-type="pmid">
         10074188
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arbour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ekande
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Cote
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Lachance
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chagnon
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         73
        </volume>
        <year>
         1999
        </year>
        <fpage>
         3326
        </fpage>
        <lpage>
         3337
        </lpage>
        <pub-id pub-id-type="pmid">
         10074187
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arbour
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Newcombe
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neuroinvasion by human respiratory coronaviruses
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         74
        </volume>
        <year>
         2000
        </year>
        <fpage>
         8913
        </fpage>
        <lpage>
         8921
        </lpage>
        <pub-id pub-id-type="pmid">
         10982334
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graman
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nosocomial viral respiratory infections
        </article-title>
        <source>
         Semin Respir Infect
        </source>
        <volume>
         4
        </volume>
        <year>
         1989
        </year>
        <fpage>
         253
        </fpage>
        <lpage>
         260
        </lpage>
        <pub-id pub-id-type="pmid">
         2697050
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ijaz
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Brunner
          </surname>
          <given-names>
           A.H.
          </given-names>
         </name>
         <name>
          <surname>
           Sattar
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Nai
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson-Lussenburg
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Survival characteristics of airborne human coronavirus 229-E
        </article-title>
        <source>
         J Gen Virol
        </source>
        <volume>
         66
        </volume>
        <year>
         1985
        </year>
        <fpage>
         2743
        </fpage>
        <lpage>
         2748
        </lpage>
        <pub-id pub-id-type="pmid">
         2999318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.W.N.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Survival of 229-E and OC-43 human coronaviruses in suspension and on surfaces after drying. Effect of chemical disinfection
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         46
        </volume>
        <year>
         2000
        </year>
        <fpage>
         55
        </fpage>
        <lpage>
         60
        </lpage>
        <pub-id pub-id-type="pmid">
         11023724
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Soupre
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Giroux
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Alix
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Parscau
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Legrand
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nasal colonisation with coronavirus and apnea of the premature newborn
        </article-title>
        <source>
         Acta Paediatr
        </source>
        <volume>
         82
        </volume>
        <year>
         1993
        </year>
        <fpage>
         238
        </fpage>
        <lpage>
         238
        </lpage>
        <pub-id pub-id-type="pmid">
         8388276
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Soupre
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Legrand
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Giroux
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rubio
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           de Parscau
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neonatal nosocomial respiratory infection with coronavirus : a prospective study in a neonatal intensive care unit
        </article-title>
        <source>
         Acta Paediatr
        </source>
        <volume>
         84
        </volume>
        <year>
         1995
        </year>
        <fpage>
         617
        </fpage>
        <lpage>
         620
        </lpage>
        <pub-id pub-id-type="pmid">
         7670241
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gagneur
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Legrand
          </surname>
          <given-names>
           M.C.
          </given-names>
         </name>
         <name>
          <surname>
           Salmon
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baron
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prospective evaluation of community-acquired and nosocomial viral respiratory tract infections in a NPICU
        </article-title>
        <source>
         Pediatr Res
        </source>
        <volume>
         45
        </volume>
        <year>
         1999
        </year>
        <fpage>
         174A
        </fpage>
        <lpage>
         174A
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goldwater
          </surname>
          <given-names>
           P.N.
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ryan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Thompson
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Burrell
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A survey of nosocomial respiratory viral infections in a children's hospital : occult respiratory infections in patients admitted during an epidemic season
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         12
        </volume>
        <year>
         1991
        </year>
        <fpage>
         231
        </fpage>
        <lpage>
         238
        </lpage>
        <pub-id pub-id-type="pmid">
         2061581
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chany
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Moscovici
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Lebon
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Rousset
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Association of coronavirus with neonatal necrotizing enterocolitis
        </article-title>
        <source>
         Pediatrics
        </source>
        <volume>
         69
        </volume>
        <year>
         1982
        </year>
        <fpage>
         209
        </fpage>
        <lpage>
         214
        </lpage>
        <pub-id pub-id-type="pmid">
         6276855
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Brouard
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Petitjean
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Eugene-Ruellan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Freymuth
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infections à coronavirus humains. Importance et diagnostic
        </article-title>
        <source>
         Presse M
        </source>
        <volume>
         27
        </volume>
        <year>
         1998
        </year>
        <fpage>
         1813
        </fpage>
        <lpage>
         1817
        </lpage>
       </element-citation>
      </ref>
      <ref id="BIB45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falsey
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           McCann
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Criddle
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Formica
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wycoff
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The « common cold » in frail older persons : impact of rhinovirus and coronavirus in a senior daycare center
        </article-title>
        <source>
         J Am Geriatr Soc
        </source>
        <volume>
         45
        </volume>
        <year>
         1997
        </year>
        <fpage>
         706
        </fpage>
        <lpage>
         711
        </lpage>
        <pub-id pub-id-type="pmid">
         9180664
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB46">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sizun
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baron
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Soupre
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Giroux
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           de Parscau
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infections nosocomiales liées au virus respiratoire syncytial : quelles mesures d'hygiène ?
        </article-title>
        <source>
         Arch Pédiatr
        </source>
        <volume>
         3
        </volume>
        <year>
         1996
        </year>
        <fpage>
         723
        </fpage>
        <lpage>
         727
        </lpage>
        <pub-id pub-id-type="pmid">
         8881187
        </pub-id>
       </element-citation>
      </ref>
      <ref id="BIB47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          Centers for Disease Control and Prevention
         </collab>
        </person-group>
        <article-title>
         Guidelines for prevention of nosocomial pneumonia
        </article-title>
        <source>
         MMWR. Morb Mortal Wkly Rep
        </source>
        <volume>
         46
        </volume>
        <year>
         1997
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         79
        </lpage>
        <pub-id pub-id-type="pmid">
         9011775
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <fn-group>
      <fn id="FTR1">
       <label>
        1
       </label>
       <p>
        Travail financé en partie par la Société française de pédiatrie (bourse de DEA), le ministère de la santé (PHRC 97) et le CCLIN–Ouest. A. Gagneur est boursier de la Société française de pédiatrie.
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
  </pmc-articleset>
 </body>
</html>